<?xml version="1.0" encoding="utf-8"?>
<documents>
  <document>
    <id>319611</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.cfps.org.uk/uploads.php?file=eyehealthaprilwithchangesfinal20april09_2_.pdf]]&gt;</url>
    <title>10 questions to ask if you are scrutinising local eye health provision</title>
    <publicationDate>2009-04-20T00:00:00</publicationDate>
    <publisher>The Centre for Public Scrutiny</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,RETINA,LENS,RETINOPATHY,LOW VISION,DIABETIC RETINOPATHY,CATARACT,EYES AND VISION,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In April 2009 the Centre for Public Scrutiny in association with Local Optical Committee Support Unit (LOCSU), the Association of Optometrists (AOP), the Federation of Ophthalmic and Dispensing Opticians (FODO) and the Association of British Dispensing Opticians (ABDO)&amp;nbsp;published this guide as part of a series to help Overview and Scrutiny Committeee (OSCs) carry out their work around various health, healthcare and social care topics. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=441" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=441" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=441" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83968</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4019186.pdf]]&gt;</url>
    <title>12 key points on consent: the law in England</title>
    <publicationDate>2001-08-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,SURGERY,ETHICS AND PROFESSIONAL STANDARDS,PERIOPERATIVE MANAGEMENT,LOW VISION,INFORMED CONSENT,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS,CONSENT AND ASSENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance is from the Department of Health and aims to answer the most frequently asked questions about consent law in England.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The questions do not cover all situations and for more detail consult the Reference guide to consent for examination or treatment, available from the Department of Health order line 0300 123 1002 (minicom 0300 123 1003).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>329710</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329710]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Diagnosis</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,GLAUCOMA AEU 2009,CONDITIONS,GLAUCOMA,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Diagnosis - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc2.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/articles/Diagnosis.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;Diagnosis of chronic open angle glaucoma (COAG), suspected COAG and ocular hypertension (OHT)&lt;/H2&gt;
&lt;H3 align=left&gt;Mr John Sparrow, Consultant Ophthalmologist, Bristol Eye Hospital.&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Established international clinical and research standards were adopted by NICE. The glaucoma guideline recommendations on diagnosis of COAG, suspected COAG and OHT were taken from established clinical and research practice and methods. These are the principles of diagnosis which underpin the evidence base which informs and supports glaucoma management. &lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;Summary of NICE recommendations on diagnosis&lt;/H3&gt;
&lt;P&gt;NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;http://guidance.nice.org.uk/CG85&lt;/A&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;See chapter 4 ‘Diagnosis of patients with ocular hypertension, chronic open angle glaucoma and suspected chronic open angle glaucoma’, p.72.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Tests recommended at diagnosis for COAG, Suspected COAG &amp;amp; OHT are: Goldmann Applanation Tonometry (slit-lamp mounted), central corneal thickness, peripheral anterior chamber configuration using gonioscopy, visual field central thresholding test using standard automated perimetry, optic nerve assessment, with dilatation, using stereoscopic slit lamp biomicroscopy with fundus examination.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Use Van Herick’s peripheral anterior chamber depth assessment as an alternative to gonioscopy if clinical circumstances rule out gonioscopy.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Obtain an optic nerve head image at diagnosis for baseline documentation.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;All of the following should be available at each clinical episode to all healthcare professionals involved in a person’s care: records of all previous tests and images relevant to COAG and OHT assessment; records of past medical history which could affect drug choice; current systemic and topical medication; glaucoma medication record; drug allergies and intolerances.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;People with suspected optic nerve damage or repeatable visual field defect, or both, should be referred to a consultant ophthalmologist for consideration of a definitive diagnosis and formulation of a management plan.&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Diagnosis of OHT and suspected COAG and formulation of a management plan should be made by a suitably trained healthcare professional with a specialist qualification (when not working under the supervision of a consultant ophthalmologist) and relevant experience.&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Summary of evidence update&lt;/H3&gt;
&lt;P&gt;The update identified only observational comparative studies. Cost effectiveness analyses of relevance to diagnosis were not identified. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Conclusion&lt;/H3&gt;
&lt;P&gt;None of the studies identified currently alter the key elements of the recommendations on diagnosis. For these to be altered there would need to be evidence of improvements in effectiveness and/or cost effectiveness and/or safety of alternative approaches.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329710:2" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Diagnosis Evidence Tree&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Diagnosis - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc9.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_summaries/DiagnosisSearchSummary.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;AEU searches:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PubMed; EMBASE 1996 to date ; CINAHL 1981 to date ; AMED 1985 to date; BNI 1985 to date; NHS Evidence - eyes and vision.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline 1996 to date; EMBASE 1996 to date ; CINAHL 1981 to date; AMED 1985 to date; PsycInfo 2002 to date; The Cochrane Library.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt;&amp;nbsp;January 2008 to 7th October 2009&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;AEU searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;OvidSP (Athens Account required)&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/EM&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 653px; HEIGHT: 344px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Diagnosis Evidence Tree - Glaucoma AEU 2009" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329710/nelhImp_0000_aeu_TT_Diag.jpg" width=689 height=364&gt;&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;Search Strategy:&lt;BR&gt;&lt;/H3&gt;
&lt;P&gt;AEU searches:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/ScreeningSearchHistory.pdf" target="_blank"&gt;Screening&lt;/A&gt; search strategy&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/OpticDiscImaging.pdf" target="_blank"&gt;Optic disc imaging&lt;/A&gt;&amp;nbsp;search strategy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NICE Guideline searches:&lt;BR&gt;See Appendix C: Search Strategies of the 2009 NICE guidance. &lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG85FullGuidelineAppendices.pdf" target="_blank"&gt;CG85 Glaucoma: full guideline appendices&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/GlaucomaAEU2009_JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>330473</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=330473]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Evidence Tree</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS,GLAUCOMA AEU 2009,ANNUAL EVIDENCE UPDATES,GLAUCOMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Glaucoma - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc1.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/EvidenceTree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/EvidenceTree.pdf" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Evidence Tree for the entire Annual Evidence Update for Glaucoma 2009&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=690 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID330473/nelhImp_0000_aeu_TT_Main.jpg" width=615 name=nelh_tempImage0&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>329673</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329673]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Home Page</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Glaucoma - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;23rd November 2009 
&lt;P&gt;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329673/nelhImp_0000_patientundergoingtonometry.jpg" width=208 height=152&gt;&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329673/nelhImp_0001_Glaucomatousopticnervehead.jpg" width=208 height=153&gt;&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Example of low vision from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329673/nelhImp_0002_Exampleoflowvisionfromglaucoma.jpg" width=209 height=151&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This Evidence Update presents the key recommendations for clinical practice and service organisation outlined in the recent NICE glaucoma guideline and reviews the new evidence that has emerged since its development. In addition routine NHS information (data and statistics) on glaucoma care and the uncertainties in the diagnosis and management of glaucoma and service provision are presented.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We welcome feedback about resources that we identify, do contact us if you would like to comment.After you have browsed the pages, please take a moment to complete our survey (5 mins). &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/Feedback/feedback.aspx" target="_blank"&gt;Click here to take the survey&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Contents:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Topics Covered -&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329669:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329710:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329711:1" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Treatment:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329715:1" name=internalLink&gt;Pharmacological&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329738:1" name=internalLink&gt;Surgical and laser&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;&lt;A href="nelh:329678:1" name=internalLink&gt;Service provision&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329744:1" name=internalLink&gt;Patient Information&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329734:0" name=internalLink&gt;Information on glaucoma from the NHS Information Centre for health and social care&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:329770:1" name=internalLink&gt;UK Database of Uncertainties about the Effects of Treatments (DUETs) on Glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330473:0" name=internalLink&gt;Overall Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/GlaucomaAEU2009_JournalSpread.pdf" target="_blank"&gt;Journal Spread&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/Glossary.pdf" target="_blank"&gt;Glossary&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330454:0" name=internalLink&gt;Methodology and search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/fp_aeu_glaucoma_1109.asp" target="_blank"&gt;low vision version&lt;/A&gt; of this AEU is also available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Acknowledgements:&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;The Management Team based at Moorfields Eye Hospital NHS Foundation Trust are grateful to all our panel of contributors:&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Ms Cecilia Fenerty, Consultant Ophthalmologist, Manchester Royal Eye Hospital.&lt;/P&gt;
&lt;P&gt;Ms Wendy Franks, Consultant Ophthalmologist, Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust.&lt;/P&gt;
&lt;P&gt;Ms Mary Freeman, Consultant Nurse in Ophthalmology Sheffield Teaching Hospitals NHS Foundation Trust.&lt;/P&gt;
&lt;P&gt;Miss Susana Ramirez-Florez, Consultant Ophthalmic Surgeon, Peterborough &amp;amp; Stamford Hospitals NHS Foundation Trust.&lt;/P&gt;
&lt;P&gt;Mr John Sparrow, Consultant Ophthalmologist, Bristol Eye Hospital.&lt;/P&gt;
&lt;P&gt;Dr Paul Spry Consultant Hospital Optometrist, Bristol Eye Hospital.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Our thanks also to:&lt;/P&gt;
&lt;P&gt;Shaun Kirupairatnum - R&amp;amp;D Graphic Web Designer, Moorfields Eye Hospital NHS Foundation Trust &lt;/P&gt;
&lt;P&gt;The NHS Information Centre for health and social care&lt;/P&gt;
&lt;P&gt;and&lt;/P&gt;
&lt;P&gt;Our External Reference Group and everyone involved in the development and publicising of this annual evidence update.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Images&amp;nbsp;courtesy of &lt;/EM&gt;&lt;A href="http://www.nei.nih.gov/index.asp" target="_blank"&gt;&lt;EM&gt;National Eye Institute, National Institutes of Health&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>329734</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329734]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Information on glaucoma from the NHS Information Centre for health and social care</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,GLAUCOMA,ANNUAL EVIDENCE UPDATES,CONDITIONS,GLAUCOMA AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Glaucoma - Information on glaucoma from the NHS Information Centre for health and social care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/routineNHSDataOnGlaucoma.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/RoutineNHSDataGlaucoma.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673&amp;amp;pgID=1" target="_blank"&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The &lt;STRONG&gt;NHS Information Centre for health and social care&lt;/STRONG&gt; is England's central, authoritative source of health and social care information. The website includes statistics and data collections including Hospital Episode Statistics (HES). &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;HES is a data warehouse containing details of all admissions to NHS hospitals in England and also details of all NHS outpatient appointments in England.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The following NHS IC publications include&lt;STRONG&gt; data&lt;/STRONG&gt; &lt;STRONG&gt;specific to glaucoma&lt;/STRONG&gt;:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;EM&gt;HES… on Glaucoma.&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This article gives an overview of the condition and highlights relating to the 2007-08 HES data. &lt;A href="http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&amp;amp;categoryID=758" target="_blank"&gt;http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&amp;amp;categoryID=758&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Prescriptions dispensed in the community, statistics for 1998 to 2008: England Bulletin.&lt;/EM&gt;&lt;/STRONG&gt; [Published July 2009]&lt;/P&gt;
&lt;P&gt;Point 28, page 11 refers to the treatment of glaucoma:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;“BNF section 11.6 (Treatment of Glaucoma) saw a rise in [Net Ingredient Cost] NIC of £12.2 million (12.5 per cent).&lt;/LI&gt;
&lt;LI&gt;The cost of latanoprost rose by 10.3 per cent (£4.8 million) although items dispensed rose by 0.8 per cent.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;There was increased use of several drugs (with NIC increasing accordingly) including bimatoprost which saw a 24.1 per cent increase in both items dispensed and NIC.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Use of travoporost increased by 12.2 per cent with NIC rising by 23.7 per cent (£1.3 million).&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Prescribing of timolol fell although prescribing of timolol in combination with other products has increased” &lt;BR&gt;– see also table 10, page 32. &lt;BR&gt;&lt;A href="http://www.ic.nhs.uk/webfiles/publications/presdisp98-08/Prescriptions_Dispensed_in_the_Community_1998_2008_England_a.pdf" target="_blank"&gt;http://www.ic.nhs.uk/webfiles/publications/presdisp98-08/Prescriptions_Dispensed_in_the_Community_1998_2008_England_a.pdf&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Prescription Cost Analysis 2008.&lt;/EM&gt;&lt;/STRONG&gt; [Published April 2009]&lt;/P&gt;
&lt;P&gt;Prescription Cost Analysis (PCA) provides details of the number of items and the net ingredient cost of all prescriptions dispensed in the community in England. Search the report for data tables for products relating to the treatment of glaucoma.&lt;BR&gt;&lt;A href="http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-2008" target="_blank"&gt;http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-2008&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;General NHS IC data:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;EM&gt;&lt;STRONG&gt;Eye care section&lt;/STRONG&gt;&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;The IC Eye care section includes data on General Ophthalmic Services - workforce and activity statistics including the number of sight tests and optical voucher items etc. &lt;BR&gt;&lt;A href="http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/eye-care" target="_blank"&gt;http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/eye-care&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;People Registered as Blind and Partially Sighted.&lt;/STRONG&gt; &lt;/EM&gt;2008. England&lt;BR&gt;Registrations (at 31 March 2008)&lt;BR&gt;&lt;A href="http://www.ic.nhs.uk/statistics-and-data-collections/social-care/adult-social-care-information/people-registered-as-blind-and-partially-sighted-2008-england" target="_blank"&gt;http://www.ic.nhs.uk/statistics-and-data-collections/social-care/adult-social-care-information/people-registered-as-blind-and-partially-sighted-2008-england&lt;/A&gt; &lt;BR&gt;(N.B please note this does not break down by condition)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>329669</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329669]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Introduction</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Glaucoma - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_intro.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/Introduction.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to 2009 Glaucoma AEU contents page&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=center&gt;&lt;IMG id=nelh_tempImage0 height=218 alt="Examples of vision loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329669/nelhImp_0000_Exampleoflowvisionfromglaucoma16.11.07.jpg" width=329 border=0 name=nelh_tempImage0&gt;&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Introduction by Parul Desai, Clinical Lead NHS Evidence - eyes and vision.&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The NICE Glaucoma Guideline was published in April 2009.&lt;/STRONG&gt; [1]. Its scope covers the diagnosis and management of chronic open angle glaucoma (COAG), glaucoma suspects, and ocular hypertension (OHT) which is a strong risk factor for developing glaucoma.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This Evidence Update&lt;/STRONG&gt; presents the Guideline’s key recommendations and messages for clinical practice and service organisation, and reviews new evidence that has emerged since its development.&amp;nbsp; It provides a means for accessing the guideline, supports its dissemination and implementation, and ensures that its evidence base is kept up to date. &lt;/P&gt;
&lt;P&gt;In addition it presents routine NHS information (data and statistics) on glaucoma care, and uncertainties in the diagnosis and management of glaucoma and service provision.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;COAG&lt;/STRONG&gt; is a common and potentially blinding condition, attributable to about 10% of UK blindness registrations.&amp;nbsp; It is often asymptomatic until severe visual damage has occurred, with or without raised intra-ocular pressure. Once diagnosed, people with COAG need lifelong monitoring so that any progression of visual damage can be detected.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Epidemiology.&lt;/STRONG&gt;&amp;nbsp; Around 2% of people older than 40 years have COAG, rising to almost 10% in people older than 75 years in white Europeans. The prevalence may be higher in people of black African or black Caribbean descent or who have a family history of glaucoma. Approximately 10% of UK blindness registrations are attributed to glaucoma.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;NPSA Rapid Response Report June 2009&lt;/STRONG&gt; [2] - highlighted the risk of deterioration of vision as a result of delayed, postponed or cancelled out-patient follow-up appointments for glaucoma; and called for a review of patient profiles and booking systems to be completed by December 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Search strategy&lt;/STRONG&gt; - this involved re-running the NICE search strategy for the Guideline from January 2008 to October 2009, and the Glaucoma AEU 2009 search strategy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Topic Summaries&lt;/STRONG&gt; - these were provided by members of the NICE Guideline Development Group who reviewed the search findings and summarised the new evidence for each of the following Guideline chapters: diagnosis, monitoring, pharmacological treatment , surgical and laser treatment,&amp;nbsp; service provision,&amp;nbsp; and provision of information for patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Uncertainties&lt;/STRONG&gt; identified in the NICE Guideline and relevant Cochrane reviews were further examined and presented using the UK Database of Uncertainties of the Effects of Treatments (DUETs) methodology.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Routine NHS data&lt;/STRONG&gt; on the glaucoma care was sourced from the NHS Information Centre for Health and Social Care.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key documents:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;http://guidance.nice.org.uk/CG85&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. National Patient Safety Agency. Preventing delay to follow-up for patients with glaucoma. Rapid Response Report 2009; NPSA/2009/RRR004. Gateway reference: 11994.&amp;nbsp; &lt;A href="http://www.nrls.npsa.nhs.uk/resources/type/alerts/?entryid45=61908" target="_blank"&gt;http://www.nrls.npsa.nhs.uk/resources/type/alerts/?entryid45=61908&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Contents:&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Topics Covered -&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329710:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329711:1" name=internalLink&gt;Monitoring&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Treatment:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:329715:1" name=internalLink&gt;Pharmacological&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329738:1" name=internalLink&gt;Surgical and laser&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;&lt;A href="nelh:329678:1" name=internalLink&gt;Service provision&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329744:0" name=internalLink&gt;Patient Information&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:329734:0" name=internalLink&gt;Information on glaucoma from the NHS Information Centre for health and social care &lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:329770:1" name=internalLink&gt;UK DUETs on Glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330473:0" name=internalLink&gt;Overall Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/GlaucomaAEU2009_JournalSpread.pdf" target="_blank"&gt;Journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/Glossary.pdf" target="_blank"&gt;Glossary&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330454:0" name=internalLink&gt;Methodology and search strategy&lt;/A&gt;&lt;A href="nelh:330454:0" name=internalLink&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;STRONG&gt;Acknowledgements:&lt;/STRONG&gt;&lt;BR&gt;&lt;BR&gt;
&lt;P&gt;The Management Team based at Moorfields Eye Hospital NHS Foundation Trust are grateful to all our panel of contributors:&lt;/P&gt;
&lt;P&gt;Ms Cecilia Fenerty, Consultant Ophthalmologist, Manchester Royal Eye Hospital.&lt;/P&gt;
&lt;P&gt;Ms Wendy Franks, Consultant Ophthalmologist, Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust.&lt;/P&gt;
&lt;P&gt;Ms Mary Freeman, Consultant Nurse in Ophthalmology, Sheffield Teaching Hospitals NHS Foundation Trust.&lt;/P&gt;
&lt;P&gt;Miss Susana Ramirez-Florez, Consultant Ophthalmic Surgeon, Peterborough &amp;amp; Stamford Hospitals NHS Foundation Trust.&lt;/P&gt;
&lt;P&gt;Mr John Sparrow, Consultant Ophthalmologist, Bristol Eye Hospital.&lt;/P&gt;
&lt;P&gt;Dr Paul Spry Consultant Hospital Optometrist, Bristol Eye Hospital.&lt;/P&gt;
&lt;P&gt;Our thanks also to:&lt;/P&gt;
&lt;P&gt;Shaun Kirupairatnum - R&amp;amp;D Graphic Web Designer, Moorfields Eye Hospital NHS Foundation Trust &lt;/P&gt;
&lt;P&gt;The NHS Information Centre for health and social care&lt;/P&gt;
&lt;P&gt;and&lt;/P&gt;
&lt;P&gt;Our External Reference Group and everyone involved in the development and publicising of this annual evidence update.&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;FONT size=2&gt;Back to 2009 Glaucoma AEU contents page&lt;/FONT&gt;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>330454</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=330454]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Methodology</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA AEU 2009,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Glaucoma - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/Methodology.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Methodology&lt;/H2&gt;
&lt;P&gt;The last Annual Evidence Update (AEU) for Glaucoma was carried out in November 2008. In April 2009 NICE published guidance on glaucoma. [1] This AEU serves as an update to both the last AEU and the NICE guidance, and includes articles published in 2008 and 2009. &lt;/P&gt;
&lt;P&gt;The 2009 NICE search strategy for the Guideline was re-run from January 2008 to October 2009. The search strategy for the NHS Evidence – eyes and vision Glaucoma AEU (AEU Searches) was also run and these results added to the NICE results. &lt;/P&gt;
&lt;P&gt;An initial search was run on 21st August 2009 and an update search on 7th October 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;AEU Searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PubMed; EMBASE 1996 to date ; CINAHL 1981 to date ; AMED 1985 to date; BNI 1985 to date; NHS Evidence - eyes and vision.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline 1996 to date; EMBASE 1996 to date ; CINAHL 1981 to date; AMED 1985 to date; PsycInfo 2002 to date; The Cochrane Library.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Period of Search:&lt;/STRONG&gt; January 2008 to 7th October 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Accessed using:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;AEU Searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;OvidSP (Athens Account required)&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Inclusion criteria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis)&lt;/LI&gt;
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials &lt;/LI&gt;
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys). &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 2008 on and not included in a previous AEU. &lt;/LI&gt;
&lt;LI&gt;Relevancy to topics included in the 2009 AEU (diagnosis, monitoring, treatment – pharmacological, treatment – surgery &amp;amp; laser, service provision and patient education.) &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Method&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;The search outputs were exported into Reference Manager bibliographic software. Outputs from the AEU Searches were added to the relevant NICE search output for each topic:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;‘Screening’ and ‘Optic disc imaging’ to Diagnosis;&lt;/LI&gt;
&lt;LI&gt;‘Visual field progression’ to Monitoring;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;‘Medical management’ to Treatment;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;‘Patient education and ‘Living with glaucoma’ to ‘Provision of information for patients’&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The results for each topic were automatically de-duplicated. Articles which had appeared in the 2008 AEU search output were also automatically de-duplicated and then further duplicate results removed manually. &lt;/P&gt;
&lt;P&gt;The results were then sifted for relevance and categorised by publication type.&amp;nbsp; Results were also categorised by potential AEU topic sub-heading. The resultant articles were then passed to the topic contributors for further sifts for relevance. The results were re-categorised according to topic and publication type where necessary. &lt;/P&gt;
&lt;P&gt;NHS Evidence – eyes and vision was sifted on 10th November 2009 with records indexed with Glaucoma to ensure that the above search included all the pertinent articles. Relevant guidelines and uncertainties were identified during this search.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Search strategy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;See Appendix C: Search Strategies of the 2009 NICE guidance. CG85 Glaucoma: full guideline appendices&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NHS Evidence – eyes and vision Glaucoma AEU Searches:&lt;/P&gt;
&lt;P&gt;Search History – &lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/ScreeningSearchHistory.pdf" target="_blank"&gt;Screening&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Search History – &lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/OpticDiscImaging.pdf" target="_blank"&gt;Optic disc imaging&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Search History – &lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/VisualFieldProgression.pdf" target="_blank"&gt;Visual field progression&lt;/A&gt; &amp;nbsp;&lt;BR&gt;Search History – &lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/MedicalManagement.pdf" target="_blank"&gt;Medical management&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Search History – &lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/PatientEducation.pdf" target="_blank"&gt;Patient education&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Search History – &lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/LivingWithSearchHistory.pdf" target="_blank"&gt;Living with glaucoma&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;KP 12/11/09&lt;/P&gt;
&lt;P&gt;1. NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;http://guidance.nice.org.uk/CG85&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>329711</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329711]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Monitoring</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Monitoring - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc6.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/articles/Monitoring.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673&amp;amp;pgID=1" target="_blank"&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Monitoring of patients with ocular hypertension, chronic open angle glaucoma and suspected chronic open angle glaucoma&lt;/H2&gt;
&lt;P&gt;Miss Susana Ramirez-Florez, MD, FRCSEd, FRCOpth&lt;BR&gt;Consultant Ophthalmic Surgeon, Peterborough &amp;amp; Stamford Hospitals NHS Foundation Trust&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The NICE Guideline focused on the clinical tests for disease monitoring and the frequency intervals for follow-up visits for patients with chronic open angle glaucoma (COAG), those suspected of having COAG and those with ocular hypertension (OHT).&amp;nbsp; The recommendations were mainly based on clinical consensus due to limited quality or inexistent evidence to address these fundamental questions&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Summary of NICE Recommendations for Monitoring Glaucoma &lt;/H3&gt;
&lt;P&gt;NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;http://guidance.nice.org.uk/CG85&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;See chapter 5 ‘Monitoring of patients with ocular hypertension, chronic open angle glaucoma and suspected chronic open angle glaucoma’, p.92.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;A.&amp;nbsp;&lt;U&gt;Clinical Tests:&lt;/U&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Intraocular Pressure Measurement&lt;/EM&gt;&lt;/STRONG&gt; should be undertaken by slit lamp mounted Goldmann Applanation Tonometry at each clinical visit. &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Anterior Chamber Depth Assessment, Gonioscopy and Central Corneal Thickness: &lt;/STRONG&gt;&lt;/EM&gt;Van Herick’s technique should be used to assess the anterior chamber depth &lt;U&gt;at each visit&lt;/U&gt;, and repeating Gonioscopy and central corneal thickness measurement when clinically indicated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Visual Fields Assessment&lt;/STRONG&gt; should be performed using Standard Automated perimetry (central thresholding test) for patients with established glaucoma and for those suspected of having glaucoma with previous suspicious visual fields.&amp;nbsp; Supra-threshold perimetry should be used for monitoring patients with OHT and glaucoma suspects with normal visual fields. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Optic Nerve Assessment&lt;/EM&gt;&lt;/STRONG&gt; by stereoscopic slit lamp biomicroscopic examination of the optic nerve head should be performed for all patients with OHT, COAG, and those suspected of having glaucoma at each monitoring visit.&amp;nbsp; Where there is an inadequate view of the optic nerve, pupils should be dilated.&lt;/P&gt;
&lt;P&gt;Where a change in optic nerve status is documented by slit lamp biomicroscopy, a new benchmark image of the optic nerve should be made.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;B.&amp;nbsp;&lt;U&gt;Monitoring Intervals:&lt;/U&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A range of monitoring intervals for patients with COAG, OHT or suspected of having COAG, are recommended based on the risks of conversion to, or progression of COAG, perceived by the health care professional.&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;&lt;BR&gt;Summary of New Evidence &lt;/H3&gt;
&lt;P&gt;Three secondary publications and two observational studies were identified in the update. Of these there was no new evidence contradicting the NICE Guideline recommendations on this topic.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical Tests&lt;BR&gt;&lt;/STRONG&gt;The following are of interest as they may have implications for the monitoring of patients with COAG, OHT or those who are suspected of having COAG:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Intra-ocular pressure&lt;/EM&gt;&lt;/STRONG&gt; – 2 secondary publications:&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Intra-ocular pressure fluctuation in IOP measurement&lt;/EM&gt; [1]&lt;BR&gt;This is a systematic review on the importance of IOP variables such as: peak, trough, short-term, long-term fluctuation. Current literature suggests that a random IOP measurement is a poor surrogate for IOP levels throughout the day and across visits. Surrogates such as supine IOP or IOP following water drinking may also provide an indication of the range of IOP fluctuation.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Intra-ocular pressure fluctuation as a risk factor for glaucoma progression &lt;/EM&gt;[2] &lt;BR&gt;This review found no conclusive evidence that IOP fluctuation/variation are independent risk factors for glaucoma progression. Whether or not fluctuation or variation is also important will continue to be debated until continuous IOP measurement becomes a reality making it possible to adequately measure IOP throughout the diurnal and nocturnal periods to get an accurate assessment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Visual field assessment&lt;/EM&gt;&lt;/STRONG&gt; – &lt;EM&gt;visual field progression&lt;/EM&gt; [3]&lt;BR&gt;This review considered the techniques of event-based and trend analysis for detecting visual field progression.&amp;nbsp; Each approach has strengths and limitations and as yet there is no consensus on which is the most appropriate.&lt;/P&gt;
&lt;P&gt;Event-based analysis: takes into consideration individual points of the visual field over time rather than the entire field. It uses single events of significant change relative to a reference examination or baseline, and is usually less influenced by outliers. &lt;/P&gt;
&lt;P&gt;Trend analysis uses point wise linear regression analysis (PLRA), i.e. a linear regression on the mean deviation or individual test locations (point wise).&amp;nbsp; It has the advantage of detecting individualized change earlier, but is more susceptible to the effect of outliers. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Optic disc imaging&lt;/EM&gt;&lt;/STRONG&gt; - two observational studies:&lt;/P&gt;
&lt;P&gt;a) Findings from a small observational longitudinal study evaluating the ability of Topographic Change Analysis (TCA) to detect optic disc progression in patients with glaucoma observed longitudinally with both confocal scanning laser tomography (CSLT) and conventional disc photography, report that TCA may perform at least as well as either the individual or best combination of observer classifications of disc photographs. [4]&lt;/P&gt;
&lt;P&gt;b)&amp;nbsp; Findings from an observational cohort study [5] examining concordance among clinicians reviewing 3 Heidelberg retina tomography (HRT) printouts used to detect progression, the Moorfields regression analysis (MRA), the TCA, and trend analysis (TA), and comparisons with progression identified by stereophotographs, reported poor agreement between progression identified by HRT and masked stereophotograph assessment . These results suggest that assessment of the HRT and stereophotography may be identifying different aspects of structural change.&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;References &lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;1. Sultan, M. B., S. L. Mansberger, and P. P. Lee. Understanding the importance of IOP variables in glaucoma: a systematic review. Survey of Ophthalmology. 2009; 54(6):643-62. Epub ahead of print Aug 8 2009. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19665744" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19665744&lt;/A&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. Singh, K. and A. Shrivastava. Intraocular pressure fluctuations: how much do they matter? Current Opinion in Ophthalmology 2009;20(2):84-87&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19248311" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19248311&lt;/A&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;3. Chang, R. T. and D. L. Budenz. Diagnosing glaucoma progression. International Ophthalmology Clinics 2008; 48(4):13-28 &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18936634" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18936634&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;4. Chauhan, B. C., et al. Optic disc progression in glaucoma: comparison of confocal scanning laser tomography to optic disc photographs in a prospective study. Investigative Ophthalmology &amp;amp; Visual Science 2009; 50(4):1682-91.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19060290" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19060290&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;5. Vizzeri, G., et al. Clinicians agreement in establishing glaucomatous progression using the Heidelberg retina tomograph. Ophthalmology 2009;116(1):14-24.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19010552" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19010552&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329711:2" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Monitoring - Evidence Tree&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Monitoring - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc8.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_summaries/MonitoringSearchSummary.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673&amp;amp;pgID=1" target="_blank"&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;AEU searches:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PubMed; EMBASE 1996 to date ; CINAHL 1981 to date ; AMED 1985 to date; BNI 1985 to date; NHS Evidence - eyes and vision.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline 1996 to date; EMBASE 1996 to date ; CINAHL 1981 to date; AMED 1985 to date; PsycInfo 2002 to date; The Cochrane Library.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt;&amp;nbsp;January 2008 to 7th October 2009&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;AEU searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;OvidSP (Athens Account required)&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;IMG style="WIDTH: 648px; HEIGHT: 350px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Monitoring Evidence Tree - Glaucoma AEU 2009" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329711/nelhImp_0000_aeu_TT_Mon.jpg" width=689 height=364&gt;&lt;/P&gt;
&lt;H3 align=left&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3 align=left&gt;Search Strategy:&lt;BR&gt;&lt;/H3&gt;
&lt;P&gt;AEU searches:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/VisualFieldProgression.pdf" target="_blank"&gt;Visual Field Progression&lt;/A&gt; search strategy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NICE Guideline searches:&lt;BR&gt;See Appendix C: Search Strategies of the 2009 NICE guidance. &lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG85FullGuidelineAppendices.pdf" target="_blank"&gt;CG85 Glaucoma: full guideline appendices&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/GlaucomaAEU2009_JournalSpread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329711:1" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Monitoring Topic Summary&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>329744</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329744]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Provision of information for patients</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,GLAUCOMA,ANNUAL EVIDENCE UPDATES,CONDITIONS,GLAUCOMA AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Provision of information for patients - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/articles/PatientEducation.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673&amp;amp;pgID=1" target="_blank"&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Provision of information for patients&lt;/H2&gt;
&lt;H3&gt;&lt;BR&gt;Mary Freeman (RGN, OND, MBA, MA), Consultant Nurse in Ophthalmology Sheffield Teaching Hospitals NHS Foundation Trust&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Summary of NICE recommendations for provision of information for patients&lt;/H2&gt;
&lt;P&gt;NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;http://guidance.nice.org.uk/CG85&lt;/A&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;See chapter ‘Provision of information for patients’, p.243.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;The provision of information to patients regarding their clinical condition and its management is an integral aspect of their care. This is particularly important in the management of ocular hypertension (OHT)&amp;nbsp;and glaucoma because patients are in the main, asymptomatic and require life long topical therapy to control progression or to minimise risk of developing chronic open angle glaucoma (COAG). &lt;/P&gt;
&lt;P&gt;Not only does improved understanding and involvement reduce stress and uncertainty but it is also thought to potentially improve adherence to medication and monitoring appointments, thus minimising the risk of sight loss.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Recommendations&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;"Offer people the opportunity to discuss their diagnosis, prognosis and treatment; and provide them with relevant information in an accessible format at initial and subsequent visits. This may include information on the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;their specific condition (OHT, suspected COAG and COAG), its life-long implications and their prognosis for retention of sight&lt;/LI&gt;
&lt;LI&gt;that COAG in the early stages and OHT and suspected COAG are symptomless&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;that most people treated for COAG will not go blind&lt;/LI&gt;
&lt;LI&gt;that once lost, sight cannot be recovered&lt;/LI&gt;
&lt;LI&gt;that glaucoma can run in families and that family members may wish to be tested for the disease&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;the importance of the person’s role in their own treatment – for example, the ongoing regular application of eye drops to preserve sight&lt;/LI&gt;
&lt;LI&gt;the different types of treatment options, including mode of action, frequency and severity of side effects, and risks and benefits of treatment, so that people are able to be active in the decision-making process&lt;/LI&gt;
&lt;LI&gt;how to apply eye drops, including technique (punctal occlusion and devices) and hygiene (storage)&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;the need for regular monitoring as specified by the healthcare professional&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;methods of investigations during assessment&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;how long each appointment is likely to take and whether the person will need any help to attend (for example, driving soon after pupil dilatation would be inadvisable)&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;support groups&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;compliance aids (such as dispensers) available from their GP or community pharmacist&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Letter of Vision Impairment (LVI), Referral of Vision Impaired Patient (RVI) and Certificate of Vision Impairment (CVI) registration&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Driver and Vehicle Licensing Agency (DVLA) regulations."&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;EM&gt;Section 11.2. Summary of recommendations on provision of information for patients. p245. NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;/EM&gt;&lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;&lt;EM&gt;http://guidance.nice.org.uk/CG85&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; Reproduced with permission from NICE.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Summary of New Evidence&lt;BR&gt;&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;A review of new evidence relating to the effects of interventions on adherence to topical therapy was revisited since the publication of the NICE glaucoma guidelines. This revealed several observational studies with limitations that reduce the quality of the evidence.&amp;nbsp; One intervention review [1], which included 8 studies, unfortunately all of short duration, examined the effect of an educational and “tailored” programme, reminder devices and drug comparisons of varying dosage frequencies. Whilst recommendation of a particular intervention is not possible due to limited methodological quality, there is some evidence to support the notion that educational programmes can improve adherence to therapy. Reminder devices may also be effective [1, 2, 3], and there is evidence that simplifying drop regimes can also be beneficial [1, 2, 3].&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In other studies, barriers to adherence with glaucoma medications were explored [3, 4]. Again, a tailored approach to patient education was felt to improve motivation for adherence, particularly at point of diagnosis and during the initial consultations, both to ease anxiety and develop good drop application techniques. Whilst these observational studies also had limitations, the importance of the patient’s ability in understanding the consequences of poor adherence in relation to disease progression was identified. Fear of possible long-term side effects and lack of feedback relating to drop efficacy was found to be a possible de motivator in using glaucoma therapy. Studies suggested that remembering to instil drops may be linked to routine and a reliance on regular daily events appeared important in triggering memory and improving adherence. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Practical aspects relating to instillation may be more of a concern for the “older” patient, where co morbidity associated with age, may compound the problem [3, 4]. Problems associated with drop instillation, however may also be a concern for the younger patient [5, 6] and there was some evidence that non- adherence is higher in this group [3].&amp;nbsp; Educational programmes that offer solutions in overcoming&amp;nbsp; barriers/problems relating to age, individual differences and lifestyle may be a way of reducing non-adherence to therapy [3,4,7]. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Interestingly, not all studies reviewed, found a direct correlation between level of knowledge about glaucoma and its treatment, [8] although many agree that a focus on discipline and aids to improving memory, adds value [3,4,8]. Longer duration studies are needed for reliable conclusions to be drawn with regard to this area. Whilst non-adherence may be higher in non- white population [5], it is unclear as to why ethnicity is a factor in adherence. This however is an important consideration when targeting educational programmes as the disease in the black population is often more advanced at diagnosis and more aggressive in its progression than in the white. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Several studies have also identified reduced adherence when living alone and this may also place more emphasis on education that supports improving instillation techniques [2, 6]. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Persistence may be influenced by ocular side effects of topical therapy experienced by patients [9] and one cohort study [10] suggests that as the number of separate glaucoma therapies, increases, patient persistence decreases.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;1. Gray TA, Orton LC, Henson D, Harper R, Waterman H. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD006132. DOI: 10.1002/14651858.CD006132.pub2. &lt;BR&gt;&lt;A href="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006132/frame.html" target="_blank"&gt;http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006132/frame.html&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. Djafari F; Lesk MR; Harasymowycz PJ; Desjardins D; Lachaine J.&amp;nbsp; Determinants of adherence to glaucoma medical therapy in a long-term patient population. Journal of Glaucoma 2009;18(3):238-243 &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19295380" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19295380&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;3. Olthoff CM; Hoevenaars JG; Van den Borne BW; Webers CA; Schouten JS. Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients. Graefe's archive for clinical and experimental ophthalmology 2009;247(2):235-243&amp;nbsp; &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18802720" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18802720&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;4. Lacey J;Cate H;Broadway DC. Barriers to adherence with glaucoma medications: A qualitative research study. Eye 2009;23(4):924-932&amp;nbsp; &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18437182" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/18437182&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;5. Sleath B; Ballinger R; Covert D; Robin AL; Byrd JE; Tudor G. Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients. American Journal of Geriatric Pharmacotherapy April 2009;7(2):67-73&amp;nbsp;&amp;nbsp; &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19447359" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/19447359&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;6. Sleath BL;Krishnadas R;Cho M;Robin AL;Mehta R;Covert D;Tudor G. Patient-reported barriers to glaucoma medication access, use, and adherence in southern India. Indian Journal of Ophthalmology Jan -Feb 2009; 57(1):63-68 &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19075417" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19075417&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;7. Schwartz GF;Quigley HA. Adherence and persistence with glaucoma therapy. Survey of Ophthalmology 2008: 53 (6 suppl): S57-68&amp;nbsp;&amp;nbsp; &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19038625" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/19038625&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;8. Hoevenaars JG;Schouten JS;van den Borne B;Beckers HJ;Webers CA. Will improvement of knowledge lead to improvement of compliance with glaucoma medication? Acta Ophthalmologica 2008;86(8):849-855 &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18507734" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18507734&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;9. Zimmerman TJ;Hahn SR;Gelb L;Tan H;Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Journal of Ocular Pharmacology and Therapeutics 2009; 25(2):145-142&amp;nbsp; &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19284321" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19284321&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;10. Higginbotham EJ, HansenJ; Davis EJ, Walt JG, Guckian A. Glaucoma medication persistence with a fixed combination versus multiple bottles. Current Medical Research and Opinion. 2009;25(10):2543-7 &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19731993" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19731993&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329744:2" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Patient Information &amp;nbsp;Evidence Tree&lt;/A&gt;&lt;A href="nelh:329715:2" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Provision of information for patients - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc10.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_summaries/PatientInformatioSearchSummary.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673&amp;amp;pgID=1" target="_blank"&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;AEU searches:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PubMed; EMBASE 1996 to date ; CINAHL 1981 to date ; AMED 1985 to date; BNI 1985 to date; NHS Evidence - eyes and vision.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline 1996 to date; EMBASE 1996 to date ; CINAHL 1981 to date; AMED 1985 to date; PsycInfo 2002 to date; The Cochrane Library.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of search:&lt;/STRONG&gt;&amp;nbsp;January 2008 to 7th October 2009&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;AEU searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;OvidSP (Athens Account required)&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Patient Information Evidence Tree - Glaucoma AEU 2009" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329744/nelhImp_0000_aeu_TT_PatInfo.jpg" width=656 height=332&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Search Strategy:&lt;BR&gt;&lt;/H3&gt;
&lt;P&gt;AEU searches:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/PatientEducation.pdf" target="_blank"&gt;Patient Education&lt;/A&gt;&amp;nbsp;search strategy&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/LivingWithSearchHistory.pdf" target="_blank"&gt;Living with Glaucoma&lt;/A&gt; search strategy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NICE Guideline searches:&lt;BR&gt;See Appendix C: Search Strategies of the 2009 NICE guidance. &lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG85FullGuidelineAppendices.pdf" target="_blank"&gt;CG85 Glaucoma: full guideline appendices&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/GlaucomaAEU2009_JournalSpread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;&lt;A href="nelh:329744:1" name=internalLink&gt;
&lt;P align=right&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Patient Information&amp;nbsp;-&amp;nbsp;Topic Summary&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>329678</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329678]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Service Provision</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,GLAUCOMA,ANNUAL EVIDENCE UPDATES,CONDITIONS,GLAUCOMA AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Service Provision - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/articles/ServiceProvision.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;A href="nelh:329673:1" name=internalLink&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;H2&gt;Service Provision&lt;/H2&gt;
&lt;H2&gt;Paul GD Spry. PhD BSc(Hons) MCOptom DipGlauc&lt;BR&gt;Consultant Hospital Optometrist, Bristol Eye Hospital&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Summary of NICE Guideline recommendations on Service Provision.&lt;/H2&gt;
&lt;P&gt;NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;http://guidance.nice.org.uk/CG85&lt;/A&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;See chapter 10 ‘Service Provision’, p.220.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;1.&amp;nbsp; Refer people with suspected optic nerve damage or repeatable visual field defect, or both, to a consultant ophthalmologist for consideration of a definitive diagnosis and formulation of a management plan.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2.&amp;nbsp; Diagnosis of ocular hypertension (OHT) and suspected chronic open angle glaucoma (COAG) and formulation of a management plan should be made by a suitably trained healthcare professional with: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;a specialist qualification (when not working under the supervision of a consultant ophthalmologist) and &lt;/LI&gt;
&lt;LI&gt;relevant experience.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;3.&amp;nbsp; Healthcare professionals involved in the diagnosis of OHT and COAG suspect status and preliminary identification of COAG should be trained in case detection and referral refinement and be able to identify abnormalities based on relevant clinical tests and assessments. They should understand the principles of diagnosis of OHT and COAG and be able to perform and interpret all of the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;medical and ocular history&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;differential diagnosis&lt;/LI&gt;
&lt;LI&gt;Goldmann applanation tonometry (slit lamp mounted)&lt;/LI&gt;
&lt;LI&gt;standard automated perimetry (central thresholding test)&lt;/LI&gt;
&lt;LI&gt;central supra-threshold perimetry&lt;/LI&gt;
&lt;LI&gt;stereoscopic slit lamp biomicroscopic examination of anterior segment&lt;/LI&gt;
&lt;LI&gt;examination of the posterior segment using a slit lamp binocular indirect ophthalmoscopy&lt;/LI&gt;
&lt;LI&gt;gonioscopy&lt;/LI&gt;
&lt;LI&gt;Van Herick’s peripheral anterior chamber depth assessment&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;CCT measurement.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;4.&amp;nbsp; People with a diagnosis of OHT, suspected COAG or COAG should be monitored and treated by a trained healthcare professional who has all of the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;a specialist qualification (when not working under the supervision of a consultant ophthalmologist)&lt;/LI&gt;
&lt;LI&gt;relevant experience&lt;/LI&gt;
&lt;LI&gt;ability to detect a change in clinical status.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;5.&amp;nbsp; Healthcare professionals involved in the monitoring and treatment of people with OHT, suspected COAG and established COAG should be trained to make management decisions on all of the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;risk factors for conversion to COAG&lt;/LI&gt;
&lt;LI&gt;coexisting pathology&lt;/LI&gt;
&lt;LI&gt;risk of sight loss&lt;/LI&gt;
&lt;LI&gt;monitoring and clinical status change detection (for example, visual field changes, stereoscopic slit lamp biomicroscopic examination of anterior segment and posterior segment)&lt;/LI&gt;
&lt;LI&gt;pharmacology of IOP-lowering medications&lt;/LI&gt;
&lt;LI&gt;treatment changes for COAG, COAG suspect status and OHT (with consideration given to relevant contraindications and interactions).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;6.&amp;nbsp; People with a confirmed diagnosis of OHT or suspected COAG and who have an established management plan may be monitored (but not treated) by a suitably trained healthcare professional with knowledge of OHT and COAG, relevant experience and ability to detect a change in clinical status. The healthcare professional should be able to perform and interpret all of the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Goldmann applanation tonometry (slit lamp mounted)&lt;/LI&gt;
&lt;LI&gt;standard automated perimetry (central thresholding test)&lt;/LI&gt;
&lt;LI&gt;central supra-threshold perimetry (this visual field strategy may be used to monitor people with OHT or COAG suspect status when they have normal visual field)&lt;/LI&gt;
&lt;LI&gt;stereoscopic slit lamp biomicroscopic examination of the anterior segment&lt;/LI&gt;
&lt;LI&gt;Van Herick’s peripheral anterior chamber depth assessment&lt;/LI&gt;
&lt;LI&gt;examination of the posterior segment using slit lamp binocular indirect ophthalmoscopy.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;7.&amp;nbsp; Healthcare professionals who diagnose, treat or monitor people independently of consultant ophthalmologist supervision should take full responsibility for the care they provide.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Also, the guideline development group (GDG) made the following research recommendation, “In people identified on primary examination as exhibiting possible COAG, OHT of suspected COAG, what is the comparative effectiveness of diagnosis by different healthcare professions?”&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&lt;BR&gt;Summary of New Evidence&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;Although a small number of new studies were identified as related to the topic organisation of care, their relevance to care pathways employed in England and Wales for people with COAG, OHT or COAG suspect status was limited to issues surrounding referral [1 and 2] and as such were outside the scope if the guideline. &lt;BR&gt;No new evidence of any quality level was identified on diagnosis, monitoring or treatment by non-medical healthcare professionals (HCPs), or different grade of medically trained HCPs. No new information on the impact of training or specialist qualification amongst non-medical healthcare professionals on any of these areas of clinical practice was available.&lt;BR&gt;&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Conclusion&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;Data available on diagnosis, treatment and monitoring of patient groups covered by the NICE glaucoma guideline remains scant and limited to a small number of older observational studies and one randomised controlled trial. The research recommendation, stated above, made by the GDG at the time of NICE guideline publication remains a highly appropriate subject for further research. [See the UK DUETs module for more information].&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Additionally, gaps in the evidence exist regarding relative effectiveness of different healthcare professions (ophthalmologists, optometrists, orthoptists and ophthalmic nurses) in monitoring and treating patients would inform future guideline updates. In particular, information on diagnosis, treatment and monitoring, analysed by different levels of training and experience both within and between professions and also by case mix, may substantially impact of future models of care and so would be informative.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;A further subject of increasing relevance to glaucoma care provision not present when the guideline was published concerns non-medical independent prescribing for appropriate glaucoma patients. Information on relative clinical effectiveness of new classes of non-medical independent prescribing HCP (optometrists, ophthalmic nurses) is therefore sought. &lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;References&lt;BR&gt;&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;1.&amp;nbsp; Bourne RR, French KA, Chang L, Borman AD, Hingorani M, Newsom WD. Can a community optometrist-based referral refinement scheme reduce false-positive glaucoma hospital referrals without compromising quality of care? The community and hospital allied network glaucoma evaluation scheme (CHANGES). Eye 2009 Jul 31. [Epub ahead of print]&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19648892" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19648892&lt;/A&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2.&amp;nbsp; Pierscionek TJ, Moore JE, Pierscionek BK. Referrals to ophthalmology: optometric and general practice comparison. Ophthalmic &amp;amp; Physiological Optics. 2009 Jan;29(1):32-40.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19154278" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19154278&lt;EM&gt;&lt;/EM&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329678:2" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma - Service Provision Evidence Tree&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Service Provision - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc11.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_summaries/ServiceProvisionSearchSummary.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline 1996 to date; EMBASE 1996 to date ; CINAHL 1981 to date; AMED 1985 to date; PsycInfo 2002 to date; The Cochrane Library.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt;&amp;nbsp;January 2008 to 7th October 2009&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;OvidSP (Athens Account required)&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 647px; HEIGHT: 345px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Service Provision Evidence Tree - Glaucoma AEU 2009" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329678/nelhImp_0000_aeu_TT_SerPro.jpg" width=689 height=364&gt;&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;Search Strategy:&lt;/H3&gt;
&lt;P&gt;NICE Guideline searches:&lt;BR&gt;See Appendix C: Search Strategies of the 2009 NICE guidance. &lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG85FullGuidelineAppendices.pdf" target="_blank"&gt;CG85 Glaucoma: full guideline appendices&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/GlaucomaAEU2009_JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329678:1" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Service Provision&amp;nbsp;-&amp;nbsp;Topic Summary&lt;/A&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;/P&gt;
&lt;P align=right&gt;Back to contents page&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>329715</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329715]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Treatment - Pharmacological</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,GLAUCOMA AEU 2009,CONDITIONS,ANNUAL EVIDENCE UPDATES,GLAUCOMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Treatment - Pharmacological - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc7.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/articles/TreatmentPharmacological.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673&amp;amp;pgID=1" target="_blank"&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Pharmacological Treatment of Ocular Hypertension, Suspected Glaucoma and Chronic Open Angle Glaucoma.&lt;/H2&gt;
&lt;H3&gt;Ms Cecilia Fenerty Consultant Ophthalmologist, Manchester Royal Eye Hospital&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H2&gt;Summary of NICE Guideline recommendations:&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;http://guidance.nice.org.uk/CG85&lt;/A&gt; &lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;See chapter 6 ‘Overview of treatment’, p.110; &lt;/LI&gt;
&lt;LI&gt;chapter 7 ‘Treatment of ocular hypertension and suspected chronic open angle glaucoma’, p.115; and&lt;/LI&gt;
&lt;LI&gt;chapter 8 ‘Treatment of chronic open angle glaucoma’, p.158.&lt;BR&gt;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;OL style="MARGIN-RIGHT: 0px"&gt;
&lt;LI&gt;&lt;STRONG&gt;Treatment algorithms&lt;/STRONG&gt; for COAG, ocular hypertension and suspected glaucoma are presented to inform management.&amp;nbsp; Published clinical and economic evidence on: treatment efficacy, treatment side effects and complications, and risk of disease progression in a patient’s lifetime with or without treatment, were considered in designing these algorithms.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Relevant &lt;STRONG&gt;co-morbidities and potential drug interactions&lt;/STRONG&gt; should be checked for each patient, before initiating medical therapy.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Target IOP&lt;/STRONG&gt; - since all available medications act by reducing intra-ocular pressure (IOP), the guideline recognises the concept of establishing a target IOP when treating patients.&amp;nbsp; Target IOP is defined in the guidance as ‘a clinically judged IOP considered to be sufficiently low to minimise or arrest disease progression or onset, and avoid disability from sight loss within a patient’s life-time’. It is recommended that all patients should have their adherence to treatment, and drop instillation technique checked, especially when the target IOP is not achieved after initiating medical therapy.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;&lt;STRONG&gt;Ocular Hypertension (OHT) or suspected glaucoma&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treatment of every patient with OHT or suspected glaucoma was not found to be cost effective in preventing visual loss. Treatment was therefore recommended for certain higher risk OHT subgroups assessed by three risk factors; the age of the patient, the untreated IOP and the central corneal thickness.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Evidence was considered comparing the effectiveness of different pharmacological agents and economic consideration given to the cost of these treatments and costs related to adverse events arising from treatment. Certain subgroups of OHT patients are recommended to receive beta-blockers as first line treatment assuming there are no contraindications. Other sub-groups of OHT patients (and those who have contraindications to beta-blockers) are recommended to receive prostaglandin analogues.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Patients recommended for treatment were found to be at minimal risk of progression on reaching certain age thresholds, and NICE guidance then recommends that cessation of treatment is considered for these age groups.&amp;nbsp;&amp;nbsp;&amp;nbsp; This represents new evidence, previously not available.&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;OHT pathway (monitoring and treatment for people with OHT and people with suspected COAG who have high IOP):&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 610px; HEIGHT: 194px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="OHT Pathway (extract from NICE Guidance CG85)" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329715/nelhImp_0002_NICEGlaucomaAlgorithmTreatmentPharmacological.JPG" width=622 height=205&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Extract from Algorithm 2 – OHT Pathway (OHT and COAG suspects ith high IOP), p.66. NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;/EM&gt;&lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;&lt;EM&gt;http://guidance.nice.org.uk/CG85&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; Reproduced with permission from NICE.&lt;/EM&gt;&lt;/P&gt;
&lt;BLOCKQUOTE style="MARGIN-RIGHT: 0px" dir=ltr&gt;
&lt;P&gt;Beta-blockers are more cost effective than prostaglandin analogues treating patients with IOP&amp;gt;25 – 32 mmHg and CCT 555- 590microns until the age of 60years. Prostaglandin analogues are more cost effective than beta-blockers in treating patients with IOP &amp;gt; 21 – 25mmHg and CCT&amp;lt;555 microns until the age of 65 years, and in patients with IOP &amp;gt; 25 – 32mmHg and CCT &amp;lt;555 microns until the age of 80 years. &lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;UL&gt;
&lt;LI&gt;Patients with IOP &amp;gt; 32mmHg are recommended for treatment with prostaglandin analogues at any age and with any corneal measurement.Patients with suspected glaucoma but with normal IOP, or OHT patients with risk factors outside the parameters described above, are not recommended for treatment.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;&lt;STRONG&gt;Established COAG&lt;/STRONG&gt;&amp;nbsp;- these patients are recommended to receive treatment based on the extent of visual field loss using a modified Hodapp classification available in the NICE document.&lt;BR&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;P&gt;Those with early to moderate visual field loss, and at risk of developing significant visual loss in their lifetime, should be treated with a prostaglandin analogue.&lt;BR&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Those with advanced visual loss should be offered surgery, although a prostaglandin analogue should be offered as interim therapy.&lt;BR&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;If any patient prefers to avoid surgery, or if they are unsuitable for surgery, they may continue on this medical therapy, assuming it is effective.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;
&lt;P&gt;All patients with OHT or COAG recommended for treatment in the guideline may be offered alternative medical therapy if they are intolerant to the medications recommended as first choice. Furthermore those patients who fail to achieve their target IOP with the first choice medication may be offered alternative medical therapy, and it is recognised that more than one agent may be required under these circumstances.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;P&gt;Those patients with COAG who are intolerant to medications, or those who do not achieve their target IOP, should be offered surgery after trying two alternative pharmacological agents. Economic analysis has determined that preservative-free preparations should only be offered to those patients with an allergy to preservatives if they have OHT with high risk of converting to COAG, or indeed established COAG.&amp;nbsp; &lt;/P&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;H2&gt;&lt;BR&gt;Summary of New Evidence &lt;BR&gt;&lt;BR&gt;&lt;/H2&gt;
&lt;H3&gt;Prostaglandin Analogues-&lt;BR&gt;&lt;/H3&gt;
&lt;P&gt;NICE guidance did not seek to compare efficacy of medications within the same drug classification. The following publications compare the efficacy and tolerability of the three prostaglandin analogues available at the time of publication. On balance there appears to be little difference in efficacy between these agents although travoprost and bimatoprost may be associated with higher rates of hyperaemia than latanoprost. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;Secondary Publications:&lt;/EM&gt;&lt;/P&gt;&lt;EM&gt;&lt;/EM&gt;
&lt;P&gt;&lt;BR&gt;[1], [2], [3], [4], and [5]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The above publications represent systematic reviews and meta- analyses, however many interventional publications regarding prostaglandin analogues and other medications are published every year. These studies are often expensive to perform are therefore frequently funded by the pharmaceutical companies who manufacture these drugs. We are reminded that careful scrutiny of the results of these studies is recommended to ensure they support the authors’ conclusions.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;EM&gt;Observational Study:&lt;/EM&gt;&lt;/P&gt;&lt;EM&gt;
&lt;P&gt;&lt;BR&gt;&lt;/EM&gt;[6]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;At the time of publication of the NICE glaucoma guidance only three prostaglandin analogues were available; latanoprost, travaprost and bimatoprost. None of these medications were available in preservative-free formulation. However since then a new prostaglandin, tafluprost, has been licensed for use and preservative free preparation is also available.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Interventional study:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;[7]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Combination Therapy:&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;Nice guidance mainly focussed on initial treatment of ocular hypertension and COAG. Although the guidance acknowledges that more than one medication may be required to achieve the target IOP, the efficacy of medications used&amp;nbsp;to&amp;nbsp;supplement the first choice recommended therapies has not been addressed. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;BR&gt;Secondary Publications:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;[8] and [9]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Interventional Study:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;[10]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Side effects:&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;&lt;/STRONG&gt;The visible side effects of prostaglandin analogues (e.g. hyperaemia and pigmentary changes to the iris) are well known, but the significance of changes to the corneal thickness not been clear. The Ocular Hypertension Treatment Study now provides evidence that over a 4 year period these changes may be so small as not to have significant effect on IOP measurement.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;Observational Study:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;[11]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Long term effects&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In choosing appropriate therapies side effects and tolerability are important and have implications for patient adherence and persistence with therapy. The following publications address these issues. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;Observational Studies:&lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;[12], [13], [14], and [15]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;New treatment modalities for glaucoma and novel drug delivery systems.&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Further studies will be required before these translate into licensed therapeutic options, but these may be options for the treatment of glaucoma in the future:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;Interventional Studies:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;[10], [16] and [17]&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&lt;BR&gt;References:&lt;BR&gt;&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;1. Cheng J, Wei R. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clinical Therapeutics 2008;30(4):622-33.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18498911" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/18498911&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. Journal of Glaucoma 2008 Dec;17(8):667-73.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19092464" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19092464&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;3. Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee CW, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clinical Ophthalmology 2009;3:447-56.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19684868" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19684868&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;4. Honrubia F, Garcia-Sanchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. British Journal of Ophthalmology 2009 Mar;93(3):316-21.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19019922" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19019922&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;5. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Survey of Ophthalmology 2008 Nov;53 Suppl1:S69-S84.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19038626" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19038626&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;6. Alasbali T, Smith M, Geffen N, Trope GE, Flanagan JG, Jin Y, et al. Discrepancy between results and abstract conclusions in industry- vs nonindustry-funded studies comparing topical prostaglandins. American Journal of Ophthalmology 2009 Jan;147(1):33-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18760766" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18760766&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;7. Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.[see comment]. Acta ophthalmologica Supplement 2008;242:14-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18752510" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18752510&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;8. Cheng JW, Li Y, Wei RL. Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost. Ophthalmic Research 2009 Jun 23;42(2):99-105.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19546601" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19546601&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;9. Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs &amp;amp; Aging 2008;25(9):729-59.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18729546" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18729546&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;10. Denis P, Lafuma A, Berdeaux G. Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database. Clinical Ophthalmology 2008;2(2):321-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19668723" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19668723&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;11. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA, et al. Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology 1556;115(9):1550-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18378313" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/18378313&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;12. Lafuma A, Berdeaux G. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database. Current Medical Research and Opinion 2008;24(5):1519-27.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18413015" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18413015&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;13. Lafuma A, Laurendeau C, Berdeaux G. Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database. Journal of medical economics 2008;11(3):485-97.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19450100" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19450100&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;14. Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. Journal of Ocular Pharmacology and Therapeutics 2009 Apr;25(2):145-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19284321" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19284321&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;15. Rahman MQ, Montgomery DM, Lazaridou MN. Surveillance of Glaucoma Medical Therapy in a Glasgow Teaching Hospital: 26 Years Experience. British Journal of Ophthalmology 2009 Sep 24. [Epub ahead of print]&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19628493" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19628493&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;16. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a Potential Ophthalmic Delivery System for Dorzolamide Hydrochloride. AAPS PharmSciTech 2009;10(3):808-19.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19536653" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19536653&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;17. Robin AL, Clark AF, Covert DW, Krueger S, Bergamini MV, Landry TA, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. American Journal of Ophthalmology 2009 Jan;147(1):45-50.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18789793" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18789793&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329715:2" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Pharmacological Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Treatment - Pharmacological - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc13.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_summaries/TreatmentPharmacologicalSearchSummary.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673&amp;amp;pgID=1" target="_blank"&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;AEU searches:&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PubMed; EMBASE 1996 to date ; CINAHL 1981 to date ; AMED 1985 to date; BNI 1985 to date; NHS Evidence - eyes and vision.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline 1996 to date; EMBASE 1996 to date ; CINAHL 1981 to date; AMED 1985 to date; PsycInfo 2002 to date; The Cochrane Library.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt;&amp;nbsp;January 2008 to 7th October 2009&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;AEU searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;OvidSP (Athens Account required)&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Treatment - Pharmacological - Evidence Tree - Glaucoma AEU 2009" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329715/nelhImp_0003_aeu_TT_Treat.jpg" width=797 height=252&gt;&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;Search Strategy:&lt;BR&gt;&lt;/H3&gt;
&lt;P&gt;AEU search:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_history/MedicalManagement.pdf" target="_blank"&gt;Medical Management&lt;/A&gt;&amp;nbsp;search strategy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NICE Guideline searches:&lt;BR&gt;See Appendix C: Search Strategies of the 2009 NICE guidance. &lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG85FullGuidelineAppendices.pdf" target="_blank"&gt;CG85 Glaucoma: full guideline appendices&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/GlaucomaAEU2009_JournalSpread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329715:1" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Treatment Pharmacological -&amp;nbsp;Topic Summary&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>329738</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329738]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Treatment - Surgical and Laser</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SURGERY,SURGERY,GLAUCOMA,HEAD &amp; NECK,EYE,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Treatment - Surgical and Laser - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc5.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/articles/TreatmentSurgicalLaser.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673&amp;amp;pgID=1" target="_blank"&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Surgical and laser treatment of chronic open angle glaucoma&lt;/H2&gt;
&lt;H3&gt;Wendy Franks, Consultant Ophthalmologist, Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust&lt;/H3&gt;
&lt;H2&gt;&lt;BR&gt;&lt;BR&gt;Summary of NICE recommendations for laser and surgical interventions for glaucoma:&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NICE guidance CG85: Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension, April 2009. &lt;A href="http://guidance.nice.org.uk/CG85" target="_blank"&gt;http://guidance.nice.org.uk/CG85&lt;/A&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;See chapter 6 ‘Overview of treatment’, p.110 and &lt;/LI&gt;
&lt;LI&gt;chapter 8 ‘Treatment of chronic open angle glaucoma’, p.158.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Surgical interventions:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In the guideline the penetrating surgical procedure under consideration was trabeculectomy, and the non-penetrating surgical procedures were deep sclerectomy and viscocanalostomy.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Offer surgery where two medications have failed to control IOP and/or visual field loss and there is a risk of progression to blindness.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Surgical intervention is cost effective for advanced glaucoma therefore offer surgery for advanced disease at presentation ( &amp;gt;12dB visual field loss by Humphrey 24/2 perimetry).&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Offer treatment for advanced disease with a prostaglandin agonist whilst awaiting surgery for advanced glaucoma.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;If trabeculectomy surgery is undertaken adjunctive antiproliferative treatment should be offered.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Laser trabeculoplasty:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The laser treatments under consideration in the guideline were argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT).&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No studies were identified of sufficient quality to compare prostaglandin agonists and laser trabeculoplasty as primary treatment.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;No evidence was identified to show a difference in effect on IOP lowering or visual field loss between selective laser trabeculoplasty and argon laser trabeculoplasty.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Laser trabeculoplasty may be offered to if medical treatment is unsuccessful and if surgical treatment is declined.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;There was no evidence of the superiority of either ALT or SLT and no evidence of an improved outcome by repeat treatments by SLT compared to ALT. Trabeculectomy lowers IOP more than deep sclerectomy or viscocanalostomy but there is a higher incidence of complications with trabeculectomy surgery. Where trabeculectomy is the procedure chosen, there is evidence that per-operative adjunctive 5 fluorouracil and mitomycin achieve lower IOP's but at the expense of a higher risk of complications.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&lt;BR&gt;Summary of new evidence: &lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;BR&gt;Systematic reviews and secondary studies:&lt;/EM&gt;&lt;/STRONG&gt; three systematic reviews of interest were identified.&lt;/P&gt;
&lt;P&gt;A Cochrane review of beta irradiation as an adjunct to trabeculectomy surgery in a total of 551 eyes found that use of beta irradiation compared to no irradiation was associated with lower IOP but a higher risk of cataract. Beta irradiation is not available in the UK apart from two specialist centres and its use was not considered in the guidance. The studies did not compare beta irradiation to pharmacological antiproliferative agents. No change in the guidance is recommended on the basis of the review. [1].&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Non penetrating glaucoma surgery with mitomycin C was compared to trabeculectomy with mitomycin C in a total of 459 eyes. IOP lowering was superior in eyes undergoing trabeculectomy but there were fewer complications with non-penetrating surgery. Visual field loss was not compared.&amp;nbsp; This adds to the evidence given in the guidance but does not alter it and the choice of surgical technique is for agreement between the surgeon and the patient. [2]&lt;/P&gt;
&lt;P&gt;A review of non penetrating glaucoma surgery with and without collagen implant failed to show superior IOP lowering in either group. [3]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies:&lt;/EM&gt;&lt;/STRONG&gt; six were identified and their results support the guidance.&lt;/P&gt;
&lt;P&gt;The Collaborative Initial Glaucoma Treatment Study ( CIGTS)&amp;nbsp; enrolled 607 patients and reported on visual field and optic disc outcomes in eyes treated with initial medical or initial surgical therapy. After eight years follow up progression of &amp;gt;3 decibels of visual field loss occurred in 21.3% of the surgical group and 25.8% of the medicine group. Less visual field loss occurred in those with advanced disease at presentation in the surgery group and the authors conclude that surgery is superior for advanced disease at presentation except for patients with diabetes. [4]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Disc progression was assessed after five years of follow up in 382 eyes. Disc progression occurred in 10% of the group treated initially with medical therapy and 3% of those treated with initial surgery. The NICE recommendation of offering surgery to those presenting with advanced disease is unchanged. [5]&lt;/P&gt;
&lt;P&gt;A prospective randomised controlled study of a single preoperative application of 5-fluorouracil reported from 228 eyes of 243 enrolled after three years of follow up. No difference in outcome was found in terms of visual field loss and optic disc progression. More eyes achieved an IOP of &amp;lt;17mmHg in the treated group. [6]&lt;/P&gt;
&lt;P&gt;A prospective randomised controlled study of non penetrating glaucoma surgery with implant and mitomycin C versus trabeculectomy with mitomycin C of 93 eyes with a 4 year follow up showed success in terms of IOP lowering in 51% cases of non penetrating surgery compared to 72% for the trabeculectomy surgery eyes. This result does not affect the guidance. Other than failure to lower IOP complications were more common in eyes undergoing trabeculectomy. [7]&lt;/P&gt;
&lt;P&gt;Selective laser trabeculoplasty was compared to prostaglandin agonist therapy in a small randomised controlled study. IOP lowering was superior in the medically treated group. [8]&lt;/P&gt;
&lt;P&gt;A randomised controlled trial of selective laser trabeculoplasty versus argon laser trabeculoplasty showed no difference in IOP lowering at one year. The guidance is unchanged by the outcomes of these studies. [9]&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Case series&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Two large case series have been reported and are of interest. &lt;/P&gt;
&lt;P&gt;Outcomes of 314 cases of viscocanalostomy (VC) over 6 years were reported from two surgeons. Of 174 cases of combined phacoviscocanalostomy 76% had a successful outcome in terms of IOP lowering and of 104 undergoing VC alone 67 % were successful. A small sample had pseudoexfoliative glaucoma and of these 100% of those having phacoviscocanalostomy&amp;nbsp; were successful compared to 63 % undergoing VC alone. Combined surgery was not considered in the guidance but this series suggests that further investigation is warranted to ascertain if VC may have a superior outcome when combined with cataract surgery for eyes with pseudoexfoliation. If supported by randomised controlled studies in the future new guidance as to treatment of co-morbidity of cataract and glaucoma may need to be produced. [10]&lt;/P&gt;
&lt;P&gt;A 21 year follow up of 841 eyes treated under the care of one surgeon showed a probability of a successful outcome in terms of IOP control of 0.96 at one year, 0.83 at 10 years and 0.79 at 20 years. The probability of not being blind at one year was 0.98 and at 10 years 0.83. 50 % of eyes showed visual field progression after 21 years of follow up and 8% needed further surgery. These results are of interest in informing patients about their choice of treatment and the likely outcome. [11]&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;1. Kirwan JF, Rennie C, Evans JR. Beta radiation for glaucoma surgery. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD003433. DOI: 10.1002/14651858.CD003433.pub2.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003433/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003433/frame.html&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. Cheng, J. W., et al. Efficacy and tolerability of nonpenetrating glaucoma surgery augmented with&lt;BR&gt;mitomycin C in treatment of open-angle glaucoma: a meta-analysis. Canadian Journal of Ophthalmology 2009;44(1):76-82.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19169318" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/19169318&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;3. Cheng, J. W., et al. Efficacy and tolerability of nonpenetrating filtering surgery with and without implant in treatment of open angle glaucoma: a quantitative evaluation of the evidence. Journal of Glaucoma 2009;18(3):233-37&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19295379" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/19295379&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;4. Musch, D. C., et al. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology 2009;116(2):200-07.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19019444" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/19019444&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;5. Parrish, R. K., et al. Five-year follow-up optic disc findings of the Collaborative Initial Glaucoma&lt;BR&gt;Treatment Study. American Journal of Ophthalmology 2009;147(4):717-24.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19152871" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/19152871&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;6. Wong, T. T., et al. The Singapore 5-Fluorouracil Trabeculectomy Study. Effects on Intraocular Pressure Control and Disease Progression at 3 Years. Ophthalmology 2009;116(2):175-84.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19187822" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/19187822&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;7. Russo, V., et al. Nonpenetrating deep sclerectomy with reticulated hyaluronic acid implant versus punch trabeculectomy: A prospective clinical trial. European Journal of Ophthalmology 2008; 18(5):751-57.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18850554" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/18850554&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;8. Nagar, M., E. Luhishi, and N. Shah. Intraocular pressure control and fluctuation: The effect of treatment with selective laser trabeculoplasty. British Journal of Ophthalmology 2009;93(4):497-501.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19106150" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/19106150&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;9. Russo, V., et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with uncontrolled open-angle glaucoma. European Journal of Ophthalmology 2009;19(3):429-34.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/19396790" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/19396790&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;10. Wishart, P. K., et al. Long-term results of viscocanalostomy in pseudoexfoliative and primary open angle glaucoma. Clinical &amp;amp; Experimental Ophthalmology 2008;36(2):148-55.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/18352871" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/18352871&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;11. Bevin, T. H., A. C. B. Molteno, and P. Herbison. Otago glaucoma surgery outcome study: Long-term results of 841 trabeculectomies. Clinical and Experimental Ophthalmology 2008;36(8):731-37&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19128377" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19128377&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329738:2" name=internalLink&gt;&lt;A href="nelh:329738:2" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Surgical and Laser Evidence Tree&lt;/A&gt;&lt;A href="nelh:329715:2" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 AEU on Glaucoma - Treatment - Surgical and Laser - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/aeu_glaucoma_1109_doc12.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/search_summaries/TreatmentSurgicalLaserSearchSummary.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Please click here to view 2008 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673" target="_blank"&gt;&lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=329673&amp;amp;pgID=1" target="_blank"&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Medline 1996 to date; EMBASE 1996 to date ; CINAHL 1981 to date; AMED 1985 to date; PsycInfo 2002 to date; The Cochrane Library.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt;&amp;nbsp;January 2008 to 7th October 2009&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NICE Guideline searches:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;OvidSP (Athens Account required)&lt;/LI&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;The Cochrane Library&lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;B&gt;&lt;SPAN style="FONT-FAMILY: Arial; COLOR: black"&gt;&lt;/SPAN&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 836px; HEIGHT: 282px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID329738/nelhImp_0000_aeu_TT_Treat.jpg" width=879 height=302&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Search Strategy:&lt;/H3&gt;
&lt;P&gt;NICE Guideline searches:&lt;BR&gt;See Appendix C: Search Strategies of the 2009 NICE guidance. &lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/CG85FullGuidelineAppendices.pdf" target="_blank"&gt;CG85 Glaucoma: full guideline appendices&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/GlaucomaAEU2009_JournalSpread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329738:1" name=internalLink&gt;2009 Annual Evidence Update on Glaucoma -&amp;nbsp;Treatment&amp;nbsp;Surgical and Laser&amp;nbsp;-&amp;nbsp;Topic Summary&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>329770</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=329770]]&gt;</url>
    <title>2009 Annual Evidence Update on Glaucoma - Uncertainties in the management of glaucoma</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>KNOWN UNCERTAINTY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Glaucoma - Uncertainties in the management of glaucoma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What clinical questions would you like answered on Glaucoma?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision is collaborating in the development of UK DUETs - the UK Database of Uncertainties about the Effects of Treatments.&lt;/P&gt;
&lt;P&gt;DUETs has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp;&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians. &lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments 
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines 
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The following uncertainties have been identified by the DUETs team and NHS Evidence - eyes and vision team.&amp;nbsp;&amp;nbsp; Please note, in order to commence&amp;nbsp;work with&amp;nbsp;the glaucoma DUETs module, we have concentrated&amp;nbsp;on addressing&amp;nbsp;the&amp;nbsp; uncertainties that were identified in the&amp;nbsp;April 2009 NICE guideline on Chronic Open Angle Glaucoma and also&amp;nbsp;those identified in&amp;nbsp;Cochrane systematic reviews. &amp;nbsp;&lt;/STRONG&gt;&lt;STRONG&gt;Over the next few months we will&amp;nbsp;identify other&amp;nbsp;uncertainties&amp;nbsp;relating to glaucoma. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis/Monitoring/Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327504:0" name=internalLink&gt;Screening for prevention of optic nerve damage due to chronic open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327536:0" name=internalLink&gt;What is the clinical and cost effectiveness of different monitoring intervals for detection of disease progression in Chronic Open Angle Glaucoma patients at risk of progression?&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327544:0" name=internalLink&gt;What is the optimal surveillance regime to improve ocular hypertension?&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment - Pharmacological&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327496:0" name=internalLink&gt;Anti-vascular endothelial growth factor for neovascular glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327521:0" name=internalLink&gt;Medical interventions for primary open angle glaucoma and ocular hypertension&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331006:0" name=internalLink&gt;Medical interventions for treating chronic primary angle-closure glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327523:0" name=internalLink&gt;Medical versus surgical interventions for open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment - Surgery &amp;amp; Laser&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327499:0" name=internalLink&gt;Aqueous shunts for glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327505:0" name=internalLink&gt;Beta radiation for glaucoma surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327552:0" name=internalLink&gt;Canaloplasty for primary open-angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327508:0" name=internalLink&gt;Interventions for normal tension glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327513:0" name=internalLink&gt;Intraoperative 5-Fluorouracil for glaucoma surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327507:0" name=internalLink&gt;Intra-operative Mitomycin C for glaucoma surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327515:0" name=internalLink&gt;Iridectomy or iridotomy for preventing angle-closure glaucoma&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330994:0" name=internalLink&gt;Laser peripheral iridoplasty for angle-closure&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327512:0" name=internalLink&gt;Laser trabeculoplasty for open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327530:0" name=internalLink&gt;Laser trabeculoplasty plus topical medical treatment for open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331002:0" name=internalLink&gt;Lens extraction for chronic angle-closure glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327516:0" name=internalLink&gt;Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327522:0" name=internalLink&gt;Needling for encapsulated trabeculectomy filtering blebs&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327514:0" name=internalLink&gt;Non-penetrating filtration surgery versus trabeculectomy for open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:331012:0" name=internalLink&gt;One site versus two site phacotrabeculectomy for primary open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327511:0" name=internalLink&gt;Peripheral iridotomy for pigmentary glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327506:0" name=internalLink&gt;Postoperative 5-Fluorouracil for glaucoma surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327543:0" name=internalLink&gt;What is the effectiveness and cost-effectiveness of initial argon, diode or selective laser trabeculoplasty treatment compared to PGA alone or laser + PGA in combination in COAG patients?&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Service Provision&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327547:0" name=internalLink&gt;In patients identified on primary examination as exhibiting possible COAG, OHT or glaucoma suspect status, what is the comparative effectiveness of diagnosis by different healthcare professions?&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Education/Adherence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327502:0" name=internalLink&gt;Interventions for improving adherence to ocular hypotensive therapy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327551:0" name=internalLink&gt;What is the clinical and cost effectiveness of providing glaucoma patients with a ‘glaucoma card’ or individual record of care compared to standard treatment?&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Complementary Therapy&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327489:0" name=internalLink&gt;Acupuncture for glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327920:0" name=internalLink&gt;Acupuncture for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330984:0" name=internalLink&gt;Exercise &lt;U&gt;&lt;FONT color=#0000ff&gt;for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330983:0" name=internalLink&gt;Ginkgo biloba &lt;U&gt;&lt;FONT color=#0000ff&gt;for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330982:0" name=internalLink&gt;Herbal remedies (including cannabis and cannabinoids) &lt;FONT color=#0000ff&gt;for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/FONT&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330986:0" name=internalLink&gt;Homeopathy &lt;U&gt;&lt;FONT color=#0000ff&gt;for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330987:0" name=internalLink&gt;Meditation (including relaxation techniques) &lt;U&gt;&lt;FONT color=#0000ff&gt;for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327922:0" name=internalLink&gt;Megavitamins for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327517:0" name=internalLink&gt;Neuroprotection for prevention and treatment of glaucoma in adults&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327916:0" name=internalLink&gt;Neuroprotective agents i.e. memantine for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;A href="nelh:330927:0" name=internalLink&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;Special diets for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330985:0" name=internalLink&gt;Spinal manipulation &lt;U&gt;&lt;FONT color=#0000ff&gt;for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330988:0" name=internalLink&gt;Therapeutic touch &lt;U&gt;&lt;FONT color=#0000ff&gt;for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327511:0" name=internalLink&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;If you are aware of or have&amp;nbsp;identified any uncertainties in the management of&amp;nbsp;Glaucoma please let us know.&amp;nbsp; You can contact us via our &lt;/STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/EYES/ContactUs.aspx" target="_blank"&gt;feedback form&lt;/A&gt;&lt;/STRONG&gt;&lt;STRONG&gt;.&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>377524</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=377524]]&gt;</url>
    <title>2010 Annual Evidence Update on Age-related macular degeneration - Emerging evidence</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,ANNUAL EVIDENCE UPDATES,AMD,CONDITIONS,AMD AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on AMD - Emerging evidence - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/aeu_amd_0610_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Emerging%20Evidence.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Please click here to view 2009 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Emerging evidence for the frequency of treatment with anti-VEGF agents in neovascular AMD&lt;/H2&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;Praveen Patel &lt;BR&gt;MA FRCOphth&lt;BR&gt;Locum Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust&lt;/H3&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Introduction&lt;/H2&gt;
&lt;P&gt;Recent advances in treatment for neovascular age-related macular degeneration (nAMD) have seen the introduction of agents which block the action of vascular endothelial growth factor-A (VEGF). The two commonly used agents are ranibizumab and bevacizumab.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Ranibizumab is licensed in the UK [1] for the treatment of nAMD using a treatment strategy of continuous monthly dosing over 24 months (on the basis of the results of phase III trials). A 2008 NICE technology appraisal guidance on ranibizumab and pegaptanib for the treatment of age-related macular degeneration and Royal College of Ophthalmologists (RCOphth) guidelines (2009) are available [2, 3, 4]. However in view of the large number of treatments needed to achieve the effect shown in trials, subsequent clinical trials have concentrated on attempting to achieve similar efficacy while reducing the number of ranibizumab injections needed. In view of the cost of ranibizumab therapy and in view of delays in licensing, ophthalmologists started using bevacizumab, the full length anti-VEGF IgG monoclonal antibody, off-label in the UK, after reports of efficacy demonstrated in case reports and case series.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The RCOphth has issued guidance on the off-label use of intravitreal bevacizumab (Avastin) in nAMD which states that at present, whilst waiting for further research to be published, “the College does not recommend the routine use of intravitreal bevacizumab for choroidal neovascularisation over anti-VEGFs which are already licensed for that indication, and recommended by NICE”, [5-p.4.]. Furthermore a recent NHS Database of Abstracts of Reviews of Effects (DARE) abstract of a 2009 systematic review by Schouten et al on the effect of bevacizumab in exudative AMD concluded that “The results of this review suggested that patients with age-related macular degeneration experienced improvements in visual acuity and central retinal thickness after treatment with bevacizumab. [However], the low quality of the very limited evidence made the reliability of the authors' conclusions unclear”, [6, 7]. A June 2010 BMJ editorial discussing the findings of the recently published ABC trial in using bevacizumab for the treatment of neovascular AMD concludes that “the off label use of bevacizumab should not be encouraged until the large randomised trials comparing it with ranibizumab report their findings”, [49].&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The NICE guidance [3] is due for review in August 2011. The Department of Health has recently requested “an assessment of the evidence base on the safety and effectiveness of bevacizumab for AMD and related eye conditions to provide an indication of the evidence that might be available for NICE to consider updating current guidance”. An NHS National Institute for Health Research (NIHR) Health Technology Assessment (HTA) report has therefore been commissioned (May 2010) with an expected publication date of early 2011 [8].&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Uncertainty exists about the best way of applying the results of phase III trials of anti-VEGF agents with continuous 4 weekly dosing to the real world with a less resource and patient intensive treatment regimen. Ongoing trials are also evaluating newer therapies (VEGF trap-eye) and combination treatments (intravitreal dexamethsaone implant or brachytherapy with ranibizumab). These trials have been initiated with the hope of reducing the burden of treatment and the results are eagerly awaited.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Below&amp;nbsp;are links to&amp;nbsp;a discussion of published/completed clinical trials reporting efficacy outcomes and conclusions from key trials relating to ranibizumab, bevacizumab and combination treatment followed by a summary of relevant ongoing clinical trials highlighting the primary outcome measure and estimated study completion date.&lt;BR&gt;On to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="nelh:377524:2" name=internalLink&gt;2010 AMD AEU Emerging Evidence Published/Completed Clinical Trials&lt;/A&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="nelh:377524:3" name=internalLink&gt;&lt;A href="nelh:377524:3" name=internalLink&gt;2010 AMD AEU Emerging Evidence Ongoing Clinical Trials&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Conflict of Interest:&lt;/STRONG&gt;&lt;BR&gt;Praveen Patel is a principal investigator in the ABC trial. He has received educational travel grants from Novartis UK. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;1. European Medicines Agency (EMEA). Lucentis: European Public Assessment Report (EPAR).&lt;BR&gt;&lt;A href="http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm" target="_blank"&gt;http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;2. The Royal College of Ophthalmologists. Age-related macular degeneration guidelines for management. 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3. NICE technology appraisal guidance 155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf" target="_blank"&gt;http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. NICE technology appraisal guidance 155: Quick reference guide: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English" target="_blank"&gt;http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;5. The Royal College of Ophthalmologists. Intravitreal use of Bevacizumab (Avastin) in age related macular degeneration. 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/published-guidelines/AVASTIN_-_The_Intravitreal_Use_of_Bevacizumab_-_24th_February_2009.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/published-guidelines/AVASTIN_-_The_Intravitreal_Use_of_Bevacizumab_-_24th_February_2009.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6. Centre for Reviews and Dissemination - Database of Abstracts of Reviews of Effects. Structured abstract of:&lt;BR&gt;Schouten JS, Heij EC, Webers CA, Lundqvist IJ, Hendrikse F.&amp;nbsp; A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2009; 247(1): 1-11 &lt;BR&gt;&lt;A href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?LinkFrom=OAI&amp;amp;ID=12009101829" target="_blank"&gt;http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?LinkFrom=OAI&amp;amp;ID=12009101829&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;7. Schouten JS, Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2009; 247(1): 1-11&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18843500" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18843500&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;8. Bevacizumab (Avastin) for choroidal neovascularisation associated with wet age-related macular degeneration and other eye conditions: an assessment of the evidence base on clinical effectiveness and safety. HTA Technology Assessment Report. Start date May 2010. Publication date Early 2011.&lt;BR&gt;&lt;A href="http://www.hta.ac.uk/project/2281.asp" target="_blank"&gt;http://www.hta.ac.uk/project/2281.asp&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;49. Chakravarthy U. Editorial: Bevacizumab for the treatment of neovascular age related macular degeneration. BMJ 2010; 340: c2834&lt;BR&gt;&lt;A href="http://www.bmj.com/cgi/content/full/340/jun09_4/c2834" target="_blank"&gt;http://www.bmj.com/cgi/content/full/340/jun09_4/c2834&lt;/A&gt; &lt;BR&gt;[Abstract not yet available on PubMed]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:377524:4" name=internalLink&gt;&lt;STRONG&gt;Full list of Emerging evidence&amp;nbsp;topic summary references&lt;/STRONG&gt;&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377524:2" name=internalLink&gt;2010 AMD AEU Emerging Evidence Published/Completed Clinical Trials&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377524:3" name=internalLink&gt;&lt;A href="nelh:377524:3" name=internalLink&gt;2010 AMD AEU Emerging Evidence Ongoing Clinical Trials&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on AMD - Emerging evidence - Published/Completed clinical trials&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/aeu_amd_0610_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Emerging%20Evidence.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377524:1" name=internalLink&gt;Back to 2010 AMD AEU Emerging Evidence Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;Published/Completed clinical trials:&lt;BR&gt;Emerging evidence for the frequency of treatment with anti-VEGF agents in neovascular AMD.&lt;/H2&gt;
&lt;P align=left&gt;Praveen Patel. MA FRCOphth. Locum Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Ranibizumab&lt;/DIV&gt;&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="#ContD"&gt;A. Continuous Dosing&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="#QTreat"&gt;B. Quarterly Treatment&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="#IndTreat"&gt;C. Individualised treatment&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="#Bevac"&gt;Bevacizumab&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="#Comb"&gt;Combination (ranibizumab and PDT)&lt;/A&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2 align=left&gt;Ranibizumab&lt;/H2&gt;
&lt;H3&gt;&lt;BR&gt;&lt;A name=ContD&gt;A. Continuous Dosing&lt;/A&gt;&lt;/H3&gt;
&lt;P&gt;Published 2 year outcomes of the safety and efficacy of continuous monthly ranibizumab have been published. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;ANCHOR trial&lt;BR&gt;&lt;/STRONG&gt;Published. [9, 10, 11].&lt;/P&gt;
&lt;P&gt;This multi-centre RCT of 423 patients compared monthly intravitreous ranibizumab injections (either 0.3mg or 0.5mg) with verteporfin photodynamic therapy (PDT) for the treatment of predominantly classic neovascular (wet) age-related macular degeneration (AMD). The primary outcome measure was the proportion of patients losing less than 15 letters.&lt;/P&gt;
&lt;P&gt;Efficacy Outcomes&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;64.3%, 94.3% and 96.4% of patients achieved the primary outcome in the PDT, 0.3mg and the 0.5mg ranibizumab group respectively.&lt;/LI&gt;
&lt;LI&gt;Continuous dosing was used with 12 injections over 12 months.&lt;/LI&gt;
&lt;LI&gt;Efficacy was maintained in year 2 with continuous dosing.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The trial concluded that&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ranibizumab is superior to PDT for the treatment of predominantly classic sub-type of wet AMD using monthly intravitreal injections.&lt;/LI&gt;&lt;/UL&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;MARINA trial&lt;/STRONG&gt;&lt;BR&gt;Published. [10, 12, 13, 14, 15].&lt;/P&gt;
&lt;P&gt;This multi-centre RCT of 716 patients compared monthly intravitreous ranibizumab injections (either 0.3mg or 0.5mg) with sham treatment for the treatment of minimally classic and occult wet AMD. The primary outcome measure was the proportion of patients losing less than 15 letters.&lt;/P&gt;
&lt;P&gt;Efficacy Outcomes&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;62.2%, 94.5% and 94.6% of patients achieved the primary outcome in the sham, 0.3mg and the 0.5mg ranibizumab group respectively.&lt;/LI&gt;
&lt;LI&gt;Continuous dosing was used with 24 injections over 24 months.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The trial concluded that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ranibizumab is superior to sham treatment for the treatment of minimally classic and occult sub-types of wet AMD using monthly intravitreal injections.&lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;&lt;BR&gt;&lt;BR&gt;&lt;A name=QTreat&gt;B. Quarterly Treatment&lt;/A&gt; (PIER and EXCITE trials)&lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;PIER study&lt;BR&gt;&lt;/STRONG&gt;Published. [16]&lt;/P&gt;
&lt;P&gt;This multi-centre RCT of 184 patients compared intravitreous ranibizumab injections (either 0.3 mg or 0.5 mg) given monthly for 3 months (loading phase of treatment) then quarterly with sham treatment for the treatment of all sub-types of wet AMD. The primary outcome measure was the mean change in visual acuity at 12 months. No optical coherent tomography (OCT) evaluations were performed in this study.&lt;/P&gt;
&lt;P&gt;Efficacy Outcomes&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mean change in visual acuity was -16.3, -1.6 and -0.2 letters in the sham, 0.3 mg and the 0.5 mg ranibizumab groups respectively.&lt;/LI&gt;
&lt;LI&gt;The treatment effect declined after the loading phase during the quarterly phase of treatment.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The trial concluded that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Ranibizumab given monthly for 3 months then quarterly is superior to sham treatment for the treatment of wet AMD.&lt;/LI&gt;&lt;/UL&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;EXCITE study&lt;BR&gt;&lt;/STRONG&gt;Completed and reported at international conference. [17, 18, 19, 20].&lt;/P&gt;
&lt;P&gt;This multi-centre RCT compared intravitreous ranibizumab injections (either 0.3mg or 0.5mg) given monthly for 3 months (loading phase of treatment) then quarterly treatment with continuous, monthly dosing with ranibizumab for the treatment of all sub-types of wet AMD. The primary outcome measure was the mean change in visual acuity at 12 months.&lt;/P&gt;
&lt;P&gt;Efficacy Outcomes&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mean change in visual acuity was +4.9, +3.8, +8.3 letters in the 0.3 mg quarterly, 0.5mg quarterly and 0.3 mg monthly dosing ranibizumab groups.&lt;/LI&gt;
&lt;LI&gt;The treatment effect achieved in the loading phase declined during the quarterly phase of treatment.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The outcomes of both the PIER and EXCITE trials strongly suggested that better outcomes are achieved with continuous monthly treatment over quarterly treatment strategies. &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&lt;BR&gt;&lt;A name=IndTreat&gt;C. Individualised treatment&lt;/A&gt;&lt;/H2&gt;
&lt;H3&gt;&lt;BR&gt;1. Open-label extension&lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;HORIZON trial&lt;/STRONG&gt;&lt;BR&gt;Completed and reported at international conference. [21, 22, 23].&lt;/P&gt;
&lt;P&gt;This was a multi-centre, open-label extension study for patients exiting the phase III clinical trials with ranibizumab. Both ranibizumab-treated and ranibizumab-naïve patients where treated with 0.5mg ranibizumab on a prn basis for 2 years. OCT imaging was not mandatory and investigators were allowed to retreat patients without standardised retreatment criteria. Primary outcome measures were the incidence and severity of ocular and nonocular adverse events. Secondary outcome measures were best-corrected visual acuity (VA) assessed every 3 months.&lt;/P&gt;
&lt;P&gt;Efficacy Outcomes&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Of 600 initial-ranibizumab treated patients, 69% received injections (median, 4 and range 1-21 during the 2 year extension study. Two year data was available on 384 of 600 patients.&lt;/LI&gt;
&lt;LI&gt;For this 384 patient cohort, median Snellen visual acuity increased 3 lines from 20/100 to 20/50 during the initial 2 year continuous dosing phase III studies but then decreased 2 lines from HORIZON baseline visual acuity during the 2 years of the open-label extension to 20/80.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The outcomes of the HORIZON trial suggests a decrease in visual acuity results from switching from a continuous dosing strategy to a non-standardised, variable dosing approach.&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;&lt;BR&gt;2. OCT guided retreatment with fixed monthly visits&lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;The PRONTO study&lt;/STRONG&gt;&lt;BR&gt;Published. [24, 25].&lt;/P&gt;
&lt;P&gt;This prospective, open-label, single-centre study of intravitreous ranibizumab for the treatment of nAMD used an OCT guided, variable dosing strategy in patients seen monthly for 24 months. The treatment strategy was a loading phase of three injections given at monthly intervals followed by monthly review with OCT and pro re nata (prn) retreatment if pre-specified retreatment criteria were fulfilled. Two year results have been published recently. &lt;/P&gt;
&lt;P&gt;Main Outcomes&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;40 patients were enrolled with 37 completing 2 year follow-up.&lt;/LI&gt;
&lt;LI&gt;Mean change in visual acuity was +11.1 letters and the OCT central retinal thickness reduced by a mean of 212 um.&lt;/LI&gt;
&lt;LI&gt;43% of patients gained 15 letter or more in visual acuity.&lt;/LI&gt;
&lt;LI&gt;Mean (median) of 9.9 (9) injections respectively over 24 months.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Study conclusions&lt;BR&gt;This open-label study reported that a variable dosing regimen with intravitreal ranibizumab resulted in comparable visual acuity outcomes from phase III studies over 24 months but with fewer injections.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;SUSTAIN study&lt;/STRONG&gt;&lt;BR&gt;Completed and reported at international conference. [26, 27, 28].&lt;/P&gt;
&lt;P&gt;This phase IIIb, open-label, multi-centre study of 531 patients with subfoveal neovascular AMD who were wither treatment naïve or had completed treatment with ranibizumab or verteporfin photodynamic therapy. A treatment strategy of 3 injections given monthly during the loading phase of treatment with further follow-up at monthly intervals and retreatment given on a prn basis if there was a decrease in vision of 5 letter or more or an increase in central retinal thickness on OCT imaging of 100 um or more.&lt;/P&gt;
&lt;P&gt;Efficacy Outcomes&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Interim results from 69 treatment naïve patients completing 12 months follow-up were presented at international conference [28].&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Compared with baseline, means visual acuity at month 12 improved by approximately 9 letters after the loading phase of 3 injections and 7 letters at 12 months.&lt;/LI&gt;
&lt;LI&gt;Over 12 months the mean number of injections was 5.3.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Conclusions&lt;BR&gt;This interim analysis suggested a fall off of efficacy after the loading phase of treatment when this individualised retreatment strategy was used with monthly follow-up visits.&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;3. Treat and Extend Strategy&lt;/H3&gt;
&lt;P&gt;In an attempt to reduce the burden of care by both reducing the number of treatments and hospital visits, investigators have suggested an alternative to variable-dosing with fixed interval hospital visits by attempting to increase the interval between visits when a fluid free macula is achieved. However there are no large scale trials reporting the outcome of this strategy for the treatment of nAMD.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&lt;A name=Bevac&gt;Bevacizumab&lt;/A&gt;&lt;/H2&gt;
&lt;P&gt;Until recently, reports of the outcome of intravitreous bevacizumab therapy of the treatment of nAMD have been limited to prospective or retrospective open-label case series. With relatively few high-quality randomised controlled trials reporting results it is therefore difficult to draw conclusions relating to frequency of treatment and numbers of treatment needed. A 2010 systematic review by Schmucker et al concluded that “Given the lack of controlled data, the widespread off-label use of bevacizumab is not justified in clinical practice. On the other hand, a major challenge in the management of patients who require repeated antivascular endothelial growth factor injections is the high cost of ranibizumab. This dilemma underlines the need for head-to-head studies comparing both vascular endothelial growth factor antibodies, or, at least, well conducted randomized controlled trials evaluating intravitreal bevacizumab”, [29-p.218.].&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;ABC trial&lt;BR&gt;&lt;/STRONG&gt;Completed. Published. [30, 31, 32].&lt;/P&gt;
&lt;P&gt;A double-masked, multi-centre RCT comparing intravitreous bevacizumab (1.25mg) to standard of care (either PDT, pegaptanib or sham) for the treatment of all sub-types of wet AMD. The primary outcome measure was the proportion of patients gaining15 letters or more in visual acuity in the 2 groups. The bevacizumab treatment strategy was one injection every 6 weeks for 3 visits (loading phase)&amp;nbsp; followed by prn retreatment using 6 weekly study visits (minimum of 3 injections and maximum of 9 injections). &lt;/P&gt;
&lt;P&gt;Efficacy Outcomes&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;3.0% and 32.3% of patients in the standard care and bevacizumab groups met the primary outcome measure at 1 year (54 weeks).&lt;/LI&gt;
&lt;LI&gt;Mean (median) number of treatments was 7 (7). The treatment effect declined after the loading phase during the quarterly phase of treatment.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The trial concluded that&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Bevacizumab given as part of a variable-treatment dosing strategy using 6 weekly visits is superior to standard treatment for wet AMD.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Primary and secondary outcomes have been published. The investigators have not yet published full details of the retreatment strategy, [data received from trial investigators - see &lt;A href="nelh:377524:1" name=internalLink&gt;Conflict of Interest statement&lt;/A&gt;].&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&lt;BR&gt;&lt;A name=Comb&gt;Combination&lt;/A&gt; (ranibizumab and PDT)&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;The MONT BLANC (European enrolment) and DENALI (US/Canada enrolment) trials form part of the SUMMIT programme of research. These are randomised controlled trials comparing verteporfin photodynamic therapy (PDT) and ranibizumab against ranibizumab monotherapy alone.&lt;/P&gt;
&lt;P&gt;Both trials have been completed and reported at international conference.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In the &lt;STRONG&gt;MONT BLANC&lt;/STRONG&gt; study [33, 34, 35, 36, 37,38], ranibizumab was delivered as 3 loading injections with further injections based on retreatment criteria during maintenance phase of treatment). In the combination therapy group, PDT was given at baseline then when required based on leakage on fluorescein angiography.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In the &lt;STRONG&gt;DENALI&lt;/STRONG&gt; study [38, 39] there were 3 groups: 1. Ranibizumab monotherapy with continuous monthly dosing; 2. Ranibizumab montherapy delivered as 3 loading injections with further injections based on retreatment criteria during maintenance phase of treatment); 3. The combination therapy group with ranibizumab given as 3 loading injections then further injections based on retreatment critera. PDT was given at baseline then when required based on leakage on fluorescein angiography.&lt;/P&gt;
&lt;P&gt;The primary completion date was October 2009 and the trial design was presented at international conferences in 2009. The primary outcome measure used was change in best-corrected visual acuity (BCVA) (letters) at month 12 and the proportion of patients with a treatment-free interval of at least 3 months duration. &lt;/P&gt;
&lt;P&gt;Efficacy Outcomes Mont Blanc Study&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Visual acuity gain was +4.4 letters in the monotherapy group and +2.5 letters in the combination therapy group.&lt;/LI&gt;
&lt;LI&gt;In both groups the visual acuity declined after the loading phase during the maintenance phase (7.1 letters to 4.4 letter gain in the monotherapy group and 4.6 letters to 2.5letter gain in combination therapy group).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Efficacy Outcomes of the DENALI Study have not yet been presented (expected to be presented at international conference - American Academy of Ophthalmology (AAO) in October 2010).&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;On to: &lt;A href="nelh:377524:3" name=internalLink&gt;2010 AMD AEU Emerging Evidence Ongoing Clinical Trials&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3 align=left&gt;&lt;BR&gt;&lt;BR&gt;References:&lt;/H3&gt;
&lt;P&gt;9. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin&lt;BR&gt;photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57–65.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19118696" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19118696&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;10. Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye Clinical Trial Results from MARINA and ANCHOR. Ophthalmology 2010 Feb 27. [Epub ahead of print]&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20189654" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20189654&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;11. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology 2009 Jan;127(1):13-21.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19139332" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19139332&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355:1419–31.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17021318" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17021318&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology 2007 Nov;125(11):1460-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17998507" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17998507&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;14. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 Oct;114(10):1868-75.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17628683" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17628683&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;15. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 Feb;114(2):246-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17270674" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17270674&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;16. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. American Journal of Ophthalmology 2008 Feb;145(2):239-48.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18222192" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18222192&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17. EXCITE - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (ARMD).&lt;BR&gt;NCT00275821&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/show/NCT00275821" target="_blank"&gt;http://clinicaltrials.gov/show/NCT00275821&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;18. Bolz M, Schmidt-Erfurth U. Ranibizumab EXCITE study: Exploring the value of optical coherence tomography for the management of ranibizumab therapy in age-related macular degeneration. 2008. 8th EURETINA Congress, 22–25 May 2008, Vienna.&lt;BR&gt;&lt;A href="http://www.euretina.org/Events/08Vienna/freepaper_desc.asp?id=164" target="_blank"&gt;http://www.euretina.org/Events/08Vienna/freepaper_desc.asp?id=164&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;19. M. Neuner-Jehle&amp;nbsp; B. Scassellati-Sforzolini&amp;nbsp; T. P. Dryja&amp;nbsp; C. Paulding&amp;nbsp; S. Lewitzky&amp;nbsp; Y. He&amp;nbsp; L. Farrer&amp;nbsp;&amp;nbsp; EXCITE trial: Investigation of potential correlation between clinical pharmacogenetics and Best-Corrected Visual Acuity (BCVA) response in patients with neovascular AMD treated with ranibizumab. 2009. 9th EURETINA Congress, 14-17 May 2009, NICE.&lt;BR&gt;&lt;A href="http://www.euretina.org/site/meetings/nice09/details.asp?id=85&amp;amp;cat=free" target="_blank"&gt;http://www.euretina.org/site/meetings/nice09/details.asp?id=85&amp;amp;cat=free&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;20. B. Eldem&amp;nbsp; P. Lanzetta&amp;nbsp; U. Schmidt-Erfurth&amp;nbsp; R. O. Schlingemann. Analysis of visual acuity profiles in patients with neovascular AMD treated every 3 months with ranibizumab in the EXCITE trial. 2009. 9th EURETINA Congress, 14-17 May 2009, NICE.&lt;BR&gt;&lt;A href="http://www.euretina.org/site/meetings/nice09/details.asp?id=5&amp;amp;cat=free" target="_blank"&gt;http://www.euretina.org/site/meetings/nice09/details.asp?id=5&amp;amp;cat=free&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;21. An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO &lt;BR&gt;NCT00379795&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00379795" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00379795&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;22. Brown DM, Wang P-W, Scott LC. HORIZON extension trial of Ranibizumab for wet AMD: subanalysis of year 1 results. Abstract PO248 presented at the AAO/SOE Joint Annual Meeting, 8–11 November 2008, Atlanta. &lt;BR&gt;&lt;A href="http://aao.scientificposters.com/aaoView.cfm?pid=248&amp;amp;yr=2008" target="_blank"&gt;http://aao.scientificposters.com/aaoView.cfm?pid=248&amp;amp;yr=2008&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;Or use the poster search page at &lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/A&gt; [search for 248; amend year to 2008].&lt;BR&gt;&amp;nbsp;&lt;BR&gt;23. M. Singer, P. Wong, P.-W. Wang, L. Scott. HORIZON Extension Trial of Ranibizumab (LUCENTIS®) for Neovascular Age-Related Macular Degeneration (AMD): Two-Year Safety and Efficacy Results. ARVO 2009.&amp;nbsp; &lt;A href="http://arvo.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=795c1c80-f22d-4de7-a518-03eb755bc2ba&amp;amp;cKey=d4978586-7946-4aef-a731-196700c36ce4" target="_blank"&gt;http://arvo.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=795c1c80-f22d-4de7-a518-03eb755bc2ba&amp;amp;cKey=d4978586-7946-4aef-a731-196700c36ce4&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;24. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology 2007 Apr;143(4):566-83.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17386270" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17386270&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;25. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American Journal of Ophthalmology 2009 Jul;148(1):43-58.e1. Epub 2009 Apr 18.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19376495" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19376495&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;26. SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration&lt;BR&gt;NCT00331864&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00331864" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00331864&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;27. Meyer CH, Eter N, Holz FG, et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial [abstract]. Investigative Ophthalmology &amp;amp; Visual Science 2008;49:E-abstract 273.&lt;BR&gt;&lt;A href="http://abstracts.iovs.org/cgi/content/abstract/49/5/273?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Meyer&amp;amp;title=ranibizumab&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;resourcetype=HWCIT,HWELTR" target="_blank"&gt;http://abstracts.iovs.org/cgi/content/abstract/49/5/273?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Meyer&amp;amp;title=ranibizumab&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;resourcetype=HWCIT,HWELTR&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;28. American Academy of Ophthalmology 2009 Paper. PO254 Visual Acuity Recovery After Single Ranibizumab Re-treatment in SUSTAIN Patients With Acute Visual Acuity Loss of More Than 5 Letters. &lt;BR&gt;Abstracts of the meeting can be searched here by keyword.&lt;BR&gt;&lt;A href="http://aao.scientificposters.com/aaoView.cfm?pid=254&amp;amp;yr=2009" target="_blank"&gt;http://aao.scientificposters.com/aaoView.cfm?pid=254&amp;amp;yr=2009&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;Or use the poster search page at &lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/A&gt; [search for 254; amend year to 2009].&lt;/P&gt;
&lt;P&gt;29. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 2010 May;21(3):218-26.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20393293" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20393293&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;30. Tufail A, Patel P, Egan C, ABC Trial Investigators et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study BMJ 2010;340:c2459&lt;BR&gt;&lt;A href="http://www.bmj.com/cgi/content/abstract/340/jun09_4/c2459" target="_blank"&gt;http://www.bmj.com/cgi/content/abstract/340/jun09_4/c2459&lt;/A&gt; &lt;BR&gt;[Abstract not yet available on PubMed]&lt;/P&gt;
&lt;P&gt;31. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Patel PJ, Bunce C, Tufail A; ABC Trial Investigators. Trials. 2008 Oct 14;9:56.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18854025" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18854025&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;32. Additional Outcomes From the ABC Trial - A Double-Masked, Randomised Controlled Trial of Avastin (Bevacizumab) Intravitreal Injections for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Age-Related Macular Degeneration (AMD). P.J. Patel, W. Xing, C. Bunce, A. Tufail, The ABC Trial Investigators. ARVO 2010.&lt;BR&gt;&lt;A href="http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2511&amp;amp;sKey=849ede37-a91a-41a2-8802-627a981b1021&amp;amp;cKey=7699db19-e3a3-4725-8bc8-70fdb5457a45&amp;amp;mKey=%7b1EA90E66-C548-49E0-9F05-30DA7938D511%7d" target="_blank"&gt;http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2511&amp;amp;sKey=849ede37-a91a-41a2-8802-627a981b1021&amp;amp;cKey=7699db19-e3a3-4725-8bc8-70fdb5457a45&amp;amp;mKey=%7b1EA90E66-C548-49E0-9F05-30DA7938D511%7d&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;33. 24-Month Randomized, Double-Masked, Controlled, Multicenter, Phase II Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to AMD.&lt;BR&gt;NCT00433017&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/402101/NCT00433017" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/402101/NCT00433017&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;34. Bandello, F.M. Visual Acuity and OCT Response Profiles: Twelve-Month MONT BLANC Results. Number: 583 — 2009. AAO 2009; Scientific Posters.&lt;BR&gt;Search page: &lt;BR&gt;&lt;A href="http://aao.scientificposters.com/" target="_blank"&gt;http://aao.scientificposters.com&lt;/A&gt; &lt;BR&gt;Abstracts/Posters of the meeting can be searched here by keyword/poster number.&lt;/P&gt;
&lt;P&gt;35. Ley AM, et al "Combination therapy with verteporfin PDT and ranibizumab: Twelve-month efficacy and safety results of the MONT BLANC study" AAO 2009; American Academy of Ophthalmology 2009 Paper. Abstract PA005. &lt;BR&gt;&lt;A href="http://www.aao.org/meetings/annual_meeting/program/upload/2009-Final-Program_AAO-Papers.pdf" target="_blank"&gt;http://www.aao.org/meetings/annual_meeting/program/upload/2009-Final-Program_AAO-Papers.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;36. Wiedemann, P. Efficacy of Ranibizumab Alone or in Combination With Verteporfin Photodynamic Therapy Analyzed by Demographic and Baseline Variables in the MONT BLANC Study. Number: 572 — 2009. AAO 2009; Scientific Posters.&lt;BR&gt;Search page: &lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/A&gt;&lt;BR&gt;Abstracts/Posters of the meeting can be searched here by keyword/poster number.&lt;/P&gt;
&lt;P&gt;37. Schmidt Erfurth U. Verteporfin Photodynamic therapy and ranibizumab combination for subfoveal CNV secondary to AMD: 12 month efficacy. Results of the Mont Blanc study. Retina Congress Scientific Abstracts, 2009.&lt;BR&gt;&lt;A href="http://www.asrs.org/meetings_and_events/annual_meeting/retina_congress/meeting_abstracts/" target="_blank"&gt;http://www.asrs.org/meetings_and_events/annual_meeting/retina_congress/meeting_abstracts/&lt;/A&gt; [Available for members of American Society of Retina Specialists].&lt;/P&gt;
&lt;P&gt;38. Update on the SUMMIT Program: Three Randomized Clinical Trials Evaluating Combination Treatment With Photodynamic Therapy and Anti-VEGF Agents.&amp;nbsp; Sr Author:&amp;nbsp; Peter K Kaiser MD. American Academy of Ophthalmology 2009 Poster:&amp;nbsp; 253.&lt;BR&gt;Search page: &lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/A&gt; &lt;BR&gt;Abstracts/Posters of the meeting can be searched here by keyword/poster number.&lt;/P&gt;
&lt;P&gt;39. Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization&lt;BR&gt;NCT00436553&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00436553" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00436553&lt;/A&gt; &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="nelh:377524:4" name=internalLink&gt;&lt;STRONG&gt;Full list of Emerging evidence topic summary references&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377524:3" name=internalLink&gt;2010 AMD AEU Emerging Evidence Ongoing Clinical Trials&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377524:1" name=internalLink&gt;Back to 2010 AMD AEU Emerging Evidence Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Please click here to view 2009 AEU&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on AMD - Emerging evidence - Ongoing clinical trials&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/aeu_amd_0610_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Emerging%20Evidence.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377524:1" name=internalLink&gt;Back to 2010 AMD AEU Emerging Evidence Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Ongoing clinical trials:&lt;BR&gt;Emerging evidence for the frequency of treatment with anti-VEGF agents in neovascular AMD.&lt;/H2&gt;
&lt;P&gt;Praveen Patel. MA FRCOphth. Locum Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust&lt;/P&gt;
&lt;H3&gt;Ranibizumab and Bevacizumab&lt;/H3&gt;
&lt;P&gt;There are several ongoing head-to-head randomised controlled trials comparing the efficacy of bevacizumab to ranibizumab using 4 weekly study visits. These should also inform retreatment strategies as some arms include non-continuous, variable-dosing strategies. These are briefly listed below:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;CATT&lt;/STRONG&gt;&lt;BR&gt;Active, not recruiting. No journal publications identified. [40].&lt;/P&gt;
&lt;P&gt;Single-masked RCT in the US of bevacizumab vs ranibizumab.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treatment Arms:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Continuous 2 yr dosing arms for bevacizumab or ranibizumab.&lt;/LI&gt;
&lt;LI&gt;Continuous 1 yr dosing then variable, prn dosing of either bevacizumab or ranibizumab.&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Primary outcome measure: mean change in visual acuity at 24 months.&lt;/LI&gt;
&lt;LI&gt;Estimated study completion date: February 2012.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;IVAN&lt;BR&gt;&lt;/STRONG&gt;Ongoing. No journal publications identified. [41].&lt;/P&gt;
&lt;P&gt;Double-masked RCT in the UK of bevacizumab vs ranibizumab.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treatment Arms include either continuous or variable-dosing strategies for bevacizuamab vs ranibizumab.&lt;/LI&gt;
&lt;LI&gt;The primary outcome measure is visual acuity at 24 months.&lt;/LI&gt;
&lt;LI&gt;Estimated study completion date 31/12/2010 (as per &lt;A href="http://www.controlled-trials.com/ISRCTN92166560" target="_blank"&gt;http://www.controlled-trials.com/ISRCTN92166560&lt;/A&gt;, accessed 15th May 2010).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;EQUAL study&lt;/STRONG&gt;&lt;BR&gt;Ongoing. No journal publications identified. [42].&lt;/P&gt;
&lt;P&gt;Double-masked RCT in the Netherlands of bevacizumab vs ranibizumab.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treatment Arms are either variable-dosing strategies (3 injections then prn) for bevacizuamab vs ranibizumab.&lt;/LI&gt;
&lt;LI&gt;The primary outcome measure is mean visual acuity at 12 months.&lt;/LI&gt;
&lt;LI&gt;Estimated study completion July 2011 (as per&amp;nbsp; &lt;A href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331" target="_blank"&gt;http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331&lt;/A&gt;, accessed 15th May 2010).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;VIBERA&lt;/STRONG&gt;&lt;BR&gt;Recruiting. No journal publications identified. [43].&lt;/P&gt;
&lt;P&gt;Double-masked RCT in Germany of bevacizumab vs ranibizumab.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treatment Arms are variable-dosing strategies (3 injections then prn) for bevacizuamab vs ranibizumab.&lt;/LI&gt;
&lt;LI&gt;The primary outcome measure is the proportion of patients losing less than 15 letters visual acuity at 12 months.&lt;/LI&gt;
&lt;LI&gt;Estimated study completion is not clear as it is still recruiting (as per &lt;A href="http://clinicaltrials.gov/ct2/show/NCT00559715?term=VIBERA&amp;amp;rank=1" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00559715?term=VIBERA&amp;amp;rank=1&lt;/A&gt; accessed 15th May 2010).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;MANTA&lt;BR&gt;&lt;/STRONG&gt;Not yet recruiting, No journal publications identified. [44].&lt;/P&gt;
&lt;P&gt;The Austrian MANTA study began assigning an anticipated 320 AMD patients in June 2008 to three monthly bevacizumab or ranibizumab injections, with additional treatment as needed.&lt;/P&gt;
&lt;P&gt;Double-masked RCT in Austria of bevacizumab vs ranibizumab.&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treatment Arms are variable-dosing strategies (3 injections then prn) for bevacizuamab vs ranibizumab.&lt;/LI&gt;
&lt;LI&gt;The primary outcome measure is the change in visual acuity.&lt;/LI&gt;
&lt;LI&gt;Estimated study completion is not clear (as per &lt;A href="http://clinicaltrials.gov/ct2/show/NCT00710229?term=MANTA&amp;amp;rank=1" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00710229?term=MANTA&amp;amp;rank=1&lt;/A&gt; accessed 15th May 2010). &lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Combination&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Brachytherapy and ranibizumab &lt;BR&gt;MERLOT study &lt;BR&gt;&lt;/STRONG&gt;Recruiting. No journal publications identified. [45].&lt;/P&gt;
&lt;P&gt;A single-masked RCT of epimacular brachytherapy and ranibizumab vs ranibizumab monotherapy in patients who have already commenced anti-VEGF therapy.&lt;BR&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treatment Arms&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Epimacular brachytherapy with ranibizumab (variable-dosing) or&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;ranibizumab monotherapy.&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Primary outcome measure is the mean change in visual acuity at 24 months and mean number of retreatment injections at 24 months.&lt;/LI&gt;
&lt;LI&gt;Estimated study completion is November 2013 (as per &lt;A href="http://clinicaltrials.gov/ct2/show/study/NCT01006538#desc" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/study/NCT01006538#desc&lt;/A&gt; accessed 15th May 2010).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Ranibizumab + intravitreal dexamethasone implant (Ozurdex)&lt;BR&gt;&lt;/STRONG&gt;Completed and reported at international conference. [46, 47].&lt;/P&gt;
&lt;P&gt;A double-masked RCT of an intravitreal dexamethasone implant and ranibizumab vs ranibizumab monotherapy in patients who have already commenced anti-VEGF therapy.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treatment Arms:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Intravitreal dexamethasone implant (Ozurdex) with ranibizumab (variable-dosing after 2 injections) or&lt;/LI&gt;
&lt;LI&gt;ranibizumab monotherapy.&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Primary outcome measure is the time to retreatment with ranibizumab (1-6 months).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Outcomes:&lt;/P&gt;
&lt;P&gt;The study is complete and results have been presented at ARVO 2010. The injection of the Intravitreal dexamethasone implant delays the time to a 3rd ranibizumab injection with the 75th percentile of injection-free interval of 12 weeks in the implant group vs 8 weeks in the control ranibizumab group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Vascular Endothelial Growth Factor (VEGF) Trap-Eye&lt;BR&gt;VIEW-2 study&lt;/STRONG&gt;&lt;BR&gt;Active, not recruiting. No journal publications identified. [48].&lt;/P&gt;
&lt;P&gt;A double-masked RCT of VEGF Trap-Eye vs ranibizumab monotherapy in patients with nAMD.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Treatment Arms:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;VEGF Trap-Eye given (either 0.5mg or 2.0mg) every 8 weeks (with single additional dose at 4 weeks) during the first year. In second year, variable-dosing as frequently as 4 weeks but no less frequently than every 12 weeks.&lt;/LI&gt;
&lt;LI&gt;VEGF Trap-Eye given (2.0mg) every 4 weeks during the first year. In second year, variable-dosing as frequently as 4 weeks but no less frequently than every 12 weeks.&lt;/LI&gt;
&lt;LI&gt;Ranibizumab (0.5 mg) every 4 weeks during the first year. In second year, variable-dosing as frequently as 4 weeks but no less frequently than every 12 weeks.&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Primary outcome measure is the proportion of patients who maintain vision at week 52 (loss of less than 15 letters).&lt;/LI&gt;
&lt;LI&gt;Estimated final data collection for primary outcome measure is October 2010 (as per &lt;A href="http://clinicaltrials.gov/show/NCT00637377" target="_blank"&gt;http://clinicaltrials.gov/show/NCT00637377&lt;/A&gt; accessed 15th May 2010).&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:377524:1" name=internalLink&gt;Back to 2010 AMD AEU Emerging Evidence Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;40. Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)&lt;BR&gt;NCT00593450&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/427247/catt" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/427247/catt&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;41. A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation (IVAN)&lt;BR&gt;ISRCTN92166560&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/489097/ivan" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/489097/ivan&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;42. The EQUAL study: A randomised trial to study the EQUivalence of three monthly intravitreal injections and additional injections as needed of bevacizumab (Avastin) and ranibizumab (Lucentis) on visual acuity in patients with exudative age-related macular degeneration.&lt;BR&gt;NTR1331&lt;BR&gt;&lt;A href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331" target="_blank"&gt;http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;43. Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA)&lt;BR&gt;NCT00559715&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00559715?term=NCT00559715" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00559715?term=NCT00559715&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;44. Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration&lt;BR&gt;NCT00710229&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/453037/" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/453037/&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;45. Macular EpiRetinal Brachytherapy Versus Lucentis Only Treatment (MERLOT). A Randomised Controlled Trial of Epimacular Brachytherapy Versus Ranibizumab Monotherapy for the Treatment of Subfoveal Choroidal Neovascularisation Associated With Wet Age-related Macular Degeneration in Patients Who Have Commenced Anti-VEGF Therapy&lt;BR&gt;NCT01006538&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/707491/MERLOT" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/707491/MERLOT&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;46. Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-VEGF Treatment in Patients With Age-Related Macular Degeneration&lt;BR&gt;NCT00511706&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00511706" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00511706&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;47. Safety and Efficacy of OZURDEX (Dexamethasone Intravitreal Implant) as Adjunctive Therapy to Lucentis in Patients With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). A. Loewenstein, B. D. Kuppermann, D. Weinberger, M. Goldstein, M. Singer, C.-C. Liu, J. Lou, X.-Y. Li and S. M. Whitcup. Investigative Ophthalmology &amp;amp; Visual Science. Investigative Ophthalmology &amp;amp; Visual Science. 2010 51: E-Abstract 1255. &lt;BR&gt;&lt;A href="http://abstracts.iovs.org/cgi/content/abstract/51/5/1255" target="_blank"&gt;http://abstracts.iovs.org/cgi/content/abstract/51/5/1255&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;48. Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)&lt;BR&gt;NCT00637377&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00637377" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00637377&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:377524:4" name=internalLink&gt;&lt;STRONG&gt;Full list of Emerging evidence topic summary references&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377524:1" name=internalLink&gt;Back to 2010 AMD AEU Emerging Evidence Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377524:2" name=internalLink&gt;Back to 2010 AMD AEU Emerging Evidence Published/Completed Clinical Trials&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Please click here to view 2009 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on AMD - Emerging evidence - All References&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:377524:1" name=internalLink&gt;Back to 2010 AMD AEU Emerging Evidence Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;All References: &lt;BR&gt;Emerging evidence for the frequency of treatment with anti-VEGF agents in neovascular AMD.&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. European Medicines Agency (EMEA). Lucentis: European Public Assessment Report (EPAR).&lt;BR&gt;&lt;A href="http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm" target="_blank"&gt;http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. The Royal College of Ophthalmologists. Age-related macular degeneration guidelines for management. 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;3. NICE technology appraisal guidance 155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf" target="_blank"&gt;http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;4. NICE technology appraisal guidance 155: Quick reference guide: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English" target="_blank"&gt;http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;5. The Royal College of Ophthalmologists. Intravitreal use of Bevacizumab (Avastin) in age related macular degeneration. 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/published-guidelines/AVASTIN_-_The_Intravitreal_Use_of_Bevacizumab_-_24th_February_2009.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/published-guidelines/AVASTIN_-_The_Intravitreal_Use_of_Bevacizumab_-_24th_February_2009.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;6. Centre for Reviews and Dissemination - Database of Abstracts of Reviews of Effects. Structured abstract of:&lt;BR&gt;Schouten JS, Heij EC, Webers CA, Lundqvist IJ, Hendrikse F.&amp;nbsp; A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2009; 247(1): 1-11 &lt;BR&gt;&lt;A href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?LinkFrom=OAI&amp;amp;ID=12009101829" target="_blank"&gt;http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?LinkFrom=OAI&amp;amp;ID=12009101829&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;7. Schouten JS, Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2009; 247(1): 1-11&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18843500" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18843500&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;8. Bevacizumab (Avastin) for choroidal neovascularisation associated with wet age-related macular degeneration and other eye conditions: an assessment of the evidence base on clinical effectiveness and safety. HTA Technology Assessment Report. Start date May 2010. Publication date Early 2011.&lt;BR&gt;&lt;A href="http://www.hta.ac.uk/project/2281.asp" target="_blank"&gt;http://www.hta.ac.uk/project/2281.asp&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;9. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin&lt;BR&gt;photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57–65.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19118696" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19118696&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;10. Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye Clinical Trial Results from MARINA and ANCHOR. Ophthalmology 2010 Feb 27. [Epub ahead of print]&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20189654" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20189654&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;11. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology 2009 Jan;127(1):13-21.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19139332" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19139332&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355:1419–31.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17021318" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17021318&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;13. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology 2007 Nov;125(11):1460-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17998507" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17998507&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;14. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 Oct;114(10):1868-75.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17628683" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17628683&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;15. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 Feb;114(2):246-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17270674" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17270674&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;16. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. American Journal of Ophthalmology 2008 Feb;145(2):239-48.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18222192" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18222192&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;17. EXCITE - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (ARMD).&lt;BR&gt;NCT00275821&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/show/NCT00275821" target="_blank"&gt;http://clinicaltrials.gov/show/NCT00275821&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;18. Bolz M, Schmidt-Erfurth U. Ranibizumab EXCITE study: Exploring the value of optical coherence tomography for the management of ranibizumab therapy in age-related macular degeneration. 2008. 8th EURETINA Congress, 22–25 May 2008, Vienna.&lt;BR&gt;&lt;A href="http://www.euretina.org/Events/08Vienna/freepaper_desc.asp?id=164" target="_blank"&gt;http://www.euretina.org/Events/08Vienna/freepaper_desc.asp?id=164&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;19. M. Neuner-Jehle&amp;nbsp; B. Scassellati-Sforzolini&amp;nbsp; T. P. Dryja&amp;nbsp; C. Paulding&amp;nbsp; S. Lewitzky&amp;nbsp; Y. He&amp;nbsp; L. Farrer&amp;nbsp;&amp;nbsp; EXCITE trial: Investigation of potential correlation between clinical pharmacogenetics and Best-Corrected Visual Acuity (BCVA) response in patients with neovascular AMD treated with ranibizumab. 2009. 9th EURETINA Congress, 14-17 May 2009, NICE.&lt;BR&gt;&lt;A href="http://www.euretina.org/site/meetings/nice09/details.asp?id=85&amp;amp;cat=free" target="_blank"&gt;http://www.euretina.org/site/meetings/nice09/details.asp?id=85&amp;amp;cat=free&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;20. B. Eldem&amp;nbsp; P. Lanzetta&amp;nbsp; U. Schmidt-Erfurth&amp;nbsp; R. O. Schlingemann. Analysis of visual acuity profiles in patients with neovascular AMD treated every 3 months with ranibizumab in the EXCITE trial. 2009. 9th EURETINA Congress, 14-17 May 2009, NICE.&lt;BR&gt;&lt;A href="http://www.euretina.org/site/meetings/nice09/details.asp?id=5&amp;amp;cat=free" target="_blank"&gt;http://www.euretina.org/site/meetings/nice09/details.asp?id=5&amp;amp;cat=free&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;21. An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO &lt;BR&gt;NCT00379795&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00379795" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00379795&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;22. Brown DM, Wang P-W, Scott LC. HORIZON extension trial of Ranibizumab for wet AMD: subanalysis of year 1 results. Abstract PO248 presented at the AAO/SOE Joint Annual Meeting, 8–11 November 2008, Atlanta. &lt;BR&gt;&lt;A href="http://aao.scientificposters.com/aaoView.cfm?pid=248&amp;amp;yr=2008" target="_blank"&gt;http://aao.scientificposters.com/aaoView.cfm?pid=248&amp;amp;yr=2008&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;Or use the poster search page at &lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/A&gt; [search for 248; amend year to 2008].&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;23. M. Singer, P. Wong, P.-W. Wang, L. Scott. HORIZON Extension Trial of Ranibizumab (LUCENTIS®) for Neovascular Age-Related Macular Degeneration (AMD): Two-Year Safety and Efficacy Results. ARVO 2009. Program#/Poster#: 3093.&lt;BR&gt;&lt;A href="http://arvo.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2281&amp;amp;sKey=795c1c80-f22d-4de7-a518-03eb755bc2ba&amp;amp;cKey=d4978586-7946-4aef-a731-196700c36ce4" target="_blank"&gt;http://arvo.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2281&amp;amp;sKey=795c1c80-f22d-4de7-a518-03eb755bc2ba&amp;amp;cKey=d4978586-7946-4aef-a731-196700c36ce4&lt;/A&gt;&lt;BR&gt;or search Presentations for 3093 at &lt;A href="http://arvo.abstractsonline.com/Plan/start.aspx" target="_blank"&gt;http://arvo.abstractsonline.com/Plan/start.aspx&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;24. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology 2007 Apr;143(4):566-83.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17386270" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17386270&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;25. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American Journal of Ophthalmology 2009 Jul;148(1):43-58.e1. Epub 2009 Apr 18.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19376495" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19376495&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;26. SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration&lt;BR&gt;NCT00331864&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00331864" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00331864&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;27. Meyer CH, Eter N, Holz FG, et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial [abstract]. Investigative Ophthalmology &amp;amp; Visual Science 2008;49:E-abstract 273.&lt;BR&gt;&lt;A href="http://abstracts.iovs.org/cgi/content/abstract/49/5/273?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Meyer&amp;amp;title=ranibizumab&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;resourcetype=HWCIT,HWELTR" target="_blank"&gt;http://abstracts.iovs.org/cgi/content/abstract/49/5/273?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Meyer&amp;amp;title=ranibizumab&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;resourcetype=HWCIT,HWELTR&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;28. American Academy of Ophthalmology 2009 Paper. PO254 Visual Acuity Recovery After Single Ranibizumab Re-treatment in SUSTAIN Patients With Acute Visual Acuity Loss of More Than 5 Letters. &lt;BR&gt;Abstracts of the meeting can be searched here by keyword.&lt;BR&gt;&lt;A href="http://aao.scientificposters.com/aaoView.cfm?pid=254&amp;amp;yr=2009" target="_blank"&gt;http://aao.scientificposters.com/aaoView.cfm?pid=254&amp;amp;yr=2009&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;Or use the poster search page at &lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/A&gt; [search for 254; amend year to 2009].&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;29. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 2010 May;21(3):218-26.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20393293" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20393293&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;30. Tufail A, Patel P, Egan C, ABC Trial Investigators et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study BMJ 2010;340:c2459&lt;BR&gt;&lt;A href="http://www.bmj.com/cgi/content/abstract/340/jun09_4/c2459" target="_blank"&gt;http://www.bmj.com/cgi/content/abstract/340/jun09_4/c2459&lt;/A&gt; &lt;BR&gt;[Abstract not yet available on PubMed]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;31. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Patel PJ, Bunce C, Tufail A; ABC Trial Investigators. Trials. 2008 Oct 14;9:56.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18854025" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18854025&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;32. Additional Outcomes From the ABC Trial - A Double-Masked, Randomised Controlled Trial of Avastin (Bevacizumab) Intravitreal Injections for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Age-Related Macular Degeneration (AMD). P.J. Patel, W. Xing, C. Bunce, A. Tufail, The ABC Trial Investigators. ARVO 2010.&lt;BR&gt;&lt;A href="http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2511&amp;amp;sKey=849ede37-a91a-41a2-8802-627a981b1021&amp;amp;cKey=7699db19-e3a3-4725-8bc8-70fdb5457a45&amp;amp;mKey=%7b1EA90E66-C548-49E0-9F05-30DA7938D511%7d" target="_blank"&gt;http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2511&amp;amp;sKey=849ede37-a91a-41a2-8802-627a981b1021&amp;amp;cKey=7699db19-e3a3-4725-8bc8-70fdb5457a45&amp;amp;mKey=%7b1EA90E66-C548-49E0-9F05-30DA7938D511%7d&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;33. 24-Month Randomized, Double-Masked, Controlled, Multicenter, Phase II Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to AMD.&lt;BR&gt;NCT00433017&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/402101/NCT00433017" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/402101/NCT00433017&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;34. Bandello, F.M. Visual Acuity and OCT Response Profiles: Twelve-Month MONT BLANC Results. Number: 583 — 2009. AAO 2009; Scientific Posters.&lt;BR&gt;Search page: &lt;BR&gt;&lt;A href="http://aao.scientificposters.com/" target="_blank"&gt;http://aao.scientificposters.com&lt;/A&gt; &lt;BR&gt;Abstracts/Posters of the meeting can be searched here by keyword/poster number.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;35. Ley AM, et al "Combination therapy with verteporfin PDT and ranibizumab: Twelve-month efficacy and safety results of the MONT BLANC study" AAO 2009; American Academy of Ophthalmology 2009 Paper. Abstract PA005.&lt;BR&gt;&lt;A href="http://www.aao.org/meetings/annual_meeting/program/upload/2009-Final-Program_AAO-Papers.pdf" target="_blank"&gt;http://www.aao.org/meetings/annual_meeting/program/upload/2009-Final-Program_AAO-Papers.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;36. Wiedemann, P. Efficacy of Ranibizumab Alone or in Combination With Verteporfin Photodynamic Therapy Analyzed by Demographic and Baseline Variables in the MONT BLANC Study. Number: 572 — 2009. AAO 2009; Scientific Posters.&lt;BR&gt;Search page: &lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/A&gt;&lt;BR&gt;Abstracts/Posters of the meeting can be searched here by keyword/poster number.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;37. Schmidt Erfurth U. Verteporfin Photodynamic therapy and ranibizumab combination for subfoveal CNV secondary to AMD: 12 month efficacy. Results of the Mont Blanc study. Retina Congress Scientific Abstracts, 2009.&lt;BR&gt;&lt;A href="http://www.asrs.org/meetings_and_events/annual_meeting/retina_congress/meeting_abstracts/" target="_blank"&gt;http://www.asrs.org/meetings_and_events/annual_meeting/retina_congress/meeting_abstracts/&lt;/A&gt; [Available for members of American Society of Retina Specialists].&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;38. Update on the SUMMIT Program: Three Randomized Clinical Trials Evaluating Combination Treatment With Photodynamic Therapy and Anti-VEGF Agents.&amp;nbsp; Sr Author:&amp;nbsp; Peter K Kaiser MD. American Academy of Ophthalmology 2009 Poster:&amp;nbsp; 253.&lt;BR&gt;Search page: &lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/A&gt; &lt;BR&gt;Abstracts/Posters of the meeting can be searched here by keyword/poster number.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;39. Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization&lt;BR&gt;NCT00436553&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00436553" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00436553&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;40. Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)&lt;BR&gt;NCT00593450&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/427247/catt" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/427247/catt&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;41. A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation (IVAN)&lt;BR&gt;ISRCTN92166560&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/489097/ivan" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/489097/ivan&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;42. The EQUAL study: A randomised trial to study the EQUivalence of three monthly intravitreal injections and additional injections as needed of bevacizumab (Avastin) and ranibizumab (Lucentis) on visual acuity in patients with exudative age-related macular degeneration.&lt;BR&gt;NTR1331&lt;BR&gt;&lt;A href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331" target="_blank"&gt;http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;43. Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA)&lt;BR&gt;NCT00559715&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00559715?term=NCT00559715" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00559715?term=NCT00559715&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;44. Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration&lt;BR&gt;NCT00710229&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/453037/" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/453037/&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;45. Macular EpiRetinal Brachytherapy Versus Lucentis Only Treatment (MERLOT). A Randomised Controlled Trial of Epimacular Brachytherapy Versus Ranibizumab Monotherapy for the Treatment of Subfoveal Choroidal Neovascularisation Associated With Wet Age-related Macular Degeneration in Patients Who Have Commenced Anti-VEGF Therapy&lt;BR&gt;NCT01006538&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/707491/MERLOT" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/707491/MERLOT&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;46. Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-VEGF Treatment in Patients With Age-Related Macular Degeneration&lt;BR&gt;NCT00511706&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00511706" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00511706&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;47. Safety and Efficacy of OZURDEX (Dexamethasone Intravitreal Implant) as Adjunctive Therapy to Lucentis in Patients With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). A. Loewenstein, B. D. Kuppermann, D. Weinberger, M. Goldstein, M. Singer, C.-C. Liu, J. Lou, X.-Y. Li and S. M. Whitcup. Investigative Ophthalmology &amp;amp; Visual Science. Investigative Ophthalmology &amp;amp; Visual Science. 2010 51: E-Abstract 1255. &lt;BR&gt;&lt;A href="http://abstracts.iovs.org/cgi/content/abstract/51/5/1255" target="_blank"&gt;http://abstracts.iovs.org/cgi/content/abstract/51/5/1255&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;48. Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)&lt;BR&gt;NCT00637377&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00637377" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00637377&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;49. Chakravarthy U. Editorial: Bevacizumab for the treatment of neovascular age related macular degeneration. BMJ 2010; 340: c2834&lt;BR&gt;&lt;A href="http://www.bmj.com/cgi/content/full/340/jun09_4/c2834" target="_blank"&gt;http://www.bmj.com/cgi/content/full/340/jun09_4/c2834&lt;/A&gt; &lt;BR&gt;[Abstract not yet available on PubMed]&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377524:1" name=internalLink&gt;Back to 2010 AMD AEU Emerging Evidence Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>377527</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=377527]]&gt;</url>
    <title>2010 Annual Evidence Update on Age-related macular degeneration - Future Sight Loss</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,ANNUAL EVIDENCE UPDATES,AMD,CONDITIONS,AMD AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Age-related macular degeneration - Future Sight Loss&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/aeu_amd_0610_doc2.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt; &lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Future%20Sight%20Loss%20from%20AMD.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt; &lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Please click here to view 2009 AEU&lt;/A&gt;&lt;/P&gt; &lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt; &lt;H2&gt;&lt;BR&gt;Future Sight Loss from AMD&lt;/H2&gt; &lt;BR&gt;&lt;H3&gt;Darwin Minassian, EpiVision.&lt;BR&gt;Angela Reidy, EpiVision.&lt;/H3&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;BR&gt;&lt;EM&gt;Future Sight Loss UK (2): An epidemiological and economic model for sight loss in the decade 2010-2020.&lt;/EM&gt; Report prepared for RNIB by Darwin Minassian and Angela Reidy, EpiVision. June 2009.&lt;A href="http://www.rnib.org.uk/aboutus/Research/reports/eyehealth/fsuk/Pages/fsuk.aspx" target="_blank"&gt;http://www.rnib.org.uk/aboutus/Research/reports/eyehealth/fsuk/Pages/fsuk.aspx&lt;/A&gt; &lt;BR&gt;&lt;/P&gt; &lt;H2&gt;&lt;BR&gt;Introduction&lt;/H2&gt; &lt;P&gt;The study was commissioned by the Royal National Institute of Blind People in 2008 as the lead for research in the UK Vision Strategy. The objective was to estimate the current and future prevalence of the main eye disorders and the expected numbers with sight loss in the UK. Costs to society were estimated, and the interlinked epidemiological and economic findings provide estimates available to inform the UK Vision strategy. An aspect of the work aimed to project the number of cases with age-related macular degeneration (AMD) and the numbers with sight loss attributable to AMD for the UK population in the period 2010-2020, taking into account the expected beneficial effect of the new anti-VEGF therapies. &lt;/P&gt; &lt;P&gt;A ‘System Dynamics’ approach was used in constructing an epidemiological computer model to simulate the dynamics of the disease in large populations. The model computed the pool of cases (numbers with AMD and with sight loss due to AMD) over the simulation period, taking into account the expected demographic changes. Other determinants taken into account included: the starting prevalence; incidence; mortality; and the expected efficacy and coverage of anti-VEGF treatment. &lt;/P&gt; &lt;H2&gt;&lt;BR&gt;Main findings &lt;/H2&gt; &lt;P&gt;The main findings for the UK were: &lt;STRONG&gt;608,213&lt;/STRONG&gt; persons in 2010 are estimated to have AMD, and this is expected to increase to &lt;STRONG&gt;755,867&lt;/STRONG&gt; by the end of the decade.&amp;nbsp; Numbers with sight loss from AMD are expected to rise from 223,224 in 2010 to 291,982 by 2020. Cases with sight loss due to Neovascular AMD are expected to increase from 145,697 to 189,890 by the end of the decade. These estimates are made under the assumption that the anti-VEGF treatment covers 75% of those eligible. With 90% coverage, numbers with sight loss are expected to rise to 187,523 by the year 2020. &lt;/P&gt; &lt;H2&gt;&amp;nbsp;&lt;BR&gt;Conclusion&lt;/H2&gt; &lt;P&gt;In conclusion, the model predicts that the beneficial effects of the treatment would be outweighed by the strong anticipated demographic ‘aging’ effect. This reaffirms the importance of continuing efforts to develop more effective and more broadly applicable therapies for AMD.&lt;/P&gt; &lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt; &lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>377438</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=377438]]&gt;</url>
    <title>2010 Annual Evidence Update on Age-related macular degeneration - Home Page</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,ANNUAL EVIDENCE UPDATES,AMD,CONDITIONS,AMD AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Age-related macular degeneration - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;14th&amp;nbsp;June 2010&lt;/P&gt;
&lt;P align=center&gt;&lt;IMG style="WIDTH: 180px; HEIGHT: 144px" id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="colour fundus photograph of left eye with suspected classic CNVM" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0004_classiccnv2c1rogers.jpg" width=272 height=205&gt;&amp;nbsp;&amp;nbsp; &lt;IMG style="WIDTH: 184px; HEIGHT: 146px" id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Vision with AMD" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262254/nelhImp_0001_kidsbottom.png" width=184 height=147&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Classic CNV FFA AMD" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID377438/nelhImp_0000_classiccnv1.JPG" width=176 height=143&gt;&lt;/P&gt;
&lt;P&gt;Age-related macular degeneration is one of the commonest causes of certifiable visual impairment in the UK. &lt;/P&gt;
&lt;P&gt;The &lt;STRONG&gt;2010 Evidence Update focuses on the management of neovascular (wet) AMD&lt;/STRONG&gt; and highlights the: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;key evidence base underpinning current interventions (key randomised controlled trials and current guidance);&lt;/LI&gt;
&lt;LI&gt;new evidence that is likely to inform a change in clinical practice;&lt;/LI&gt;
&lt;LI&gt;emerging evidence for Lucentis, Avastin and combination treatments from key RCTs that have recently reported at scientific conferences but not yet published in peer reviewed literature;&lt;/LI&gt;
&lt;LI&gt;current uncertainties in the effectiveness of treatments. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;We welcome feedback about resources that we identify, do contact us if you would like to comment. After you have browsed the pages, please take a moment to complete our survey (5 mins). &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/Feedback/feedback.aspx" target="_blank"&gt;Click here to take the survey&lt;/A&gt;&lt;/P&gt;
&lt;H3&gt;Contents&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;Topics covered:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:377451:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377527:0" name=internalLink&gt;AMD – Future sight loss from AMD. &lt;BR&gt;&lt;/A&gt;&lt;EM&gt;Future Sight Loss UK (2): An epidemiological and economic model for sight loss in the decade 2010-2020. EpiVision. RNIB. 2009&lt;BR&gt;&lt;BR&gt;&lt;/EM&gt;&lt;/LI&gt;
&lt;LI&gt;Ranibizumab (Lucentis): Rationale for current practice: Current recommended treatment regime.&lt;BR&gt;&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Introduction.&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377475:3" name=internalLink&gt;Evidence base for current treatment.&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377475:4" name=internalLink&gt;Clinical practice points.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Emerging evidence for the frequency of treatment with anti-VEGF agents in neovascular AMD.&lt;BR&gt;&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:377524:1" name=internalLink&gt;Introduction.&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377524:2" name=internalLink&gt;Published/Completed clinical trials&lt;/A&gt;.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377524:3" name=internalLink&gt;Ongoing clinical trials.&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:377548:0" name=internalLink&gt;UK DUETs on AMD&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:377475:2" name=internalLink&gt;Evidence Tree -&amp;nbsp;Current evidence base for treatment of AMD: Ranibizumab (Lucentis).&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20-%20Journal%20spread.pdf" target="_blank"&gt;Journal spread&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Glossary.pdf" target="_blank"&gt;Glossary&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:377544:0" name=internalLink&gt;Methodology and search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:262086:0" name=internalLink&gt;Images of AMD from National Knowledge Week 2007&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;BR&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/fp_aeu_amd_0610.asp" target="_blank"&gt;low vision version&lt;/A&gt; of this AEU is also available.&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Acknowledgements:&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;The Management Team based at Moorfields Eye Hospital NHS Foundation Trust would like to thank all those who contributed to the preparation and promotion of this Evidence Update, particularly: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Our panel of Contributors who voluntarily contributed their time and expertise to provide the Topic Commentaries –&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;Robin D Hamilton&lt;/STRONG&gt;, Consultant Ophthalmic Surgeon, Moorfields Eye Hospital NHS Foundation Trust, London.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Praveen Patel&lt;/STRONG&gt;, Locum Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Darwin Minassian&lt;/STRONG&gt;, EpiVision.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Angela Reidy&lt;/STRONG&gt;, EpiVision.&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Professor &lt;STRONG&gt;Usha Chakravarthy&lt;/STRONG&gt;, Consultant Ophthalmologist Royal Victoria Hospital Belfast, Professor of Ophthalmology and Visual Sciences Queen’s University Belfast and &lt;STRONG&gt;Adnan Tufail,&lt;/STRONG&gt; Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust for their assistance in the AEU scoping discussions.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Shaun Kirupairatnam&lt;/STRONG&gt; (R&amp;amp;D Graphic Web Designer, Moorfields Eye Hospital) for his support in developing the collection's complementary site.&lt;/LI&gt;
&lt;LI&gt;The &lt;STRONG&gt;External Reference Group&lt;/STRONG&gt; for their guidance.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Images courtesy of Medical Illustration Department at &lt;A href="http://www.moorfields.nhs.uk/Home" target="_blank"&gt;Moorfields Eye Hospital NHS Foundation Trust&lt;/A&gt; and &lt;A href="http://www.nei.nih.gov/index.asp" target="_blank"&gt;National Eye Institute, National Institutes of Health&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>377451</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=377451]]&gt;</url>
    <title>2010 Annual Evidence Update on Age-related macular degeneration - Introduction</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,ANNUAL EVIDENCE UPDATES,AMD,CONDITIONS,AMD AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Age-related macular degeneration - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/aeu_amd_0610_doc1.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Introduction.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Introduction&lt;/H2&gt;
&lt;P&gt;Age-related macular degeneration is one of the commonest causes of certifiable visual impairment in the UK. &lt;/P&gt;
&lt;P&gt;The 2010 Evidence Update focuses on the management of neovascular (wet) AMD and highlights the: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;key evidence base underpinning current interventions (key randomised controlled trials and current guidance);&lt;/LI&gt;
&lt;LI&gt;new evidence that is likely to inform a change in clinical practice;&lt;/LI&gt;
&lt;LI&gt;emerging evidence for Lucentis, Avastin and combination treatments from key RCTs that have recently reported at scientific conferences but not yet published in peer reviewed literature;&lt;/LI&gt;
&lt;LI&gt;current uncertainties in the effectiveness of treatments. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Commentaries have been provided by &lt;STRONG&gt;Robin Hamilton&lt;/STRONG&gt;, Consultant Ophthalmic Surgeon, Moorfields Eye Hospital NHS Foundation Trust, &lt;STRONG&gt;Praveen Patel&lt;/STRONG&gt;, Locum Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust and &lt;STRONG&gt;Angela Reidy&lt;/STRONG&gt; and &lt;STRONG&gt;Darwin Minassian&lt;/STRONG&gt;, EpiVision.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Key documents&lt;/H2&gt;
&lt;P&gt;The most recent professional body and NICE guidance on AMD formed the benchmark for the AEU. These include:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Royal College of Ophthalmologists (RCOphth)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The Royal College of Ophthalmologists. Age-related macular degeneration guidelines for management. 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;The Royal College of Ophthalmologists. Ranibizumab: the clinician’s guide to commencing, continuing and discontinuing treatment. 2008&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;The Royal College of Ophthalmologists. Intravitreal use of Bevacizumab (Avastin) in age related macular degeneration. 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/published-guidelines/AVASTIN_-_The_Intravitreal_Use_of_Bevacizumab_-_24th_February_2009.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/published-guidelines/AVASTIN_-_The_Intravitreal_Use_of_Bevacizumab_-_24th_February_2009.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;NICE Guidance&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NICE technology appraisal guidance 155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf" target="_blank"&gt;http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;EMEA&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;European Medicines Agency (EMEA). Lucentis: European Public Assessment Report (EPAR).&lt;BR&gt;&lt;A href="http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm" target="_blank"&gt;http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;European Medicines Agency (EMEA). Lucentis: EPAR summary for the public.&lt;BR&gt;&lt;A href="http://www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en1.pdf" target="_blank"&gt;http://www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en1.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Searches were limited to 2007 on to ensure full coverage since searches were undertaken for the RCOphth and NICE guidance.&lt;/P&gt;
&lt;P&gt;This guidance is non-prescriptive and allows clinicians to re-treat based on signs of disease activity.&amp;nbsp; This reflects the evidence and uncertainly about the optimal, individualised retreatment strategies with anti-VEGF agents for neovascular AMD. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key secondary publications&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Vedula SS, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD005139. DOI: 10.1002/14651858.CD005139.pub2.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005139/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005139/frame.html&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment 2008 May;12(16):iii-201.&lt;BR&gt;&lt;A href="http://www.hta.ac.uk/execsumm/summ1216.htm" target="_blank"&gt;http://www.hta.ac.uk/execsumm/summ1216.htm&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A &lt;STRONG&gt;list of Systematic Reviews&lt;/STRONG&gt; on AMD with links to PubMed abstracts is available on the eyes and vision specialist collection at: &lt;A href="http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=320320" target="_blank"&gt;http://www.library.nhs.uk/EYES/ViewResource.aspx?resID=320320&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Clinical Knowledge Summaries (CKS)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Macular degeneration - age-related. March 2010.&lt;BR&gt;&lt;A href="http://www.cks.nhs.uk/macular_degeneration_age_related" target="_blank"&gt;http://www.cks.nhs.uk/macular_degeneration_age_related&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;Includes summary on: &lt;BR&gt;•&amp;nbsp;Confirmed age-related macular degeneration&lt;BR&gt;•&amp;nbsp;Diagnosis of age-related macular degeneration&lt;BR&gt;•&amp;nbsp;Suspected age-related macular degeneration&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Referral pathway for wet age-related macular degeneration (wet AMD)&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;DH Letter Gateway Reference 14098 issued on 1 April 2010 to chairs of primary care trusts, highlighting the importance of rapid referral for people who are suspected of having wet age-related macular degeneration and to ask that local referral pathways be reviewed in light of this.&lt;BR&gt;&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_115007.pdf" target="_blank"&gt;http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_115007.pdf&lt;/A&gt;&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;AMD - advice to optometrists. Optical Federation. May 2010.&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;Guidance for optometrists from the Optical Federation hosted on the College of Optometrists website.&lt;BR&gt;&lt;A href="http://www.college-optometrists.org/download.cfm/docid/9E9C4219-24EE-4899-BC449F6569CE6144" target="_blank"&gt;http://www.college-optometrists.org/download.cfm/docid/9E9C4219-24EE-4899-BC449F6569CE6144&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;HTA Proposed Technology Assessment Report&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bevacizumab (Avastin) for choroidal neovascularisation associated with wet age-related macular degeneration and other eye conditions: an assessment of the evidence base on clinical effectiveness and safety. HTA Technology Assessment Report. Start date May 2010. Publication date Early 2011.&lt;BR&gt;&lt;A href="http://www.hta.ac.uk/project/2281.asp" target="_blank"&gt;http://www.hta.ac.uk/project/2281.asp&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Contents&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;Topics covered: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:377451:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377527:0" name=internalLink&gt;AMD – Future sight loss from AMD. &lt;BR&gt;&lt;/A&gt;&lt;EM&gt;Future Sight Loss UK (2): An epidemiological and economic model for sight loss in the decade 2010-2020. EpiVision. RNIB. 2009&lt;BR&gt;&lt;BR&gt;&lt;/EM&gt;&lt;/LI&gt;
&lt;LI&gt;Ranibizumab (Lucentis): Rationale for current practice: Current recommended treatment regime.&lt;BR&gt;&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Introduction.&lt;BR&gt;&lt;/LI&gt;&lt;/A&gt;
&lt;LI&gt;&lt;A href="nelh:377475:3" name=internalLink&gt;Evidence base for current treatment.&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377475:4" name=internalLink&gt;Clinical practice points.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Emerging evidence for the frequency of treatment with anti-VEGF agents in neovascular AMD.&lt;BR&gt;&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:377524:1" name=internalLink&gt;Introduction.&lt;BR&gt;&lt;/LI&gt;&lt;/A&gt;
&lt;LI&gt;&lt;A href="nelh:377524:2" name=internalLink&gt;Published/Completed clinical trials&lt;/A&gt;.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:377524:3" name=internalLink&gt;Ongoing clinical trials.&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:377548:0" name=internalLink&gt;UK DUETs on AMD&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:377475:2" name=internalLink&gt;Evidence Tree -&amp;nbsp;Current evidence base for treatment of AMD: Ranibizumab (Lucentis).&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20-%20Journal%20spread.pdf" target="_blank"&gt;Journal spread&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Glossary.pdf" target="_blank"&gt;Glossary&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:377544:0" name=internalLink&gt;Methodology and search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:262086:0" name=internalLink&gt;Images of AMD from National Knowledge Week 2007&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;&lt;/EM&gt;&lt;EM&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/fp_aeu_amd_0610.asp" target="_blank"&gt;low vision version&lt;/A&gt; of this AEU is also available.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Acknowledgements:&lt;/H2&gt;
&lt;P&gt;The Management Team based at Moorfields Eye Hospital NHS Foundation Trust would like to thank all those who contributed to the preparation and promotion of this Evidence Update, particularly: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Our panel of Contributors who voluntarily contributed their time and expertise to provide the Topic Commentaries –&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;Robin D Hamilton&lt;/STRONG&gt;, Consultant Ophthalmic Surgeon, Moorfields Eye Hospital NHS Foundation Trust, London.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Praveen Patel&lt;/STRONG&gt;, Locum Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Darwin Minassian&lt;/STRONG&gt;, EpiVision.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Angela Reidy&lt;/STRONG&gt;, EpiVision.&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Professor &lt;STRONG&gt;Usha Chakravarthy&lt;/STRONG&gt;, Consultant Ophthalmologist Royal Victoria Hospital Belfast, Professor of Ophthalmology and Visual Sciences Queen’s University Belfast and &lt;STRONG&gt;Adnan Tufail,&lt;/STRONG&gt; Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust for their assistance in the AEU scoping discussions.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;Shaun Kirupairatnam&lt;/STRONG&gt; (R&amp;amp;D Graphic Web Designer, Moorfields Eye Hospital) for his support in developing the collection's complementary site.&lt;/LI&gt;
&lt;LI&gt;The &lt;STRONG&gt;External Reference Group&lt;/STRONG&gt; for their guidance.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Management Team&lt;/H2&gt;
&lt;P&gt;Miss Parul Desai.&lt;BR&gt;Consultant in Ophthalmology and Public Health, Moorfields Eye Hospital NHS Foundation Trust, London.&lt;BR&gt;Clinical Lead, NHS Evidence – eyes and vision.&lt;/P&gt;
&lt;P&gt;Karen Poole, MSc, MCLIP.&lt;BR&gt;Information Specialist/Librarian, NHS Evidence – eyes and vision.&lt;/P&gt;
&lt;P&gt;Jenny Wood.&lt;BR&gt;Information Co-ordinator, NHS Evidence – eyes and vision.&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>377544</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=377544]]&gt;</url>
    <title>2010 Annual Evidence Update on Age-related macular degeneration - Methodology</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,ANNUAL EVIDENCE UPDATES,AMD,CONDITIONS,AMD AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Age-related macular degeneration - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Methodology.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Methodology&lt;/H2&gt;
&lt;P&gt;This is the fourth Annual Evidence Update (AEU) for age-related macular degeneration carried out by NHS Evidence - eyes and vision. This AEU focuses on the management of neovascular (wet) AMD using and highlights the key evidence base underpinning current interventions including key randomised controlled trials (RCTs) and current guidance for the use of Ranibizumab (Lucentis).&lt;/P&gt;
&lt;P&gt;The most recent professional body and NICE guidance on AMD formed the benchmark for the AEU. These include:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Royal College of Ophthalmologists (RCOphth)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf" target="_blank"&gt;The Royal College of Ophthalmologists. Age-related macular degeneration guidelines for management. 2009.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf" target="_blank"&gt;The Royal College of Ophthalmologists. Ranibizumab: the clinician’s guide to commencing, continuing and discontinuing treatment. 2008&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NICE Guidance&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf" target="_blank"&gt;NICE technology appraisal guidance 155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Searches were limited to 2007 on to ensure full coverage since searches were undertaken for the RCOphth and NICE guidance. &lt;/P&gt;
&lt;P&gt;This AEU serves as an update to both the &lt;A href="nelh:315036:0" name=internalLink&gt;Therapeutic intervention: anti-VEGF therapy&lt;/A&gt; section of the last AEU and the RCOphth and NICE guidance, and includes articles published from 2007.&lt;/P&gt;
&lt;P&gt;An initial search was run on 18th March 2010 and an update search on 28th April 2010.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PubMed 2007 to date; EMBASE 2007 to date; Cochrane Central Register of Controlled Trials; and NHS Evidence - eyes and vision.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; January 2007 to 28th April 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases&lt;/A&gt; (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clcentral_articles_fs.html" target="_blank"&gt;Cochrane Central Register of Controlled Trials&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;/A&gt; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Inclusion criteria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis and review articles).&lt;/LI&gt;
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials).&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys).&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 2007 on.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Relevancy to focus of the 2010 AMD AEU: Ranibizumab (Lucentis): Rationale for current practice: Current recommended treatment regime. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Method &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The search outputs were exported into Reference Manager bibliographic software.&lt;/P&gt;
&lt;P&gt;The results were automatically de-duplicated. Further duplicate results were removed manually. &lt;/P&gt;
&lt;P&gt;The results were then sifted for relevance and categorised by potential AEU topic sub-heading (e.g. frequency of treatment, side effects, comparison with Bevacizumab). Clinical trial names were also highlighted. The resultant articles were then passed to the topic contributors for further sifts for relevance. &lt;/P&gt;
&lt;P&gt;NHS Evidence – eyes and vision was sifted on 16th March 2010 with records indexed with ‘Age related macular degeneration’ to ensure that the above search included all the pertinent articles. An update search was run on 7th June 2010. Relevant guidelines, key documents and seminal articles and uncertainties were identified during this search.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Search strategy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Evidence – eyes and vision AMD AEU Search Strategy available &lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMD%20AEU%202010%20search%20history.pdf" target="_blank"&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Additional references&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In some cases additional peripheral references, published since 2007 but not identified in the targeted Ranibizumab (Lucentis) search, have been included to support commentary. Some older seminal research, published prior to 2007, which still contributes to the evidence base for the current management of AMD in the NHS has also been included in the topic summaries. These are identified in the reference list of the relevant topic summary. Finally guidance and clinical trial data are also referenced.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;KP 04/06/10&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>377475</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=377475]]&gt;</url>
    <title>2010 Annual Evidence Update on Age-related macular degeneration - Ranibizumab (Lucentis)</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,ANNUAL EVIDENCE UPDATES,AMD,CONDITIONS,AMD AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on AMD - Ranibizumab (Lucentis) - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/aeu_amd_0610_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Ranibizumab.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Please click here to view 2009 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&lt;BR&gt;Ranibizumab (Lucentis):&lt;BR&gt;Rationale for current practice: Current recommended treatment regime.&lt;/H2&gt;
&lt;H3 align=left&gt;Robin D Hamilton&lt;BR&gt;MBBS, DM(dist), MRCOphth&lt;BR&gt;Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London&lt;/H3&gt;
&lt;H2 align=left&gt;&lt;BR&gt;Introduction&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P align=left&gt;Recent advances in pharmacotherapy against Vascular Endothelial Growth Factor-A (VEGF-A) have provided clinicians with increasingly better outcomes for treatment of neovascular Age-related macular degeneration (AMD). Current treatment of neovascular AMD worldwide is based around two of these anti-VEGF drugs:&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;Ranibizumab&lt;/STRONG&gt; (Lucentis, Novartis Pharma AG, Basel, Switzerland and Genetch Inc., South San Francisco, California, USA), a recombinant, humanised monoclonal antibobody Fab fragment, and&amp;nbsp;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;STRONG&gt;Bevacizumab&lt;/STRONG&gt; (Avastin, Roche, Basel, Switzerland and Genentech), a full-length monoclonal antibody. &lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Lucentis was approved by the US Food and Drug Administration (FDA) for ophthalmic use in June 2006 [1] (monthly 0.5mg intravitreal injection) and by the European Medicines Agency (EMEA) in 2007 [2], [3] whereas Avastin is approved by the EMEA and FDA for treatment of cancer and not for ophthalmic use and so is only being used off-label for intravitreal use in AMD. Pharmaceutical company independent head-to-head studies comparing Lucentis and Avastin trials are currently under way in the UK (IVAN study), the USA (CATT study), the Netherlands (EQUAL) and Germany (VIBERA) [4, 5, 6, 7], but the first results are not expected until the end of 2010.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A 2008 Cochrane review of antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration evaluated evidence for treatment with anti-VEGFs including ranibizumab [8] and a 2008 Health Technology Assessment assessed the clinical effectiveness and cost-effectiveness of ranibizumab and pegaptanib [9]. Two recent review papers, one by Mitchell et al aiming to generate evidence-based and consensus recommendations for treatment indication and assessment, retreatment and monitoring [10] and the other by Chakravarthy, Evans and Rosenfeld [11] examining the pathogenesis of AMD and recent advances in its management have also been published.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The &lt;STRONG&gt;current treatment approach&lt;/STRONG&gt; for neovascular AMD recommended by the Royal College of Ophthalmologists (RCOphth) [12, 13] and the National Institute for Clinical Excellence (NICE) [14] is with intravitreal ranibizumab.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The 2008 Quick reference guide to the NICE technology appraisal guidance covering ranibizumab for the treatment of AMD states that:&lt;/P&gt;
&lt;P&gt;“1. Ranibizumab, within its marketing authorisation, is recommended as an option for the treatment of wet age-related macular degeneration if:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;all of the following circumstances apply in the eye to be treated:&lt;BR&gt;–&amp;nbsp;the best-corrected visual acuity is between 6/12 and 6/96&lt;BR&gt;–&amp;nbsp;there is no permanent structural damage to the central fovea&lt;BR&gt;–&amp;nbsp;the lesion size is less than or equal to 12 disc areas in greatest linear dimension&lt;BR&gt;–&amp;nbsp;there is evidence of recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes)&lt;BR&gt;and&lt;/LI&gt;
&lt;LI&gt;the cost of ranibizumab beyond 14 injections in the treated eye is met by the manufacturer.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;2. It is recommended that treatment with ranibizumab should be continued only in people who maintain adequate response to therapy. Criteria for discontinuation should include persistent deterioration in visual acuity and identification of anatomical changes in the retina that indicate inadequate response to therapy. It is recommended that a national protocol specifying criteria for discontinuation is developed.” [15 – p.1]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Secondary Publications:&lt;BR&gt;[2], [3], [8], [9], [10], [11], [12], [13], [14] and [15]&lt;/P&gt;
&lt;P&gt;News/Unpublished Trials:&lt;BR&gt;[1], [4], [5], [6] and [7]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Below&amp;nbsp;are links to&amp;nbsp;a discussion of the evidence base for the use of ranibizumab. Clinical practice points are then highlighted.&lt;BR&gt;On to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="nelh:377475:3" name=internalLink&gt;2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Evidence Base&lt;/A&gt;&lt;BR&gt;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;&lt;A href="nelh:377475:4" name=internalLink&gt;2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis) Clinical Practice Points&lt;/A&gt;&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Conflict of Interest:&lt;BR&gt;&lt;/STRONG&gt;No conflict of interests&amp;nbsp;to declare - 2010.&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;References:&lt;/P&gt;
&lt;P&gt;&lt;/STRONG&gt;1. NHS National electronic Library for Medicines (NeLM) News Service. Lucentis (ranibizumab) approved in the US for treatment of wet age-related macular degeneration &lt;BR&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/487976/487977/487979/" target="_blank"&gt;http://www.nelm.nhs.uk/en/NeLM-Area/News/487976/487977/487979/&lt;/A&gt;&amp;nbsp; [Accessed online 21/05/2010]&lt;/P&gt;
&lt;P&gt;2. European Medicines Agency (EMEA). Lucentis: European Public Assessment Report (EPAR).&lt;BR&gt;&lt;A href="http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm" target="_blank"&gt;http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;3. European Medicines Agency (EMEA). Lucentis: EPAR summary for the public.&lt;BR&gt;&lt;A href="http://www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en1.pdf" target="_blank"&gt;http://www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en1.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation (IVAN)&lt;BR&gt;ISRCTN92166560&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/489097/ivan" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/489097/ivan&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;5. Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)&lt;BR&gt;NCT00593450&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/427247/catt" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/427247/catt&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;6. The EQUAL study: A randomised trial to study the EQUivalence of three monthly intravitreal injections and additional injections as needed of bevacizumab (Avastin) and ranibizumab (Lucentis) on visual acuity in patients with exudative age-related macular degeneration.&lt;BR&gt;NTR1331&lt;BR&gt;&lt;A href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331" target="_blank"&gt;http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;7. Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA)&lt;BR&gt;NCT00559715&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00559715?term=NCT00559715" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00559715?term=NCT00559715&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;8. Vedula SS, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD005139. DOI: 10.1002/14651858.CD005139.pub2.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005139/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005139/frame.html&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;9. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment 2008 May;12(16):iii-201.&lt;BR&gt;&lt;A href="http://www.hta.ac.uk/execsumm/summ1216.htm" target="_blank"&gt;http://www.hta.ac.uk/execsumm/summ1216.htm&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;10. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Pruente C, Schmidt-Erfurth UM, Tano Y, Wolf S. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British Journal of Ophthalmology. 2010. 94 (1):2-13. Epub 2009 May 13.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19443462" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19443462&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;11. Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration. BMJ 2010 Mar 6;340(7745):526-30.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20189972" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20189972&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12. The Royal College of Ophthalmologists. Age-related macular degeneration guidelines for management. 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. The Royal College of Ophthalmologists. Ranibizumab: the clinician’s guide to commencing, continuing and discontinuing treatment. 2008&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;14. NICE technology appraisal guidance 155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf" target="_blank"&gt;http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15. NICE technology appraisal guidance 155: Quick reference guide: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English" target="_blank"&gt;http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:377475:5" name=internalLink&gt;Full list of Ranibizumab (Lucentis) topic summary references&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="nelh:377475:3" name=internalLink&gt;2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Evidence Base&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:4" name=internalLink&gt;2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis) Clinical Practice Points&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:2" name=internalLink&gt;2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on AMD - Ranibizumab (Lucentis) - Evidence Base&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/aeu_amd_0610_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Ranibizumab.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Back to 2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;Ranibizumab (Lucentis): Evidence base for current treatment&lt;/H2&gt;
&lt;P align=left&gt;Robin D Hamilton. MBBS, DM(dist), MRCOphth. Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;The major studies that the treatment algorithms included in the NICE technology appraisal guidance and the RCOphth guidance are based upon are discussed below [12, 13, 14, 15].&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;ANCHOR&lt;/STRONG&gt;&lt;BR&gt;The 2 year results of the ANCHOR study were reported in 2009 [16, 17, 18]. This was a multi-centre randomised control trial (RCT) of 423 patients comparing photodynamic therapy (PDT) with monthly intravitreal ranibizumab injections (0.3 or 0.5mg) for the treatment of predominantly classic neovascular AMD. The primary outcome measure was the proportion of patients losing less than 15 letters.&lt;/P&gt;
&lt;P&gt;Key findings:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Primary outcome was achieved in 64.3% in the PDT group versus 94.3% and 96.4% for the 0.3mg and 0.5mg ranibizumab groups respectively.&lt;/LI&gt;
&lt;LI&gt;Continuous dosing regime: 12 injections over 12 months.&lt;/LI&gt;
&lt;LI&gt;Efficacy maintained to 2nd year.&lt;/LI&gt;
&lt;LI&gt;Ranibizumab superior to PDT.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;MARINA&lt;/STRONG&gt;&lt;BR&gt;This was a multi-centre RCT focused at looking at all those patients with neovascular AMD who respond poorly to PDT treatment, minimally classic and occult AMD. First published in 2006 other reports have followed, [17, 19, 20, 21, 22]. Ranibizumab injections (0.3 or 0.5mg) were compared to sham in 716 patients over 2 years. The primary outcome was the proportion of patients losing less than 15 letters. Further subgroup analysis showed that the most important predictors of visual acuity (VA) outcomes were, in decreasing order of importance, baseline VA score, choroidal neovascularisation (CNV) lesion size, and age [22].&lt;/P&gt;
&lt;P&gt;Key findings:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The primary outcome was achieved in 62.2% of the sham patients compared with 9.5% and 94.6% for the 0.3mg and 0.5mg ranibizumab respectively.&lt;/LI&gt;
&lt;LI&gt;Continuous dosing regime 24 injections over 24 months.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;PIER&lt;/STRONG&gt;&lt;BR&gt;This multi-centre RCT in 184 patients with predominantly or minimally classic or occult with no classic CNV lesions (all subtypes) compared intravitreal ranibizumab (0.3 or 0.5mg) administered monthly for three months and then quarterly for 12 months [23]. The primary endpoint was mean change from baseline VA at month 12. &lt;/P&gt;
&lt;P&gt;Key findings:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The mean changes from baseline VA at 12 months were -16.3, -1.6, and -0.2 letters for the sham, 0.3 mg, and 0.5 mg groups, respectively.&lt;/LI&gt;
&lt;LI&gt;Initial letter gain and treatment effect declined in the ranibizumab groups during quarterly dosing (e.g., at three months the mean changes from baseline VA had been gains of 2.9 and 4.3 letters for the 0.3 mg and 0.5 mg doses, respectively). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;PrONTO&lt;/STRONG&gt;&lt;BR&gt;This was a 2-year prospective, single-centre, uncontrolled, variable-dosing regimen with intravitreal ranibizumab based on Optical Coherence Tomography (OCT) Imaging of Patients with Neovascular Age-Related Macular Degeneration (AMD). AMD patients with neovascularization involving the central fovea and a central retinal thickness (CRT) of at least 300 microm as measured by OCT were enrolled to receive 3 consecutive monthly intravitreal injections of ranibizumab (0.5 mg) [24, 25]. During the first year, retreatment with ranibizumab was performed at each monthly visit if any criterion was fulfilled:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;an increase in OCT-CRT of at least 100 microns.&lt;/LI&gt;
&lt;LI&gt;a loss of 5 letters or more.&lt;BR&gt;During the second year, the retreatment criteria were amended to include:&lt;/LI&gt;
&lt;LI&gt;retreatment if any qualitative increase in the amount of fluid was detected using OCT.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Key findings:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Forty patients were enrolled and 37 completed the 2-year study.&lt;/LI&gt;
&lt;LI&gt;At month 24, the mean visual acuity (VA) improved by 11.1 letters and the OCT-CRT decreased by 212 microm.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;VA improved by 15 letters or more in 43% of patients.&lt;/LI&gt;
&lt;LI&gt;Average of 9.9 injections over 24 months.&lt;/LI&gt;
&lt;LI&gt;OCT-guided variable-dosing regimen with intravitreal ranibizumab resulted in VA outcomes comparable with the outcomes from the phase III clinical studies, but fewer intravitreal injections were required.&lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;&lt;BR&gt;Combination treatments&lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;FOCUS&lt;/STRONG&gt;&lt;BR&gt;This multi-centre RCT was designed to assess the efficacy and adverse-events profile of combined treatment with ranibizumab and PDT in patients with predominantly classic CNV secondary to neovascular age-related macular degeneration. Patients received monthly intravitreal injections of ranibizumab 0.5 mg or sham injections and all patients received PDT on day zero, then quarterly as needed. Primary outcome was the proportion of patients losing less than 15 letters [26]. &lt;/P&gt;
&lt;P&gt;Key findings:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;At month 24, the primary outcome was achieved in 88% of ranibizumab + PDT patients compared to 75% for PDT alone.&lt;/LI&gt;
&lt;LI&gt;25% had gained at least 15 letters compared to 7% for PDT alone.&lt;/LI&gt;
&lt;LI&gt;Ranibizumab + PDT patients exhibited less lesion growth and greater reduction of CNV leakage and subretinal fluid accumulation, and required fewer PDT retreatments, than PDT-alone patients (mean = 0.4 vs 3.0 PDT retreatments). &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;However, the RCOphth guidelines for management state that “At present there is insufficient evidence to indicate that combined therapy is better than monotherapy with ranibizumab”, [12 – p.45]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Secondary Publications:&lt;BR&gt;[12], [13], [14] and [15]&lt;/P&gt;
&lt;P&gt;Interventional Studies:&lt;BR&gt;[16], [17], [18], [19], [20], [21], [22], [23] and [26]&lt;/P&gt;
&lt;P&gt;Observational Studies:&lt;BR&gt;[24] and [25]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;On to: &lt;A href="nelh:377475:4" name=internalLink&gt;2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis) Clinical Practice Points&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;12. The Royal College of Ophthalmologists. Age-related macular degeneration guidelines for management. 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. The Royal College of Ophthalmologists. Ranibizumab: the clinician’s guide to commencing, continuing and discontinuing treatment. 2008&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;14. NICE technology appraisal guidance 155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf" target="_blank"&gt;http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15. NICE technology appraisal guidance 155: Quick reference guide: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English" target="_blank"&gt;http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;16. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009 Jan;116(1):57-65.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19118696" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19118696&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;17. Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye Clinical Trial Results from MARINA and ANCHOR. Ophthalmology 2010 Feb 27.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20189654" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20189654&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;18. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology 2009 Jan;127(1):13-21.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19139332" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19139332&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;19. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355:1419–31.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17021318" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17021318&lt;/A&gt; &lt;BR&gt;&lt;EM&gt;Older reference to support commentary not identified in specific 2007- Ranibizumab (Lucentis) AMD search.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;20. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology 2007 Nov;125(11):1460-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17998507" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17998507&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;21. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 Oct;114(10):1868-75.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17628683" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17628683&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;22. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 Feb;114(2):246-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17270674" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17270674&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;23. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. American Journal of Ophthalmology 2008 Feb;145(2):239-48.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18222192" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18222192&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;24. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology 2007 Apr;143(4):566-83.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17386270" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17386270&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;25. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American Journal of Ophthalmology 2009 Jul;148(1):43-58.e1. Epub 2009 Apr 18.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19376495" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19376495&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;26. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. American Journal of Ophthalmology 2008 May;145(5):862-74. Epub 2008 Mar 5.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18321465" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18321465&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:377475:5" name=internalLink&gt;Full list of Ranibizumab (Lucentis) topic summary&amp;nbsp;references&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:4" name=internalLink&gt;2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis) Clinical Practice Points&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:2" name=internalLink&gt;2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Back to 2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Please click here to view 2009 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on AMD - Ranibizumab (Lucentis) - Clinical Practice Points&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/aeu_amd_0610_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Ranibizumab.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Back to 2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Please click here to view 2009 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&lt;BR&gt;Ranibizumab (Lucentis): Clinical Practice Points&lt;/H2&gt;
&lt;P align=left&gt;Robin D Hamilton. MBBS, DM(dist), MRCOphth. Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Why treat neovascular AMD?&lt;/STRONG&gt;&lt;BR&gt;A systematic review covering the period 1985 to 2005 assessed studies reporting outcomes for untreated patients with neovascular AMD. At baseline in this review, 20% had a VA which was worse than 6/60, and this had increased to 76% by year 3 [27].&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Which subtypes of neovascular AMD should be considered for treatment?&lt;/STRONG&gt;&lt;BR&gt;All three major subtypes (predominantly classic, minimally classic occult (with no classic component)) of CNV respond to ranibizumab [16, 19].&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;Which lesions should be considered for Ranibizumab treatment?&lt;/STRONG&gt;&lt;BR&gt;Following the technology appraisal by NICE, the treatment of choice for lesions with subfoveal involvement (juxtafoveal should be included in this group) is Ranibizumab 0.5mg, [14]. Treatment is indicated when:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;there is an active subfoveal neovascularisation of any lesion type.&lt;/LI&gt;
&lt;LI&gt;Best Corrected Visual Acuity is 6/96 (logMar 1.2 or 24 ETDRS letters) or better.&lt;/LI&gt;
&lt;LI&gt;There is no permanent structural damage to the fovea.&lt;/LI&gt;
&lt;LI&gt;There is evidence of disease progression, defined by:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;The appearance of sight threatening CNV which was not previously suspected or thought to be present.&lt;/LI&gt;
&lt;LI&gt;Evidence of new haemorrhage and/or subretinal fluid.&lt;/LI&gt;
&lt;LI&gt;A documented recent visual decline in the presence of CNV.&lt;/LI&gt;
&lt;LI&gt;An increase in CNV size between visits.&lt;/LI&gt;&lt;/UL&gt;&lt;/UL&gt;
&lt;P&gt;The initial baseline VA is not a limiting factor for response to Ranibizumab as all baseline subgroups gained with treatment [22, 28].&lt;/P&gt;
&lt;P&gt;Trials did not include cases with:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Haemorrhage or serous pigment epithelial detachment involving greater than 50% of the CNV. &lt;/LI&gt;
&lt;LI&gt;Glaucoma or raised IOP.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Advanced cataract&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;However, there is no evidence to suggest that ranibizumab should be withheld in the populations. It has been suggested that ranibizumab therapy should be completed before cataract surgery, [29, 30].&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Treatment is not recommended for patients with the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Structural foveal damage either from advanced subretinal fibrosis or geographic atrophy involving the centre of the fovea.&lt;/LI&gt;
&lt;LI&gt;Confounding severe ocular disease such as rhegmatogenous retinal detachment or vitreous or preretinal haemorrhage obscuring the centre of the macula.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Initiation of treatment&lt;/STRONG&gt;&lt;BR&gt;Loading dose of 3 consecutive monthly injections of ranizibumab appears optimal as this is when the majority of patients experienced most VA gain in all studies with the largest gain occuring after the first injection. Early treatment is important as delay in initiation can lead to substantial visual loss. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Appropriate time intervals for continuation&lt;/STRONG&gt;&lt;BR&gt;The initial 3 injections and the rapidity of these is crucial as mentioned above and clinical trials suggest that a monthly regimen of ranibizumab intravitreal injections demonstrated the best VA outcomes. The results from flexible regimen, as documented in the PrONTO study [24, 25] and the SUSTAIN study (completed and reported at international conference) [31, 32], show that guided dosing with fewer ranibizumab injections and close monthly monitoring can maintain efficacy outcomes. If there is no active disease, then continued treatment is not necessary but the patient should be monitored closely, particularly in the first 12 months. If there is any evidence of disease activity, retreatment should begin as soon as possible to maintain good visual outcomes.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Therapy after 2 years&lt;/STRONG&gt;&lt;BR&gt;The Horizon study was an extension of the MARINA and ANCHOR studies and in the 3rd year 61% of patients needed some additional treatments, [33, 34]. In this study, there was some deterioration of vision but better visual and anatomical outcomes at 2 years were of good predictive value. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Is treatment safe?&lt;BR&gt;&lt;/STRONG&gt;In a review of the ANCHOR, MARINA, PIER and SAILOR studies, of the 3252 patients receiving over 28500 intravitreal injections, the rate of presumed endophthalmitis was 0.05% and serious intraocular inflammation (0.03%) (review completed and reported at international conference) [35]. Further recent research on the clinical safety of ranibizumab has also been published. [36, 37].&lt;/P&gt;
&lt;P&gt;The risk of arterial thromboembolic events, including non-fatal myocardial infarction, non-fatal stroke and death from a vascular or unknown cause was similar in the 2 larger studies. In MARINA the risk for sham was 3.8%, 4.6% for 0.3mg Ranibizumab and 4.6% for 0.5mg ranibizumab. In the ANCHOR study, the risk was 4.2% for PDT, 4.4% and 5.0% for 0.3mg and 0.5mg ranibizumab respectively. Even though this risk is low, the benefit-risk profile should be discussed with each individual patient with particular care taken to those with perceived to be at increased risk such as those with:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Recent history of Stroke or myocardial infarction&lt;/LI&gt;
&lt;LI&gt;Uncontrolled hypertension&lt;/LI&gt;
&lt;LI&gt;Uncontrolled angina&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Secondary Publications:&lt;BR&gt;[14], [27], [29], [30] and [36]&lt;/P&gt;
&lt;P&gt;Interventional Studies:&lt;BR&gt;[16], [19], [22] and [37]&lt;/P&gt;
&lt;P&gt;Observational Studies:&lt;BR&gt;[24], [25], and [28]&lt;/P&gt;
&lt;P&gt;News/Unpublished Trials:&lt;BR&gt;[31], [32], [33], [34] and [35]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Back to 2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;14. NICE technology appraisal guidance 155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf" target="_blank"&gt;http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009 Jan;116(1):57-65.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19118696" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19118696&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;19. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355:1419–31.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17021318" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17021318&lt;/A&gt; &lt;BR&gt;&lt;EM&gt;Older reference to support commentary not identified in specific 2007- Ranibizumab (Lucentis) AMD search.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;22. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 Feb;114(2):246-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17270674" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17270674&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;27. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008 Jan;115(1):116-26. Epub 2007 Aug 6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17675159" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17675159&lt;/A&gt; &lt;BR&gt;&lt;EM&gt;Additional reference to support commentary not identified in specific Ranibizumab (Lucentis) AMD search.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;28. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. American Journal of Ophthalmology 2007 Dec;144(6):850-857. Epub 2007 Oct 22.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17949673" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17949673&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;29. Amoaku W. Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment. Eye 2009 Nov;23(11):2140-2.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18670458" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18670458&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;30. The Royal College of Ophthalmologists. Ranibizumab: the clinician’s guide to commencing, continuing and discontinuing treatment. 2008&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;31. SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration&lt;BR&gt;NCT00331864&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00331864" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00331864&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;32. Meyer CH, Eter N, Holz FG, et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial [abstract]. Investigative Ophthalmology &amp;amp; Visual Science 2008;49:E-abstract 273.&lt;BR&gt;&lt;A href="http://abstracts.iovs.org/cgi/content/abstract/49/5/273?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Meyer&amp;amp;title=ranibizumab&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;resourcetype=HWCIT,HWELTR" target="_blank"&gt;http://abstracts.iovs.org/cgi/content/abstract/49/5/273?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Meyer&amp;amp;title=ranibizumab&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;resourcetype=HWCIT,HWELTR&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;33. An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO &lt;BR&gt;NCT00379795&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00379795" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00379795&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;34. M. Singer, P. Wong, P.-W. Wang, L. Scott. HORIZON Extension Trial of Ranibizumab (LUCENTIS®) for Neovascular Age-Related Macular Degeneration (AMD): Two-Year Safety and Efficacy Results. ARVO 2009. Program#/Poster#: 3093.&lt;BR&gt;&lt;A href="http://arvo.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2281&amp;amp;sKey=795c1c80-f22d-4de7-a518-03eb755bc2ba&amp;amp;cKey=d4978586-7946-4aef-a731-196700c36ce4" target="_blank"&gt;http://arvo.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2281&amp;amp;sKey=795c1c80-f22d-4de7-a518-03eb755bc2ba&amp;amp;cKey=d4978586-7946-4aef-a731-196700c36ce4&lt;/A&gt;&lt;BR&gt;or search Presentations&amp;nbsp;for 3093 at &lt;A href="http://arvo.abstractsonline.com/Plan/start.aspx" target="_blank"&gt;http://arvo.abstractsonline.com/Plan/start.aspx&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;35. Boyer DS, Chung CY, Tuomi L. A Safety Overview of Ranibizumab in Patients With Wet AMD: ANCHOR, MARINA, PIER, and SAILOR Studies. Abstract PO247 presented at the AAO/SOE Joint Annual Meeting, 8–11 November 2008, Atlanta. &lt;A href="http://aao.scientificposters.com/aaoView.cfm?pid=247&amp;amp;yr=2008" target="_blank"&gt;http://aao.scientificposters.com/aaoView.cfm?pid=247&amp;amp;yr=2008&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;&lt;EM&gt;Or use the poster search page at &lt;/EM&gt;&lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;&lt;EM&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt; [search for 247; amend year to 2008].&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;36. Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opinion on Drug Safety 2010 Jan;9(1):149-65.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20001757" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20001757&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;37. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009 Sep;116(9):1731-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19643495" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19643495&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:377475:5" name=internalLink&gt;Full list of Ranibizumab (Lucentis) topic summary references&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:2" name=internalLink&gt;2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:3" name=internalLink&gt;Back to 2010 AEU on AMD Ranibizumab (Lucentis)&amp;nbsp;Evidence Base&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Back to 2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on AMD - Ranibizumab (Lucentis) - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0610/aeu_amd_0610_doc5.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20Evidence%20Tree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Please click here to view 2009 AEU&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Back to 2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Ranibizumab (Lucentis) - Evidence Tree&lt;/H2&gt;
&lt;H3&gt;Databases searched:&amp;nbsp;&lt;/H3&gt;
&lt;UL&gt;
&lt;LI&gt;PubMed 2007 to date; EMBASE 2007 to date; Cochrane Central Register of Controlled Trials; and NHS Evidence - eyes and vision.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; January 2007 to 28th April 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;Cochrane Central Register of Controlled Trials&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Inclusion criteria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;•&amp;nbsp;Publication types:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis and review articles).&lt;/LI&gt;
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials).&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys).&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 2007 on.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Relevancy to focus of the 2010 AMD AEU: Ranibizumab (Lucentis): Rationale for current practice: Current recommended treatment regime. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 600px; HEIGHT: 333px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="AMD Ranibizumab Evidence Tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID377475/nelhImp_0000_evsl_topic_rani.jpg" width=396 height=217&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0610/pdf/AMDAEU2010%20-%20Journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Back to 2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on AMD - Ranibizumab (Lucentis) - All References&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Back to 2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&lt;BR&gt;All References:&lt;BR&gt;Ranibizumab (Lucentis): Rationale for current practice: Current recommended treatment regime.&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1. NHS National electronic Library for Medicines (NeLM) News Service. Lucentis (ranibizumab) approved in the US for treatment of wet age-related macular degeneration &lt;BR&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/487976/487977/487979/" target="_blank"&gt;http://www.nelm.nhs.uk/en/NeLM-Area/News/487976/487977/487979/&lt;/A&gt;&amp;nbsp; [Accessed online 21/05/2010]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;2. European Medicines Agency (EMEA). Lucentis: European Public Assessment Report (EPAR).&lt;BR&gt;&lt;A href="http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm" target="_blank"&gt;http://www.ema.europa.eu/humandocs/Humans/EPAR/lucentis/lucentis.htm&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;3. European Medicines Agency (EMEA). Lucentis: EPAR summary for the public.&lt;BR&gt;&lt;A href="http://www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en1.pdf" target="_blank"&gt;http://www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en1.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;4. A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation (IVAN)&lt;BR&gt;ISRCTN92166560&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/489097/ivan" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/489097/ivan&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;5. Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)&lt;BR&gt;NCT00593450&lt;BR&gt;&lt;A href="http://www.controlled-trials.com/mrct/trial/427247/catt" target="_blank"&gt;http://www.controlled-trials.com/mrct/trial/427247/catt&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;6. The EQUAL study: A randomised trial to study the EQUivalence of three monthly intravitreal injections and additional injections as needed of bevacizumab (Avastin) and ranibizumab (Lucentis) on visual acuity in patients with exudative age-related macular degeneration.&lt;BR&gt;NTR1331&lt;BR&gt;&lt;A href="http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331" target="_blank"&gt;http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1331&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;7. Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA)&lt;BR&gt;NCT00559715&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00559715?term=NCT00559715" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00559715?term=NCT00559715&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;8. Vedula SS, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD005139. DOI: 10.1002/14651858.CD005139.pub2.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005139/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005139/frame.html&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;9. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment 2008 May;12(16):iii-201.&lt;BR&gt;&lt;A href="http://www.hta.ac.uk/execsumm/summ1216.htm" target="_blank"&gt;http://www.hta.ac.uk/execsumm/summ1216.htm&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;10. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Pruente C, Schmidt-Erfurth UM, Tano Y, Wolf S. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British Journal of Ophthalmology. 2010. 94 (1):2-13. Epub 2009 May 13.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19443462" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19443462&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;11. Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration. BMJ 2010 Mar 6;340(7745):526-30.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20189972" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20189972&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;12. The Royal College of Ophthalmologists. Age-related macular degeneration guidelines for management. 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/AMD_GUIDELINES_FINAL_VERSION_Feb_09.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;13. The Royal College of Ophthalmologists. Ranibizumab: the clinician’s guide to commencing, continuing and discontinuing treatment. 2008&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;14. NICE technology appraisal guidance 155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf" target="_blank"&gt;http://www.nice.org.uk/nicemedia/pdf/TA155Guidance.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;15. NICE technology appraisal guidance 155: Quick reference guide: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration, August 2008.&lt;BR&gt;&lt;A href="http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English" target="_blank"&gt;http://guidance.nice.org.uk/TA155/QuickRefGuide/pdf/English&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;16. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009 Jan;116(1):57-65.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19118696" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19118696&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;17. Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye Clinical Trial Results from MARINA and ANCHOR. Ophthalmology 2010 Feb 27.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20189654" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20189654&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;18. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology 2009 Jan;127(1):13-21.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19139332" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19139332&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;19. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355:1419–31.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17021318" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17021318&lt;/A&gt; &lt;BR&gt;Older reference to support commentary not identified in specific 2007- Ranibizumab (Lucentis) AMD search.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;20. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology 2007 Nov;125(11):1460-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17998507" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17998507&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;21. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 Oct;114(10):1868-75.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17628683" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17628683&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;22. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 Feb;114(2):246-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17270674" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17270674&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;23. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. American Journal of Ophthalmology 2008 Feb;145(2):239-48.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18222192" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18222192&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;24. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. American Journal of Ophthalmology 2007 Apr;143(4):566-83.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17386270" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17386270&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;25. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American Journal of Ophthalmology 2009 Jul;148(1):43-58.e1. Epub 2009 Apr 18.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19376495" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19376495&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;26. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. American Journal of Ophthalmology 2008 May;145(5):862-74. Epub 2008 Mar 5.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18321465" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18321465&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;27. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008 Jan;115(1):116-26. Epub 2007 Aug 6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17675159" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17675159&lt;/A&gt; &lt;BR&gt;Additional reference to support commentary not identified in specific Ranibizumab (Lucentis) AMD search.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;28. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. American Journal of Ophthalmology 2007 Dec;144(6):850-857. Epub 2007 Oct 22.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17949673" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17949673&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;29. Amoaku W. Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment. Eye 2009 Nov;23(11):2140-2.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18670458" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18670458&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;30. The Royal College of Ophthalmologists. Ranibizumab: the clinician’s guide to commencing, continuing and discontinuing treatment. 2008&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;31. SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration&lt;BR&gt;NCT00331864&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00331864" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00331864&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;32. Meyer CH, Eter N, Holz FG, et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial [abstract]. Investigative Ophthalmology &amp;amp; Visual Science 2008;49:E-abstract 273.&lt;BR&gt;&lt;A href="http://abstracts.iovs.org/cgi/content/abstract/49/5/273?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Meyer&amp;amp;title=ranibizumab&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;resourcetype=HWCIT,HWELTR" target="_blank"&gt;http://abstracts.iovs.org/cgi/content/abstract/49/5/273?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=1&amp;amp;author1=Meyer&amp;amp;title=ranibizumab&amp;amp;andorexacttitle=and&amp;amp;andorexacttitleabs=and&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;resourcetype=HWCIT,HWELTR&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;33. An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO &lt;BR&gt;NCT00379795&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00379795" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00379795&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;34. M. Singer, P. Wong, P.-W. Wang, L. Scott. HORIZON Extension Trial of Ranibizumab (LUCENTIS®) for Neovascular Age-Related Macular Degeneration (AMD): Two-Year Safety and Efficacy Results. ARVO 2009. Program#/Poster#: 3093.&lt;BR&gt;&lt;A href="http://arvo.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2281&amp;amp;sKey=795c1c80-f22d-4de7-a518-03eb755bc2ba&amp;amp;cKey=d4978586-7946-4aef-a731-196700c36ce4" target="_blank"&gt;http://arvo.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2281&amp;amp;sKey=795c1c80-f22d-4de7-a518-03eb755bc2ba&amp;amp;cKey=d4978586-7946-4aef-a731-196700c36ce4&lt;/A&gt;&lt;BR&gt;or search Presentations&amp;nbsp;for 3093 at &lt;A href="http://arvo.abstractsonline.com/Plan/start.aspx" target="_blank"&gt;http://arvo.abstractsonline.com/Plan/start.aspx&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;35. Boyer DS, Chung CY, Tuomi L. A Safety Overview of Ranibizumab in Patients With Wet AMD: ANCHOR, MARINA, PIER, and SAILOR Studies. Abstract PO247 presented at the AAO/SOE Joint Annual Meeting, 8–11 November 2008, Atlanta. &lt;A href="http://aao.scientificposters.com/aaoView.cfm?pid=247&amp;amp;yr=2008" target="_blank"&gt;http://aao.scientificposters.com/aaoView.cfm?pid=247&amp;amp;yr=2008&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;BR&gt;Or use the poster search page at &lt;A href="http://aao.scientificposters.com/aaoSearch.cfm" target="_blank"&gt;http://aao.scientificposters.com/aaoSearch.cfm&lt;/A&gt; [search for 247; amend year to 2008].&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;36. Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opinion on Drug Safety 2010 Jan;9(1):149-65.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20001757" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20001757&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;37. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009 Sep;116(9):1731-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19643495" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19643495&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377475:1" name=internalLink&gt;Back to 2010 AEU on&amp;nbsp;AMD Ranibizumab (Lucentis)&amp;nbsp;Introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>377548</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=377548]]&gt;</url>
    <title>2010 Annual Evidence Update on Age-related macular degeneration - Uncertainties in the management of AMD</title>
    <publicationDate>2010-06-14T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>KNOWN UNCERTAINTY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,ANNUAL EVIDENCE UPDATES,AMD,CONDITIONS,AMD AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Age-related macular degeneration - Uncertainties in the management of AMD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;What clinical questions would you like answered on AMD?&lt;/H2&gt;
&lt;P&gt;NHS Evidence - eyes and vision is collaborating in the development of UK DUETs - the UK Database of Uncertainties about the Effects of Treatments.&lt;/P&gt;
&lt;P&gt;DUETs has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp;&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians. &lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems.&lt;/P&gt;
&lt;P&gt;The following uncertainties have been identified by the NHS Evidence - eyes and vision team. As new Systematic Reviews are identified by the eyes and vision team further DUETs on AMD will be added.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Therapeutic interventions&lt;BR&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/eyes/viewResource.aspx?resid=377561" target="_blank"&gt;Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/eyes/viewResource.aspx?resid=377779" target="_blank"&gt;Appropriate duration and optimal treatment regimen of anti-vascular endothelial growth factor modalities for exudative age-related macular degeneration &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/eyes/viewResource.aspx?resid=377628" target="_blank"&gt;Appropriate duration and optimal treatment regimen of anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Eyes/ViewResource.aspx?resID=377887" target="_blank"&gt;Bevacizumab (safety and efficacy) in the treatment of age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Eyes/ViewResource.aspx?resID=377857" target="_blank"&gt;Interventions for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/DUETs/viewResource.aspx?resid=377894" target="_blank"&gt;Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/eyes/viewResource.aspx?resid=377778" target="_blank"&gt;Long-term effects of anti-vascular endothelial growth factor therapies for exudative age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/eyes/viewResource.aspx?resid=377625" target="_blank"&gt;Long-term effects of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Eyes/ViewResource.aspx?resID=377890" target="_blank"&gt;Optimal dosing regime/re-treatment benefits of anti-vascular endothelial growth factor modalities in the treatment of age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/eyes/viewResource.aspx?resid=377777" target="_blank"&gt;Ranibizumab compared to bevacizumab (clinical effectiveness and cost effectiveness) in the treatment of exudative age-related macular degeneration (AMD)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313208:0" name=internalLink&gt;Antioxidant multivitamin supplements in malnourished people to slow progression of age-related macular degeneration to more severe stages of the disease&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313207:0" name=internalLink&gt;Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313213:0" name=internalLink&gt;Any multivitamin or single component antioixidant supplement for age-related macular degeneration to slow or prevent progression&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:312989:0" name=internalLink&gt;Dietary antioxidants and primary prevention of age-related macular degeneration&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313169:0" name=internalLink&gt;Ginkgo biloba extract for age-related macular degeneration&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313212:0" name=internalLink&gt;Lutein or zeaxanthin for age-related macular degeneration to slow or prevent distance visual acuity loss or progression&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313185:0" name=internalLink&gt;Omega 3 fatty acids to halt progression of age-related macular degeneration&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313182:0" name=internalLink&gt;Omega 3 fatty acids to prevent age-related macular degeneration&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313209:0" name=internalLink&gt;Types of anti-oxidant multivitamin supplements used to slow or prevent progression of age-related macular degeneration important&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313210:0" name=internalLink&gt;Vitamin E for age-related macular degeneration to slow distance visual acuity change or progression&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:313211:0" name=internalLink&gt;Zinc for age-related macular degeneration to prevent progression&lt;/A&gt;&lt;BR&gt;Originally identified in 2009 AMD AEU. Updated for 2010 AMD AEU.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;If you are aware of or identified any uncertainties in the management of AMD please let us know.&amp;nbsp; You can contact us via our &lt;A href="http://www.library.nhs.uk/EYES/ContactUs.aspx" target="_blank"&gt;feedback form&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;Back to 2010&amp;nbsp;AMD AEU contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>388208</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=388208]]&gt;</url>
    <title>2010 Annual Evidence Update on Amblyopia - Clinical Outcomes of Amblyopia and/or its Treatment</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,ANNUAL EVIDENCE UPDATES,CONDITIONS,AMBLYOPIA,AMBLYOPIA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on Amblyopia - Clinical Outcomes of Amblyopia and/or its Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_amblyopia_0910/aeu_amblyopia_0910_doc2.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/Articles/ClinicalOutcomesMikeClarkeFinalversion.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Clinical Outcomes of Amblyopia and/or its Treatment&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Michael P Clarke&lt;BR&gt;Consultant Paediatric Ophthalmologist, Royal Victoria Infirmary, &lt;BR&gt;Newcastle upon Tyne Hospitals NHS Foundation Trust&lt;BR&gt;Reader in Ophthalmology, Newcastle University&lt;/H3&gt;
&lt;P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="#Intro"&gt;Introduction&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#Refract"&gt;Refractive adaptation&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#Penal"&gt;Penalisation vs patching&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#Monit"&gt;Electronic monitoring of occlusion&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#Age"&gt;Age of treatment&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#Sustain"&gt;Sustained effect of treatment/Recurrence of amblyopia&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#Success"&gt;Success rates following treatment&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="#Ref"&gt;References&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;&lt;A name=Intro&gt;Introduction&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;This update considers evidence published since the 1997 Health Technology Assessment (HTA) report on preschool vision screening (1) concerning clinical outcomes of the treatment of strabismic and/or refractive amblyopia. The trend suggested by recent studies is towards a reduction in the intensity and duration of treatment, without any worsening of treatment outcomes. It has been demonstrated that a significant proportion of children have an incomplete response to both traditional and reduced intensity/duration treatment. &lt;/P&gt;
&lt;P&gt;Secondary publication:&lt;BR&gt;[1]&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;/A&gt;&lt;BR&gt;&lt;A name=Refract&gt;Refractive adaptation&lt;/H2&gt;
&lt;P&gt;Refractive adaptation, i.e. spectacle wear for a set time, has been demonstrated to be a distinct component of amblyopia treatment for both refractive and strabismic amblyopia in Pediatric Eye Disease Investigator Group (PEDIG) and other trials (2) (3) (4) (5) (6). Progressive improvements in acuity are seen in some cases for up to 30 weeks following refractive correction. It is suggested that, in cases where significant ametropia or anisometropia is present, that occlusion or penalisation treatment is deferred until no further improvement in acuity occurs. The Royal College of Ophthalmologists (RCOphth) 2006 guideline concludes that “Improvement in acuity following refractive correction should be allowed to plateau prior to treatment with occlusion or atropine – this may take 16 – 22 weeks” (7).&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The 2009 Cochrane review Interventions for unilateral refractive amblyopia also states that “In some cases of unilateral refractive amblyopia it appears that there is a treatment benefit from refractive correction alone. Where amblyopia persists there is some evidence that adding occlusion further improves vision. It remains unclear which treatment regimes are optimal for individual patients. The nature of any dose/response effect from occlusion still needs to be clarified (8).” &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Secondary publications:&lt;BR&gt;[4], [7] and [8]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Interventional studies:&lt;BR&gt;[3], [5] and [6]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational study:&lt;BR&gt;[2]&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;/A&gt;&lt;BR&gt;&lt;A name=Penal&gt;Penalisation vs patching&lt;/H2&gt;
&lt;P&gt;Penalisation of the better seeing eye with atropine drops or ointment has been demonstrated to be as effective as patching for moderate amblyopia (20/40 to 20/100; 6/12 to 6/30) (9) (10), and in a small trial for severe amblyopia, (11). Use of atropine at the weekends only has been subsequently shown to be as effective as daily instillation of atropine (12) (13) (11). Initial improvement in acuity appears to be more rapid with occlusion, but no significant differences were found in most studies between the two forms of treatment at time points beyond 6 months follow up (reference (14) excepted).&amp;nbsp; A shift in fixation preference does not seem to be required for atropine treatment to be effective in strabismic amblyopia (15) - one postulated mechanism for the effect is the degradation of higher spatial frequencies by pupil dilation and loss of accommodation. While atropine is as effective as occlusion for treating amblyopia, and may be a more acceptable form of treatment as it is less cosmetically obtrusive than occlusion, it is less controllable (as once instilled the effects last for up to 2 weeks) and is, rarely, associated with reversal of amblyopia (16) (17).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The 2010 Cochrane review Conventional occlusion versus pharmacologic penalization for amblyopia states that “Both conventional occlusion and atropine penalization produce visual acuity improvement in the amblyopic eye. Atropine penalization appears to be as effective as conventional occlusion, although the magnitude of improvement differed among the three trials [included in the review]. Atropine penalization can be used as first line treatment for amblyopia” (18).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The 2010 Cochrane review Interventions for strabismic amblyopia also states that “Occlusion, whilst wearing necessary refractive correction, appears to be more effective than refractive correction alone in the treatment of strabismic amblyopia” (19).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;While some non randomised studies report excellent results from full time (generally all waking hours bar one) occlusion (20) (21), one randomised study has demonstrated that 2 hours of occlusion is equally effective as 6 hours for moderate (20/40 to 20/80; 6/12 to 6/24) amblyopia (22) and a further randomised study reported 6 hours occlusion to be as effective as full time occlusion for visual acuities between 20/100 and 20/400 (6/30 to 6/120) (23). Near visual activities do not seem to add to the effect of occlusion (24) and this is highlighted in the Cochrane review on Interventions for strabismic amblyopia which concludes that “The benefit of combining near activities with occlusion is unproven”. This review also states that “No RCTs were found that assessed the role of either partial occlusion or optical penalisation to refractive correction for strabismic amblyopia” (19).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Secondary publications:&lt;BR&gt;[18], and [19]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Interventional studies:&lt;BR&gt;[10], [11], [13], [14], [15], [22], [23] and [24]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational studies:&lt;BR&gt;[9], [12], [16], [17], [20], and [21]&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;/A&gt;&lt;BR&gt;&lt;A name=Monit&gt;Electronic monitoring of occlusion&lt;/H2&gt;
&lt;P&gt;Studies using electronic monitoring of the actual dose of occlusion received by children with amblyopia show that, especially for higher prescribed doses of occlusion, the actual dose received is much less than that prescribed in many cases (25) (26) (27). This is particularly the case for younger (15 to 3 months) children (28) and may be associated with socioeconomic status (29). Concordance with the prescribed occlusion dose may be improved by the provision of written information (30) (31), and by allowing parents to tailor the regime according to their circumstances (32).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Studies using electronic monitoring support the findings of randomised trials suggesting lower doses of patching may be equally effective as more intensive regimes. There appears to be an effect on the total dose of occlusion received (22), with cumulative occlusion doses exceeding 50 hours, and dose rates &amp;gt; or =1 hour per day resulting in lower residual amblyopia and a greater proportion of the deficit corrected (33). Further, one study showed that most of children achieved their best visual acuity with 150 to 250 hours' cumulative occlusion dose (34), while another suggested a maximum effect with 400 hours occlusion (35).&amp;nbsp; The UK Monitored Occlusion Treatment of Amblyopia Study (MOTAS) study suggested that more than 80% of the improvement during occlusion occurred within 6 weeks of the start of treatment (36).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Interventional studies:&lt;BR&gt;[25], [30], [31], and [33]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational studies:&lt;BR&gt;[26], [27], [28], [29], [32], [34], [35], and [36]&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;/A&gt;&lt;BR&gt;&lt;A name=Age&gt;Age of treatment&lt;/H2&gt;
&lt;P&gt;Treatment of amblyopia has traditionally not been considered over the age of around 7 years, as it has been believed that the visual system no longer has plasticity beyond this age. Recent work has shown that treatment can be, at least partially, effective in some older children (37) (38), however treatment may be less effective in children over the age of 12 (39). As in younger children, refractive adaptation occurs (40) and atropine has similar effect to occlusion (41) with one study finding occlusion to be more effective in older children (42).&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A recent systematic review by Schmucker C et al concluded that “Uncertainties remain about the age at which treatment for amblyopia or its risk factors is most effective. Beside methodological limitations, the design of the studies [included in the review] made it challenging to address this question sufficiently (43).” &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Secondary publication:&lt;BR&gt;[43]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Interventional studies:&lt;BR&gt;[38], [39], [41], and [42]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational studies:&lt;BR&gt;[37], and [40]&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;/A&gt;&lt;BR&gt;&lt;A name=Sustain&gt;Sustained effect of treatment/Recurrence of amblyopia&lt;/H2&gt;
&lt;P&gt;The issue of whether the effects of treatment are sustained, following cessation of treatment, has been considered in a number of studies. There is some evidence that the treatment effect is sustained in approximately 80% of cases at least for one year after cessation of treatment (44) (45), dropping with longer term follow up to 60 to 70% of cases (46) (47).&amp;nbsp; One study found 24% of patients to have recurrent amblyopia, with recurrence being more likely if treatment was stopped abruptly rather than weaned (48). The risk of recurrence was higher, in one study, for those participants with better visual acuity at the time of cessation of treatment; a greater number of lines improved during the previous treatment, and a history of recurrence (49). &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Orthotropia or excellent stereoacuity at the time of patching cessation did not appear to have a protective effect on the risk of recurrence (49). Other studies have found recurrence to be linked to hypermetropic anisometropia (50) and mixed refractive/strabismic amblyopia (51). Other authors prefer to maintain treatment with occlusion up to the age of 10 years (52). Improvements in acuity may occur in a proportion of amblyopic eyes later in life if vision deteriorates in the better eye due to other pathology (53) (54).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Interventional study:&lt;BR&gt;[45]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational studies:&lt;BR&gt;[44], [46], [47], [48], [49], [50], [51], [52], [53], and [54]&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&lt;/A&gt;&lt;BR&gt;&lt;A name=Success&gt;Success rates following treatment&lt;/H2&gt;
&lt;P&gt;It is a consistent theme of recent studies (although often not explicitly commented on) that many children do not attain normal acuity in the amblyopic eye following treatment.&lt;BR&gt;Using a criterion of =20/40 acuity at the end of treatment, one study found success rates of between 60 and 74% (55). Worse acuity at the start of treatment and older age at the start of treatment have been reported to predict a poor response to treatment (55) (23) (56) (57). There are a number of small observational studies which suggest there is evidence of structural abnormalities in some eyes responding poorly to treatment (58), (59).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Secondary publication:&lt;BR&gt;[55]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Interventional studies:&lt;BR&gt;[23], [56], [57]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational studies:&lt;BR&gt;[58] and [59]&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;A name=Ref&gt;References:&lt;/H2&gt;
&lt;P&gt;(1) &amp;nbsp;Snowdon SK, Stewart-Brown SL. Preschool vision screening. Health Technology Assessment 1997;1(8):1-85.&lt;BR&gt;&lt;A href="http://www.hta.ac.uk/952" target="_blank"&gt;http://www.hta.ac.uk/952&lt;/A&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(2) &amp;nbsp;Stewart CE, Moseley MJ, Fielder AR, Stephens DA, MOTAS C. Refractive adaptation in amblyopia: quantification of effect and implications for practice. British Journal of Ophthalmology 2004 Dec;88(12):1552-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15548811" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15548811&lt;/A&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(3) &amp;nbsp;Wallace DK, Pediatric Eye Disease Investigator Group, Edwards AR, Cotter SA, Beck RW, Arnold RW, et al. A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children. Ophthalmology 2006 Jun;113(6):904-12.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16751033" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16751033&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(4) &amp;nbsp;Moseley MJ, Fielder AR, Stewart CE. The optical treatment of amblyopia. [Review] [16 refs]. Optometry &amp;amp; Vision Science 2009 Jun;86(6):629-33.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19417699" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19417699&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(5) &amp;nbsp;Cotter SA, Pediatric Eye Disease Investigator Group, Edwards AR, Wallace DK, Beck RW, Arnold RW, et al. Treatment of anisometropic amblyopia in children with refractive correction. Ophthalmology 2006 Jun;113(6):895-903.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16751032" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16751032&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(6) &amp;nbsp;Cotter SA, Edwards AR, Arnold RW, Astle WF, Barnhardt CN, Beck RW, et al. Treatment of strabismic amblyopia with refractive correction. American Journal of Ophthalmology 2007 Jun;143(6):1060-3.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17524783" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17524783&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(7) &amp;nbsp;Paediatric Subcommittee of the Royal College of Ophthalmologists. Guidelines for the Management of Amblyopia. Royal College of Ophthalmologists; 2006.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/GuidelinesfortheManagementofAmblyopia.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/GuidelinesfortheManagementofAmblyopia.pdf&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(8) &amp;nbsp;Shotton K, Powell C, Voros G, Hatt SR. Interventions for unilateral refractive amblyopia. [Review] [33 refs]. Cochrane Database of Systematic Reviews (4):CD005137, 2008 2008;(4):CD005137.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005137/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005137/frame.html&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(9) &amp;nbsp;Simons K, Gotzler KC, Vitale S. Penalization versus part-time occlusion and binocular outcome in treatment of strabismic amblyopia. Ophthalmology 1997 Dec;104(12):2156-60.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9400778" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/9400778&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(10) &amp;nbsp;Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. Archives of Ophthalmology 2002 Mar;120(3):268-78.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11879129" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11879129&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(11) &amp;nbsp;Repka MX, Kraker RT, Beck RW, Birch E, Cotter SA, Holmes JM, et al. Treatment of severe amblyopia with weekend atropine: results from 2 randomized clinical trials. Journal of Aapos: American Association for Pediatric Ophthalmology &amp;amp; Strabismus 2009 Jun;13(3):258-63.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19541265" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19541265&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(12) &amp;nbsp;Simons K, Stein L, Sener EC, Vitale S, Guyton DL. Full-time atropine, intermittent atropine, and optical penalization and binocular outcome in treatment of strabismic amblyopia. Ophthalmology 1997 Dec;104(12):2143-55.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9400777" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/9400777&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(13) &amp;nbsp;Repka MX, Cotter SA, Beck RW, Kraker RT, Birch EE, Everett DF, et al. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology 2004 Nov;111(11):2076-85.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15522375" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15522375&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(14) &amp;nbsp;Pediatric Eye Disease Investigator Group. A comparison of &lt;BR&gt;atropine and patching treatments for moderate amblyopia by patient age, cause of amblyopia, depth of amblyopia, and other factors. Ophthalmology 2003;110(8):1632-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12917184" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12917184&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(15) &amp;nbsp;Pediatric Eye Disease Investigator Group. The course of moderate amblyopia treated with atropine in children: experience of the amblyopia treatment study. American Journal of Ophthalmology 2003 Oct;136(4):630-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14516802" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/14516802&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(16) &amp;nbsp;Hainline BC, Sprunger DT, Plager DA, Neely DE, Guess MG. Reverse amblyopia with atropine treatment. Binocular Vision and Strabismus Quarterly 2009;24(1):25-31.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19323646" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19323646&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(17) &amp;nbsp;Kaye SB, Chen SI, Price G, Kaye LC, Noonan C, Tripathi A, et al. Combined optical and atropine penalization for the treatment of strabismic and anisometropic amblyopia. Journal of Aapos: American Association for Pediatric Ophthalmology &amp;amp; Strabismus 2002 Oct;6(5):289-93.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12381987" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12381987&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(18) &amp;nbsp;Li T, Shotton K. Conventional occlusion versus pharmacologic penalization for amblyopia. [Review] [43 refs]. Cochrane Database of Systematic Reviews (4):CD006460, 2009 2009;(4):CD006460.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006460/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006460/frame.html&lt;/A&gt; &lt;BR&gt;&lt;BR&gt;&lt;BR&gt;(19) &amp;nbsp;Shotton K, Elliott S. Interventions for strabismic amblyopia. [Review] [31 refs]. Cochrane Database of Systematic Reviews (2):CD006461, 2008 2008;(2):CD006461.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006461/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006461/frame.html&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(20) &amp;nbsp;Scott WE, Kutschke PJ, Keech RV, Pfeifer WL, Nichols B, Zhang L. Amblyopia treatment outcomes. Journal of Aapos: American Association for Pediatric Ophthalmology &amp;amp; Strabismus 2005 Apr;9(2):107-11.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15838435" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15838435&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(21) &amp;nbsp;Chekitaan, Karthikeyan B, Meenakshi S. The results of treatment of anisomyopic and anisohypermetropic amblyopia. International Ophthalmology 2009 Aug;29(4):231-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18553062" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18553062&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(22) &amp;nbsp;Repka MX, Beck RW, Holmes JM, Birch EE, Chandler DL, Cotter SA, et al. A randomized trial of patching regimens for treatment of moderate amblyopia in children. Archives of Ophthalmology 2003 May;121(5):603-11.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12742836" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12742836&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(23) &amp;nbsp;Holmes JM, Kraker RT, Beck RW, Birch EE, Cotter SA, Everett DF, et al. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology 2003 Nov;110(11):2075-87.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14597512" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/14597512&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(24) &amp;nbsp;Pediatric Eye Disease Investigator Group. A randomized trial of near versus distance activities while patching for amblyopia in children aged 3 to less than 7 years. Ophthalmology 2008 Nov;115(11):2071-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18789533" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18789533&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(25) &amp;nbsp;Stewart CE, Stephens DA, Fielder AR, Moseley MJ, ROTAS C. Objectively monitored patching regimens for treatment of amblyopia: randomised trial. BMJ 2007 Oct 6;335(7622):707.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17855283" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17855283&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(26) &amp;nbsp;Searle A, Norman P, Harrad R, Vedhara K. Psychosocial and clinical determinants of compliance with occlusion therapy for amblyopic children. Eye 2002 Mar;16(2):150-5.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11988815" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11988815&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(27) &amp;nbsp;Donnelly UM, Stewart NM, Hollinger M. Prevalence and outcomes of childhood visual disorders. Ophthalmic Epidemiology 2005 Aug;12(4):243-50.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16033745" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16033745&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(28) &amp;nbsp;Chua BE, Johnson K, Martin F. A retrospective review of the associations between amblyopia type, patient age, treatment compliance and referral patterns. Clinical &amp;amp; Experimental Ophthalmology 2004 Apr;32(2):175-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15068435" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15068435&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(29) &amp;nbsp;Hudak DT, Magoon EH. Poverty predicts amblyopia treatment failure. Journal of Aapos: American Association for Pediatric Ophthalmology &amp;amp; Strabismus 1997 Dec;1(4):214-5.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10532766" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/10532766&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(30) &amp;nbsp;Newsham D. A randomised controlled trial of written information: the effect on parental non-concordance with occlusion therapy. British Journal of Ophthalmology 2002 Jul;86(7):787-91.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12084751" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12084751&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(31) &amp;nbsp;Loudon SE, Fronius M, Looman CW, Awan M, Simonsz B, van der Maas PJ, et al. Predictors and a remedy for noncompliance with amblyopia therapy in children measured with the occlusion dose monitor. Investigative Ophthalmology &amp;amp; Visual Science 2006 Oct;47(10):4393-400.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17003431" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17003431&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(32) &amp;nbsp;Tripathi A, O'Donnell NP, Holden R, Kaye L, Kaye SB. Occlusion therapy for the treatment of amblyopia: letting the parents decide. Ophthalmologica 2002 Nov;216(6):426-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12566886" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12566886&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(33) &amp;nbsp;Stewart CE, Fielder AR, Stephens DA, Moseley MJ. Treatment of unilateral amblyopia: factors influencing visual outcome. Investigative Ophthalmology &amp;amp; Visual Science 2005 Sep;46(9):3152-60.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16123414" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16123414&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(34) &amp;nbsp;Stewart CE, Stephens DA, Fielder AR, Moseley MJ, MOTAS C. Modeling dose-response in amblyopia: toward a child-specific treatment plan. Investigative Ophthalmology &amp;amp; Visual Science 2007 Jun;48(6):2589-94.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17525188" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17525188&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(35) &amp;nbsp;Cleary M. Efficacy of occlusion for strabismic amblyopia: can an optimal duration be identified? British Journal of Ophthalmology 2000 Jun;84(6):572-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10837378" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/10837378&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(36) &amp;nbsp;Stewart CE, Moseley MJ, Stephens DA, Fielder AR. Treatment dose-response in amblyopia therapy: the Monitored Occlusion Treatment of Amblyopia Study (MOTAS). Investigative Ophthalmology &amp;amp; Visual Science 2004 Sep;45(9):3048-54.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15326120" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15326120&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(37) &amp;nbsp;Pediatric Eye Disease Investigator Group. A prospective, pilot study of treatment of amblyopia in children 10 to &amp;lt;18 years old. American Journal of Ophthalmology 2004 Mar;137(3):581-3.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15013894" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15013894&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(38) &amp;nbsp;Singh I, Sachdev N, Brar GS, Kaushik S. Part-time occlusion therapy for amblyopia in older children. Indian Journal of Ophthalmology 2008 Nov;56(6):459-63.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18974515" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18974515&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(39) &amp;nbsp;Scheiman MM, Hertle RW, Beck RW, Edwards AR, Birch E, Cotter SA, et al. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Archives of Ophthalmology 2005 Apr;123(4):437-47.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15824215" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15824215&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(40) &amp;nbsp;Harvey EM, Dobson V, Clifford-Donaldson CE, Miller JM. Optical treatment of amblyopia in astigmatic children: the sensitive period for successful treatment. Ophthalmology 2007 Dec;114(12):2293-301.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18054643" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18054643&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(41) &amp;nbsp;Scheiman MM, Hertle RW, Kraker RT, Beck RW, Birch EE, Felius J, et al. Patching vs atropine to treat amblyopia in children aged 7 to 12 years: a randomized trial. Archives of Ophthalmology 2008 Dec;126(12):1634-42.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19064841" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19064841&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(42) &amp;nbsp;Menon V, Shailesh G, Sharma P, Saxena R. Clinical trial of patching versus atropine penalization for the treatment of anisometropic amblyopia in older children. Journal of Aapos: American Association for Pediatric Ophthalmology &amp;amp; Strabismus 2008 Oct;12(5):493-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18534880" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18534880&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(43) &amp;nbsp;Schmucker C, Kleijnen J, Grosselfinger R, Riemsma R, Antes G, Lange S, et al. Effectiveness of early in comparison to late(r) treatment in children with amblyopia or its risk factors: a systematic review. [Review] [36 refs]. Ophthalmic Epidemiology 2010 Jan;17(1):7-17.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20100095" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20100095&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(44) &amp;nbsp;Bowman RJ, Williamson TH, Andrews RG, Aitchison TC, Dutton GN. An inner city preschool visual screening programme: long-term visual results. British Journal of Ophthalmology 1998 May;82(5):543-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9713063" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/9713063&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(45) &amp;nbsp;Hertle RW, Scheiman MM, Beck RW, Chandler DL, Bacal DA, Birch E, et al. Stability of visual acuity improvement following discontinuation of amblyopia treatment in children aged 7 to 12 years. Archives of Ophthalmology 2007 May;125(5):655-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17502505" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17502505&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(46) &amp;nbsp;Simonsz-Toth B, Loudon SE, van Kempen-du SH, van de Graaf ES, Groenewoud JH, Simonsz HJ. [Evaluation of visual acuity in a historical cohort of 137 patients treated for amblyopia by occlusion 30-35 years ago]. [German]. Klinische Monatsblatter fur Augenheilkunde 2007 Jan;224(1):40-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17260318" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17260318&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(47) &amp;nbsp;Leiba H, Shimshoni M, Oliver M, Gottesman N, Levartovsky S. Long-term follow-up of occlusion therapy in amblyopia. Ophthalmology 2001 Sep;108(9):1552-5.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11535448" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11535448&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(48) &amp;nbsp;Holmes JM, Beck RW, Kraker RT, Astle WF, Birch EE, Cole SR, et al. Risk of amblyopia recurrence after cessation of treatment. Journal of Aapos: American Association for Pediatric Ophthalmology &amp;amp; Strabismus 2004 Oct;8(5):420-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15492733" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15492733&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(49) &amp;nbsp;Holmes JM, Melia M, Bradfield YS, Cruz OA, Forbes B, Pediatric Eye Disease Investigator Group. Factors associated with recurrence of amblyopia on cessation of patching. Ophthalmology 2007 Aug;114(8):1427-32.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17363058" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17363058&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(50) &amp;nbsp;Levartovsky S, Oliver M, Gottesman N, Shimshoni M. Long-term effect of hypermetropic anisometropia on the visual acuity of treated amblyopic eyes. British Journal of Ophthalmology 1998 Jan;82(1):55-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9536882" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/9536882&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(51) &amp;nbsp;Tacagni DJ, Stewart CE, Moseley MJ, Fielder AR. Factors affecting the stability of visual function following cessation of occlusion therapy for amblyopia. Graefes Archive for Clinical &amp;amp; Experimental Ophthalmology 2007 Jun;245(6):811-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17047980" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17047980&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(52) &amp;nbsp;Bhola R, Keech RV, Kutschke P, Pfeifer W, Scott WE. Recurrence of amblyopia after occlusion therapy. Ophthalmology 2006 Nov;113(11):2097-100.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17074568" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17074568&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(53) &amp;nbsp;El Mallah MK, Chakravarthy U, Hart PM. Amblyopia: is visual loss permanent? British Journal of Ophthalmology 2000 Sep;84(9):952-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10966943" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/10966943&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(54) &amp;nbsp;Rahi JS, Logan S, Borja MC, Timms C, Russell-Eggitt I, Taylor D. Prediction of improved vision in the amblyopic eye after visual loss in the non-amblyopic eye. Lancet 2002 Aug 24;360(9333):621-2.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12241937" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12241937&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(55) &amp;nbsp;Flynn JT, Woodruff G, Thompson JR, Hiscox F, Feuer W, Schiffman J, et al. The therapy of amblyopia: an analysis comparing the results of amblyopia therapy utilizing two pooled data sets. Transactions of the American Ophthalmological Society 1999;97:373-90.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10703134" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/10703134&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(56) &amp;nbsp;Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, Beck RW, Holmes JM, Cotter SA, et al. A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years. Archives of Ophthalmology 2008 Aug;126(8):1039-44.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18695096" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18695096&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(57) &amp;nbsp;Repka MX, Wallace DK, Beck RW, Kraker RT, Birch EE, Cotter SA, et al. Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Archives of Ophthalmology 2005 Feb;123(2):149-57.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15710809" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15710809&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(58) &amp;nbsp;Aguirre F, Mengual E, Hueso JR, Moya M. Comparison of normal and amblyopic retinas by optical coherence tomography in children. European Journal of Ophthalmology 2010 Mar;20(2):410-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19967663" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19967663&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;(59) &amp;nbsp;Liu H, Zhong L, Zhou X, Jin QZ. Macular abnormality observed by OCT in children with amblyopia failing to achieve normal visual acuity after long-term treatment. Journal of Pediatric Ophthalmology &amp;amp; Strabismus 2010 May 24;47(1):17-23.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20128549" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20128549&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:388208:2" name=internalLink&gt;2010 AEU on Amblyopia - Clinical Outcomes - Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on Amblyopia - Clinical Outcomes - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_amblyopia_0910/aeu_amblyopia_0910_doc6.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/Evidence_Trees/ClinicaloutcomesAmblyopiaEvidenceTree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;Clinical Outcomes of Amblyopia&amp;nbsp;- Evidence Tree&lt;/H2&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;BR&gt;Databases searched:&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;Medline 1997 to date; EMBASE 1997 to date; Cochrane Central Register of Controlled Trials; and NHS Evidence - eyes and vision.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;BR&gt;Period of search:&lt;/STRONG&gt; January 1997 to 29th June 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;Cochrane Central Register of Controlled Trials&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Inclusion criteria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;•&amp;nbsp;Publication types:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis and review articles).&lt;/LI&gt;
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials).&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys).&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from&amp;nbsp;1997 on.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Relevancy to focus of the 2010&amp;nbsp;Amblyopia AEU: Clinical and functional outcomes of amblyopia and/or its treatment.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID388208/nelhImp_0000_aeu_amb_clinical.jpg" width=587 height=294&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/AmblyopiaAEU2010-Journalspread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:388208:1" name=internalLink&gt;2010 AEU on Amblyopia - Clinical Outcomes of Amblyopia and/or its Treatment&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>388479</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=388479]]&gt;</url>
    <title>2010 Annual Evidence Update on Amblyopia - Evidence Tree</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,ANNUAL EVIDENCE UPDATES,CONDITIONS,AMBLYOPIA,AMBLYOPIA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Amblyopia - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_amblyopia_0910/aeu_amblyopia_0910_doc5.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/Evidence_Trees/FullAmblyopiaEvidenceTree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Main Evidence Tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID388479/nelhImp_0001_aeu_amb_Main.jpg" width=537 height=330&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>388210</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=388210]]&gt;</url>
    <title>2010 Annual Evidence Update on Amblyopia - Functional Outcomes of Amblyopia and/or its Treatment</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,ANNUAL EVIDENCE UPDATES,CONDITIONS,AMBLYOPIA,AMBLYOPIA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on Amblyopia - Functional Outcomes of Amblyopia&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_amblyopia_0910/aeu_amblyopia_0910_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/Articles/FunctionalOutcomesJillCarltonFinalversion.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Functional Outcomes of Amblyopia and/or its Treatment&lt;/H2&gt;
&lt;H3&gt;&lt;BR&gt;Jill Carlton&lt;BR&gt;Research Associate, Health Economics and Decision Science, &lt;BR&gt;ScHARR, University of Sheffield&lt;/H3&gt;
&lt;H2&gt;&lt;BR&gt;Introduction&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;The clinical outcomes of amblyopia treatment are clearly defined, however the functional outcomes of amblyopia and/or its treatment are less so. These may be considered in terms of visual functioning (incorporating activities of every day life; education and employment) and quality of life (such as psychosocial implications including relationships with others). Visual functioning assessment methods are often determined using clinical markers (for example, reading speed).&amp;nbsp; Quality of life assessment in terms of amblyopia and/or its treatment can be made using patient/parent reported outcome measures, but there are no specific paediatric instruments for this purpose for amblyopia. Recent advances in patient/parent reported outcome measures have included the development of two questionnaires; the Amblyopia Treatment Index (ATI) (1) and the Amblyopia &amp;amp; Strabismus Questionnaire (A&amp;amp;SQ) (2) (3) (4) (5). These measures have been used to report the impact of amblyopia and/or its treatment at the time of therapy (ATI), or in adulthood (A&amp;amp;SQ).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational studies:&lt;BR&gt;[1], [2], [3], [4], and [5]&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;Visual Functioning (everyday life at school/work; impact on education and employment)&lt;/H3&gt;
&lt;H3&gt;&lt;BR&gt;Education and employment&lt;/H3&gt;
&lt;P&gt;The impact of amblyopia upon educational attainment is not conclusive. One study reported no association (6) whilst another reported a borderline trend (7). Similarly, no association between was found between the presence of amblyopia and paid employment (6).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational studies:&lt;BR&gt;[6] and [7]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Risk of vision loss in the better seeing eye&lt;/H3&gt;
&lt;P&gt;One of the motivations cited for treating amblyopia is the consequence of visual impairment as a result of disease or injury to the better seeing eye. A case study undertaken by the British Ophthalmic Surveillance Unit (BOSU) reported that "the minimum risk for visual impairment by age 95 was 32.9 per 100,000 total population. The projected lifetime risk of permanent vision loss for an individual with amblyopia was at least 1.2%" (8).&amp;nbsp;Data from the Blue Mountains Eye Study reported that “Incident 5 year visual impairment in the better seeing eye in people at risk of vision loss worse than 6/12 occurred in 9/27 participants with amblyopia (33.3%), compared with 264/2114 without amblyopia (12.5%); relative risk (RR): 2.7, 95% confidence interval (CI): 1.5 to 4.6.” (7).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational studies:&lt;BR&gt;[7] and [8]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Impact of treatment modality upon quality of life and functioning&lt;/H3&gt;
&lt;P&gt;The ATI has been used to assess the impact of treatment modality upon quality of life. One study found that both occlusion therapy and atropine were well-tolerated treatments. The atropine group were found to have better treatment compliance, reported less adverse effects and experienced less social stigma compared to the patching group; however this was not statistically significant (9).&amp;nbsp; In a further study exploring treatment outcomes of atropine regimens, the ATI results suggested that atropine is a well-tolerated treatment option, also in terms of impact on social stigma,&amp;nbsp;irrespective of instillation regimens (daily or weekend only) (10).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Interventional study:&lt;BR&gt;[10]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational study:&lt;BR&gt;[9]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Quality of Life (well-being/depression, bullying, psycho-social issues)&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;The psychosocial aspect of amblyopia (and more specifically its treatment) has been reported. As part of the ALSPAC study Horwood et al found some association between glasses-wear and bullying; and occlusion therapy and bullying (11). The social stigma associated with glasses and patching has been further explored in a qualitative study where children and parents of children with amblyopia were interviewed. This small scale-study (n=41) reported amblyopia therapy to have adverse consequences for a child’s psychosocial wellbeing. (12). Amblyopia has been found to impact upon a child’s self-esteem, specifically the feeling of social acceptance.&amp;nbsp; This has been reported to be correlated with occlusion therapy (but not with a history of strabismus or glasses-wear) (13).&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In an observational study within a UK-based RCT, Hrisos et al assessed the emotional impact of amblyopia treatment in preschool children (14). Results of a parental questionnaire found that both glasses-wear and patching caused some form of upset or distress for the child; and that patching was significantly more upsetting than glasses only. Despite this, parental reported behavioural scores did not suggest any adverse effect on the child’s global well-being either during or after cessation of treatment.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The psychological impact of amblyopia has been explored in teenagers and found to be correlated to the severity of amblyopia, as assessed by Visual Function-14 (VF-14) and a psychological impact score questionnaire (15). Sabri et al assessed quality of life using the VF-14 (a measure that was initially designed to capture health-related quality of life (HRQoL) implications of cataract, but has subsequently been used in other ophthalmological groups) and developed their own eight-item questionnaire. This psychological impact score questionnaire was derived following a review of existing literature and discussion groups involving clinicians and amblyopic teenagers. Both questionnaires found statistically significant differences between the scores of the control group (n=120) and case group (n=120). However the newly developed questionnaire was reported to be more sensitive in discriminating between cases of mild and moderate to severe amblyopia (15). This was in contrast with another study who found no reduction in quality of life in an adult population when assessed using the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) questionnaire (16).&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The psychosocial implications of amblyopia and/or its treatment are intrinsically linked to treatment compliance. This has been explored in a number of studies. Parental motivation and knowledge have been shown to be associated with treatment adherence (17) (18).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Observational studies:&lt;BR&gt;[11], [12], [13], [14], [15], [16], [17], and [18] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Cost-effectiveness of treatment for amblyopia&lt;/H2&gt;
&lt;P&gt;Two studies assessing the cost effectiveness of treatment for amblyopia (based on US and German data) concluded that treatment for amblyopia is likely to be very cost effective, (19) (20). There is some uncertainty regarding the effect of amblyopia on quality of life and utility and further studies would need to be undertaken to supply data to provide a full picture of cost-effectiveness for this area, (20).&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Secondary Publications:&lt;BR&gt;[19] and [20]&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Cost-effectiveness of screening for amblyopia&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;A recent Health Technology Assessment (HTA) report analysed the costs and effects of six alternative screening options (age at screening and tests employed) (21). The results showed that based on the cost per case of amblyopia prevented, screening at either 3 or 4 years prevented additional cases at a low absolute cost (£3000–6000). When these results were extrapolated to estimate the cost per quality-adjusted life-year (QALY) gained, the reference case analysis found that no form of screening is likely to be cost-effective at currently accepted values of a QALY. The results showed that cost-effectiveness of screening for amblyopia is dependent upon the long-term utility effects of unilateral vision loss, but there is limited evidence on any such effect. Additionally, if quality of life implications of treatment were applied (for example, bullying in school) this&amp;nbsp;may improve the cost-effectiveness of early screening. &lt;/P&gt;
&lt;P&gt;Another&amp;nbsp;recent systematic review examining the effectiveness of screening preschool children for amblyopia concluded that the effectiveness of population-based preschool vision screening programmes could not be sufficiently assessed by the literature available at the time of the review but that bullying and other psychosocial factors should form part of the outcome assessments for screening programmes (22). This systematic review has been included in the Centre for Review’s and Dissemination’s Database of Abstracts of Reviews of Effects (DARE) and they conclude that: “This was generally a well-conducted review. The conclusions reflected the evidence presented and are likely to be reliable.” (23).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Secondary Publications:&lt;BR&gt;[21], [22] and [23]&lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Edited 29-09-10&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;References:&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;(1) &amp;nbsp;Holmes JM, Strauber S, Quinn GE, Cole SR, Felius J, Kulp M, et al. Further validation of the Amblyopia Treatment Index parental questionnaire. Journal of Aapos: American Association for Pediatric Ophthalmology &amp;amp; Strabismus 2008 Dec;12(6):581-4.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18976946" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18976946&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(2) &amp;nbsp;van de Graaf ES, van der Sterre GW, Polling JR, van KH, Simonsz B, Simonsz HJ. Amblyopia &amp;amp; Strabismus Questionnaire: design and initial validation. Strabismus 2004 Sep;12(3):181-93.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15370526" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15370526&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(3) &amp;nbsp;van de Graaf ES, van der Sterre GW, van Kempen-du SH, Simonsz B, Looman CW, Simonsz HJ. Amblyopia and Strabismus Questionnaire (A&amp;amp;SQ): clinical validation in a historic cohort. Graefes Archive for Clinical &amp;amp; Experimental Ophthalmology 2007 Nov;245(11):1589-95.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17549509" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17549509&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(4) &amp;nbsp;Felius J, Beauchamp GR, Stager DR, Sr., van de Graaf ES, Simonsz HJ. The Amblyopia and Strabismus Questionnaire: English translation, validation, and subscales. American Journal of Ophthalmology 2007 Feb;143(2):305-10.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17157801" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17157801&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(5) &amp;nbsp;van de Graaf ES, Felius J, van Kempen-du SH, Looman CW, Passchier J, Kelderman H, et al. Construct validation of the Amblyopia and Strabismus Questionnaire (A&amp;amp;SQ) by factor analysis. Graefes Archive for Clinical &amp;amp; Experimental Ophthalmology 2009 Sep;247(9):1263-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19495785" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19495785&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(6) &amp;nbsp;Rahi JS, Cumberland PM, Peckham CS. Does amblyopia affect educational, health, and social outcomes? Findings from 1958 British birth cohort. BMJ 2006 Apr 8;332(7545):820-5.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16520328" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16520328&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(7) &amp;nbsp;Chua B, Mitchell P. Consequences of amblyopia on education, occupation, and long term vision loss. British Journal of Ophthalmology 2004 Sep;88(9):1119-21.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15317699" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15317699&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(8) &amp;nbsp;Rahi J, Logan S, Timms C, Russell-Eggitt I, Taylor D. Risk, causes, and outcomes of visual impairment after loss of vision in the non-amblyopic eye: a population-based study. Lancet 2002 Aug 24;360(9333):597-602.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12241931" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12241931&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(9) &amp;nbsp;Holmes JM, Beck RW, Kraker RT, Cole SR, Repka MX, Birch EE, et al. Impact of patching and atropine treatment on the child and family in the amblyopia treatment study. Archives of Ophthalmology 2003 Nov;121(11):1625-32.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14609923" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/14609923&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(10) &amp;nbsp;Repka MX, Cotter SA, Beck RW, Kraker RT, Birch EE, Everett DF, et al. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology 2004 Nov;111(11):2076-85.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15522375" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15522375&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(11) &amp;nbsp;Horwood J, Waylen A, Herrick D, Williams C, Wolke D. Common visual defects and peer victimization in children. Investigative Ophthalmology and Visual Science 2005 Apr;46(4):1177-81.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15790876" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15790876&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(12) &amp;nbsp;Koklanis K, Abel LA, Aroni R. Psychosocial impact of amblyopia and its treatment: a multidisciplinary study. Clinical &amp;amp; Experimental Ophthalmology 2006 Nov;34(8):743-50.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17073896" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17073896&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(13) &amp;nbsp;Webber AL, Wood JM, Gole GA, Brown B. Effect of amblyopia on self-esteem in children. Optometry &amp;amp; Vision Science 2008 Nov;85(11):1074-81.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18981922" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18981922&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(14) &amp;nbsp;Hrisos S, Clarke MP, Wright CM. The emotional impact of amblyopia treatment in preschool children: randomized controlled trial. Ophthalmology 2004 Aug;111(8):1550-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15288987" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15288987&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(15) &amp;nbsp;Sabri K, Knapp CM, Thompson JR, Gottlob I. The VF-14 and psychological impact of amblyopia and strabismus. Investigative Ophthalmology &amp;amp; Visual Science 2006 Oct;47(10):4386-92.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17003430" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17003430&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(16) &amp;nbsp;Hirneiss C, Schmid-Tannwald C, Kernt M, Kampik A, Neubauer AS. The NEI VFQ-25 vision-related quality of life and prevalence of eye disease in a working population. Graefes Archive for Clinical &amp;amp; Experimental Ophthalmology 2010 Jan;248(1):85-92.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19763598" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19763598&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(17) &amp;nbsp;Searle A, Norman P, Harrad R, Vedhara K. Psychosocial and clinical determinants of compliance with occlusion therapy for amblyopic children. Eye 2002 Mar;16(2):150-5.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11988815" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11988815&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(18) &amp;nbsp;Loudon SE, Passchier J, Chaker L, de VS, Fronius M, Harrad RA, et al. Psychological causes of non-compliance with electronically monitored occlusion therapy for amblyopia. British Journal of Ophthalmology 2009 Nov;93(11):1499-503.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19661070" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19661070&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(19) &amp;nbsp;Membreno JH, Brown MM, Brown GC, Sharma S, Beauchamp GR. A cost-utility analysis of therapy for amblyopia. Ophthalmology 2002 Dec;109(12):2265-71.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12466169" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12466169&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(20) &amp;nbsp;Konig HH, Barry JC. Cost effectiveness of treatment for amblyopia: an analysis based on a probabilistic Markov model. British Journal of Ophthalmology 2004 May;88(5):606-12.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15090409" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15090409&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(21) &amp;nbsp;Carlton J, Karnon J, Czoski-Murray C, Smith KJ, Marr J. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation. [Review] [181 refs]. Health Technology Assessment (Winchester, England) 2008 Jun;12(25):iii-194.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18513466" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18513466&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(22) &amp;nbsp;Schmucker C, Grosselfinger R, Riemsma R, Antes G, Lange S, Lagreze W, et al. Effectiveness of screening preschool children for amblyopia: a systematic review. [Review] [43 refs]. BMC Ophthalmology 2009;9:3.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19607693" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19607693&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;(23)&amp;nbsp;&amp;nbsp;Centre for Review’s and Dissemination’s Database of Abstracts of Reviews of Effects (DARE) review of: Schmucker C, Grosselfinger R, Riemsma R, Antes G, Lange S, Lagreze W, et al. Effectiveness of screening preschool children for amblyopia: a systematic review. [Review] [43 refs]. BMC Ophthalmology 2009;9:3.&lt;BR&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009108990" target="_blank"&gt;http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009108990&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:388210:2" name=internalLink&gt;2010 AEU on Amblyopia -&amp;nbsp;Functional Outcomes - Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on Amblyopia - Functional Outcomes - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_amblyopia_0910/aeu_amblyopia_0910_doc7.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/Evidence_Trees/FunctionaloutcomesAmblyopiaEvidenceTree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;Functional Outcomes of Amblyopia&amp;nbsp;- Evidence Tree&lt;/H2&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;BR&gt;Databases searched:&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;Medline 1997 to date; EMBASE 1997 to date; Cochrane Central Register of Controlled Trials; and NHS Evidence - eyes and vision.&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;BR&gt;Period of Search:&lt;/STRONG&gt; January 1997 to 29th June 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;Cochrane Central Register of Controlled Trials&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Inclusion criteria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;•&amp;nbsp;Publication types:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis and review articles).&lt;/LI&gt;
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials).&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys).&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from&amp;nbsp;1997 on.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Relevancy to focus of the 2010&amp;nbsp;Amblyopia AEU: Clinical and functional outcomes of amblyopia and/or its treatment.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID388210/nelhImp_0000_aeu_amb_functional.jpg" width=566 height=290&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/AmblyopiaAEU2010-Journalspread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:388210:1" name=internalLink&gt;2010 AEU on Amblyopia -&amp;nbsp;Functional Outcomes of Amblyopia and/or its Treatment&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387860</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=387860]]&gt;</url>
    <title>2010 Annual Evidence Update on Amblyopia - Guidelines and reviews</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,ANNUAL EVIDENCE UPDATES,CONDITIONS,AMBLYOPIA,AMBLYOPIA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Amblyopia - Guidelines and reviews&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_amblyopia_0910/aeu_amblyopia_0910_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/Articles/GuidelinesandCochrane.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Amblyopia Guidelines, Cochrane systematic reviews and Centre for Reviews and Dissemination (CRD) DARE and HTA&amp;nbsp;records&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Guidelines&lt;/H2&gt;
&lt;P&gt;Royal College of Ophthalmologists&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/GuidelinesfortheManagementofAmblyopia.pdf" target="_blank"&gt;Guidelines for the management of amblyopia&lt;/A&gt; (2006)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;National Screening Committee, UK&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.screening.nhs.uk/policydb.php?policy_id=45" target="_blank"&gt;National Screening Committee policy - vision defect screening (in children)&lt;/A&gt; (2006)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Department of Health&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_118525.pdf" target="_blank"&gt;Healthy Child Programme: pregnancy and the first five years of life&lt;/A&gt; (2009)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;American Academy of Ophthalmology&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=b35859cf-9431-48fe-9115-30ee45780cbe" target="_blank"&gt;Summary Benchmark: Amblyopia&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=930d01f2-740b-433e-a973-cf68565bd27b" target="_blank"&gt;Preferred Practice Pattern - Amblyopia&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;American Optometric Association (AOA)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.aoa.org/documents/CPG-4.pdf" target="_blank"&gt;Optometric Clinical Practice Guideline: Care of the Patient with Amblyopia&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Cochrane Reviews&lt;/H2&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006460/frame.html" target="_blank"&gt;Conventional occlusion versus pharmacologic penalization for amblyopia&lt;BR&gt;&lt;/A&gt;Tianjing Li, Kate Shotton&lt;BR&gt;October 2009&lt;BR&gt;Edited (no change to conclusions), published in Issue 7, 2010. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006461/frame.html" target="_blank"&gt;Interventions for strabismic amblyopia&lt;/A&gt;&lt;BR&gt;Kate Shotton, Sue Elliott&lt;BR&gt;January 2008&lt;BR&gt;New search for studies and content updated (no change to conclusions), published in Issue 1, 2010. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005137/frame.html" target="_blank"&gt;Interventions for unilateral refractive amblyopia&lt;/A&gt;&lt;BR&gt;Kate Shotton, Christine Powell, Gerasimos Voros, Sarah R Hatt&lt;BR&gt;2008&lt;BR&gt;Edited (no change to conclusions), published in Issue 3, 2009.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005136/frame.html" target="_blank"&gt;Interventions for stimulus deprivation amblyopia&lt;/A&gt;&lt;BR&gt;Aileen Antonio-Santos, Satyanarayana S Vedula, Sarah R Hatt, Christine Powell&lt;BR&gt;2007&lt;BR&gt;Edited (no change to conclusions), published in Issue 1, 2009.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005020/frame.html" target="_blank"&gt;Vision screening for amblyopia in childhood&lt;/A&gt;&lt;BR&gt;Christine Powell, Sarah R Hatt&lt;BR&gt;July 2009 &lt;BR&gt;Edited (no change to conclusions), published in Issue 3, 2009.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005023/frame.html" target="_blank"&gt;Vision screening for correctable visual acuity deficits in school-age children and adolescents&lt;/A&gt;&lt;BR&gt;Christine Powell, Susanne Wedner, Sarah R Hatt&lt;BR&gt;2004&lt;BR&gt;Edited (no change to conclusions), published in Issue 3, 2009.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Health Technology Assessments&lt;/H2&gt;
&lt;P&gt;&lt;A href="http://www.hta.ac.uk/952" target="_blank"&gt;Preschool vision screening&lt;/A&gt;&lt;BR&gt;Snowdon SK, Stewart-Brown SL. &lt;BR&gt;HTA 1997;1(8):1-85.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32008100030" target="_blank"&gt;The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and stabismus in children up to the ages of 4-5 years: a systematic review and economic evaluation&lt;/A&gt;&lt;BR&gt;Carlton J, Karnon J, Czoski-Murray C, Smith KJ, Marr J&lt;BR&gt;2008&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32007000886" target="_blank"&gt;A comparison and discussion of the methods, findings, adaptability and decisions resulting from two reviews of vision screening in children undertaken in the UK and Germany&lt;/A&gt;&lt;BR&gt;Riemsma RP and Kleijnen J&lt;BR&gt;2007&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Recent Database of Abstracts of Reviews of Effects (DARE) &lt;/H2&gt;
&lt;P&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009109815" target="_blank"&gt;Diagnostic accuracy of vision screening tests for the detection of amblyopia and its risk factors: a systematic review&lt;/A&gt;&lt;BR&gt;Schmucker C, Grosselfinger R, Riemsma R, Antes G, Lange S, Lagreze W, Kleijnen J&lt;BR&gt;2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12009108990" target="_blank"&gt;Effectiveness of screening preschool children for amblyopia: a systematic review&lt;/A&gt;&lt;BR&gt;Schmucker C, Grosselfinger R, Riemsma R, Antes G, Lange S, Lagreze W, Kleijnen J&lt;BR&gt;2009&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Other Systematic Reviews&lt;/H2&gt;
&lt;P&gt;Click &lt;A href="nelh:322620:0" name=internalLink&gt;here&lt;/A&gt; to access the list of Systematic Reviews on Ocular motility, amblyopia and strabismus available on the eyes and vision specialist collection.&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387844</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=387844]]&gt;</url>
    <title>2010 Annual Evidence Update on Amblyopia - Home Page</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,ANNUAL EVIDENCE UPDATES,CONDITIONS,AMBLYOPIA,AMBLYOPIA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Amblyopia - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;27th&amp;nbsp;September 2010&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Boy wearing patch" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID387844/nelhImp_0003_AmblyopiaNIH3RefAR02.jpg" width=150 height=170&gt;&amp;nbsp; &lt;IMG style="WIDTH: 228px; HEIGHT: 170px" id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Girls wearing patches" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID387844/nelhImp_0001_AmblyopiaNIH4RefAR04.jpg" width=247 height=184&gt;&amp;nbsp; &lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="Boy having drops in eye" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID387844/nelhImp_0002_AmblyopiaNIH5RefAR03.jpg" width=220 height=170&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Amblyopia&lt;/STRONG&gt; is the term used to describe the clinical scenario of impaired vision, most commonly affecting one eye, which arises through degraded visual stimulation during critical periods of visual development in early childhood. Clinicians treating ophthalmic disease in children always have to consider, and often have to manage, amblyopia - either as the main disorder causing impaired vision or as a contributing condition. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;We welcome feedback about resources that we identify, do contact us if you would like to comment. After you have browsed the pages, please take a moment to complete our survey (5 mins). &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/Feedback/feedback.aspx" target="_blank"&gt;Click here to take the survey&lt;/A&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;The 2010 Evidence Update focuses on the clinical and functional outcomes of amblyopia and highlights the: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;clinical outcomes of treatment - focussing on aspects of visual acuity, stereopsis, and ocular alignment;&lt;/LI&gt;
&lt;LI&gt;functional outcomes of treatment - focussing on aspects of quality of life and visual functioning;&lt;/LI&gt;
&lt;LI&gt;adverse events of treatment;&lt;/LI&gt;
&lt;LI&gt;current uncertainties in the effectiveness of treatments.&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;BR&gt;Contents&lt;/H2&gt;
&lt;P&gt;Topics covered: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:387861:0" name=internalLink&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/A&gt; &lt;/STRONG&gt;by Jugnoo Rahi, Reader in Ophthalmic Epidemiology/Honorary Consultant Ophthalmologist, Institute of Child Health UCL.&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:388208:0" name=internalLink&gt;&lt;STRONG&gt;Clinical Outcomes of Amblyopia and/or its Treatment&lt;/STRONG&gt; &lt;/A&gt;&lt;/STRONG&gt;by Michael P Clarke, Consultant Paediatric Ophthalmologist, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Reader in Ophthalmology, Newcastle University;&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:388210:0" name=internalLink&gt;&lt;STRONG&gt;Functional Outcomes of Amblyopia and/or its Treatment&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; by Jill Carlton, Research Associate, ScHARR, University of Sheffield.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:387774:0" name=internalLink&gt;UK DUETs on Amblyopia&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:387860:0" name=internalLink&gt;Guidelines and Cochrane reviews&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:388479:0" name=internalLink&gt;Main Evidence Tree&lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/AmblyopiaAEU2010-Journalspread.pdf" target="_blank"&gt;Journal spread&lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/GlossaryAmblyopia%20AEU.pdf" target="_blank"&gt;Glossary&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:388213:0" name=internalLink&gt;Methodology and search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;A &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_amblyopia_0910/fp_aeu_amblyopia_0910.asp" target="_blank"&gt;low vision version &lt;/A&gt;of this AEU is also available.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Acknowledgments&lt;/H2&gt;
&lt;P&gt;The Management Team based at Moorfields Eye Hospital NHS Foundation Trust would like to thank all those who contributed to the preparation and promotion of this Evidence Update, particularly: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Our panel of Contributors who voluntarily contributed their time and expertise to provide the Topic Commentaries –&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Jill Carlton, Research Associate, ScHARR, University of Sheffield;&lt;/LI&gt;
&lt;LI&gt;Michael P Clarke, Consultant Paediatric Ophthalmologist, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Reader in Ophthalmology, Newcastle University;&lt;/LI&gt;
&lt;LI&gt;Jugnoo Rahi, Reader in Ophthalmic Epidemiology/Honorary Consultant Ophthalmologist, Institute of Child Health UCL.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Shaun Kirupairatnam (R&amp;amp;D Graphic Web Designer, Moorfields Eye Hospital) for his support in developing the collection's complementary site.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;The Amblyopia AEU Scoping Group and External Reference Group for their guidance.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Management Team&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Miss Parul Desai.&lt;BR&gt;Consultant in Ophthalmology and Public Health, Moorfields Eye Hospital NHS Foundation Trust, London.&lt;BR&gt;Clinical Lead, NHS Evidence – eyes and vision.&lt;/P&gt;
&lt;P&gt;Karen Poole, MSc, MCLIP.&lt;BR&gt;Information Specialist/Librarian, NHS Evidence – eyes and vision.&lt;/P&gt;
&lt;P&gt;Jenny Wood.&lt;BR&gt;Information Co-ordinator, NHS Evidence – eyes and vision. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Images&lt;BR&gt;&lt;/STRONG&gt;Images courtesy of &lt;A href="http://www.nei.nih.gov/index.asp" target="_blank"&gt;National Eye Institute, National Institutes of Health&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387861</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=387861]]&gt;</url>
    <title>2010 Annual Evidence Update on Amblyopia - Introduction</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,ANNUAL EVIDENCE UPDATES,CONDITIONS,AMBLYOPIA,AMBLYOPIA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Amblyopia - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_amblyopia_0910/aeu_amblyopia_0910_doc1.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/Articles/IntroductionJugnooRahiFinalversion.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;
&lt;H2 align=left&gt;&lt;BR&gt;Introduction&lt;/H2&gt;
&lt;H3&gt;Jugnoo Rahi, &lt;BR&gt;Reader in Ophthalmic Epidemiology/Honorary Consultant Ophthalmologist, Institute of Child Health, UCL.&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Amblyopia is the term used to describe the clinical scenario of impaired vision, most commonly affecting one eye, which arises through degraded visual stimulation during critical periods of visual development in early childhood (1;2). This condition has long intrigued clinicians and scientists by providing a model for investigating human visual development and neural plasticity within the visual system (1;2). &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Clinicians treating ophthalmic disease in children always have to consider, and often have to manage, amblyopia - either as the main disorder causing impaired vision or as a contributing condition. It is likely that around 2 in every 100 children in the UK and similar populations have the most common form of amblyopia, which is related to refractive error and/or strabismus, although prevalence estimates vary with the case definition applied (3). The management of amblyopia accounts for a high proportion of the workload in paediatric ophthalmology and orthoptics. Significant health care resources have long been directed at the detection and treatment of affected children with two objectives in mind. Firstly, to improve acuity in the affected eye(s) and thus the potential for binocular vision and more ‘normal’ visual functioning and secondly to reduce the known risk of visual disability later in life should the sight of the non-amblyopic eye be impaired by disease or injury, (4-7). &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Over the past few decades, population screening programmes were established ad hoc in the UK for early detection of children with amblyopia. Following two major reviews of the research evidence the United Kingdom National Screening Committee (UK NSC) recently re-launched its full programme of universal childhood screening for vision and ophthalmic disorders (originally recommended in 2006). It is now part of the new national Child Health Promotion Programme. As shown in figure 1 below, the component primarily directed at amblyopia comprises visual acuity testing of children aged 4 to 5 years using LogMAR scaled crowded acuity charts, through an orthoptic led service.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Importantly, the UK NSC considers that there is no robust research evidence to support any alternative vision/ eyes screening programme in childhood.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;H3&gt;&lt;BR&gt;Figure 1&lt;/H3&gt;
&lt;P&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;H3&gt;&lt;BR&gt;Summary of data from:&lt;/H3&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;UL&gt;
&lt;LI&gt;UK National Screening Committee (2006) Recommendations for screening and surveillance for vision and ophthalmic disorders in childhood.&lt;BR&gt;[see Vision Defects: The UK NSC policy on Vision defects screening in children. Available at &lt;A href="http://www.screening.nhs.uk/vision-child" target="_blank"&gt;http://www.screening.nhs.uk/vision-child&lt;/A&gt;] (8)&lt;/LI&gt;
&lt;LI&gt;Hall, D.M.B. and Elliman, D. (2006) Health for all children .4th ed (revised). Oxford: Oxford University Press. (9)&lt;/LI&gt;
&lt;LI&gt;Department of Health (2008) The Child Health Promotion Programme 2008. (10)&lt;BR&gt;[superseded by: Department of Health (2009) Healthy Child Programme: pregnancy and the first five years of life London: UK Department of Health. Available at &lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_118525.pdf" target="_blank"&gt;http://www.dh.gov.uk/prod_consum_dh/groups/&lt;BR&gt;dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_118525.pdf&lt;/A&gt;] &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Figure 1 summarising screening programme" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID387861/nelhImp_0000_Introfigure1.JPG" width=571 height=525&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In the past few years much research effort has been directed at identifying the ‘real life’ functional adverse consequences of having amblyopia per se.(4;11). The findings suggest that, at a population level, it may be difficult to discern differences in various dimensions of life between those with amblyopia and those without, even though the impact at an individual level may be considerable (12). More recently there has been a focus on assessing the degree to which the potential functional consequences of amblyopia are diminished in the long term through improved vision achieved through occlusion or penalization treatment. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This NHS Evidence update on amblyopia summarises this recent information on the effectiveness of treatment (clinical outcomes) and its impact on functional outcomes.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;References:&lt;/H2&gt;
&lt;P&gt;(1) &amp;nbsp;Wiesel TN. Postnatal development of the visual cortex and the influence of environment. Nature 1982;299:583-91.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/6811951" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/6811951&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(2) &amp;nbsp;Levi DM, Carkeet A. Amblyopia:a consequence of abnormal visual development. In: Simons K, editor. Early Visual Development - Normal and Abnormal. 1st ed. New York: Oxford University Press; 1993. p. 391-408.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(3) &amp;nbsp;Snowdon S, Stewart-Brown S. Preschool vision screening: results of a systematic review. University of York: NHS Centre for Reviews and Dissemination; 1997. Report No.: CRD Report 9.&lt;BR&gt;&lt;A href="http://www.hta.ac.uk/952" target="_blank"&gt;http://www.hta.ac.uk/952&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(4) &amp;nbsp;Chua B, Mitchell P. Consequences of amblyopia on education, occupation, and long-term vision loss. Br J Ophthalmol 2004;88:1119-21.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15317699" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15317699&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(5) &amp;nbsp;van Leeuwen R, Eijkemans MJC, Vingerling JR, Hofman A, de Jong PTVM, Simonsz H. Risk of bilateral visual impairment in individuals with amblyopia: the Rotterdam study. Br J Ophthalmol 2007;91:1450-1.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17522151" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17522151&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(6) &amp;nbsp;Rahi JS, Logan S, Cortina Borja M, Timms C, Russell-Eggitt IM, Taylor DSI. Prediction of improved vision in the amblyopic eye after visual loss in the non-amblyopic eye. The Lancet 2002;360:621-2.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12241937" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12241937&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(7) &amp;nbsp;Rahi JS, Logan S, Timms C, Russell-Eggitt I, Taylor DSI. Risk, causes, and outcomes of visual impairment after loss of vision in the non-amblyopic eye: a population-based study. The Lancet 2002;360:597-602.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12241931" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12241931&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(8) &amp;nbsp;UK National Screening Committee. Recommendations for screening and surveillance for vision and ophthalmic disorders in childhood. 2006.&lt;BR&gt;&lt;A href="http://www.screening.nhs.uk/vision-child" target="_blank"&gt;http://www.screening.nhs.uk/vision-child&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(9) &amp;nbsp;Hall DMB, Elliman D. Health for all children. 4th ed (revised) ed. Oxford: Oxford University Press; 2010.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(10) &amp;nbsp;Department of Health. The Child Health Promotion Programme 2008. London: Department of Health ; 2008.&lt;BR&gt;Revised edition available at &lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_118525.pdf" target="_blank"&gt;http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_118525.pdf&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(11) &amp;nbsp;Rahi JS, Cumberland P, Peckham CS. Does amblyopia affect educational, health, and social outcomes? BMJ 2006;332:820-5.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16520328" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16520328&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;(12) &amp;nbsp;Adams GGW, Karas MP. Effect of amblyopia on employment prospects. Br J Ophthalmol 1999;83:380.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10365058" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/10365058&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>388213</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=388213]]&gt;</url>
    <title>2010 Annual Evidence Update on Amblyopia - Methodology</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,ANNUAL EVIDENCE UPDATES,CONDITIONS,AMBLYOPIA,AMBLYOPIA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Amblyopia - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/MethodologyAmblyopia%202010.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&lt;BR&gt;Methodology&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P align=left&gt;This is the first Annual Evidence Update (AEU) for Amblyopia carried out by NHS Evidence - eyes and vision. This AEU focuses on the clinical and functional outcomes of amblyopia and highlights the clinical outcomes of treatment (focussing on aspects of visual acuity, stereopsis, and ocular alignment); functional outcomes of treatment (focussing on aspects of quality of life and visual functioning); adverse events of treatment and current uncertainties in the effectiveness of treatments. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The most recent professional body guidance on Amblyopia formed one benchmark for the AEU:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Royal College of Ophthalmologists (RCOphth)&lt;BR&gt;&lt;/STRONG&gt;The Royal College of Ophthalmologists. &lt;A href="http://www.rcophth.ac.uk/docs/publications/GuidelinesfortheManagementofAmblyopia.pdf" target="_blank"&gt;Guidelines for the management of amblyopia&lt;/A&gt;. 2006.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Searches were limited to 1997 and the update considers evidence published since the 1997 Health Technology Assessment (HTA) report on preschool vision screening concerning clinical outcomes of the treatment of strabismic and/or refractive amblyopia.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;An initial search was run on 19th April 2010 and an update search on 29th June 2010.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Databases searched: &lt;BR&gt;&lt;/STRONG&gt;•&amp;nbsp;Medline 1997 to date; EMBASE 1997 to date; Cochrane Central Register of Controlled Trials; and NHS Evidence - eyes and vision.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Period of Search:&lt;/STRONG&gt; January 1997 to 29th June 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Accessed using: &lt;BR&gt;&lt;/STRONG&gt;•&amp;nbsp;&lt;A href="http://www.library.nhs.uk/booksandjournals/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases&lt;/A&gt; (NHS Athens Account required)&lt;BR&gt;•&amp;nbsp;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clcentral_articles_fs.html" target="_blank"&gt;Cochrane Central Register of Controlled Trials&lt;/A&gt; &lt;BR&gt;•&amp;nbsp;&lt;A href="http://www.library.nhs.uk/Eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Inclusion criteria&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis and review articles).&lt;/LI&gt;
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials).&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys).&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 1997 on. &lt;/LI&gt;
&lt;LI&gt;Relevancy to focus of the 2010 Amblyopia AEU: clinical and functional outcomes of amblyopia.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Method &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The search outputs were exported into Reference Manager bibliographic software.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The results were automatically de-duplicated. Further duplicate results were removed manually. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The results were then sifted for relevance and categorised by potential AEU topic sub-heading (e.g. compliance; quality of life). Clinical trial names were also highlighted. The resultant articles were then passed to the topic contributors for further sifts for relevance. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;NHS Evidence – eyes and vision was sifted on 19th April 2010 with records indexed with ‘Amblyopia’ to ensure that the above search included all the pertinent articles. An update search was run on 21st September 2010. Relevant guidelines, key documents and seminal articles and uncertainties were identified during these searches.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Search strategy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Evidence – eyes and vision AMD AEU Search Strategy available at:&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/AmblyopiaAEU2010searchhistory.pdf" target="_blank"&gt;http://evslarchive.moorfields.nhs.uk/amblyopia_docs_0910/pdf/AmblyopiaAEU2010searchhistory.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;KP 21/09/10&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387774</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=387774]]&gt;</url>
    <title>2010 Annual Evidence Update on Amblyopia - Uncertainties in the management of Amblyopia</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>KNOWN UNCERTAINTY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,ANNUAL EVIDENCE UPDATES,CONDITIONS,AMBLYOPIA,AMBLYOPIA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Amblyopia - Uncertainties in the management of Amblyopia&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:387844:1" name=internalLink&gt;&lt;A href="http://www.library.nhs.uk/Eyes/ViewResource.aspx?resID=387844" target="_blank"&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&lt;BR&gt;What clinical questions would you like answered on Amblyopia?&lt;/H2&gt;
&lt;P align=left&gt;&lt;BR&gt;NHS Evidence - eyes and vision is collaborating in the development of UK DUETs - the UK Database of Uncertainties about the Effects of Treatments.&lt;/P&gt;
&lt;P&gt;DUETs has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp;&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians. &lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments 
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines 
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems. Please note therefore that uncertainties about screening for amblyopia are not included here.&lt;/P&gt;
&lt;P&gt;The following uncertainties have been identified by the NHS Evidence - eyes and vision team. As new Systematic Reviews are identified by the eyes and vision team further DUETs on amblyopia will be added.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Amblyopia UK DUETs&lt;BR&gt;&lt;/H2&gt;
&lt;P&gt;&lt;A href="nelh:387795:0" name=internalLink&gt;Conventional occlusion versus pharmacologic penalization for amblyopia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:387827:0" name=internalLink&gt;Effectiveness of early in comparison to late(r) treatment in children with amblyopia or its risk factors&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:387831:0" name=internalLink&gt;Effect of near vision tasks on visual acuity in children with amblyopia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:387808:0" name=internalLink&gt;Interventions for strabismic amblyopia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:387823:0" name=internalLink&gt;Interventions for stimulus deprivation amblyopia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:387820:0" name=internalLink&gt;Interventions for unilateral refractive amblyopia&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;If you are aware of or have identified any uncertainties in the management of&amp;nbsp;Amblyopia&amp;nbsp;please let us know.&amp;nbsp; You can contact us via our &lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/EYES/ContactUs.aspx" target="_blank"&gt;&lt;STRONG&gt;feedback form&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="nelh:387844:0" name=internalLink&gt;Back to 2010&amp;nbsp;Amblyopia AEU contents page&amp;nbsp;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393787</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=393787]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Epidemiology</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc1.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/epidemiology.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;Databases searched: NHS Evidence - eyes and vision; PubMed; EMBASE; CINAHL; AMED; BNI. &lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;UL&gt;Accessed using: 
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/advanced/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases &lt;/A&gt;(NHS Athens Account required) 
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&lt;STRONG&gt;Secondary&lt;/STRONG&gt;&lt;/H2&gt;Olsen J, Berdeaux G. Costs of glaucoma in Denmark. Value in Health 2009;12(7): A455. 
&lt;H2&gt;&lt;/H2&gt;
&lt;H2&gt;Observational&lt;/H2&gt;
&lt;P&gt;Chauhan BC, Mikelberg FS, Artes PH, Balazsi AG, Leblanc RP, Lesk MR, et al. Canadian Glaucoma Study: 3. Impact of Risk Factors and Intraocular Pressure Reduction on the Rates of Visual Field Change. Archives of Ophthalmology 2010 Oct;128(10):1249-55&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20696979" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Czudowska MA, Ramdas WD, Wolfs RC, Hofman A, Jong PT, Vingerling JR, et al. Incidence of Glaucomatous Visual Field Loss: A Ten-Year Follow-up from the Rotterdam Study. Ophthalmology 2010 Jun 28.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20591487" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Finkelstein J, Cha E. Hypertension and glaucoma: A population-based study. Journal of Clinical Hypertension 2010;12.&lt;/P&gt;
&lt;P&gt;Kuzin AA, Varma R, Reddy HS, Torres M, Azen SP. Ocular Biometry and Open-Angle Glaucoma: The Los Angeles Latino Eye Study. Ophthalmology 2010 Jun 4.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20570359" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lin HC, Chien CW, Hu CC, Ho JD. Comparison of Comorbid Conditions between Open-Angle Glaucoma Patients and a Control Cohort A Case-Control Study. Ophthalmology 2010 Nov;117(11):2088-95&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20570357" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Perera SA, Wong TY, Tay WT, Foster PJ, Saw SM, Aung T. Refractive error, axial dimensions, and primary open-angle glaucoma: the Singapore Malay Eye Study. Archives of Ophthalmology 2010 Jul;128(7):900-5&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20625053" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Stein JD, Newman-Casey PA, Niziol LM, Gillespie BW, Lichter PR, Musch DC. Association between the use of glaucoma medications and mortality. Archives of Ophthalmology 2010 Feb;128(2):235-40.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20142548" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Tan GS, Wong TY, Fong C-W, Aung T. Diabetes, metabolic abnormalities, and glaucoma: The Singapore Malay Eye Study. Archives of Ophthalmology 2009;127(10):1354-61.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19822853" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;Back to 2010 Glaucoma AEU contents page&lt;/A&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on Glaucoma - Epidemiology- Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc1.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/epidemiology.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Glaucoma -Epidemiology - Evidence Tree&lt;/P&gt;
&lt;P&gt;Databases searched:&lt;BR&gt;PubMed; EMBASE; CINAHL; AMED; BNI; NHS Evidence - eyes and vision.&lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;Accessed using: 
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required) &lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed &lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision &lt;/A&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Inclusion criteria:&lt;BR&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: 
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis) 
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials) 
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys). &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 2009 onwards and not included in a previous AEU. 
&lt;LI&gt;Relevant to topics included in the 2010 AEU (diagnosis, monitoring, treatment – pharmacological, treatment – surgery &amp;amp; laser, service provision and patient education.) &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine.&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Epidemiology Evidence Tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID393787/nelhImp_0000_aeu_glau_epid.jpg" width=689 height=364&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/GlaucomaAEU2010-JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393787:1" name=internalLink&gt;2010 AEU on Glaucoma - Epidemiology&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;&lt;/LI&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>394184</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=394184]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Evidence Tree</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/A&gt;&lt;/P&gt;Glaucoma - Evidence Tree 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision; PubMed; EMBASE; CINAHL; AMED; BNI. &lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;STRONG&gt;Period of search:&lt;/STRONG&gt; January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using&lt;/STRONG&gt;: &lt;/P&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/advanced/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases &lt;/A&gt;(NHS Athens Account required) 
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed&lt;/A&gt; 
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;BR&gt;
&lt;P&gt;&lt;/A&gt;&lt;STRONG&gt;&lt;BR&gt;Inclusion criteria&lt;/STRONG&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;P&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis).&lt;/LI&gt;
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials).&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys).&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from&amp;nbsp;2009 onwards and not included in a previous AEU.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Relevant to topics included in the 2010 AEU (epidemiology, medical management, optical disk imaging, screening and visual field progression)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="2010 Glaucoma AEU Evidence Tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID394184/nelhImp_0000_aeu_glau_Main.jpg" width=689 height=844&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393792</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=393792]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Home Page</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published&lt;/STRONG&gt;: 22 November 2010&lt;/P&gt; &lt;P&gt;&lt;IMG style="WIDTH: 127px; HEIGHT: 121px" id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID393792/nelhImp_0000_Exampleoflowvisionfromglaucoma.jpg" width=194 height=166&gt;&lt;IMG style="WIDTH: 127px; HEIGHT: 121px" id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID393792/nelhImp_0001_patientundergoingtonometry.jpg" width=194 height=166&gt;&lt;IMG style="WIDTH: 127px; HEIGHT: 121px" id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID393792/nelhImp_0002_Glaucomatousopticnervehead.jpg" width=194 height=166&gt;&lt;/P&gt; &lt;P&gt;This Evidence Update reviews the new evidence that has emerged since the 2009 Annual Evidence Update. &lt;/P&gt; &lt;P&gt;We welcome feedback about resources that we identify, do contact us if you would like to comment. After you have browsed the pages, please take a moment to complete our survey (5 mins). &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/Feedback/feedback.aspx" target="_blank"&gt;Click here to take the survey &lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Contents:&lt;/STRONG&gt; &lt;/P&gt; &lt;P&gt;Topics Covered -&lt;/P&gt; &lt;LI&gt;&lt;A href="nelh:393786:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="nelh:393787:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="nelh:393836:0" name=internalLink&gt;Screening&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="nelh:393788:0" name=internalLink&gt;Medical management&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="nelh:393904:0" name=internalLink&gt;Optical disk imaging&lt;/A&gt;&lt;/LI&gt; &lt;LI&gt;&lt;A href="nelh:393905:0" name=internalLink&gt;Visual field progression&lt;/A&gt;&lt;/LI&gt; &lt;UL&gt;&lt;/UL&gt; &lt;P&gt;&lt;A href="nelh:329770:1" name=internalLink&gt;UK Database of Uncertainties about the Effects of Treatments (DUETs) on Glaucoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="nelh:330473:0" name=internalLink&gt;Overall Evidence Tree&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/GlaucomaAEU2009_JournalSpread.pdf" target="_blank"&gt;Journal Spread&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1109/Glossary.pdf" target="_blank"&gt;Glossary&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="nelh:330454:0" name=internalLink&gt;Methodology and search strategy&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;A &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1109/fp_aeu_glaucoma_1109.asp" target="_blank"&gt;low vision version&lt;/A&gt; of this AEU is also available.&lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;H3&gt;Acknowledgements:&lt;/H3&gt; &lt;P&gt;&lt;BR&gt;The Management Team based at Moorfields Eye Hospital NHS Foundation Trust are grateful to:&lt;/P&gt; &lt;P&gt;Shaun Kirupairatnum - R&amp;amp;D Graphic Web Designer, Moorfields Eye Hospital NHS Foundation Trust &lt;/P&gt; &lt;P&gt;The NHS Information Centre for health and social care&lt;/P&gt; &lt;P&gt;and&lt;/P&gt; &lt;P&gt;Our External Reference Group and everyone involved in the development and publicising of this annual evidence update.&lt;BR&gt;&lt;/P&gt; &lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393786</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=393786]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Introduction</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;2010 Annual Evidence Update on Glaucoma - Introduction&lt;/H2&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc8.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/introduction.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Eyes/ViewResource.aspx?resID=329673&amp;amp;tabID=289&amp;amp;catID=9856" target="_blank"&gt;Please click here to view 2009 AEU&lt;/A&gt; &lt;BR&gt;&lt;A href="http://www.library.nhs.uk/Eyes/ViewResource.aspx?resID=393792&amp;amp;tabID=289&amp;amp;catID=9856" target="_blank"&gt;Back to 2010 Glaucoma AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Examples of vision for glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID393786/nelhImp_0000_Exampleoflowvisionfromglaucoma16.11.07.jpg" width=554 height=332&gt; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Introduction by &lt;STRONG&gt;Parul Desai&lt;/STRONG&gt;, Clinical Lead NHS Evidence - eyes and vision. &lt;BR&gt;&lt;BR&gt;This 2010 Evidence Update presents and reviews new evidence that has emerged since the 2009 Evidence Update. &lt;BR&gt;&lt;BR&gt;Chronic open-angle glaucoma (COAG) is a blinding condition, attributable to about 10% of UK blindness registrations. It is often asymptomatic until severe visual damage has occurred, with or without raised intra-ocular pressure. Once diagnosed, people with COAG need lifelong monitoring so that any progression of visual damage can be detected. &lt;/P&gt;
&lt;P&gt;COAG is defined in the &lt;A href="nelh:312919:0" name=internalLink&gt;2009 NICE Guideline&lt;/A&gt; as 'glaucoma without evident secondary cause which follows a chronic time course and occurs in the presence of an open anterior chamber angle (the trabecular meshwork is visible on gonioscopy)'. &lt;/P&gt;
&lt;P&gt;Epidemiology. Around 2% of people older than 40 years have COAG, rising to almost 10% in people older than 75 years in white Europeans. The prevalence may be higher in people of black African or black Caribbean descent or who have a family history of glaucoma. Approximately 10% of UK blindness registrations are attributed to glaucoma.&lt;/P&gt;
&lt;P&gt;Contents:&lt;BR&gt;Topics Covered -&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:393787:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393836:0" name=internalLink&gt;Screening&lt;/A&gt;&lt;/LI&gt;&lt;A href="nelh:393788:0" name=internalLink&gt;
&lt;LI&gt;Medical Management&lt;/LI&gt;&lt;/A&gt;
&lt;LI&gt;&lt;A href="nelh:393904:0" name=internalLink&gt;Optic Disk Imaging&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:393905:0" name=internalLink&gt;Assessment of Visual Field Progression&lt;/A&gt;&lt;/LI&gt;&lt;A href="nelh:394026:0" name=internalLink&gt;UK DUETs on Glaucoma&lt;BR&gt;&lt;/A&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/entireevidencetree.pdf" target="_blank"&gt;Overall Evidence Tree&lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/GlaucomaAEU2010-JournalSpread.pdf" target="_blank"&gt;Journal spread&lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/Glossary.pdf" target="_blank"&gt;Glossary&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:393959:0" name=internalLink&gt;Methodology and search strategy&lt;/A&gt;&lt;/UL&gt;The NHS Clinical Knowledge Summaries offer the following scenarios in the management of glaucoma and ocular hypertension: &lt;BR&gt;Scenario: &lt;A href="nelh:389346:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;BR&gt;Scenario: &lt;A href="nelh:389348:0" name=internalLink&gt;Chronic open angle glaucoma&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt;&lt;/LI&gt; 
&lt;UL&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Acknowledgements:&lt;BR&gt;The Management Team based at Moorfields Eye Hospital NHS Foundation Trust are grateful to:&lt;BR&gt;Shaun Kirupairatnum - R&amp;amp;D Graphic Web Designer, Moorfields Eye Hospital NHS Foundation Trust &lt;BR&gt;The NHS Information Centre for health and social care&lt;BR&gt;and&lt;BR&gt;Our External Reference Group and everyone involved in the development and publicising of this annual evidence update.&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393788</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=393788]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Medical Management</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Medical Management&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/medicalmanagement.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:393792:1" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;Databases searched: NHS Evidence - eyes and vision; PubMed; EMBASE; CINAHL; AMED; BNI. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;Accessed using: &lt;BR&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/advanced/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases &lt;/A&gt;(NHS Athens Account required)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;
&lt;H2&gt;Secondary&lt;/H2&gt;
&lt;P&gt;Berenson K, Arora S, Kymes S, Hollander DA, Fiscella R, Burk C, et al. Cost benefit analysis of bimatoprost compared with other prostaglandin analogues in patients with primary open angle glaucoma (POAG) in the United States: A payer's perspective. Journal of Managed Care Pharmacy 2010;16(2): 1083-1087 &lt;BR&gt;&lt;BR&gt;Bhowmik D, Sansgiry SS. An economic analysis to evaluate anti-glaucoma pharmacotherapy. Value in Health 2009;12(3).&lt;/P&gt;
&lt;P&gt;Cheng J-W, Xi G-L, Wei R-L, Cai J-P, Li Y. Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis. Current Therapeutic Research - Clinical and Experimental 2009;70(4):335-50.&lt;/P&gt;
&lt;P&gt;Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. Journal of Glaucoma 2009 Dec;18(9):652-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20010242" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kymes SM, Plotzke MR, Kass MA, Boland MV, Gordon MO. Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension. Archives of Ophthalmology 2010 May;128(5):613-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20457984" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Peeters A, Schouten JS, Severens JL, Hendrikse F, Prins MH, Webers CA. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension: A cost-effectiveness analysis. Acta Ophthalmologica 2010 Aug 20.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20731623" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Schmier JK, Covert DW. First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results. Clinical Ophthalmology 2010;4:437-45&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20505836" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Peeters A, Webers CA, Prins MH, Zeegers MP, Hendrikse F, Schouten JS. Quantifying the effect of intraocular pressure reduction on the occurrence of glaucoma. Acta Ophthalmologica 2010 Feb;88(1):5-11.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19432875" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Schwartz GF, Tan J, Kotak S. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs. Journal of Ocular Pharmacology and Therapeutics 2009 Dec;25(6):555-61.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20028264" target="_blank"&gt;Link to PubMed abstract here&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database of Systematic Reviews 2010;2:CD006539.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20166085" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Sultan MB, Mansberger SL, Lee PP. Understanding the importance of IOP variables in glaucoma: a systematic review. Survey of Ophthalmology 2009 Nov;54(6):643-62.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19665744" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Tanna AP, Rademaker AW, Stewart WC, Feldman RM. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. Archives of Ophthalmology 2010 Jul;128(7):825-33.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20625041" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Vinuesa MJ, Vinuesa I, Daz S, Martin I, Soto J, Fernandez-Arias I. Conjunctival hyperaemia associated with the fixed combinations of latanoprost/timolol and bimatoprost/ timolol in the treatment of ocular hypertension or glaucoma. Value in Health 2009;12(7): A453 &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;
&lt;H2&gt;Interventional &lt;/H2&gt;
&lt;P&gt;Denis P, Baudouin C, Bron A, Nordmann JP, Renard JP, Rouland JF, et al. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmology 2010;10:4.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20181282" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Fristrom B, Uusitalo H. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. Acta Ophthalmologica 2010 Feb;88(1):37-43.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19900212" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Archives of Ophthalmology 2010 Mar;128(3):276-87.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20212196" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Katz LJ, Cohen JS, Batoosingh AL, Felix C, Shu V, Schiffman RM. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. American Journal of Ophthalmology 2010 Apr;149(4):661-71.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20346780" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Miglior S, Grunden JW, Kwok K. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye 2010 Jul;24(7):1234-42.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20019759" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Palmberg P, Kim EE, Kwok KK, Tressler CS. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. European Journal of Ophthalmology 2010 Jan 13;20(4):708-18.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20099236" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Shedden A, Adamsons IA, Getson AJ, Laurence JK, Lines CR, Hewitt DJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure in a randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology 2010 Dec; 248(12):1757-64.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20437244" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmologica 2010 Feb;88(1):12-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20420586" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Varma R, Hwang LJ, Grunden JW, Bean GW. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy. British Journal of Ophthalmology 2010 Jan;94(1):80-4 &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19692375" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;Observational&lt;/H2&gt;
&lt;P&gt;Alm A, Grunden JW, Kwok KK. Five-year, Multicenter Safety Study of Fixed-combination Latanoprost/Timolol (Xalacom) for Open-angle Glaucoma and Ocular Hypertension. Journal of Glaucoma 2010 May 29&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20520568" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Maguire A, Thompson M. Epidemiology of glaucoma and drug utilization in UK primary care. Pharmacoepidemiology and Drug Safety (PDS) 2009;18(S1):S143.&lt;/P&gt;
&lt;P&gt;Maguire A, MacLachlan S. Quantification of patient population impact of contra-indications: Glaucoma therapy. Pharmacoepidemiology and Drug Safety (PDS) 2009;18(S1):S100&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;O'Hare F, Jeganathan VS, Rokahr CG, Rogers SL, Crowston JG. Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients. Clinical &amp;amp; Experimental Ophthalmology 2009 Dec;37(9):849-54.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20092593" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on Glaucoma - Medical Management - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/medicalmanagement.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;Glaucoma -Medical Management- Evidence Tree &lt;/P&gt;
&lt;P&gt;Databases searched:&lt;BR&gt;PubMed; EMBASE; CINAHL; AMED; BNI; NHS Evidence - eyes and vision.&lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;Accessed using: 
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required) &lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed &lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision &lt;/A&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Inclusion criteria:&lt;BR&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: 
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis) 
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials) 
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys). &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 2009 onwards and not included in a previous AEU. 
&lt;LI&gt;Relevant to topics included in the 2010 AEU (diagnosis, monitoring, treatment – pharmacological, treatment – surgery &amp;amp; laser, service provision and patient education.) &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="/libraryImages/Eyes%20and%20Vision/contentID393788/nelhImp_0001_aeu_glau_mm.jpg"&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/GlaucomaAEU2010-JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393787:0" name=internalLink&gt;2010 AEU on Glaucoma - Epidemiology&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;&lt;/LI&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393959</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=393959]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Methodology</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;A href="nelh:377438:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methodology&lt;/STRONG&gt;&lt;BR&gt;The last Annual Evidence Update (AEU) for Glaucoma was carried out in November 2009. This AEU serves as an update to the last AEU, and includes articles published in 2009 and 2010.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The Medical Management search was run on 24th August, the Epidemiology and Living With searches on 27th August, and the ODI, Patient Education, Screening and Visual Field Progression searches on 31st August 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched&lt;/STRONG&gt;: &lt;/P&gt;
&lt;P&gt;PubMed; EMBASE; CINAHL; AMED; BNI; NHS Evidence - eyes and vision.&lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;Accessed using: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/advanced/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases&lt;/A&gt; (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision &lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis)&lt;/LI&gt;
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials)&lt;/LI&gt;
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys). &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 2009 onwards and not included in a previous AEU. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Relevancy to topics included in the 2010 AEU (diagnosis, monitoring, treatment – pharmacological, treatment – surgery &amp;amp; laser, service provision and patient education.) &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Method &lt;/P&gt;
&lt;P&gt;The search outputs were exported into Reference Manager bibliographic software. &lt;/P&gt;
&lt;P&gt;The results for each topic were automatically de-duplicated. Articles which had appeared in the 2009 AEU search output were also automatically de-duplicated and then further duplicate results removed manually. &lt;/P&gt;
&lt;P&gt;The results were then sifted for relevance and categorised by publication type. Results were also categorised by potential AEU topic sub-heading. The resultant articles were then passed to the clinical lead for further sifts for relevance. The results were re-categorised according to topic and publication type where necessary. &lt;/P&gt;
&lt;P&gt;NHS Evidence – eyes and vision was sifted on 15th November 2010 with records indexed with Glaucoma to ensure that the above search included all the pertinent articles. Relevant guidelines and uncertainties were identified during this search.&lt;/P&gt;
&lt;P&gt;NHS Evidence – eyes and vision Glaucoma AEU Searches:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/search_history/EpidemiologySearchHistory.pdf" target="_blank"&gt;Search History - Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/search_history/Screening.pdf" target="_blank"&gt;Search History – Screening &lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/search_history/MedicalManagement.pdf" target="_blank"&gt;Search History – Medical management &lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/search_history/OpticDiscImaging.pdf" target="_blank"&gt;Search History – Optic disc imaging &lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/search_history/VisualFieldProgression.pdf" target="_blank"&gt;Search History – Visual field progression &lt;/A&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/search_history/PatientEducation.pdf" target="_blank"&gt;Search History – Patient education&lt;/A&gt; &lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/search_history/LivingWithSearchHistory.pdf" target="_blank"&gt;Search History – Living with glaucoma &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;TR 22/11/10&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;ALIGN=RIGHT&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;Return to 2010 Annual Evidence Update on Glaucoma home page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393904</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=393904]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Optical Disk Imaging</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Optical Disk Imaging&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/opticaldiskimaging.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Databases searched: NHS Evidence - eyes and vision; PubMed; EMBASE; CINAHL; AMED; BNI. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;Accessed using: &lt;BR&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/advanced/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases &lt;/A&gt;(NHS Athens Account required)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Observational&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Saito H, Tsutsumi T, Araie M, Tomidokoro A, Iwase A. Sensitivity and Specificity of the Heidelberg Retina Tomograph II Version 3.0 in a Population-based Study: The Tajimi Study. Ophthalmology 2009;116(10):1854-61.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19660814" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Medeiros FA, Alencar LM, Zangwill LM, Bowd C, Sample PA, Weinreb RN. Prediction of functional loss in glaucoma from progressive optic disc damage. Archives of Ophthalmology 2009;127(10):1250-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19822839" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on Glaucoma - Optical Disk Imaging - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/opticaldiskimaging.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;Glaucoma - Optical Disk Imaging- Evidence Tree&lt;/P&gt;
&lt;P&gt;Databases searched:&lt;BR&gt;PubMed; EMBASE; CINAHL; AMED; BNI; NHS Evidence - eyes and vision.&lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;Accessed using: 
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required) &lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed &lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision &lt;/A&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Inclusion criteria:&lt;BR&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: 
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis) 
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials) 
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys). &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 2009 onwards and not included in a previous AEU. 
&lt;LI&gt;Relevant to topics included in the 2010 AEU (diagnosis, monitoring, treatment – pharmacological, treatment – surgery &amp;amp; laser, service provision and patient education.) &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID393904/nelhImp_0000_aeu_glau_odi.jpg"&gt;&lt;/P&gt;&lt;/LI&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/GlaucomaAEU2010-JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393787:1" name=internalLink&gt;2010 AEU on Glaucoma - Epidemiology&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;&lt;/LI&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393836</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=393836]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Screening</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc2.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/screening.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Databases searched: NHS Evidence - eyes and vision; PubMed; EMBASE; CINAHL; AMED; BNI. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;Accessed using: &lt;BR&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/advanced/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases &lt;/A&gt;(NHS Athens Account required)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Observational&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Lockwood AJ, Kirwan JF, Ashleigh Z. Optometrists referrals for glaucoma assessment: a prospective survey of clinical data and outcomes. Eye 2010 Sep;24(9):1515-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20559331" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Syam P, Rughani K, Vardy SJ, Rimmer T, Fitt A, Husain T, et al. The Peterborough scheme for community specialist optometrists in glaucoma: a feasibility study. Eye 2010 Jul;24(7):1156-64&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20186167" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on Glaucoma - Screening - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc2.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/screening.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;Glaucoma - Screening- Evidence Tree &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Databases searched:&lt;BR&gt;PubMed; EMBASE; CINAHL; AMED; BNI; NHS Evidence - eyes and vision.&lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;Accessed using: 
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required) &lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed &lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;/A&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Inclusion criteria:&lt;BR&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: 
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis) 
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials) 
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys). &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 2009 onwards and not included in a previous AEU. 
&lt;LI&gt;Relevant to topics included in the 2010 AEU (diagnosis, monitoring, treatment – pharmacological, treatment – surgery &amp;amp; laser, service provision and patient education.) &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="2010 AEU on Glaucoma - Screening - Evidence Tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID393836/nelhImp_0000_aeu_glau_screen.jpg" width=689 height=364&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/GlaucomaAEU2010-JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393787:1" name=internalLink&gt;2010 AEU on Glaucoma - Epidemiology&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;&lt;/LI&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>394026</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=394026]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Uncertainties in the management of glaucoma</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Uncertainties in the management of glaucoma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc6.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/uncertainities.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&lt;STRONG&gt;What clinical questions would you like answered on Glaucoma?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision is collaborating in the development of UK DUETs - the UK Database of Uncertainties about the Effects of Treatments.&lt;/P&gt;
&lt;P&gt;DUETs has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp;&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians. &lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments 
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines 
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The following uncertainties have been identified by the DUETs team and NHS Evidence - eyes and vision team since the&amp;nbsp;2009 Annual Evidence Update&lt;/STRONG&gt;&lt;STRONG&gt;.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis/Monitoring/Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Treatment - Pharmacological&lt;/STRONG&gt;&lt;/P&gt;&lt;A href="nelh:345280:0" name=internalLink&gt;
&lt;P&gt;Anti-vascular endothelial growth factor agents for treatment of macular edema secondary to central retinal vein occlusion&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:345262:0" name=internalLink&gt;Haemodilution for retinal vein occlusion&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:331006:0" name=internalLink&gt;
&lt;P&gt;Medical interventions for treating chronic primary angle-closure glaucoma&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;STRONG&gt;Treatment - Surgery &amp;amp; Laser&lt;/STRONG&gt;&lt;/P&gt;&lt;A href="nelh:330994:0" name=internalLink&gt;
&lt;P&gt;Laser peripheral iridoplasty for angle-closure&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:331002:0" name=internalLink&gt;Lens extraction for chronic angle-closure glaucoma&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:331012:0" name=internalLink&gt;One site versus two site phacotrabeculectomy for primary open angle glaucoma&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;STRONG&gt;Service Provision&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Education/Adherence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Complementary Therapy&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;&lt;A href="nelh:330984:0" name=internalLink&gt;
&lt;P&gt;Exercise for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:330983:0" name=internalLink&gt;Ginkgo biloba for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330982:0" name=internalLink&gt;Herbal remedies (including cannabis and cannabinoids) for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG&lt;/A&gt;)&lt;/P&gt;&lt;A href="nelh:330986:0" name=internalLink&gt;
&lt;P&gt;Homeopathy for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:330987:0" name=internalLink&gt;Meditation (including relaxation techniques) for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:330985:0" name=internalLink&gt;Spinal manipulation for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG&lt;/A&gt;)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:330988:0" name=internalLink&gt;Therapeutic touch for Ocular Hypertension (OHT) and Chronic Open Angle Glaucoma (COAG)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;If you are aware of or have identified any uncertainties in the management of Glaucoma please let us know.&amp;nbsp; You can contact us via our &lt;A href="http://www.library.nhs.uk/EYES/ContactUs.aspx" target="_blank"&gt;feedback form&lt;/A&gt;.&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;FONT size=2&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;&lt;FONT size=2&gt;Back to 2010 Glaucoma AEU contents page&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>393905</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=393905]]&gt;</url>
    <title>2010 Annual Evidence Update on Glaucoma - Visual Field Progression</title>
    <publicationDate>2010-11-22T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS,GLAUCOMA AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Glaucoma - Visual Field Progression&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc5.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/visualfieldprogression.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;Databases searched: NHS Evidence - eyes and vision; PubMed; EMBASE; CINAHL; AMED; BNI. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt;
&lt;P&gt;Accessed using: &lt;BR&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/advanced/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases &lt;/A&gt;(NHS Athens Account required)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;BR&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;
&lt;H2&gt;Interventional&lt;/H2&gt;
&lt;P&gt;van der Schoot J, Reus NJ, Colen TP, Lemij HG. The ability of short-wavelength automated perimetry to predict conversion to glaucoma. Ophthalmology 2010 Jan;117(1):30-4.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19896194" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Observational&lt;/H2&gt;
&lt;P&gt;Kotecha A, Spratt A, Bunce C, Garway-Heath DF, Khaw PT, Viswanathan A. Optic disc and visual field changes after trabeculectomy. Investigative ophthalmology &amp;amp; visual science 2009;50(10):4693-9. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19474409" target="_blank"&gt;Link to PubMed abstract here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;Back to 2010 Glaucoma AEU contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on Glaucoma - Visual Field Progression - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1110/aeu_glaucoma_1110_doc5.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt; &lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/evidence_trees/visualfieldprogression.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:393792:0" name=internalLink&gt; &lt;P align=right&gt;Back to 2010 Glaucoma AEU contents page&lt;/P&gt; &lt;P&gt;&lt;/A&gt;Glaucoma -Visual Field Progression - Evidence Tree &lt;/P&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;Databases searched:&lt;BR&gt;PubMed; EMBASE; CINAHL; AMED; BNI; NHS Evidence - eyes and vision.&lt;/P&gt; &lt;P&gt;Period of Search: January 2009 to 31st August 2010&lt;/P&gt; &lt;P&gt;Accessed using: &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/booksandjournals/default.aspx" target="_blank"&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required) &lt;/A&gt; &lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank"&gt;PubMed &lt;/A&gt; &lt;LI&gt;&lt;A href="http://www.library.nhs.uk/Eyes/" target="_blank"&gt;NHS Evidence - Eyes and Vision&lt;/A&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;Inclusion criteria:&lt;BR&gt;Included articles had to meet the following criteria: &lt;/P&gt; &lt;UL&gt; &lt;LI&gt;Publication types: &lt;UL&gt; &lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis) &lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials) &lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys). &lt;/LI&gt;&lt;/UL&gt; &lt;LI&gt;Published from 2009 onwards and not included in a previous AEU. &lt;LI&gt;Relevant to topics included in the 2010 AEU (diagnosis, monitoring, treatment – pharmacological, treatment – surgery &amp;amp; laser, service provision and patient education.) &lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;&lt;/P&gt; &lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt;&lt;/P&gt;&lt;/LI&gt; &lt;P&gt;&lt;EM&gt;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="2010 AEU on Glaucoma - Evidence Tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID393905/nelhImp_0000_aeu_glau_vfp.jpg" width=689 height=364&gt;&lt;/EM&gt;&lt;/P&gt; &lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1110/pdf/GlaucomaAEU2010-JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393787:0" name=internalLink&gt;2010 AEU on Glaucoma - Epidemiology&lt;BR&gt;&lt;/A&gt;&lt;A href="nelh:393792:0" name=internalLink&gt;Back to 2010 Glaucoma AEU contents page&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;&lt;/LI&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345572</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345572]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Cardiovascular morbidity and mortality associated with Retinal Vein Occlusion</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Cardiovascular morbidity and mortality associated with RVO - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_0309_doc6.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Articles/CardiovascularmorbidityandmortalityRVO.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&lt;BR&gt;Cardiovascular morbidity and mortality associated with Retinal Vein Occlusion&lt;/H2&gt;
&lt;H3 align=left&gt;Miss Sobha Sivaprasad, &lt;BR&gt;Consultant Ophthalmologist, &lt;BR&gt;King’s College Hospital, London.&lt;/H3&gt;
&lt;H3&gt;&lt;BR&gt;Is Retinal Vein Occlusion (RVO) a predictor for the future development of stroke?&lt;/H3&gt;
&lt;P&gt;Tsaloumas and associates reported in 2000 that RVO did not increase the rate of stroke development in a hospital-based study on 549 RVO patients after a mean follow-up period of 9.08 years [1]. These findings were confirmed in a retrospective population based study in Taiwan on 350 RVO patients versus 2100 controls, [2].&lt;/P&gt;
&lt;P&gt;However, asymptomatic cerebral infarction are more common in RVO patients, [3]. Similarly, a population-based study utilizing pooled data from the Atherosclerosis Risk in Communities and Cardiovascular Health Studies [4] reported that carotid artery plaque, are more common in patients with RVO but this association was not noted in another population-based study, [5]. In conclusion, there is insufficient evidence to confirm that RVO is a predictor of stroke.&lt;/P&gt;
&lt;P&gt;A body of evidence is available from observational studies.&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;[1], [2], [3], [4] and [5]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Is RVO associated with increased mortality?&lt;/H3&gt;
&lt;P&gt;The &lt;STRONG&gt;body of evidence from observational studies&lt;/STRONG&gt; on this subject are conflicting. Participants with branch RVO at baseline did not have an increased 8-year risk of mortality due to ischemic heart disease in the Beaver Dam study, [6]. A recent population based study showed that RVO does not predict acute myocardiac infarction [7]. Similarly, reports also show that RVO is not associated with cerebrovascular mortality, [8, 9]. &lt;/P&gt;
&lt;P&gt;However, Cugati et al [10] found that men with RVO are associated with a non-significant 2.3-fold higher risk of cerebrovascular mortality for all ages in a pooled cohort of two-population based studies. In another population-based study (the Beijing Eye Study) [11], RVO was significantly associated with an increased overall mortality rate in subjects aged below 69 years. The association with cardiovascular mortality has also been noted in other studies [12, 13, 14]. Based on the current evidence, careful cardiovascular assessment and treatment of cardiovascular risk factors are advocated in patients with RVO especially in young men [14].&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;[6], [7], [8], [9], [10], [11], [12], [13] and [14 – small study]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Ameliorate cardiovascular morbidity and mortality&lt;/H3&gt;
&lt;P&gt;It is crucial that all cardiovascular risk factors be identified and treated in patients with RVO. Aspirin is now not licensed for the primary prevention of vascular events. If aspirin is used in primary prevention, the balance of benefits and risks should be considered for each individual, particularly the presence of risk factors [15]. Given that there is insufficient evidence to suggest that RVO is a risk factor for stroke or vascular mortality, the role of aspirin in RVO remains equivocal.&lt;/P&gt;
&lt;P&gt;Secondary Publication:&lt;BR&gt;[15]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;References:&lt;/H3&gt;
&lt;P&gt;1. Tsaloumas M D, Kirwan, J, Vinall, H., O’Leary M B, Prior P, Kritzinger E E, Dodson P M. Nine year follow up study of morbidity and mortality in retinal vein occlusion. Eye 2000;14: 821-827.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11584836" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11584836&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;2. Ho JD, Liou SW, Lin HC. Retinal vein occlusion and the risk of stroke development: a five-year follow-up study. American Journal of Ophthalmology 2009 Feb;147(2):283-90.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18835470" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18835470&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;3. Ueda Y, Kanazawa S, Ohira A, Miyamura N, Takaki T, Kitaoka T, et al. Retinal vascular obstruction and asymptomatic cerebral infarction. Japanese Journal of Ophthalmology 2002 Mar;46(2):209-14.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12062229" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12062229&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;4. Wong TY, Larsen EK, Klein R, Mitchell P, Couper DJ, Klein BE, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities &amp;amp; Cardiovascular Health studies. Ophthalmology 2005 Apr;112(4):540-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15808241" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15808241&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;5. Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Investigative Ophthalmology &amp;amp; Visual Science 2008 Oct;49(10):4297-302.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18539932" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18539932&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;6. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. &lt;BR&gt;Transactions of the American Ophthalmological Society 2000;98:133-41.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11190017" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11190017&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;7. Hu CC, Ho JD, Lin HC. Retinal vein occlusion and the risk of acute myocardial infarction (correction of infraction): a 3-year follow-up study. British Journal of Ophthalmology 2009 Jun;93(6):717-20.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19208680" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19208680&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;8. Mansour AM, Walsh JB, Henkind P. Mortality and morbidity in patients with central retinal vein occlusion. Ophthalmologica 1992; 204(4);199–203.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1513551" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/1513551&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;9. Elman MJ, Bhatt AK, Quinlan PM, Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990;97(11):1543-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2255527" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/2255527&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;10. Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein R, Klein BE, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007 Mar;114(3):520-4.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17141315" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17141315&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;11. Xu L, Liu WW, Wang YX, Yang H, Jonas JB. Retinal vein occlusions and mortality: the Beijing Eye Study. American Journal of Ophthalmology 2007 Dec;144(6):972-3. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18036874" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18036874&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12. Rubinstein K, Jones B. Retinal vein occlusion: long term prospects, 10 years follow-up of 143 patients. British Journal of Ophthalmology 1976; 60; 148-150.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1268175" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/1268175&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;13. Martin SC, Butcher A, Martin N, Farmer J, Dobson PM, Bartlett WA, et al. Cardiovascular risk assessment in patients with retinal vein occlusion. British Journal of Ophthalmology 2002 Jul;86(7):774-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12084748" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12084748&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;14. Priluck IA, Robertson DM, Hollenhorst RW. Long-term follow-up of occlusion of the central retinal vein in young adults, American Journal of Ophthalmology 1980 Aug;90(2):190-202.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/6158866" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/6158866&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;15. MHRA. Aspirin: not licensed for primary prevention of thrombotic vascular disease. MHRA Drug Safety Update: Volume 3 Issue 3, October 2009. p.10. &lt;BR&gt;&lt;A href="http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&amp;amp;dDocName=CON059813&amp;amp;RevisionSelectionMethod=LatestReleased" target="_blank"&gt;http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&amp;amp;dDocName=CON059813&amp;amp;RevisionSelectionMethod=LatestReleased&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345572:2" name=internalLink&gt;Cardiovascular morbidity and mortality associated with RVO - Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Cardiovascular morbidity and mortality associated with RVO - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_1109_doc11.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Evidence_Trees/Cardiovascularmorbiditysearchsummaryandevidencetree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision; PubMed; Medline; EMBASE; CINAHL; AMED; BNI; and PsycINFO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;January 2002 to 15th February 2010&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Sifting:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;One search was undertaken and the results sifted manually into five topics: Epidemiology; Diagnosis, Management of CRVO; Management of BRVO; and Cardiovascular morbidity and mortality associated with RVO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Definitions:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Secondary publications include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses. &lt;/P&gt;
&lt;P&gt;Interventional studies include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;Observational studies include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;IMG style="WIDTH: 631px; HEIGHT: 331px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Cardiovascular morbidity Evidence Tree - RVO AEU 2010" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345572/nelhImp_0000_aeu_rvo_cmm.jpg" width=689 height=364&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/RVOAEU2010-Journalspread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345572:1" name=internalLink&gt;2010&amp;nbsp;AEU on RVO&amp;nbsp;- Cardiovascular morbidity and mortality associated with RVO -&amp;nbsp;Topic Summary&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345563</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345563]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Diagnosis</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Diagnosis - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_0309_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Articles/DiagnosisofRVO.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Diagnosis of Retinal Vein Occlusion&lt;/H2&gt;
&lt;H3&gt;Miss Sobha Sivaprasad, &lt;BR&gt;Consultant Ophthalmologist, &lt;BR&gt;King’s College Hospital, London.&lt;/H3&gt;
&lt;H3&gt;&lt;BR&gt;Clinical Features&lt;/H3&gt;
&lt;P&gt;The Standard Care versus Corticosteroid in Retinal Vein Occlusion (SCORE) study [1] summarised the definitions of the different types of retinal vein occlusions (RVO) based &lt;STRONG&gt;on clinical examination&lt;/STRONG&gt; as follows: &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Central Retinal Vein Occlusion (CRVO): An eye that has retinal haemorrhage or other biomicroscopic evidence of retinal vein occlusion (e.g., telangiectatic capillary bed) and a dilated venous system (or previously dilated venous system) in all 4 quadrants.&lt;/LI&gt;
&lt;LI&gt;Branch Vein Occlusion (BRVO): An eye that has retinal haemorrhage or other biomicroscopic evidence of retinal vein occlusion (e.g., telangiectatic capillary bed) and a dilated venous system (or previously dilated venous system) in =1 quadrant of retina drained by the affected vein.&lt;/LI&gt;
&lt;LI&gt;Hemiretinal vein occlusion (HRVO): An eye that has retinal haemorrhage or other biomicroscopic evidence of retinal vein occlusion (e.g., telangiectatic capillary bed) and a dilated venous system (or previously dilated venous system) in &amp;gt;1 quadrant but &amp;lt; all 4 quadrants. Typically, an HRVO is a retinal vein occlusion that involves 2 altitudinal quadrants.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;Interventional study:&lt;BR&gt;[1]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Classification&amp;nbsp; - Colour fundus photographs&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;Similarly, the SCORE study [1] also used the following classification on standard Early Treatment Diabetic Retinopathy Study (ETDRS) [2] 7-field film colour stereoscopic &lt;STRONG&gt;fundus photographs&lt;/STRONG&gt; and Reading Centre grading definitions:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;CRVO: Abnormalities are found in all 4 quadrants of the retina. Acute retinal findings may include dilated and tortuous veins, scattered intraretinal haemorrhage, soft exudates/cotton wool spots, macular oedema, and papillary oedema. Late findings may include collateral vessels on the disc and retina, persistent venous dilation and tortuosity, perivenous sheathing, arteriolar narrowing, and macular abnormalities (chronic macular oedema and retinal pigment epithelial changes).&lt;/LI&gt;
&lt;LI&gt;BRVO: Present when dilated veins and retinal haemorrhages occupy 1, 2, or 3 quadrants of the retina. A typical BRVO occupies a wedge-shaped area. The occlusion often contains macular oedema, soft exudates/cotton wool spots, and both deep and superficial retinal haemorrhages confined to the quadrant fed by the branch vein.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;HRVO (a BRVO subtype): Present when there are features intermediate in extent between CRVO and BRVO. HRVO affects either the superior or inferior retinal hemispheres, and the retinal haemorrhages involved are nearly equal in 2 altitudinal quadrants (the nasal and temporal aspects) of the involved hemisphere.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;The agreement of both the clinical examination by the clinicians and the Reading centre grading of the fundus photographs was excellent in the SCORE Study.&lt;/P&gt;
&lt;P&gt;Interventional study:&lt;BR&gt;[1]&lt;/P&gt;
&lt;P&gt;Observational study:&lt;BR&gt;[2]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Assessment - Fundus Fluorescein Angiography&lt;/H3&gt;
&lt;P&gt;The RVO can be classified into two distinct entities based on the extent of retinal non-perfusion in fundus fluorescein angiography (FFA) - the ischaemic form and the non-ischaemic form. The two types of RVO have different prognosis. Patients with ischaemic CRVO are at risk of neovascular glaucoma. This risk of iris neovascularisation is higher if the area of retinal ischaemia (retinal non-perfusion as determined by FFA) is &amp;gt;10 disc diameters, [3]. About 20–36% of the central retinal vein occlusions are ischaemic, and the majority of patients in this group develop rubeosis, [3, 4, 5].&lt;/P&gt;
&lt;P&gt;The 2009 Royal College of Ophthalmologists RVO Interim guidelines [6] states that ischaemic central retinal vein occlusion is associated with one or more of the following characteristics: &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Poor visual acuity (44% of eyes with vision of &amp;lt;6/60 develop rubeosis&lt;/LI&gt;
&lt;LI&gt;Relative afferent pupillary defect&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Presence of multiple dark deep intra-retinal haemorrhages&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Presence of multiple cotton wool spots&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Fluorescein angiography showing greater than 10 disc areas of retinal capillary non-perfusion&lt;/LI&gt;
&lt;LI&gt;Electrodiagnostic tests (ERG): reduced b wave amplitude, reduced b:a ratio and prolonged b-wave implicit time&amp;nbsp; (for further details see ERG section below)&lt;/LI&gt;
&lt;LI&gt;Degree of retinal vein dilatation and tortuosity&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;A link between causal factors and RVO can also be established by classifying RVO according to sites of occlusion and the presence of optic nerve head swelling (ONHS): arteriovenous crossing RVO (AV-RVO); optic cup RVO (OC-RVO); and optic nerve sited RVO. Optic nerve sited RVOs were further divided on the basis of presence (ONHS-RVO) and absence (NONHS-RVO) of ONHS, [7]. Higher prevalence of hypertension and smoking is noted in the AV-RVO. The association of Primary open angle glaucoma and CRVO was noted only in cases without ONHS. RVOs with ONHS was reported to occur in younger people, with a higher proportion of males, and a lower prevalence of hypertension and primary open angle glaucoma (POAG), suggesting the need to investigate this group of patients for other causal factors, [7].&lt;/P&gt;
&lt;P&gt;Secondary Publication:&lt;BR&gt;[6]&lt;/P&gt;
&lt;P&gt;Interventional study:&lt;BR&gt;[3]&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;[4], [5], and [7]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Other assessment tools:&lt;/H3&gt;
&lt;H3&gt;Optical coherent tomography (OCT)&lt;/H3&gt;
&lt;P&gt;The SCORE study [8] also investigated the relationship between visual acuity and morphologic variables on OCT in the study population of 655 participants. Patients with CRVO are more likely than participants in the BRVO patients to have worse baseline visual acuity letter score, a higher OCT-measured centre point thickness, a larger mean area of retinal thickening as measured on fundus photography, and a larger mean area of fluorescein leakage. This is because CRVO affects a larger portion of the retina and retinal circulation (and involves both halves of the macula), whereas BRVO affects a smaller portion of the retina and retinal circulation. OCT-measured centre point thickness represents a useful tool for the detection and monitoring of macular oedema in retinal vein occlusion.&lt;/P&gt;
&lt;P&gt;Interventional study:&lt;BR&gt;[8]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Electroretinography&lt;/H3&gt;
&lt;P&gt;Electroretinography (ERG) provides an objective measure of the loss of retinal function in CRVO. Both the timing and amplitude of the 30-Hz flicker, reflecting predominantly cone photoreceptor function, are good predictors of neovascular complications [9]. Interocular comparison of amplitude is a good solution for avoiding the variability of ERG. An interocular amplitude ratio of flicker ERG of 60% is a succinct, useful parameter in clinical practices for differentiating ischemic from nonischemic CRVO [10]. Moreover, an implicit times of 35.0 ms or higher (&amp;gt; 0.5 SD from mean) with photopic 30 Hz flicker ERG is an useful predictor of neovascularisation, [11].&amp;nbsp; Decreased b/a amplitude ratio is also a predictor of neovascular glaucoma, [12, 13].&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;[9], [10], [11], [12 - small study] and [13 - small study].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Multifocal electroretinography (mf-ERG)&lt;/H3&gt;
&lt;P&gt;The amplitudes of the negative waves (N1) and positive (P1) waves of the first order kernel correlate well with the cone density distribution, [14]. The mf-ERG abnormalities noted in CRVO are P1 amplitude reduction and P1 and N1 implicit time delay, [15]. Macular ischemia as measured by fluorescein angiography correlates well with the prolonged implicit time on the first-order kernel response in mf-ERG, but no significant correlation was detected between the responses of mf-ERG and the OCT findings, [16].&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;[14 - small study], [15] and [16 - small study]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Perimetry&lt;/H3&gt;
&lt;P&gt;The Micro Perimeter 1 (MP-1) is a newly introduced perimetry system that combines digital fundus imaging with automatic microperimetry in a single instrument. A retinal sensitivity map obtained with the MP-1 yields more information about central macular function because it documents each individual area in which function may be disturbed. Retinal sensitivity using MP-1 correlated with retinal thickness in patients with macular oedema secondary to BRVO, [17]. MP-I is also a useful tool in monitoring response to treatment with intravitreal triamcinolone and antiVEGf agents, [17, 18].&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;&lt;EM&gt;Emerging knowledge around recent developments in clinical practices for which there is as yet no evidence base.&lt;/EM&gt;&lt;BR&gt;[17 – small study] and [18 – small study]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Carotid Doppler studies in RVO&lt;/H3&gt;
&lt;P&gt;There is no evidence on the use of carotid Doppler for screening of asymptomatic carotid atherosclerosis in RVO, [19, 20].&lt;/P&gt;
&lt;P&gt;Secondary Publication:&lt;BR&gt;[19]&lt;/P&gt;
&lt;P&gt;Observational study:&lt;BR&gt;[20]&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;References:&lt;/H3&gt;
&lt;P&gt;1. Scott IU, Blodi BA, Ip MS, VanVeldhuisen PC, Oden NL, Chan CK, et al. SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology 2009 Apr;116(4):756-61.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19344824" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19344824&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;2. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991; May;98(5 Suppl):786-806.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2062513" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/2062513&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;3. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Retinal Vein Occlusion Study Group N Report. Ophthalmology 1995;102:1434-44.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9097789" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/9097789&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;4. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983 May; 90(5):458–474.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/6877778" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/6877778&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;5. Quinlan PM, Elman MJ, Bhatt AK, et al. The natural course of central retinal vein occlusion. American Journal of Ophthalmology 1990; 110:118–123.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2378375" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/2378375&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;6. The Royal College of Ophthalmologists. Retinal Vein Occlusion (RVO): Interim Guidelines, February 2009. p.9.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;7. Beaumont PE, Kang HK. Clinical characteristics of retinal venous occlusions occurring at different sites. British Journal of Ophthalmology 2002 May;86(5):572-80. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11973257" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11973257&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;8. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, et al. SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology 2009 Mar;116(3):504-12.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19167078" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19167078&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;9. Severns ML, Johnson MA. Predicting outcome in central retinal vein occlusion using the flicker electroretinogram. Archives of Ophthalmology 1993; 111:1123–1130.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7688951" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/7688951&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;10. Kuo HK, Kuo MT, Chen YJ, Wu PC, Chen CH, Chen YH. The flicker&lt;BR&gt;electroretinogram interocular amplitude ratio is a strong prognostic indicator of neovascularization in patients with central retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 2010 Feb;248(2):185-9. [Epub ahead of print 2009 Oct 8].&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19813018" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19813018&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;11. Kjeka O, Bredrup C, Krohn J. Photopic 30 Hz flicker electroretinography predicts ocular neovascularization in central retinal vein occlusion. Acta Ophthalmologica Scandinavica. 2007 Sep;85(6):640-3. [Epub ahead of print 2007 Apr 2].&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17403019" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17403019&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12. Sabates R, Hirose T, Wallace McMeel J. Electroretinography in the prognosis and classification of central retinal vein occlusion. Archives of Ophthalmology 1983; 101(2):232–235.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/6824467" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/6824467&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;13. Breton ME, Schueller AW, Montzka DP. Electroretinogram b-wave implicit time and b/a wave ratio as a function of intensity in central retinal vein occlusion. Ophthalmology. 1991 Dec;98(12):1845-53.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1723186" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/1723186&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14. Hvarfner C, Andreasson S, Larsson J. Multifocal electroretinogram in branch retinal vein occlusion. American Journal of Ophthalmology 2003 Dec;136(6):1163-5.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14644234" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/14644234&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;15. Dolan FM, Parks S, Keating D, Dutton GN, Evans AL. Multifocal electroretinographic features of central retinal vein occlusion. Investigative Ophthalmology &amp;amp; Visual Science 2003 Nov;44(11):4954-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14578422" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/14578422&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;16. Hvarfner C, Andreasson S, Larsson J. Multifocal electroretinography and fluorescein angiography in retinal vein occlusion. Retina 2006 Mar;26(3):292-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16508429" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16508429&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;17. Yamaike N, Kita M, Tsujikawa A, Miyamoto K, Yoshimura N. Perimetric sensitivity with the micro perimeter 1 and retinal thickness in patients with branch retinal vein occlusion. American Journal of Ophthalmology 2007 Feb;143(2):342-4.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17258527" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17258527&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;18. Kriechbaum K, Prager F, Geitzenauer W, Benesch T, Schütze C, Simader C,Schmidt-Erfurth U. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. Ophthalmology. 2009 Dec;116(12):2415-21. [Epub ahead of print 2009 Sep 10].&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19744723" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19744723&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;19. Rotsos TG, Moschos MM. Cystoid macular edema. Clinical Ophthalmology 2008 Dec;2(4):919-30.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19668445" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19668445&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;20. Lyons-Wait VA, Anderson SF, Townsend JC, De LP. Ocular and systemic findings and their correlation with hemodynamically significant carotid artery stenosis: A retrospective study. Optometry and Vision Science 2002;79(6):353-62.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12086301" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12086301&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345563:2" name=internalLink&gt;2010 AEU on RVO -&amp;nbsp;Diagnosis - Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Diagnosis - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_1109_doc8.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Evidence_Trees/Diagnosissearchsummaryandevidencetree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision; PubMed; Medline; EMBASE; CINAHL; AMED; BNI; and PsycINFO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;January 2002 to 15th February 2010&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Sifting:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;One search was undertaken and the results sifted manually into five topics: Epidemiology; Diagnosis, Management of CRVO; Management of BRVO; and Cardiovascular morbidity and mortality associated with RVO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Definitions:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Secondary publications include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses. &lt;/P&gt;
&lt;P&gt;Interventional studies include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;Observational studies include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys.&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;IMG style="WIDTH: 637px; HEIGHT: 322px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Diagnosis Evidence Tree - RVO AEU 2010" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345563/nelhImp_0000_aeu_rvo_Diag.jpg" width=689 height=364&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/RVOAEU2010-Journalspread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345563:1" name=internalLink&gt;2010&amp;nbsp;AEU on RVO&amp;nbsp;-&amp;nbsp;Diagnosis -&amp;nbsp;Topic Summary&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345533</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345533]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Epidemiology</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Epidemiology - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_0309_doc2.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Articles/EpidemiologyofRVO.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Epidemiology of Retinal Vein Occlusion&lt;/H2&gt;
&lt;H3&gt;Miss Sobha Sivaprasad, &lt;BR&gt;Consultant Ophthalmologist, &lt;BR&gt;King’s College Hospital, London.&lt;/H3&gt;
&lt;H3&gt;&lt;BR&gt;Introduction&lt;/H3&gt;
&lt;P&gt;Retinal vein occlusions (RVO) are a common cause of reduced vision due to retinal vascular disease. Branch retinal vein occlusions (BRVO) occur more frequently than central retinal vein occlusion (CRVO), [1] [2] [3]. &lt;/P&gt;
&lt;H3&gt;Prevalence and Incidence&lt;BR&gt;Prevalence:&amp;nbsp;&amp;nbsp; &lt;BR&gt;&lt;/H3&gt;
&lt;P&gt;Pooled analysis from population based studies in the USA, Australia, Europe and Asia [3], provide age-gender standardized prevalence in the adult population for:&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;Any retinal vein occlusion (RVO)&lt;/TD&gt;
&lt;TD&gt;5.20 per 1000&amp;nbsp; (95% C.I. 4.40 - 5.99)&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;Branch retinal vein occlusion (BRVO)&lt;/TD&gt;
&lt;TD&gt;4.42 per 1000&amp;nbsp; (95% C.I. 3.56 - 5.19)&lt;BR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;Central retinal vein occlusion (CRVO)&lt;/TD&gt;
&lt;TD&gt;0.50 per 1000&amp;nbsp; (95% C.I&amp;nbsp; 0.61 – 0.99)&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;No gender differences were observed; prevalence of any RVO increases with age; and age-gender standardized prevalence of any RVO varied by race [3]: 
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;Whites&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;3.7 per 1000&amp;nbsp; (95% C.I. 2.8 – 4.6)&lt;BR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;Blacks&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;3.9 per 1000&amp;nbsp; (95% C.I. 1.8 – 6.0)&lt;BR&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;Asians&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;5.7 per 1000&amp;nbsp; (95% C.I.&amp;nbsp; 4.5 – 6.8)&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;Hispanics&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;6.9 per 1000&amp;nbsp; (95% C.I.&amp;nbsp; 5.7 – 8.3)&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P&gt;A&amp;nbsp;recent population based study from Japan reports a higher prevalence of retinal vein occlusion amongst Japanese people – prevalence of any retinal vein occlusion 2.1%; prevalence of BRVO as 2.0%; and for CRVO as 0.2%). [4]&lt;/P&gt;
&lt;H3&gt;Cumulative Incidence:&lt;/H3&gt;
&lt;P&gt;The cumulative 10 year incidence for any RVO has been reported as being 1.6%, [5].&amp;nbsp; The cumulative 15 year incidence for BRVO has been reported as being 1.8% and that for CRVO as being 0.8%, [6].&lt;/P&gt;
&lt;P&gt;Secondary Publication:&lt;BR&gt;[3]&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;[1], [2], [4], [5], and [6]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Aetiology and risk factors &lt;/H3&gt;
&lt;H3&gt;Cardiovascular risk factors:&lt;/H3&gt;
&lt;P&gt;Established cardiovascular risk factors are the predominant medical associations for both CRVO and BRVO. A systematic review of 21 studies on 2916 cases and 28646 controls on atherosclerotic risk factors for any type of RVO showed that hypertension (OR, 3.5; 95% confidence interval [CI], 2.5-5.1) and hyperlipidaemia (OR, 2.5; 95% CI, 1.7-3.7) were significantly associated with any form of RVO; the association was less pronounced for diabetes mellitus (OR, 1.5; 95% CI, 1.1-2.0). Similar results were found in cases with central RVO and branch RVO. The percentage of cases with any form of RVO attributed to hypertension was 47.9% (95% CI, 31.2%-63.1%), to diabetes mellitus was 4.9% (95% CI, 0.8%-11.5%), and to hyperlipidaemia was 20.1% (95% CI, 5.9%-43.8%), [7]. In the older age group (&amp;gt;50 years), up to 64% of patients have hypertension. A new diagnosis of uncontrolled hypertension is a common finding. Inadequately controlled hypertension is associated with recurrence of RVO in the same eye or fellow eye involvement, [8]. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;Hyperlipidaemia (cholesterol &amp;gt; 6.5 mmol/l) is the predominant association in the younger age group (&amp;lt; 50 years) of patients with retinal vein occlusion and is associated in up to 50% of older patients [8]. Disorders in lipoprotein metabolism may contribute to the aetiology of RVO, [9].&lt;/P&gt;
&lt;P&gt;Secondary Publications:&lt;BR&gt;[7] and [8]&lt;/P&gt;
&lt;P&gt;Observational study:&lt;BR&gt;[9]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Glaucoma&lt;/H3&gt;
&lt;P&gt;Cup-to-disk ratio is a significant predictor of risk of incident RVO [10]. Current evidence suggests an association between CRVO and glaucoma and ocular hypertension (OHT) with a subsequent fall in intraocular pressure (IOP) in the involved eye [11]. Many patients have raised intraocular pressure in the fellow uninvolved eye. It is important to exclude glaucoma/OHT in the fellow eye of any patient with CRVO/ Hemi-central retinal vein occlusion (HCRVO); if present, elevated IOP should be treated to reduce the risk of that eye developing a vein occlusion or damage due to glaucoma. There may be no benefit to prescribing IOP-lowering drops for involved eyes whose IOP is already normal, [12].&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;[10], [11 - small study] and [12]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Thrombophilia&lt;/H3&gt;
&lt;P&gt;Thrombophilic risk factors include hyperhomocysteinemia, MTHFR gene mutation, factor V Leiden mutation, protein C and S deficiency, antithrombin deficiency, prothrombin gene mutation, anticardiolipin antibodies and lupus anticoagulant.&amp;nbsp; Several systematic reviews exist on different aspects of thrombophilia risk factors of RVO. Higher plasma total homocysteine levels and antiphospholipid antibodies are associated with retinal vein occlusions. Serum folates are also noted to be lower in retinal vascular occlusion. There was no evidence of an association of serum vitamin B12 and homozygosity for the MTHFR C677T genotype with vein occlusions, [13, 14, and 15]. Similarly, there is insufficient evidence to recommend screening for Protein S and Protein C deficiency, antithrombin deficiency, prothrombin gene mutation, and Factor V Leiden in patients with RVO. Older patients with any of the common vascular risk factors do not require thrombophilic screening. It is more useful to preserve thrombophilic screening to younger patients without known risk factors such as hypertension and hyperlipidemia, [16, 17, 18].&lt;/P&gt;
&lt;P&gt;Secondary Publications:&lt;BR&gt;[13], [14], [15], [16], [17] and [18]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Other associations&lt;/H3&gt;
&lt;UL&gt;
&lt;LI&gt;Myeloproliferative disorders occur in 1% of patients presenting with retinal vein occlusion, [19, 20].&lt;/LI&gt;
&lt;LI&gt;Inflammatory diseases that cause or are associated with retinal vasculitis such as Behçets disease, polyarteritis nodosa, sarcoidoisis, Wegener’s Granulomatosis and Goodpasture’s Syndrome, [21, 22, 23].&lt;/LI&gt;
&lt;LI&gt;Chronic renal failure and other secondary causes of hypertension and diabetes e.g. acromegaly, Cushing’s syndrome [24]. Renal dysfunction has been associated with RVO in epidemiological studies, [6, 25, 26]&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Secondary causes of hypercholesterolaemia eg hypothyroidism. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency in red blood cells have a significantly decreased risk of development of RVO [27]&lt;/LI&gt;
&lt;LI&gt;The axial lengths of BRVO eyes tend to be shorter than those of unaffected eyes [28, 29].&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;&lt;EM&gt;Emerging knowledge around recent developments in clinical practices for which there is as yet no evidence base.&lt;BR&gt;&lt;/EM&gt;[19 – small study (case study)], [20 – small study (case study)], [21 – small study (case study)], [22 – small study (case study)], [23 – small study (case study)], [24 -&amp;nbsp; small study (case study)], [25] [26], [27], [28] and [29 – small study].&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;References:&lt;/H3&gt;
&lt;P&gt;1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Transactions of the American Ophthalmological Society 2000;98:133– 41, discussion 141–3.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11190017" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11190017&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;2. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Archives of Ophthalmology 1996;114:1243–7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8859084" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/8859084&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;3. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010 Feb;117(2):313-9.e1 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20022117" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20022117&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;4. Yasuda M, Kiyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y, et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama Study. Investigative Ophthalmology and Visual Science 2010 Jan 13.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20071683" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20071683&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;5. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Archives of Ophthalmology 2006 May;124(5):726-32.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16682596" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16682596&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;6. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Archives of Ophthalmology 2008 Apr;126(4):513-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18413521" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18413521&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;7. O'Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Archives of Ophthalmology 2008 May;126(5):692-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18474782" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18474782&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;8. The Royal College of Ophthalmologists. Retinal Vein Occlusion (RVO): Interim Guidelines, February 2009. p.7.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;9. Stojakovic T, Scharnagl H, Marz W, Winkelmann BR, Boehm BO, Schmut O. Low density lipoprotein triglycerides and lipoprotein(a) are risk factors for retinal vascular occlusion. Clinica chimica acta; international journal of clinical chemistry 2007 Jul;382(1-2):77-81.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17481600" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17481600&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;10. Klein BE, Meuer SM, Knudtson MD, Klein R. The relationship of optic disk cupping to retinal vein occlusion: the Beaver Dam Eye Study. American Journal of Ophthalmology 2006 May;141(5):859-62.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16527230" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16527230&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;11. Sherpa D, Shakya S, Shrestha JK. Association of primary glaucomas with retinal vein occlusion. Kathmandu University Medical Journal (KUMJ ) 2008 Jan;6(1):49-54.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18604115" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18604115&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12. Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology 2004 Jan;111(1):133-41.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14711725" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/14711725&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;13. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. American Journal of Ophthalmology 2003 Dec;136(6):1136-50.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14644226" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/14644226&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;14. McGimpsey SJ, Woodside JV, Cardwell C, Cahill M, Chakravarthy U. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology 2009 Sep;116(9):1778-87.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19729099" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19729099&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;15. Janssen MC, den HM, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thrombosis and Haemostasis 2005 Jun;93(6):1021-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15968383" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15968383&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;16. Rehak M, Rehak J, Muller M, Faude S, Faude F, Siegemund A, et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thrombosis and Haemostasis 2008 May;99(5):925-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18449423" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18449423&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;17. Lahey JM, Kearney JJ, Tunc M. Hypercoagulable states and central retinal vein occlusion. Current Opinion in Pulmonary Medicine 2003 Sep;9(5):385-92.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12904708" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12904708&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;18. Fegan CD. Central retinal vein occlusion and thrombophilia. Eye (Lond) 2002 Jan;16(1):98-106.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11913903" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11913903&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;19. Cheung CM, Tsaloumas MD. Acute myeloid leukaemia presenting as retinal vein occlusion and eyelid swelling. Eye (Lond) 2002 Mar;16(2):202-3.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11988828" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11988828&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;20. Lee LC, Howes EL, Bhisitkul RB. Systemic non-Hodgkin's lymphoma with optic nerve infiltration in a patient with AIDS. Retina 2002 Feb;22(1):75-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11884882" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11884882&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;21. Oba K, Uematsu M, Kurihara J, Kazumori S, Mine M. Occlusive retinal vasculitis in a boy with systemic lupus erythematosus. Japanese Journal of Clinical Ophthalmology 2004;58(7):1303-7.&lt;BR&gt;[Abstract available on EMBASE – article in Japanese]&lt;/P&gt;
&lt;P&gt;22. Helvaci MR, Ozcura F, Hacioglu A, Civi K. A Behcet's case presenting with central retinal vein occlusion: Case report. Turkiye Klinikleri Journal of Medical Sciences 2008;28(3):403-7.(1)&lt;BR&gt;&lt;A href="http://tipbilimleri.turkiyeklinikleri.com/abstract_50528.html" target="_blank"&gt;http://tipbilimleri.turkiyeklinikleri.com/abstract_50528.html&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;23. Shenoy R, Elagib el NM, al SH, Amer A. Limited Wegener's granulomatosis presenting as multiple retinal vascular occlusions. Indian Journal of Ophthalmology 2002;50(2):135-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez/12194572" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/sites/entrez/12194572&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;24. Chai SM, Mathur R, Ong SG. Retinal vasculopathy in Fanconi anemia. Ophthalmic surgery, lasers &amp;amp; imaging : the official journal of the International Society for Imaging in the Eye 2009 Sep;40(5):498-500.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19772276" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19772276&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;25. Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Investigative Ophthalmology &amp;amp; Visual Science 2008 Oct;49(10):4297-302.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18539932" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18539932&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;26. Shahsuvaryan ML, Melkonyan AK. Central retinal vein occlusion risk profile: a case-control study. European Journal of Ophthalmology 2003 Jun;13(5):445-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12841567" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/12841567&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;27. Pinna A, Carru C, Solinas G, Zinellu A, Carta F. Glucose-6-phosphate dehydrogenase deficiency in retinal vein occlusion. Investigative Ophthalmology &amp;amp; Visual Science 2007 Jun;48(6):2747-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17525208" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17525208&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;28. Tsai SC, Chen HY, Chen CY. Relationship between retinal vein occlusion and axial length. Kaohsiung Journal of Medical Sciences 2003 Sep;19(9):453-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14604320" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/14604320&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;29. Talu S, Stefanut C. [Axial length and branch retinal vein occlusion]. Oftalmologia 2004;48(1):81-4.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15279426" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15279426&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345533:2" name=internalLink&gt;2010 AEU on RVO - Epidemiology - Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Epidemiology - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_1109_doc7.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Evidence_Trees/Epidemiologysearchsummaryandevidencetree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision; PubMed; Medline; EMBASE; CINAHL; AMED; BNI; and PsycINFO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;January 2002 to 15th February 2010&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Sifting:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;One search was undertaken and the results sifted manually into five topics: Epidemiology; Diagnosis, Management of CRVO; Management of BRVO; and Cardiovascular morbidity and mortality associated with RVO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Definitions:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Secondary publications include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses. &lt;/P&gt;
&lt;P&gt;Interventional studies include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;Observational studies include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 589px; HEIGHT: 374px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Epidemiology Evidence Tree - RVO AEU 2010" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345533/nelhImp_0001_aeu_rvo_epid.jpg" width=558 height=351&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/RVOAEU2010-Journalspread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345533:1" name=internalLink&gt;2010&amp;nbsp;AEU on RVO&amp;nbsp;-&amp;nbsp;Epidemiology -&amp;nbsp;Topic Summary&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345560</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345560]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Evidence Tree</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Retinal Vein Occlusion - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_1109_doc12.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Evidence_Trees/FullRVOEvidenceTree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;A href="nelh:329673:0" name=internalLink&gt;&lt;/P&gt;&lt;/A&gt;
&lt;H2&gt;Evidence Tree for the entire Annual Evidence Update for RVO 2010&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG style="WIDTH: 559px; HEIGHT: 539px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Main Evidence Tree - RVO AEU 2010" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345560/nelhImp_0000_aeu_rvo_Main.jpg" width=395 height=537&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision; PubMed; Medline; EMBASE; CINAHL; AMED; BNI; and PsycINFO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;January 2002 to 15th February 2010&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Sifting:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;One search was undertaken and the results sifted manually into five topics: Epidemiology; Diagnosis, Management of CRVO; Management of BRVO; and Cardiovascular morbidity and mortality associated with RVO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Definitions:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Secondary publications include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses. &lt;/P&gt;
&lt;P&gt;Interventional studies include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;Observational studies include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345418</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345418]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Home Page</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SURGERY,SURGERY,RETINA,RETINAL VASCULAR OCCLUSION,HEAD &amp; NECK,EYE,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Retinal Vein Occlusion - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Published: &lt;/STRONG&gt;15th March 2010&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Ischaemic BRVO - Fluorescein" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345418/nelhImp_0000_BRVO1F.JPG" width=145 height=110&gt;&amp;nbsp;&lt;IMG style="WIDTH: 157px; HEIGHT: 109px" id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Ischaemic BRVO - Colour" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345418/nelhImp_0001_BRVO2C.JPG" width=149 height=109&gt;&amp;nbsp;&amp;nbsp;&lt;IMG style="WIDTH: 145px; HEIGHT: 109px" id=nelh_tempImage5 border=0 name=nelh_tempImage5 alt="Ischaemic CRVO - Fluorescein" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345418/nelhImp_0005_CRVO4F.JPG" width=142 height=109&gt;&amp;nbsp;&lt;IMG style="WIDTH: 142px; HEIGHT: 110px" id=nelh_tempImage4 border=0 name=nelh_tempImage4 alt="Ischaemic CRVO - Colour" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345418/nelhImp_0004_CRVO3C.JPG" width=137 height=110&gt;&lt;/P&gt;
&lt;P&gt;The 2010 Retinal Vein Occlusion Annual Evidence Update highlights the key evidence base underpinning current interventions, new evidence that is likely to inform a change in clinical practice, emerging knowledge from key randomised controlled trials and current uncertainties in the effectiveness of treatments.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We welcome feedback about resources that we identify, do contact us if you would like to comment.After you have browsed the pages, please take a moment to complete our survey (5 mins). &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/Feedback/feedback.aspx" target="_blank"&gt;Click here to take the survey&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Contents&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;Topics covered:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:345419:0" name=internalLink&gt;Introduction&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345533:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345563:0" name=internalLink&gt;Diagnosis&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345577:0" name=internalLink&gt;Management of Central Retinal Vein Occlusion&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345591:0" name=internalLink&gt;Management of Branch Retinal Vein Occlusion&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345572:0" name=internalLink&gt;Cardiovascular morbidity and mortality associated with Retinal Vein Occlusion&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:345440:0" name=internalLink&gt;UK DUETs on Retinal Vein Occlusion&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:345560:0" name=internalLink&gt;Overall Evidence Tree&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/RVOAEU2010-Journalspread.pdf" target="_blank"&gt;Journal spread&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Glossary.pdf" target="_blank"&gt;Glossary&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:345607:0" name=internalLink&gt;Methodology and search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/fp_aeu_rvo_0310.asp" target="_blank"&gt;low vision version&lt;/A&gt; of this AEU is also available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Acknowledgements:&lt;/H3&gt;
&lt;P&gt;The Management Team based at Moorfields Eye Hospital NHS Foundation Trust would like to thank all those who contributed to the preparation and promotion of this Evidence Update, particularly: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Our panel of Contributors who voluntarily contributed their time and expertise to provide the Topic Commentaries –&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;from the development group of the Royal College of Ophthalmologists Interim Guidelines for RVO :&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Mr Winfried Amoaku, Assoc. Prof/Reader in Ophthalmology and Vis Sciences and Hon Consultant Ophthalmologist, Nottingham University Hospital, Nottingham.&lt;/LI&gt;
&lt;LI&gt;Miss Sobha Sivaprasad, Consultant Ophthalmologist, King’s College Hospital, London. &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Miss Parul Desai&amp;nbsp; - Consultant in Ophthalmology and Public Health, Moorfields Eye Hospital NHS Foundation Trust, London.&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Laurence Lane&amp;nbsp;and the Medical Illustration Department, Moorfields Eye Hospital NHS Foundation Trust. &lt;/LI&gt;
&lt;LI&gt;Shaun Kirupairatnam (Research &amp;amp; Development Graphic Web Designer, Moorfields Eye Hospital) for his support in developing the collection's complementary site.&lt;/LI&gt;
&lt;LI&gt;The External Reference Group for their guidance.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Images courtesy of Medical Illustration Department at Moorfields Eye Hospital NHS Foundation Trust&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345419</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345419]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Introduction</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Retinal Vein Occlusion - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_0309_doc1.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Articles/Introduction.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;Back to 2010 RVO AEU contents page&lt;/P&gt;
&lt;P align=left&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Introduction by Parul Desai, Clinical Lead NHS Evidence - eyes and vision.&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;Retinal vein occlusion (RVO) is a common vasculopathy affecting adults, which may lead to visual impairment in one or both eyes, and is associated with other common systemic comorbid conditions.&amp;nbsp; It is broadly classified as central (CRVO) or branch (BRVO) retinal vein occlusion (with hemi-retinal occlusion considered as a sub-type of the latter).&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The evidence base for the management of these entities is dominated by two randomised controlled trials that reported between 15 and 25 years ago.&amp;nbsp; Since then several new interventions have emerged that include intra-ocular administration of corticosteroids or anti-VEGF agents, together with a number of other therapeutic and surgical options and diagnostic assessment tools.&amp;nbsp; The effectiveness of these remain largely unsupported by strong evidence and this was reflected in both the need for, and the publication of, the Interim Guidance by the Royal College of Ophthalmologists in 2009.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This &lt;STRONG&gt;Update focuses on the Management of Retinal Vein Occlusions&lt;/STRONG&gt;, and highlights the:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;key evidence base underpinning current interventions&lt;/LI&gt;
&lt;LI&gt;new evidence that is likely to inform a change in clinical practice&lt;/LI&gt;
&lt;LI&gt;emerging knowledge from key RCTs that have recently reported at scientific conferences but not yet published in peer reviewed literature&lt;/LI&gt;
&lt;LI&gt;current uncertainties in the effectiveness of treatments&lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;Key documents&lt;/H3&gt;
&lt;P&gt;The most recent professional body and NICE guidance on RVO formed the benchmark for the AEU.&amp;nbsp; These include:&lt;/P&gt;
&lt;P&gt;Royal College of Ophthalmologists (RCOphth)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf" target="_blank"&gt;Retinal Vein Occlusion Interim Guidelines February 2009&lt;BR&gt;&lt;/A&gt;&lt;EM&gt;Retinal Vein Occlusion Guidelines 2004 (no longer available online) &lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;NICE Guidance&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://guidance.nice.org.uk/IPG334/Guidance/pdf/English" target="_blank"&gt;Arteriovenous crossing sheathotomy for branch retinal vein occlusion&lt;/A&gt; IPG334 (2010). Updated March 2010 (revises Interventional Procedures Guidance no. 72, July 2004)&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Searches were limited to the period since the searches were completed for the original guideline (2002) as the interim guideline did not undertake a full systematic search on all topic areas.&lt;/P&gt;
&lt;H3&gt;Secondary publications&lt;/H3&gt;
&lt;P&gt;Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD007324. DOI: 10.1002/14651858.CD007324.pub2.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007324/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007324/frame.html&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:247436:0" name=internalLink&gt;Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion&lt;BR&gt;&lt;/A&gt;Centre for Reviews and Dissemination - NHS Economic Evaluation Database &lt;BR&gt;&lt;EM&gt;Review of: Brown GC, Brown MM, Sharma S, Busbee B, Brown H. Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion. Ophthalmic Epidemiology 2002 Feb;9(1):1-10.&lt;BR&gt;&lt;/EM&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11815891" target="_blank"&gt;&lt;EM&gt;http://www.ncbi.nlm.nih.gov/pubmed/11815891&lt;/EM&gt;&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;NICE Proposed Technology Appraisals &lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;NICE. Macular oedema (retinal vein occlusion) – dexamethasone. &lt;A href="http://www.nice.org.uk/ourguidance/niceguidancebytype/technologyappraisals/proposedappraisals/proposedappraisalsnowave.jsp#Macular oedema (retinal vein occlusion) - dexamethasone" target="_blank"&gt;NICE Proposed Technology Appraisal&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;NICE. Macular oedema with central retinal vein occulsion (CRVO) - ranibizumab. &lt;A href="http://www.nice.org.uk/ourguidance/niceguidancebytype/technologyappraisals/proposedappraisals/proposedappraisalsnowave.jsp#Macular oedema with central retinal vein occulsion (CRVO) - ranibizumab" target="_blank"&gt;NICE Proposed Technology Appraisal&lt;/A&gt;. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Other research&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;Older research contributing to the evidence base for the current management of Retinal Vein Occlusion in the NHS includes:&lt;/P&gt;
&lt;P&gt;Central Vein Occlusion Study&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:102049:0" name=internalLink&gt;A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.&amp;nbsp;&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:102048:0" name=internalLink&gt;Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.&amp;nbsp;&lt;/A&gt;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:102050:0" name=internalLink&gt;Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7508322" target="_blank"&gt;Central vein occlusion study of photocoagulation therapy. Baseline findings. Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7508321" target="_blank"&gt;Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7688950" target="_blank"&gt;Baseline and early natural history report. The Central Vein Occlusion Study.&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10163466" target="_blank"&gt;Laser therapy for central retinal vein obstruction. &lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Branch Vein Occlusion Study&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:102045:0" name=internalLink&gt;Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group.&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:102046:0" name=internalLink&gt;Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group.&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Contents&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;Topics covered:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:345419:0" name=internalLink&gt;Introduction&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345533:0" name=internalLink&gt;Epidemiology&lt;/A&gt;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345563:0" name=internalLink&gt;Diagnosis&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345577:0" name=internalLink&gt;Management of Central Retinal Vein Occlusion&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345591:0" name=internalLink&gt;Management of Branch Retinal Vein Occlusion&lt;BR&gt;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345572:0" name=internalLink&gt;Cardiovascular morbidity and mortality associated with Retinal Vein Occlusion&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;A href="nelh:345440:0" name=internalLink&gt;UK DUETs on Retinal Vein Occlusion&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;A href="nelh:345560:0" name=internalLink&gt;Overall Evidence Tree&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/RVOAEU2010-Journalspread.pdf" target="_blank"&gt;Journal spread&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Glossary.pdf" target="_blank"&gt;Glossary&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:345607:0" name=internalLink&gt;Methodology and search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that an in-depth appraisal of the content or quality of each reference cited has not been performed and their inclusion does not imply endorsement.&amp;nbsp; We recommend that a full appraisal is completed using the appropriate checklist provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/fp_aeu_rvo_0310.asp" target="_blank"&gt;low vision version&lt;/A&gt; of this AEU is also available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Acknowledgements:&lt;/H3&gt;
&lt;P&gt;The Management Team based at Moorfields Eye Hospital NHS Foundation Trust would like to thank all those who contributed to the preparation and promotion of this Evidence Update, particularly: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Our panel of Contributors who voluntarily contributed their time and expertise to provide the Topic Commentaries –&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;from the development group of the Royal College of Ophthalmologists Interim Guidelines for RVO :&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Mr Winfried Amoaku, Assoc. Prof/Reader in Ophthalmology and Vis Sciences and Hon Consultant Ophthalmologist, Nottingham University Hospital, Nottingham.&lt;/LI&gt;
&lt;LI&gt;Miss Sobha Sivaprasad, Consultant Ophthalmologist, King’s College Hospital, London. &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Miss Parul Desai&amp;nbsp; - Consultant in Ophthalmology and Public Health, Moorfields Eye Hospital NHS Foundation Trust, London.&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Laurence Lane&amp;nbsp;and the Medical Illustration Department, Moorfields Eye Hospital NHS Foundation Trust. &lt;/LI&gt;
&lt;LI&gt;Shaun Kirupairatnam (Research &amp;amp; Development Graphic Web Designer, Moorfields Eye Hospital) for his support in developing the collection's complementary site.&lt;/LI&gt;
&lt;LI&gt;The External Reference Group for their guidance.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to 2010 RVO AEU contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345591</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345591]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Management of Branch Retinal Vein Occlusion</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Management of BRVO - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_0309_doc5.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Articles/ManagementofBRVO.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Management of Branch Retinal Vein Occlusion&lt;/H2&gt;
&lt;H3&gt;&lt;BR&gt;Miss Parul Desai&lt;BR&gt;Consultant in Ophthalmology and Public Health&lt;BR&gt;Moorfields Eye Hospital, London&lt;/H3&gt;
&lt;P&gt;&lt;IMG style="WIDTH: 146px; HEIGHT: 120px" id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Ischaemic BRVO - Fluorescein" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345591/nelhImp_0001_BRVO1F.JPG" width=150 height=120&gt;&amp;nbsp;&lt;IMG style="WIDTH: 163px; HEIGHT: 120px" id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Ischaemic BRVO - Colour" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345591/nelhImp_0002_BRVO2C.JPG" width=167 height=120&gt;&amp;nbsp;&amp;nbsp; &amp;nbsp;&lt;IMG style="WIDTH: 145px; HEIGHT: 120px" id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="Ischaemic BRVO - Fluorescein" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345591/nelhImp_0003_BRVO3F.JPG" width=154 height=120&gt;&amp;nbsp;&lt;IMG style="WIDTH: 159px; HEIGHT: 120px" id=nelh_tempImage3 border=0 name=nelh_tempImage3 alt="Ischaemic BRVO - Colour" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345591/nelhImp_0004_BRVO4C.JPG" width=168 height=120&gt;&lt;/P&gt;
&lt;P&gt;Branch retinal vein occlusion (BRVO) is a common retinal vasculopathy associated with significant visual morbidity resulting from persistent macular oedema, macular ischemia, retinal neovascularisation, vitreous haemorrhage, or a combination of these. Over 25 years on, the Branch Vein Occlusion Study (BVOS) [1] continues to form the evidence base for the current management of BRVO. This has been further supported by a recent systematic review [2], which also concluded that there is a lack of strong evidence for the effectiveness of many of the interventions advocated for BRVO. The cost effectiveness for the management of macula oedema secondary to BRVO as proposed in the BVOS study has been demonstrated using cost utility analysis [3]. A 2007 study showed that patients with either central or branch retinal vein occlusion with macular oedema have significant impact on their quality of life, and as a result of this they were willing to undergo potentially invasive treatment. [4].&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Branch Vein Occlusion Study:&lt;/H3&gt;
&lt;P&gt;The findings of the Branch Vein Occlusion Study (BVOS) [1] were reported in 1984, and as such full text is not easily accessible on-line.&amp;nbsp; It was a multicentre RCT which evaluated (a) whether grid macular laser photocoagulation improved visual acuity (VA) in patients with VA of 6/12 or worse resulting from macular oedema secondary to BRVO, and&amp;nbsp; (b) whether peripheral scatter argon laser photocoagulation was useful in preventing the development of neovascularisation and vitreous haemorrhage.&lt;BR&gt;&amp;nbsp; &lt;BR&gt;(a) 139 patients were randomized to either grid macular laser photocoagulation within the involved macular region (n=71) or to no laser treatment (n=68). The groups were well matched at baseline in terms of risk factors, duration of symptoms, and visual acuity; and there was an average follow up of 3.1 years for 68% of the participants.&lt;/P&gt;
&lt;P&gt;(b) 319 patients were randomized to either scatter laser (n=160) or observation (n=159).&amp;nbsp; They all had BRVO between 3 and 18 months of onset. They either had at least 5 disc diameters involvement with no associated neovascularisation; or associated with retinal neovascularisation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key findings-&lt;/STRONG&gt;&lt;/P&gt;
&lt;H3&gt;Macula Oedema&lt;/H3&gt;
&lt;UL&gt;
&lt;LI&gt;Macular grid laser photocoagulation is an effective treatment for macular oedema and improves vision in eyes with VA of 6/12 to 6/60.&amp;nbsp; The grid laser group had statistically significant improvements in visual acuity with 65% (28/43) treated versus 37% (13/35) controls gaining 2 or more lines of vision over consecutive visits (P= 0.014).&amp;nbsp; More untreated patients (17%) than treated patients (12%) also experienced a decrease in VA, although this finding was not statistically significant (P=0.43).&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Treatment should be postponed for 3 months after the onset to allow for any spontaneous resolution to occur and to allow some reduction in haemorrhage.&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Fluorescein angiography is recommended before any treatment to determine level of macular ischaemia, which may limit the value of laser photocoagulation.&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Grid laser treatment is unlikely to help in eyes with BRVO of more than 1 year’s duration and VA of 6/60 or worse.&lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;&lt;BR&gt;Neovascularisation&lt;/H3&gt;
&lt;UL&gt;
&lt;LI&gt;Scatter laser photocoagulation can effectively treat retinal neovascularisation.&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Disc or retinal neovascularisation is an indication for laser photocoagulation to the ischaemic retina (sector photocoagulation).&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Waiting until vitreous haemorrhage occurs before laser treatment does not adversely affect the visual prognosis.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Secondary publication&lt;BR&gt;[2] and [3]&lt;/P&gt;
&lt;P&gt;Interventional study&lt;BR&gt;[1]&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Observational study:&lt;BR&gt;[4]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Newer Treatments&lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;1.&amp;nbsp;Intravitreal Corticosteroid -&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) for Branch Retinal Vein Occlusion Study&lt;/STRONG&gt; [5].&lt;BR&gt;This is a recently reported multicentre RCT, of 411 participants comparing the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone with standard care (grid laser photocoagulation in eyes without dense macular haemorrhage and deferral of photocoagulation until haemorrhage clears in eyes with dense macular haemorrhage) for eyes with vision loss associated with macular oedema secondary to branch retinal vein occlusion (BRVO).&amp;nbsp; The main outcome measure was gain in visual acuity of 15 or more letters from baseline to month 12.&lt;/P&gt;
&lt;P&gt;Outcomes –&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;29%, 26%, and 27% of participants achieved the primary outcome in the standard care, 1-mg, and 4-mg groups, respectively. No significant difference in visual acuity outcomes (gain, mean change, or loss) were demonstrated among the 3 groups at 12 months.&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Standard care and intravitreal triamcinolone in either the 1-mg or 4-mg dose are all likely associated with a better visual outcome than the natural history of macular oedema secondary to BRVO. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Adverse events –&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The rates of adverse events were higher in the 4-mg triamcinolone group compared with the 1-mg and standard care groups.&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;The rates of elevated intraocular pressure and cataract were similar for the standard care and 1-mg groups, but higher in the 4-mg group.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;The rate of infectious endophthalmitis in the trial was 0.1% (1 of 914) per injection.&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The Trial concluded that for clinical practice – &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Grid photocoagulation as applied in the SCORE Study remains the standard care for patients with vision loss associated with macular oedema secondary to BRVO who have characteristics similar to participants in the SCORE-BRVO trial.&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Grid photocoagulation should remain the benchmark against which other treatments are compared in clinical trials for eyes with vision loss associated with macular oedema secondary to BRVO.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Interventional study:&lt;BR&gt;[5]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;2.&amp;nbsp;Adventitial Sheathotomy&lt;/H3&gt;
&lt;P&gt;There is currently no strong evidence supporting the routine use of adventitial sheathotomy to improve visual acuity in eyes with BRVO.&lt;/P&gt;
&lt;P&gt;Secondary publications &lt;BR&gt;[2], [6], [7] and [8]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;3.&amp;nbsp; &amp;nbsp;Haemodilution&lt;/H3&gt;
&lt;P&gt;There is insufficient evidence to recommend routine use of haemodilution to improve visual acuity or prevent neovascularisation following BRVO.&lt;/P&gt;
&lt;P&gt;Secondary publication&lt;BR&gt;[2]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;4. &amp;nbsp;Anti-VEGF&lt;/H3&gt;
&lt;P&gt;There is increasing interest in the use of intravitreal anti–vascular endothelial growth factor for the treatment of BRVO, but as yet there is insufficient evidence to support their use in routine practice.&lt;/P&gt;
&lt;P&gt;Secondary publications&lt;BR&gt;[2], [8] and [9] &lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Recently reported at specialist conferences&lt;/H3&gt;
&lt;H3&gt;Ozurdex: The Geneva study&lt;/H3&gt;
&lt;P&gt;Study of a biodegradable intravitreal implant of dexamethasone 350 µg or 700 µg (Ozurdex, Allergan Inc., Irvine, CA). Patients treated with 2 different doses of Oxurdex gained 10 letters in 60 days. These patients were more likely to gain 15 letters than sham treated patients. [10 and 11]. The data has not yet been published in a peer-reviewed journal. Macular oedema (retinal vein occlusion) – dexamethasone is currently one of NICE’s Proposed Technology Appraisals. A scoping workshop is due to take place in March 2010. [12]&lt;/P&gt;
&lt;H3&gt;The BRAVO study&amp;nbsp; - anti-VEGF agents&lt;/H3&gt;
&lt;P&gt;The BRAVO Study was a multicentre double blind RCT which compared monthly intravitreal injections of 0.3 and 0.5mg ranibizumab with sham controlled injections. Results at 6 months showed that approximately 95% of patients completed the study at Month 6.&amp;nbsp; Both doses of Lucentis showed a clinically and statistically significant improvement in the mean change in BCVA at 6 months from baseline and when compared to sham injections. The mean gain in BCVA was observed at Day 7 with a 7.6- and 7.4-letter gain in the Lucentis 0.3 mg and 0.5 mg groups, respectively, compared with +1.9 letters in the sham group. This improvement continued to Month 6 when the 0.mg ranibizumab attained an 18 letter gain. [13]. The data has not yet been published in a peer-reviewed journal.&lt;/P&gt;
&lt;P&gt;Secondary Publications:&lt;BR&gt;[10] and [12]&lt;/P&gt;
&lt;P&gt;Unpublished trials:&lt;BR&gt;[11 and 13]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;References:&lt;/H3&gt;
&lt;P&gt;1. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. American Journal of Ophthalmology. 1984; 98(3):271-82.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/6383055" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/6383055&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;2. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007 May;114(5):835-54.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17397923" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17397923&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;3a. Brown GC, Brown MM, Sharma S, Busbee B, Brown H. Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion. Ophthalmic Epidemiology 2002 Feb;9(1):1-10.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11815891" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/11815891&lt;/A&gt; &lt;BR&gt;3b. Review in: Centre for Reviews and Dissemination - NHS Economic Evaluation Database&lt;BR&gt;&lt;A href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;amp;ID=22002006206" target="_blank"&gt;http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;amp;ID=22002006206&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;4. Chang MA, Fine HF, Bass E, Bressler SB, Schachat AP, Solomon SD, et al. Patients' preferences in choosing therapy for retinal vein occlusions. Retina 2007 Jul;27(6):789-97&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17621191" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17621191&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;5. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Archives of Ophthalmology 2009 Sep;127(9):1115-28.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19752420" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19752420&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;6. NICE. Arteriovenous crossing sheathotomy for branch retinal vein occlusion. IP Guidance Number: NICE Interventional Procedure Guidance 72. 2004.&lt;BR&gt;&lt;A href="http://www.nice.org.uk/ipg72" target="_blank"&gt;http://www.nice.org.uk/ipg72&lt;/A&gt;&lt;BR&gt;&lt;EM&gt;NICE has reviewed this guidance (2010) and is reassessing the procedure. New guidance will be published as a result.&amp;nbsp; Until the new guidance is published the NHS should continue to follow the recommendations in the guidance. See below for the Interventional Procedures Overview.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;7. NICE. Arteriovenous crossing sheathotomy for branch retinal vein occlusion (Interventional Procedures Overview). 2009.&lt;BR&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=download&amp;amp;o=46351" target="_blank"&gt;http://www.nice.org.uk/guidance/index.jsp?action=download&amp;amp;o=46351&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8. The Royal College of Ophthalmologists. Retinal Vein Occlusion (RVO): Interim Guidelines, February 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Current Opinion in Ophthalmology 2008 May;19(3):234-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18408499" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18408499&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;10. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs &amp;amp; Aging 2010;27(2):117-34. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20104938" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20104938&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;11. A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion. ClinicalTrials.gov Identifier: NCT00168324&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00168324?term=NCT00168324&amp;amp;rank=1" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00168324?term=NCT00168324&amp;amp;rank=1&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12. NICE. Macular oedema (retinal vein occlusion) – dexamethasone. &lt;A href="http://www.nice.org.uk/ourguidance/niceguidancebytype/technologyappraisals/proposedappraisals/proposedappraisalsnowave.jsp#Macular oedema (retinal vein occlusion) - dexamethasone" target="_blank"&gt;NICE Proposed Technology Appraisal&lt;/A&gt;.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;13. Campochiaro P. Safety and efficacy of intravitreal ranibizumab (LUCENTIS) in patients with macular edema secondary to branch retinal vein occlusion: the BRAVO Study. Program and abstracts of Retina Congress 2009; September 30-October 4, 2009; New York, NY.&lt;BR&gt;See &lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/12/Phase-III-trial-data-for-ranibizumab-Lucentis-in-treatment-of-macula-oedema-due-to-retinal-vein-occlusion-/" target="_blank"&gt;http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/12/Phase-III-trial-data-for-ranibizumab-Lucentis-in-treatment-of-macula-oedema-due-to-retinal-vein-occlusion-/&lt;/A&gt; for a summary of the most recent presented data at the Retina Congress in October 2009 from the NHS National electronic Library for Medicines.&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345591:2" name=internalLink&gt;2010 AEU on RVO - Management of BRVO&amp;nbsp;- Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Management of BRVO - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_1109_doc10.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Evidence_Trees/ManagementBRVOsearchsummaryandevidencetree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision; PubMed; Medline; EMBASE; CINAHL; AMED; BNI; and PsycINFO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;January 2002 to 15th February 2010&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Sifting:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;One search was undertaken and the results sifted manually into five topics: Epidemiology; Diagnosis, Management of CRVO; Management of BRVO; and Cardiovascular morbidity and mortality associated with RVO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Definitions:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Secondary publications include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses. &lt;/P&gt;
&lt;P&gt;Interventional studies include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;Observational studies include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Management of BRVO Evidence Tree - RVO AEU 2010" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345591/nelhImp_0000_aeu_rvo_brvo.jpg" width=554 height=353&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/RVOAEU2010-Journalspread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345577:1" name=internalLink&gt;&lt;A href="nelh:345591:1" name=internalLink&gt;2010&amp;nbsp;AEU on RVO&amp;nbsp;-&amp;nbsp;Management of BRVO -&amp;nbsp;Topic Summary&lt;/A&gt;&lt;A href="nelh:345533:1" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345577</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345577]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Management of Central Retinal Vein Occlusion</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Management of CRVO - Topic Summary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_0309_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Articles/ManagementofCRVO.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;Management of Central Retinal Vein Occlusion&lt;/H2&gt;
&lt;H3 align=left&gt;Mr. Winfried Amoaku, &lt;BR&gt;Assoc Prof/Reader in Ophthalmology and Vis Sciences and Hon Consultant Ophthalmologist, &lt;BR&gt;Nottingham University Hospital, Nottingham.&lt;/H3&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="Ischaemic CRVO - Fluorescein" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345577/nelhImp_0001_CRVO1F.JPG" width=145 height=120&gt;&amp;nbsp;&lt;IMG style="WIDTH: 166px; HEIGHT: 120px" id=nelh_tempImage3 border=0 name=nelh_tempImage3 alt="Ischaemic CRVO - Colour" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345577/nelhImp_0002_CRVO2C.JPG" width=161 height=120&gt;&amp;nbsp; &amp;nbsp;&lt;IMG id=nelh_tempImage5 border=0 name=nelh_tempImage5 alt="Ischaemic CRVO - Fluorescein" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345577/nelhImp_0003_CRVO4F.JPG" width=145 height=120&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage4 border=0 name=nelh_tempImage4 alt="Ischaemic CRVO - Colour" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345577/nelhImp_0004_CRVO3C.JPG" width=139 height=120&gt;&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Introduction&lt;/H3&gt;
&lt;P&gt;A 2007 systematic review concluded that there is a lack of strong evidence for the effectiveness of many of the interventions to improve visual acuity in patients with central retinal vein occlusion (CRVO). It concluded that panretinal photocoagulation resulted in regression of the neovascular complications of CRVO. The current evidence for the role of haemodilution to improve vision is conflicting, and the results of ongoing RCTs on intravitreal triamcinolone, anti-vascular endothelial growth factor agents, and chorioretinal anastomosis are awaited with interest. [1].&lt;/P&gt;
&lt;P&gt;Secondary Publication:&lt;BR&gt;[1]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Natural history of central retinal vein occlusion (CRVO)&lt;/H3&gt;
&lt;P&gt;The natural history data from the 1995 CVOS study [2] demonstrated that visual outcome of CRVO depends on the visual acuity at presentation, with initial visual acuity of 20/40 or better having a better prognosis&amp;nbsp; for retaining good vision. Only 20% of eyes with initial visual acuity of 20/50-20/200 improve spontaneously to 20/50 while 80% of patients with baseline vision worse than 20/200 remain at this level or worsen. Furthermore, the longer the duration of macular oedema, the more the structural damage at the fovea so it is justifiable that early treatment be initiated. &lt;/P&gt;
&lt;P&gt;Interventional study:&lt;BR&gt;[2]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Management of non-ischaemic central retinal vein occlusion&lt;/H3&gt;
&lt;P&gt;This type of central retinal vein occlusion carries a better prognosis than the ischaemic type of CRVO. It is important to investigate for all the known cardiovascular risk factors. Thrombophilia screening is advocated only for those under the age of 50 years, patients with bilateral RVO, when tests for common cardiovascular risk factors for RVO are negative, a history of previous thromboses or a family history of thrombosis, [3]. Timely identification and treatment of risk factors reduces the risk of recurrent RVO and RVO in the other eye. Care should be taken to review these subjects regularly as there is a 30% risk of conversion to ischaemic CRVO [4, p.9]. It is generally advised that non-ischaemic eyes should have initial follow up every 1-3 months for 6 months. [4] &lt;/P&gt;
&lt;P&gt;Secondary Publications:&lt;BR&gt;[3], and [4]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Management of ischaemic central retinal vein occlusion (iCRVO) and anterior segment neovascularisation&lt;/H3&gt;
&lt;P&gt;An initial evaluation of risk factors and the appropriate treatment of the present risks must proceed alongside management of the ocular findings.&lt;/P&gt;
&lt;H3&gt;Laser pan-retinal photocoagulation:&lt;/H3&gt;
&lt;UL&gt;
&lt;LI&gt;The evidence from the CVOS study [2] supports the use of laser pan-retinal photocoagulation (PRP) when iris new vessels (INV) or angle new vessels (ANV) are visible. iCRVO should ideally be monitored monthly for new vessels iris and/ or angle. However, as this is not logistically possible in most centres, 2-3 monthly reviews may be sufficient, unless there are particular risk factors [4, p.10].&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Pan-retinal photocoagulation is advocated at the earliest sign of iris new vessels or angle new vessels. In circumstances when regular follow-up is impractical, prophylactic treatment may be appropriate. Pan-retinal laser photocoagulation for CRVO with INV or ANV requires 1500 – 2000 of 500-micron burns at the retina. This is best applied with 0.05-0.1 seconds duration applications one burn width apart with sufficient energy to produce a pale burn in the retina. Treatment is usually placed in the periphery avoiding areas of retinal haemorrhage. Some cases require further treatment if the iris neovascularisation fails to regress. Follow-up after 6 months for ischaemia (&amp;gt; 10DD non-perfusion) should be every 3 months for 1 year.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Subsequent follow-up for all patients will depend upon laser treatment and complications but will not normally be required after 2 years in uncomplicated cases. The development of disc collaterals +/- resolution of the CRVO should lead to discharge from clinical supervision. [4] &lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;Other interventions: &lt;/H3&gt;
&lt;UL&gt;
&lt;LI&gt;There is no proven protective effect of intravitreal triamcinolone acetonide on anterior segment neovascularisation, [5]. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;There are several case series with short follow-ups that show that rubeosis can be decreased or even abolished transiently with anti-VEGF agents (ranibizumab and bevacizumab), representing an emerging knowledge around recent developments in clinical practices for which there is as yet no evidence base. [6, 7, 8, 9].&amp;nbsp; No RCTs are currently available. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Secondary Publications:&lt;BR&gt;[4] and [7]&lt;/P&gt;
&lt;P&gt;Interventional studies:&lt;BR&gt;[2], [5 – small study]&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;&lt;EM&gt;Emerging knowledge around recent developments in clinical practices for which there is as yet no evidence base.&lt;/EM&gt;&lt;BR&gt;[6 – small study], [8] and [9 – small study (case study)]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Management of established neovascular glaucoma&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;The aim of management of this condition in a blind eye is to keep the eye pain free. This is usually achieved by topical steroids and atropine. However, if the eye has any visual potential intraocular pressure should be controlled with topical pressure-lowering agents or cyclo-ablative procedures, [4, p.11].&lt;/P&gt;
&lt;H3&gt;Other interventions:&lt;/H3&gt;
&lt;UL&gt;
&lt;LI&gt;Intravitreal and intracameral bevacizumab has been shown to cause regression of iris new vessels and decrease angle obstruction. Comparative case series indicate that iris new vessels regress faster after intravitreal bevacizumab with PRP than with PRP alone. The reports also suggest that bevacizumab may reduce the need for surgical interventions and may also serve as a useful adjunct to filtering surgery, [10 and 11].&amp;nbsp; &lt;EM&gt;These represent &lt;BR&gt;emerging knowledge around recent developments in clinical practices for which there is as yet no evidence base.&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Secondary Publication:&lt;BR&gt;[4]&lt;/P&gt;
&lt;P&gt;Interventional study:&lt;BR&gt;[10 – small study]&lt;/P&gt;
&lt;P&gt;Observational study:&amp;nbsp; &lt;BR&gt;[11 – small study]&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;Macular oedema&lt;/H3&gt;
&lt;P&gt;Macular oedema (MO) following CRVO results from leakage of perifoveal capillaries, resulting in visual loss.&amp;nbsp; A 2007 study showed that patients with either central or branch retinal vein occlusion with macular oedema have significant impact on their quality of life, and as a result of this they were willing to undergo potentially invasive treatment. [12].&lt;/P&gt;
&lt;H3&gt;Macular laser:&lt;/H3&gt;
&lt;P&gt;Randomised controlled trials have failed to indicate benefit from grid laser treatment, but a trend in favour of treatment has been observed in younger patients, [13]. Although there was significant reduction in the severity of macular oedema in treated eyes compared to controls there was no visual acuity benefit. &lt;/P&gt;
&lt;H3&gt;Intravitreal Corticosteroid:&lt;/H3&gt;
&lt;P&gt;Injections of preserved triamcinolone (Kenalog) have been commonly administered as treatment of macular oedema secondary to central retinal vein occlusion, with reports of short-lived benefits [14, 15 and 16].&amp;nbsp; A Cochrane review recently concluded that there was inadequate evidence for the use of intravitreal steroids for macular oedema secondary to CRVO, due to a paucity of RCTs and well-designed observational studies on the topic, and awaited the findings of the SCORE study that was ongoing at the time of the review, [17]. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) study&lt;/STRONG&gt; encompassed 2 multicentre, randomized, Phase III clinical trials on macular oedema due to RVO (one for CRVO [18] and one for BRVO [19]). 271 patients with macular oedema due to CRVO and visual acuity between 19 and 73 letters were randomized to 3 arms of 1mg and 4mg preservative free intravitreal triamcinolone and sham and re-treated every 4 months based on stringent re-treatment criteria. The primary outcome of the trial was the proportion of participants who had a gain in visual acuity letter score of 15 or more from baseline to month 12.&lt;BR&gt;&lt;BR&gt;Both 1-mg and 4-mg dose had better visual acuity outcomes over 12 months [18]:&lt;BR&gt;&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;7%, 27%, and 26% of participants achieved the primary outcome in the observation, 1-mg, and 4-mg dose groups, respectively. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;The odds of achieving the primary outcome were 5.0 times greater in each of the 1-mg and 4mg dose groups than the observation group. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Both treatment groups had a similar mean loss of visual acuity letter score (1 to 2 letter loss) compared with a mean loss of 12 letters in the observation group.&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;The 1 mg dose treatment group had a superior safety profile to that of the 4-mg dose. [18].&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;EM&gt;Linked SCORE studies for information: [20, 21, 22, 23 and 24].&lt;BR&gt;&lt;BR&gt;&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;A&amp;nbsp; biodegradable &lt;STRONG&gt;intravitreal implant of dexamethasone&lt;/STRONG&gt; 350 µg or 700 µg (Ozurdex, Allergan Inc., Irvine, CA), [25] delivered 6 monthly has a better safety profile and more prolonged effect on the macular oedema than triamcinolone in a Phase 3 RCT (Geneva Study) that compared the outcome of Ozurdex to sham at 6 months. [26] The data has not yet been published in a peer-reviewed journal. In June 2009 the United States Food and Drug Administration (US FDA) approved dexamethasone intravitreal biodegradable implant (Ozurdex) 0.7mg for the treatment of macular oedema following BRVO or CRVO [27]. In the UK Macular oedema (retinal vein occlusion) – dexamethasone is currently one of NICE’s Proposed Technology Appraisals. A scoping workshop is due to take place in March 2010. [28]&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;Intra-vitreal anti-VEGF agents:&lt;/H3&gt;
&lt;P&gt;All three known intravitreal anti-VEGF agents (pegaptanib sodium, ranibizumab and bevacizumab) have been investigated for treatment of macular oedema. &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;A phase II randomized double-masked multicenter trial evaluating the safety, efficacy, and pharmacokinetics of intravitreal injections of pegaptanib sodium versus sham injections in patients with recent vision loss due to macular oedema secondary to CRVO showed that 6 weekly pegaptanib 0.3mg pegaptanib resulted in a +7.1 letter gain at 6 months, [29].&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;The recently completed CRUISE study evaluated the efficacy and safety of monthly intravitreal ranibizumab 0.3 mg and 0.5 mg injections compared to sham in 392 subjects with CRVO related MO and reported that the mean gain in visual acuity (ETDRS letters) was +12.7 and +14.9 with the 0.3mg and 0.5mg compared to the sham group at 6 months, [30]. The data has not been published in a peer-reviewed journal. Macular oedema with central retinal vein occlusion (CRVO) – ranibizumab is currently one of NICE’s Proposed Technology Appraisals. A scoping workshop is due to take place in March 2010, [31].&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;The studies on intravitreal bevacizumab are predominantly case-series, without control arms and with short follow-ups. Summary of evidence from these studies indicate that with a dose of 1.25mg on a PRN dosing schedule, approximately 50% improve 2 or more lines of vision while up to 90% show stabilisation of vision by 12 months, [32]. Patients with CRVO of less than 3 months duration had slightly better outcomes compared to long-standing macular oedema. Better outcomes were also demonstrated in patients with good baseline visual acuity (visual acuity of 20/40 or better). Studies that evaluated the difference in outcome between eyes with non-ischaemic CRVO and ischaemic CRVO demonstrated better final visual outcome in the non-ischaemic CRVO group probably due to better baseline visual acuity. &lt;BR&gt;&lt;BR&gt;However, the mean changes in visual acuity in both groups were not significantly different.&amp;nbsp; The outcomes were also not influenced by previous treatments. Patients that have had a number of previous treatments including laser, intravitreal triamcinolone acetonide (IVTA) and/or other anti-VEGF agents seem to do as well as treatment–naive cases. The change in visual acuity did not also correlate with the reduction in central macular thickness except in eyes with short duration of CRVO. Rebound oedema has been noted in a small proportion of cases. None of the reports showed any changes to existing collaterals. No patients developed iris neovascularisation during the study periods. There were also no reports of conversion of non-ischaemic to ischaemic type during the study period. However, future RCTs with longer follow-up will provide more information on the optimal dosing schedule, [33, 34 and 35].&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Secondary Publications:&lt;BR&gt;[16], [17], [25], [28], [31], and [32] &lt;/P&gt;
&lt;P&gt;Interventional studies:&lt;BR&gt;[13], [15], [18], [19], [24] and [29]&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;[12], [14], [20], [21], [22], [23], [33], [34], and [35] &lt;/P&gt;
&lt;P&gt;Unpublished trials:&lt;BR&gt;[26], [27] and [30]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Chorioretinal Venous Anastomosis&lt;/H3&gt;
&lt;P&gt;Chorio-retinal anastomosis is an experimental treatment but the results of the studies to date have not consistently shown a benefit to the procedure and the procedure is associated with adverse effects, [36, 37, 38, 39, and 40]. &lt;/P&gt;
&lt;P&gt;A 2004 Australian review of Yag laser chorioretinal anastomosis in CRVO concluded that there is only the level IV evidence available describing this experimental procedure, which may have the potential to cause serious side effects in unsuccessful patients. It recommended discontinuation of the technology. [41]&lt;/P&gt;
&lt;P&gt;Secondary Publications:&lt;BR&gt;[36], [38], [39], [40] and [41].&lt;/P&gt;
&lt;P&gt;Observational study:&lt;BR&gt;[37]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Radial Optic Neurotomy (RON)&lt;/H3&gt;
&lt;P&gt;Radial optic neurotomy is a surgical procedure by which a radial incision is made on the nasal part of the sclera ring at the level of the lamina cribrosa after a standard pars plana vitrectomy. The objective of this incision is to relieve pressure on the central retinal vein at the level of the sclera outlet to improve venous outflow in eyes with CRVO. At present, there is insufficient evidence to recommend RON, [42, 43, 44, 45, 46, 47, and 48].&lt;/P&gt;
&lt;P&gt;Secondary Publications:&lt;BR&gt;[47] and [48]&lt;/P&gt;
&lt;P&gt;Observational studies:&lt;BR&gt;[42], [43], [44], [45], and [46]&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;References:&lt;/H3&gt;
&lt;P&gt;1. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007 Mar;114(3):507-19, 524.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17324695" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17324695&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;2. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Retinal Vein Occlusion Study Group N Report. Ophthalmology 1995;102:1434-44.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9097789" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/9097789&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;3. Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Internal Medicine Journal 2008 Dec;38(12):904-10.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19120547" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19120547&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;4. The Royal College of Ophthalmologists. Retinal Vein Occlusion (RVO): Interim Guidelines, February 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;5. Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kadkhodaei S. Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial. Graefe's Archive for Clinical and Experimental Ophthalmology 2006 Dec;244(12):1601-6. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16738858" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16738858&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;6. Brouzas D, Charakidas A, Moschos M, Koutsandrea C, Apostolopoulos M, Baltatzis S. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma. Clinical Ophthalmology 2009;3:685-8.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20054417" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20054417&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;7. Martínez-Carpio PA, Bonafonte-Márquez E, Heredia-García CD, Bonafonte-Royo S. [Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review]. [Article in Spanish]. Archivos de la Sociedad Espanola Oftalmologia. 2008 Oct;83(10):579-88.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18855277" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18855277&lt;/A&gt; &lt;BR&gt;Additional reference to support commentary not identified in original Retinal Vein Occlusion search.&lt;/P&gt;
&lt;P&gt;8. Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. British Journal of Ophthalmology. 2009 May;93(5):589-93. Epub 2008 Dec 15.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19074917" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19074917&lt;/A&gt;&lt;BR&gt;Additional reference to support commentary not identified in original Retinal Vein Occlusion search.&lt;/P&gt;
&lt;P&gt;9. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006 Mar;26(3):354-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16508439" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16508439&lt;/A&gt; &lt;BR&gt;Additional reference to support commentary not identified in original Retinal Vein Occlusion search.&lt;BR&gt;&lt;BR&gt;10. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. European Journal of Ophthalmology 2009 May;19(3):435-41.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19396791" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19396791&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;11. Beutel J, Peters S, Luke M, Aisenbrey S, Szurman P, Spitzer MS, et al. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol 2008 Sep 20. [Epub ahead of print]&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18811641" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18811641&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12. Chang MA, Fine HF, Bass E, Bressler SB, Schachat AP, Solomon SD, et al. Patients' preferences in choosing therapy for retinal vein occlusions. Retina 2007 Jul;27(6):789-97&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17621191" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17621191&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;13. Central Retinal Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Archives of Ophthalmology 1997;115: 486-491.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9109757" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/9109757&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;14. Roth DB, Cukras C, Radhakrishnan R, Feuer WJ, Yarian DL, Green SN, et al. Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. Ophthalmic Surgery, Lasers &amp;amp; Imaging 2008 Nov;39(6):446-54.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19065973" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19065973&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;15. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. American Journal of Ophthalmology 2005 Oct;140(4):695-702. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16226521" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16226521&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;16. Sharma A, Kuppermann D, Kenney MC. Use of intravitreal triamcinolone in the treatment of macular edema related to retinal vein occlusion. Open Ophthalmology Journal 2008;2:68-72.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19517029" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19517029&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17. Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD007324. DOI: 10.1002/14651858.CD007324.pub2.&lt;BR&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007324/frame.html" target="_blank"&gt;http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007324/frame.html&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;18. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Archives of Ophthalmology 2009 Sep;127(9):1101-14.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19752419" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19752419&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;19. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Archives of Ophthalmology 2009 Sep;127(9):1115-28.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19752420" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19752420&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;20. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, et al. SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology 2009 Mar;116(3):504-12.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19167078" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19167078&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;21. Scott IU, Blodi BA, Ip MS, VanVeldhuisen PC, Oden NL, Chan CK, et al. SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology 2009 Apr;116(4):756-61.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19344824" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19344824&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;22. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, et al. SCORE Study report 3: study design and baseline characteristics. Ophthalmology 2009 Sep;116(9):1770-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19619896" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19619896&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;23. Domalpally A, Blodi BA, Scott IU, Ip MS, Oden NL, Lauer AK, et al. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4. Archives of Ophthalmology 2009 Nov;127(11):1461-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19901211" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19901211&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;24. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. American Journal of Ophthalmology 2009 Nov;148(5):725-32.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19674727" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19674727&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;25. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs &amp;amp; Aging 2010;27(2):117-34. &lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20104938" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/20104938&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;26. A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion. ClinicalTrials.gov Identifier: NCT00168324&lt;BR&gt;&lt;A href="http://clinicaltrials.gov/ct2/show/NCT00168324?term=NCT00168324&amp;amp;rank=1" target="_blank"&gt;http://clinicaltrials.gov/ct2/show/NCT00168324?term=NCT00168324&amp;amp;rank=1&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;27. NHS National electronic Library for Medicines (NeLM) News Service. Horizon Scanning: FDA approves dexamethasone intravitreal implant (Ozurdex™) for use in macular oedema.&lt;BR&gt;&lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---June/19/Horizon-Scanning-FDA-approves-dexamethasone-intravitreal-implant-Ozurdex-for-use-in-macular-oedema-/" target="_blank"&gt;http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---June/19/Horizon-Scanning-FDA-approves-dexamethasone-intravitreal-implant-Ozurdex-for-use-in-macular-oedema-/&lt;/A&gt; [Accessed online 03/03/2010],&lt;/P&gt;
&lt;P&gt;28. NICE. Macular oedema (retinal vein occlusion) – dexamethasone. &lt;A href="http://www.nice.org.uk/ourguidance/niceguidancebytype/technologyappraisals/proposedappraisals/proposedappraisalsnowave.jsp#Macular oedema (retinal vein occlusion) - dexamethasone" target="_blank"&gt;NICE Proposed Technology Appraisal&lt;/A&gt;.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;29. Wroblewski JJ, Wells JA, III, Adamis AP, Buggage RR, Cunningham ET, Jr., Goldbaum M, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology 2009 Apr;127(4):374-80.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19365011" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19365011&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;30. Brown D. Safety and efficacy of intravitreal ranibizumab (LUCENTIS) in patients with macular edema secondary to central retinal vein occlusion: CRUISE Study. Program and abstracts of Retina Congress 2009; September 30-October 4, 2009; New York, NY. &lt;BR&gt;See &lt;A href="http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/12/Phase-III-trial-data-for-ranibizumab-Lucentis-in-treatment-of-macula-oedema-due-to-retinal-vein-occlusion-/" target="_blank"&gt;http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/12/Phase-III-trial-data-for-ranibizumab-Lucentis-in-treatment-of-macula-oedema-due-to-retinal-vein-occlusion-/&lt;/A&gt; for a summary of the most recent presented data at the Retina Congress in October 2009 from the NHS National electronic Library for Medicines.&lt;/P&gt;
&lt;P&gt;31. NICE. Macular oedema with central retinal vein occulsion (CRVO) - ranibizumab. &lt;A href="http://www.nice.org.uk/ourguidance/niceguidancebytype/technologyappraisals/proposedappraisals/proposedappraisalsnowave.jsp#Macular oedema with central retinal vein occulsion (CRVO) – ranibizumab" target="_blank"&gt;NICE Proposed Technology Appraisal&lt;/A&gt;.&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;32. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Annals of&amp;nbsp; Pharmacotherapy 2007 Apr;41(4):614-25.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17355998" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17355998&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;33. Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 2010 Feb;248(2):155-9. Epub 2009 Sep 9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19763601" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19763601&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;34. Tao Y, Hou J, Jiang YR, Li XX, Jonas JB. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye 2009 Aug 21.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19696805" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19696805&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;35. Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefe's Archive for Clinical and Experimental Ophthalmology 2009 Dec;247(12):1635-41.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19633982" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19633982&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;36. Berker N, Batman C. Surgical treatment of central retinal vein occlusion. Acta Ophthalmologica 2008 May;86(3):245-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18494725" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18494725&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;37. Lu N, Wang NL, Li ZH, Wang GL, Zhang F, Peng XY. Laser-induced chorioretinal venous anastomosis using combined lasers with different wavelengths. Eye (Lond) 2007 Jul;21(7):962-7.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16710438" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16710438&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;38. Nofal MA. Surgical treatment of retinal vein occlusion. CME Journal Ophthalmology 2002;6(3):74-8.&lt;BR&gt;No abstract available on PubMed&lt;/P&gt;
&lt;P&gt;39. Prenner JL, Busbee BG. Surgical management of central retinal vein occlusions. Techniques in Ophthalmology 2009;7(1):25-9.&lt;BR&gt;&lt;A href="http://journals.lww.com/techniques-in-ophthalmology/Fulltext/2009/03000/Surgical_Management_of_Central_Retinal_Vein.7.aspx" target="_blank"&gt;http://journals.lww.com/techniques-in-ophthalmology/Fulltext/2009/03000/Surgical_Management_of_Central_Retinal_Vein.7.aspx&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;40. Suzuki Y. Therapy for retinal vein occlusion - Retinal vascular surgery. Folia Ophthalmologica Japonica 2002;53(5):331-4.&lt;BR&gt;No abstract available on PubMed&lt;/P&gt;
&lt;P&gt;41. Centre for Reviews and Dissemination Health Technology Assessment Database. Mundy L, Merlin T, Hodgkinson B, Parrella A. Yag laser for blocked retinal venouscirculation to prevent or restore visual loss in patients suffering non-ischemic central retinal vein occlusion. Horizon Scanning Prioritising Summary - Volume 3. Adelaide Health Technology Assessment (AHTA). 2004&lt;BR&gt;&lt;A href="http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;amp;ID=32006000589" target="_blank"&gt;http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&amp;amp;ID=32006000589&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;42. Callizo J, Kroll P, Mennel S, Schmidt JC, Meyer CH. Radial optic neurotomy for central retinal vein occlusion: long-term retinal perfusion outcome. Ophthalmologica 2009;223(5):313-9.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19420979" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/19420979&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;43. Arevalo JF, Garcia RA, Wu L, Rodriguez FJ, Dalma-Weiszhausz J, Quiroz-Mercado H, et al. Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES). Retina 2008 Oct;28(8):1044-52.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18779709" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/18779709&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;44. Hasselbach HC, Ruefer F, Feltgen N, Schneider U, Bopp S, Hansen LL, et al. Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases. Graefe's Archive for Clinical and Experimental Ophthalmology 2007 Aug;245(8):1145-56.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17219118" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/17219118&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;45. Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE, Borkowski LM. Radial optic neurotomy with adjunctive intraocular triamcinolone for central retinal vein occlusion: 63 consecutive cases. Retina 2006 Mar;26(3):306-13.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16508431" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16508431&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;46. Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE. Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina 2006 Mar;26(3):297-305.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16508430" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16508430&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;47. Beck AP, Ryan EA, Lou PL, Kroll AJ. Controversies regarding radial optic neurotomy for central retinal vein occlusion. International Ophthalmology Clinics 2005;45(4):153-61.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16199974" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/16199974&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;48. Parodi MB, Lanzetta P, Guarnaccia G, Friberg T. Surgical treatments of central retinal vein occlusion. Seminars in Ophthalmology 2003 Sep;18(3):142-6.&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15513475" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/pubmed/15513475&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345577:2" name=internalLink&gt;2010 AEU on RVO - Management of CRVO&amp;nbsp;- Evidence Tree&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 AEU on RVO - Management of CRVO - Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_rvo_0310/aeu_rvo_1109_doc9.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/Evidence_Trees/ManagementCRVOsearchsummaryandevidencetree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision; PubMed; Medline; EMBASE; CINAHL; AMED; BNI; and PsycINFO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;January 2002 to 15th February 2010&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Sifting:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;One search was undertaken and the results sifted manually into five topics: Epidemiology; Diagnosis, Management of CRVO; Management of BRVO; and Cardiovascular morbidity and mortality associated with RVO.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Definitions:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Secondary publications include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses. &lt;/P&gt;
&lt;P&gt;Interventional studies include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;Observational studies include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys.&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="Management of CRVO Evidence Tree - RVO AEU 2010" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID345577/nelhImp_0000_aeu_rvo_crvo.jpg" width=603 height=353&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/RVOAEU2010-Journalspread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345577:1" name=internalLink&gt;&lt;A href="nelh:345577:1" name=internalLink&gt;2010&amp;nbsp;AEU on RVO&amp;nbsp;-&amp;nbsp;Management of CRVO -&amp;nbsp;Topic Summary&lt;/A&gt;&lt;A href="nelh:345533:1" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345607</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345607]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Methodology</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;2&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Retinal Vein Occlusion - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/MethodologyRVO2010.doc.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Methodology&lt;/H2&gt;
&lt;P&gt;&lt;BR&gt;This is the first Annual Evidence Update (AEU) for Retinal Vein Occlusion carried out by NHS Evidence – eyes and vision. &lt;/P&gt;
&lt;P&gt;In February 2009 the Royal College of Ophthalmologists (RCOphth) published their &lt;STRONG&gt;Retinal Vein Occlusion (RVO): Interim Guideline&lt;/STRONG&gt;, [1]. However as this interim guideline did not undertake a full systematic search on all topic areas, searches for this AEU were undertaken from 2002 to date; the period since searches were completed for the RCOphth 2004 full RVO guideline. This AEU will serve as an update to the guideline. &lt;/P&gt;
&lt;P&gt;An initial search was run on 25th November 2009 and an update search on 15th February 2010.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Databases searched:&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;PubMed; Medline 1950 to date; EMBASE 1980 to date; CINAHL 1981 to date; AMED 1985 to date; BNI 1985 to date; PsycInfo 1806 to date; NHS Evidence - eyes and vision.&lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;&lt;BR&gt;Period of Search: January 2002 to 15th February 2010&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Accessed using:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;NHS Evidence Health Information Resources - Healthcare Databases (NHS Athens Account required)&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;PubMed&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;NHS Evidence - Eyes and Vision &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;Inclusion criteria&lt;/H3&gt;
&lt;P&gt;Included articles had to meet the following criteria: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types:&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;Secondary publications (including Cochrane systematic reviews, systematic reviews, reviews, meta or cost analysis)&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Interventional studies (randomised controlled trials and controlled clinical trials).&amp;nbsp;&lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Observational studies (cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys).&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;Published from 2002 on. &lt;BR&gt;&lt;/LI&gt;
&lt;LI&gt;Relevancy to topics included in the 2010 RVO AEU (epidemiology; diagnosis; management of CRVO; management of BRVO and Cardiovascular morbidity and mortality associated with Retinal Vein Occlusion). &lt;/LI&gt;&lt;/UL&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;Method&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;The search outputs were exported into Reference Manager bibliographic software.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The results were automatically de-duplicated. Further duplicate results were removed manually. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The results were then sifted for relevance and categorised by topic (epidemiology; diagnosis; management of CRVO; management of BRVO and Cardiovascular morbidity and mortality associated with Retinal Vein Occlusion) and by publication type.&amp;nbsp; Results were also categorised by potential AEU topic sub-heading. The resultant articles were then passed to the topic contributors for further sifts for relevance. The results were re-categorised according to topic and publication type where necessary.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;NHS Evidence – eyes and vision was sifted on 23rd December 2009 with records indexed with ‘Retinal vascular occlusion’to ensure that the above search included all the pertinent articles. Relevant guidelines, key documents and seminal articles and uncertainties were identified during this search.&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Search strategy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Evidence – eyes and vision RVO AEU Search Strategy available &lt;A href="http://evslarchive.moorfields.nhs.uk/rvo_docs_0310/pdf/RVOAEU2010searchstrategy.pdf" target="_blank"&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Additional references&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Some&amp;nbsp;older seminal research, published prior to 2002, which still contributes to the evidence base for the current management of Retinal Vein Occlusion in the NHS, has been included in the topic summaries e.g. the Central Vein Occlusion Study and the Branch Vein Occlusion Study (trials that reported between 15 and 25 years ago). &lt;/P&gt;
&lt;P&gt;In some&amp;nbsp;topic summaries&amp;nbsp;additional peripheral references, published since 2002 but not identified in the targeted Retinal Vein Occlusion search, have been included to support commentary. These are identified in the reference list of the relevant topic summary. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;KP 09/03/10&lt;/P&gt;
&lt;P&gt;[1] The Royal College of Ophthalmologists. Retinal Vein Occlusion (RVO): Interim Guidelines, February 2009.&lt;BR&gt;&lt;A href="http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf" target="_blank"&gt;http://www.rcophth.ac.uk/docs/publications/published-guidelines/RVO_Guidelines_Feb_2009.pdf&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;BR&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345440</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=345440]]&gt;</url>
    <title>2010 Annual Evidence Update on Retinal Vein Occlusion - Uncertainties in the management of Retinal Vein Occlusion</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>KNOWN UNCERTAINTY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,ANNUAL EVIDENCE UPDATES,CONDITIONS,RETINAL VEIN OCCLUSION,RETINAL VEIN OCCLUSION AEU 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Retinal Vein Occlusion - Uncertainties in the management of Retinal Vein Occlusion&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;What clinical questions would you like answered on RVO?&lt;/H2&gt;
&lt;P&gt;NHS Evidence - eyes and vision is collaborating in the development of UK DUETs - the UK Database of Uncertainties about the Effects of Treatments.&lt;/P&gt;
&lt;P&gt;DUETs has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp;&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians. &lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments 
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines 
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems.&lt;/P&gt;
&lt;P&gt;The following uncertainties have been identified by the NHS Evidence - eyes and vision team. As new Systematic Reviews are identified by the eyes and vision team further DUETs on retinal vein occlusion will be added.&lt;/P&gt;
&lt;H3&gt;&lt;BR&gt;Retinal vein occlusion&lt;BR&gt;&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:345262:0" name=internalLink&gt;Haemodilution for retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Central retinal vein occlusion&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:345280:0" name=internalLink&gt;Anti-vascular endothelial growth factor agents for treatment of macular edema secondary to central retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:345263:0" name=internalLink&gt;Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:345284:0" name=internalLink&gt;Chorioretinal venous anastomosis for central retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:345273:0" name=internalLink&gt;Hemodilution to improve visual acuity in central retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:345275:0" name=internalLink&gt;Intravitreal corticosteroids to improve visual acuity in central retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:345208:0" name=internalLink&gt;Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:345288:0" name=internalLink&gt;Radial optic neurotomy for central retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;&lt;BR&gt;Branch retinal vein occlusion&lt;/H3&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="nelh:345295:0" name=internalLink&gt;Adventitial sheathotomy in branch retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:345296:0" name=internalLink&gt;Anti-vascular endothelial growth factor for branch retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:345294:0" name=internalLink&gt;Hemodilution to improve visual acuity in branch retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="nelh:345290:0" name=internalLink&gt;Intravitreal corticosteroids to improve visual acuity in branch retinal vein occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;If you are aware of or have identified any uncertainties in the management of&amp;nbsp;Retinal&amp;nbsp;Vein Occlusion&amp;nbsp;please let us know.&amp;nbsp; You can contact us via our &lt;/STRONG&gt;&lt;A href="http://www.library.nhs.uk/EYES/ContactUs.aspx" target="_blank"&gt;&lt;STRONG&gt;feedback form&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:345418:0" name=internalLink&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>382915</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.niesr.ac.uk/pdf/dp349.pdf]]&gt;</url>
    <title>A Cost-benefit Analysis of Cataract Surgery based on the English Longitudinal Survey of Ageing</title>
    <publicationDate>2009-11-19T00:00:00</publicationDate>
    <publisher>National Institute of Economic and Social Research</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This paper uses the English Longitudinal Survey of Ageing to explore the self-report effect of cataract operations on eyesight. Calibrating the results to an existing study of the effect of imperfect eyesight on qualty of life, the impact of cataract operations on quality-adjusted life-years is found to be very similar to that established in specific studies and well above the costs of cataract operations. The implications of this for the treatment of medical care in the national accounts are discussed.&lt;/P&gt;
&lt;P&gt;The National Institute of Economic and Social Research (NIESR)&amp;nbsp;is&amp;nbsp;an independent economic research institute. They publish a series of Discusion Papers, the purpose of which&amp;nbsp;is&amp;nbsp;to foster the interchange of ideas at an early stage and to describe work in progress. This is NIESR Discussion Paper No. 349.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=493" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=493" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=493" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298386</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.vision2020uk.org.uk/core_files/A%20Fundamental,%20final,%206.2.07.pdf]]&gt;</url>
    <title>A fundamental right to sight</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>VISION 2020 UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NATIONAL SERVICE FRAMEWORKS (NSFS) AND EYE HEALTH,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A fundamental right to sight - a contribution to the national service frameworks for older people and long-term conditions and independence, well-being and choice. &lt;/P&gt;
&lt;P&gt;Paper prepared in January 2007 by the Domiciliary Eye Care Committee to ensure that those who are entitled to receive domiciliary eye care are aware of its availability and have access to it.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The report is aimed&amp;nbsp;those with an&amp;nbsp;interest in eye health including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Primary Care Trusts 
&lt;LI&gt;commissioning groups and consortia 
&lt;LI&gt;Local Optical Committees&amp;nbsp; 
&lt;LI&gt;Health Departments&amp;nbsp; 
&lt;LI&gt;other stakeholders involved in the planning and provision of primary ophthalmic services. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=425" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=425" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=425" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310687</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17355741]]&gt;</url>
    <title>A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Current Medical Research and Opinion</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Current Medical Research Opinion (Curr Med Res Opin) 2007 March 23(3) 601-8.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To compare the efficacy of latanoprost, bimatoprost and travoprost for lowering IOP in patients with glaucoma. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESEARCH DESIGN AND METHODS:&lt;/STRONG&gt; In order to carry out this meta-analysis, randomized trials (2001-2004) were identified on Medline and EMBASE using the following key words: glaucoma, ocular hypertension (OHT), randomization, trial, latanoprost, bimatoprost and travoprost. The studies had to compare at least two prostaglandin analogues as mono-therapy. Cross-over experimental designs were excluded. The main outcome measure was IOP at final visit. Statistical analyses included random effects, pooled estimates of treatment effects, tests for publication bias, and random-effects models to obtain adjusted treatment effects on final IOP after lowering for baseline IOP, and duration of follow-up. Random effects Poisson regression models were used to estimate the adjusted effects of treatments on response rates (IOP &amp;lt; 18 mmHg). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Nine studies were used in the analysis. Patient mean age varied from 56.7 to 68.8 years and baseline IOP ranged from 22.3 to 26.5 mmHg. Three hundred and seventy-eight patients were treated with bimatoprost, 385 with travoprost and 555 with latanoprost. Patients treated with travoprost and bimatoprost had lower IOP levels at the end of follow-up (-0.98 mmHg [95% CI: -2.08; 0.13; p = 0.08] and -1.04 mmHg [95% CI: -2.11;0.04; p = 0.06], respectively) than those treated with latanoprost. The combined effect of newer prostaglandin analogues (bimatoprost/travoprost) was an adjusted decrease of 1.00 mmHg [95% CI: -1.91;-0.10], p = 0.03], or a 17% higher adjusted response rate (Incidence Rate Ratio 1.17, 95% CI, 1.00-1.35, p = 0.04), compared to latanoprost. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Travoprost and bimatoprost may have greater efficacy in lowering IOP for patients with OHT or glaucoma.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=104" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289063</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1227.pdf]]&gt;</url>
    <title>A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration</title>
    <publicationDate>2008-08-09T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment programme (HTA)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RETINA,AGE RELATED MACULAR DEGENERATION,DETERMINANTS,OUTCOMES,ECONOMICS,ECONOMICS,EYE DISORDERS,ADULTS,POPULATION BASED &amp; PREVENTATIVE SERVICES,SCREENING,HEALTH ECONOMICS,DISEASE/CONDITION GROUPS,EYE AND VISION PROBLEMS,ASSESSMENT AND PLANNING,COMMISSIONING,COST EFFECTIVENESS,EYES AND VISION,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,METHODS,COSTING,ANALYSIS,SERVICES,COMMISSIONING PROCESS,CONDITIONS,PRIORITISE INVESTMENT,COMMISSIONING COMPETENCIES,2008-JULY,MONTHLY ADDITIONS,ANALYSIS &amp; RESEARCH,POPULATIONS,GROUPS,AGE GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Systematic review published in Health Technology Assessment 2008 Vol 12 No 27. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims and objectives&lt;BR&gt;&lt;/STRONG&gt;The aim of this study was to estimate the cost-effectiveness of screening for AMD by developing a decision analytic model that incorporated and assessed all of the above criteria. At the outset it was recognised that there was likely to be significant uncertainty in key areas of the model, and an objective of the study was to identify the major areas of uncertainty, and so inform future research priorities in this disease area.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;BR&gt;&lt;/STRONG&gt;Systematic literature reviews of the major electronic databases took place in March 2004 and were updated in January 2005. These reviews covered the epidemiology and natural history of AMD, the screening and treatment effectiveness and health-related quality of life relating to AMD. A hybrid cohort–individual sampling model was implemented to describe the range of pathways between the incidence of age-related maculopathy (ARM) and death via clinical presentation and treatment at different stages of the disease.&lt;/P&gt;
&lt;P&gt;Significant shortfalls in the data available from the literature were apparent, so a range of primary data sources were also used to populate the model. To obtain estimates for the value of parameters deemed to be within an expert's remit, data describing some parameters were elicited from relevant experts. The data identified informed probability distributions describing the uncertainty around the model parameters.&lt;/P&gt;
&lt;P&gt;To incorporate joint parameter uncertainty (i.e. correlations between parameters), the AMD natural history model was calibrated probabilistically. Randomly sampled sets of input parameters were assigned weights representing the accuracy of their predictions of a set of observed model outputs.&lt;/P&gt;
&lt;P&gt;The analysis of the AMD screening model estimated the costs, numbers of quality-adjusted life-years (QALYs) and cases of blindness in a general population sample of 50-year-olds over the remainder of their lifetime, for 16 alternative screening options (including no screening). The reference case analysis incorporated current treatment options of laser photocoagulation and photodynamic therapy. Sensitivity analyses describing six alternative sets of intervention strategies, based on horizon scanning of potential future treatments for AMD, were also undertaken.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;&lt;BR&gt;There remains significant uncertainty about whether any form of screening for AMD is cost-effective. However, annual screening from age 60 years seems to provide the highest mean net benefits, but this is based on a cost-effectiveness estimate that has very poor precision (high levels of uncertainty). The probabilistic sensitivity analysis shows that the 95% credible interval for annual screening from age 60 years ranges from this option dominating the previous option to an incremental cost per QALY of over £0.5 million. Plotting a cost-effectiveness acceptability frontier shows that although annual screening from age 60 years has the highest net benefits at a value of QALY of £30,000, the associated probability of this option being the most cost-effective option is only around 20%.&lt;/P&gt;
&lt;P&gt;The sensitivity analyses around potential future treatment options indicate that screening may become more cost-effective with the new treatments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;The conclusions focus on the interpretation of the results from the perspective of defining the major areas of uncertainty, which were defined as:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Disease progression (due to the available data, the model was built around progression of visual acuity, despite a preference for contrast sensitivity). 
&lt;LI&gt;Rates of clinical presentation (informed by local data from the Sheffield photodynamic therapy (PDT) clinic and responses from a survey of general ophthalmologists). Problems with this approach included a small sample of patients, the fact that the PDT database was not validated, a limited response to the survey of ophthalmologists and inconsistencies in the responses received. 
&lt;LI&gt;Screening test and optician effectiveness (elicited data described the probability that individuals undertaking the simple screening test at home who notice an abnormality would then present at an optician's). The model assumes that optometrists accurately refer all cases of dry and wet AMD on to hospital ophthalmologists, while not referring any cases of early ARM. 
&lt;LI&gt;Treatment effectiveness (a lack of long-term follow-up data inevitably requires the use of weak assumptions to extrapolate the observed effectiveness data). 
&lt;LI&gt;Costs of blindness (a binary threshold for costs associated with blindness was incorporated, but such costs would be more appropriately described on a continuum).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Future research may be best targeted at assessing how routine data may be used to describe clinical presentation rates of ARM. Other potential&amp;nbsp; studies include a pilot study of the effectiveness&amp;nbsp; of screening and opticians' referral patterns for AMD and a costing study of blindness as a continuum of association with deterioration in vision.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102049</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9097789&amp;query_hl=7]]&gt;</url>
    <title>A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.</title>
    <publicationDate>1995-10-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Oct 1995, vol. 102, no. 10, p. 1434-44, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To answer whether prophylactic panretinal photocoagulation (PRP) in ischemic central vein occlusion (CVO) prevents development of 2 clock hours of iris neovascularization or any angle neovascularization (TC-INV/ANV) or whether it is more appropriate to apply PRP only when TC-INV/ANV occurs. &lt;/P&gt;
&lt;P&gt;METHODS: Multicenter randomized controlled clinical trial in eyes with ischemic CVO. Eyes were assigned to immediate prophylactic PRP (90 eyes) or to frequent close observation (91 eyes). If TC-INV/ANV developed, untreated eyes received PRP and previously treated eyes received supplemental PRP. &lt;/P&gt;
&lt;P&gt;RESULTS: In both groups, TC-INV/ANV developed less often in prophylactically treated than untreated eyes, but the difference was not statistically significant when adjusted for baseline imbalance. Treatment of TC-INV/ANV was followed by prompt regression (within 1 month) in 18 (56%) of 32 previously untreated eyes and in 4 (22%) of 18 eyes that had had prophylactic treatment. All eyes except eight eventually stabilized without neovascularization. TC-INV/ANV was correlated with the amount of nonperfused retina (P = 0.0001) and extent of retinal hemorrhage (P = 0.03). Males were at higher risk than females for TC-INV/ANV (P = 0.01), as were patients with occlusions of less than one month duration (P = 0.01). &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Prophylactic PRP does not totally prevent TC-INV/ANV, and prompt regression of TC-INV/ANV in response to PRP is more likely to occur in eyes that have not been treated previously. The authors recommend careful observation with frequent follow-up examinations in the early months (including undilated slit-lamp examination of the iris and gonioscopy) and prompt PRP of eyes in which TC-INV/ANV develops. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;central vein occlusion management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102048:0" name=internalLink&gt;Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102050:0" name=internalLink&gt;Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7508322&amp;amp;query_hl=16" target="_blank"&gt;Central vein occlusion study of photocoagulation therapy. Baseline findings. Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7508321&amp;amp;query_hl=16" target="_blank"&gt;Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7688950&amp;amp;query_hl=16" target="_blank"&gt;Baseline and early natural history report. The Central Vein Occlusion Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10163466&amp;amp;query_hl=23" target="_blank"&gt;Laser therapy for central retinal vein obstruction.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102056</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11594943&amp;query_hl=27]]&gt;</url>
    <title>A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9.</title>
    <publicationDate>2001-10-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ AGE RELATED MACULAR DEGENERATION,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of ophthalmology, {Arch-Ophthalmol}, Oct 2001, vol. 119, no. 10, p. 1439-52, ISSN: 0003-9950.&lt;/EM&gt;&lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: Experimental and observational data suggest that micronutrients with antioxidant capabilities may retard the development of age-related cataract. &lt;/P&gt;
&lt;P&gt;OBJECTIVE: To evaluate the effect of a high-dose antioxidant formulation on the development and progression of age-related lens opacities and visual acuity loss. &lt;/P&gt;
&lt;P&gt;DESIGN: The 11-center Age-Related Eye Disease Study (AREDS) was a double-masked clinical trial. Participants were randomly assigned to receive daily oral tablets containing either antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg) or no antioxidants. Participants with more than a few small drusen were also randomly assigned to receive tablets with or without zinc (80 mg of zinc as zinc oxide) and copper (2 mg of copper as cupric oxide) as part of the age-related macular degeneration trial. Baseline and annual (starting at year 2) lens photographs were graded at a reading center for the severity of lens opacities using the AREDS cataract grading scale. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURES: Primary outcomes were (1) an increase from baseline in nuclear, cortical, or posterior subcapsular opacity grades or cataract surgery, and (2) at least moderate visual acuity loss from baseline (&amp;gt;/=15 letters). Primary analyses used repeated-measures logistic regression with a statistical significance level of P =.01. Serum level measurements, medical histories, and mortality rates were used for safety monitoring. &lt;/P&gt;
&lt;P&gt;RESULTS: Of 4757 participants enrolled, 4629 who were aged from 55 to 80 years had at least 1 natural lens present and were followed up for an average of 6.3 years. No statistically significant effect of the antioxidant formulation was seen on the development or progression of age-related lens opacities (odds ratio = 0.97, P =.55). There was also no statistically significant effect of treatment in reducing the risk of progression for any of the 3 lens opacity types or for cataract surgery. For the 1117 participants with no age-related macular degeneration at baseline, no statistically significant difference was noted between treatment groups for at least moderate visual acuity loss. No statistically significant serious adverse effect was associated with treatment. &lt;/P&gt;
&lt;P&gt;CONCLUSION: Use of a high-dose formulation of vitamin C, vitamin E, and beta carotene in a relatively well-nourished older adult cohort had no apparent effect on the 7-year risk of development or progression of age-related lens opacities or visual acuity loss.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;cataract management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102061</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11594942&amp;query_hl=27]]&gt;</url>
    <title>A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.</title>
    <publicationDate>2001-10-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RETINA,AGE RELATED MACULAR DEGENERATION,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology, {Arch-Ophthalmol}, Oct 2001, vol. 119, no. 10, p. 1417-36, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: Observational and experimental data suggest that antioxidant and/or zinc supplements may delay progression of age-related macular degeneration (AMD) and vision loss. &lt;/P&gt;
&lt;P&gt;OBJECTIVE: To evaluate the effect of high-dose vitamins C and E, beta carotene, and zinc supplements on AMD progression and visual acuity. &lt;/P&gt;
&lt;P&gt;DESIGN: The Age-Related Eye Disease Study, an 11-center double-masked clinical trial, enrolled participants in an AMD trial if they had extensive small drusen, intermediate drusen, large drusen, noncentral geographic atrophy, or pigment abnormalities in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye. At least 1 eye had best-corrected visual acuity of 20/32 or better. Participants were randomly assigned to receive daily oral tablets containing: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg); (2) zinc, 80 mg, as zinc oxide and copper, 2 mg, as cupric oxide; (3) antioxidants plus zinc; or (4) placebo. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURES: (1) Photographic assessment of progression to or treatment for advanced AMD and (2) at least moderate visual acuity loss from baseline (&amp;gt; or =15 letters). Primary analyses used repeated-measures logistic regression with a significance level of.01, unadjusted for covariates. Serum level measurements, medical histories, and mortality rates were used for safety monitoring. &lt;/P&gt;
&lt;P&gt;RESULTS: Average follow-up of the 3640 enrolled study participants, aged 55-80 years, was 6.3 years, with 2.4% lost to follow-up. Comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc (odds ratio (OR), 0.72; 99% confidence interval (CI), 0.52-0.98). The ORs for zinc alone and antioxidants alone are 0.75 (99% CI, 0.55-1.03) and 0.80 (99% CI, 0.59-1.09), respectively. Participants with extensive small drusen, nonextensive intermediate size drusen, or pigment abnormalities had only a 1.3% 5-year probability of progression to advanced AMD. Odds reduction estimates increased when these 1063 participants were excluded (antioxidants plus zinc: OR, 0.66; 99% CI, 0.47-0.91; zinc: OR, 0.71; 99% CI, 0.52-0.99; antioxidants: OR, 0.76; 99% CI, 0.55-1.05). Both zinc and antioxidants plus zinc significantly reduced the odds of developing advanced AMD in this higher-risk group. The only statistically significant reduction in rates of at least moderate visual acuity loss occurred in persons assigned to receive antioxidants plus zinc (OR, 0.73; 99% CI, 0.54-0.99). No statistically significant serious adverse effect was associated with any of the formulations. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Persons older than 55 years should have dilated eye examinations to determine their risk of developing advanced AMD. Those with extensive intermediate size drusen, at least 1 large druse, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants plus zinc such as that used in this study.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;age related macular degeneration management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15808240&amp;amp;query_hl=36" target="_blank"&gt;Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15136320&amp;amp;query_hl=36" target="_blank"&gt;Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11925463&amp;amp;query_hl=36" target="_blank"&gt;The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the age-related eye disease study: AREDS Report No. 7.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11097601&amp;amp;query_hl=36" target="_blank"&gt;Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389237</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.sense.org.uk/Resources/Sense/Publications/Documents/Sense%20of%20Urgency.pdf]]&gt;</url>
    <title>A sense of urgency</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Sense</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Sense, a UK national charity that supports and campaigns for children and adults who are deafblind,&amp;nbsp;commissioned independent, expert research on the numbers of deafblind people now and over the next twenty years. The Centre for Disability Research (CeDR) &lt;A href="nelh:389245:0" name=internalLink&gt;report&lt;/A&gt;, summarised in this document, found that the deafblind population has been significantly underestimated and is set to rise dramatically.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=497" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=497" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=497" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317944</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18486098]]&gt;</url>
    <title>A systematic literature review of surgical interventions for limbal stem cell deficiency in humans</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American Journal of Ophthalmology (Am J Ophthalmol) 2008 Aug;146(2):251-259. Epub 2008 May 16. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To evaluate the relative benefits and to identify any adverse effects of surgical interventions for limbal stem cell deficiency (LSCD). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN: &lt;/STRONG&gt;Systematic literature review. METHODS: We searched the following electronic databases from January 1, 1989 through September 30, 2006: MEDLINE, EMBASE, Science citation index, BIOSIS, and the Cochrane Library. In addition, reference lists were scanned to identify any additional reports. The quality of published reports was assessed using standard methods. The main outcome measure was improvement in vision of at least two Snellen lines of best-corrected visual acuity (BCVA). Data on adverse outcomes also were collected. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Twenty-six studies met the inclusion criteria. There were no randomized controlled studies. All 26 studies were either prospective or retrospective case series. For bilateral severe LSCD, keratolimbal allograft was the most common intervention with systemic immunosuppression. Other interventions included eccentric penetrating keratolimbal allografts and cultivated autologous oral mucosal epithelial grafts. An improvement in BCVA of two lines or more was reported in 31% to 67% of eyes. For unilateral severe LSCD, the most common surgical intervention was contralateral conjunctival limbal autograft, with 35% to 88% of eyes gaining an improvement in BCVA of two lines or more. The only study evaluating partial LSCD showed an improvement in BCVA of two lines or more in 39% of eyes. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Studies to date have not provided strong evidence to guide clinical practice on which surgery is most beneficial to treat various types of LSCD. Standardized data collection in a multicenter LSCD register is suggested.&lt;/P&gt;
&lt;P class=pmid&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=61" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317952</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17641695]]&gt;</url>
    <title>A systematic literature review of the evidence on benchmarks for cataract surgery waiting time</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Canadian Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Canadian Journal of Ophthalmology (Can J Ophthalmol) 2007 Aug;42(4):543-51.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; This review offered critical input to the work of Canadian federal-provincial-territorial Deputy Ministers of Health on establishing evidence-based benchmarks for waiting times (WTs) for cataract surgery. The study purpose was to synthesize the evidence regarding the relations among patient characteristics, WT, and health outcomes for patients on waiting lists for cataract surgery. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic literature review was conducted using the Cochrane methodology. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Seventeen studies were considered. The studies varied in their quality, study design, sample characteristics, and outcome measures. Because of the heterogeneity in studies, a qualitative analysis was used. Key findings were: individuals with cataracts are at an increased risk of falls, hip fractures, and motor vehicle crashes, the absence of pre-existing eye disease, and better baseline visual acuity and visual function are associated with better outcomes, and average WTs of 6-12 months are associated with a decline in visual acuity in patients while waiting. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;INTERPRETATION:&lt;/STRONG&gt; Although the evidence does not indicate a precise benchmark, it does support timely access to surgery for individuals undergoing cataract surgery. In December 2005, health ministers set a goal to provide cataract surgery within 16 weeks for patients at high risk.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=32" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310689</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/9663224]]&gt;</url>
    <title>A systematic overview of the incidence of posterior capsule opacification</title>
    <publicationDate>1998-07-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 1998 Jul; 105(7): 1213-21&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; Reported rates of posterior capsule opacification (PCO) vary widely and are based on various definitions of PCO, varying lengths and intervals of follow-up, and the use of different surgical techniques, intraocular lens (i.o.l.) designs, and methods of IOL implantation. This study was designed to obtain a more precise overall estimate of the incidence of PCO and to explore factors that might influence the rate of PCO development. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; A meta-analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Published articles were selected for study based on a computerized MEDLINE search of the literature and a manual search of the bibliographies of relevant articles. Articles meeting selected inclusion criteria were reviewed systematically, and the reported data were abstracted and synthesized using the statistical techniques of meta-analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURE:&lt;/STRONG&gt; Pooled estimates of the proportion of eyes developing PCO at three postoperative timepoints--1 year, 3 years, and 5 years--were measured. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; There is significant heterogeneity among published rates of PCO. The overall pooled estimates (95% confidence limits) of the incidence of PCO were 11.8% (9.3%-14.3%) at 1 year, 20.7% (16.6%-24.9%) at 3 years, and 28.4% (18.4%-38.4%) at 5 years after surgery. There is no evidence of a significant decline in PCO incidence during the study period. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Visually significant PCO develops in more than 25% of patients undergoing standard extracapsular cataract extraction or phacoemulsification with posterior chamber intraocular lens implantation over the first 5 years after surgery. Patient characteristics, surgical techniques, and differences in research design and reporting may account for some of the variability in reported rates. However, no specific factors were identified in the authors' analysis. More precise estimates of incidence and identification of risk factors for PCO will depend on the development of a standardized measurement of PCO and wider adoption of more rigorous study methodology.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=8" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310690</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14988875]]&gt;</url>
    <title>A systematic review of anatomical and visual function outcomes in preterm infants after scleral buckle and vitrectomy for retinal detachment</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Advances in Neonatal Care: official journal of the National Association of Neonatal Nurses</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL TEARS AND DETACHMENT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Advances in Neonatal Care (Adv Neonatal Care) 2004 Feb;4(1):10-9&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; This article is a systematic review of the literature examining the anatomical and visual function outcomes after scleral buckle and/or vitrectomy for Stage 4 or 5 retinopathy of prematurity. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MATERIALS AND METHODS:&lt;/STRONG&gt; The literature published between 1994 through May 2003 was reviewed via a computer search accessing MEDLINE via OVID. Eight applicable studies were retrieved and analyzed. The study designs were descriptive, retrospective, non-comparative, consecutive case series. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The postoperative anatomical outcomes varied dramatically between studies with retinal reattachment rates of 0.8% to 90%. Surgeries that achieved a 50% or higher rate of reattachment occurred primarily between 2 and 9 months of age. Surgeries that occurred between 7 and 11 months of age achieved a lower percentage of retinal reattachment. Further, the longer the duration of follow-up, the lower the percentage of retinas that remained attached. Most importantly, at least in these reports, the degree of retinal reattachment did not correlate well with the level of visual function. One report demonstrated no statistical correlation between visual and anatomical success. Poor visual outcomes were noted in both timely and delayed cases of surgical reattachment of the retina. Many of the reports described challenges in accurately measuring low levels of vision.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=191" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310694</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16793269]]&gt;</url>
    <title>A systematic review of diagnostic studies in myasthenia gravis</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>Neuromuscular Disorders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Neuromuscular Disorders (Neuromuscul Disord) 2006 Jul; 16(7):459-67. Epub 2006 Jun 21. &lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;We performed a systematic review to identify studies that reported the accuracy of tests for the diagnosis of myasthenia gravis. We identified 20 studies of reasonable, although variable, methodological quality upon which to base estimates of the accuracy of the ice test, rest test, Tensilon test, acetylcholine receptor antibodies, repetitive nerve stimulation and single fiber electromyography for the diagnosis of myasthenia gravis. After examining inter-study heterogeneity for each diagnostic modality, we calculated pooled estimates of sensitivity and specificity as well as positive and negative likelihood ratios. Results are reported separately for ocular and generalized myasthenia. Studies that have examined the performance of anti-acetylcholine receptor antibody testing and single fiber electromyography were generally of better quality than those that examined other diagnostic modalities. We suggest that caution should be exercised in the interpretation of the diagnostic performance of these tests given the methodological limitations of the studies upon which test performance is based.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=132" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317962</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/10655188]]&gt;</url>
    <title>A systematic review of drug induced ocular reactions in diabetes</title>
    <publicationDate></publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2000 Feb;84(2):144-9.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIMS:&lt;/STRONG&gt; To conduct a systematic review of drug induced adverse ocular effects in diabetes to determine if this approach identified any previously unrecognised adverse drug effects; to make a preliminary assessment of the feasibility of this approach in identifying adverse drug reactions; and to assess the current accessibility of this information to prescribing physicians. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Literature search of online biomedical databases. The search strategy linked eye disorders with adverse drug reactions and diabetes. Source journals were classified as medical, pharmaceutical, diabetes related, or ophthalmological. It was determined whether the reactions identified were recorded in drug datasheets and the British National Formulary. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; 63 references fulfilled the selection criteria, of which 45 were considered to be relevant to the study. The majority of these were case reports but cross sectional surveys, case-control and cohort studies, and review articles were also identified. 61% of the reactions were not recorded in the British National Formulary and 41% were not recorded in the datasheets. 55% appeared in specialist ophthalmology journals. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This is a feasible approach to the identification of adverse drug reactions. Adverse reactions not listed in the most commonly used reference sources were found. The majority were published in specialist ophthalmology journals which might not be seen by prescribing physicians.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the&amp;nbsp;eyes and vision specialist collection&amp;nbsp;management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=4" target="_blank"&gt;here &lt;/A&gt;to view the appraisal. &amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372635</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19358198]]&gt;</url>
    <title>A systematic review of outcomes following surgical decompression for dysthyroid orbitopathy.</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Laryngoscope</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NHS CORE CONTENT WITHOUT A CATEGORY,ORBIT,THYROID EYE DISEASE,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Laryngoscope. 2009 Jun;119(6):1106-15&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVES:&lt;/STRONG&gt; To systematically review and compare the surgical outcomes of orbital decompression for dysthyroid orbitopathy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Data sources used were PubMed, EMBASE, and Cochrane search for English-language literature from January 1990 to April 2008, combined with manual review of citations within article bibliographies. Citations acquired from the targeted search were filtered independently by two researchers. Relevant articles were reviewed to obtain information including interventions and outcome measures. Articles were then assigned level-of-evidence grades as defined by the Oxford Centre for Evidence-Based Medicine. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A total of 516 citations were generated from which 135 abstracts were regarded as potentially relevant. After other relevant articles identified from the bibliography and duplicate articles excluded, 56 studies were available for analysis. Fifty studies were identified as level 4 and six as level 3 evidence. A total of 2,315 patients were pooled, from which 4,176 orbits were decompressed. Fifteen different surgical techniques were broadly identified. The most common surgical indication was cosmesis. Decompression by combined transpalpebral-endoscopic technique resulted in the highest average reduction in postoperative proptosis. The largest improvement in visual acuity was after coronal approach orbital decompression. The overall complication rate was 9.3%. The most significant complications were vision loss and cerebral vascular accident. The highest complication rate was associated with combined endoscopic and transpalpebral decompression. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; There are myriad techniques in practice for decompressing the orbit, but no one technique has yet to achieve consistently good outcome and low complication rates. The reporting of outcomes should conform to a minimum dataset. &lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=277" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310697</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14966173]]&gt;</url>
    <title>A systematic review of Terson's syndrome: frequency and prognosis after subarachnoid haemorrhage</title>
    <publicationDate>2004-03-01T00:00:00</publicationDate>
    <publisher>Journal of Neurology, Neurosurgery and Psychiatry</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VITREOUS BODY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Neurology, Neurosurgery and Psychiatry (J Neurol Neurosurg Psychiatry) 2004 Mar; 75(3):491-3.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To review systematically the frequency and prognostic significance of vitreous haemorrhage in patients with subarachnoid haemorrhage (Terson's syndrome). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Papers relating to vitreous haemorrhage in patients with subarachnoid haemorrhage were retrieved. The only studies considered were those with at least 10 consecutive cases of subarachnoid haemorrhage with or without vitreous haemorrhage. The frequency of vitreous haemorrhage in such cases was calculated in prospective and retrospective studies. Mortality was compared in patients with and without Terson's syndrome. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; 154 papers were reviewed. Three prospective studies and six retrospective studies satisfied the inclusion criteria. Of 181 patients with subarachnoid haemorrhage assessed prospectively (mean age, 51.7 years), 24 (13%) had vitreous haemorrhage; among 1086 retrospective records, 37 (3%) had documented vitreous haemorrhage (p&amp;lt;0.001). Patients with Terson's syndrome had higher Hunt and Hess grades than those without (mean grade, 3.6 v 2.6). Patients with Terson's syndrome were also more likely to die (13 of 30 (43%) v 31 of 342 (9%); odds ratio 4.8; p&amp;lt;0.001). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Prospective studies show a higher frequency of Terson's syndrome than retrospective studies, suggesting that vitreous haemorrhage is not well documented. Vitreous haemorrhage is an adverse prognostic finding in patients with subarachnoid haemorrhage.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=192" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317961</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18582396]]&gt;</url>
    <title>A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Current Medical Research and Opinion</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Current Medical Research &amp;amp; Opinion (Curr Med Res Opin) 2008 Aug;24(8):2265-70. Epub 2008 Jun 25&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; To classify the comparative quantity and quality of the RCT evidence of pharmacological treatment for glaucoma. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHOD:&lt;/STRONG&gt; A systematic review of MEDLINE, EMBASE Cochrane CENTRAL and relevant conference proceedings was conducted up to March 2007. RCTs recruiting adults with primary open angle glaucoma (POAG) and/or ocular hypertension (OH) receiving any topical medication or placebo were included. RCTs containing a prostaglandin treatment arm were specifically considered. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A total of 510 publications were identified. Of these, 181 studies had a prostaglandin treatment arm. The median study duration was 12 weeks (IQR 4-13) and 78% of included trials had a duration of 3 months or less. The four studies over 1 year in duration all included a latanoprost and timolol treatment arm. There was a lack of data on younger populations (median of the mean ages of included patients was 63.4 years [IQR: 61-66 years]). Caucasians constituted 79.6% of the studied population. Evidence by ethnicity as well as by co-morbidity, was scarce. The primary outcome for 92% of studies was IOP reduction; little was reported on other indicators. Most trials reported adverse events, with hyperaemia most commonly reported. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; The RCT evidence base for glaucoma treatment is extensive. This systematic review is the first to consider the characteristics of all RCTs containing a prostaglandin arm. The majority of trials are of short duration and focus on IOP as the efficacy outcome. The limitations of this study are that only trials with a prostaglandin treatment arm are included and due to the large number of included trials only top line data were extracted.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=79" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310700</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/10545578]]&gt;</url>
    <title>A systematic review of vision screening tests for the detection of amblyopia</title>
    <publicationDate>1999-11-01T00:00:00</publicationDate>
    <publisher>Pediatrics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Pediatrics 1999 Nov; 104(5 Pt 2): 1220-2&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To review the test characteristics and the quality of evidence regarding available screening tests for the detection of amblyopia in preschool-aged children to help primary care practitioners select a screening strategy. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Systematic review of published studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DATA SOURCES:&lt;/STRONG&gt; The MEDLINE database was searched from 1966 through January 1999 using a broad and inclusive strategy. A total of 9551 citations were identified. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;STUDY SELECTION:&lt;/STRONG&gt; All studies that compared the results of commercially available screening tests in preschool-aged children to ophthalmologic examination. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DATA EXTRACTION:&lt;/STRONG&gt; The setting of the study, the age of the population, the type of screening test, criteria for a positive screen, criteria for the ophthalmologic examination, test characteristics, and measures of reliability were abstracted by 2 reviewers for each selected study. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DATA SYNTHESIS:&lt;/STRONG&gt; Four eligible articles were identified that studied the test characteristics of 3 screening tests. None of these studies were performed in a primary care setting. Each study used different criteria for failure of the ophthalmologic examination. None of the studies measured observer or test reliability. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Few high-quality data exist regarding the performance of preschool vision screening. Important future work should include the development of a consensus gold standard ophthalmologic examination and evaluation of screening tests in the primary care setting.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=5" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372630</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18843500]]&gt;</url>
    <title>A systematic review on the effect of bevacizumab in exudative age-related macular degeneration</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Graefe's Archives for Clinical and Experimental Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Graefes Archives Clinical &amp;amp; Experimental Ophthalmology. 2009 Jan;247(1):1-11. Epub 2008 Oct 9&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; To provide evidence for the effect of bevacizumab on visual acuity (VA) and central retinal thickness (CRT) in exudative age-related macular degeneration &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic review of all articles of bevacizumab for exudative AMD was conducted. Articles published up to March 2008 were identified in Medline, Embase, the Cochrane Controlled Trials Register and references from included articles. Search terms were "Bevacizumab or Avastin" and "Macula* or ARMD or AMD or intra(-)vitreal or intra(-)vitreous". Three observers participated in the data retrieval and assignment of the quality scores. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A total of 561 articles were retrieved. Three randomised controlled trials (RCT) and 23 before-and-after studies of patients (n = 1,435) who had received bevacizumab were published. Inclusion criteria varied. Lack of masking was the main methodological shortcoming. These RCTs showed that bevacizumab is more effective than PDT. Bevacizumab was given intravenously or as intravitreal injection. The latter was given once, or repeatedly every 4 weeks, and with or without additional injection when a recurrence occurred, mostly based on visual acuity and/or findings from optical coherence tomography. After intravenous administration, the weighted mean change in VA was +12.8 ETDRS letters (range +11 to +14) and the weighted mean change for CRT was -129 microm (range -100 to -202). For the 23 studies with intravitreal injections, the change in VA was +8.6 letters (range +2 to +26) and the change in CRT was -90 microm (range -46 to -190). The incidence of adverse events was low. The change in VA was 2.7 letters higher for studies with a higher quality vs lower quality. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Visual acuity improves and central retinal thickness decreases in patients with exudative AMD after bevacizumab. There is no reasonable doubt that this is caused by bevacizumab. It is likely that a randomised controlled trial will show that bevacizumab is equivalent in effect to ranibizumab, which showed a change in ETDRS of +5.9 letters for occult or minimally classic CNV and +9.8 letters for classic CNV after three monthly injections in two large RCTs.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=271" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298373</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.vision2020uk.org.uk/core_files/Network%201000%20Survey%202%20-%20Access%20to%20Services%20-%20October%202008(1).doc]]&gt;</url>
    <title>Access to information, services and support for people with visual impairment</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>VISION 2020 UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ LOW VISION,LIVING WITH VISUAL IMPAIRMENT,VISUAL IMPAIRMENT,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report published in October 2008 presents findings from the Network 1000 Survey 2.&amp;nbsp;&amp;nbsp; The report focuses upon data relating to access to information, services and support and presents data in relation to:&lt;/P&gt;
&lt;P&gt;1)&amp;nbsp;Current experience of eye clinics and low vision clinics.&lt;/P&gt;
&lt;P&gt;2)&amp;nbsp;Experience in the eye clinic at time of certification as blind or partially sighted.&lt;/P&gt;
&lt;P&gt;3)&amp;nbsp;Experience of services in the year following registration as blind or partially sighted.&lt;/P&gt;
&lt;P&gt;4)&amp;nbsp;Experience of services in the last year.&lt;/P&gt;
&lt;P&gt;5)&amp;nbsp;Services offered to the family of the visually impaired person.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=423" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=423" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=423" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102347</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/01/45/14/04014514.pdf]]&gt;</url>
    <title>Action on cataracts - good practice guidance</title>
    <publicationDate>2000-02-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,CATARACT,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Good Practice Guidance&amp;nbsp;written by NHS Executive and published in February 2000 by Department of Health.&amp;nbsp;&amp;nbsp; The purpose of the document is to assist managers and health professionals to review and improve the management of cataract service. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310702</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15883279]]&gt;</url>
    <title>Acute endophthalmitis following cataract surgery: a systematic review of the literature</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,ENDOPHTHALMITIS,VITREOUS BODY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: Archives of Ophthalmology (Arch Ophthalmol) 2005 May;123(5):613-20.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVES:&lt;/STRONG&gt; To determine the reported incidence of acute endophthalmitis following cataract extraction over time and to explore possible contributing factors, such as type of cataract incision. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A systematic review of English-language articles was conducted by performing a broad search of PubMed from 1963 through March 2003 using such terms as cataract extraction, endophthalmitis, and postoperative complication. Additional studies were identified from bibliographies of relevant articles and published proceedings. Surgical approach was recorded, when available. Pooled incidence rates and relative risks of developing endophthalmitis using different incision techniques were assessed. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; From 4916 unique, potentially relevant citations, 215 studies that addressed endophthalmitis and met the selection criteria were analyzed. A total of 3 140 650 cataract extractions were pooled resulting in an overall rate of 0.128% of postcataract endophthalmitis. However, the incidence of acute endophthalmitis changed over time, with a significant increase since 2000 compared with previous decades (relative risk, 2.44 [95% confidence interval, 2.27-2.61]). The rate of endophthalmitis was 0.265% in the 2000-2003 period, 0.087% in the 1990s, 0.158% in the 1980s, and 0.327% during the 1970s. Furthermore, an upward trend in rates after 1992 was noted, compared with 1991 and prior. Incision type appeared to significantly influence risk, as endophthalmitis following clear corneal cataract extraction during the 1992-2003 period was 0.189% compared with 0.074% (relative risk, 2.55 [95% confidence interval, 1.75-3.71]) for scleral incision and 0.062% (relative risk, 3.06 [95% confidence interval, 2.48-3.76]) for limbal incision. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This systematic review indicates that the incidence of endophthalmitis associated with cataract extraction has increased over the last decade. This upward trend in endophthalmitis frequency coincides temporally with the development of sutureless clear corneal incisions.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=167" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342371</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aop.org.uk/uploaded_files/glaucoma_faqs_6th_revision_11-02-2010.pdf]]&gt;</url>
    <title>Advice on NICE glaucoma guidelines</title>
    <publicationDate>2009-04-24T00:00:00</publicationDate>
    <publisher>Association of Optometrists (AOP)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Following the publication of the NICE glaucoma guideline in&amp;nbsp;April 2009, the Association for British Dispensing Opticians, (ABDO), the Association of Optometrists (AOP) and the Federation of Ophthalmic and Dispensing Opticians (FODO) issued their advice on the implementation of the NICE guideline.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This document was last revised on&amp;nbsp;11 February&amp;nbsp;2010. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317964</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18347620]]&gt;</url>
    <title>Age-related macular degeneration and low-vision rehabilitation: a systematic review</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Canadian Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Canadian Journal of Ophthalmology (Can J Ophthalmol) 2008 Apr;43(2):180-7.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Because of the prevalence and devastating consequences of age-related macular degeneration (AMD), a systematic review devoted to low-vision rehabilitation and AMD seems timely and appropriate. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Several electronic databases were searched for studies from 1980 to 2006 involving individuals with low vision or visual impairment and rehabilitation interventions. Studies were assessed for quality and level of evidence. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The findings indicate that standard low-vision rehabilitation programs, conventional in-clinic assessments, and optical devices are effective ways of managing and living with vision loss. Areas of unmet need include determining which types of orientation and mobility programs and devices are most effective and developing methods of matching assistive technologies with the individual's visual and environmental requirements. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;INTERPRETATION:&lt;/STRONG&gt; Additional randomized controlled trials with similar intervention comparisons and outcome measures are needed to form stronger conclusions for the most effective low-vision rehabilitation interventions for individuals with AMD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=76" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317978</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18242575]]&gt;</url>
    <title>Alcohol consumption and the risk of age-related macular degeneration: a systematic review and meta-analysis</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American Journal of Ophthalmology (Am J Ophthalmol) 2008 Apr;145(4):707-715. Epub 2008 Feb 1. &lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To review systematically the evidence currently available on alcohol consumption and the risk of age-related macular degeneration (AMD). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN: &lt;/STRONG&gt;Systematic review and meta-analysis of observational studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Seven databases were searched systematically with no limits on the year or language of publication for prospective cohort studies. References identified from pertinent reviews and articles also were retrieved. Two reviewers independently searched the above databases and selected the studies using prespecified standardized criteria. These criteria included appropriate adjustment for age and smoking in the analysis. Of the 441 studies identified initially, five cohort studies met the selection criteria. Data extraction and study quality evaluation were performed independently by two reviewers and results were pooled quantitatively using meta-analytic methods. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The five cohort studies included 136,946 people, among whom AMD developed in 1923 (1,513 early and 410 late). Pooled results showed that heavy alcohol consumption was associated with an increased risk of early AMD (pooled odds ratio, 1.47; 95% confidence interval, 1.10 to 1.95), whereas the association between heavy alcohol consumption and risk of late AMD was inconclusive. There were insufficient data to evaluate a dose-response association between alcohol consumption and AMD or the association between moderate alcohol consumption and AMD. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Heavy alcohol consumption (more than three standard drinks per day) is associated with an increased risk of early AMD. Although this association seems to be independent of smoking, residual confounding effects from smoking cannot be excluded completely.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=64" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>315029</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315029]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Epidemiology</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0609/aeu_amd_0609_doc2.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/Epidemiology.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:286963:0" name=internalLink&gt;Please click here to view 2008 AEU epidemiology section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date ; NHS Evidence - eyes and vision&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 2 May 2008 to 11 May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; NHS Evidence Health Information Resources, Healthcare Databases&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Epidemiology evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID315029/nelhImp_0001_evsl_topic_epid_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. New England Journal of Medicine 2008; 358(24):2606-2617. &lt;A href="http://content.nejm.org/cgi/content/extract/358/24/2606" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Coleman HR, Chan CC, Ferris FL, Chew EY. Age-related macular degeneration. Lancet 2008;372(9652):1835-1845. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19027484" target="_blank"&gt;[PubMed abstract 19027484]&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Cackett P, Tay WT, Aung T, Wang JJ, Shankar A, Saw SM, Mitchell P, Wong TY. Education, socio-economic status and age-related macular degeneration in Asians: the Singapore Malay Eye Study. British Journal of Ophthalmology 2008;92(10):1312-1315. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18664503" target="_blank"&gt;[PubMed abstract 18664503]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Klein R, Meuer SM, Knudtson MD, Klein BE. The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study. American Journal of Ophthalmology 2008;146(5):692-699. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18672224" target="_blank"&gt;[PubMed abstract 18672224]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye 2008;22(7)905-911. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17332762" target="_blank"&gt;[PubMed abstract 17332762]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Klein R, Knudtson MD, Lee KE, Klein BE. Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: the Beaver Dam Eye Study. Archives of Ophthalmology 2009;127(2):193-199. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19204238" target="_blank"&gt;[PubMed abstract 19204238]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors and Preventative Factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Loane E, Kelliher C, Beatty S, Nolan JM. The rationale and evidence base for a protective role of macular pigment in age-related maculopathy. British Journal of Ophthalmology 2008; 92(9):1163-1168. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18669545" target="_blank"&gt;[PubMed abstract 18669545]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18982929" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Wang JJ, Rochtchina E, Smith W, Klein R, Klein BE, Joshi T, Sivakumaran TA, Iyengar S, Mitchell P. Combined effects of complement factor H genotypes, fish consumption, and inflammatory markers on long-term risk for age-related macular degeneration in a cohort. American Journal of Epidemiology 2009;169(5):&amp;nbsp;633-641.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19074778" target="_blank"&gt;[PubMed abstract 19074778]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Liew G, Mitchell P, Wong TY, Iyengar SK, Wang JJ. CKD increases the risk of age-related macular degeneration. Journal of the American Society of Nephrology 2008;19(4):806-811.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18216312" target="_blank"&gt;[PubMed abstract 18216312]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors&amp;nbsp;: Smoking&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Cong R, Zhou B, Sun Q, Gu H, Tang N, Wang B. Smoking and the risk of age-related macular degeneration: a meta-analysis. Annals of Epidemiology 2008;18(8)647-656. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18652983" target="_blank"&gt;[PubMed abstract 18652983]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lois N, Abdelkader E, Reglitz K, Garden C, Ayres JG. Environmental tobacco smoke exposure and eye disease. British Journal of Ophthalmology 2008;92(10):1304-1310. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18658170" target="_blank"&gt;[PubMed abstract 18658170]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Tuo J, Ross RJ, Reed GF, Yan Q, Wang JJ, Bojanowski CM, Chew EY, Feng X, Olsen TW, Ferris FL, Mitchell P, Chan CC. The HtrA1 promoter polymorphism, smoking, and age-related macular degeneration in multiple case-control samples. Ophthalmology 2008;115(11):1891-1898.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18718667" target="_blank"&gt;[PubMed abstract 18718667]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors&amp;nbsp;: Diet and Nutrition&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Evans JR, Henshaw KS. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD000253. DOI: 10.1002/14651858.CD000253.pub2. &lt;A href="nelh:236522:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Evans J. Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis. Eye 2008;22(6):751-760. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18425071" target="_blank"&gt;[PubMed abstract 18425071]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Parekh N. Dietary fats and age-related macular degeneration. Topics in Clinical Nutrition. 2008;23(4):347-357.&lt;/P&gt;
&lt;P&gt;Chong EWT, Kreis AJ, Wong TY, Simpson JA, Guymer RH. Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: A systematic review and meta-analysis. Archives of Ophthalmology 2008;126(6)826-33. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18541848" target="_blank"&gt;[PubMed abstract 18541848]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Carpentier S, Knaus M, Suh M. Associations between lutein, zeaxanthin, and age-related macular degeneration: an overview. Critical Reviews in Food Science &amp;amp; Nutrition 2009;49(4):313-326. &lt;A href="http://www.informaworld.com/smpp/content~db=all~content=a908799934" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chong EW, Simpson JA, Robman LD, Hodge AM, Aung KZ, English DR, Giles GG, Guymer RH. Red meat and chicken consumption and its association with age-related macular degeneration. American Journal of Epidemiology 2009;169(7):867-876. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19234096" target="_blank"&gt;[PubMed abstract 19234096]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kaushik S, Wang JJ, Flood V, Tan JS, Barclay AW, Wong TY, Brand-Miller J, Mitchell P. Dietary glycemic index and the risk of age-related macular degeneration.&amp;nbsp;American Journal of Clinical Nutrition&lt;BR&gt;2008;88(4):1104&amp;nbsp;1110. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18842800" target="_blank"&gt;[PubMed abstract 18842800]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;SanGiovanni JP, Chew EY, Agron E, Clemons TE, Ferris FL, Gensler G, Lindblad AS, Milton RC, Seddon JM, Klein R, Sperduto RD, Age-Related Eye Disease Study Research Group. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Archives of Ophthalmology 2008;126(9):1274-1279. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18779490" target="_blank"&gt;[PubMed abstract 18779490]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Augood C, Chakravarthy U, Young I, Vioque J, de Jong PT, Bentham G, Rahu M, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vingerling JR, Fletcher AE. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. American Journal of Clinical Nutrition 2008;88(2):398-406. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18689376" target="_blank"&gt;[PubMed abstract 18689376]&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Cho E, Hankinson SE, Rosner B, Willett WC, Colditz GA. Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration. American Journal of Clinical Nutrition 2008; 87(6):1837-1843. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18541575" target="_blank"&gt;[PubMed abstract 18541575]&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.ajcn.org/cgi/reprint/87/6/1837" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Fletcher AE, Bentham GC, Agnew M, Young IS, Augood C, Chakravarthy U, de Jong PT, Rahu M, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vingerling JR, Vioque J. Sunlight exposure, antioxidants, and age-related macular degeneration. Archives of Ophthalmology 2008;126(10):1396-1403. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18852418" target="_blank"&gt;[PubMed abstract 18852418]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;SanGiovanni JP, Agron E, Clemons TE, Chew EY. Omega-3 long-chain polyunsaturated fatty acid intake inversely associated with 12-year progression to advanced age-related macular degeneration. Archives of Ophthalmology 2009; 127(1):110-112. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19139352" target="_blank"&gt;[PubMed abstract 19139352]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors: Alcohol&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Boekhoorn SS, Vingerling JR, Hofman A, de Jong PT. Alcohol consumption and risk of aging macula disorder in a general population: the Rotterdam Study. Archives of Ophthalmology 2008; 126(6):834-839. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18541849" target="_blank"&gt;[PubMed abstract 18541849]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors: Cardiovascular&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Archives of Internal Medicine 2009;169(4):335-341.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19237716" target="_blank"&gt;[PubMed abstract 19237716]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies &lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Nguyen-Khoa BA, Goehring EL, Werther W, Gower EW, Do DV;Jones JK. Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Archives of Ophthalmology 2008;126(9):1280-1286. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18779491" target="_blank"&gt;[PubMed abstract 18779491]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors&amp;nbsp;- Cataract Surgery&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bockelbrink A, Roll S, Ruether K, Rasch A, Greiner W, Willich SN.&lt;BR&gt;Cataract Surgery and the Development or Progression of Age-related Macular Degeneration: A Systematic Review. Survey of Ophthalmology 2008;53(4):359-367. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18572053" target="_blank"&gt;[PubMed abstract 18572053]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chew EY, Sperduto RD, Milton RC, Clemons TE, Gensler GR, Bressler SB, Klein R, Klein BE, Ferris FL. Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25. Ophthalmology 2009;116(2):297-303. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19091420" target="_blank"&gt;[PubMed abstract 19091420]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Ho L, Boekhoorn SS, Liana, van Duijn CM, Uitterlinden AG, Hofman A, de Jong PT, Stijnen T, Vingerling JR. Cataract surgery and the risk of aging macula disorder: the rotterdam study. Investigative Ophthalmology &amp;amp; Visual Science 2008;49(11):4795-4800. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18599571" target="_blank"&gt;[PubMed abstract 18599571]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Genetics&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Boekhoorn SS, Isaacs A, Uitterlinden AG, van Duijn CM, Hofman A, de Jong PT, Vingerling JR. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology 2008;115(11):1899-1903. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18708255" target="_blank"&gt;[PubMed abstract 18708255]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18704199" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;Klein R, Knudtson MD, Klein BE, Wong TY, Cotch MF, Liu K, Cheng CY, Burke GL, Saad MF, Jacobs DR, Sharrett AR. Inflammation, complement factor h, and age-related macular degeneration: the Multi-ethnic Study of Atherosclerosis. Ophthalmology 2008;115(10):1742-1749. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18538409" target="_blank"&gt;[PubMed abstract 18538409]&lt;/A&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Despriet DD, van Duijn CM, Oostra BA, Uitterlinden AG, Hofman A, Wright AF, ten Brink JB, Bakker A, de Jong PT, Vingerling JR, Bergen AA, Klaver CC. Complement component C3 and risk of age-related macular degeneration. Ophthalmology 2009;116(3)474-480. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19168221" target="_blank"&gt;[PubMed abstract 19168221]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19019448" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevalence &amp;amp; Incidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Kawasaki R, Wang JJ, Ji GJ, Taylor B, Oizumi T, Daimon M, Kato T, Kawata S, Kayama T, Tano Y, Mitchell P, Yamashita H, Wong TY. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 2008;115(8):1376-1381. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18222000" target="_blank"&gt;[PubMed abstract 18222000]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kawasaki R, Wang JJ, Aung T, Tan DT, Mitchell P, Sandar M, Saw SM, Wong TY, Singapore Malay Eye Study Group. Prevalence of age-related macular degeneration in a Malay population: the Singapore Malay Eye Study. Ophthalmology 2008;115(10):1735-1741. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18439679" target="_blank"&gt;[PubMed abstract 18439679]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Klein R, Knudtson MD, Lee KE, Gangnon RE, Klein BE. Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2008;115(9):1460-1467. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18762073" target="_blank"&gt;[PubMed abstract 18762073]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Co-morbidities&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Tan JS, Wang JJ, Liew G, Rochtchina E, Mitchell P. Age-related macular degeneration and mortality from cardiovascular disease or stroke. British Journal of Ophthalmology 2008;92(4):509-512. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18310310" target="_blank"&gt;[PubMed abstract 18310310]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Seitzman RL, Mangione C, Ensrud KE,&amp;nbsp;Cauley JA, Stone KL, Cummings SR, Hochberg MC, Hillier TA, Yu F, Coleman AL. Postmenopausal hormone therapy and age-related maculopathy in older women. Ophthalmic Epidemiology 2008;15:(5)308-316. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18850467" target="_blank"&gt;[PubMed abstract 18850467]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Social Implications&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Tournier M, Moride Y, Lesk M, Ducruet T, Rochon S. The depletion of susceptibles effect in the assessment of burden-of-illness: the example of age-related macular degeneration in the community-dwelling elderly population of Quebec. Canadian Journal of Clinical Pharmacology/Journal Canadien de Pharmacologie Clinique 2008;15(1):e22-e35. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18579928" target="_blank"&gt;[PubMed abstract 18579928]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methodology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publication&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Wong TY, Hyman L. Population-Based Studies in Ophthalmology.&amp;nbsp; American Journal of Ophthalmology 2008;146(5):656-663. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18984085" target="_blank"&gt;[PubMed abstract 18984085]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reporting Quality&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publication&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Fung AE, Palanki R, Bakri SJ, Depperschmidt E, Gibson A. Applying the CONSORT and STROBE Statements to Evaluate the Reporting Quality of Neovascular Age-related Macular Degeneration Studies. Ophthalmology 2009;116(2):286-296. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19091408" target="_blank"&gt;[PubMed abstract 19091408]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ongoing Trials&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Guymer RH, Dimitrov PN, Varsamidis M, Lim LL, Baird PN, Vingrys AJ, Robman L. Can HMG Co-A reductase inhibitors ('statins') slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS). Clinical Interventions In Aging&lt;BR&gt;2008;3(3):581-593.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18982929" target="_blank"&gt;[PubMed abstract 18982929]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/AMD%20AEU%202009%20-%20Journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315031</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315031]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Evidence Tree</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/test/aeu_amd_0609/aeu_amd_0609_doc1.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/entire_evidence_tree.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:287613:0" name=internalLink&gt;Please click here to view 2008 AEU evidence tree section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Evidence tree for whole AEU" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID315031/nelhImp_0000_evsl_topic_tree_1.jpg" width=650 height=869&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/AMD%20AEU%202009%20-%20Journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315030</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315030]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Genetics and age-related macular degeneration</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Genetics and age-related macular degeneration&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0609/aeu_amd_0609_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/Genetics%20and%20AMD.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:286964:0" name=internalLink&gt;Please click here to view 2008 AEU&amp;nbsp;genetics section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date ; NHS Evidence - eyes and vision&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 2 May 2008 to 11 May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; NHS Evidence Health Information Resources, Healthcare Databases&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Genetics and AMD evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID315030/nelhImp_0000_evsl_topic__gen_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publication&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Patel N, Adewoyin T, Chong NV. Age-related macular degeneration: a perspective on genetic studies. Eye 2008;22(6):768-776. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17491602" target="_blank"&gt;[PubMed abstract 17491602]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Nitsch D, Douglas I, Smeeth L, Fletcher A. Age-related macular degeneration and complement activation-related diseases: a population-based case-control study. Ophthalmology 2008;115(11):1904-1910. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18801575" target="_blank"&gt;[PubMed 18801575]&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Ng TK, Chen LJ, Liu DT, Tam PO, Chan WM, Liu K, Hu YJ, Chong KK, Lau CS, Chiang SW, Lam DS, Pang CP. Multiple gene polymorphisms in the complement factor h gene are associated with exudative age-related macular degeneration in chinese. Investigative Ophthalmology &amp;amp; Visual Science 2008;49(8):3312-3317. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18421087" target="_blank"&gt;[PubMed abstract 18421087]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kim IK, Ji F, Morrison MA, Adams S, Zhang Q, Lane AM, Capone A, Dryja TP, Ott J, Miller JW, DeAngelis MM. Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration. Molecular Vision 2008;14:1487-1495. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18704199" target="_blank"&gt;[PubMed abstract 18704199]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hogg RE, Dimitrov PN, Dirani M, Varsamidis M, Chamberlain MD, Baird PN, Guymer RH, Vingrys AJ. Gene-environment interactions and aging visual function: a classical twin study. Ophthalmology 2009;116(2):263-269. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19019448" target="_blank"&gt;[PubMed abstract 19019448]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/AMD%20AEU%202009%20-%20Journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315038</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315038]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Guidelines</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Guidelines&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following guidelines have been published since the 2008 AMD evidence update:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;National Institute for Health and Clinical Excellence (NICE)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:293082:0" name=internalLink&gt;Ranibizumab and pegaptanib for the treatment of age-related macular degeneration - August 2008&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:293210:0" name=internalLink&gt;
&lt;P&gt;Implantation of miniature lens systems for advanced age-related macular degeneration - August 2008&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Royal College of Ophthalmologists &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:223921:0" name=internalLink&gt;Age-related macular degeneration guidelines for management - February 2009&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:274436:0" name=internalLink&gt;The Intravitreal use of Bevacizumab (Avastin) in Age Related Macular Degeneration - February 2009&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:289318:0" name=internalLink&gt;Ranibizumab: the clinician’s guide to commencing, continuing and discontinuing treatment - June 2008&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to 2009 AMD Annual Evidence Update&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315032</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315032]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Living with AMD</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Living with AMD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0609/aeu_amd_0609_doc8.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/Living%20with%20AMD.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:286954:0" name=internalLink&gt;Please click here to view 2008 AEU&amp;nbsp;living with AMD&amp;nbsp;section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date ; NHS Evidence - eyes and vision&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 2 May 2008 to 11 May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; NHS Evidence Health Information Resources, Healthcare Databases&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Living with AMD evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID315032/nelhImp_0000_evsl_topic__living_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Lee L, Packer TL, Tang SH, Girdler S. Self-management education programs for age-related macular degeneration: a systematic review. Australasian Journal on Ageing 2008;27(4):170-176. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19032617" target="_blank"&gt;[PubMed abstract 19032617]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Owsley C, McGwin G. Driving and age-related macular degeneration. Journal of Visual Impairment &amp;amp; Blindness 2008;102(10):621-636. &lt;A href="http://www.afb.org/jvib/jvibabstractNew.asp?articleid=jvib021007" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Finger RP, Fleckenstein M, Holz FG, Scholl HP,&amp;nbsp;Quality of life in age-related macular degeneration: a review of available vision-specific psychometric tools. Quality of Life Research 2008;17(4):559-574. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18365767" target="_blank"&gt;[PubMed abstract 18365767]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Eklund K, Sjostrand J, Dahlin-Ivanoff S. A randomized controlled trial of a health-promotion programme and its effect on ADL dependence and self-reported health problems for the elderly visually impaired. Scandinavian Journal of Occupational Therapy 2008;15(2):68-74. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17852958" target="_blank"&gt;[PubMed abstract 17852958]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Rovner BW, Casten RJ. Preventing late-life depression in age-related macular degeneration. American Journal of Geriatric Psychiatry 2008; 16(6):454-459 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18515689" target="_blank"&gt;[PubMed abstract 18515689]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Warrian KJ, Lorenzana LL, Lankaranian D, Dugar J, Wizov SS, Spaeth GL.&amp;nbsp;Assessing age-related macular degeneration with the ADREV performance-based measure. Retina 2009;29(1):80-90. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18854790" target="_blank"&gt;[PubMed abstract 18854790]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Khan JC, Shahid H, Thurlby DA, Yates JR, Moore AT. Charles Bonnet syndrome in age-related macular degeneration: the nature and frequency of images in subjects with end-stage disease. Ophthalmic Epidemiology 2008;15(3):202-208 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18569816" target="_blank"&gt;[PubMed abstract 18569816]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Szabo SM, Janssen PA, Khan K, Potter MJ, Lord SR. Older women with age-related macular degeneration have a greater risk of falls: a physiological profile assessment study. Journal of the American Geriatrics Society 2008;56(5):800-807. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18363677" target="_blank"&gt;[PubMed abstract 18363677]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lamoureux EL, Pallant JF, Pesudovs K, Tennant A, Rees G, O'Connor PM, Keeffe JE. Assessing participation in daily living and the effectiveness of rehabiliation in age related macular degeneration patients using the impact of vision impairment scale. Ophthalmic Epidemiology&amp;nbsp;2008;15(2):105-113. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18432494" target="_blank"&gt;[PubMed abstract 18432494]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Wysong A, Lee PP, Sloan FA. Longitudinal incidence of adverse outcomes of age-related macular degeneration. Archives of Ophthalmology 2009;127(3):320-327. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19273797" target="_blank"&gt;[PubMed abstract 19273797]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/AMD%20AEU%202009%20-%20Journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315033</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315033]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Low Vision Aids and AMD</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Low Vision Aids and AMD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0609/aeu_amd_0609_doc7.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/Low%20vision%20aids%20and%20AMD.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:286966:0" name=internalLink&gt;Please click here to view 2008 AEU low vision aids section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date ; NHS Evidence - eyes and vision &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 2 May 2008 to 11 May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; NHS Evidence Health Information Resources, Healthcare Databases&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Low vision aids and AMD evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID315033/nelhImp_0000_evsl_topic__low_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Hooper P, Jutai JW, Strong G, Russell-Minda E. Age-related macular degeneration and low-vision rehabilitation: A systematic review. Canadian Journal of Ophthalmology 2008;43(2):180-187 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18347620" target="_blank"&gt;[PubMed abstract 18347620]&lt;/A&gt;&amp;nbsp;&lt;A href="http://article.pubs.nrc-cnrc.gc.ca/RPAS/rpv?hm=HInit&amp;amp;calyLang=eng&amp;amp;journal=cjo&amp;amp;volume=43&amp;amp;afpf=i08-001.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/AMD%20AEU%202009%20-%20Journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315034</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315034]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Retinal imaging for diagnosis</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Retinal imaging for diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0609/aeu_amd_0609_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/Retinal%20screening%20for%20diagnosis.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:286908:0" name=internalLink&gt;Please click here to view 2008 AEU&amp;nbsp;retinal imaging&amp;nbsp;section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date ; NHS Evidence - eyes and vision&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 2 May 2008 to 11 May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; NHS Evidence Health Information Resources, Healthcare Databases&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Retinal imaging for diagnosis evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID315034/nelhImp_0000_evsl_topic__img_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Secondary publications&lt;BR&gt;&lt;/EM&gt;Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration. Health Technology Assessment (Winchester, England) 2008;12(27 iii): 124 &lt;A href="nelh:289063:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Autofluoresence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Secondary publication&lt;/EM&gt;&lt;BR&gt;Schmitz-Valckenberg S, Fleckenstein M, Scholl HPN, Holz FG. Fundus Autofluorescence and Progression of Age-related Macular Degeneration. Survey of Ophthalmology 2009;54(1):96-117. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19171212" target="_blank"&gt;[PubMed abstract 19171212]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Microperimetry - diagnosis and monitoring&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Secondary publication&lt;BR&gt;&lt;/EM&gt;Rohrschneider K, Bultmann S, Springer C. Use of fundus perimetry (microperimetry) to quantify macular sensitivity. Progress in Retinal and Eye Research 2008;27(5):536-548. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18723109" target="_blank"&gt;[PubMed abstract 18723109]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review- OCT -diagnosis and monitoring&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Secondary publication&lt;/EM&gt;&lt;BR&gt;Sakata LM, DeLeon-Ortega J, Sakata V, Girkin CA. Optical coherence tomography of the retina and optic nerve - A review. Clinical and Experimental Ophthalmology 2009;37(1):90-99. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19338607" target="_blank"&gt;[PubMed abstract 19338607]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/AMD%20AEU%202009%20-%20Journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315035</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315035]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Surgical intervention: Macular translocation</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SURGERY,SURGERY,HEAD &amp; NECK,EYE,RETINA,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Surgical intervention: Macular translocation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0609/aeu_amd_0609_doc6.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/Surgical%20intervention%20-%20macular%20translocation.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:286890:0" name=internalLink&gt;Please click here to view 2008 AEU&amp;nbsp;surgical interventions&amp;nbsp;section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date ; NHS Evidence - eyes and vision&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 2 May 2008 to 11 May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; NHS Evidence Health Information Resources, Healthcare Databases&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Surgical interventions evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID315035/nelhImp_0000_evsl_topic__surg_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary studies&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Giansanti F, Eandi CM, Virgili G. Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD006931. DOI: 10.1002/14651858.CD006931.pub2. &lt;A href="nelh:312217:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Eandi CM, Giansanti F, Virgili G. Macular translocation for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD006928. DOI: 10.1002/14651858.CD006928.pub2.&amp;nbsp;&lt;A href="nelh:295758:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chieh JJ, Stinnett SS, Toth CA. Central and pericentral retinal sensitivity after macular translocation surgery. Retina 2008;28(10):1522-1529 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18827740" target="_blank"&gt;[PubMed abstract 18827740]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Chen FK, Patel PJ, Uppal GS, Rubin GS, Coffey PJ, Aylward GW, Da CL. A comparison of macular translocation with patch graft in neovascular age-related macular degeneration. Investigative Ophthalmology &amp;amp; Visual Science 2009;50(4):1848-1855 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19060287" target="_blank"&gt;[PubMed abstract 19060287]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Joeres S, Llacer H, Heussen FM, Weiss C, Kirchhof B, Joussen AM. Optical coherence tomography on autologous translocation of choroid and retinal pigment epithelium in age-related macular degeneration. Eye 2008;22(6):782-789 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17332766" target="_blank"&gt;[PubMed abstract 17332766]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Maaijwee K, Joussen AM, Kirchhof B, van Meurs JC. Retinal pigment epithelium (RPE)-choroid graft translocation in the treatment of an RPE tear: preliminary results. British Journal of Ophthalmology 2008; 92(4):526-529 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18369068" target="_blank"&gt;[PubMed abstract 18369068]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Heussen FM, Fawzy NF, Joeres S, Lux A, Maaijwee K, Meurs JC, Kirchhof B, Joussen AM. Autologous translocation of the choroid and RPE in age-related macular degeneration: 1-year follow-up in 30 patients and recommendations for patient selection. Eye 2008;22(6):799-807 &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17641681" target="_blank"&gt;[PubMed abstract 17641681]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/AMD%20AEU%202009%20-%20Journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315036</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315036]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Therapeutic interventions : Anti-VEGF therapy</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Therapeutic interventions : Anti-VEGF therapy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/aeu_amd_0609/aeu_amd_0609_doc5.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/Therpeutic%20intervention%20-%20antiVEGF%20therapy.pdf" target="_blank"&gt;Please click here to download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:286965:0" name=internalLink&gt;Please click here to view 2008 AEU therapeutic interventions section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date ; NHS Evidence - eyes and vision&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 2 May 2008 to 11 May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; NHS Evidence Health Information Resources, Healthcare Databases&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the NHS Evidence - eyes and vision management team has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications include&lt;/STRONG&gt; Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies include&lt;/STRONG&gt; randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies include&lt;/STRONG&gt; cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Therapeutic interventions evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID315036/nelhImp_0000_evsl_topic__ther_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anti VEGF - general &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technology Assessment 2008;12(16 iii):107. &lt;A href="nelh:297609:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Dadgostar H, Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 2008;22(6):761-767. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18388961" target="_blank"&gt;[PubMed abstract 18388961]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Vedula SS, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2008, Issue 2. Art. No.: CD005139. DOI: 10.1002/14651858.CD005139.pub2. &lt;A href="nelh:283679:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. British Medical Bulletin 2008;&amp;nbsp;85:127-149. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18334518" target="_blank"&gt;[PubMed abstract 18334518]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM. Anti-Vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration. A Report by the American Academy of Ophthalmology. Ophthalmology 2008;115(10):1837-1846. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18929163" target="_blank"&gt;[PubMed abstract 18929163]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anti-VEGF - Ranibizumab (Lucentis)&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Fletcher EC, Chong NV.&amp;nbsp;Looking beyond Lucentis on the management of macular degeneration. Eye 2008;22(6):742-750. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18188178" target="_blank"&gt;[PubMed abstract 18188178]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Effectiveness and Resource Allocation 2008;6.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18573218" target="_blank"&gt;[PubMed abstract 18573218]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MARINA&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Brown MM, Brown GC, Brown HC, Peet J. A Value-Based Medicine Analysis of Ranibizumab for the Treatment of Subfoveal Neovascular Macular Degeneration. Ophthalmology&amp;nbsp;2008;115(6):1039-1045. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17976724" target="_blank"&gt;[PubMed abstract 17976724]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;ANCHOR&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of -Ophthalmology 2009;127(1):13-21. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19139332" target="_blank"&gt;[PubMed abstract 19139332]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19118696" target="_blank"&gt;[PubMed abstract 19118696]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FOCUS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group.&lt;BR&gt;Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. American Journal of Ophthalmology 2008;145(5):862-874. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18321465" target="_blank"&gt;[PubMed abstract 18321465]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anti VEGF - Bevacizumab (Avastin)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Schouten JSAG, Heij EC, Webers CAB, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 2009;247(1):1-11. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18843500" target="_blank"&gt;[PubMed abstract 18843500]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008;28(10):1387-1394. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18827735" target="_blank"&gt;[PubMed abstract 18827735]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Anti-VEGF - Pegaptanib (Macugen)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP. Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health 2008; 11(4):563-574. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18179676" target="_blank"&gt;[PubMed abstract 18179676]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional&amp;nbsp;studies&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;VISION &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Leys A, Zlateva G, Shah SN, Patel M. Quality of life in patients with age-related macular degeneration: results from the VISION study. Eye&amp;nbsp;2008;22(6):792-798. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17585313" target="_blank"&gt;[PubMed abstract 17585313]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Adverse effects - Anti VEGF&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, Klancnik J, Cooney M. Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Injections in An Office Setting. American Journal of Ophthalmology&amp;nbsp;2008;145(5):879-882. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18329624" target="_blank"&gt;[PubMed abstract 18329624]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Adverse events/Safety - Bevacizumab (Avastin)&lt;BR&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY, Qureshi S. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115(11):1911-1915. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18672291" target="_blank"&gt;[PubMed abstract 18672291]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y. Complications in patients after intravitreal injection of bevacizumab. Acta Opthalmologica 2008;86(4):372-376. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18028234" target="_blank"&gt;[PubMed abstract 18028234]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gelisken F, Ziemssen F, Voelker M, Bartz-Schmidt KU, Inhoffen W.&amp;nbsp;Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye 2009;23(3):694-702. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18239678" target="_blank"&gt;[PubMed abstract 18239678]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, Blumenkranz MS. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008;28(8):1151-1158. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18685542" target="_blank"&gt;[PubMed abstract 18685542]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clinical &amp;amp; Experimental&amp;nbsp;Ophthalmology 2008;36(3):252-256. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18412594" target="_blank"&gt;[PubMed abstract 18412594]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Adverse events/safety - Pegaptanib (Macugen)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, Goldbaum M, Katz B, Guyer D. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.&amp;nbsp; British Journal of Ophthalmology 2008;92(12):1606-1611. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18614570" target="_blank"&gt;[PubMed abstract 18614570]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0609/pdf/AMD%20AEU%202009%20-%20Journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>315037</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=315037]]&gt;</url>
    <title>AMD Annual Evidence Update 15 - 21 June 2009 : Uncertainties in the management of age-related macular degeneration</title>
    <publicationDate>2009-06-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2009]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 15 - 21 June 2009 : Uncertainties in the management of age-related macular degeneration&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to 2009 AMD AEU contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What clinical questions would you like answered on AMD?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Evidence - eyes and vision is collaborating in the development of DUETs - the Database of Uncertainties about the Effects of Treatments.&lt;/P&gt;
&lt;P&gt;DUETs has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp;&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians. &lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments 
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines 
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The following uncertainties have been identified by the DUETs team and NHS Evidence - eyes and vision team.&amp;nbsp;&amp;nbsp; Please note, in order to commence&amp;nbsp;work with&amp;nbsp;our DUETs module, we have concentrated&amp;nbsp;on addressing&amp;nbsp;one aspect of&amp;nbsp;the uncertainties that are currently surrounding AMD.&amp;nbsp;&amp;nbsp;&lt;/STRONG&gt;&lt;STRONG&gt;Over the next few months we will&amp;nbsp;identify other&amp;nbsp;uncertainties&amp;nbsp;relating to AMD. &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313208:0" name=internalLink&gt;Antioxidant multivitamin supplements in malnourished people to slow progression of age-related macular degeneration to more severe stages of the disease&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313207:0" name=internalLink&gt;Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313213:0" name=internalLink&gt;Any multivitamin or single component antioixidant supplement for age-related macular degeneration to slow or prevent progression&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:312989:0" name=internalLink&gt;Dietary antioxidants and primary prevention of age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313169:0" name=internalLink&gt;Ginkgo biloba extract for age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313212:0" name=internalLink&gt;Lutein or zeaxanthin for age-related macular degeneration to slow or prevent distance visual acuity loss or progression&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313185:0" name=internalLink&gt;Omega 3 fatty acids to halt progression of age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313182:0" name=internalLink&gt;Omega 3 fatty acids to prevent age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313209:0" name=internalLink&gt;Types of anti-oxidant multivitamin supplements used to slow or prevent progression of age-related macular degeneration important&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313210:0" name=internalLink&gt;Vitamin E for age-related macular degeneration to slow distance visual acuity change or progression&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:313211:0" name=internalLink&gt;Zinc for age-related macular degeneration to prevent progression&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;If you are aware of or identified any uncertainties in the management of AMD please let us know.&amp;nbsp; You can contact us via our &lt;/STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/feedback.asp" target="_blank"&gt;&lt;STRONG&gt;feedback form&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;.&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2009" target="_blank"&gt;Back to AEU 2009 contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>286963</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=286963]]&gt;</url>
    <title>AMD Annual Evidence Update 16 - 22 June 2008 : Epidemiology</title>
    <publicationDate>2008-06-16T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEALTH &amp; WELLBEING,LATER LIFE,SCREENING AND SURVEILLANCE,EYESIGHT,SCREENING,EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 16 - 22 June 2008 : Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/aeu_amd_0608/aue_amd_0608_doc2.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/Epidemiology.pdf" target="_blank"&gt;Please click here to&amp;nbsp;download printable&amp;nbsp;(PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260481:0" name=internalLink&gt;Click here to view 2007&amp;nbsp;NKW epidemiology&amp;nbsp;section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2008" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 28 February 2007 to 2 May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; Dialog Datastar&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Epidemiology evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID286963/nelhImp_0003_evsl_topic_epid_1_updated.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General overview of epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publication&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Klein R.&amp;nbsp; Overview of progress in the epidemiology of age-related macular degeneration.&amp;nbsp;&amp;nbsp; Ophthalmic Epidemiology, {Ophthalmic-Epidemiol}, Jul-Aug 2007, vol.14, no. 4, p. 184-7, 33 refs, ISSN: 0928-6586.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17896295" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Classification&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Zayit-Soudry S, Moroz I, Loewenstein A.&amp;nbsp; Retinal Pigment Epithelial Detachment.&amp;nbsp; Survey of Ophthalmology {SURV-OPHTHALMOL}, 2007, Vol/Iss/Pg. 52/3(227-243), ISSN: 0039-6257. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17472800" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevalence &amp;amp; Incidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Zlateva GP, Javitt JC, Shah SN, Zhou Z, Murphy JG.&amp;nbsp; Comparison of comorbid conditions between neovascular age-related macular degeneration patients&amp;nbsp;and&amp;nbsp;a control cohort in the medicare population.&amp;nbsp; Retina (Philadelphia&amp;nbsp; Pa.), {Retina-Philadelphia-Pa}, Nov-Dec 2007,vol. 27, no. 9, p. 1292-9, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18046240" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Andersen MVN, Rosenberg T, la Cour M, Kiilgaard JF, Prause JU, Alsbirk PH, Borch JK,Peto T, Carstensen B, Bird AC.&amp;nbsp; Prevalence of Age-Related Maculopathy and Age-Related Macular Degeneration among the Inuit in Greenland. The Greenland Inuit Eye Study.&amp;nbsp; Ophthalmology {OPHTHALMOLOGY},&amp;nbsp; 2008, Vol/Iss/Pg. 115/4 (700-707.e1), ISSN: 0161-6420.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18267341" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Bressler SB, Muñoz B, Solomon SD, West SK. Racial differences in&amp;nbsp; the prevalence of age-related macular degeneration: The Salisbury Eye Evaluation (SEE) Project.&amp;nbsp; Archives of Ophthalmology {ARCH-OPHTHALMOL}, 2008, Vol/Iss/Pg. 126/2(241-245), ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18268216" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gupta SK, Murthy GVS, Morrison N, Price GM, Dherani M, John N, Fletcher AE, Chakravarthy U.&amp;nbsp; Prevalence of early and late age-related macular degeneration in a rural population in Northern India: The INDEYE feasibility study.&amp;nbsp; Investigative Ophthalmology and Visual Science {INVEST-OPHTHALMOL-VIS-SCI}, 2007, Vol/Iss/Pg. 48/3 (1007-1011), ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17325139" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors&amp;nbsp;: Tobacco Smoking&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Tan JSL, Mitchell P, Kifley A, Flood V, Smith W, Wang JJ.&amp;nbsp; Smoking and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study.&amp;nbsp;&amp;nbsp; Archives of Ophthalmology, {Arch-Ophthalmol}, Aug 2007, vol. 125, no.8, p. 1089-95, ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17698756" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Neuner B, Wellmann J, Dasch B, Behrens T, Claes B, Dietzel M, Pauleikhoff D, Hense HW.&amp;nbsp; Modeling smoking history: a comparison of different approaches in the MARS study on age-related maculopathy.&amp;nbsp; Annals of Epidemiology, {Ann-Epidemiol}, Aug 2007 (epub: 25 May 2007),vol. 17, no. 8, p. 615-21, ISSN: 1047-2797.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17531503" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Klein R, Knudtson MD, Cruickshanks KJ, Klein BEK.&amp;nbsp; Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study.&amp;nbsp; Archives of Ophthalmology, {Arch-Ophthalmol}, Jan 2008, vol. 126, no.1, p. 115-21, ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18195228" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors : Diet &amp;amp; Nutrition &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Christen WG, Manson JE, Glynn RJ, Gaziano JM, Chew EY, Buring JE, Hennekens CH.&amp;nbsp; Beta carotene supplementation and age-related maculopathy in a randomized trial of US physicians.&amp;nbsp; Archives of Ophthalmology, {Arch-Ophthalmol}, Mar 2007, vol. 125, no.3, p. 333-9, ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17353403" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;O'Connell ED,&amp;nbsp;Nolan JM,&amp;nbsp;Stack J,&amp;nbsp;Greenberg D, Kyle J, Maddock L, Beatty S.&amp;nbsp; Diet and risk factors for age-related maculopathy.&amp;nbsp; The American Journal of Clinical&amp;nbsp;Nutrition, {Am-J-Clin-Nutr}, Mar 2008, vol. 87, no. 3, p. 712-22, ISSN: 0002-9165.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18326611" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Tan JSL, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P.&amp;nbsp; Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study.&amp;nbsp; Ophthalmology,&amp;nbsp; {Ophthalmology},&amp;nbsp; Feb&amp;nbsp; 2008&amp;nbsp; (epub: 30 Jul 2007), vol.115, no. 2, p. 334-41, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17664009" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Delcourt C, Carrière I, Cristol JP, Lacroux A, Gerber M.&amp;nbsp; Dietary fat and the risk of age-related maculopathy: the POLANUT study.&amp;nbsp; European Journal of Clinical Nutrition, {Eur-J-Clin-Nutr}, Nov 2007(epub: 14 Feb 2007), vol. 61, no. 11, p. 1341-4, ISSN: 0954-3007.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17299457" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Morris MS, Jacques PF, Chylack LT, Hankinson SE, Willett WC, Hubbard LD, Taylor A.&amp;nbsp; Intake of zinc and antioxidant micronutrients and early age-related maculopathy lesions.&amp;nbsp; Ophthalmic Epidemiology, {Ophthalmic-Epidemiol},&amp;nbsp; Sep-Oct 2007, vol.14, no. 5, p. 288-98, ISSN: 0928-6586.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17994438" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Chiu CJ,&amp;nbsp; Milton RC,&amp;nbsp; Klein R,&amp;nbsp; Gensler G,&amp;nbsp; Taylor A.&amp;nbsp; Dietary carbohydrate and the progression of age-related macular degeneration: a prospective study from the Age-Related Eye Disease Study.&amp;nbsp; The American Journal of Clinical Nutrition, {Am-J-Clin-Nutr}, Oct 2007, vol. 86, no. 4, p. 1210-8, ISSN: 0002-9165.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17921404" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Chiu CJ, Milton RC, Gensler G, Taylor A.&amp;nbsp; Association between dietary glycemic index and age-related macular degeneration in nondiabetic participants in&amp;nbsp; the&amp;nbsp; Age-Related Eye Disease Study.&amp;nbsp; The American Journal of Clinical Nutrition, {Am-J-Clin-Nutr}, Jul 2007, vol. 86, no. 1, p. 180-8, ISSN: 0002-9165.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17616779" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;San Giovanni JP, Chew EY, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Sperduto RD.&amp;nbsp; The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22.&amp;nbsp; Archives&amp;nbsp;of Ophthalmology, {Arch-Ophthalmol}, Sep 2007, vol. 125, no.9, p. 1225-32, ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17846363" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Alexander SL, Linde-Zwirble WT, Werther W, Depperschmidt EE, Wilson LJ, Palanki R, Saroj N, Butterworth SL, Ianchulev T.&amp;nbsp; Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology, {Ophthalmology}, Dec 2007, vol. 114, no. 12, p. 2174-8, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18054636" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors : Alcohol&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chong EWT, Kreis AJ, Wong TY, Simpson JA, Guymer RH.&amp;nbsp; Alcohol Consumption and the Risk of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.&amp;nbsp; American Journal of Ophthalmology {AM-J-OPHTHALMOL}, 2008, Vol/Iss/Pg.145/4 (707-715.e2), ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18242575" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Knudtson MD, Klein R, Klein BEK.&amp;nbsp; Alcohol consumption and the 15-year cumulative incidence of age-related macular degeneration.&amp;nbsp; American Journal of Ophthalmology, {Am-J-Ophthalmol}, Jun 2007, vol.143, no. 6, p. 1026-9, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17524768" target="_blank"&gt;[abstract]&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors : Cardiovascular &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Fraser-Bell S,&amp;nbsp; Wu J, Klein R, Azen SP, Hooper C, Foong AWP, Varma R.&amp;nbsp; Cardiovascular Risk Factors and Age-related Macular Degeneration:&amp;nbsp; The Los Angeles Latino Eye Study.&amp;nbsp;&amp;nbsp; American Journal of Ophthalmology {AM-J-OPHTHALMOL}, 2008, Vol/Iss/Pg.145/2 (308-316), ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18222193" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Tan JSL, Mitchell P, Smith W, Wang JJ.&amp;nbsp; Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study.&amp;nbsp; Ophthalmology,&amp;nbsp;{Ophthalmology},&amp;nbsp;Jun&amp;nbsp; 2007&amp;nbsp; (epub: 01 Feb 2007), vol.114, no. 6, p. 1143-50, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17275090" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors : Inflammatory markers&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Boekhoorn SS, Vingerling JR, Witteman JCM, Hofman A, de-Jong PTVM.&amp;nbsp; C-reactive protein level and risk of aging macula disorder: The Rotterdam Study.&amp;nbsp; Archives of Ophthalmology, {Arch-Ophthalmol}, Oct 2007, vol. 125, no.10, p. 1396-401, ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17923549" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors : Genetics &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Montezuma SR, Sobrin L, Seddon JM.&amp;nbsp; Review of genetics in age related macular degeneration.&amp;nbsp; Seminars in Ophthalmology {SEMIN-OPHTHALMOL}, 2007, Vol/Iss/Pg. 22/4 (229-240), eISSN: 1744-5205, ISSN: 0882-0538.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18097986" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lotery A, Trump D.&amp;nbsp; Progress in defining the molecular biology of age related macular degeneration.&amp;nbsp; Human Genetics {HUM-GENET}, 2007, Vol/Iss/Pg. 122/3-4 (219-236), ISSN:0340-6717.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17659362" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Swaroop A, Branham KE, Chen W, Abecasis G.&amp;nbsp; Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits.&amp;nbsp; Human Molecular Genetics, {Hum-Mol-Genet}, 15 Oct 2007, vol. 16 Spec No. 2, p. R174-82, 129 refs, ISSN: 0964-6906.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17911160" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Luo L, Harmon J, Yang X, Chen H, Patel S, Mineau G, Yang Z, Constantine R, Buehler J, Kaminoh Y, Ma X, Wong TY, Zhang M, Zhang K.&amp;nbsp; Familial aggregation of age-related macular degeneration in the Utah population.&amp;nbsp; Vision Research, {Vision-Res}, Feb 2008, vol. 48, no. 3, p. 494-500,ISSN: 0042-6989.&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18252239" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lin JM, Wan L, Tsai YY, Lin HJ, Tsai Y, Lee CC, Tsai CH, Tseng SH, Tsai FJ.&amp;nbsp; Pigment Epithelium Derived Factor Gene Met72Thr Polymorphism Is Associated With Increased Risk of Wet Age-related Macular Degeneration.&amp;nbsp; American Journal of Ophthalmology {AM-J-OPHTHALMOL}, 2008, Vol/Iss/Pg. 145/4 (716-721.e2), ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18226801" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hughes AE, Orr N, Patterson C, Esfandiary H, Hogg R, McConnell V, Silvestri G, Chakravarthy U.&amp;nbsp; Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking.&amp;nbsp;&amp;nbsp; PLoS Medicine {PLOS-MED}, 2007, Vol/Iss/Pg. 4/12 (1993-2000), eISSN:1549-1676, ISSN: 1549-1277.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18162041" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Jones MM, Manwaring N, Wang JJ, Rochtchina E, Mitchell P, Sue CM.&amp;nbsp; Mitochondrial DNA haplogroups and age-related maculopathy.&amp;nbsp; Archives of Ophthalmology, {Arch-Ophthalmol}, Sep 2007, vol. 125, no.9, p. 1235-40, ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17846364" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Baird PN, Robman LD, Richardson AJ, Dimitrov PN, Tikellis G, Mccarty CA, Guymer RH.&amp;nbsp; Gene-environment interaction in progression&amp;nbsp; of&amp;nbsp; AMD: The CFH gene, smoking and exposure to chronic infection.&amp;nbsp; Human Molecular Genetics {HUM-MOL-GENET}, 01 MAY 2008, Vol/Iss/Pg. 17/9 (1299-1305), eISSN: 1460-2083, ISSN: 0964-6906.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18203751" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hughes AE, Orr N, Patterson C, Esfandiary H, Hogg R, McConnell V, Silvestri G, Chakravarthy U.&amp;nbsp; Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking.&amp;nbsp; PLoS Medicine, {PLoS-Med},&amp;nbsp; Dec 2007, vol. 4, no. 12, p. e355, ISSN:1549-1676.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18162041" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Weger M, Renner W, Steinbrugger I, Köfer K, Wedrich A, Groselj-Strele A, El-Shabrawi Y, Schmut O, Haas A.&amp;nbsp; Association of the HTRA1 -625G&amp;gt;A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population.&amp;nbsp; Molecular Vision, {Mol-Vis}, 2007 (epub), vol. 13, p. 1274-9, ISSN:1090-0535.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17679948" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Pulido JS, McConnell JP, Lennon RJ, Bryant SC, Peterson LM, Berger PB, Somers V, Highsmith WE.&amp;nbsp; Relationship between age-related macular degeneration associated variants of complement factor H and LOC387715 with coronary artery disease.&amp;nbsp; Mayo Clinic Proceedings {MAYO-CLIN-PROC}, 2007, Vol/Iss/Pg.&amp;nbsp; 82/3(301-307), ISSN: 0025-6196.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17352366" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Francis PJ, George S, Schultz DW, Rosner B, Hamon S, Ott J, Weleber RG, Klein ML, Seddon JM.&amp;nbsp; The LOC387715 gene, smoking, body&amp;nbsp; mass index, environmental associations with advanced age-related macular degeneration.&amp;nbsp; Human Heredity {HUM-HERED}, 2007, Vol/Iss/Pg. 63/3-4 (212-218), ISSN: 0001-5652.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17347568" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Scott WK, Schmidt S, Hauser MA, Gallins P, Schnetz-Boutaud N, Spencer KL, Gilbert JR, Agarwal A, Postel EA, Haines JL, Pericak-Vance MA.&amp;nbsp; Independent Effects of Complement Factor H Y402H Polymorphism and Cigarette Smoking on Risk of Age-Related Macular Degeneration.&amp;nbsp; Ophthalmology {OPHTHALMOLOGY}, 2007, Vol/Iss/Pg. 114/6 (1151-1156), ISSN: 0161-6420.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17241667" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publication&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chuo JY, Wiens M, Etminan M, Maberley DAL.&amp;nbsp; Use of lipid-lowering agents for the prevention of age-related macular degeneration:&amp;nbsp; A meta-analysis of observational studies.&amp;nbsp; Ophthalmic Epidemiology {OPHTHALMIC-EPIDEMIOL}, 2007, Vol/Iss/Pg. 14/6 (367-374), eISSN: 1744-5086, ISSN: 0928-6586.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18161610" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Klein R, Knudtson MD, Klein BEK.&amp;nbsp; Statin use and the five-year incidence and progression of age-related macular degeneration.&amp;nbsp; American Journal of Ophthalmology, {Am-J-Ophthalmol}, Jul 2007 (epub: 02 May 2007), vol. 144, no. 1, p. 1-6, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17475196" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Co-morbidities&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Robman L, Mahdi OS, Wang JJ, Burlutsky G, Mitchell P, Byrne G, Guymer R, Taylor H.&amp;nbsp; Exposure to Chlamydia pneumoniae infection and age-related macular degeneration: the Blue Mountains Eye Study.&amp;nbsp; Investigative Ophthalmology &amp;amp; Visual Science, {Invest-Ophthalmol-Vis-Sci}, Sep 2007, vol. 48, no. 9, p. 4007-11, ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17724180" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Cheung N, Shankar A, Klein R, Folsom AR, Couper DJ, Wong TY.&amp;nbsp; Age-related macular degeneration and cancer mortality in the atherosclerosis risk in communities study.&amp;nbsp; Archives of Ophthalmology {ARCH-OPHTHALMOL}, 2007, Vol/Iss/Pg. 125/9(1241-1247), ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17846365" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Pham TQ, Cugati S, Rochtchina E, Mitchell P, Maloof A, Wang JJ.&amp;nbsp; Early age-related maculopathy in eyes after cataract surgery.&amp;nbsp; Eye (London England), {Eye}, Apr 2007 (epub: 27 Jan 2006), vol. 21, no. 4, p. 512-7, ISSN: 0950-222X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16440007" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/SearchHistory.pdf" target="_blank"&gt;Please click here to view search strategy for classification&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/SearchHistory_v2.pdf" target="_blank"&gt;Please click here to view search strategy for risk factors, incidence &amp;amp; prevalence&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/journal%20spread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>287613</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=287613]]&gt;</url>
    <title>AMD Annual Evidence Update 16 - 22 June 2008 : Evidence Tree</title>
    <publicationDate>2008-06-16T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEALTH &amp; WELLBEING,LATER LIFE,SCREENING AND SURVEILLANCE,EYESIGHT,SCREENING,EYES AND VISION,AMD,ANNUAL EVIDENCE UPDATES,AMD AEU 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 16 - 22 June 2008 : Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/aeu_amd_0608/aue_amd_0608_doc1.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/AMD%20AEU%20Evidence%20Tree.pdf" target="_blank"&gt;Please click here&amp;nbsp;to download printable&amp;nbsp;(PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2008" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Evidence tree for the entire AMD Annual Evidence Update&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched: &lt;/STRONG&gt;February 2007 to May 2008&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp; &lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Evidence tree for whole AMD AEU" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID287613/nelhImp_0000_evsl_topic_tree_1.jpg" width=650 height=869&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>286964</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=286964]]&gt;</url>
    <title>AMD Annual Evidence Update 16 - 22 June 2008 : Genetics and age related macular degeneration</title>
    <publicationDate>2008-06-16T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SCREENING,EYESIGHT,SCREENING AND SURVEILLANCE,LATER LIFE,HEALTH &amp; WELLBEING,AMD AEU 2008,AMD,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 16 - 22 June 2008 : Genetics and age related macular degeneration&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/aeu_amd_0608/aue_amd_0608_doc3.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/Genetics_AMD.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:262211:0" name=internalLink&gt;Click here to view 2007 NKW genetics section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2008" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 23 March 2007 to 6 May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; Dialog Datastar&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Genetics &amp;amp; AMD topic tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID286964/nelhImp_0001_evsl_topic__genetics_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Overview&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Montezuma SR, Sobrin L, Seddon JM. Review of genetics in age related macular degeneration.&amp;nbsp; Seminars in Ophthalmology, {Semin-Ophthalmol}, Oct-Dec 2007, vol. 22, no. 4, p. 229-40, 161 refs, ISSN: 0882-0538. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18097986" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Scholl HPN, Fleckenstein M, Charbel IP, Keilhauer C, Holz FG, Weber BHF.&amp;nbsp; An update on the genetics of age-related macular degeneration.&amp;nbsp; Molecular Vision, {Mol-Vis},&amp;nbsp; 2007&amp;nbsp; (epub),&amp;nbsp; vol. 13, p. 196-205, 94 refs, ISSN: 1090-0535.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17327825" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Swaroop A, Branham K, Chen W, Abecasis G.&amp;nbsp; Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits.&amp;nbsp; Human&amp;nbsp;Molecular&amp;nbsp;Genetics, {Hum-Mol-Genet}, 15 Oct 2007, vol. 16 Spec No. 2, p. R174-82, 129 refs, ISSN: 0964-6906.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17911160" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Delcourt C.&amp;nbsp; Application of nutrigenomics in eye health.&amp;nbsp; Forum of Nutrition, {Forum-Nutr}, 2007, vol. 60, p. 168-75, 62 refs,ISSN: 1660-0347.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17684413" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;DeWan A, Bracken MB, Hoh J. Two genetic pathways for age-related macular degeneration.&amp;nbsp; Current Opinion in Genetics &amp;amp; Development, {Curr-Opin-Genet-Dev}, Jun 2007&amp;nbsp; (epub:&amp;nbsp; 27&amp;nbsp; Apr 2007), vol. 17, no. 3, p. 228-33, 46 refs, ISSN:0959-437X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17467263" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Stone EM. Editor(s): Caskey, Austin, Hoxie.&amp;nbsp; Macular degeneration.&amp;nbsp; Annual Review of Medicine {ANNU-REV-MED}, 2007, Vol/Iss/Pg. 58/(477-490),&amp;nbsp; ISSN: 0066-4219, ISBN: 0824305582, 9780824305581.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16922634" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Chromosome 1q – Complement Factor H (CFH)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Schmidt CQ, Herbert AP, Hocking HG, Uhrín D, Barlow PN.&amp;nbsp; Translational Mini-Review Series on Complement Factor H: Structural and functional correlations for factor H.&amp;nbsp; Clinical and Experimental Immunology {CLIN-EXP-IMMUNOL}, 2008, Vol/Iss/Pg. 151/1 (14-24), eISSN: 1365-2249, ISSN: 0009-9104.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18081691" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;De-Córdoba SR, De-Jorge EG.&amp;nbsp; Translational Mini-Review Series on Complement Factor H: Genetics and disease associations of human complement factor H.&amp;nbsp; Clinical and Experimental Immunology {CLIN-EXP-IMMUNOL}, 2008, Vol/Iss/Pg. 151/1 (1-13), eISSN: 1365-2249, ISSN: 0009-9104.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18081690" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lotery A, Trump D.&amp;nbsp; Progress in defining the molecular biology of age related macular degeneration.&amp;nbsp; Human Genetics, {Hum-Genet}, Nov 2007 (epub: 21 Jul 2007), vol. 122,no. 3-4, p. 219-36, 198 refs, ISSN: 0340-6717.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17659362" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Richards A, Kavanagh D, Atkinson JP. Editor(s): Alt FW. Inherited Complement Regulatory Protein Deficiency Predisposes to Human Disease in Acute Injury and Chronic Inflammatory States. The Examples of Vascular Damage in Atypical Hemolytic Uremic Syndrome and Debris Accumulation in Age-Related Macular Degeneration.&amp;nbsp;&amp;nbsp; Advances in Immunology {ADV-IMMUNOL}, 2007, Vol/Iss/Pg. 96/- (141-177), ISSN: 0065-2776, ISBN: 0123737095, 9780123737090.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17981206" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Saunders RE, Abarrategui GC, Frémeaux BV, Goicoechea De-Jorge E,&amp;nbsp; Goodship THJ, López TM, Noris M, Ponce CIM, Remuzzi G, Rodríguez De-Córdoba S, Sánchez CP, Skerka C, Zipfel PF, Perkins SJ.&amp;nbsp; The interactive factor H-atypical hemolytic uremic syndrome mutation database and website:&amp;nbsp; Update&amp;nbsp; and&amp;nbsp; integration of membrane cofactor&amp;nbsp;protein and factor I mutations with structural models.&amp;nbsp; Human&amp;nbsp;Mutation {HUM-MUTAT}, 2007, Vol/Iss/Pg. 28/3 (222-234), ISSN:1059-7794. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17089378" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Williamson JF,&amp;nbsp; McLure CA,&amp;nbsp; Baird PN,&amp;nbsp; Male D, Millman J, Lawley B, Ashdown ML, Keating PJ, Dawkins RL.&amp;nbsp; Novel sequence elements define ancestral haplotypes of the region encompassing complement factor H.&amp;nbsp; Human Immunology {HUM-IMMUNOL}, 2008,&amp;nbsp; Vol/Iss/Pg.&amp;nbsp; 69/3 (207-219), ISSN: 0198-8859. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18396214" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Droz I, Mantel I, Ambresin A, Faouzi M, Schorderet DF, Munier FL.&amp;nbsp; Genotype-phenotype correlation of age-related macular degeneration: influence of complement factor H polymorphism.&amp;nbsp; The&amp;nbsp; British&amp;nbsp; Journal&amp;nbsp; of&amp;nbsp; Ophthalmology,&amp;nbsp; {Br-J-Ophthalmol}, Apr 2008(epub: 22 Jan 2008), vol.92, no.4, p.513-7, ISSN: 1468-2079.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18211923" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Shuler RK Jr, Schmidt S, Gallins P, Hauser MA, Scott WK, Caldwell J, Agarwal A, Haines JL, Pericak-Vance-MA, Postel EA.&amp;nbsp; Peripheral reticular pigmentary change is associated with complement factor H polymorphism (Y402H) in age-related macular degeneration.&amp;nbsp; Ophthalmology,&amp;nbsp;{Ophthalmology},&amp;nbsp;Mar&amp;nbsp;2008&amp;nbsp;(epub: 11 Dec 2007), vol.115, no. 3, p. 520-4, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18067970" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Spencer KL, Hauser MA, Olson LM, Schnetz-Boutaud N, Scott WK, Schmidt S, Gallins P, Agarwal A, Postel EA, Pericak-Vance MA, Haines JL.&amp;nbsp; Haplotypes spanning the complement factor H gene are protective against age-related macular degeneration.&amp;nbsp; Investigative&amp;nbsp; Ophthalmology &amp;amp; Visual Science, {Invest-Ophthalmol-Vis-&lt;BR&gt;Sci}, Sep 2007, vol. 48, no. 9, p. 4277-83, ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17724217" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Thompson CL,&amp;nbsp;&amp;nbsp; Jun-G,&amp;nbsp;&amp;nbsp; Klein BEK,&amp;nbsp;&amp;nbsp; Klein R, Capriotti J, Lee KE, Iyengar SK.&amp;nbsp; Genetics of pigment changes and geographic atrophy.&amp;nbsp; Investigative Ophthalmology &amp;amp; Visual Science, {Invest-Ophthalmol-Vis-Sci}, Jul 2007, vol. 48, no. 7, p. 3005-13, ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17591865" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Narayanan R, Butani V, Boyer DS, Atilano SR, Resende GP,&amp;nbsp; Kim DS, Chakrabarti S, Kuppermann BD, Khatibi N, Chwa M, Nesburn AB, Kenney C.&amp;nbsp; Complement factor H polymorphism in age-related macular degeneration.&amp;nbsp; Ophthalmology,&amp;nbsp;{Ophthalmology},Jul 2007 (epub: 16 Feb 2007), vol.114, no. 7, p. 1327-31, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17306880" target="_blank"&gt;[abstract]&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;Ennis S, Goverdhan S, Cree A, Hoh J, Collins A, Lotery A.&amp;nbsp; Fine-scale linkage disequilibrium mapping of age-related&amp;nbsp; macular degeneration in the complement factor H gene region.&amp;nbsp;&amp;nbsp; The&amp;nbsp;British&amp;nbsp;Journal&amp;nbsp;of&amp;nbsp; Ophthalmology,&amp;nbsp; {Br-J-Ophthalmol}, Jul 2007 (epub: 21 Feb 2007), vol. 91, no. 7, p. 966-70, ISSN: 0007-1161.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17314151" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Fisher SA, Rivera A, Fritsche LG, Babadjanova G, Petrov S, Weber BHF.&amp;nbsp; Assessment of the contribution of CFH and chromosome&amp;nbsp; 10q26 AMD susceptibility loci in a Russian population isolate.&amp;nbsp; The British&amp;nbsp; Journal of&amp;nbsp;Ophthalmology,&amp;nbsp; {Br-J-Ophthalmol}, May 2007 (epub: 18 Oct 2006), vol. 91, no. 5, p. 576-8, ISSN: 0007-1161.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17050575" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Chromosome 10q&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publication &lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Churchill AJ, Carter JG. A potential therapeutic target in age-related macular degeneration.&amp;nbsp; Therapy {THERAPY}, 2007, Vol/Iss/Pg. 4/2 (167-170), eISSN: 1744-831X, ISSN: 1475-0708.&amp;nbsp; &lt;A href="http://www.futuremedicine.com/doi/abs/10.2217/14750708.4.2.167" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Wang JJ, Ross RJ, Tuo J, Burlutsky G, Tan AG, Chan CC, Favaloro EJ, Williams A, Mitchell P.&amp;nbsp; The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study.&amp;nbsp; Ophthalmology,&amp;nbsp;{Ophthalmology},&amp;nbsp; Apr&amp;nbsp; 2008&amp;nbsp; (epub: 02 Aug 2007), vol.115, no. 4, p. 693-9, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17675241" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Shuler RK Jr,&amp;nbsp;&amp;nbsp; Schmidt S, Gallins P, Hauser MA, Scott WK, Caldwell J, Agarwal A, Haines JL, Pericak-Vance MA, Postel EA.&amp;nbsp; Phenotype analysis of patients with the risk variant LOC387715 (A69S) in age-related macular degeneration.&amp;nbsp; American&amp;nbsp;Journal of Ophthalmology, {Am-J-Ophthalmol}, Feb 2008 (epub: 03 Dec 2007), vol. 145, no. 2, p. 303-307, ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18061132" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gibbs D, Yang Z, Constantine R, Ma X, Camp NJ, Yang X, Chen H, Jorgenson A, Hau V, DeWan A, Zeng J, Harmon J, Buehler J, Brand JM, Hoh J, Cameron DJ, Dixit M, Tong Z, Zhang K.&amp;nbsp; Further mapping of 10q26&amp;nbsp; supports&amp;nbsp; strong&amp;nbsp; association&amp;nbsp; of&amp;nbsp; HTRA1 polymorphisms with age-related macular degeneration.&amp;nbsp; Vision&amp;nbsp;Research {VIS-RES}, 2008, Vol/Iss/Pg. 48/5 (685-689), ISSN:0042-6989. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18207215" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lu F, Hu J, Zhao P, Lin Y, Yang Y, Liu-X, Fan Y, Chen B, Liao S, Du-Q, Lei C, Cameron DJ, Zhang K, Yang Z.&amp;nbsp;&amp;nbsp; HTRA1 variant increases risk to neovascular age-related&amp;nbsp; macular degeneration in Chinese population.&amp;nbsp; Vision&amp;nbsp;Research, {Vision-Res}, Nov 2007 (epub: 27 Sep 2007), vol. 47, no. 24, p. 3120-3, ISSN: 0042-6989.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17904186" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Ross RJ, Bojanowski CM, Wang JJ, Chew EY, Rochtchina E, Ferris FL 3rd, Mitchell P, Chan CC, Tuo J.&amp;nbsp;&amp;nbsp; The LOC387715&amp;nbsp; polymorphism&amp;nbsp; and&amp;nbsp; age-related&amp;nbsp; macular&amp;nbsp; degeneration: Replication in three case-control samples.&amp;nbsp; Investigative Ophthalmology and Visual Science {INVEST-OPHTHALMOL-VIS-SCI}, 2007, Vol/Iss/Pg. 48/3 (1128-1132), ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17325155" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Leveziel N, Souied EH, Richard F, Barbu V, Zourdani A, Morineau G, Zerbib J, Coscas G, Soubrane G, Benlian P.&amp;nbsp;&amp;nbsp; PLEKHA1-LOC387715-HTRA1 polymorphisms and exudative age-related macular degeneration in the French population.&amp;nbsp; Molecular Vision, {Mol-Vis}, 2007 (epub), vol. 13, p. 2153-9, ISSN:1090-0535.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18079691?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kondo N, Honda S, Ishibashi K, Tsukahara Y, Negi A.&amp;nbsp; LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population.&amp;nbsp; American&amp;nbsp;Journal of Ophthalmology, {Am-J-Ophthalmol}, Oct 2007 (epub:09 Aug 2007), vol. 144, no. 4, p. 608-12, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17692272" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Cameron DJ, Yang Z, Gibbs D, Chen H, Kaminoh Y, Jorgensen A, Zeng J, Luo L, Brinton E, Brinton G, Brand JM, Bernstein PS, Zabriskie NA, Tang S, Constantine R, Tong Z, Zhang-K.&amp;nbsp; HTRA1 variant confers similar&amp;nbsp; risks&amp;nbsp; to&amp;nbsp; geographic&amp;nbsp; atrophy&amp;nbsp; and neovascular age-related macular degeneration.&amp;nbsp; Cell&amp;nbsp; Cycle&amp;nbsp; (Georgetown Tex.), {Cell-Cycle}, 2 May 2007 (epub: 16 May 2007), vol. 6, no. 9, p. 1122-5, ISSN: 1551-4005.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17426452" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other genetic factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Lin JM, Wan L, Tsai YY, Lin HJ, Tsai Y, Lee CC, Tsai CH, Tsai FJ, Tseng SH.&amp;nbsp; HTRA1 polymorphism in dry and wet age-related macular degeneration.&amp;nbsp; Retina&amp;nbsp;(Philadelphia&amp;nbsp; Pa.), {Retina-Philadelphia-Pa}, Feb 2008, vol.28, no. 2, p. 309-13, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18301036" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lin JM, Wan L, Tsai YY, Lin HJ, Tsai Y, Lee CC, Tsai CH, Tseng SH, Tsai FJ.&amp;nbsp; Pigment Epithelium-Derived Factor Gene Met72Thr Polymorphism Is Associated With Increased Risk of Wet Age-related Macular Degeneration.&amp;nbsp; American Journal of Ophthalmology {AM-J-OPHTHALMOL}, 2008, Vol/Iss/Pg.145/4 (716-721.e2), ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18226801" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kondo N, Honda S,&amp;nbsp; Ishibashi K, Tsukahara Y, Negi A.&amp;nbsp; Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.&amp;nbsp; Investigative Ophthalmology &amp;amp; Visual Science, {Invest-Ophthalmol-Vis-Sci}, Mar 2008, vol. 49, no. 3, p. 1101-5, ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18326737" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Tsai YY, Lin JM, Wan L, Lin HJ, Tsai Y, Lee CC, Tsai CH, Tsai FJ, Tseng SH.&amp;nbsp; Interleukin gene polymorphisms in age-related macular degeneration.&amp;nbsp; Investigative Ophthalmology &amp;amp; Visual Science, {Invest-Ophthalmol-Vis-Sci}, Feb 2008, vol. 49, no. 2, p. 693-8, ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18235016" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Boekhoorn SS, Vingerling JR, Uitterlinden AG, Van-Meurs JBJ, Van-Duijn CM, Pols HAP, Hofman A, De-Jong PTVM.&amp;nbsp; Estrogen receptor (alpha) gene polymorphisms associated with incident aging macula disorder.&amp;nbsp; Investigative Ophthalmology and Visual Science {INVEST-OPHTHALMOL-VIS-SCI}, 2007, Vol/Iss/Pg. 48/3 (1012-1017), ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17325140" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Richardson AJ, Islam FMA, Guymer RH, Cain M, Baird PN.&amp;nbsp; A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration.&amp;nbsp; Molecular Vision, {Mol-Vis}, 2007 (epub), vol. 13, p. 2148-52, ISSN:1090-0535.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18079689" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Maller JB,&amp;nbsp; Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM.&amp;nbsp; Variation in complement factor 3 is associated with risk of age-related macular degeneration.&amp;nbsp; Nature&amp;nbsp;Genetics,&amp;nbsp;{Nat-Genet}, Oct 2007 (epub: 02 Sep 2007), vol. 39,no. 10, p. 1200-1, ISSN: 1546-1718.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17767156" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Yates JRW, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, Clayton DG, Hayward C, Morgan J, Wright AF, Armbrecht AM, Dhillon B, Deary IJ, Redmond E, Bird AC, Moore AT.&amp;nbsp; Complement C3 variant and the risk of age-related macular degeneration.&amp;nbsp; The New England Journal of Medicine, {N-Engl-J-Med}, 9 Aug 2007 (epub:18 Jul 2007), vol. 357, no. 6, p. 553-61, ISSN: 1533-4406.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17634448" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Fisher SA, Rivera A, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Rudolph G, Weber BHF.&amp;nbsp; Case-control genetic association study of fibulin-6 (FBLN6 or HMCN1) variants in age-related macular degeneration (AMD).&amp;nbsp;&amp;nbsp;Human Mutation,&amp;nbsp; {Hum-Mutat},&amp;nbsp; Apr&amp;nbsp; 2007,&amp;nbsp; vol. 28, no. 4, p. 406-13,ISSN: 1098-1004.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17216616" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Spencer KL, Hauser MA, Olson LM, Schmidt S, Scott WK, Gallins P, Agarwal A, Postel EA, Pericak-Vance MA, Haines JL.&amp;nbsp; Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration.&amp;nbsp; Human Molecular Genetics, {Hum-Mol-Genet}, 15 Aug 2007 (epub: 18 Jun 2007), vol. 16, no. 16, p. 1986-92, ISSN: 0964-6906.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17576744" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Mori K, Horie IK, Kohda M, Kawasaki I, Gehlbach PL, Awata T, Yoneya S, Okazaki Y, Inoue S.&amp;nbsp; Association of the HTRA1 gene&amp;nbsp; variant&amp;nbsp; with&amp;nbsp; age-related&amp;nbsp; macular degeneration in the Japanese population.&amp;nbsp; Journal&amp;nbsp; of&amp;nbsp; Human&amp;nbsp; Genetics, {J-Hum-Genet}, 2007 (epub: 14 Jun 2007),vol. 52, no. 7, p. 636-41, ISSN: 1434-5161.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17568988" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Research methodology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chen X, Liu CT, Zhang M, Zhang H.&amp;nbsp; A forest-based approach to identifying gene and gene gene interactions.&amp;nbsp; Proceedings of the National Academy of Sciences of the United States of&amp;nbsp; America, {Proc-Natl-Acad-Sci-USA}, 4 Dec 2007 (epub: 28 Nov 2007), vol. 104, no. 49, p. 19199-203, ISSN: 1091-6490. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18048322" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/GeneticsSearchHistory.pdf" target="_blank"&gt;Please click here to view search strategy &lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>286954</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=286954]]&gt;</url>
    <title>AMD Annual Evidence Update 16 - 22 June 2008 : Living with AMD</title>
    <publicationDate>2008-06-16T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SCREENING,EYESIGHT,SCREENING AND SURVEILLANCE,LATER LIFE,HEALTH &amp; WELLBEING,AMD AEU 2008,AMD,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 16 - 22 June 2008 : Living with AMD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/aeu_amd_0608/aue_amd_0608_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/Living%20with%20AMD.pdf" target="_blank"&gt;Please click here to&amp;nbsp;download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:262254:0" name=internalLink&gt;Click here to view 2007&amp;nbsp;NKW living with AMD&amp;nbsp;section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2008" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 4 May 2007 to 13 May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; Dialog Datastar&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Living with AMD evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID286954/nelhImp_0000_evsl_topic__living_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Quality of Life&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Brown MM, Brown GC, Brown H. Value-based medicine and interventions for macular degeneration.&amp;nbsp; Current Opinion in Ophthalmology, 2007 May, vol. 18, no.3, p.194-200, (46 ref), ISSN: 1040-8738.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17435425" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Aspinall PA, Hill AR, Dhillon B, Armbrecht AM, Nelson P, Lumsden C,Farini-Hudson E, Brice R, Vickers A, Buchholz P.&amp;nbsp; Quality of life and relative importance: A comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration.&amp;nbsp; British Journal of Ophthalmology {BR-J-OPHTHALMOL}, 2007, Vol/Iss/Pg. 91/6 (766-772), ISSN: 0007-1161.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17229802" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lotery A, Xu-X, Zlatava G, Loftus J.&amp;nbsp; Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. The&amp;nbsp; British Journal of Ophthalmology, {Br-J-Ophthalmol}, Oct 2007 (epub: 15 May 2007), vol. 91, no. 10, p. 1303-7, ISSN: 0007-1161.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17504847" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Sahel José A, Bandello F, Augustin A, Maurel F, Negrini C, Berdeaux GH.&amp;nbsp; Health-related quality of life and utility in patients with age-related macular degeneration.&amp;nbsp; Archives of Ophthalmology,{Arch-Ophthalmol}, Jul 2007, vol. 125, no.7, p. 945-51, ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17620576" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Activities of Daily Living&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19.&amp;nbsp; Ophthalmic Epidemiology, {Ophthalmic-Epidemiol},&amp;nbsp; Jul-Aug 2007, vol.14, no. 4, p. 205-15, ISSN: 0928-6586.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17896299" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Psychological/mental health and Depression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Rovner BW, Casten RJ, Hegel MT, Leiby BE, Tasman WS.&amp;nbsp; Preventing depression in age-related macular degeneration.&amp;nbsp; Archives of General Psychiatry, {Arch-Gen-Psychiatry}, Aug 2007, vol.64, no. 8, p. 886-92, ISSN: 0003-990X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17679633" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Rovner BW,&amp;nbsp; Casten RJ, Hegel MT, Hauck WW, Tasman WS.&amp;nbsp; Dissatisfaction with performance of valued activities predicts depression in age-related macular degeneration.&amp;nbsp; International Journal of Geriatric&amp;nbsp; Psychiatry,&amp;nbsp; {Int-J-Geriatr-Psychiatry}, Aug 2007, vol. 22, no. 8, p. 789-93, ISSN: 0885-6230.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17199237" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Sun C, Tikellis G, Klein R, Steffens DC, Larsen E, Wong TY. Depressive symptoms and age-related macular degeneration in older people: the cardiovascular health study.&amp;nbsp; Ophthalmic Epidemiology, {Ophthalmic-Epidemiol},&amp;nbsp; May-Jun 2007, vol. 14, no. 3, p. 127-33, ISSN: 0928-6586.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17613847" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Wahl H, Schilling O, Becker S. Age-related macular degeneration and change in psychological control: role of time since diagnosis and functional ability.&amp;nbsp; Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 2007 Mar, vol. 62B, no. 2,&amp;nbsp; p.&amp;nbsp; P90-7, (35 ref), ISSN:1079-5014.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17379677" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic impact&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.&amp;nbsp; Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.&amp;nbsp; PharmacoEconomics, {Pharmacoeconomics}, 2008, vol. 26, no. 1, p.57-73, ISSN: 1170-7690.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18088159" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ocular comorbidity interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Lamoureux EL, Hooper CY,&amp;nbsp; Lim-L,&amp;nbsp; Pallant J,Hunt N, Keeffe JE, Guymer RH.&amp;nbsp; Impact of cataract surgery on quality of life in patients with early age-related macular degeneration.&amp;nbsp; Optometry and Vision Science: official publication of the American Academy of Optometry, {Optom-Vis-Sci}, Aug 2007, vol. 84, no. 8, p.683-8, ISSN: 1040-5488.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17700333" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/LivingWithAMDlSearchHistory.pdf" target="_blank"&gt;Please click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/journal%20spread.pdf" target="_blank"&gt;Please click here to view&amp;nbsp;journal spread&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>286966</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=286966]]&gt;</url>
    <title>AMD Annual Evidence Update 16 - 22 June 2008 : Low Vision Aids and AMD</title>
    <publicationDate>2008-06-16T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,EYESIGHT,SCREENING AND SURVEILLANCE,SCREENING,LATER LIFE,HEALTH &amp; WELLBEING,AMD AEU 2008,AMD,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 16 - 22 June 2008 : Low Vision Aids and AMD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/aeu_amd_0608/aue_amd_0608_doc5.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/Low%20Vision%20Aids%20%20AMD.pdf" target="_blank"&gt;Please click here to&amp;nbsp;download printable&amp;nbsp;(PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:262217:0" name=internalLink&gt;Click here to view 2007 NKW low vision aids&amp;nbsp;section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2008" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 26 March 2007 to 13 May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; Dialog Datastar&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Low vision aids evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID286966/nelhImp_0000_evsl_topic_low_vision_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Low Vision Aids &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational Studies&lt;/EM&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Marston JR, Loomis JM, Klatzky RL, Golledge RG.&amp;nbsp; Nonvisual route following with guidance from a simple haptic or auditory display.&amp;nbsp; Journal of Visual Impairment Blindness, 2007 Apr, vol. 101, no. 4, p.203-11, (16 ref), ISSN: 0145-482X. &lt;A href="http://www.afb.org/afbpress/pubjvib.asp?DocID=jvib0104toc" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Stelmack JA, Moran D, Dean D, Massof RW. Short- and long-term effects of an intensive inpatient vision rehabilitation program.&amp;nbsp; Arch Phys Med Rehabil 2007 Jun; 88(6):691-5, ISSN: 0003-9993. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17532888%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/VisionAidslSearchHistory.pdf" target="_blank"&gt;Please click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/journal%20spread.pdf" target="_blank"&gt;Please click here to view publication spread&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>286908</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=286908]]&gt;</url>
    <title>AMD Annual Evidence Update 16 - 22 June 2008 : Retinal imaging for diagnosis</title>
    <publicationDate>2008-06-16T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEALTH &amp; WELLBEING,LATER LIFE,SCREENING AND SURVEILLANCE,EYESIGHT,SCREENING,EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 16 - 22 June 2008 : Retinal imaging for diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/aeu_amd_0608/aue_amd_0608_doc6.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/Retinal%20imaging%20for%20diagnosis.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:261980:0" name=internalLink&gt;Click here to view 2007&amp;nbsp;NKW&amp;nbsp;retinal imaging introduction&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2008" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 9 March 2007 to&amp;nbsp;7 May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; Dialog Datastar&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Evidence tree for retinal imaging" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID286908/nelhImp_0001_evsl_topic__img_1_updated.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Fundal Autofluoresence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bartlett H, Eperjesi F. Use of fundus imaging in quantification of age-related macular change. Survey of Ophthalmology, {Surv-Ophthalmol}, Nov-Dec 2007, vol. 52, no.6, p. 655-71, 88 refs, ISSN: 0039-6257.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18029272" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Schmitz-Valckenberg S, Holz FG, Bird AC, Spaide RF. Fundus autofluorescence imaging: Review and perspectives. Retina {RETINA}, 2008, Vol/Iss/Pg.28/3 (385-409), ISSN:0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18327131" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Vaclavik V,&amp;nbsp; Vujosevic S, Dandekar SS, Bunce C,Peto T, Bird AC.&amp;nbsp; Autofluorescence imaging in age-related macular degeneration complicated by choroidal neovascularization: a prospective study.&amp;nbsp; Ophthalmology,{Ophthalmology},Feb 2008 (epub: 28 Jun 2007), vol.115,no.2,p.342-6, ISSN:1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17599415" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Vujosevic S, Vaclavik V, Bird AC, Leung I, Dandekar S, Peto T.&amp;nbsp; Combined grading for choroidal neovascularisation: colour, fluorescein angiography and autofluorescence images.&amp;nbsp; Graefe's Archive of Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie, {Graefes-Arch-Clin-Exp-Ophthalmol}, Oct 2007 (epub: 12 Apr 2007), vol. 245, no. 10, p. 1453-60, ISSN: 0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17429674" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OCT&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Drexler W, Fujimoto JG. State-of-the-art retinal optical coherence tomography.&amp;nbsp; Progress in Retinal and Eye Research, {Prog-Retin-Eye-Res}, Jan 2008 (epub: 11 Aug&amp;nbsp; 2007), vol.27, no.1, p.45-88, 181 refs, ISSN:1350-9462.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18036865" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Joeres S, Tsong JW, Updike PG, Collins AT, Dustin L, Walsh-AC, Romano PW, Sadda SR.&amp;nbsp; Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration.&amp;nbsp; Investigative Ophthalmology &amp;amp; Visual Science, {Invest-Ophthalmol-Vis-Sci}, Sep 2007, vol. 48, no. 9, p. 4300-7, ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17724220" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Coscas F, Coscas G, Souied E,&amp;nbsp; Tick S, Soubrane G.&amp;nbsp; Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration.&amp;nbsp; American Journal of Ophthalmology, {Am-J-Ophthalmol}, Oct 2007 (epub: 15 Aug 2007), vol. 144, no. 4, p. 592-9, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17698019" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Zhang N, Hoffmeyer GC, Young ES, Burns RE, Winter KP, Stinnett SS, Toth CA, Jaffe GJ.&amp;nbsp; Optical coherence tomography reader agreement in neovascular age-related macular degeneration.&amp;nbsp; American Journal of Ophthalmology,{Am-J-Ophthalmol}, Jul 2007 (epub: 23 May 2007), vol. 144, no. 1, p. 37-44, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17509508" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Talks J, Koshy Z, Chatzinikolas K. Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration. The British Journal of Ophthalmology,{Br-J-Ophthalmol}, May 2007(epub: 06 Dec 2006), vol. 91, no. 5, p. 600-1, ISSN: 0007-1161.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17151058" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Patel PJ,&amp;nbsp; Chen FK,&amp;nbsp; Ikeji F,&amp;nbsp; Xing W, Bunce C, Da-Cruz L, Tufail A.&amp;nbsp; Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration. Investigative Ophthalmology &amp;amp; Visual Science, {Invest-Ophthalmol-Vis-Sci}, Mar 2008, vol. 49, no. 3, p. 1084-8, ISSN: 0146-0404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18326734" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U.&amp;nbsp; Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation.&amp;nbsp; The British Journal of Ophthalmology, {Br-J-Ophthalmol}, Mar 2008, vol. 92, no. 3, p. 361-4, ISSN: 1468-2079.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18303157" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Michels S,&amp;nbsp; Pircher M, Geitzenauer W, Simader C, Götzinger E, Findl O,Schmidt EU, Hitzenberger CK.&amp;nbsp; Value of polarisation-sensitive optical coherence tomography in diseases affecting the retinal pigment epithelium.&amp;nbsp; The British Journal of Ophthalmology, {Br-J-Ophthalmol}, Feb 2008, vol. 92, no. 2, p. 204-9, ISSN: 1468-2079.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18227201" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Ahlers C,&amp;nbsp; Simader C, Geitzenauer W, Stock G, Stetson P, Dastmalchi S, Schmidt EU.&amp;nbsp; Automatic segmentation in three-dimensional analysis of fibrovascular pigmentepithelial detachment using high-definition optical coherence tomography.&amp;nbsp; The British Journal of Ophthalmology, {Br-J-Ophthalmol}, Feb 2008 (epub: 26 Oct 2007), vol. 92, no. 2, p. 197-203, ISSN: 1468-2079.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17965102" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT,&amp;nbsp; Walsh AC, Romano PW, Sadda SR.&amp;nbsp; Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related&amp;nbsp; macular degeneration.&amp;nbsp; Ophthalmology, {Ophthalmology}, Feb 2008 (epub: 12 Jul 2007), vol. 115, no. 2, p. 347-354.e2, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17628685" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/ImagingSearchHistory.pdf" target="_blank"&gt;Please click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/journal%20spread.pdf" target="_blank"&gt;Please click here to view publication spread&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>286890</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=286890]]&gt;</url>
    <title>AMD Annual Evidence Update 16 - 22 June 2008 : Surgical intervention: Macular Translocation</title>
    <publicationDate>2008-06-16T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,EYESIGHT,SCREENING AND SURVEILLANCE,SCREENING,LATER LIFE,SURGERY,SURGERY,HEALTH &amp; WELLBEING,EYE,HEAD &amp; NECK,AMD AEU 2008,RETINA,AMD,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 16 - 22 June 2008 : Surgical intervention: Macular Translocation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/aeu_amd_0608/aue_amd_0608_doc7.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/Surgical%20intervention%20-%20Macular%20Translocation.pdf" target="_blank"&gt;Please click here to&amp;nbsp;download printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:261333:0" name=internalLink&gt;Click here to view 2007&amp;nbsp;NKW surgical section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2008" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 9 March 2007 to 12 May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; Dialog Datastar&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Surgery evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID286890/nelhImp_0000_evsl_topic__surg_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Overview of all surgical techniques &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Falkner CI, Leitich H, Frommlet F, Bauer P, Binder S. The end of submacular surgery for age-related macular degeneration? A meta-analysis. Graefe's&amp;nbsp;Archive for Clinical and Experimental Ophthalmology {GRAEFE-S-ARCH-CLIN-EXP-OPHTHALMOL},&amp;nbsp; 2007, Vol/Iss/Pg. 245/4 (490-501), ISSN:0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16673139" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation - Overview and Rationale&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;da-Cruz L,&amp;nbsp; Chen FK,&amp;nbsp; Ahmado A,&amp;nbsp; Greenwood J,&amp;nbsp; Coffey P. RPE transplantation and its role in retinal disease.&amp;nbsp; Progress in Retinal and Eye Research, {Prog-Retin-Eye-Res}, Nov 2007 (epub:&amp;nbsp; 25&amp;nbsp; Jul&amp;nbsp; 2007),&amp;nbsp; vol.&amp;nbsp; 26,&amp;nbsp; no. 6, p. 598-635, ISSN: 1350-9462. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17920328" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Binder S, Stanzel BV, Krebs I, Glittenberg C. Transplantation of the RPE in AMD. &amp;nbsp;Progress in Retinal and Eye research, {Prog-Retin-Eye-Res}, Sep 2007 (epub:&amp;nbsp; 06&amp;nbsp; Mar&amp;nbsp; 2007),&amp;nbsp; vol.&amp;nbsp; 26,&amp;nbsp; no.&amp;nbsp; 5, p. 516-54, ISSN: 1350-9462.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17532250" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Abe T,&amp;nbsp; Yoshida M,&amp;nbsp; Yoshioka Y, Wakusawa R, Tokita-Ishikawa Y, Seto H, Tamai M, Nishida K. Iris pigment epithelial cell transplantation for degenerative retinal diseases.&amp;nbsp; Progress in Retinal and Eye Research {PROG-RETINAL-EYE-RES}, 2007, Vol/Iss/Pg. 26/3 (302-321), ISSN: 1350-9462.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17324604" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Transplantation surgery - outcomes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Tezel TH, Del-Priore LV, Berger AS, Kaplan HJ.&amp;nbsp; Adult Retinal Pigment Epithelial Transplantation in Exudative Age-related Macular Degeneration.&amp;nbsp; American Journal of Ophthalmology {AM-J-OPHTHALMOL}, 2007, Vol/Iss/Pg. 143/4 (584-595.e2), ISSN: 0002-9394. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17303061" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Treumer F, Bunse A, Klatt C, Roider J.&amp;nbsp; Autologous retinal pigment epithelium choroid sheet transplantation in age related macular degeneration: Morphogical and functional results.&amp;nbsp; British Journal of Ophthalmology {BR-J-OPHTHALMOL}, 2007, Vol/Iss/Pg. 91/3 (349-353), ISSN: 0007-1161. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17035275" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Joussen AM,&amp;nbsp; Joeres S, Fawzy N, Heussen F M A, Llacer H, van-Meurs JC, Kirchhof B.&amp;nbsp; Autologous Translocation of the Choroid and Retinal Pigment Epithelium in Patients with Geographic Atrophy.&amp;nbsp; Ophthalmology&amp;nbsp; {OPHTHALMOLOGY},&amp;nbsp; 2007,&amp;nbsp; Vol/Iss/Pg.&amp;nbsp; 114/3&amp;nbsp; (551-560), ISSN: 0161-6420. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17324697" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;MacLaren RE,&amp;nbsp;&amp;nbsp;&amp;nbsp; Uppal GS,&amp;nbsp;&amp;nbsp; Balaggan KS,&amp;nbsp;&amp;nbsp; Tufail A,&amp;nbsp;&amp;nbsp; Munro PMG, Milliken AB, Ali RR, Rubin GS, Aylward GW, da-Cruz L.&amp;nbsp; Autologous Transplantation of the Retinal Pigment Epithelium and Choroid in the Treatment of Neovascular Age-Related Macular Degeneration.&amp;nbsp; Ophthalmology {OPHTHALMOLOGY}, 2007, Vol/Iss/Pg. 114/3 (561-570.e2), ISSN: 0161-6420.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17324698" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Rabenlehner D,&amp;nbsp; Stanzel BV, Krebs I, Binder S, Goll A.&amp;nbsp; Reduction of iatrogenic RPE lesions in AMD patients: evidence for wound healing?" Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie {Graefes-Arch-Clin-Exp-Ophthalmol}, Mar 2008 (epub: 18 Aug 2007), vol. 246, no. 3, p. 345-52, ISSN: 0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17704936" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Translocation - outcomes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Ziemssen F, Lüke M, Bartz-Schmidt KU, Gelisken F. Time-dependent effects on contrast sensitivity, near and distance acuity: Difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation.&amp;nbsp; Graefe's Archive for Clinical and Experimental Ophthalmology {GRAEFE-S-ARCH-CLIN-EXP-OPHTHALMOL}, 2008, Vol/Iss/Pg. 246/5 (653-659), ISSN: 0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18071731" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lüke M,&amp;nbsp; Ziemssen F, Bartz-Schmidt KU,&amp;nbsp; Gelisken Faik. Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration - a report of 1 year results.&amp;nbsp; Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie, {Graefes-Arch-Clin-Exp-Ophthalmol}, Dec 2007 (epub: 09 Mar 2007), vol. 245, no. 12, p. 1831-6, ISSN: 0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17347809" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Uppal G,&amp;nbsp; Milliken A,&amp;nbsp; Lee J,&amp;nbsp; Acheson J, Hykin P, Tufail A, da Cruz L.&amp;nbsp; New algorithm for assessing patient suitability for macular translocation surgery. Clinical &amp;amp; Experimental Ophthalmology, {Clin-Experiment-Ophthalmol}, Jul 2007, vol. 35, no. 5, p. 448-57, ISSN: 1442-6404.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17651250" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Aisenbrey S, Bartz-Schmidt KU,&amp;nbsp; Walter P,&amp;nbsp; Hilgers RD,&amp;nbsp; Ayertey H, Szurman P, Thumann G.&amp;nbsp; Long-term follow-up of macular translocation with 360° retinotomy for exudative age-related macular degeneration.&amp;nbsp; Archives&amp;nbsp;of Ophthalmology {ARCH-OPHTHALMOL}, 2007, Vol/Iss/Pg. 125/10 (1367-1372), ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17923545" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Maaijwee K, Van-Den-Biesen PR, Missotten T, Van-Meurs JC.&amp;nbsp; Angiographic evidence for revascularization of an RPE-choroid graft in patients with age-related macular degeneration. Retina {RETINA}, 2008, Vol/Iss/Pg. 28/3 (498-503), ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18327145" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Nguyen-Nhung X,&amp;nbsp;&amp;nbsp; Besch D,&amp;nbsp; Bartz-Schmidt K,&amp;nbsp; Gelisken F, Trauzettel-Klosinski S. Reading performance with low-vision aids and vision-related quality of life after macular translocation surgery in patients with age-related macular degeneration. Acta ophthalmologica Scandinavica, {Acta-Ophthalmol-Scand}, Dec 2007 (epub: 25 Jul 2007), vol. 85, no. 8, p. 877-82, ISSN: 1600-0420.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17651462" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/SurgicalSearchHistory.pdf" target="_blank"&gt;Please click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/journal%20spread.pdf" target="_blank"&gt;Please click here to view publication spread&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>286965</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=286965]]&gt;</url>
    <title>AMD Annual Evidence Update 16 - 22 June 2008 : Therapeutic intervention: Anti-VEGF therapy</title>
    <publicationDate>2008-06-16T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEALTH &amp; WELLBEING,LATER LIFE,SCREENING AND SURVEILLANCE,EYESIGHT,SCREENING,EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD AEU 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 16 - 22 June 2008 : Therapeutic intervention: Anti-VEGF therapy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/aeu_amd_0608/aue_amd_0608_doc8.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/Therapeutic%20Intervention%20-%20Anti-VEGF%20therapy.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:262178:0" name=internalLink&gt;Click here to view 2007 NKW&amp;nbsp;therapeutic interventions&amp;nbsp;section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDAEU2008" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date ; EMBASE 1996 to date ; CINAHL 1982 to date ; AMED ; BNI 1994 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period of Search:&lt;/STRONG&gt; 14 March 2007 to 9 May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Accessed using:&lt;/STRONG&gt; Dialog Datastar&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement. We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series, population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Therapeutics evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID286965/nelhImp_0000_evsl_topic__ther_1.jpg" width=650 height=344&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General role of Anti-VEGFS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Emerson MV, Lauer AK.&amp;nbsp; Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.&amp;nbsp; BioDrugs: Clinical Immunotherapeutics Biopharmaceuticals and Gene Therapy, {BioDrugs}, 2007, vol. 21, no. 4, p. 245-57, 100 refs, ISSN:1173-8804.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17628122" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lantry LE. Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications.&amp;nbsp; Current Opinion in Molecular Therapeutics,{Curr-Opin-Mol-Ther}, Dec 2007, vol. 9, no. 6, p. 592-602, 76 refs, ISSN: 1464-8431.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18041670" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Andreoli CM, Miller JW.&amp;nbsp; Anti-vascular endothelial growth factor therapy for ocular neovascular disease.&amp;nbsp; Current Opinion in Ophthalmology, {Curr-Opin-Ophthalmol}, Nov 2007, vol. 18, no. 6, p. 502-8, 49 refs, ISSN: 1040-8738.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18163003" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Augustin AJ, Offermann I. Combination therapy for choroidal neovascularisation.&amp;nbsp; Drugs&amp;nbsp;and&amp;nbsp;Aging {DRUGS-AGING}, 2007,&amp;nbsp; Vol/Iss/Pg. 24/12 (979-990), ISSN: 1170-229X.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Understanding monoclonal antibodies.&amp;nbsp; Drug and Therapeutics Bulletin {DRUG-THER-BULL}, 2007, Vol/Iss/Pg. 45/7 (55-56), ISSN: 0012-6543.&amp;nbsp; &lt;A href="http://dtb.bmj.com/cgi/content/abstract/45/7/55" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hussain N, Ghanekar Y, Kaur I.&amp;nbsp; The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.&amp;nbsp; Indian Journal of Ophthalmology, {Indian-J-Ophthalmol}, Nov-Dec 2007,vol. 55, no. 6, p. 445-50, 56 refs, ISSN: 0301-4738.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17951902" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Azad R, Chandra P, Gupta R.&amp;nbsp; The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian Journal of Ophthalmology, {Indian-J-Ophthalmol}, Nov-Dec 2007,vol. 55, no. 6, p. 441-3, 18 refs, ISSN: 0301-4738.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17951901" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Nagpal M, Nagpal K, Nagpal PN. &amp;nbsp;A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian Journal of Ophthalmology, {Indian-J-Ophthalmol}, Nov-Dec 2007,vol. 55, no. 6, p. 437-9, 12 refs, ISSN: 0301-4738.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17951900" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;A view on new drugs for macular degeneration.&amp;nbsp; Drug and therapeutics bulletin, {Drug-Ther-Bull}, Jul 2007, vol. 45, no. 7, p. 49-52, 26 refs, ISSN: 0012-6543.&amp;nbsp; &lt;A href="http://dtb.bmj.com/cgi/reprint/45/7/49" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina (Philadelphia&amp;nbsp; Pa.), {Retina-Philadelphia-Pa}, Jun 2007, vol.27, no. 5, p. 523-34, 67 refs, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17558312" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Kaiser PK.&amp;nbsp; Verteporfin photodynamic therapy and anti-angiogenic drugs: Potential for combination therapy in exudative age-related macular degeneration.&amp;nbsp; Current Medical Research and Opinion {CURR-MED-RES-OPIN}, 2007, Vol/Iss/Pg. 23/3 (477-487), ISSN: 0300-7995.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17355729" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bevacizumab (Avastin)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary Publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology.&amp;nbsp; Indian Journal of Ophthalmology, {Indian-J-Ophthalmol}, Nov-Dec 2007, vol. 55, no. 6, p. 417-20, 53 refs, ISSN: 0301-4738.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17951896" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Meyerle CB, Freund KB, Iturralde D, Spaide RF, Sorenson JA, Slakter JS, Klancnik JM, Fisher YL, Cooney MJ, Yannuzzi LA.&amp;nbsp; Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina {RETINA}, 2007, Vol/Iss/Pg. 27/4 (451-457), ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17420697" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Lazic R, Gabric N.&amp;nbsp; Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.&amp;nbsp; Ophthalmology, {Ophthalmology}, Jun 2007, vol. 114, no. 6, p. 1179-85, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17544776" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Brantley MA Jr,&amp;nbsp;Fang AM,&amp;nbsp;King JM,&amp;nbsp;Tewari A, Kymes SM, Shiels A.&amp;nbsp; Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.&amp;nbsp; Ophthalmology,&amp;nbsp;{Ophthalmology},&amp;nbsp;Dec&amp;nbsp; 2007,&amp;nbsp;vol. 114, no. 12,&amp;nbsp;p.2168-73, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18054635" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M,&amp;nbsp;Dehghan MH, Moradian S.&amp;nbsp; Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.&amp;nbsp; BMC Ophthalmology, {BMC-Ophthalmol}, 2007 (epub), vol. 7, p. 10, ISSN:1471-2415.&amp;nbsp;&amp;nbsp; [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17555600" target="_blank"&gt;abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://www.biomedcentral.com/content/pdf/1471-2415-7-10.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Chen CY, Wong TY, Heriot WJ.&amp;nbsp; Intravitreal Bevacizumab (Avastin) for Neovascular Age-related Macular Degeneration: A Short-term Study.&amp;nbsp; American Journal of Ophthalmology {AM-J-OPHTHALMOL}, 2007, Vol/Iss/Pg.143/3 (510-512), ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17317398" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bevacizumab (Avastin) - outcomes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Lynch SS, Cheng CM.&amp;nbsp; Bevacizumab for neovascular ocular diseases.&amp;nbsp; The&amp;nbsp;Annals of Pharmacotherapy, {Ann-Pharmacother}, Apr 2007 (epub: 13 Mar 2007), vol. 41, no. 4, p. 614-25, 69 refs, ISSN: 1542-6270.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17355998" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Goff MJ,&amp;nbsp;&amp;nbsp; Johnson RN,&amp;nbsp; McDonald HR,&amp;nbsp; Ai E, Jumper JM, Fu A.&amp;nbsp; Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.&amp;nbsp; Retina (Philadelphia&amp;nbsp; Pa.), {Retina-Philadelphia-Pa},&amp;nbsp; Apr-May 2007,vol. 27, no. 4, p. 432-8, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17420694" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bashshur ZF,&amp;nbsp;&amp;nbsp; Haddad ZA,&amp;nbsp; Schakal A,&amp;nbsp; Jaafar RF, Saab M, Noureddin BN.&amp;nbsp; Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.&amp;nbsp; American Journal of Ophthalmology, {Am-J-Ophthalmol}, Feb 2008 (epub: 11 Dec 2007), vol. 145, no. 2, p. 249-256, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18067876" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Weigert G,&amp;nbsp;&amp;nbsp; Michels S,&amp;nbsp;&amp;nbsp; Sacu S,&amp;nbsp; Varga A,&amp;nbsp; Prager F,&amp;nbsp; Geitzenauer W, Schmidt-Erfurth U.&amp;nbsp; Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.&amp;nbsp; The British Journal of Ophthalmology, {Br-J-Ophthalmol}, Mar 2008, vol. 92, no. 3, p. 356-60, ISSN: 1468-2079. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18303156" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp;&lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN.&amp;nbsp; Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.&amp;nbsp; Archives of Ophthalmology, {Arch-Ophthalmol}, Oct 2007, vol. 125, no. 10, p. 1357-61, ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17923543" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp;&lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Jonas JB, Spandau UH, Schlichtenbrede F. Short term complications of intravitreal injections of triamcinolone and bevacizumab.&amp;nbsp; Eye {EYE}, 2008, Vol/Iss/Pg. 22/4 (590-591), eISSN: 1476-5454, ISSN:0950-222X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18292795" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Colucciello M.&amp;nbsp; Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: short-term optical coherence tomography results.&amp;nbsp; Journal of Ocular Pharmacology and Therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics, {J-Ocul-Pharmacol-Ther}, Feb 2008, vol. 24, no. 1, p. 15-24, ISSN: 1080-7683.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18201136" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Cleary CA,&amp;nbsp; Jungkim S,&amp;nbsp; Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M.&amp;nbsp; Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.&amp;nbsp; Eye {EYE}, 2008,&amp;nbsp; Vol/Iss/Pg.&amp;nbsp; 22/1 (82-86), eISSN: 1476-5454, ISSN:0950-222X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17891059" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ.&amp;nbsp; Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): Results of the pan-american collaborative retina study group(PACORES).&amp;nbsp; Graefe's Archive for Clinical and Experimental Ophthalmology {GRAEFES-ARCH-CLIN-EXP-OPHTHALMOL}, 2008, Vol/Iss/Pg.&amp;nbsp; 246/1 (81-87), ISSN:0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17674014" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Goverdhan SV, Lochhead J.&amp;nbsp; Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration.&amp;nbsp;&amp;nbsp; The British Journal of Ophthalmology, {Br-J-Ophthalmol}, Feb 2008 (epub: 26 Oct 2007), vol. 92, no. 2, p. 210-2, ISSN: 1468-2079.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17965104" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Ladewig MS,&amp;nbsp; Karl SE, Hamelmann V, Helb HM, Scholl HPN, Holz FG, Eter N.&amp;nbsp; Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.&amp;nbsp; Graefe's Archive for Clinical and Experimental Ophthalmology {GRAEFE-S-ARCH-CLIN-EXP-OPHTHALMOL}, 2008, Vol/Iss/Pg.&amp;nbsp; 246/1 (17-25), ISSN:0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17701197" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Arias L, Caminal JM, Rubio M, Pujol O, Arruga J. Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization.&amp;nbsp; European Journal of Ophthalmology, {Eur-J-Ophthalmol}, Nov-Dec 2007,vol. 17, no. 6, p. 992-5, ISSN: 1120-6721.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18050131" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Pedersen R, Soliman W, Lund AH, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab.&amp;nbsp; Acta Ophthalmologica Scandinavica, {Acta-Ophthalmol-Scand}, Aug 2007&lt;BR&gt;(epub: 18 May 2007), vol. 85, no. 5, p. 526-33, ISSN: 1395-3907.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17511757" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Jonas JB, Libondi T, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Sauder G, SpandauUHM.&amp;nbsp; Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmologica Scandinavica, {Acta-Ophthalmol-Scand}, Aug 2007(epub: 27 Feb 2007), vol. 85, no. 5, p. 563-5, ISSN: 1395-3907.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17324219" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J.&amp;nbsp; Short-term intraocular pressure changes after intravitreal injection of bevacizumab.&amp;nbsp; Canadian Journal of Ophthalmology {CAN-J-OPHTHALMOL}, 2007, Vol/Iss/Pg. 42/6 (807-811), ISSN: 0008-4182.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18026202" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Stifter E, Michels S, Prager F, Georgopoulos M, Polak K, Hirn C, Schmidt-Erfurth U.&amp;nbsp; Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.&amp;nbsp; American&amp;nbsp; Journal of Ophthalmology, {Am-J-Ophthalmol}, Dec 2007 (epub: 04 Oct 2007), vol. 144, no. 6, p. 886-892, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17916314" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU.&amp;nbsp; Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.&amp;nbsp; Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv&amp;nbsp; für&amp;nbsp; klinische&amp;nbsp; und&amp;nbsp; experimentelle Ophthalmologie,{Graefes-Arch-Clin-Exp-Ophthalmol}, Jul 2007 (epub: 21 Dec 2006), vol. 245, no. 7, p. 941-8, ISSN: 0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17186262" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Falkenstein IA,Cheng L,Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).&amp;nbsp; Retina&amp;nbsp; (Philadelphia&amp;nbsp; Pa.),&amp;nbsp; {Retina-Philadelphia-Pa}, Oct 2007, vol. 27, no. 8, p. 1044-7, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18040242" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bevacizumab (Avastin) - complications&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Lazic R, Gabric N.&amp;nbsp; Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.&amp;nbsp; Graefe's Archive for Clinical and Experimental Ophthalmology {GRAEFE-S-ARCH-CLIN-EXP-OPHTHALMOL}, 2007, Vol/Iss/Pg.&amp;nbsp; 245/1 (68-73), ISSN:0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17111146" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi ASD, Kokame GT, Lin-Steven-G,&amp;nbsp; Rauser ME, Kaiser PK. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.&amp;nbsp; Retina&amp;nbsp;(Philadelphia&amp;nbsp; Pa.),&amp;nbsp;{Retina-Philadelphia-Pa}, Jun 2007, vol.27, no. 5, p. 541-51, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17558314" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Ronan SM, Yoganathan P, Chien FY, Corcóstegui IA, Blumenkranz MS, Deramo VA, Elner SG,Fastenberg DA, Johnson MW, López M, Mateo C, Moshfeghi DM, Navarro R, Rosenblatt BJ, Sanislo SR, Saxe SJ, Zacks DN.&amp;nbsp; Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.&amp;nbsp; Retina (Philadelphia&amp;nbsp; Pa.), {Retina-Philadelphia-Pa}, Jun 2007, vol.27, no. 5, p. 535-40, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17558313" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Jonas JB,&amp;nbsp;Spandau UH, Rensch F,&amp;nbsp;Von-Baltz S, Schlichtenbrede F.&amp;nbsp; Infectious and noninfectious endophthalmitis after intravitreal bevacizumab.&amp;nbsp; Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, {J-Ocul-Pharmacol-Ther}, Jun 2007, vol. 23, no. 3, p. 240-2, ISSN: 1080-7683.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17593007" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ranibizumab (Lucentis)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications &lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Kourlas H, Abrams P.&amp;nbsp; Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.&amp;nbsp; Clinical Therapeutics,&amp;nbsp; {Clin-Ther},&amp;nbsp; Sep&amp;nbsp; 2007,&amp;nbsp; vol.&amp;nbsp; 29, no. 9, p.1850-61, 24 refs, ISSN: 0149-2918.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18035187" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Campochiaro PA. Targeted pharmacotherapy of retinal diseases with ranibizumab.&amp;nbsp; Drugs of Today {DRUGS-TODAY}, 2007, Vol/Iss/Pg. 43/8 (529-537), ISSN:1699-4019.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17925884" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kaiser PK, Do DV. Ranibizumab for the treatment of neovascular AMD.&amp;nbsp; International Journal of Clinical Practice, {Int-J-Clin-Pract}, Mar 2007, vol. 61, no. 3, p. 501-9, 58 refs, ISSN: 1368-5031.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17313620" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Singh RP, Kaiser PK.&amp;nbsp; Role of ranibizumab in management of macular degeneration.&amp;nbsp; Indian Journal of Ophthalmology, {Indian-J-Ophthalmol}, Nov-Dec 2007,vol. 55, no. 6, p. 421-5, 33 refs, ISSN: 0301-4738.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17951897" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Blick SKA, Keating GM, Wagstaff AJ.&amp;nbsp; Ranibizumab.&amp;nbsp; Drugs, {Drugs}, 2007, vol. 67, no. 8, p. 1199-206; discussion 1207-9,29 refs, ISSN: 0012-6667.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17521219" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Zarbin M, Szirth B. Current treatment of age-related macular degeneration.&amp;nbsp; Optometry&amp;nbsp;and&amp;nbsp;Vision&amp;nbsp;Science : official publication of the American Academy&amp;nbsp; of&amp;nbsp; Optometry,&amp;nbsp; {Optom-Vis-Sci}, Jul 2007, vol. 84, no. 7, p.559-72, 81 refs, ISSN: 1040-5488.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17632299" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Singh RP, Schachat A.&amp;nbsp; Ranibizumab in the treatment of age-related macular degeneration.&amp;nbsp; Aging Health {AGING-HEALTH}, 2007,&amp;nbsp; Vol/Iss/Pg.&amp;nbsp; 3/1 (9-14), eISSN:1745-5103, ISSN: 1745-509X.&amp;nbsp; &lt;A href="http://www.futuremedicine.com/doi/abs/10.2217/1745509X.3.1.9" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Ranibizumab&lt;/STRONG&gt; (Lucentis) Outcomes&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publication&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Brown MM, Brown GC, Brown H. Value-based medicine and interventions for macular degeneration.&amp;nbsp; Current Opinion in Ophthalmology, {Curr-Opin-Ophthalmol}, May 2007,vol. 18, no. 3, p. 194-200, 46 refs, ISSN: 1040-8738.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17435425" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://www.library.nhs.uk/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bhatnagar P, Spaide RF, Takahashi BS, Peragallo JH, Freund KB, Klancnik JM, Cooney MJ, Slakter JS, Sorenson JA, Yannuzzi LA.&amp;nbsp; Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina&amp;nbsp;(Philadelphia&amp;nbsp; Pa.), {Retina-Philadelphia-Pa}, Sep 2007, vol.27, no. 7, p. 846-50, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17891007" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Pegaptanib (Macugen)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.&amp;nbsp; Ophthalmology, {Ophthalmology}, Sep 2007 (epub: 23 May 2007), vol.114, no. 9, p. 1702-12, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17509689" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Mills E, Heels-Ansdell D, Kelly S, Guyatt G.&amp;nbsp; A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects.&amp;nbsp; Journal of Clinical Epidemiology, {J-Clin-Epidemiol}, May 2007 (epub:11 Dec 2006), vol. 60, no. 5, p. 456-60, ISSN: 0895-4356.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17419956" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Earnshaw SR, Moride Y, Rochon S.&amp;nbsp; Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.&amp;nbsp; Clinical Therapeutics, {Clin-Ther}, Sep 2007, vol. 29, no. 9, p.2096-106; discussion 2094-5, ISSN: 0149-2918.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18035208" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.&amp;nbsp; Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.&amp;nbsp;&amp;nbsp;PharmacoEconomics,&amp;nbsp;{Pharmacoeconomics}, 2007, vol.25,&amp;nbsp; no. 10, p.863-79, ISSN: 1170-7690.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17887807" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.&amp;nbsp; A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.&amp;nbsp;&amp;nbsp;Ophthalmology, {Ophthalmology}, Jun 2007 (epub: 23 Feb 2007), vol.114, no. 6, p. 1170-8, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17320964" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Pegaptanib (Macugen) Outcomes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Quiram PA, Hassan TS, Williams GA.&amp;nbsp; Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.&amp;nbsp; Retina (Philadelphia&amp;nbsp; Pa.), {Retina-Philadelphia-Pa}, Sep 2007, vol. 27, no. 7, p. 851-6, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17891008" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Ehlers JP, Fintak DR, Gupta OP, Regillo CD, Fineman MS, Ho AC.&amp;nbsp; Pegaptanib for choroidal neovascularization in treatment-naïve exudative age-related macular degeneration.&amp;nbsp; Ophthalmic Surgery Lasers &amp;amp; Imaging: the official journal of the International Society for Imaging in the Eye, {Ophthalmic-Surg-Lasers-Imaging}, Sep-Oct 2007, vol. 38, no. 5, p. 371-7, ISSN: 1542-8877.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17955841" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MARINA&lt;/STRONG&gt;&amp;nbsp;&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chang TS,&amp;nbsp; Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR.&amp;nbsp; Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.&amp;nbsp; Archives of Ophthalmology, {Arch-Ophthalmol}, Nov 2007, vol. 125, no.11, p. 1460-9, ISSN: 0003-9950.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17998507" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp;&lt;A href="http://archopht.ama-assn.org/" target="_blank"&gt;[full text available via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kaiser PK, Blodi BA, Shapiro H, Acharya NR.&amp;nbsp; Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.&amp;nbsp;&amp;nbsp; Ophthalmology, {Ophthalmology}, Oct 2007 (epub: 12 Jul 2007), vol.114, no. 10, p. 1868-75, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17628683" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;ANCHOR&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR.&amp;nbsp; Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.&amp;nbsp; American&amp;nbsp;Journal of Ophthalmology, {Am-J-Ophthalmol}, Dec 2007 (epub: 22 Oct 2007), vol. 144, no. 6, p. 850-857, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17949673" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PIER &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional study&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N.&amp;nbsp; Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.&amp;nbsp; American Journal of Ophthalmology, {Am-J-Ophthalmol}, Feb 2008, vol.145, no. 2, p. 239-248, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18222192" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Ranibizumab&lt;/STRONG&gt; (Lucentis) &amp;amp; &lt;STRONG&gt;Bevacizumab&lt;/STRONG&gt; (Avastin)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Brown DM, Regillo CD.&amp;nbsp; Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.&amp;nbsp; American Journal of Ophthalmology, {Am-J-Ophthalmol}, Oct 2007, vol.144, no. 4, p.627-37, 35 refs, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17893015" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Dafer RM, Schneck M, Friberg TR, Jay WM. Intravitreal ranibizumab and bevacizumab:&amp;nbsp; a review of risk.&amp;nbsp; Seminars in Ophthalmology, {Semin-Ophthalmol}, Jul-Sep 2007, vol. 22, no.3, p.201-4, 31 refs, ISSN: 0882-0538.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17763246" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Raftery J, Clegg A, Jones J, Tan SC, Lotery A.&amp;nbsp; Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.&amp;nbsp; The British Journal of Ophthalmology, {Br-J-Ophthalmol}, Sep 2007(epub: 12 Apr 2007), vol. 91, no. 9, p. 1244-6, ISSN: 0007-1161.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17431015" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Ranibizumab&lt;/STRONG&gt; (Lucentis) &amp;amp;&amp;nbsp;Pegaptanib (Macugen)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Takeda AL, Colquitt J, Clegg AJ, Jones J.&amp;nbsp; Pegaptanib and&amp;nbsp; ranibizumab for neovascular age-related macular degeneration: a systematic review.&amp;nbsp; The British Journal of Ophthalmology, {Br-J-Ophthalmol}, Sep 2007 (epub:&amp;nbsp; 02&amp;nbsp; May&amp;nbsp; 2007), vol.91, no.9, p. 1177-82, 18 refs, ISSN:0007-1161.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17475698" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;A href="http://bjo.bmj.com/" target="_blank"&gt;[full text via Athens]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I.&amp;nbsp; Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.&amp;nbsp; Drugs &amp;amp; Aging, {Drugs-Aging}, 2007, vol. 24, no. 8, p. 643-62, 70refs, ISSN: 1170-229X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17702534" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Bevacizumab&lt;/STRONG&gt; (Avastin) &amp;amp; Pegaptanib (Macugen)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Falkenstein IA,&amp;nbsp; Cheng L,&amp;nbsp; Morrison VL, Kozak I, Tammewar AM, Freeman WR.&amp;nbsp; Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration.&amp;nbsp; Retina (Philadelphia&amp;nbsp; Pa.), {Retina-Philadelphia-Pa}, Jul-Aug 2007,vol.27, no.6, p.701-6, ISSN: 0275-004X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17621178" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bayés M, Rabasseda X, Prous JR. Gateways to Clinical Trials.&amp;nbsp; Methods and Findings in Experimental and Clinical Pharmacology {METHODS-FIND-EXP-CLIN-PHARMACOL}, 2007, Vol/Iss/Pg. 29/8 (547-583),ISSN: 0379-0355.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18040531" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/TherapeuticSearchHistory.pdf" target="_blank"&gt;Please click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_doc_0608/journal%20spread.pdf" target="_blank"&gt;Please click here to view journal spread&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>288315</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=288315]]&gt;</url>
    <title>AMD Annual Evidence Update 16 - 22 June 2008 : Uncertainties in the management of Age Related Macular Degeneration</title>
    <publicationDate>2008-06-16T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ HEALTH &amp; WELLBEING,SCREENING,EYESIGHT,SCREENING AND SURVEILLANCE,LATER LIFE,EYES AND VISION,AMD AEU 2008,ANNUAL EVIDENCE UPDATES,AMD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD Annual Evidence Update 16 - 22 June 2008 : Uncertainties in the management of Age Related Macular Degeneration&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;What clinical questions would you like answered on AMD?&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The NLH Eyes and Vision Specialist Library is collaborating in the development of DUETS – &lt;A href="http://www.duets.nhs.uk/" target="_blank"&gt;the Database of Uncertainties about the Effects of Treatments&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;DUETS has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians.&lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments &lt;/LI&gt;
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines &lt;/LI&gt;
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems.&lt;/P&gt;
&lt;P&gt;If you are aware of or identified any uncertainties in the management of AMD please let us know.&amp;nbsp; You can contact us via our &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/feedback.asp" target="_blank"&gt;feedback form&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>260877</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=260877]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Abbreviations</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD,ANNUAL EVIDENCE UPDATES,AMD NKW 2007]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Abbreviations&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=1 width="100%"&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;AAO&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; American Academy of Ophthalmology&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;AF&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Autofluoresence&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;AMD&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Age-Related Macular Degeneration&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;ANCHOR&lt;/TD&gt;
&lt;TD&gt;Anti-VEGF Antibody for the Treatment of predominantly&amp;nbsp;Classic Choroidal Neovascularisation in Age-Related Macular Degeneration&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;Anti-VEGF&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; anti-Vascular Endothelial Factor&amp;nbsp;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;ApoE&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Apolipoprotein E&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;AREDS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Age Related Eye Disease Study&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CBS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Charles Bonnet Syndrome&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CCTV&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Closed circuit television&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CFH&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Complement Factor H&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CNV&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Choroidal neovascular membrane&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DHA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Docosahexaenoic acid&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;EMEA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; European Medicines Evaluation Agency&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;ERM&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Epi-retinal membrane&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;FFA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Fundus Fluorescein Angiography&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;FA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Geographic Atrophy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;IBD&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Identity-by-descent&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;IBS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Identity-by-state&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;LCD&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Liquid crystal display&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;LVA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;&amp;nbsp;Low vision aid&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;MT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Macular translocation&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NICE&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; National Institute for Health and Clinical Excellence&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NKW&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; National Knowledge Week&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;OCT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;&amp;nbsp;Optical Coherence Tomography&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PDT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Photodynamic Therapy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PED&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Retinal pigment epithelium detachment&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PRL&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Preferred retinal location&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;QoL&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Quality of life&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RCA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Regulation of complement activation&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RCOphth&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Royal College of Ophthalmologists&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RCT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Randomised controlled trial &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RPE&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Retinal pigment epithelium&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;SCR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Short concensus repeat sequence&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;SES&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Steady eye strategy&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;SNP&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Single nucleotide polymorphisms&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;TRL&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; Trained retinal locus&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;VISION&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp; VEGF Inhibition in Ocular Neovascularisation Clinical Trials&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>261980</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=261980]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - Introduction</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD,ANNUAL EVIDENCE UPDATES,AMD NKW 2007]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Samantha Mann MD, MRCOphth, Specialist Registrar, Moorfields Eye Hospital NHS Foundation Trust&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc11.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Diagnosis%20Introduction.pdf" target="_blank"&gt;Click here for printable (PDF) version&lt;/A&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/nkw_amd_doc11.html" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;The contribution of newer imaging techniques, such as Optical Coherence Tomography (OCT) and Autofluorescence (AF) imaging, towards the diagnosis of Age-Related Macular Degeneration (AMD).&lt;/H2&gt;
&lt;H2&gt;&lt;BR&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Introduction&lt;/H2&gt;
&lt;P&gt;There are several different phenotypes of AMD [1], but only some of which are amenable to treatment at the current time; namely neovascular AMD. [2-5]&amp;nbsp;&amp;nbsp; With the rapid development of therapeutic interventions in the past decade such as photodynamic therapy (PDT) and more recently the Anti-VEGF treatments [5.6], there has been an increasing emphasis on the timely and effective detection and diagnosis of these different phenotypes of AMD in order to instigate treatment where appropriate.&lt;/P&gt;
&lt;P&gt;Current routine diagnostic imaging techniques include digital colour photography and fluorescein angiography as the gold standard. [7,8]&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt; The latter involves the injection of fluorescein dye (5mls of 20%) into the antecubital vein of the patient with its inherent risks of nausea, vomiting, allergy and anaphylaxis.&amp;nbsp;&amp;nbsp; More recently non-invasive imaging techniques such as Optical Coherence Tomography (OCT) and Autofluorescence (AF) imaging, have been introduced into clinical practice.&amp;nbsp; Assessment of their relative contribution to the diagnosis of AMD is particularly relevant in the context of patient safety in order to reduce unnecessary investigations and risks, and for the efficient use of limited health service resources.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;OCT&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What is OCT?&lt;/LI&gt;
&lt;LI&gt;What is the role of OCT in the diagnosis of AMD?&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;AF&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What is AF?&lt;/LI&gt;
&lt;LI&gt;What is the role of AF in the diagnosis of AMD?&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp; &amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="OCT image" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261980/nelhImp_0000_Introduction-OCT.png" width=313 height=166&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="AF image" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261980/nelhImp_0001_Introduction-AF.png" width=241 height=169&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; This is an OCT image&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;This is an AF image&lt;/P&gt;
&lt;P&gt;taken from: &lt;A href="http://eyephoto.ophth.wisc.edu/ResearchAreas/oct/oct7.htm" target="_blank"&gt;http://eyephoto.ophth.wisc.edu/ResearchAreas/oct/oct7.htm&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref5.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp; Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39(5):367-374. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7604360%5Buid%5D&amp;amp;WebEnv=0ueZHPAs5ByfgYkD9ahUGUC8WhCDuwWkVPWqBz2-Y4y3UmINTXnsmJcjl6GpSpoEHn-NZQ85Jsypg%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; MPS. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109(9):1242-1257. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=1718252%5Buid%5D+AND+(%221991%2F01%22%5BPDAT%5D+%3A+%221991%2F12%22%5BPDAT%5D)&amp;amp;WebEnv=0ISYiXA3CtjgL4s8VU75CLIABE5ix8gDw6iQNTAjX_--LTXg09gPrgk12g0Qr2sUiLo8M1ZHMQ3DM%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; TAP. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117(10):1329-1345. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10532441%5Buid%5D&amp;amp;WebEnv=0EGJakIgabhLwgDNdei8P_rOVLuqil-Tugx8Io5fO_PuCaNMDHaNy2LtT8JWByjAdU38rfXGPIITd%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD&amp;nbsp;et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol. 2003;121(9):1253-1268. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12963608%5Buid%5D&amp;amp;WebEnv=05GT2e_s_9F9sNR5akpk7aJSxy3iAvooqbL0qzIzYxMNEpUR2vScgamUjE8ZJpMoA5lI7050VQP3p%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006;19(3):361-372. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16935211%5Buid%5D&amp;amp;WebEnv=0DPCp4NP2GMKWgSNR590XR--gqi9gjlDG8rKxYiPL447Dnq9czCL3DOs5yxUDPacaZmGYsCYXkTe1%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp; Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40(3):352-368. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15947805%5Buid%5D&amp;amp;WebEnv=0w-OZNfvGp9vTZt0mi0WEeybP4ZxInRDStzxdZJC0K48Rru-Op4XpO-OvzYMSyrf7pIJuk_aiAdzV%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. Age Related Macular Degeneration. Royal College of Ophthalmologists.&amp;nbsp;February 2000. &lt;A disabled href="nelh:29910:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Preferred Practice Pattern Age Related Macular Degeneration. American Academy of Ophthalmology 2006. &lt;A href="nelh:95490:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to&amp;nbsp;Knowledge Week contents&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>261985</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=261985]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - What is Autofluorescence (AF) Imaging?</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD,ANNUAL EVIDENCE UPDATES,AMD NKW 2007]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - What is Autofluorescence (AF) Imaging?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Samantha Mann MD, MRCOphth, Specialist Registrar, Moorfields Eye Hospital NHS Foundation Trust&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc4.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Diagnosis%20What%20is%20Autofluorescence%20Imaging.pdf" target="_blank"&gt;Click here for printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/Diagnosis%20What%20is%20Autofluorescence%20Imaging.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;What is Autofluorescence (AF) Imaging?&lt;/H2&gt;
&lt;P&gt;Autofluorescence imaging (AF), using a confocal Laser Scanning Ophthalmoscope, is a recent technique that has been developed to allow ‘in vivo’ imaging of the RPE of the retina.[1] &amp;nbsp;It assesses the accumulation of the lipid aggregate lipofuscin, with age, which is believed to be toxic to cells and may play a role in the pathogenesis of macular degeneration.[2,3]&lt;/P&gt;
&lt;P&gt;Substantial research now suggests that lipofuscin is derived from residual bodies that result from incompletely digested photoreceptor outer segments that are phagocytosed by the RPE.[3,4]&amp;nbsp; The levels of lipofuscin increase with age and in some disease states.&lt;/P&gt;
&lt;P&gt;AF imaging has now become an important diagnostic tool in various retinal diseases but has yet to establish a role in AMD diagnosis.[5,6]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;How does AF imaging work?&lt;/H2&gt;
&lt;P&gt;It was Delori who discovered that excitation of lipofuscin with short wavelength light resulted in emission of light, with a maximum wavelength of 620-630 nm, which could be detected both in vitro and in vivo. [2,7]&amp;nbsp; With appropriate barrier filters, a confocal scanning laser ophthalmoscope (SLO) could be used to record fundus AF within the RPE.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;To image fundus AF, three machine types have been described, the Heidelberg Retina Angiograph (HRA), the Rodenstock cSLO and the Zeiss prototype SM 30-4024.[8] &amp;nbsp;The field of view is set to between 30° and 40° depending on the machine used and in all, the confocal detection unit uses a pinhole aperture to suppress light originating from outside the focal plane.&amp;nbsp; This enhanced the image contrast. To produce an image, an argon blue laser (488nm) is used for excitation and emitted light is detected above a barrier filter which is inserted in front of the detector. The cut off wavelength of the filter varies from 500 to 521nm, depending on the type of machine.[1] &amp;nbsp;Several images are then taken, aligned and an average image calculated using image analysis software.[1,9]&amp;nbsp; The brightest images have been obtained with the HRA and Zeiss prototype.[8]&amp;nbsp; Media opacities limit the quality of the image in all machines.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Interpretation of the image&lt;/H2&gt;
&lt;P&gt;Fundus autofluorescence generally appears grey and the intensity increases (i.e becomes more white) with age. The highest intensity is at the posterior pole (between 5°and 15° from the fovea), it then dips at the fovea and reduces again toward the periphery.[10]&amp;nbsp; The optic disc and retinal blood vessels are shown as black structures and remain consistent regardless of age (see Figure 1).&amp;nbsp; This indicates that the image is not caused by reflected light as the disc is the most reflectant feature of the fundus.[11]&amp;nbsp; The distribution of lipofuscin generally matches that of rods and reflects the pattern of age- related loss of rod photoreceptors. [10]&amp;nbsp; Areas of melanolipofuscin in pigment clumps produce increased AF and appear white. In disease states, further increased AF (seen as white or light grey areas) is believed to represent lipofuscin-laden RPE cells which are a marker for areas at increased risk of atrophy.[6,9]&amp;nbsp; As atrophy occurs, the autofluorescence becomes dark and represents removal of atrophic RPE cells. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Colour photograph of normal fundus" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261985/nelhImp_0000_Colourphotoofnormalfundus.png" width=296 height=223&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="AF image of normal fundus" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261985/nelhImp_0001_AFimageofnormalfundus.png" width=244 height=231&gt;&lt;/P&gt;
&lt;H3&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;BR&gt;Figure 1: Colour fundus photograph (right) and autofluorescence image (left) of normal fundus &lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;&lt;STRONG&gt;Courtesy of Ms S Mann's MD thesis collection&lt;/STRONG&gt;&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/ref5.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref5.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp; von Ruckmann A, Fitzke FW, Bird AC. Distribution of fundus autofluorescence with a scanning laser ophthalmoscope. Br J Ophthalmol. 1995;79(5):407-412. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7612549%5Buid%5D&amp;amp;WebEnv=0F5wk9RMVnxFz0P0qfUGcLVlEH8FxRuPKQeDr0r8kv9iM0M9-BMqUivm84JjJf89o9BVkf_PPc48u%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; Dorey CK, Wu G, Ebenstein D et al. Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci. 1989;30(8):1691-1699. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=2759786%5Buid%5D&amp;amp;WebEnv=0E-qkBLia8N37T2L5eQF5atpSU5IYqfT4Zs2In5wDCAOWZZEuwHmBuX-U0h2SAnxxX6FqFmgWkECQ%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.Okubo A, Sameshima M, Unoki K et al. Ultrastructural changes associated with accumulation of inclusion bodies in rat retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2000;41(13):4305-4312. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11095631%5Buid%5D&amp;amp;WebEnv=0e08WT4u77KPHFAFloyfBeGhyITzyE7H0whI7vIO0VsaKmO4mke4gou-8T-HOwUK6RNxpW2Iw5cig%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; Katz ML, Drea CM, Eldred GE et al. Influence of early photoreceptor degeneration on lipofuscin in the retinal pigment epithelium. Exp Eye Res. 1986;43(4):561-573. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=3792460%5Buid%5D&amp;amp;WebEnv=0ueZHPAs5B6hhgihIZdAvFlLiEyD9e5PXJ2Z897dxkz3VmLOYEEbm1loSI8Bs1zYTb-vbmFKrssbG%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; von Ruckmann A, Fitzke FW, Bird AC. In vivo fundus autofluorescence in macular dystrophies. Arch Ophthalmol. 1997;115(5):609-615. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9152128%5Buid%5D&amp;amp;WebEnv=0YLuHm88a6Yc9n7Vxe5VUFD1BwlV8SFag347jG379Cjx7hsSYcaX2mZ9DQd4ZqYt-I582rtTWQd4W%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp; Lois N, Halfyard AS, Bird AC, Fitzke FW. Quantitative evaluation of fundus autofluorescence imaged "in vivo" in eyes with retinal disease. Br J Ophthalmol. 2000;84(7):741-745. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10873986%5Buid%5D&amp;amp;WebEnv=0jXouIsdd2kIbjd8ez8gwrsMEkYjO_0kO7QDSpXiZzsPKt3U2kdPylt7YRwdNdzzMDIIpUiaWIlIE%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp; Delori FC, Dorey CK, Staurenghi G et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci. 1995;36(3):718-729. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7890502%5Buid%5D&amp;amp;WebEnv=0QNJZPJjWEv0WdWffliJwj_xj1ExOYTk-jiGZj8LasfZRrOzdv2AaOFiONpNnIw1YCqPCXDWvkSAR%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp; Kabanarou, S. A, Bellman, C., Crossland, M. D., Culham, L. E., Fine, E. M., and Rubin, G. S. Psychophysical mapping of the blindspot: A validation study. ARVO Abstract . 2003.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp; Holz FG, Bellmann C, Margaritidis M et al. Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1999;237(2):145-152. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9987631%5Buid%5D&amp;amp;WebEnv=0NOFiTHAuOM9nbLRxGYT3HCWnOZUTSWEApvaxZdVP8X3DqX9hS7LJ0AG7QoG5ZolsEKit2QVksGEC%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp; Delori FC, Goger DG, Dorey CK. Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. Invest Ophthalmol Vis Sci. 2001;42(8):1855-1866. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11431454%5Buid%5D&amp;amp;WebEnv=029bPp4qP-ZtBVY4IsaVfFdrJe1lfqgfQSGYfxV0_zAM0tjiA6M2Dh-qh3tuMJ605JIKmrbnCQCbt%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp; von Ruckmann A, Fitzke FW, Bird AC. Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope. Invest Ophthalmol Vis Sci. 1997;38(2):478-486. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9040481%5Buid%5D&amp;amp;WebEnv=03EnFs99yWDbn7gWDHNikyaSPknrh7GChhBWXLeiLLuZfMDsjvEvPY3-v3uba4W6J3PMSmLKGsxDz%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>261978</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=261978]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - What is OCT</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD NKW 2007,ANNUAL EVIDENCE UPDATES,AMD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - What is OCT&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Samantha Mann MD, MRCOphth, Specialist Registrar, Moorfields Eye Hospital NHS Foundation Trust&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc3.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Diagnosis%20What%20is%20OCT2.pdf" target="_blank"&gt;Click here for printable (PDF) version&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/Diagnosis%20What%20is%20OCT2.pdf" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;What is OCT?&lt;/H2&gt;
&lt;P&gt;Optical coherence tomography (OCT) is a relatively new diagnostic modality that provides high-resolution, cross-sectional imaging of ocular tissues in vivo. It is predominantly used for posterior segment imaging to measure retinal and macula thickness and has been used to study and monitor diseases such as vitreomacular traction, epiretinal membranes, macular holes and macular oedema in diabetes, vein occlusions and uveitis. [1,2] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;How does OCT work?&lt;/H2&gt;
&lt;P&gt;The technique is analogous to ultrasound, except that the use of light (wavelength 843nm) rather than sound waves enables a higher longitudinal resolution up to 10µm.[1]&amp;nbsp; An interferometer is used to split the low coherence infrared light into a probe beam which is directed into the eye and a second beam aimed at a reference mirror. The reflected light from the retinal tissue and reference mirror then interact to produce an interference pattern which is detected and processed into a signal.[3] &amp;nbsp;Strong reflections occur at the interface between materials of different refractive indices and from tissues with high scattering coefficients. Micro-structural ‘distances’ within the eye can be measured from the ‘echo’ time taken for the light to reflect from the various structures within the eye. This provides ultrasound-A-scan-like information at a single point.[2] &amp;nbsp;A 2-dimensional B-mode tomographic image is then generated by simultaneously performing and displaying 100 longitudinal adjacent scans. Although media opacities such as vitreous haemorrhage and corneal oedema which reduce the intensity of incident light may limit the quality of images, good quality pictures are still obtainable through mild to moderate cataract.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="OCT of healthy macular" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261978/nelhImp_0000_WhatisOCTImage1.png" width=594 height=274&gt;&lt;/P&gt;
&lt;H3&gt;Figure 1: OCT of healthy macula&lt;BR&gt;taken from: &lt;A href="http://eyephoto.ophth.wisc.edu/ResearchAreas/oct/oct7.htm" target="_blank"&gt;http://eyephoto.ophth.wisc.edu/ResearchAreas/oct/oct7.htm&lt;/A&gt;&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Interpretation of the OCT&amp;nbsp; image&lt;/H2&gt;
&lt;P&gt;The final image is then displayed in false colour. Dark colour (blue and black) represent regions of low relative optical reflectivity (i.e fluid within the retina) and bright colours (red and white) represent regions of high optical reflectivity.&amp;nbsp; Conventionally, the image is orientated with the vitreous cavity superiorly which is non-reflective and black (see Figure 1). The normal fovea is identified by its characteristic depression and its thickness has been calculated as 147 +/- 17µm in normal eyes.[4] &amp;nbsp;The posterior hyaloid is sometimes seen as a visible blue membrane. Posterior to this, at the inner retinal margin, a highly reflective red band corresponds to the nerve fibre layer. The intermediate layers of retina exhibit moderate reflectivity and the dark layer immediately posterior to this represents the photoreceptor outer segments. Beneath this, a further highly reflective red layer corresponds to the RPE and choriocapillaris and lastly another dark layer of minimal reflectivity represents the choroid and sclera.[5] &amp;nbsp;Retinal blood vessels are identified by their increased back scatter and by blocking the reflections from the RPE and choriocapillaris. The larger choroidal vessels have minimally reflective dark lumens.[1]&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref5.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp; Hrynchak P, Simpson T. Optical coherence tomography: an introduction to the technique and its use. Optom Vis Sci. 2000;77(7):347-356. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10939312%5Buid%5D&amp;amp;WebEnv=0061Lj2to3Xjb9c9vE9tmMS2zZIbt-TOqy0brqKVccZbeRQ8r0C2wFYIKbBD2XDR6Nbp6oh67sdi8%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; Baumal CR. Clinical applications of optical coherence tomography. Curr Opin Ophthalmol. 1999;10(3):182-188. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10537777%5Buid%5D&amp;amp;WebEnv=0tMDhnJ4waZ_2BmnXZz-4-6rC1x8POAB1M_J79dIjLDSQgY7Z9oxHRLewmrnFpQ0FFKOLUh11IcXi%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; Jaffe GJ, Caprioli J. Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol. 2004;137(1):156-169. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=14700659%5Buid%5D&amp;amp;WebEnv=0YKFt9LIHIsPM5AE8eHz3i6LGjk6dUIa3Dy0HR3h9ZmukSlpaD1k7mdgS1tUDt_9pT4xp34z2cq8l%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Rutledge B&amp;nbsp;et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol. 1995;113(8):1019-1029. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7639652%5Buid%5D&amp;amp;WebEnv=0nbmszfzB5GWDkxgSIHFA0WqJePZkEv1VviwPmA3TNagJYG0R1i_65x2njTXUQzQPvAVr14iSYtYS%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; Voo I, Mavrofrides EC, Puliafito CA. Clinical applications of optical coherence tomography for the diagnosis and management of macular diseases. Ophthalmol Clin North Am. 2004;17(1):21-31. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15102511%5Buid%5D&amp;amp;WebEnv=0YTuEGKu3yHyTq7eHV38K_svtYryM-DZX5HXNv65x-ljvh4UcbZm2ogCORCfIVfJml5ikmCtNQdQW%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>261986</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=261986]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - What is the role of AF in the diagnosis of AMD?</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD NKW 2007,ANNUAL EVIDENCE UPDATES,AMD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - What is the role of AF in the diagnosis of AMD?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Samantha Mann MD, MRCOphth, Specialist Registrar, Moorfields Eye Hospital NHS Foundation Trust&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc5.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Diagnosis%20What%20is%20the%20role%20of%20AF%20in%20the%20diagnosis%20of%20AMD2.pdf" target="_blank"&gt;Click here for printable (PDF) version&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Autofluorescence (AF) imaging is a relatively newer, fast imaging technique which has been less extensively investigated. Its use for imaging the different phenotypes of AMD is described below.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;AF for Choroidal neovascular membrances (CNV)&lt;/H2&gt;
&lt;P&gt;•&amp;nbsp;AF imaging of CNV is less well characterised than that for GA.[1,2]&lt;BR&gt;•&amp;nbsp;In general, little data exist to differentiate the different phenotypes of CNV with AF.[3]&amp;nbsp; &lt;BR&gt;•&amp;nbsp;AF outlines a greater total area of the CNV lesion than that evident from&amp;nbsp; fluorescein angiography (FFA), suggesting that this may provide a more accurate delineation of the lesion.[4]&lt;BR&gt;•&amp;nbsp;Increased AF may be seen adjacent to leaking areas of CNV seen on FFA.[4]&lt;BR&gt;•&amp;nbsp;Increased AF may represent proliferation of RPE cells around the lesion or debris within macrophages.[3,4]&lt;BR&gt;•&amp;nbsp;RPE may be intact with preserved AF in early CNV lesions, but is lost in late lesions with disciform scars.[4]&lt;BR&gt;•&amp;nbsp;There appears to be a different pathogenesis for the development of CNV with no increased AF occurring before its development.[3]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage7 border=0 name=nelh_tempImage7 alt="colour fundus photograph of occult CNV" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261986/nelhImp_0008_AFofoccultCNV1.png" width=298 height=273&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="AF image of occult CNV" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261986/nelhImp_0001_AFofoccultCNV2.png" width=267 height=259&gt;&lt;/P&gt;
&lt;H3&gt;Figure 1:&amp;nbsp; Colour Fundus Photograph (right) and AF image (left) of occult CNV &lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Courtesy of Ms S Mann's MD thesis collection&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;AF for Retinal Pigment Epithelial&amp;nbsp;Detachment (PED)&lt;/H2&gt;
&lt;P&gt;•&amp;nbsp;Retinal pigment epithelial detachments (PED) have been shown to have relatively normal levels of autofluorescence over the lesion itself (see Figure 2) which could be explained by the fact that PED’s occur as a result of changes to Bruch’s membrane with the anatomy and function of the RPE remaining relatively undisturbed.[4]&amp;nbsp; &lt;BR&gt;•&amp;nbsp;PED’s older than 6 months have shown a mild, diffusely increased autofluorescence corresponding exactly with the detached area and this persisted for 2 months after the detachment had flattened.[5] &lt;BR&gt;•&amp;nbsp;RPE tears –the area of denuded RPE appears dark with absence of AF and the rolled RPE gives a heterogeneous pattern with an intensity similar to background AF.&amp;nbsp; The AF signal may arise as a combination of RPE lipofuscin and blockage from melanin within the RPE.[6]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Fundus fluorescein angiogram of retinal pigment epithelial detachment and adjacent CNV lesion" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261986/nelhImp_0002_AFimageofPEDwithadjacentCNVlesion.png" width=309 height=251&gt;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="AF image of retinal pigment epithelial detachment and adjacent CNV lesion" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261986/nelhImp_0003_AFimageofPEDwithadjacentCNVlesion2.png" width=297 height=249&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;H3&gt;Figure 2: Fundus fluorescein angiogram (right) and&amp;nbsp;AF image (left) of Retinal Pigment Epithelial Detachment and adjacent&amp;nbsp;CNV lesion&lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;Courtesy of Ms S Mann's MD thesis collection&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;AF for Geographic Atrophy&lt;/H2&gt;
&lt;P&gt;•&amp;nbsp;Geographic atrophy is associated with decreased autofluorescence corresponding to areas of RPE atrophy and photoreceptor loss which is symmetrical between eyes.[7]&lt;BR&gt;•&amp;nbsp;Areas of increased AF at the posterior pole,&amp;nbsp; observed around areas of atrophy&amp;nbsp; may precede the development and enlargement of further atrophy.[8,9]&lt;BR&gt;•&amp;nbsp;AF may therefore play a role in detecting those at high risk of visual loss from further enlargement of areas of GA.&lt;BR&gt;•&amp;nbsp;AF is particularly useful at detecting smaller areas of atrophy that can be obscured by drusen on the colour image.[10]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage3 border=0 name=nelh_tempImage3 alt="colour fundus photograph of geographic atrophy with drusen" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261986/nelhImp_0004_AFimagingofGAwithdrusen1.png" width=287 height=250&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage4 border=0 name=nelh_tempImage4 alt="AF image of geographic atrophy with drusen" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261986/nelhImp_0005_AFimagingofGAwithdrusen2.png" width=273 height=252&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;H3&gt;Figure 3: Colour fundus photograph (right) and AF imaging (left) of Geographic Atrophy&amp;nbsp;with drusen.&lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;Courtesy of Ms S Mann's MD thesis collection&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage5 border=0 name=nelh_tempImage5 alt="Colour fundus photograph of geographic atrophy with surrounding increase autofluorescence" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261986/nelhImp_0006_AFofGAwithsurroundingincreaseAF.png" width=288 height=218&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage6 border=0 name=nelh_tempImage6 alt="AF image of geographic atrophy with surrounding increase autofluorescence" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261986/nelhImp_0007_AFofGAwithsurroundingincreaseAF2.png" width=220 height=220&gt;&lt;/P&gt;
&lt;H3&gt;Figure 4: Colour fundus photograph (right) and AF imaging (left)&amp;nbsp;of Geographic Atrophy with&amp;nbsp;surrounding increase autofluorescence. &lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;Courtesy of Ms S Mann's MD thesis collection&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Summary of the role of AF in AMD diagnosis&lt;/H2&gt;
&lt;P&gt;Autofluorescence imaging is a relatively newer non-contact, fast imaging technique which has been less extensively investigated. Its use appears to be primarily aimed at detecting areas of increased AF in eyes with GA which provides diagnostic and prognostic information regarding disease progression.[11] &amp;nbsp;The technique also very easily detects areas of atrophy at the macula as dark areas, especially when obscured by drusen. Quantitative analysis is also possible with computer driven planimetry techniques and this would be invaluable when assessing GA as part of a trial or study.[10] &amp;nbsp;AF in PED and CNV have not been studied sufficiently to be able to comment on its use in diagnosis. AF may however play a role in RPE tear diagnosis as it is easy to detect [6] and avoids the need for a fluorescein angiogram. Further larger studies calculating sensitivity and specificity of diagnosis of AMD are needed before AF can be recommended as a diagnostic test in isolation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/ref5.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref5.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp; Smith RT, Chan JK, Busuoic M, Sivagnanavel V, Bird AC, Chong NV. Autofluorescence characteristics of early, atrophic, and high-risk fellow eyes in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2006;47(12):5495-5504. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17122141%5Buid%5D&amp;amp;WebEnv=0yAUMYV6nAgI0gtLkrQDjqimwJ32DqLXBxZZ1rMyLk2cUkCLvNx0MlH2FYp6i3HfvPpxEalggYTh2%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; Einbock W, Moessner A, Schnurrbusch UE, Holz FG, Wolf S; FAM Study Group. Changes in fundus autofluorescence in patients with age-related maculopathy. Correlation to visual function: a prospective study. Graefes Arch Clin Exp Ophthalmol. 2005;243(4):300-305. &lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; McBain VA, Townend J, Lois N. Fundus autofluorescence in exudative age-related macular degeneration. Br J Ophthalmol. 2007;91(4):491-6.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16956913%5Buid%5D&amp;amp;WebEnv=0r0u2w2gGQnUeBhas0pOBji16axi0Hnx3HMQz14W-fGRGS3wsrdtdofuouIHKrPmJ4_xxoCdNsA_i%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; Dandekar SS, Jenkins SA, Peto T, Scholl HP, Sehmi KS, Fitzke FW et al. Autofluorescence imaging of choroidal neovascularization due to age-related macular degeneration. Arch Ophthalmol. 2005;123(11):1507-1513. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16286612%5Buid%5D&amp;amp;WebEnv=0w8O-8a_ug9QZeNQsi5bVzORPurSzoeDlOhC7DJTlP6d-rxhCHHZp2UQVQEMMdqPtsIr8sI8pA5vX%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; von Ruckmann A, Fitzke FW, Bird AC. Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope. Invest Ophthalmol Vis Sci. 1997;38(2):478-486. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9040481%5Buid%5D&amp;amp;WebEnv=0QoqgfwYN70YDgzHalAg0ezXc2DnXOOkGv8_818I6k_gFIZggQJcZZYpdXNG9TKY_nJFZ3fHdIrAF%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp; Karadimas P, Paleokastritis GP, Bouzas EA. Fundus autofluorescence imaging findings in retinal pigment epithelial tear. Eur J Ophthalmol. 2006;16(5):767-769. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17061235%5Buid%5D&amp;amp;WebEnv=0xSf53nzj0somqOB5G-22kCiI5aRk71JWKJyYqtdituWAqFmAzOE81qhUGsQrxlzMx4BWH_5LAm8S%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp; Bellmann C, Jorzik J, Spital G, Unnebrink K, Pauleikhoff D, Holz FG. &amp;nbsp;Symmetry of bilateral lesions in geographic atrophy in patients with age-related macular degeneration. Arch Ophthalmol. 2002;120(5):579-584. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12003606%5Buid%5D&amp;amp;WebEnv=0-56Ujpol5lPoSeqv0V_2-f91vjK94tiezPhOF4JGZ2hMP7s5wrjbZEDFnq8lLffleG-blCyRIrpX%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp; Holz FG, Bellmann C, Margaritidis M, Schutt&amp;nbsp;F, Otto TP, Volcker HE.&amp;nbsp; Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1999;237(2):145-152. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9987631%5Buid%5D&amp;amp;WebEnv=0jYLJlaS_7Q8x7RkIzgxKuCSD9GgviWkEmGoqfXvRfKSUG41g998BATV-sY7qY2bemrRzVg38kGOY%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp; Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE.&amp;nbsp; Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;42(5):1051-1056. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11274085%5Buid%5D&amp;amp;WebEnv=0eG1-5HIIbeMtwbeJocRYqJItBcxWhtHVG-tMYIEK0EtGNv9IQilTYwtHCMMuhCMOEm-VCVl-YEab%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10. Sunness JS, Ziegler MD, Applegate CA. Issues in quantifying atrophic macular disease using retinal autofluorescence. Retina. 2006;26(6):666-672. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16829810%5Buid%5D&amp;amp;WebEnv=0cqB_QE2Q4TQheQXtXkSy66QnnN_FFktO6qC9zaQzzGuRMhNGKtArvMe2yVgHOxphQ_K1Oqj0ssq-%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, Dreyhaupt J, Wolf S, Scholl HP&amp;nbsp;et al. Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci. 2006;47(6):2648-2654. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16723482%5Buid%5D&amp;amp;WebEnv=0LZqVaV1hvpX7V-TWRXhe3TYBEyOqzIosZ1-ma-AJ44Flh5snFknn5ZQF2rJmk7C7N0Ki_mSnsAEl%40D45F01E966570F20_0142SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>261981</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=261981]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - What is the role of OCT in the diagnosis of AMD?</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD NKW 2007,ANNUAL EVIDENCE UPDATES,AMD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Diagnosis - What is the role of OCT in the diagnosis of AMD?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Samantha Mann MD, MRCOphth, Specialist Registrar, Moorfields Eye Hospital NHS Foundation Trust&lt;/EM&gt; &lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc2.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Diagnosis%20What%20is%20the%20role%20of%20OCT%20in%20the%20diagnosis%20of%20AMD2.pdf" target="_blank"&gt;Click here for printable PDF version&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/Diagnosis%20What%20is%20the%20role%20of%20OCT%20in%20the%20diagnosis%20of%20AMD2.pdf" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Optical Coherence Tomography (OCT)&amp;nbsp;has been used to characterise a wide variety of retinal pathology and has been correlated with histological findings.[1]&amp;nbsp; OCT may be used to establish a diagnosis, evaluate the clinical course of a disorder and monitor treatment efficacy. Its role in the diagnosis of various phenotypes of age related macular degeneration (AMD) as reported in observational studies is summarised here. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;OCT for Choroidal Neovascular Membrane (CNV)&lt;/H2&gt;
&lt;P&gt;Findings from observational studies report -&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Only 1 study was specifically designed to assess the accuracy of OCT in the diagnosis of AMD subtypes compared to fluorescein angiography.[2]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;OCT can document the presence of CNV (both occult and classic neovascular membranes).[2,3]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Cannot distinguish clearly between types of CNV – and as such cannot replace fundus fluorescein angiography (FFA) as a diagnostic test to inform management for therapeutic intervention.[2]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;May serve to inform prioritisation of those in need of FFA to identify potentially treatable CNV.[2]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;May serve to aid assessment of presence of a membrane through haemorrhage.[4]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Cannot sufficiently distinguish between active and inactive membranes.[5]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Limitations with fixation in patients with AMD may affect quality of OCT image.[6,7]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="Poorly defined CNV (Occult)" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261981/nelhImp_0000_poorlydefinedCNV%28occult%29.png" width=590 height=245&gt;&lt;/P&gt;
&lt;H3&gt;Figure 1: Poorly defined Choroidal Neovascular Membrane (Occult)&amp;nbsp; Standard 9B. Fundus fluorescein angiogram (right); OCT image (left)&lt;/H3&gt;
&lt;H3&gt;Taken from: &lt;A href="http://eyephoto.ophth.wisc.edu/ResearchAreas/" target="_blank"&gt;http://eyephoto.ophth.wisc.edu/ResearchAreas/&lt;/A&gt;&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;OCT for Retinal Pigment Epithelial Detachment (PED)&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Pigment epithelial detachments appear as focal elevations of the reflective RPE band over an optically clear space (See Figure 2).[9] &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;CNV may be difficult to detect in the presence of a high PED.[3,9](3,9).&amp;nbsp; The presence of a notch on OCT may be diagnostically important in diagnosing CNV in association with PED.[9]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;RPE tear – On OCT the classic, regular, dome shaped aspect has a ‘pleated’ or ‘tent–like’ profile.[10]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage3 border=0 name=nelh_tempImage3 alt="Serous RPE detachment (PED)" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261981/nelhImp_0001_SerousRPEDetachment%28PED%29.png" width=583 height=417&gt;&lt;/P&gt;
&lt;H3&gt;Figure 2: Serous RPE detachment (PED) Standard 8A&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Colour fundus photograph (top right); OCT image (top left); fluorescein angiograme (bottom)&lt;/H3&gt;
&lt;H3&gt;Taken from: &lt;A href="http://eyephoto.ophth.wisc.edu/ResearchAreas/" target="_blank"&gt;http://eyephoto.ophth.wisc.edu/ResearchAreas/&lt;/A&gt;&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;OCT for Geographic Atrophy (GA)&lt;/H2&gt;
&lt;P&gt;•&amp;nbsp;Soft drusen may be identified as elevations of the RPE.[3]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Atrophy is seen as thinning of the retina with an increased reflectivitiy of the choroid caused by lack of pigment in the RPE (see Figure 3).[3]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Focal areas of hyperpigmentation are seen as areas of increased reflectivity.[3]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Due to the absence of the hypereflective band from the RPE in GA, the anterior choroid may be misinterpreted as fibrotic tissue from an inactive CNV.[5]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Overall OCT offers no additional information over conventional imaging in GA.[4]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="OCT of Geographic Atrophy (GA)" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261981/nelhImp_0002_OCTofgeographicatrophy.png" width=607 height=255&gt;&lt;/P&gt;
&lt;H3&gt;Figure 3: OCT of Geographic Atrophy (GA)&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Colour fundus photograph (right); OCT image left &lt;/H3&gt;
&lt;P&gt;&lt;STRONG&gt;Taken from: &lt;/STRONG&gt;&lt;A href="http://eyephoto.ophth.wisc.edu/ResearchAreas/" target="_blank"&gt;&lt;STRONG&gt;http://eyephoto.ophth.wisc.edu/ResearchAreas/&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Summary of the role of OCT in AMD diagnosis&lt;/H2&gt;
&lt;P&gt;OCT is a non-invasive, fast, non-contact imaging technique which readily displays intra-retinal, subretinal and sub-RPE fluid, but is limited in its imaging of the choroid due to poor penetration. It also lacks dynamic information and is unable to differentiate between active and inactive lesions.&amp;nbsp; Fixation appears to be a problem to get good quality images especially for measurement data. &lt;/P&gt;
&lt;P&gt;With regards to using conventional OCT for diagnosis of AMD, it appears promising for RPE detachments, but is often unable to detect underlying CNV. Its role in CNV detection has a good sensitivity and specificity but is unable to detect individual components of CNV lesions in all cases and therefore is unlikely to replace fluorescein angiography at present. It may however play a role in the screening of suspected CNV. Images of GA appear to be less useful and can be misleading and difficult to interpret in isolation. OCT therefore has a limited role in diagnosis of GA. With the advent of ultra high resolution OCT [11], which has addressed some of the limitations of conventional OCT, further studies may show an increasing role in the diagnosis of various types of AMD. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/ref5.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref5.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp;Puliafito CA, Hee MR, Lin CP, Reichel E, Schuman JS, Duker JS&amp;nbsp;et al. Imaging of macular diseases with optical coherence tomography. Ophthalmology. 1995;102(2):217-229. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7862410%5Buid%5D+AND+(%221995%22%5BPDAT%5D+%3A+%221995%22%5BPDAT%5D)&amp;amp;WebEnv=0kRnkrbybz2mRm8YFiaES3wNjBiJHgZMpIELQMNYq-HUr3jUqUeQB3tkQkFxpgUuXct_eDtM-smdl%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; Sandhu SS, Talks SJ. Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes. Br J Ophthalmol. 2005;89(8):967-970. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16024845%5Buid%5D&amp;amp;WebEnv=0FkwIfgFv1xFDbsm-fweSlYwEFA6_5VPmMPy9DrvjdpPZ0cZVlnmU3FtyYpjSmJJOnB9tCl6bcv_l%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; Hee MR, Baumal CR, Puliafito CA, Duker JS, Reichel E, Wilkins JR&amp;nbsp;et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology. 1996;103(8):1260-1270. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8764797%5Buid%5D&amp;amp;WebEnv=0cmB0qM6wfMXCCO9Zcn25fJ6LIwWHCOGuj6xv-ZEu5HjzMuL0xM5rCpADiZY065Miz_711Bzks9Qt%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; Spraul CW, Lang GE, Lang GK. [Value of optical coherence tomography in diagnosis of age-related macular degeneration. Correlation of fluorescein angiography and OCT findings]. Klin Monatsbl Augenheilkd. 1998;212(3):141-148. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9592738%5Buid%5D&amp;amp;WebEnv=0SoUqK-GD_T4YuzbaQadqM8hIqSdqYcxracVVhnwyAUrg8nrL1Cjts8wKUpfQSQ9SqBcq2hQLAHLA%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; Ahlers C, Michels S, Elsner H, Birngruber R, Pruente C, Schmidt-Erfurth U. Topographic angiography and optical coherence tomography: a correlation of imaging characteristics. Eur J Ophthalmol. 2005;15(6):774-781. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16329065%5Buid%5D&amp;amp;WebEnv=0HWhH24mLLqUN_SIqEhPTnFiI3k5bPeWY5J_f05kOT-9Qi0rhLXP9mPbTz48Zs7MZY-USeb7Vc0Im%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp; Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol. 2002;134(4):566-576. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12383814%5Buid%5D&amp;amp;WebEnv=0GZ2CuEGSHr5bf8N2SkC8APjUlKck5OBGpM-mK7C2R79Dv-aN9sKWSLGg2SDT24vG_tL4GWO_Aiwf%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;&amp;nbsp;Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina. 2005;25(6):691-696. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16141855%5Buid%5D&amp;amp;WebEnv=0VvlR6y20lhzWO8eDUbMrXwlRErZBIWS3yVyL72N45jYR_bkE9kyRiEdFB4z2APICMCUv6FJKYUxu%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp; Van de MA, Sandhu SS, Talks SJ. Correlation of optical coherence tomography and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes. Br J Ophthalmol. 2006;90(3):304-306. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16488950%5Buid%5D&amp;amp;WebEnv=0Gq7JYZ-2pIAg7aSbhmpue-Lf9kHH1iyGzFaCg27zrje1EwVPhavdbKnvVkwh4mKZrGPZB7lHsRck%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;&amp;nbsp;Sato T, Iida T, Hagimura N, Kishi S. Correlation of optical coherence tomography with angiography in retinal pigment epithelial detachment associated with age-related macular degeneration. Retina. 2004;24(6):910-914. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15579989%5Buid%5D&amp;amp;WebEnv=0TvBZb_6pr6mMyKQtk98_Wm5Uo6Yi_qWLnLyRBnnZIjS2a_ynDSu52KYzZs_A3JKOU2CyW36TIAbB%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp; Giovannini A, Amato G, Mariotti C, Scassellati-Sforzolini B. Optical coherence tomography in the assessment of retinal pigment epithelial tear. Retina. 2000;20(1):37-40. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10696745%5Buid%5D&amp;amp;WebEnv=0oe1xpTMR2NE-8941o6kr1owUR_AmZHvqha-tEzqT0sABnMWJQRJjf0WDxZcruYIMz69M-RnWQMrt%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp; Ko TH, Fujimoto JG, Schuman JS, Paunescu LA, Kowalevicz AM,&amp;nbsp; Hartl I&amp;nbsp;et al. Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology. Ophthalmology. 2005;112(11):1922. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16183127%5Buid%5D&amp;amp;WebEnv=0VSOL5-AbMS6dfrm5fg64fGMiCaywVwhDalvXU7jvua27-6htvlDiEhkMY6ALzCCbBx6YWgGo5o8Y%4025621FE266671670_0095SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>260481</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=260481]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Epidemiology</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD NKW 2007,AMD,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Jennifer Evans PhD, Lecturer, International Centre for Eye Health, London School of Hygiene and Tropical Medicine&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Drusen - Intermediate" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID260481/nelhImp_0000_Drusenintermediate.jpg" width=191 height=144&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt=Disciform src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID260481/nelhImp_0001_Epidemioldisc.jpg" width=191 height=144&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="Geographic atrophy" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID260481/nelhImp_0002_EpidGA.jpg" width=191 height=144&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc10.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Epidemiology.pdf" target="_blank"&gt;Click here for printable version (PDF)&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/Epidemiology.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Age-related macular degeneration (AMD) is the degeneration of the central area of the retina (macula) in older people. There are two types of AMD - geographic atrophy and neovascular disease. Geographic atrophy is a sharply demarcated area of partial or complete depigmentation where there has been atrophy of the retinal pigment epithelium.&amp;nbsp; Neovascular AMD occurs when new blood vessels grow under the retinal pigment epithelium and occasionally into the subretinal space leading to haemorrhage and scarring. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;People with drusen and pigmentary abnormalities are at increased risk of AMD. Drusen are deposits of lipid material underneath the retinal pigment epithelium within Bruch’s membrane which can be seen as yellowish spots on the retina. Pigmentary abnormalities include hyperpigmentation and hypopigmentation. &lt;/P&gt;
&lt;P&gt;AMD is usually diagnosed in people aged 50 years and above when there is no other obvious cause for the degeneration. &lt;/P&gt;
&lt;P&gt;The existing professional body guidance (&lt;A href="nelh:29910:0" name=internalLink&gt;Royal College of Ophthalmologists&amp;nbsp;&lt;/A&gt;and &lt;A href="nelh:95490:0" name=internalLink&gt;American Academy of Ophthalmology&lt;/A&gt;) summarise the key epidemiological evidence on AMD.&amp;nbsp; Since the more recent AAO report there has been the development of a simplified severity scale for AMD[1], publication of data on the incidence of AMD over 15 years in the Beaver Dam Eye Study [2] and report of a systematic review of polyunsaturated fatty acids.[3]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Classification &lt;/H2&gt;
&lt;P&gt;There are a number of classification schemes for AMD.[4-7] &amp;nbsp;Colour fundus photographs or digitized images are graded for drusen characteristics (size, type, area), pigmentary abnormalities (increased pigment, depigmentation, geographic atrophy) and presence of abnormalities characteristic of neovascular AMD (retinal pigment epithelial detachment, serous or haemorrhagic sensory retinal detachment, subretinal or sub-retinal pigment epithelial haemorrhage, subretinal fibrous tissue).[6]&lt;/P&gt;
&lt;P&gt;A simplified severity scale has been developed which is suitable for clinical use.[1] &lt;/P&gt;
&lt;P&gt;In this report the term AMD is used to describe geographic atrophy and/or neovascular AMD. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Prevalence and incidence&lt;/H2&gt;
&lt;P&gt;The prevalence of AMD in white people aged 40 years and above in Europe, North America and Australia has been estimated at 1.5% (95% confidence intervals(CI) 1.4% to 1.6%) using data from six large population-based studies.[8] &lt;/P&gt;
&lt;P&gt;The prevalence of neovascular AMD (1.0%, 95% CI 0.9% to 1.1%) is slightly higher than geographic atrophy (0.8%, 95% CI 0.8% to 0.9%).[8]&lt;/P&gt;
&lt;P&gt;The prevalence of AMD increases with increasing age. People aged 80 years and above have an estimated prevalence of AMD of 12% (95% CI 11% to 13%).[8]&lt;/P&gt;
&lt;P&gt;Early signs of AMD, such as large drusen (&amp;gt;=125 µm) are more common. Approximately one in three women aged 80 years and above are estimated to have large drusen (prevalence 29.2% 95% CI 26.3% to 32.3%).[8]&lt;/P&gt;
&lt;P&gt;In general, white people have a higher prevalence of AMD compared to black people and Hispanic people although some studies have reported a similar prevalence of early signs of the disease (drusen/pigmentary abnormalities) in white and Hispanic people.[9-16]&lt;/P&gt;
&lt;P&gt;Pooled data from three population-based studies estimated the prevalence of AMD in black women to be 0.68% (95% CI 0.57% to 0.80%) at ages 50 to 54 rising to 2.44% (95% CI 1.85% to 3.20%).[8]&lt;/P&gt;
&lt;P&gt;In the Los Angeles Latino Study the prevalence of AMD in Hispanic people aged 40 years and above was 0.43% (95% CI 0.28% to 0.63%) and ranged from 0.22% at ages 50-59 to 8.47% at ages 80 and above.[15]&lt;/P&gt;
&lt;P&gt;One in 4 people aged 75 years and above can expect to develop early signs of the disease (drusen/pigmentary abnormalities) over 15 years and 1 in 12 people aged 75 years and above are likely to develop AMD.[2]&amp;nbsp; This estimate allows for the competing risk of death and gives the probability of developing AMD over 15 years or before death, whichever comes first. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Risk factors &lt;/H2&gt;
&lt;P&gt;The following risk factors are associated with the development of AMD &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Age:&lt;/EM&gt;&lt;/STRONG&gt; is the main risk factor for AMD. 0.2% of women and 0.3% of men have AMD at ages 50 to 54 compared to 1.5% women/2% men in the 70 to 74 age-group and 16.4% women/11.9% men aged 80 years and above.[8] &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Ocular lesions:&lt;/EM&gt;&lt;/STRONG&gt; The presence of large drusen (&amp;gt;125?m), soft indistinct drusen, extensive drusen area and hyperpigmentation are all associated with an increased risk of developing AMD.[2,17-21]&amp;nbsp; One recent study suggests that people with larger numbers of small hard drusen are at increased risk of developing soft indistinct drusen and pigmentary abnormalities.[2] &amp;nbsp;This finding may mean that there is a continuum from small hard drusen to advanced AMD. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Tobacco smoking:&lt;/EM&gt;&lt;/STRONG&gt; Tobacco smoking is the main modifiable risk factor for AMD. Current smokers have a two to three-fold increased risk of developing AMD and there is a dose-response relationship with pack-years of smoking.[22-29]&amp;nbsp; Public health interventions to help people stop smoking will play an important role in reducing the incidence of AMD in the population.[30] &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Antioxidant vitamin supplementation:&lt;/EM&gt;&lt;/STRONG&gt; Although the results of observational studies have been inconsistent [31-50] evidence from randomized controlled trials, in particular the Age-Related Eye Disease Study study, suggests that supplementation with a combination of beta-carotene, vitamin C, vitamin E and zinc may slow the progression of the disease in people with early signs of the condition such as large drusen or AMD in one eye.[51;52] &amp;nbsp;There is not enough evidence to recommend antioxidant supplementation for people in the general population who do not have signs of AMD.[53]&lt;/P&gt;
&lt;P&gt;Although generally regarded as safe, antioxidant supplements may have harmful effects.&amp;nbsp; Smokers who take beta-carotene may be at increased risk of lung cancer [54;55] and vitamin E supplementation in people with diabetes or vascular disease may increase the risk of heart failure.[56] &lt;/P&gt;
&lt;P&gt;The following risk factors are the subject of current research but there is not enough evidence for clear recommendations as yet.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Lutein and zeaxanthin:&lt;/STRONG&gt;&lt;/EM&gt; are carotenoid pigments that are found in a wide variety of vegetables, in particular green leafy plants such as spinach and kale and in some animal products such as egg yolks.[57] Levels of macular pigment are affected by the amount of these carotenoids in the diet.[58;59]&lt;/P&gt;
&lt;P&gt;Observational studies of the association between serum, dietary and retinal levels of these carotenoids and AMD have been inconclusive.[31-34;37;39;41-43;45;47;60-64] &amp;nbsp;One small trial showed some benefit to supplementation with lutein in people with AMD.[65] Currently there is not enough evidence to recommend lutein and zeaxanthin supplements to prevent or slow down the progression of AMD, however, a diet rich in vegetables, particularly green leafy vegetables, will improve levels of macular pigment and may be beneficial. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Polyunsaturated fatty acids:&lt;/EM&gt;&lt;/STRONG&gt; The retina contains high levels of polyunsaturated fatty acids, in particular docosahexaenoic acid (DHA). There is some evidence for omega-3 fatty acids such as DHA playing a role in primary prevention of AMD however not enough to recommend dietary supplementation.[3]&amp;nbsp; Including oily fish in the diet is currently advised for other health reasons and may reduce the risk of developing AMD. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Cardiovascular disease:&lt;/EM&gt;&lt;/STRONG&gt; Raised blood pressure has been associated with AMD in some [66-69] but not all [13,70,71] studies. There is no evidence that antihypertensive medication or treatments to lower blood pressure can prevent the development or progression of the disease.[72]&amp;nbsp; People with AMD may be at increased risk of coronary heart disease [73], stroke [74] and cardiovascular mortality.[75] However, findings have been inconsistent - some&amp;nbsp; studies have found no association between history of cardiovascular disease and AMD.[68,70] &lt;/P&gt;
&lt;P&gt;Inflammatory biomarkers (for example C-reactive protein) have been associated with cardiovascular disease and their role in AMD is being investigated.[76] Some studies suggest that these inflammatory biomarkers are associated with AMD [77,78] whereas others do not.[79]&amp;nbsp; Genetic factors (see genetic section) also point to a possible inflammatory role in AMD with complement factor H gene implicated in the pathogenesis of AMD.[80]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;HMG CoA Reductase Inhibitors (statins) protect against cardiovascular disease by reducing dyslipidaemia.[81]&amp;nbsp; There is inconsistent evidence for an association between statins and AMD.[82-88] &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Light exposure:&lt;/EM&gt;&lt;/STRONG&gt; Inconsistent results have been found for the effect of light exposure on risk of developing AMD. This may reflect the difficulties in estimating lifetime light exposure accurately. A recent European wide population-based study found a two-fold increased risk of AMD associated with relatively high middle of the day light exposures (Fletcher et al, IOVS 2005; 46: E-abstract 3307). &lt;/P&gt;
&lt;P&gt;The following risk factors are unlikely to be important in the development of AMD&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Educational status/social class:&lt;/EM&gt;&lt;/STRONG&gt; Although a number of studies have suggested that increasing years of education are associated with a decreased risk of AMD [89-90] the observed trends have been weak and several studies have found no association.[91,92] &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Alcohol intake:&lt;/EM&gt;&lt;/STRONG&gt; Alcohol consumption has damaging oxidative effects on many organs in the body. Observed associations between alcohol consumption and AMD have been weak or no association has been seen.[14,26,89, 93-101] &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Ocular factors:&lt;/EM&gt;&lt;/STRONG&gt; Refractive error or hyperopia has been suggested as a risk factor for development of AMD. Positive findings in cross-sectional studies have not been confirmed by the results of larger population-based prospective studies.[102-104] &amp;nbsp;There is no evidence for an association with axial length.[105,106]&amp;nbsp; There is inconsistent evidence for an association between iris colour and development of AMD. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Diabetes:&lt;/EM&gt;&lt;/STRONG&gt; and AMD appear to be unrelated. Many studies have investigated this relationship but few studies have found any link.[107] &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Obesity:&lt;/EM&gt;&lt;/STRONG&gt; In general, reported findings suggest an increased risk of AMD with increasing body mass index (BMI) and abdominal obesity[89,108,109] however, again results have been inconsistent. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Gender/sex hormones:&lt;/EM&gt;&lt;/STRONG&gt; Many prevalence studies show a higher prevalence of ARM and AMD in women. Much of this increased risk, however, can be attributed to the fact that women live longer.[110]&amp;nbsp; Markers of exposure to oestrogen in women, such as age at menarche and menopause and use of hormone replacement therapy have not been consistently associated with AMD.[66;89;111-119] &lt;/P&gt;
&lt;P&gt;The Women’s Health Initiative clinical trial of hormone therapy randomised women to conjugated equine oestrogens (CEE), CEE with progestin (CEE+P) or to placebo. Over 4,000 women aged 65 years and above in this trial were evaluated for the presence of AMD after an average of 5 years treatment.&amp;nbsp; Overall there was no association between oestrogen supplementation and development of AMD.[120] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Visual impairment and blindness&lt;/H2&gt;
&lt;P&gt;Pooled data from six large population-based studies in Europe, North American and Australia estimated the prevalence of visual loss caused by AMD to be 3.5% (95% CI 3.0 to 4.1%) in white people aged 75 years and above.[121] &amp;nbsp;This corresponds well with estimates from a large population-based survey in people aged 75 years and above in the UK which found a prevalence of visual impairment due to AMD of 3.7% (95% CI 3.2% to 4.2%).[122].&lt;/P&gt;
&lt;P&gt;There are estimated to be approximately 200,000 people with visual loss due to AMD in the UK.[123,124] &amp;nbsp;This number will increase as the population ages. It is estimated there will be 239,000 (95% CI 168,000 to 346,000) people visually impaired due to AMD in the UK by 2011.[121]&lt;/P&gt;
&lt;P&gt;Over half of 33,000 people certified as blind or partially sighted in 1999/2000 were affected by AMD.[123]&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref3.pdf" target="_blank"&gt;&amp;nbsp;Click here&amp;nbsp;to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction/Classification&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. &amp;nbsp;Age-Related Eye Disease Study Research Group. A Simplified Severity Scale for Age-Related Macular Degeneration: AREDS Report No. 18. Arch Ophthalmol 2005;123(11):1570-4. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16286620&amp;amp;query_hl=60&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. &amp;nbsp;Klein R, Klein BEK, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-Year Cumulative Incidence of Age-Related Macular Degeneration: The Beaver Dam Eye Study. Ophthalmology 2007;114(2):253-62. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17270675%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3. &amp;nbsp;Hodge WG, Schachter HM, Barnes D, Pan Y, Lowcock EC, Zhang L et al. Efficacy of [omega]-3 Fatty Acids in Preventing Age-Related Macular Degeneration: A Systematic Review. Ophthalmology 2006;113(7):1165-73. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16815401%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. &amp;nbsp;Klein R, Davis MD, Magli YL, Segal P, Klein BEK, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991;98(7):1128-34. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=1843453&amp;amp;query_hl=97&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5. &amp;nbsp;Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39(5):367-74. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=7604360&amp;amp;query_hl=94&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6. &amp;nbsp;The Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. American Journal of Ophthalmology 2001;2001 Nov;132(5):668-81. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11704028%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. &amp;nbsp;Seddon JM, Sharma S, Adelman RA. Evaluation of the Clinical Age-Related Maculopathy Staging System. Ophthalmology 2006;113(2):260-6. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16458093%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevalence &amp;amp; Incidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;8. &amp;nbsp;Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564-72. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15078675%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9. &amp;nbsp;Klein R, Rowland ML, Harris MI. Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. Ophthalmology 1995;102(3):371-81. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7891973%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10. &amp;nbsp;Schachat AP, Hyman L, Leske MC, Connell AM, Wu SY. Features of age-related macular degeneration in a black population. The Barbados Eye Study Group. Arch Ophthalmol 1995;113(6):728-35. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7786213%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11. &amp;nbsp;Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999;106(6):1049-55. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10366070%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12. &amp;nbsp;Klein R, Clegg L, Cooper LS, Hubbard LD, Klein BEK, King WN et al. Prevalence of Age-related Maculopathy in the Atherosclerosis Risk in Communities Study. Arch Ophthalmol 1999;117(9):1203-10. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10496392%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. &amp;nbsp;Klein R, Klein BEK, Marino EK, Kuller LH, Furberg C, Burke GL et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology 2003;110(1):25-33. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12511342%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14. &amp;nbsp;Cruickshanks KJ, Hamman RF, Klein R, Nondahl DM, Shetterly SM. The prevalence of age-related maculopathy by geographic region and ethnicity. The Colorado-Wisconsin Study of Age-Related Maculopathy. Arch Ophthalmol 1997;115(2):242-50. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9046260%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15. &amp;nbsp;Varma R, Fraser-Bell S, Tan S, Klein R, Azen SP. Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology 2004;111(7):1288-97. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15234128%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16. &amp;nbsp;Munoz B, Klein R, Rodriguez J, Snyder R, West SK. Prevalence of Age-Related Macular Degeneration in a Population-Based Sample of Hispanic People in Arizona: Proyecto VER. Arch Ophthalmol 2005;123(11):1575-80. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16286621%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ocular Lesions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;17. &amp;nbsp;van Leeuwen R, Klaver CCW, Vingerling JR, Hofman A, de Jong PTVM. The Risk and Natural Course of Age-Related Maculopathy: Follow-up at 61/2 Years in the Rotterdam Study. Arch Ophthalmol 2003;121(4):519-26. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12695249%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;18. &amp;nbsp;Klein R, Klein BEK, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology 2002;109(10):1767-79. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12359593%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;19. &amp;nbsp;Wang JJ, Foran S, Smith W, Mitchell P. Risk of Age-Related Macular Degeneration in Eyes With Macular Drusen or Hyperpigmentation: The Blue Mountains Eye Study Cohort. Arch Ophthalmol 2003;121(5):658-63. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12742843%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;20. &amp;nbsp;Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study Severity Scale for Age-Related Macular Degeneration: AREDS Report No. 17. Arch Ophthalmol 2005;123(11):1484-98. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16286610&amp;amp;query_hl=62&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;21. &amp;nbsp;Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol 1997;115(6):741-7.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9194725%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Tobacco Smoking&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;22. &amp;nbsp;Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001;108(4):697-704. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11297486%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;23. &amp;nbsp;Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-Year Incidence of Age-Related Maculopathy: The Blue Mountains Eye Study. Arch Ophthalmol 2002;120(10):1357-63. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12365915%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;24. &amp;nbsp;Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 1996;276(14):1147-51. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8827967%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;25. &amp;nbsp;Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996;276(14):1141-6. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8827966%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;26. &amp;nbsp;Klein R, Klein BEK, Tomany SC, Moss SE. Ten-Year Incidence of Age-related Maculopathy and Smoking and Drinking: The Beaver Dam Eye Study. Am.J.Epidemiol. 2002;156(7):589-98. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12244027%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;27. &amp;nbsp;Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye 2004;19(9):935-44. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16151432%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;28. &amp;nbsp;Solberg Y, Rosner M, Belkin M. The Association Between Cigarette Smoking and Ocular Diseases. Surv.Ophthalmol. 1998;42(6):535-47. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9635902%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;29. &amp;nbsp;Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JRW, Bradley M et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006;90(1):75-80. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16361672%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;30. &amp;nbsp;Kelly SP, Thornton J, Lyratzopoulos G, Edwards R, Mitchell P. Smoking and blindness. BMJ 2004;328(7439):537-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15001482%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Antioxidant vitamin supplementation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;31. &amp;nbsp;Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MOM. Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. Am.J.Epidemiol. 1988;128:700-10. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=3421236%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;32. &amp;nbsp;Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994;272(18):1413-20. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7933422%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;33. &amp;nbsp;Mares-Perlman JA, Klein R, Klein BE, Greger JL, Brady WE, Palta M et al. Association of zinc and antioxidant nutrients with age-related maculopathy. Arch Ophthalmol 1996;114(8):991-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8694736%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;34. &amp;nbsp;VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BEK, Brady WE, Palta M. Associations between Antioxidant and Zinc Intake and the 5-Year Incidence of Early Age-related Maculopathy in the Beaver Dam Eye Study. Am.J.Epidemiol. 1998;148(2):204-14. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9676703%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;35. &amp;nbsp;Christen WG, Ajani UA, Glynn RJ, Manson JE, Schaumberg DA, Chew EC et al. Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy. Am.J.Epidemiol. 1999;149(5):476-84. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=10067908%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;36. &amp;nbsp;Smith W, Mitchell P, Webb K, Leeder SR. Dietary antioxidants and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 1999;106(4):761-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10201600%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;37. &amp;nbsp;Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G, Millen AE et al. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am.J.Epidemiol. 2001;2001 Mar 1;153(5):424-32. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11226974%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;38. &amp;nbsp;Cho E, Hung S, Willett WC, Spiegelman D, Rimm EB, Seddon JM et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am.J.Clin.Nutr. 2001;73(2):209-18. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11157315%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;39. &amp;nbsp;Flood V, Smith W, Wang JJ, Manzi F, Webb K, Mitchell P. Dietary antioxidant intake and incidence of early age-related maculopathy : The blue mountains eye study. Ophthalmology 2002;109(12):2272-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12466170%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;40. &amp;nbsp;Kuzniarz M, Mitchell P, Flood VM, Wang JJ. Use of vitamin and zinc supplements and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2002;9(4):283-95.&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12187426%5BUID%5D" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;41. &amp;nbsp;Snellen ELM, Verbeek ALM, van den Hoogen GWP, Cruysberg JRM, Hoyng CB. Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmologica Scandinavica 2002;80(4):368-71. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12190777%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;42. &amp;nbsp;Cho E, Seddon JM, Rosner B, Willett WC, Hankinson SE. Prospective Study of Intake of Fruits, Vegetables, Vitamins, and Carotenoids and Risk of Age-Related Maculopathy. Arch Ophthalmol 2004;122(6):883-92. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15197064%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;43. &amp;nbsp;van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JCM, Klaver CCW, Hofman A et al. Dietary Intake of Antioxidants and Risk of Age-Related Macular Degeneration. JAMA 2005;294(24):3101-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16380590%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;44. &amp;nbsp;Moeller SM, Parekh N, Tinker L, Ritenbaugh C, Blodi B, Wallace RB et al. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Intitiative. Arch Ophthalmol 2006;124(8):1151-62. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16908818%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;45. &amp;nbsp;Eye Disease Case-Control Study Group. Antioxidant status and neovascular age-related macular degeneration. Arch Ophthalmol 1993;111(1):104-9. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7678730%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;46. &amp;nbsp;West S, Vitale S, Hallfrisch J, Munoz B, Muller D, Bressler S et al. Are antioxidants or supplements protective for age-related macular degeneration? Arch Ophthalmol 1994;112(2):222-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8311777%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;47. &amp;nbsp;Mares-Perlman JA, Brady WE, Klein R, Klein BE, Bowen P, Stacewicz-Sapuntzakis M et al. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch Ophthalmol 1995;113(12):1518-23. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7487619%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;48. &amp;nbsp;Delcourt C, Cristol JP, Tessier F, Leger CL, Descomps B, Papoz L. Age-related macular degeneration and antioxidant status in the POLA study. POLA Study Group. Pathologies Oculaires Liees a l'Age. Arch Ophthalmol 1999;117(10):1384-90. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10532448%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;49. &amp;nbsp;Simonelli F, Zarrilli F, Mazzeo S, Verde V, Romano N, Savoia M et al. Serum oxidative and antioxidant parameters in a group of Italian patients with age-related maculopathy. Clinica Chimica Acta 2002;320(1-2):111-5. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11983208%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;50. &amp;nbsp;Dasch B, Fuhs A, Schmidt J, Behrens T, Meister A, Wellmann J et al. Serum levels of macular carotenoids in relation to age-related maculopathy: the Muenster Aging and Retina Study (MARS). Graefes Arch Clin.Exp.Ophthalmol. 2005;243(10):1028-35. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15909159%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;51. &amp;nbsp;Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;2001 Oct;119(10):1417-36. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11594942%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;52. &amp;nbsp;Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2006;%19;(2):CD000254. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=236523&amp;amp;tabID=289" target="_blank"&gt;[Cochrane Review]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;53. &amp;nbsp;Evans JR, Henshaw K. Antioxidant vitamin and mineral supplementation for preventing age-related macular degeneration. Cochrane Database Syst Rev. 2000(2):CD000253. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=236522&amp;amp;tabID=289" target="_blank"&gt;[Cochrane Review]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;54. &amp;nbsp;The Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N.Engl.J Med. 1994;330(15):1029-35. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8127329%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;55. &amp;nbsp;Omenn G.S., Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N.Engl.J.Med. 1996;334:1150-5. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8602180%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;56. &amp;nbsp;The HOPE and HOPE-TOO Trial Investigators. Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial. JAMA 2005;293(11):1338-47. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15769967%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Lutein and zeaxanthin&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;57. &amp;nbsp;Mares-Perlman JA, Millen AE, Ficek TL, Hankinson SE. The Body of Evidence to Support a Protective Role for Lutein and Zeaxanthin in Delaying Chronic Disease. Overview. J.Nutr. 2002;132(3):518S-524. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11880585%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;58. &amp;nbsp;O'Connell E, Neelam K, Nolan J, Au Eong KG, Beatty S. Macular carotenoids and age-related maculopathy. Ann Acad Med Singapore 2006;35(11):821-30. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17160199%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;59. &amp;nbsp;Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: The LUNA study. Experimental Eye Research 2007 84(4);718-28&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17306793%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;60. &amp;nbsp;Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE. Macular Pigment in Donor Eyes with and without AMD: A Case-Control Study. Invest.Ophthalmol.Vis.Sci. 2001;42(1):235-40. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11133874%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;61. &amp;nbsp;Goldberg J, Flowerdew G, Tso MOM, Brody JA. Age-related macular degeneration and cataract: are dietary antioxidants protective? Am.J.Epidemiol. 1988;128:904-5. [abstract]&lt;/P&gt;
&lt;P&gt;62. &amp;nbsp;Beatty S, Murray IJ, Henson DB, Carden D, Koh HH, Boulton ME. Macular Pigment and Risk for Age-Related Macular Degeneration in Subjects from a Northern European Population. Invest. Ophthalmol.Vis.Sci. 2001;42(2):439-46. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11157880%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;63. &amp;nbsp;Gale CR, Hall NF, Phillips DIW, Martyn CN. Lutein and Zeaxanthin Status and Risk of Age-Related Macular Degeneration. Invest.Ophthalmol.Vis.Sci. 2003;44(6):2461-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12766044%5BUID%5D" target="_blank"&gt;abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;64. &amp;nbsp;Sanders TAB, Haines AP, Wormald R, Wright LA, Obeid O. Essential fatty acids, plasma cholesterol, and fat-soluble vitamins in subjects with age-related maculopathy and matched control subjects. Am.J.Clin.Nutr. 1993;57:428-33. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8438779%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;65. &amp;nbsp;Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004;75(4):216-30. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15117055%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cardiovascular disease&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;66. &amp;nbsp;AREDS. Risk factors associated with age-related macular degeneration ; A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology 2000;107(12):2224-32. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11097601+" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;67. &amp;nbsp;Hyman L, Schachat AP, He Q, Leske MC, for the Age-Related Macular Degeneration Risk Factors Study Group. Hypertension, Cardiovascular Disease, and Age-Related Macular Degeneration. Arch Ophthalmol 2000;118(3):351-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10721957+" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;68. &amp;nbsp;Klein R, Klein BEK, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: The Beaver Dam eye study. Ophthalmology 2003;110(4):636-43. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12799274%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;69. &amp;nbsp;van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44(9):3771-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12939290%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;70. &amp;nbsp;Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1993;100(3):406-14. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8460013%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;71. &amp;nbsp;Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Oshima Y, Ishibashi T et al. Risk factors for age related maculopathy in a Japanese population: the Hisayama study. Br J Ophthalmol 2003;87(4):469-72. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12642312%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;72. &amp;nbsp;Wong T, Mitchell P. The eye in hypertension. Lancet. 2007;369(9559):425-35. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17276782+" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;73. &amp;nbsp;Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-Related Macular Degeneration and Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. Ophthalmology 2007;114(1):86-91. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17198851%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;74. &amp;nbsp;Wong TY, Klein R, Sun C, Mitchell P, Couper DJ, Lai H et al. Age-Related Macular Degeneration and Risk for Stroke. Ann Intern Med 2006;145(2):98-106. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16847292%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;75. &amp;nbsp;AREDS Research Group. Associations of Mortality With Ocular Disorders and an Intervention of High-Dose Antioxidants and Zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch Ophthalmol 2004;122(5):716-26. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15136320%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;76. &amp;nbsp;Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The Role of Inflammation in the Pathogenesis of Age-related Macular Degeneration. Surv.Ophthalmol. 2006;51(2):137-52. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16500214%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;77. &amp;nbsp;Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association Between C-Reactive Protein and Age-Related Macular Degeneration. JAMA 2004;291(6):704-10. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=14871913%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;78. &amp;nbsp;Seddon JM, George S, Rosner B, Rifai N. Progression of Age-Related Macular Degeneration: Prospective Assessment of C-Reactive Protein, Interleukin 6, and Other Cardiovascular Biomarkers. Arch Ophthalmol 2005;123(6):774-82. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15955978%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;79. &amp;nbsp;McGwin G, Hall TA, Xie A, Owsley C. The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study. Br J Ophthalmol 2005;89(9):1166-70. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16113374%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;80. &amp;nbsp;Haddad S, Chen CA, Santangelo SL, Seddon JM. The Genetics of Age-Related Macular Degeneration: A Review of Progress to Date. Surv.Ophthalmol. 2006;51(4):316-63. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16818082%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;81. &amp;nbsp;Guymer RH, Chiu AW, Lim L, Baird PN. HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration? Surv.Ophthalmol. 2005;50(2):194-206. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15749309%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;82. &amp;nbsp;Hall NF, Gale CR, Syddall H, Phillips DIW, Martyn CN. Risk of macular degeneration in users of statins: cross sectional study. The BMJ 2001;323(7309):375-6. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11509429%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;83. &amp;nbsp;McGwin G, Jr., Owsley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. Br J Ophthalmol 2003;87(9):1121-5. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12928279%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;84. &amp;nbsp;McGwin J, Xie A, Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology 2005;112(3):488-94. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15745779%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;85. &amp;nbsp;Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol. 2004;137(4):615-24. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15059698%5BUID%5D" target="_blank"&gt;[abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;86. &amp;nbsp;Klein R, Klein BEK, Tomany SC, Danforth LG, Cruickshanks KJ. Relation of Statin Use to the 5-Year Incidence and Progression of Age-Related Maculopathy. Arch Ophthalmol 2003;121(8):1151-5. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12912693%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;87. &amp;nbsp;Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher AE. A case control study of age related macular degeneration and use of statins. Br J Ophthalmol 2005;89(9):1171-5. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16113375%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;88. &amp;nbsp;van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326(7383):255-6. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12560276%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Educational Status&amp;nbsp;and social class&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;89. &amp;nbsp;Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992;110(12):1701-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=1281403%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;90. &amp;nbsp;Klein R, Klein BE, Jensen SC, Moss SE. The relation of socioeconomic factors to the incidence of early age-related maculopathy: the Beaver Dam eye study. Am J Ophthalmol 2001;132(1):128-31. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11438075%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;91. &amp;nbsp;Klein R, Klein BEK, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: The national health and nutrition examination survey III. Ophthalmology 1999;106(6):1056-65. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10366071%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;92. &amp;nbsp;Fraser-Bell S, Donofrio J, Wu J, Klein R, Azen SP, Varma R. Sociodemographic factors and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. Am J Ophthalmol 2005;139(1):30-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15652825%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Alcohol&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;93. &amp;nbsp;Obisesan TO, Hirsch R, Kosoko O, Carlson L, Parrott M. Moderate wine consumption is associated with decreased odds of developing age-related macular degeneration in NHANES-1. J.Am.Geriatr.Soc. 1998;46(1):1-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9434658" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;94. &amp;nbsp;Krishnaiah S, Das T, Nirmalan PK, Nutheti R, Shamanna BR, Rao GN et al. Risk Factors for Age-Related Macular Degeneration: Findings from the Andhra Pradesh Eye Disease Study in South India. Invest.Ophthalmol.Vis.Sci. 2005;46(12):4442-9.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16303932%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;95. &amp;nbsp;Buch H, Vinding T, la Cour M, Jensen GB, Prause JU, Nielsen NV. Risk factors for age-related maculopathy in a 14-year follow-up study: the Copenhagen City Eye Study. Acta Ophthalmologica Scandinavica 2005;83(4):409-18. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16029262%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;96. &amp;nbsp;Ritter LL, Klein R, Klein BE, Mares P, Jensen SC. Alcohol use and age-related maculopathy in the Beaver Dam Eye Study. Am.J.Ophthalmol. 1995;120(2):190-6. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7639303%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;97. &amp;nbsp;Moss SE, Klein R, Klein BE, Jensen SC, Meuer SM. Alcohol consumption and the 5-year incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 1998;105(5):789-94. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9593377%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;98. &amp;nbsp;McCarty CA, Mukesh BN, Fu CL, Mitchell P, Wang JJ, Taylor HR. Risk Factors for Age-Related Maculopathy: The Visual Impairment Project. Arch Ophthalmol 2001;119(10):1455-62. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11594944%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;99. &amp;nbsp;Smith W, Mitchell P. Alcohol intake and age-related maculopathy. Am.J.Ophthalmol. 1996;122(5):743-5. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8909224%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;100. &amp;nbsp;Ajani UA, Christen WG, Manson JE, Glynn RJ, Schaumberg D, Buring JE et al. A prospective study of alcohol consumption and the risk of age-related macular degeneration. Ann.Epidemiol. 1999;9(3):172-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10192649%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;101. &amp;nbsp;Cho E, Hankinson SE, Willett WC, Stampfer MJ, Spiegelman D, Speizer FE et al. Prospective study of alcohol consumption and the risk of age-related macular degeneration. Arch Ophthalmol 2000;118:681-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10815161%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ocular Factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;102. &amp;nbsp;Klein R, Klein BEK, Jensen SC, Cruickshanks KJ. The Relationship of Ocular Factors to the Incidence and Progression of Age-Related Maculopathy. Arch Ophthalmol 1998;116(4):506-13. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9565051%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;103. &amp;nbsp;Wang JJ, Jakobsen KB, Smith W, Mitchell P. Refractive status and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. Clinical &amp;amp; Experimental Ophthalmology 2004;32(3):255-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15180836%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;104. &amp;nbsp;Age-Related Eye Disease Study Group. Risk Factors for the Incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19. Ophthalmology 2005;112(4):533-9. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15808240%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;105. &amp;nbsp;Arnarsson A, Sverrisson T, Stefansson E, Sigurdsson H, Sasaki H, Sasaki K et al. Risk Factors for Five-Year Incident Age-related Macular Degeneration: The Reykjavik Eye Study. American Journal of Ophthalmology 2006;142(3):419. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16935586%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;106. &amp;nbsp;Ulvik SO, Seland JH, Wentzel-Larsen T. Refraction, axial length and age-related maculopathy. Acta Ophthalmologica Scandinavica 2005;83(5):419-23. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16187985%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diabetes&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;107. &amp;nbsp;Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol 1999;6(2):125-43. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10420212%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Obesity&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;108. &amp;nbsp;Delcourt C, Michel F, Colvez A, Lacroux A, Delage M, Vernet MH et al. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol. 2001;8(4):237-49. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11471092%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;109. &amp;nbsp;Seddon JM, Cote J, Davis N, Rosner B. Progression of Age-Related Macular Degeneration: Association With Body Mass Index, Waist Circumference, and Waist-Hip Ratio. Arch Ophthalmol 2003;121(6):785-92. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12796248%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Gender/Sex Hormones&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;110. &amp;nbsp;Evans JR. Risk Factors for Age-related Macular Degeneration. Prog.Ret.Eye Res. 2001;20(2):227-53. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11173253%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;111. &amp;nbsp;Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust.N.Z.J.Ophthalmol. 1997;25:S13-S15. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9267614%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;112. &amp;nbsp;Snow KK, Cote J, Yang W, Davis NJ, Seddon JM. Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women. American Journal of Ophthalmology 2002;134(6):842-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12470752%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;113. &amp;nbsp;Defay R, Pinchinat S, Lumbroso S, Sutan C, Delcourt C, The Pola Study Group. Sex steroids and age-related macular degeneration in older French women: the POLA study. Ann.Epidemiol. 2004;14(3):202-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15036224%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;114. &amp;nbsp;Nirmalan PK, Katz J, Robin AL, Ramakrishnan R, Krishnadas R, Thulasiraj RD et al. Female Reproductive Factors and Eye Disease in a Rural South Indian Population: The Aravind Comprehensive Eye Survey. Invest.Ophthalmol.Vis.Sci. 2004;45(12):4273-6. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15557432%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;115. &amp;nbsp;Abramov Y, Borik S, Yahalom C, Fatum M, Avgil G, Brzezinski A et al. The effect of hormone therapy on the risk for age-related maculopathy in postmenopausal women. Menopause 2004;11:62-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=14716184%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;116. &amp;nbsp;Freeman EE, Bressler SB, West SK. Hormone replacement therapy, reproductive factors, and age-related macular degeneration: the Salisbury Eye Evaluation Project. Ophthalmic Epidemiol. 2005;12:37-45. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15848919%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;117. &amp;nbsp;Fraser-Bell S, Wu J, Klein R, Azen SP, Varma R. Smoking, Alcohol Intake, Estrogen Use, and Age-related Macular Degeneration in Latinos: The Los Angeles Latino Eye Study. American Journal of Ophthalmology 2006;141(1):79-87. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16386980%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;118. &amp;nbsp;Klein BE, Klein R, Lee KE. Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: the beaver dam eye study. American Journal of Ophthalmology 2000;130(3):322-6. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11020411%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;119. &amp;nbsp;Vingerling JR, Dielemans I, Witteman JCM, Hofman A, Grobbee DE, de Jong PTVM. Macular degeneration and early menopause: a case-control study. BMJ 1995;310:1570-1. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7787646%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;120. &amp;nbsp;Haan MN, Klein R, Klein BE, Deng Y, Blythe LK, Seddon JM et al. Hormone therapy and age-related macular degeneration: the Women's Health Initiative Sight Exam Study. Arch Ophthalmol 2006;124:988-92. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16832022%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Visual impairment and blindness&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;121. &amp;nbsp;Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age-related macular degeneration in the UK? Br.J.Ophthalmol. 2003;87:312-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12598445%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;122. &amp;nbsp;Evans JR, Fletcher AE, Wormald RPL. Age-related macular degeneration causing visual impairment in people aged 75 years and above in Britain. Ophthalmology 2004;111:513-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15019328%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;123. &amp;nbsp;Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England &amp;amp; Wales. BMC Public Health 2006;6(1):58. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16524463%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>262211</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=262211]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Genetics and age related macular degeneration</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD NKW 2007]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Genetics and age related macular degeneration&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Mr Andrew Webster, Senior Lecturer, UCL Institute of Ophthlamology, Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust. &lt;/EM&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage3 border=0 name=nelh_tempImage3 alt="Genome map" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262211/nelhImp_0000_Genomemap.jpg" width=170 height=129&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Central scotoma &amp;amp; distortion " src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262211/nelhImp_0001_Centralscotomaanddistortion.png" width=184 height=145&gt;&lt;IMG id=nelh_tempImage6 border=0 name=nelh_tempImage6 alt="central scotoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262211/nelhImp_0003_kidsbottom.png" width=175 height=130&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc1.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Genetics.pdf" target="_blank"&gt;Click here for printable (PDF) version&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to home page contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/Genetics.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Recent research has significantly improved our understanding of the role of hereditary factors in the pathogenesis of Age Related Macular Degeneration (AMD) and this is reflected in existing professional body guidance.[1]&amp;nbsp; Study methods have included : linkage analysis, candidate gene analysis, and sib-pair analysis.&amp;nbsp; The key genetic evidence that underpins our current knowledge of the genetic basis of AMD is summarised here.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Linkage Analysis&lt;/H2&gt;
&lt;P&gt;Twin and Sibship Studies have demonstrated a strong genetic component in the development of AMD.&amp;nbsp; Concordance rates of 90-100% in monozygotic twins compared to 48% in dizygotic twins have been observed in early studies, [2-4] and sibship studies suggest a relative risk to siblings of sufferers versus population controls of between 1.9 to 9.0.[5-8]&lt;/P&gt;
&lt;P&gt;Studies on larger mono and di-zygotic twin cohorts have estimated heritability, this being the proportion of the total variation of the trait in the population that is due to genetic factors.&amp;nbsp; An estimate for early AMD was 45% (95% CI 35-53) with this being higher for soft drusen and more than 20 hard drusen.[9]&amp;nbsp; This agreed with the estimate of 46% for all types of AMD (95% CI 12-73) with this increasing when more advanced stages were analysed separately.[10] Recently a study of 110 sib-pairs, analysed number of hard drusen as a quantitative trait and estimated the heritability as 63% (CI 43-77).[11] &amp;nbsp;More than 20 hard drusen were seen in 26 individuals suggesting a heritability of nearly 100%.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Candidate Gene Analysis &lt;/H2&gt;
&lt;P&gt;The direct influence of specific candidate genes has been under intense and prolonged investigation, particularly as many monogenic disorders for which genes are known, manifest certain components of AMD such as increased level of lipofuscin in the RPE, drusen deposit, atrophy and changes at the level of Bruch’s membrane.&amp;nbsp; Specific examples of candidate genes causing monogenic disorders include :&amp;nbsp; fibulin-3 gene causing dominant drusen; VMD2 encoding bestrophin causative of Best macular dystrophy, TIMP-3 (tissue inhibitor of metalloprotease 3) causing Sorsby disease, the ABCA4 gene causing Stargardt macular dystrophy and the RDS gene causative of a dominant macular dystrophy.[12-16]&amp;nbsp; To date, there is no consistent evidence to suggest that specific coding variants or haplotypes of any gene causing monogenic macular disease, also confer a risk to the development of AMD, even despite the phenotypic similarities, although the effects of rare variants in ABCA4 remain contentious.[15, 17-24] &amp;nbsp;Of interest is the suggestion that rare variants in two genes, fibulin-5 and fibulin-6, members of the same family of genes as fibulin-3, causative of dominant drusen, may be enriched in a small number of individuals with AMD.[25,26]&lt;/P&gt;
&lt;P&gt;The Apolipoprotein E (ApoE) protein product has been shown to be a constituent of retinal drusen.[27,28] The apoE haplotype is determined by two closely linked coding SNPs giving three out of a possible four population alleles, &lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;e&lt;/SPAN&gt;&lt;/SPAN&gt;2, &lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;e&lt;/SPAN&gt;3 and &lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;e&lt;/SPAN&gt;4.&amp;nbsp;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;e&lt;/SPAN&gt;4 the least prevalent allele, has been shown to be enriched in those with Alzheimer disease, coronary artery disease and stroke [29], and it was&amp;nbsp; expected that it may also be enriched in patients with AMD.[27,30]&amp;nbsp;&amp;nbsp; Both these studies found that &lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;e&lt;/SPAN&gt;4 was instead enriched in controls suggesting a protective influence of this allele (odds ratio 0.43) in the development of AMD. The significance of this gene remains to be determined on further cohorts of patients from other centres, and its analysis is confounded by the effect of &lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;e&lt;/SPAN&gt;4 on longevity. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Sib-Pair Analysis &lt;/H2&gt;
&lt;P&gt;In order to identify novel genes that contribute to the risks of developing a complex disorder such as AMD, candidate gene analysis is not sufficient, and traditional linkage analysis methods, in which a single causative gene with high-penetrance is assumed, cannot be employed. Instead, approaches examining allele sharing in affected siblings have been used. A full genome scan, using markers across all chromosomes, is performed to determine whether each sib-pair shares 0, 1 or 2 alleles. If parental DNA is available, the power of this strategy is increased considerably, such that identity-by-descent (IBD), of chromosomal regions can be inferred, when the parental genotypes are informative, and non-informativity of the parents be detected otherwise. When parental information is absent, as is usually the case for a late-onset disorder such as AMD, the degree of IBD has to be inferred statistically, as the only information available is the genotypes of the siblings (which gives a proportion identity-by-state (IBS) ).&amp;nbsp; This approach can identify chromosomal regions for further detailed investigation.&lt;/P&gt;
&lt;P&gt;A meta-analysis of six independent sib-pair studies has recently been published [31] and includes over 900 families. Such a pooling of results gives strongest evidence for susceptibility loci on chromosomes 1q, 10q and 16. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Chromosome 1q – Complement Factor H (CFH)&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In early 2005, four papers were published, from independent groups, elucidating the same gene on chromosome 1q. Two of the studies used the information from the sib-pair analyses discussed above to examine a large region on chromosome 1q25-32 using association of single nucleotide polymorphisms (SNPs) in cases against controls.[32,33]&amp;nbsp; A third study, recognised a single attractive candidate gene in the 1q region and screened SNPs in that gene directly in cases against controls.[34]&amp;nbsp; The fourth study [35] employed a different methodology entirely. Making no prior assumptions about the possible location of AMD susceptibility genes, Klein et al performed a full-genome association study on 96 patients and 50 controls using a high-density 100k SNP array. One highly significant SNP, even after using a conservative Bonferroni correction for 100k independent experiments, resided in the intronic sequence of a gene, Complement Factor H (HF1 or CFH). CFH is one of an array of genes within the regulation of complement activation (RCA) region of chromosome 1q, which encodes proteins active in the complement cascade. Further analysis of the gene, by all four groups [32-35], showed the significant association of AMD with those heterozygous or homozygous for the minor allele at codon 402, histidine as opposed to tyrosine (allele frequency 0.3, 0.7 respectively) when compared to those homozygous for the low risk allele. The odds-ratio found by Klein et al were 4.6 (95% CI 2-11) for heterozygotes and 7.4 (95% CI 3-19) for homozygotes and these consistent with the findings of the other groups and subsequent studies.&lt;/P&gt;
&lt;P&gt;CFH protein is&amp;nbsp;manufactured predominantly in the liver and exported to the serum. It plays a role in the regulation of the alternative pathway of complement and is an important inhibitor of its activation. Local expression within the pigment epithelium of the retina has also been demonstrated [34] and it remains to be seen whether local, systemic or a combination of mechanisms affect retinal susceptibility to AMD. The protein contains twenty short consensus repeat sequences (SCR) and the one harbouring residue 402 is important in the binding of heparin and C-reactive protein. It is of interest that abrogation of the gene naturally in patients and iatrogenically in mice causes renal failure due to membranoproliferative glomerulonephritis [36,37], and that affected patients demonstrate early onset macular drusen[38].&amp;nbsp;The discovery has pointed towards complement dysregulation as an important factor in the pathogenesis of the disease and suggests other important components of complement as having a role in AMD aetiology. Of interest is that the prevalence of the high-risk&amp;nbsp; CFH 402Y allele is lower in Japanese where there is a lower prevalence of the disease[39].&amp;nbsp; Other than the polymorphism at codon 402 in this gene, other haplotypes of the region may also confer susceptibility to AMD. One example, is the deletion of two neighbouring genes, CFHR1 and CFHR3, which occurs in 20% of Caucasian chromosomes and appears to confer protection against the disease, independent to the effect of CFH402.[40]&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Chromosome 10q &lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A second susceptibility locus, on chromosome 10q, has also received much attention. In particular, two adjacent genes in the region were highlighted as possible susceptibility factors - PLEKHA1, which encodes TAPP1, a leukocyte activating protein; and LOC387715, a transcript of unknown function expressed in the placenta[41].&amp;nbsp; SNPs within&amp;nbsp; the PLEKHA1/LOC387715 region have been observed to be significantly skewed in patients with AMD compared to controls,&amp;nbsp; which have been shown to be arising from a single non-synonymous coding SNP in LOC387715,&amp;nbsp; Asn69Ser [42]. &lt;/P&gt;
&lt;P&gt;LOC387715 has no orthologues in the genomes of other organisms apart from primates, does not resemble the sequence of other known proteins or protein domains, and has a restricted tissue expression pattern, which includes the retina and placenta. The susceptibility, like CFH behaves in a semi-dominant manner, increasing with one or two copies of the serine allele.&amp;nbsp; Further research is required to discover the role of this gene in health and disease and this may illuminate a novel biological pathway important in pathogenesis.&lt;/P&gt;
&lt;P&gt;Recently, a distinct SNP polymorphism, 6000 bases distant from LOC387715 p.Asn69, has been shown to confer a similar susceptibility to AMD and lies within the promotor region of the neighbouring gene, Htra1.[43,44] Htra1 encodes a protein of the serine-protease family, one role of which is turnover of extracellular amtrix. it is ubiquitously expressed, is expressed in RPE and is found to be upregulated in joints following chronic inflammation such as arthritis [45]. The specific promotor SNP (rs11200638) appears to effect the expression of Htra1 [43] and so is an excellent candidate for a genetic variation influencing AMD-risk. The role of LOC387715 requires further evaluation, as its high-linkage disequlibrium with rs11200638 and its similar prevalence, leaves open the possibility that all of the effect of the 10q locus is due to this latter polymorphism. Whichever gene, or combination of genes at this locus, is responsible for AMD risk, it is clear that the odds-ratios are at least as large as those reported for CFH.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Complement Factor B gene (BF)&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A further susceptibility gene has been recently identified [46].&amp;nbsp; The region harbouring the complement factor B gene (BF), which acts as a complement activator, is tightly coupled with factor H in the control of complement activation. The gene lies on chromosome 6p21 in the MHC III region. This region was not previously highlighted during sib-pair studies [31], and this is likely due to the small effect of haplotypes at this locus.&amp;nbsp; Examination of allele frequencies and genotypes provide early indications that susceptibility conferred by CFH and BF is not likely to act independently, consistent conceptually with each acting upon the same biological pathway.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/ref4.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref4.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;References &lt;/H2&gt;
&lt;H2&gt;Introduction&lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp; Preferred Practice Plan: Age Related Macular Degeneration. American Academy of Ophthalmology&amp;nbsp;2006 &lt;A href="nelh:95490:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Linkage analysis &lt;/H2&gt;
&lt;P&gt;2.&amp;nbsp; Klein ML, Mauldin WM, Stoumbos VD. Heredity and age-related macular degeneration. Observations in monozygotic twins. Arch Ophthalmol 1994;112:932-937 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8031273%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; Meyers SM, Greene T, Gutman FA. A twin study of age-related macular degeneration. Am J Ophthalmol 1995;120:757-766 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8540549%5Buid%5D&amp;amp;WebEnv=084vqkK_ETRBRx9k-nfimRRlpNbyzTO1VI0BTwOs0U1SP9ltJMpZKwY2oO3C0fUROZKWMmsE9kw-8%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; Gottfredsdottir MS, Sverrisson T, Musch DC, Stefansson E. Age related macular degeneration in monozygotic twins and their spouses in Iceland. Acta Ophthalmol Scand 1999;77:422-425 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10463414%5Buid%5D&amp;amp;WebEnv=03NMMz0HOq8ewhJMrHJD_h953rL1vqyx337MTcUSek23hnzitjelkl08R1HJKiwU-ZkPRfkAGAdJF%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J Ophthalmol 1997;123:199-206 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9186125%5Buid%5D&amp;amp;WebEnv=0MXZXamy9mEPyi3ZFvETP5hLILvfjSEqfUKYGmIrbR6TMe5dJEkN7rZbQS2XkAOEf5PA9t-WY5yBK%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp; Silvestri G, Johnston PB, Hughes AE. Is genetic predisposition an important risk factor in age-related macular degeneration? Eye 1994;8:564-568 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7835454%5Buid%5D&amp;amp;WebEnv=0iMGC0xBzRDSnn0bUAqWjqVYz4E6Hc9XiCayj1TRVsMrrJh1sm2g0t7xTWL9ib2Tou5khoHWZIf08%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp; Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998a;116:1646-1651 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9869796%5Buid%5D&amp;amp;WebEnv=0VuOzNG8AzNrMApuRU-M-StrAt8Msf6hvr5_xQ8aSeO5z-uffdPFixoCvE_RSFad9fx88n8oZ5toC%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp; Heiba IM, Elston RC, Klein BE, Klein R. Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study. Genet Epidemiol 1994;11:51-67 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8013888%5Buid%5D&amp;amp;WebEnv=0MZZbtlaRaEQoRpSgvuzKySWIq7eSaXq3MVePIIRB3bDweqxARO-7sJzJr6Xxl1Z8GPTvAl5J5Iv2%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp; Hammond CJ, Webster AR, Snieder H, Bird AC, Gilbert CE, Spector HD.&amp;nbsp;&amp;nbsp; Genetic influence on early age-related maculopathy: a twin study.Ophthalmology. 2002 Apr;109(4):730-6. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11927430%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp; Seddon JM, Cote J, Page WF, Aggen SH, Neale MC.&amp;nbsp; The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol. 2005 Mar;123(3):321-7. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15767473%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp; Munch IC, Sander B, Kessel L, Hougaard JL, Taarnhoj NC, Sorensen TI et al. &amp;nbsp;Heredity of small hard drusen in twins aged 20-46 years. Invest. Ophthalmol. Vis. Sci. 2007 Feb;48(2):833-8.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17251485%5Buid%5D&amp;amp;WebEnv=0oy1jhDTljSwCVUb9LjAgKIodw1HVZ6EJMRcvTAoh7WzpgpKxwgprO7ba-cb4ki_UKGUoSVBHyNKCUp%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Candidate gene analysis &lt;/H2&gt;
&lt;P&gt;12.&amp;nbsp; Stone EM, Lotery AJ, Munier FL, Heon E, Piguet B, Guymer RH et al. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat. Genet. 1999 Jun;22(2):199-202. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10369267%5Buid%5D&amp;amp;WebEnv=0xIf2pdaG9sV6thbkG_SKFz5N6FMxkrJdlf9LItB20NEgdcF6_E0vt2E1isfEg9FjasICj8mngJxYzv%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp; Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T et al.&amp;nbsp; Identification of the gene responsible for Best macular dystrophy. Nat Genet. 1998 Jul;19(3):241-7 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9662395%5Buid%5D&amp;amp;WebEnv=0JNZWJPlHstLW5UTYILwKvh1TnjEnFbBINjFYdVDsliJFyqbS5jePWg_Jr9rt8qIMosmNSJtSyeRGyU%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp; Weber BH, Vogt G, Pruett RC, Stoehr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat. Genet. 1994 Dec;8(4):352-6. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7894485%5Buid%5D&amp;amp;WebEnv=0cNy_lsHinguuYxQqc8ANdiPJ9HAn2EGFJhsItZGdob0rgKfKOvRQQvRogncidR3NfCsPDDyzceEBvw%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp; Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A et al. &amp;nbsp;A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat. Genet. 1997 Mar;15(3):236-46. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9054934%5Buid%5D&amp;amp;WebEnv=0xYf6GkVOcsDLwcdRGy605bwNqIL-Y5Jf7eBrTtBhsd97dPasajmvHmmPjDfNT3N84slDryHeg4osnH%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp; Wells J, Wroblewski J, Keen J, Inglehearn C, Jubb C, Eckstein A et al. &amp;nbsp;Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy. Nat Genet. 1993 Mar;3(3):213-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8485576%5Buid%5D&amp;amp;WebEnv=0-R3OdyzpWOEwahDr9m-0CxbaZxKCzER3EfNaE5PXjQ5KjY1tnzWApkdcf9bLkOd-43Ljk1m8_89WIg%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp; Allikmets R, Shroyer NF, Singh N, Seddon JM, Lewis RA, Bernstein PS et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science 1997;277:1805-1807 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9295268%5Buid%5D&amp;amp;WebEnv=0m-NcQKsejgAzl_L5Qme9411-Qosoi6gCalnth9eFmkzrvGtQicHq12iJshKQr4qlLpuTT9eRQu5_%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp; Stone EM, Webster AR, Vandenburgh K, Streb LM, Hockney RR, Lotery AJ, Sheffield VC. Allelic variation in ABCR associated with Stargardt disease but not age-related macular degeneration. Nat Genet 1998;20:328-329. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9843201%5Buid%5D&amp;amp;WebEnv=0q52ASqdfQqj7yu3IflZQc9GSXN2BeS3X8eonKJvDow1XVJFi4qO8AwlV33SpH1SZG0W34CrWcjoh%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp; Kuroiwa S, Kojima H, Kikuchi T, Yoshimura N.&amp;nbsp; ATP binding cassette transporter retina genotypes and age related macular degeneration: an analysis on exudative non-familial japanese patients. Br J Ophthalmol. 1999 May;83(5):613-5. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10216065%5Buid%5D&amp;amp;WebEnv=08UErkFF66i-hWuiSMEwZT0NKeAFC-68Nr7GoplciGJQX0lL6NSGplvOO2lxtYmAGJpPe_S6hIMib%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp; De La Paz MA, Guy VK, Abou-Donia S, Heinis R, Bracken B, Vance JM et al.&amp;nbsp; Analysis of the Stargardt disease gene (ABCR) in age-related macular degeneration. Ophthalmology. 1999 Aug;106(8):1531-6. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10442900%5Buid%5D&amp;amp;WebEnv=0PR8umy7h7v9_jkghnU70zX4SNF4zxXr3q9YYMnoyjf3GM93t7c9mP-hzK4Gen21cLJKr4q1nkP_-%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;21.&amp;nbsp; Dryja TP, Briggs CE, Berson EL, Rosenfeld PJ, Abitbol M. ABCR gene and age-related macular degeneration. Science 1998;279:1107 &lt;A href="http://www.sciencemag.org/cgi/reprint/279/5354/1107a.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;22.&amp;nbsp; Klaver CCW, Assink JJM, Bergen AAB, van Duijn CM. ABCR gene and age-related macular degeneration. Science 1998c;279:1107 &lt;A href="http://www.sciencemag.org/cgi/reprint/279/5354/1107a.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp; Allikmets R. Further evidence for an association of ABCR alleles with age-related macular degeneration. The International ABCR Screening Consortium. Am. J. Hum. Genet. 2000 Aug;67(2):487-91. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10880298%5Buid%5D&amp;amp;WebEnv=0PA1jCe8faEoR256ZM1JrJo1y_1r_QTrwp1qsTmDJdxy9gGG1lTFVeT8fS5bSkmrQVR4AeZ2U7rE_X4%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;24.&amp;nbsp; Guymer RH, Heon E, Lotery AJ, Munier FL, Schorderet EF, Baird PN et al.&amp;nbsp; Variation of codons 1961 and 2177 of the Stargardt disease gene is not associated with age-related macular degeneration.&amp;nbsp;&amp;nbsp; Arch Ophthalmol. 2001 May;119(5):745-51.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11346402%5Buid%5D&amp;amp;WebEnv=0tgDJGe9B3ZRVfiUIZv_-8O8HS96AMtBQArQ8AdLcDmjznDL4tzh41BBX9YIBSqAXchPO2rCr7GQFYj%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;25.&amp;nbsp; Stone EM, Braun TA, Russell SR, Kuehn MH, Lotery AJ, Moore PA et al.&amp;nbsp; Missense variations in the fibulin 5 gene and age-related macular degeneration. N. Engl. J. Med. 2004 Jul 22;351(4):346-53.&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15269314%5Buid%5D&amp;amp;WebEnv=0gX_tUB7q6qHA_lhdBDrb9_Px6UnfhKW1Mk70yqfXzFrdJ9Bu0DiUlKziKe5-R7cTdP55_-EtuibeX6%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;26.&amp;nbsp; Schultz DW, Klein ML, Humpert AJ, Luzier CW, Persun V, Schain M et al. &amp;nbsp;Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family. Hum. Mol. Genet. 2003 Dec 15;12(24):3315-23. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=14570714%5Buid%5D&amp;amp;WebEnv=0zYruOsLGuvNhBybyPuBsjKxM3xvhtzY-7XA0LmPUs2IWGfEz9wNrtOtDSBm4a6-LbjnJVBy0Y-lCpK%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;27.&amp;nbsp; Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet 1998b;63:200-206 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9634502%5Buid%5D&amp;amp;WebEnv=0og1dolcdjS7DWurzLv78kjdu6RdpAavnYyRaGyIgG3RTnN7mE36jnb93eZta2mp096o-48M9QPxK%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;28.&amp;nbsp; Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000 May;14(7):835-46 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10783137%5Buid%5D&amp;amp;WebEnv=0I1YLx5K2ejxq1engUu_Hy_JXxq6FfPwsFAeaRyU5CXLVT5iq4y-rBaSAS9pqYx_Sjo4QoykLQttT%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;29.&amp;nbsp; Chapman J, Korczyn AD, Karussis DM, Michaelson DM. The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology. 2001 Oct 23;57(8):1482-5. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11673593%5Buid%5D&amp;amp;WebEnv=0eE16uTGM3e425mQho8IQJIUw7_e7MtHuYUb1NIJq1p0VSDySFHpLUzjTG1rkWki7mVN_4W4Xmo_-oT%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;30.&amp;nbsp; Souied EH, Benlian P, Amouyel P, Feingold J, Lagarde JP, Munnich A et al. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol. 1998 Mar;125(3):353-9. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9512153%5Buid%5D&amp;amp;WebEnv=0VzlGwHhz4maWv2stfq1FWZ6z0VJKLMSkbpMHr1NYXkvp_thiTXQRlt5oYVilEeo9xCkip3ylYIM2%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Sib-Pair Analysis &lt;/H2&gt;
&lt;P&gt;31.&amp;nbsp; Fisher SA, Abecasis GR, Yashar BM, Zareparsi S, Swaroop A, Iyengar SK et al.&amp;nbsp; Meta-analysis of genome scans of age-related macular degeneration. Hum. Mol. Genet. 2005 Aug 1;14(15):2257-64. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15987700%5Buid%5D&amp;amp;WebEnv=02yb_YqIjCG9-M-y1HOWLOpvoeCm6AXUHmMNKXe26jiwiaLiIAzM05LneOwp5Gkaj6jCxQdZIstcr1C%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Chromosome 1q&lt;/H2&gt;
&lt;P&gt;32.&amp;nbsp; Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005 Apr 15;308(5720):421-4. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15761121%5Buid%5D&amp;amp;WebEnv=00b1Sqv4kXX02kD1UE6oYlFEd7hSzJblMKp8vRobOAU9nRqwqQ3rwGgyzVzabuPTbkbIVVZPmsLlg%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;33.&amp;nbsp; Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P et al.&amp;nbsp; Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005 Apr 15;308(5720):419-21. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15761120%5Buid%5D&amp;amp;WebEnv=0ZNZEyHyRpTdhkeyweG9Dz2VVQBTfodA-76SFuRMDgzdsOEsaoZYf1_l1vza4OaiBvV9gK5F2cwgD%40255D5EAC66958F10_0003SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;34.&amp;nbsp; Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI et al.&amp;nbsp; A common haplotype in the complement regulatory gene factor H (HF1/CFH)&amp;nbsp; predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 2005 May 17;102(20):7227-32. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15870199%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;35.&amp;nbsp; Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C et al. &amp;nbsp;Complement factor H polymorphism in age-related macular degeneration. Science. 2005 Apr 15;308(5720):385-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15761122%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;36.&amp;nbsp; Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J, Walport MJ, Botto M. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat. Genet. 2002 Aug;31(4):424-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12091909%5Buid%5D&amp;amp;WebEnv=0slGaMPddXdLPh6fHwI7n8W80db3dtTdx2ZwYBibeYTZ7tCVTP6WjLKFFmqJSy6adGvBiM9xWyG1Sho%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;37.&amp;nbsp; Ying L, Katz Y, Schlesinger M, Carmi R, Shalev H, Haider N et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 1999 Dec;65(6):1538-46. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10577907%5Buid%5D&amp;amp;WebEnv=0QMqb4dZWJ04QITg_lFiZsrMhKZwyMDkk8pWyP8kOTNRIXX6MNAxBQh847WxwuzhZLiKk5ELi99FxOf%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;38.&amp;nbsp; Duvall-Young J, MacDonald MK, McKechnie NM. Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. Br J Ophthalmol. 1989 Apr;73(4):297-302. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=2713310%5Buid%5D&amp;amp;WebEnv=0_irJzZ_R5XQC7k1PB-P6fm58pMigniz0Liw5kWZtxf4tHGOaRORnevFY4mm0horIqBTaLQcK5atBr6%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;39.&amp;nbsp; Okamoto H, Umeda S, Obazawa M, Minami M, Noda T, Mizota A et al.&amp;nbsp; Complement factor H polymorphisms in Japanese population with age-related macular degeneration. Mol. Vis. 2006 Mar 612:156-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16541016%5Buid%5D&amp;amp;WebEnv=0hj9RyXC2-vFr_CvpS-6AFn6CVdviYBwvd0rj4ilIYIHwnFKuTCV0_SJixUuUX_Ny6gXDp0u7gvK9g2%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;40.&amp;nbsp; Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat. Genet. 2006 Oct;38(10):1173-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16998489%5Buid%5D&amp;amp;WebEnv=0SBf1yaJsznrj3-TPQBvdxYlKnXc5cyxDErlkunYKWcabDOHxdEv3DqgeqE08MX9JtZ842wj0QydJbE%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Chromosome 10q &lt;/H2&gt;
&lt;P&gt;41.&amp;nbsp; Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am. J. Hum. Genet. 2005 Sep;77(3):389-407. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16080115%5Buid%5D&amp;amp;WebEnv=0YkFF5NdM0s91cDTEep6GrwlD8-ozIqas4RLuA3vlNiXXNRMFqsluFbpHyejxRSCzTszM9YX1CO6m2h%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;42.&amp;nbsp; Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum. Mol. Genet. 2005 Nov 1;14(21):3227-36. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16174643%5Buid%5D&amp;amp;WebEnv=0-s62oRlYhli0uaQQ0Yipr0-Zgp1oCqiKBNqps4PWg56YQLFQKJgzsQ56w8Ytm2pQY6km_C0V9niriv%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;43&amp;nbsp;&amp;nbsp; Yang Z, Camp NJ, Sun H, Tong Z, Gibbs D, Cameron DJ et al.&amp;nbsp;A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science. 2006 Nov 10;314(5801):992-3. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17053109%5Buid%5D&amp;amp;WebEnv=05eT_xWu6uFTmpZzkk1J422VswYetHho-jUhFCIM931cSe2zr4YtoS-EuHF7ZnoTAzWZpD-5uuLDZb5%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;44.&amp;nbsp; Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 2006 Nov 10;314(5801):989-92. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17053108%5Buid%5D&amp;amp;WebEnv=0VrldxccqnmHfUoPvfiYQ_o8gv_DJfhhfavksh7x5aKh1F1OvOb1Jqu1wKNk5EjQw--Sil0MRki3UGp%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;45.&amp;nbsp; Grau S, Richards PJ, Kerr B, Hughes C, Caterson B, Williams AS et al. The role of human HtrA1 in arthritic disease. J. Biol. Chem. 2006 Mar 10;281(10):6124-9. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16377621%5Buid%5D&amp;amp;WebEnv=0pCqXU_1AiK_CUDMglyHTouIa5_h9c93U7F1af8DEhvc6vTJmHblPc_XYAvSzUVkVyJb1U2zBAzjCiH%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Complement Factor B gene (BF)&lt;/H2&gt;
&lt;P&gt;46.&amp;nbsp; Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K; AMD Genetics Clinical Study Group, Hageman GS, Dean M, Allikmets R. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 2006 Apr;38(4):458-62. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16518403%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>262086</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=262086]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Images</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD NKW 2007]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week: Images - 18-24 June 2007&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Images (colour fundus photographs and fundus fluorescein angiograms) representing the different stages and types of Age Related Macular Degeneration are provided here :&amp;nbsp;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Early age related macular disease - drusen&lt;/LI&gt;
&lt;LI&gt;Advanced wet AMD - disciform scar&lt;/LI&gt;
&lt;LI&gt;Advanced dry AMD - geographic atrophy&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Subtypes of Wet (neovascular) AMD&amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Pigment epithelial detachment (PED)&lt;/LI&gt;
&lt;LI&gt;Classic Choroidal neovascular membrane &lt;/LI&gt;
&lt;LI&gt;Occult Choroidal neovascular membrane&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Fundus fluorescein angiography (FFA) is the gold standard imaging technique in routine clinical practice, used to differentiate the different sub-types of wet (neovascular) AMD: pigment epithelial detachment (PED), and classic or occult neovascular membranes.&amp;nbsp; FFA images are provided where relevant. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;All images are provided by Imaging Services at Moorfields Eye Hospital NHS Foundation Trust.&lt;/EM&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;4&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Drusen&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Early&amp;nbsp;age-related maculopathy: Drusen&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=228 alt="Colour fundus photograph of left eye with hard drusen" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0026_harddrusen.jpg" width=276 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;Colour fundus photograph of left eye&amp;nbsp;with hard drusen &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=180 alt="colour fundus photograph of right eye with intermediate drusen" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0027_intermediate.jpg" width=239 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;Colour fundus photograph of right eye&amp;nbsp;with intermediate drusen&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage2 height=211 alt="colour fundus photograph of right eye with soft drusen" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0028_softdrusen.jpg" width=265 border=0 name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P&gt;Colour fundus photograph of right eye&amp;nbsp;with soft drusen &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Courtesy of Ms S Mann, MD Thesis Collection, Specialist Registrar, Moorfields Eye Hospital NHS Foundation Trust&lt;/EM&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;2&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Geographic Atrophy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Advanced disease: Geographic Atrophy (GA)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=205 alt="Colour fundus photograph of right eye with advanced dry AMD" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0008_ga1gerrish.jpg" width=272 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Colour fundus photograph of right eye with advanced dry AMD - geographic atrophy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=205 alt="colour fundus photograph of left eye with advanced dry AMD" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0010_ga2gerrish.jpg" width=272 border=0 name=nelh_tempImage1&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Colour fundus photograph of left eye with advanced dry AMD&amp;nbsp;- geographic atrophy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=205 alt="Colour fundus photograph of left eye with advanced dry AMD" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0012_ga2phelps.jpg" width=272 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;Colour fundus photograph of left eye with advanced dry AMD - geographic atrophy&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Courtesy of Imaging Services at Moorfields Eye Hospital NHS Foundation Trust. &lt;/EM&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Disciform&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Advanced disease: Disciform&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=205 alt="Colour fundus photograph of left eye with end-stage wet AMD, disciform scar" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0019_amdc1lawrence.jpg" width=272 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Color fundus photograph of&amp;nbsp;left eye with end-stage wet AMD, disciform scar&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=205 alt="colour fundus photograph of right eye with end-stage wet AMD, disciform scar" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0020_amdc2lawrence.jpg" width=272 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;Colour fundus&amp;nbsp;photograph of&amp;nbsp;right eye with end-stage wet AMD, disciform scar&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Courtesy of Imaging Services at Moorfields Eye Hospital NHS Foundation Trust. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;PED&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Subtypes of wet AMD lesions: Pigment Epithelial Detachment (PED)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=205 alt="Colour fundus photograph of left eye with PED" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0021_pedc1rumbold.jpg" width=272 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Colour fundus photograph of left eye with PED&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage2 height=205 alt="PED left eye: FFA mid venous phase" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0023_pedf2rumbold.jpg" width=256 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;PED left eye : FFA mid venous phase&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 height=205 alt="PED left eye: FFA late venous phase" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0024_pedf3rumbold.jpg" width=256 border=0 name=nelh_tempImage3&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;PED left eye : FFA late venous phase&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage4 height=205 alt="PED left eye: FFA late phase" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0025_pedf4rumbold.jpg" width=256 border=0 name=nelh_tempImage4&gt;&lt;/P&gt;
&lt;P&gt;PED left eye&amp;nbsp;: FFA late phase&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Courtesy of&amp;nbsp;Imaging Services&amp;nbsp;at Moorfields Eye Hospital NHS Foundation Trust. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;7&lt;/pageID&gt;&lt;pageSequence&gt;7&lt;/pageSequence&gt;&lt;pageTitle&gt;Classic&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Subtypes of wet AMD lesions: Classic Choroidal Neovascular membrane (CNVM)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=205 alt="colour fundus photograph of left eye with suspected classic CNVM" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0004_classiccnv2c1rogers.jpg" width=272 border=0 name=nelh_tempImage1&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Colour fundus photograph of&amp;nbsp;left eye with&amp;nbsp;suspected classic CNVM&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=205 alt="Classic CNV Left eye : FFA arterio-venous phase" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0001_classiccnv2f1rogers.jpg" width=256 border=0 name=nelh_tempImage1&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Classic CNV left eye : FFA aterio-venous phase&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=205 alt="Classic CNV left eye : FFA mid venous phase" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0002_classiccmv2f2rogers.jpg" width=256 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Classic CNV left eye : FFA mid venous phase&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 height=205 alt="Classic CNV left eye : FFA late phase" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0003_classiccnv2f3rogers.jpg" width=256 border=0 name=nelh_tempImage3&gt;&lt;/P&gt;
&lt;P&gt;Classic CNV left eye : FFA late phase&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Courtesy of Imaging Services at Moorfields Eye Hospital NHS Foundation Trust. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;3&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Occult&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Subtypes of wet AMD lesions: Occult choroidal neovascular membrane (CNVM)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=205 alt="Colour fundus photograph of left eye with suspected occult CNVM" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0013_occult1cmarcuson.jpg" width=272 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Colour fundus photograph of left eye with suspected occult CNVM&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=205 alt="Occult CNV left eye : FFA early venous phase" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0014_occult1fmarcuson.jpg" width=256 border=0 name=nelh_tempImage1&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Occult CNV left eye : FFA early venous phase&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage2 height=205 alt="Occult CNV left eye: FFA mid venous phase" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0015_occult2fmarcuson.jpg" width=256 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Occult CNV left eye : FFA mid venous phase&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 height=205 alt="Occult CNV left eye: FFA late phase" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262086/nelhImp_0016_occult3fmarcuson.jpg" width=256 border=0 name=nelh_tempImage3&gt;&lt;/P&gt;
&lt;P&gt;Occult CNV left eye : FFA late phase&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Courtesy of Imaging Services at Moorfields Eye Hospital NHS Foundation Trust. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>262254</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=262254]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Living with AMD</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,AMD,AMD NKW 2007]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Living with AMD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Macular Disease Society / EVSL Management Team&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="Normal Vision " src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262254/nelhImp_0000_NormalVision.png" width=184 height=147&gt;&amp;nbsp;&lt;/EM&gt;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Vision with AMD" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262254/nelhImp_0001_kidsbottom.png" width=184 height=147&gt;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Amsler grid test" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262254/nelhImp_0002_AmslerGridTest.png" width=186 height=197&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;Abbreviations&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc9.html" target="_blank"&gt;Click here&amp;nbsp;to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/MDS%20Living%20with%20AMD%20.pdf" target="_blank"&gt;Click here&amp;nbsp;for printable (PDF) version&lt;/A&gt;&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/MDS%20Living%20with%20AMD%20.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;An overview of patients’ experiences of living with age related macular degeneration (AMD) was reported in a survey of members of the &lt;A href="http://www.maculardisease.org/" target="_blank"&gt;Macular Disease Society&lt;/A&gt;.[1]&amp;nbsp; Whilst it was primarily aimed at identifying their experiences with health care, it also served to highlight those related to changes in vision and the impact of the diagnosis on their well-being.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Experience with the health services&lt;/EM&gt;&lt;/STRONG&gt; - Over 50% of survey participants thought that at the time of their diagnostic consultation, their specialist was not interested in them as a person and 40% were dissatisfied with their diagnostic consultation because of staff attitude, lack of time for the consultation, and inadequate provision of information and advice about the condition. About 15% thought their general practitioner (GP) was well informed about macular disease but 31% thought their GP was not well informed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Visual changes&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp; - 78% of survey participants reported experiencing visual changes following onset of AMD.&amp;nbsp; The most frequently reported visual changes included : blurring of vision (46%) , problems seeing at night (38%), flashes of light (42%), problems with depth perception (28%), and visual hallucinations (25%).&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Well being&lt;/EM&gt;&lt;/STRONG&gt; -&amp;nbsp; 61% reported feeling anxious and depressed and 4% reported feeling suicidal, when given their diagnosis and the limitations in interventional options.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Quality of life&lt;/H2&gt;
&lt;P&gt;Decreased visual function, irrespective of the pathological reason for the decrease, is associated with diminished quality of life and functional activities of living.[2]&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;More specifically, recent systematic reviews [3, 4] provide evidence for the impact of AMD on quality of life, which includes functional impairment, depression, anxiety and emotional distress. Numerous measures of quality of life have been used in the literature, and it is likely that the effect of AMD on quality of life may be underestimated by inappropriate use and interpretation of health status and utility measures as quality of life measures.[4]&lt;/P&gt;
&lt;P&gt;When presented with the scenario of visual loss secondary to AMD through time trade off and standard gamble methods, health care professionals (ophthalmologists) and the general public may underestimate the value patients with mild, moderate, and severe ARMD attach to their vision and visual health.[5,6]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Activities of daily living –&amp;nbsp;&amp;nbsp; “What I miss” &lt;/H2&gt;
&lt;P&gt;About 60% of patients with AMD report loss of a valued activity.[7]&lt;/P&gt;
&lt;P&gt;Small qualitative studies frequently report that patients with low vision from AMD (and other causes) missed being independent, being able to do things on their own, they missed the spontaneity of being able to do what they wanted to do when they wanted to do it, and they missed their hobbies.[8, 9, 10]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Boredom and Loneliness&lt;/H2&gt;
&lt;P&gt;Qualitative studies report on the strong feelings of boredom as people found it difficult to fill their days, and in addition, for some, isolation and loneliness were real problems.[8]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Depression&lt;/H2&gt;
&lt;P&gt;Prospective observational studies have reported 24-33% of patients with AMD with recent visual loss as being depressed.[11 - 14]&lt;/P&gt;
&lt;P&gt;Minimally depressed patients with AMD, who would not be considered depressed according to current diagnostic standards, have been reported to suffer from decreased&amp;nbsp; vision function that cannot be accounted for by the severity of their eye disease or general medical problems.[15]&lt;/P&gt;
&lt;P&gt;Patients reporting the loss of a valued, discretionary activity have been observed to have worse visual acuity and more depressive symptoms and affective distress than other subjects. Affective distress occurs in AMD, largely to the extent that valued activities are relinquished because of vision loss.[7] &lt;/P&gt;
&lt;P&gt;Risk factors for depression in AMD are not well-defined, except for the degree of functional impairment and impending or actual loss of vision in the second eye. Behavioral and self-management programs may be effective in managing depression associated with AMD, but few studies have been performed, and none using drugs or multimodal therapy.[3, 13]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Visual Hallucinations - Charles Bonnet Syndrome &lt;/H2&gt;
&lt;P&gt;Charles Bonnet syndrome (CBS) is characterized by complex visual hallucinations in otherwise psychologically normal people, and associated with visual loss usually in later life, usually appearing after a period of worsening sight. The condition is named after the Swiss naturalist and philosopher who first described it in 1760 in his grandfather.&amp;nbsp;&amp;nbsp; The common conditions leading to the syndrome are age related macular degeneration, followed by glaucoma and cataract.[16]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Patients usually possess insight into the unreality of their visual experiences, which are commonly pleasant but may sometimes cause distress.&amp;nbsp; The hallucinations consist of well-defined, organized, and clear images over which the subject has little control. They may last from a few seconds to hours, and may persist for a few days to many years, changing in frequency and complexity, and they usually have no personal meaning.&amp;nbsp; People experiencing CBS realize that their hallucinations although interesting are not real. The hallucinations may be composed of patterns, lines . mosaics etc, or they may be more complicated and composed of groups of people, animals, or landscapes.[17]&lt;/P&gt;
&lt;P&gt;It is believed that they represent release phenomena due to de-afferentation of the visual association areas of the cerebral cortex, leading to a form of phantom vision. Cognitive defects, social isolation, and sensory deprivation have also been implicated in the etiology of this condition.[17]&lt;/P&gt;
&lt;P&gt;The condition often goes unrecognized in clinical practice, due to both lack of awareness among doctors and patients' reluctance to admit to hallucinatory experiences, for fear of being labeled mentally unstable.[17]&amp;nbsp; About 25% of patients with AMD&amp;nbsp;report visual hallucinations but less than half of them felt able to mention this to a health care professional.[1] &amp;nbsp;Of those that did report hallucinatory symptoms, the majority did not receive an explanation for them from the health care professionals.&lt;/P&gt;
&lt;P&gt;There is no universally effective therapeutic intervention, but awareness and empathy from health care professionals are important components of management and counseling.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Referral and Registration of Visual Impairment &lt;/H2&gt;
&lt;P&gt;Prior to 2005, a person with a sight loss would be included on the local register of visually impaired persons via the BD8 form, filled out by the hospital ophthalmologist. Since 2005, a new process has been introduced by the &lt;A href="http://www.dh.gov.uk/en/PolicyAndGuidance/HealthAndSocialCareTopics/Optical/DH_4074843" target="_blank"&gt;Department of Health&lt;/A&gt; that offers a route into low vision services from a variety of different entry points. There are three forms in use.&lt;/P&gt;
&lt;P&gt;The &lt;A href="nelh:156963:0" name=internalLink&gt;LVL (Low Vision Leaflet)&lt;/A&gt; is a self-referral letter for optometrists to give to people who present to them with low vision. &lt;/P&gt;
&lt;P&gt;The &lt;A href="nelh:102231:0" name=internalLink&gt;RVI (Referral of Visual Impairment)&lt;/A&gt; may be issued by staff in the hospital eye service to refer the patient (with consent) for a social care assessment as needs arise.&lt;/P&gt;
&lt;P&gt;The &lt;A href="nelh:84014:0" name=internalLink&gt;CVI (Certificate of Visual Impairment)&lt;/A&gt; – a certificate establishing eligibility for registration as either sight impaired (previously partially sighted) or severely sight impaired (previously blind).&amp;nbsp; It has replaced the BD8 form that served this function.&amp;nbsp; It requires the signature of a consultant ophthalmologist.&amp;nbsp; Registration is voluntary but does entitle people to various &lt;A href="nelh:98727:0" name=internalLink&gt;benefits and concessions&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Access to Low Vision Services &lt;/H2&gt;
&lt;P&gt;A patient does not need to be registered as visually impaired to be eligible for low vision and rehabilitation intervention. They just need to be of a level of vision that would make them eligible for registration. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Patient Information&lt;/H2&gt;
&lt;P&gt;In addition, local societies and national groups provide both specific advice on living with AMD and general help dealing with sight loss.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:61305:0" name=internalLink&gt;Action for Blind People&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;National Freephone Helpline: 0800 915 4666&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:229061:0" name=internalLink&gt;Macular Disease Society&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Telephone: 0845 241 2041&lt;/P&gt;
&lt;P&gt;Email: &lt;A href="mailto:info@maculardisease.org" target="_blank"&gt;info@maculardisease.org&lt;/A&gt; &lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;A href="nelh:29474:0" name=internalLink&gt;RNIB&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Helpline: 0845 766 9999&lt;/P&gt;
&lt;P&gt;Email: &lt;A href="mailto:helpline@rnib.org.uk" target="_blank"&gt;helpline@rnib.org.uk&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref9.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;References &lt;/H2&gt;
&lt;P&gt;1.&amp;nbsp; Mitchell J, Bradley P, Anderson SJ, Ffytche T, Bradley C.&amp;nbsp; Perceived quality of health care in macular disease: a survey of members of the Macular Disease Society.Br J Ophthalmol. 2002 Jul;86(7):777-81 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12084749%5Buid%5D&amp;amp;WebEnv=0h_0W85ellETQUmTIhNehevcxXd8ToyD44aj4TRWBzGY5Ml5Hjcv9p_BwdDF3_WcNbTqYDxYgSewD6a%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; Knudtson MD, Klein BEK, Klein R, Cruickshanks KJ, Lee KE. Age-related eye disease, quality of life, and functional activity.A Archives of Ophthalmology 2005, Vol/Iss/Pg. 123/6 (807-814)&amp;nbsp;&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15955982%5Buid%5D&amp;amp;WebEnv=0rGF8AuzbsMEuwAvG9ROF5a203YNsk1C-fvgju5K8olQxmgO-ye8OkgPUNuDKY9t8aCU0wrM6iKgeh-%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; Berman K, Brodaty H.&amp;nbsp; Psychosocial effects of age-related macular degeneration. Int Psychogeriatr. 2006 Sep;18(3):415-28. Epub 2006 Feb 8.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16466594%5Buid%5D&amp;amp;WebEnv=0PR8umy7h7v9_jkghnU70zX4BNAYJ9OIFelh9ZNedWQUYTsB6Y9bec1t_cOY1_5Tr8iqKVDFN1ozKSC%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes. 2006 Dec 21;4:97.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17184527%5Buid%5D&amp;amp;WebEnv=0J4ZpcBpA7thbXTF8IVtwr-WTxU4lcwBUckN4jVaSzsc1yMTt9F6PuLlS42r2N1fm1sWU_p8jy-2Mc2%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; Brown GC, Brown MM, Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration.Can J Ophthalmol. 2000 Apr;35(3):127-33. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10812481%5Buid%5D&amp;amp;WebEnv=0AS8q0CMx1KbP4zyzvnjTFmgSDAB4JWhIrz7G-osOCLadd--vu_eGNLLUYwYDQQv5rkShPPk69lgvdg%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp; Stein JD, Brown MM, Brown GC, Hollands H, Sharma S. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members.Br J Ophthalmol. 2003 Jan;87(1):8-12. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12488253%5Buid%5D&amp;amp;WebEnv=0k9Mtw8J_mxVuH8jxifqwRZmh1fXubxMCVW9MwNCCHp4MyvS3uR3aT_EWEhNZ1kJ4q6qcvI8Sio7jpN%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp; Rovner BW, Casten RJ.&amp;nbsp; Activity loss and depression in age-related macular degeneration.Am J Geriatr Psychiatry. 2002 May-Jun;10(3):305-10. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11994218%5Buid%5D&amp;amp;WebEnv=0brBhGv2cBZ9aQItL9SGZxBGU4nJl6rBN-hhwOockQPoSxOG_XeKvFAS65wUBDFJ-kYGc_M7LOCKyjj%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp; Palmer S.&amp;nbsp; Factors which Influence the use of Low Vision Aids Visibility May 2005. &lt;A href="nelh:102007:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp; Moore LW, Miller M.&amp;nbsp; Older men's experiences of living with severe visual impairment.J Adv Nurs. 2003 Jul;43(1):10-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12801392%5Buid%5D&amp;amp;WebEnv=00D1M4nmzTXeaZ7SqEko2iiYuYbtw1cOtHsP5VKGhY2ieO3f13_B92Glt4vspaIJviAcIV4wwS_F5RO%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp; Moore LW. Severe visual impairment in older women. West J Nurs Res. 2000 Aug;22(5):571-88; discussion 588-95. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10943172%5Buid%5D&amp;amp;WebEnv=0lj5VgBt19xsGcTqUvd8Q7GzKye4uc-Jrq0cltxMOsXmN0_bm1SGumZ6rPk-rNRP5QaXTP3xg9fnJjh%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp; Horowitz A, Reinhardt JP, Kennedy GJ.&amp;nbsp; Major and subthreshold depression among older adults seeking vision rehabilitation services.Am J Geriatr Psychiatry. 2005 Mar;13(3):180-7. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15728748%5Buid%5D&amp;amp;WebEnv=0Pu14yO3skEqXCu4RMVDI1NcyJNq4gkrrqso_cmQVD08vggJjxC3VnTXsiyb8qMA7pRx9Lfme7MXZCh%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp; Rovner BW, Casten RJ, Tasman WS.&amp;nbsp; Effect of depression on vision function in age-related macular degeneration.Arch Ophthalmol. 2002 Aug;120(8):1041-4. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12149057%5Buid%5D&amp;amp;WebEnv=0vIWicL0gC97ht0D9FW1XdlTEbl0S6OI2_DEaJcdp_MMS73AXae0UT0DiH4bM1ZHA36I6c4Edu4bCkq%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp; Rovner BW, Casten RJ. Neuroticism predicts depression and disability in age-related macular degeneration. J Am Geriatr Soc. 2001 Aug;49(8):1097-100.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11555073%5Buid%5D&amp;amp;WebEnv=0s7tYtYrn-WzmdxxiDCHzHfj9kQAShyWyux-g0Rn3dJuLGw-i8B8Qg5FBtNqgUGUGJEwXJUXKAG-oIm%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp; Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, et al.&amp;nbsp; Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001 Oct;108(10):1893-900; discussion 1900-1.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11581068%5Buid%5D&amp;amp;WebEnv=0IFbvGTCEUQKSxPGGfJwxOVsvEeRBA6wSot8dgzjjl18on6qS4dmQ3_LXafUC0DwYogrQIGDkAs2Udx%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp; Rovner-Barry-W, Casten-Robin-J, Hegel-Mark-T, Tasman-William-S. Minimal depression and vision function in age-related macular degeneration. Ophthalmology,&amp;nbsp;Oct 2006 (epub: 07 Aug 2006), vol. 113, no. 10, p. 1743-7 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16893569%5Buid%5D&amp;amp;WebEnv=0X6xIopnKRWCg-b3eijy_GG9cy96fNiDl3bunV3j7lHTdoDnoQ5rgsGWAP6jelzgb6muYbR-gk_cXV5%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp; Jacob A, Prasad S, Boggild M, Chandratre S. Charles Bonnet syndrome--elderly people and visual hallucinations. BMJ. 2004 Jun 26;328(7455):1552-4. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15217875%5Buid%5D&amp;amp;WebEnv=0ckBhdZtFYT4mqBmYXKGwCi3qHTixF1tIrlBdpaECxAfbT4dwArFjxF-cN8XnviU_fxYavKYMW9mWCF%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp; Menon GJ, Rahman I, Menon SJ, Dutton GN.&amp;nbsp; Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome.Surv Ophthalmol. 2003 Jan-Feb;48(1):58-72. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12559327%5Buid%5D&amp;amp;WebEnv=0nmNEx-SBLtT5fY2BrvHKVTKn-r3KHu8vMTc-UzHjnf9ssWM8ekzGS4gDx-T1uZEQlYSFjl67K7HQ37%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Patient Information:&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.rnib.org.uk/xpedio/groups/public/documents/PublicWebsite/public_rnib003641.hcsp" target="_blank"&gt;RNIB Patient information Leaflet&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>262217</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=262217]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Low Vision Aids and AMD</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD NKW 2007,AMD,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Low Vision Aids and AMD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Jane Macnaughton MCOptom, Optometrist, Visiting Lecturer, City University, London, Director of CLEARVIEW Training. Member of the Council, College of Optometrists.&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 border=0 name=nelh_tempImage3 alt="Normal vision" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262217/nelhImp_0003_NormalVision.png" width=184 height=147&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="Vision with AMD" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262217/nelhImp_0004_kidsbottom.png" width=184 height=147&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Amsler Grid Test" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262217/nelhImp_0005_AmslerGridTest.png" width=186 height=175&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc8.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Low%20Vision%20Aids%20and%20AMD.pdf" target="_blank"&gt;Click here for printable (PDF) version&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/Low%20Vision%20Aids%20and%20AMD.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P align=left&gt;In the early stages of dry age related macular degeneration (geographical atrophy), patients most commonly complain of blurred vision and reading text appears ‘jumbled.’ In wet age related macular degeneration (neovascular), vision initially appears distorted (metamorphopsia).&amp;nbsp; In both cases, onset tends to be asymmetrical but eventually both eyes are usually affected. With progression, a loss of central vision, or central scotoma, is common to both types of age related macular degeneration (AMD).&amp;nbsp; This can result in a reduction or loss in several functional components of vision:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;visual acuity &lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;contrast sensitivity&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;visual field &lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;colour perception &lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;fixation ability &lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;glare recovery&amp;nbsp;&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;stereoacuity&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;Everyday tasks e.g. recognising faces and reading might become increasingly difficult or impossible.&amp;nbsp; Peripheral vision is not affected by AMD, so that navigational vision from the peripheral field is spared. [1, 2]&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;The purpose of low vision rehabilitation&lt;/STRONG&gt; is to utilise or enhance the patient’s residual vision in order that he or she may continue to perform daily living tasks and retain the best quality of life.&amp;nbsp; An important component of rehabilitation is the amount of training and exposure needed to become proficient with the use of low vision aids (LVAs) – optical and non-optical.&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;An optical low vision aid (LVA)&lt;/STRONG&gt; is any device that alters the image focus, size, contrast, brightness, color or directionality of an object through the use of lenses or other technology.&amp;nbsp; Optical LVAs are intended: 1) to improve visual acuity by enlarging images or by clarifying images through improved illumination, color, or contrast enhancement, or 2) to enhance the field of view.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;Low Vision Aids -&amp;nbsp;Magnification &lt;/H2&gt;
&lt;P align=left&gt;Magnification can help with detailed tasks.&amp;nbsp; There are four approaches to magnification, and often a combination of these are used:&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;STRONG&gt;i.&amp;nbsp;&amp;nbsp;&amp;nbsp; Increasing the size of the object (Relative size magnification).&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp; &lt;BR&gt;The retinal image size can be simply increased by increasing the size of the object.&amp;nbsp; The most commonly encountered practice of this is with enlarged print.&amp;nbsp; Examples include large print books, maps, newspapers, magazines and greeting cards; large button telephones, watches and clocks. &lt;/P&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage0 border=0 name=nelh_tempImage0 alt="Large print tube and bus maps" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262217/nelhImp_0000_Largeprinttubemap.jpg" width=300 height=225&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=left&gt;Image 1 :&amp;nbsp;&amp;nbsp;Example of large print: Large Print tube and bus maps – issued by London Regional Transport &lt;BR&gt;(photo provided by courtesy of Jane Macnaughton)&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;EM&gt;ii.&amp;nbsp;&amp;nbsp;&amp;nbsp; Bringing the object closer to the eye – (Optical aids)&lt;BR&gt;&lt;/EM&gt;&lt;/STRONG&gt;When an object is brought closer towards the eye, it appears larger.&amp;nbsp;&amp;nbsp;&amp;nbsp; Its image can be&amp;nbsp;focused on the retina using a simple optical devices such as magnifying lens mounted in suitable housing to facilitate handling e.g. hand magnifiers, stand magnifiers and spectacle magnifiers.&amp;nbsp; Illuminated versions of hand and stand magnifiers are available, and more recently with LED light sources which have superior light quality.&amp;nbsp; Magnifiers are used at, or within the focal length of the magnifying lens, which amounts to a relatively short working distance.&amp;nbsp; This limits the level of magnification that is practical to achieve.&amp;nbsp; Page navigation difficulties are also a limiting factor for the use of hand and stand magnifiers, Motor skills and training on the use of these devices are likely to influence page navigation.[3] &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;EM&gt;iii.&amp;nbsp;&amp;nbsp; Reproducing an image of the object electronically - (Electronic optical aids)&lt;BR&gt;&lt;/EM&gt;&lt;/STRONG&gt;The magnified image is electronically produced onto a display screen or monitor with magnification levels significantly higher than with optical devices.&amp;nbsp; A major advantages of electronic vision enhancement systems (EVES)&amp;nbsp;is their ability to enhance contrast, thus improving the visibility of the image.&amp;nbsp; These include -&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;Conventional CCTV&lt;/EM&gt; - this is the most commonly recognised EVES.&amp;nbsp; A camera with an integral zoom system is set above a moveable XY Table on which the object is placed. This captures an image of the object which is then displayed ‘live’ onto the monitor in front of the patient, typically at eye level.&amp;nbsp; It is also now possible to combine a desktop computer with a CCTV system; dual presentation is managed on a split screen.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;Portable Optical Mouse systems&lt;/EM&gt; – here the camera is set within an optical ‘computer’ mouse that fits into the patient’s hand.&amp;nbsp; The mouse is then moved over the printed text or object and the image is displayed onto a television or computer screen.&lt;/P&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage1 border=0 name=nelh_tempImage1 alt="Portable optical mouse system" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262217/nelhImp_0001_Portableopticalmousesystem.png" width=382 height=255&gt;&lt;/P&gt;
&lt;P align=left&gt;Image 2.&amp;nbsp;&amp;nbsp; Portable Optical Mouse system&lt;BR&gt;(photo source :&amp;nbsp; Bierley)&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;Video magnifiers&lt;/EM&gt; – these are essentially portable CCTV systems, with rechargeable battery packs capable of sustaining up to several hours of usage.&amp;nbsp; A single unit incorporates both the display screen and the camera and is placed over the object at a fixed distance.&amp;nbsp; Some are small enough to put in a pocket or handbag.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="portable video magnifier" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262217/nelhImp_0002_portablevideomagnifier.jpg" width=305 height=229&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;Image 3. Pocket Reader: Portable video magnifier, Set at 7x magnification, Small and lightweight, Reading and writing, Charging/mains power&lt;BR&gt;(photo provided by courtesy of Jane Macnaughton)&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;Head-mounted device (HMD) systems&lt;/EM&gt; - these are generally small, compact and portable, and can be used to magnify near, intermediate and distant objects. The&amp;nbsp;miniature camera, usually hand held or set within an optical mouse is connected to a high quality liquid crystal display screen (LCD) set in front of the patient’s eyes.&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;EM&gt;iv.&amp;nbsp;&amp;nbsp; Telescopic magnification&lt;BR&gt;&lt;/EM&gt;&lt;/STRONG&gt;Near vision telescopes may be cemented or clipped onto the front surface of the patient’s spectacles.&amp;nbsp; Whilst this confers a greater working distance, they may not be well tolerated because of their weight and cosmetic appearance. &lt;/P&gt;
&lt;P align=left&gt;Telescopic magnification is also the principal method of magnifying a distant object.&amp;nbsp; With training, use of a telescopic aid can offer a significant improvement in face recognition tasks and may be useful in reducing the handicap associated with this disability. [4]&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;Sourcing Low Vision Aids&lt;/H2&gt;
&lt;P align=left&gt;Most optical Low Vision Aids are prescribed through the Hospital Eye Service, local Blind Society or by a dedicated practitioner who is prescribing low vision devices on behalf of the Primary Care Trust.&amp;nbsp; To find out who prescribes aids at a local level, patients are directed to local Social Services.&lt;/P&gt;
&lt;P align=left&gt;In addition, both the Partially Sighted Society and the Royal National Institute for the Blind offer low vision assessments and training.&lt;/P&gt;
&lt;P align=left&gt;Most electronic devices are bough direct from the suppliers, although the RNIB and some local blind societies have a number of devices available for demonstration purposes.&amp;nbsp; Funding for those patients who are still in employment and who require specialist equipment for work is available from &lt;A href="http://www.jobcentreplus.gov.uk/JCP/Customers/HelpForDisabledPeople/AccesstoWork/" target="_blank"&gt;Access to Work (AtW)&lt;/A&gt; :&amp;nbsp; information is found via the local JobCentre.&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;Environmental Adaptation - Improved lighting for AMD &lt;/H2&gt;
&lt;P align=left&gt;Good lighting is important for performing near tasks such as reading, and to enhance contrast sensitivity.&amp;nbsp; The Chartered Institution of Building Services Engineers [5] recommends that illuminance levels for the elderly should be increased by 50-100%.&amp;nbsp; CIBSE recommends illuminance levels of 300 lux for sustained reading or sewing for younger patients with an increase to 450-600 lux in elderly patients and to approximately 1000 lux in patients with AMD.&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;Eccentric Viewing and Steady Eye Strategy&lt;/H2&gt;
&lt;P align=left&gt;Steady eye strategy (SES), involves keeping the eye still and moving the text from right to left.&amp;nbsp; Eccentric viewing (EV) is a technique by which the patient will view an object eccentric to the fovea, with a preferred retinal location, (PRL).&amp;nbsp; Both techniques are used in AMD patients with central scotomata and may be used either together or independently.&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;Eccentric viewing is usually established at an early age in patients with a congenital macular loss; the patient may not be aware that they are looking to the side of an object, or not looking directly at an individual.&amp;nbsp; Several small studies have looked at the development of eccentric viewing and the PRL [6-11], with one study suggesting an early development of a repeatable PRL in elderly patients with AMD&amp;nbsp;within a few months of scotoma development [8], and another proposing the use of a trained retinal locus (TRL), with a further increase in reading performance.[6] &lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;The Effectiveness of Low Vision Aids &lt;/H2&gt;
&lt;P align=left&gt;There is a need for high quality research in this area as evidence from the peer-reviewed published literature to inform choices about provision of optical low vision aids, is inconclusive.&lt;/P&gt;
&lt;P align=left&gt;A &lt;A href="nelh:254067:0" name=internalLink&gt;systematic review&lt;/A&gt; [12] assessing the effectiveness of optical devices for adults with low vision reported on the paucity of high quality evidence in the peer-reviewed published literature to inform choices about provision of optical low vision aids.&amp;nbsp; The best evidence consisted of seven small, prospectively controlled clinical studies comparing the performance of optical low vision aids for reading tasks at various distances in a controlled indoor setting: – &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Evidence of preferences and use of aids were anecdotal.&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Sustained use of low visual aids in the subject’s life setting, resources required in terms of costs and training associated with each alternative.&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;The link between the type of device use and health related quality of life were unknown.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;EM&gt;More recently a Cochrane review&lt;/EM&gt;&lt;/STRONG&gt; [13] assessed the effectiveness of reading aids for adults with low vision.&amp;nbsp; This review included any randomised controlled trials in which any device or aid used for reading had been compared to another device or aid in people aged 16 or over with low vision.&amp;nbsp; It concluded that – &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Findings reported from small studies of unclear quality and weak design comparing various types of electronic or optical devices were inconclusive&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;There was no evidence supporting the use of a specific type of electronic or optical device for the most common profiles of a LVA user.&lt;/DIV&gt;&lt;/LI&gt;
&lt;LI&gt;
&lt;DIV align=left&gt;Prism spectacles used for eccentric viewing techniques were no more effective than conventional spectacles for people with age-related macular degeneration [14]&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref8.pdf" target="_blank"&gt;Click here&amp;nbsp;to view search strategy&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;References &lt;/H2&gt;
&lt;P align=left&gt;1.&amp;nbsp; Understanding age-related macular degeneration (AMD). RNIB. &lt;A href="http://www.rnib.org.uk/xpedio/groups/public/documents/PublicWebsite/public_rnib003635.hcsp" target="_blank"&gt;[webpage]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;2.&amp;nbsp; Making things easier to see - See for yourself. RNIB. &lt;A href="http://www.rnib.org.uk/xpedio/groups/public/documents/PublicWebsite/public_easiertosee.hcsp" target="_blank"&gt;[webpage]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;3.&amp;nbsp; Bowers-Alex, Cheong-Allen-M-Y, Lovie-Kitchin-Jan-E.&amp;nbsp;Reading with optical magnifiers: page navigation strategies and&amp;nbsp;difficulties.&amp;nbsp; Optometry and vision science, Jan 2007, vol. 84, no. 1, p. 9-20. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17220774%5Buid%5D&amp;amp;WebEnv=0l543v8icbC8PBQP4E0jbr4upEL6b3Wqa1FO_ACKgzrXA9bv-idoFlZstcC_Iuq4sjZ9pe2VM_qC499%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;4.&amp;nbsp; Tejeria L, Harper RA, Artes PH, Dickinson CM. The British journal of ophthalmology. Face recognition in age related macular degeneration: perceived disability, measured disability, and performance with a bioptic device.&amp;nbsp;&amp;nbsp; Br-J-Ophthalmol, Sep 2002, vol. 86, no. 9, p. 1019-26. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12185131%5Buid%5D&amp;amp;WebEnv=0ea1EJQAlPemNniiAoW4nC00w57rVtEHRZCZZrIY-7VKWSe-kQV-LF1RCZrr-sQvSSVUzi39emLRz71%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;5.&amp;nbsp; Providing visibility for an ageing workforce. Factfile No 10. The Society of Light and Lighting, Part of the Chartered Institution of Building Services Engineers. November 2006.&amp;nbsp;&lt;A href="http://www.cibse.org/pdfs/Factfile10web.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;6.&amp;nbsp; Déruaz A, Goldschmidt M, Whatham AR, Mermoud C, Lorincz EN, Schnider A, Safran AB.&amp;nbsp;A technique to train new oculomotor behavior in patients with central macular scotomas during reading related tasks using scanning laser ophthalmoscopy: immediate functional benefits and gains retention.&amp;nbsp; BMC Ophthalmology, 2006 (epub), vol. 6, p. 35. &lt;A href="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1693567&amp;amp;blobtype=pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;7. &amp;nbsp;Nilsson UL, Frennesson C, Nilsson SE.&amp;nbsp; Location and stability of a newly established eccentric retinal locus suitable for reading, achieved through training of patients with a dense central scotoma.&amp;nbsp; Optometry and vision science, Dec 1998, vol. 75, no. 12, p. 873-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9875992%5Buid%5D&amp;amp;WebEnv=00V1Wtd5BsXVO1HirEZ3eAvIuePs8WQOCdoCCaKnM7OImO5Y5_5s96YhWilslCLAN5A2_NGx8SMeYOO%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;8.&amp;nbsp; Crossland MD, Culham LE, Kabanarou SA, Rubin GS.&amp;nbsp;Preferred retinal locus development in patients with macular disease.&amp;nbsp; Ophthalmology, Sep 2005, vol. 112, no. 9, p. 1579-85. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16087239%5Buid%5D&amp;amp;WebEnv=0coBVN0IpvTHka42aXyuUCxwqb-vvGRthCkCZsaK9estDTPvDZV4jRj1-d_XbVKfQ6xbN1nw9Wm0lJZ%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;9.&amp;nbsp; Nilsson UL, Frennesson C, Nilsson SEG. Patients with AMD and a large absolute central scotoma can be trained successfully to use eccentric viewing, as demonstrated in a scanning laser ophthalmoscope.&amp;nbsp; Vision research, Jul 2003, vol. 43, no. 16, p. 1777-87.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12818347%5Buid%5D&amp;amp;WebEnv=04zqps4cnbFz9Q596J2zWsfJiJrKxUdoiSLtDyCAGOzv8ZvLB9uRW6uEmye_gOD8jtEQIcEG-UDy9Fr%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;10. &amp;nbsp;Déruaz A, Matter M, Whatham AR, Goldschmidt M, Duret F, Issenhuth M, Safran AB.&amp;nbsp; Can fixation instability improve text perception during eccentric fixation in patients with central scotomas?&amp;nbsp; The British journal of ophthalmology,&amp;nbsp;Apr 2004, vol. 88, no. 4, p. 461-3.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15031154%5Buid%5D&amp;amp;WebEnv=0Ac8XvoDPTKevN7PfvAO-FmESjwLSB-hKqEq0Pon9KX_rd2lHTOLGP6NonQYAwI7k_kW4tgmH9tvUWz%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;11.&amp;nbsp; Verezen CA, Meulendijks CFM, Hoyng CB, Klevering BJ.&amp;nbsp; Long-term evaluation of eccentric viewing spectacles in patients with bilateral central scotomas.&amp;nbsp; Optometry and vision science, Feb 2006, vol. 83, no. 2, p. 88-95. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16501410%5Buid%5D&amp;amp;WebEnv=0Pu14yO3skEqXCu4RMVDI1NcyJNq4gkrrqso_cmQVD08vggJjxC3VnTXsiyb8qMA7pRx9Lfme7MXZCh%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;12.&amp;nbsp; Adams E, Flynn K, Alligood E, Johnson T.&amp;nbsp;Optical&amp;nbsp;devices for adults with low vision: a systematic review of published studies of effectiveness.&amp;nbsp; Boston Technology Assessment Unit 2003. &lt;A href="nelh:254067:0" name=internalLink&gt;[full text]&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;13.&amp;nbsp;&amp;nbsp;Virgili G, Acosta R.&amp;nbsp; Reading aids for adults with low vision.&amp;nbsp;&lt;BR&gt;Cochrane database of systematic reviews (Online),&amp;nbsp; 2006 (epub), no. 4, p. CD003303. &amp;nbsp;&lt;A href="nelh:237745:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P align=left&gt;14.&amp;nbsp; Smith HJ, Dickinson CM, Cacho I, Reeves BC, Harper RA.&amp;nbsp;&amp;nbsp;&amp;nbsp;A randomized controlled trial to determine the effectiveness of prism spectacles for patients with age-related macular degeneration.&amp;nbsp; Archives of ophthalmology, Aug 2005, vol. 123, no. 8, p. 1042-50. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16087836%5Buid%5D&amp;amp;WebEnv=0lr5h2_qh0xat1G70v9PTnqgK3ArR1OJwtnPGpxmX_b-00Bec42RulGsDsb-kEkFQoaor7YVa9ic1bF%40264F2A3E66FB4C90_0135SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>261333</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=261333]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Surgical intervention: Macular Translocation</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,EYE,HEAD &amp; NECK,SURGERY,SURGERY,AMD NKW 2007,ANNUAL EVIDENCE UPDATES,AMD,RETINA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Surgical intervention: Macular Translocation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Mr Lyndon da Cruz, MBBS, MA, FRCOphth, PhD, FRACO, Consultant Ophthalmic Surgeon, Specialist in Medical and Surgical Retina, Moorfields Eye Hospital, London. &lt;/EM&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&amp;nbsp; &lt;IMG id=nelh_tempImage4 border=0 name=nelh_tempImage4 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261333/nelhImp_0000_Surgery-WetAMD.jpg" width=191 height=144&gt;&amp;nbsp;&lt;/EM&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;&lt;IMG id=nelh_tempImage2 border=0 name=nelh_tempImage2 alt="Central scotoma and distortion" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261333/nelhImp_0002_Centralscotomaanddistortion.png" width=191 height=163&gt; &lt;IMG id=nelh_tempImage5 border=0 name=nelh_tempImage5 alt="" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID261333/nelhImp_0001_SurgeryClassic.jpg" width=191 height=144&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc7.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Surgery.pdf" target="_blank"&gt;Click here for printable (PDF) version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/Surgery.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;Introduction&lt;/H2&gt;
&lt;P&gt;Surgery for Age-Related Macular Degeneration (AMD) has evolved over the past 20 years with various techniques being used to try and improve or stabilise vision.&amp;nbsp; Of all of these techniques the one that continues to be used with some evidence base and good documentation in the literature is 360 degree or full - macular translocation. This technique is practiced at a few centres in the UK with specialist vitreo-retinal surgical units. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Macular Translocation (MT)&lt;/H2&gt;
&lt;P&gt;Macular translocation is a surgical procedure that was first described in 1993 by Robert Machemer as a way to treat acute Neovascular Age-Related Macular Degeneration (wet AMD). The initial case series demonstrated that the surgery was feasible and that it could restore vision.[1, 2]&amp;nbsp; The concept of macular translocation is different to many of the current alternatives treatments for wet degeneration.&amp;nbsp; This is because all of the other treatments are directed at treating the new vessels that grow beneath the macula.&amp;nbsp; In translocation the retina is moved away from the abnormal vessels to an area of normal retinal pigment epithelium (RPE) and choroid.&amp;nbsp; As such the nature of the disease process and the type of new vessels are secondary to the state of the retina in determining outcome when surgery occurs.&amp;nbsp; The operation is usually reserved for the second eye to lose vision due to the chance of long-term torsional diplopia.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Surgery&lt;/H2&gt;
&lt;P&gt;One of the major problems in terms of macular translocation as a treatment for wet AMD has been the complexity and length of the surgery. The surgery can be carried out under local or general anaesthesia. The technique is well described in the literature.[3, 4, 5]&amp;nbsp; Essentially, following a vitrectomy, the retina is detached by infusion of a balanced salt solution under it.&amp;nbsp; The entire perimeter of the retina is cut so that it is only attached to the optic disc and is freely mobile. The abnormal vessels are removed and the retina is reattached with the macula rotated away from the original disease site.&amp;nbsp; The eye is then filled with silicone oil.&amp;nbsp; At a second operation, the whole globe is rotated in the opposite direction with muscle surgery in order to remove the induced torsion from the translocation. The silicone is then removed from the eye.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Outcomes – evidence base&lt;/H2&gt;
&lt;P&gt;The outcomes data concerning macular translocation surgery has been based mainly on large case series’ and a prospective randomised control trial. In the single prospective, randomised, non-masked, monocentre, pilot-trial, 50 eyes of 50 patients were randomly assigned to either macular translocation or photodynamic therapy PDT.[6]&amp;nbsp; Improvement of one or more ETDRS lines was found in 56% of patients undergoing translocation and 16% of the eyes in the PDT arm.&amp;nbsp; This difference was highly statistically significantly. In terms of preventing severe vision loss, 80% of eyes in the translocation group and 64% in the PDT group had less than three ETDRS lines of vision loss. This was not statistically significant. There were significant complications in the translocation group with Retinal detachment in six eyes and residual diplopia in five patients. Despite the significant difference in final visual outcome in favour of translocation it was concluded by the authors that in the light of outcomes from the anti-VEGF medications the use of translocation as a primary treatment for wet AMD was not indicated [6]. No published trial of translocation versus anti-VEGF agents is available.&lt;/P&gt;
&lt;P&gt;The other sources of information in terms of outcomes are the many case series reported. The largest series’ show; In 50 eyes, vision was improved by 2 or more Snellen lines in 33 eyes (66%) and remained stable (+/-1 line) in 14 eyes (28%), 3 eyes (6%) experienced a deterioration of 2 or more lines. The final vision was 20/50 or better in 32% of the cases [7]; In 90 eyes visual acuity increased by 15 or more letters in 24 patients, remained stable in 37 patients, and deteriorated by 15 or more letters in 29 patients at 12 months postoperatively [5]; In 61 eyes median distance acuity improved from approximately 20/125 before surgery to approximately 20/80 (Snellen equivalents to logMAR)) by 12 months after surgery.[8] &amp;nbsp;Most recent series have shown an average significant increase in distance vision following translocation surgery. All are uncontrolled and the method of reporting vision varies. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Complications&lt;/H2&gt;
&lt;P&gt;The major complications of translocation include (range of frequency of occurrence given as percentage):&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Proliferative Vitreoretinopathy –18-24% [5,6,7]&lt;/LI&gt;
&lt;LI&gt;Retinal Detachment - 19-24% within 12 months [5,6]&lt;/LI&gt;
&lt;LI&gt;Macular Oedema - 28-44% [5,6,8]&lt;/LI&gt;
&lt;LI&gt;CNV Recurrence - 3-56% [5,6,7,8]&lt;/LI&gt;
&lt;LI&gt;Epiretinal Membrane (ERM) - 8%-23% [5,8,9]&lt;/LI&gt;
&lt;LI&gt;Hypotony - 2-28% [5,6,7,8,9]&lt;/LI&gt;
&lt;LI&gt;Corneal Decompensation - 1- 5% [5,9]&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Findings from recently completed trials will be reporting shortly on other complications e.g. angle closure glaucoma.[10] &lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Quality of life (QoL)&lt;/H2&gt;
&lt;P&gt;Quality of life has become a more important part of treatment outcome and is especially relevant where treatments may be efficacious but cause complications. The literature for QoL and translocation is small but reflects the conflict of good visual outcome in the presence of complex surgery and complications.&amp;nbsp; The series reported by Cahill show the overall improvement in QoL after translocation reflecting the improvement in visual acuity.&amp;nbsp; The groups with the greatest improvement were those that had the greatest visual recovery.&amp;nbsp; In the prospective randomized trial of MT versus PDT the quality of life data showed stability of QoL for both treatments. The greater improvement in visual acuity after translocation was not reflected by a proportional improvement in QoL.&amp;nbsp; The authors commented that this is likely due to the improvement in acuity being tempered by the complications in the surgical group.[11,12,13]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Strabismus&lt;/H2&gt;
&lt;P&gt;The second part of the macular translocation operation is the globe counter – rotation.&amp;nbsp; This is necessary as the translocation rotates the visual image up to 50 degrees. Many different techniques have been described.[3, 14] &amp;nbsp;The induced torsion is intolerable for the patient even in the presence of improved vision.&amp;nbsp; The number of patients left with torsional diplopia varies in the reported series between 6% [7], 8% [15], 18% [9], 23% [16], 28% [5] (before further muscle surgery.&amp;nbsp; Holgado comments that despite improved vision between operations (ie before counter-rotation) all 67 patients in the report used the unoperated eye (the eye without torsion) to ambulate. Following the counter-rotation 86% fixed with the better seeing eye and 8% had persisting diplopia.&amp;nbsp; Many patients with persisting diplopia choose to occlude the rotated eye for ambulation and then use it for reading and detailed vision when stationary with a head tilt. For patients with good outcomes from macular translocation persistent torsional diplopia remains the most&amp;nbsp;disabling sequelae and the greatest challenge to manage.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Information for patients and practitioners&lt;/H2&gt;
&lt;H3&gt;Nice guidelines&lt;/H3&gt;
&lt;P&gt;Currently the technique has been reviewed by NICE. They report that current evidence on the safety and efficacy of macular translocation does not appear adequate for this procedure to be used without special arrangements for consent and for audit or research.&amp;nbsp; As such all translocation carried out in the UK requires appropriate consenting and approval from the governance body within the trust to be carried out.&amp;nbsp; The NICE review report preceded the publication of the prospective trial of PDT versus translocation discussed previously.&lt;/P&gt;
&lt;H3&gt;Future &lt;/H3&gt;
&lt;P&gt;The advent of anti-VEGF based treatments such as Lucentis, Avastin and Macugen have given a very good alternative to translocation surgery in patients with severe wet AMD. The indications for this type of surgery have been significantly reduced and now are essentially large sub-macular haemorrhage, sub-foveal RPE tears and failure of anti-VEGF and PDT treatments. Translocation is rarely a first line treatment. The continuing role of translocation surgery is likely to reduce over the next few years as the growth in new treatments for AMD lead to earlier presentation and more effective non-surgical therapy.&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref7.pdf" target="_blank"&gt;Click here to view search strategy&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/ref7.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;H3&gt;Macular Translocation&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;1.&amp;nbsp;Machemer R,&amp;nbsp;Steinhorst UH. Retinal separation, retinotomy, and macular relocation I: experimental studies in the rabbit eye. Graefes Arch Clin Exp Ophthalmol 1993;231:629-634 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8258396%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Machemer R,&amp;nbsp;Steinhorst UH. Retinal separation, retinotomy, and macular relocation II: a surgical approach for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1993;231:635-641 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8258397%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Surgery&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Eckardt C, Eckardt U,&amp;nbsp;Conrad HG. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:313-325 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10208265%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Toth CA, Freedman SF. Macular translocation with 360-Degree peripheral retinectomy: Impact of technique and surgical experience on visual outcomes. Retina 2001;21(4):293-303 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11508873%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Aisenbury S, Lafaut BA, Szurman P, Grisanti S, Luke C, Krott R et al. &amp;nbsp;Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol2002 Apr;120(4):451-9 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11934318%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Outcomes&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P et al. &amp;nbsp;Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol. 2007 Jan 12; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17219106%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Pertile C,&amp;nbsp;Claes C. Macular translocation with 360-degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularisation. Am J Ophthalmol 2002;134:560-565 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12383813%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Mruthyunjaya P, Stinnett SS,&amp;nbsp;Toth CA. Change in visual function after macular translocation with 360° retinectomy for neovascular age-related macular degeneration. Ophthalmology 2004;111(9):1715-1724 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15350328%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Complications&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Abdel-Meguid A, Lappas A, Hartmann K, Auer F, Schrage N, Thumann G, Kirchoff B. One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br J Ophthalmol 2003;87:615-621 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12714406%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;10.&amp;nbsp;Uppal G, Lee J, Acheson J, Milliken A, Hykin P, Tufail A, da Cruz L.&amp;nbsp; A New Algorithm for Assessing Patient Suitability for Macular Translocation Surgery Clin. Exp. Ophthalmol. In Press&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Quality of life&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Cahill MT, Stinnett SS, Banks AD, Freedman SF, Toth CA. Quality of life after macular translocation with 360° peripheral retinectomy for age-related macular degeneration. Ophthalmology, 2005, 112:1;144-151. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15629835%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Cahill MT, Banks AD, Stinnett SS, Toth CA. &amp;nbsp;Vision-related quality of life in patients with bilateral severe age-related macular degeneration. Ophthalmology,&amp;nbsp; 2005, 112:1;152-8. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15629836%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Luke M, Ziemssen F, Bartz-Schmidt KU, Gelisken F.&amp;nbsp; Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration - a report of 1 year results.&amp;nbsp; Graefes Arch Clin Exp Ophthalmol. 2007 Mar 9; [Epub ahead of print] &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17347809%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Strabismus&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Holgado S, Enyedi LB, Toth CA, Freedman SF. Extraocular muscle surgery for extorsion after macular translocation surgery new surgical technique and clinical management. Ophthalmology. 2006 Jan;113(1):63-9. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16290047%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Holgado S, Toth CA, Freedman SF. Fixation switch and diplopia after full macular translocation surgery. J AAPOS. 2007 Apr;11(2):114-9.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17321176%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Fujikado T, Ohji M, Kusaka S, Hayashi A, Kamei M, Okada A et al. Visual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathy. Am J Ophthalmol 2001;131:101-110 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11162984%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Macular translocation for age-related macular degeneration. National Institute for Clinical Excellence. March 2004 &lt;A disabled href="nelh:35364:0" name=internalLink&gt;[full text]&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;/H2&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>262178</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=262178]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Therapeutic intervention: Anti-VEGF therapy</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD NKW 2007,AMD,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Therapeutic intervention: Anti-VEGF therapy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Mr Yit Chiun Yang MBChB FRCOphth, Consultant Ophthalmologist, Ophthalmic Research Director, Medical Retina Department, Wolverhampton Eye Hospital. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&amp;nbsp; &lt;IMG id=nelh_tempImage7 border=0 name=nelh_tempImage7 alt="Occult AMD" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262178/nelhImp_0000_SurgeryClassic.jpg" width=177 height=134&gt;&amp;nbsp;&amp;nbsp;&lt;/EM&gt;&lt;EM&gt;&lt;IMG id=nelh_tempImage6 border=0 name=nelh_tempImage6 alt="Wet AMD" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262178/nelhImp_0001_Surgery-WetAMD.jpg" width=177 height=134&gt;&amp;nbsp; &lt;/EM&gt;&lt;EM&gt;&lt;IMG id=nelh_tempImage3 border=0 name=nelh_tempImage3 alt="Central scotoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID262178/nelhImp_0002_kidsbottom.png" width=184 height=147&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;&lt;A href="nelh:260877:0" name=internalLink&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd_0607/nkw_amd_doc6.html" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/Anti%20VEGF%20Tx%20.pdf" target="_blank"&gt;Click here for printable (PDF) version&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/Anti%20VEGF%20Tx%20.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;Developments in treatment of AMD - Anti VEGF therapy&lt;/H2&gt;
&lt;P&gt;Developments in recent years in the management of AMD have centred around the “wet” form of the disease.&amp;nbsp; The wet form of age related macular degeneration is characterized by the development of abnormal choroidal neovascularisation (CNV) beneath the retinal layer of the central macula which often leads to permanent macular scarring and photoreceptor damage and severe visual loss.&amp;nbsp; These angiographic lesions are classified as classic, predominantly classic, minimally classic and occult; and by their location in relation to the fovea.&amp;nbsp;&amp;nbsp; The main objective when treating wet AMD is therefore to preserve visual function by reducing or preventing macular scarring and photoreceptor loss by way of controlling or arresting the progression of choroidal neovascularisation. &lt;/P&gt;
&lt;P&gt;The management of a patient with wet AMD has for the most part been limited to specific subtypes of AMD related CNV, with thermal laser photocoagulation [1-4]&amp;nbsp; initially, followed more recently by photodynamic therapy with verteporfin (PDT) where applicable.[5-8]&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Direct thermal laser photocoagulation&lt;/EM&gt;&lt;/STRONG&gt; was largely indicated for small extra-foveal lesions, and its effectiveness was limited by the resultant scotoma in the central visual field, and high recurrence rate. [1-4]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Photodynamic Therapy with Vertporfin (PDT)&lt;/EM&gt;&lt;/STRONG&gt; (Visudyne: Marketing Authorisation Holder - Novartis Europharm Ltd) was shown to be effective in clinical trials in patients with classic and predominantly classic sub-foveal choroidal CNV.[5,6] Visual benefit was limited in a large proportion of patients, particularly those with large lesion size and those classified as minimal classic or occult CNV membranes; and continued growth of lesion size a frequent complication.[7,8]&lt;/P&gt;
&lt;P&gt;National Institute for Health and Clinical Excellence &lt;A href="http://www.nice.org.uk/pdf/68_PDTGuidance.pdf" target="_blank"&gt;guidance on PDT&lt;/A&gt;&amp;nbsp;[9] was issued in 2003 and its indications were for classic subfoveal CNV, and for predominantly classic subfoveal CNV where treatment was part of ongoing clinical outcome studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Notably the most significant development&lt;/EM&gt;&lt;/STRONG&gt; for management options for all sub-types and sizes of angiographic AMD lesions has only been in the past 2 years with the introduction of intra-ocular anti-angiogenesis (anti-VEGF) agents, which are the focus of this section.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Anti-angiogenesis – Anti VEGF&lt;/H2&gt;
&lt;P&gt;Research on the underlying angiogenic stimuli to choroidal neovascularisation has led to the development of anti-vascular endothelial growth factor (anti-VEGF) therapeutic options for the management of AMD, and in particular anti-vascular endothelial growth factor A (Anti-VEGF-A), for use in all subtypes of wet AMD lesions.[10-13] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Anti-VEGF-A agents&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;Currently there are two licensed anti-VEGF-A agents which are available for treatment of wet AMD –&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Pegatanib&amp;nbsp;&amp;nbsp; &lt;BR&gt;•&amp;nbsp;Ranibizumab&lt;/P&gt;
&lt;P&gt;A third agent Bevacizumab which may have similar effects to Ranibizumab is licensed for the treatment of bowel cancer, but is not licensed for the treatment of ocular disease. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Pegaptanib (Macugen,OSI/Eyetech/Pfizer)&amp;nbsp; &lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;This was the first to be developed.&amp;nbsp; It is a large oligonucleotide molecule consisting of a 28-base ribonucleic acid which can bind to and block the activity of extracellular VEGF-A, specifically, the 165 amino-acid isoform (VEGF165).&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Evidence of the effectiveness of Pegaptanib in the management of AMD is from two concurrent double-masked RCTs – VISION (VEGF Inhibition in Ocular Neovascularisation Clinical Trials) - that were designed to be combined for final analyses.[14]&lt;/P&gt;
&lt;P&gt;The VISION trial reported that multiple intra-vitreal injections of 0.3mg Pegaptanib were significantly more effective in preventing visual loss compared to sham injections. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Summary points from VISION trials [14]&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Patient group:&lt;/EM&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;All wet AMD lesion types; but minimally classic and occult lesions with demonstrable indicators of disease progression&lt;BR&gt;•&amp;nbsp;Acuity between 6/12 and 1/60.&amp;nbsp; &lt;BR&gt;•&amp;nbsp;1186 patients randomised to four treatment groups (1.0 mg, 0.3mg, 3.0mg and sham injection)&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Intervention&lt;/EM&gt;&amp;nbsp;&amp;nbsp; :&amp;nbsp;Six weekly intravitreal injections for 48 weeks&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Primary end-point:&lt;/EM&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks. &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Outcomes:&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;In the combined analysis of the primary end point (for a total of 1186 patients), efficacy was demonstrated, without a dose–response relationship, for all three doses of pegaptanib&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;PDT was allowed, at investigators’ discretion in 26% of patients who were predominantly classic at baseline.&amp;nbsp; Out of 72 patients with predominant classic in the 0.3mg group, 49 patients received one or more PDT at some time during first 12 months of follow up.&amp;nbsp; Out of 76 patients with predominant classic in the sham group, 62 patients received one or more PDT during first 12 months of follow up.&amp;nbsp; A reduced requirement for PDT in the 0.3mg group indirectly suggests a treatment benefit. &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;At 12 months, the proportion of patients with less than 15 letter loss (primary endpoint) in the 0.3mg group was 70% versus 55% in the sham group, p&amp;lt;0.001.&amp;nbsp; The difference in acuity outcome between these two groups was not influenced by other factors such as lesion type and size or PDT treatment on multiple regression analysis.&amp;nbsp; This suggests that Macugen monotherapy was efficacious for all lesion types.&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Severe ocular or systemic adverse events were rare.&amp;nbsp; Out of 7545 injections performed in 1186 patients in 12 months, there were 12 episodes of endophthalmitis in 12 patients.&amp;nbsp; The risk of endophthalmitis was 1.3% per year per patient or 0.16% per injection.[15] &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;At 12 months, patients were randomly reassigned to continue treatment or discontinue treatment in such a way as to minimise the number of injections performed and also to allow some patients who were on sham treatment in first 12 months to receive treatment (rescue therapy concept).&amp;nbsp; &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;As such, patients who continued treatment for two years had better mean acuity than those who stopped treatment or continued sham treatment (p&amp;lt;0.05) indicating that continuing Macugen into the second year confers benefit.&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;A third paper published by the VISION group reported enhanced efficacy in a selected group of patients defined by early disease but the numbers analysed were very small and the validity of the analysis is therefore uncertain.[16]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Its long-term effectiveness and safety is not known beyond 2 years.[17]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Licensing of Pegaptanib&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;It has been licensed in the USA since 2004 and has had widespread use since then. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;It was licensed in Europe by the EMEA in Feb 2006 and launched in the UK in May 2006.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Licensing label specifications&lt;/STRONG&gt;:&lt;/EM&gt;&amp;nbsp; approval of Macugen 0.3mg was based on the prespecified primary efficacy end point at week 54. [14]&amp;nbsp;&amp;nbsp; It is indicated for Wet AMD with a recommended dosing of one intravitreal injection every 6 weeks (9 in one year).[18] &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Cost:&lt;/STRONG&gt;&lt;/EM&gt; The basic NHS cost of one pre-filled syringe for single use is £514.00.[18] &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Use in clinical practice&lt;/STRONG&gt;&lt;/EM&gt; - NICE has just published &lt;A href="http://www.nice.org.uk/page.aspx?o=435210" target="_blank"&gt;draft guidance&lt;/A&gt; for &lt;A href="http://guidance.nice.org.uk/page.aspx?o=435391" target="_blank"&gt;consultation&lt;/A&gt; on the use of Pegaptanib in the NHS - 14 June 2007&lt;/P&gt;
&lt;P&gt;&lt;A href="http://guidance.nice.org.uk/page.aspx?o=207024" target="_blank"&gt;NICE guidance on Pegaptanib is expected in September 2007. [19]&amp;nbsp;&lt;/A&gt;&amp;nbsp; As such its use in the NHS in England and Wales has not been routinely commissioned. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Ranibizumab (Lucentis, Genentech/Novartis) -&amp;nbsp; &lt;/H2&gt;
&lt;P&gt;This is the second anti-VEGF-A agent to be developed.&amp;nbsp; It is a recombinant, humanized fragment of a monoclonal IgG antibody containing the antigen binding sequence capable of binding and inhibiting all isoforms of VEGF-A by preventing VEGF-A molecules from binding normally to their receptors on endothelial cells ( VEGF-R1,VEGF-R2).&amp;nbsp; Evidence of its effectiveness in the management of wet AMD is from two large double-masked randomised phase III clinical trials (MARINA-2005; and ANCHOR 2006).[20,21]&amp;nbsp; It has been shown to be effective in preventing visual loss in all subtypes of wet AMD, and in sizeable proportion of patients to improve visual acuity. Its long-term effectiveness and safety beyond 24 months is not known.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Summary points from MARINA and ANCHOR trials&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;MARINA Study&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp; - the minimally classic/Occult Trial of the Anti-VEGF Antibody, Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration.[20]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;716 patients with minimally classic or Occult no classic lesion subtypes enrolled into two year prospective study and randomised to receive monthly intravitreal injections of either Ranibizumab 0.3mg, Ranibizumab 0.5mg or sham injections.&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Primary end-point: less than 15 letter loss of acuity score at 12 months.&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;At month 12, &amp;gt; 94% of patients in both treatment groups lost fewer than 15 letters compared to only 62.2% in the sham group(p&amp;lt;0.001).&amp;nbsp; At 24 month the difference was even greater with the treated group achieving &amp;gt;90% with fewer than 15 letter loss compared to only 52.9% at 24 months(p&amp;lt;0.001).&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Sub group analysis did not demonstrate any effect from other factors such as lesion size, baseline acuity or lesion subtype.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Of particular note was the observation that &amp;gt;33% of patients had improved visual acuity of &amp;gt; 15 letters at month 12 which was maintained through to month 24.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;EM&gt;ANCHOR trial&lt;/EM&gt;&lt;/STRONG&gt; - The Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularisation in Age-Related Macular Degeneration.[21]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;423 patients with predominantly classic lesions were enrolled and randomised to receive, either monthly Ranibizumab 0.3mg plus sham PDT or monthly Ranibizumab 0.5mg plus sham PDT or Standard protocol PDT plus monthly sham injections.&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;The study was designed to evaluate efficacy and safety of monthly intravitreal Ranibizumab in patients predominantly classic subtype of wet AMD.&amp;nbsp; Primary efficacy endpoint was pre specified as proportion of patients losing &amp;lt;15 letters between baseline and month 12.&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;At month 12, 96.4% of patients treated with Ranibizumab 0.5mg had fewer than 15 letter&amp;nbsp; loss compared to only 64.3% (p&amp;lt;0.001).&amp;nbsp; Also of note was the observation that 40.3% of patients on Ranibizumab 0.5% had &amp;gt;15 letter gain compared to only 5.6% of patients treated with standard protocol PDT.&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;At month 24, the visual acuity outcomes were maintained.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Serious adverse events were also low.&amp;nbsp; &lt;/EM&gt;&lt;/STRONG&gt;&lt;BR&gt;There was a &amp;lt;0.1% risk of endophthalmitis per injection.&amp;nbsp; Arterial thromboembolic events were found in 2.1% of treated patients (18/874) compared with 1.1% (5/441) in the first year but this had equalised by month 24 to 3% (14/466) of treated versus 3.2% (7/216) in the controls.[20]&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Other clinical studies on Ranibizumab (Lucentis) yet to publish include -&amp;nbsp; &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;PIER&amp;nbsp;[22,23], PrONTO, &lt;A href="http://www.controlled-trials.com/mrct/trial/189635/lucentis" target="_blank"&gt;SAILOR&lt;/A&gt;&amp;nbsp;[24], &lt;A href="http:/www.controlled-trials.com/mrct/trial/143603/excite+and+ranibizumab" target="_blank"&gt;EXCITE &lt;/A&gt;[25] – investigating less frequent dosing regimes.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;PROTECT (Europe), FOCUS (USA)&amp;nbsp; -examining the role of combination treatment with PDT &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Preliminary findings from the FOCUS trial have been reported.[26]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;&lt;A href="http://www.controlled-trials.com/mrct/trial/189635/lucentis" target="_blank"&gt;SAILOR&lt;/A&gt;/&lt;A href="http://clinicaltrials.gov/ct/show/NCT00331864?order=21" target="_blank"&gt;SUSTAIN&lt;/A&gt; – studying its longer term safety and efficacy.[24,27] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Licensing: &lt;/EM&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;It was licensed in the USA in 2006.&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;It was licensed in Europe by the EMEA in &lt;A href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en1.pdf" target="_blank"&gt;22 Jan 2007&lt;/A&gt; [28]&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Licensing Label specifications:&lt;/STRONG&gt;&lt;/EM&gt; Ranibizumab is indicated for wet AMD by monthly intravitreal injections as long as there is residual macular thickening or elevation due to active neovascular leakage.[25]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Cost&lt;/STRONG&gt;:&lt;/EM&gt;&amp;nbsp; The basic cost of one vial of Lucentis (0.5mg in 0.05ml) is £716.20 (Moorfields Pharmacy).&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Use in clinical practice&lt;/STRONG&gt;&lt;/EM&gt; - NICE has just published &lt;A href="http://www.nice.org.uk/page.aspx?o=435210" target="_blank"&gt;draft guidance&lt;/A&gt; for &lt;A href="http://guidance.nice.org.uk/page.aspx?o=435391" target="_blank"&gt;consultation&lt;/A&gt; on the use of Lucentis in the NHS - 14 June 2007.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://guidance.nice.org.uk/page.aspx?o=207024" target="_blank"&gt;NICE guidance on Lucentis&amp;nbsp;is expected in September 2007&lt;/A&gt;.[19]&amp;nbsp; As such its use in the NHS in England and Wales has not been routinely commissioned. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Bevacizumab (Avastin, Genentech) &lt;/H2&gt;
&lt;P&gt;This has been developed, approved and licensed for intravenous infusion in the treatment of colorectal carcinoma.&amp;nbsp; Avastin and Lucentis are both derived from the same murine monoclonal IgG antibody against VEGF-A.&amp;nbsp; The main difference at the molecular level between Avastin and Lucentis is that Avastin is a full length antibody engineered from a humanized Fab (antigen binding) fragment.&amp;nbsp; Avastin is therefore a larger molecule (150kd) with two antigen binding sites (Fab) and lucentis is a much smaller molecule (48kd) with one binding site.&amp;nbsp; This alteration lengthens the systemic half life from a few hours to 3 weeks making it more suitable as a systemic chemotherapy agent.&amp;nbsp; Theoretically Avastin would appear to be less suitable than Lucentis for the treatment for wet AMD for the following reasons highlighted by Ferrara in a recent article: [29]&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Penetration of a molecule like Avastin into the retina and choriod from intravitreal injections in primate and rabbit studies was inconclusive.[30,31,32] &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Full length antibody, like Avastin may trigger complement mediated or cell mediated cytoxicity through inflammatory cells via the Fc (cell binding) part of the IgG molecule.[33] &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;The systemic half life of a fragment is only a few hours which theoretically confers extra safety in terms of systemic complications such as arterial-thrombolic events.&amp;nbsp; In addition, systemic circulation of Fab fragment (Lucentis) have not been found to be significant.[34] &lt;/P&gt;
&lt;P&gt;The molecular similarities between Avastin and Lucentis led to the seminal case report of a patient with persistent CNV leakage associated with AMD, treated with intra-ocular Avastin resulting in resolution of sub-retinal fluid.[35]&amp;nbsp;&amp;nbsp; Since then there has been widespread “off-label” intra-vitreal use of Avastin globally.&amp;nbsp; Anecdotal evidence from these case series’ suggest it may be useful in the short term for limiting visual loss.[36-39] &lt;/P&gt;
&lt;P&gt;Published data on efficacy and safety of Avastin is limited and confined to short term follow up only [36,38-41]&amp;nbsp; To date there remains a lack of good clinical evidence of its dose, frequency, effectiveness and safety of the intra-ocular use of Avastin.&lt;/P&gt;
&lt;P&gt;Despite these issues and concerns within the ophthalmic community, a large number of patients with wet AMD have been treated with intravitreal avastin.[41]&amp;nbsp;&amp;nbsp; A significant factor contributing to the rapid spread of its use is its comparatively lower cost compared to the licensed alternatives (Macugen and Lucentis). &lt;BR&gt;&amp;nbsp; &lt;BR&gt;Currently in the UK, pharmacies with a specials manufacturing licence are able to supply at competitive prices. At present the basic NHS cost from Moorfields Pharmacy is £85 + VAT and deliver per single use pre-filled syringe, inclusive of delivery. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Licensing - &lt;/EM&gt;&lt;/STRONG&gt;Bevacizumab has been developed, approved and licensed for intravenous infusion in the treatment of colorectal carcinoma.&amp;nbsp; It is not licensed for any ocular use.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Use in clinical practice&lt;/STRONG&gt;&lt;/EM&gt; – it is not widely available in the NHS.&amp;nbsp; It is used more frequently “off-label” in the private sector.&amp;nbsp; Clinical governance and clinical risk issues relating to the use of an off-label option instead of licensed medicines such as Lucentis or Macugen or other future licensed products (which may have even greater safety and efficacy profiles) need to be considered.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Current and planned clinical research on the effectiveness and safety of intra-vitreal Avastin &lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;&lt;A href="http://www.nrr.nhs.uk/ViewDocument.asp?ID=N0141184532" target="_blank"&gt;Avastin v best available NHS treatment for AMD &lt;/A&gt;[42]&lt;BR&gt;•&amp;nbsp;&lt;A href="http://www.nei.nih.gov/news/statements/amd_therapy.asp" target="_blank"&gt;Lucentis v Avastin -&amp;nbsp; NEI&lt;/A&gt; [43] &lt;BR&gt;•&amp;nbsp;&lt;A href="http://www.controlled-trials.com/isrctn/pf/92166560" target="_blank"&gt;Lucentis v Avastin – ivan trial - UK&lt;/A&gt; [44]&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P align=right&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_amd/amd_docs/ref6.pdf" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref6.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;References&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp; Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopthy. Three year results from randomised clinical trials. Arch Ophthalmol 1986; 104:694-701. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=2423061%5Buid%5D+AND+(%221986%22%5BPDAT%5D+%3A+%221986%22%5BPDAT%5D)&amp;amp;WebEnv=0GR22l27ZYXaFq6RVSB_97LNMm1mLnGyJzlmf022SdHUPvFRV4YYWSi_85HlUBUDGMtJ-6S2BAWtQ%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp; Macular Photocoagulation Study Group. Recurrent choroidal neovascularisation after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 1986; 104:503-512. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=2420315%5Buid%5D&amp;amp;WebEnv=0T7yRifNgty40yb9LPx3CXD7nc4WQHIWgbJwf5nw4NnzkZRgyVqW4N3dopsXf3Vri77IofaQqkJKg%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp; Macular Photocoagulation Study Group.&amp;nbsp; Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration.&amp;nbsp; Arch Ophthalmol 1991; 109: 1220-1231. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=1718250%5Buid%5D+AND+(%221991%22%5BPDAT%5D+%3A+%221991%22%5BPDAT%5D)&amp;amp;WebEnv=0YLuHm88a6sf8Dm-heQFEpTMZM95oJcZS6hUo96FOK6euhbKAQ3P2eBwvIRhqPCFnx54T-DNUQ8pg%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp; Macular Photocoagulation Study Group.&amp;nbsp; Visual outcome after laser photocoagulation for subfoveal choroidal neovascularisation secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity.&amp;nbsp; Arch Ophthalmol 1994; 112:480-488. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7512334%5Buid%5D+AND+(%221994%22%5BPDAT%5D+%3A+%221994%22%5BPDAT%5D)&amp;amp;WebEnv=071KfzaAMWmz3bih7F4-Qz1sUiEiNSpdVBCzMulvLYuZ5WNge5cSaO8S5pl6HyvW4N4w2HvwUQgwX%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.&amp;nbsp; Photodynamic therapy of subfoveal choroidal neovascularisation in age related macular degeneration with verteporfin: one year results of 2 randomised trials – TAP report 1.&amp;nbsp; Arch Ophthalmol 1999; 117: 1329-45. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10532441%5Buid%5D+AND+(%221999%22%5BPDAT%5D+%3A+%221999%22%5BPDAT%5D)&amp;amp;WebEnv=0psq0WHQEapmZU2KrOL-DWFsDEl03Rj3Lrt54U8i6QPrW9qdvlcXX61wHl9jJptKmoitvQ1ldco_q%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.&amp;nbsp; Photodynamic therapy of subfoveal choroidal neovascularisation in age related macular degeneration with verteporfin: two-year results of 2 randomised clinical trials – TAP report 2.&amp;nbsp; Arch Ophthalmol 2001; 119:198-207 &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11176980%5Buid%5D+AND+(%222001%22%5BPDAT%5D+%3A+%222001%22%5BPDAT%5D)&amp;amp;WebEnv=0Upwp0dbgxStVfxS6rXU74t-2daKWNPSNNyYCuYMGF-7KwabtYsG4OOi566iZq8DukoYJcDfRkx7T%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp; Verteporfin in Photodynamic Therapy Study Group.&amp;nbsp; Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: two-year results of a randomised clinical trial including lesions with occult with no classic choroidal neovascularisation – Verteporfin in Photodynamic Therapy report 2. &lt;BR&gt;Am J Ophthalmol 2001; 131:541-560. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11336929%5Buid%5D&amp;amp;WebEnv=0y5UB53dFoTeFuqxOInT1ia_1Vr2FeLXujqmaiMLaDrHWkNgnhWhMSs2KnVbojolF8peTdBDRY4C_%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in pathologic myopia with verteporfin: one-year results of a randomised clinical trial including lesions with occult with no classic choroidal neovascularisation - VIP Report 1.&amp;nbsp; Ophthalmology 2001; 108:841-52. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=11320011%5Buid%5D+AND+(%222001%22%5BPDAT%5D+%3A+%222001%22%5BPDAT%5D)&amp;amp;WebEnv=0TkyoYEj4WyAT7byJPDgrjwwnhm6uK5WgOwuXxnRMB0ioZqqtcgi4K0uS5zXM4Fj747-4YodGkHQf%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp; Guidance on the use of photodynamic therapy for age-related macular degeneration. National Institute for Clinical Excellence. September 2003&amp;nbsp; &lt;A href="nelh:30479:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp; Ferrara N, Carver-Moore K, Chen H,&amp;nbsp; Dowd M, Lu L, O’Shea KS, Powell-Braxton L, Hillan KJ, Moore MW.&amp;nbsp; Heterozygous embryonic lethality induced by targeted inactivation of VEGF gene.&amp;nbsp;&amp;nbsp;Nature&amp;nbsp;1996 Apr 4;380 (6573): 439-42. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8602242%5Buid%5D+AND+(%221996%22%5BPDAT%5D+%3A+%221996%22%5BPDAT%5D)&amp;amp;WebEnv=0NwFFSGc8WgvGebVfGBloVRXfCaLZUlvUxJQX1WFto0CVqekj_zgJ-4Pcd0oHRmeO-Kyqq7r4s1eb%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp; PA D'Amore Mechanisms of retinal and choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 1994 35: 3974-3979. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=7525506%5Buid%5D&amp;amp;WebEnv=0f6WjXnt8PUB9yeQetIglOvup5bYBxcHvGPsYz2rqOE4reguJuYiWqnhKYoucufgqwX3j5XvqAuzP%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp; Growth factors in age-related macular degeneration: pathogenic and therapeutic implications. Frank RN. Ophthalmic Res. 1997;29(5):341-53. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=9323725%5Buid%5D&amp;amp;WebEnv=0li40kSId4xuXL_bMvFQmaK2Q_jGcI_qLS5_nfCXyKXnDvzfjt932CpfOCebFburPCyHKI7lZkThn%40255D405C66EAF800_0073SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp; The role of vascular endothelial growth factor (VEGF) in abnormal vascular changes in the adult rat eye. Yu MJ, Shen WY, Lai MC, Constable IJ, Papadimitriou JM, Rakoczy PE.&amp;nbsp; Growth Factors. 2000;17(4):301-12. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10801078%5Buid%5D&amp;amp;WebEnv=0Af1KAJaoUV91n04LE-qa2qHzCEXFf1hk0sV10o30hui-da7DYBMGLz4xDWLkYOux3PIEWNhq_LJYc-%40263F452C67155A90_0183SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Pegaptanib (Macugen)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp; Gragoudas ES, Adamis AP, Cunningham ET, Jr., et al.&amp;nbsp; Pegaptanib for neovascular age-related macular degeneration. &lt;BR&gt;N Engl J Med 2004;351:2805-16. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15625332&amp;amp;query_hl=61&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp; VISION Clinical Trial Group ( D’Amico DJ et al).&amp;nbsp; Pegaptanib sodium for neovascular agerelated macular degeneration: two year safety results of the two year prospective, multicentre, controlled clinical trials.&amp;nbsp; Ophthalmology 2006; 113: 992-1001. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16647134" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp; Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis.&amp;nbsp; Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group.&amp;nbsp; Retina. 2005 Oct-Nov;25(7):815-27 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16205558" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17. VISION Study Group.&amp;nbsp;&amp;nbsp; Year 2 efficacy results of 2 randomised controlled clinincal trials of pegaptanib for neovascular age-related macular degeneration.&amp;nbsp;Ophthalmol 2006 ;113:1508-21. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16828500" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp; Ocular diagnostic and peri-operative preparations and photodynamic treatment – Pegaptanib SodiumBritish National Formulary No.53 Section 11.8.2 &lt;A href="http://www.bnf.org/bnf/bnf/current/5556.htm" target="_blank"&gt;[webpage]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp; Macular degeneration (age-related) – pegaptanib and ranibizumab.&amp;nbsp; National Institute for Health and Clinical Excellence &lt;A href="http://guidance.nice.org.uk/page.aspx?o=207024" target="_blank"&gt;[webpage]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ranibizumab (Lucentis)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp; Rosenfeld PJ, Brown DM, Heier JS, Boyer DS et al for the MARINA Study Group. Ranibizumab for Neovascular Age-Related Macular Degeneration.&amp;nbsp; N Engl J Med 2006; 355:1419-31.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=17021318&amp;amp;query_hl=150&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;21. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS et al -ANCHOR Study Group.&amp;nbsp; Subgroup Analysis. Ranibizumab vrs Verteporfin for Neovascular Age-Related Macular Degeneration.&amp;nbsp; N Engl J Med 2006; 355:1432-44. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17021319%5Buid%5D&amp;amp;WebEnv=09iCB9E1lqbtZJXRsnZRa0O8ydISzGtj3U5vS3hObO1bowwnNtI5ztoADK23zLWf86tUgXufK30IN51%40263F452C67155A90_0183SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;22.&amp;nbsp;&amp;nbsp;&amp;nbsp;Dugel PU. Ranibizumab treatment of patients with ocular diseases. Int Ophthalmol Clin. 2006 Fall;46(4):131-40.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17060799%5Buid%5D&amp;amp;WebEnv=0GP2GrEwGkIMNEWK_hc2N6ZgvXETYTlBxvH2AJ7Th7Hb30gPN2v6lrZ4OqO5XFFhA63iJKuWhiLYVNt%40263F452C67155A90_0183SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp; Lucentis – Scientific Discussion. European Public Assessment Report.&amp;nbsp; European Medicines Agency. January 2007 &lt;A href="http://emea.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en6.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;24.&amp;nbsp; SAILOR. Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Monotherapy - Intravitreal Ranibizumab Alone to Treat Age-Related Macular Degeneration. [&lt;A href="http://www.controlled-trials.com/mrct/trial/189635/lucentis" target="_blank"&gt;trial details]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;25.&amp;nbsp;&amp;nbsp;EXCITE - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (ARMD) &lt;A href="http://www.controlled-trials.com/mrct/trial/143603/excite+and+ranibizumab" target="_blank"&gt;[trial details]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;26.&amp;nbsp;Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC et al. FOCUS : Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.&amp;nbsp; Archives of ophthalmology,&amp;nbsp;Nov 2006, vol. 124, no. 11, p. 1532-42,&amp;nbsp;&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=17101999" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;27.&amp;nbsp; SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. &lt;A href="http://clinicaltrials.gov/ct/show/NCT00331864;jsessionid=B9735FA156CC2C79E2D6A6E29B151234?order=25" target="_blank"&gt;[trial details]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;28.&amp;nbsp;&amp;nbsp;European Public Assessment Report. Lucentis – EPAR summary for the public. European Medicines Agency 2007. &lt;A href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en1.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bevacizumab (Avastin)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;29.&amp;nbsp; Ferrara N, Damico L, Shams N, Lowman H, Kim R.&amp;nbsp;&amp;nbsp; Development of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular Age related macular degeneration.&amp;nbsp; Retina 2006;26:859-70. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17031284%5Buid%5D&amp;amp;WebEnv=0_0IB2hg8GIVhwOC6yhqt7n9Om5Xt8VzdTtKuHWoAcSleHchtgoYnsZna2g6yi0vwnyRYYrWK3yemsy%40263F452C67155A90_0183SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;30.&amp;nbsp; Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006 Mar;26(3):262-9.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16508424%5Buid%5D&amp;amp;WebEnv=03_nHMunjRwR8GvKKsaMVkoq5o5nvvzCB8n6XUee_Yc7zg_dA7tVckQtfYrEAs1gmbce4OfHnUIMsZm%40263F452C67155A90_0183SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;31.&amp;nbsp; Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J.&amp;nbsp; Human retinal molecular weight exclusion limit and estimate of species variation.&amp;nbsp; Invest Ophthalmol vis Sci 2003;44:2141-46. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=12714654%5Buid%5D&amp;amp;WebEnv=0fKdA-9FvZoL4-Gwete9lljexB7T41xHiQ0UCf2rDDP7rpBxl7ecOG13tlAUAJMfV3P6uPvXZQ8NqLz%40263F452C67155A90_0183SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;32.&amp;nbsp; Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V&amp;nbsp;et al.&amp;nbsp;&amp;nbsp; Comparisons of the intraocular tissue distribution, pharmacokinetics and safety of 125 I-labelled full length and Fab antibodies in rhesus monkeys following intravitreal administration.&amp;nbsp;&amp;nbsp; Toxicol Pathol 1999;27:536-44. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=10528633%5Buid%5D&amp;amp;WebEnv=0IeYIz4CwJPYrFP_uUNTklQzWb97F9wwVbEQVUzBGfD1-nAgAn5mQArkya6HumXNbUT0v7sM2yQIbZV%40263F452C67155A90_0183SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;33.&amp;nbsp; Raghavan M, Bjorkman PJ.&amp;nbsp;&amp;nbsp; Fc receptors and their interactions with immunoglobulins.&amp;nbsp;&amp;nbsp; Annu Rev Cell Dev Biol 1996;12:181-220. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=8970726%5Buid%5D+AND+(%221996%22%5BEDAT%5D+%3A+%221996%22%5BEDAT%5D)&amp;amp;WebEnv=0jWLqRk8BgkHEk9MZzm7ZHZwUEVb9FtPEAL3kYcY5Prjeaf9QiQkatoHn78p23a-T4Q7Nk6KZ_J4D7t%40263F452C67155A90_0183SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;34.&amp;nbsp; Reff ME, Hariharan K, Braslawsky G.&amp;nbsp;&amp;nbsp; Future of monoclonal antibodies in the treatment of hematologic malignancies.&amp;nbsp; Cancer Control 2002;152-166. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=((%22forecasting%22%5BTIAB%5D+NOT+Medline%5BSB%5D)+OR+%22forecasting%22%5BMeSH+Terms%5D+OR+Future%5BText+Word%5D)+AND+(%22antibodies,+monoclonal%22%5BMeSH+Terms%5D+OR+monoclonal+antibodies%5BText+Word%5D)+AND+(%22therapy%22%5BSubheading%5D+OR+(%22therapeutics%22%5BTIAB%5D+NOT+Medline%5BSB%5D)+OR+%22therapeutics%22%5BMeSH+Terms%5D+OR+treatment%5BText+Word%5D)+AND+(haematologic+malignancies%5BText+Word%5D+OR+(%22hematologic+neoplasms%22%5BTIAB%5D+NOT+Medline%5BSB%5D)+OR+%22hematologic+neoplasms%22%5BMeSH+Terms%5D+OR+hematologic+malignancies%5BText+Word%5D)&amp;amp;WebEnv=02Obd0y9_VaSHq9a-HzlF8fNaNEKU9vf2DtcpgVWuG63FZXOpSD99FlmjuGZWLIAoxj7Ep5fssiGy7G%40263F452C67155A90_0183SID&amp;amp;WebEnvRq=1" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;35.&amp;nbsp;Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.&amp;nbsp;&lt;BR&gt;Ophthalmic surgery lasers &amp;amp; imaging&amp;nbsp;Jul-Aug 2005, vol. 36, no. 4, p. 331-5. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16156152%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;36.&amp;nbsp; Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ.&amp;nbsp; Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72 e5. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16458968%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;37.&amp;nbsp; Maturi RK, Bleau LA, Wilson DL.&amp;nbsp; Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.&amp;nbsp; Retina 2006;26:270-4. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16508425&amp;amp;query_hl=85&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;38.&amp;nbsp; Spaide RF, Laud K, Fine HF, Klancnik JM, Meyerle CB, Yannuzzi LA&amp;nbsp;et al.&amp;nbsp; Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.&amp;nbsp; Retina 2006;26:383-90. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16603955&amp;amp;query_hl=111&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;39.&amp;nbsp; Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN.&amp;nbsp; Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16815245%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;40.&amp;nbsp; Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW et al.&amp;nbsp; Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.&amp;nbsp; Retina 2006;26:495-511. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16770255&amp;amp;query_hl=113&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;41.&amp;nbsp; A E Fung, P J Rosenfeld and E Reichel&amp;nbsp;&amp;nbsp; The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (11): 1344-9.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16854824&amp;amp;query_hl=130&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;42.&amp;nbsp;&amp;nbsp;A randomised, double-masked, Phase III study of the efficacy and safety of Avastin (Bevacizumab) intravitreal injections compared to best available therapy in subjects with choroidal neovascularisation secondary to AMD. National Research Register. [Project record]&lt;/P&gt;
&lt;P&gt;43.&amp;nbsp; National Institutes of Health stimulates the Development and Testing of New Therapies for Advanced Age-Related Macular Degeneration (AMD). National Eye Institutes statement.&amp;nbsp;December 2006.&amp;nbsp; &lt;A href="http://www.nei.nih.gov/news/statements/amd_therapy.asp" target="_blank"&gt;[statement]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;44.&amp;nbsp; A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation (IVAN).&amp;nbsp; &lt;A href="http://www.controlled-trials.com/isrctn/pf/92166560" target="_blank"&gt;[study details]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AMDNKW" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>262327</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=262327]]&gt;</url>
    <title>AMD National Knowledge Week 18 - 24 June 2007 : Uncertainties in the management of Age Related Macular Degeneration</title>
    <publicationDate>2007-06-18T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AMD NKW 2007,AMD,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;AMD National Knowledge Week 18 - 24 June 2007 : Uncertainties in the management of Age Related Macular Degeneration&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;What clinical questions would you like answered on AMD?&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The NLH Eyes and Vision Specialist Library is collaborating in the development of DUETS – &lt;A href="http://www.duets.nhs.uk/" target="_blank"&gt;the Database of Uncertainties about the Effects of Treatments&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;DUETS has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians.&lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments &lt;/LI&gt;
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines &lt;/LI&gt;
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems.&lt;/P&gt;
&lt;P&gt;If you are aware of or identified any uncertainties in the management of AMD please let us know.&amp;nbsp; You can contact us via our &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/feedback.asp" target="_blank"&gt;feedback form&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=262327&amp;amp;tabID=290" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>89357</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/Clinical-Privileges.pdf]]&gt;</url>
    <title>American Optometric Association Guidelines for delineation of clinical privileges</title>
    <publicationDate></publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NHS CORE CONTENT WITHOUT A CATEGORY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document presents guidelines for the delineation of clinical privileges for Optometrists. It&amp;nbsp;was&amp;nbsp;published by the American Optometric Association and revised in 2003.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The guideline explains the process by which privileges are requested, recommended and granted and includes models&amp;nbsp;that can be&amp;nbsp;reviewed and modified by hospitals to meet specific criteria for their own delineation process.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=116" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=116" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=116" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310703</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16965489]]&gt;</url>
    <title>An evidence-based analysis of surgical interventions for uncomplicated rhegmatogenous retinal detachment</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Acta Ophthalmologica Scandinavica</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL TEARS AND DETACHMENT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Acta Ophthalmologica Scandinavica (Acta Ophthalmol Scan) 2006 Oct; 84(5):606-12.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To evaluate the various surgical interventions available for uncomplicated rhegmatogenous retinal detachment. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Reports of controlled clinical trials of surgical interventions (pneumatic retinopexy, scleral buckling and vitrectomy) for uncomplicated rhegmatogenous retinal detachment indexed in MEDLINE from 1968 to January 2006 were included. The primary outcomes evaluated included single-operation reattachment rates, multiple reoperation reattachment rates and improvements in visual acuity (VA). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; We found five controlled trials (two randomized) comparing the efficacy of pneumatic retinopexy versus scleral buckling. The single-operation reattachment rates were higher for scleral buckling, but the final reattachment rates were similar. We found nine controlled trials (four randomized) evaluating vitrectomy. There were no statistically significant differences between retinal reattachment rates or final visual acuities, except in one randomized and one non-randomized controlled trial in which the VAs were significantly better in the vitrectomy than the scleral buckling group. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Pneumatic retinopexy is a possible alternative to scleral buckling in the treatment of uncomplicated rhegmatogenous retinal detachment. The rates of missed or new retinal breaks after pneumatic retinopexy, however, are higher than following scleral buckling. The clinical outcomes of vitrectomy for rhegmatogenous retinal detachment compare favourably.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=124" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310706</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16307709]]&gt;</url>
    <title>Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma</title>
    <publicationDate>2005-11-01T00:00:00</publicationDate>
    <publisher>Current Medical Research and Opinion</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Current Medical Research and Opinion (Curr Med Res Opin) 2005 Nov;21(11):1875-83.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; The objective of this review was to evaluate different measures of efficacy of the intraocular pressure (IOP) lowering lipid class agents bimatoprost, latanoprost and travoprost in the treatment of primary open angle glaucoma. Study arms of timolol in trials including the above mentioned lipid class drugs were also included. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;MEDLINE and EMBASE were searched for randomized clinical trials including one or more of the lipid class drugs bimatoprost, latanoprost and travoprost. The study results were pooled, and the simple, weighted IOP-lowering efficacy was compared among the lipid class drugs and timolol, where data were available. Efficacy parameters were reviewed, including mean reduction of IOP and percentage of patients achieving different levels of IOP. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; 161 articles were identified of which 42 were included in the analysis. A total of 9295 patients participated in the included trials. Based on all studies, timolol on average had a weighted mean IOP reduction of 22.2%, while latanoprost, travoprost and bimatoprost had a weighted mean IOP reduction of 26.7%, 28.7% and 30.3%, respectively. Analysis of target achievement to various IOP levels shows that bimatoprost seems more efficacious than latanoprost. The direct comparisons (head-to-head studies) also show that bimatoprost is the most efficacious treatment, however it is not conclusive whether latanoprost or travoprost is better in reducing IOP. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This review shows that bimatoprost seems to be the most efficacious treatment in lowering IOP. Head-to-head studies confirm this.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=150" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310712</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14711439]]&gt;</url>
    <title>Anthocyanosides of Vaccinium myrtillus (bilberry) for night vision - a systematic review of placebo-controlled trials</title>
    <publicationDate>2004-01-31T00:00:00</publicationDate>
    <publisher>Surveys of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Surveys of Ophthalmology (Surv Ophthalmol) 2004 Jan-Feb;49(1):38-50&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;We have systematically reviewed placebo-controlled trials of V. myrtillus-extracted anthocyanosides for evidence of positive effects on night vision. Searches of computerized databases and citations in retrieved articles identified 30 trials with outcome measures relevant to vision in reduced light. Of these, 12 were placebo-controlled. The 4 most recent trials were all randomized controlled trials (RCTs) and were negative in outcome. A fifth RCT and 7 non-randomized controlled trials reported positive effects on outcome measures relevant to night vision. Negative outcome was associated with more rigorous methodology but also with lower dose level and extracts from geographically distinct sources that may differ in anthocyanoside composition. Healthy subjects with normal or above average eyesight were tested in 11 of the 12 trials. The hypothesis that V. myrtillus anthocyanosides improves normal night vision is not supported by evidence from rigorous clinical studies. There is a complete absence of rigorous research into the effects of the extract on subjects suffering impaired night vision due to pathological eye conditions. Evidence from methodologically weaker trials and auxiliary evidence from animal studies, trials of synthetic anthocyanosides, and a recent randomized controlled trial of Ribes nigrum (black currant) anthocyanosides may warrant further trials of V. myrtillus anthocyanosides in subjects with impaired night vision.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=195" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342488</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18425071]]&gt;</url>
    <title>Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Eye</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: &lt;/EM&gt;&lt;EM&gt;Eye (Lond).&lt;/EM&gt;&lt;EM&gt; 2008 Jun;22(6):751-60. Epub 2008 Apr 18.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;INTRODUCTION:&lt;/STRONG&gt; The aim of this review was to examine the evidence as to whether antioxidant vitamin or mineral supplements prevent the development of AMD or slow down its progression. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Randomised trials comparing antioxidant vitamin and/or mineral supplement to control were identified by systematic electronic searches (updated August 2007) and contact with investigators. Data were pooled after investigating clinical and statistical heterogeneity. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; There was no evidence that antioxidant (vitamin E or beta-carotene) supplementation prevented AMD. A total of 23 099 people were randomised in three trials with treatment duration of 4-12 years; pooled risk ratio=1.03 (95% CI, 0.74-1.43). There was evidence that antioxidant (beta-carotene, vitamin C, and vitamin E) and zinc supplementation slowed down the progression to advanced AMD and visual acuity loss in people with signs of the disease (adjusted odds ratio=0.68, 95% CI, 0.53-0.87 and 0.77, 95% CI, 0.62-0.96, respectively). The majority of people were randomised in one trial (AREDS, 3640 people randomised). There were seven other small trials (total randomised 525). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Current evidence does not support the use of antioxidant vitamin supplements to prevent AMD. People with AMD, or early signs of the disease, may experience some benefit from taking supplements as used in the AREDS trial. Potential harms of high-dose antioxidant supplementation must be considered. These may include an increased risk of lung cancer in smokers (beta-carotene), heart failure in people with vascular disease or diabetes (vitamin E) and hospitalisation for genitourinary conditions (zinc).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=239" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79260</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/older/MDantiox.html]]&gt;</url>
    <title>Antioxidants for macular degeneration</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Summary produced by Bandolier of an AREDS&amp;nbsp;randomized, placebo-controlled clinical trial on the use of antioxidant supplements and zinc for age-related macular degeneration and vision loss.&amp;nbsp; &amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394537</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007325/frame.html]]&gt;</url>
    <title>Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion</title>
    <publicationDate>2010-11-19T00:00:00</publicationDate>
    <publisher>John Wiley &amp; Sons, Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=abstractTitle&gt;Background&lt;/DIV&gt;Central retinal vein occlusion (CRVO) is a common retinal vascular disorder in which macular edema (ME) may develop, with a consequent reduction in visual acuity. The visual prognosis in CRVO-ME is poor in a substantial proportion of patients, especially those with the ischemic subtype, and until recently there has been no treatment of proven benefit. Macular grid laser treatment is ineffective, and whilst a few recent randomized controlled trials (RCTs) suggest short-term gains in visual acuity with intravitreal steroids for patients with non-ischemic CRVO-ME, there is no established treatment for ischemic CRVO-ME. Anti-vascular endothelial growth factor (anti-VEGF) agents have been used to treat ME resulting from a variety of causes and may represent a treatment option for CRVO-ME.&lt;BR&gt;&lt;BR&gt;
&lt;DIV class=abstractTitle&gt;Objectives&lt;/DIV&gt;To investigate the effectiveness and safety of intravitreal anti-VEGF agents in the treatment of CRVO-ME.&lt;BR&gt;&lt;BR&gt;
&lt;DIV class=abstractTitle&gt;Search strategy&lt;/DIV&gt;We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (&lt;I&gt;The Cochrane Library&lt;/I&gt; 2010, Issue 8), MEDLINE (January 1950 to August 2010), EMBASE (January 1980 to August 2010), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to August 2010), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 1937 to August 2010), OpenSIGLE (January 1950 to August 2010), the &lt;I&gt;meta&lt;/I&gt;Register of Controlled Trials (&lt;I&gt;m&lt;/I&gt;RCT) (&lt;A href="http://www.controlled-trials.com/" target="_blank"&gt;www.controlled-trials.com&lt;/A&gt;) and ClinicalTrials.gov (&lt;A href="http://www.clinicaltrials.gov/" target="_blank"&gt;www.clinicaltrials.gov&lt;/A&gt;). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 10 August 2010.&lt;BR&gt;&lt;BR&gt;
&lt;DIV class=abstractTitle&gt;Selection criteria&lt;/DIV&gt;We considered RCTs that compared intravitreal anti-VEGF agents of any dose or duration to sham injection or no treatment. We focused on studies that included individuals of any age or gender with unilateral or bilateral disease and a minimum of six months follow up. Secondarily, we considered non-randomized studies with the same criteria, but did not conduct a separate electronic search for these.&lt;BR&gt;&lt;BR&gt;
&lt;DIV class=abstractTitle&gt;Data collection and analysis&lt;/DIV&gt;Two review authors independently assessed trial quality and extracted data.&lt;BR&gt;&lt;BR&gt;
&lt;DIV class=abstractTitle&gt;Main results&lt;/DIV&gt;We found two RCTs that met the inclusion criteria after independent and duplicate review of the search results. These RCTs utilized different anti-VEGF agents which cannot be assumed to be directly comparable. We, therefore, performed no meta-analysis. Evidence from these trials and from other non-randomized case series is summarized in this review.&lt;BR&gt;&lt;BR&gt;
&lt;DIV class=abstractTitle&gt;Authors' conclusions&lt;/DIV&gt;Ranibizumab and pegaptanib sodium have shown promise in the short-term treatment of non-ischemic CRVO-ME. However, effectiveness and safety data from larger RCTs with follow up beyond six months are not yet available. There are no RCT data on anti-VEGF agents in ischemic CRVO-ME. The use of anti-VEGF agents to treat this condition therefore remains experimental.&lt;BR&gt;]]&gt;</body>
  </document>
  <document>
    <id>317982</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18929163]]&gt;</url>
    <title>Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2008 Oct; 115(10):1837-46&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To examine the evidence about the safety and efficacy of anti-vascular endothelial growth factor (VEGF) pharmacotherapies for the treatment of neovascular age-related macular degeneration (AMD). &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Literature searches were conducted in May and October 2007 in PubMed with no date restrictions, limited to articles published in English, and in the Cochrane Central Register of Controlled Trials without a language limitation and yielded 310 citations. The first author reviewed the abstracts of these articles and selected 73 articles of possible clinical relevance for review by the panel. The panel deemed 64 of these articles sufficiently clinically relevant to review in full text and assigned ratings of level of evidence to each of the selected articles with the guidance of the panel methodologists. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Eleven studies provided level I evidence for intravitreal pegaptanib and ranibizumab for neovascular AMD; there were no studies rated level I for bevacizumab for neovascular AMD. Five studies were rated as level II, which included studies of ranibizumab and bevacizumab, and the remaining 38 articles retrieved were rated as level III. The studies do not provide information about long-term results or the value (comparative effectiveness) and cost-effectiveness of combined therapies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Review of the available literature to date suggests that anti-VEGF pharmacotherapy, delivered by intravitreal injection, is a safe and effective treatment for neovascular AMD for up to 2 years. There is level I evidence to support this conclusion for pegaptanib and ranibizumab, but none for bevacizumab at this time.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=77" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102046</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6383055&amp;query_hl=61]]&gt;</url>
    <title>Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group.</title>
    <publicationDate>1984-09-15T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American Journal of Ophthalmology, {Am-J-Ophthalmol}, 15 Sep 1984, vol. 98, no. 3, p. 271-82, ISSN: 0002-9394.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;The Branch Vein Occlusion Study is a multi-center, randomized, controlled clinical trial designed to answer several questions regarding the management of complications of branch vein occlusion. This report discusses the question, Is argon laser photocoagulation useful in improving visual acuity in eyes with branch vein occlusion and macular edema reducing vision to 20/40 or worse? One hundred thirty-nine eligible eyes were assigned randomly to either a treated or an untreated control group. Comparing treated patients to control patients (mean follow-up 3.1 years for all study eyes), the gain of at least two lines of visual acuity from baseline maintained for two consecutive visits was significantly greater in treated eyes (P = .00049, logrank test). Because of this improvement in visual acuity with argon laser photocoagulation of macular edema from branch vein occlusion, we recommend laser photocoagulation for patients with macular edema associated with branch vein occlusion who meet the eligibility criteria of this study. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;branch vein occlusion management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102045:0" name=internalLink&gt;Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=3531958&amp;amp;query_hl=64" target="_blank"&gt;Argon laser photocoagulation for macular edema in branch vein occlusion.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102045</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2417579&amp;query_hl=61]]&gt;</url>
    <title>Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group.</title>
    <publicationDate>1986-01-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology, {Arch-Ophthalmol}, Jan 1986, vol. 104, no. 1, p. 34-41, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;The Branch Vein Occlusion Study is a multicenter, randomized, controlled clinical trial designed to answer several questions regarding the management of complications of branch vein occlusion. This report addresses the questions, Can peripheral scatter argon laser photocoagulation prevent the development of neovascularization? and Can peripheral scatter argon laser photocoagulation prevent vitreous hemorrhage? To answer the first question, 319 eyes were assigned randomly to either a treated or an untreated control group. Comparing treated patients with control patients (average follow-up time, 3.7 years), the development of neovascularization was significantly less in treated eyes (P = .009, log rank test). To answer the second question, 82 eyes were assigned randomly to either a treated or untreated control group. Comparing treated patients with control patients (average follow-up time, 2.8 years), the development of vitreous hemorrhage was significantly less in treated eyes (P = .005, log rank test). Although the Branch Vein Occlusion Study was not designed to determine whether peripheral scatter treatment should be applied before rather than after the development of neovascularization, data accumulated in this study suggest that peripheral scatter treatment should be applied after the development of neovascularization rather than before the development of neovascularization. Because the occurrence of vitreous hemorrhage was lessened by peripheral scatter argon laser photocoagulation, we recommend laser photocoagulation for patients with branch vein occlusion who have developed neovascularization and who meet the eligibility criteria of this study. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;branch vein occlusion management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102046:0" name=internalLink&gt;Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=3531958&amp;amp;query_hl=64" target="_blank"&gt;Argon laser photocoagulation for macular edema in branch vein occlusion.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79183</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band92/b92-3.html]]&gt;</url>
    <title>Aspirin and cataracts</title>
    <publicationDate>2001-10-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This article&amp;nbsp;published in&amp;nbsp;issue 92 of the Bandolier Journal in&amp;nbsp;October 2001 discusses&amp;nbsp;the effect of aspirin&amp;nbsp;on the prevention of cataracts.]]&gt;</body>
  </document>
  <document>
    <id>310717</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/12227131]]&gt;</url>
    <title>Aspirin in diabetic retinopathy. A systematic review</title>
    <publicationDate>2002-09-01T00:00:00</publicationDate>
    <publisher>Endocrinology and metabolism clinics of North America</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Endocrinology and metabolism clinics of North America (Endocrinol Metab Clin North Am) 2002 Sep;31(3):779-93.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;Diabetes mellitus is a risk factor for eye disease that can lead to blindness. There have been both concerns that aspirin use might worsen diabetic retinopathy, as well as hopes that aspirin might be beneficial in treating it. We investigated whether there are beneficial effects of aspirin alone and in combination with other antiplatelet agents in the treatment of diabetic retinopathy, and the relative hazards for the development of high-risk proliferative retinopathy following aspirin treatment. We conducted a sensitive search for randomized controlled trials combined with index terms for identifying studies on aspirin treatment in diabetic retinopathy in the Cochrane Library (issue 4, 2001) and Medline (1966 to October, 2001). We examined randomized controlled clinical trials in diabetic patients with (non) proliferative diabetic retinopathy and aspirin treatment alone or in combination with dipyramidole versus placebo administration. Two independent reviewers judged trial eligibility, collected details of study population, interventions, and outcomes using a standard data extraction form. One reviewer assessed the quality of trial reporting. We identified six publications pertinent to our objective. Aspirin dosages ranged from 650 mg to 990 mg daily, the dose of dipyridamole, used in only one trial, was 225 mg per day. Studies lasted 8 weeks to 5 years. All trials showed that aspirin alone or in combination with dipyridamole neither lowered nor increased the risk of the development of diabetic retinopathy. The results suggest that there are no ocular contraindications to taking aspirin if required as part of a treatment for cardiovascular diseases or other medical indications.&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=209" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310721</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/12862194]]&gt;</url>
    <title>Assessment of diagnostic tests to inform policy decisions - visual electrodiagnosis</title>
    <publicationDate>2003-04-01T00:00:00</publicationDate>
    <publisher>International Journal of Technology Assessment in Health Care</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: International Journal of Technology Assessment in Health Care (Int J Technol Assess Health Care) 2003 Spring; 19(2):373-83.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVES:&lt;/STRONG&gt; To conduct a systematic review of the evidence for the effectiveness of five visual electrodiagnostic tests to inform the Medical Services Advisory Committee (MSAC) of the Department of Health and Ageing (Australia) in its decision in allocating public funding for new technologies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;We searched the biomedical literature to identify English-language articles published from 1966 to September 2000. We assessed validity of methodology of included studies against the following criteria: investigators (i) compared test with an appropriate reference test; (ii) tested an appropriate spectrum of patients; (iii) masked assessment of study and reference tests; (iv) measured the study test independently of clinical information; and (v) measured the reference test before any interventions. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Sixty-one articles met inclusion criteria for critical appraisal: nineteen were cross-sectional studies that compared a study test with another test, thirty-four were case-control studies that compared a test in a group of patients with an eye disease to a group of subjects without eye disease, and eight studies were case series. None of the included studies met all of the validity criteria. Only four studies provided enough information to calculate diagnostic characteristics but were flawed due to inclusion of patients already diagnosed with disease or lack of an appropriate reference test and, thus, overestimated test accuracy. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Identified studies did not provide sufficient valid evidence of the clinical value of the five visual tests in diagnosing diseases of the retina or optic nerve. Thus, MSAC recommended that the tests not be supported by public funding.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=203" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310724</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16916985]]&gt;</url>
    <title>Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>American Journal of Epidemiology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American Journal of Epidemiology (Am J Epidemiol) 2006 Nov 1; 164(9): 813-22. Epub 2006 Aug 17.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;A possible association between apolipoprotein E polymorphisms and age-related macular degeneration has been investigated numerous times, with conflicting results. A previous analysis pooling results from four studies (Schmidt et al., Ophthalmic Genet 2002;23:209-23) suggested an association, but those investigators did not document allele frequencies, the magnitude of the association, or the possible genetic mode of action. Thus, the authors searched MEDLINE from 1966 to December 2005 for any English-language studies reporting genetic associations. Data and study quality were assessed in duplicate. Pooling was performed while checking for heterogeneity and publication bias. Frequencies of the E2 and E4 alleles in Caucasians were approximately 8% and 15%, respectively. Allele- and genotype-based tests of association indicated a risk effect of up to 20% for E2 and a protective effect of up to 40% for E4. E2 appeared to act in a recessive mode and E4 in a dominant mode. There appears to be a differential effect of the E2 and E4 alleles on the risk of age-related macular degeneration, although the possibility of survivor bias needs to be ruled out more definitively.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality&amp;nbsp;appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=125" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317987</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18591929]]&gt;</url>
    <title>Association between MYOC.mt1 promotor polymorphism and risk of primary open-angle glaucoma: a systematic review and meta-analysis</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Medical Science Monitor: international medical journal of experimental and clinical research</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Medical Science Monitor : international journal of experimental and clinical research (Med Sci Monit) 2008 Jul;14(7):RA87-93.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND: &lt;/STRONG&gt;The aim was to review all published studies that investigated the association between MYOC.mt1 polymorphism and the risk of primary open-angle glaucoma (POAG). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MATERIAL/METHODS:&lt;/STRONG&gt; Electronic databases were searched for relevant articles in English. Inclusion and exclusion criteria were established according to the criteria of the Cochrane Methods Group. Studies were included if participants were patients with POAG (adult- or juvenile-onset), had extractable data on both genotypes of MYOC.mt1, phenotypes of severity, and reasonable controls. Statistical analysis was performed using SPSS 13.0 for Windows and RevMan 4.2. Four case-control studies of 835 cases and 530 controls were included in the meta-analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The pooled odds ratio (OR) to develop POAG with and without MYOC.mt1 from a fixed-effects model was 1.06 (95%CI: 0.81-1.38, P=0.67), i.e. MYOC.mt1 carriers did not have significantly higher risk of developing POAG than non-carriers. There was also no significant association between the -1000G allele and increased risk (OR=1.05, 95%CI: 0.83-1.32, P=0.71). Comprehensive summarization was done to determine the influence of MYOC.mt1 on the severity of optic disk changes and visual function loss in POAG cases. There was evidence of publication bias from funnel-plot asymmetry and Egger's test. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Evidence for an association between MYOC.mt1 and the risk of POAG is limited. These results suggest that MYOC.mt1 polymorphism does not have significant influence on the risk of POAG development or its severity. However, the evidence of publication bias suggests that more large prospective cohort studies with precise design are required to confirm an association between MYOC.mt1 and POAG.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=82" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320386</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18472000]]&gt;</url>
    <title>Association of tumour necrosis factor alpha (TNF-alpha) polymorphisms with Graves' disease: A meta-analysis</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Clinical Biochemistry</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ THYROID &amp; PARATHYROID DISORDERS,ENT AND AUDIOLOGY,EYES AND VISION,CONDITIONS,ORBIT,GRAVES' DISEASE,HYPERTHYROIDISM,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Clinical Biochemistry (Clin Biochem) 2008 Jul;41(10-11):881-6. Epub 2008 Apr 26.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To quantitatively summarize the association between tumour necrosis factor alpha (TNF-alpha) gene polymorphisms and Graves' disease.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN AND METHODS&lt;/STRONG&gt;: Relevant studies were identified from the following electronic databases: Cochrane Library, MEDLINE, EMBASE and Chinese Bio-medicine Database. A meta-analysis of relevant studies was performed. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; This meta-analysis included 10 case-control studies, which included 2271 Graves' disease cases and 2633 controls. The combined results based on all studies showed that there was significant difference in genotype distribution (-308A/G; -308G/G; -863C/C; -863C/A; -1031C/T) between Graves' disease and controls. When stratifying for race, statistically significant results were observed in three genotype distribution (-863C/C; -863C/A; -1031C/T) between Graves' disease and controls among Asians. Statistically significant results were observed in only two genotype distribution (-308A/G; -308G/G) between Graves' disease and controls among Caucasians. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This meta-analysis suggests that TNF-alpha gene polymorphisms at positions -308 (G-308A), -863 (C-863A), and -1031 (T-1031C) were associated with Graves' disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=80" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310758</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11772573]]&gt;</url>
    <title>Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update</title>
    <publicationDate>2002-01-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2002 Jan; 109(1): 13-24&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To assess commonly used cataract surgery bacterial endophthalmitis prophylaxis techniques based on a systematic literature review and evidence rating. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CLINICAL RELEVANCE:&lt;/STRONG&gt; Prophylactic techniques to decrease the risk of bacterial endophthalmitis related to cataract surgery are commonly used, but the evidence justifying their use is unclear. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;LITERATURE REVIEWED:&lt;/STRONG&gt; A MEDLINE search of the literature published in English or with English abstracts from 1966 to 2000 was performed using various combinations of relevant key words. Eighty-eight peer-reviewed papers were identified and judged worthy of review on the basis of predefined criteria. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;No prophylactic technique received the highest of three possible clinical recommendations (A, crucial to clinical outcome). Preoperative povidone-iodine preparation received the intermediate clinical recommendation (B, moderately important to clinical outcome). All other reported prophylactic interventions, including postoperative subconjunctival antibiotic injection, preoperative lash trimming, preoperative saline irrigation, preoperative topical antibiotics, antibiotic-containing irrigating solutions, and the use of intraoperative heparin, received the lowest clinical recommendation (C, possibly relevant but not definitely related to clinical outcome) based on weak and often conflicting evidence justifying their use. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; With regard to bacterial endophthalmitis prophylaxis in cataract surgery, current literature most strongly supports the use of preoperative povidone-iodine antisepsis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=216" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>332153</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/ARMD-sight-loss-asprin-treatment-no-benefit.aspx]]&gt;</url>
    <title>Behind the Headlines – Aspirin no help for sight loss in the elderly</title>
    <publicationDate>2009-12-02T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Aspirin “could stop you going blind”, according to the Daily Express, which reports that taking aspirin daily can cut the risk of developing age-related macular degeneration by almost a fifth.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Aspirin “could stop you going blind”, according to the Daily Express, which reports that taking aspirin daily can cut the risk of developing age-related macular degeneration by almost a fifth. Age-related macular degeneration is a common cause of visual loss in the elderly. It occurs when the cells in the centre of the retina become progressively damaged. This damage eventually causes the loss of central vision, making reading and writing impossible for some people. The research behind this study was robust and well-conducted, but the results have been incorrectly reported in the Daily Express. The large study, which lasted several years, found that aspirin had no significant effect on the risk of developing age-related macular generation, a point the researchers clearly highlight in their written results. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a well-designed and well-conducted study, the results of which have been incorrectly reported in the press. This study found that low-dose aspirin had no effect in preventing age-related macular degeneration, a common cause of sight loss in the elderly. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/12December/Pages/ARMD-sight-loss-asprin-treatment-no-benefit.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Christen WG, Glynn RJ, Chew EY, Buring JE. Low-Dose Aspirin and Medical Record Confirmed Age-related Macular Degeneration in a Randomized Trial of Women. Ophthalmology 2009; 116: 2386-2392&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>322579</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/GlaucomaEyeDropCure.aspx]]&gt;</url>
    <title>Behind the Headlines – Eye drops 'heal glaucoma'</title>
    <publicationDate>2009-08-10T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Treatment with a new type of eye drop “cures blindness in early tests”, according to The Daily Telegraph.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Treatment with a new type of eye drop “cures blindness in early tests”, according to &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt; The newspaper said that research by a team of Italian scientists tested the drops in rats and then found that vision improved in three people tested with new eye drops. Glaucoma is usually treated using eye drops that reduce the pressure in the eyeball and thereby prevent further damage to the optic nerve and retina. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is early research in a case series of patients whose vision was failing even though they were being treated for their long-standing glaucoma. Although this small study had limited statistical power it has demonstrated improvements compared with the period before the three patients were treated. Studies like this usually precede more robust investigations of potential new treatments, and only the results of long-term, randomised controlled trials will provide definitive answers about the potential benefits of using NGF eye drops.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/08August/Pages/GlaucomaEyeDropCure.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lambiase A, Aloe L, Centofanti M &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.pnas.org/content/early/2009/07/31/0906678106.abstract" target="_blank"&gt;Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma&lt;/A&gt;. PNAS, [Published online before print] August 3, 2009 &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>302109</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/12December/Pages/Blindsight.aspx]]&gt;</url>
    <title>Behind the headlines: 'Blindsight' phenomenon</title>
    <publicationDate>2008-12-23T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OPTIC NERVE AND VISUAL PATHWAYS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;On 23 December 2008 The Daily Telegraph reported "A man who was left completely blind by multiple strokes has been able to navigate an obstacle course using only his "sense" of where hazards lie".&amp;nbsp;&amp;nbsp; This story is based on a case report of a man demonstrating ‘blindsight’, an ability that has previously only been described in monkeys. The man’s blindness was caused by strokes and was a result of damage to the brain rather than his eyes.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Follow the link to see the National Knowledge Service commentary on this news item.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Behind the headlines provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/EM&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news &lt;/EM&gt;
&lt;LI&gt;&lt;EM&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and &lt;/EM&gt;
&lt;LI&gt;&lt;EM&gt;become a trusted resource for journalists and others involved in the dissemination of health news&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317103</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/06June/Pages/CanOptimismImproveSight.aspx]]&gt;</url>
    <title>Behind the headlines: Can optimism aid your vision</title>
    <publicationDate>2009-06-05T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;EM&gt;&lt;/EM&gt;
&lt;P&gt;On Friday 5th June 2009 the Daily Telegraph reported that a "positive outlook improves your vision".&amp;nbsp; It said that research has shown that people with a "sunny outlook" take in more visual information, proving that a "positive attitude really can improve performance". &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Follow the link to see the NHS Knowledge Service commentary on this news item.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Behind the headlines provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/EM&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news &lt;/EM&gt;
&lt;LI&gt;&lt;EM&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and &lt;/EM&gt;
&lt;LI&gt;&lt;EM&gt;become a trusted resource for journalists and others involved in the dissemination of health news&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325149</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/Colourblindmonkeyscured.aspx]]&gt;</url>
    <title>Behind the Headlines: Colour blind monkeys 'cured'</title>
    <publicationDate>2009-09-17T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LOW VISION,CONDITIONS,COLOUR VISION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Scientists have cured colour blindness in monkeys,” said &lt;EM&gt;The Daily Telegraph&lt;/EM&gt;. It said this signals hope for millions of sufferers with the condition and other more serious defects such as age-related macular degeneration. Full colour vision was restored by gene therapy in two adult monkeys born without the ability to distinguish between the colours red and green. The newspaper said that this type of colour blindness mostly affects men and affects about one in 30,000 people.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The importance of this small animal study lies in its implications for human disease and this has yet to be tested. Although colour blindness is not a life-threatening disease it can be disabling and the fact that the researchers have shown a cure for a similar condition in monkeys brings the day closer when other cone diseases in humans could be treated in this way.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/09September/Pages/Colourblindmonkeyscured.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Mancuso K, Hauswirth WH, Li Q,&amp;nbsp; et al.&amp;nbsp;&lt;A href="http://www.nature.com/nature/journal/vaop/ncurrent/full/nature08401.html" target="_blank"&gt;Gene therapy for red–green colour blindness in adult primates.&lt;/A&gt; Nature advance online publication 16 September 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>294850</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/09September/Pages/Genetherapyforblindness.aspx]]&gt;</url>
    <title>Behind the headlines: Gene therapy for blindness</title>
    <publicationDate>2008-09-23T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;On 23 September The Daily Express&amp;nbsp;reported that the “Blind will ‘see’ within few days of gene therapy.” It said trials have shown that a revolutionary new therapy cures a form of inherited blindness within days. &lt;/P&gt;
&lt;P&gt;The Daily Mail&lt;EM&gt; &lt;/EM&gt;also covered the story and said that an injection of genes directly into the retina could “reverse blindness in hundreds of thousands of patients”.&amp;nbsp;&amp;nbsp; The newspapers report that within two years it could treat other inherited diseases of the retina and in five years could be ready for testing on those who have age-related macular degeneration.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;EM&gt;
&lt;P&gt;Follow the link to see the National Knowledge Service commentary on this news item.&lt;/P&gt;
&lt;P&gt;Behind the headlines provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/P&gt;
&lt;P&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and 
&lt;LI&gt;become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394535</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/lasers-used-to-treat-cataracts.aspx]]&gt;</url>
    <title>Behind the Headlines: New laser treatment for cataracts</title>
    <publicationDate>2010-11-19T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;***replace this text with the first 2-3 paragraphs from BtH article***&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The multiple parts to this research have been well-reported and produce a logical story of why these researchers believe this innovation to be an improvement on the current techniques that are used. They mention a few limitations, some of which revolve around the early nature of the research.&lt;/P&gt;
&lt;P&gt;See the &lt;A href="http://www.nhs.uk/news/2010/11November/Pages/lasers-used-to-treat-cataracts.aspx" target="_blank"&gt;entire NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Palanker DV, Blumenkranz MS, Andersen D &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://stm.sciencemag.org/content/2/58/58ra85.abstract" target="_blank"&gt;Femtosecond Laser–Assisted Cataract Surgery with Integrated Optical Coherence Tomography.&lt;/A&gt; &lt;EM&gt;Science Translational Medicine 2010&lt;/EM&gt; 2: 58ra85&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>392398</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.lookupinfo.org/includes/documents/2010/b/best_practice_guide_v3.pdf]]&gt;</url>
    <title>Best Practice Guide: Enhanced eye tests for people with a learning disability</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>Seeability</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,BENEFITS AND CONCESSIONS,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Guidance on arranging enhanced eye tests for people with learning difficulties&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=505" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=505" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=505" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310761</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11973241]]&gt;</url>
    <title>Blindness and visual impairment in the Americas and the Carribean</title>
    <publicationDate>2002-05-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2002 May;86(5):498-504.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; To summarise available data on the prevalence and causes of visual impairment and blindness in the Americas and the Caribbean. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; The published literature was searched in Medline and LILACS using the following key words: blindness, visual impairment, prevalence. Articles were reviewed, and the references of the articles were also searched for relevant articles, which were also reviewed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Using the mortality in children under the age of 5 as an indicator, the overall prevalence of childhood blindness (in the under age 15 group) for the region was estimated at 0.45/1000, with the majority (67%) living in countries with mortality of children under age 5 above 30/1000 live births. Corneal opacities were more common in countries where the under 5 year mortality are above 30/1000 live births and retinopathy of prematurity (ROP) was an important cause in countries with intermediate death rates. For adults, overall blindness rates were not estimated because of the social, economic, and ethnic diversity in the region. The primary causes of visual loss in adults in the Americas were age related eye diseases, notably cataract and glaucoma in the African-American and Hispanic populations, and age related macular degeneration in the white population. Uncorrected refractive error was a significant cause of decreased vision across ages, ethnic groups, and countries. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; More data are needed on the magnitude and causes of visual loss for the Caribbean and Latin American countries. Rates of blindness and visual loss from available data within these countries are widely disparate. Prevention and control of avoidable blindness needs to be an ongoing focus in this region.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=210" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289961</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcophth.ac.uk/core/core_picker/download.asp?id=310]]&gt;</url>
    <title>Blood borne viral infections and ophthalmic surgery</title>
    <publicationDate></publicationDate>
    <publisher>The Royal College of Ophthalmologists</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CORNEA,GLAUCOMA,RETINA,LENS,UVEAL TRACT,LID,OCULAR MOTILITY,ORBIT,VITREOUS BODY,REFRACTIVE ERROR,OPTIC NERVE AND VISUAL PATHWAYS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Document published by the Royal College of Ophthalmologists on 10 July 2008 providing a synopsis of the current guidance and published research on safe practice for minimising the risks of transmission of infection during surgery from the ophthalmologist's perspective.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;It also provides advice for ophthalmic surgeons who are HIV, hepatitis B or hepatitis C positive in relation to continuing surgical practice. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=407" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=407" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=407" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143774</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/rss/newsAndRssArticle.aspx?uri=http://www.library.nhs.uk/resources/?id=66145]]&gt;</url>
    <title>Can inhaled corticosteriods cause cataracts?</title>
    <publicationDate>2003-09-19T00:00:00</publicationDate>
    <publisher>NHS Centre for Reviews and Dissemination (NHS CRD)</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Hitting the Headlines', produced by the Centre for Reviews and Dissemination, offers an analysis of the evidence behind selected news stories which have been reported in national newspapers.&amp;nbsp;&amp;nbsp; The aim is to provide&amp;nbsp;health professionals and the public with information about the accuracy of reporting of research in the press.&amp;nbsp;&amp;nbsp; Summaries are posted on the National Library for Health website within 48 hours of newspaper publication. &lt;/P&gt;
&lt;P&gt;This article was&amp;nbsp;produced on 19 September 2003 following news stories issued in three national news stories on 18 September 2003.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89365</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.eyesite.ca/english/program-and-services/policy-statements-guidelines/pediatric-guidelines.htm]]&gt;</url>
    <title>Canadian Pediatric Guidelines: Ophthalmological Assessment in Infants and Children</title>
    <publicationDate></publicationDate>
    <publisher>Canadian Ophthalmological Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,CORNEA,LACRIMAL,RETINA,LENS,REFRACTIVE ERROR,OCULAR MOTILITY,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Canadian Pediatric Guidelines on ophthalmological assessment in infants and children&amp;nbsp;published by&amp;nbsp;the Canadian Ophthalmological Society, published 2004.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;There are two sections, the first includes information on history taking and examination techniques, interpretation of terms used by parents,&amp;nbsp;signs and symptoms&amp;nbsp;and developmental milestones.&amp;nbsp;&amp;nbsp; The second looks at the components of the eye examination, visual acuity, alignment, refraction, fundoscopy, slit lamp and assessment of intraocular pressure. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=98" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=98" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=98" target="_blank"&gt;NO&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318010</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18572053]]&gt;</url>
    <title>Cataract surgery and the development or progression of age-related macular degeneration: a systematic review</title>
    <publicationDate>2008-07-31T00:00:00</publicationDate>
    <publisher>Surveys of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,LENS,AGE RELATED MACULAR DEGENERATION,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Surveys of Ophthalmology (Surv Ophthalmol) 2008 Jul-Aug;53(4):359-67.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Age-related macular degeneration and cataract are the most frequent eye disorders of elderly people worldwide. The aim of this systematic review was to evaluate the effect of cataract surgery on the development and progression of age-related macular degeneration. Data were collected by means of a systematic literature search in 28 databases and an additional update in Pubmed. Search results were evaluated using pre-defined inclusion and exclusion criteria. All relevant publications were rated in terms of scientific quality and analyzed regarding their results. The literature search generated a total of 2,827 hits. Seven publications on five observational studies and two non-randomized clinical trials were eligible for analysis. The observational studies provided some evidence for an increased incidence of late age-related macular degeneration, respectively, for a promoting influence of cataract surgery on the progression of early types of age-related macular degeneration. The clinical trials did yield inconsistent results. In conclusion, only a small number of published studies investigated the development or progression of age-related macular degeneration following cataract surgery. The scientific level of evidence of these articles was not high and results were inconsistent, nevertheless a promoting influence of cataract surgery on the progression of early age-related macular degeneration can be assumed.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=58" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372637</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19091848]]&gt;</url>
    <title>Cataract surgical coverage remains lower in women</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology 2009 Mar;93(3):295-8. Epub 2008 Dec 17&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BACKGROUND: &lt;/STRONG&gt;Cataract remains the leading cause of global blindness. Evidence from population-based surveys, carried out up to 2000, and the launch of the VISION 2020 initiative to address avoidable blindness showed that women in low- and middle-income countries had a lower cataract surgical coverage (CSC) than men. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A systematic review identified population-based surveys reporting CSC in low- and middle-income countries published since 2000. Researchers extracted data on sex-specific CSC rates and estimated the overall CSC differences using meta-analyses. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Among the 23 surveys selected for this review, 21 showed higher CSC among men. The Peto odds ratio revealed that men were 1.71 times (95% CI 1.48 to 1.97) more likely to have cataract surgery than women. The risk difference in the rates of surgery varied from -0.025 to 0.276, and the combined average was 0.116 (95% CI 0.082 to 0.149). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DISCUSSION:&lt;/STRONG&gt; Gender inequity in use of cataract surgical services persists in the low- and middle-income countries. It is estimated in this study that blindness and severe visual impairment from cataract could be reduced by around 11% in the low- and middle-income countries if women were to receive cataract surgery at the same rate as men. Additional effort globally is needed to ensure that women receive the benefits of cataract surgery at the same rate as men.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=279" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102068</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10030553&amp;query_hl=49]]&gt;</url>
    <title>Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group.</title>
    <publicationDate>1999-02-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETIC RETINOPATHY,RETINOPATHY,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American Journal of Ophthalmology, {Am-J-Ophthalmol}, Feb 1999, vol. 127, no. 2, p. 137-41, ISSN: 0002-9394.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To describe the causes of and risk factors for persistent severe visual loss occurring in the Early Treatment Diabetic Retinopathy Study (ETDRS). &lt;/P&gt;
&lt;P&gt;METHODS: The ETDRS was a randomized clinical trial investigating photocoagulation and aspirin in 3,711 persons with mild to severe nonproliferative or early proliferative diabetic retinopathy. Severe visual loss, defined as best-corrected visual acuity of less than 5/200 on at least two consecutive 4-month follow-up visits, developed in 257 eyes (219 persons). Of these 257 eyes, 149 (127 persons) did not recover to 5/200 or better at any visit (persistent severe visual loss). Ocular characteristics of these eyes were compared with those of eyes with severe visual loss that improved to 5/200 or better at any subsequent visit. Characteristics of patients with severe visual loss that did and did not improve and those without severe visual loss were also compared. &lt;/P&gt;
&lt;P&gt;RESULTS: Severe visual loss that persisted developed in 149 eyes of 127 persons. In order of decreasing frequency, reasons recorded for persistent visual loss included vitreous or preretinal hemorrhage, macular edema or macular pigmentary changes related to macular edema, macular or retinal detachment, and neovascular glaucoma. Compared with all patients without persistent severe visual loss, patients with persistent severe visual loss had higher mean levels of hemoglobin A1c (10.4% vs 9.7%; P = .001) and higher levels of cholesterol (244.1 vs 228.5 mg/dl; P = .0081) at baseline. Otherwise, patients with persistent severe visual loss were similar to patients with severe visual loss that improved and to those without severe visual loss. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Persistent severe visual loss was an infrequent occurrence in the ETDRS. Its leading cause was vitreous or preretinal hemorrhage, followed by macular edema or macular pigmentary changes related to macular edema and retinal detachment. The low frequency of persistent severe visual loss in the ETDRS is most likely related to the nearly universal intervention with scatter photocoagulation (either before or soon after high-risk proliferative diabetic retinopathy developed) and the intervention with vitreous surgery when clinically indicated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102063" target="_blank"&gt;Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=10&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102064" target="_blank"&gt;Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102065" target="_blank"&gt;Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102066" target="_blank"&gt;Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102067" target="_blank"&gt;Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2740076&amp;amp;query_hl=73" target="_blank"&gt;Detection of diabetic macular edema. Ophthalmoscopy versus photography--Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8287162&amp;amp;query_hl=73" target="_blank"&gt;C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062510&amp;amp;query_hl=102" target="_blank"&gt;Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062511&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062514&amp;amp;query_hl=73" target="_blank"&gt;Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062515&amp;amp;query_hl=73" target="_blank"&gt;Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062516&amp;amp;query_hl=73" target="_blank"&gt;Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1507375&amp;amp;query_hl=113" target="_blank"&gt;Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10577530&amp;amp;query_hl=108" target="_blank"&gt;Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1543449&amp;amp;query_hl=94" target="_blank"&gt;Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9477980&amp;amp;query_hl=106" target="_blank"&gt;Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7661748&amp;amp;query_hl=73" target="_blank"&gt;Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7826294&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8790092&amp;amp;query_hl=91" target="_blank"&gt;Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9230827&amp;amp;query_hl=73" target="_blank"&gt;Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10604663&amp;amp;query_hl=94" target="_blank"&gt;Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15735198&amp;amp;query_hl=97" target="_blank"&gt;Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8545570&amp;amp;query_hl=100" target="_blank"&gt;Accommodative amplitudes in the Early Treatment Diabetic Retinopathy Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>279001</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.vision2020uk.org.uk/core_files/Childrens%20Support%20FINAL_PRINT.pdf]]&gt;</url>
    <title>Childrens Eye Health: A report on vision screening for children</title>
    <publicationDate>2007-10-12T00:00:00</publicationDate>
    <publisher>Association of Optometrists (AOP)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,IN CHILDHOOD,LIVING WITH VISUAL IMPAIRMENT,REFRACTIVE ERROR,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A report&amp;nbsp;published in October 2007, written by the Association of Optometrists (AOP), Association of British Dispensing Opticians (ABDO), College of Optometrists (CoO) and Federation of Ophthalmic and Dispensing Opticians (FODO).&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318018</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18417559]]&gt;</url>
    <title>Chronic health problems and risk of accidental injury in the workplace: a systematic literature review</title>
    <publicationDate></publicationDate>
    <publisher>Occupational and Environmental Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Occupational &amp;amp; Environmental Medicine (Occup Environ Med) 2008 Nov;65(11):757-64. Epub 2008 Apr 16.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVES:&lt;/STRONG&gt; To investigate whether common important health conditions and their treatments increase risks of occupational injury. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic search was conducted of MEDLINE, EMBASE and PsycINFO databases from inception to November 2006 employing terms for occupational injury, medications, and a broad range of diseases and impairments. Papers related solely to driving, alcohol, or substance abuse were excluded, as were studies that did not allow analysis of injury risk. For each paper that was retrieved we abstracted standard information on the population, design, exposure(s), outcome(s), response rates, confounders and effect estimates; and rated the quality of information provided. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; We found 38 relevant papers (33 study populations): 16 studies were of cross-sectional design, 13 were case-control and 4 were prospective. The overall quality was rated as excellent for only two studies. Most commonly investigated were problems of hearing (15 studies), mental health (11 studies) and vision (10 studies). For impaired hearing, neurotic illness, diabetes, epilepsy and use of sedating medication there were moderate positive associations with occupational injury (odds ratios 1.5-2.0), but there were major gaps in the evidence base. Studies covering vision did not present risks by category of eye disease; no evidence was found on psychotic illness; for diabetes, epilepsy and cardiovascular disease there were remarkably few papers; studies seldom distinguished risks by sub-category of external cause or anatomical site and nature of injury; and exposures and outcomes were mostly ascertained by self-report at a single time point, with a lack of clarity about exposure timings. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Improved research is needed to define the risks of occupational injury arising from common health complaints and treatments. Such research should delineate exposures and outcomes in more detail, and ensure by design that the former precede the latter.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=88" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342478</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18854733]]&gt;</url>
    <title>Cigarette smoking and primary open angle glaucoma: a systematic review</title>
    <publicationDate>2008-10-31T00:00:00</publicationDate>
    <publisher>Journal of Glaucoma</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Glaucoma. 2008 Oct-Nov;17(7):558-66&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To evaluate the epidemiologic evidence for a causal association between tobacco smoking and primary open angle glaucoma (POAG). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Systematic review, including quality assessment, of published analytical epidemiologic studies and evaluation of the evidence using established causality criteria (strength, consistency, temporality, dose response, reversibility, and biologic plausibility). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Eleven papers describing 9 case-control studies, 1 prospective cohort study, and a paper describing a pooled analysis based on 2 prospective cohort studies were included in the review. The methodologic quality of most included studies was poor. The strongest studies methodologically were the cohort studies on which the pooled analysis was based. Neither the prospective cohort study (rate ratio not reported) nor the pooled analysis of 2 prospective cohort studies (adjusted rate ratio 0.9) found an association between smoking and POAG. There was a significant positive association between smoking and POAG in only 2 of the case-control studies (adjusted odds ratio 2.9 and 10.8). There was no evidence of a dose-response relationship with smoking or of reversibility of effect in the studies where this was assessed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This systematic review provided little evidence for a causal association between smoking and development of POAG. Given the limited evidence from high quality studies, and the possibility that flaws in many of the studies reviewed biased the results toward the null, further high quality research to confirm our conclusions is needed. However, it remains important to warn ophthalmic patients of the dangers of smoking and provide cessation support owing to the clear evidence of links between smoking and other ocular and systemic diseases.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=238" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318035</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16980921]]&gt;</url>
    <title>Cigarette smoking and thyroid eye disease: a systematic review</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Eye</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NHS CORE CONTENT WITHOUT A CATEGORY,ORBIT,THYROID EYE DISEASE,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Eye 2007 Sep;21(9):1135-45. Epub 2006 Sep 15&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To evaluate the epidemiological evidence for a causal association between tobacco smoking and thyroid eye disease (TED). &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Systematic review, including quality assessment, of published epidemiological studies and evaluation of the evidence using established causality criteria. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Fourteen papers describing 15 studies were included. There was a positive association between smoking and TED in four case-control studies when compared with control patients with Graves' disease but no ophthalmopathy (odds ratio (OR) 1.94-10.1) and in seven case-control studies in which control subjects did not have thyroid disease (OR 1.22-20.2). Two cohort studies examined the occurrence of new cases of TED; one study found an increased incidence of TED with smoking. Four cohort studies investigated progression or outcome of treatment in patients with established TED, three finding an association between smoking and poorer outcome. The quality of the studies was variable, but the association with smoking was strong in the most methodologically rigorous studies. Other evidence supporting a causal link was a consistent association across studies, a dose-response effect, a reduced risk of TED in ex-smokers, and a temporal relationship. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; This systematic review provided strong evidence for a causal association between smoking and development of TED. Current-smokers were also more likely to experience disease progression or poorer outcome of treatment. Patients with Graves' disease and the general public should be educated about the risk of smoking and TED. These findings suggest that patients with Graves' disease or TED who are smokers should be given effective support to stop smoking.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=49" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333153</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1360.pdf]]&gt;</url>
    <title>Colour vision testing for diabetic retinopathy: a systematic review of diagnostic accuracy and economic evaluation</title>
    <publicationDate>2009-12-16T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment programme (HTA)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Systematic review published in Health Technology Assessment 2009 Vol 13 No 60.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives&lt;BR&gt;&lt;/STRONG&gt;This project had three main objectives. These were:&lt;BR&gt;1.To report the findings of a systematic review to determine (1) the diagnostic performance of CVT options to identify and/or monitor the progression of DR, and (2) the preferences of patients in relation to incorporating CVT in the retinopathy screening programme. &lt;BR&gt;2.To report the findings of a survey of the clinical leads and programme managers of the NSPDR to determine what tests are currently used in the detection and management of DR, over and above the requirements of the programme, as well as their views on future research priorities. &lt;BR&gt;3.To review previous economic studies of DR screening with CVT and develop a cost-effectiveness model to evaluate the potential efficiency of incorporating CVT into the current DR screening programme. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;BR&gt;A systematic review of the diagnostic performance of CVT and patient preferences towards CVT was carried out. Both published and unpublished literature were identified from systematic searches of electronic sources including MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA) database (from database inception to September 2008); hand searching; consultation with experts in the field; and the NSPDR.&lt;/P&gt;
&lt;P&gt;Study selection, data extraction and quality assessment were undertaken by two reviewers independently. Studies were assessed for methodological quality using QUADAS (Quality for Assessing Diagnostic Accuracy Studies) and were combined in a structured narrative synthesis. Sensitivities and specificities were plotted in receiver operating characteristic space when appropriate.&lt;/P&gt;
&lt;P&gt;A survey of NSPDR clinical leads and programme managers was carried out using an online survey that was emailed to 192 potential participants. The objective of the survey was to assess which diagnostic tools are used routinely by the local centres over and above those specified by the NSPDR, as well as to assess the views of the clinical leads and programme managers on future research priorities.&lt;/P&gt;
&lt;P&gt;We identified previous economic evaluations of CVT screening for DR by adapting the diagnostic accuracy search strategy by replacing diagnostic filter terms with economics filter terms. We expanded the electronic sources searched to include specialist economic evaluation databases.&lt;/P&gt;
&lt;P&gt;Based on studies identified in the systematic review of diagnostic accuracy, we developed a decision tree and Markov model to estimate the incremental costs and effects of adding CVT to the current NSPDR using digital photography of the retina. Evidence on additional parameters, such as the incidence of DR in the screened population, costs of diagnosis and treatment, and the effectiveness of laser photocoagulation therapy, was collected through critical appraisal of the literature. We developed two models to evaluate cost per quality-adjusted life-year (QALY) in type 1 and type 2 diabetes.&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;BR&gt;Results&lt;BR&gt;&lt;/STRONG&gt;A total of 25 studies were located reporting on CVT, including 18 presenting 2 × 2 diagnostic accuracy data. The quality of studies and reporting was generally poor.&lt;/P&gt;
&lt;P&gt;The automated or computerised CVTs reported variable sensitivities (63–97%) and specificities (71–95%). One study reported good diagnostic accuracy estimates for the combination of computerised CVT and retinal photography for detection of sight-threatening diabetic retinopathy, but this single study included very few cases of retinopathy in total. Results for the other types of CVT (pseudoisochromatic plates, anomaloscopes, and colour arrangement tests) were heterogeneous but largely inadequate for screening for DR; most performed little better than chance, having Youden indices (sensitivity + specificity – 100%) close to zero.&lt;/P&gt;
&lt;P&gt;No studies were located that addressed patient preferences relating to colour vision screening for DR.&lt;/P&gt;
&lt;P&gt;Retinal photography is universally employed as the primary method for retinal screening by centres responding to the survey of current practice; none used CVT. The most frequently cited preference for future research was the use of optical coherence tomography for the detection of clinically significant macular oedema.&lt;/P&gt;
&lt;P&gt;Our search of the economic evaluation literature found no previous studies describing the cost and effects of any type of CVT.&lt;/P&gt;
&lt;P&gt;As only one small study directly compared the diagnostic accuracy of CVT with that of retinal photography, the results of our economic model, based on that study, are imprecise. Furthermore, that study estimated a high sensitivity and specificity of CVT compared with the other 17 CVT studies in our review. Therefore, the results of our economic model should be treated cautiously until further evidence is available.&lt;/P&gt;
&lt;P&gt;Our economic evaluation suggested that the addition of CVT to the current national screening programme could be cost-effective if it adequately increases sensitivity and is relatively inexpensive. The base-case analysis indicated that the cost per QALY gained is £6364 and £12,432 for type 1 and type 2 diabetes respectively. However, our probabilistic sensitivity analysis highlighted the substantial probability that CVT is not diagnostically accurate enough to be either an effective or a cost-effective addition to current screening methods. Better quality diagnostic accuracy studies directly comparing the incremental value of CVT in addition to retinal photography are needed before drawing conclusions on cost-effectiveness.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Discussion&lt;/STRONG&gt;&lt;BR&gt;Not all CVTs have been evaluated; those that have were generally not considered in the context of a retinal photography-based screening setting. There are insufficient data on any predictive/protective value of CVT. There is a lack of primary studies evaluating the efficiency of including CVT in DR screening.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;Implications for service provision&lt;BR&gt;•There is insufficient evidence to support the use of CVT alone, or in combination with retinal photography, as a method for screening for retinopathy in patients with diabetes. The evidence that is available is limited in quantity and is of generally poor quality. &lt;BR&gt;•Limited evidence on variations of the automated Sussex Gratings Machine, when combined with retinal photography, indicated some promise. However, this technology has not been independently evaluated and cost-effectiveness has not been proven. Probabilistic sensitivity analysis highlighted the substantial probability that CVT is not diagnostically accurate enough to be either an effective or cost-effective addition to current screening methods. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Suggested research priorities&lt;/STRONG&gt;&lt;BR&gt;•CVT was not identified as a research priority by survey respondents; around one-third of respondents considered optical coherence tomography to be a research priority. &lt;BR&gt;•Any study carried out to resolve outstanding uncertainties would have to evaluate the addition of CVT to retinal photography and be prospective; generalisable to a screening population; independent of test developers; designed to account for lens yellowing, iris colour, macular pigment density and other clinical factors; and compliant with STARD reporting guidelines. &lt;BR&gt;•Any future studies should consider the consequences of positive and negative tests in terms of subsequent treatment/prevention options, costs and participant outcomes. &lt;BR&gt;•Activity-based cost analyses detailing the resource use of the various manual and automated CVT strategies are also necessary. These studies should estimate the capital and labour costs of implementing CVT in typical primary care trust diabetic populations. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>236021</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_063958.pdf]]&gt;</url>
    <title>Commissioning toolkit for community based eye care services</title>
    <publicationDate>2007-01-17T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,COMMISSIONING,SERVICE SECTORS,COMMUNITY AND DOMICILIARY SERVICES,TOOLKITS,DISEASE/CONDITION GROUPS,EYE AND VISION PROBLEMS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Commissioning toolkit published by the Department of Health&amp;nbsp;on 17 January 2007.&amp;nbsp; The&amp;nbsp;aim is to provide PCTs and practice based commissioners with practical advice on commissioning community based eye care services.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The toolkit builds on the evaluation of the chronic eye care pilots which tested community based pathways for glaucoma, age related macular degeneration and low vision services. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>278997</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.primarycarecontracting.nhs.uk/uploads/Optometry/jan_07/community_eye_care_services_review_core_final.doc]]&gt;</url>
    <title>Community Eye Care Services: Review of local schemes for low vision, glaucoma and acute care</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>NHS Primary Care Contracting</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document published in January 2007 contains a review of local examples of community eye care services.&amp;nbsp;&amp;nbsp; It has been developed as part of the Department of Health's on-going programme of support for community eye care servicesin partnership with NHS Primary Care Contracting.&amp;nbsp; It complements and sits alongside the 'commissioning toolkit' development by the Department of Health. &lt;/P&gt;
&lt;P&gt;This PCC resource also supports the delivery of key Department of Health policy objectives for both commissioning and provision of high quality local services, closer to where patients live, moving appropriate primary care services outside the hospital setting, and providing greater choice and accessibility of services to patients. It supports the objectives within recent publications such as the White paper 'Our health, our care, our say: a new direction for community services', Practice Based Commissioning guidance, and the NHS Operating Framework for 2007-08.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250844</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=DetailsSearch&amp;Term=9780093%5BUID%5D]]&gt;</url>
    <title>Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures</title>
    <publicationDate>1998-10-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;American Journal of Ophthalmology [Am J Ophthalmol]. 1998 Oct; 126(4):487-97.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PubMed Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;PURPOSE: To determine if intraocular pressure plays a part in the pathogenic process of normal-tension glaucoma. &lt;/P&gt;
&lt;P&gt;METHODS: One eye of each eligible subject was randomized either to be untreated as a control or to have intraocular pressure lowered by 30% from baseline. Eyes were randomized if they met criteria for diagnosis of normal-tension glaucoma and showed documented progression or high-risk field defects that threatened fixation or the appearance of a new disk hemorrhage. The clinical course (visual field and optic disk) of the group with lowered intraocular pressure was compared with the clinical course when intraocular pressure remained at its spontaneous untreated level. &lt;/P&gt;
&lt;P&gt;RESULTS: One hundred-forty eyes of 140 patients were used in this study. Sixty-one were in the treatment group, and 79 were untreated controls. Twenty-eight (35%) of the control eyes and 7 (12%) of the treated eyes reached end points (specifically defined criteria of glaucomatous optic disk progression or visual field loss). An overall survival analysis showed a statistically significant difference between the two groups (P &amp;lt; .0001). The mean survival time +/-SD of the treated group was 2,688 +/- 123 days and for the control group, 1,695 +/- 143 days. Of 34 cataracts developed during the study, 11 (14%) occurred in the control group and 23 (38%) in the treated group (P = .0075), with the highest incidence in those whose treatment included filtration surgery. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Intraocular pressure is part of the pathogenic process in normal-tension glaucoma. Therapy that is effective in lowering intraocular pressure and free of adverse effects would be expected to be beneficial in patients who are at risk of disease progression.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9780094%5BUID%5D" target="_blank"&gt;The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma.&amp;nbsp; Collaborative Normal-Tension Glaucoma Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=14597032%5BUID%5D" target="_blank"&gt;Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma.&amp;nbsp;&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11384564%5BUID%5D" target="_blank"&gt;Risk factors for progression of visual field abnormalities in normal-tension glaucoma.&amp;nbsp; &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11158794%5BUID%5D" target="_blank"&gt;Natural history of normal-tension glaucoma.&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15646475%5BUID%5D" target="_blank"&gt;Some clinical Implications of the collaborative normal tension glaucoma study.&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342475</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.cmj.org/Periodical/paperlist.asp?id=LW20081119560912508566&amp;linkintype=pubmed]]&gt;</url>
    <title>Comparison of laser epithelial keratomileusis and photorefractive keratectomy for the correction of myopia: a meta-analysis</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Chinese Medical Journal</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,REFRACTIVE ERROR,SHORT SIGHT (MYOPIA),CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Chinese Medical Journal, 2008, Vol 121 No 22: 2331-2335&lt;/EM&gt;&lt;/P&gt;
&lt;P align=justify&gt;&lt;B&gt;Background&lt;/B&gt; &amp;nbsp;It is unclear whether a laser epithelial keratomileusis (LASEK) has any significant advantage over a photorefractive keratectomy (PRK) for correcting myopia. We undertook this meta-analysis of randomized controlled trials to examine possible differences in efficacy, accuracy, safety and side-effects between two methods, LASEK and PRK, for correcting myopia.&lt;/P&gt;&lt;B&gt;&lt;/B&gt;
&lt;P align=justify&gt;&lt;B&gt;Methods&lt;/B&gt; &amp;nbsp;A systematic literature retrieval was conducted in the PubMed, EMBASE, Chinese Bio-medicine Database, and Cochrane Controlled Trials Register to identify potentially relevant randomized controlled trials. The statistical analysis was performed using a RevMan 4.2 software. The results included efficacy outcomes (proportion of eyes with uncorrected visual acuity (UCVA)= 20/20 at 1 month and 12 months post-treatment), accuracy outcomes (proportion of eyes within ±0.50 diopters (D) of target refraction at 1 month and 12 months post-treatment), safety outcomes (loss of =2 lines of best spectacle-corrected visual acuity (BSCVA) at = 6 months post-treatment), mean pain scores on day 1 post-treatment, and mean corneal haze scores at 6 and 12 months post-treatment.&lt;/P&gt;&lt;B&gt;&lt;/B&gt;
&lt;P align=justify&gt;&lt;B&gt;Results&lt;/B&gt; &amp;nbsp;Seven articles describing a total of 604 eyes with myopia from 0 to –9.0 D were identified in this meta-analysis. The combined results showed that the efficacy and accuracy outcomes between the two groups at 1 month and 12 months post-treatment were comparable. No patient lost = 2 lines of BSCVA at = 6 months post-treatment in four relevant trials. Compared with PRK, LASEK did not relieve discomfort on day 1 post-treatment or reduce corneal haze intensity at 6 and 12 months post-treatment.&lt;/P&gt;&lt;B&gt;&lt;/B&gt;
&lt;P align=justify&gt;&lt;B&gt;Conclusions&lt;/B&gt; &amp;nbsp;According to the available data, LASEK does not appear to have any advantage over PRK for correcting myopia from 0 to –9.0 D. This meta-analysis focuses mainly on the comparison of the early, mid-term and mid-long term results of the two methods. Additional studies to compare the long-term (&amp;gt;one year) results should be considered.&lt;/P&gt;
&lt;P align=justify&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=236" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103437</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.orthoptics.org.uk/orthoptists/Orthoptic_competency_standards.pdf]]&gt;</url>
    <title>Competency standards and professional practice guidelines</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>British and Irish Orthoptic Society (BIOS)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ OCULAR MOTILITY,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document presents the national standards of practice and guidelines developed by the Professional Development Committee of the British Orthoptic Society.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The first section includes essential and desirable standards relating to the management of the orthoptic service, section 2 includes standards relating to staff development, education and professional responsiblities, section&amp;nbsp;3 relates to patient care and the final section provides guidelines for orthoptic practice. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalint=275" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=275" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=275" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267363</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.orthoptics.org.uk/BIOS_Competencies_Standards_-_Extended_Roles_-_Master_Handbook.pdf]]&gt;</url>
    <title>Competency standards and professional practice guidelines for the extended role of the orthoptist</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>British and Irish Orthoptic Society (BIOS)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CATARACT,OCULAR MOTILITY,REFRACTIVE ERROR,STRABISMUS,AMBLYOPIA,OPTIC NERVE AND VISUAL PATHWAYS,LENS,RETINA,GLAUCOMA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The role of the Orthoptist has expanded significantly in recent years.&amp;nbsp;&amp;nbsp;The aim of these new competency standards and professional practice guidelines, published in&amp;nbsp;2006, &amp;nbsp;is&amp;nbsp;to ensure that the quality of provision of clinical services is maintained and to provide&amp;nbsp;a benchmark against which orthoptists can measure their competence. &lt;/P&gt;
&lt;P&gt;This document&amp;nbsp;contain the following sections: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Glaucoma diagnostics and monitoring services 
&lt;LI&gt;Stroke assessment and rehabilitation 
&lt;LI&gt;Retinoscopy and refraction 
&lt;LI&gt;Visual field assessment 
&lt;LI&gt;Visual field assessment of children with special needs 
&lt;LI&gt;Cataract assessment 
&lt;LI&gt;Specific learning difficulties 
&lt;LI&gt;Neuro-ophthalmology 
&lt;LI&gt;Low vision assessment and low vision aids&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=364" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=364" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=364" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310764</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15019397]]&gt;</url>
    <title>Confocal microscopy: a report by the American Academy of Ophthalmology</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,KERATITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: Ophthalmology 2004 Feb; 111(2):396-406&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To review the available evidence for the use of confocal microscopy in diagnosing infectious keratitis and for other applications for ophthalmic practice. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A MEDLINE search of the peer-reviewed literature for the years 1990 to 2001 yielded 94 citations. The search was limited to studies of human subjects published in English with abstracts. The Ophthalmic Technology Assessment Committee Cornea Panel evaluated these 94 articles for possible clinical relevance and selected 51 (54%) for content review by the panel members. Of these 51 articles, 24 were selected for the panel methodologist to review and rate according to the strength of evidence. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Of the 24 articles, 21 (87.5%) were classified as case reports or case series and were rated as level III evidence. Three articles were classified as independent, masked, or objective comparisons performed in a narrow spectrum of patients or in a nonconsecutive series of patients and were rated as level II evidence. No studies were rated as level I evidence, defined as an independent masked comparison of an appropriate spectrum of consecutive patients. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Confocal microscopy is a new technology with clinical applications in ophthalmology. Although confocal microscopy has been used in other fields of medicine, the optical transparency of the cornea and other structures of the eye provides a unique opportunity to apply this technology. The targeted literature review of 24 articles found no level I studies to support the use of confocal microscopy in the management of eye disorders. Three level II studies pertained to promising clinical applications of the confocal microscope and provided evidence that supports the use of confocal microscopy as an adjunctive modality for diagnosing Acanthamoeba keratitis. The remaining 21 articles, rated as level III evidence, focus on the use of confocal microscopy to facilitate the diagnosis of infectious keratitis, including amoebic and fungal, but currently there are no definitive studies of its role in the differential diagnosis of this condition. There are also level III studies that support the use of the confocal microscope in refractive surgery. Facilitating the diagnosis of infectious keratitis and applying the confocal microscope to refractive surgery may hold the greatest promise of this new technology.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=190" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372425</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19019922]]&gt;</url>
    <title>Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology. 2009 Mar;93(3)316-21. Epub 2008 Nov 19.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; To conduct a meta-analysis of randomised clinical trials (RCTs) in order to evaluate the development of conjunctival hyperaemia after the use of latanoprost versus travoprost and bimatoprost, in patients with ocular hypertension or glaucoma. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; In order to identify the potentially relevant RCTs, a systematic literature retrieval was conducted in Medline, Embase and Cochrane Controlled Trials Register (1995-April 2007) databases The outcome measure was the appearance of conjunctival hyperaemia during the study. Statistical analyses included the calculation of odds ratio (OR) and its respective confidence interval, along with intertrial statistical heterogeneity. Publication bias was evaluated through a funnel plot, and a sensitivity analysis was also performed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; In total, 13 RCTs involving 2222 patients with ocular hypertension or glaucoma were included, five comparing latanoprost versus travoprost, seven comparing latanoprost versus bimatoprost and one comparing latanoprost versus travoprost and bimatoprost. The combined results showed that latanoprost produced lower occurrence of conjunctival hyperaemia than both travoprost (OR = 0.51; 95% CI 0.39 to 0.67, p&amp;lt;0.0001) and bimatoprost (OR = 0.32; 95% CI 0.24 to 0.42, p&amp;lt;0.0001). No significant heterogeneity was found between the included RCTs. There was no evidence of publication bias. In the sensitivity analysis performed, none of the clinical trials included in this meta-analysis has an important impact in the global estimation of OR. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; According to available data, the use of latanoprost is associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=278" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103440</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.orthoptics.org.uk/orthoptists/cpd.pdf]]&gt;</url>
    <title>Continuing professional development</title>
    <publicationDate>2004-08-01T00:00:00</publicationDate>
    <publisher>British and Irish Orthoptic Society (BIOS)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document was produced in August 2004 by British Orthoptic Society for orthoptists to record their continuing professional development portfolio.&amp;nbsp; The first section provides an introduction to CPD, the advantages, key principles, experiential learning, reflective practice and BOS scheme for orthoptists.&amp;nbsp;&amp;nbsp; The second,&amp;nbsp;third and fourth sections provide an opportunity for orthoptists to record their work experience, current activities and objectives,&amp;nbsp;professional development plan and reflections on the process. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalint=276" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=275" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=275" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79270</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band63/b63-2.html]]&gt;</url>
    <title>Corneal abrasion treatment</title>
    <publicationDate>1999-05-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CORNEAL ABRASION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This summary&amp;nbsp;published in issue 63 of the&amp;nbsp;Bandolier&amp;nbsp;Journal&amp;nbsp;discusses the effectiveness of eye patching/padding on recovery rate and&amp;nbsp;level of pain&amp;nbsp;after accidental corneal abrasion.&amp;nbsp;&amp;nbsp;&amp;nbsp;]]&gt;</body>
  </document>
  <document>
    <id>310765</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16113367]]&gt;</url>
    <title>Corticosteriod treatment of periorbital haemangioma of infancy: a review of the evidence</title>
    <publicationDate>2005-09-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ORBIT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2005 Sep;89(9):1134-8.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; To systematically review the literature for corticosteroid treatment of periorbital haemangioma of infancy (HOI) and determine the relative efficacy and safety of oral, topical and intralesional corticosteroids. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; PubMed and the Cochrane Library were queried using keywords, and further articles were obtained by reviewing bibliographies. Inclusion and exclusion criteria were applied to create a subset of literature for analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Systematic review revealed 81 original reports of periorbital HOI cases treated with steroids. Most studies and case series failed to document refractive error or visual acuity before and after treatment. Of cases meeting inclusion criteria, five patients received topical steroids and 25 patients received intralesional steroids. Patients receiving intralesional injections tended to demonstrate reduced astigmatism at follow up after treatment (21 of 28). The lack of studies with relevant objective ophthalmological end points prevented statistical meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Intralesional injections may reduce refractive error, while the efficacy of topical steroids is unclear. Studies measuring objective ophthalmic data before and after treatment are sparse, and more studies are needed to determine the relative efficacy of different steroids. There are insufficient data to estimate the incidence of steroid side effects in patients treated with steroids for periorbital HOI or complications of intralesional injections in particular.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=158" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310766</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16127338]]&gt;</url>
    <title>Cumulative meta-analysis of the relationship between useful field of view and driving performance in older adults: current and future implications</title>
    <publicationDate>2005-08-01T00:00:00</publicationDate>
    <publisher>Optometry and Vision Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DRIVING,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Optometry and Vision Science (Optom Vis Sci) 2005 Aug;82(8):724-31&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; Driving is a complex behavior that requires the utilization of a wide range of individual abilities. Identifying assessments that not only capture individual differences, but also are related to older adults' driving performance would be beneficial. This investigation examines the relationship between the Useful Field of View (UFOV) assessment and objective measures of retrospective or concurrent driving performance, including state-recorded accidents, on-road driving, and driving simulator performance. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHOD: &lt;/STRONG&gt;The PubMed and PsycINFO databases were searched to retrieve eight studies that reported bivariate relationships between UFOV and these objective driving measures. Cumulative meta-analysis techniques were used to combine the effect sizes in an attempt to determine whether the strength of the relationship was stable across studies and to assess whether a sufficient number of studies have been conducted to validate the relationship between UFOV and driving performance. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A within-group homogeneity of effect sizes test revealed that the samples could be thought of as being drawn from the same population, Q [7] = 11.29, p (one-tailed) = 0.13. Therefore, the effect sizes of eight studies were combined for the present cumulative meta-analysis. The weighted mean effect size across the studies revealed a large effect (Cohen's d = 0.945), with poorer UFOV performance associated with negative driving outcomes. This relationship was robust across multiple indices of driving performance and several research laboratories. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This convergence of evidence across numerous studies using different methodologies confirms the importance of the UFOV assessment as a valid and reliable index of driving performance and safety. Recent prospective studies have confirmed a relationship between UFOV performance and future crashes, further supporting the use of this instrument as a potential screening measure for at-risk older drivers.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=157" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251396</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://curriculum.rcophth.ac.uk/]]&gt;</url>
    <title>Curriculum for Ophthalmic Specialist Training</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>The Royal College of Ophthalmologists</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,CORNEA,CONJUNCTIVA,RETINA,UVEAL TRACT,LENS,LID,LACRIMAL,OCULAR MOTILITY,GLOBE,ORBIT,VITREOUS BODY,REFRACTIVE ERROR,OPTIC NERVE AND VISUAL PATHWAYS,LOW VISION,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In August 2007&amp;nbsp;specialist training in&amp;nbsp;the UK changes to the unified training grade.&amp;nbsp; In Ophthalmology this will be&amp;nbsp;known as Ophthalmic Specialist Training or OST.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The Curriculum Sub-Committee of the Education Committee at The Royal College of Ophthalmologies has developed a new updated Curricular for this programme.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The Curriculum for specialist training in ophthalmology describes the outcomes of 7 years of postgraduate training which leads to a certificate of completed training (CCT).&amp;nbsp;&amp;nbsp; The essential or core requirements are described by a series of nested learning outcomes.&amp;nbsp; These are derived from a description of what a consultant ophthalmologist, as a health care professional in the UK, is able to do and how they approach their practice. &lt;/P&gt;
&lt;P&gt;The Curriculum is a web-based document. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=362" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=362" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=362" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102014</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.vision2020uk.org.uk/core_files/Falls-Report.doc]]&gt;</url>
    <title>Deteriorating vision, falls and older people: the links</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Visibility</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ LOW VISION SERVICES,IN LATER LIFE,EYES AND VISION,LOW VISION,LIVING WITH VISUAL IMPAIRMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Report produced by Susan Campbell in May 2005 for Visibility (the trading name of GWSSB - formerly Glasgow and West Scotland Society for the Blind).&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;In 2003/4 the Greater Glasgow NHS Board commissioned Visibility to conduct an identification project exploring why some people who are visually impaired, are not accessing the aids and equipment, information and support that could improve their quality of life.&amp;nbsp;&amp;nbsp; During the identification project, 36% of participants mentioned that they had fallen or tripped as a result of their sight loss and so&amp;nbsp;Visibility established this further piece of research within the Clydebank area to explore the relationship between deteriorating vision, falls and older people.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Following an introduction and background information the report contains sections on the role of visual impairment, methodology, participants profile, what people said about their eyesight, what people said about their falls, perceptions of sight loss,&amp;nbsp; identification of vision problems, conclusions and recommendations.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_Evidence/showappraisal.asp?appraisalint=281" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=281" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=281" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>94988</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/RACGPGuidelines/Diabetesmanagement/200910diabetesmanagementingeneralpractice.pdf]]&gt;</url>
    <title>Diabetes Management in General Practice</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Royal Australian College of General Practitioners</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,LENS,RETINOPATHY,CATARACT,REFRACTIVE ERROR,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This booklet produced by the Royal Australian College of General Practioners with Diabetes Australia titled Diabetes Managment in General Practice: Guidelines for Type 2 Diabetes&amp;nbsp;(Fifteenth edition 2009/10) aims to provide a readable summary of current guidelines and recommendations on the management of type 2 diabetes.&amp;nbsp;&amp;nbsp; Please see section 9.5, page&amp;nbsp;63 for details on damage to eyes including refractive errors, cataracts, retinopathy and maculopathy. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=203" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=203" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=203" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310768</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15154948]]&gt;</url>
    <title>Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis</title>
    <publicationDate>2004-06-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Diabetic Medicine (Diabet Med) 2004 Jun; 21(6):609-14&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; The association of diabetes mellitus with primary open-angle glaucoma has been controversial. The study aimed to examine the strength of this association through a detailed meta-analysis of studies published in peer-reviewed journals. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A comprehensive search for articles published through 2002 was performed and data were abstracted. Prior to meta-analysis, all studies were evaluated for publication bias and heterogeneity. Pooled odds ratio (OR) was calculated using the random and the fixed-effects model. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Twelve studies published between 1987 and 2001 were included (five case-control studies and seven cross-sectional studies). Significant heterogeneity among the studies was detected (P = 0.023). No evidence of publication bias was found (P = 0.37). The association of diabetes mellitus with primary open-angle glaucoma was statistically significant assuming either a random effects [OR = 1.50, 95% confidence interval (CI) 1.16, 1.93], or a fixed-effects model (OR = 1.27, 95% CI 1.10, 1.45). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Our meta-analysis results suggest that diabetic patients are at significantly increased risk of developing primary open-angle glaucoma. Clinicians should be aware of this possibility.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=185" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>341930</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19669781]]&gt;</url>
    <title>Diagnostic accuracy of vision screening tests for the detection of amblyopia and its risk factors: a systematic review</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>Graefe's Archives for Clinical and Experimental Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Graefes Arch Clin Exp Ophthalmol. 2009 Nov;247(11):1441-54. Epub 2009 Aug 11.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AIM&lt;/STRONG&gt;: This systematic review evaluates the diagnostic accuracy of preschool vision screening tests for the detection of amblyopia and its risk factors. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: The literature searches were conducted in nine bibliographic databases. No limitation to a specific study design, year of publication or language was applied. Studies were included if they compared a vision screening test with a reference test (gold standard) in children from the general population. In addition, the studies had to provide sufficient data to calculate diagnostic accuracy (sensitivity and specificity). Full-text articles were assessed for studies that satisfied the inclusion criteria using the "Quality of Diagnostic Accuracy Studies (QUADAS)" checklist. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Two studies with a longitudinal design and 25 cross-sectional studies met the inclusion criteria. One of the longitudinal studies compared a screening programme in children between 1 and 2 years of age with a re-examination at the age of 8. The sensitivity for the screening programme was 86% (range: 64-97%) and the specificity 99% (range: 98-99%). The second longitudinal study compared screening examinations at 8, 12, 18, 25 and 31 months, with a re-examination at the age of 37 months. In this study, the sensitivity of the screening examination increased with age, while the specificity remained unchanged. The cross-sectional studies evaluated different screening settings, visual acuity tests, auto- or photorefractors and stereo tests. A large variety of reference tests, differing criteria for defining amblyopia and its risk factors and methodological limitations of the studies prevented a valid data interpretation. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Diagnostic test accuracy of preschool vision screening tests can only be sufficiently investigated after establishing age-related values defining amblyopia, refractive errors and binocular disorders. To address these questions, we recommend a controlled longitudinal study design.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=252" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>103477</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.orthoptics.org.uk/orthoptists/dictionary.pdf]]&gt;</url>
    <title>Dictionary of common terms in orthoptic practice</title>
    <publicationDate>2001-01-01T00:00:00</publicationDate>
    <publisher>British and Irish Orthoptic Society (BIOS)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ OCULAR MOTILITY,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This glossary was produced by the British Orthoptic Society in 2001.&amp;nbsp;&amp;nbsp;The document is divided into three sections, definitions of common terms, orthoptic abbreviations and conversion charts. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_Evidence/showappraisal.asp?appraisalint=274" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=274" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=274" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318041</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17923720]]&gt;</url>
    <title>Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis</title>
    <publicationDate>2007-10-13T00:00:00</publicationDate>
    <publisher>British Medical Journal (BMJ)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: BMJ 2007 Oct 13;335(7623):755. Epub 2007 Oct 8. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To evaluate the effectiveness of dietary antioxidants in the primary prevention of age related macular degeneration (AMD). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Systematic review and meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DATA SOURCES:&lt;/STRONG&gt; Search of seven databases without limits on year or language of publication, and retrieval of references in pertinent reviews and articles. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Two reviewers independently searched the databases and selected the studies, using standardised criteria. Randomised clinical trials and prospective cohort studies were included. Of the 4192 abstracts initially identified, 12 studies (nine prospective cohort studies and three randomised clinical trials) met the selection criteria and were included. Data extraction and study quality evaluation were independently reviewed, using standardised criteria. Results were pooled quantitatively using meta-analytic methods. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The nine prospective cohort studies included 149 203 people, with 1878 incident cases of early AMD. The antioxidants investigated differed across studies, and not all studies contributed to the meta-analysis of each antioxidant. Pooled results from prospective cohort studies indicated that vitamin A, vitamin C, vitamin E, zinc, lutein, zeaxanthin, alpha carotene, beta carotene, beta cryptoxanthin, and lycopene have little or no effect in the primary prevention of early AMD. The three randomised clinical trials did not show that antioxidant supplements prevented early AMD. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; There is insufficient evidence to support the role of dietary antioxidants, including the use of dietary antioxidant supplements, for the primary prevention of early AMD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=30" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318045</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18541848]]&gt;</url>
    <title>Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology (Arch Ophthalmol) 2008 Jun;126(6):826-33.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To systematically review the evidence on dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration (AMD). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Seven databases were systematically searched with no limits on publication year or language using standardized criteria. Randomized controlled trials and prospective cohort, case-control, and cross-sectional studies were included. Of 2754 abstracts identified, 3 prospective cohort, 3 case-control, and 3 cross-sectional studies met the criteria. Measures of associations were pooled quantitatively using meta-analytic methods. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Nine studies provided data on a total sample of 88 974 people, including 3203 AMD cases. A high dietary intake of omega-3 fatty acids was associated with a 38% reduction in the risk of late AMD (pooled odds ratio [OR], 0.62; 95% confidence interval [CI], 0.48-0.82). Fish intake at least twice a week was associated with a reduced risk of both early AMD (pooled OR, 0.76; 95% CI, 0.64-0.90) and late AMD (pooled OR, 0.67; 95% CI, 0.53-0.85). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt;&amp;nbsp;Although this meta-analysis suggests that consumption of fish and foods rich in omega-3 fatty acids may be associated with a lower risk of AMD, there is insufficient evidence from the current literature, with few prospective studies and no randomized clinical trials, to support their routine consumption for AMD prevention.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=63" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310742</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04april/pages/doesgamingimprovevision.aspx]]&gt;</url>
    <title>Does gaming improve vision?</title>
    <publicationDate>2009-03-30T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Forget carrots, playing video games helps you see in the dark,” reported &lt;EM&gt;The Independent&lt;/EM&gt;.&amp;nbsp;&amp;nbsp; It said that research suggests that a person’s nighttime vision gets better after playing action games. The newspaper said that scientists have found that games involving aiming and shooting can significantly improve the ability to “see objects in twilight conditions, when colours fade into different shades of grey”. It continued that playing video games could be just as effective as contact lenses, glasses or surgery in improving visual 'contrast sensitivity'&amp;nbsp;- the ability to distinguish objects that do not stand out clearly against their background.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Follow the link to see the National Knowledge Service commentary on this news item.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Behind the headlines provides an unbiased and evidence-based analysis of health stories that make the news.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;The service is intended for both the public and health professionals and endeavours to:&lt;/EM&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;EM&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news &lt;/EM&gt;
&lt;LI&gt;&lt;EM&gt;provide an authoritative resource for GPs which they can rely on when talking to patients, and &lt;/EM&gt;
&lt;LI&gt;&lt;EM&gt;become a trusted resource for journalists and others involved in the dissemination of health news&lt;/EM&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310770</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11754714]]&gt;</url>
    <title>Does this patient have temporal arteritis?</title>
    <publicationDate>2002-01-02T00:00:00</publicationDate>
    <publisher>JAMA: the journal of the American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: JAMA 2002 Jan 2;287(1):92-101&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONTEXT:&lt;/STRONG&gt; Clinicians must be able to confidently diagnose temporal arteritis (TA), since failure to make a correct diagnosis may lead to irreversible visual loss as well as inappropriate evaluation and treatment of headache, fatigue, and other potential presenting symptoms. The diagnostic value of particular signs and symptoms among patients with suspected TA is unknown. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To determine the accuracy of historical features, physical examination, and erythrocyte sedimentation rate (ESR) in diagnosis of TA. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DATA SOURCES:&lt;/STRONG&gt; We performed a MEDLINE search of English-language articles published between January 1966 and July 2000 and a hand search of bibliographies of retrieved articles, previous reviews, monographs, and textbooks. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;STUDY SELECTION: &lt;/STRONG&gt;Studies that provided detailed clinical information on patients who had been referred for temporal artery biopsy. Of 114 studies retrieved, 41 met our inclusion criteria; 21 included both biopsy-positive and biopsy-negative patients and formed the core of our review. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DATA EXTRACTION:&lt;/STRONG&gt; Both authors independently reviewed each study to determine eligibility, abstracted data using a standardized instrument, and classified study quality using predetermined criteria. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DATA SYNTHESIS:&lt;/STRONG&gt; The prevalence of TA in the general population is less than 1%. However, in our 21 core studies, 39% of patients referred for temporal artery biopsy had positive results. The only 2 historical features that substantially increased the likelihood of TA among patients referred for biopsy were jaw claudication (positive likelihood ratio [LR], 4.2; 95% confidence interval [CI], 2.8-6.2) and diplopia (positive LR, 3.4; 95% CI, 1.3-8.6). The absence of any temporal artery abnormality was the only clinical factor that modestly reduced the likelihood of disease (negative LR, 0.53; 95% CI, 0.38-0.75). Predictive physical findings included temporal artery beading (positive LR, 4.6; 95% CI, 1.1-18.4), prominence (positive LR, 4.3; 95% CI, 2.1-8.9), and tenderness (positive LR, 2.6; 95% CI, 1.9-3.7). Normal ESR values indicated much less likelihood of disease (negative LR for abnormal ESR, 0.2; 95% CI, 0.08-0.51). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; A small number of clinical features are helpful in predicting the likelihood of a positive temporal artery biopsy among patients with a clinical suspicion of disease; the most useful finding is a normal ESR, which makes TA unlikely.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=217" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>299770</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=299770]]&gt;</url>
    <title>Driving and glaucoma</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Later Life Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LATER LIFE,HEALTH &amp; WELLBEING,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Driving and glaucoma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Parul Desai, Clinical Lead, &lt;A href="http://www.library.nhs.uk/eyes/" target="_blank"&gt;Eyes &amp;amp; Vision Specialist Library&lt;/A&gt;&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp; &lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;BR&gt;Primary open angle glaucoma (POAG) is a chronic, progressive optic neuropathy characterised by structural changes of the optic nerve and thinning of the retinal nerve fibre layer.&amp;nbsp; This results in loss of visual function which is manifest as a visual field defect beginning in the peripheral field of vision.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;BR&gt;It is estimated that about 1- 2% of persons over the age of 40 years [1-6] have glaucoma and about half of those with glaucoma may be unaware that they have the disease [7,8]. The prevalence of glaucoma increases with age [9, 10, 11]. A recent meta-analysis estimates that the prevalence of glaucoma in those aged over 70yrs is about 16%, 6% and 3% in black, white and Asian populations, respectively [9].&amp;nbsp;&amp;nbsp;&amp;nbsp; It accounts for 10.2% of certification for visual impairment and 10.9% of registrations for persons severely visually impaired in England and Wales [14]. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Impact and implications for driving&lt;/STRONG&gt;&lt;BR&gt;Loss of vision from progressive field loss has an impact on vision-dependent daily activities including difficulty with driving [15]. Depending on their level of visual acuity and the amount of visual field loss that has taken place, many people with glaucoma may continue to drive a car.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;It has been observed that persons with glaucoma exhibit higher level of avoidance of driving in challenging situations e.g. at night, during rush hour, in busy traffic or high speed areas and with children [16]. However, for a considerable number of persons with glaucoma, progressive vision and field loss will render them ineligible to drive.&amp;nbsp; During an average follow-up of 7 years, it is estimated that 20% (95%C.I 16%-25%) of patients (median age 64years),&amp;nbsp; with primary open angle glaucoma may fail to meet the visual field criteria for fitness to drive as specified by the UK Driver and Vehicle Licensing Authority (DVLA) [17]. &lt;/P&gt;
&lt;P&gt;The loss of one’s driving licence is a particularly significant life event resulting in loss of mobility and social independence.&amp;nbsp; One of the most important factors that patients rated for the importance of the management and treatment of their glaucoma was their ability to continue to drive [18]. Elderly people who have stopped driving have been observed to be at greater risk of worsening depressive symptoms [19]. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Fitness to drive and visual standards for driving&lt;/STRONG&gt;&lt;BR&gt;The &lt;A href="http://www.dvla.gov.uk/media/pdf/medical/aagv1.pdf" target="_blank"&gt;DVLA&lt;/A&gt;&amp;nbsp; is legally responsible for assessing whether a driver in the UK is medically fit enough to drive a vehicle or not [20]. The Royal College of Ophthalmologists also provides guidance on the visual standards for driving [21]. Essentially, to drive a car (Group 1 vehicle) a driver should have adequate acuity and field of vision.&amp;nbsp; A driver should be able to read a standard number plate in good light at 20m with glasses or contact lenses (if worn), with both eyes open.&amp;nbsp; This is about 6/10 on the standard Snellen visual acuity chart.&amp;nbsp; In most circumstances this is sufficient.&amp;nbsp; Anyone with an eye condition such as glaucoma also needs to demonstrate adequate visual field.&amp;nbsp; In these circumstances the legal requirement is 120 degrees of horizontal field and 20 degrees of field above and below fixation.&amp;nbsp; Anyone with a field defect in both eyes must by law, inform the DVLA.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient information&lt;/STRONG&gt;&lt;BR&gt;The RNIB has a range of information on &lt;A href="http://www.rnib.org.uk/xpedio/groups/public/documents/publicwebsite/public_scacdrivingvisreqs.hcsp" target="_blank"&gt;driving and sight loss&lt;/A&gt;, including a brief section on the &lt;A href="http://www.rnib.org.uk/xpedio/groups/public/documents/publicwebsite/public_scacdrivingvisreqs.hcsp#P10_914" target="_blank"&gt;standard eyesight requirement&lt;/A&gt;. If night vision is a particular concern, the College of Optometrists has a webpage of information on &lt;A href="nelh:93654:0" name=internalLink&gt;night vision and driving&lt;/A&gt;. Further afield, the Royal Australian and New Zealand College of Ophthalmologists covers &lt;A href="nelh:93573:0" name=internalLink&gt;vision and driving&lt;/A&gt; and New South Wales Multicultural Health Communication Services provides an online leaflet of &lt;A href="nelh:105597:0" name=internalLink&gt;vision tips for safe driving&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Glaucoma Annual Evidence Update 2008&lt;/STRONG&gt;&lt;BR&gt;The &lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;third annual evidence update on glaucoma&lt;/A&gt; covering epidemiology, screening, medical management, optic disc imaging, visual field progression, patient education and living with glaucoma is available on the &lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Eyes &amp;amp; Vision Specialist Library&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Friedman DS, Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15078671%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:1661-9.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8874440%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994;112:821-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8002842%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;4. Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, Menage MJ. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-504. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=1454314%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5. Mitchell P, Rochtchina E, Lee AJ, Wang JJ.&amp;nbsp; Bias in self-reported family history and relationship to glaucoma: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2002;9:333-45. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12528918%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6. Coffey M, Reidy A, Wormald R, Xian WX, Wrigth L, Courtney P.&amp;nbsp; Prevalence of Glaucoma in the west of Ireland. Br J Ophthalmol. 1993 Jan;77(1):17-21 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8435391%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;7. Reidy A, Minassian DC, Vafidis G, Joseph , Farrow S, Wu J, Desai P, Connolly A. Prevalence of serious eye disease and visual impairment in a north London population:population-based cross-sectional study.&amp;nbsp; BMJ 1998 May 30;316(7145):1643-6 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9603746%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp; Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;266:369-74. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=2056646%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38:83-91. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9008633%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D.&amp;nbsp; Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis.&amp;nbsp;&amp;nbsp; Invest Ophthalmol Vis Sci.&amp;nbsp; 2006; 47 (10): 4254-61 ]&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=17003413%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994;112:821-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8002842%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Synder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001;119(12):1819-26.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11735794%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. Wensor MD, McCarty CA, Stanislavsky YL, Livingstone PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology 1998;105:733-9.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9544649%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England &amp;amp; Wales. BMC public health (electronic resource), {BMC-Public-Health}, 2006 (epub), vol. 6, p. 58,&amp;nbsp; &lt;A href="http://www.biomedcentral.com/content/pdf/1471-2458-6-58.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15. Varma R, Wu J, Chong K, Azen SP, Hays RD, Los Angeles Latino Eye Study Group. Impact of severity and bilaterality of visual impairment on health-related quality of life. Ophthalmology 2006; 113: 1846-53. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16889831" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16. McGwin G, Mays A, Joiner W, Decarlo DK, McNeal S, Owsley C. Is glaucoma associated with motor vehicle collision involvement and driving avoidance? Invest Ophthalmol and Vis Sci 2004; 45 (11); 3934-9. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15505039" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17. Owen VMF, Crabb DP, White ET, Viswanathan AC, Garwat-Heath DF, Hitchings RA. Glaucoma and fitness to drive: using binocular visual fields to predict a milestone to blindness. Invest Ophthalmol Vis Sci 2008; 49: 2449-55. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18515585" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;18. Bhargava JS, Patel B, Foss AJ, Avery AJ, King AJ. Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis. Invest Ophthalmol Vis Sci 2006; 47: 2885-8. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16799029" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;19. Fonda SJ, Wallace RB, Herzog AR. Changes in driving patterns and worsening of depressive symptoms among older adults. J Gertontol B Psychol Soc Sci 2001; 56: S343-51. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11682595" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;20. Drivers Medical Group, DVLA Swansea, September 2008,6,39-41. At a glance guide to the current Medical Standards of Fitness to Drive, Visual Standards. &lt;A href="http://www.dvla.gov.uk/media/pdf/medical/aagv1.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;21. Royal College of Ophthalmologists, April 2005 Visual Standards for Driving. &lt;A href="nelh:154944:0" name=internalLink&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>377862</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/avastin-cancer-drug-treat-wet-AMD.aspx]]&gt;</url>
    <title>Drug trialled for AMD eye condition</title>
    <publicationDate>2010-06-11T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A cancer drug “could save eyesight of tens of thousands”, says the &lt;EM&gt;Daily Mail.&lt;/EM&gt; The newspaper reported on a trial that has assessed the drug bevacizumab (trade name Avastin) as a potential treatment for ‘wet’ age-related macular degeneration (AMD), a form of the progressive eye condition.&lt;/P&gt;
&lt;P&gt;The research compared bevacizumab to existing treatments such as laser therapy and a drug called pegaptanib, which the researchers considered to be “standard care” NHS treatments. They found that, over the course of a year, bevacizumab both prevented further vision loss and improved vision compared with “standard care” options.&lt;/P&gt;
&lt;P&gt;However, this study did not compare bevacizumab to a similar type of drug called ranibizumab (Lucentis), which has recently been approved as an AMD treatment by NICE. In order for bevacizumab to be approved for use within the NHS it must compare favourably to ranibizumab treatment as a method for improving vision in AMD. This was a small study and, although promising, further follow up is needed in a larger population to assess the benefits of bevacizumab for AMD.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was a relatively small study, but it has shown promising results that bevacizumab may be an effective treatment for wet age-related macular degeneration compared with standard care. The researchers grouped various treatments, including placebo, as “standard care”, which they say is both a strength and a weakness of their study. They say that it is a strength because the group featured two active treatments that a patient would receive in the NHS (plus the sham treatment), but that this is also a weakness as it does not allow comparisons with a single treatment. Notably, including a placebo in the control group may have exaggerated the real difference between bevacizumab and other active treatments, since the placebo was likely to have had no effect on patients’ vision.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/avastin-cancer-drug-treat-wet-AMD.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Tufail A, Patel PJ, Egan C et al. &lt;A href="http://www.bmj.com/cgi/content/abstract/340/jun09_4/c2459" target="_blank"&gt;Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study&lt;/A&gt;. &lt;EM&gt;BMJ&lt;/EM&gt; 2010;340:c2459&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>102291</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band133/b133-7.html]]&gt;</url>
    <title>Dry eye incidence</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LACRIMAL,DRY EYE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This article published in issue 133 of the Bandolier Journal in March 2005 provides a summary of the Beaver Dam study, specifically about the incidence of dry eye in a given population.]]&gt;</body>
  </document>
  <document>
    <id>102065</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2062512&amp;query_hl=46]]&gt;</url>
    <title>Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.</title>
    <publicationDate>1991-05-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Source: Ophthalmology, {Ophthalmology}, May 1991, vol. 98, no. 5 Suppl, p. 766-85, ISSN: 0161-6420.&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;The Early Treatment Diabetic Retinopathy Study (ETDRS) enrolled 3711 patients with mild-to-severe nonproliferative or early proliferative diabetic retinopathy in both eyes. One eye of each patient was assigned randomly to early photocoagulation and the other to deferral of photocoagulation. Follow-up examinations were scheduled at least every 4 months and photocoagulation was initiated in eyes assigned to deferral as soon as high-risk proliferative retinopathy was detected. Eyes selected for early photocoagulation received one of four different combinations of scatter (panretinal) and focal treatment. This early treatment, compared with deferral of photocoagulation, was associated with a small reduction in the incidence of severe visual loss (visual acuity less than 5/200 at two consecutive visits), but 5-year rates were low in both the early treatment and deferral groups (2.6% and 3.7%, respectively). Adverse effects of scatter photocoagulation on visual acuity and visual field also were observed. These adverse effects were most evident in the months immediately following treatment and were less in eyes assigned to less extensive scatter photocoagulation. Provided careful follow-up can be maintained, scatter photocoagulation is not recommended for eyes with mild or moderate nonproliferative diabetic retinopathy. When retinopathy is more severe, scatter photocoagulation should be considered and usually should not be delayed if the eye has reached the high-risk proliferative stage. The ETDRS results demonstrate that, for eyes with macular edema, focal photocoagulation is effective in reducing the risk of moderate visual loss but that scatter photocoagulation is not. Focal treatment also increases the chance of visual improvement, decreases the frequency of persistent macular edema, and causes only minor visual field losses. Focal treatment should be considered for eyes with macular edema that involves or threatens the center of the macula.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102063:0" name=internalLink&gt;Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102064:0" name=internalLink&gt;Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102066:0" name=internalLink&gt;Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102067:0" name=internalLink&gt;Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102068:0" name=internalLink&gt;Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2740076&amp;amp;query_hl=73" target="_blank"&gt;Detection of diabetic macular edema. Ophthalmoscopy versus photography--Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8287162&amp;amp;query_hl=73" target="_blank"&gt;C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062510&amp;amp;query_hl=102" target="_blank"&gt;Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062511&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062514&amp;amp;query_hl=73" target="_blank"&gt;Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062515&amp;amp;query_hl=73" target="_blank"&gt;Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062516&amp;amp;query_hl=73" target="_blank"&gt;Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1507375&amp;amp;query_hl=113" target="_blank"&gt;Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10577530&amp;amp;query_hl=108" target="_blank"&gt;Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1543449&amp;amp;query_hl=94" target="_blank"&gt;Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9477980&amp;amp;query_hl=106" target="_blank"&gt;Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7661748&amp;amp;query_hl=73" target="_blank"&gt;Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7826294&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8790092&amp;amp;query_hl=91" target="_blank"&gt;Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9230827&amp;amp;query_hl=73" target="_blank"&gt;Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10604663&amp;amp;query_hl=94" target="_blank"&gt;Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15735198&amp;amp;query_hl=97" target="_blank"&gt;Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8545570&amp;amp;query_hl=100" target="_blank"&gt;Accommodative amplitudes in the Early Treatment Diabetic Retinopathy Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102072</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2465518&amp;query_hl=53]]&gt;</url>
    <title>Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group.</title>
    <publicationDate>1988-10-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETIC RETINOPATHY,RETINOPATHY,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Oct 1988, vol. 95, no. 10, p. 1321-34, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;Six patients are described, each of whom underwent early vitrectomy for advanced, active, proliferative diabetic retinopathy (PDR) in an eye with useful vision. These cases were selected to illustrate the spectrum of retinopathy severity for which early vitrectomy should be considered and the favorable outcome that can follow this procedure. None of the eyes that had an unfavorable result after early vitrectomy is presented. The eyes most suitable for early vitrectomy are those in which both fibrous proliferations and at least moderately severe new vessels are present, and in which extensive scatter photocoagulation has already been carried out or is precluded by vitreous hemorrhage.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=10&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102070" target="_blank"&gt;Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102069" target="_blank"&gt;Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102071" target="_blank"&gt;Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102073" target="_blank"&gt;Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102071</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2465517&amp;query_hl=53]]&gt;</url>
    <title>Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group.</title>
    <publicationDate>1988-10-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Oct 1988, vol. 95, no. 10, p. 1307-20, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;Three hundred seventy eyes with advanced, active, proliferative diabetic retinopathy (PDR) and visual acuity of 10/200 or better were randomly assigned to either early vitrectomy or conventional management. After 4 years of follow-up, the percentage of eyes with a visual acuity of 10/20 or better was 44% in the early vitrectomy group and 28% in the conventional management group. The proportion with very poor visual outcome was similar in the two groups. The advantage of early vitrectomy tended to increase with increasing severity of new vessels. In the group with the least severe new vessels, no advantage of early vitrectomy was apparent.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=10&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102070" target="_blank"&gt;Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102069" target="_blank"&gt;Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102072" target="_blank"&gt;Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102073" target="_blank"&gt;Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102073</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2196036&amp;query_hl=58]]&gt;</url>
    <title>Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5.</title>
    <publicationDate>1990-07-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology, {Arch-Ophthalmol}, Jul 1990, vol. 108, no. 7, p. 958-64, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;Six hundred sixteen eyes with recent severe diabetic vitreous hemorrhage reducing visual acuity to 5/200 or less for at least 1 month were randomly assigned to either early vitrectomy or deferral of vitrectomy for 1 year. The proportion of eyes with visual acuity of 10 /20 or better was higher in the early vitrectomy group than in the deferral group throughout the 4-year follow-up period. Up to the 18-month visit, the early group had a higher proportion of eyes with visual acuity of no light perception. An increased chance of obtaining good vision with early vitrectomy was clearly present in the type I diabetes group, particularly in patients who developed severe vitreous hemorrhage after less than 20 years of diabetes, a patient group tending to have more severe proliferative retinopathy. This advantage was not found in the type II diabetes group, in which patients were older and tended to have less severe retinopathy. The findings of this and previous Diabetic Retinopathy Vitrectomy Study reports support early vitrectomy in eyes known or suspected to have very severe proliferative diabetic retinopathy as a means of increasing the chance of restoring or maintaining good vision.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=10&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102070" target="_blank"&gt;Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102069" target="_blank"&gt;Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102071" target="_blank"&gt;Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102072" target="_blank"&gt;Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102069</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2865943&amp;query_hl=53]]&gt;</url>
    <title>Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group.</title>
    <publicationDate>1985-11-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of ophthalmology, {Arch-Ophthalmol}, Nov 1985, vol. 103, no. 11, p. 1644-52, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;Six hundred sixteen eyes with recent severe diabetic vitreous hemorrhage reducing visual acuity to 5/200 or less for at least one month were randomly assigned to either early vitrectomy or deferral of vitrectomy for one year. After two years of follow-up, 25% of the early vitrectomy group had visual acuity of 10/20 or better compared with 15% in the deferral group (P = .01). In patients with Type I diabetes, who were on the average younger and had more-severe proliferative retinopathy, there was a clear-cut advantage for early vitrectomy, as reflected in the percentage of eyes recovering visual acuity of 10/20 or better (36% vs 12% in the deferral group, P = .0001). No such advantage was found in the Type II diabetes group (16% in the early group vs 18% in the deferral group), but evidence that this advantage differed by diabetes type was of borderline significance.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=10&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102070" target="_blank"&gt;Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102071" target="_blank"&gt;Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102072" target="_blank"&gt;Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102073" target="_blank"&gt;Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>292107</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rnib.org.uk/aboutus/Research/reports/edemp/Documents/NFER_GB_Report.doc]]&gt;</url>
    <title>Educational provision for blind and partially sighted children and young people in Britain: 2007</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ LOW VISION,LIVING WITH VISUAL IMPAIRMENT,IN CHILDHOOD,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In 2007 the RNIB commissioned the National Foundation for Educational Research (NFER) to carry out an online survey of local authorities in&amp;nbsp;England, Scotland and Wales.&amp;nbsp; The aims of the study were:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ascertain the numbers and characteristics of children and young people with visual impairments (and other disabilities) within local authorities across the three countries 
&lt;LI&gt;identify and map the type of educational and other provision made for such children and young people&amp;nbsp; 
&lt;LI&gt;explore how and to what extent such provision is supported (both professionally and through ongoing training for staff).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This&amp;nbsp;report was&amp;nbsp;made available on the RNIB website on 11 August 2008.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=420" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=420" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=420" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>292109</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rnib.org.uk/aboutus/Research/reports/edemp/Documents/2008_7_NFER_England_Report.doc]]&gt;</url>
    <title>Educational provision for blind and partially sighted children and young people in England: 2007</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,IN CHILDHOOD,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In 2007 the RNIB commissioned the National Foundation for Educational Research (NFER) to carry out an online survey of local authorities in&amp;nbsp;England, Scotland and Wales.&amp;nbsp; The aims of the study were:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;ascertain the numbers and characteristics of children and young people with visual impairments (and other disabilities) within local authorities across the three countries 
&lt;LI&gt;identify and map the type of educational and other provision made for such children and young people&amp;nbsp; 
&lt;LI&gt;explore how and to what extent such provision is supported (both professionally and through ongoing training for staff).&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This report, made available on RNIB website on 11 August 2008, &amp;nbsp;presents the data received from the English Visual Impairment services, with some data from Great Britain as a whole, where this provides useful comparative information.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=420" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=420" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=420" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318047</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17964657]]&gt;</url>
    <title>Effect of Acrysof versus silicone or polymethyl methacrylate intraocular lens on posterior capsule opacification</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2008 May;115(5):830-8. Epub 2007 Oct 26.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To investigate the effect of AcrySof intraocular lenses (IOLs) on the development of posterior capsule opacification (PCO) compared with silicone or polymethyl methacrylate (PMMA) IOLs for patients with senile cataracts. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Meta-analysis of randomized controlled trials (RCTs). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Patient data from previously reported RCTs. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A comprehensive literature search was performed using the Cochrane Collaboration methodology to identify RCTs comparing AcrySof with silicone or PMMA IOLs in patients with senile cataract. A meta-analysis was performed on the results of RCTs. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Posterior capsule opacification score, neodymium:yttrium-aluminum-garnet (Nd:YAG) capsulotomy rate, and best-corrected visual acuity (BCVA) of 0.5 or better after cataract surgery. RESULTS: In total, 10 RCTs involving 1202 eyes with senile cataract were included in this meta-analysis. The results suggested that AcrySof had lower PCO scores than round-edged silicone IOLs (standard mean difference [SMD], -0.25; 95% confidence interval [CI], -0.42 to -0.08; P = 0.003) and a somewhat higher PCO score than sharp-edged silicone IOLs (SMD, 0.48; 95% CI, 0.29-0.68; P&amp;lt;0.00001). AcrySof had a lower Nd:YAG capsulotomy rate than round-edged silicone IOLs (odds ratio [OR], 0.29; 95% CI, 0.14-0.62; P = 0.001) and did not differ from sharp-edged IOLs (OR, 1.72; 95% CI, 0.23-13.13; P = 0.60). AcrySof had a lower PCO score (SMD, -1.07; 95% CI, -1.29 to -0.85; P&amp;lt;0.00001) and a lower Nd:YAG capsulotomy rate (OR, 0.09; 95% CI, 0.04-0.20; P&amp;lt;0.00001) than round-edged PMMA IOLs. Furthermore, there was no significant difference in BCVA between AcrySof and round-edged silicone IOLs (OR, 2.28; 95% CI, 0.66-7.82; P = 0.19) or PMMA IOLs (OR, 3.20; 95% CI, 0.78-13.16; P = 0.11). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; AcrySof and sharp-edged silicone IOLs are similarly effective in inhibition of PCO after cataract surgery. In patients implanted with the AcrySof lens, significantly less PCO developed than in those who had round-edged silicone or PMMA IOLs. The results of this meta-analysis support the theory that a major factor in preventing PCO development is a sharp-edged IOL design.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=81" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310773</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16671966]]&gt;</url>
    <title>Effect of inhaled corticosteriods on risk of development of cataract: a meta-analysis</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>Fundamental &amp; Clinical Pharmacology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Fundamental and Clinical Pharmacology (Fundam Clin Pharmacol) 2006 Jun; 20(3):305-9&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;The objective of this study was to quantify the risk of cataract among users of inhaled corticosteroids (ICS). Studies that examined the association of ICS use with risk of cataract were identified through computerized (MEDLINE, EMBASE), manual searches using Index Medicus, and checking cross-references to recover all published articles and scientific session abstracts. Pooled odds ratio (OR) with 95% confidence intervals (CI) were estimated using two methods, fixed effects Mantel-Haenszel model and random effects DerSimonian-Laird model. Four studies satisfied all the inclusion/exclusion criteria and were included in the analysis. The pooled OR (95% CI) by the Mantel-Haenszel method was 1.48 (1.39-1.57) and by the DerSimonian-Laird method was 1.48 (1.30-1.68). The test for heterogeneity was not significant. A total number of nine negative studies would be required to make the results of our meta-analysis non-significant. Number needed to harm is 16 with 95% CI of 13-19. Contrary to popular belief, inhaled ICS may be associated with systemic side effects like cataract as shown by this meta-analysis. The risk of increased cataract shown in our analysis needs to be weighted against the benefits of ICS. Further evaluations are required to clarify the causal association between the dosage and duration of drug use.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=119" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342470</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19006748]]&gt;</url>
    <title>Effect of intraocular lens design on posterior capsule opacification</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Journal of Cataract and Refractive Surgery</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Cataract &amp;amp; Refractive Surgery 2008 Nov;34(11):1976-85.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Posterior capsule opacification (PCO) remains the most common long-term complication after cataract surgery. Many studies have attempted to identify factors that influence the development of PCO. The aim of this systematic review based on Cochrane methodology was to summarize the effects of intraocular lens (IOL) geometry, including modifications of the IOL optic (especially optic edge design) and haptics, on the development of PCO. Twenty-six prospective randomized controlled trials with a follow-up of at least 12 months were included. In 5 of 7 studies, visual acuity was better in sharp-edged IOLs than in round-edged IOL. The PCO score was significantly lower with sharp-edged IOLs but did not differ significantly between 1-piece and 3-piece open-loop IOLs. Because of the significant difference in the PCO score, sharp-edged IOL optics should be preferred to round-edged IOL optics.&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click here to &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=235" target="_blank"&gt;view&lt;/A&gt; the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342485</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.afb.org/jvib/jvibabstractNew.asp?articleid=jvib030404]]&gt;</url>
    <title>Effectiveness of assistive technologies for low vision rehabilitation: a systematic review</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Journal of Visual Impairment &amp; Blindness</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Visual Impairment &amp;amp; Blindness, 2009 Apr; 103(4): 210-22&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; A systematic review of all types of assistive devices indicated the need for more research related to performance measurements and the effectiveness of vision rehabilitation devices.&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=231" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372614</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18836050]]&gt;</url>
    <title>Effectiveness of cataract surgery in reducing driving-related difficulties: a systematic review and meta-analysis</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Injury Prevention</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DRIVING,LIVING WITH VISUAL IMPAIRMENT,LENS,CATARACT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Injuries Prevention. 2008 Oct; 14(5):324-8&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVES: &lt;/STRONG&gt;To assess the effects of cataract surgery in improving vision and driving performance while reducing driving-related difficulties. DESIGN: Systematic review and meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DATA SOURCES:&lt;/STRONG&gt; Twelve electronic databases were searched from the date of inception of each database to May 2007. Other sources of potentially relevant information were also identified and examined. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;REVIEW METHODS: &lt;/STRONG&gt;Eligible study designs included randomized controlled trials (RCT), non-RCT, quasi-experimental, case-control, controlled-before-and-after, and cohort studies that examined driving-related indicators in patients undergoing cataract surgery. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; The outcome measures included any type of driving-related indicator. A secondary outcome measure was motor vehicle (MV) crash involvement. RESULTS: Seven studies were included in the review and five in the meta-analysis. The overall pooled odds ratio (OR) was 0.12 (95% CI 0.10 to 0.16). Results suggest that the risk of driving-related difficulties was reduced by 88% following cataract surgery. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Cataract surgery is associated with an 88% reduction in the risk of driving-related difficulties. This supports the efficacy of cataract surgery to improve driving in older people, as well as positive implications for a reduction in MV crashes, overall traffic safety, and individual well-being.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=254" target="_blank"&gt;here&lt;/A&gt; to view the appraisal&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310776</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/10972578]]&gt;</url>
    <title>Effectiveness of screening and monitoring tests for diabetic retinopathy - a systematic review</title>
    <publicationDate>2000-07-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Source: Diabetic Medicine (Diabet Med) 2000 Jul;17(7):495-506&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIMS:&lt;/STRONG&gt; To determine which screening and monitoring tests for diabetic retinopathy are most effective and under what circumstances. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A systematic review of the English language literature, published from 1983 to April 1999. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Available studies are generally limited in their ability to answer the important questions on the effectiveness of tests for early detection of diabetic retinopathy. No randomized controlled trials were identified although primary studies exist for two screening tests: ophthalmoscopy, either direct or indirect, and retinal photography, using either mydriasis or non-mydriasis. Retinal photography under mydriasis appears to be the most effective test, with the majority reporting levels of sensitivity in excess of 80%. However effectiveness is compromised when photographs are ungradable. Ophthalmoscopy can also reach acceptable standards of sensitivity and specificity. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Based on an assessment of available cohort studies, the most effective strategy for testing is the use of mydriatic retinal photography with the additional use of ophthalmoscopy for cases where photographs are ungradable. This does not exclude the use of ophthalmoscopy alone for opportunistic case finding but there is evidence of considerable variation in effectiveness of this test.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=227" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310777</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/9522788]]&gt;</url>
    <title>Effectiveness of screening older people for impaired vision in community setting: systematic review of evidence from randomised controlled trials</title>
    <publicationDate>1998-02-28T00:00:00</publicationDate>
    <publisher>British Medical Journal (BMJ)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,IN LATER LIFE,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: BMJ 1998 Feb 28;316(7132):660-3.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To assess whether population screening for impaired vision among older people in the community leads to improvements in vision. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Systematic review of randomised controlled trials of population screening in the community that included any assessment of vision or visual function with at least 6 months' follow up. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;SUBJECTS:&lt;/STRONG&gt; Adults aged 65 or over. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURE:&lt;/STRONG&gt; Proportions with visual impairment in intervention and control groups with any method of assessing visual impairment. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; There were no trials that primarily assessed visual screening. Outcome data on vision were available for 3494 people in five trials of multiphasic assessment. All the trials used self reported measures for vision impairment, both as screening tools and as outcome measures. The inclusion of a visual screening component in the assessment did not result in improvements in self reported visual problems (pooled odds ratio 1.04:95% confidence interval 0.89 to 1.22). A small reduction (11%) in the number of older people with self reported visual problems cannot be excluded. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Screening of asymptomatic older people in the community is not justified on present evidence. Visual impairment in this age group can usually be reduced with treatment. It is unclear why no benefit was seen. Further work is needed to clarify what interventions are appropriate for older people with unreported impairment of vision.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=9" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>341935</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19607693]]&gt;</url>
    <title>Effectiveness of screening preschool children for amblyopia: A systematic review</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>BMC Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source:&lt;/EM&gt; &lt;EM&gt;BMC Ophthalmol. 2009 Jul 16;9:3.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Amblyopia and amblyogenic factors like strabismus and refractive errors are the most common vision disorders in children. Although different studies suggest that preschool vision screening is associated with a reduced prevalence rate of amblyopia, the value of these programmes is the subject of a continuing scientific and health policy discussion. Therefore, this systematic review focuses on the question of whether screening for amblyopia in children up to the age of six years leads to better vision outcomes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Ten bibliographic databases were searched for randomised controlled trials, non-randomised controlled trials and cohort studies with no limitations to a specific year of publication and language. The searches were supplemented by handsearching the bibliographies of included studies and reviews to identify articles not captured through our main search strategy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Five studies met the inclusion criteria. Of these, three studies suggested that screening is associated with an absolute reduction in the prevalence of amblyopia between 0.9% and 1.6% (relative reduction: between 45% and 62%). However, the studies showed weaknesses, limiting the validity and reliability of their findings. The main limitation was that studies with significant results considered only a proportion of the originally recruited children in their analysis. On the other hand, retrospective sample size calculation indicated that the power based on the cohort size was not sufficient to detect small changes between the groups. Outcome parameters such as quality of life or adverse effects of screening have not been adequately investigated in the literature currently available. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Population based preschool vision screening programmes cannot be sufficiently assessed by the literature currently available. However, it is most likely that the present systematic review contains the most detailed description of the main limitations in current available literature evaluating these programmes. Therefore, future research work should be guided by the findings of this publication.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=253" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>373443</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science/journal/0011393X]]&gt;</url>
    <title>Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>Current Therapeutic Research</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Current Therapeutic Research 2009. Aug;70(4):335-350.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/SPAN&gt;&lt;/STRONG&gt; A 2005 meta-analysis suggests that lowering intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG) is beneficial in reducing the risk for visual field loss in the long term. &lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: bold"&gt;&lt;TYPESTYLE value="smcaps"&gt;Objective:&lt;/SPAN&gt;&lt;/SPAN&gt; The aim of this meta-analysis was to compare the efficacy and toler-ability of travoprost and latanoprost in patients with OAG or OHT. 
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: bold"&gt;&lt;TYPESTYLE value="smcaps"&gt;Methods:&lt;/SPAN&gt;&lt;/SPAN&gt; Pertinent studies published from 1996 to 2008 were identified using systematic searches of major literature databases, including the Cochrane Library, MEDLINE, EMBASE, and the Chinese Biomedicine Database. Internet searches of major search engines, professional associations' Web sites, and manufacturers' databases were also performed. Randomized controlled trials (RCTs) comparing the effects of travoprost 0.004% and latanoprost 0.005% in patients with OAG or OHT were selected. The primary efficacy measure was the weighted mean difference (WMD) in the IOP reduction (IOPR). The primary tolerability measure was the relative risk (RR) for adverse events. The pooled effects were calculated using the random-effects model. 
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: bold"&gt;&lt;TYPESTYLE value="smcaps"&gt;Results:&lt;/SPAN&gt;&lt;/SPAN&gt; Seventeen studies (1491 patients) were included in the meta-analysis, 4 of which were of poor quality based on Jadad scoring. Travoprost was associated with significantly greater diurnal mean IOPRs compared with latanoprost at 2 weeks and 2 months (WMDs [95% CI] mm Hg: 2 weeks, 1.47 [0.33 to 2.62]; 2 months, 0.71 [0.04 to 1.38]); these values were not significant at 1 (0.81 [-0.78 to 2.40]), 3 (0.01 [-0.50 to 0.52]), and 6 months (0.27 [-0.40 to 0.95]). When the 4 studies of low quality were excluded, no significant treatment differences in diurnal IOPR were found. IOPR measured at 5 pm was significantly greater with travoprost compared with latanoprost at 2 weeks (WMD [95% CI], 0.87 mm Hg [0.40 to 1.33]); these values were not significant at 1 (WMD [95% CI], 0.60 mm Hg [0.00 to 1.20], 2 (0.65 [-0.69 to 1.99]), 3 (0.04 [-0.51 to 0.59]), 6 (0.00 [-0.68 to 0.68]), and 12 months (0.30 [-0.36 to 0.96]). Travoprost was associated with a significantly greater frequency of hyperemia than was latanoprost (RR = 1.72 [95% CI, 1.33 to 2.23]). Rates of serious ocular adverse events did not differ significantly between travoprost and latanoprost (cystoid macular edema: RR = 0.22 [95% CI, 0.03 to 1.76]; cataract: RR = 2.29 [95% CI, 0.90 to 5.83]). 
&lt;P&gt;&lt;SPAN style="FONT-WEIGHT: bold"&gt;&lt;TYPESTYLE value="smcaps"&gt;Conclusions:&lt;/SPAN&gt;&lt;/SPAN&gt; The findings from the present meta-analysis of these 17 RCTs suggest that there were no significant differences between travoprost and latanoprost in IOPR in these patients with OHT or OAG. Both agents were generally well tolerated.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=287" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372419</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19232016]]&gt;</url>
    <title>Efficacy and tolerability of latanoprost compared to dorzolamide combined with timolol in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trials</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Journal of Ocular Pharmacology &amp; Therapeutics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Ocular Pharmacology &amp;amp; Therapeutics. 2009 Feb;25(1):55-64&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; The aim of this study was to evaluate the efficacy and tolerability of latanoprost, compared with the combination of dorzolamide and timolol, in the treatment of patients with elevated intraocular pressure (IOP). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Pertinent randomized, controlled trials were identified through systematic searches of the Cochrane Library, PubMed, EMBASE, Chinese Biomedicine Database, and internet searches of meeting abstracts and the manufacturers' databases. The main efficacy measures were the IOP reduction (IOPR), including diurnal mean IOPR, and 10:00 IOPR. The main tolerability measure was withdrawal due to adverse events and individual adverse events. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Fourteen (14) studies involving 2149 patients were included in the meta-analysis. Latanoprost was significantly more effective in lowering diurnal mean IOP than combined dorzolamide and timolol in patients with IOP insufficiently controlled by timolol alone, with a weighted mean difference (WMD) for the diurnal mean IOPR% of 3.12 (95% confidence interval, 0.47-5.78) at 3 months, and latanoprost was as effective as the combination of dorzolamide and timolol in patients without baseline timolol treatment. The combination of dorzolamide and timolol was associated with numerically greater reductions in 10:00 IOP, compared with latanoprost in patients with or without timolol treatment at baseline: only the result in patients with baseline timolol treatment at 1 month was statistically significant (WMD -4.14: range, -5.78 to -2.50). The combination of dorzolamide and timolol was less tolerated than latanoprost, with pooled relative risk for withdrawals due to adverse events being 0.34 (range, 0.13-0.84). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS: &lt;/STRONG&gt;Latanoprost was associated with significantly greater efficacy in lowering diurnal mean IOP than combined dorzolamide and timolol in patients with IOP insufficiently controlled by timolol alone, and latanoprost was as effective as combined dorzolamide and timolol in patients without baseline timolol treatment. The combination of dorzolamide and timolol was less tolerated than latanoprost.&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=275" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372417</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19295379]]&gt;</url>
    <title>Efficacy and tolerability of nonpenetrating filtering surgery with and without implant in treatment of open angle glaucoma: a quantitative evaluation of the evidence</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Journal of Glaucoma</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Glaucoma. 2009 Mar;18(3):233-7&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To evaluate the efficacy and tolerability of nonpenetrating filtering surgery augmented with implant (NPFSI) compared with nonpenetrating filtering surgery without implant (NPFS) in the treatment of patients with open angle glaucoma. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Pertinent studies were selected through extensive searches of the Cochrane Library, PubMed, Embase, and American Association of Ophthalmology (AAO) and Association for Research in Vision and Ophthalmology (ARVO) meeting abstracts. Seven controlled clinical trials meeting the predefined criteria were systematically reviewed by meta-analysis. The main outcome measures were percentage intraocular pressure (IOP) reduction, complete success rates, and qualified success rates. The pooled estimates were carried out in RevMan version 4.2 software. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;The weighted mean difference of the percentage IOP reduction from baseline were 6.7% (95% confidence intervals: -3.8 to 17.2) when comparing NPFSI with NPFS. NPFSI was associated with numerically greater, but nonsignificant, IOP lowering efficacy than NPFS. The pooled risk differences comparing NPFSI with NPFS were 0.13 (-0.02 to 0.28) in complete success rate and 0.09 (-0.04 to 0.21) in qualified success rate. Numerically greater, but nonsignificant, proportions of NPFSI patients than NPFS patients achieved the target end point IOP. NPFSI resulted in the same incidences of postoperative complications as NPFS. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; NPFSI was associated with equivalent efficacy to standard NPFS in lowering IOP. Comparable proportions of patients reached the IOP target with NPFSI and NPFS. Both surgeries were well tolerated.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=273" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372422</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19169318]]&gt;</url>
    <title>Efficacy and tolerability of nonpenetrating glaucoma surgery augmented with mitomycin C in treatment of open-angle glaucoma: a meta-analysis</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Canadian Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Canadian Journal of Ophthalmology. 2009 Feb;44(1):76-82&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To evaluate the efficacy and tolerability of nonpenetrating glaucoma surgery (NPGS) augmented with mitomycin C (MMC) compared with trabeculectomy (TE) plus MMC in the treatment of patients with open-angle glaucoma. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Systematic review and meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Eight clinical trials, including 4 cohort and 4 randomized, enrolled 459 eyes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Pertinent studies were selected through extensive searches of the Cochrane Library, MEDLINE, EMBASE, and meeting abstracts. Efficacy measures were weighted mean differences (WMDs) for the percentage intraocular pressure (IOP) reduction and relative risks (RRs) for success rates. Tolerability measures were RRs for adverse events. Pooled estimates were carried out in RevMan software v. 4.2. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; NPGS augmented with MMC was associated with a numerically smaller but nonsignificant percentage reduction in IOP compared with TE plus MMC, with a WMD of -1.27% (95% CI -5.61 to 3.07) at 1 year, -4.55% (-10.35 to 1.24) at 2 years, -0.82% (-8.80 to 7.17) at 3 years, and -6.16% (-25.97 to 13.65) at 4 years. Significantly greater proportions of TE plus MMC patients than NPGS augmented with MMC patients achieved the target IOP without antiglaucoma medication at the end point, with a pooled RR of 0.74 (0.63-0.86). NPGS augmented with MMC was associated with a significantly lower frequency of shallow anterior chamber and cataract than TE plus MMC, with pooled RRs of 0.31 (0.16-0.60) and 0.23 (0.11-0.47), respectively. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; NPGS augmented with MMC was associated with IOP-lowering efficacy comparable to that of TE plus MMC. However, significantly fewer patients achieved the target IOP with NPGS augmented with MMC than with TE plus MMC. NPGS augmented with MMC was better tolerated than TE plus MMC.&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=276" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342467</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19092464]]&gt;</url>
    <title>Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Journal of Glaucoma</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Glaucoma 2008 Dec;17 (8):667-73&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; This systematic meta-analysis was performed to evaluate the intraocular pressure (IOP) lowering effects and tolerability of latanoprost, bimatoprost, and travoprost. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Clinical trials published up to July 2006 were thoroughly searched using all available databases and resources. The inclusion criteria were prospective randomized controlled clinical trials; patients with primary open-angle glaucoma or ocular hypertension; and prostaglandin monotherapy, without systemic/ocular medications or laser/surgery that could affect IOP within the past 3 months. Study quality was assessed with the Jadad scoring system, and potential bias was eliminated by robust statistical and independent reviews of publications. The main outcome measures were efficacy assessed by IOP (taken at 8 AM, noon, 4 PM, and 8 PM) change at 3 months from baseline and tolerability assessed by the incidence of conjunctival hyperemia. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Eight trials were identified (n=1610 patients). IOP change from baseline was statistically significantly greatest with bimatoprost, compared with latanoprost at all time points [weighted mean (WM) 8 AM: WM=0.50 mm Hg; P=0.05; 95% confidence intervals (CIs) 0.01-0.99; noon: WM=1.17 mm Hg; P&amp;lt;0.001; 95% CI 0.68-1.66; 4 PM: WM=0.78 mm Hg; P=0.003; 95% CI 0.26-1.29; 8 PM: WM=0.67 mm Hg; P=0.04; 95% CI 0.02-1.32], and with travoprost during the daytime (8 AM: WM=1.02 mm Hg; P=0.004; 95% CI 0.32-1.72; noon: WM=0.86 mm Hg; P=0.02; 95% CI 0.12-1.59). Latanoprost and travoprost were comparable in their ability to reduce IOP at all time points (P&lt;OR=0.82). P="0.05;" &lt; 0.70-1.00]. CI 95% risk="0.59;" relative bimatoprost: vs. travoprost 0.50-0.69; P&lt;0.001; [latanoprost and latanoprost with less was hyperemia of incidence The&gt; 
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; The findings suggest a greater efficacy of bimatoprost compared with latanoprost and travoprost, although the incidence of hyperemia was lower with the latter 2 agents.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=234" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318051</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18460539]]&gt;</url>
    <title>Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2008 Jun;92(6):729-34. Epub 2008 May 6. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; To evaluate the efficacy of the fixed combination ocular hypotensive therapies compared with their non-fixed components used concomitantly for lowering intraocular pressure (IOP) in glaucoma and ocular hypertension. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic review of the literature, up to May 2007, without limits on year or language of publication was performed. Seven randomised controlled trials (n = 2,083 eyes) were identified. Assessment of methodological quality was made using standardised criteria. Results were pooled quantitatively using meta-analysis methods, and statistical analysis was performed using STATA software. The difference in mean intraocular pressure (mm Hg) from baseline between the fixed combination and non-fixed component therapies was compared. Non-inferiority in terms of efficacy was set at an upper confidence limit of &amp;lt; or =1.5 mm Hg for all time points (hour (Hr)0, Hr2 and Hr8) and evaluated at 12 weeks. Safety was evaluated from data on adverse events as reported in the included studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Of the 679 abstracts identified, seven randomised controlled trials met the selection criteria. The quality scores of included studies were high (mean of 29.4, maximum score 30). The mean differences (95% CI) and p values at 12 weeks were as follows: 0.200 mm Hg, (CI -0.106 to 0.507), p = 0.20 for Hr0, 0.393 mm Hg (CI 0.038 to 0.747), p = 0.03 for Hr2 and 0.501 mm Hg (CI 0.156 to 0.846), p = 0.004 for Hr8. Although both Hr2 and Hr8 showed statistical significance favouring the non-fixed combinations, the non-inferiority measure &amp;lt; or =1.5 mm Hg upper confidence limit was not exceeded. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Fixed combination therapies are equally safe and effective at lowering IOP as their non-fixed components administered concomitantly.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=67" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392618</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19686307]]&gt;</url>
    <title>Efficacy of different dry eye treatments with artificial tears or ocular lubricants: A systematic review</title>
    <publicationDate>2009-08-14T00:00:00</publicationDate>
    <publisher>Ophthalmic and Physiological Optics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LACRIMAL,DRY EYE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmic Physiol Opt. 2009 Nov;29(6):573-83. Epub 2009 Aug 14.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE&lt;/STRONG&gt;: To objectively review the outcome of clinical studies where rose bengal stain (RB) has been used as an outcome measure to assess the efficacy of artificial tears (AT) in patients with dry eye.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: From peer-reviewed articles published between 1947 and 2008, information was sought on dry eye status, as reported using a grading scheme, after use of RB as a diagnostic test, before and after use of a specific regimen of artificial tears or ocular lubricants for approximately 30 days. Mean baseline scores and post-treatment scores were calculated, along with the net change and the percentage change in the RB scores.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: From a total of 33 suitable data sets, published between 1985 and 2006, the group mean pre-treatment RB score was 4.25 +/- 1.55 (+/-S.D.), which decreased to 2.84 +/- 1.24 after 30 days of treatment. This represented a net change of -1.43 (95% CI of -1.04 to -1.45). For use of traditional AT (saline, hypromellose, etc), the net change was -0.95, it was -1.33 for use of carbomer (polyacrylic acid) gels and -2.10 for hyaluronic acid (HA) products. These changes represented net improvements of 25.9 +/- 18.4%, 38.0 +/- 20.7% and 41.8 +/- 16.3% respectively. The greater change with HA was not associated with a lower final outcome score, but with higher pre-treatment scores.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Based on RB grading schemes used by numerous different clinicians over many years, treatment of dry eye with artificial tears or ocular lubricants can be expected to improve the condition of the exposed ocular surface. Assuming no improvement without treatment, a 30 days treatment period can be projected to produce an overall improvement of around 25%, but with no unambiguous statistical differences between product types.&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=303" target="_blank"&gt;here &lt;/A&gt;to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310791</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17224119]]&gt;</url>
    <title>Efficacy of different intraocular lens materials and optic edge designs in preventing posterior capsular opacification: a meta-analysis</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American Journal of Ophthalmology (Am J Ophthalmol) 2007 Mar;143(3):428-36. Epub 2006 Dec 28&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To evaluate the efficacy of different intraocular lens (IOL) materials and optic edge designs in preventing posterior capsular opacification (PCO). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Systematic review and meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Pertinent studies were selected through an electronic search of the Cochrane Library, MEDLINE, and Embase. The randomized controlled trials meeting the predefined criteria were reviewed systematically by meta-analysis. The treatment effects were measured as risk difference, and the pooled estimates were computed according to a random effect model. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; In total, 23 randomized controlled trials were included in the present meta-analysis. The pooled risk differences of Nd:YAG laser capsulotomy rates were -24% (95% confidence interval [CI], -29% to -20%) comparing acrylic with polymethylmethacrylate (PMMA) lenses; -9% (95% CI, -17% to -1%) comparing silicone with PMMA lenses; 14% (95% CI, -8% to 36%) comparing hydrogel with PMMA lenses; 4% (95% CI, -2% to 10%) comparing silicone with acrylic lenses; 19% (95% CI, 8% to 30%) comparing hydrogel with acrylic lenses; and 28% (95% CI, 10% to 46%) comparing hydrogel with silicone lenses. The pooled risk differences of PCO rates were -39% (95% CI, -47% to -31%) comparing acrylic with PMMA lenses; -14% (95% CI, -29% to 0%) comparing silicone with acrylic lenses; 56% (95% CI, 36% to 75%) comparing hydrogel with acrylic lenses; and 48% (95% CI, 31% to 64%) comparing hydrogel with silicone lenses. When comparing sharp with rounded-edge designs, pooled risk differences of capsulotomy rates were -47% (95% CI, -77% to -17%) in PMMA lenses, -22% (95% CI, -47% to 2%) in acrylic lenses, and -9% (95% CI, -17% to 0%) in silicone lenses; pooled risk differences of PCO rates were -28% (95% CI, -50% to -7%) in acrylic lenses and -37% (95% CI, -46% to -27%) in silicone lenses. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; The rates of PCO and Nd:YAG laser capsulotomy may be influenced by different IOL biomaterials and optic edge designs. The lenses made by acrylic and silicone and those with sharp optic edges are superior in lowering the rates of PCO and laser capsulotomy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=16" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310788</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16815401]]&gt;</url>
    <title>Efficacy of omega-3 fatty acids in preventing age-related macular degeneration: a systematic review</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2006 Jul; 113(7):1165-72; quiz 1172-3, 1178&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;TOPIC:&lt;/STRONG&gt; What is the evidence for efficacy of dietary and/or supplemental omega-3 fatty acids in preventing age-related macular degeneration (AMD)? &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CLINICAL RELEVANCE:&lt;/STRONG&gt; Age-related macular degeneraion is the leading cause of blindness and vision impairment in persons older than 50 years living in North America. There is no cure for AMD, and treatment does not usually restore vision but only prevents disease progression to a modest degree. omega-3 fatty acids are considered potentially important antioxidants and are being considered as an arm of the Age-Related Eye Disease Study II clinical trial. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS/LITERATURE REVIEWED:&lt;/STRONG&gt; Keywords were searched in Medline, Pre-Medline, Embase, and the Cochrane Library on Ovid. There was no restriction on the year or language of publication. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; There were 6 observational studies found, but the specific outcomes, exposures, and covariates studied all varied greatly. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; There is some clinical evidence for protection of AMD from omega-3 fatty acids. However, the results are not consistent. Hence, our conclusion is that this issue is neither clearly supported nor refuted by the present world literature. This is an intriguing and extremely important question but needs further study first with prospective cohort designs and, if positive, randomized clinical trials.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=28" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>262819</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band155/b155-6.html]]&gt;</url>
    <title>Eggs and eyes</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ AGE RELATED MACULAR DEGENERATION,RETINA,DETERMINANTS,OUTCOMES,FOOD,FOOD &amp; NUTRITION,EYE DISORDERS,BLINDNESS,ADULTS,AGE GROUPS,OLDER PEOPLE,EYES AND VISION,PUBLIC HEALTH,CONDITIONS,2008,2008-JULY,MONTHLY ADDITIONS,GROUPS,POPULATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This article published in issue 155 of Bandolier discusses&amp;nbsp;the&amp;nbsp;role of eggs (lutein and zeaxanthin) in relation to age-related macular degeneration.&amp;nbsp;]]&gt;</body>
  </document>
  <document>
    <id>310792</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15121434]]&gt;</url>
    <title>Epidemiological association between cigarette smoking and primary open-angle glaucoma: a meta-analysis</title>
    <publicationDate>2004-06-01T00:00:00</publicationDate>
    <publisher>Public Health</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Public Health 2004 Jun;118(4):256-61&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; The role of cigarette smoking as a risk factor for primary open-angle glaucoma (POAG) remains controversial. The aim of this study was to examine this association by conducting a detailed meta-analysis of studies published in peer-reviewed literature on the subject. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A comprehensive search for articles published up 31 December 2002 was performed, reviews of each study were conducted, and data were abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Our analysis was based on seven reports. We found no evidence of publication bias or heterogeneity among the studies. The summary odds ratios from a fixed-effects model were 1.37 (95% CI: 1.00-1.87) for current smokers and 1.03 (95% CI: 0.77-1.38) for past smokers. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Our meta-analysis results suggest that current smokers are at significantly increased risk of developing POAG. Efforts should be directed towards augmenting the campaign against smoking by adding the increased risk of POAG to the better-known arguments against smoking.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=186" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310795</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15232600]]&gt;</url>
    <title>Epidemiology of diabetic retinopathy and macular oedema: a systematic review</title>
    <publicationDate>2004-10-01T00:00:00</publicationDate>
    <publisher>Eye</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Eye 2004 Oct;18(10):963-83&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIMS:&lt;/STRONG&gt; To systematically review the literature on the prevalence and incidence of diabetic retinopathy (DR) and macular oedema (MO). &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A search of the bibliographic databases (Medline, Embase, CINAHL) was conducted up to October 2001. Selected relevant studies were scrutinized and included in the review. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A total of 359 studies were included. The studies were reported in nearly 100 different journals and in over 50 countries. The majority of the studies were US-based, with large studies such as the Wisconsin Epidemiologic Study of Diabetic Retinopathy dominating the literature. The studies were quite dated and highly heterogeneous in nature in terms of patient selection with variable inclusion criteria (age range, gender, diabetes duration and type, ethnicity, comorbidity, and DR status, assessment, and classification). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS: &lt;/STRONG&gt;There are inconsistencies between epidemiological studies, and differences in study methods may contribute to conflicting reports of prevalence and incidence of DR and MO in diabetic populations. As new therapies for DR and its associated complications emerge, the need to capture and monitor new epidemiological data becomes increasingly important to be able to assess the impact and effectiveness of these therapies. Robust, longitudinal capture of patient data is, therefore, essential to evaluate the impact of current practice on the epidemiology of diabetic eye complications.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=181" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102050</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9097788&amp;query_hl=7]]&gt;</url>
    <title>Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.</title>
    <publicationDate>1995-10-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Oct 1995, vol. 102, no. 10, p. 1425-33, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To evaluate the efficacy of macular grid photocoagulation in preserving or improving central visual acuity in eyes with macular edema due to central vein occlusion (CVO) and best-corrected visual acuity of 20/50 or poorer. &lt;/P&gt;
&lt;P&gt;METHODS: Patients with angiographically documented macular edema due to CVO were entered into a multicenter randomized controlled clinical trial supported by the National Eye Institute. Eligibility was determined based on both clinical examination findings and photographic documentation evaluated at a photograph reading center. Eyes were assigned randomly to macular grid photocoagulation (77 eyes) or no treatment (78 eyes). Patients were followed every 4 months for 3 years or until the end of the study. The outcome measure was visual acuity. &lt;/P&gt;
&lt;P&gt;RESULTS: The study population consisted of 155 eyes in 155 patients. There was no difference between treated and untreated eyes in visual acuity at any point during the follow-up period. Initial median visual acuity was 20/160 in treated eyes and 20/ 125 in control eyes. Final median visual acuity was 20 /200 in treated eyes and 20/160 in control eyes. However, treatment clearly reduced angiographic evidence of macular edema. &lt;/P&gt;
&lt;P&gt;CONCLUSION: The results of this study do not support a recommendation for macular grid photocoagulation for the population meeting the Central Vein Occlusion Study macular edema group eligibility criteria. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;central vein occlusion management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102048:0" name=internalLink&gt;Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102049:0" name=internalLink&gt;A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7508322&amp;amp;query_hl=16" target="_blank"&gt;Central vein occlusion study of photocoagulation therapy. Baseline findings. Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7508321&amp;amp;query_hl=16" target="_blank"&gt;Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7688950&amp;amp;query_hl=16" target="_blank"&gt;Baseline and early natural history report. The Central Vein Occlusion Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10163466&amp;amp;query_hl=23" target="_blank"&gt;Laser therapy for central retinal vein obstruction.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310797</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/13678388]]&gt;</url>
    <title>Evaluation of the effectiveness of laser in situ keratomileusis and photorefractive keratectomy for myopia: a meta-analysis</title>
    <publicationDate>2003-08-01T00:00:00</publicationDate>
    <publisher>Journal of Medical Investigation: JMI</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,REFRACTIVE ERROR,SHORT SIGHT (MYOPIA),CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Medical Investigation (J Med Invest) 2003 Aug;50(3-4):180-6.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To evaluate the effectiveness of laser in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) for correcting myopia. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Study selection, data extraction, and quality assessment were performed by two of authors independently. Summary odds ratios and 95% confidence intervals were calculated by DerSimonian &amp;amp; Laird random-effects model and Mantel-Haenszel (fixed-effects) model. All calculations were based on an intention-to-treat and per protocol analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Five hundred and eighty eyes (476 patients) from 5 randomized controlled trials were included in this study. At &amp;gt; or = 6 months follow-up, by random-effects model, the pooled odds ratios (OR, for LASIK vs. PRK) of postoperative uncorrected visual acuity (UCVA) of 20/20 or better for all trials were 1.31 (95% CI=0.77-2.22) by per protocol analysis and 1.18 (95% CI=0.74-1.88) by intention-to-treat analysis. In the refractive outcome, the pooled OR of the postoperative spherical equivalent refraction within +/-0.5 diopter (D) of emmetropia did not show any statistical significance, for which the OR were 0.75 (95% CI=0.48-1.18) by per protocol analysis and 0.70 (95% CI=0.47-1.04) by intention-to-treat analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; LASIK and PRK were found to be similarly effective for the correction of myopia from -1.5 to -15.0 D in a greater than 6 month follow-up.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=202" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298587</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.vision2020uk.org.uk/ukvisionstrategy/core/core_picker/download.asp?id=63]]&gt;</url>
    <title>Evidence base to support the UK Vision Strategy</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CORNEA,GLAUCOMA,RETINA,LENS,UVEAL TRACT,LID,LACRIMAL,OCULAR MOTILITY,ORBIT,VITREOUS BODY,REFRACTIVE ERROR,LOW VISION,OPTIC NERVE AND VISUAL PATHWAYS,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Briefing paper&amp;nbsp;published in November 2008 by the RNIB.&amp;nbsp;&amp;nbsp;The objective of the&amp;nbsp;paper is to provide a review of the current evidence base that informs and supports the strategic aims of the UK Vision Strategy.&amp;nbsp; Three key areas are considered. 
&lt;P&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;the current and future impacts of sight loss, including the&lt;BR&gt;health, social and economic impacts; 
&lt;LI&gt;current practice and access to services; and&amp;nbsp; 
&lt;LI&gt;national and local initiatives in eye care which could provide a framework for informing future policy and development. Our paper aims to present a briefing on the challenges and also the opportunities facing eye care.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=408" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=408" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=408" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>310809</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17074559]]&gt;</url>
    <title>Evidence for superior efficacy and safety of LASIK over photorefractive keratectomy for correction of myopia</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,REFRACTIVE ERROR,SHORT SIGHT (MYOPIA),CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2006 Nov;113(11):1897-908&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To examine possible differences in efficacy and safety between LASIK and photorefractive keratectomy (PRK) for correction of myopia. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Meta-analysis/systematic review. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Patient data from previously reported prospective randomized controlled trials (PRCTs) and a systematic review of prospective case series in the Food and Drug Administration (FDA) clinical trials database. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A comprehensive literature search was performed using the Cochrane Collaboration methodology to identify PRCTs comparing LASIK and PRK for correction of myopia. A meta-analysis was performed on the results of PRCTs. In parallel, a systematic review of prospective data from FDA case series of LASIK and PRK for correction of myopia was undertaken. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Key efficacy outcomes (uncorrected visual acuity [UCVA] &amp;gt; or = 20/20, +/-0.50 diopters [D] of the target mean refractive spherical equivalent) and safety outcomes (loss of &amp;gt; or =2 lines of best spectacle-corrected visual acuity [BSCVA], final BSCVA &amp;gt; or = 20/40, and final BSCVA &amp;lt; 20/25 where preoperative BSCVA was &amp;gt; or =20/20). RESULTS: Seven PRCTs were identified comparing PRK (683 eyes) and LASIK (403 eyes) for correction of myopia. More LASIK patients achieved UCVA &amp;gt; or = 20/20 at 6 months (odds ratio, random effects model [95% confidence interval], 1.72 [1.14-2.58]; P = 0.009) and 12 months (1.78 [1.15-2.75], P = 0.01). Loss of &amp;gt; or =2 lines of BSCVA at 6 months was less frequent with LASIK (2.69 [1.01-7.18], P = 0.05). Data from 14 LASIK (7810 eyes) and 10 PRK (4414 eyes) FDA laser approval case series showed that more LASIK patients achieved UCVA of 20/20 or better at 12 months (1.15 [1.03-1.29], P = 0.01), significantly more LASIK patients were within +/-0.50 D of target refraction at 6 months (1.38 [1.26-1.50], P&amp;lt;0.00001) and 12 months (1.21 [1.08-1.36], P = 0.0009) after treatment, and loss of &amp;gt; or =2 lines of BSCVA at 6 months was less frequent with LASIK (2.91 [2.22-3.83], P&amp;lt;0.00001). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; LASIK appears to have efficacy and safety superior to those of PRK. However, the data examined are from studies conducted &amp;gt; or =5 years ago. It is therefore unclear how our findings relate to present-day methods and outcomes. Further trials comparing contemporary equipment and techniques are needed to reevaluate the relative merits of these procedures.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=121" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310802</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17290205]]&gt;</url>
    <title>Evidence for the effect of omega-3 fatty acids on progression of age-related macular degeneration: a systematic review</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Retina</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Retina 2007 Feb; 27(2):216-21&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; As part of a larger systematic review on the effect of omega-3 fatty acids on eye health, the aim of this report was to appraise and synthesize the evidence for the effects of omega-3 fatty acids in slowing down the progression of age-related macular degeneration (AMD) and/or decreasing the rate of progression to advanced forms of AMD. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A comprehensive search was undertaken in six databases (MEDLINE, PreMEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, CAB Health, and Dissertation Abstracts). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Two unique studies, one randomized clinical trial (RCT) and one prospective cohort study, satisfied the eligibility criteria and were included in the review. The RCT reported evidence on the effect of omega-3 fatty acids in slowing down the progression of AMD. The prospective cohort study addressed the question: what is the evidence that omega-3 fatty acids decrease the rate of progression to advanced forms of AMD? &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Clinical research on this topic is scarce. Only two studies were eligible to be included in this review. Although one study result indicated efficacy of preventing AMD progression to its advanced form, this result needs to be duplicated and supported by future research.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=19" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310805</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17460154]]&gt;</url>
    <title>Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the Amercian Academy of Neurology</title>
    <publicationDate>2007-06-01T00:00:00</publicationDate>
    <publisher>Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Neurology 2007 Jun 12;68(24)2144-9. Epub 2007 Apr 25.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To perform a systematic review of the relevant literature and to provide evidence-based guidelines for the medical treatment of ocular myasthenia. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Medline, EMBASE, and the Cochrane Neuromuscular Disease Group Register were searched for articles of possible relevance to the medical treatment of ocular myasthenia. The titles and abstracts of all articles, as well as the full texts of all potentially relevant manuscripts, were read by both reviewers. Experts in the field were also contacted to identify other published or unpublished literature. All articles were evaluated using predefined criteria to evaluate their methodologic quality. Data from these articles were extracted to address two questions: 1) Are there any effective treatments for symptoms of ocular myasthenia? 2) Are there any treatments that reduce the risk of progression from ocular to generalized myasthenia gravis (MG)? &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A single randomized controlled trial compared the efficacy of intranasal neostigmine to placebo for the treatment of ocular symptoms. Methodologic limitations of this study preclude any firm conclusions. A second randomized controlled trial compared the efficacy of corticotropin with placebo, but outcome was reported in terms of a quantification of the range of eye movements. For this reason, the results of the second study could not be used to address the issues of improvement in ocular symptoms or the risk of progression to generalized MG. This review did not identify any randomized controlled trials addressing the risk of progression to generalized MG but did identify five observational studies reporting the effects of corticosteroids on progression to generalized MG, two of which also reported the effects of azathioprine. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RECOMMENDATIONS:&lt;/STRONG&gt; The absence of high-quality evidence means that it is not possible to make any evidence-based recommendations regarding the effects of cholinesterase inhibitors, corticosteroids, or other immunosuppressive agents with respect to improvement of ocular symptoms. There is similarly an absence of evidence regarding the effects of cholinesterase inhibitors on the risk of progression to generalized myasthenia gravis (MG). Based on data from several observational studies, corticosteroids and azathioprine are of uncertain benefit in terms of their effect on the risk of progression to generalized MG.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=12" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>341832</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcophth.ac.uk/core/core_picker/download.asp?id=99]]&gt;</url>
    <title>Examination requirements for Ophthalmic Specialist Training</title>
    <publicationDate>2010-01-18T00:00:00</publicationDate>
    <publisher>The Royal College of Ophthalmologists</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Letter issued by&amp;nbsp;the Vice President and Chairman of the Examinations Committee of the Royal College of Ophthalmologists on 18 January 2010 outlining the examination requirements for Ophthalmic Specialist Training.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=478" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=478" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=478" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101393</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.joannabriggs.edu.au/pdf/BPISEng_6_1.pdf]]&gt;</url>
    <title>Eye care for intensive care patients</title>
    <publicationDate>2002-01-01T00:00:00</publicationDate>
    <publisher>The Joanna Briggs Institute for Evidence Based Nursing &amp; Midwifery</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CONJUNCTIVA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Best Practice Information Sheet on eye care for intensive care patients published in 2002.&amp;nbsp;&amp;nbsp; The information sheet is based upon a systematic literature review conducted under the supervision of The Joanna Briggs Institute for Evidence Based Nursing and Midwifery.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The information sheet covers eye problems in the intensive care unit, loss of protective mechanisms, potential problems,&amp;nbsp;a review of the findings and a summary of recomendations. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=266" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=266" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=266" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>338698</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/eye-test-for-diagnosing-Alzheimers-disease.aspx]]&gt;</url>
    <title>Eye scan could detect Alzheimer's</title>
    <publicationDate>2010-01-15T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The &lt;EM&gt;Daily Mirror&lt;/EM&gt; says there could be a “high street eye test for Alzheimer's” within five years. The newspaper says that new research in mice has shown that placing a harmless fluorescent dye into the retina of the eye could identify dying nerve cells, which are an early sign of Alzheimer's.&lt;/P&gt;
&lt;P&gt;The model developed in this study is a novel way of studying the death of eye nerve cells in living animals. This research mainly tested whether the technique could detect cell death in the retinas of rodents, including in animals with rodent versions of the human diseases glaucoma and Alzheimer’s disease. However, it did not test whether the technique could effectively distinguish between different diseases in animals or what the results can tell us about the health of nerve cells in the brain.&lt;/P&gt;
&lt;P&gt;Diagnosing Alzheimer’s disease is complicated, and additional tests to help&amp;nbsp; identify the condition would be useful. While this technique merits further research, it is too soon to say that the test might be successful in humans or can be used to single out Alzheimer’s disease as a cause of someone’s symptoms.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The model developed in this study is a novel way of studying cell death in the retinas of living animal models and, as such, is likely to be a useful research tool. This study mainly tested whether the technique could detect cell death in the retinas of rodents, including in animal models of the human diseases glaucoma and Alzheimer’s disease. It did not focus on how well the technique could distinguish between different diseases in animals, or what the results of the test can tell us about the health of nerve cells in the brain.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/eye-test-for-diagnosing-Alzheimers-disease.aspx" target="_blank"&gt;NHS Choices commentary &lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Cordeiro MF, Guo L, Coxon KM &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.nature.com/cddis/journal/v1/n1/full/cddis20093a.html" target="_blank"&gt;Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo&lt;/A&gt;. Cell Death and Disease (2010)&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>383074</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://eyewiki.aao.org/Main_Page]]&gt;</url>
    <title>EyeWiki</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;EyeWiki is&amp;nbsp;a collaboration of the American Academy of Ophthalmology and&amp;nbsp; several subspecialty and special interest societies.&amp;nbsp; EyeWiki is a single site where ophthalmologists, other physicians, patients and the public can view detailed content written by ophthalmologists covering the vast spectrum of eye disease, diagnosis and treatment. Any qualified ophthalmologist, or ophthalmologist in training, is invited to contribute content and post it immediately.&lt;/P&gt;
&lt;P&gt;Categories covered include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Cataract/Anterior Segment&lt;/LI&gt;
&lt;LI&gt;Cornea/External Disease&lt;/LI&gt;
&lt;LI&gt;Glaucoma&lt;/LI&gt;
&lt;LI&gt;Neuro-ophthalmology/Orbit&lt;/LI&gt;
&lt;LI&gt;Oculoplastics/Orbit&lt;/LI&gt;
&lt;LI&gt;Pediatric Ophthalmology/Strabismus&lt;/LI&gt;
&lt;LI&gt;Refractive Management/Intervention&lt;/LI&gt;
&lt;LI&gt;Retina/Vitreous&lt;/LI&gt;
&lt;LI&gt;Uveitis&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=494" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=494" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=494" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102034</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523884&amp;query_hl=7]]&gt;</url>
    <title>Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.</title>
    <publicationDate>2003-01-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology, {Arch-Ophthalmol}, Jan 2003, vol. 121, no. 1, p. 48-56, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including the effect of EMGT treatment. &lt;/P&gt;
&lt;P&gt;SETTING /PARTICIPANTS: Two hundred fifty-five open-angle glaucoma patients randomized to argon laser trabeculoplasty plus topical betaxolol or no immediate treatment (129 treated; 126 controls) and followed up every 3 months. &lt;/P&gt;
&lt;P&gt;METHODS: Progression was determined by perimetric and photographic optic disc criteria. Patient-based risk of progression was evaluated using Cox proportional hazard regression models and was expressed as hazard ratios (HR) with 95% confidence intervals (95% CI). &lt;/P&gt;
&lt;P&gt;RESULTS: After 6 years, 53% of patients progressed. In multivariate analyses, progression risk was halved by treatment (HR = 0.50; 95% CI, 0.35-0.71). Predictive baseline factors were higher intraocular pressure (IOP) (ie, the higher the baseline IOP, the higher the risk), exfoliation, and having both eyes eligible (each of the latter 2 factors doubled the risk), as well as worse mean deviation and older age. Progression risk decreased by about 10% with each millimeter of mercury of IOP reduction from baseline to the first follow-up visit (HR = 0.90 per millimeter of mercury decrease; 95% CI, 0.86-0.94). The first IOP at that visit (3 months' follow-up) was also related to progression (HR = 1.11 per millimeter of mercury higher; 95% CI, 1.06-1.17), as was the mean IOP at follow-up (HR = 1.13 per millimeter of mercury higher; 95% CI, 1.07-1.19). The percent of patient follow-up visits with disc hemorrhages was also related to progression (HR = 1.02 per percent higher; 95% CI, 1.01-1.03). No other factors were identified. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Patients treated in the EMGT had half of the progression risk of control patients. The magnitude of initial IOP reduction was a major factor influencing outcome. Progression was also increased with higher baseline IOP, exfoliation, bilateral disease, worse mean deviation, and older age, as well as frequent disc hemorrhages during follow-up. Each higher (or lower) millimeter of mercury of IOP on follow-up was associated with an approximate 10% increased (or decreased) risk of progression. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10571351&amp;amp;query_hl=36" target="_blank"&gt;Early Manifest Glaucoma Trial: design and baseline data.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12780410&amp;amp;query_hl=36" target="_blank"&gt;Measuring visual field progression in the Early Manifest Glaucoma Trial.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15021220&amp;amp;query_hl=36" target="_blank"&gt;Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial.&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:102035:0" name=internalLink&gt;
&lt;P&gt;Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102007</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.vision2020uk.org.uk/core_files/Low%20Vision.pdf]]&gt;</url>
    <title>Factors which Influence the use of Low Vision Aids</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Visibility</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Research project report produced in May 2005 by Visibility (Glasgow and West of Scotland Society for the Blind GWSSB) on the factors that influence the use of low vision aids.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This&amp;nbsp;small scale qualititative study jointly funded by the Greater Glasgow NHS Board and Visibility was set up to explore people's experiences of low vision aids, how the aids fit into their lives and what factors influence usage of vision aids. &lt;/P&gt;
&lt;P&gt;Following the introduction, the report includes&amp;nbsp;sections on&amp;nbsp;low vision aids and services, effectiveness of low vision support, the aims, objectives and methodology used, profile of the participants, living with low vision, usage of low vision aids, views on service provision, factors influencing usage, local services, the national picture, wider context of assistive technology, discussion, conclusion and recommendations.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=280" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=280" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=280" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>177392</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rnib.org.uk/eyehealth/Documents/Feeling_great_looking_good_PDF.pdf]]&gt;</url>
    <title>Feeling great, looking good</title>
    <publicationDate>2006-09-06T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,RETINA,LENS,AGE RELATED MACULAR DEGENERATION,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The RNIB's 'Feeling great, looking good' campaign report was launched on Wednesday 6 September 2006.&amp;nbsp;&amp;nbsp; The report discusses a link between obesity and some common eye conditions that cause blindness such as age-related macular degeneration, diabetic retinopathy and cataracts.&amp;nbsp;&amp;nbsp; The report also provides general information on eye health.&amp;nbsp;&amp;nbsp;&amp;nbsp; The report was supported by Boots Opticians. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=356" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=356" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=356" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381791</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/omega-3-oily-fish-may-slow-amd.aspx]]&gt;</url>
    <title>Fish 'may slow AMD eye problem'</title>
    <publicationDate>2010-07-27T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A weekly dose of oily fish may help prevent the most common cause of blindness in old age,” said the &lt;EM&gt;Daily Express.&lt;/EM&gt; The newspaper said that a US study found that people who ate at least one portion of oily fish a week cut their risk of advanced age-related macular degeneration (AMD) by 60% compared with people who ate fewer portions.&lt;/P&gt;
&lt;P&gt;This study compared the diet of more than 2,000 older adults and recorded whether or not they had AMD. As the study assessed both of these factors at only a single point in time it is not possible to say whether people’s diets directly affected their development of AMD. The small number of people with advanced AMD also reduces confidence in the results from this study.&lt;/P&gt;
&lt;P&gt;Previous studies, including more reliable &lt;A href="http://www.nhs.uk/news/Pages/Newsglossary.aspx#Cohortstudy" target="_blank"&gt;cohort studies&lt;/A&gt;, have already suggested a link between consuming higher levels of omega-3 fatty acids and reduced AMD risk. As such, this new study does not add much to our knowledge. The best way to determine whether omega-3 supplementation can reduce the risk of AMD would be to conduct a&amp;nbsp;&lt;A href="http://www.nhs.uk/news/Pages/Newsglossary.aspx#Randomisedcontrolledtrial(RCT)" target="_blank"&gt;randomised controlled trial&lt;/A&gt; directly testing omega-3 against a placebo.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study showed an association between level of consumption of fish and shellfish high in omega-3 fatty acids and advanced AMD. However, it has a number of limitations that need to be taken into account:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;This study assessed diet and the presence of AMD at the same point in time, and cannot show what the participants’ fish eating habits were before the development of AMD. Therefore, it is not possible to say whether these eating habits may have directly influenced risk of developing AMD. 
&lt;LI&gt;The only significant association found was between advanced AMD 3 and lower consumption of fish and shellfish high in omega-3 fatty acids. However, the number of participants who had advanced AMD was small (only 68 people). Therefore, the results of this analysis may not be very robust. It is not clear why the researchers chose to divide AMD into three types, as previous studies have relied on simpler early- and late-AMD categories. 
&lt;LI&gt;The researchers carried out multiple statistical analyses. This increases the likelihood that some significant differences may be found by chance. 
&lt;LI&gt;As with all studies of this type, other factors that differ between groups with higher and lower fish consumption may be influencing the results. The researchers did take some of these into account, but there may be unknown or unmeasured factors still having an effect. 
&lt;LI&gt;People may find it difficult to recall their food intake accurately over an extended period, and therefore there may be inaccuracies. 
&lt;LI&gt;A number of previous studies have suggested that oily fish may slow or prevent AMD. It may be the case that these preliminary findings, which have received a great deal of media and internet attention, could influence the fish consumption of people with AMD and distort any potential relationships that may or may not exist between diet and AMD. However, the researchers thought this was unlikely to affect the current study, as it was carried out between 1993 and 1995, which they say was before published associations between fish consumption and AMD were first made. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Studies have already suggested a link between eating higher levels of omega-3 fatty acids and reduced risk of AMD, and the current study does not add much to our knowledge. The best way to determine whether omega-3 supplementation could be used to reduce risk of AMD would be to carry out a randomised controlled trial.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/July07/Pages/omega-3-oily-fish-may-slow-amd.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Swenor BK, Bressler S, Caulfield L, West SK. &lt;A href="http://www.ophsource.org/periodicals/ophtha/article/S0161-6420(10)00377-5/abstract" target="_blank"&gt;The Impact of Fish and Shellfish Consumption on Age-Related Macular Degeneration&lt;/A&gt;. &lt;EM&gt;Opthalmology&lt;/EM&gt;, July 13 2010 [Online publication]&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>101379</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.assoc-optometrists.org/uploaded_files/pdf/fm-tcl-info1.pdf]]&gt;</url>
    <title>Fitting &amp; Management of Therapeutic Contact Lenses</title>
    <publicationDate></publicationDate>
    <publisher>Association of Optometrists (AOP)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ CORNEA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document was&amp;nbsp;produced on behalf of the Association of Optometrists, Hospital Optometrists Committee as part of the Hospital Optometrists Series.&amp;nbsp; It was written by Mr Chris Steele B.Sc., MCOptom, DipCLP in November 2000.&lt;/P&gt;
&lt;P&gt;The document provides a definition of therapeutic contact lens, the aims and implications of use, classification and characteristics of type, fitting of lenses and complications.&amp;nbsp; The&amp;nbsp;five aims namely, relief of pain, promotion of corneal healing, mechanical support and protection, maintenance of corneal hydration and drug delivery are then explored in more depth. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=261" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=261" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=261" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>84014</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_078294.pdf]]&gt;</url>
    <title>Form CVI: explanatory notes for consultants ophthalmologists and hospital eye clinic staff</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CERTIFICATION OF VISUAL IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance from the Department of Health&amp;nbsp;explains how to use the Certificate of Vision Impairment 2003&amp;nbsp;form which&amp;nbsp;replaced the BD8 (1990) from 1 September 2005.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The form formally certifies someone as partially sighted or as blind so that the local council can register him/her.&amp;nbsp; It's&amp;nbsp;second purpose is to&amp;nbsp;record a standard range of diagnostic and other data that may be used for epidemiological analysis.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This guidance was last updated in September 2007.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342493</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19542771]]&gt;</url>
    <title>Foundations in newborn care. Pain management during retinopathy of prematurity eye examinations: A systematic review</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Advances in Neonatal Care: official journal of the National Association of Neonatal Nurses</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,RETINOPATHY OF PREMATURITY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: &lt;/EM&gt;&lt;EM&gt;Adv Neonatal Care.&lt;/EM&gt;&lt;EM&gt; 2009 Jun;9(3):99-110.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Retinopathy of prematurity (ROP) remains a concern for many preterm infants. Early detection and timely treatment have been shown to be effective in improving visual outcomes; moreover, it is crucial that a series of indirect ophthalmic examinations be performed until an infant is considered no longer at risk for the disease. The purpose of this systematic review is to summarize and evaluate the published evidence regarding characteristics and effectiveness of pain management interventions during the ROP examination. Implications for practice are discussed and suggestions for further research are made. Despite the general consensus that ROP examination is a painful procedure with considerable amount of discomfort, evidence shows that pain management during the ROP examination is inadequate. Although there are currently clear recommendations and guidelines for performing the ROP examination, there are no standard protocols for pharmacological and nonpharmacological pain management during the ROP examination. This is an area where much work is still needed to address the needs of the infant during this critical examination.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=240" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296506</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_089514.pdf]]&gt;</url>
    <title>Framing the contribution of allied health professionals: deliving high-quality healthcare</title>
    <publicationDate>2008-10-21T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Report issued by the Department of Health on 21 October 2008.&amp;nbsp; This document frames&amp;nbsp;the next stage review for allied health professionals and describes the improved AHP service offer to patients and the public.]]&gt;</body>
  </document>
  <document>
    <id>323256</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rnib.org.uk/aboutus/Research/reports/eyehealth/Documents/FSUK_Report.pdf]]&gt;</url>
    <title>Future sight loss UK (1): The economic impact of partial sight and blindness in the UK adult population</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Future sight loss UK is an RNIB funded research initiative on the current and future prevalence and costs relating to sight loss. &lt;/P&gt;
&lt;P&gt;The research aims to inform the UK Vision Strategy and RNIB strategy. &lt;/P&gt;
&lt;P&gt;Future sight loss UK encompasses two research studies:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the economic impact of partial sight and blindness in the UK adult population 
&lt;LI&gt;an epidemiological and economic model for sight loss in the decade 2010 to 2020&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=445" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=445" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=445" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323263</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rnib.org.uk/aboutus/Research/reports/eyehealth/Documents/FSUK_2.pdf]]&gt;</url>
    <title>Future sight loss UK (2): An epidemiological and economic model for sight loss in the decade 2010-2020</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Future sight loss UK is an RNIB funded research initiative on the current and future prevalence and costs relating to sight loss. &lt;/P&gt;
&lt;P&gt;The research aims to inform the UK Vision Strategy and RNIB strategy. &lt;/P&gt;
&lt;P&gt;Future sight loss UK encompasses two research studies&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the economic impact of partial sight and blindness in the UK adult population 
&lt;LI&gt;an epidemiological and economic model for sight loss in the decade 2010-2020&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=447" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=447" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=447" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310812</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11262681]]&gt;</url>
    <title>Gender and blindness: a meta-analysis of population-based prevalence surveys</title>
    <publicationDate>2001-02-01T00:00:00</publicationDate>
    <publisher>Ophthalmic Epidemiology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmic Epidemiology (Ophthalmic Epidemiol) 2001 Feb;8(1):39-56.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Many individual surveys of blindness have reported slightly higher rates of blindness for women. In order to gain a continent-by-continent and global sense of the burden of blindness by sex we conducted a meta-analysis of published, population-based surveys of blindness. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHOD: &lt;/STRONG&gt;Published reports were collected using a predetermined search protocol involving commercial electronic databases, hand-searching of references and direct contact with researchers. Studies were included that were population-based, included clinical examination and had a minimum sample size of 1000. The studies were critically appraised to determine methodological rigour. Data were analysed using the Cochrane Collaboration Review Manager. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The overall odds ratio (age-adjusted) of blind women to men is 1.43 (95% CI 1.33-1.53), ranging from 1.39 (95% CI 1.20-1.61) in Africa, 1.41 (95% CI 1.29-1.54) in Asia, and 1.63 (95% CI 1.30-2.05) in industrialised countries. There was good homogeneity of findings from Africa, Asia, and the industrialised countries. Globally, women bear excess blindness compared to men. In these surveys, overall, women account for 64.5% of all blind people. The excess of blindness in women was marked among the elderly and not due only to differential life expectancy. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; The excess burden of blindness among women is likely due to a number of factors, which are different in industrialised countries compared to developing countries. Particular attention to gender differences in blindness is needed in the creation of targets for blindness reduction and in the development of interventions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=223" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>239356</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_063957.pdf]]&gt;</url>
    <title>General Ophthalmic Services Review</title>
    <publicationDate>2007-01-17T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;General Ophthalmic Services Review&amp;nbsp;written&amp;nbsp;by the Department of Health&amp;nbsp;and published on 17 January 2007.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The primary focus of the review was&amp;nbsp;to examine how to support PCTs in commissioning a wider range of community based eye care services, where this is likely to improve patient experience and provide a cost-effective way of increasing capacity and choice. &lt;/P&gt;
&lt;P&gt;The findings are in relation to the framework for primary ophthalmic services, the position of dispensing opticians in relation to the NHS, Local Optical Committees, and the administration of General Ophthalmic Services payments.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>296200</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_089257.pdf]]&gt;</url>
    <title>General Ophthalmic Services: income-related employment and support allowance and changes to GOS forms</title>
    <publicationDate>2008-10-14T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Dear Colleague letter issued on 14 October&amp;nbsp;2008 containing information about the introduction of income-related Employment and Support Allowance, and GOS form changes]]&gt;</body>
  </document>
  <document>
    <id>371550</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_114691.pdf]]&gt;</url>
    <title>General Ophthalmic Services: increases to NHS sight test fee from 1 April 2010</title>
    <publicationDate>2010-03-25T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,REFRACTIVE ERROR,LOW VISION,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Dear Colleague letter published on 25 March 2010 announcing the&amp;nbsp;increases in&amp;nbsp;NHS sight test fees and NHS domiciliary fees applicable from 1st April 2010.]]&gt;</body>
  </document>
  <document>
    <id>381688</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_117483.pdf]]&gt;</url>
    <title>General Ophthalmic Services: payments for continuing education and training and pre-registration supervisors grant</title>
    <publicationDate>2010-07-14T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT face=Arial&gt;
&lt;P&gt;Dear Colleague letter from Derek Busby, Eye Care Services Commissioning Directorate, published on 14 July 2010. &lt;/P&gt;
&lt;P&gt;The letter covers a) the arrangements for payments for loss of earnings in respect of continuing education and training undertaken by optometrists and ophthalmic medical practitioners on PCT lists and the level of payment in respect of 2009 CET which is payable this year; and b) the pre-registration supervisors grant from 1 April 2010.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=introText&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>304458</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_093250.pdf]]&gt;</url>
    <title>General Ophthalmic Services: payments to persons suspended from general ophthalmic services performers lists</title>
    <publicationDate>2009-01-15T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guidance published by the Department of Health on 15 January 2009 to assist primary care trusts calculate how much should be paid to persons suspended from ophthalmic performers lists.]]&gt;</body>
  </document>
  <document>
    <id>308510</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_095921.pdf]]&gt;</url>
    <title>General Optical Council (Constitution) Order 2009: consultation report</title>
    <publicationDate>2009-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Consultation report published on 9 March 2009 by Department of Health. &lt;/P&gt;
&lt;P class=introText&gt;The General Optical Council (Constitution) Order 2009 was published in draft for consultation between 15 August and 7 November 2008. This report provides information on the outcome of that consultation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288972</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band157/b157-6.html]]&gt;</url>
    <title>Genes and age-related macular degeneration</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This summary&amp;nbsp;published in issue&amp;nbsp;157 of the&amp;nbsp;Bandolier&amp;nbsp;Journal&amp;nbsp;discusses the paper written by D A Schaumberg "A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors" published in Archives of Ophthalmology 2007 125: 55-62.]]&gt;</body>
  </document>
  <document>
    <id>298584</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=298584]]&gt;</url>
    <title>Glaucoma Annual Evidence Update : 24-30 November 2008 : Assessment of Visual Field Progression</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma Annual Evidence Update : 24-30 November 2008 : Assessment of Visual Field Progression&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1108/aeu_glaucoma_1108_doc6.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/topic_trees/vfp_topic_tree.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273535:0" name=internalLink&gt;Click here to view 2007 NKW Visual Field Progression section&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back&amp;nbsp;to contents&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Assessment of Visual Field Progression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt;&amp;nbsp;AMED, BNI, CINAHL, EMBASE, EVSL, PubMed&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; October 2007 - October 2008&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&lt;/EM&gt;&amp;nbsp; &lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID298584/nelhImp_0001_evsl_topic_vfp.jpg"&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Chauhan BC, Garway-Heath DF, Goni FJ, Rossetti L, Bengtsson B, Viswanathan AC, Heijl A. Practical recommendations for measuring rates of visual field change in glaucoma.&lt;EM&gt; Br J Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;92 (Pt 4)&lt;/STRONG&gt;: 569-73. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18211935" target="_blank"&gt;PubMed abstract (PM:18211935)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Bengtsson B, Heijl A. A visual field index for calculation of glaucoma rate of progression. &lt;EM&gt;Am J Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;145 (Pt 2)&lt;/STRONG&gt;: 343-53. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18078852" target="_blank"&gt;PubMed abstract (PM:18078852)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Broman AT, Quigley HA, West SK, Katz J, Munoz B, Bandeen-Roche K, Tielsch JM, Friedman DS, Crowston J, Taylor HR, Varma R, Leske MC, Bengtsson B, Heijl A, He M, Foster PJ. Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2008; &lt;STRONG&gt;49 (Pt 1)&lt;/STRONG&gt;: 66-76. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18172076" target="_blank"&gt;PubMed abstract (PM:18172076)]&lt;/A&gt; 
&lt;P&gt;Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE. Canadian Glaucoma Study. 2. Risk factors for the progression of open-angle glaucoma. &lt;EM&gt;Arch Ophthalmol &lt;/EM&gt;2008' &lt;STRONG&gt;126 (Pt 8)&lt;/STRONG&gt;: 1030-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18695095" target="_blank"&gt;PubMed abstract (PM:18695095)&lt;/A&gt;] 
&lt;P&gt;Heijl A, Bengtsson B, Chauhan BC, Lieberman MF, Cunliffe I, Hyman L, Leske MC. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;115 (Pt 9)&lt;/STRONG&gt;: 1557-65. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18378317" target="_blank"&gt;PubMed abstract (PM:18378317)&lt;/A&gt;] 
&lt;P&gt;Kovalska M, Grieshaber MC, Schotzau A, Katamay R, Hauenstein D, Flammer J, Orgul S. Detection of visual field progression in glaucoma. &lt;EM&gt;Klin Monatsbl Augenheilkd&lt;/EM&gt;&amp;nbsp;2008; &lt;STRONG&gt;225 (Pt 5)&lt;/STRONG&gt;: 342-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18454368" target="_blank"&gt;PubMed abstract (PM:18454368)&lt;/A&gt;] 
&lt;P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/search_history/VisualFieldProgression.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>298229</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=298229]]&gt;</url>
    <title>Glaucoma Annual Evidence Update : 24-30 November 2008 : Epidemiology</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA NKW 2008,GLAUCOMA,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma Annual Evidence Update : 24-30 November 2008 : Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1108/aeu_glaucoma_1108_doc2.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/topic_trees/epidemiology_topic_tree.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273449:0" name=internalLink&gt;Click here to view&amp;nbsp;2007 NKW Epidemiology section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Epidemiology&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched: &lt;/STRONG&gt;AMED, BNI, CINAHL, EMBASE,&amp;nbsp;EVSL, PubMed&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched: &lt;/STRONG&gt;October 2007 - October 2008&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has&amp;nbsp;not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&lt;/EM&gt;&amp;nbsp;&lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID298229/nelhImp_0001_evsl_topic_epid_1.jpg"&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;Fukuoka S, Aihara M, Iwase A, Araie M. Intraocular pressure in an ophthalmologically normal Japanese population. &lt;EM&gt;Acta Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;86 (Pt 4)&lt;/STRONG&gt;: 434-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18039350" target="_blank"&gt;PubMed abstract (PM:18039350)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Classification&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Friedman DS, Gazzard G, Min CB, Broman AT, Quigley H, Tielsch J, Seah S, Foster PJ. Age and sex variation in angle findings among normal Chinese subjects:&amp;nbsp;a comparison of UBM, Scheimpflug, and gonioscopic assessment of the anterior chamber angle. &lt;EM&gt;J Glaucoma&lt;/EM&gt; 2008; &lt;STRONG&gt;17 (Pt 1)&lt;/STRONG&gt;: 5-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18303376" target="_blank"&gt;PubMed abstract (PM:18303376)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Incidence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Astrom S, Stenlund H, Linden C. Incidence and prevalence of pseudoexfoliations and open-angle glaucoma in northern Sweden. II. Results after 21 years of follow-up. &lt;EM&gt;Acta Ophthalmol Scand &lt;/EM&gt;2007; 85 (Pt 8): 832-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17986292" target="_blank"&gt;PubMed abstract (PM:17986292)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevalence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Astrom S, Linden C. Incidence and prevalence of pseudoexfoliation and open-angle glaucoma in northern Sweden. I. Baseline report. &lt;EM&gt;Acta Ophthalmol Scand&lt;/EM&gt; 2007; &lt;STRONG&gt;85 (Pt 5)&lt;/STRONG&gt;: 828-31. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17986290" target="_blank"&gt;PubMed abstract (PM:17986290)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Ryskulova A, Turczyn K, Makuc DM, Cotch MF, Klein RJ, Janiszewski R. Self-reported age-related eye diseases and visual impairment in the United States: results of the 2002 National Health Interview Survey. &lt;EM&gt;Am J Public Health&lt;/EM&gt; 2008; &lt;STRONG&gt;98 (Pt 3)&lt;/STRONG&gt;: 454-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18235074" target="_blank"&gt;PubMed abstract (PM:18235074)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Sakata K, Sakata LM, Sakata VM, Santini C, Hopker LM, Bernardes R, Yabumoto C, Moreira AT. Prevalence of glaucoma in a South Brazilian population: Projeto Glaucoma. &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2007; &lt;STRONG&gt;48 (Pt 11)&lt;/STRONG&gt;: 497-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17962447" target="_blank"&gt;PubMed abstract (PM:17962447)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Shen SY, Wong TY, Foster PJ, Loo JL, Rosman M, Loon SC, Wong WL, Saw SM, Aung T. The prevalence and types of glaucoma in malay people: the Singapore Malay Eye Study. &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2008; &lt;STRONG&gt;49 (Pt 9)&lt;/STRONG&gt;: 3846-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18441307" target="_blank"&gt;PubMed abstract (PM:18441307)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Topouzis F, Coleman AL, Harris A, Koskosas A, Founti P, Gong G, Yu F, Anastasopoulos E, Pappas T, Wilson MR. Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. &lt;EM&gt;Am J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;145 (Pt 2)&lt;/STRONG&gt;: 327-35. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18045565" target="_blank"&gt;PubMed abstract (PM:18045565)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Wong TY, Chong EW, Wong W, Rosman M, Aung T, Loo J, Shen S, Loon S, Tan DTH, Tai ES, Saw S. Prevalence and causes of low vision and blindness in an urban Malay population: The Singapore Malay Eye Study. &lt;EM&gt;Arch Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;126 (pt 8)&lt;/STRONG&gt;: 1091-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18695104" target="_blank"&gt;PubMed abstract (PM:18695104)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevalence of&amp;nbsp;blindness &amp;amp; visual impairment from Glaucoma&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Chu M, Ai H, Peng J, Wang Y, Yang X. Sampling survey of prevalence and cause of visual impairment in Shaanxi Province. &lt;EM&gt;International Journal of Ophthalmology &lt;/EM&gt;2008: 1412-1415. [Free abstract not yet available from on pubmed or journal publisher (&lt;A href="http://www.world-eye.cn/ijo/english.htm" target="_blank"&gt;www.world-eye.cn/ijo/english.htm&lt;/A&gt;)]&lt;/P&gt;
&lt;P&gt;Liang YB, Friedman DS, Wong TY, Zhan SY, Sun LP, Wang JJ, Duan XR, Yang XH, Wang FH, Zhou Q, Wang NL. Prevalence and causes of low vision and blindness in a rural Chinese adult population:&amp;nbsp;the Handan Eye Study. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;epub ahead of print&lt;/STRONG&gt;: 4 Aug. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18684506" target="_blank"&gt;PubMed abstract (PM:18684506)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Wu M, Yip JLY, Kuper H. Rapid Assessment of Avoidable Blindness in Kunming, China. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;115 (Pt 6)&lt;/STRONG&gt;: 969-74. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17953988" target="_blank"&gt;PubMed abstrat (PM:17953988)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bron A, Chaine G, Villain M, Colin J, Nordmann JP, Renard JP, Rouland JF. [Risk factors for primary open-angle glaucoma]. &lt;EM&gt;J Fr Ophtalmol &lt;/EM&gt;2008; &lt;STRONG&gt;31 (Pt 4)&lt;/STRONG&gt;: 435-44. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18563046" target="_blank"&gt;PubMed abstract (PM:18563046)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Amerasinghe N, Wong TY, Wong WL, Mitchell P, Shen SY, Loon SC, Saw SM, Foster PJ, Aung T. Determinants of the optic cup to disc ratio in an Asian population: the Singapore Malay Eye Study (SiMES). &lt;EM&gt;Arch Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;126 (Pt 8)&lt;/STRONG&gt;: 1101-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18695105" target="_blank"&gt;PubMed abstract (PM:18695105)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Casson RJ, Gupta A, Newland HS, McGovern S, Muecke J, Selva D, Aung T. Risk factors for primary open-angle glaucoma in a Burmese population: the Meiktila Eye Study. &lt;EM&gt;Clin Experiment Ophthalmol &lt;/EM&gt;2007;&amp;nbsp;&lt;STRONG&gt;35 (Pt 8)&lt;/STRONG&gt;: 739-44. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17997778" target="_blank"&gt;PubMed abstract&amp;nbsp;(PM:17997778)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Chopra V, Varma R, Francis BA, Wu J, Torres M, Azen SP. Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino Eye Study. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2008; &lt;STRONG&gt;115 (Pt 2)&lt;/STRONG&gt;: 227-232. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17716734" target="_blank"&gt;PubMed abstract (PM:17716734)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;115 (Pt 1)&lt;/STRONG&gt;: 85-93. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17629563" target="_blank"&gt;PubMed abstract (PM:17629563)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Motsko SP, Jones JK. Is there an association between hypothyroidism and open-angle glaucoma in an elderly population?: an epidemiologic study.&lt;EM&gt; Ophthalmology&lt;/EM&gt; 2008; &lt;STRONG&gt;115 (Pt 9)&lt;/STRONG&gt; 1581-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18355921" target="_blank"&gt;PubMed abstract (PM:18355921)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Muskens RP, de Voogd S, Wolfs RC, Witteman JC, Hofman A, de Jong&amp;nbsp;PT, Stricker BH, Jansonius NM. Systemic antihypertensive medication and incident open-angle glaucoma. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2007; &lt;STRONG&gt;114 (Pt 12)&lt;/STRONG&gt;: 2221-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17568677" target="_blank"&gt;PubMed abstract (PM:17568677)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Nemesure B, Honkanen R, Hennis A, Wu SY, Leske MC. Incident open-angle glaucoma and intraocular pressure. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2007; &lt;STRONG&gt;114 (Pt 10)&lt;/STRONG&gt;: 1810-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17583352" target="_blank"&gt;PubMed abstract (PM:17583352)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Pasquale LR, Rosner BA, Hankinson SE, Kang JH. Attributes of female reproductive aging and their relation to primary open-angle glaucoma: a prospective study. &lt;EM&gt;J Glaucoma &lt;/EM&gt;2007; &lt;STRONG&gt;16 (Pt 7)&lt;/STRONG&gt;: 598-605. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18091177" target="_blank"&gt;PubMed abstract (PM:18091177)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Tarkkanen A, Reunanen A, Kivela T. Frequency of systemic vascular diseases in patients with primary open-angle glaucoma and exfoliation glaucoma. &lt;EM&gt;Acta Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;86 (Pt 6)&lt;/STRONG&gt;: 598-602. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18435818" target="_blank"&gt;PubMed abstract (PM:18435818)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors - diet and lifestyle&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Coleman AL, Stone KL, Kodjebacheva G, Yu F, Pedula KL, Ensrud KE, Cauley JA, Hochberg MC, Topouzis F, Badala F, Mangione CM. Glaucoma risk and the consumption of fruits and vegetables among older women in the study of osteoporotic fractures. &lt;EM&gt;Am J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;145 (Pt 6)&lt;/STRONG&gt;: 1081-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18355790" target="_blank"&gt;PubMed abstract (PM:18355790)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Kang JH, Willett WC, Rosner BA, Hankinson SE, Pasquale LR. Caffeine consumption and the risk of primary open-angle glaucoma: a prospective cohort study. &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2008; &lt;STRONG&gt;49 (Pt 5)&lt;/STRONG&gt;: 1924-31. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18263806" target="_blank"&gt;PubMed abstract (PM:18263806)&lt;/A&gt;]&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors - genetics&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/STRONG&gt;Abu-Amero KK, Morales J, Bosley TM, Mohamed GH, Cabrera VM. The role of mitochondrial haplogroups in glaucoma: a study in an Arab population. &lt;EM&gt;Mol Vis&lt;/EM&gt; 2008; &lt;STRONG&gt;14&lt;/STRONG&gt;: 518-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18385785" target="_blank"&gt;PubMed abstract (PM:18385785)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;Abu-Amero KK, Morales J, Mohamed GH, Osman MN, Bosley TM. Glutathione S-transferase M1 and T1 polymorphisms in Arab glaucoma patients.&lt;EM&gt;&amp;nbsp;Mol Vis &lt;/EM&gt;2008; &lt;STRONG&gt;14&lt;/STRONG&gt;: 425-30. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18334963" target="_blank"&gt;PubMed abstract (PM:18334963)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Chakrabarti S, Rao KN, Kaur I, Parikh RS, Mandal AK, Chandrasekhar G, Thomas R. The LOXL1 gene variations are not associated with primary open-angle and primary angle-closure glaucomas. &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2008; &lt;STRONG&gt;49 (Pt 6)&lt;/STRONG&gt;: 2343-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18223248" target="_blank"&gt;PubMed abstract (PM:18223248)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;de Voogd S, Wolfs RC, Jansonius NM, Uitterlinden AG, Pols HA, Hofman A, de Jong PT. Estrogen receptors alpha and beta and the risk of open-angle glaucoma: the Rotterdam Study. &lt;EM&gt;Arch Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;126 (Pt 1)&lt;/STRONG&gt;: 110-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18195227" target="_blank"&gt;PubMed abstract (PM:18195227)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Green CM, Kearns LS, Wu J, Barbour JM, Wilkinson RM, Ring MA, Craig JE, Wong TL, Hewitt AW, Mackey DA. How significant is a family history of glaucoma?: experience from the Glaucoma Inheritance Study in Tasmania. &lt;EM&gt;Clin Experiment Ophthalmol &lt;/EM&gt;2007; &lt;STRONG&gt;35 (pt 9)&lt;/STRONG&gt;; 793-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18173405" target="_blank"&gt;PubMed abstract (PM:18173405)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;He M, Liu B, Huang W, Zhang J, Yin Q, Zheng Y, Wang D, Ge J. Heritability of optic disc and cup measured by the Heidelberg Retinal Tomography in Chinese: the Guangzhou Twin Eye Study. &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2008; &lt;STRONG&gt;49 (Pt 4)&lt;/STRONG&gt;: 1350-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18385049" target="_blank"&gt;PubMed abstract (PM:18385049)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors for progression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications &lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Rivera JL, Bell NP, Feldman RM. Risk factors for primary open angle glaucoma progression: what we know and what we need to know. &lt;EM&gt;Curr Opin Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;19 (Pt 2)&lt;/STRONG&gt;: 102-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18301282" target="_blank"&gt;PubMed abstract (PM:18301282)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Broman AT, Quigley HA, West SK, Katz J, Munoz B, Bandeen-Roche K, Tielsch JM, Friedman DS, Crowston J, Taylor HR, Varma R, Leske MC, Bengtsson B, Heijl A, He M, Foster PJ. Estimating the rate of progressive visual field damage in those with open-angle glaucoma from cross-sectional data. &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2008; &lt;STRONG&gt;49 (Pt 1)&lt;/STRONG&gt;: 66-76. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18172076" target="_blank"&gt;PubMed abstract (PM:18172076)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Fang EN, Law SK, Walt JG, Chiang TH, Williams EN. The prevalence of glaucomatous risk factors in patients from a managed care setting: a pilot evaluation. &lt;EM&gt;Am J Manag Care &lt;/EM&gt;2008; &lt;STRONG&gt;14 (1 Suppl)&lt;/STRONG&gt;: S28-S36. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18284313" target="_blank"&gt;PubMed abstract (PM:18284313)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Health care utilisation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Ang GS, Ng WS, Zuara-Blanco A. The influence of the new general ophthalmic services (GOS) contract in optometrist referrals for glaucoma in Scotland. &lt;EM&gt;Eye&lt;/EM&gt; 2007: &lt;STRONG&gt;epub ahead of print&lt;/STRONG&gt;: 30 Nov. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18049484" target="_blank"&gt;PubMed abstract (PM:18049484)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Mortality&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Wu SY, Nemesure B, Hennis A, Schachat AP, Hyman L, Leske MC. Open-angle glaucoma and mortality: the Barbados Eye Studies. &lt;EM&gt;Arch Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;126 (Pt 3)&lt;/STRONG&gt;: 365-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18332317" target="_blank"&gt;PubMed abstract (PM:18332317)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Xu L, Wang YX, Jonas JB. Glaucoma and mortality in the Beijing Eye Study. &lt;EM&gt;Eye&lt;/EM&gt; 2008; &lt;STRONG&gt;22 (Pt 3)&lt;/STRONG&gt;: 434-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18188176" target="_blank"&gt;PubMed abstract (PM:18188176)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic evaluation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. &lt;EM&gt;Pharmacoeconomics &lt;/EM&gt;2007; &lt;STRONG&gt;25 (Pt 4)&lt;/STRONG&gt;: 287-308. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17402803" target="_blank"&gt;PubMed abstract (PM:17402803)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk and litigation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Ali MN, Fraser SG. Medicolegal aspects of glaucoma. &lt;EM&gt;Clinical Risk&lt;/EM&gt; 2007; &lt;STRONG&gt;13&lt;/STRONG&gt;: 12-6. [&lt;A href="http://cr.rsmjournals.com/cgi/reprint/13/1/12.pdf" target="_blank"&gt;Fulltext pdf from publisher (RSM)&lt;/A&gt;]&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/search_history/EpidemiologySearchHistory.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299437</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=299437]]&gt;</url>
    <title>Glaucoma Annual Evidence Update : 24-30 November 2008 : Evidence Tree</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma Annual Evidence Update : 24-30 November 2008 : Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1108/aeu_glaucoma_1108_doc1.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/topic_trees/EvidenceTree.pdf" target="_blank"&gt;Click here to view PDF&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Evidence Tree for the entire Glaucoma National Knowledge Week&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched: &lt;/STRONG&gt;AMED, BNI, CINAHL, EMBASE, EVSL, PubMed&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; October 2007 - October 2008 &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage5 name=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID299437/nelhImp_0000_evsl_topic_tree_main.jpg"&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>298592</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=298592]]&gt;</url>
    <title>Glaucoma Annual Evidence Update : 24-30 November 2008 : Low Vision and Living With Glaucoma</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma Annual Evidence Update : 24-30 November 2008 : Low Vision and Living With Glaucoma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1108/aeu_glaucoma_1108_doc8.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/topic_trees/livingWith%20_topic_tree.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273476:0" name=internalLink&gt;Click here to view 2007 NKW Living with Glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Low Vision &amp;amp; Living with Glaucoma&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; AMED, BNI, CINAHL, EMBASE, EVSL, PubMed&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; October 2007 - October 2008 &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp;&lt;/EM&gt; &lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID298592/nelhImp_0002_evsl_topic_lglv.jpg"&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Low vision - general&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Girdler S, Packer TL, Boldy D. The impact of age-related vision loss. &lt;EM&gt;OTJR: Occupation, Participation &amp;amp; Health &lt;/EM&gt;2008; &lt;STRONG&gt;28 (Pt 3)&lt;/STRONG&gt;. [&lt;A href="http://www.otjronline.com/view.asp?rID=29410" target="_blank"&gt;Publisher abstract (OTJR)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Living with glaucoma - general&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Janz NK, Wren PA, Guire KE, Musch DC, Gillespie BW, Lichter PR. Fear of blindness in the Collaborative Initial Glaucoma Treatment Study: patterns and correlates over time. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2007; &lt;STRONG&gt;114 (Pt 12)&lt;/STRONG&gt;: 2213-20. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17490746" target="_blank"&gt;PubMed abstract (PM:17490746)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Coleman AL. Sources of binocular suprathreshold visual field loss in a cohort of older women being followed for risk of falls (an American Ophthalmological Society thesis). &lt;EM&gt;Trans Am Ophthalmol Soc &lt;/EM&gt;2007; &lt;STRONG&gt;105&lt;/STRONG&gt;: 312-29. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18427619" target="_blank"&gt;PubMed abstract (PM:18427619)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Friedman DS, Freeman E, Munoz B, Jampel HD, West SK. Glaucoma and mobility performance: the Salisbury Eye Evaluation Project. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2007; &lt;STRONG&gt;114 (Pt 12)&lt;/STRONG&gt;: 2232-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17980433" target="_blank"&gt;PubMed abstract (PM:17980433)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Sharma T, Salmon JF. Ten-year outcomes in newly diagnosed glaucoma patients: mortality and visual function. &lt;EM&gt;Br J Ophthalmol &lt;/EM&gt;2007; &lt;STRONG&gt;91 (Pt 10)&lt;/STRONG&gt;: 1282-4. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17475705" target="_blank"&gt;PubMed abstract (PM:17475705)&lt;/A&gt;]&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Activities of Daily Living&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Kotecha A, O'Leary N, Melmoth D, Grant S, Crabb D. The functional consequences of glaucoma for eye-hand co-ordination. &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2008: epub ahead of print. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18806294" target="_blank"&gt;PubMed abstract (PM:18806294)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Activities of Daily Living - Driving&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Strong JG, Jutai JW, Russell-Minda E, Evans M. Driving and low vision: validity of assessments for predicting performance of drivers. &lt;EM&gt;Journal of Visual Impairment &amp;amp; Blindness&lt;/EM&gt; 2008. [&lt;A href="http://www.afb.org/jvib/jvibabstractNew.asp?articleid=jvib020603" target="_blank"&gt;Publisher abstract (JVIB)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Haymes SA, LeBlanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Glaucoma and on-road driving performance. &lt;EM&gt;Invest Ophthalmol Vis Sci&lt;/EM&gt; 2008; &lt;STRONG&gt;49 (Pt 7)&lt;/STRONG&gt;: 3035-41. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18326696" target="_blank"&gt;PubMed abstract (PM:18326696)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Owen VM, Crabb DP, White ET, Viswanathan AC, Garway-Heath DF, Hitchings RA. Glaucoma and fitness to drive: using binocular visual fields to predict a milestone to blindness. &lt;EM&gt;Invest Ophthalmol Vis Sci&lt;/EM&gt; 2008; &lt;STRONG&gt;49 (Pt 6)&lt;/STRONG&gt;: 2449-55. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18515585" target="_blank"&gt;PubMed abstract (PM:18515585)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Awareness&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Alexander RL, Miller NA, Cotch MF, Janiszewski R. Factors that influence the receipt of eye care. &lt;EM&gt;Am J Health Behav&lt;/EM&gt; 2008; &lt;STRONG&gt;32 (Pt 5)&lt;/STRONG&gt;: 547-56. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18241139" target="_blank"&gt;PubMed abstract (PM: 18241139)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Danesh-Meyer HV, Deva NC, Slight C, Tan YW, Tarr K, Carroll SC, Gamble G. What do people with glaucoma know about their condition?:&amp;nbsp;a comparative cross-sectional incidence and prevalence survey. &lt;EM&gt;Clin Experiment Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;36 (Pt 1)&lt;/STRONG&gt;: 13-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18190599" target="_blank"&gt;PubMed abstract (PM:18190599)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Hennis A, Wu SY, Nemesure B, Honkanen R, Leske MC. Awareness of incident open-angle glaucoma in a population study: the Barbados Eye Studies. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2007; &lt;STRONG&gt;114 (Pt 10)&lt;/STRONG&gt;: 1816-21. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17698198" target="_blank"&gt;PubMed abstract (PM:17698198)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Juzych MS, Randhawa S, Shukairy A, Kaushal P, Gupta A, Shalauta N. Functional health literacy in patients with glaucoma in urban settings. &lt;EM&gt;Arch Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;112 (Pt 5)&lt;/STRONG&gt;: 718-24. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18474786" target="_blank"&gt;PubMed abstract (PM:18474786)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Quality of Life&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Severn P, Fraser S, Finch T, May C. Which quality of life score is best for glaucoma patients and why? &lt;EM&gt;BMC Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;8 (Pt 2)&lt;/STRONG&gt;: online only. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18215284" target="_blank"&gt;PubMed abstract (PM:18215284)&lt;/A&gt;] [&lt;A href="http://www.biomedcentral.com/1471-2415/8/2" target="_blank"&gt;Free fulltext from publisher (doi:10.1186/1471-2415-8-2)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Swamy BN, Cumming RG, Ivers R, Clemson L, Cullen J, Hayes MF, Tanzer M, Mitchell PR. Vision screening for frail older people: a randomized trial. &lt;EM&gt;Br J Ophthalmol &lt;/EM&gt;2008: epub ahead of print. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18614568" target="_blank"&gt;PubMed abstract (PM:18614568)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Aspinall PA, Johnson ZK, Azuara-Blanco A, Montarzino A, Brice R, Vickers A. Evaluation of quality of life and priorities of patients with glaucoma. &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2008; &lt;STRONG&gt;49 (Pt 5)&lt;/STRONG&gt;: 1907-15. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18436824" target="_blank"&gt;PubMed abstract (PM:18436824)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Bechetoille A, Arnould B, Bron A, Baudouin C, Renard JP, Sellem E, Brouquet Y, Denis P, Nordmann JP, Rigeade MC, Bassols A, Benmedjahed K, Guillemin I, Rouland JF. Measurement of health-related quality of life with glaucoma: validation of the Glau-QoL 36-item questionnaire. &lt;EM&gt;Acta Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;86 (Pt 1)&lt;/STRONG&gt;: 71-80. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17725614" target="_blank"&gt;PubMed abstract (PM:17725614)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Esteban JJN, Martinez MS, Navalon PG, Serrano OP, Patino JRC, Puron MEC, Martinez-Vizcaino V. Visual impairment and quality of life: Gender differences in the elderly in Cuenca, Spain. &lt;EM&gt;Qual Life Res&lt;/EM&gt; 2008; &lt;STRONG&gt;17 (Pt 1)&lt;/STRONG&gt;: 37-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18026851" target="_blank"&gt;PubMed abstract (PM: 18026851)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Freeman EE, Munoz B, West SK, Jampel HD, Friedman DS. Glaucoma and quality of life: the Salisbury Eye Evaluation. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;115 (Pt 2)&lt;/STRONG&gt;: 233-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17655930" target="_blank"&gt;PubMed abstract (PM:17655930)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Janz NK, Wren PA, Guire KE, Musch DC, Gillespie BW, Lichter PR. Fear of blindness in the Collaborative Initial Glaucoma Treatment Study: patterns and correlates over time. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2007; &lt;STRONG&gt;114 (Pt 12)&lt;/STRONG&gt;: 2213-20. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17490746" target="_blank"&gt;PubMed abstract (PM:17490746)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Kean-Cowdin R, Wang Y, Wu J, Azen SP, Varma R. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;115 (Pt 6)&lt;/STRONG&gt;: 941-948 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17997485" target="_blank"&gt;PubMed abstract (PM:17997485)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Lamoureux EL, Chong E, Wang JJ, Saw SM, Aung T, Mitchell P, Wong TY. Visual impairment, causes of vision loss, and falls: the Singapore Malay Eye Study. &lt;EM&gt;Invest Ophthalmol Vis Sci&lt;/EM&gt; 2008; &lt;STRONG&gt;49 (Pt 2)&lt;/STRONG&gt;: 528-33. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18234995" target="_blank"&gt;PubMed abstract (PM:18234995)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Lee BS, Kymes SM, Nease RF, Sumner W, Siegfried CJ, Gordon MO. The impact of anchor point on utilities for 5 common ophthalmic diseases. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;115 (Pt 5)&lt;/STRONG&gt;: 898-903. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17826833" target="_blank"&gt;PubMed abstract (PM:17826833)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Muir KW, Santiago-Turla C, Stinnett SS, Herndon LW, Allingham RR, Challa P, Lee PP. Health literacy and vision-related quality of life. &lt;EM&gt;Br J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;92 (Pt 6)&lt;/STRONG&gt;: 779-82. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18460538" target="_blank"&gt;PubMed abstract (PM:18460538)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Skalicky S, Goldberg I. Depression and quality of life in patients with glaucoma: a cross-sectional analysis using the Geriatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15. &lt;EM&gt;J Glaucoma&lt;/EM&gt; 2008; &lt;STRONG&gt;17 (Pt 7)&lt;/STRONG&gt;: 546-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18854731" target="_blank"&gt;PubMed abstract (PM:18854731)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Thygesen J, Aagren M, Arnavielle S, Bron A, Frohlich SJ, Baggesen K, Azuara-Blanco A, Buchholz P, Walt JG. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. &lt;EM&gt;Curr Med Res Opin &lt;/EM&gt;2008; &lt;STRONG&gt;24 (Pt 6)&lt;/STRONG&gt;: 1763-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18559164" target="_blank"&gt;PubMed abstract (PM:18559164)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Wu SY, Hennis A, Nemesure B, Leske MC. Impact of glaucoma, lens opacities, and cataract surgery on visual functioning and related quality of life: the Barbados Eye Studies. &lt;EM&gt;Invest Ophthalmol Vis Sci&lt;/EM&gt; 2008; &lt;STRONG&gt;49 (Pt 4)&lt;/STRONG&gt;: 1333-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18385046" target="_blank"&gt;PubMed abstract (PM:18385046)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Adherence to treatment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Ashaye AO, Adeoye AO. Characteristics of patients who dropout from a glaucoma clinic. &lt;EM&gt;J Glaucoma &lt;/EM&gt;2008; &lt;STRONG&gt;17 (Pt 3)&lt;/STRONG&gt;: 227-32. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18414110" target="_blank"&gt;PubMed abstract (PM:18414110)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Friedman DS, Hahn SR, Gelb L, Tan J, Shah SN, Kim EE, Zimmerman TJ, Quigley HA. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;115 (Pt 8)&lt;/STRONG&gt;: 1320-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18321582" target="_blank"&gt;PubMed abstract (PM: 18321582)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Kholdebarin R, Campbell RJ, Jin Y, Buys YM, Beiko G, Birt C, Damji K, Feldman F, Lajaoie C, Kulkarni S, Martow J, Sakamoto T, Spencer J, Trope GE. Multicenter study of compliance and drop administration in glaucoma. &lt;EM&gt;Can J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;43 (Pt 4)&lt;/STRONG&gt;: 454-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18711461" target="_blank"&gt;PubMed abstract (PM: 18711461)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. &lt;EM&gt;Eye &lt;/EM&gt;2008: epub ahead of print. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18437182" target="_blank"&gt;PubMed abstract (PM:18437182)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;A href="http://www.afb.org/jvib/jvibabstractNew.asp?articleid=JVIB000905" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/search_history/LivingWithSearchHistory.pdf" target="_blank"&gt;Click here to view search strategy &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>298633</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=298633]]&gt;</url>
    <title>Glaucoma Annual Evidence Update : 24-30 November 2008 : Medical Management</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma Annual Evidence Update : 24-30 November 2008 : Medical Management&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1108/aeu_glaucoma_1108_doc4.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/topic_trees/medicalManagement_topic_tree.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273514:0" name=internalLink&gt;Click here to view 2007 NKW Medical Management section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Medical Management&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; AMED, BNI, CINAHL, EMBASE, EVSL, PubMed&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; Ovtober 2007 - October 2008&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp;&lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications &lt;/STRONG&gt;include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies &lt;/STRONG&gt;include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies &lt;/STRONG&gt;include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 name=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID298633/nelhImp_0001_evsl_topic_mm.jpg"&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Lee CW, Buckley F, Costello S, Kelly S. A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma. &lt;EM&gt;Curr Med Res Opin&lt;/EM&gt; 2008; &lt;STRONG&gt;24 (Pt 8)&lt;/STRONG&gt;: 2265-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18582396" target="_blank"&gt;PubMed abstract (PM:18582396)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Macleod SM, Clark R, Forrest J, Bain M, Bateman N, Azuara-Blanco A. A review of glaucoma treatment in Scotland 1994-2004. &lt;EM&gt;Eye&lt;/EM&gt; 2008; &lt;STRONG&gt;22 (Pt 2)&lt;/STRONG&gt;: 251-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17001326" target="_blank"&gt;PubMed abstract (PM:17001326)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;115 (Pt 7)&lt;/STRONG&gt;: 1117-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18082886" target="_blank"&gt;PubMed abstract (PM:18082886)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Martikainen JE, Hakkinen U, Enlund H. Adoption of new antiglaucoma drugs in Finland: impact of changes in copayment. &lt;EM&gt;Clin Ther&lt;/EM&gt; 2007; &lt;STRONG&gt;29 (Pt 11)&lt;/STRONG&gt;: 2468-76. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18158088" target="_blank"&gt;PubMed abstract (PM:18158088)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;McCarty CA, Mukesh BN, Kitchner TE, Hubbard WC, Wilke RA, Burmester JK, Patchett RB. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project. &lt;EM&gt;J Glaucoma&lt;/EM&gt; 2008; &lt;STRONG&gt;17 (Pt 5)&lt;/STRONG&gt;: 372-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18703947" target="_blank"&gt;PubMed abstract (PM:18703947)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Monotherapy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Loon SC, Liew G, Fung A, Reid SE, Craig JC. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. &lt;EM&gt;Clin Experiment Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;36 (Pt 3)&lt;/STRONG&gt;: 281-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18412600" target="_blank"&gt;PubMed abstract (PM:18412600)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Interventional studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Cantor LB, Safyan E, Liu CC, Batoosingh AL. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. &lt;EM&gt;Curr Med Res Opin &lt;/EM&gt;2008; &lt;STRONG&gt;24 (Pt 7)&lt;/STRONG&gt;: 2035-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18534052" target="_blank"&gt;PubMed abstract (PM:18534052)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prostaglandin Analogues&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Hodge WG, Lachaine J, Steffensen I, Murray C, Barnes D, Foerster V, Ducruet T, Morrison A. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. &lt;EM&gt;Br J Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;92 (Pt 1)&lt;/STRONG&gt;: 7-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18156371" target="_blank"&gt;PubMed abstract (PM:18156371)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Teus MA, Arranz-Marquez E. Prostaglandin F2alpha analogues in glaucoma management. &lt;EM&gt;Expert Rev Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;3 (Pt 2)&lt;/STRONG&gt;: 203-9 [&lt;A href="http://www.expert-reviews.com/doi/abs/10.1586/17469899.3.2.203" target="_blank"&gt;Publisher abstract (Expert Rev Ophthalmol)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Ang GS, Kersey JP, Shepstone L, Broadway DC. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial. &lt;EM&gt;Br J Ophthalmol&lt;/EM&gt;&amp;nbsp;2008; &lt;STRONG&gt;92 (Pt 8)&lt;/STRONG&gt;: 1129-33. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18511540" target="_blank"&gt;PubMed abstract (PM:18511540)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI. Duration of IOP reduction with travoprost BAK-free solution. &lt;EM&gt;J Glaucoma &lt;/EM&gt;2008; &lt;STRONG&gt;17 (Pt 3)&lt;/STRONG&gt;: 217-22. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18414108" target="_blank"&gt;PubMed abstract (PM:18414108)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Sharpe ED, Williams RD, Stewart JA, Nelson LA, Stewart WC. A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. &lt;EM&gt;J Ocul Pharmacol Ther&lt;/EM&gt; 2008; &lt;STRONG&gt;24 (Pt 4)&lt;/STRONG&gt;: 408-13. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18627340" target="_blank"&gt;PubMed abstract (PM: 18627340)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Brasnu E, Brignole-Baudouin F, Riancho L, Guenoun JM, Warnet JM, Baudouin C. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. &lt;EM&gt;Curr Eye Res &lt;/EM&gt;2008; &lt;STRONG&gt;33 (Pt 4)&lt;/STRONG&gt;: 303-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18398704" target="_blank"&gt;PubMed abstract (PM:18398704)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Combination therapy&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. &lt;EM&gt;Drugs &amp;amp; Aging &lt;/EM&gt;2007; &lt;STRONG&gt;24 (Pt 12)&lt;/STRONG&gt;: 1007-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18020533" target="_blank"&gt;PubMed abstract (PM: 18020533)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Combination vs monotherapy and fixed combination&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure:&amp;nbsp;a systematic review. &lt;EM&gt;Br J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;92 (Pt 6)&lt;/STRONG&gt;: 729-34. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18460539" target="_blank"&gt;PubMed abstract (PM: 18460539)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Denis P, Le Pen C, Umuhire D, Berdeaux G. Treatment carryover impacts on effectiveness of intraocular pressure lowering agents, estimated by a discrete event simulation model. &lt;EM&gt;Eur J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;18 (Pt 1)&lt;/STRONG&gt;: 44-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18203084" target="_blank"&gt;PubMed abstract (PM:18203084)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Herceg M, Noecker R. Travoprost/timolol fixed combination. &lt;EM&gt;Expert Opin Pharmacother &lt;/EM&gt;2008; &lt;STRONG&gt;9 (Pt 6)&lt;/STRONG&gt;: 1059-65. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18377347" target="_blank"&gt;PubMed abstract (PM:18377347)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I.&amp;nbsp;Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. &lt;EM&gt;J Glaucoma&lt;/EM&gt; 2008; &lt;STRONG&gt;17 (Pt 3)&lt;/STRONG&gt;: 211-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18414107" target="_blank"&gt;PubMed abstract (PM:18414107)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Feldman RM, Stewart RH, Stewart WC, Jia G, Smugar SS, Galet VA. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma. &lt;EM&gt;Curr Med Res Opin &lt;/EM&gt;2008; &lt;STRONG&gt;24 (Pt 8)&lt;/STRONG&gt;: 2403-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18627642" target="_blank"&gt;PubMed abstract (PM:18627642)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Kaback M, Scoper SV, Arzeno G, James JE, Hua SY, Salem C, Dickerson JE, Landry TA, Bergamini MV. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2008; &lt;STRONG&gt;115 (Pt 10)&lt;/STRONG&gt;: 1728-34. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18538406" target="_blank"&gt;PubMed abstract (PM:18538406)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Rossetti L, Karabatsas CH, Topouzis F, Vetrugno M, Centofanti M, Boehm A, Viswanathan A, Vorwerk C, Goldblum D. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2007; &lt;STRONG&gt;114 (Pt 12)&lt;/STRONG&gt;: 2244-51. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17459480" target="_blank"&gt;PubMed abstract (PM:17459480)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. &lt;EM&gt;Br J Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;92 (Pt 10)&lt;/STRONG&gt;: 1387-92. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18621791" target="_blank"&gt;PubMed abstract (PM:18621791)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;van der Valk R, Webers CA, Hendrikse F, de Vogel SC, Prins MH, Schouten JS. Predicting intraocular pressure change before initiating therapy: timolol versus latanoprost. &lt;EM&gt;Acta Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;86 (Pt 4)&lt;/STRONG&gt;: 415-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18028236" target="_blank"&gt;PubMed abstract (PM:18028236)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Side effects, safety and stability, efficacy &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Trattler W, Noecker RJ, Earl ML. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension. &lt;EM&gt;Adv Ther&lt;/EM&gt; 2008; &lt;STRONG&gt;25 (Pt 3)&lt;/STRONG&gt;: 179-89. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18351298" target="_blank"&gt;PubMed abstract (PM:18351298)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. &lt;EM&gt;Acta Ophthalmol &lt;/EM&gt;2008: epub ahead of print. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18537937" target="_blank"&gt;PubMed abstract (PM:18537937)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Beckers HJM, Schouten JSAG, Webers CAB, Valk R, Hendrikse F. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. &lt;EM&gt;Graefes Arch Clin Exp Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;246 (Pt 10)&lt;/STRONG&gt;: 1485-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18575878" target="_blank"&gt;PubMed abstract (PM: 18575878)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Goldberg I, Li XY, Selaru P, Paggiarino D. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. &lt;EM&gt;Eur J Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;18 (Pt 3)&lt;/STRONG&gt;: 408-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18465724" target="_blank"&gt;PubMed abstract (PM:18465724)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Kashkouli MB, Rezaee R, Nilforoushan N, Salimi S, Foroutan A, Naseripour M. Topical antiglaucoma medications and lacrimal drainage system obstruction. &lt;EM&gt;Ophthal Plast Reconstr Surg &lt;/EM&gt;2008; &lt;STRONG&gt;24 (Pt 3)&lt;/STRONG&gt;: 172-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18520829" target="_blank"&gt;PubMed abstract (PM:18520829)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. &lt;EM&gt;J Glaucoma &lt;/EM&gt;2008; &lt;STRONG&gt;17 (Pt 5)&lt;/STRONG&gt;: 350-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18703943" target="_blank"&gt;PubMed abstract (PM:18703943)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Seider N, Miller B, Beiran I. Topical glaucoma therapy as a risk factor for nasolacrimal duct obstruction. &lt;EM&gt;Am J Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;145 (Pt 1)&lt;/STRONG&gt;: 120-3. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17915187" target="_blank"&gt;PubMed abstract (PM:17915187)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Long-term effects of treatment&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Wu SY, Nemesure B, Hennis A, Schachat AP, Hyman L, Leske MC. Open-angle glaucoma and mortality: the Barbados Eye Studies. &lt;EM&gt;Arch Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;126 (Pt 3)&lt;/STRONG&gt;: 365-70. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18332317" target="_blank"&gt;PubMed abstract (PM:18332317)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Xu L, Wang YX, Jonas JB. Glaucoma and mortality in the Beijing Eye Study. &lt;EM&gt;Eye &lt;/EM&gt;2008; &lt;STRONG&gt;22 (Pt 3)&lt;/STRONG&gt;: 434-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18188176" target="_blank"&gt;PubMed abstract (PM:18188176)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cost effectiveness/implications to the health service&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Hommer A, Thygesen J, Ferreras A, Wickstrom J, Friis MM, Buchholz P, Walt JG. A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma. &lt;EM&gt;Eur J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;18 (Pt 5)&lt;/STRONG&gt;: 778-86. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18850558" target="_blank"&gt;PubMed abstract (PM:18850558)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Schmier JK, Covert DW, Robin AL. Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective. &lt;EM&gt;Curr Med Res Opin &lt;/EM&gt;2007; &lt;STRONG&gt;23 (Pt 11)&lt;/STRONG&gt;: 2867-75. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17922980" target="_blank"&gt;PubMed abstract (PM:17922980)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Hommer A, Wickstrom J, Friis MM, Steeds C, Thygesen J, Ferreras A, Gouws P, Buchholz P. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective. &lt;EM&gt;Curr Med Res Opin &lt;/EM&gt;2008; &lt;STRONG&gt;24 (Pt 4)&lt;/STRONG&gt;: 1057-63. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18315942" target="_blank"&gt;PubMed abstract (PM:18315942)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Iskedjian M, Walker JH, Desjardins O, Covert D, Einarson TR. Cost comparison of prostaglandin analogues:&amp;nbsp;a Canadian population-based analysis. &lt;EM&gt;J Med Econ &lt;/EM&gt;2008; &lt;STRONG&gt;11 (Pt 2)&lt;/STRONG&gt;: 299-310. [&lt;A href="http://www.pjbpubs.com/cms.asp?pageid=2772#299-310" target="_blank"&gt;Publisher abstract (J Med Econ)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Lachaine J, Hodge WG, Steffensen I, Murray C, Barnes D, Foerster V, Ducruet T, Mensinkai S. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. &lt;EM&gt;Can J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;43 (Pt 1)&lt;/STRONG&gt;: 33-41. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18219345" target="_blank"&gt;PubMed abstract (PM:18219345)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Lafuma A, Berdeaux G. Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database. &lt;EM&gt;Curr Med Res Opin&lt;/EM&gt; 2007; &lt;STRONG&gt;23 (Pt 12)&lt;/STRONG&gt;: 3009-16. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17958945" target="_blank"&gt;PubMed abstract (PM:17958945)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Martikainen JE, Hakkinen U, Enlund H. Adoption of new antiglaucoma drugs in Finland: impact of changes in copayment. &lt;EM&gt;Clin Ther &lt;/EM&gt;2007; &lt;STRONG&gt;29 (Pt 11)&lt;/STRONG&gt;: 2468-76. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18158088" target="_blank"&gt;PubMed abstract (PM:18158088)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Payet S, Denis P, Berdeaux G, Launois R. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France. &lt;EM&gt;Clin Drug Investig &lt;/EM&gt;2008; &lt;STRONG&gt;28 (Pt 3)&lt;/STRONG&gt;: 183-98. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18266403" target="_blank"&gt;PubMed abstract (PM:18266403)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Rylander NR, Vold SD. Cost analysis of glaucoma medications. &lt;EM&gt;Am J Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;145 (Pt 1)&lt;/STRONG&gt;: 106-13. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18154755" target="_blank"&gt;PubMed abstract (PM:18154755)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Stewart WC, Stewart JA, Nasser QJ, Mychaskiw MA. Cost-effectiveness of treating ocular hypertension. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2008; &lt;STRONG&gt;115 (Pt 1)&lt;/STRONG&gt;: 94-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18166406" target="_blank"&gt;PubMed abstract (PM:18166406)&lt;/A&gt;]&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/search_history/MedicalManagement.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents&lt;/A&gt; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299316</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=299316]]&gt;</url>
    <title>Glaucoma Annual Evidence Update : 24-30 November 2008 : Optic Disc Imaging</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma Annual Evidence Update : 24-30 November 2008 : Optic Disc Imaging&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1108/aeu_glaucoma_1108_doc5.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/topic_trees/odi_topic_tree.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273534:0" name=internalLink&gt;Click here to view 2007 Optic Disc Imaging section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Optic Disc Imaging&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt;&amp;nbsp;AMED, BNI, CINAHL, EMBASE, EVSL, PubMed&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; October 2007 - October 2008&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp;&lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 name=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID299316/nelhImp_0000_evsl_topic_odi.jpg"&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Garway-Heath DF. Correlation of visual changes with disc morphology. &lt;EM&gt;Eye&lt;/EM&gt; 2007; &lt;STRONG&gt;21&lt;/STRONG&gt;: S29-S33. [&lt;A href="http://www.nature.com/eye/journal/v21/n1s/full/6702885a.html" target="_blank"&gt;Publisher abstract&amp;nbsp;(Eye)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Greenfield DS, Weinreb RN. Role of optic nerve imaging in glaucoma clinical practice and clinical trials. &lt;EM&gt;Am J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;145 (Pt 4)&lt;/STRONG&gt;: 598-603. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18295183" target="_blank"&gt;PubMed abstract (PM:18295183)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Lin SC, Singh K, Jampel HD, Hodapp EA, Smith SD, Francis BA, Dueker DK, Fechtner RD, Samples JS, Schuman JS, Minckler DS. Optic nerve head and retinal nerve fiber layer analysis: a report by the American Academy of Ophthalmology. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2007; &lt;STRONG&gt;114 (Pt 10)&lt;/STRONG&gt;: 193-49. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17908595" target="_blank"&gt;PubMed abstract (PM:17908595)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Gordon-Bennett PS, Ioannidis AS, Papageorgiou K, Andreou PS. A survey of investigations used for the management of glaucoma in hospital service in the United Kingdom. &lt;EM&gt;Eye&lt;/EM&gt; 2008; &lt;STRONG&gt;22 (Pt 11)&lt;/STRONG&gt;: 1410-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18219340" target="_blank"&gt;PubMed abstract (PM:18219340)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Halkiadakis I, Kipioti A, Emfietzoglou I, Grigoropoulos V, Katsis A, Alimisi S, Vergados I, Theodossiadis P, Theodossiadis GP. Comparison of optical coherence tomography and scanning laser polarimetry in glaucoma, ocular hypertension, and suspected glaucoma. &lt;EM&gt;Ophthalmic Surg Lasers Imaging&lt;/EM&gt; 2008; &lt;STRONG&gt;39 (Pt 2)&lt;/STRONG&gt;: 125-32. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18435336" target="_blank"&gt;PubMed abstract (PM:18435336)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Leung CK, Cheung CY, Lin DS, Pang CP, Lam DS, Weinreb RN. Longitudinal variability of optic disc and retinal nerve fiber layer measurements. &lt;EM&gt;Invest Ophthalmol Vis Sci&lt;/EM&gt; 2008; &lt;STRONG&gt;49 (Pt 11)&lt;/STRONG&gt;: 4886-92. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18539940" target="_blank"&gt;PubMed abstract (PM:18539940)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OCT (Optical Coherence Tomography)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Chang R, Budenz DL. New developments in optical coherence tomography for glaucoma. &lt;EM&gt;Curr Opin Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;19 (Pt 2)&lt;/STRONG&gt;: 127-35. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18301286" target="_blank"&gt;PubMed abstract (PM:18301286)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Brusini P, Zeppieri M, Tosoni C, Parisi L, Felletti M, Salvetat ML. Stratus-OCT imaging in early glaucomatous and in ocular hypertensive patients with and without frequency-doubling technology abnormalities. &lt;EM&gt;Eye&lt;/EM&gt; 2008; &lt;STRONG&gt;22 (Pt 3)&lt;/STRONG&gt;: 406-13. [P&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17304263" target="_blank"&gt;ubMed abstract (PM:17304263)&lt;/A&gt;]&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Tzamalis A, Kynigopoulos M, Schlote T, Haefliger I. Improved reproducibility of retinal nerve fiber layer thickness measurements with the repeat-scan protocol using the Stratus OCT in normal and glaucomatous eyes. &lt;EM&gt;Graefes Arch Clin Exp Ophthalmol&lt;/EM&gt; 2008: epub ahead of print. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18810480" target="_blank"&gt;PubMed abstract (PM:18810480)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HRT (Heidelberg Retinal Tomography)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary Publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Siam GA, Gheith ME, de Barros DS, Lin AP, Moster MR. Limitations of the Heidelberg retina tomograph. &lt;EM&gt;Ophthalmic Surg Lasers Imaging&lt;/EM&gt; 2008; &lt;STRONG&gt;39 (Pt 3)&lt;/STRONG&gt;: 262-4 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18556958" target="_blank"&gt;PubMed abstract (PM:18556958)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Strouthidis NG, Garway-Heath DF. New developments in Heidelberg retina tomograph for glaucoma. &lt;EM&gt;Curr Opin Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;19 (Pt 2)&lt;/STRONG&gt;: 141-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18301288" target="_blank"&gt;PubMed abstract (PM:18301288)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Bergin C, Garway-Heath DF, Crabb DP. Evaluating the effect of the new alignment algorithm for longitudinal series of Heidelberg retina tomography images. &lt;EM&gt;Acta Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;86 (Pt 2)&lt;/STRONG&gt;: 207-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17986295" target="_blank"&gt;PubMed abstract (PM:17986295)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Fayers T, Strouthidis NG, Garway-Heath DF. Monitoring glaucomatous progression using a novel Heidelberg Retina Tomograph event analysis. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2007; &lt;STRONG&gt;114 (Pt 11)&lt;/STRONG&gt;: 1973-80. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17662455" target="_blank"&gt;PubMed abstract (PM:17662455)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Ferreras A, Pablo LE, Larrosa JM, Polo V, Pajarin AB, Honrubia FM. Discriminating between normal and glaucoma-damaged eyes with the Heidelberg Retina Tomograph 3. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2008; &lt;STRONG&gt;115 (Pt 5)&lt;/STRONG&gt;: 775-781. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17870171" target="_blank"&gt;PubMed abstract (PM:17870171)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Ferreras A, Pablo LE, Pajarin AB, Larrosa JM, Polo V, Pueyo V. Diagnostic ability of the Heidelberg Retina Tomograph 3 for glaucoma. &lt;EM&gt;Am J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;145 (Pt 2)&lt;/STRONG&gt;: 354-359. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18078851" target="_blank"&gt;PubMed abstract (PM:18078851)]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gabriele ML, Wollstein G, Bilonick RA, Burgansky-Eliash Z, Ishikawa H, Kagemann LE, Schuman JS. Comparison of parameters from Heidelberg Retina Tomographs 2 and 3. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2008; &lt;STRONG&gt;115 (Pt 4)&lt;/STRONG&gt;: 673-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17719642" target="_blank"&gt;PubMed abstract (PM:17719642)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Oddone F, Centofanti M, Rossetti L, Iester M, Fogagnolo P, Capris E, Manni G. Exploring the Heidelberg Retinal Tomograph 3 diagnostic accuracy across disc sizes and glaucoma stages: a multicenter study. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2008; &lt;STRONG&gt;115 (Pt 8)&lt;/STRONG&gt;: 1358-65. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18321579" target="_blank"&gt;PubMed abstract (PM:18321579)]&amp;nbsp;&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;GdX (Nerve Fibre Analyser)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Lemij HG, Reus NJ. New developments in scanning laser polarimetry for glaucoma. &lt;EM&gt;Curr Opin Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;19 (Pt 2)&lt;/STRONG&gt;: 136-40. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18301287" target="_blank"&gt;PubMed abstract (PM:18301287)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Paranjothy B, Shunmugam M, Azuara-Blanco A. The quality of reporting of diagnostic accuracy studies in glaucoma using scanning laser polarimetry. &lt;EM&gt;J Glaucoma&lt;/EM&gt; 2007; &lt;STRONG&gt;16 (Pt 8)&lt;/STRONG&gt;: 670-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18091453" target="_blank"&gt;PubMed abstract (PM:18091453)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Baraibar B, Sanchez-Cano A, Pablo LE, Honrubia FM. Preperimetric glaucoma assessment with scanning laser polarimetry (GDx VCC): analysis of retinal nerve fiber layer by sectors. &lt;EM&gt;J Glaucoma&lt;/EM&gt; 2007; &lt;STRONG&gt;16 (Pt 8)&lt;/STRONG&gt;: 659-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18091451" target="_blank"&gt;PubMed abstract (PM:18091451)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Ferreras A, Pablo LE, Pajarin AB, Garcia-Feijoo J, Honrubia FM. Scanning laser polarimetry: logistic regression analysis for perimetric glaucoma diagnosis. &lt;EM&gt;Eye &lt;/EM&gt;2008: epub ahead of print. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18309332" target="_blank"&gt;PubMed abstract (PM:18309332)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Medeiros FA, Bowd C, Zangwill LM, Patel C, Weinreb RN. Detection of glaucoma using scanning laser polarimetry with enhanced corneal compensation. &lt;EM&gt;Invest Ophthalmol Vis Sci&lt;/EM&gt; 2007; &lt;STRONG&gt;48 (Pt 7)&lt;/STRONG&gt;: 3146-53. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17591884" target="_blank"&gt;PubMed abstract (PM: 17591884)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Medeiros FA, Vizzeri G, Zangwill LM, Alencar LM, Sample PA, Weinreb RN. Comparison of retinal nerve fiber layer and optic disc imaging for diagnosing glaucoma in patients suspected of having the disease. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2008; &lt;STRONG&gt;115 (Pt 8)&lt;/STRONG&gt;: 1340-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18207246" target="_blank"&gt;PubMed abstract (PM:18207246)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Comparisons of types of imaging&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Badala F, Nouri-Mahdavi K, Raoof DA, Leeprechanon N, Law SK, Caprioli J. Optic disk and nerve fiber layer imaging to detect glaucoma. &lt;EM&gt;Am J Ophthalmol&lt;/EM&gt; 2007; &lt;STRONG&gt;144 (Pt 5)&lt;/STRONG&gt;: 724-32. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17868631" target="_blank"&gt;PubMed abstract (PM:17868631)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Bozkurt B, Yilmaz PT, Irkec M. Relationship between Humphrey 30-2 SITA Standard Test, Matrix 30-2 threshold test, and Heidelberg retina tomograph in ocular hypertensive and glaucoma patients. &lt;EM&gt;J Glaucoma&lt;/EM&gt; 2008; &lt;STRONG&gt;17 (Pt 3)&lt;/STRONG&gt;: 203-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18414106" target="_blank"&gt;PubMed abstract (PM:18414106)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Assessing photographs&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Jampel HD, Friedman D, Quigley H, Vitale S, Miller R, Knezevich F, Ding Y. Agreement among glaucoma specialists in assessing progressive disc changes from photographs in open-angle glaucoma patients. &lt;EM&gt;Am J Ophthalmol&lt;/EM&gt; 2008: epub ahead of print. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18790472" target="_blank"&gt;PubMed abstract (PM:18790472)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Lehmann MV, Mardin CY, Martus P, Bergua A. 3D vs 2D qualitative and semiquantitative evaluation of the glaucomatous optic disc atrophy using computer-assisted stereophotography. &lt;EM&gt;Eye&lt;/EM&gt; 2008; &lt;STRONG&gt;22 (Pt 5)&lt;/STRONG&gt;: 628-35. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17401328" target="_blank"&gt;PubMed abstract (PM:17401328)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/search_history/OpticDiscImaging.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299251</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=299251]]&gt;</url>
    <title>Glaucoma Annual Evidence Update : 24-30 November 2008 : Patient Education</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma Annual Evidence Update : 24-30 November 2008 : Patient Education&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1108/aeu_glaucoma_1108_doc6.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/topic_trees/pe_topic_tree.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273482:0" name=internalLink&gt;Click here to view 2007 NKW Patient Education section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Education &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&amp;nbsp;&lt;/STRONG&gt;AMED, BNI, CINAHL, EMBASE, EVSL, PubMEd&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; October 2007 - October 2008&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp; &lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage3 name=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID299251/nelhImp_0001_evsl_topic_pe.jpg"&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;STRONG&gt;Awareness&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;Alexander RL, Miller NA, Cotch MF, Janiszewski R. Factors that influence the receipt of eye care. &lt;EM&gt;Am J Health Behav&lt;/EM&gt; 2008; &lt;STRONG&gt;32 (Pt 5)&lt;/STRONG&gt;: 547-56. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18241139" target="_blank"&gt;PubMed abstract (PM:18241139)&lt;/A&gt;]&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;Danesh-Meyer HV, Deva NC, Slight C, Tan YW, Tarr K, Carroll SC, Gamble G. What do people with glaucoma know about their condition?:&amp;nbsp;a comparative cross-sectional incidence and prevalence survey. &lt;EM&gt;Clin Experiment Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;36 (Pt 1)&lt;/STRONG&gt;: 13-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18190599" target="_blank"&gt;PubMed abstract (PM:18190599)&lt;/A&gt;]&lt;/P&gt;
&lt;P align=left&gt;Juzych MS, Randhawa S, Shukairy A, Kaushal P, Gupta A, Shalauta N.&amp;nbsp;Functional health literacy in patients with glaucoma in urban settings. &lt;EM&gt;Arch Ophthalmol &lt;/EM&gt;2008; &lt;STRONG&gt;126 (Pt 5)&lt;/STRONG&gt;: 718-24. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18474786" target="_blank"&gt;PubMed abstract (PM:18474786)&lt;/A&gt;]&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Adherence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies &lt;/STRONG&gt;&lt;/EM&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Friedman DS, Quigley HA, Gelb L, Tan J, Margolis J, Shah SN, Kim EE, Zimmerman T, Hahn SR. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). &lt;EM&gt;Invest Ophthalmol Vis Sci &lt;/EM&gt;2007; &lt;STRONG&gt;48 (Pt 11)&lt;/STRONG&gt;: 5052-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17962457" target="_blank"&gt;PubMed abstract (PM:17962457)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. &lt;EM&gt;Can J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;43 (Pt 4)&lt;/STRONG&gt;: 454-61. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18711461" target="_blank"&gt;PubMed abstract (PM:18711461)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/search_history/PatientEducation.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents page&amp;nbsp;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>299273</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=299273]]&gt;</url>
    <title>Glaucoma Annual Evidence Update : 24-30 November 2008 : Screening</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma Annual Evidence Update : 24-30 November 2008 : Screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/aeu_glaucoma_1108/aeu_glaucoma_1108_doc3.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/topic_trees/screening_topic_tree.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt; &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273499:0" name=internalLink&gt;Click here to view 2007 NKW Screening section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&amp;nbsp;&lt;/STRONG&gt;AMED, BNI, CINAHL, EMBASE, EVSL, PubMed&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; October 2007 - October 2008&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp; &lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage4 name=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID299273/nelhImp_0000_evsl_topic_screening.jpg"&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Burr JM, Mowatt G, Hernandez R, Siddiqui MAR, Cook J, Lourenco T, Ramsay C, Vale L, Fraser C, Azuara-Blanco A, Deeks J, Cairns J, Wormald R, McPherson S, Rabindranath K, Grant A. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. &lt;EM&gt;Health Technol Assess &lt;/EM&gt;2007; &lt;STRONG&gt;11 (Pt 41)&lt;/STRONG&gt;: 1-190. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17927922" target="_blank"&gt;PubMed abstract (PM: 17927922)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Mowatt G, Burr JM, Cook JA, Siddiqui MA, &amp;nbsp;Ramsay CR, Fraser C, Azuara-Blanco A, Deeks JJ. Screening tests for detecting open angle glaucoma: systematic review and meta-analysis. &lt;EM&gt;Invest Ophthalmol Vis Sci&lt;/EM&gt; 2008: epub ahead of print. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18614810" target="_blank"&gt;PubMed abstract (PM:18614810)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Stoutenbeek R, de Voogd S, Wolfs RC, Hofman A, de Jong PT, Jansonius NM. The additional yield of a periodic screening programme for open-angle glaucoma: a population-based comparison of incident glaucoma cases detected in regular ophthalmic care with cases detected during screening. &lt;EM&gt;Br J Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;92 (Pt 9)&lt;/STRONG&gt;: 1222-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18723743" target="_blank"&gt;PubMed abstract (PM:18723743)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Structural OCT&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Nouri-Mahdavi K, Nikkhou K, Hoffman DC, Law SK, Caprioli J. Detection of early glaucoma with optical coherence tomography (StratusOCT). &lt;EM&gt;J Glaucoma&lt;/EM&gt; 2008; &lt;STRONG&gt;17 (Pt 3):&lt;/STRONG&gt; 183-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18414102" target="_blank"&gt;PubMed abstract (PM: 18414102)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Parikh RS, Parikh S, Sekhar GC, Kumar RS, Prabakaran S, Babu JG, Thomas R. Diagnostic capability of optical coherence tomography (Stratus OCT 3) in early glaucoma. &lt;EM&gt;Ophthalmology &lt;/EM&gt;2007; &lt;STRONG&gt;114 (Pt 12):&lt;/STRONG&gt; 2238-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17561260" target="_blank"&gt;PubMed abstract (PM:17561260)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Structural ONH (optic nerve head) assessment&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Alencar LM, Bowd C, Weinreb RN, Zangwill LM, Sample PA, Medeiros FA. Comparison of HRT-3 glaucoma probability score and subjective stereophotograph assessment for prediction of progression in glaucoma. &lt;EM&gt;Invest Ophthalmol Vis Sci&lt;/EM&gt; 2008; &lt;STRONG&gt;49 (Pt 5):&lt;/STRONG&gt; 1898-906. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18436823" target="_blank"&gt;PubMed abstract (PM:18436823)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Bergin C, Garway-Heath DF, Crabb DP. Evaluating the effect of the new alignment algorithm for longitudinal series of Heidelberg retina tomography images. &lt;EM&gt;Acta Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;86 (Pt 2)&lt;/STRONG&gt;: 207-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17986295" target="_blank"&gt;PubMed abstract (PM:17986295)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Ferreras A, Pablo LE, Larrosa JM, Polo V, Pajarin AB, Honrubia FM. Discriminating between normal and glaucoma-damaged eyes with the Heidelberg Retina Tomograph 3. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2008; &lt;STRONG&gt;115 (Pt 5)&lt;/STRONG&gt;: 775-781. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17870171" target="_blank"&gt;PubMed abstract (PM:17870171)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Khouri AS, Szirth BC, Shahid KS, Fechtner RD. Software-assisted optic nerve assessment for glaucoma tele-screening. &lt;EM&gt;Telemed J E Health&lt;/EM&gt; 2008; &lt;STRONG&gt;14 (Pt 3)&lt;/STRONG&gt;: 261-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18570550" target="_blank"&gt;PubMed abstract (PM:18570550)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Structural GDx&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Parikh RS, Parikh SR, Kumar RS, Prabakaran S, Babu JG, Thomas R. Diagnostic capability of scanning laser polarimetry with variable cornea compensator in Indian patients with early primary open-angle glaucoma. &lt;EM&gt;Ophthalmology&lt;/EM&gt; 2008; &lt;STRONG&gt;115 (Pt 7)&lt;/STRONG&gt;: 1167-1172. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18061269" target="_blank"&gt;PubMed abstract (PM: 18061269)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;IOP (intra-ocular pressure) assessment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Elmallah MK, Asrani SG. New ways to measure intraocular pressure. &lt;EM&gt;Curr Opin Ophthalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;19 (Pt 2)&lt;/STRONG&gt;: 122-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18301285" target="_blank"&gt;PubMed abstract (PM: 18301285)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Functional tests&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Sakata LM, DeLeon-Ortega J, Girkin CA. Selective perimetry in glaucoma diagnosis. &lt;EM&gt;Curr Opin Ophthalmol&lt;/EM&gt; 2007; &lt;STRONG&gt;18 (Pt 2)&lt;/STRONG&gt;: 115-21. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17301612" target="_blank"&gt;PubMed abstract (PM: 17301612)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Vaegan, Rahman AM, Sanderson GF. Glaucoma affects steady state VEP contrast thresholds before psychophysics. &lt;EM&gt;Optom Vis Sci&lt;/EM&gt; 2008; &lt;STRONG&gt;85 (Pt 7)&lt;/STRONG&gt;: 547-58. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18594348" target="_blank"&gt;PubMed abstract (PM:18594348)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Structural vs functional tests&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Bozkurt B, Yilmaz PT, Irkec M. Relationship between Humphrey 30-2 SITA Standard Test, Matrix 30-2 threshold test, and Heidelberg retina tomograph in ocular hypertensive and glaucoma patients. &lt;EM&gt;J Glaucoma&lt;/EM&gt; 2008; &lt;STRONG&gt;17 (Pt 3)&lt;/STRONG&gt;: 203-10. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18414106" target="_blank"&gt;PubMed abstract (PM:18414106)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Emerging Technology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Observational studies&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Abdel-Ghafar RA, Morris T. Progress towards automated detection and characterization of the optic disc in glaucoma and diabetic retinopathy. &lt;EM&gt;Med Inform Internet Med&lt;/EM&gt; 2007; &lt;STRONG&gt;32 (Pt 1)&lt;/STRONG&gt;: 19-25. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17365641" target="_blank"&gt;PubMed abstract (PM: 17365641)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Blazquez F, Sebastian MA, Anton A. [Detection of glaucoma using SisGlaTel: acceptability and satisfaction among participants, and problems detected.] &lt;EM&gt;Arch Soc Esp Oftalmol&lt;/EM&gt; 2008; &lt;STRONG&gt;83 (Pt 9)&lt;/STRONG&gt;: 533-8.[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18803125" target="_blank"&gt;PubMed abstract (PM:18803125)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic evaluations and cost-effectiveness&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Secondary publications&lt;/EM&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Hernandez R, Rabindranath K, Fraser C, Vale L, Blanco AA, Burr JM. Screening for open angle glaucoma: systematic review of cost-effectiveness studies. &lt;EM&gt;J Glaucoma&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/EM&gt;2008; &lt;STRONG&gt;17 (Pt 3)&lt;/STRONG&gt;: 159-68. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18414099" target="_blank"&gt;PubMed abstract (PM:18414099)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Hernandez RA, Burr JM, Vale LD. Economic evaluation of screening for open-angle glaucoma. &lt;EM&gt;Int J Technol Assess Health Care&lt;/EM&gt; 2008; &lt;STRONG&gt;24 (Pt 2)&lt;/STRONG&gt;: 203-11. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18400124" target="_blank"&gt;PubMed abstract (PM: 18400124)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;Peeters A, Schouten JS, Webers CA, Prins MH, Hendrikse F, Severens JL. Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist. &lt;EM&gt;Eye&lt;/EM&gt; 2008; &lt;STRONG&gt;22 (Pt 3)&lt;/STRONG&gt;; 354-62. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17128205" target="_blank"&gt;PubMed abstract (PM:17128205)&lt;/A&gt;]&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/search_history/ScreeningSearchHistory.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1108/JournalSpread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Back to contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>310814</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15621077]]&gt;</url>
    <title>Glaucoma drainage devices: a systematic literature review and current controversies</title>
    <publicationDate>2005-01-31T00:00:00</publicationDate>
    <publisher>Surveys of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Surveys of Ophthalmology (Surv Ophthalmol) 2005 Jan-Feb;50(1):48-60.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;Glaucoma drainage devices create alternate aqueous pathways by channeling aqueous from the anterior chamber through a long tube to an equatorial plate that promotes bleb formation. Glaucoma drainage devices are being used more frequently in the treatment of glaucoma that does not respond to medications or trabeculectomy operations. In certain conditions, such as neovascular glaucoma, iridio-corneal syndrome, penetrating keratoplasty with glaucoma, glaucoma following retinal detachment surgery, and so on, it is becoming the primary operation. This review provides a systematic review of the literature and outlines the current controversies involving different glaucoma drainage devices and their design, overall surgical success, and complications following glaucoma drainage device insertion.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=179" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>273535</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273535]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Assessment of Visual Field Progression</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2007,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Assessment of Visual Field Progression&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:298584:0" name=internalLink&gt;Click here to view 2008 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1107/nkw_glaucoma_1107_doc5.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/Assessment%20of%20Visual%20Field%20Progression.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:201821:0" name=internalLink&gt;Click here to view 2006 NKW Visual Field Progression section&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Assessment of Visual Field Progression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date, Embase 1996 to date &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; June 2006 to October 2007&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&lt;/EM&gt;&amp;nbsp; &lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;.&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=343 alt="Assessment of visual field progression evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273535/nelhImp_0001_visualFieldProgression.jpg" width=650 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Nouri MK, Hoffman D, Ralli M, Caprioli J. Comparison of methods to predict visual field progression in glaucoma. Archives of Ophthalmology,&amp;nbsp;Sep 2007, vol. 125, no. 9, p. 1176-81, ISSN: 0003-9950. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17846355%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Strouthidis NG, Scott A, Viswanathan AC, Crabb DP, Garway-Heath DF. Monitoring glaucomatous visual field progression: the effect of a novel spatial filter. Investigative Ophthalmology &amp;amp; Visual Science,&amp;nbsp;Jan 2007, vol. 48, no. 1, p. 251-7, ISSN: 0146-0404. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17197540%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kim TW, Zangwill LM, Bowd C, Sample PA, Shah N, Weinreb RN. Retinal nerve fiber layer damage as assessed by optical coherence tomography in eyes with a visual field defect detected by frequency doubling technology perimetry but not by standard automated perimetry. Ophthalmology, Jun 2007 (epub: 18 Jan 2007), vol. 114, no. 6, p. 1053-7, ISSN: 1549-4713.&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17239441%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Total%20Journal%20Spread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Assessment%20of%20visual%20field%20progression%20.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273449</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273449]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Epidemiology</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,GLAUCOMA NKW 2007,ANNUAL EVIDENCE UPDATES,GLAUCOMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:286963:0" name=internalLink&gt;Click here to view 2008 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1107/nkw_glaucoma_1107_doc1.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/Epidemiology.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:201827:0" name=internalLink&gt;Click here to view&amp;nbsp;2006 NKW Epidemiology section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;Epidemiology&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched: &lt;/STRONG&gt;Medline 1996 to date, Embase 1996 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched: &lt;/STRONG&gt;June 2006 to October 2007&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&lt;/EM&gt;&amp;nbsp;&lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;Centre for Evidence-Based Medicine&lt;/A&gt;. &lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=344 alt="Epidemiology evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273449/nelhImp_0003_epidemiologytest2.jpg" width=650 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Loyo-Berríos NI, Blustein JN, Primary-open glaucoma and myopia: a narrative review.&amp;nbsp; WMJ : official publication of the State Medical Society of Wisconsin,&amp;nbsp;Apr 2007, vol. 106, no. 2, p. 85-9, 95, 56 refs, ISSN: 1098-1861. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17479825%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Boland MV, Quigley HA, Risk factors and open-angle glaucoma: Classification and application. Journal of Glaucoma, 2007, Vol/Iss/Pg. 16/4 (406-418), ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17571004%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Fechtner RD, Khouri AS. Evolving global risk assessment of ocular hypertension to glaucoma. Current Opinion in Ophthalmology,&amp;nbsp;Mar 2007, vol. 18, no. 2, p. 104-9, 42 refs, ISSN: 1040-8738. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17301610%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Dueker DK, Singh K, Lin SC, Fechtner RD, Minckler DS, Samples JR, Schuman JS. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology,&amp;nbsp;Sep 2007, vol. 114, no. 9, p. 1779-87, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17822980%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Miglior S, Torri V, Zeyen T, Pfeiffer N, Cunha Vaz J, Adamsons I, Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. American Journal of Ophthalmology,&amp;nbsp;Aug 2007 (epub: 04 Jun 2007), vol. 144, no. 2, p. 266-275, ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17543874%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17016527%5Buid%5D" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;Miglior S, Pfeiffer N, Torri V, Zeyen T, Cunha Vaz J, Adamsons I. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology,&amp;nbsp;Jan 2007 (epub: 27 Oct 2006), vol. 114, no. 1, p. 3-9, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17070596%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Xu L, Wang Y, Wang S, Wang Y, Jonas JB,&amp;nbsp;High myopia and glaucoma susceptibility the Beijing Eye Study. Ophthalmology, Feb 2007 (epub: 21 Nov 2006), vol. 114, no. 2, p. 216-20, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17123613%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Landers JA, Henderson TR, Craig JE. Optic nerve head parameters of an indigenous population living within Central Australia. Clinical and Experimental Ophthalmology, 2006, Vol/Iss/Pg. 34/9 (852-856), eISSN: 1442-9071, ISSN: 1442-6404. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17181616%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Wu-SY, Nemesure B, Hennis A, Leske MC. Nine-year changes in intraocular pressure: the Barbados Eye Studies. Archives of Ophthalmology, Nov 2006, vol. 124, no. 11, p. 1631-6, ISSN: 0003-9950. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17102013%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;de Voogd S, Ikram MK, Wolfs RCW, Jansonius NM, Witteman JCM, Hofman A, de Jong PTVM. Is Diabetes Mellitus a Risk Factor for Open-Angle Glaucoma?. The Rotterdam Study. Ophthalmology, 2006, Vol/Iss/Pg. 113/10 (1827-1831), ISSN: 0161-6420. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16884777%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Pasquale LR, Kang JH, Manson JE, Willett WC, Rosner BA, Hankinson SE. Prospective study of type 2 diabetes mellitus and risk of primary open-angle glaucoma in women. Ophthalmology, Jul 2006 (epub: 06 Jun 2006), vol. 113, no. 7, p. 1081-6, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16757028%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K, Izumi Y, Matsumoto M, Mishima HK. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. Journal of the Neurological Sciences&amp;nbsp;15 JUL 2006, Vol /Iss/Pg. 246/1-2 (79-83), ISSN: 0022-510X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16564058%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gong G, Kosoko-Lasaki S, Haynatzki G, Lynch HT, Lynch JA, Wilson MR. Inherited, familial and sporadic primary open-angle glaucoma. Journal of the National Medical Association,&amp;nbsp;May 2007, vol. 99, no. 5, p. 559-63, ISSN: 0027-9684. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17534014%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevalence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Casson RJ, Newland HS, Muecke J, McGovern S, Abraham L, Shein WK, Selva D, Aung T. Prevalence of glaucoma in rural Myanmar: the Meiktila Eye Study. The British Journal of Ophthalmology, Jun 2007, vol. 91, no. 6, p. 710-4, 29 refs, ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17510475%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Topouzis F, Wilson MR, Harris A, Anastasopoulos E, Yu F, Mavroudis L, Pappas T, Koskosas A, Coleman AL.Prevalence of Open-Angle Glaucoma in Greece: The Thessaloniki Eye Study. American Journal of Ophthalmology 2007, Vol/Iss/Pg. 144/4 (511-519.e1), ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17893012%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;He M, Foster PJ, Ge J, Huang W, Zheng Y, Friedman DS, Lee PS, Khaw PT. Prevalence and clinical characteristics of glaucoma in adult Chinese: a population-based study in Liwan District, Guangzhou. Investigative Ophthalmology &amp;amp; Visual Science Jul 2006, vol. 47, no. 7, p. 2782-8, ISSN: 0146-0404. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16799014%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Perruccio AV, Badley EM, Trope GE. Self-reported glaucoma in Canada: findings from population-based surveys, 1994-2003. Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie, Apr 2007, vol. 42, no. 2, p. 219-26, ISSN: 0008-4182. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17392843%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kosoko LO, Gong G, Haynatzki G, Wilson MR. Race, ethnicity and prevalence of primary open-angle glaucoma. Journal of the National Medical Association, Oct 2006, vol. 98, no. 10, p. 1626-9, ISSN: 0027-9684. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17052053%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Friedman DS, Jampel HD, Muñoz B, West SK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Archives of Ophthalmology,&amp;nbsp;Nov 2006, vol. 124, no. 11, p. 1625-30, ISSN: 0003-9950. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17102012%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Adegbehingbe BO, Majengbasan TO. Ocular health status of rural dwellers in south-western Nigeria. The Australian Journal of Rural Health,&amp;nbsp;Aug 2007, vol. 15, no. 4, p. 269-72, ISSN: 1038-5282.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17617092%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Incidence&lt;/H3&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Leske-M-Cristina, Wu-S-Y, Honkanen-R, Nemesure-B, Schachat-A, Hyman-L, Hennis-A. Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies. Ophthalmology, Jun 2007 (epub: 30 Mar 2007), vol. 114, no. 6, p. 1058-64, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17397925%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Prevalence, blindness &amp;amp; visual impairment from Glaucoma&lt;/H3&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Avisar R, Friling R, Snir M, Avisar I, Weinberger D. Estimation of prevalence and incidence rates and causes of blindness in Israel, 1998-2003.&amp;nbsp; The Israel Medical Association Journal : IMAJ,&amp;nbsp;Dec 2006, vol. 8, no. 12, p. 880-1, ISSN: 1565-1088. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17214111%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Onakpoya OH, Adeoye AO, Akinsola FB, Adegbehingbe BO. Prevalence of blindness and visual impairment in Atakunmosa West Local Government area of southwestern Nigeria. Tanzania Health Research Bulletin, May 2007, vol. 9, no. 2, p. 126-31, ISSN: 0856-6496. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17722416%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Dineen B, Bourne RRA, Jadoon Z, Shah SP, Khan MA, Foster A, Gilbert CE, Khan MD.Causes of blindness and visual impairment in Pakistan. The Pakistan national blindness and visual impairment survey.The British Journal of Ophthalmology, Aug 2007 (epub: 17 Jan 2007), vol. 91, no. 8, p. 1005-10, ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17229806%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Khandekar R, Mohammed AJ, Raisi AA. Prevalence and causes of blindness &amp;amp; low vision; before and five years after 'VISION 2020' initiatives in Oman: a review. Ophthalmic Epidemiology,&amp;nbsp;Jan-Feb 2007, vol. 14, no. 1, p. 9-15, ISSN: 0928-6586. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17365813%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Shahriari HA, Izadi S, Rouhani MR, Ghasemzadeh F, Maleki AR. Prevalence and causes of visual impairment and blindness in Sistan-va- Baluchestan Province, Iran: Zahedan Eye Study. British Journal of Ophthalmology, 2007, Vol/Iss/Pg. 91/5 (579-584), ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17124245%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology,&amp;nbsp;Aug 2006, vol. 113, no. 8, p. 1354-62, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16877074%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Schémann JF, Inocencio F, de-Lourdes Monteiro M, Andrade J, Auzemery A, Guelfi Y. Blindness and low vision in Cape Verde Islands: results of a national eye survey. Ophthalmic Epidemiology, Aug 2006, vol. 13, no. 4, p. 219-26, ISSN: 0928-6586. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16877280%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Xu L, Wang Y, Li Y, Wang Y, Cui T, Li J, Jonas JB. Causes of Blindness and Visual Impairment in Urban and Rural Areas in Beijing. The Beijing Eye Study. Ophthalmology&amp;nbsp;2006, Vol/Iss/Pg. 113/7 (1141.e1-1141.e3), ISSN: 0161-6420. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16647133%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;General &lt;/H3&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Leske MC. Open-angle glaucoma - An epidemiologic overview. Ophthalmic Epidemiology&amp;nbsp;2007, Vol/Iss/Pg. 14/4 (166-172), eISSN: 1744-5086, ISSN: 0928-6586. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17896292%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Bahrami H. Causal inference in primary open angle glaucoma: Specific discussion on intraocular pressure. Ophthalmic Epidemiology&amp;nbsp; 01 AUG 2006, Vol/Iss /Pg. 13/4 (283-289), eISSN: 1744-5086, ISSN: 0928-6586. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16877288%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Population projections&lt;/H3&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Hitzl W, Bunce C, Reitsamer HA, Grabner G, Hornykewycz K. The projected increase in glaucoma due to the aging population in Austria from 2001 to 2031: results based on data of the Salzburg-Moorfields Collaborative Glaucoma Study. European journal of Ophthalmology, Jan-Feb 2007, vol. 17, no. 1, p. 45-52, ISSN: 1120-6721. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17294382%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Health care utilisation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Owen CG, Carey IM, De Wilde S, Whincup PH, Wormald R, Cook DG. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003.The British journal of ophthalmology,&amp;nbsp;Jul 2006, vol. 90, no. 7, p. 861-8, ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16782949%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Epidemiology.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Total%20Journal%20Spread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273744</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273744]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Evidence Tree</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2007,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Evidence Tree&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1107/nkw_glaucoma_1107_doc8.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/Evidence%20Tree.pdf" target="_blank"&gt;Click here to view PDF&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Evidence Tree for the entire Glaucoma National Knowledge Week&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched: &lt;/STRONG&gt;Medline 1996 to date, Embase 1996 to date, Cinahl 1982 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched: &lt;/STRONG&gt;June 2006 to October 2007&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 height=869 alt="Evidence Tree for all knowledge week topics " src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273744/nelhImp_0001_topicTreeMain.jpg" width=650 border=0 name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273250</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273250]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Images</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2007,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Optic Disc Imaging&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The&amp;nbsp;images&amp;nbsp;shown on the next&amp;nbsp;three pages&amp;nbsp;are&amp;nbsp;an additional item to the&amp;nbsp;section on Optic Disc Imaging Diagnosis and Disease Monitoring, providing examples of the methods recently introduced into clinical practice. &amp;nbsp;Please click on the above links to&amp;nbsp;access the pages. &lt;/P&gt;
&lt;P&gt;All&amp;nbsp;images have been&amp;nbsp;provided by&amp;nbsp;Mr David Garway-Heath and&amp;nbsp;Patricio Schlottman, Glaucoma Research Unit, Moorfields Eye Hospital NHS Foundation Trust. &lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Return to 2007 Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=AEUGLA2008" target="_blank"&gt;Go to 2008 Glaucoma Annual Evidence Update&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;10&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Heidelberg Retina Tomograph (HRT)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Heidelberg Retina Tomograph assesses optic nerve topography using scanning laser tomography to produce the 3-dimensional images, which allow precise measurements of optic nerve head parameters. The printout provides numerous parameters.&amp;nbsp; The most valuable of these include measures of Cup Shape&amp;nbsp;(the more negative the better), Rim Area and Rim Volume (the higher the better), as well as several NFL (nerve fibre layer) height measures.&amp;nbsp; Valuable discriminant parameters are also calculated by the software.&amp;nbsp; The most clinically useful analysis uses the Moorfield’s Algorithm, which evaluates the ONH by sector and classifies each sector and the overall ONH as within normal limits, borderline or outside normal limits.&lt;/P&gt;
&lt;P&gt;HRT is not affected by corneal compensation issues of birefringence and retardation, so that it can generate an accurate measurement without having to remove the patient’s contact lenses and it works well even if a patient has had refractive surgery.&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;Figure 1: HRT topography and reflection image of a patient with a supero temporal notch with its corresponding visual field defect.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Figure 2:&amp;nbsp;&amp;nbsp;Example of a Heidelberg Retina Tomograph (HRT) printout.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Figure 1. HRT topography and reflection image of a patient with a supero temporal notch with its corresponding visual field defect.&lt;/EM&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=286 alt="HRT supero-temporal Rim Area notch" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0000_HRTsupero-temporalRimAreanotch.png" width=549 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=407 alt="VF Infero-nasal corresponding defect" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0001_VFInfero-nasalcorrespondingdefect.png" width=432 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Figure 2. Example of a Heidelberg Retina Tomograph (HRT) printout.&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=521 alt="HRT printout" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0015_HRTprintout.png" width=402 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;All&amp;nbsp;images&amp;nbsp;provided by&amp;nbsp;Mr David Garway-Heath and&amp;nbsp;Patricio Schlottman, Glaucoma Research Unit, Moorfields Eye Hospital NHS Foundation Trust. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;12&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;GDx Nerve Fibre Analyser&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The GDx Nerve Fibre Analyser is an instrument that uses confocal scanning laser polarimetry to determine the thickness of the nerve fibre layer. The GDx detects nerve fibre loss, not vision loss.&amp;nbsp; Detection of thinning of the nerve fibre layer may be correlated with risk of glaucoma or progression but&amp;nbsp;thinning of the nerve fibre layer isn't always due to glaucoma; other factors such as aging and vessel occlusions may cause thinning of the nerve fibre layer, so the analysis should&amp;nbsp;be interpreted with caution. &lt;/P&gt;
&lt;P&gt;The newest generation of the GDX has a special feature called a corneal compensator; the compensation adjusts for the polarization properties of the cornea, which would otherwise interfere with interpretation the nerve fibre layer images&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Figure 3:&amp;nbsp;GDx Thickness map and table of parameters colour coded for the corresponding normal distribution.&lt;/P&gt;
&lt;P&gt;Figure 4:&amp;nbsp;GDx thickness maps, Deviation Maps and Visual Fields plots of various degrees of glaucoma severity.&lt;/P&gt;
&lt;P&gt;Figure 5: GDx RNFL thickness map (sup) and Deviation Map (inf) showing a wedge defect of the RNFL with its corresponding visual field defect.&lt;/P&gt;
&lt;P&gt;Figure 6: Corresponding visual field&lt;/P&gt;
&lt;P&gt;Figure 7: GDx Printout&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Figure 3. GDx Thickness map and table of parameters colour coded for the corresponding normal distribution&lt;/EM&gt;.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=388 alt="GDx Thickness map" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0003_GDxThicknessMap.png" width=344 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 height=321 alt="Table of parameters" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0004_Tableofparameterscolourcodedforthecorrespondingnormaldistribution.png" width=388 border=0 name=nelh_tempImage3&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Figure 4. GDx thickness maps, Deviation Maps and Visual Fields plots of various degrees of glaucoma severity.&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=230 alt="GDx thickness maps, deviation maps &amp;amp; visual field plots" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0016_GDxthicknessmaps%2CDeviationMapsandVisualFieldsplotsofvariousdegreesofglaucomaseverity.png" width=624 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Figure 5. GDx RNFL thickness map (sup) and Deviation Map (inf) showing a wedge defect of the RNFL with its corresponding visual field defect.&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=436 alt="GDx RNFL thickness map (sup) and Deviation Map (inf)" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0017_GDxRNFLthicknessmap%28sup%29andDeviationMap%28inf%29showingawedgedefectoftheRNFL.png" width=202 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Figure 6. Corresponding visual field&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=408 alt="Print out of Visual field test" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0018_Correspondingvisualfield.png" width=437 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Figure 7. GDx Printout&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=585 alt="GDx Printout" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0019_GDxprintout.png" width=444 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;All&amp;nbsp;images&amp;nbsp;provided by&amp;nbsp;Mr David Garway-Heath and&amp;nbsp;Patricio Schlottman, Glaucoma Research Unit, Moorfields Eye Hospital NHS Foundation Trust. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;16&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Stratus Optical Coherence Tomographer&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;The Stratus Optical Coherence Tomographer (OCT) is a noncontact, noninvasive tomographic imaging technique utilizing short coherence length light.&lt;/P&gt; &lt;P&gt;It uses the echo delay time of light back-scattered from various layers of the retina to create a two-dimensional, cross-sectional image of ocular tissue.&amp;nbsp;&amp;nbsp; NFL (nerve fibre layer) thickness is measured directly from the scan using an automated computer algorithm. NFL and total retinal thickness are summarized by clock hour and by quadrant, as well as by overall mean thickness.&amp;nbsp; Unlike ONH (optic nerve head) analysers and confocal scanning laser ophthalmoscopes, no reference plane is required to determine NFL thickness, since OCT provides an absolute cross-sectional measurement of retinal substructure from which the NFL thickness is calculated.&lt;/P&gt; &lt;P&gt;Figure 8:&amp;nbsp;Stratus OCT printouts&lt;/P&gt; &lt;P&gt;Figure 9: OCT RNFL graphic representation against a colour code representation of normal distributions.&lt;/P&gt; &lt;P&gt;Figure 10. OCT table of parameters in a colour coded presentation. The table on the right assigns a colour to each normal distribution&amp;nbsp;&lt;BR&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Figure 8. Stratus OCT printouts. On the left, an RNFL 3.4 scan, which is a circular scan around the optic measuring the thickness of the RNFL. On the right, an Optic Disc Scan, which is a radially distributed scan made of 6 lines centred on the optic disc. The optic Disc Scan measures stereometric parameters of the optic nerve head.&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt; &lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;IMG id=nelh_tempImage4 height=281 alt="Stratus OCT - RNFL" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0009_RNFLthickness.png" width=401 border=0 name=nelh_tempImage4&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;IMG id=nelh_tempImage4 height=280 alt="Optic disc scan" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0010_OpticDiscScan.png" width=404 border=0 name=nelh_tempImage4&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Figure 9. OCT RNFL graphic representation against a colour code representation of normal distributions.&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0020_OCTgraphicrepresentation.png" name=nelh_tempImage5&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0021_2.png" name=nelh_tempImage1&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0022_1.png" name=nelh_tempImage0&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Figure 10. OCT table of parameters in a colour coded presentation. The table on the right assigns a colour to each normal distribution &lt;/STRONG&gt;percentile.&lt;/EM&gt;&lt;/P&gt; &lt;P&gt;&lt;IMG id=nelh_tempImage8 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273250/nelhImp_0023_OCTtableofparametersinacolourcodedpresentation.png" name=nelh_tempImage8&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;All&amp;nbsp;images&amp;nbsp;provided by&amp;nbsp;Mr David Garway-Heath and Patricio Schlottman, Glaucoma Research Unit, Moorfields Eye Hospital NHS Foundation Trust. &lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273476</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273476]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Low vision and living with glaucoma</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2007,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Low vision and living with glaucoma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:298592:0" name=internalLink&gt;Click here to view 2008 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1107/nkw_glaucoma_1107_doc7.asp" target="_blank"&gt;Click here to view low vision version &lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/Low%20vision%20and%20living%20with%20Glaucoma.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:156959:0" name=internalLink&gt;Click here to view 2006 NKW Low Vision Services&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:201807:0" name=internalLink&gt;Click here to view 2006 NKW Living with Glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Low Vision &amp;amp; Living with Glaucoma&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date, Embase 1996 to date, Cinahl 1982 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; June 2006 to October 2007&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp;&lt;/EM&gt; &lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;.&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=343 alt="Low vision aids and living with glaucoma evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273476/nelhImp_0000_lowVision.jpg" width=650 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Glaucoma-specific&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Whiteside MM, Wallhagen MI, Pettengill E. A new look at the old. Sensory impairment in older adults: part 2: vision loss... 15th in a series. American Journal of Nursing, 2006 Nov, vol. 106, no. 11, p. 52-62, (20 ref), ISSN: 0002-936X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17068436%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Ang GS, Eke T. Lifetime visual prognosis for patients with primary open-angle glaucoma. Eye (London England),&amp;nbsp;May 2007 (epub: 17 Feb 2006), vol. 21, no. 5, p. 604-8, ISSN: 0950-222X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16485015%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gieser DK, Tracy Williams R, O'Connell W, Pasquale LR, Rosenthal BP, Walt JG, Katz LM, Siegartel LR, Wang L, Rosenblatt LC, Stern LS, Doyle JJ. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study. Journal of Glaucoma,&amp;nbsp;Oct 2006, vol. 15, no. 5, p. 419-25, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16988605%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Bhargava JS, Patel B, Foss AJE, Avery AJ, King AJ. Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis. Investigative Ophthalmology &amp;amp; Visual Science,&amp;nbsp;Jul 2006, vol. 47, no. 7, p. 2885-8, ISSN: 0146-0404. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16799029%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Jampel HD, Frick KD, Janz NK, Wren PA, Musch DC, Rimal R, Lichter PR. Depression and mood indicators in newly diagnosed glaucoma patients. American Journal of Ophthalmology, Aug 2007 (epub: 11 Jun 2007), vol. 144, no. 2, p. 238-244, ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17560843%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Low Vision General&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary Publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Virgili G,&amp;nbsp;Acosta R.&amp;nbsp; Reading aids for adults with low vision. Cochrane Database of Systematic Reviews, 2007, no. 3, (CD003303)&amp;nbsp; Source notes: Update Software, online or CD-ROM, updated quarterly, ISSN: 1469-493X. &lt;A disabled href="nelh:237745:0" name=internalLink&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Lamoureux EL, Pallant JF, Pesudovs K, Rees G, Hassell JB, Keeffe JE. The effectiveness of low-vision rehabilitation on participation in daily living and quality of life. Investigative Ophthalmology &amp;amp; Visual Science, Apr 2007, vol. 48, no. 4, p. 1476-82, ISSN: 0146-0404. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17389474%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Williams GP, Pathak RV, Austin MW, Lloyd AP, Millington IM, Bennett A. Quality of life and visual rehabilitation: an observational study of low vision in three general practices in West Glamorgan. Eye (London England),&amp;nbsp;Apr 2007 (epub: 03 Feb 2006), vol. 21, no. 4, p. 522-7, ISSN: 0950-222X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16456593%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Stelmack JA, Moran D, Dean D, Massof RW. Short and Long-Term Effects of an Intensive Inpatient Vision Rehabilitation Program. Archives of Physical Medicine and Rehabilitation, 2007, Vol/Iss/Pg. 88/6 (691-695), ISSN: 0003-9993. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17532888%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Cimarolli VR. Perceived overprotection and distress in adults with visual impairment. Rehabilitation Psychology 2006, Vol/Iss/Pg. 51/4 (338-345), ISSN: 0090-5550. &lt;A href="http://content.apa.org/journals/rep/51/4/338" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;De-Boer MR, Twisk J, Moll AC, Völker DHJM, De Vet HCW, Van Rens GHMB. Outcomes of low-vision services using optometric and multidisciplinary approaches: A non-randomized comparison. Ophthalmic and Physiological Optics, 2006, Vol/Iss/Pg. 26/6 (535-544), eISSN: 1475-1313, ISSN: 0275-5408. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17040417%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Varma R, Wu J, Chong K, Azen SP, Hays RD. Impact of Severity and Bilaterality of Visual Impairment on Health-Related Quality of Life. Ophthalmology, 2006, Vol/Iss/Pg. 113/10 (1846-1853), ISSN: 0161-6420. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16889831%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Patel D, Baker H, Murdoch I. Barriers to uptake of eye care services by the Indian population living in Ealing, west London. Health Education Journal, 2006, Vol/Iss/Pg. 65/3 (267-276), ISSN: 0017-8969. &lt;A href="http://hej.sagepub.com/cgi/content/abstract/65/3/267" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Strobel W, Fossa J, Arthanat S, Brace J. Technology for access to text and graphics for people with visual impairments and blindness in vocational settings. Journal of Vocational Rehabilitation, 2006, vol. 24, no. 2, p. 87-95, (39 ref), ISSN: 1052-2263. &lt;/P&gt;
&lt;P&gt;Gold D, Zuvela B, Hodge WG. Perspectives on low vision service in Canada: A pilot study. Canadian Journal of Ophthalmology, 2006, Vol/Iss /Pg. 41/3 (348-354), ISSN: 0008-4182. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16767191%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Cimarolli VR, Wang SW. Differences in social support among employed and unemployed adults who are visually impaired. Journal of Visual Impairment and Blindness&amp;nbsp;2006, Vol/Iss/Pg. 100/9 (545-556), ISSN: 0145-482X. &lt;A href="http://www.afb.org/jvib/jvibabstractNew.asp?articleid=JVIB000905" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Low%20vision%20and%20living%20with%20glaucoma%20.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Total%20Journal%20Spread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273514</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273514]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Medical Management</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,GLAUCOMA NKW 2007,ANNUAL EVIDENCE UPDATES,GLAUCOMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Medical Management&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:298633:0" name=internalLink&gt;Click here to view 2008 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1107/nkw_glaucoma_1107_doc3.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/Medical%20Management.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:201779:0" name=internalLink&gt;Click here to view 2006 NKW Medical Management section&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Medical Management&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date, Embase 1996 to date.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; June 2006 to October 2007&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp;&lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications &lt;/STRONG&gt;include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies &lt;/STRONG&gt;include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies &lt;/STRONG&gt;include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;IMG id=nelh_tempImage0 height=343 alt="Medical management evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273514/nelhImp_0000_medicalManagement.jpg" width=650 border=0 name=nelh_tempImage0&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prostaglandin Analogues&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Plosker GL, Keam SJ. Bimatoprost: A pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. PharmacoEconomics, 2006, Vol/Iss/Pg. 24/3 (297-314), ISSN: 1170-7690. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16519552%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G.&amp;nbsp; A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Current Medical Research and Opinion, 2007, Vol /Iss/Pg. 23/3 (601-608), ISSN: 0300-7995. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17355741%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Ishida N, Odani KN, Shimazaki A, Hara H. Prostanoids in the therapy of glaucoma. Cardiovascular Drug Reviews, 2006, Vol/Iss/Pg. 24/1 (1-10), ISSN: 0897-5957. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16939629%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Li N, Chen X, Zhou Y, Wei M, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta- analysis of randomized controlled trials. Clinical &amp;amp; Experimental Ophthalmology,&amp;nbsp;Nov 2006, vol. 34, no. 8, p. 755-64, ISSN: 1442-6404. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17073898%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Narayanaswamy A, Neog A, Baskaran M, George R, Lingam V, Desai C, Rajadhyaksha V. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian Journal of Ophthalmology, Mar-Apr 2007, vol. 55, no. 2, p. 127-31, ISSN: 0301-4738. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17322603%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G, Carassa R, Mastropasqua L, Quaranta L, Marchini G, Ratiglia R, Orzalesi N. An evaluation of the rate of nonresponders to latanoprost therapy. Journal of Glaucoma&amp;nbsp;2006, Vol/Iss/Pg. 15/3 (238-243), ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16778647%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Noecker RJ, Earl ML, Mundorf TK, Silverstein SM, Phillips MP. Comparing bimatoprost and travoprost in black Americans. Current Medical Research and Opinion&amp;nbsp;2006, Vol /Iss/Pg. 22/11 (2175-2180), ISSN: 0300-7995. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17076978%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Wang Y, Bolós J, Serradell N. Tafluprost. Prostanoid FP receptor agonist, antiglaucoma drug. Drugs of the Future, 2006, Vol/Iss/Pg. 31/9 (788-792), ISSN: 0377-8282. [abstract]&lt;/P&gt;
&lt;P&gt;Cantor LB, Hoop J, Morgan L, WuDunn D, Catoira Y, Bournias T, Cantor L, Dirks M, Duzman E, Mansouri A, Mundorf T, Simmons S, Williams R. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. British Journal of Ophthalmology&amp;nbsp;2006, Vol/Iss/Pg. 90/11 (1370-1373), ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16825272%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Side effects, safety and stability, efficacy &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Fung AT, Reid SE, Jones MP, Healey PR, McCluskey PJ, Craig JC. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. The British Journal of Ophthalmology, Jan 2007 (epub: 06 Sep 2006), vol. 91, no. 1, p. 62-8, 45 refs, ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16956912%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Arranz Marquez E, Teus MA. Effect of age on the development of a latanoprost-induced increase in iris pigmentation. Ophthalmology,&amp;nbsp;Jul 2007 (epub: 16 Feb 2007), vol. 114, no. 7, p. 1255-8, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17306877%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Baratz KH, Nau CB, Winter EJ, McLaren JW, Hodge DO, Herman DC, Bourne WM. Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the Ocular Hypertension Treatment Study. Cornea&amp;nbsp;2006, Vol/Iss/Pg. 25/9 (1046-1052), ISSN: 0277-3740. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17133051%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Erkin EF, Celik P, Kayikçioglu O, Deveci HM, Sakar A. Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients. Ophthalmologica.&amp;nbsp; Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift für Augenheilkunde,&amp;nbsp;2006, vol. 220, no. 5, p. 332-7, ISSN: 0030-3755. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16954712%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Harasymowycz PJ, Papamatheakis DG, Ennis M, Brady M, Gordon KD. Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma. Cornea,&amp;nbsp;Jan 2007, vol. 26, no. 1, p. 34-41, ISSN: 0277-3740. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17198011%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gutiérrez-Ortiz C, Teus MA, Bolivar G. Short-term effects of latanoprost on anterior chamber depth in patients with glaucoma or ocular hypertension. Investigative Ophthalmology &amp;amp; Visual Science,&amp;nbsp;Nov 2006, vol. 47, no. 11, p. 4856-9, ISSN: 0146-0404. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17065498%5Buid%5D" target="_blank"&gt;abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Cracknell KP, Grierson I, Hogg P, Majekodunmi AA, Watson P, Marmion V. Melanin in the trabecular meshwork is associated with age, POAG but not Latanoprost treatment. A masked morphometric study. Experimental Eye Research,&amp;nbsp;Jun 2006 (epub: 17 Nov 2005) , vol. 82, no. 6, p. 986-93, ISSN: 0014-4835. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16297910%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Doshi M, Edward DP, Osmanovic S.&amp;nbsp; Clinical course of bimatoprost-induced periocular skin changes in Caucasians. Ophthalmology, Nov 2006 (epub: 28 Aug 2006), vol. 113, no. 11, p. 1961-7, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16935336%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gonzalez JR, Baiza-Duran L, Quintana Hau J, Tornero-Montaño&amp;nbsp;R, Castaneda-Hernandez G, Ortiz M et al.&amp;nbsp; Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation. Journal of Clinical Pharmacology, Jan 2007, vol. 47, no. 1, p. 121-6, ISSN: 0091-2700. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17192510%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lee AJ, Wang JJ, Kifley A, MitchellP. Open-Angle Glaucoma and Cardiovascular Mortality. The Blue Mountains Eye Study. Ophthalmology, 2006, Vol/Iss/Pg. 113/7 (1069-1076), ISSN: 0161-6420. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16815396%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Whitson JT, Ochsner KI, Moster MR, Sullivan EK, Andrew RM, Silver LH, Wells DT, James JE, Bosworth CF, Dickerson JE, Landry TA, Bergamini MVW. The Safety and Intraocular Pressure-Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1. Ophthalmology, 2006, Vol/Iss/Pg. 113/8 (1333-1339), ISSN: 0161-6420. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16877072%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Holló G, Chiselita D, Petkova N, Cvenkel B, Liehneova I, Izgi B, Berta A, Szaflik J, Turacli E, Stewart WC. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. European Journal of Ophthalmology,&amp;nbsp;Nov-Dec 2006, vol. 16, no. 6, p. 816-23, ISSN: 1120-6721. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17191187%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Topouzis F, Melamed S, Danesh Meyer H, Wells AP, Kozobolis V, Wieland H, Andrew R, Wells D. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004 %/timolol 0.5% to once-daily latanoprost 0.005% /timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. European Journal of Ophthalmology, Mar-Apr 2007, vol. 17, no. 2, p. 183-90, ISSN: 1120-6721. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17415690%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, Hua SY, Sullivan EK, Montgomery DB, Wells DT, Bergamini MVW. &amp;nbsp;Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. Journal of Glaucoma, Jan 2007, vol. 16, no. 1, p. 98-103, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17224758%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Harasymowycz P, Hutnik CML, Nicolela M, Stewart WC. Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension. Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie,&amp;nbsp;Feb 2007, vol. 42, no. 1, p. 75-81, ISSN: 0008-4182. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17361245%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cost effectiveness/implications to the health service&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Schmier&amp;nbsp;JK, Halpern MT, Jones ML. The economic implications of glaucoma: A literature review. PharmacoEconomics&amp;nbsp;2007, Vol/Iss/Pg. 25/4 (287-308), ISSN: 1170-7690.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17402803%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: Estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. PharmacoEconomics, 2006, Vol/Iss/Pg. 24/3 (251-264), ISSN: 1170-7690. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16519547%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Koleva D, Motterlini N, Schiavone M, Garattini L. Medical costs of glaucoma and ocular hypertension in Italian referral centres: A prospective study. Ophthalmologica, 2007, Vol/Iss/Pg. 221/5 (340-347), ISSN: 0030-3755. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17728557%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Bhosle MJ, Reardon G, Camacho FT, Anderson RT, Balkrishnan R. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population. American Journal Geriatric Pharmacotherapy, 2007, Vol/Iss/Pg. 5/2 (100-111), ISSN: 1543-5946. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17719512%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Combination vs monotherapy and fixed combination&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Noecker RJ, Awadallah NS, Kahook MY. Travoprost 0.004 %/timolol 0.5% fixed combination. Drugs of Today, 2007, Vol/Iss/Pg. 43/2 (77-83), ISSN: 0025-7656. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17353945%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Frampton JE, Perry CM. Topical dorzolamide 2 %/timolol 0.5% ophthalmic solution: A review of its use in the treatment of glaucoma and ocular hypertension. Drugs and Aging, 2006, Vol/Iss/Pg. 23/12 (977-995), ISSN: 1170-229X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17154662%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Frampton JE. Topical brimonidine 0.2 %/timolol 0.5% ophthalmic solution: In glaucoma and ocular hypertension. Drugs and Aging, 2006, Vol/Iss/Pg. 23/9 (753-761), ISSN: 1170-229X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17020399%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Webers CAB, van der Valk R, Schouten JSAG, Zeegers MP, Prins MH, Hendrikse F. Intraocular Pressure-Lowering Effect of Adding Dorzolamide or Latanoprost to Timolol. A Meta-analysis of Randomized Clinical Trials. Ophthalmology, 2007, Vol/Iss/Pg. 114/1 (40-46), ISSN: 0161-6420. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17070584%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, Whitcup SM. Twice-daily 0.2% brimonidine-0.5 % timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Archives of Ophthalmology, Sep 2006, vol. 124, no. 9, p. 1230-8, ISSN: 0003-9950. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16966616%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hommer AA double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03 %/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. European Journal of Ophthalmology, Jan-Feb 2007, vol. 17, no. 1, p. 53-62, ISSN: 1120-6721. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17294383%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA. Comparison of initial intraocular pressure response with topical (beta)-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the ocular hypertension treatment study. Archives of Ophthalmology, 2007, Vol/Iss/Pg. 125/4 (454-459), ISSN: 0003-9950. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17420364%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Higginbotham EJ. Treating ocular hypertension to reduce glaucoma risk: When to treat? Drugs 2006, Vol/Iss/Pg. 66/8 (1033-1039), ISSN: 0012-6667. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16789790%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Wadhwa SD, Higginbotham EJ. Strategies to reduce the progression of glaucoma. Aging Health, 2007, Vol/Iss/Pg. 3/3 (397-403), eISSN: 1745-5103, ISSN: 1745-509X. &lt;A href="http://www.ingentaconnect.com/content/fm/ahe/2007/00000003/00000003/art00016" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Henness S, Harrison TS, Keating GM. Ocular carteolol: A review of its use in the management of glaucoma and ocular hypertension. Drugs and Aging 2007, Vol/Iss/Pg. 24/6 (509-528), ISSN: 1170-229X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17571916%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Vass C, Hirn S, Sycha T, Findl O, Bauer P, Schmetterer L. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database of Systematic Reviews 2007 Vol/Iss/Page. -/4. Article number: CD003167. ISSN: 1469-493X &lt;A href="nelh:270874:0" name=internalLink&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Pharmacological neuroprotection &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Chidlow G, Wood JPM, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs&amp;nbsp;2007, Vol/Iss/Pg. 67/5 (725-759), ISSN: 0012-6667. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17385943%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17571916%5Buid%5D" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Medical%20Management%20search%20history%20.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Total%20Journal%20Spread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents &lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273534</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273534]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Optic Disc Imaging Diagnosis and Disease Monitoring</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2007,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Optic Disc Imaging Diagnosis and Disease Monitoring&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:299316:0" name=internalLink&gt;Click here to view 2008 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1107/nkw_glaucoma_1107_doc4.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/Diagnosis%20&amp;amp;%20Disease%20Management.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:187787:0" name=internalLink&gt;Click here to view 2006 NKW Diagnosis section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:201795:0" name=internalLink&gt;Click here to view 2006 NKW Disease Monitoring section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Optic Disc Imaging : Diagnosis and Disease Monitoring&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched:&lt;/STRONG&gt; Medline 1996 to date, Embase 1996 to date&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; June 2006 to October 2007&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp;&lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=343 alt="Diagnosis &amp;amp; Disease Monitoring Evidence Tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273534/nelhImp_0001_diagDiseaseManagement.jpg" width=650 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OCT (Optical Coherence Tomography)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;Sehi M, Guaqueta DC, Feuer WJ, Greenfield DS.&amp;nbsp;A comparison of structural measurements using 2 Stratus optical coherence tomography instruments. Journal of Glaucoma, May 2007, vol. 16, no. 3, p. 287-92, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17438421%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Wu Z, Vazeen M, Varma R, Chopra V, Walsh AC, LaBree LD, Sadda SR. Factors associated with variability in retinal nerve fiber layer thickness measurements obtained by optical coherence tomography. Ophthalmology, Aug 2007 (epub: 23 Mar 2007), vol. 114, no. 8, p. 1505-12, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17367862%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Mastropasqua L, Brusini P, Carpineto P, Ciancaglini M, Di Antonio L, Zeppieri MW, Parisi L. Humphrey matrix frequency doubling technology perimetry and optical coherence tomography measurement of the retinal nerve fiber layer thickness in both normal and ocular hypertensive subjects. Journal of Glaucoma,&amp;nbsp;Aug 2006, vol. 15, no. 4, p. 328-35, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16865011%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Anton A, Moreno-Montañes J, Blázquez F, Alvarez A, Martín B, Molina B. Usefulness of optical coherence tomography parameters of the optic disc and the retinal nerve fiber layer to differentiate glaucomatous, ocular hypertensive, and normal eyes. Journal of Glaucoma, Jan 2007, vol. 16, no. 1, p. 1-8, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17224742%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kim TW, Zangwill LM, Bowd C, Sample PA, Shah N, Weinreb RN. Retinal nerve fiber layer damage as assessed by optical coherence tomography in eyes with a visual field defect detected by frequency doubling technology perimetry but not by standard automated perimetry. Ophthalmology, Jun 2007 (epub: 18 Jan 2007), vol. 114, no. 6, p. 1053-7, ISSN: 1549-4713.&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17239441%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HRT (Heidelberg Retinal Tomography)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Hawker MJ, Vernon SA, Tattersall CL, Dua HS. Detecting glaucoma with RADAAR: the Bridlington Eye Assessment Project.The British Journal of Ophthalmology, Jun 2006, vol. 90, no. 6, p. 744-8, ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16714266%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Thomas R, Muliyil J, Simha-RA, Parikh RS.&amp;nbsp; Heidelberg Retinal Tomograph (HRT 2) parameters in primary open angle glaucoma and primary angle closure glaucoma: a comparative study in an Indian population. Ophthalmic Epidemiology, Oct 2006, vol. 13, no. 5, p. 343-50, ISSN: 0928-6586. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17060113%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hoffmann EM, Boden C, Zangwill LM, Bowd C, Medeiros FA, Crowston JG, Sample PA, Weinreb RN. Intereye spatial relationship of abnormal neuroretinal rim locations in glaucoma patients from the diagnostic innovations in glaucoma study. American Journal of Ophthalmology, May 2007 (epub: 26 Mar 2007), vol. 143, no. 5, p. 781-7, ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17379176%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;De La Rosa MG, Gonzalez Hernandez M, Lozano Lopez V, Mendez MS, De La Vega RR. Optic disc tomography and perimetry in controls, glaucoma suspects, and early and established glaucomas. Optometry and Vision Science 2007, Vol/Iss/Pg. 84/1 (33-41), ISSN: 1040-5488. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17220776%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kourkoutas D, Buys YM, Flanagan JG, Hatch WV, Balian C, Trope GE. Comparison of glaucoma progression evaluated with Heidelberg retina tomograph II versus optic nerve head stereophotographs. Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie, Feb 2007, vol. 42, no. 1, p. 82-8, ISSN: 0008-4182. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17361246%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kalaboukhova L, Fridhammar V, Lindblom B. Glaucoma follow-up by the Heidelberg retina tomograph--new graphical analysis of optic disc topography changes. Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie, Jun 2006 (epub: 12 Oct 2005), vol. 244, no. 6, p. 654-62, ISSN: 0721-832X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16220279%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HRT - normative database&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Zelefsky JR, Harizman N, Mora R, Ilitchev E, Tello C, Ritch R, Liebmann JM. Assessment of a race-specific normative HRT-III database to differentiate glaucomatous from normal eyes. Journal of Glaucoma, Dec 2006, vol. 15, no. 6, p. 548-51, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17106370%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hawker MJ, Vernon SA, Tattersall CL, Dua HS. Linear regression modeling of rim area to discriminate between normal and glaucomatous optic nerve heads: the Bridlington Eye Assessment Project. Journal of Glaucoma, Jun-Jul 2007, vol. 16, no. 4, p. 345-51, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17570996%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;GdX (Nerve Fibre Analyser)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Medeiros FA, Doshi R, Zangwill LM, Vasile C, Weinreb RN. Long-term variability of GDx VCC retinal nerve fiber layer thickness measurements. Journal of Glaucoma, May 2007, vol. 16, no. 3, p. 277-81, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17438419%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Essock EA, Gunvant P, Zheng Y, Garway-Heath DF, Kotecha A, Spratt A. Predicting visual field loss in ocular hypertensive patients using wavelet-fourier analysis of GDx scanning laser polarimetry. Optometry and Vision Science : official publication of the American Academy of Optometry, May 2007, vol. 84, no. 5, p. 380-7, ISSN: 1040-5488. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17502818%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Georgopoulos GT, Halkiadakis I, Patsea E, Papakonstantinou D, Alexiou M, Vergados I, Andreanos D, Theodossiadis G, Moschos-M. Study of patients with ocular hypertension with scanning laser polarimetry and short-wavelength automatic perimetry. Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift für Augenheilkunde, 2006, vol. 220, no. 6, p. 361-7, ISSN: 0030-3755. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17095880%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Shaikh A, Salmon JF. The role of scanning laser polarimetry using the GDx variable corneal compensator in the management of glaucoma suspects. The British Journal of Ophthalmology, Dec 2006 (epub: 02 Aug 2006), vol. 90, no. 12, p. 1454-7, ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16885189%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Yu S, Tanabe T, Hangai M, Morishita S, Kurimoto Y, Yoshimura N. Scanning laser polarimetry with variable corneal compensation and optical coherence tomography in tilted disk. American Journal of Ophthalmology,&amp;nbsp;Sep 2006, vol. 142, no. 3, p. 475-82, ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16935594%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Comparison with VF&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Subbiah S, Sankarnarayanan S, Thomas PA, Nelson JCA. Comparative evaluation of optical coherence tomography in glaucomatous, ocular hypertensive and normal eyes. Indian Journal of Ophthalmology, Jul-Aug 2007, vol. 55, no. 4, p. 283-7, ISSN: 0301-4738. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17595477%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Iester M, Perdicchi A, De Feo F, Fiesoletti E, Amodeo S, Sanna G, Leonardi A, Calabria G. Comparison between GDx VCC parameter and achromatic perimetry in glaucoma patients. Journal of Glaucoma,&amp;nbsp;Aug 2006, vol. 15, no. 4, p. 281-5, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16865003%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Diagnosis%20and%20disease%20monitoring.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Total%20Journal%20Spread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273482</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273482]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Patient Education</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,GLAUCOMA NKW 2007,ANNUAL EVIDENCE UPDATES,GLAUCOMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Patient Education&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:299251:0" name=internalLink&gt;Click here to view 2008 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1107/nkw_glaucoma_1107_doc6.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/Patient%20Education.pdf" target="_blank"&gt;Click here to view PDF version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:197249:0" name=internalLink&gt;Click here to view 2006 NKW Patient Education section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Education &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched: &lt;/STRONG&gt;Medline 1996 to date, Embase 1996 to date, Cinahl 1982 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched:&lt;/STRONG&gt; June 2006 to October 2007&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp; &lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=343 alt="Patient education tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273482/nelhImp_0001_patEducation.jpg" width=650 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Communication/Education&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Hartmann CW, Rhee DJ. The patient's journey: glaucoma. BMJ, 2006 Oct 7, vol. 333, no. 7571, p. 738-9, ISSN: 0959-8146. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17023466%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Adherence&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Tsai -JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Current Opinion in Ophthalmology,&amp;nbsp;Apr 2006, vol. 17, no. 2, p. 190-5, 52 refs, ISSN: 1040-8738.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16552255%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kahook MY. Developments in dosing aids and adherence devices for glaucoma therapy: current and future perspectives. Expert Review of Medical Devices,&amp;nbsp;Mar 2007, vol. 4, no. 2, p. 261-6, 30 refs, ISSN: 1743-4440.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17359230%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Bhosle MJ, Reardon G, Camacho FT, Anderson RT, Balkrishnan R. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population. The American Journal of Geriatric Pharmacotherapy,&amp;nbsp;Jun 2007, vol. 5, no. 2, p. 100-11, ISSN: 1543-5946.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17719512%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Lievens CW, Gunvant P, Newman J, Gerstner M, Simpson C. Effect of Proview self-tonometry on pharmaceutical compliance. Clinical &amp;amp; Experimental Optometry : journal of the Australian Optometrical Association,&amp;nbsp;Nov 2006, vol. 89, no. 6, p. 381-5, ISSN: 0816-4622.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17026606%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Flowers B, Wand M, Piltz SJ, Berke SJ, Day D, Teague J, Smoot TM, Landry TA, Bergamini MVW, Mallick S. Patients' and physicians' perceptions of the travoprost dosing aid: An open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension. Clinical Therapeutics, 2006, Vol/Iss/Pg. 28/11 (1803-1811) , ISSN: 0149-2918.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17213000%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Nordmann JP, Denis P, Vigneux M, Trudeau E, Guillemin I, Berdeaux G. Development of the conceptual framework for the Eye-Drop Satisfaction Questionnaire (EDSQ) in glaucoma using a qualitative study. BMC Health Services Research,&amp;nbsp;2007 (epub), vol. 7, p. 124, ISSN: 1472-6963.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17683594%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Ngan R, Lam DL, Mudumbai RC, Chen PP. Risk factors for noncompliance with follow-up among normal-tension glaucoma suspects. American Journal of Ophthalmology, Aug 2007, vol. 144, no. 2, p. 310-1, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17659968%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Schwartz GF, Platt R, Reardon G, Mychaskiw MA. Accounting for Restart Rates in Evaluating Persistence with Ocular Hypotensives. Ophthalmology&amp;nbsp;2007, Vol/Iss/Pg. 114/4 (648-652), ISSN: 0161-6420.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17398318%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Pappa C, Hyphantis T, Pappa S, Aspiotis M, Stefaniotou M, Kitsos G, Psilas K, Mavreas V. Psychiatric manifestations and personality traits associated with compliance with glaucoma treatment. Journal of Psychosomatic Research,&amp;nbsp;Nov 2006, vol. 61, no. 5, p. 609-17, ISSN: 0022-3999.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17084138%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gwira JA, Vistamehr S, Shelsta H, Bashford K, Forster S, Palmisano&amp;nbsp; P, Shafranov G, Shields MB. Factors associated with failure to follow up after glaucoma screening: a study in an African American population. Ophthalmology, Aug 2006 (epub: 12 Jun 2006), vol. 113, no. 8, p. 1315-9, ISSN: 1549-4713.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16769119%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Muir KW, Santiago TC, Stinnett SS, Herndon LW, Allingham RR, Challa P, Lee PP. Health literacy and adherence to glaucoma therapy. American Journal of Ophthalmology, Aug 2006, vol. 142, no. 2, p. 223-6, ISSN: 0002-9394.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16876500%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Awareness&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Observational studies &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Mansouri K, Orgül S, Meier-Gibbons F, Mermoud A. Awareness about glaucoma and related eye health attitudes in Switzerland: a survey of the general public. Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift für Augenheilkunde, 2006, vol. 220, no. 2, p. 101-8, ISSN: 0030-3755.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16491032%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Cross V, Shah P, Bativala R, Spurgeon P. ReGAE 2: Glaucoma awareness and the primary eye-care service: Some perceptions among African Caribbeans in Birmingham UK. Eye 2007, Vol/Iss/Pg. 21/7 (912-920), eISSN: 1476-5454, ISSN: 0950-222X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16902494%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Dietlein TS, Jordan J, Dinslage S, Krieglstein GK. What do glaucoma specialists know about their patients? Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie, Jul 2006 (epub: 15 Nov 2005), vol. 244, no. 7, p. 859-62, ISSN: 0721-832X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16292519%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Patient%20education.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Total%20Journal%20Spread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents page&amp;nbsp;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273499</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273499]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Screening</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2007,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Screening&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="nelh:299273:0" name=internalLink&gt;Click here to view 2008 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1107/nkw_glaucoma_1107_doc2.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/Screening.pdf" target="_blank"&gt;Click here to view PDF version &lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:182443:0" name=internalLink&gt;Click here to view 2006 NKW Screening section&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Databases searched: &lt;/STRONG&gt;Medline 1996 to date, Embase 1996 to date&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Period searched: &lt;/STRONG&gt;June 2006 to October 2007&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Users should note that the EVSL has not performed an in-depth appraisal of the content or quality of each reference cited and their inclusion does not imply endorsement.&amp;nbsp; &lt;EM&gt;We recommend that a full appraisal is completed using the appropriate check-list provided by the &lt;/EM&gt;&lt;A href="http://www.cebm.net/index.aspx?o=1157" target="_blank"&gt;&lt;EM&gt;Centre for Evidence-Based Medicine&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;. &lt;/EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt; include&amp;nbsp;Cochrane systematic reviews, systematic reviews, reviews and meta or cost analyses.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt; include randomised controlled trials and controlled clinical&amp;nbsp;trials &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt; include cohorts, case control trials, validation studies, observational or comparative studies, case reports/series,&amp;nbsp;population based cross-sectional and cohort studies and qualitative surveys. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence Tree&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=343 alt="Screening evidence tree" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID273499/nelhImp_0000_screening.jpg" width=650 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;General &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Hatt S, Wormald R, Burr J. Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database of Systematic Reviews 2006, Vol/Iss/Pg. -/4, Article number: CD006129, ISSN: 1469-493X. &lt;A href="nelh:239258:0" name=internalLink&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Structural ONH (optic nerve head) assessment&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Zelefsky JR, Harizman N, Mora R, Ilitchev E, Tello C, Ritch R, Liebmann JM. Assessment of a race-specific normative HRT-III database to differentiate glaucomatous from normal eyes. Journal of Glaucoma, Dec 2006, vol. 15, no. 6, p. 548-51, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17106370%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Subbiah S, Sankarnarayanan S, Thomas PA, Nelson JCA.&amp;nbsp; Comparative evaluation of optical coherence tomography in glaucomatous, ocular hypertensive and normal eyes. Indian Journal of Ophthalmology, Jul-Aug 2007, vol. 55, no. 4, p. 283-7, ISSN: 0301-4738. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17595477%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Iester M, Perdicchi A, De Feo F, Fiesoletti E, Amodeo S, Sanna G, Leonardi A, Calabria G.&amp;nbsp; Comparison between GDx VCC parameter and achromatic perimetry in glaucoma patients. Journal of Glaucoma, Aug 2006, vol. 15, no. 4, p. 281-5, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16865003%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Hawker MJ, Vernon SA, Tattersall CL, Dua HS. Detecting glaucoma with RADAAR: the Bridlington Eye Assessment Project. The British Journal of Ophthalmology,&amp;nbsp;Jun 2006, vol. 90, no. 6, p. 744-8, ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16714266%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Wu-Z, Vazeen Mi, Varma-R, Chopra-V, Walsh AC, LaBree LD, Sadda SR. Factors associated with variability in retinal nerve fiber layer thickness measurements obtained by optical coherence tomography. Ophthalmology,&amp;nbsp;Aug 2007 (epub: 23 Mar 2007), vol. 114, no. 8, p. 1505-12, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17367862%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Horn FK, Brenning A, Jünemann AG, Lausen B. Glaucoma detection with frequency doubling perimetry and short- wavelength perimetry. Journal of Glaucoma 2007, Vol/Iss/Pg. 16/4 (363-371), ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17570999%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;De La Rosa MG, Gonzalez HM, Lozano LV, Mendez MS, De La Vega RR. Optic disc tomography and perimetry in controls, glaucoma suspects, and early and established glaucomas. &amp;nbsp;Optometry and Vision Science 2007, Vol/Iss/Pg. 84/1 (33-41), ISSN: 1040-5488. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17220776%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Kim Tae W, Zangwill LM, Bowd C, Sample PA, Shah N, Weinreb RN. Retinal nerve fiber layer damage as assessed by optical coherence tomography in eyes with a visual field defect detected by frequency doubling technology perimetry but not by standard automated perimetry. Ophthalmology, Jun 2007 (epub: 18 Jan 2007), vol. 114, no. 6, p. 1053-7, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17239441%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Yu S, Tanabe T, Hangai M, Morishita S, Kurimoto Y, Yoshimura-N. Scanning laser polarimetry with variable corneal compensation and optical coherence tomography in tilted disk. American Journal of Ophthalmology,&amp;nbsp;Sep 2006, vol. 142, no. 3, p. 475-82, ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16935594%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Shaikh A, Salmon JF. The role of scanning laser polarimetry using the GDx variable corneal compensator in the management of glaucoma suspects. The British Journal of Ophthalmology, Dec 2006 (epub: 02 Aug 2006), vol. 90, no. 12, p. 1454-7, ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16885189%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Anton A, Moreno Montañes J, Blázquez F, Alvarez A, Martín B, Molina B. Usefulness of optical coherence tomography parameters of the optic disc and the retinal nerve fiber layer to differentiate glaucomatous, ocular hypertensive, and normal eyes. Journal of Glaucoma, Jan 2007, vol. 16, no. 1, p. 1-8, ISSN: 1057-0829. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17224742%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;IOP (intra-ocular pressure) assessment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Maino AP, Morgan LH, Hercules BL, Tullo AB. Are disposable prisms an adequate alternative to standard Goldmann tonometry prisms in glaucoma patients? Ophthalmology, Oct 2006, vol. 113, no. 10, p. 1837-41, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17011960%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies &lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Grieshaber MC, Schoetzau A, Zawinka C, Flammer J, Orgul S. Effect of central corneal thickness on dynamic contour tonometry and Goldmann applanation tonometry in primary open-angle glaucoma. Archives of Ophthalmology,&amp;nbsp;Jun 2007, vol. 125, no. 6, p. 740-4, ISSN: 0003-9950. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17562982%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Functional tests&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;North RV, Jones AL, Hunter E, Morgan JE, Wild JM. Evaluation of the high specificity Screening Program (C-20-1) of the Frequency Doubling Technology (FDT) perimeter in clinical practice. Eye (London England), Jun 2006 (epub: 24 Jun 2005), vol. 20, no. 6, p. 681-7, ISSN: 0950-222X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=15999135%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Leeprechanon N, Giangiacomo A, Fontana H, Hoffman D, Caprioli J. Frequency-doubling perimetry: comparison with standard automated perimetry to detect glaucoma. American Journal of Ophthalmology,&amp;nbsp;Feb 2007 (epub: 27 Nov 2006), vol. 143, no. 2, p. 263-271, ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17178091%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Hong S, Chung W, Hong YJ, Seong GJ. Discriminating ability of Humphrey matrix perimetry in early glaucoma patients. Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift für Augenheilkunde, 2007, vol. 221, no. 3, p. 195-9, ISSN: 0030-3755. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17440283%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Gardiner SK, Anderson DR, Fingeret M, McSoley JJ, Johnson CA. Evaluation of decision rules for frequency-doubling technology screening tests. Optometry and Vision Science : official publication of the American Academy of Optometry,&amp;nbsp;Jul 2006, vol. 83, no. 7, p. 432-7, ISSN: 1040-5488. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16840859%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Krueger RR, Ramos EJC. How might corneal elasticity help us understand diabetes and intraocular pressure? Journal of Refractive Surgery (Thorofare N.J. : 1995),&amp;nbsp;Jan 2007, vol. 23, no. 1, p. 85-8, 38 refs, ISSN: 1081-597X. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17003413%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Interventional studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA. Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study. Investigative Ophthalmology &amp;amp; Visual Science, Sep 2006, vol. 47, no. 9, p. 3896-903, ISSN: 0146-0404. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16936102%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Canadian Glaucoma Study Group. Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses. Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie,&amp;nbsp;Oct 2006, vol. 41, no. 5, p. 566-75, ISSN: 0008-4182. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17016527%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Choi J, Kim KH, Jeong J, Cho HS, Lee CH, Kook MS. Circadian fluctuation of mean ocular perfusion pressure is a consistent risk factor for normal-tension glaucoma. Investigative Ophthalmology &amp;amp; Visual Science, Jan 2007, vol. 48, no. 1, p. 104-11, ISSN: 0146-0404. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17197523%5Buid%5D" target="_blank"&gt;[abstract]&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;BR&gt;Xu L, Wang Y, Yang H, Jonas JB. Differences in Parapapillary Atrophy between Glaucomatous and Normal Eyes: The Beijing Eye Study. American Journal of Ophthalmology&amp;nbsp;2007, Vol/Iss/Pg. 144/4 (541-546), ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17651676%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Bennett SL, Hewitt AW, Poulsen JL, Kearns LS, Morgan JE, Craig JE, Mackey DA. Screening for glaucomatous disc changes prior to diagnosis of glaucoma in myocilin pedigrees. Archives of Ophthalmology, Jan 2007, vol. 125, no. 1, p. 112-6, ISSN: 0003-9950. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17210861%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk factor - Central Corneal Thickness&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Secondary Publications&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Dueker DK, Singh K, Lin SC, Fechtner RD, Minckler DS, Samples JR, Schuman JS. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology, Sep 2007, vol. 114, no. 9, p. 1779-87, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17822980%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Observational studies&lt;/STRONG&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Behki R, Damji KF, Crichton A.&amp;nbsp; Canadian perspectives in glaucoma management: The role of central corneal thickness. Canadian Journal of Ophthalmology 2007, Vol/Iss /Pg. 42/1 (66-74), ISSN: 0008-4182. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17361244%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Pakravan M, Parsa A, Sanagou M, Parsa CF. Central corneal thickness and correlation to optic disc size: a potential link for susceptibility to glaucoma. The British Journal of Ophthalmology, Jan&amp;nbsp; 2007 (epub: 14 Sep 2006), vol. 91, no. 1, p. 26-8, ISSN: 0007-1161. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16973656%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Rogers DL, Cantor RN, Catoira Y, Cantor LB, WuDunn D. Central corneal thickness and visual field loss in fellow eyes of patients with open-angle glaucoma. American Journal of Ophthalmology,&amp;nbsp;Jan 2007 (epub: 31 Aug 2006), vol. 143, no. 1, p. 159-61, ISSN: 0002-9394. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17188056%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Lee ES, Kim CY, Ha SJ, Seong GJ, Hong YJ. Central corneal thickness of Korean patients with glaucoma. Ophthalmology, May 2007 (epub: 21 Feb 2007), vol. 114, no. 5, p. 927-30, ISSN: 1549-4713. &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=17316807%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Papadia M, Sofianos C, Iester M, Bricola G, Mete M, Traverso CE. Corneal thickness and visual field damage in glaucoma patients. Eye (London England), Jul 2007 (epub: 28 Apr 2006), vol. 21, no. 7, p. 943-7, ISSN: 0950-222X.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;amp;Cmd=DetailsSearch&amp;amp;Term=16645628%5Buid%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Screening.pdf" target="_blank"&gt;Click here to view search strategy&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1107/search_strategies/Total%20Journal%20Spread.pdf" target="_blank"&gt;Click here to view journal spread&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to knowledge week contents page&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>273738</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=273738]]&gt;</url>
    <title>Glaucoma National Knowledge Week: 19-25 November 2007 : Uncertainties in the management of Glaucoma</title>
    <publicationDate>2007-11-19T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2007,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: 19-25 November 2007 : Uncertainties in the management of Glaucoma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The NLH Eyes and Vision Specialist Library is collaborating in the development of DUETS – &lt;A href="http://www.duets.nhs.uk/" target="_blank"&gt;the Database of Uncertainties about the Effects of Treatments&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;DUETS has been established to publish uncertainties that cannot currently be answered reliably by referring to up-to-date systematic reviews of existing research evidence.&amp;nbsp; It is being developed to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians.&lt;/P&gt;
&lt;P&gt;DUETs draws on three main sources to identify uncertainties about the effects of treatments:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;patients', carers' and clinicians' questions about the effects of&amp;nbsp;&amp;nbsp; treatments &lt;/LI&gt;
&lt;LI&gt;research recommendations in reports of systematic reviews and clinical guidelines &lt;/LI&gt;
&lt;LI&gt;ongoing research, both systematic reviews in preparation and new 'primary' studies &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;DUETs does not include unanswered questions about the frequency, causes and diagnosis of health problems.&lt;/P&gt;
&lt;P&gt;If you are aware of or identified any uncertainties in the management of&amp;nbsp;Glaucoma please let us know.&amp;nbsp; You can contact us via our &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/feedback.asp" target="_blank"&gt;feedback form&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?pagename=NKWGLA2007" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>212425</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=212425]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Abbreviations - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS,GLAUCOMA NKW 2006,GLAUCOMA,ANNUAL EVIDENCE UPDATES]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Abbreviations - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp; 
&lt;TABLE width="100%" border=1&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;A&amp;amp;E&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Accident &amp;amp; Emergency&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;AAO&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;American Academy of Ophthalmology&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;BNF&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;British National Formulary&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CfH&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Connecting for Health&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;CVI&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Certificate of Visual Impairment&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DH&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Department of Health&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DOAS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Do Once and Share&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;DVLA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Driving Vehicle Licensing Authority&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;EGS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;European Glaucoma Society&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;EMGTS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Early Manifest Glaucoma Trial&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;FDP&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Frequency doubling perimetry&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;GDx&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Scanning laser polarimetry&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;GDxVCC&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Scanning laser polarimetry with 'variable' corneal compensation&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;GHT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Glaucoma hemifield test&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;HRT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Heidelberg Retina Tomograph&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;HTA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Health Technology Assessment&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;ILVS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Interdisciplinary low vision service&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;
&lt;P&gt;&amp;nbsp;IOP&lt;/P&gt;&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Intraocular pressure&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;LVA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Low vision aid&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;LVL&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Low vision leaflet&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;MDP&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Motion detection perimetry&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NHS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;National Health Service&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NHS ISB&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;NHS Information Standards Board&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;NSC&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;National Screening Committee&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;OBS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Output based specifications&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;OCT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Optical coherence tomograph&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;OHT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Ocular hypertension&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;OHTS&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Ocular Hypertension Treatment Study&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;ONH&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Optic Nerve Head&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;POAG&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Primary Open Angle Glaucoma&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PCT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Primary Care Trust&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PLR&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Pointwise linear regression&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PPP&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Preferred Practice Plan&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;PSD&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Perimetry Pattern Standard Deviation&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RCO&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Royal College of Ophthalmologists&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RCT&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Randomised controlled trial&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RNFL&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Retinal nerve fibre layer&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RNIB&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Royal National Institute for the Blind&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;RVI&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Referral of visual impairment&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;SAP&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Static automated perimetry&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;SWAP&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Short wavelength automated perimetry&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;&amp;nbsp;TCA&lt;/TD&gt;
&lt;TD&gt;&amp;nbsp;Topographic change analysis&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>201779</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=201779]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Current trends in medical management - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2006]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Current trends in medical management - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;IMG id=nelh_tempImage0 height=121 alt="A glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201779/nelhImp_0000_glaucomaeye.jpg" width=178 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="Patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201779/nelhImp_0001_tonometry.jpg" width=178 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="example of visual loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0005_lossglaucoma.jpg" width=178 border=0 name=nelh_tempImage2&gt;&lt;/H2&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Mr David Broadway BSc, MBBS, DO(RCS), MD, FRCOphth&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/viewResource.aspx?resID=212425&amp;amp;code=3199269fccad447e9ba5720fb4853a55" target="_blank"&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc10.asp" target="_blank"&gt;Click here to view low vision version&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Current%20Trends%20in%20Medical%20Management.pdf" target="_blank"&gt;Click here to download pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273514:0" name=internalLink&gt;Click here to view 2007 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction&lt;BR&gt;&lt;/STRONG&gt;The mainstay of glaucoma management is reduction of intraocular pressure (IOP), which is usually achieved with topical medications that can reduce aqueous production and/or increase trabecular or uveo-scleral outflow. In the majority of patients it is accepted that topical ocular-hypotensive drugs, when available, should be tried as initial therapy when clinically indicated [1,2] and that adequate reduction in IOP reduces the risk of long term visual field loss[3].&lt;/P&gt;
&lt;P&gt;Topical medications include prostaglandin/prostamide analogues, beta-blockers, carbonic anhydrase inhibitors, sympathomimetics/alpha2-agonists, cholinergic agonists/miotics and combination products. Less commonly used systemic medications include a carbonic anhydrase inhibitor (oral or intravenous acetazolamide) and osmotic diuretics (oral glycerol or intravenous mannitol). Details of all antiglaucomatous medications available in the UK are provided in the &lt;A href="http://www.bnf.org/bnf/" target="_blank"&gt;British National Formulary&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Topical medication efficacy&lt;/STRONG&gt;&lt;BR&gt;There is evidence that prostaglandin analogues are more potent in lowering IOP in comparison with beta-blockers, [4-6] although at a greater cost, long-term health-economic studies are required to determine their clinical cost-effectiveness[7]. The prostamide, bimatoprost, appears to be slightly more potent, or at least equipotent[5,8,9], in comparison with the prostaglandin analogues (latanoprost and travoprost), but has a slightly worse side-effect profile[10]. The potentially greater efficacy of bimatoprost may override the side-effect issues and make the overall cost-effectiveness attractive [11,12]. Travoprost may be more effective in patients of African origin in comparison with latanoprost or timolol [13]. Latanoprost appears to have the better side-effect profile (for the prostaglandin/prostamide class of drug) and this is better than that associated with use of combined timolol and dorzolamide [14] As a second-line therapy latanoprost has been shown to provide safe, effective therapy with high persistency, at an acceptable cost [15] Even when medications are equally efficacious, greater tolerability [16,17] has significant potential economic advantages (eg when comparing dorzlamide and brinzolamide) [18]. Furthermore, ‘switching’ therapy may be more economic than ‘adding’ to previously prescribed drugs [19], particularly if the initial therapy has failed [20], although this may be at the cost of slightly reduced efficacy [21].&lt;/P&gt;
&lt;P&gt;It is accepted, however, that there is still a need to define therapeutic standards with respect to efficacy in reducing IOP consistently over a 24-hour period to a level that will preserve the visual field and protect the optic nerve without inducing tachyphylaxis, intolerance [22-24] or poor adherence [25] Health economics are also important and two major independent factors have been identified to explain the bulk of total cost variance: drug treatment changes and the presence of glaucoma as opposed to ocular hypertension [26]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Management principles&lt;BR&gt;&lt;/STRONG&gt;The principles of medical management have changed little in recent years and the evidence that it is beneficial to certain patient groups was strengthened by the findings of several large prospective studies [1,27-31], which have provided evidence that appropriate reduction in IOP reduces the rate of disease progression [3,32]. It should be stressed, however, that management should be tailored to the individual patient [33].&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Update&lt;/STRONG&gt;&lt;BR&gt;Since publication of the four main guidance documents [34,35,36,37], the principles of medical management for glaucoma have remained stable. The main change has been an increase in the medical armamentarium with the provision of more combination therapies and more preservative free preparations. &lt;/P&gt;
&lt;P&gt;Theoretically the use of combination therapy improves patient adherence with anti-glaucomatous therapy, reduces costs and minimizes exposure to topical medication vehicle, buffer and preservative. &lt;/P&gt;
&lt;P&gt;Combinations of beta-blockers with prostaglandin/prostamide analogues (Xalacom™, DuoTrav™, GanFort®), a carbonic anhydrase inhibitor (Cosopt™) or an alpha2-agonist (Combigan™) are now available. There is evidence that the fixed-combination products are safe and efficacious, being equipotent or more potent than the individual components, either alone or in unfixed combination (Xalacom™[38-44], DuoTrav™ [45], GanFort® [46],&amp;nbsp; Cosopt™[47-50], Combigan™ [51,52]).&lt;/P&gt;
&lt;P&gt;The availability of more preservative-free topical anti-glaucomatous medications has increased the choice of therapy for patients intolerant to preservatives such as benzalkonium chloride or benzododecinium bromide. A number of topical beta-blockers, and more recently a carbonic anhydrase inhibitor (dorzolamide), have become available as unit-dose, preservative-free preparations. Preservative-free beta-blockers appear to be as efficacious as preserved preparations [53], induce less conjunctival inflammation [54,55] and cause less local side-effects [56]. &lt;/P&gt;
&lt;P&gt;Information about recently introduced anti-glaucomatous drugs is available at the &lt;A href="http://www.emea.eu.int/" target="_blank"&gt;European Medicines Agency &lt;/A&gt;website.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Alternative and complimentary medications&lt;BR&gt;&lt;/STRONG&gt;At present there is no proven evidence that any alternative, or complimentary, medications are of benefit in treating non-IOP-dependent mechanisms in glaucoma. A neuroprotection clinical trial is underway to determine whether memantine (an NMDA-receptor antagonist that affects glutamate transmission) can reduce the risk of progressive glaucomatous damage (ClinicalTrials.gov Identifiers NCT00141882, NCT00168350). Memantine is already licensed for the treatment of moderate to severe Alzheimer’s disease.&lt;BR&gt;Ginkgo biloba extract as a complementary anti-glaucomatous agent may also have potential value. Ginkgo biloba extract has numerous properties that in theory should be beneficial; including increased ocular blood flow, antioxidant activity, platelet activating factor inhibitory activity, nitric oxide inhibition, and neuroprotective activity [57].&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;/STRONG&gt;&lt;BR&gt;Two recommended websites for patient information about glaucoma and the management of glaucoma are those of The International Glaucoma Association (&lt;A href="http://www.iga.org.uk/" target="_blank"&gt;www.iga.org.uk&lt;/A&gt;) and The Royal National Institute for the Blind (&lt;A href="http://www.rnib.org.uk/" target="_blank"&gt;www.rnib.org.uk&lt;/A&gt;).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication&amp;nbsp;types of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication dates of cited references&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA&amp;nbsp;et al (The Collaborative Initial Glaucoma Treatment Study Group). Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medication or surgery. Ophthalmology 2001;108:1943-1953. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=102033&amp;amp;tabID=289" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD004399. DOI: 10.1002/14651858.CD004399.pub2. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=190286" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;3. Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15994659%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma 2003;12:463-5. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=14646679&amp;amp;query_hl=41&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47 Suppl 1:S105-115. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12204706&amp;amp;query_hl=3&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-1185. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15921747&amp;amp;query_hl=43&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. Orme M, Boler A. Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: A systematic review of economic evidence. PharmacoEconomics 2006;24:743-750. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16898845&amp;amp;query_hl=7&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36:504-511. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=11895065&amp;amp;query_hl=45&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002;19:231-248. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12027782&amp;amp;query_hl=47&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10. Choplin N, Bernstein P, Batoosingh AL, Whitcup SM. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol. 2004;49 Suppl 1:S19-25. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15016558&amp;amp;query_hl=49&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11. Walt JG, Lee JT. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49 Suppl 1:S36-44. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15016560&amp;amp;query_hl=52&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12. Noecker RJ, Walt JG. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol. 2006;141 Suppl 1: S15-21. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16389056&amp;amp;query_hl=52&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. Halpern MT, Covert DW, Robin AL. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc. 2002;100:109-118.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12545683%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14. Bron AM, Emmerich KH. Latanoprost versus combined timolol and dorzolamide. Surv Ophthalmol. 2002;47 Suppl 1:S148-154.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12204712&amp;amp;query_hl=58&amp;amp;itool=pubmed_docsum" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15. Rouland JF, Le-Pen C, Benhaddi H, Piriou E, Lilliu H, Kenisberg PA et al. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years. Eur J Ophthalmol. 2005;15:562-580. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16167287&amp;amp;query_hl=10&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16. Tsukamoto H, Noma H, Mukai S, Ikeda H, Mishima HK. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. J Ocul Pharmacol Ther. 2005;21:395-399. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16245966%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17. Tsukamoto H, Noma H, Matsuyama S, Ikeda H, Mishima HK. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. J Ocul Pharmacol Ther. 2005;21:170-173. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15857284&amp;amp;query_hl=15&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;18. Rouland JF, Le Pen C, Pinto CG, Berto P, Berdeaux G. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma in four European countries. PharmacoEconomics 2003;21:201-213.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12558470&amp;amp;query_hl=68&amp;amp;itool=pubmed_docsum" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;19. Stewart WC, Leech J, Sharpe ED, Kulze J, Ellyn J, Day DG. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension. Am J Managed Care 2002;8:S240-248. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12188166&amp;amp;query_hl=69&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;20. Costagliola C, Parmeggiani F, Sebastiani A. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother. 2003;4:1775-1788. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=14521487&amp;amp;query_hl=70&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;21. Gandolfi SA, Rossetti L, Cimino L, Mora P, Tardini M, Orzalesi N. Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications: a two-center randomized prospective trial. J Glaucoma 2003;12:347-353. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12897580&amp;amp;query_hl=72&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;22. Obstbaum SA, Cioffi GA, Krieglstein GK, Fennerty MB, Alm A, Araie M et al. Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis. Clin Ther. 2004;26:2102-2120. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15823774&amp;amp;query_hl=31&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;23. Vass C, Findl O, Sycha T, Bauer P, Schmetterer L. Medical interventions for primary open angle glaucoma and ocular hypertension. (Protocol) Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD003167. DOI: 10.1002/14651858.CD003167.pub2. &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003167/frame.html" target="_blank"&gt;[protocol]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;24. Gray TA, Orton L, Henson D, Harper R, Waterman H. Interventions for improving adherence to ocular hypotensive therapy. (Protocol) Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD006132. DOI: 10.1002/14651858.CD006132. &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006132/frame.html" target="_blank"&gt;[protocol]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;25. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology 2004;112:953-961.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15885795&amp;amp;query_hl=75&amp;amp;itool=pubmed_docsum" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;26. Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004;13:283-290. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15226656&amp;amp;query_hl=77&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;27. The Collaborative Normal Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126(4):487-497.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=9780093&amp;amp;query_hl=36&amp;amp;itool=pubmed_docsum" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;28. The Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=9780094&amp;amp;query_hl=39&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;29. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS) 7: The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-440. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=102015" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;30. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller&amp;nbsp;JP&amp;nbsp;et al (The Ocular Hypertension Treatment Study Group). The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents onset of primary open angle glaucoma. Arch Ophthalmol 2002;120:701-713. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=102037" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;31. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M (The Early Manifest Glaucoma Treatment Study Group). Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Treatment Trial. Arch Ophthalmol 2002;120:1268-1279. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=102035" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;32. Sycha T, Vass C, Findl O, Bauer P, Groke I, Schmetterer L, Eichler H.&amp;nbsp;&amp;nbsp;Interventions for normal tension glaucoma. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD002222. DOI: 10.1002/14651858.CD002222. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=189228" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;33. Fechtner RD. Glaucoma therapeutics. Clin Exp Ophthalmol. 2003;31:6-9. [no abstract available]&lt;/P&gt;
&lt;P&gt;34. Guidelines for the management of open angle glaucoma and ocular hypertension 2004. Royal College of Ophthalmologists (2004) &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=93140&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;35. Preferred Practice Pattern - Primary Open Angle Glaucoma Suspect. American Academy of Ophthalmology (AAO) (revised September 2005) &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89381&amp;amp;tabID=288" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;36. Preferred Practice Pattern - Primary Open Angle Glaucoma.&amp;nbsp; American Academy of Ophthalmology (2005) &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89380&amp;amp;tabID=288" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;37. Terminology and guidelines for glaucoma (II edition). The European Glaucoma Society (2003) &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156796&amp;amp;tabID=288" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;38 Higginbotham EJ. The safety and efficacy of fixed-combination timolol and latanoprost in the treatment of glaucoma: Review of two clinical trials. Today's Ther Trends 2003;21:61-70. [no abstract available]&lt;/P&gt;
&lt;P&gt;39. Magacho L, Reis R, Shetty RK, Santos LC, Avila MP. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology 2006;113:442-445. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16458964&amp;amp;query_hl=49&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;40. Konstas AGP, Boboridis K, Tzetzi D, Kallinderis K, Jenkins JN. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123:898-902. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16009829&amp;amp;query_hl=91&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;41. Diestelhorst M, Larsson LI. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88:199-203. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16263174&amp;amp;query_hl=93&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;42. Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893-899. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12486510%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;43. Higginbotham EJ, Diestelhorst M, Pfeiffer N, Rouland JF, Alm A. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol. 2002;47 Suppl 1:S133-140. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12204710&amp;amp;query_hl=110&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;44. Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120:915-922. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12096962&amp;amp;query_hl=110&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;45. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1-7. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15990081&amp;amp;query_hl=102&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;46. European Medicines Agency. European Public Assessment Report (EPAR) : GanFort EPAR summary for the public. EMEA/H/C/668. Last updated April 2006. &lt;A href="http://www.emea.eu.int/humandocs/%20PDFs/EPAR/ganfort/066806en1.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;47. Henderer JD, Wilson RP, Moster MR,&amp;nbsp;Myers J, Schmidt C, Fontanarosa J. Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30mmHg. J Glaucoma 2005;14:267-270. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15990605&amp;amp;query_hl=101&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;48. Gugleta K, Orgül S, Flammer J. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices. Curr Med Res Opin. 2003;19:330-335.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12841926&amp;amp;query_hl=101&amp;amp;itool=pubmed_docsum" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;49. Francis BA, Du LT, Berke S, Ehrenshaus M, Minckler DS et al. Comparing the fixed combination dorzolamide-timolol (Cosopt®) to concomitant administration of 2% dorzolamide (Trusopt®) and 0.5% timolol - A randomized controlled trial and a replacement study. J Clin Pharm Ther 2004;29:375-380. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15271105&amp;amp;query_hl=100&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;50. Bacharach J, Delgado MF, Iwach AG. Comparison of the efficacy of the fixed-combination timolol /dorzolamide versus concomitant administration of timolol and dorzolamide. J Ocul Pharmacol Ther. 2003;19:93-96. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12804053&amp;amp;query_hl=96&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;51. Goñi FJ. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol. 2005;15:581-590. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16167288&amp;amp;query_hl=95&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;52. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005;21:337-348. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16117698&amp;amp;query_hl=107&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;53. Mundorf TK, Ogawa T, Naka HA, Novack GD, Crockett RS, US Istalol Study Group. 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Clin-Ther. 2004;26:541-551. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15189751&amp;amp;query_hl=109&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;54. Manni G, Centofanti M, Oddone F, Parravano M, Bucci MG. Interleukin-1(beta) tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol. 2005;139:72-77. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15652830&amp;amp;query_hl=111&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;55. Bauduoin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005;5:459-463. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16131924&amp;amp;query_hl=93&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;56. Pisella PJ, Pouliquen P, Baudouin C, Grasso CM. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Evid Based Eye Care 2002;3:140-141. [no abstract available]&lt;/P&gt;
&lt;P&gt;57. Ritch R. Complementary therapy for the treatment of glaucoma: a perspective. Ophthalmol Clin North Am. 2005;18:597-609. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16314222&amp;amp;query_hl=89&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[abstract]&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>187787</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=187787]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Emerging Technology:  Optic disc imaging - diagnosis  November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2006]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Emerging Technology:  Optic disc imaging - diagnosis  November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=121 alt="A glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID187787/nelhImp_0000_glaucomaeye.jpg" width=178 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;IMG id=nelh_tempImage2 height=121 alt="example of visual loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0005_lossglaucoma.jpg" width=178 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="Patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID187787/nelhImp_0002_tonometry.jpg" width=178 border=0 name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;David Garway-Heath BSc(Hons) MBBS, MD, FRCS, FRCOphth&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;Abbreviations&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc3.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Emerging%20Technology%20-%20Optic%20Disc%20Imaging%20-%20Diagnosis.pdf" target="_blank"&gt;Please click here to download pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273534:0" name=internalLink&gt;Click here to view 2007 update&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction&lt;BR&gt;&lt;/STRONG&gt;In addition to stereophotography, there are three quantitative imaging devices currently in widespread use for glaucoma management. These are confocal scanning laser tomography (Heidelberg retina tomograph [HRT]; Heidelberg Engineering, Heidelberg, Germany), scanning laser polarimetry with ‘variable’ corneal compensation (GDxVCC; Carl Zeiss Meditec Inc.,Dublin, CA) and optical coherence tomography (StratusOCT; Carl Zeiss Meditec Inc., Dublin, CA). &amp;nbsp;The performance of these devices for diagnosis[1] and identifying progression[2] has recently been reviewed. Some of the literature cited relates to older versions of these technologies, such as the GDx NFA (with ‘fixed’ corneal compensation) and OCT2 (which has reduced sampling in the axial direction compared with StratusOCT).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Current guidance&lt;BR&gt;&lt;/STRONG&gt;The &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89380&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;American Academy of Ophthalmology Preferred Practice Patterns&lt;/A&gt; (AAO PPP)[3] highlights the importance of the examination of optic nerve head (ONH) and retinal nerve fibre layer (RNFL), the preferred technique being magnified stereoscopic visualization (as with the slit-lamp biomicroscope). Documentation should be performed by colour stereophotography or computer-based image analysis of the ONH and retinal RNFL, or, in the absence of these technologies, by non-stereoscopic ONH photography or by a detailed drawing of the ONH, although these are considered less desirable alternatives to stereophotography or computer-based imaging.&lt;/P&gt;
&lt;P&gt;The guidance from the &lt;A disabled href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156796&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;European Glaucoma Society (EGS)&lt;/A&gt;[4]&amp;nbsp;is less prescriptive, stating that colour disc photos are useful for patient documentation, with stereoscopic photography being the preferred method, and that new technologies may aid clinical management.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recent evidence&lt;/STRONG&gt;&lt;BR&gt;The evidence for the role of quantitative imaging devices in identifying glaucoma is considered in a number&amp;nbsp;of systematic reviews, including: the Blue Cross Blue Shield Tec report (2003),[5] NHS R&amp;amp;D Health Technology Assessment Programme “Detecting and monitoring glaucoma” report (2005),[6] and the Alberta Heritage Foundation for Medical Research Health Technology Assessment Unit report (2006).[7] These reports, and other primary publications, consider the devices’ sensitivity and specificity, facility to predict glaucoma, safety, clinical applicability, and whether the use of these devices improves health outcomes. There are no data on the effect on health outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sensitivity and specificity&lt;BR&gt;&lt;/STRONG&gt;A useful summary of the ability of a ‘diagnostic algorithm’ of a device to identify disease is the ‘sensitivity’ (percentage with disease that is correctly identified as having the disease), which is ideally given at a fixed ‘specificity’ (percentage without disease that is correctly identified as not having the disease) of 90% or 95%. However, there are many factors to take into account when evaluating reports of sensitivity and specificity. There may be biases in the study design (for instance, the instruments are evaluated in patients selected because they have an abnormal appearing ONH or RNFL) or the diagnostic algorithms are tested in the population in which they were derived. Ideally, diagnostic algorithms should be tested in new populations.[6, 8, 9] Furthermore, consideration needs to be given of the extent to which the characteristics of a study population match those of the clinic.&amp;nbsp; Frequently, in reports of device performance, instruments are tested in a highly selected population.&lt;/P&gt;
&lt;P&gt;The reporting of the ‘diagnostic’ ability of devices is generally poor[10] and usually rather simplistic, with a single ‘sensitivity and specificity’ being reported, whereas, in reality, the sensitivity and specificity varies according to disease severity. Devices perform better when disease is more severe.[6, 11] The corollary of this is that the likelihood of disease increases considerably with the degree of test result abnormality.[8] This information is rarely utilised.&lt;/P&gt;
&lt;P&gt;The guidance from the EGS[4] makes the important point that “…the process of categorising patients by means of imaging device measurements is not the same as diagnosis. Diagnosis must also integrate all the other available information about the patient, including clinical assessment of the ONH and RNFL, visual field and risk factors including age, IOP and family history.” Thus, the output of imaging devices needs to be placed in the context of other clinical information, and there are methods to statistically formalise this.[12, 13] When the measurements from these devices are considered in the context of other quantitative data, such as visual function test results or intraocular pressure level, their clinical usefulness is enhanced. &lt;/P&gt;
&lt;P&gt;The relative performance of the imaging devices is best compared when all instruments are tested in the same patient group. One study may be cited as a guide.[8] In a cohort of 107 patients with glaucomatous visual field loss (70% with early glaucoma) and 76 normal subjects, there was no statistical difference between the sensitivity and specificity of the HRT, GDxVCC and Stratus OCT. At a specificity of 95%, the instruments had a sensitivity of between about 60% and 70%.&lt;/P&gt;
&lt;P&gt;Generally, when comparing the quantitative imaging devices with the clinical evaluation of stereoscopic ONH photographs, studies find a similar performance between all devices and clinicians.[14, 15] However, most studies, compare experts (and usually the consensus of experts) with the instruments.[14, 15] This does not reflect the usual clinical situation, where an expert may not be available and a consensus opinion is rare.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prediction of visual field loss&lt;BR&gt;&lt;/STRONG&gt;Blue Cross Blue Shield Tec report[5] suggested that, in the absence of direct evidence, indirect evidence for the use of quantitative scanning devices is needed, including the demonstration that the addition of quantitative imaging improves the prediction of the development of visual loss. It was considered that current best evidence (a positive predictive value of 22% for the HRT to predict visual field loss in ocular hypertension)[16] was insufficient to permit conclusions concerning the effects of quantitative imaging for the diagnosis or management of glaucoma. However, more recent data from the confocal scanning laser ophthalmoscopy ancillary study to the Ocular Hypertension Treatment Study (OHTS) identifies that the HRT Moorfields Regression Analysis classification “outside normal limits” in the temporal superior ONH sector has a positive predictive value of 40% to identify future conversion to glaucoma (according to OHTS endpoints).[17] &lt;/P&gt;
&lt;P&gt;RNFL thickness measured with the GDx NFA (fixed corneal compensation) has been found to be an independent predictor of visual field loss in glaucoma suspects followed in the longitudinal Diagnostic Innovations in Glaucoma Study (DIGS).[18] Similarly, baseline RNFL thickness measured with the OCT2 predicted progression to visual field loss or stereophotographic ONH change in glaucoma suspects in the DIGS cohort.[19]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Safety&lt;BR&gt;&lt;/STRONG&gt;The HRT and GDx are considered to be safe, non-invasive diagnostic imaging techniques.[7] There are no adverse reports for OCT.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical applicability&lt;/STRONG&gt;&lt;BR&gt;Few studies report the proportion of patients in whom adequate quality images can be obtained. One study, in which typical selection criteria were applied, found that adequate quality images were obtained in 87% of subjects with the GDx VCC, 90% with the Stratus OCT and 92% with the HRT.[8] In a typical clinic population, the proportions were 88% with the GDx NFA and 80% with the HRT.[6] These figures should be taken as an approximate guide, because it is difficult to achieve a common baseline for the comparison of image quality in different instruments. Factors that contribute to difficulty in acquiring high quality images include: extreme miosis, cataracts, poor tear film/corneal disease, nystagmus, large peripapillary atrophy, macular disease, and light fundus pigmentation.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Image acquisition times are typically much faster than the time taken for visual field testing.[6]&amp;nbsp; Both the HRT and GDx are outpatient procedures that can be performed by a trained technician in an office or clinical setting.[7]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Please click&amp;nbsp;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212566&amp;amp;tabID=290" target="_blank"&gt;here&lt;/A&gt; to view two sample slides provided by Mr David Garway Heath. &amp;nbsp;Mr Garway Heath is a consultant based at Moorfields Eye Hospital NHS Foundation Trust. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication types of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication dates of cited references&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Zangwill LM, Bowd C. Retinal nerve fiber layer analysis in the diagnosis of glaucoma. Curr Opin Ophthalmol. 2006. 17: 120-131. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16552246%5BUID%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;2. Giangiacomo A, Garway-Heath D, Caprioli J. Diagnosing glaucoma progression: current practice and promising technologies. Curr Opin Ophthalmol. 2006. 17: 153-162. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16552250%5BUID%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;3. (AAO). AAO. Primary Open angle glaucoma. Preferred Practice Pattern. 2005.&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89380&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. Society EG. Terminology and guidelines for glaucoma. 2003.&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156796&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5. Retinal nerve fiber layer analysis for the diagnosis and management of glaucoma. TEC bulletin (Online). 2003. 20: 19-22. &lt;/P&gt;
&lt;P&gt;6. Kwartz AJ, Henson DB, Harper RA, Spencer AF, McLeod D. The effectiveness of the Heidelberg Retina Tomograph and laser diagnostic glaucoma scanning system (GDx) in detecting and monitoring glaucoma. Health Technol Assess. 2005. 9: 1-148. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=191112" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. Alberta Heritage Foundation for Medical Research. Confocal scanning laser ophthalmoscopy and scanning laser polarimetry for early diagnosis of glaucoma. 2006 &lt;A href="http://www.ihe.ca/documents/hta/TechNote_No_55.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8. Medeiros FA, Zangwill LM, Bowd C, Weinreb RN. Comparison of the GDx VCC scanning laser polarimeter, HRT II confocal scanning laser ophthalmoscope, and stratus OCT optical coherence tomograph for the detection of glaucoma. Arch Ophthalmol. 2004. 122: 827-837. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15197057%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9. Tannenbaum DP, Hoffman D, Lemij HG, Garway-Heath DF, Greenfield DS, Caprioli K. Variable corneal compensation improves discrimination between normal and glaucomatous eyes with the scanning laser polarimeter. Ophthalmology. 2004. 111: 259-264.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15019373%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10. Shunmugam M, Azuara-Blanco A. The quality of reporting of diagnostic accuracy studies in glaucoma using the Heidelberg retina tomograph. Invest Ophthalmol Vis Sci. 2006. 47: 2317-2323.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16723439%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11. Medeiros FA, Zangwill LM, Bowd C, Sample PA, Weinreb RN. Influence of disease severity and optic disc size on the diagnostic performance of imaging instruments in glaucoma. Invest Ophthalmol Vis Sci. 2006. 47: 1008-1015. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16505035%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12. Shah NN, Bowd C, Medeiros FA,&amp;nbsp;Weinreb RN, Sample PA, Hoffmann em, Zangwill LM. Combining structural and functional testing for detection of glaucoma. Ophthalmology. 2006. 113: 1593-1602.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16949444%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. Garway-Heath DF, Friedman DS. How should results from clinical tests be integrated into the diagnostic process? Ophthalmology. 2006. 113: 1479-1480. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16949440%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14. Deleon-Ortega JE, Arthur SN, McGwin G, Jr, Xie A, Monheit BE, Girkin CA. Discrimination between glaucomatous and nonglaucomatous eyes using quantitative imaging devices and subjective optic nerve head assessment. Invest Ophthalmol Vis Sci. 2006. 47: 3374-3380.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16877405%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15. Greaney MJ, Hoffman DC, Garway-Heath DF,&amp;nbsp;Nakla M, Coleman AL, Caprioli J. Comparison of optic nerve imaging methods to distinguish normal eyes from those with glaucoma. Invest Ophthalmol Vis Sci. 2002. 43: 140-145. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11773024%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16. Kamal DS, Garway-Heath DF, Hitchings RA, Fitzke FW. Use of sequential Heidelberg retina tomograph images to identify changes at the optic disc in ocular hypertensive patients at risk of developing glaucoma. Br J Ophthalmol. 2000. 84: 993-998.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=10966952%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp;&lt;A href="http://bjo.bmjjournals.com/cgi/reprint/84/9/993" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL et al. Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2005. 123: 1188-1197. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16157798%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;18. Mohammadi K, Bowd C, Weinreb RN, Medeiros FA, Sample PA, Zangwill LM. Retinal nerve fiber layer thickness measurements with scanning laser polarimetry predict glaucomatous visual field loss. American journal of ophthalmology. 2004. 138: 592-601. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15488786%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;19. Lalezary M, Medeiros FA, Weinreb RN, Bowd C, Sample PA, Tavares IM. Baseline optical coherence tomography predicts the development of glaucomatous change in glaucoma suspects. Am J Ophthalmol. 2006. 142: 576-582. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=17011848%5BUID%5D" target="_blank"&gt;[abstract]&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>201821</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=201821]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Emerging Technology: Assessment of visual field progression - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS,GLAUCOMA NKW 2006,ANNUAL EVIDENCE UPDATES,GLAUCOMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Emerging Technology: Assessment of visual field progression - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=121 alt="A glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201821/nelhImp_0000_glaucomaeye.jpg" width=178 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="Patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201821/nelhImp_0001_tonometry.jpg" width=178 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;IMG id=nelh_tempImage2 height=121 alt="example of visual loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0005_lossglaucoma.jpg" width=178 border=0 name=nelh_tempImage2&gt; 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&lt;EM&gt;Mr Ananth Viswanathan BSc, MBBS, FRCOphth, MD&lt;/EM&gt; 
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;ANANTH &lt;P MD FRCOphth, MBBS, BSc, Viswanathan,&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc2.asp" target="_blank"&gt;&lt;STRONG&gt;Click here to view low vision version&lt;/STRONG&gt; &lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Emerging%20Technology%20-%20Assessment%20of%20Visual%20Field%20Progression.pdf" target="_blank"&gt;Click here to download pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273535:0" name=internalLink&gt;Click here to view 2007 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;/P&gt;
&lt;P&gt;High quality sources of evidence no longer use ‘clinical impression’ to assess visual field change in glaucoma. Instead, the results of automated perimetry are subjected to numerical analysis in an attempt to quantify the degree of change in visual field series. The two main approaches to this type of analysis are known as trend analysis and event analysis. Since 2002, when searches were performed for current glaucoma guidance, some authors reported on trend analysis [1-4], some on event analysis [5-21] and some on both [22-28].&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Trend analysis&lt;/STRONG&gt;&lt;BR&gt;Trend analysis measures the rate of change of the visual field and the statistical significance of that rate. Measures may be made for each test point (pointwise linear regression [PLR]) or on a cluster basis. &lt;/P&gt;
&lt;P&gt;PLR has been used to identify morphological factors predictive of visual field progression, such as small neuroretinal rim area [1], large beta zone of peripapillary atrophy [1] and optic disc haemorrhage [2].&lt;/P&gt;
&lt;P&gt;It has been suggested that basing PLR criteria on clusters derived from morphological measures increases specificity [4].&lt;/P&gt;
&lt;P&gt;Trend analysis is implemented in the PROGRESSOR software (Moorfields Eye Hospital, London, UK / Medisoft Ltd., Leeds, UK) and in Peridata (Peridata Software GmbH, Huerth, Germany). &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Event analysis&lt;BR&gt;&lt;/STRONG&gt;Event analysis uses the first few visual fields in a series as a baseline, then compares subsequent visual fields to that baseline to determine whether change has occurred.&lt;/P&gt;
&lt;P&gt;There is no universally accepted definition of an ‘event’: different definitions produce different methods of analysis which do not agree well [21].&lt;/P&gt;
&lt;P&gt;It is of paramount importance to require extra follow-up tests to confirm possible progression using event analysis. Otherwise, spurious diagnosis of progression may result.[19, 20]&lt;/P&gt;
&lt;P&gt;Event analysis has been used to investigate treatment effects in ocular hypertension [14,15] primary open angle glaucoma [16,17] and normal pressure glaucoma.[18] It has been used to study the natural history of untreated glaucoma [13] and to investigate possible risk factors for visual field progression such as recurrent optic disc haemorrhage [8, 10], resistive index of ophthalmic and short posterior ciliary arteries [6], severity of presenting visual field loss [8, 9], higher baseline intraocular pressure, pseudoexfoliation, bilateral disease and older age [8]. It has been used in the development of neural networks to classify visual field progression in glaucoma [7] and in the validation of predictive models for conversion in ocular hypertension. [5]&lt;/P&gt;
&lt;P&gt;Event analysis is implemented in the Glaucoma Progression Analysis (GPA) software for the Humphrey Field Analyzer (Carl Zeiss Meditec Inc., Dublin, CA, USA).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Comparison of trend and event analysis&lt;BR&gt;&lt;/STRONG&gt;Since both techniques share a common objective, separate studies employing either trend or event analysis may produce similar results. For example, both methods have implicated fluctuations in intraocular pressure as a possible risk factor for glaucomatous visual field progression [9,28] and both have found no association between central corneal thickness and glaucomatous visual field progression.[3,25] &lt;/P&gt;
&lt;P&gt;When the two methods are directly compared, there is poor [26] to moderate [27] agreement. This may be because each of the two methods may be at its best in differing clinical scenarios: to quote Artes and Chauhan [22] ‘…while event-based analyses may have merit when there are a limited number of observations, with longer follow-up and frequency of examinations the rate of change or its statistical significance may provide more clinically useful information.’&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Courtesy of Mr Ananth Viswanathan please click &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212204&amp;amp;tabID=290" target="_blank"&gt;here&lt;/A&gt; to view example screens from the PROGRESSOR software.&amp;nbsp; Mr Viswanathan is a consultant surgeon employed by Moorfields Eye Hospital and is an inventor of the PROGRESSOR software. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;U&gt;&lt;FONT color=#606420&gt;Please click here to view publication types of cited references&lt;/FONT&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view&amp;nbsp;publication dates of cited references&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Jonas JB, Martus P, Horn FK, Junemann A, Korth M, Budde WM.&amp;nbsp; Predictive factors of the optic nerve head for development or progression of glaucomatous visual field loss. Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2613-8.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15277484&amp;amp;query_hl=5&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. Kono Y, Sugiyama K, Ishida K, Yamamoto T, Kitazawa Y.&amp;nbsp; Characteristics of visual field progression in patients with normal-tension glaucoma with optic disk&amp;nbsp; hemorrhages.&amp;nbsp; Am J Ophthalmol. 2003 Apr;135(4):499-503. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12654367%5BUID%5D" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3. Jonas JB, Stroux A, Velten I, Juenemann A, Martus P, Budde WM.&amp;nbsp; Central corneal thickness correlated with glaucoma damage and rate of progression.&amp;nbsp; Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1269-74. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15790889&amp;amp;query_hl=10&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. Wilkins MR, Fitzke FW, Khaw PT.&amp;nbsp; Pointwise linear progression criteria and the detection of visual field change in a glaucoma trial.&amp;nbsp;&amp;nbsp; Eye. 2006 Jan;20(1):98-106. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15650759%5BUID%5D" target="_blank"&gt;[Abstract]&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;5. Medeiros FA, Weinreb RN, Sample PA, Gomi CF, Bowd C, Crowston JG, Zangwill LM.&amp;nbsp; Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthalmol. 2005 Oct;123(10):1351-60.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16219726&amp;amp;query_hl=14&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6. Martinez A, Sanchez M.&amp;nbsp;&amp;nbsp; Predictive value of colour Doppler imaging in a prospective study of visual field progression in primary open-angle glaucoma.&amp;nbsp;&amp;nbsp; Acta Ophthalmol Scand. 2005 Dec;83(6):716-22.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16396650&amp;amp;query_hl=17&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. Lin A, Hoffman D, Gaasterland DE, Caprioli J.&amp;nbsp; Neural networks to identify glaucomatous visual field progression.&amp;nbsp; Am J Ophthalmol. 2003 Jan;135(1):49-54.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12504697&amp;amp;query_hl=19&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group.&amp;nbsp; Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.&amp;nbsp; Arch Ophthalmol. 2003 Jan;121(1):48-56.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12523884&amp;amp;query_hl=21&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9. Nakagami T, Yamazaki Y, Hayamizu F.&amp;nbsp; Prognostic factors for progression of visual field damage in patients with normal-tension glaucoma. Jpn J Ophthalmol. 2006 Jan-Feb;50(1):38-43. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16453186&amp;amp;query_hl=23&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10.Kim SH, Park KH.&amp;nbsp; The relationship between recurrent&amp;nbsp;optic disc hemorrhage and glaucoma progression.&amp;nbsp;&amp;nbsp; Ophthalmology. 2006 Apr;113(4):598-602. Epub 2006 Feb 17. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16488014%5BUID%5D" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11.Boden C, Blumenthal EZ, Pascual J, McEwan G, Weinreb RN, Medeiros F, Sample PA.&amp;nbsp;&amp;nbsp; Patterns of glaucomatous visual field progression identified by three progression criteria.&amp;nbsp; Am J Ophthalmol. 2004 Dec;138(6):1029-36.&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15629296&amp;amp;query_hl=35&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12. Heijl A, Leske MC, Bengtsson B, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group.&amp;nbsp; Measuring visual field progression in the Early Manifest Glaucoma Trial.&amp;nbsp; Acta Ophthalmol Scand. 2003 Jun;81(3):286-93. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12780410&amp;amp;query_hl=37&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. Wilson MR, Kosoko O, Cowan CL Jr, Sample PA, Johnson CA, Haynatzki G, Enger C, Crandall D.&amp;nbsp; Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol. 2002 Sep;134(3):399-405.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12208252&amp;amp;query_hl=40&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14. Kamal D, Garway-Heath D, Ruben S, O'Sullivan F, Bunce C, Viswanathan A, Franks W, Hitchings R.&amp;nbsp; Results of the betaxolol versus placebo treatment trial in ocular hypertension.&amp;nbsp; Graefes Arch Clin Exp Ophthalmol. 2003 Mar;241(3):196-203. Epub 2003 Feb 19. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12644943&amp;amp;query_hl=49&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO.&amp;nbsp;&amp;nbsp; The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.&amp;nbsp; Arch Ophthalmol. 2002 Jun;120(6):701-13. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12049574&amp;amp;query_hl=43&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I;&amp;nbsp; European Glaucoma Prevention Study (EGPS) Group. Results of the European Glaucoma Prevention Study. .Ophthalmology. 2005 Mar;112(3):366-75. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15745761&amp;amp;query_hl=46&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group.&amp;nbsp; Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12365904&amp;amp;query_hl=51&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;18.Anderson DR; Normal Tension Glaucoma Study.&amp;nbsp; Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003 Apr;14(2):86-90. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12698048&amp;amp;query_hl=55&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;19. Keltner JL, Johnson CA, Levine RA, Fan J, Cello KE, Kass MA, Gordon MO.&amp;nbsp; Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study.&amp;nbsp; Arch Ophthalmol. 2005 Sep;123(9):1201-6.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16157799&amp;amp;query_hl=59&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;20. Kim J, Dally LG, Ederer F, Gaasterland DE, VanVeldhuisen PC, Blackwell B, Sullivan EK, Prum B, Shafranov G, Beck A, Spaeth GL; AGIS Investigators.&amp;nbsp; The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing progression of glaucoma from visual field fluctuations.&amp;nbsp; Ophthalmology. 2004 Nov;111(11):2109-16. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15522379&amp;amp;query_hl=64&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;21. Lee AC, Sample PA, Blumenthal EZ, Berry C, Zangwill L, Weinreb RN.&amp;nbsp; Infrequent confirmation of visual field progression. Ophthalmology. 2002 Jun;109(6):1059-65.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=12045044&amp;amp;query_hl=68&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;22. Artes PH, Chauhan BC.&amp;nbsp; Longitudinal changes in the visual field and optic disc in glaucoma. Prog Retin Eye Res. 2005 May;24(3):333-54. Epub 2005 Jan 24. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=15708832&amp;amp;query_hl=70&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;23. Asman P, Wild JM, Heijl A.&amp;nbsp; Appearance of the pattern deviation map as a function of change in area of localized field loss. Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3099-106. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15326126%5BUID%5D" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;24. Artes PH, Nicolela MT, LeBlanc RP, Chauhan BC. Visual field progression in glaucoma: total versus pattern deviation analyses. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4600-6. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16303955%5BUID%5D" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;25. Chauhan BC, Hutchison DM, LeBlanc RP, Artes PH, Nicolela MT.&amp;nbsp; Central corneal thickness and progression of the visual field and optic disc in glaucoma. Br J Ophthalmol. 2005 Aug;89(8):1008-12.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16024855%5BUID%5D" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;26. Haymes SA, Hutchison DM, McCormick TA, Varma DK, Nicolela MT, LeBlanc RP, Chauhan BC.Glaucomatous visual field progression with frequency-doubling technology and standard automated perimetry in a longitudinal prospective study Invest Ophthalmol Vis Sci. 2005 Feb;46(2):547-54. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15671281%5BUID%5D" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;27. Nouri-Mahdavi K, Caprioli J, Coleman AL, Hoffman D, Gaasterland D. Pointwise linear regression for evaluation of visual field outcomes and comparison with the advanced glaucoma intervention study methods.&amp;nbsp; Arch Ophthalmol. 2005 Feb;123(2):193-9.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15710815%5BUID%5D" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;28. Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, Caprioli J; Advanced Glaucoma Intervention Study.&amp;nbsp; Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study Ophthalmology. 2004 Sep;111(9):1627-35. &amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15350314%5BUID%5D" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>201795</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=201795]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Emerging Technology: Optic disc imaging - disease monitoring  November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2006]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Emerging Technology: Optic disc imaging - disease monitoring  November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=121 alt="A glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201795/nelhImp_0000_glaucomaeye.jpg" width=178 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="Patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201795/nelhImp_0001_tonometry.jpg" width=178 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="example of visual loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0005_lossglaucoma.jpg" width=178 border=0 name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;David Garway Heath BSc(Hons), MBBS, MD, FRCS, FRCOphth&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc4.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Emerging%20Technology%20-%20Optic%20Disc%20Imaging%20-%20Monitoring.pdf" target="_blank"&gt;Please click here to download pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273534:0" name=internalLink&gt;Click here to view 2007 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;BR&gt;In addition to stereophotography, there are three quantitative imaging devices currently in widespread use for glaucoma management. These are confocal scanning laser tomography (Heidelberg retina tomograph [HRT]; Heidelberg Engineering, Heidelberg, Germany), scanning laser polarimetry with ‘variable’ corneal compensation (GDxVCC; Carl Zeiss Meditec Inc.,Dublin, CA) and optical coherence tomography (StratusOCT; Carl Zeiss Meditec Inc., Dublin, CA). The performance of these devices for diagnosis[1] and identifying progression[2] has recently been reviewed. Some of the literature cited relates to older versions of these technologies, such as the GDx NFA (with ‘fixed’ corneal compensation) and OCT2 (which has reduced sampling in the axial direction compared with StratusOCT).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Current guidance&lt;/STRONG&gt;&lt;BR&gt;The &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89380&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;AAO PPP[3]&lt;/A&gt; recommend the documentation of the ONH and RNFL appearance by imaging, photography, or drawing. The frequency of examination is advised as: 6 – 18 months for stable patients (depending on duration of control) and 2 to 12 months for patients with poorly-controlled IOP or signs of progression, and 6 – 24 months for glaucoma suspects (depending on risk level) and 3 – 12 months for high risk glaucoma suspects with poorly-controlled IOP. &lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=93140&amp;amp;tabID=288" target="_blank"&gt;Royal College of Ophthalmologists’ guidelines&lt;/A&gt;[4] recommend, at baseline, an ONH drawing “which may be usefully supplemented by disc photography +/or digital computerised scanning of the disc/nerve fibre layer”. The frequency of monitoring depends on the level of IOP control achieved, the age of the patient and the severity of the disease. Progression may be confirmed by comparison of current status with baseline appearance. &lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156796&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;European Glaucoma Society guidelines[5]&lt;/A&gt; state that “imaging is likely to play a role in the future for longitudinal follow-up.”&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recent evidence&lt;BR&gt;&lt;/STRONG&gt;In recent years, the evidence to support the application of imaging technologies for monitoring glaucoma has been building. However, there are barriers to the successful demonstration of the role of quantitative imaging in glaucoma progression detection. These include the lack of an external ‘gold standard’ for progression with which to compare the imaging devices [6,7,8] and the rapid progress in technology, which changes faster than typical glaucoma progresses.[6] &lt;/P&gt;
&lt;P&gt;Recent evidence demonstrates that imaging and visual function tests for glaucomatous progression agree poorly [6, 7, 8] and challenges the prevailing view that imaging tools are more useful early in the course of the disease and visual function tests later in the course.[7, 8]&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Imaging techniques to monitor for progression&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;ONH photography&lt;BR&gt;&lt;/EM&gt;Photography has some advantages over quantitative imaging devices. For instance, features related to glaucoma progression, such as increasing peripapillary atrophy and disc haemorrhages, are evident in photographs, but are not readily apparent in other images.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The assessment of progression from photographs is subjective, although in trained hands sensitivity and agreement is fair. Repeat gradings from stereophotography have been evaluated for agreement and for the sensitivity and specificity of progression determination (with the Ocular Hypertension Treatment Study Endpoint committee as the reference standard). Agreement (kappa) ranged from 0.65 to 0.83, specificity from 98% to 100% and sensitivity from 64% to 81%.&amp;nbsp;[9] Agreement between observers is better with stereoscopic than with monoscopic photography. [10]&lt;/P&gt;
&lt;P&gt;The greatest barrier to the routine use of ONH photographs is the lack of appropriate viewing systems, although new technology is available that permits the viewing of stereoscopic photographs in 3-dimensions on the computer screen.[11]&lt;/P&gt;
&lt;P&gt;Most studies report the performance of expert observers (and usually a consensus of experts) in identifying progression from ONH photographs. There are no reports of the ability of non-expert observers to identify progression.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Heidelberg retina tomograph&lt;BR&gt;&lt;/EM&gt;An analysis technique, identifying change at the level of groups of pixels in the HRT images, has been developed.[12] This technique, Topographic Change Analysis (TCA), was tested in a longitudinal data set of 84 patients and 41 normal subjects, followed for a median of 7.5 years. The criteria for change were adjusted to achieve similar progression rates with the HRT and visual field analyses.[7] When the specificity for HRT and visual field was approximately at 86 - 90% and 81 - 90%, respectively, 42% of the eyes with glaucoma were found to be progressing by each of HRT and visual field. However, the agreement for progression between the two was poor. This suggests approximately equal sensitivity of the HRT and visual field to detect progression in established glaucoma. Similar results have been reported for ocular hypertension.[8] 198 patients with ocular hypertension and 21 normal subjects were followed for a median of 6.0 and 5.3 years, respectively. When progression criteria for the HRT and visual field were matched to give about 90% specificity, the progression rates were similar, with 33% and 32% progressing by HRT and visual field criteria, respectively. Agreement, however, was poor, with only 12% of subjects progressing by HRT and visual field criteria. These findings suggest that both imaging and perimetry are required if progression is not to be missed in patients with ocular hypertension or early manifest glaucoma. However, studies have yet to identify the implication of identified structural progression for subsequent visual function.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;GDx&lt;/EM&gt;&lt;BR&gt;Few data are available for this technology as a result of several changes in hardware and analysis software. However, polarimetry is likely to be able to detect progression because measurements discriminate well between normal and glaucomatous eyes,[13] predict glaucomatous visual loss in at-risk eyes,[14] and are highly reproducible.[15] In one study, limits of change were derived from a test retest study.[16] 17 eyes with a disc hemorrhage were followed for an average of 30.7 months and 5 (29%) exhibited change in GDx NFA parameters greater than the limits for change. Progressive RNFL thickness change has also been documented following anterior ischaemic optic neuropathy[17] and traumatic optic neuropathy.[18]&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;OCT&lt;BR&gt;&lt;/EM&gt;Longitudinal data are scarce because technology development has resulted in hardware changes. However, OCT imaging is likely to be able to detect progression because OCT RNFL thickness measurements discriminate well between normal and glaucomatous eyes[19] and are highly reproducible.[20] There is one report of a longitudinal study in glaucomatous and glaucoma suspect subjects.[21] 64 eyes of 37 subjects were imaged over a median 4.7 years. OCT progression was defined as change from baseline greater than twice the device reproducibility error in 2 of 3 consecutive follow-up scans. VF progression was defined as a reduction in mean deviation of 2 dB from baseline in 2 of 3 consecutive visits. 22% of eyes progressed by OCT alone, 9% by VF alone and 3% by OCT and VF. The relative sensitivity of the OCT and visual fields to detect progression cannot be assessed directly in the absence of data regarding the specificity of the criteria applied. &lt;/P&gt;
&lt;P&gt;The finding is similar to the reports of HRT progression, with relatively poor agreement between imaging and visual function measures of progression. There are various possible explanations to account for this. The most likely is that measurement ‘noise’ has masked some of the change, so that progression may be missed by either or both imaging and visual field testing. Alternatively, retinal ganglion cell dysfunction may result in visual function change, but without change in images. And change in images may represent alteration to non-neuronal structures, such as the lamina cribrosa. However, a tentative conclusion is that imaging &lt;U&gt;and&lt;/U&gt; visual field testing should be performed in the follow-up of glaucoma patients and suspects.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication types of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication dates of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Zangwill LM, Bowd C. Retinal nerve fiber layer analysis in the diagnosis of glaucoma. Curr Opin Ophthalmol. 2006. 17: 120-131. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16552246%5BUID%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;2. Giangiacomo A, Garway-Heath D, Caprioli J. Diagnosing glaucoma progression: current practice and promising technologies. Curr Opin Ophthalmol. 2006. 17: 153-162. [&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16552250%5BUID%5D" target="_blank"&gt;abstract&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;3. (AAO). AAO. Primary Open angle glaucoma. Preferred Practice Pattern. 2005.&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89380&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;[full text]&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. Royal College of Ophthalmologists. Guidelines for the management of open angle glaucoma and ocular hypertension. 2004. &lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=93140&amp;amp;tabID=288" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/P&gt;
&lt;P&gt;5. Society EG. Terminology and guidelines for glaucoma. 2003.&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156796&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6. Kwartz AJ, Henson DB, Harper RA, Spencer AF, McLeod D. The effectiveness of the Heidelberg Retina Tomograph and laser diagnostic glaucoma scanning system (GDx) in detecting and monitoring glaucoma. Health Technol Assess. 2005. 9: 1-148. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=191112&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. Artes P, H., Chauhan B, C. Longitudinal changes in the visual field and optic disc in glaucoma. Progress in retinal and eye research. 2005. 24: 333-354.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15708832%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8. Strouthidis NG, Scott A, Peter NM, Garway-Heath DF. Optic disc and visual field progression in ocular hypertensive subjects: detection rates, specificity, and agreement. Invest Ophthalmol Vis Sci. 2006. 47: 2904-2910. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16799032%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9. Parrish RK, 2nd, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz MC., et al. Test-retest reproducibility of optic disk deterioration detected from stereophotographs by masked graders. Am J Ophthalmol. 2005. 140: 762-764.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16226544%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10. Morgan JE, Sheen NJ, North RV, Choon Y, Ansari E. Digital imaging of the optic nerve head: monoscopic and stereoscopic analysis. Br J Ophthalmol. 2005. 89: 879-884. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15965171%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp;&lt;A href="http://bjo.bmjjournals.com/cgi/reprint/89/7/879" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11. Morgan JE, Sheen NJ, North RV, Goyal R, Morgan S, Ansari E, Wild JM. Discrimination of glaucomatous optic neuropathy by digital stereoscopic analysis. Ophthalmology. 2005. 112: 855-862. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15878066%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12. Chauhan BC, Blanchard JW, Hamilton DC, LeBlanc RP. Technique for detecting serial topographic changes in the optic disc and peripapillary retina using scanning laser tomography. Invest Ophthalmol Vis Sci. 2000. 41: 775-782. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=10711693%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. Tannenbaum DP, Hoffman D, Lemij HG, Garway-Heath DF, Greenfield DS, Caprioli J. Variable corneal compensation improves discrimination between normal and glaucomatous eyes with the scanning laser polarimeter. Ophthalmology. 2004. 111: 259-264.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15019373%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14. Mohammadi K, Bowd C, Weinreb RN, Medeiros FA, Sample PA, Zangwill LM. Retinal nerve fiber layer thickness measurements with scanning laser polarimetry predict glaucomatous visual field loss. American journal of ophthalmology. 2004. 138: 592-601. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15488786%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15. Lleo-Perez A, Ortuno-Soto A, Rahhal MS, Martinez-Soriano F, Sanchis-Gimeno JA. Intraobserver reproducibility of retinal nerve fiber layer measurements using scanning laser polarimetry and optical coherence tomography in normal and ocular hypertensive subjects. Eur J Ophthalmol. 2004. 14: 523-530. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%28Lleo%20Perez%20A%5BAuth%5D%20AND%20Ortuno%20Soto%20A%5BAuth%5D%29%20AND%20%22European%20journal%20of%20ophthalmology%22%5BJour%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16. Boehm MD, Nedrud C, Greenfield DS, Chen PP. Scanning laser polarimetry and detection of progression after optic disc hemorrhage in patients with glaucoma. Arch Ophthalmol. 2003. 121: 189-194&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12583784%5BUID%5D" target="_blank"&gt;.[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17. Colen TP, van Everdingen JA, Lemij HG. Axonal loss in a patient with anterior ischemic optic neuropathy as measured with scanning laser polarimetry. Am J Ophthalmol. 2000. 130: 847-850. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11124316%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;18. Meier FM, Bernasconi P, Sturmer J, Cauberg MJ, Landau K. Axonal loss from acute optic neuropathy documented by scanning laser polarimetry. Br J Ophthalmol. 2002. 86: 285-287. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11864884%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp;&lt;A href="http://bjo.bmjjournals.com/cgi/reprint/86/3/285" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;19. Medeiros FA, Zangwill LM, Bowd C, Weinreb RN. Comparison of the GDx VCC scanning laser polarimeter, HRT II confocal scanning laser ophthalmoscope, and stratus OCT optical coherence tomograph for the detection of glaucoma. Arch Ophthalmol. 2004. 122: 827-837. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15197057%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;20. Budenz DL, Chang RT, Huang X, Knighton RW,Tielsch JM. Reproducibility of retinal nerve fiber thickness measurements using the stratus OCT in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2005. 46: 2440-2443. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15980233%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;21. Wollstein G, Schuman JS, Price LL, Aydin A, Stark PC. Optical coherence tomography longitudinal evaluation of retinal nerve fiber layer thickness in glaucoma. Arch Ophthalmol. 2005. 123: 464-470&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15824218%5BUID%5D" target="_blank"&gt;.[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>201827</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=201827]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Epidemiology - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2006,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Epidemiology - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=121 alt="A glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201827/nelhImp_0000_glaucomaeye.jpg" width=178 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="Patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201827/nelhImp_0001_tonometry.jpg" width=178 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="example of visual loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0005_lossglaucoma.jpg" width=178 border=0 name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Parul Desai, Shona Burman-Roy, Jennifer Wood&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc5.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Epidemiology.pdf" target="_blank"&gt;Please click here to download pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273449:0" name=internalLink&gt;Click here to view 2007 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Primary open angle glaucoma (POAG) is a chronic optic neuropathy with structural optic nerve and retinal nerve fibre layer changes associated with progressive retinal ganglion cell death and visual field defect.&amp;nbsp; Ocular hypertension (OHT) is the term used to indicate that intra-ocular pressure (IOP) is consistently above two standard deviations of the mean with other ocular findings within normal limits.&lt;/P&gt;
&lt;P&gt;The existing professional body guidance [1, 2, 3] summarises the key epidemiological evidence on glaucoma.&amp;nbsp; Additional knowledge since these were published further supports the evidence on known risk factors, [4] and the effect of variations in case definitions in different studies on estimates of prevalence and provides an analysis of causes for certification of visual impairment for England and Wales.[5]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Prevalence of POAG &lt;BR&gt;&lt;/STRONG&gt;This is estimated to be about 1- 2% in persons over the age of 40 years [6-12] and about half of those with glaucoma may be unaware that they have the disease.[13, 14] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Incidence of POAG&lt;/STRONG&gt;&lt;BR&gt;Population based cohort studies report that the 5 year cumulative incidence of glaucoma is about 0.5%-0.6%.[15, 16]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Risk Factors&lt;BR&gt;&lt;/STRONG&gt;The main risk factors associated with glaucomatous optic neuropathy include:&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;elevated IOP&lt;/EM&gt; –&amp;nbsp; several population-based studies have demonsrated that the prevalence [7, 8, 17] and incidence of POAG increases as the level of IOP increases.[16,18, 19]&amp;nbsp; In addition, population based studies have shown that about one in 10 persons with elevated IOP have glaucomatous field loss.[20]&amp;nbsp; Data from longitudinal studies indicate that 10% of persons with untreated OHT develop glaucoma in 5 years. [21]&lt;/P&gt;
&lt;P&gt;Findings from randomised controlled trials and other studies suggest that IOP may be a modifiable risk factor for glaucoma i.e. the more IOP is lowered, the more likely it is that progression of glaucomatous optic neuropathy is inhibited.[22-31]&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;older age&lt;/EM&gt; – the prevalence of glaucoma increases with age [4, 7, 8, 13,17, 32] rising from about 1-2% in those 40 years and over, to about 4% or more in those over 80 years of age.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;family history of glaucoma&lt;/EM&gt; –&amp;nbsp; is estimated that individuals with a family history of glaucoma in first degree relatives are at least 3 times more likely to develop glaucoma.[33-38]&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;racial background&lt;/EM&gt; – Age adjusted prevalence of POAG has been observed to be higher in individuals of West African, African-Caribbean, and Hispanic origins.[4, 8, 13, 17, 39- 41]&amp;nbsp; It is also possible that racial background may be a proxy for other factors that contribute to the observed differences between racial groups.[42 - 44] &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;central corneal thickness&lt;/EM&gt;&amp;nbsp;- thinner central corneal thickness has been observed to be a risk factor for glaucomatous optic nerve damage, but there is no conclusive evidence that it is a risk factor for progression of established damage.[45-47]&amp;nbsp; In addition, it has recently emerged that central corneal thickness may be significant in the interpretation of the accuracy of IOP measurements by applanation tonometry.[24, 45, 48-52]&amp;nbsp; As yet no standard nomogram correcting applanation IOP measurement for central corneal thickness has been validated.[53, 54]&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Other factors&lt;/EM&gt; – the association between POAG and systemic hypertension, cardiovascular disease, diabetes mellitus and myopia has not been demonstrated consistently.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Visual impairment and blindness&lt;BR&gt;&lt;/STRONG&gt;The most recent analysis of causes for certification as visually impaired (partially sighted) and severely visually impaired (blind) in England and Wales during the calendar period April 1999-March 2000 show that glaucoma was the second most frequent cause for certification.[5] It accounted for 10.2% of certification for visual impairment and 10.9% of registrations for persons severely visually impaired in England and Wales.[5]&amp;nbsp;&amp;nbsp; Overall rates of certification for severe visual impairment were 6.32 per 100,000 population and this has remained consistent since the last analysis in 1990-91 when rates were 6 per 100,000 population.[55] &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication types of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication dates of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;BR&gt;1.&amp;nbsp;American Academy of Ophthalmology. Preferred Practice Plan Primary Open Angle Glaucoma. 2005.&amp;nbsp; &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89380&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE&amp;amp;catID=9856" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Royal College of Ophthalmologists Guidelines for the management of open angle glaucoma and ocular hypertension 2004. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=93140&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;European Glaucoma Society Terminology and Guidelines for Glaucoma (II Edition) 2003. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156796&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D.&amp;nbsp; Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis.&amp;nbsp;&amp;nbsp; Invest Ophthalmol Vis Sci.&amp;nbsp; 2006; 47 (10): 4254-61 ]&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=17003413%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England &amp;amp; Wales. BMC public health (electronic resource), {BMC-Public-Health}, 2006 (epub), vol. 6, p. 58,&amp;nbsp; &lt;A href="http://www.biomedcentral.com/content/pdf/1471-2458-6-58.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Friedman DS, Wolfs RC, O'Colmain BJ,&amp;nbsp;Klein BE, Taylor HR, West S et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15078671%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:1661-9.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8874440%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994;112:821-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8002842%5BUID%5D" target="_blank"&gt;[abstract]&amp;nbsp;&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Klein BE, Klein R, Sponsel WE, Franke T, Cantor LB, Martone J, Menage MJ. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-504. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=1454314%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Mitchell P, Rochtchina E, Lee AJ, Wang JJ. &amp;nbsp;Bias in self-reported family history and relationship to glaucoma: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2002;9:333-45. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12528918%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Coffey M, Reidy A, Wormald R, Xian WX, Wrigth L, Courtney P.&amp;nbsp; Prevalence of Glaucoma in the west of Ireland. Br J Ophthalmol. 1993 Jan;77(1):17-21 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8435391%5BUID%5D" target="_blank"&gt;[abstract]&amp;nbsp;&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Reidy A, Minassian DC, Vafidis G, Joseph , Farrow S, Wu J, Desai P, Connolly A. Prevalence of serious eye disease and visual impairment in a north London population:population-based cross-sectional study.&amp;nbsp; BMJ 1998 May 30;316(7145):1643-6 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9603746%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;266:369-74. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=2056646%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38:83-91. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9008633%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;deVoogd S, Ikram MK, Wolfs RC, Jansonius NM, Hofman A, de Jong PT.&amp;nbsp; Incidence of open angle glaucoma in a general elderly population.&amp;nbsp;&amp;nbsp; Ophthalmology 2005;112:1487-1493 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16039716%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology 2002;109:1047-51.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12045042%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Synder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol 2001;119(12):1819-26.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11735794%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Leske MC, Connell AM, Wu SY, Nemesure B, Li X, Schachat A et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol 2001;119:89-95. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11146731%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci 2003;44:3783-9.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12939292%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;20.&amp;nbsp;Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt J, Singh K. &amp;nbsp;Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109:1090-5.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=1867550%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;21.&amp;nbsp;Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13; discussion 829-30.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12049574%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;22.&amp;nbsp;Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:487-97.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9780093%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp;The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:498-505.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9780094%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;24.&amp;nbsp;Gordon MO, Beiser JA, Brandt JD, Heuer DJ, Higginbotham EK, Johnson CA et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20; discussion 829-30.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12049575%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;25.&amp;nbsp;Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48-56.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12523884%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;26.&amp;nbsp;Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12365904%5BUID%5D" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;27.&amp;nbsp;The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol 2000;130:429-40.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11024415%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;28.&amp;nbsp;Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111:1627-35.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15350314%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;29.&amp;nbsp;Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennet GR, Wilson MR et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 2004;122(6):813-20.&amp;nbsp;&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15197055%5BUID%5D" target="_blank"&gt; [abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;30.&amp;nbsp;The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-up Study: 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol 1995;120(6):718-31.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8540545%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;31.&amp;nbsp;Ederer F, Gaasterland DA, Dally LG, Kim J, VanVeldhuisen PC, Blackwell B et al., The Advanced Glaucoma Intervention Study (AGIS); 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology 2004;111(10):651-64.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15051195%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;32.&amp;nbsp;Wensor MD, McCarty CA, Stanislavsky YL, Livingstone PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology 1998;105:733-9.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9544649%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;33.&amp;nbsp;Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. Arch Ophthalmol 1994;112:69-73.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8285897%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;34.&amp;nbsp;Wolfs RC, Klaver CC, Ramrattan RS, van Duijn CM, Hofman A, de Jong PT. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1640-5.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9869795%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;35.&amp;nbsp;Klein BE, Klein R, Lee KE. Heritability of risk factors for primary open-angle glaucoma: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 2004;45:59-62.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=14691154%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;36.&amp;nbsp;Duggal P, Klein AP, Lee KE, Lyengar SK, Klein R, Bailey-Wilson JE et al. A genetic contribution to intraocular pressure: the beaver dam eye study. Invest Ophthalmol Vis Sci 2005;46(2):555-60. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15671282%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;37.&amp;nbsp;Sung VC, Koppens JM, Vernon SA, Pawson P, Rubinstein M, King AJ, Tattersall CL.&amp;nbsp; Longitudinal glaucoma screening for siblings of patients with primary open angle glaucoma: the Nottingham Family Glaucoma Screening Study. Br J Ophthalmol 2006 Jan; 90 (1):59-63 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16361669%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;38.&amp;nbsp;Weih LM, Nanjan M, McCarty CA, Taylor HR.&amp;nbsp; Prevalence and predictors of open-angle glaucoma: results from the visual impairment project.&amp;nbsp; Ophthalmology. 2001 Nov;108(11) 1966-72 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11713063%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;39.&amp;nbsp;Varma R, Ying-Lai M, Francis BA, Nguyen BB, Deneen J, Wilson MR et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004;111:1439-48.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15288969%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;40.&amp;nbsp;Rotchford AP, Johnson GJ. Glaucoma in Zulus: a population-based cross-sectional survey in a rural district in South Africa. Arch Ophthalmol 2002;120:471-8.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11934321%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;41.&amp;nbsp;Rotchford AP, Kirwan JF, Muller MA, Johnson GJ, Roux P. Temba glaucoma study: a population-based cross-sectional survey in urban South Africa. Ophthalmology 2003;110:376-82.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=12578784%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;42.&amp;nbsp;Mountain JL, Risch N. Assessing genetic contributions to phenotypic differences among 'racial' and 'ethnic' groups. Nat Genet 2004;36(11 Suppl):S48-53.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15508003%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;43.&amp;nbsp;Bamshad M. Genetic influences on health: does race matter? JAMA 2005;294:937-46.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16118384%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;44.&amp;nbsp;Higginbotham EJ. How much influence do socioeconomic factors have on glaucoma prevalence and therapeutic outcomes? Arch Ophth 2006 124(8):1185-6&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16908823%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;45.&amp;nbsp;Medeiros FA, Sample PA, Zangwill LM, Bowd C, Aihara M, Weinreb RN. Corneal thickness as a risk factor for visual field loss in patients with preperimetric glaucomatous optic neuropathy. Am J Ophthalmol 2003;136:805-13.&amp;nbsp;&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=14597030%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;46.&amp;nbsp;Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Ophthalmol 2004;122:17-21.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=14718289%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;47.&amp;nbsp;Jonas JB, Stroux A, Velten I, Juenemann A, Martus P, Budde WM. Central corneal thickness correlated with glaucoma damage and rate of progression. Invest Ophthalmol Vis Sci 2005;46:1269-74.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15790889%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;48.&amp;nbsp;Shah S, Chatterjee A, Mathai M, Kelly SP, Kwartz J, Henson D, McLeod D. Relationship between corneal thickness and measured intraocular pressure in a general ophthalmology clinic. Ophthalmology 1999;106:2154-60.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=10571352%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;49.&amp;nbsp;Whitacre MM, Stein RA, Hassanein K. The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 1993;115:592-6.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=8488910%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;50.&amp;nbsp;Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 2001;108:1779-88.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11581049%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;51.&amp;nbsp;Stodtmeister R. Applanation tonometry and correction according to corneal thickness. Acta Ophthalmol Scand 1998;76(3):319-24.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9686845%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;52.&amp;nbsp;Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 2000;44:367-408.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=10734239%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;53.&amp;nbsp;Shimmyo M, Ross AJ, Moy A, Mostafavi R. Intraocular pressure, Goldmann applanation tension, corneal thickness, and corneal curvature in Caucasians, Asians, Hispanics, and African Americans. Am J Ophthalmol 2003;136:603-13.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=14516799%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;54.&amp;nbsp;Orssengo GJ, Pye DC. Determination of the true intraocular pressure and modulus of elasticity of the human cornea in vivo. Bull Math Biol 1999;61:551-72.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;55.&amp;nbsp;Evans J. Causes of partial sight and blindness in England and Wales 1990-91. In Studies on Medical and Population Subjects.&amp;nbsp; No. 57 HMSO ;1995&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>182522</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=182522]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Glaucoma Clinical Care Pathway and Dataset - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,GLAUCOMA NKW 2006,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Glaucoma Clinical Care Pathway and Dataset - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=102 alt="DOAS glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182522/nelhImp_0003_doas_logo_v3forNKW.jpg" width=348 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&lt;U&gt;&lt;/U&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Giash Ahmed&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc6.asp" target="_blank"&gt;Please click here to see low vision version&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Glaucoma%20Clinical%20Care%20Pathway%20%20Dataset.pdf" target="_blank"&gt;Please click here to download pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Glaucoma management has been evolving rapidly in recent years and several models exist emphasising co-management between professional groups and between primary and secondary care.&amp;nbsp;&amp;nbsp; The Department of Health continues to spend time and resources invetigating alternative&amp;nbsp;models for the delivery and organisation of ophthalmic services in the NHS –not surprisingly with glaucoma services playing a prominent role &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=83623&amp;amp;tabID=290" target="_blank"&gt;(National Eye Care Services Steering Report – 2004).[1]&lt;/A&gt;&amp;nbsp; These, together with the wider developments in service provision and organisation introduced in the NHS, highlight the need for meaningful communication between health professionals and patients, and transfer of information between primary and secondary care computer systems (or independent service providers where relevant). &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.connectingforhealth.nhs.uk/" target="_blank"&gt;NHS Connecting for Health[2]&lt;/A&gt; (CfH) is an agency of the &lt;A href="http://www.dh.gov.uk/Home/fs/en" target="_blank"&gt;Department of Health,[3]&lt;/A&gt; and its purpose is to deliver the National Programme for IT. One of the components of this programme is the development of the &lt;A href="http://www.connectingforhealth.nhs.uk/delivery/programmes/nhscrs/" target="_blank"&gt;NHS Care Record Services[4]&lt;/A&gt; - an electronic store of over 50 million health and care records to be accessible by health professionals where and when they are needed. It will also give patients secure internet access to their own health record.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The information for each&amp;nbsp;NHS Care Record is held in&amp;nbsp;a number of places and it is envisaged that this information will be automatically brought together when required. A summary of care and clinical history will be held on a national database known as the &lt;A href="http://www.connectingforhealth.nhs.uk/delivery/programmes/spine" target="_blank"&gt;NHS Spine[5]&lt;/A&gt; to ensure that particularly important patient information is always accessible e.g. this will include data such as name, address, NHS number and date of birth, and clinical information such as allergies, adverse reactions to drugs and details of any visits to A&amp;amp;E.&amp;nbsp; More in-depth details will be held locally where most care is delivered&amp;nbsp;e.g. this will include detailed personal health information, such as records of conditions, medications, operations, tests and investigations for diagnosis and monitoring of response to treatment. &amp;nbsp;Thus, the core nationally available information together with the more detailed local information, combine to produce the patient’s complete record.&lt;/P&gt;
&lt;P&gt;The vision for the NHS is for all clinical data to be held electronically through the NHS Care Record Service.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Connecting for Health’s &lt;A href="http://www.connectingforhealth.nhs.uk/delivery/serviceimplementation/nks/doas" target="_blank"&gt;Do Once and Share Programme (DOAS)[6]&lt;/A&gt; was specifically set up to commission clinically led projects to develop templates for care pathways and datasets that would inform the development of the NHS Care Record, its presentation to the user through the Common User Interface and ultimately, its use in practice in a clinical setting.&amp;nbsp; In addition these would also inform development of CfH’s Output-Based Specifications (OBS) to be used by Local Service Providers to deliver IT systems and services that are fit for purpose for the NHS.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The DOAS programme is composed of 42 projects focusing on a clinical topic or condition, including &lt;A href="http://www.doasglaucoma.org/" target="_blank"&gt;glaucoma,[7]&lt;/A&gt; &lt;A href="http://www.rcophth.ac.uk/about/college/doas-cataract" target="_blank"&gt;cataract[8]&lt;/A&gt; and &lt;A href="http://www.doas-ded.org/PAGES/Article.asp?Sec=12&amp;amp;S=12" target="_blank"&gt;diabetic eye disease.[9]&lt;/A&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.doasglaucoma.org/" target="_blank"&gt;DOAS Glaucoma[7]&lt;/A&gt; project has produced a &lt;A href="http://www.doasglaucoma.org/Documents/DOAS%20Glaucoma%20Clinical%20Care%20Pathway%20and%20Dataset%20-%20June%202006%20v1.0.pdf" target="_blank"&gt;clinical care pathway and dataset[10]&lt;/A&gt; that have had national multi-professional consultation, patient involvement, and that have been formally approved by all professional bodies:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; •&amp;nbsp;The Royal College of Ophthalmologists&lt;BR&gt;&amp;nbsp;&amp;nbsp; •&amp;nbsp;The College of Optometrists&lt;BR&gt;&amp;nbsp;&amp;nbsp; •&amp;nbsp;Royal College of Nursing&lt;BR&gt;&amp;nbsp;&amp;nbsp; •&amp;nbsp;Royal College of General Practitioners&lt;BR&gt;&amp;nbsp;&amp;nbsp; •&amp;nbsp;British and Irish Orthoptic Society&lt;/P&gt;
&lt;P&gt;The Glaucoma Clinical Care Pathway and Dataset represent the clinical information required to manage a patient with glaucoma along each step of the care pathway from detection and referral to diagnosis, care plan and management.&amp;nbsp; They are evidence-based and incorporate clinical standards for glaucoma management (&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89380&amp;amp;tabID=288&amp;amp;catID=9856" target="_blank"&gt;American Academy of Ophthalmology,[11]&lt;/A&gt; &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156796&amp;amp;tabID=288" target="_blank"&gt;European Glaucoma Society,[12]&lt;/A&gt; and &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=93140&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;Royal College of Ophthalmologists[13])&lt;/A&gt;.&amp;nbsp; Their presentation explicitly indicates those data items that&amp;nbsp;represent the minimum (“essential) required to meet clinical standards at specific stages in the patient’s care pathway.&amp;nbsp;&amp;nbsp; Data items representing higher "desirable" standards are also incorporated&amp;nbsp;e.g. for investigation and objective documentation of clinical examination.&amp;nbsp;&amp;nbsp;“Desirable” data items&amp;nbsp;depend on availability of equipment and compatibility of existing commercial software systems, or aspects of clinical care that are currently being introduced into practice as a result of research and developments in technology.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The Glaucoma Clinical Care Pathway and Dataset will be used in primary and secondary care (and by alternative providers where relevant).&amp;nbsp;&amp;nbsp; It will serve to document clinical management and facilitate transfer of relevant information within and between clinical teams to enable consistent patient care.&amp;nbsp; Some examples include:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp; •&amp;nbsp;For referral of a patient from primary care to the Hospital Eye Service for confirmation of diagnosis and development of care plan; &lt;BR&gt;&amp;nbsp;&amp;nbsp; •&amp;nbsp;For assessment of patients’ ability to manage their medication (and subsequently compliance) and if necessary alerting the GP for support in the community at home.&lt;BR&gt;&amp;nbsp;&amp;nbsp; •&amp;nbsp;For monitoring of disease and response to treatment – the dataset incorporates standards for frequency of monitoring and the assessments required – whether this is in a specialist Ophthalmologist clinic or Nurse-led / Optometrist led clinic / shared care service.&lt;/P&gt;
&lt;P&gt;Having achieved multi-professional consensus and approval of its clinical content, the Glaucoma Clinical Care Pathway and Dataset is being further developed as an information standard, in order to facilitate utilisation of common codes and terminology; and consistent and accurate transfer of information within and between NHS IT systems.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.isb.nhs.uk/" target="_blank"&gt;NHS Information Standards Board[14]&lt;/A&gt; was established in 2001 to provide an independent mechanism for the approval of information standards in the NHS.&amp;nbsp; The board ensure that a&amp;nbsp;proposed information standard has demonstrated its fitness for purpose, safety, inter-operability and implementation through the &lt;A href="http://www.isb.nhs.uk/about-information-standards" target="_blank"&gt;assurance process.[15]&lt;/A&gt;&amp;nbsp; Once approved by the ISB as an information standard, all IT services and suppliers in the NHS are required to implement it within their systems.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;CfH are supporting the development of the Glaucoma Clinical Care Pathway and Dataset to become an NHS information standard, approved by the NHS ISB. Details of progress will be made available at the &lt;A href="http://www.doasglaucoma.org/" target="_blank"&gt;DOAS Glaucoma[7]&lt;/A&gt; website.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication types of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication dates of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References/ Links&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;National Eye Care Steering Services Group – First Report, 2004. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=83623&amp;amp;tabID=290" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Connecting for Health &lt;A href="http://www.connectingforhealth.nhs.uk/" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Department of Health &lt;A href="http://www.dh.gov.uk/Home/fs/en" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;NHS Care Record Service &lt;A href="http://www.connectingforhealth.nhs.uk/delivery/programmes/nhscrs/" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;NHS Spine &lt;A href="http://www.connectingforhealth.nhs.uk/delivery/programmes/spine" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;DOAS Programme &lt;A href="http://www.connectingforhealth.nhs.uk/delivery/serviceimplementation/nks/doas" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;DOAS Glaucoma &lt;A href="http://www.doasglaucoma.org/" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;DOAS Cataract &lt;A href="http://www.rcophth.ac.uk/about/college/doas-cataract" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;DOAS Diabetic Eye Disease &lt;A href="http://www.doas-ded.org/PAGES/Article.asp?Sec=12&amp;amp;S=12" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;DOAS Glaucoma Clinical Care Pathway and Dataset &lt;A href="http://www.doasglaucoma.org/Documents/DOAS%20Glaucoma%20Clinical%20Care%20Pathway%20and%20Dataset%20-%20June%202006%20v1.0.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;American Academy of Ophthalmologists - Preferred Practice Pattern - Primary Open Angle Glaucoma. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89380&amp;amp;tabID=288&amp;amp;catID=9856" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Terminology and Guidelines for Glaucoma. Second Edition. European Glaucoma Society. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156796&amp;amp;tabID=288" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Royal College of Ophthalmologists -&amp;nbsp; Guidelines for management of open angle glaucoma and ocular hypertension (2004) &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=93140&amp;amp;tabID=288&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;NHS Information Standards Board &lt;A href="http://www.isb.nhs.uk/" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;NHS ISB Assurance Process &lt;A href="http://www.isb.nhs.uk/about-information-standards" target="_blank"&gt;[website]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;All websites last accessed on 20 November 2006.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>201807</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=201807]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Living with glaucoma - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2006,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Living with glaucoma - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2 align=left&gt;&lt;IMG id=nelh_tempImage0 height=121 alt="A glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201807/nelhImp_0000_glaucomaeye.jpg" width=178 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="Patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID201807/nelhImp_0001_tonometry.jpg" width=178 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="example of visual loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0005_lossglaucoma.jpg" width=178 border=0 name=nelh_tempImage2&gt;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Marek Karas and Anita Lightstone&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week Contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc7.asp" target="_blank"&gt;Please click here to view&amp;nbsp;low vision version&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Living%20with%20glaucoma.pdf" target="_blank"&gt;Please click here to download pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273476:0" name=internalLink&gt;Click here to view 2007 update&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The term low vision is used when a person's vision cannot be fully corrected by regular glasses, contact lenses or medical or surgical treatment so that everyday activities such as reading, watching TV, cooking, driving etc. are difficult to do. &lt;/P&gt;
&lt;P&gt;Most people develop low vision because of eye diseases such as glaucoma, age related macular degeneration, diabetic retinopathy.&amp;nbsp; Each of these conditions causes different types of effects in a person's vision and the visual acuity of people with low vision can vary widely.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Glaucoma patients&lt;/EM&gt;&lt;/STRONG&gt; with low vision typically have loss of peripheral vision which primarily pose problems with mobility, but near visual tasks such as reading may also be difficult.&amp;nbsp; The types of problems experienced depend on the position and degree of visual field loss that has occurred e.g.&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Loss of visual field in only one eye will be compensated for by a full visual field in the unaffected eye. &lt;BR&gt;•&amp;nbsp;Loss of areas of the binocular visual field will have a greater impact.&amp;nbsp; &lt;BR&gt;•&amp;nbsp;Loss from an inferior field defect will affect mobility more than a superior loss.&amp;nbsp;&amp;nbsp; &lt;BR&gt;•&amp;nbsp;If field loss involves the central field of vision then this will pose problems for reading and recognising faces.&lt;/P&gt;
&lt;P&gt;Driving – Many people with glaucoma may continue to drive a car, but this will depend on the level of visual acuity and the amount of visual field loss that has taken place.&amp;nbsp; If only one eye is affected it is not necessary to inform the DVLA.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.dvla.gov.uk/media/pdf/medical/aagv1.pdf" target="_blank"&gt;DVLA&lt;/A&gt; is legally responsible for assessing whether a driver is medically fit enough to drive a vehicle or not.[1]&amp;nbsp;&amp;nbsp; The Royal College of Ophthalmologists also provides guidance on the &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=154944&amp;amp;tabID=288" target="_blank"&gt;visual standards for driving&lt;/A&gt;.[2] &lt;/P&gt;
&lt;P&gt;Essentially, to drive a car (Group 1 vehicle) a driver should have adequate acuity and field of vision.&amp;nbsp; A driver should be able to read a standard number plate in good light at 20m with glasses or contact lenses (if worn), with &lt;U&gt;both&lt;/U&gt; eyes open.&amp;nbsp; This is about 6/10 on the standard Snellen visual acuity chart.&amp;nbsp; In most circumstances this is sufficient.&amp;nbsp; Anyone with an eye condition such as glaucoma also needs to demonstrate adequate visual field.&amp;nbsp; In these circumstances the legal requirement is 120 degrees of horizontal field and 20 degrees of field above and below fixation.&amp;nbsp; Anyone with a field defect in both eyes must by law, inform the DVLA.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Referral and Registration of Visual Impairment &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Prior to 2005, a person with a sight loss would be included on the local register of visually impaired persons via the BD8 form, filled out by the hospital ophthalmologist. Since 2005, a new process has been introduced by the &lt;A href="http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Optical/OpticalDocumentsArticle/fs/en?CONTENT_ID=4074843&amp;amp;chk=q%2B1fLr" target="_blank"&gt;Department of Health &lt;/A&gt;that offers a route into low vision services from a variety of different entry points. There are three forms in use.[3]&lt;/P&gt;
&lt;P&gt;The &lt;A disabled href="nelh:156963:0" name=internalLink&gt;&lt;A href="nelh:156963:0" name=internalLink&gt;LVL (Low Vision Leaflet)&lt;/A&gt;&lt;/A&gt; is a self-referral letter for optometrists to give to people who present to them with low vision. &lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=102231&amp;amp;tabID=290" target="_blank"&gt;RVI (Referral of Visual Impairment)&lt;/A&gt; may be issued by staff in the hospital eye service to refer the patient (with consent) for a social care assessment as needs arise.&lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=84014&amp;amp;tabID=290" target="_blank"&gt;CVI (Certificate of Visual Impairment)&lt;/A&gt; – a certificate establishing eligibility for registration as either sight impaired (previously partially sighted) or severely sight impaired (previously blind).&amp;nbsp; It has replaced the BD8 form that served this function.&amp;nbsp; It requires the signature of a consultant ophthalmologist.&amp;nbsp; Registration is voluntary but does entitle people to various &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=98727&amp;amp;tabID=292" target="_blank"&gt;benefits and concessions&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access to Low Vision Services &lt;BR&gt;&lt;/STRONG&gt;A patient does not need to be registered as visually impaired to be eligible for low vision and rehabilitation intervention. They just need to be of a level of vision that would make them eligible for registration. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patient Information&lt;BR&gt;&lt;/STRONG&gt;In addition local societies and national groups provide both specific advice on living with Glaucoma and general help dealing with sight loss.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=101311&amp;amp;tabID=292" target="_blank"&gt;The International Glaucoma Association (IGA) &lt;/A&gt;&lt;BR&gt;IGA sight line: 01233 64 81 70&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.gdba.org.uk/" target="_blank"&gt;The Guide Dogs for the Blind Association&lt;/A&gt;&lt;BR&gt;Tel: 0118 983 5555 &lt;BR&gt;Email: &lt;A href="mailto:guidedogs@guidedogs.org.uk" target="_blank"&gt;guidedogs@guidedogs.org.uk&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication types of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication dates of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;1. Drivers Medical Group, DVLA Swansea, August 2006,6,36-38. At a glance guide to the current Medical Standards of Fitness to Drive, Visual Standards. &lt;A href="http://www.dvla.gov.uk/media/pdf/medical/aagv1.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. Royal College of Ophthalmologists, April 2005 Visual Standards for Driving. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=154944&amp;amp;tabID=288" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3. Department of Health, The identification, referral and registration of sight loss: action for social services departments and optometrists, and explanatory notes. August 2005. &lt;A href="http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/Optical/OpticalDocumentsArticle/fs/en?CONTENT_ID=4074843&amp;amp;chk=q%2B1fLr" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>156959</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=156959]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Low Vision Service - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS,GLAUCOMA NKW 2006,ANNUAL EVIDENCE UPDATES,GLAUCOMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Low Vision Service - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=121 alt="A glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID156959/nelhImp_0000_glaucomaeye.jpg" width=178 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="Patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID156959/nelhImp_0001_tonometry.jpg" width=178 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;IMG id=nelh_tempImage2 height=121 alt="example of visual loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0005_lossglaucoma.jpg" width=178 border=0 name=nelh_tempImage2&gt; &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Marek Karas and Anita Lightstone&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;Abbreviatons&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc8.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Low%20Vision%20Service.pdf" target="_blank"&gt;Please click here to download pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273476:0" name=internalLink&gt;Click here to view 2007 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What is a Low Vision Service?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The basic elements and minimum standards for the provision of a low vision service were proposed by the RNIB in 1999.[1]&amp;nbsp; These recommend that a low vision &lt;STRONG&gt;&lt;EM&gt;service&lt;/EM&gt;&lt;/STRONG&gt; should incorporate a range of integrated multi-disciplinary and multi-agency services (provided by ophthalmologists, optometrists, dispensing opticians, ophthalmic nurses, occupational therapists, rehabilitation workers and social workers) to enable people with low vision to make the best use of their remaining eyesight.&amp;nbsp; The combination of services and type of assistance that can provided will depend on the position and degree of visual field loss that has occurred, together with an assessment of their individual social, physiological, recreational, medical and emotional needs.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Similarly national standards for services provided to visually impaired adults by social services departments (or organisations providing such services on their behalf) were proposed by the&lt;A href="http://www.adss.org.uk/eyes.shtml" target="_blank"&gt; Association of Directors of Social Services (ADSS)&lt;/A&gt; in 2002.[2]&amp;nbsp; The 16 standards provide a national framework against which a local authority can monitor and measure its own performance.&lt;/P&gt;
&lt;P&gt;As a minimum, a low vision service should provide the following: &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;essential information, especially when a sight problem is diagnosed&lt;BR&gt;•&amp;nbsp;a check on the appropriateness of a person’s current prescription for glasses or contact lenses and an assessment of the usefulness of&amp;nbsp; their remaining vision&lt;BR&gt;•&amp;nbsp;a selection of low vision aids and non-optical aids to daily living&lt;BR&gt;•&amp;nbsp;advice on changes to the home environment, such as better lighting&lt;BR&gt;•&amp;nbsp;follow-up services and on-going training and support&lt;BR&gt;•&amp;nbsp;referral to other specialists if necessary (e.g. for hearing loss).&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Areas that low vision and rehabilitation services can concentrate on are:&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;&lt;EM&gt;Help with mobility&lt;/EM&gt;. Use of basic techniques to help people compensate for a loss of visual field allow for safer travel. This can be training on how to scan with the remaining field to the use of symbol or more complex mobility canes. The use of a guide dog is also a mobility aid.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;•&amp;nbsp;Help with detail&lt;/EM&gt;. Use of enlargement, magnification and clear print will help with detailed tasks.&lt;/P&gt;
&lt;P&gt;Optical low vision services are primarily centred in the hospital eye service.[3]&amp;nbsp; Here low vision aids such as hand and stand magnifiers, illuminated magnifiers, telescopic lenses for both distance and near, and spectacle mounted magnifiers, are prescribed.&amp;nbsp; The increasing availability of illuminated hand held magnifiers and electronic magnification devices have begun to replace spectacle mounted devices.[4]&lt;/P&gt;
&lt;P&gt;Rehabilitation workers for the visually impaired, working within social services, have provided home visits to give advice on adapting everyday tasks and provide specialist equipment and make adaptations to the home. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Variations in Low Vision Services&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Surveys of low vision services have reported that:-&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;low vision services across the UK were variable in coverage, had differing standards and often worked in isolation from other health and social care provision and that the advice given by a low vision clinic would often not be fed back to other professionals involved in home visits.[3,5]&lt;BR&gt;&amp;nbsp;&lt;BR&gt;•&amp;nbsp;better access and co-ordination of services was central to patients’&amp;nbsp; needs.[6]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Effectiveness of Low Vision Aids and Mobility Training&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Local service reviews&lt;/EM&gt; report high levels of patient satisfaction with the services based on multi-agency and multi-disciplinary models and that the services provided were sufficient to meet patients’ needs.[7,8]&lt;/P&gt;
&lt;P&gt;Patient training and support after low vision aids have been provided have been reported to be necessary factors for maximising use of remaining vision, reinforcing the need for integrated service delivery.[9] &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Systematic Reviews&lt;/EM&gt; – two have recently been published.&amp;nbsp; One on low vision aids and the other on orientation and mobility training.[10,11]&lt;BR&gt;&amp;nbsp; &lt;BR&gt;Overall these revealed:&lt;BR&gt;•&amp;nbsp;a paucity of high quality research evidence in this area to inform choice of type of optical aid or type of training to meet the needs of persons with low vision&lt;BR&gt;•&amp;nbsp;The patient population for research in this area was also dominated by age related macular degeneration, with glaucoma patients representing about 7-10% of the patients studied.&amp;nbsp;&amp;nbsp; &lt;BR&gt;•&amp;nbsp;No specific studies on glaucoma patients were identified for inclusion in these reviews.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Current Developments&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;The National Eye Care Services Steering Group report [12] proposed a new care pathway for low vision services and several models of service delivery are being piloted across England.&amp;nbsp; A report evaluating these pilots is expected to be presented in January 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Further sources of advice on low vision services&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=102001&amp;amp;tabID=290" target="_blank"&gt;Directory of local services RNIB Website &lt;BR&gt;&lt;/A&gt;RNIB’s Helpline on 0845 766 9999&lt;/P&gt;
&lt;P&gt;•&amp;nbsp;the national &lt;A href="http://www.lowvision.org.uk/index.html" target="_blank"&gt;Low Vision Consensus group &lt;/A&gt;has a network of committees around the UK which organise local services. &lt;/P&gt;
&lt;P&gt;•&amp;nbsp;Local Sensory Needs Teams within a council. Community Support by local Councils. This aims to support people with disabilities and other special needs to lead independent lives. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication types of cited references&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication dates of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;BR&gt;1.&amp;nbsp;Low vision sevices.&amp;nbsp; Recommendations for future service delivery in the UK.&amp;nbsp;&amp;nbsp; Low Vision Consenus Group. 1999.&amp;nbsp; RNIB, London [full text]&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Progress in Sight – National Standards for Social Care for visually impaired adults.&amp;nbsp; 2002.&amp;nbsp; Disabilities Committee of the Association of Directors of Social Services , London &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156957&amp;amp;tabID=288" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;Culham LE, Ryan B, Jackson AJ et al.&amp;nbsp; Low vision services for vision rehabilitation in the UK.&amp;nbsp; Br J Ophthalmol 2002; 86(7): 743-7 &lt;A href="http://bjo.bmj.com/cgi/reprint/86/7/743" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;Crossland MD, Silver JH.Thirty Years in an urban Low Vision Clinic: Changes in prescribing habits of Low Vision Practitioners.&amp;nbsp; Optometry and Vision Science 82, 7, 617-622 &lt;A href="http://www.homepages.ucl.ac.uk/~smgxmdc/lva.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Ryan B, Culham L.&amp;nbsp; Fragmented Vision: Survey of low vision services in the UK. 1999. RNIB, London. &lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Ryan, B.M., L, Our better vision. What people need from low vision services in the UK. 1999, Royal National Institute for the Blind: London.&lt;/P&gt;
&lt;P&gt;7. Collins, J and Skilton K,. Low Vision Services in South Devon: a multi-agency, multi-disciplinary approach. Ophthalmic Physio Opt 2004 24 (4): p355-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15228515%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Wolffson, J. Clincial audit of the RNIB Judd Street Low Vision Rehabilitation Service. in SLRR. 2005. London&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Factors which Influence the use of Low Vision Aids.&amp;nbsp; 2005.&amp;nbsp; Visibility &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=102007&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Optical devices for adults with low vision: a systematic review of published studies of effectiveness &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=83440&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Orientation and mobility training for adults with low vision Cochrane Review &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=149173&amp;amp;tabID=290" target="_blank"&gt;[full text]&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Department of Health, First report of the National Eye Care Services Steering Group April 2004. &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=83623&amp;amp;tabID=290" target="_blank"&gt;[full text] &lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;H3&gt;&lt;/H3&gt;&lt;/U&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>197249</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=197249]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Patient education - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,GLAUCOMA NKW 2006,ANNUAL EVIDENCE UPDATES,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Patient education - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&lt;IMG id=nelh_tempImage0 height=121 alt="A glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID197249/nelhImp_0000_glaucomaeye.jpg" width=178 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 style="WIDTH: 175px; HEIGHT: 122px" height=121 alt="Patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID197249/nelhImp_0001_tonometry.jpg" width=178 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;IMG id=nelh_tempImage2 height=121 alt="example of visual loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0005_lossglaucoma.jpg" width=178 border=0 name=nelh_tempImage2&gt;&lt;/H2&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Professor Heather Waterman RN PhD&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc9.asp" target="_blank"&gt;Please click here to view&amp;nbsp;low vision version&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Patient%20Education.pdf" target="_blank"&gt;Please click here to download pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273482:0" name=internalLink&gt;Click here to view 2007 update&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;There appears to be consensus in the literature that patients should be educated about their eye disease so that they can participate in the management of their disease and prevent further loss of vision [1].&amp;nbsp; Non-adherence with ocular hypotensive treatment is a common problem in the management of glaucoma.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The Royal College of Ophthalmologists suggests that ophthalmic departments should use pre or self prepared handouts for the benefit of patients and their carers.[2]&amp;nbsp; The European Glaucoma Society additionally proposes using audio-visual information to support written and verbal education to improve patient’s adherence to therapy.[3] &amp;nbsp;The American Academy of Ophthalmology states that education and involvement of patients in their glaucoma management is a treatment goal and that some patients might find peer support groups or counselling useful.[4] &amp;nbsp;However, there are no specific recommendations made in professional body guidance to indicate the effectiveness of these or other methods of educating patients.&amp;nbsp; &lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&lt;STRONG&gt;What do patients know?&lt;/STRONG&gt;&lt;/P&gt;
&lt;H3&gt;Awareness of the condition&lt;/H3&gt;
&lt;P&gt;A number of studies have been conducted over the last eight years showing that patients with glaucoma have poor levels of understanding of their condition.[1,5,6,7,8,9]&amp;nbsp; Amongst these are two studies which report a high proportion of patients with glaucoma were unable to identify their topical therapy [6,7] and another which shows that &amp;lt;20% could answer all questions on how glaucoma affects the eye.[8]&amp;nbsp;&amp;nbsp; In a small qualitative study, it was found that a large proportion of patients did not know the reason for referral to an ophthalmology clinic and following the consultation some were still unclear about their diagnosis.[5]&amp;nbsp;&amp;nbsp; Altogether the results suggest that ignorance about glaucoma is a major problem in its management and that there is an urgent need for patients to receive more information.[1]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;A few other studies focussed on patients’ beliefs and/or perceptions of glaucoma.[10,11] For example, one study found that some people thought that glaucoma was ‘cancer’ whilst others believed it was ‘trachoma’. [10]&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Socio-demographic factors&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Other studies have attempted to investigate relationships between patient characteristics and knowledge of glaucoma.&amp;nbsp;&amp;nbsp; Attebo al (1997) report that higher educational and occupational levels were associated with an increased patient awareness and knowledge of glaucoma.[10]&amp;nbsp; Similarly, lack of knowledge in glaucoma patients has been found to be associated with low level of education, [12,13] recent diagnosis, high age and no preference for Internet as source of information.[12]&amp;nbsp;&amp;nbsp; Socioeconomic differences have also been found to be correlated with glaucoma patients’ knowledge about glaucoma and its treatment.[12]&amp;nbsp; Evidence suggests that patient from low socioeconomic groups are in need of more help to understand glaucoma than those from middle to higher groups.[12]&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;BR&gt;What do patients want to know?&lt;/H2&gt;
&lt;H3&gt;Content of educational programmes &lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;One key study questioned patients with glaucoma and found they wanted to be told:&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;the course and possible consequences of glaucoma, &lt;BR&gt;2.&amp;nbsp;IOP is risk factor, &lt;BR&gt;3.&amp;nbsp;about adverse events,&amp;nbsp; &lt;BR&gt;4.&amp;nbsp;there was no cure for glaucoma, &lt;BR&gt;5.&amp;nbsp;the need for regular checkups, &lt;BR&gt;6.&amp;nbsp;eye drops may be needed after surgery, &lt;BR&gt;7.&amp;nbsp;how to put in eye drops, rate of progression of glaucoma, &lt;BR&gt;8.&amp;nbsp;how to cope with glaucoma, &lt;BR&gt;9.&amp;nbsp;how to function better with glaucoma, &lt;BR&gt;10.&amp;nbsp;resources or rehabilitation for visually impaired, &lt;BR&gt;11.&amp;nbsp;social psychological aspects &lt;BR&gt;12.&amp;nbsp;and work related aspects of glaucoma.[1]&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Effectiveness of patient education &lt;/H3&gt;
&lt;P&gt;A recent systematic review of quantitative research concluded that patients who are more knowledgeable of their condition are more likely to be adherent to treatment.[14]&amp;nbsp; A few studies have been identified which have investigated the effectiveness of educational programmes. [11,13,15]&amp;nbsp;&amp;nbsp; The findings show that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Education improves patients’ knowledge however none of the studies carried out long term follow up of retention of knowledge.&amp;nbsp;&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;There is little evidence on how education may change adherence behaviour or how it helps patients cope practically and psychologically with glaucoma.&amp;nbsp;&amp;nbsp;&amp;nbsp; [1] &lt;/LI&gt;
&lt;LI&gt;Furthermore, the most effective methods for educational intervention for glaucoma have not yet been identified.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication types of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication dates of cited references&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;1. Hoevenaars JGM;Schouten JSA;van d;Beckers HJM;Webers CAB Knowledge base and preferred methods of obtaining knowledge of glaucoma patients European Journal of Ophthalmology. 2005;15(1)32-40 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15751237%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. Guidelines for the management of open angle glaucoma and ocular hypertension 2004. Royal College of Ophthalmologists (2004) &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=93140&amp;amp;tabID=288" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3. Terminology and guidelines for glaucoma (II edition). The European Glaucoma Society (2003) &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=156796&amp;amp;tabID=288" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. Preferred Practice Pattern - Primary Open Angle Glaucoma.&amp;nbsp; American Academy of Ophthalmology (2005) &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=89380&amp;amp;tabID=288" target="_blank"&gt;[full text]&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; Burns J, Barret G, Murdoch I. The experiences of patients with suspected glaucoma.&amp;nbsp; A qualitative study.&amp;nbsp; Ophthalmic Nursing: International Journal of Ophthalmic Nursing 2001;5(3):8-11 [no abstract available]&lt;/P&gt;
&lt;P&gt;6. Deokule S, Sadiq S, Shah S. Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms. Ophthalmic &amp;amp; physiological optics : the Journal of the British College of Ophthalmic Opticians (Optometrists) 2004;24(1):9-15 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=14687196%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. Labiris G, Fanariotis M, Christoulakis C, Petounis A, Kitsos G, Aspiotis, Psillas K. Tele-ophthalmology and conventional ophthalmology using a mobile medical unit in remote Greece. Journal of Telemedicine and Telecare 2003;9:296-299 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=14599335%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8. Sheppard J, Warner J, Kelley K. An evaluation of the effectiveness of a nurse-led glaucoma monitoring clinic. Ophthalmic Nursing: International Journal of Ophthalmic Nursing 2003;7(2)15-21 [no abstract available]&lt;/P&gt;
&lt;P&gt;9. Herndon LW, Brunner TM, Neff-Rollins J. The Glaucoma Research Foundation Survey:&amp;nbsp; Patient understanding of glaucoma and its treatment American Journal of Ophthalmology 2006;141(1):S22-29 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16389057%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10. Attebo K, Mitchell P, Cumming R, Smith W. Knowledge and beliefs about common eye diseases.&amp;nbsp; Aust NZ J&amp;nbsp;Ophthalmology&amp;nbsp;1997;25:283-287 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9395831%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11. Rendell J. Effect of health education on patients' beliefs about glaucoma and compliance Insight (American Society of Ophthalmic Registered Nurses) 2000;25(4);112-118 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11908028%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12. Hoevenaars JGMM, Schouten JSAG, van de Borne BW, Beckers HJM, Webers CAB. Socioeconomic differences in glaucoma patients’ knowledge, need for information and expectations of treatments Acta Ophthalmol Scand 2006;84:84-91 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16445444%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13. Kharod BV, Johnson PB, Nesti HA, Rhee DJ. Effect of written instructions on accuracy of self reporting medication regimen in glaucoma patients Journal of Glaucoma 2006;15(3):244-247 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16778648%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14. Olthoff CMG, Schouten JSAG, van de Borne BW, Webers CAB. Noncompliance with ocular hyptensive treatment in patients with glaucoma or ocular hypertension Ophthalmology 2005;112:953-961 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15885795%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15. Oermann MH, Needham CA, Dobal MT, Sinishtaj L, Lange MP. Filling the waiting time in the clinic with education about glaucoma Insight (American Society of Ophthalmic Registered Nurses).2001;6(3):77-80 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11677506%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week&amp;nbsp;contents&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>212204</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=212204]]&gt;</url>
    <title>Glaucoma National Knowledge Week: PROGRESSOR - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS,GLAUCOMA NKW 2006,ANNUAL EVIDENCE UPDATES,GLAUCOMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: PROGRESSOR - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Progressor is a trend analysis for identifying progression in serial visual fields. It is a software package which analyses visual field progression using pointwise linear regression of sensitivity on time.&lt;/P&gt;
&lt;P&gt;Image 1 is a Humphrey Field Analyser (HFA) representation of the visual fields of the right and left eye of the Demonstration Patient.&amp;nbsp;This visual field test would normally be carried out each time the glaucoma patient attends clinic. The darker areas correspond to more severe loss&amp;nbsp;in&amp;nbsp;each&amp;nbsp;field.&lt;/P&gt;
&lt;P&gt;Image 2 is from PROGESSOR and indicates the significance of change for each point tested in the visual fields of the patient. Each bar represents a HFA test conducted at clinic. The&amp;nbsp;length of the bars&amp;nbsp;indicate the amount of change in&amp;nbsp;visual field sensitivities and the colour corresponds to the significance of the change at each point.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Image 3&amp;nbsp;provides the colour key for the significance of change, where a positive slope indicates improvement, a negative slope deterioration and grey indicates no change.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Image 4 shows the same left and right eye visual fields using a HFA, however,&amp;nbsp;a binocular test has also been performed. &amp;nbsp;It can be seen that each field compensates for the other in the binocular view.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Image 1&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 height=330 alt="image 1 - print out of visual field using Humphrey Field Analyser" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID212204/nelhImp_0001_Slide2.png" width=481 border=0 name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Image&amp;nbsp;2&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=330 alt="image 2 - PROGRESSOR screen print" src="https://rmsadmin.nelh.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID212204/nelhImp_0000_Slide1.png" width=481 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;Image 3&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage2 height=330 alt="Image 3 - colour key for PROGRESSOR " src="https://rmsadmin.nelh.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID212204/nelhImp_0002_Slide3.png" width=481 border=0 name=nelh_tempImage2&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Image 4&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage3 height=330 alt="Image 4 - Humphrey Field Analyser" src="https://rmsadmin.nelh.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID212204/nelhImp_0003_Slide4.png" width=481 border=0 name=nelh_tempImage3&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Mr Ananth Viswanathan is a Consultant surgeon employed&amp;nbsp;by Moorfields Eye Hospital and is an inventor of the PROGRESSOR software.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>212566</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=212566]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Sample slides - visual field, PROGRESSOR and HRT progression. November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA,GLAUCOMA NKW 2006,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Sample slides - visual field, PROGRESSOR and HRT progression. November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Below is an example of a female patient in her mid 40s.&amp;nbsp; The visual field 'grey scale' shows&amp;nbsp;an inferior nasal step in the right eye and the corresponding PROGRESSOR analysis shows&amp;nbsp;fairly rapid progression (and then stabilization following trabeculectomy).&amp;nbsp;&amp;nbsp; The left eye has a stable normal field.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=480 alt="Visual Field 'grey scale' and corresponding PROGRESSOR" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID212566/nelhImp_0000_Picture2.gif" width=640 border=0 name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The next slide shows the HRT progression (red pixels on the disc image), quantified in the graph. There is rapid progression and then some stabilization following the trabeculectomy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 height=471 alt="HRT Progression" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID212566/nelhImp_0001_Picture1.gif" width=601 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>182443</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=182443]]&gt;</url>
    <title>Glaucoma National Knowledge Week: Screening - November 2006</title>
    <publicationDate>2006-11-27T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,GLAUCOMA,ANNUAL EVIDENCE UPDATES,GLAUCOMA NKW 2006]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Glaucoma National Knowledge Week: Screening - November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 height=121 alt="a glaucomatous optic nerve head" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0002_glaucomaeye.jpg" width=178 border=0 name=nelh_tempImage0&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage1 height=121 alt="patient undergoing tonometry" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0003_tonometry.jpg" width=178 border=0 name=nelh_tempImage1&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;IMG id=nelh_tempImage2 height=121 alt="example of visual loss from glaucoma" src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID182443/nelhImp_0005_lossglaucoma.jpg" width=178 border=0 name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Kashif Qureshi&lt;/EM&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=212425&amp;amp;tabID=290" target="_blank"&gt;Abbreviations&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/nkw_glaucoma_1106/nkw_glaucoma_doc1.asp" target="_blank"&gt;Please click here to view low vision version&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/glaucoma_docs_1106/Screening.pdf" target="_blank"&gt;Please click here&amp;nbsp;to download&amp;nbsp;pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:273499:0" name=internalLink&gt;Click here to view 2007 update&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;No national programme for screening for glaucoma exists in England at present.&amp;nbsp; Instead detection of potential cases of Primary Open Angle Glaucoma relies almost entirely on opportunistic case finding by optometrists performing NHS Eye Tests.&lt;/P&gt;
&lt;P&gt;The &lt;A href="http://www.nsc.nhs.uk/" target="_blank"&gt;National Screening Committee (NSC)&lt;/A&gt; convened a workshop on screening for glaucoma in September 2001 to consider a review of the published literature evaluating the effectiveness and appropriateness of screening for open angle glaucoma.[1, 2]&amp;nbsp;&amp;nbsp; At that time the NSC concluded that screening should not be offered.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;More specifically the review reported that:[1, 2]&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Screening criteria&lt;/EM&gt; -&amp;nbsp;some but not all of the NSC screening criteria were met&lt;/P&gt;
&lt;P dir=ltr style="MARGIN-RIGHT: 0px"&gt;&lt;EM&gt;The screening test&lt;/EM&gt; :&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;No single screening test was available to discriminate between normal persons and those with POAG.&amp;nbsp;&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Visual field testing and intra-ocular pressure (IOP) were likely to be a “best-choice” test combination&lt;/LI&gt;
&lt;LI&gt;Static automated perimetry (SAP) visual field testing identifies abnormalities after a significant proportion of axons have already been already damaged which may be too late for a screening test.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Methods for optic nerve head assessment lacked specificity for discriminating between structural abnormalities with no functional damage and glaucomatous eyes.&amp;nbsp; The need for normative parameters was highlighted.&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;NHS Eye Tests &lt;/H2&gt;
&lt;P&gt;Based on epidemiological evidence &lt;EM&gt;free&lt;/EM&gt; NHS Eye Tests [3] are available: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;annually for persons over the age of 40 years with a family history of glaucoma.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;every 2 years for healthy adults up to the age of 70 years&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;annually for those over 70 years&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Other risk factors for POAG, such as race are not considered for entitlement for a free eye test.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;More recently &lt;/H2&gt;
&lt;P&gt;A number of studies have been conducted over the past 5 years which have provided additional information on:&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Risk factors for glaucoma&lt;/EM&gt;&lt;/STRONG&gt; – most notably the role of central corneal thickeness in assessment of IOP.&amp;nbsp; The Ocular Hypertension Treatment Study (OHTS) and Early Manifest Glaucoma Study (EMGTS).[4,5]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Structural optic nerve head assessment&lt;/EM&gt;&lt;/STRONG&gt; - Approaches to quantitative structural assessment (confocal scanning laser ophthalmoscopy, scanning laser polarimetry (GDx) and ocular coherence tomography (OCT)) have continued to develop, as has collection of normative data.[6-11]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Functional evaluations of the optic nerve&lt;/EM&gt;&lt;/STRONG&gt;, such as frequency doubling perimetry (FDP), short wavelength automated perimetry (SWAP) and motion detection perimetry (MDP) have been evaluated for their role in identification of damage, earlier and prior to establishment of functional loss.[12,13]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Health Technology Assessment 2005&lt;/EM&gt;&lt;/STRONG&gt; - Kwartz et al [14] examined the effectiveness of structural and functional tests for the detection and monitoring of POAG and concluded that the techniques assessed, Humphrey Field Analyser (HFA), optic nerve head tomography (HRT) and scanning laser perimetry (GDx), were amenable for use in the clinical environment but that:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;There was poor agreement for detection of glaucoma between the modalities assessed: HFA, HRT, GDx.&lt;/LI&gt;
&lt;LI&gt;No single modality had sufficient diagnostic precision to be used in isolation.&lt;/LI&gt;
&lt;LI&gt;Neither the HRT nor GDx should be viewed as a replacement for visual field examination.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Further research was needed into aspects of the structure versus function relationship in glaucoma.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;EM&gt;Combination of structural and functional testing&lt;/EM&gt;&lt;/STRONG&gt; – i.e. combining visual function specific tests with optical imaging structural test results for detection of glaucoma:&amp;nbsp; FDP, SWAP, OCT, GDx, and confocal scanning laser ophthalmoscopy.&amp;nbsp;&amp;nbsp; The findings of Shah et al broadly demonstrated that a combination of parameters from structural tests and functional tests improved the sensitivity of glaucoma detection.[15]&amp;nbsp; The parameters chosen for combination would depend on the sensitivity and specificity required. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;EM&gt;Forthcoming reviews &lt;BR&gt;&lt;/EM&gt;&lt;/STRONG&gt;a.&amp;nbsp;&amp;nbsp;The NSC is due to review its existing recommendations in 2007.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;b.&amp;nbsp; It is anticipated that this will be informed by a systematic review on the clinical and cost-effectiveness of screening for open angle glaucoma commissioned by the Health Technology Assessment (HTA) programme.[16]&amp;nbsp; This review will specifically :&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;examine the most valid and acceptable tests or combination of tests for population screening and diagnosis of glaucoma&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;assess how testing affects patient management and outcome&lt;/LI&gt;
&lt;LI&gt;examine the effectiveness of glaucoma interventions&lt;/LI&gt;
&lt;LI&gt;model the effects of treatment on the prevention of long-term visual impairment&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;estimate the relative cost-effectiveness of alternative screening strategies and diagnostic pathways. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This HTA review is due to report in 2007.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Types%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication types of cited references&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/Documents/Publication%20Years%20Glaucoma%20NKW.pdf" target="_blank"&gt;Please click here to view publication dates of cited references&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;References:&lt;/H2&gt;
&lt;P&gt;1. &amp;nbsp;Spry P, Sparrow J. An Evaluation of Open Angle Glaucoma against the NSC Criteria for Screening Viability, Effectiveness and Appropriateness. UK National&amp;nbsp;Screening Committee 2001 &lt;A href="http://www.library.nhs.uk/eyes/ViewResource.aspx?resID=61002&amp;amp;tabID=289" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/A&gt;2.&amp;nbsp; National Library for Health, Screening Specialist Library. National Screening Committee policy - glaucoma screening&amp;nbsp;2005. &lt;A href="http://www.library.nhs.uk/screening/ViewResource.aspx?resID=61003&amp;amp;tabID=288&amp;amp;catID" target="_blank"&gt;[link here]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;&amp;nbsp;Head of General Ophthalmic Services, Department of Health. Frequency of GOS sight tests and Memorandum of Understanding. January 2002. &lt;A href="http://www.dh.gov.uk/assetRoot/04/08/46/15/04084615.pdf" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. &amp;nbsp;Gordon M, Beiser J, Brandt J, Heuer D, Higginbotham E, Johnson C et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Archives of Ophthalmology 2002 Oct;120:714-20. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%22Arch%20Ophthalmol%22%5BJournal%5D%20AND%20%28Beiser%20J%5BAuth%5D%20AND%20Gordon%20M%5BAuth%5D%29%20AND%20%28%222002/01/01%22%5BPDAT%5D%20%3A%20%222002/12/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5.&amp;nbsp; Heijl A, Leske M, Bengtsson B, Hyman L, Bengtsson B, Hussein M.&amp;nbsp;Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.&amp;nbsp;Archives of Ophthalmology 2002;120(10):1268-79. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%28Heijl%20A%5BAuth%5D%20AND%20Leske%20M%5BAuth%5D%20AND%20Bengtsson%20B%5BAuth%5D%29%20AND%20%22Archives%20of%20ophthalmology%22%5BJour%5D%20AND%20%28%222002/01/01%22%5BPDAT%5D%20%3A%20%222002/12/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;6. &amp;nbsp;Wollstein G, Garway-Heath DF, Fontana L,&amp;nbsp;Hitchings RA. Identifying early glaucomatous changes. Comparison between expert clinical assessment of optic disc photographs and confocal scanning ophthalmoscopy. Ophthalmology 2000;107(12):2272-7.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11097609%5BUID%5D" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;7. &amp;nbsp;Zangwill LM, Bowd C, Berry CC, Williams J, Blumenthal EZ, Sanchez-Galeana CA,&amp;nbsp;et al. Discriminating between normal&amp;nbsp;and glaucomatous eyes using Heidelberg Retina Tomograph, GDx Nerve Fiber Analyzer&amp;nbsp;and Optical Coherence Tomograph. Archives of Ophthalmology 2001;119(7):985-993. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%22Arch%20Ophthalmol%22%5BJournal%5D%20AND%20%28Zangwill%20L%5BAuth%5D%20AND%20Bowd%20C%5BAuth%5D%29%20AND%20%28%222001/01/01%22%5BPDAT%5D%20%3A%20%222001/12/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;8. &amp;nbsp;Brusini P, Salvetat ML, Parisi L, Zeppieri M, Tosoni C. Discrimination between normal and early glaucomatous eyes with scanning laser polarimeter with fixed and variable corneal compensator settings. European Journal of Ophthalmology 2005 Jul-Aug;15(4):468-76. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%22Eur%20J%20Ophthalmol%22%5BJournal%5D%20AND%20%28Brusini%20P%5BAuth%5D%20AND%20Salvetat%20ML%5BAuth%5D%29%20AND%20%28%222005/01/01%22%5BPDAT%5D%20%3A%20%222005/12/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;&amp;nbsp;Funaki S, Shirakashi M, Yaoeda K, Abe H, Kunimatsu S, Suzuki Y et al. Specificity and sensitivity of glaucoma detection in the Japanese population using scanning laser polarimetry. The British Journal of Ophthalmology 2002 Jan;86(1):70-4.&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%22Br%20J%20Ophthalmol%22%5BJournal%5D%20AND%20%28Funaki%20S%5BAuth%5D%20AND%20Shirakashi%20M%5BAuth%5D%29%20AND%20%28%222002/01/01%22%5BPDAT%5D%20%3A%20%222002/12/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;10. &amp;nbsp;Reus N,.Lemij HG. Diagnostic accuracy of the GDx VCC for glaucoma. Ophthalmology 2004 Oct;111(10):1860-5. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%22Ophthalmology%22%5BJournal%5D%20AND%20%28Reus%5BAuth%5D%20AND%20Lemij%20H%5BAuth%5D%29%20AND%20%28%222004/01/01%22%5BPDAT%5D%20%3A%20%222004/10/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;&amp;nbsp;Liu X, Ling Y, Luo R, Ge J, Zheng X. Optical coherence tomography in measuring retinal nerve fiber layer thickness in normal subjects and patients with open-angle glaucoma. Chinese Medical Journal 2001 May;114(5):524-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%28Liu%20X%5BAuth%5D%20AND%20Ling%20Y%5BAuth%5D%29%20AND%20%22Chinese%20medical%20journal%22%5BJour%5D%20AND%20%28%222001/01/01%22%5BPDAT%5D%20%3A%20%222001/12/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;12. &amp;nbsp;Chandrasekhar G, Kunjam V, Rao VS, Nutheti R. Humphrey visual field and frequency doubling perimetry in the diagnosis of early glaucoma. Indian Journal of Ophthalmology 2003 Mar;51(1):35-8. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%28Chandrasekhar%5BAuth%5D%20AND%20Kunjam%20V%5BAuth%5D%29%20AND%20%22Indian%20journal%20of%20ophthalmology%22%5BJour%5D%20AND%20%28%222003/01/01%22%5BPDAT%5D%20%3A%20%222003/12/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&amp;nbsp;&lt;A href="http://www.ijo.in/article.asp?issn=0301-4738;year=2003;volume=51;issue=1;spage=35;epage=38;aulast=Chandrasekhar" target="_blank"&gt;[full text]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;&amp;nbsp;Mok KH, Lee VW, So KF. Retinal nerve fiber layer measurement by optical coherence tomography in glaucoma suspects with short-wavelength perimetry abnormalities. Journal of Glaucoma, 2003 Feb;12(1):45-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%28Mok%20K%5BAuth%5D%20AND%20lee%20V%5BAuth%5D%29%20AND%20%22Journal%20of%20glaucoma%22%5BJour%5D%20AND%20%28%222003/01/01%22%5BPDAT%5D%20%3A%20%222003/03/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;&amp;nbsp;Kwartz AJ,&amp;nbsp;Henson DB,&amp;nbsp;Harper RA,&amp;nbsp;Spencer AF,&amp;nbsp;McLeod D. The effectiveness of the Heidelberg Retina Tomograph and laser diagnostic glaucoma scanning system (GDx) in detecting and monitoring glaucoma. Health Technol Assess 2005 Nov;9(46):1–148. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%22Health%20Technol%20Assess%22%5BJournal%5D%20AND%20Kwartz%20AJ%5BAuth%5D%20AND%20%28%222005/01/01%22%5BPDAT%5D%20%3A%20%222005/12/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;&amp;nbsp;Shah NN, Bowd C, Medeiros FA, Weinreb RN, Sample PA, Hoffmann EM, Zangwill LM. Combining structural and functional testing for detection of glaucoma. Ophthalmology 2006 Sep; 113(9):1479-80. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=%28Shah%20NN%5BAuth%5D%20AND%20Bowd%20C%5BAuth%5D%29%20AND%20%22Ophthalmology%22%5BJour%5D%20AND%20%28%222006/1/1%22%5BPDAT%5D%20%3A%20%222006/12/31%22%5BPDAT%5D%29" target="_blank"&gt;[abstract]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;&amp;nbsp;Burr J. The clinical and cost-effectiveness of screening for open angle glaucoma. NHS Health Technology Assessment programme, 2005-2007 [&lt;A href="http://www.hta.nhsweb.nhs.uk/ProjectData/1_project_record_notpublished.asp?PjtId=1446&amp;amp;SearchText=)." target="_blank"&gt;project details&lt;/A&gt;]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;Back to Knowledge Week contents&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>378683</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.abdo.org.uk/pdfs/gos/Glaucoma%20RR%20OHT%20ESP%20Pathway%20(June%202010).pdf]]&gt;</url>
    <title>Glaucoma referral refinement and OHT enhanced service pathways following updated NICE guidance</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Association of British Dispensing Opticians (ABDO)</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=2&gt;
&lt;P&gt;The LOC Support Unit (LOCSU) has launched a revised pathway for Intraocular Pressure (IOP) Refinement which has been amended to incorporate &lt;A href="nelh:333941:0" name=internalLink&gt;joint advice&lt;/A&gt;&amp;nbsp;recently issued by the Royal College of Ophthalmologists and the College of Optometrists on referrals for patients with raised intraocuIar pressure. &lt;/P&gt;&lt;/FONT&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=491" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=491" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=491" target="_blank"&gt;NO&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>310815</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17383730]]&gt;</url>
    <title>Global cost-effectiveness of cataract surgery</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,COMMISSIONING,ASSESSMENT AND PLANNING,DISEASE/CONDITION GROUPS,EYE AND VISION PROBLEMS,COST EFFECTIVENESS,COMMISSIONING COMPETENCIES,PRIORITISE INVESTMENT,COMMISSIONING PROCESS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2007 Sep;114(9):1670-8. Epub 2007 Mar 26&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To determine the cost-effectiveness of cataract surgery worldwide and to compare it with the cost-effectiveness of comparable medical interventions. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Meta-analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Approximately 12,000 eyes in the studies selected. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Articles were identified by searching the literature using the phrase cataract surgery, in combination with the terms cost, cost-effectiveness, and cost-utility. Terms used for the comparable medical interventions search included epileptic surgery, hip arthroplasty, knee arthroplasty, carpal tunnel surgery, and defibrillator implantation. The search was restricted to the years 1995 through 2006. Cataract surgery costs were converted to 2004 United States dollars (US$). Cost-utility was calculated using: (1) costs discounted at 3% for 12 years with a discounted quality-adjusted life years (QALY) gain of 1.25 years, and (2) costs discounted at 3% for 5 years with a discounted QALY gain of 0.143 years. The Cataract Surgery Affordability Index (CSAI) for each country was calculated by dividing the cost of cataract surgery by the gross national income per capita for the year 2004. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Cost-utility in 2004 US$/QALY and affordability of cataract surgery relative to the United States. RESULTS: Cost-utility values for cataract surgery (first eye) varied from $245 to $22,000/QALY in Western countries and from $9 to $1600 in developing countries. In developed countries, the cost-effectiveness of cataract surgery estimated by Choosing Interventions That Are Cost Effective ranged from, in international dollars (I$), I$730 to I$2400/disability-adjusted life years (DALY) averted, and I$90 to I$370/DALY averted in developing countries. The CSAI varied from 17% to 189% in developed countries and 29% to 133% in developing countries compared with the United States. The cost-utility of other comparable medical interventions was: epileptic surgery, $4000 to $20,000/QALY; hip arthroplasty, $2300 to $4800/QALY; knee arthroplasty, $6500 to $12,700/QALY; carpal tunnel surgery, $140 to $280/QALY; and defibrillator implantation, $700 to $23,000/QALY. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; The cost-utility of cataract surgery varies substantially, depending how the benefit is assessed and on the duration of the assumed benefit. Cataract surgery is comparable in terms of cost-effectiveness to hip arthroplasty, is generally more cost-effective than either knee arthroplasty or defibrillator implantation, and is cost-effective when considered in absolute terms. The operation is considerably cheaper in Europe and Canada compared with the United States and is affordable in many developing countries, particularly India.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=40" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298404</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rnib.org.uk/professionals/healthsocialcare/goodpracticeguide/Pages/goodpractice.aspx]]&gt;</url>
    <title>Good practice in sight</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LOW VISION SERVICES,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guide, published by the RNIB in October 2008, is designed to help local authorities and their adult social services departments in England provide high quality services that meet the needs of blind and partially sighted adults. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=426" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=426" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=426" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>291446</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.assoc-optometrists.org/uploaded_files/aop_updated_guidance_on_drs_final_aug_07.pdf]]&gt;</url>
    <title>Guidance for optometrists in relation to diabetic retinopathy screening schemes</title>
    <publicationDate></publicationDate>
    <publisher>Association of Optometrists (AOP)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DIABETIC RETINOPATHY,RETINA,RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Guidance document published by Association of Optometrists in August 2007 about diabetic retinopathy screening.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The guidance also deals with the option of offering a private diabetic eye check to patients who do not wish to remain in the national programme. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=418" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=418" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=418" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287683</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_084743.pdf]]&gt;</url>
    <title>Guidance for Primary Care Trusts on General Ophthalmic Services Contracts</title>
    <publicationDate>2008-05-07T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Four new regulations have been laid before Parliament, which make changes to arrangements for primary ophthalmic services. Implementation of the new regulations needs to be completed by 1 August 2008. Transitional Provisions allow PCTs to work as if the main regulations were already in force to enable implementation to be complete by August.&lt;/P&gt;
&lt;P&gt;These documents should be drawn to the attention of staff dealing with primary Ophthalmic Services.&lt;/P&gt;
&lt;P&gt;Published on&amp;nbsp;7 May 2008, this document provides guidance on contracts for the provision of primary ophthalmic services which are being introduced to replace the ophthalmic list system.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287687</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_084745.pdf]]&gt;</url>
    <title>Guidance for Primary Care Trusts on ophthalmic performers list management</title>
    <publicationDate>2008-05-13T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Four new regulations have been laid before Parliament, which make changes to arrangements for primary ophthalmic services. Implementation of the new regulations needs to be completed by 1 August 2008. Transitional Provisions allow PCTs to work as if the main regulations were already in force to enable implementation to be complete by August.&lt;/P&gt;
&lt;P&gt;These documents should be drawn to the attention of staff dealing with primary Ophthalmic Services.&lt;/P&gt;
&lt;P&gt;This document published on 13 May provides guidance and best practice advice to Primary Care Trusts on the National Health Service (Performers Lists) Amendment Regulations 2008.&amp;nbsp;&amp;nbsp; These regulations amend the National Health Service Performers Lists Regulations 2004 and introduce local performer lists for primary ophthalmic services. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83918</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_104895.pdf]]&gt;</url>
    <title>Guidance on direct payments: For community care, services for carers and children's services - England 2009</title>
    <publicationDate>2009-09-04T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,SERVICE SECTORS,FINANCE AND FUNDING,HEALTH AND SOCIAL CARE,EYES AND VISION,PATIENT AND PUBLIC INVOLVEMENT,PPI IN PRACTICE,BENEFITS AND CONCESSIONS,LIVING WITH VISUAL IMPAIRMENT,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,LOW VISION,INDIVIDUAL INVOLVEMENT,PATIENT CHOICE,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS,SOCIAL CARE,COMMUNITY AND DOMICILIARY SERVICES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=teaserText&gt;Direct Payments are cash payments made in lieu of social service provisions, to individuals who have been assessed as needing services.&lt;/P&gt;
&lt;DIV&gt;
&lt;P&gt;They can be made to disabled people aged 16 or over, to people with parental responsibility for disabled children, and to carers aged 16 or over in respect of carer services. &lt;/P&gt;
&lt;P&gt;The aim of a direct payment is to give more flexibility in how services are provided to many individuals who are assessed eligible for social services support. By giving individuals money in lieu of social care services people have greater choice and control over their lives, and are able to make their own decisions about how their care is delivered.&amp;nbsp; This will help increase opportunities for independence, social inclusion and enhanced self-esteem. Direct payment schemes can facilitate this by building links with local health, housing, education, learning and skills councils and other agencies.&lt;/P&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>333497</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcophth.ac.uk/core/core_picker/download.asp?id=677]]&gt;</url>
    <title>Guidance on entry to specialist training for 2011</title>
    <publicationDate>2010-12-16T00:00:00</publicationDate>
    <publisher>The Royal College of Ophthalmologists</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CORNEA,GLAUCOMA,RETINA,LENS,UVEAL TRACT,LID,LACRIMAL,OCULAR MOTILITY,ORBIT,VITREOUS BODY,REFRACTIVE ERROR,OPTIC NERVE AND VISUAL PATHWAYS,CANCER,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ 1&lt;/FIRSTPAGE&gt;&lt;FIRSTPAGEID&gt;1&lt;/FIRSTPAGEID&gt;&lt;PAGE&gt;&lt;PAGEID&gt;1&lt;/PAGEID&gt;&lt;PAGESEQUENCE&gt;-1&lt;/PAGESEQUENCE&gt;&lt;PAGETITLE&gt;&lt;/PAGETITLE&gt;&lt;PAGEBODY&gt;&lt;P&gt;Guidance from&amp;nbsp;The Royal College of Ophthalmologists for the 2011 Specialty&amp;nbsp;Training recruitment round.&amp;nbsp;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=457" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=457" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=457" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&amp;gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>287688</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_084750.pdf]]&gt;</url>
    <title>Guidance on Primary Ophthalmic Services Regulations 2008</title>
    <publicationDate>2008-05-13T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Four new regulations have been laid before Parliament, which make changes to arrangements for primary ophthalmic services. Implementation of the new regulations needs to be completed by 1 August 2008. &lt;/P&gt;
&lt;P&gt;Transitional Provisions allow PCTs to work as if the main regulations were already in force to enable implementation to be complete by August.&lt;/P&gt;
&lt;P&gt;These documents should be drawn to the attention of staff dealing with primary Ophthalmic Services.&lt;/P&gt;
&lt;P&gt;This document published on 13 May&amp;nbsp;2008 provides guidance on Primary Ophthalmic Services Regulations 2008.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289757</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_086016.pdf]]&gt;</url>
    <title>Guidance on redemption of NHS optical vouchers</title>
    <publicationDate>2008-07-04T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Guidance published on 4 July 2008 by the Department of Health.&lt;/P&gt;
&lt;P&gt;The guidance describes&amp;nbsp;the arrangements for requesting information about optical vouchers and redemption of optical vouchers following the introduction of the National Health Service (Optical Charges and Payments) Amendment (No 2) Regulations 2008 and the issue of NHS (Redemption of Optical Vouchers) Determination 2008. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>84029</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4079053.pdf]]&gt;</url>
    <title>Guidance on the microbiological safety of human organs, tissues and cells used in transplantation</title>
    <publicationDate>2000-08-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,CORNEA,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guidance was published by the Department of Health in August 2000.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Transplant surgery is now well established in the NHS and is responsible for saving many lives. However, transplantation carries a risk of transmitting infection from donor to recipient via the transplanted organs, tissues or cells. Contamination can also be acquired from the environment during processing or transportation of organs. &lt;/P&gt;
&lt;P&gt;The aim of the&amp;nbsp;guidance is to minimise the risk of microbiological infection or contamination, whilst taking the balance of risk and benefit for the recipient into account. It has been reviewed in the light of changes to donor assessment and testing procedures. The updated guidance sets out new recommendations for identifying and assessing donors, carrying out microbiological tests and interpreting test results. It also deals with environmental safety and advises on risk management during transportation and storage. Annexes provide supporting information. Cites numerous references.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330481</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcophth.ac.uk/core/core_picker/download.asp?id=404]]&gt;</url>
    <title>Guide for delivery of Ophthalmic Specialist Training (OST)</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>The Royal College of Ophthalmologists</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Royal College of Ophthalmologists interim guidance document&amp;nbsp;on the delivery of Ophthalmic Specialist Training published in February 2009. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>94643</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.topalbertadoctors.org/informed_practice/clinical_practice_guidelines/complete%20set/Cataracts/cataract_guideline.pdf]]&gt;</url>
    <title>Guideline for Surgical and Non Surgical Management of Cataract in the Otherwise Healthy Adult Eye</title>
    <publicationDate></publicationDate>
    <publisher>Alberta Clinical Practice Guidelines Program</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline produced by the Cataract Working Party of the Alberta Clinical Practice Guidelines Program was last reviewed&amp;nbsp;in 2008.&amp;nbsp; The guidelines are for practitioners and include sections on etiology, background including prevention, diagnosis and management, indications and contraindications of surgery, pre and postoperative care and follow up and also section on advice to patients.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=196" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=196" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=196" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>94837</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.racgp.org.au/redbook/12]]&gt;</url>
    <title>Guidelines for preventative activities in general practice - glaucoma</title>
    <publicationDate></publicationDate>
    <publisher>Royal Australian College of General Practitioners</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the section concerning glaucoma in the&amp;nbsp;seventh edition (2009) of the Royal Australian College of General Practitioners Red Book ‘Guidelines for Preventive Activities in General Practice’.&amp;nbsp;&amp;nbsp;&amp;nbsp; The recommendations are based on current evidence based guidelines, usually Australian guidelines such as those endorsed by the National Health and Medical Research Council (NHMRC). Where these are not available or recent, other Australian sources e.g. National Health Foundation are looked at and then Canadian or US preventive guidelines are considered.&amp;nbsp;&amp;nbsp; The guide does not include tertiary prevention or detailed information on the management of risk factors or early disease and does not make recommendations about tertiary prevention. &lt;/P&gt;
&lt;P&gt;As the information is based on the best available guidelines at the time of writing, the guide usually remains current for no more than 2 years. &lt;/P&gt;
&lt;P&gt;For each activity there is a paragraph summarising the key recommendations and a question and answer table outlining the details. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=202" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=202" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=202" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>94987</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.racgp.org.au/redbook/5-2]]&gt;</url>
    <title>Guidelines for preventive activities in general practice - visual and hearing impairment</title>
    <publicationDate></publicationDate>
    <publisher>Royal Australian College of General Practitioners</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EAR &amp; AUDITORY SYSTEM DISORDERS,ENT AND AUDIOLOGY,EYES AND VISION,CONDITIONS,SPECIALTIES,CONDITIONS,REFRACTIVE ERROR,LOW VISION,GLAUCOMA,RETINA,LENS,HEARING DISORDERS/ DEAFNESS,GENERAL EAR &amp; AUDITORY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the section concerning visual and hearing impairment&amp;nbsp;in the seventh edition (2009) of the Royal Australian College of General Practitioners Red Book ‘Guidelines for Preventive Activities in General Practice’.&amp;nbsp;&amp;nbsp;&amp;nbsp; The recommendations are based on current evidence based guidelines, usually Australian guidelines such as those endorsed by the National Health and Medical Research Council (NHMRC). Where these are not available or recent, other Australian sources e.g. National Health Foundation are looked at and then Canadian or US preventive guidelines are considered.&amp;nbsp;&amp;nbsp; The guide does not include tertiary prevention or detailed information on the management of risk factors or early disease and does not make recommendations about tertiary prevention. &lt;/P&gt;
&lt;P&gt;As the information is based on the best available guidelines at the time of writing, the guide usually remains current for no more than 2 years. &lt;/P&gt;
&lt;P&gt;For each activity there is a paragraph summarising the key recommendations and a question and answer table outlining the details. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=205" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=205" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=205" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89274</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.eyesite.ca/english/program-and-services/policy-statements-guidelines/retinophaty.pdf]]&gt;</url>
    <title>Guidelines for screening examinations for retinopathy of prematurity</title>
    <publicationDate></publicationDate>
    <publisher>Canadian Ophthalmological Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ PHYSICAL (&lt;72HRS),NEWBORN,VISION,SCHOOL ENTRY,PHYSICAL (6-8 WKS),EYES,EYES,EYES AND VISION,CHILD,SCREENING,CONDITIONS,RETINOPATHY,RETINA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The following guidelines&amp;nbsp;for screening premature infants for retinopathy of prematurity were &amp;nbsp;published in the Canadian Journal of Ophthalmology in August 2001.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;They were produced by the Canadian Association of Pediatric Ophthalmologists Ad Hoc Committee on Standards of Screening Examination for Retinopathy of Prematurity and are recommended by the Canadian Ophthalmology Society, the&amp;nbsp;Canadian Association of Pediatric Ophthalmologists and the Canadian Pediatric Society.&amp;nbsp;&amp;nbsp;The third and fourth pages of the pdf file are&amp;nbsp;a&amp;nbsp;commentary&amp;nbsp;on the guidelines. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=97" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=97" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=97" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333538</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_110251.pdf]]&gt;</url>
    <title>H1N1 Virus (Swine Flu) advice for PCTs and Primary Ophthalmic Services Contractors</title>
    <publicationDate>2009-12-16T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,SERVICE SECTORS,QUALITY AND MONITORING,PATIENT SAFETY,PRIMARY CARE SERVICES,EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guidance published by the Department of Health on 16 December 2009&amp;nbsp;providing advice on the implications of the H1N1 Virus (Swine Flu) for primary ophthalmic services.]]&gt;</body>
  </document>
  <document>
    <id>310816</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14675361]]&gt;</url>
    <title>Health information needs of visually impaired people: a systematic review of the literature</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>Health and Social Care in the Community</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Health &amp;amp; Social Care in the Community (Health Soc Care Community) 2004 Jan:12(1):1-24&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;Access to, and provision of, information is key to reducing health inequalities in health and social care. However, information is not always accessible and does not always meet the needs of specific groups. One such group is people who are visually impaired. The aim of the present study was to identify the health information needs of visually impaired people, and highlight major gaps in the literature. A systematic review of the literature was undertaken following, where possible, the NHS Centre for Reviews and Dissemination framework. Modifications included the sources searched, the critical appraisal checklist used (Critical Skills Training in Appraisal for Librarians) and the method of data synthesis. Out of the 1114 references identified, only 16 met the inclusion criteria. Quality of reporting of the literature was poor, and this must be taken into consideration when interpreting the findings of this review. The majority of studies were concerned with information for healthy living (e.g. health promotion). The focus of the remaining studies was on information about visual impairment or coping with visual impairment, and about accessing health services (e.g. medication labels and appointment letters). The majority of studies conducted to date have concentrated on the format of information. There are surprisingly few empirical studies which have examined the health information needs of this group. A number of gaps in the literature have been identified. These relate to the types of health information, non-format aspects of information (e.g. content and timing), sources of health and social care information, treating visually impaired people as a heterogeneous group, and recognising the value of actively involving visually impaired people in the research process. Although this review has identified a number of implications for practice, the paucity of evidence places a heavier onus on future research. Visually impaired people are likely to have unique health and social care information needs which are worthy of exploration in their own right.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=196" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>330514</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_097373.pdf]]&gt;</url>
    <title>Healthcare Travel Costs Scheme: Instructions and guidance for the NHS</title>
    <publicationDate>2009-04-02T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,BENEFITS AND CONCESSIONS,LIVING WITH VISUAL IMPAIRMENT,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,LOW VISION,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Document published by the Department of Health in April 2009&amp;nbsp;providing instructions to NHS organisations on their requirements in implementing the Healthcare Travel Costs Scheme and good practice guidance to aid organisations. &lt;/P&gt;
&lt;P&gt;From 1 April 2009, provider trusts will no longer be reimbursed for HTCS costs through the PbR tariff.&amp;nbsp;&amp;nbsp;HTCS expenditure should be recharged to the PCT where the patient is ordinarily resident. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>341940</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19729099]]&gt;</url>
    <title>Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism, and Risk of Retinal Vein Occlusion: A Meta-analysis</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology. 2009 Sep;116(9):1778-1787.e1.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE&lt;/STRONG&gt;: To assess the role of plasma total homocysteine (tHcy) concentrations and homozygosity for the thermolabile variant of the methylenetetrahydrofolate reductase (MTHFR) C677T gene as risk factors for retinal vascular occlusive disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN&lt;/STRONG&gt;: Retinal vein occlusion (RVO) is an important cause of vision loss. Early meta-analyses showed that tHcy was associated with an increased risk of RVO, but a significant number of new studies have been published. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PARTICIPANTS AND/OR CONTROLS&lt;/STRONG&gt;: RVO patients and controls. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Data sources included MEDLINE, Web of Science, and PubMed searches and searching reference lists of relevant articles and reviews. Reviewers searched the databases, selected the studies, and then extracted data. Results were pooled quantitatively using meta-analytic methods. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES&lt;/STRONG&gt;: tHcy concentrations and MTHFR genotype. RESULTS: There were 25 case-control studies for tHcy (1533 cases and 1708 controls) and 18 case-control studies for MTHFR (1082 cases and 4706 controls). The mean tHcy was on average 2.8 micromol/L (95% confidence interval [CI], 1.8-3.7) greater in the RVO cases compared with controls, but there was evidence of between-study heterogeneity (P&amp;lt;0.001, I(2) = 93%). There was funnel plot asymmetry suggesting publication bias. There was no evidence of association between homozygosity for the MTHFR C677T genotype and RVO (odds ratio [OR] 1.20; 95% CI, 0.84-1.71), but again marked heterogeneity (P = 0.004, I(2) = 53%) was observed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: There was some evidence that elevated tHcy was associated with RVO, but not homozygosity for the MTHFR C677T genotype. Both analyses should be interpreted cautiously because of marked heterogeneity between the study estimates and possible effect of publication bias on the tHcy findings. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;FINANCIAL DISCLOSURE(S)&lt;/STRONG&gt;: The author(s) have no proprietary or commercial interest in any materials discussed in this article.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=251" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310818</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/12598445]]&gt;</url>
    <title>How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom</title>
    <publicationDate>2003-03-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2003 Mar;87(3):312-7.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIMS:&lt;/STRONG&gt; To predict the burden of blindness, partial sight, and visual impairment (binocular visual acuity 6/18 or less) due to late stage age related macular degeneration (AMD) in the ageing population of the United Kingdom. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic review, followed by a request for data, was used to establish a pooled prevalence of AMD and corresponding visual loss. Prevalence figures were applied to the UK population. Using UK population trends, the future burden of AMD over the coming decade was established. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Pooled data from six studies showed that the prevalence of visual loss caused by AMD increased exponentially from the age of 70-85 years of age, with 3.5% (95% CI 3.0 to 4.1) having visual impairment beyond the age of 75 years. The authors estimate that there are currently 214 000 (95% CI 151 000 to 310 000) with visual impairment caused by AMD (suitable for registration). This number is expected to increase to 239 000 (95% CI 168 000 to 346 000) by the year 2011. Currently there are 172 000 (95% CI 106 000 to 279 000) and 245 000 (95% CI 163 000 to 364 000) with geographical and neovascular AMD, respectively. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Estimates of visual impairment agree with official statistics for the number registered partially sighted or blind, caused by AMD, and are well below other figures often cited. Although these estimates are associated with wide confidence intervals (CI) and a number of caveats, they represent the best available data, which can be used to guide health and social care provision for older people in the UK setting. Implications for low vision services are outlined.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=207" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318835</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.vision2020uk.org.uk/ukvisionstrategy/core/core_picker/download.asp?id=45]]&gt;</url>
    <title>Implementation Plan for England 2009-2014</title>
    <publicationDate></publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CERTIFICATION OF VISUAL IMPAIRMENT,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The UK Vision Strategy is a VISION 2020 UK initiative led by the RNIB to develop a unified plan for action on all issues relating to sight loss and eye health across the four countries of the UK.&lt;/P&gt;
&lt;P&gt;The implementation plans outline the scope of work required to deliver tangible improvements.&amp;nbsp; Within each country plan, priority areas have been set up against the three key outcomes of the strategy.&amp;nbsp;&amp;nbsp; The plans will enable regional and local areas to take the next steps in improving eye care and sight loss services. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=440" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=440" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=440" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>84240</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4106720.pdf]]&gt;</url>
    <title>Improving Diabetes Services - The NSF Two Years On</title>
    <publicationDate>2005-03-23T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NATIONAL SERVICE FRAMEWORKS (NSFS) AND EYE HEALTH,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=teaserText&gt;This document published by the Department of Health in March 2005 highlights the progress made over the two years following the publication of the Diabetes National Service Framework&amp;nbsp;Delivery Strategy.&lt;/P&gt;
&lt;P class=teaserText&gt;The Diabetes National Service Framework set out the first ever set of national standards for the treatment of diabetes to raise the quality of NHS services and reduce unacceptable variations between them. &lt;/P&gt;
&lt;P class=teaserText&gt;Chapter 6&amp;nbsp;Support for service delivery includes an update on&amp;nbsp;the progress&amp;nbsp;of the retinal screening programme. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>310821</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16228217]]&gt;</url>
    <title>Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Graefe's Archives for Clinical and Experimental Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,UVEAL TRACT,UVEITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Graefe's Archives for Clinical and Experimental Ophthalmology (Graefes Arch Clin Exp Ophthalmol) 2006 Mar;224(3):281-90. Epub 2005 Oct 14.&lt;/EM&gt; &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Juvenile rheumatoid arthritis (JRA) is the most common systemic cause of pediatric uveitis in Europe and North America. Uveitis is commonly perceived as a frequent sequela of JRA and JRA-associated uveitis is commonly considered to have a complicated course with frequent adverse visual outcomes. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; We performed a systematic literature search for series of consecutive patients with JRA (as defined by the American College of Rheumatology criteria) reporting on the frequency of uveitis and/or complications of uveitis, published between January 1980 and December 2004. The main outcome measures were: the cumulative incidence of uveitis in JRA, the cumulative incidence of adverse visual outcome and that of complications in JRA-associated uveitis. Additionally, the influence of gender, presence of antinuclear antibody (ANA) and disease onset subtype to the likelihood of developing uveitis were examined. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Analysis of pooled data from the 26 eligible series suggested a cumulative incidence of uveitis in JRA of 8.3% [95% confidence intervals (CI), 7.5-9.1%]. The cumulative incidence of uveitis varied according to geographic location, being highest in Scandinavia, then the US, then Asia and lowest in India. JRA-associated uveitis was more common in pauciarticular than polyarticular onset patients [odds ratio (OR) = 3.2, 95% CI, 2.33-4.36] and in ANA-positive than ANA-negative patients (OR = 3.18, 95% CI, 2.22-4.54). Female gender was only a weak risk factor for the development of uveitis in JRA patients (OR = 1.69, 95% CI 1.09-2.62) and was not statistically significant after considering disease onset subtypes. In JRA-associated uveitis the cumulative incidence of cumulative incidence of adverse outcome (visual acuity &amp;lt; 20/40 OU) was 9.2% (95% CI: 4.7-15.8) of cataracts 20.5% (95% CI: 15.5-26.3), of glaucoma 18.9% (95% CI: 14.4-24.2) and of band keratopathy 15.7% (95% CI: 10.9-21.7). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION: &lt;/STRONG&gt;The cumulative incidence of uveitis in JRA varies according to geographic location, presence of ANA, type of JRA onset and gender. Uveitis, adverse visual outcome, and complications in JRA are less frequent than commonly accepted.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=144" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311019</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15883278]]&gt;</url>
    <title>Incidence of acute endophthalmitis following penetrating keratoplasty: a systemtic review</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: Archives of Ophthalmology (Arch Ophthalmol) 2005 May;123(5):605-9.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE: &lt;/STRONG&gt;To determine the incidence of acute endophthalmitis following penetrating keratoplasty (PK) over time. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic review of English-language articles was conducted by performing a broad search of the PubMed database from 1963 through March 2003 using such keywords as penetrating keratoplasty, endophthalmitis, and postoperative complication. Additional studies were identified from bibliographies of relevant articles and published proceedings. The proportion of eyes with acute endophthalmitis as a postoperative complication was recorded, and pooled incidence rates were assessed over time. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; From 1870 unique, potentially relevant citations, 66 original studies that addressed endophthalmitis and met the selection criteria were analyzed. A total of 90 549 PKs were pooled, resulting in an overall estimate of 0.382% post-PK endophthalmitis, but a change over time was noted. The rate of endophthalmitis was 0.200% in the 2000-2003 period, 0.453% in the 1990s, 0.376% in the 1980s, and 0.142% during the 1970s. Furthermore, a downward trend in the incidence of endophthalmitis after 1992 was observed compared with 1991 and earlier.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This systematic review indicates that the incidence of endophthalmitis associated with PK has declined during the last decade.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=168" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102033</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11713061&amp;query_hl=5]]&gt;</url>
    <title>Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery.</title>
    <publicationDate>2001-11-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Nov 2001, vol. 108, no. 11, p. 1943-53, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To report interim outcome data, using all available follow-up through 5 years after treatment initiation, in the Collaborative Initial Glaucoma Treatment Study (CIGTS). &lt;/P&gt;
&lt;P&gt;DESIGN: Randomized clinical trial. &lt;/P&gt;
&lt;P&gt;PARTICIPANTS: Six hundred seven newly diagnosed glaucoma patients. &lt;/P&gt;
&lt;P&gt;METHODS: In a randomized clinical trial, 607 patients with newly diagnosed open-angle glaucoma were initially treated with either medication or trabeculectomy (with or without 5-fluorouracil). After treatment onset and early follow-up, patients were evaluated clinically at 6-month intervals. In addition, quality of life telephone interviews were conducted at similar frequency to the clinical visits. Patients in both arms of CIGTS were treated aggressively in an effort to reduce intraocular pressure (IOP) to a level at or below a predetermined target pressure specific for each individual eye. Visual field (VF) scores were analyzed by time-specific comparisons and by repeated measures models. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURES: VF loss was the primary outcome variable in CIGTS. Secondary outcomes of visual acuity (VA), IOP, and cataract were also studied. &lt;/P&gt;
&lt;P&gt;RESULTS: On the basis of completed follow-up through 4 years and partially completed through 5 years, VF loss did not differ significantly by initial treatment. Over the entire period of follow-up, surgical patients had a greater risk of substantial VA loss compared with medical patients. However, by 4 years after treatment, the average VA in the two groups was about equal. Over the course of follow-up, IOP in the medicine group has averaged 17 to 18 mmHg, whereas that in the surgery group averaged 14 to 15 mmHg. The rate of cataract requiring removal was greater in the surgically treated group. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Both initial medical or initial surgical therapy result in about the same VF outcome after up to 5 years of follow-up. VA loss was greater in the surgery group, but the differences between groups seem to be converging as follow-up continues. When aggressive treatment aimed at substantial reduction in IOP from baseline is used, loss of VF can be seen to be minimal in general. Because 4 to 5 years of follow-up in a chronic disease is not adequate to draw treatment conclusions, these interim CIGTS outcomes do not support altering current treatment approaches to open-angle glaucoma.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10201583&amp;amp;query_hl=29" target="_blank"&gt;The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11442181&amp;amp;query_hl=29" target="_blank"&gt;Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS).&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11320018&amp;amp;query_hl=29" target="_blank"&gt;Quality of life in newly diagnosed glaucoma patients : The Collaborative Initial Glaucoma Treatment Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11713062&amp;amp;query_hl=29" target="_blank"&gt;The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12698052&amp;amp;query_hl=29" target="_blank"&gt;Collaborative Initial Glaucoma Treatment Study: a summary of results to date.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12766064&amp;amp;query_hl=29" target="_blank"&gt;The collaborative initial glaucoma treatment study: baseline visual field and test-retest variability.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311023</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16051363]]&gt;</url>
    <title>Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis</title>
    <publicationDate>2005-09-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,UVEAL TRACT,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2005 Sep;112(9):1599-607&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To examine the association between ultraviolet light exposure and uveal melanoma. DESIGN: Meta-analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A review of 133 published reports on risk factors for uveal melanoma revealed 12 studies that provided sufficient information to calculate odds ratios (ORs) and standard errors for ultraviolet light exposure factors. Data from these studies were extracted and categorized into intermittent ultraviolet exposure factors (welding, outdoor leisure, photokeratitis) and chronic ultraviolet exposure factors (occupational sunlight exposure, birth latitude, lifetime ultraviolet exposure index). Summary statistics were calculated for all risk factors reported by &amp;gt; or =4 independent studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN EXPOSURE MEASURES:&lt;/STRONG&gt; Welding, outdoor leisure, photokeratitis, occupational sunlight exposure, birth latitude, and lifetime ultraviolet exposure index. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; For intermittent ultraviolet exposure, welding was found to be a significant risk factor (5 studies, 1137 cases; OR, 2.05 [95% confidence interval [CI], 1.20-3.51]). Outdoor leisure was found to be nonsignificant (4 studies, 1332 cases; OR, 0.86 [95% CI, 0.71-1.04]). Photokeratitis conferred susceptibility in 3 reports studying this variable, but there were too few studies to validate meta-analyses. For chronic ultraviolet exposure, meta-analysis found occupational sunlight exposure to be a borderline nonsignificant risk factor for development of uveal melanoma (4 studies, 572 cases; OR, 1.37 [95% CI, 0.96-1.96]). Latitude of birth was found to be nonsignificant (5 studies, 1765 cases; OR, 1.08 [95% CI, 0.67-1.74]). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; This meta-analysis yielded inconsistent results associating ultraviolet light with development of uveal melanoma. There was evidence implicating welding as a possible risk factor for uveal melanoma.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=156" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311025</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14522756]]&gt;</url>
    <title>Interventions for angle-closure glaucoma: an evidence-based update</title>
    <publicationDate>2003-10-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: Ophthalmology 2003 Oct;110(10):1869-78; quiz 1878-9, 1930&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE: &lt;/STRONG&gt;To assess the interventions to treat acute angle closure (AAC) and primary angle closure (PAC) with or without glaucomatous optic neuropathy. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CLINICAL RELEVANCE:&lt;/STRONG&gt; Primary angle closure is one of the leading causes of blindness in East Asia. At present, there are few clinical guidelines on the optimal treatment of AAC or PAC in the affected or contralateral eye. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; All randomized clinical trials, prospective controlled clinical trials, nonprospective controlled clinical trials, and retrospective case series with &amp;gt;50 cases that evaluated treatments for AAC or PAC were included. Studies published in the English language were identified from MEDLINE, PubMed, EMBASE, and the Cochrane Collaborations, as well as by a hand search of the reference lists of important articles. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Nine randomized clinical trials and 24 nonrandomized clinical trials and large case series were evaluated. Laser peripheral iridotomy (LPI) has been found to be as effective as surgical peripheral iridectomy in randomized clinical trials of the affected and contralateral eyes of AAC or PAC patients with or without evidence of glaucoma. In another randomized clinical trial, latanoprost was found to decrease intraocular pressure (IOP) more than timolol for PAC in patients for whom LPI alone failed. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This review suggests that LPI should be recommended for the treatment of affected and contralateral eyes of AAC patients. In patients with PAC and insufficient treatment with LPI, latanoprost eye drops may decrease IOP more than timolol. There is still insufficient evidence about other interventions for the treatment of AAC and PAC.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=201" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311026</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17397923]]&gt;</url>
    <title>Interventions for branch retinal vein occlusion: an evidence-based systematic review</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2007 May;114(5):835-54. Epub 2007 Mar 30&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;TOPIC:&lt;/STRONG&gt; To assess the evidence on interventions to improve visual acuity (VA) and to treat macular edema and/or neovascularization secondary to branch retinal vein occlusion (BRVO). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CLINICAL RELEVANCE:&lt;/STRONG&gt; Branch retinal vein occlusion is the second most common retinal vascular disease. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS/LITERATURE REVIEWED:&lt;/STRONG&gt; English and non-English articles were retrieved using a keyword search of Medline (1966 onwards), Embase, the Cochrane Collaboration, the National Institute of Health Clinical Trials Database, and the Association for Research in Vision and Ophthalmology Annual Meeting Abstract Database (2003-2005). This was supplemented by hand searching references of review articles. Two investigators independently identified all randomized clinical trials (RCTs) with more than 3 months' follow-up. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; From 4332 citations retrieved, 12 RCTs were identified. There were 5 RCTs on laser photocoagulation. Grid macular laser photocoagulation was effective in improving VA in 1 large multicenter RCT, the Branch Vein Occlusion Study (BVOS), but 2 smaller RCTs found no significant difference. The BVOS showed that scatter retinal laser photocoagulation was effective in preventing neovascularization and vitreous hemorrhage in patients with neovascularization, but a subsequent RCT found no significant effect. Randomized clinical trials evaluating intravitreal steroids (n = 2), hemodilution (n = 3), ticlopidine (n = 1), and troxerutin (n = 1) showed limited or no benefit. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; There is limited level I evidence for any interventions for BRVO. The BVOS showed that macular grid laser photocoagulation is an effective treatment for macular edema and improves vision in eyes with VA of 20/40 to 20/200, and that scatter laser photocoagulation can effectively treat neovascularization. The effectiveness of many new treatments is unsupported by current evidence.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=13" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311028</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17324695]]&gt;</url>
    <title>Interventions for central retinal vein occlusion: an evidence-based systematic review</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2007 Mar;114(3):507-19, 524&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;TOPIC:&lt;/STRONG&gt; To assess the evidence for the effectiveness of interventions to improve visual acuity (VA) and prevent or treat neovascularization secondary to central retinal vein occlusion (CRVO). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CLINICAL RELEVANCE: &lt;/STRONG&gt;Central retinal vein occlusion is a common cause of visual morbidity and blindness. Many different interventions have been advocated, but the evidence justifying their use remains unclear. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS/LITERATURE REVIEWED:&lt;/STRONG&gt; English and non-English language articles were retrieved using a keyword search of Medline (1966 onwards), Embase, the Cochrane Collaboration, the National Institutes of Health Clinical Trials database, and the Association for Research in Vision and Ophthalmology (2003-2005). This was supplemented by manually searching references of review articles. Two investigators independently identified all randomized clinical trials (RCTs) on interventions in CRVO with more than 3 months' follow-up. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Of 4133 citations retrieved, 17 RCTs comparing intervention with a control group were identified. There were 4 RCTs on laser photocoagulation. Grid macular laser photocoagulation did not improve VA in CRVO with macular edema. Prophylactic panretinal photocoagulation did not prevent angle and iris neovascularization in ischemic CRVO, but resulted in regression of angle and iris neovascularization and reduced progression to neovascular glaucoma. There were 4 RCTs that reported improvement in VA with inpatient hemodilution, 2 RCTs with no significant improvement, and 1 RCT showing deterioration in VA after outpatient hemodilution. Randomized clinical trials evaluating ticlodipine, troxerutin, and streptokinase showed a limited or no benefit. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This review found limited level I evidence for any intervention to improve VA in patients with CRVO. Panretinal photocoagulation resulted in regression of neovascularization. Hemodilution may improve vision in some patients, but the data conflict. More robust randomized controlled trials evaluating current treatments for CRVO are needed. The results of ongoing RCTs on intravitreal triamcinolone, anti-vascular endothelial growth factor agents, and chorioretinal anastomosis are awaited with interest.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=17" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342503</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18952646]]&gt;</url>
    <title>Interventions for diabetic macular oedema: a systematic review of the literature</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology. 2008 Dec;92(12):1581-90. Epub 2008 Oct 24. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVES:&lt;/STRONG&gt; This review discusses the evolution of the treatment of diabetic macular oedema and gives helpful guidelines in the treatment of diabetic macular oedema based on available evidence to date. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A literature search of all English articles from the Medline and Cochrane database was performed. The search was limited to only English randomised controlled clinical trials in humans. Overall, 93 articles were cited from 1979 to 2007. Of these, 31 articles corresponded to subject matter. Studies were evaluated on a standardised data extraction form and tabulated for easy review. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; There is good evidence that laser treatment preserves vision in eyes with diabetic macular oedema (DMO). However, laser is a potentially destructive form of treatment which may be of greater benefit in combination with newer forms of treatment such as intravitreal steroid or intravitreal antiangiogenic agents. Current evidence does not support a clear benefit for surgical intervention in DMO. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Although laser treatment remains the cornerstone of treatment in diabetic macular oedema, the literature is beginning to support combination therapy. Using one or two intravitreal injections to reduce central macular thickness followed by focal or grid laser to give a sustained response may offer an alternative to treatment in DMO.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=246" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322557</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15359253]]&gt;</url>
    <title>Interventions for intermittent distance exotropia: a review</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Eye</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,STRABISMUS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Eye 2005 Jun:19(6):617-21&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; Management decisions in intermittent distance exotropia vary and lack well-defined clinical guidelines. We undertook a systematic review in an attempt to clarify the effects of various surgical and nonsurgical treatments and to establish the significance of factors such as age with respect to outcome. The review was undertaken in collaboration with the Cochrane Eyes and Vision Group. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Electronic and manual searches were undertaken to identify randomised controlled trials of surgical or nonsurgical treatments for intermittent distance exotropia. We also contacted researchers active in this field for information about further published or unpublished studies. There were no language restrictions. Study abstracts identified from the searches were analysed independently by the two reviewers (SR and LG) and marked for inclusion, exclusion, or consideration. Reviewer analysis was compared and full papers for appropriate studies were requested. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; No randomised controlled trials were found that met our selection criteria. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; The current literature consists mainly of retrospective reviews. These are difficult to compare and analyse due to variations in definition, intervention criteria, and outcome measures. However, there appears to be an agreement that the nonsurgical treatment is more appropriate in small-angle deviations or as a supplement to surgery. Studies supporting both early and late surgical intervention were found, so the optimal timing of surgical intervention could not be concluded. There is a need for robust clinical trials to improve the evidence base for the management of this condition.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click&lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=166" target="_blank"&gt; here &lt;/A&gt;to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311036</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11902989]]&gt;</url>
    <title>Interventions for mucuous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa adquisitia: a systematic literature review</title>
    <publicationDate>2002-03-01T00:00:00</publicationDate>
    <publisher>Archives of Dermatology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Dermatology (Arch Dermatol) 2002 Mar:138(3):380-4.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To identify and critically evaluate evidence from randomized controlled trials for the efficacy of treatments for mucous membrane pemphigoid (MMP)/cicatricial pemphigoid (CP) and epidermolysis bullosa acquisita (EBA). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;SEARCH STRATEGY:&lt;/STRONG&gt; Review of MEDLINE from 1966 through March 2000, EMBASE from 1980 through March 2000, and the Cochrane Controlled Trials Register (February 28, 2001) to identify randomized controlled trials for the efficacy of treatments in MMP/CP and EBA. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;SELECTION CRITERIA:&lt;/STRONG&gt; All randomized controlled trials of therapeutic interventions that included patients with MMP/CP or EBA confirmed by immunofluorescence study findings. All age groups were included. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; We found 2 small randomized controlled trials of MMP/CP, both conducted in patients with severe eye involvement. We were not able to identify a randomized controlled trial of therapeutic interventions in EBA. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; There is evidence from 2 small trials that severe ocular CP responds best to treatment with cyclophosphamide, and mild to moderate disease seems effectively suppressed by treatment with dapsone. No treatment recommendations can be made for EBA because to our knowledge no randomized controlled trials are published. Even though systemic corticosteroids are regarded as the gold standard in the treatment of MMP/CP and EBA, there is poor evidence from the literature that they are the best treatment for these diseases.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=211" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311039</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11874738]]&gt;</url>
    <title>Interventions to retard myopia progression in children: an evidence-based update</title>
    <publicationDate>2002-03-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,REFRACTIVE ERROR,SHORT SIGHT (MYOPIA),CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2002 Mar;109(3):415-21; discussion 422-5: quiz 425-6, 443. &lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;TOPIC:&lt;/STRONG&gt; To evaluate the efficacy of interventions such as eyedrops, bifocal lenses, or contact lenses in retarding the progression of myopia in myopic children. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CLINICAL RELEVANCE:&lt;/STRONG&gt; Myopia is a common ocular disorder, and high myopia (myopia at least -6.0 diopters) is associated with potentially blinding conditions. At present, there are no general guidelines on interventions that may decrease myopia progression in children, but some interventions such as contact lenses are offered on an ad hoc basis. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS OR LITERATURE REVIEWED:&lt;/STRONG&gt; English and non-English language articles published from 1968 to 2000 were retrieved using a keyword search of MEDLINE, Embase, Cochrane Library, and Science Citation Index databases. Randomized controlled trials with comparisons of the effectiveness of interventions to decrease myopia progression in myopic children were reviewed. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Ten clinical trials of different interventions to retard myopia progression were reviewed, including three trials that evaluated atropine and one trial that evaluated soft contact lenses. Atropine eye drops of 0.5% concentration were effective in clinical trials, but no significant effect was found for tropicamide or timolol eyedrops. Five of the six trials on bifocal spectacle lenses with various additions failed to show significant retardation, and results of the remaining trial were barely significant (P = 0.047). A trial of soft contact lenses failed to show significant effects. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS: &lt;/STRONG&gt;The latest evidence from randomized clinical trials does not provide sufficient information to support interventions to prevent the progression of myopia. Long-term large-scale double-masked randomized clinical trials, including cycloplegic refraction, are needed before any recommendations about interventions in clinical practice to prevent high myopia in myopic children are considered.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=212" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311063</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15921747]]&gt;</url>
    <title>Intracoluar pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials</title>
    <publicationDate>2005-07-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology. 2005 Jul;112(7):1177-85&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To estimate the intraocular pressure (IOP) reduction achieved by the most frequently prescribed glaucoma drugs and a placebo in a meta-analysis of randomized clinical trials. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Meta-analysis of randomized clinical trials. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Twenty-seven articles reporting on 28 randomized clinical trials. These articles reported 6953 participants for the trough and 6841 for the peak. METHODS: Articles published up to December 2003 were identified in the following data sources: Medline, Embase, and the Cochrane Controlled Trials Register, and references from relevant articles. Over 85% of the patients had to be diagnosed with primary open-angle glaucoma (POAG) or ocular hypertension (OH), and articles had to be written in English, German, French, or Dutch. Quality of trials was assessed by a Delphi list with additions. The pooled 1-month IOP-lowering effect from baseline at peak and trough was calculated by performing meta-analysis using the random effects model. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Absolute and relative change in IOP from baseline, for peak and trough moments. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Relative IOP reductions from baseline [mean (95% confidence interval)] were -23% (-25% to -22%) for a peak and -20% (-23% to -17%) for a trough for 0.5% betaxolol; peak, -27% (-29% to -25%), and trough, -26% (-28% to -25%), for 0.5% timolol; peak, -22% (-24% to -20%), and trough, -17% (-19% to -15%), for 2.0% dorzolamide; peak, -17% (-19% to -15%), and trough, -17% (-19% to -15%) for 1.0% brinzolamide; peak, -25% (-28% to -22%), and trough, -18% (-21% to -14%) for 0.2% brimonidine; peak, -31% (-33% to -29%), and trough, -28% (-30% to -26%) for 0.005% latanoprost; peak, -31% (-32% to -29%), and trough, -29% (-32% to -25%) for 0.004% travoprost; peak, -33% (-35% to -31%), and trough, -28% (-29% to -27%) for 0.03% bimatoprost; and peak, -5% (-9% to -1%), and trough, -5% (-10% to -0%) for the placebo. The difference in absolute IOP reduction from baseline between timolol and prostaglandin analogs or prostamide varied from -0.4 to 0.1 mmHg at trough and from 1.0 to 1.5 mmHg at peak. Quality scores of included studies were generally high, a mean of 14.2 on a scale from 0 to 20 (interquartile range, 13-16). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; This meta-analysis suggests that bimatoprost, travoprost, latanoprost, and timolol are the most effective intraocular pressure-reducing agents in POAG and OH patients.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=23" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311064</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17070584]]&gt;</url>
    <title>Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomised clinical trials</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: Ophthalmology 2007 Jan;114(1):40-6. Epub 2006 Oct 27&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To estimate the intraocular pressure (IOP)-lowering effect of 2% dorzolamide or 0.005% latanoprost when added to 0.5% timolol. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Meta-analysis of randomized clinical trials. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PARTICIPANTS: &lt;/STRONG&gt;Seventeen articles reporting on 19 study arms with 5 possible treatment combinations and 4 study arms serving as controls. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Articles written in English, German, French, or Dutch and published up to December 2004 were identified in Medline, Embase, the Cochrane Controlled Trials Register, and references from relevant articles. For the article to be considered, over 85% of the patients had to have primary open-angle glaucoma or ocular hypertension. The pooled 1- to 3-month additional IOP-lowering effect after a run-in phase on timolol was calculated by performing meta-analysis using the random effects model. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Absolute and relative changes in IOP after run-in on timolol for peak moment, trough moment, or mean diurnal curve. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;The pooled change from baseline [mean (95% confidence interval)] for 0.5% timolol varied from -0.7 mmHg (-1.2 to -0.2, for the mean diurnal curve) to -2.0 mmHg (-1.3 to -2.7, at peak). Pooled changes for 2% dorzolamide in concomitant use with 0.5% timolol were -4.1 mmHg (-4.4 to -3.8) at trough and -4.9 mmHg (-5.3 to -4.5) at peak. The fixed 2% dorzolamide and 0.5% timolol combination resulted in a pooled change of -3.8 mmHg (-4.2 to -3.4) at trough and -4.9 mmHg (-5.3 to -4.5) at peak. The concomitant use of 0.005% latanoprost and 0.5% timolol gave a pooled change from baseline of -6.0 mmHg (-6.8 to -5.2) at the mean diurnal curve. The fixed combination of 0.005% latanoprost and 0.5% timolol resulted in a mean change of -3.0 mmHg (-3.8 to -2.2) at the mean diurnal curve. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; In this meta-analysis of clinical trials, the addition of dorzolamide or latanoprost further lowers IOP in eyes on timolol. This result may not be generalizable because these trials may have included nonresponders to timolol.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=21" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342481</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19410949]]&gt;</url>
    <title>Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: &lt;/EM&gt;&lt;EM&gt;Ophthalmology.&lt;/EM&gt;&lt;EM&gt; 2009 May;116(5):902-11; quiz 912-3.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE: &lt;/STRONG&gt;To compare intravitreal triamcinolone acetonide (IVTA) injection versus no treatment or sub-Tenon triamcinolone acetonide (STTA) injection in improving visual acuity (VA) of patients with refractory diabetic macular edema (DME; unresponsive to focal laser therapy). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CLINICAL RELEVANCE:&lt;/STRONG&gt; Diabetic macular edema is the leading cause of visual loss in diabetic retinopathy. Laser therapy has been the standard of care for patients with persistent or progressive disease. More recently, it has been suggested that IVTA injection may improve VA. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS AND LITERATURE REVIEWED:&lt;/STRONG&gt; The following databases were searched: Medline (1950-September Week 2 2008), The Cochrane Library (Issue 3, 2008), and the TRIP Database (up to September 1, 2008), using no language or other limits. Randomized controlled trials were included that consisted of patients with refractory DME, those comparing IVTA injection with no treatment or STTA injection, those reporting VA outcomes, and those having a minimum follow-up of 3 months. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;In the 4 randomized clinical trials comparing IVTA injection with placebo or no treatment, IVTA injection demonstrated greater improvement in VA at 3 months, but the benefit was no longer significant at 6 months. Those who received IVTA injection had significantly higher IOP at 3 months and at 6 months. In the 2 randomized clinical trials comparing IVTA injection with STTA injection, IVTA injection demonstrated greater improvement in VA at 3 months, but not at 6 months. Intravitreal triamcinolone acetonide injection demonstrated no difference in IOP at 3 months or at 6 months. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Intravitreal triamcinolone acetonide injection is effective in improving VA in patients with refractory DME in the short-term, but the benefits do not seem to persist in the long-term. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=232" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250851</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop2.pdf]]&gt;</url>
    <title>Investigation of eye swabs and canalicular pus</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ CONJUNCTIVA,CONJUNCTIVITIS,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;National Standard Method&amp;nbsp;BSOP 2 issued in&amp;nbsp;March 2008&amp;nbsp;by the Standards Unit of the Evaluations and Standards Laboratory in the HPA's Centre for Infections.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The Standards Unit develops National Standard Methods (inluding SOPs, Algorithms and Guidance Notes) for clinical and public health microbiology.&amp;nbsp; National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. &lt;/P&gt;
&lt;P&gt;This SOP describes the processing and bacteriological investigation of specimens from the eyes with the exception of those from keratitis, endophthalmitis, hypopyon and post surgical infections (see BSOP 52).&amp;nbsp; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250853</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop52.pdf]]&gt;</url>
    <title>Investigation of intraocular fluids and corneal scrapings</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,KERATITIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;National Standard Method&amp;nbsp;BSOP 52&amp;nbsp;issued in April 2008 by the Standards Unit of the Evaluations and Standards Laboratory in the HPA's Centre for Infections.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The Standards Unit develops National Standard Methods (inluding SOPs, Algorithms and Guidance Notes) for clinical and public health microbiology.&amp;nbsp; National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. &lt;/P&gt;
&lt;P&gt;This&amp;nbsp;National Standard Method describes the processing and bacteriological investigation of intraocular fluids and corneal scrappings. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250849</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa-standardmethods.org.uk/documents/vsop/pdf/vsop21.pdf]]&gt;</url>
    <title>Isolation of viruses associated with infections of the eye: keratoconjunctivits</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CORNEA,KERATITIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;National Standard Method VSOP21 issued in February 2007 by the Standards Unit of the Evaluations and Standards Laboratory in the HPA's Centre for Infections.&amp;nbsp;Under review July 2010.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Standards Unit develops National Standard Methods (inluding SOPs, Algorithms and Guidance Notes) for clinical and public health microbiology.&amp;nbsp; National Standard Methods are a comprehensive referenced collection of clinical microbiology SOPs, algorithms (for virology and serology), and guidance notes, consisting of over 200 documents. &lt;/P&gt;
&lt;P&gt;This&amp;nbsp;National Standard Method describes the detection and isolation of viruses in material from the conjunctiva and cornea of the eye.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398122</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://bit.ly/hpgT1h]]&gt;</url>
    <title>Liberating the NHS: Eye Care: Making a Reality of Equity and Excellence</title>
    <publicationDate></publicationDate>
    <publisher>Optical Confederation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,RETINA,LENS,AGE RELATED MACULAR DEGENERATION,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The report 'Liberating the NHS: Eye Care - making a reality of equity and excellence', by Professor Nick Bosanquet, found that an estimated one third of outpatient follow up appointments could be delivered in local optical practices, which would reduce the burden on over-stretched hospitals.&lt;/P&gt;
&lt;P&gt;Professor Bosanquet of Imperial College presents the case for more community eye care, which would help ensure that eye conditions are detected and treated early, reducing the high level of avoidable blindness and creating an estimated saving of up to £4 billion a year.&lt;/P&gt;
&lt;P&gt;In the report he calls for policy makers to enable optometry to have a bigger role in achieving the Government aim for high quality local healthcare services at a reduced cost, identifying community eye care provision as a 'model service' which already exemplifies the ambitions of the Health White Paper.&lt;/P&gt;
&lt;P&gt;Established local schemes across the country demonstrate that eye care services can be delivered by optometrists in the community with the same degree of quality and reliability, and with no increased risk to the patient. Professor Bosanquet advocates the roll out of these successful local eye care services on a nationwide basis to make the best use of all available resources.&lt;/P&gt;
&lt;P&gt;Launching his new report Professor Bosanquet said: "By 2050 the number of people living with sight loss is set to increase by 115% to almost 4 million people, unless urgent action is taken now. The NHS urgently needs to free up capacity in hospital eye care services. Re-engineering eye care services as I propose is the only way of meeting this challenge. This opportunity has been missed twice in the last decade. It is vital not to miss it again which is why I wanted to undertake this review. Eye health and eye care should be flagships for NHS reform."&lt;/P&gt;
&lt;P&gt;John Baron MP, Co-Chair of the All Party Parliamentary Group on Eye Health and Visual Impairment welcomed the report and said: "Transferring hospital outpatients to the high quality care of optometrists could not only speed up their treatment but also save the NHS&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>334730</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Migraines-and-light.aspx]]&gt;</url>
    <title>Light’s effect on migraine studied</title>
    <publicationDate>2010-01-11T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OPTIC NERVE AND VISUAL PATHWAYS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Scientists have worked out why light makes migraines worse, paving the way for new treatments for the crippling headaches,” reported the Daily Mail. It said that the treatments would allow sufferers to endure light without pain so they would no longer need to shut themselves in a darkened room.</description>
    <body>&lt;![CDATA[ &lt;P&gt;"Scientists have worked out why light makes migraines worse, paving the way for new treatments for the crippling headaches,” reported the &lt;EM&gt;Daily Mail.&lt;/EM&gt; It said that the treatments would allow sufferers to endure light without pain so they would no longer need to shut themselves in a darkened room. &lt;/P&gt;
&lt;P&gt;This laboratory study identified neural pathways in the brain that may be involved&amp;nbsp;in the worsening of migraines with exposure to light. People often find that migraines are made worse by light, and the fact that some visually impaired people (who lack image-forming sight) are also affected, led researchers to speculate that non-image-forming pathways are responsible. They studied this in rats, finding that exposure to light increased the activity along certain neural pathways.&lt;/P&gt;
&lt;P&gt;These findings will be of interest to scientists, but it is unclear what clinical relevance they have. Whether these pathways can be targeted with treatments that reduce light sensitivity for migraine sufferers will need further research.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;In this laboratory study, researchers identified neural pathways that may be involved in the exacerbation of migraines following exposure to light. Photosensitivity (sensitivity to light)&amp;nbsp;is commonly associated with migraines, and the fact that some people who are visually impaired can experience this led the researchers to hypothesise that non-image-forming pathways are likely to be responsible. They were able to study this in rats, noting that exposure to light increased the activity along certain neural pathways&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/01January/Pages/Migraines-and-light.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Noseda R, Kainz V, Jakubowski M, et al. &lt;A href="http://www.nature.com/neuro/journal/vaop/ncurrent/full/nn.2475.html" target="_blank"&gt;A neural mechanism for exacerbation of headache by light&lt;/A&gt;. &lt;EM&gt;Nature Neuroscience&lt;/EM&gt; 2010; advance online publication&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>311142</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/10463412]]&gt;</url>
    <title>Long-term survival after ruthenium plaque radiotherapy for uveal melanoma.  A meta-analysis of studies including 1066 patients</title>
    <publicationDate>1999-08-01T00:00:00</publicationDate>
    <publisher>Acta Ophthalmologica Scandinavica</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,UVEAL TRACT,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Acta Ophthalmologica Scandinavica (Acta Ophthalmol Scand) 1999 Aug;77(4):414-7.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; Most case series of patients managed by brachytherapy for uveal melanoma are small and survival data show considerable inter-study variation. The aim of this study was to summarise similarly structured case series by meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic review generated 5 similarly structured case series including survival data for 1,066 patients treated by ruthenium plaque radiotherapy for uveal melanoma. After assessing the inter-study clinical heterogeneity, data were weighed for study size and pooled. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Patient and radiotherapy characteristics were largely homogenous, but tumour size varied considerably between studies. The 5-year melanoma-related mortality rate was 6% for small and medium tumours (T1/T2) and 26% for large (T3) tumours. The 5-year and 10-year melanoma-related mortality rates for a balanced set of tumours with small, medium and large tumours being present in similar proportions were 14% and 22%, respectively. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Case series of patients with uveal melanoma managed by brachytherapy may be pooled to increase sample size and study power. The present estimate of survival following ruthenium plaque radiotherapy compares favourably with previously summarised data of survival after enucleation for similarly sized tumours.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=26" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326424</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rnib.org.uk/getinvolved/campaign/healthsocialcare/Documents/Lost_and_Found_reportp.pdf]]&gt;</url>
    <title>Lost and found</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ LOW VISION,LIVING WITH VISUAL IMPAIRMENT,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Report published by the RNIB as part of their 'What would you lose?' campaign.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=448" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=448" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=448" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187147</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk/rss/newsAndRssArticle.aspx?uri=http://www.library.nhs.uk/resources/?id=186927]]&gt;</url>
    <title>Lucentis for "wet" age-related macular degeneration</title>
    <publicationDate>2006-10-06T00:00:00</publicationDate>
    <publisher>NHS Centre for Reviews and Dissemination (NHS CRD)</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ AGE RELATED MACULAR DEGENERATION,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Hitting the Headlines', produced by the Centre for Reviews and Dissemination, offers an analysis of the evidence behind selected news stories which have been reported in national newspapers.&amp;nbsp;&amp;nbsp; The aim is to provide health professionals and the public with information about the accuracy of reporting of research in the press.&amp;nbsp;&amp;nbsp; Summaries are posted on the National Library for Health website within 48 hours of newspaper publication. &lt;/P&gt;
&lt;P&gt;This article was produced on&amp;nbsp;6 October 2006 following news stories issued in&amp;nbsp;six national news stories on&amp;nbsp;5 October&amp;nbsp;2006.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267298</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band159/b159-5.html]]&gt;</url>
    <title>Lucentis versus avastin: needs must or devil drives?</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This article published in Issue 159 of Bandolier discusses the new anti-VEGF treatments for age-related macular degeneration. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79263</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band123/b123-2.html]]&gt;</url>
    <title>Lutein and age-related macular degeneration</title>
    <publicationDate>2004-05-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This article published&amp;nbsp;in&amp;nbsp;issue 123 of the Bandolier Journal in May 2004&amp;nbsp;discusses&amp;nbsp;the effects of nutritional supplements, lutein and zeaxanthin on the progression of macular degeneration.]]&gt;</body>
  </document>
  <document>
    <id>392613</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18420940]]&gt;</url>
    <title>Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease</title>
    <publicationDate>2008-04-17T00:00:00</publicationDate>
    <publisher>Annals of the Rheumatic Diseases</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,UVEAL TRACT,UVEITIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ann Rheum Dis. 2009 Oct;68(10):1528-34. Epub 2008 Apr 17.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;STRONG&gt;OBJECTIVES&lt;/STRONG&gt;: To present and analyse the literature sources regarding the management of Behçet disease (BD) identified during the systematic literature research, which formed the basis for the European League Against Rheumatism (EULAR) evidence-based recommendations for the management of BD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Problem areas and related keywords regarding the management of BD were determined by the multidisciplinary expert committee commissioned by EULAR for developing the recommendations. A systematic literature research was performed using MedLine and Cochrane Library resources through to December 2006. Meta-analyses, systematic reviews, randomised controlled trials (RCTs), open studies, observational studies, case control studies and case series' involving &amp;gt; or = 5 patients were included. For each intervention the effect size and number needed to treat were calculated for efficacy. Odds ratios and numbers needed to harm were calculated for safety issues of different treatment modalities where possible.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: The literature research yielded 137 articles that met the inclusion criteria; 20 of these were RCTs. There was good evidence supporting the use of azathioprine and cyclosporin A in eye involvement and interferon (IFN)alpha in mucocutaneous involvement. There were no RCTs with IFNalpha or tumour necrosis factor (TNF)alpha antagonists in eye involvement. Similarly controlled data for the management of vascular, gastrointestinal and neurological involvement is lacking.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION&lt;/STRONG&gt;: Properly designed, controlled studies (new and confirmatory) are still needed to guide us in managing BD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=302" target="_blank"&gt;here &lt;/A&gt;to view the appraisal.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311150</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17712074]]&gt;</url>
    <title>Management of diabetic retinopathy: a systematic review</title>
    <publicationDate>2007-08-22T00:00:00</publicationDate>
    <publisher>JAMA: the journal of the American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: JAMA 2007 Aug 22;298(8):902-16&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONTEXT: &lt;/STRONG&gt;Diabetic retinopathy (DR) is the leading cause of blindness in the working-aged population in the United States. There are many new interventions for DR, but evidence to support their use is uncertain. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To review the best evidence for primary and secondary intervention in the management of DR, including diabetic macular edema. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;EVIDENCE ACQUISITION:&lt;/STRONG&gt; Systematic review of all English-language articles, retrieved using a keyword search of MEDLINE (1966 through May 2007), EMBASE, Cochrane Collaboration, the Association for Research in Vision and Ophthalmology database, and the National Institutes of Health Clinical Trials Database, and followed by manual searches of reference lists of selected major review articles. All English-language randomized controlled trials (RCTs) with more than 12 months of follow-up and meta-analyses were included. Delphi consensus criteria were used to identify well-conducted studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;EVIDENCE SYNTHESIS:&lt;/STRONG&gt; Forty-four studies (including 3 meta-analyses) met the inclusion criteria. Tight glycemic and blood pressure control reduces the incidence and progression of DR. Pan-retinal laser photocoagulation reduces the risk of moderate and severe visual loss by 50% in patients with severe nonproliferative and proliferative retinopathy. Focal laser photocoagulation reduces the risk of moderate visual loss by 50% to 70% in eyes with macular edema. Early vitrectomy improves visual recovery in patients with proliferative retinopathy and severe vitreous hemorrhage. Intravitreal injections of steroids may be considered in eyes with persistent loss of vision when conventional treatment has failed. There is insufficient evidence for the efficacy or safety of lipid-lowering therapy, medical interventions, or antivascular endothelial growth factors on the incidence or progression of DR. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Tight glycemic and blood pressure control remains the cornerstone in the primary prevention of DR. Pan-retinal and focal retinal laser photocoagulation reduces the risk of visual loss in patients with severe DR and macular edema, respectively. There is currently insufficient evidence to recommend routine use of other treatments.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=43" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>334783</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_111032.pdf]]&gt;</url>
    <title>Management of General Ophthalmic Services budget - April 2010</title>
    <publicationDate>2010-01-12T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,SERVICE SECTORS,FINANCE AND ACCOUNTING,PRIMARY CARE SERVICES,EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guidance published by the Department of Health on 12 January 2010 explaining the arrangements for managing the General Ophthalmic Service (GOS) budget following the decision announced in the 2010 NHS Operating Framework that responsibility for budgetary management of GOS will be devolved to PCTs from 1 April 2010.]]&gt;</body>
  </document>
  <document>
    <id>299742</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aop.org.uk/uploaded_files/managing_gos_contracts_in_england.pdf]]&gt;</url>
    <title>Managing GOS contracts in England - Guidance</title>
    <publicationDate>2008-11-24T00:00:00</publicationDate>
    <publisher>Association of Optometrists (AOP)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;On 24 November 2008 the Association of British Dispensing Opticians, Association of Optometrists, British Medical Assocation and Federation of Ophthalmic and Dispensing Opticians&amp;nbsp;published their&amp;nbsp;guidance for General Ophthalmic Services (GOS) contractors in England. &lt;/P&gt;
&lt;P&gt;The guidance covers the contracts for mandatory services (sight testing in a practice) and additional services (domiciliary sight testing).&amp;nbsp; It follows the order of the parts of the contracts. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=427" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=427" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=427" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101526</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12780410&amp;query_hl=1]]&gt;</url>
    <title>Measuring visual field progression in the Early Manifest Glaucoma Trial.</title>
    <publicationDate>2003-06-01T00:00:00</publicationDate>
    <publisher>Acta Ophthalmologica Scandinavica</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source : Acta ophthalmologica Scandinavica, {Acta-Ophthalmol-Scand}, Jun 2003, vol. 81, no. 3, p. 286-93, ISSN: 1395-3907&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;AIMS: The Early Manifest Glaucoma Trial (EMGT) (316 eligible eyes) has used a new set of criteria to define visual field progression in glaucoma. This paper provides estimates of the amount of visual field worsening required to reach the EMGT definition of definite perimetric progression. &lt;/P&gt;
&lt;P&gt;METHODS: In the 148 eyes that reached definite progression, we first determined changes between baseline and the time of definite EMGT progression, both for mean deviation (MD) and for number of highly (p &amp;lt; 0.5%) significantly depressed test points in pattern deviation probability maps. Second, we studied whether such changes depended on baseline MD, intraocular pressure (IOP), age and time to progression, all of which are factors that affect the rate of field progression. &lt;/P&gt;
&lt;P&gt;RESULTS: In eyes reaching progression, the mean change in MD from baseline was -1.93 dB (SE +/- 0.20) and the mean change in number of significant points was +4.85 (SE +/- 0.35). These changes did not show linear dependency on baseline MD, IOP or time to progression. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: The average amount of field deterioration needed to reach EMGT visual field progression has been measured and expressed in more conventional units (i.e. a loss of about - 2dB in MD and an increase in about five highly significant points). These estimates will facilitate the clinical interpretation of the results of EMGT.&lt;/P&gt;
&lt;P&gt;Contact Author : Department of Ophthalmology, Malmo University Hospital, Malmo, Sweden. &lt;A href="mailto:anders.heijl@oftal.mas.lu.se" target="_blank"&gt;anders.heijl@oftal.mas.lu.se&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311152</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/9499767]]&gt;</url>
    <title>Medical prophylaxis and treatment of cystoid macular edema after cataract surgery.  The results of a meta-analysis</title>
    <publicationDate>1998-03-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 1998 Mar;105(3):397-405&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; The study aimed to determine the effectiveness of prophylactic medical intervention in reducing the incidence of cystoid macular edema (CME) and the effectiveness of medical treatment for chronic CME after cataract surgery. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; The study design was a systematic review and meta-analysis of published reports of randomized clinical trials (RCTs). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Sixteen RCTs involving 2898 eyes examining the effectiveness of medical prophylaxis of CME and 4 RCTs involving 187 eyes testing the effectiveness of medical treatment of chronic CME were used in the study. I&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;NTERVENTIONS:&lt;/STRONG&gt; Medical prophylaxis of treatment (cyclo-oxygenase inhibitors or corticosteroids) versus control (placebo or active treatment) was performed. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Incidence of angiographically diagnosed CME, incidence of clinically significant CME, and vision were measured. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Thirty-six articles reported testing a prophylactic medical intervention for CME after cataract surgery. The incidence of CME varied extensively across studies and was related to the study design used. Summary odds ratios (OR) indicated that prophylactic intervention was effective in reducing the incidence of both angiographic CME (OR = 0.36; 95% confidence interval [CI] = 0.28-0.45) and clinically relevant CME (OR = 0.49; 95% CI = 0.33-0.73). There also was a statistically significant positive effect on improving vision (OR = 1.97; 95% CI = 1.14-3.41). A combination of the results of the four RCTs testing medical therapy for chronic CME indicated a treatment benefit in terms of improving final visual acuity by two or more Snellen lines (OR = 2.67; 95% CI = 1.35-5.30). Assessment of the quality of the 20 RCTs included in the meta-analyses indicated problems in the design, execution, and reporting of a number of trials. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; A combination of the results from RCTs indicates that medical prophylaxis for aphakic and pseudophakic CME and medical treatment for chronic CME are beneficial. Because most of the RCTs performed to date have problems related to quality, a well-designed RCT is needed to confirm this result, using clinical CME and vision as outcomes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=10" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333488</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.mmc.nhs.uk/pdf/Quick%20Guide%20to%20recruitment%20in%202011%20FINAL%20SMALL%20WEB7.pdf.pdf]]&gt;</url>
    <title>Medical Specialty Training (England) Quick guide to recruitment in 2011</title>
    <publicationDate>2009-10-21T00:00:00</publicationDate>
    <publisher>Modernising Medical Careers (MMC)</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guide co-produced and designed by Medical Specialty Training (England) and specialty trainees and trainers gives applicants information on: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;what to expect 
&lt;LI&gt;what is involved 
&lt;LI&gt;how the recruitment process works 
&lt;LI&gt;where to find out more&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>311153</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18498911]]&gt;</url>
    <title>Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Clinical Therapeutics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Clinical Therapeutics (Clin Ther) 2008 Apr; 30(4):622-32&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; This meta-analysis was performed to evaluate the efficacy and tolerability of bimatoprost compared with latanoprost in reducing intraocular pressure (IOP). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Pertinent studies were identified through searches of PubMed, EMBASE, the Chinese Biomedicine Database, and the Cochrane Controlled Trials Register up to February 1, 2008, using the terms bimatoprost, Lumigan, latanoprost, and Xalatan. Searches of meeting abstracts and the manufacturers' databases were also performed. Randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated IOP were selected. The main efficacy measures were the weighted mean difference (WMD) in the percentage of IOP reduction (IOPR%) and the rate difference (RD) in the percentage of patients with a target IOP of &lt;OR=17 P &lt; events. adverse for RD the was measure tolerability main The Hg. mm&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Thirteen studies enrolling a total of 1302 patients were included in the meta-analysis. Mean age ranged from 52 to 71 years. The majority of patients for whom these data were available were women (647/1133 [57.1%]) and white (709/1019 [69.6%]). Bimatoprost was associated with greater reductions from baseline in morning IOP compared with latanoprost, with a WMD for the IOPR% of 2.59% (95% CI, 0.81 to 4.37) at 1 month (P=0.004, test for overall effect), 2.41% (95% CI, 0.58 to 4.25) at 3 months (P=0.01, test for overall effect), and 5.60% (95% CI, 2.95 to 8.26) at 6 months (P&amp;lt;0.001, test for overall effect). There was a numerically greater but nonsignificant percentage reduction in diurnal IOP with bimatoprost at 3 months compared with latanoprost, with aWMD for the IOPR% of 2.10% (95% CI,-0.46 to 4.65). Numerically greater proportions of bimatoprost patients than latanoprost patients achieved the target IOP at all time points, with a pooled RD of 5% (95% CI,-9 to 18) at 1 month, 12% (95% CI, 4 to 21) at 3 months (P=0.004, test for overall effect), and 11% (95% CI, 0 to 23) at 6 months. Bimatoprost was associated with a significantly greater frequency of hyperemia than latanoprost, with an RD of 20% (95% CI, 15 to 24). Rates of serious ocular adverse events did not differ significantly between bimatoprost and latanoprost, with an RD of -1% (95% CI,-2 to 1) for ocular inflammation and 0% (95% CI,-2 to 2) for cystoid macular edema. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Bimatoprost was associated with significantly greater efficacy in lowering morning IOP than latanoprost at all time points. Comparable proportions of patients reached the IOP target with bimatoprost and latanoprost. Both agents were well tolerated, although bimatoprost was associated with a significantly greater frequency of conjunctival hyperemia than latanoprost.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=62" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311155</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18082886]]&gt;</url>
    <title>Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2008 Jul;115(7):1117-1122.e.1. Epub 2008 Feb 20&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To evaluate efficacy and safety data of currently available ocular hypotensive medicines derived from 24-hour studies, of similar design, in patients with primary open-angle glaucoma (POAG), exfoliative glaucoma, or ocular hypertension (OH). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN: &lt;/STRONG&gt;Meta-analysis of published articles evaluating patients with POAG, exfoliative glaucoma, or OH. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;We included articles that were randomized, prospective, single- or double-masked, comparative studies of ocular hypotensive therapies over 24 hours. Each article selected contained an untreated baseline, &amp;gt;or=4-week treatment period, &amp;gt;/=20 patients per treatment arm, and &amp;gt;or=6 time points not spaced &amp;gt;5 hours apart and used Goldmann applanation or Tonopen tonometry (supine measurements) to measure intraocular pressure (IOP). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURE: &lt;/STRONG&gt;Twenty-four-hour IOP efficacy. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; This analysis included 864 separate 24-hour treatment curves from 386 patients in 28 treatment arms from 11 studies. A statistical difference in the mean diurnal pressure decrease existed between monotherapy treatments for POAG/OH patients, with bimatoprost (29%) and travoprost (27%) showing the greatest 24-hour reduction (P = 0.026). Timolol 0.5% was less effective than latanoprost (24% vs. 19% reduction) but decreased the pressure at each night time point (P = 0.0003). Dorzolamide showed a 19% 24-hour pressure reduction and brimonidine 0.2% a 14% one. In exfoliative glaucoma patients, latanoprost and travoprost showed higher baseline and treatment pressures, although the pressure reductions (29% and 31%, respectively) were greater generally than observed with POAG/OH. An evening-dosed latanoprost/timolol fixed combination reduced the pressure 33%, and the dorzolamide/timolol fixed combination (DTFC), 26%. However, the power to detect a difference for this specific comparison was probably low, due to the limited number of patients (n = 20) in the DTFC group. A statistical difference between evening-dosed (24%) and morning-dosed (18%) latanoprost (P&amp;lt;0.0001) was noted, but not between evening (27%) and morning (26%) travoprost (P = 0.074). The mean reduction of night time points was statistically lower than day time points for latanoprost (P = 0.031), timolol (P = 0.032), and brimonidine (P = 0.050), but not for dorzolamide. Dorzolamide (P = 0.60), travoprost (P = 0.064), and bimatoprost (P = 0.057) did not demonstrate nighttime pressures lower than daytime ones. The mean reduction of night time points was statistically lower than that of day time points for latanoprost (P = 0.031), timolol (P = 0.032), and brimonidine (P = 0.050), but not for dorzolamide (P = 0.60), bimatoprost (P = 0.057), travoprost (P = 0.064). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Similar relative efficacies generally exist in various classes of ocular hypotensive agents during night and day hours.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=92" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311191</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18303234]]&gt;</url>
    <title>Meta-analysis of chromovitrectomy with indocyanine green in macular hole surgery</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Ophthalmologica</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmologica 2008;222(2):123-9. Epub 2008 Feb 22. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To report a meta-analysis of the literature comparing internal limiting membrane (ILM) peeling with and without indocyanine green (ICG) staining in macular hole (MH) treatment. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A Pubmed search was conducted from January 1999 to June 2004. Manuscripts describing the anatomical and functional outcomes of vitrectomy plus ILM peeling with and without ICG application in MH surgery were reviewed. A statistical meta-analysis was performed including studies which defined anatomical outcomes as closure of the MH and disappearance of the fluid cuff and functional outcomes as improvement of 2 or more Snellen lines. A secondary outcome was to investigate the incidence of retinal pigment epithelium (RPE) alterations with and without ICG staining in MH surgery. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Results including all types of MHs in 837 eyes indicated the same anatomical success but worse functional outcomes in the group with ICG application (p = 0.0008; odds ratio = 0.587, 95% confidence interval = 0.427-0.808). A higher incidence of RPE alterations in the ICG injection group was observed. The incidence of RPE alterations was found to be 1.98%, whereas RPE changes were noted in 13.83% of 201 patients with ICG application (odds ratio = 7.998). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; This meta-analysis of previous reports comparing ILM peeling with and without intravitreal ICG application in the treatment of MHs demonstrated statistically worse functional outcomes when ICG was applied (p = 0.0008). A higher number of RPE alterations were observed in the ICG-stained group. Copyright 2008 S. Karger AG, Basel.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=89" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372415</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19450880]]&gt;</url>
    <title>Meta-analysis of medical intervention for normal tension glaucoma</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology Jul;116(7):1243-9. Epub 2009 May 17. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To evaluate the intraocular pressure (IOP) reduction achieved by the most frequently prescribed antiglaucoma drugs in patients with normal tension glaucoma (NTG). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN: &lt;/STRONG&gt;Systematic review and meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Fifteen randomized clinical trials reported 25 arms for peak IOP reduction, 16 arms for trough IOP reduction, and 13 arms for diurnal curve IOP reduction. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Pertinent publications were identified through systematic searches of PubMed, EMBASE, and the Cochrane Controlled Trials Register. The patients had to be diagnosed as having NTG. Methodological quality was assessed by the Delphi list on a scale from 0 to 18. The pooled 1-month IOP-lowering effects were calculated using the 2-step DerSimonian and Laird estimate method of the random effects model. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Absolute and relative reductions in IOP from baseline for peak and trough moments. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Quality scores of included studies were generally high, with a mean quality score of 12.7 (range, 9-16). Relative IOP reductions were peak, 15% (12%-18%), and trough, 18% (8%-27%) for timolol; peak, 14% (8%-19%), and trough, 12% (-7% to 31%) for dorzolamide; peak, 24% (17%-31%), and trough, 11% (7%-14%) for brimonidine; peak, 20% (17%-24%), and trough, 20% (18%-23%) for latanoprost; peak, 21% (16%-25%), and trough, 18% (14%-22%) for bimatoprost. The differences in absolute IOP reductions between prostaglandin analogues and timolol varied from 0.9 to 1.0 mmHg at peak and -0.1 to 0.2 mmHg at trough. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Latanoprost, bimatoprost, and timolol are the most effective IOP-lowering agents in patients with NTG.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=274" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311196</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14644226]]&gt;</url>
    <title>Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12) and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease</title>
    <publicationDate>2003-12-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American Journal of Ophthalmology (Am J Ophthalmol) 2003 Dec;136(6):1136-50&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To assess the role of plasma total homocysteine (tHcy) levels, serum folate and vitamin B(12)levels, and homozygosity for the thermolabile methylenetetrahydrofolate reductase genotype (TT) as risk factors for retinal vascular occlusive disease. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Meta-analysis of literature. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A MEDLINE search was performed to identify all published case-control studies of plasma tHcy levels, serum folate and vitamin B(12) levels, and TT genotype in persons with retinal vascular occlusive disease. Main outcome measures included calculation of plasma tHcy, serum folate, and serum vitamin B(12) standard differences and odds ratios (OR) of TT genotype between cases and controls. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; In total, 614 patients with all types of retinal vein occlusion had higher plasma tHcy levels than 762 control subjects (standard difference, 0.867; 95% confidence interval [CI] = 0.735, 0.999; P &amp;lt;.001). Plasma tHcy levels were also higher in 154 patients with retinal artery occlusion compared with 358 control subjects (standard difference 1.174; 95% CI = 0.947, 1.402; P &amp;lt;.001). Serum folates, but not vitamin B(12) levels, were lower in 287 patients with retinal vascular occlusion than in the same number of control subjects (standard difference, 0.508; 95% CI = 0.340, 0.675; P &amp;lt;.001; and -0.060; 95% CI = -0.024, 0.104; P =.474, respectively). Similar proportions of 690 patients with retinal vein occlusion and 2754 control subjects demonstrated the TT genotype (OR = 1.332; 95% CI = 0.995, 1.783; P =.054) as did 152 patients with retinal artery occlusions and 435 control subjects (OR = 1.716; 95% CI = 0.977, 3.014; P =.060). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Retinal vascular occlusion is associated with elevated plasma tHcy levels and low serum folate levels, but not serum vitamin B(12) levels and TT genotype. Until a prospective multicenter trial is undertaken, plasma tHcy levels and serum folate levels should be determined in patients with retinal vascular occlusions, and dietary supplementation with low doses of folate and vitamin B(12) should be considered for affected persons.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=197" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311200</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16956912]]&gt;</url>
    <title>Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2007 Jan;91(1):62-8. Epub 2006 Sep 6&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; To compare the efficacy and tolerability of latanoprost versus brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHOD:&lt;/STRONG&gt; Systematic review of randomised controlled trials comparing latanoprost and brimondine, identified by searches including Medline, Embase and Cochrane Controlled Trials Register. Two reviewers independently assessed trials for eligibility and quality and extracted data. Data were synthesised (random effects model) and expressed as the absolute mean intraocular pressure (IOP) reduction difference from baseline to end point for efficacy and relative risk for adverse events. Subgroup analysis and regression were used to explore heterogeneity according to patient characteristics, trial design and quality. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; 15 publications reporting on 14 trials (1784 participants) were included for meta-analysis. IOP reduction favoured latanoprost (weighted mean difference (WMD) = 1.10 mm Hg (95% confidence interval (CI) 0.57 to 1.63)). Significant heterogeneity was present (chi(2)(13) = 38.29, p = 0.001, I(2) = 66.0%). Subgroup analysis showed greater WMD for studies where data were analysed from end points &amp;gt;6 months duration, cross-over design, open-angle glaucoma or ocular hypertension and monotherapy. Multiple regression showed no significant association of WMD with trial duration (t(9) = 1.92, p = 0.09), trial design (t(9) = 1.79, p = 0.11), trial quality (t(9) = -0.46, p = 0.66), or monotherapy or adjunctive therapy (t(9) = -2.14, p = 0.06). Fatigue was less commonly associated with latanoprost (RR = 0.27, 95% CI 0.08 to 0.88). Publication bias was not evident on visual inspection of a funnel plot. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Latanoprost is more effective than brimonidine as monotherapy in lowering IOP. Brimonidine is associated with a higher rate of fatigue.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=20" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311232</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11466259]]&gt;</url>
    <title>Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.</title>
    <publicationDate>2001-08-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2001 Aug;85(8):983-90&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIM:&lt;/STRONG&gt; To evaluate the comparative efficacy and tolerance of latanoprost versus timolol through a meta-analysis of randomised controlled trials (RCTs). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Systematic retrieval of RCTs of latanoprost versus timolol to allow pooling of results from head to head comparison studies. Quality of trials was assessed based on randomisation, masking, and withdrawal. Sensitivity analyses were used to estimate the effects of quality of study on outcomes. The data sources were Medline, Embase, Scientific Citation Index, Merck Glaucoma, and Pharmacia and Upjohn ophthalmology databases. There were 1256 patients with open angle glaucoma or ocular hypertension reported in 11 trials of latanoprost versus timolol. The main outcome measures were (i) percentage intraocular pressure (IOP) reduction for efficacy; (ii) relative risk, risk difference, and number needed to harm for side effects such as hyperaemia, conjunctivitis, increased pigmentation, hypotension, and bradycardia expressed as dichotomous outcomes; and (iii) reduction in systemic blood pressure and heart rate as side effects. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Both 0.005% latanoprost once daily and 0.5% timolol twice daily reduced IOP. The percentage reductions in IOP from baseline (mean (SE)) produced by latanoprost and timolol were 30.2 (2.3) and 26.9 (3.4) at 3 months. The difference in IOP reduction between the two treatments were 5.0 (95% confidence intervals 2.8, 7.3). However, latanoprost caused iris pigmentation in more patients than timolol (relative risk = 8.01, 95% confidence intervals 1.87, 34.30). The 2 year risk with latanoprost reached 18% (51/277). Hyperaemia was also more often observed with latanoprost (relative risk =2.20, 95% confidence intervals 1.33, 3.64). Timolol caused a significant reduction in heart rate of 4 beats/minute (95% confidence interval 2, 6). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; This meta-analysis suggests that latanoprost is more effective than timolol in lowering IOP. However, it often causes iris pigmentation. While current evidence suggests that this pigmentation is benign, careful lifetime evaluation of patients is still justified.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=83" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311228</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18412600]]&gt;</url>
    <title>Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma.</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Clinical &amp; Experimental Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Clinical &amp;amp; Experimental Ophthalmology (&lt;SPAN title="Clinical &amp;amp; experimental ophthalmology."&gt;Clin Experiment Ophthalmol)&lt;/SPAN&gt; 2008 Apr;36(3):281-9&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This paper aims to compare the efficacy and tolerability of timolol versus brimonidine in the treatment of glaucoma. Comprehensive searches were performed using Medline, Embase and the Cochrane Controlled Trials Register for randomized controlled trials comparing timolol and brimonidine. Two reviewers independently assessed trials for eligibility and quality and extracted data. A random effects model was used to combine studies. Outcome was defined as the absolute mean intraocular pressure (IOP) reduction from baseline to end-point for efficacy, and relative risk (RR) for adverse events. Subgroup analysis and meta-regression were used to explore heterogeneity according to trial design and quality. Ten publications reporting on eight trials with 2387 participants were included in the meta-analysis. Two further trials were commented on qualitatively. IOP reduction was not significantly different between timolol and brimonidine. Weighted mean difference (WMD) of IOP reduction was 0.24 mmHg (favouring brimonidine) with a 95% confidence interval of -0.57 to 1.04 mmHg. There was significant heterogeneity between studies (chi(2) (13) = 73.75, P &amp;lt; 0.00001, I(2) = 91%). Subgroup analysis showed no significant WMD for studies where data were analysed from end-points &amp;gt;/=6 months or &amp;lt;6 months. Meta-regression analysis showed increased WMD IOP reduction in favour of brimonidine with increased trial quality (t(3) = -4.58, P = 0.01), but no significant association with trial duration (t(3) = 0.73, P = 0.51) or size (t(3) = -0.59, P = 0.57). The RR of ocular allergy was much lower with timolol than brimonidine (RR = 0.08, 95% confidence interval 0.01 to 0.47). Publication bias was not evident on a funnel plot, although the number of studies was small. The conclusion is that both drugs are equally effective in lowering IOP. Brimonidine is associated with a higher rate of allergy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=20" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322544</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17594698]]&gt;</url>
    <title>Meta-analysis of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics</title>
    <publicationDate>2007-08-15T00:00:00</publicationDate>
    <publisher>Cancer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: Cancer 2007 Aug 15;110(4):809-15.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; There are conflicting reports regarding the association between Chlamydia psittaci (Cps) and ocular adnexal lymphoma (OAL) and the efficacy of antibiotics for OAL. In the current study, the authors attempted to clarify the association between Cps and OAL and the efficacy of antibiotics for OAL. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Two meta-analyses were conducted. One focused on the association between Cps and OAL across geographic regions and among different studies. The other was a meta-analysis of the response of OAL to antibiotic treatment. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The authors identified 11 studies of Cps prevalence that included 458 cases of OAL from 10 different countries. Four studies regarding the efficacy of oral antibiotics to treat OAL were found. One hundred four of the 458 OAL specimens (23%) and 87 of the 346 mucosa-associated lymphoid tissue (MALT) lymphoma specimens (25%) were found to be positive for Cps. Ninety-four of the 104 Cps-positive OAL specimens (90%) came from 3 of the 11 studies. There was wide variation noted between geographic regions and even between studies from the same geographic region with regard to the rate of Cps positivity. The 4 studies concerning the efficacy of antibiotics for OAL were from Italy, Austria, Taiwan, and the U.S. and included 42 patients. Twenty patients (48%) achieved some response (complete response in 8 patients, partial response in 8 patients, and minimal response in 4 patients). Twenty patients also had stable disease, and 2 patients progressed during antibiotic therapy. Objective documentation of response (radiographs or clinical slit-lamp photographs) was available for only 3 of the 42 patients. Seven additional patients developed disease recurrence after their initial response or stable disease after antibiotic therapy; 6 of these cases of disease recurrence occurred during the first 12 months of follow-up. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS: &lt;/STRONG&gt;The findings of the current study suggest a striking variability in the association between Cps and OAL across geographic regions and even between studies from the same geographic regions. The overall rate of Cps positivity in our meta-analysis (23%) was much lower than that reported in the original report. The current study findings also suggest that antibiotics have variable efficacy against OAL. Future prospective trials with standard objective response criteria and a longer follow-up period would be necessary to evaluate the role of antibiotics in the treatment of OAL further.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision speicalist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=38" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311225</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11192141]]&gt;</url>
    <title>Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma</title>
    <publicationDate>2000-12-01T00:00:00</publicationDate>
    <publisher>Clinical Therapeutics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Source: Clinical Therapeutics (Clin Ther) 2000 Dec;22(12):1502-15&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; The purpose of this study was to indirectly quantify and compare the intraocular pressure (IOP)-lowering effects of latanoprost and brimonidine eye drops at baseline and after 3 and 6 months in the treatment of primary open-angle glaucoma. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; This meta-analysis combined data from all randomized controlled trials comparing the effects on IOP of latanoprost and brimonidine treatment in adults with a baseline IOP &amp;gt; or =20 mm Hg. MEDLINE and EMBASE were searched for reports of the ophthalmic administration of either drug versus the other, placebo, or active therapy. Included studies reported IOP as either means or differences (with SD or SE) and sample sizes. A random-effects model was used to pool data within each drug group. As a proxy for success rates, area under the curve (AUC) was calculated for the proportion of patients having an IOP &amp;lt;20 mm Hg. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; One hundred fifty-five articles reporting on 158 trials were identified; 147 papers were rejected (141 were not randomized controlled trials, 5 were duplicates, and 1 had nonextractable data), leaving 9 trials from 8 articles. A total of 2152 patients were included in the meta-analysis: 597 received latanoprost, 571 received brimonidine, and the remainder received timolol or betaxolol. Baseline IOPs were similar in patients randomized to latanoprost or brimonidine (25.3 and 24.6 mm Hg, respectively). At 3 months, latanoprost and brimonidine reduced IOP by 8.4 and 6.5 mm Hg, respectively (P = 0.004 latanoprost vs brimonidine), and at 6 months by 8.0 and 6.2 mm Hg, respectively (P = 0.045). AUC was 0.834 and 0.675 at 3 months for latanoprost and brimonidine, respectively, and 0.817 and 0.715 at 6 months, respectively (both, P &amp;lt; 0.001). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This indirect comparison of data from the available randomized clinical trials showed latanoprost to be statistically superior to brimonidine in reducing IOP in adults with primary open-angle glaucoma. Additional long-term, head-to-head comparisons of the efficacy, safety, and cost of latanoprost and brimonidine are needed to support and supplement these findings.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=226" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311218</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/9797669]]&gt;</url>
    <title>Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium</title>
    <publicationDate>1998-06-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 1998 Jun; 82(6):661-5.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND/AIMS:&lt;/STRONG&gt; Bare sclera resection with and without use of mitomycin C and conjunctival autograft placement are three surgical techniques currently in use for the treatment of primary pterygium. The purpose of this study was to determine through a meta-analysis the risk for postoperative pterygium recurrence comparing the three surgical treatment modalities. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A search through Medline for randomised controlled clinical trials comparing at least two of the three surgical techniques in the treatment of primary pterygium, along with a hand search of all references in relevant papers, was conducted. All eligible clinical trials were graded for quality utilising the Detsky score; those studies with a score of 0.5 or greater were included. The main outcome measurements were the pooled odds ratios and 95% confidence intervals for the risk of pterygium recurrence. These were calculated utilising the Mantel-Haenszel method. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Five eligible studies with an adequate quality score were retrieved, three comparing bare sclera resection with and without mitomycin C use, one comparing bare sclera resection with conjunctival autograft placement, and one comparing both. The pooled odds ratio for pterygium recurrence in patients who had only bare sclera resection was 6.1 (95% confidence intervals, 1.8 to 18.8) compared with the patients who had conjunctival autograft placement and 25.4 (9.0 to 66.7) compared with the patients who received mitomycin C. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; The odds for pterygium recurrence following surgical treatment of primary pterygium are close to six and 25 times higher if no conjunctival autograft placement is performed or if no intra/postoperative mitomycin C is used, respectively. Surgeons and clinical triallists should not be encouraged in the use of bare sclera resection as a surgical technique for primary pterygium.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=7" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79274</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/Cancer/mobmagca.html]]&gt;</url>
    <title>Mobile phones, magnetic fields and cancer</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CANCER,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Summary of several&amp;nbsp;epidemiological studies investigating&amp;nbsp;the link between mobile phones and cancers of the head.&amp;nbsp;&amp;nbsp;&amp;nbsp; The summary was written in 2003 and&amp;nbsp;contains links to related organisations such as National Institute of Environmental Health Science and the World Health Organisation]]&gt;</body>
  </document>
  <document>
    <id>389269</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.vision2020uk.org.uk/core_files/Low_Vision_Children_Standards_June.doc]]&gt;</url>
    <title>Modifications to the Department of Health’s Recommended Standards for Low Vision Services –  recognising the needs of children and young people and their families.</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>VISION 2020 UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Paper presented in June 2010&amp;nbsp;&lt;SPAN style="mso-bidi-font-size: 14.0pt; mso-bidi-font-family: Arial"&gt;by a working party from the Low Vision Services Group - Children’s sub committee based on the outcomes from the 2nd Low Vision Conference 2008 discussing Modifications to the Department of Health’s Recommended Standards for Low Vision Services –&amp;nbsp; recognising the needs of children and young people and their families.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="mso-bidi-font-size: 14.0pt; mso-bidi-font-family: Arial"&gt;The paper covers Design principles; Referral, assessment and service; Information; Service improvement, monitoring and evaluation of the service; Training and Communications.&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=499" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=499" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=499" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311209</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11110501]]&gt;</url>
    <title>Mydriasis and glaucoma: exploding the myth. A systematic review</title>
    <publicationDate>2000-10-01T00:00:00</publicationDate>
    <publisher>Diabetic Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Diabetic Medicine (Diabet Med) 2000 Oct;17(10):693-9.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIMS:&lt;/STRONG&gt; To investigate the risk of inducing acute glaucoma following mydriasis. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Systematic review of published research 1933-1999. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The risk of inducing acute glaucoma following mydriasis with tropicamide alone is close to zero, no case being identified. The risk with long-acting or combined agents is between 1 in 3,380 and 1 in 20,000. The presence of chronic glaucoma constitutes no additional risk. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Mydriasis with tropicamide alone is safe even in people with chronic glaucoma. It should be advised in all patients when thorough retinal examination is indicated.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=224" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>84238</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4032823.pdf]]&gt;</url>
    <title>National Service Framework for diabetes: delivery strategy</title>
    <publicationDate>2003-01-09T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NATIONAL SERVICE FRAMEWORKS (NSFS) AND EYE HEALTH,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=teaserText&gt;This&amp;nbsp;document from the Department of Health (DH) published in January 2003 outlines the&amp;nbsp;national targets against which local NHS performance on the standards in the National Service Framework for Diabetes can be judged. &lt;/P&gt;
&lt;P class=teaserText&gt;National service frameworks (NSFs) are long term strategies for improving specific areas of care. &lt;/P&gt;
&lt;P class=teaserText&gt;NSFs:&lt;/P&gt;
&lt;DIV&gt;
&lt;DIV class=block100&gt;
&lt;DIV class=leftFloat100&gt;
&lt;UL&gt;
&lt;LI&gt;set national standards and identify key interventions for a defined service or care group 
&lt;LI&gt;put in place strategies to support implementation 
&lt;LI&gt;establish ways to ensure progress within an agreed time scale 
&lt;LI&gt;form one of a range of measures to raise quality and decrease variations in service, introduced in The New NHS and A First Class Service. The NHS Plan re-emphasised the role of NSFs as drivers in delivering the Modernisation Agenda. &lt;/LI&gt;&lt;/UL&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;DIV class=clearAll&gt;&lt;/DIV&gt;
&lt;P&gt;Each NSF is developed with the assistance of an external reference group (ERG) which brings together health professionals, service users and carers, health service managers, partner agencies, and other advocates. ERGs adopt an inclusive process to engage the full range of views. The Department of Health supports the ERGs and manages the overall process.&lt;/P&gt;
&lt;P&gt;1.3 million people in England suffer from diabetes, and the number is increasing. The diabetes NSF is a concerted effort to make sure these people, wherever they live, receive the same excellent standard of care. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV&gt;Chapter 3 Delivering the Targets: The Next Three Years covers the systematic screening programme for diabetic retinopathy. &lt;/DIV&gt;
&lt;DIV&gt;&amp;nbsp;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>88002</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4079284.pdf]]&gt;</url>
    <title>National service framework for diabetes: One year on</title>
    <publicationDate>2004-04-08T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NATIONAL SERVICE FRAMEWORKS (NSFS) AND EYE HEALTH,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=teaserText&gt;This document published by the Department of Health in&amp;nbsp;April 2004&amp;nbsp;describes the progress made&amp;nbsp;during the first year&amp;nbsp;on the&amp;nbsp;National Service Framework&amp;nbsp;for Diabetes.&lt;/P&gt;
&lt;P class=teaserText&gt;The Diabetes National Service Framework set out the first ever set of national standards for the treatment of diabetes to raise the quality of NHS services and reduce unacceptable variations between them. &lt;/P&gt;
&lt;P class=teaserText&gt;Section 3 The Next Two Years and Beyond&amp;nbsp;includes information on the systematic retinopathy screening programme. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>88001</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4058938.pdf]]&gt;</url>
    <title>National service framework for diabetes: standards</title>
    <publicationDate>2001-12-13T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DIABETIC RETINOPATHY,RETINA,RETINOPATHY,NATIONAL SERVICE FRAMEWORKS (NSFS) AND EYE HEALTH,OUTCOMES,ENDOCRINE DISORDERS,DIABETES,STANDARDS,EYES AND VISION,PUBLIC HEALTH,FRAMES OF REFERENCE,MANAGEMENT &amp; POLICY,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS,2009 FEBRUARY,MONTHLY ADDITIONS,MANAGEMENT &amp; INTERVENTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=teaserText&gt;This document from the Department of Health (DH) published in December 2001 is the first part of the National Service Framework for Diabetes and sets out twelve new standards and the key interventions necessary to raise the standards of diabetes care.&lt;/P&gt;
&lt;P class=teaserText&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102048</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9109757&amp;query_hl=5]]&gt;</url>
    <title>Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group.</title>
    <publicationDate>1997-04-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology, {Arch-Ophthalmol}, Apr 1997, vol. 115, no. 4, p. 486-91, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To provide clinical management guidelines for eyes with central retinal vein occlusion. &lt;/P&gt;
&lt;P&gt;DESIGN: Prospective cohort study with randomized clinical trials of specific subgroups of patients. Three-year follow-up every 4 months.&lt;/P&gt;
&lt;P&gt;SETTING: Nine ophthalmology practices. &lt;/P&gt;
&lt;P&gt;PATIENTS: Seven hundred twenty-five patients with central vein occlusion. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURES: Iris neovascularization (INV), neovascular glaucoma, and visual acuity. &lt;/P&gt;
&lt;P&gt;RESULTS: Visual acuity outcome was largely dependent on initial acuity. Sixty-five percent of patients with initially good visual acuity (20/40 or better) maintained visual acuity in the same range at the end of the study. Patients with intermediate initial acuity (20/50-20/200) showed a variable outcome: 19% improved to better than 20/50, 44% stayed in the intermediate group, and 37% had final visual acuity worse than 20/200. Patients who had poor visual acuity at the first visit (&amp;lt; 20/200) had an 80% chance of having a visual acuity less than 20/200 at final visit, whether perfused or nonperfused initially. In the first 4 months of follow-up, 81 (15%) of the 547 eyes with perfusion converted to ischemia. During the next 32 months of follow-up, an additional 19% of eyes were found to have converted to ischemia for a total of 34% after 3 years. The development of nonperfusion or ischemia was most rapid in the first 4 months and progressed continuously throughout the entire duration of follow-up. Iris neovascularization of at least 2-clock hours, and/or angle neovascularization (ANV) developed in 117 (16%) of the 714 eyes. Sixty-one of the 117 eyes that had INV/ANV were initially categorized as nonperfused or indeterminate; 56 of the 117 eyes were initially categorized as perfused. When INV/ANV occurred, it was treated promptly with panretinal photocoagulation. The strongest predictors of INV/ANV were visual acuity (P &amp;lt; .001) and the amount of nonperfusion seen by fluorescein angiogram (P &amp;lt; .001). For eyes initially categorized as nonperfused or indeterminate, 35% (61/176) developed INV/ANV, compared with 10% (56/538) for eyes initially categorized as perfused. Other risk factors were venous tortuosity (P = .02), extensive retinal hemorrhage (P = .07), and duration less than 1 month (P = .08). Neovascular glaucoma that was unsuccessfully managed with medical treatment developed in only 10 eyes. No eye was enucleated. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Visual acuity at baseline is a strong predictor of visual acuity at 3 years for eyes with good vision and eyes with poor vision, but a poor predictor for intermediate acuities. Visual acuity is also a strong predictor for the development of INV /ANV, as is nonperfusion. During the course of follow-up, one third of the eyes with perfusion converted to eyes with ischemia. Clinical management guidelines, developed from these and previously reported Central Vein Occlusion Study data, are presented. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;central vein occlusion management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=9869&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102049" target="_blank"&gt;A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=9869&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102050" target="_blank"&gt;Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7508322&amp;amp;query_hl=16" target="_blank"&gt;Central vein occlusion study of photocoagulation therapy. Baseline findings. Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7508321&amp;amp;query_hl=16" target="_blank"&gt;Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7688950&amp;amp;query_hl=16" target="_blank"&gt;Baseline and early natural history report. The Central Vein Occlusion Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10163466&amp;amp;query_hl=23" target="_blank"&gt;Laser therapy for central retinal vein obstruction.&lt;/A&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311234</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16984673]]&gt;</url>
    <title>Need for high-quality studies in health technology assessments: the case of a systematic review of treatment for retinoblastoma.</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>International Journal of Technology Assessment in Health Care</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source:&amp;nbsp;&amp;nbsp;International Journal of Technology Assessment in Health Care (&lt;SPAN title="International journal of technology assessment in health care."&gt;Int J Technol Assess Health Care)&lt;/SPAN&gt; 2006 Fall;22(4):408-18&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVES:&lt;/STRONG&gt; The aim of this study was to conduct a systematic review of the evidence for treatments for retinoblastoma in children. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Seventeen electronic databases were searched. Two reviewers independently selected studies. Studies of participants diagnosed with childhood retinoblastoma, any interventions, and all clinical outcomes were eligible. Randomized and nonrandomized controlled trials and cohort studies with clear comparisons between treatment groups were included. Methodological quality was assessed. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Thirty-one observational comparative studies were included, of which twenty-seven were retrospective. The methodological quality was generally poor, with a high risk of selection bias in all studies. Although there were high levels of treatment success in many of the studies, due to the limitations of the evidence identified, it was not possible to make meaningful and robust conclusions about the relative effectiveness of different treatment approaches for retinoblastoma in children. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Good quality randomized controlled trials are required. Where controlled trials are not feasible, only high quality prospective, nonrandomized studies should be given consideration, due to the generally higher risk of bias in retrospective studies.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=122" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289691</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_085947.pdf]]&gt;</url>
    <title>NHS Next Stage Review: Our vision for primary and community care</title>
    <publicationDate>2008-07-03T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Report&amp;nbsp;published by Department of Health on 3 July 2008.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This document sets out a vision for how primary and community care services will continue to grow and develop over the next ten years.&amp;nbsp; It is a vision of a continuously improving service, where essential standards are guaranteed and excellence is rewarded.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250837</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;db=pubmed&amp;details_term=15885795%5BUID%5D]]&gt;</url>
    <title>Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review.</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, June 2005, vol 112, no 6, p953-61; ISSN 1549-4713 &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This&amp;nbsp;resource&amp;nbsp;was identified during the Glaucoma National Knowledge Week held in November 2006.&amp;nbsp;&amp;nbsp; Please &lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;click here&lt;/A&gt; to view the contents of the week. &lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;/STRONG&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PubMed Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To summarize the available scientific evidence to support clinical decisions on how to deal with noncompliance in glaucoma patients. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CLINICAL RELEVANCE:&lt;/STRONG&gt; Insufficient reduction of intraocular pressure and progression of visual field (VF) loss in glaucoma patients due to noncompliance with topical treatment may result in unnecessary therapy, with additional risks and costs. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS/LITERATURE REVIEWED:&lt;/STRONG&gt; We conducted a literature search in the databases MEDLINE, EMBASE, CINAHL, PsychInfo, and Cochrane and reference lists. Thirty-four articles describing 29 original quantitative studies, in English, German, French, or Dutch, were included. Studies on noncompliance in drug trials were excluded. Two investigators independently selected the articles and abstracted their content, before negotiating their inclusion or exclusion. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The proportions of patients who deviate from their prescribed medication regimen ranged from 5% to 80%. The impact of noncompliance on clinical outcome has not yet been established. There are no determinants sensitive and specific enough to identify potential noncompliers accurately. Patient knowledge and dose frequency can be used as starting points to improve compliance. A combination of patient education and prevention of forgetting doses seems to be successful in enhancing patient compliance. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Noncompliance with hypotensive treatment is common among glaucoma patients. However, there is no strong evidence supporting a relation between noncompliance and progression of VF loss. Only a few guidelines for clinicians can be derived from the currently available literature. Future research should be guided by clinically relevant questions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=165" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>304772</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcophth.ac.uk/core/core_picker/download.asp?id=407]]&gt;</url>
    <title>Ophthalmology as a career</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>The Royal College of Ophthalmologists</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Document published by The Royal College of Ophthalmology in January 2009.&amp;nbsp;&amp;nbsp; Sections include: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;What is ophthalmology? 
&lt;LI&gt;What is an ophthalmologist? 
&lt;LI&gt;Specialist interests in ophthalmology 
&lt;LI&gt;Do ophthalmologists work as part of a team? 
&lt;LI&gt;How do I become an ophthalmologist? 
&lt;LI&gt;The new examination structure for a trainee in ophthalmology 
&lt;LI&gt;What happens at the end of training? 
&lt;LI&gt;The future of ophthalmology 
&lt;LI&gt;Trainee perspectives and volunteer work&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=432" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=432" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=432" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311291</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17962446]]&gt;</url>
    <title>Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: a systematic review</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Investigative Ophthalmology &amp; Visual Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: Investigative Ophthalmology&amp;nbsp;and Visual Science 2007 Nov;48(11):4963-73&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To review systematically the sensitivity and specificity of optical coherence tomography (OCT) for diagnosing macular edema attributable to diabetic retinopathy compared with well-established gold standard tests such as fundus stereophotography or contact and noncontact fundus biomicroscopy. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Medline and Embase were searched electronically and six major ophthalmic journals from 1998 to 2006 were hand searched. Two reviewers independently assessed trial searches, studied quality with the QUADAS (Quality Assessment of Diagnostic Accuracy Studies) checklist, and extracted data. The target disease was clinically significant macular edema (CSME) according to Early Treatment of Diabetic Retinopathy Study (ETDRS) criteria. A bivariate model was used to obtain summary estimates of sensitivity and specificity and fit a summary receiver operating characteristic (ROC) curve. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Fifteen studies were considered eligible. These studies were of good quality for most items of the QUADAS checklist, but most studies did not report masking of examiners and did not describe how withdrawals and undetermined results were treated. Seven studies included healthy control subjects, which could have artificially enhanced OCT diagnostic performance. All but one study included both eyes of the patients without taking into account the within-subject correlation in statistical analyses. Sensitivity and specificity data could be extracted from only 6 of 15 studies, because appropriate cross tabulations of index and reference tests were not reported by the others. In five of these studies, central retinal thickness cutoffs between 230 and 300 microm were adopted to define abnormal OCT results and considered the central type of CSME only, whereas in one study a complex algorithm accounting for extrafoveal CSME was used. The design of one study was case-control and was excluded from the meta-analysis. The expected operating point on the summary ROC, a pooled estimate of all studies, corresponded to a sensitivity of 0.79 (95% CI: 0.71-0.86), a specificity of 0.88 (95% CI: 0.80-0.93), a positive likelihood ratio of 6.5 (95% CI: 4.0-10.7), and a negative likelihood ratio of 0.24 (95% CI: 0.17-0.32). These values suggest a good overall performance of OCT for diagnosing CSME. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; OCT performs well compared with fundus stereophotography or biomicroscopy to diagnose diabetic macular edema. The quality of reporting of such studies should be improved, and authors should present cross tabulations of index and reference test results. Data adjusted for within-subject correlation should also be provided, although this issue represents a challenge for systematic reviewers.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=51" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101751</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-3.pdf]]&gt;</url>
    <title>Optometic Clinical Practice Guideline: Care of the Patient with Diabetes Mellitus</title>
    <publicationDate>2002-08-01T00:00:00</publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RETINA,RETINOPATHY,DIABETIC RETINOPATHY,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on care of the patient with&amp;nbsp;Diabetes Mellitus&amp;nbsp;published by the American Optometric Association (AOA) in August 2002 (third edition).&amp;nbsp;&amp;nbsp; The guideline contains two main sections together with conclusions and references.&amp;nbsp; The first section is a statement of the problem including a description and classification of&amp;nbsp;diabetes mellitus,&amp;nbsp;epidemiology and clinical background of ocular manifestations.&amp;nbsp; The second is about the care process including diagnosis of these ocular manifestations (patient history, ocular examination, examination technique, supplemental testing) and management (basis for treatment, treatment options, patient education, prognosis and follow up and management of patients with severe, irreversible vision loss).&amp;nbsp;&amp;nbsp; There are&amp;nbsp;four appendices, optometric management of the patient with undiagnosed and diagnosed diabetes mellitus, frequency and composition of evaluation and management visits for retinal complications and the ICD-9-CM classification of ocular complications of Diabetes Mellitus.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=105" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=105" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=105" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89332</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-19.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Contact Lens Patient</title>
    <publicationDate></publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,REFRACTIVE ERROR,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on&amp;nbsp;care of the contact lens patient&amp;nbsp; published by the American Optometric Association (AOA) in&amp;nbsp;June 2006 (second edition).&amp;nbsp;&amp;nbsp;The guideline contains&amp;nbsp;two main sections together with&amp;nbsp;conclusions and references.&amp;nbsp; The first&amp;nbsp;section is a statement of the problem&amp;nbsp;including the history and epidemiology of the use of contact lenses.&amp;nbsp;&amp;nbsp;The second&amp;nbsp;is about the care process including pre-fitting considerations, contact lens examination and fitting, dispensing lenses and patient education, progress evaluations, and the management of complications (non infectious and infectious).&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=114" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=114" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=114" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89345</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-6.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Patient with Age-Related Macular Degeneration</title>
    <publicationDate></publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RETINA,AGE RELATED MACULAR DEGENERATION,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on&amp;nbsp;care of the patient with Age-Related Macular Degeneration published by the American Optometric Association (AOA) in&amp;nbsp;1994, revised&amp;nbsp;February 1999 and reviewed in 2004.&amp;nbsp;&amp;nbsp; The guideline contains&amp;nbsp;two main sections together with&amp;nbsp;conclusions and references.&amp;nbsp; The first&amp;nbsp;section is a statement of the problem&amp;nbsp;including a description and classification of ARMD, epidemiology and clinical background.&amp;nbsp; The second&amp;nbsp;is about the care process including diagnosis (patient history, ocular examination, supplemental testing) and management (basis for treatment, patient education, prognosis and management of patients with severe, irreversible vision loss).&amp;nbsp;&amp;nbsp; There are three appendices, optometric management of the patient with ARMD, frequency and composition of evaluation and management visits and the ICD-9-CM Classification of ARMD.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=104" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=104" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=104" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101745</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-4.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Patient with Amblyopia</title>
    <publicationDate>1998-10-01T00:00:00</publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ OCULAR MOTILITY,AMBLYOPIA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on care of the patient with Amblyopia published by the American Optometric Association (AOA) in June 1994,&amp;nbsp;revised in October 1998 and reviewed in 2004.&amp;nbsp; The guideline contains two main sections together with conclusions and references.&amp;nbsp; The first section is a statement of the problem including a description and classification of amblyopia, epidemiology and clinical background.&amp;nbsp; The second is about the care process including diagnosis (patient history and ocular examination) and managment (basis for treatment,&amp;nbsp;treatment options, patient education and prognosis).&amp;nbsp; &amp;nbsp;There are&amp;nbsp;four appendices, optometric management of the patient, potential components of the diagnostic evaluations, frequency and composition of evaluation and management visits and ICD-9-CM classification of functional amblyopia. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=66" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=66" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=66" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89301</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-8.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Patient with Cataract</title>
    <publicationDate></publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ LENS,CATARACT,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on the care of the patient with Cataract published by the American Optometric Association (AOA) in 1995.&amp;nbsp; The guideline was revised in March 1999 by the AOA Clinical Guidelines Coordinating Committee and reviewed in 2004.&amp;nbsp; The guideline contains sections on the description, classification and epidemiology of cataracts and the care pathway including&amp;nbsp;diagnosis,&amp;nbsp;management and treatment options. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=53" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=53" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=53" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101746</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-11.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Patient with Conjunctivitis</title>
    <publicationDate>2002-11-01T00:00:00</publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVITIS,CONJUNCTIVA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on care of the patient with Conjunctivitis&amp;nbsp;published by the American Optometric Association (AOA) in&amp;nbsp;November 2002 (second edition).&amp;nbsp;&amp;nbsp;The guideline contains two main sections together with conclusions and references.&amp;nbsp; The first section is a statement of the problem including a description and classification of&amp;nbsp;conjunctivitis, epidemiology and clinical background.&amp;nbsp; The second is about the care process including diagnosis (patient history, ocular examination, supplemental testing) and management (basis for treatment, patient education, prognosis and follow up).&amp;nbsp;&amp;nbsp; There are&amp;nbsp;four appendices, optometric management of the patient with&amp;nbsp;conjunctivits,&amp;nbsp;procedures for obtaining cultures, smears and scrapings,&amp;nbsp;frequency and composition of evaluation and management visits and the ICD-9-CM Classification of Conjunctivitis.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=99" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=99" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=99" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89291</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-9.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Patient with Open Angle Glaucoma</title>
    <publicationDate></publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on the care of the patient with Open Angle Glaucoma was first published by the American Optometric Association (AOA) in&amp;nbsp;1995.&amp;nbsp;&amp;nbsp;A second edition published in August 2002 and&amp;nbsp;this was&amp;nbsp;reviewed in 2007.&amp;nbsp; The guideline contains sections on the description, classification and epidemiology of glaucoma and the care process including&amp;nbsp;diagnosis and management.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=102" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=102" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=102" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101753</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-5.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Patient with Primary Angle Closure Glaucoma</title>
    <publicationDate>1998-10-01T00:00:00</publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on care of the patient with&amp;nbsp;Primary Angle Closure Glaucoma&amp;nbsp;published by the American Optometric Association (AOA) in 1994, revised&amp;nbsp;October 1999 and reviewd in 2001.&amp;nbsp;&amp;nbsp; The guideline contains two main sections together with conclusions and references.&amp;nbsp; The first section is a statement of the problem including a description and classification of primary angle closure glaucoma, epidemiology and clinical background.&amp;nbsp; The second is about the care process including diagnosis (patient history, ocular examination,&amp;nbsp;provocative testing and assessment) and management (basis for treatment, treatment options, recommended management protocol, patient education, prognosis and management of patients with severe, irreversible vision loss).&amp;nbsp;&amp;nbsp; There are three appendices, optometric management of the patient with acute primary ACG, frequency and composition of evaluation and management visits and the ICD-9-CM classification of Angle Closure Glaucoma.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=101" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=101" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=101" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101754</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-13.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Patient with Retinal Detachment and Periperhal Vitreoretinal Disease</title>
    <publicationDate>1999-06-01T00:00:00</publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RETINAL TEARS AND DETACHMENT,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on care of the patient with&amp;nbsp;Retinal Detachment and Peripheral Vitreoretinal Disease&amp;nbsp;published by the American Optometric Association (AOA) in 1995, revised&amp;nbsp;in 1999 and reviewed in 2004.&amp;nbsp;&amp;nbsp; The guideline contains two main sections together with conclusions and references.&amp;nbsp;&amp;nbsp; The first section is a statement of the problem including a description,&amp;nbsp;classification and epidemiology of retinal detachment, retinal breaks&amp;nbsp;and related peripheral vitreoretinal disease, followed by the clinical background of retinal breaks and detachment.&amp;nbsp; The second section concerns&amp;nbsp;the care process including diagnosis (patient history, ocular examination, supplemental testing) and management (management strategies, patient education, prognosis and management of patients with severe, irreversible vision loss).&amp;nbsp;&amp;nbsp;&amp;nbsp; There are&amp;nbsp;four appendices, optometric management of the patient with peripheral vitreoretinal disease and&amp;nbsp;retinal detachment, frequency and composition of evaluation and management visits and the ICD-9-CM classification.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=106" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=106" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=106" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101755</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-12.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Care of the Patient with Strabismus: Esotropia and Exotropia</title>
    <publicationDate>1999-06-01T00:00:00</publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,STRABISMUS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on care of the patient with&amp;nbsp;Strabismus: Esotropia and Exotropia&amp;nbsp;published by the American Optometric Association (AOA) in 1995, revised 1999 and reviewed in 2004.&amp;nbsp; The guideline contains two main sections together with conclusions and references.&amp;nbsp; The first section is a statement of the problem including a description and classification of strabismus, epidemiology and clinical background.&amp;nbsp;&amp;nbsp; The second is about the care process including diagnosis (patient history, ocular examination) and management (basis for treatment, treatment options, patient education,&amp;nbsp;management strategies and prognosis).&amp;nbsp; There are three appendices, optometric management of the patient with strabismus, frequency and composition of evaluation and management visits and the ICD-9-CM Classification of Esotropia and Exotropia.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=56" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=56" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=56" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89303</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-1.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guideline: Comprehensive Adult Eye and Vision Examination</title>
    <publicationDate></publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NHS CORE CONTENT WITHOUT A CATEGORY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on&amp;nbsp;comprehensive adult eye and vision examination&amp;nbsp;published by the American Optometric Association (AOA) in 1997 and revised in 2002 and 2005.&amp;nbsp;&amp;nbsp;The guideline contains&amp;nbsp;3 main sections, conclusion and references.&amp;nbsp; The first&amp;nbsp;section is a statement of the problem&amp;nbsp;including epidemiology, the second&amp;nbsp;is about the care process including detection and prevention, examination sequence, patient history, visual acuity, preliminary testing, refraction, ocular motility, ocular health assessment,&amp;nbsp;screening and&amp;nbsp;diagnosis and&amp;nbsp;the&amp;nbsp;third section is about&amp;nbsp;management of adults.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=112" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=112" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=112" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89327</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.aoa.org/documents/CPG-2.pdf]]&gt;</url>
    <title>Optometric Clinical Practice Guidelines: Pediatric Eye and Vision Examination</title>
    <publicationDate></publicationDate>
    <publisher>American Optometric Association (AOA)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NHS CORE CONTENT WITHOUT A CATEGORY,REFRACTIVE ERROR,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Optometric Clinical Practice Guideline on&amp;nbsp;pediatric eye and vision&amp;nbsp;examination&amp;nbsp;published by the American Optometric Association (AOA) in April 2002 (second edition).&amp;nbsp;&amp;nbsp;The guideline contains&amp;nbsp;two main sections, the&amp;nbsp; first&amp;nbsp;section being a statement of the problem&amp;nbsp;including epidemiology.&amp;nbsp; The second,&amp;nbsp;the care process, is subdivided into four categories, examination of infants and toddlers, of preschool children, school age children and the management of children.&amp;nbsp;&amp;nbsp;&amp;nbsp;Each of these sections then explains the general considerations, early detection and prevention and the examination sequence (patient history, visual acuity, refraction, binocular vision, ocular health assessment and systemic health screening and diagnosis). &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=113" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=113" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=113" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311293</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14522788]]&gt;</url>
    <title>Orbital implants in enucleation surgery: a report by the American Academy of Ophthalmology.</title>
    <publicationDate></publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2003 Oct;110(2054-61).&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To compare prosthetic and implant motility and the incidence of complications associated with porous and nonporous enucleation implants. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Literature searches conducted in January 2002 for 1985 to 2001 and May 2002 for October 2001 to 2002 retrieved relevant citations. The searches were conducted in MEDLINE and limited to articles published in English with abstracts. Panel members reviewed the articles for relevance to the assessment questions, and those considered relevant were rated according to the strength of the evidence. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;A randomized clinical trial and a longitudinal cohort study detected no difference in implant or prosthetic movement between nonpegged hydroxyapatite porous and spherical alloplastic nonporous implants. No controlled studies were retrieved that investigated whether pegging porous implants improves prosthetic movement. Several case series indicate that patients with pegged hydroxyapatite implants have some degree of improved prosthetic motility. Longitudinal cohort studies show that sclera-covered hydroxyapatite implants have higher exposure rates than sclera-covered silicone implants, and unwrapped porous polyethylene implants have higher exposure rates than unwrapped acrylic implants. There are numerous case series that document a wide range of implant exposure rates in patients with various enucleation implants. It is difficult to compare complication rates among implant types because patient populations vary, surgical techniques differ, and follow-up periods are often limited. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Based on one randomized clinical trial, spherical alloplastic nonporous and nonpegged porous enucleation implants provide similar implant and prosthetic motility when they are implanted using similar surgical techniques. Coupling the prosthesis to a porous implant with a motility peg or post appears to improve prosthetic motility, but there are few available data in the literature that document the degree of the improvement. There is a widely variable incidence of porous implant exposure, but certain surgical techniques and the type of wrapping material seem to reduce the exposure rate. Additional research is needed to document the long-term incidence of complications related to porous enucleation implants and associated surgical techniques. This includes the use of wrapping materials and what procedural modifications, both surgical and prosthetic, are most effective in reducing these complications.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=200" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311295</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18082885]]&gt;</url>
    <title>Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology.</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ ENT AND AUDIOLOGY,EYES AND VISION,THYROID &amp; PARATHYROID DISORDERS,CONDITIONS,THERAPEUTIC INTERVENTIONS,NON-DRUG TREATMENTS,GRAVES' DISEASE,HYPERTHYROIDISM,CONDITIONS,ORBIT,SYSTEMATIC REVIEWS,RADIOTHERAPY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: Ophthalmology 2008 Feb;115(2):398-409&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To investigate whether orbital radiation offers effective and safe treatment for Graves ophthalmopathy. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Medical literature databases were searched to identify all published reports relating to orbital radiation treatment for Graves ophthalmopathy. To be included in the technology assessment, reports had to provide original data, to report on a case series or uncontrolled trial of at least 100 subjects or a randomized clinical trial of any size, to focus on orbital radiation for the treatment of Graves ophthalmopathy, and to follow-up patients for at least 3 months. Abstracted data included study characteristics, patient characteristics, treatment response, and safety information. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Fourteen studies were included in the technology assessment: 5 observational studies and 9 randomized controlled trials. Three of the observational studies report on treatment response, with overall favorable outcomes for 40% to 97% of patients. Three of the observational studies provided intermediate-term safety data. The risk of definite radiation retinopathy is 1% to 2% within 10 years after treatment. Patients treated with orbital radiation did not have an increased risk of secondary malignancy or premature death. The 9 randomized trials were qualitatively heterogeneous. Patients with optic neuropathy generally were excluded from participating in the randomized trials. Three of the randomized trials were sham controlled. None of these studies showed that orbital radiation was more efficacious than sham irradiation for improving proptosis, lid fissure, or soft tissue changes such as eyelid swelling. Two of the 3 sham-controlled randomized trials demonstrated improved vertical range of motion in radiation-treated subjects compared with controls. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Systematic review of the effect of orbital radiation on Graves ophthalmopathy is limited by the lack of standardization and variable quality of published reports. Extraocular motility impairment may improve with radiotherapy, although the evidence of a treatment effect is mixed in clinical trials. Future studies are needed to determine if a potentially beneficial motility effect results in improved patient function and quality of life. Level I evidence indicates that proptosis, eyelid retraction, and soft tissue changes do not improve with radiation treatment. The efficacy of orbital radiation for compressive optic neuropathy resulting from Graves ophthalmopathy has not been investigated in clinical trials and merits further study. Radiation retinopathy, although rare, is a risk of orbital radiation, even in patients without diabetes who receive appropriate radiation dose and delivery.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=59" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311296</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18716964]]&gt;</url>
    <title>Orbital tuberculosis: a review of the literature.</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Orbit</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ORBIT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: &lt;SPAN title="Orbit (Amsterdam, Netherlands)."&gt;Orbit&lt;/SPAN&gt; 2008;27(4):267-77&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To provide an up-to-date review of the clinical presentations, investigations, and management of orbital tuberculosis (OTB). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Systematic review of the literature concerning OTB, limiting the results to English-language peer-reviewed journals. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Seventy-nine patients from 39 publications were identified as cases of OTB. The condition presents in one of five forms: classical periostitis; orbital soft tissue tuberculoma or cold abscess, with no bony involvement; OTB with bony involvement; spread from the paranasal sinuses; and tuberculous dacryoadenitis. The ocular adnexa, including the nasolacrimal system and overlying skin, may also be involved. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Diagnosis can be difficult and may necessitate an orbital biopsy, in which acid-fast bacilli (AFB) and characteristic histopathology may be seen. Growth of Mycobacterium tuberculosis (mTB) from such a specimen remains the gold standard for diagnosis. Ancillary investigations include tuberculin skin tests and chest radiography, but more recently alternatives such as whole blood interferon-gamma immunological tests and PCR-based tests of pathological specimens have proven useful. The management of OTB is complex, requiring a stringent public health strategy and high levels of patient adherence, combined with long courses of multiple anti-tuberculous medications. The interaction of the human immunodeficiency virus (HIV) with TB may further complicate management.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=86" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101272</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.wihrd.soton.ac.uk/projx/signpost/steers/STEER_2001(6).pdf]]&gt;</url>
    <title>Osteo-odonto-keratoprosthesis</title>
    <publicationDate>2001-06-01T00:00:00</publicationDate>
    <publisher>Wessex Institute for Health Research &amp; Development</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CORNEA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is a Succinct and Timely Evaluation Evidence Review (STEER) on Osteo-odonto-keratoprosthesis&amp;nbsp;published in June 2001 by the Wessex Institute&amp;nbsp;for Health Research and Development&amp;nbsp;together with Bazian Ltd.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The&amp;nbsp;STEER service aims to provide policy makers with&amp;nbsp;short evidence-based&amp;nbsp;reviews&amp;nbsp;answering a&amp;nbsp;focused question within an 8 to 10 week period.&amp;nbsp; It is an on-demand reviewing service,&amp;nbsp;mainly descriptive in nature which surveys and reports on a large number of sources of evidence.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The reports contain a summary, background information,&amp;nbsp;search strategies, evidence found, study results and conclusions.&amp;nbsp; References are given.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=253" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=253" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=253" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102067</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1407968&amp;query_hl=49]]&gt;</url>
    <title>Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group.</title>
    <publicationDate>1992-09-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Sep 1992, vol. 99, no. 9, p. 1351-7, ISSN: 0161-6420.&lt;/EM&gt;&lt;BR&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: The Early Treatment Diabetic Retinopathy Study (ETDRS) enrolled 3711 patients with mild-to-severe nonproliferative or early proliferative diabetic retinopathy in both eyes. Patients were randomly assigned to aspirin 650 mg/day or placebo. One eye of each patient was assigned randomly to early photocoagulation and the other to deferral of photocoagulation. Follow-up examinations were scheduled at least every 4 months, and photocoagulation was initiated in eyes assigned to deferral as soon as high-risk proliferative retinopathy was detected. Aspirin was not found to have an effect on retinopathy progression or rates of vitreous hemorrhage. The risk of a combined end point, severe visual loss or vitrectomy, was low in eyes assigned to deferral (6% at 5 years) and was reduced by early photocoagulation (4% at 5 years). Vitrectomy was carried out in 208 patients during the 9 years of the study. This report presents baseline and previtrectomy characteristics and visual outcome in these patients. &lt;/P&gt;
&lt;P&gt;METHODS: Information collected at baseline and during follow-up as part of the ETDRS protocol was supplemented by review of clinic charts for visual acuity and ocular status immediately before vitrectomy. &lt;/P&gt;
&lt;P&gt;RESULTS: Vitrectomy was performed in 208 (5.6%) of the 3711 patients (243 eyes) enrolled in the ETDRS. The 5-year vitrectomy rates for eyes grouped by their initial photocoagulation assignment were as follows: 2.1% in the early full scatter photocoagulation group, 2.5% in the early mild scatter group, and 4.0% in the deferral group. The 5-year rates of vitrectomy (in one or both eyes) were 5.4% in patients assigned to aspirin and 5.2% in patients assigned to a placebo. The indications for vitrectomy were either vitreous hemorrhage (53.9%) or retinal detachment with or without vitreous hemorrhage (46.1%). Before vitrectomy, visual acuity was 5/200 or worse in 66.7% of eyes and better than 20/100 in 6.2%. One year after vitrectomy, the visual acuity was 20/100 or better in 47.6% of eyes, including 24.0% with visual acuity of 20/40 or better. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: With frequent follow-up examinations and timely scatter (panretinal) photocoagulation, the 5-year cumulative rate of pars plana vitrectomy in ETDRS patients was 5.3%. Aspirin use did not influence the rate of vitrectomy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102063" target="_blank"&gt;Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=10&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102064" target="_blank"&gt;Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102065" target="_blank"&gt;Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102066" target="_blank"&gt;Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102068" target="_blank"&gt;Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2740076&amp;amp;query_hl=73" target="_blank"&gt;Detection of diabetic macular edema. Ophthalmoscopy versus photography--Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8287162&amp;amp;query_hl=73" target="_blank"&gt;C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062510&amp;amp;query_hl=102" target="_blank"&gt;Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062511&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062514&amp;amp;query_hl=73" target="_blank"&gt;Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062515&amp;amp;query_hl=73" target="_blank"&gt;Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062516&amp;amp;query_hl=73" target="_blank"&gt;Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1507375&amp;amp;query_hl=113" target="_blank"&gt;Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10577530&amp;amp;query_hl=108" target="_blank"&gt;Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1543449&amp;amp;query_hl=94" target="_blank"&gt;Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9477980&amp;amp;query_hl=106" target="_blank"&gt;Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7661748&amp;amp;query_hl=73" target="_blank"&gt;Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7826294&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8790092&amp;amp;query_hl=91" target="_blank"&gt;Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9230827&amp;amp;query_hl=73" target="_blank"&gt;Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10604663&amp;amp;query_hl=94" target="_blank"&gt;Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15735198&amp;amp;query_hl=97" target="_blank"&gt;Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8545570&amp;amp;query_hl=100" target="_blank"&gt;Accommodative amplitudes in the Early Treatment Diabetic Retinopathy Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386347</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/Partial-success-for-lab-grown-corneas.aspx]]&gt;</url>
    <title>'Partial success' for lab-grown corneas</title>
    <publicationDate>2010-08-26T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Millions of blind and partially sighted people are being given hope they will see again after artificial corneas were successfully ‘grown’ in eyes,” the Daily Express reported.&lt;/P&gt;
&lt;P&gt;This research was in 10 patients with disease of the cornea, a major cause of blindness worldwide. The patients were the first to be fitted with corneas made from biosynthetic tissue rather than conventional human donor corneas. Two years after surgery, all the implanted corneas were still viable, with no serious reactions or complications. Six of the patients had better vision than before their surgery.&lt;/P&gt;
&lt;P&gt;It is important to point out that although the results are promising, this was an early, experimental study. Far more research in much larger numbers of patients is needed before it is known if synthetic corneal implants are a viable alternative to donor corneas. The results were not all positive and the vision in these patients was still significantly poorer compared to that in patients who had corneas from human donors (although the results were similar once the 10 patients were fitted with contact lenses).&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This small early stage study found that biosynthetic corneal tissue implanted into 10 patients remained viable two years after surgery, without causing serious complications or side effects. The implants also improved vision in some patients although results were significantly poorer when compared to patients who had donor implants (until contact lenses were used). Some patients experienced problems after surgery, which reduced the potential improvements in vision.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/Partial-success-for-lab-grown-corneas.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Fagerholm P, Lagali NS, Merrett K, et al.&amp;nbsp;&lt;A href="http://stm.sciencemag.org/content/2/46/46ra61.abstract" target="_blank"&gt;A Biosynthetic Alternative to Human Donor Tissue for Inducing Corneal Regeneration: 24-Month Follow-Up of a Phase 1 Clinical Study.&lt;/A&gt; Sci Transl Med 2010; 46; 46ra61&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>311298</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17475698]]&gt;</url>
    <title>Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2007 Sep;91(9):1177-82. Epub 2007 May 2&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIMS: &lt;/STRONG&gt;To assess the clinical effectiveness of pegaptanib sodium and ranibizumab for neovascular age-related macular degeneration (AMD). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A systematic review of randomised controlled trials (RCTs) identified through searching 12 electronic databases, bibliographies and consultation with experts and manufacturers. RCTs were eligible if they assessed the effects of pegaptanib or ranibizumab with best supportive care, sham injection or photodynamic therapy (PDT) on patients with subfoveal choroidal neovascularisation associated with wet AMD and examined outcomes including visual acuity and adverse events. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Three RCTs of ranibizumab (MARINA, ANCHOR, FOCUS) and two of pegaptanib (VISION study) met the inclusion criteria. The RCTs included patients with different lesion types. The studies showed statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. These differences appeared to be clinically significant. Although adverse events were common among those receiving pegaptanib or ranibizumab, they were considered mild to moderate in nature. Meta-analysis of ranibizumab trials and indirect comparison of the two drugs were not possible due to differences in the study populations' lesion types. However, results from the RCTs of ranibizumab tended to show a greater effect on visual acuity than results from the RCT of pegaptanib. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS: &lt;/STRONG&gt;Pegaptanib and ranibizumab appear to slow or stop the progression of neovascular AMD. Uncertainty remains over the relative benefits of pegaptanib compared with ranibizumab and other unlicensed drugs (eg, Avastin), due to the nature of the evidence. Head-to-head RCTs and economic evaluations comparing these alternatives are needed.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=48" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102063</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2866759&amp;query_hl=43]]&gt;</url>
    <title>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.</title>
    <publicationDate>1985-12-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINOPATHY,RETINA,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology, {Arch-Ophthalmol}, Dec 1985, vol. 103, no. 12, p. 1796-806, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;Data from the Early Treatment Diabetic Retinopathy Study (ETDRS) show that focal photocoagulation of clinically significant diabetic macular edema substantially reduces the risk of visual loss. Focal treatment also increases the chance of visual improvement, decreases the frequency of persistent macular edema, and causes only minor visual field losses. In this randomized clinical trial, which was supported by the National Eye Institute, 754 eyes that had macular edema and mild to moderate diabetic retinopathy were randomly assigned to focal argon laser photocoagulation, while 1,490 such eyes were randomly assigned to deferral of photocoagulation. The beneficial effects of treatment demonstrated in this trial suggest that all eyes with clinically significant diabetic macular edema should be considered for focal photocoagulation. Clinically significant macular edema is defined as retinal thickening that involves or threatens the center of the macula (even if visual acuity is not yet reduced) and is assessed by stereo contact lens biomicroscopy or stereo photography. Follow-up of all ETDRS patients continues without other modifications in the study protocol.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=10&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102064" target="_blank"&gt;Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102065" target="_blank"&gt;Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102066" target="_blank"&gt;Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102067" target="_blank"&gt;Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102068" target="_blank"&gt;Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2740076&amp;amp;query_hl=73" target="_blank"&gt;Detection of diabetic macular edema. Ophthalmoscopy versus photography--Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8287162&amp;amp;query_hl=73" target="_blank"&gt;C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062510&amp;amp;query_hl=102" target="_blank"&gt;Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062511&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062514&amp;amp;query_hl=73" target="_blank"&gt;Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062515&amp;amp;query_hl=73" target="_blank"&gt;Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062516&amp;amp;query_hl=73" target="_blank"&gt;Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1507375&amp;amp;query_hl=113" target="_blank"&gt;Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10577530&amp;amp;query_hl=108" target="_blank"&gt;Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1543449&amp;amp;query_hl=94" target="_blank"&gt;Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9477980&amp;amp;query_hl=106" target="_blank"&gt;Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7661748&amp;amp;query_hl=73" target="_blank"&gt;Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7826294&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8790092&amp;amp;query_hl=91" target="_blank"&gt;Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9230827&amp;amp;query_hl=73" target="_blank"&gt;Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10604663&amp;amp;query_hl=94" target="_blank"&gt;Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15735198&amp;amp;query_hl=97" target="_blank"&gt;Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8545570&amp;amp;query_hl=100" target="_blank"&gt;Accommodative amplitudes in the Early Treatment Diabetic Retinopathy Study.&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&amp;nbsp;&lt;/H2&gt;]]&gt;</body>
  </document>
  <document>
    <id>102388</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7196564&amp;query_hl=6]]&gt;</url>
    <title>Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group.</title>
    <publicationDate>1981-07-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETIC RETINOPATHY,RETINOPATHY,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Jul 1981, vol. 88, no. 7, p. 583-600, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;Additional follow-up confirms previous reports from the Diabetic Retinopathy Study (DRS) that photocoagulation, as used in the study, reduces the risk of severe visual loss by 50% or more. Decreases of visual acuity of one or more lines and constriction of peripheral visual field due to treatment were also observed in some eyes. These harmful effects were more frequent and more severe following the DRS xenon technique. The two-year risk of severe visual loss without treatment outweighs the risk of harmful treatment effects for two groups of eyes: (1) eyes with new vessels and preretinal or vitreous hemorrhage; and (2) eyes with new vessels on or within one disc diameter of the optic disc (NVD) equaling or exceeding 1/4 to 1/3 disc area in extent, (Fig 1), even in the absence of preretinal or vitreous hemorrhage. For eyes with these characteristics, prompt treatment is usually advisable. For eyes with less severe retinopathy, DRS findings do not provide a clear choice between prompt treatment or deferral unless progression to these more severe stages occurs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2912911&amp;amp;query_hl=12" target="_blank"&gt;Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=3658347&amp;amp;query_hl=2" target="_blank"&gt;Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2409053&amp;amp;query_hl=19" target="_blank"&gt;Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=6394209&amp;amp;query_hl=4" target="_blank"&gt;Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7262408&amp;amp;query_hl=6" target="_blank"&gt;Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic retinopathy study report no. 5.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=426679&amp;amp;query_hl=9" target="_blank"&gt;Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=10&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102391" target="_blank"&gt;Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=944535&amp;amp;query_hl=11" target="_blank"&gt;Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102391</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=345173&amp;query_hl=9]]&gt;</url>
    <title>Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings.</title>
    <publicationDate>1978-01-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Jan 1978, vol. 85, no. 1, p. 82-106, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;Data from the Diabetic Retinopathy Study (DRS) show that photocoagulad inhibited the progression of retinopathy. These beneficial effects were noted to some degree in all those stages of diabetic retinopathy which were included in the Study. Some deleterious effects of treatment were also found, including losses of visual acuity and constriction of peripheral visual field. The risk of these harmful effects was considered acceptable in eyes with retinopathy in the moderate or severe retinopathy in the moderate or severe proliferative stage when the risk of severe visual loss without treatment was great. In early proliferative or severe nonproliferative retinopathy, when the risk of severe visual loss without treatment was less, the risks of harmful treatment effects assumed greater importance. In these earlier stages, DRS findings have not led to a clear choice between prompt treatment and deferral of treatment unless and until progression to a more severe stage occurs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2912911&amp;amp;query_hl=12" target="_blank"&gt;Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=3658347&amp;amp;query_hl=2" target="_blank"&gt;Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2409053&amp;amp;query_hl=19" target="_blank"&gt;Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=6394209&amp;amp;query_hl=4" target="_blank"&gt;Assessing possible late treatment effects in stopping a clinical trial early: a case study. Diabetic Retinopathy Study report No. 9.&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=10&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102388" target="_blank"&gt;Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7262408&amp;amp;query_hl=6" target="_blank"&gt;Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic retinopathy study report no. 5.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=426679&amp;amp;query_hl=9" target="_blank"&gt;Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=944535&amp;amp;query_hl=11" target="_blank"&gt;Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79265</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/older/PDTmd.html]]&gt;</url>
    <title>Photodynamic therapy for macular degeneration</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Summary produced&amp;nbsp;by Bandolier on the cost effectiveness of photodynamic therapy on macular degeneration, taking into account&amp;nbsp;type, level of visual acuity and timing of intervention.&amp;nbsp;&amp;nbsp; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372632</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18577193]]&gt;</url>
    <title>Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Acta Ophthalmologica</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Acta Ophthalmologica 2009 Mar;87(2):118-32. Epub 2008 Jun 13. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Photodynamic therapy (PDT) with verteporfin has been used less comprehensively in the treatment of exudative age-related macular degeneration (AMD), and specifically of choroidal neovascularization (CNV), since the advent of antiangiogenic therapies. Recently, there has been a renewed interest in PDT as an adjunct to these and other agents in the treatment of neovascular AMD. In light of this new development and the European Medicines Evaluation Agency's (EMEA) recent labelling decision to rescind approval for the use of PDT in occult CNV lesions, the present systematic review was undertaken to revisit the evidence supporting its clinical application. Photodynamic therapy provided the first pharmacological treatment for patients suffering from subfoveal CNV, the major cause of severe vision loss in AMD. Key clinical trials evaluating efficacy and safety have examined patients with all lesion subtypes, with the primary labelled indication (i.e. lesions containing a classic component of &amp;gt; or = 50% ) deriving from the results of the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study. The subsequent TAP Study Group post hoc categorization of lesions as predominantly classic is open to question, however, as it appears that the overall efficacy in this group only may have reflected the especially strong response in 100% classic lesions. Based on a subgroup analysis of the Verteporfin in Photodynamic Therapy Study, the indication for PDT subsequently was expanded in some jurisdictions, including that of the EMEA, to include occult lesions with no classic component. However, the subsequent Visudyne in Occult Study found no benefit in 100% occult lesions, resulting in the EMEA rescinding its approval for this indication.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click here to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311299</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14736777]]&gt;</url>
    <title>Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review.</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;&lt;SPAN title="The British journal of ophthalmology."&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol)&lt;/SPAN&gt; 2004 Feb;88(2):212-7&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND: &lt;/STRONG&gt;In 2001 the National Institute for Clinical Excellence (NICE) was asked to issue guidance for England and Wales on the use of photodynamic therapy (PDT). This process has been protracted, partly because of a dispute over the magnitude of beneficial effect. This article examines the origins of the debate about the true treatment effect size for PDT with verteporfin. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic review of the clinical effectiveness of PDT compared with current practice was undertaken. Searches in Medline, Embase, the Cochrane Library, and the Internet, updated to January 2003, revealed two fully published and four ongoing randomised controlled trials. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The results of the two published trials (TAP and VIP) consistently showed that overall, PDT with verteporfin is more effective than placebo in slowing the rate of vision loss. In the TAP trial, 12 or more subgroup analyses were undertaken on the primary outcome measure and in VIP, 10 subgroup analyses but only on a subset of the trial participants. Subgroup analysis results were found to be inconsistent between the two trials, with VIP suggesting that verteporfin was equally effective in occult as in mixed lesions and TAP suggesting that verteporfin was more effective in the predominantly classic subgroup. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DISCUSSION:&lt;/STRONG&gt; For several reasons it was considered that the most likely estimate of the predominantly classic subgroup effect size was the whole trial result. This has implications for the relationship between cost and benefit, the subject of intense debate. Results of the ongoing trials should help to clarify this subgroup effect size issue.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=194" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156779</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4131397.pdf]]&gt;</url>
    <title>Practice based commissioning: early wins and top tips</title>
    <publicationDate>2006-02-08T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Clinically focused document published in February 2006 by the Department of Health Primary Care Team.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Examples&amp;nbsp;are provided of how practice based commissioning can be used to redesign patient pathways and improve services and&amp;nbsp;the tips are based on the practice experience of those involved in setting up practice based commissioning.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The document is aimed at medical directors, directors of nursings, allied health professionals and GPs.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89276</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.eyesite.ca/english/program-and-services/policy-statements-guidelines/refractive-surgery-gl.htm]]&gt;</url>
    <title>Practice Guidelines for Refractive Surgery</title>
    <publicationDate></publicationDate>
    <publisher>Canadian Ophthalmological Society</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ REFRACTIVE ERROR,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Practice guidelines on refractive surgery approved by the Board of Directors of the Canadian Ophthalmological Society&amp;nbsp;in June 2000.&amp;nbsp;&amp;nbsp; Following&amp;nbsp;the brief definition of what refractive surgery entails are sections on suitability for surgery, consent, pre-operative ophthalmic testing, post operative care, training requirments, maintenance of equipment and the reporting of adverse reactions. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=98" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=98" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=98" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>95490</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=f413917a-8623-4746-b441-f817265eafb4]]&gt;</url>
    <title>Preferred Practice Pattern - Age Related Macular Degeneration</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ AGE RELATED MACULAR DEGENERATION,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the Preferred Practice Plan for&amp;nbsp;Age Related Macular Degeneration&amp;nbsp;originally published by the American Academy of Ophthalmology in October 2003.&amp;nbsp; It was&amp;nbsp;revised in September 2005,&amp;nbsp; September 2006 and most recently in September 2008. &lt;/P&gt;
&lt;P&gt;Preferred Practice Patterns (PPPs) are designed to identify characteristics and components of quality eye care and have been developed by a panel of experts (the Quality of Care and Knowledge Base Development Secretariat and the PPP Committee) based on the best available scientific data.&amp;nbsp; PPPs provide guidance for the pattern of practice, not for the care of a particular individual.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Each guideline is valid for five years form the date of issue unless it has been superceded by a revision.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=316" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=316" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=316" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>290531</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=930d01f2-740b-433e-a973-cf68565bd27b]]&gt;</url>
    <title>Preferred Practice Pattern - Amblyopia</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ OCULAR MOTILITY,AMBLYOPIA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the Preferred Practice Plan for&amp;nbsp;Amblyopia originally published by the American Academy of Ophthalmology in September 2007.&lt;/P&gt;
&lt;P&gt;Preferred Practice Patterns (PPPs) are designed to identify characteristics and components of quality eye care and have been developed by a panel of experts (the Quality of Care and Knowledge Base Development Secretariat and the PPP Committee) based on the best available scientific data.&amp;nbsp; PPPs provide guidance for the pattern of practice, not for the care of a particular individual.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Each guideline is valid for five years form the date of issue unless it has been superceded by a revision.&amp;nbsp; This guideline is due to be revised in 2012.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=26" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=26" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=26" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>260274</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=a80a87ce-9042-4677-85d7-4b876deed276]]&gt;</url>
    <title>Preferred Practice Pattern - Cataract in the Adult Eye</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CATARACT,LENS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the Preferred Practice Plan for Cataract in the Adult Eye published by the American Academy of Ophthalmology in September 2006.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Preferred Practice Patterns (PPPs) are designed to identify characteristics and components of quality eye care and have been developed by a panel of experts (the Quality of Care and Knowledge Base Development Secretariat and the PPP Committee) based on the best available scientific data.&amp;nbsp; PPPs provide guidance for the pattern of practice, not for the care of a particular individual.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Each guideline is valid for five years form the date of issue unless it has been superceded by a revision.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=363" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=363" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=363" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>290544</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=9d9650fb-39a3-439c-9225-5fbb013cf472]]&gt;</url>
    <title>Preferred Practice Pattern - Conjuntivitis</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ CLINICAL LIBRARY,EMERGENCY CARE,EYES AND VISION,CONJUNCTIVA,CONJUNCTIVITIS,OPHTHALMOLOGY,CONJUNCTIVITIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the Preferred Practice Pattern for&amp;nbsp;Conjunctivitis&amp;nbsp;orginally published by the American Academy of Ophthalmology in January 2006 and revised in September 2008. &lt;/P&gt;
&lt;P&gt;Preferred Practice Patterns (PPPs) are designed to identify characteristics and components of quality eye care and have been developed by a panel of experts (the Quality of Care and Knowledge Base Development Secretariat and the PPP Committee) based on the best available scientific data. &lt;/P&gt;
&lt;P&gt;PPPs provide guidance for the pattern of practice, not for the care of a particular individual. Each guideline is valid for five years from the date of issue unless it has been superceded by a revision. This guideline is due to be revised in 2013.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=12" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=12" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=12" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>290541</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3-219f-487b-a524-326ab3cecd9a]]&gt;</url>
    <title>Preferred Practice Pattern - Diabetic Retinopathy</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DIABETIC RETINOPATHY,RETINA,RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the Preferred Practice Pattern for Diabetic Retinopathy originally published by the American Academy of Ophthalmology in September 2003 and revised in September 2008.&lt;/P&gt;
&lt;P&gt;Preferred Practice Patterns (PPPs) are designed to identify characteristics and components of quality eye care and have been developed by a panel of experts (the Quality of Care and Knowledge Base Development Secretariat and the PPP Committee) based on the best available scientific data. &lt;/P&gt;
&lt;P&gt;PPPs provide guidance for the pattern of practice, not for the care of a particular individual. Each guideline is valid for five years from the date of issue unless it has been superceded by a revision. This guideline is due to be revised in 2013.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=21" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=21" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=21" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89380</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=93019a87-4649-4130-8f94-b6a9b19144d2]]&gt;</url>
    <title>Preferred Practice Pattern - Primary Open Angle Glaucoma</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the Preferred Practice Pattern for Primary Open Angle Glaucoma&amp;nbsp; published by the American Academy of Ophthalmology and revised in October 2010.&lt;/P&gt;
&lt;P&gt;Preferred Practice Patterns (PPPs) are designed to identify characteristics and components of quality eye care and have been developed by a panel of experts (the Quality of Care and Knowledge Base Development Secretariat and the PPP Committee) based on the best available scientific data.&amp;nbsp; PPPs provide guidance for the pattern of practice, not for the care of a particular individual.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Each guideline is valid for five years from the date of issue unless it has been superceded by a revision.&amp;nbsp; This guideline is due to be revised in 2015. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=316" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=316" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=316" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89381</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=e2387c8a-e51c-4c21-be20-c30fbf4f3260]]&gt;</url>
    <title>Preferred Practice Pattern - Primary Open Angle Glaucoma Suspect</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the Preferred Practice Pattern for POAG Suspect&amp;nbsp;published by the American Academy of Ophthalmology and revised in October 2010. &lt;/P&gt;
&lt;P&gt;Preferred Practice Patterns (PPPs) are designed to identify characteristics and components of quality eye care and have been developed by a panel of experts (the Quality of Care and Knowledge Base Development Secretariat and the PPP Committee) based on the best available scientific data. &lt;/P&gt;
&lt;P&gt;PPPs provide guidance for the pattern of practice, not for the care of a particular individual. Each guideline is valid for five years from the date of issue unless it has been superceded by a revision. This guideline is due to be revised in October 2015.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=317" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=317" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=317" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79272</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band74/b74-4.html]]&gt;</url>
    <title>Pre-school vision screening</title>
    <publicationDate>2000-04-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,OCULAR MOTILITY,REFRACTIVE ERROR,LOW VISION,AMBLYOPIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This article published in issue 73 of the Bandolier Journal in April 2000 discusses&amp;nbsp;pre-school vision screening.]]&gt;</body>
  </document>
  <document>
    <id>311301</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17962239]]&gt;</url>
    <title>Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review.</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Annals of the Rheumatic Diseases</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,UVEAL TRACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;SPAN title="Annals of the rheumatic diseases."&gt;Source: Annals of the Rheumatic Diseases (Ann Rheum Dis)&lt;/SPAN&gt; 2008 Jul;67(7):955-9. Epub 2007 Oct 25&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Uveitis is reported to be the most common extra-articular manifestation in spondyloarthritis (SpA); however, its prevalence and characteristics are not well established. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To perform a systematic literature review in order to examine these topics. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic literature analysis was conducted in the Medline database up to October 2006 and in the abstracts of rheumatology scientific meetings for the years 2004, 2005 and 2006. A hand search of references was also performed. Articles were analysed if they reported the prevalence or characteristics of uveitis in SpA. Data abstraction was standardised. Statistical analysis was mainly descriptive. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Among the 957 articles selected by the search, 126 articles (29,877 patients) allowed a calculation of the prevalence of uveitis in SpA; 36 articles (1989 patients) described its characteristics. The mean (SD) prevalence of uveitis was 32.7 (0.5)%; it varied with the type of SpA--for example, 33.2 (0.8)% for ankylosing spondylitis versus 25.1 (2.3)% for psoriatic arthritis. This prevalence increased with mean disease duration and was higher in HLA-B27-positive patients with an odds ratio of 4.2. Uveitis was acute in 88.7 (2.5)%, anterior in 90.5 (2.0)%, unilateral in 87.3 (2.8)%. Recurrence occurred in 50.6 (2.6)% and a reduction of visual acuity was observed in 8.3 (3.8)%. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; The prevalence of uveitis varies with disease duration and according to the type of SpA. Reduction of visual acuity is not exceptional. Because of recent promising data about the effects of anti-tumour necrosis factor therapy on uveitis flares in SpA, it was important to determine this baseline prevalence.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=97" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314346</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/10743299]]&gt;</url>
    <title>Preventing trachoma through environmental santitation: a review of the evidence base</title>
    <publicationDate>2000-02-01T00:00:00</publicationDate>
    <publisher>Bulletin of the World Health Organization</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CORNEA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Bulletin of the World Health Organization (Bull World Health Organ) 2000;78(2):258-66&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;A review of the available evidence for the associations between environmental sanitation and transmission of trachoma was undertaken with a view to identifying preventive interventions. The WHO Global Alliance for the Elimination of Trachoma by the Year 2020 (GET2020) has adopted the "SAFE" strategy, consisting of four components: Surgery, Antibiotic treatment, promotion of Facial cleanliness and initiation of Environmental changes. This review of 19 studies selected from the 39 conducted in different parts of the world shows that there is clear evidence to support the recommendation of facial cleanliness and environmental improvements (i.e. the F and E components of the SAFE strategy) to prevent trachoma. Person-to-person contact and flies appear to constitute the major transmission pathways. Improvement of personal and community hygiene has great potential for a sustainable reduction in trachoma transmission. Controlled clinical trials are needed to estimate the relative contribution of various elements to the risk of transmission of trachoma and the effectiveness of different interventions. These could show the relative attributable risks and effectiveness of interventions to achieve improvement of personal hygiene and fly control by environmental improvements, alone or in combination, and with or without antibiotic treatment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=3" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320844</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_103091.pdf]]&gt;</url>
    <title>Primary Care and Community Services: Improving eye health services</title>
    <publicationDate>2009-07-17T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Document published by Department of Health on 17 July 2009. &lt;/P&gt;
&lt;P&gt;This document is part of the ongoing Primary Care and Community Strategy to support the NHS in relation to World Class Commissioning and focuses on eye health services. &lt;/P&gt;
&lt;P&gt;It provides practical advice on how PCTs can: assess their current performance; identify their vision for the future and commission services that meet the needs of their local communities&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101376</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.assoc-optometrists.org/uploaded_files/pdf/primary_eyecare_in_the_community.pdf]]&gt;</url>
    <title>Primary eye care in the community</title>
    <publicationDate>2001-12-01T00:00:00</publicationDate>
    <publisher>Association of Optometrists (AOP)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Publication produced by the Association of Optometrists in December 2001 describing the role of optometrists in relation to eye care in the community&amp;nbsp;-what optometrists can offer Healthcare Commissioners and patients.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This publication has been updated by &lt;A href="nelh:321455:0" name=internalLink&gt;Primary&amp;nbsp;eye care in the community - a proposal for enhanced services - 2008&lt;/A&gt; however it does provide a useful summary of the skills optometrists can bring to the community. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=260" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=260" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=260" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321455</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.assoc-optometrists.org/uploaded_files/napc_joint_proposal_april_2008.pdf]]&gt;</url>
    <title>Primary eye care in the community - a proposal for enhanced services 2008</title>
    <publicationDate>2008-04-04T00:00:00</publicationDate>
    <publisher>Association of Optometrists (AOP)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ LOW VISION,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Publication updated by the AOP on behalf of ABDO, FODO and the LOC Support Unit and published in 2008.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The document is a general statement of what optometrists can do to develop community eye care. &lt;/P&gt;
&lt;P&gt;The original 2001 document on primary eye care in the community can be accessed here. &lt;/P&gt;&lt;A href="nelh:101376:0" name=internalLink&gt;
&lt;P&gt;Primary care in the community 2001&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=443" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=443" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=443" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293757</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.orthoptics.org.uk/members/BIOS_Diagramatic_OM_testing.pdf]]&gt;</url>
    <title>Professional papers no 2: guidelines for the diagrammatic documentation of strabismus</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>British and Irish Orthoptic Society (BIOS)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,STRABISMUS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Guideline published by the Professional Development Committee of the British and Irish Orthoptic Society (BIOS) in February 2008. &lt;/P&gt;
&lt;P&gt;The document outlines the approach to diagrammatic documentation of orthoptic findings recommended by BIOS. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=422" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=422" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=422" target="_blank"&gt;NO&lt;/A&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=422" target="_blank"&gt;&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>305528</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.orthoptics.org.uk/Info_for_returners_2007_final.pdf]]&gt;</url>
    <title>Professional papers no 3: information for orthoptists returning to practice</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>British and Irish Orthoptic Society (BIOS)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ OCULAR MOTILITY,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document was produced by British and Irish Orthoptic Society in February 2008.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The document offers advice on how orthoptists returning to work can bring themselves up to date and introduces concepts which may be new to those who have been away from practice including:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;continuing professional development 
&lt;LI&gt;the Knowledge and Skills Framework 
&lt;LI&gt;clinical governance&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Information is also provided on the Health Professions Council, the Health and Social Care Professions Council and the British and Irish Orthoptic Society. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=436" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=436" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=436" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289780</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.orthoptics.org.uk/orthoptists/ResearchDocument2008.pdf]]&gt;</url>
    <title>Professional papers no 4: research activities guidelines</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>British and Irish Orthoptic Society (BIOS)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document was produced by British and Irish Orthoptic Society in May 2008.&amp;nbsp;&amp;nbsp; It provides information for orthoptists about research matters including&amp;nbsp;undertaking research, research study, professional integrity, research related misconduct, copyright, intellectual property, protecting authenticity and publications.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=405" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=405" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=405" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289781</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.orthoptics.org.uk/orthoptists/Researchstrategy08_2_.pdf]]&gt;</url>
    <title>Professional papers no 5: research strategy</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>British and Irish Orthoptic Society (BIOS)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ OCULAR MOTILITY,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Professional&amp;nbsp;paper produced by the British and Irish Orthoptic Society (BIOS) in May 2008 on&amp;nbsp;the&amp;nbsp;research strategy employed by BIOS.&amp;nbsp;&amp;nbsp; The strategy highlights research targets for orthoptists and the supporting documentation that is available from the profession.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=406" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=406" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=406" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314350</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16809032]]&gt;</url>
    <title>Prognostic factors for progression of childhood optic pathway glioma: a systematic review</title>
    <publicationDate>2006-08-01T00:00:00</publicationDate>
    <publisher>European Journal of Cancer</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OPTIC NERVE AND VISUAL PATHWAYS,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: European Journal of Cancer (Eur J Cancer) 2006 Aug;42(12):1807-16. Epub 2006 Jun 30&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;A systematic literature review was carried out to evaluate best existing evidence on prognostic factors for progression of childhood optic pathway glioma. Databases were searched for relevant articles and articles selected independently by two authors. Information about study design, population, treatment, outcome and prognostic analysis were abstracted and the quality of each article was assessed. A total of 23 articles met the inclusion criteria. Many studies had important methodological limitations, regarding external and internal validity. Eleven studies evaluated possible prognostic factors in a multivariate analysis. Three high-quality studies indicated age&amp;lt;1 year as an independent prognostic factor for a worse progression-free survival. Three studies with multivariate analysis, including one high-quality study, found that children with neurofibromatosis type 1 (NF-1) have a better progression-free survival than those without NF-1. Two studies with multivariate analysis found tumour site to be a prognostic factor, both with some methodological limitations. In conclusion, this systematic review demonstrates that only a few of the prognostic factors proposed have been proven to be clinically relevant. Age&amp;lt;1 year is a clear and independent prognostic factor for progression-free survival. Other prognostic factors, such as NF-1, tumour site and others, are suggested, but are still without solid evidence and need further high-quality studies to be clearly proven.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=130" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250838</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16898845&amp;query_hl=7&amp;itool=pubmed_docsum]]&gt;</url>
    <title>Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence</title>
    <publicationDate>2006-08-01T00:00:00</publicationDate>
    <publisher>Pharmaeconomics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Pharmaeconomics, 2006; 24(8):743-50&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This&amp;nbsp;resource&amp;nbsp;was identified during the Glaucoma National Knowledge Week held in November 2006.&amp;nbsp;&amp;nbsp; Please &lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;click here&lt;/A&gt; to view the contents of the week. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PubMed Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;We conducted a systematic review of economic studies of prostaglandin analogues for the treatment of glaucoma to assess the scope of current cost-effectiveness evidence and its relevance to decision-makers. The literature search retrieved 102 studies published before July 2005; after additional hand searching of conference proceedings, 13 full-text articles and 13 abstracts met the inclusion criteria. The reviewers extracted the key characteristics of each of the economic evaluations, and all studies received a grade in five categories to summarise the quality of the study: methodology, transparency, sensitivity, relevance and overall score.The current economic literature is predominantly focused on identifying the short-term direct cost of glaucoma treatment, particularly the precise quantification of glaucoma drug costs. Using the European and US treatment guidelines as a benchmark, it is evident that the current body of literature does not satisfy the needs of decision-makers, although certain studies provide some valuable information, which is a step towards reaching this goal.The main methodological issue in the economic models is an absence of a clinically relevant long-term effectiveness measure, or where this measure is produced, there is a lack of transparency and validation of the methods used. More attention needs to be given to modelling the consequences of treatment, and those consequences should include patient compliance, control of intraocular pressure and progression of visual field deficit, since these drive both the costs and the overall outcomes.We recognise that constructing the 'ideal' clinical outcome measure represents a major challenge to researchers. As such, we have outlined a modelling framework that could be used to produce the required level of economic evidence, and ongoing clinical research (such as the Early Manifest Glaucoma Trial) could provide the validated link between intraocular pressure and disease progression, which forms an essential part of such models.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=129" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314362</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15228503]]&gt;</url>
    <title>Psychometric properties of vision-related quality of life questionnaires: a systematic review</title>
    <publicationDate>2004-07-01T00:00:00</publicationDate>
    <publisher>Ophthalmic &amp; Physiological Optics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,LENS,CATARACT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmic &amp;amp; Physiological Optics (Ophthalmic Physiol Opt) 2004 Jul:24(4):257-73.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The increased attention for quality of life (QOL) as an outcome measure has led to the development of numerous questionnaires to assess this construct in the field of ophthalmology. This article presents a systematic review on QOL questionnaires for people with vision impairments. We systematically searched and selected the literature. Furthermore, a rating list with descriptive aspects (e.g. target population) and psychometric aspects (e.g. reproducibility) was developed. The 31 questionnaires that were included in the review were rated on the basis of criteria stated in this rating list. The questionnaires were mostly targeted at cataract patients or visually impaired persons in general. Only a few of the questionnaires demonstrated sufficient psychometric quality. A recent development is the (re-)evaluation of questionnaires with Rasch analysis. This is one of the most important issues to which future research in this field should be directed.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=183" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>259745</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.qualityinoptometry.co.uk/]]&gt;</url>
    <title>Quality in Optometry: A Toolkit for Clinical Governance in Optometric Practice</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Association of Optometrists (AOP)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,REFRACTIVE ERROR,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In February 2007 the Association of Optometrists together with ABDO, the College of Optometrists and FODO&amp;nbsp;published a Clinical Governance Toolkit. &lt;/P&gt;
&lt;P&gt;The toolkit was updated in&amp;nbsp;Spring 2008&amp;nbsp;and it is&amp;nbsp;now only available online through a fully interactive&amp;nbsp;website.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In 2010 an Information Governance audit was released as the latest addition to this range of tools.&amp;nbsp; Practical help and advice are provided together with links to supporting documents and websites to enable practitioners to establish a clinical governance routine to suit their requirements.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The toolkit is based on the NHS Standards for Better Health&amp;nbsp;and has been developed by and for optometry with the intention that practices use the toolkit to assess themselves.&amp;nbsp; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386361</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcophth.ac.uk/page.asp?section=444&amp;sectionTitle=Quality+Standards]]&gt;</url>
    <title>Quality standards self-assessment tools - cataract, glaucoma, diabetic retinopathy (England, Wales and Northern Ireland), diabetic retinopathy (Scotland), age-related macular degeneration (AMD) and vitreoretinal surgery</title>
    <publicationDate>2010-08-25T00:00:00</publicationDate>
    <publisher>The Royal College of Ophthalmologists</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,RETINA,LENS,AGE RELATED MACULAR DEGENERATION,RETINOPATHY,CATARACT,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Royal College of Ophthalmologists's Quality Standards Group has produced a suite of simple self-assessment tools in draft form for the following clinical services: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;SPAN style="FONT-SIZE: 7.5pt"&gt;&lt;A title="Cataract Quality Standards" href="http://www.rcophth.ac.uk/core/core_picker/download.asp?id=622" target="_blank"&gt;&lt;FONT color=#800080&gt;cataract&lt;/FONT&gt;&lt;/A&gt;, &lt;/SPAN&gt;
&lt;LI&gt;&lt;SPAN style="FONT-SIZE: 7.5pt"&gt;&lt;A title="Glaucoma Quality Standards" href="http://www.rcophth.ac.uk/core/core_picker/download.asp?id=626" target="_blank"&gt;&lt;FONT color=#244f82&gt;glaucoma&lt;/FONT&gt;&lt;/A&gt;, &lt;/SPAN&gt;
&lt;LI&gt;&lt;SPAN style="FONT-SIZE: 7.5pt"&gt;&lt;A title="DR Quality Standards Eng, Wales, NI" href="http://www.rcophth.ac.uk/core/core_picker/download.asp?id=623" target="_blank"&gt;&lt;FONT color=#244f82&gt;diabetic retinopathy&lt;/FONT&gt;&lt;/A&gt; (England, Wales and Northern Ireland), &lt;/SPAN&gt;
&lt;LI&gt;&lt;SPAN style="FONT-SIZE: 7.5pt"&gt;&lt;A title="DR Quality Standards Scotland" href="http://www.rcophth.ac.uk/core/core_picker/download.asp?id=624" target="_blank"&gt;&lt;FONT color=#244f82&gt;diabetic retinopathy&lt;/FONT&gt;&lt;/A&gt; (Scotland), &lt;/SPAN&gt;
&lt;LI&gt;&lt;SPAN style="FONT-SIZE: 7.5pt"&gt;&lt;A title="AMD Quality Standards" href="http://www.rcophth.ac.uk/core/core_picker/download.asp?id=628" target="_blank"&gt;&lt;FONT color=#244f82&gt;age-related macular degeneration&lt;/FONT&gt;&lt;/A&gt; (AMD) and &lt;/SPAN&gt;
&lt;LI&gt;&lt;SPAN style="FONT-SIZE: 7.5pt"&gt;&lt;A title="VR Quality Standards" href="http://www.rcophth.ac.uk/core/core_picker/download.asp?id=627" target="_blank"&gt;&lt;FONT color=#244f82&gt;vitreoretinal surgery&lt;/FONT&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;They do not attempt to assess every aspect of the service in detail, but focus on areas where problems are likely to show where the service is under stress. Very few clinical services will achieve a perfect score, so the questionnaires can be used as quality improvement tools. A questionnaire on children's eye services is also under development by the Paediatric Sub-committee and a draft version is available &lt;A href="mailto:beth.barnes@rcophth.ac.uk" target="_blank"&gt;on request &lt;/A&gt;from the RCOphth.&lt;/P&gt;
&lt;P&gt;Feedback on these draft&amp;nbsp;tools is encouraged. Deadline for feedback 31&lt;SUP&gt;&lt;FONT size=2&gt;st&lt;/FONT&gt;&lt;/SUP&gt; December 2010.&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=496" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=496" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=496" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372620</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18429949]]&gt;</url>
    <title>Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Clinical Endocrinology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NHS CORE CONTENT WITHOUT A CATEGORY,ORBIT,THYROID EYE DISEASE,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Clinical Endocrinology (Oxf). 2008 Dec;69(9):943-50. Epub 2008 Apr 21&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; An association between radioiodine therapy (RAI) for Graves' disease (GD) and the development or worsening of Graves' ophthalmopathy (GO) is widely quoted but there has been no systematic review of the evidence. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;AIMS:&lt;/STRONG&gt; We undertook a systematic review of randomized controlled trials (RCTs) to assess whether RAI for GD is associated with increased risk of ophthalmopathy compared with antithyroid drugs (ATDs) or surgery. We also assessed the efficacy of glucocorticoid prophylaxis in the prevention of occurrence or progression of ophthalmopathy, when used with RAI. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; We identified RCTs regardless of language or publication status by searching six databases and trial registries. Dual, blinded data abstraction and quality assessment were undertaken. Random effects meta-analyses were used to combine the study data. Ten RCTs involving 1136 patients permitted 13 comparisons. Two RCTs compared RAI with ATD. Two RCTs compared RAI with thyroidectomy. Four RCTs compared the use of adjunctive ATD with RAI vs. RAI. Five RCTs examined the use of glucocorticoid prophylaxis with RAI. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; RAI was associated with an increased risk of ophthalmopathy compared with ATD [relative risk (RR) 4.23; 95% confidence interval (CI): 2.04-8.77] but compared with thyroidectomy, there was no statistically significant increased risk (RR 1.59, 95% CI 0.89-2.81). The risk of severe GO was also increased with RAI compared with ATD (RR 4.35; 95% CI 1.28-14.73). Prednisolone prophylaxis for RAI was highly effective in preventing the progression of GO in patients with pre-existing GO (RR 0.03; 95% CI 0.00-0.24). The use of adjunctive ATD with RAI was not associated with any significant benefit on the course of GO. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; RAI for GD is associated with a small but definite increased risk of development or worsening of Graves' ophthalmopathy compared with ATDs. Steroid prophylaxis is beneficial for patients with pre-existing GO.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=255" target="_blank"&gt;here&lt;/A&gt; to view the appraisal&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>286855</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1216.pdf]]&gt;</url>
    <title>Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment programme (HTA)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Systematic review published&amp;nbsp;in NIHR Health Technology Assessment 2008&amp;nbsp;Vol 12 No 16&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; To assess the clinical effectiveness and cost-effectiveness of ranibizumab and pegaptanib for subfoveal choroidal neovascularisation (CNV) associated with wet age-related macular degeneration (AMD). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Electronic databases were searched from inception to September 2006. Experts in the field were consulted and manufacturers’ submissions were examined. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods:&lt;/STRONG&gt; The quality of included studies was assessed using standard methods and the clinical effectiveness data were synthesised through a narrative review with full tabulation of results. A model was developed to estimate the cost-effectiveness of ranibizumab and of pegaptanib (separately), compared with current practice or best supportive care, from the perspective of the NHS and Personal Social Services. Two time horizons were adopted for each model. The first adopted time horizons determined by the available trial data. The second analysis extrapolated effects of treatment beyond the clinical trials, adopting a time horizon of 10 years. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The combined analysis of two randomised controlled trials (RCTs) of pegaptanib [0.3 mg (licensed dose), 1.0 mg and 3.0 mg] versus sham injection in patients with all lesion types was reported by three publications (the VISION study). Three published RCTs of ranibizumab were identified (MARINA, ANCHOR, FOCUS), and an additional unpublished RCT was provided by the manufacturer (PIER). Significantly more patients lost less than 15 letters of visual acuity at 12 months when taking pegaptanib (0.3 mg: 70% of patients; 1.0 mg: 71% of patients; 3.0 mg: 65% of patients) or ranibizumab (0.3 mg: 94.3–94.5%; 0.5 mg: 94.6–96.4%) than sham injection patients (55% versus pegaptanib and 62.2% versus ranibizumab) or, in the case of ranibizumab, photodynamic therapy (PDT) (64.3%). The proportion of patients gaining 15 letters or more (a clinically important outcome having a significant impact on quality of life) was statistically&lt;BR&gt;significantly greater in the pegaptanib group for doses of 0.3 and 1.0 mg but not for 3.0 mg, and for all ranibizumab groups compared to the sham injection groups or PDT. This was also statistically significant for patients receiving 0.5 mg ranibizumab plus PDT compared with PDT plus sham injection. Pegaptanib patients lost statistically significantly fewer letters after 12 months of treatment than the sham group [mean letters lost: 7.5 (0.3 mg), 6.5 (1.0 mg) or 10 (3.0 mg) vs 14.5 (sham)]. In the MARINA and ANCHOR trials, ranibizumab patients gained letters of visual acuity at 12 months whereas patients with sham injection or PDT lost about 10 letters (p &amp;lt; 0.001) and in the PIER study, ranibizumab patients lost significantly fewer than the sham injection group. Significantly fewer patients receiving pegaptanib or ranibizumab deteriorated to legal blindness compared with the control groups. Adverse events were common for both pegaptanib and ranibizumab but most were mild to moderate. Drug costs for 1 year of treatment were estimated as £4626 for pegaptanib and £9134 for ranibizumab. Nondrug costs accounted for an additional £2614 for pegaptanib and £3120 for ranibizumab. Further costs are associated with the management of injection related adverse events, from £1200 to £2100. For pegaptanib compared with usual care, the incremental cost-effectiveness ratio (ICER) ranged from £163,603 for the 2-year model to £30,986 for the 10-year model. Similarly, the ICERs for ranibizumab for patients with minimally classic and occult no classic lesions, compared with usual care, ranged from £152,464 for the 2-year model to £25,098 for the 10-year model. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Patients with AMD of any lesion type benefit from treatment with pegaptanib or ranibizumab on measures of visual acuity when compared with sham injection and/or PDT. Patients who continued treatment with either drug appeared to maintain benefits after 2 years of follow-up. When comparing pegaptanib and ranibizumab, the evidence was less clear due to the lack of direct comparison through head-to-head trials and the lack of opportunity for indirect statistical comparison due to heterogeneity. The cost-effectiveness analysis showed that the two drugs offered additional benefit over the comparators of usual care and PDT but at increased cost. Future research should encompass trials to compare pegaptanib with ranibizumab and bevacizumab, and to investigate the role of verteporfin PDT in combination with these drugs. Studies are also needed to assess adverse events outside the proposed RCTs, to consider the optimal dosing regimes of these drugs and the benefits of re-treatment after initial treatment, and to review costing in more detail. Health state utilities and their relationship with visual acuity and contrast sensitivity, the relationship between duration of vision loss and the quality of life and functional impact of vision loss, behavioural studies of those genetically at risk are other topics requiring further research.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314368</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18035187]]&gt;</url>
    <title>Ranibizumab for the treatment of neovascular age-related macular degeneration: a review</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Clinical Therapeutics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Clinical Therapeutics (Clin Ther) 2007 Sep;29(9):1850-61.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Choroidal neovascular (wet) age-related macular degeneration (ARMD) is becoming more prevalent worldwide as life expectancy continues to increase. Ranibizumab for intravitreal injection is an inhibitor of human vascular endothelial growth factor A approved by the US Food and Drug Administration for the treatment of ARMD in June 2006. The actions of ranibizumab result in reduced cell proliferation, reduced formation of new blood vessels, and minimization of vascular leakage. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; This paper reviews the pharmacologic and pharmacokinetic properties, clinical efficacy, and safety profile of ranibizumab, and pharmacoeconomic considerations associated with its use. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; MEDLINE (1966-December 2006) and International Pharmaceutical Abstracts (1970-December 2007) were searched for original research studies (Phase I, II, III, and IIIb), abstracts, and review articles concerning ranibizumab. The search terms were choroidal neovascularization, macular degeneration, Lucentis, ranibizumab, retinal degeneration, and vascular endothelial growth factor. Preference was given to Phase IlfllI studies. Selected information from the manufacturer of ranibizumab was also included. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The efficacy of ranibizumab has been studied in 3 large clinical trials having the same primary efficacy end point, the proportion of patients losing &amp;lt;15 letters from baseline at 12 months (Early Treatment of Diabetic Retinopathy Study chart). A multicenter, Phase III, randomized, double-blind, sham-controlled, 24-month clinical trial evaluated ranibizumab 0.3 and 0.5 mg in 716 patients with minimally classic or occult choroidal neovascularization (CNV) associated with ARMD. The results for the primary efficacy end point were 94.5% and 94.6% in the ranibizumab 0.3- and 0.5-mg groups, respectively, compared with 62.2% in the sham-injection group (P &amp;lt; 0.001, both ranibizumab groups vs sham injection); at 24 months, the corresponding proportions were 92.0%, 90.0%, and 52.9% (P &amp;lt; 0.001, both ranibizumab groups vs sham injection). A 2-year, Phase I/II, single-masked (masked patient and visual acuity examiner, unmasked investigator), multicenter trial evaluated the tolerability and efficacy of the combination of ranibizumab 0.5 mg and verteporfin photodynamic therapy (PDT) compared with verteporfin PDT alone in 162 patients with predominantly classic CNV. For the primary efficacy end point, the results were 90.5% for ranibizumab + PDT and 67.9% for PDT alone (P &amp;lt; 0.001). Receipt of ranibizumab + PDT was also associated with improved visual acuity, with 23.8% of patients gaining &amp;gt;15 letters from baseline, compared with 5.4% of those who received PDT alone (P = 0.003). Finally, an international Phase III, double-blind, active-controlled study compared ranibizumab 0.3 and 0.5 mg with verteporfin PDT in 423 patients with predominantly classic lesions associated with CNV secondary to ARMD. For the primary efficacy end point, the results were 35.7% for ranibizumab 0.3 mg, 40.3% for ranibizumab 0.5 mg, and 5.6% for verteporfin PDT (P &amp;lt; 0.001). Serious adverse ocular events, which occurred in association with &amp;lt; 0.1% of intravitreal injections in these trials, included retinal detachment and endophthalmitis. Less serious adverse ocular reactions occurring in &amp;lt; 2% of patients included intraocular inflammation and increased intraocular pressure. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; The findings of these 3 large clinical trials suggest that ranibizumab was effective and well tolerated in patient.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=39" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>379525</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/red-wine-and-eyesight.aspx]]&gt;</url>
    <title>Red wine affects vision</title>
    <publicationDate>2010-06-25T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Drinking wine could protect your eyes,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reported. It said that resveratrol, a substance found in red wine, could protect blood vessels in the eye being damaged by old age.&lt;/P&gt;
&lt;P&gt;The story is based on a small study in mice, investigating whether resveratrol can inhibit the abnormal growth of blood vessels in the eye. Giving the substance to mice with damaged eyes appeared to inhibit the abnormal growth of blood vessels, a condition similar to macular degeneration in humans.&lt;/P&gt;
&lt;P&gt;However, while this study is of scientific interest, there is very long way to go before we know if resveratrol can be used to treat human eye disease. This model of eye disease is different to that in humans, and clinical trials would have to test if this compound affects human blood vessels.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study suggests that high doses of the plant compound resveratrol has an inhibiting effect on abnormal blood vessel growth in the eyes of mice. It also identifies the mechanism by which this might happen. As such, it is of scientific interest. However, researchers would need more testing to see whether resveratrol or a derivative could potentially treat eye diseases in humans. Any treatment would then need to go through many stages of efficacy and safety testing in humans before it was made generally available.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/red-wine-and-eyesight.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Khan AA, Dace DS, Ryazanov AG, et al.&amp;nbsp;&lt;A href="http://ajp.amjpathol.org/cgi/content/abstract/ajpath.2010.090836v1" target="_blank"&gt;Resveratrol Regulates Pathologic Angiogenesis by a Eukaryotic Elongation Factor-2 Kinase-Regulated Pathway.&lt;/A&gt; American Journal of Pathology 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>102035</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12365904&amp;query_hl=7]]&gt;</url>
    <title>Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.</title>
    <publicationDate>2002-10-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of ophthalmology, {Arch-Ophthalmol}, Oct 2002, vol. 120, no. 10, p. 1268-79, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To provide the results of the Early Manifest Glaucoma Trial, which compared the effect of immediately lowering the intraocular pressure (IOP), vs no treatment or later treatment, on the progression of newly detected open-angle glaucoma. &lt;/P&gt;
&lt;P&gt;DESIGN: Randomized clinical trial. &lt;/P&gt;
&lt;P&gt;PARTICIPANTS: Two hundred fifty-five patients aged 50 to 80 years (median, 68 years) with early glaucoma, visual field defects (median mean deviation, -4 dB), and a median IOP of 20 mm Hg, mainly identified through a population screening. Patients with an IOP greater than 30 mm Hg or advanced visual field loss were ineligible. &lt;/P&gt;
&lt;P&gt;INTERVENTIONS: Patients were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129) or no initial treatment (n = 126). Study visits included Humphrey Full Threshold 30-2 visual field tests and tonometry every 3 months, and optic disc photography every 6 months. Decisions regarding treatment were made jointly with the patient when progression occurred and thereafter. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURES: Glaucoma progression was defined by specific visual field and optic disc outcomes. Criteria for perimetric progression were computer based and defined as the same 3 or more test point locations showing significant deterioration from baseline in glaucoma change probability maps from 3 consecutive tests. Optic disc progression was determined by masked graders using flicker chronoscopy plus side-by-side photogradings. &lt;/P&gt;
&lt;P&gt;RESULTS: After a median follow-up period of 6 years (range, 51-102 months), retention was excellent, with only 6 patients lost to follow-up for reasons other than death. On average, treatment reduced the IOP by 5.1 mm Hg or 25%, a reduction maintained throughout follow-up. Progression was less frequent in the treatment group (58/129; 45%) than in controls (78/126; 62%) (P =.007) and occurred significantly later in treated patients. Treatment effects were also evident when stratifying patients by median IOP, mean deviation, and age as well as exfoliation status. Although patients reported few systemic or ocular conditions, increases in clinical nuclear lens opacity gradings were associated with treatment (P =.002). &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: The Early Manifest Glaucoma Trial is the first adequately powered randomized trial with an untreated control arm to evaluate the effects of IOP reduction in patients with open-angle glaucoma who have elevated and normal IOP. Its intent-to-treat analysis showed considerable beneficial effects of treatment that significantly delayed progression. Whereas progression varied across patient categories, treatment effects were present in both older and younger patients, high- and normal-tension glaucoma, and eyes with less and greater visual field loss. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10571351&amp;amp;query_hl=36" target="_blank"&gt;Early Manifest Glaucoma Trial: design and baseline data.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12523884&amp;amp;query_hl=36" target="_blank"&gt;Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12780410&amp;amp;query_hl=36" target="_blank"&gt;Measuring visual field progression in the Early Manifest Glaucoma Trial.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15021220&amp;amp;query_hl=36" target="_blank"&gt;Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=30&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=9856&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102035" target="_blank"&gt;&lt;BR&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102231</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4117682.doc]]&gt;</url>
    <title>Referral of a vision impaired patient</title>
    <publicationDate>2005-08-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CERTIFICATION OF VISUAL IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;document published by the Department of Health&amp;nbsp;contains information about the referral process and&amp;nbsp;a sample referral letter (RVI).&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;RVI's can be issued by eye clinics and high street optometrists.&amp;nbsp; They can be used to alert social services to the needs of people with vision impairments in a timely manner and in advance of certification.&amp;nbsp; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371547</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_115007.pdf]]&gt;</url>
    <title>Referral pathway for wet age-related macular degeneration (wet AMD)</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;Letter issued on 1 April 2010 to chairs of primary care trusts, highlighting the importance of rapid referral for people who are suspected of having wet age-related macular degeneration and to ask that local referral pathways be reviewed in light of this.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83623</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4080999.pdf]]&gt;</url>
    <title>Report of the National Eye Care Steering Group</title>
    <publicationDate>2004-04-27T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GLAUCOMA,RETINA,LENS,AGE RELATED MACULAR DEGENERATION,CATARACT,LOW VISION,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=teaserText&gt;This is the first report of the Eye Care Services Steering Group. The group was set up by Ministers in December 2002 to develop proposals for the modernisation of NHS eyecare services, maintaining and developing an integrated, patient-centred service, and improving access, choice, waiting times and quality for all sectors of the community. &lt;/P&gt;
&lt;P class=teaserText&gt;As its first priority the Steering Group established subgroups to develop model care pathways for cataract, glaucoma, low vision and ARMD. The group aimed to deliver proposals consistent with and to support the Vision 2020 programme. The overriding objective of Vision 2020 is to eliminate avoidable blindness by the year 2020 (hence the name) through adopting three key strategies, specific disease control, human resource development and infrastructure development.&lt;/P&gt;
&lt;P class=teaserText&gt;This report was published in April 2004.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314369</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18614569]]&gt;</url>
    <title>Retinal microvascular abnormalities and cognitive dysfunction: a systematic review</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL VASCULAR OCCLUSION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Source: Br J Ophthalmology 2008 Aug;92(8):1017-25. Epub 2008 Jul 9.&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To examine the evidence for an association between cognitive impairment or dementia and the presence of retinal microvascular abnormalities. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic review of observational studies identified through searching five electronic databases and reference lists. Studies were required to have both a recognised cognitive function assessment (either a structured neuropsychological test or a clinical evaluation of dementia), and assessment of the retinal microvasculature (either characteristics associated with generalised retinopathy or changes specific to arterioles or venules). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; 6 studies were included. Studies were clinically and methodologically heterogeneous and of variable quality. Some degree of cognitive impairment was found to be associated with the presence of retinal microvascular abnormalities in all studies, although the extent of the association varied. The presence of retinal vascular signs was mostly associated with poorer verbal memory, mental speed and executive function in the general population, but not consistently associated with other cognitive modalities. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS: &lt;/STRONG&gt;There is some evidence suggesting a positive association between retinal microvascular abnormalities and cognitive impairment or dementia in elderly people and in patients with diabetes. Findings are inconclusive, and further better designed studies are required, with standardised and objective retinal vascular assessment and a range of sensitive cognitive tests.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=68" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>341911</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18931002]]&gt;</url>
    <title>Retinal microvascular abnormalities and stroke: a systematic review</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Journal of Neurology, Neurosurgery and Psychiatry</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,RETINAL VASCULAR OCCLUSION,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Source: J Neurol Neurosurg Psychiatry. 2009 Feb;80(2):158-65. Epub 2008 Oct 17.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BACKGROUND&lt;/STRONG&gt;: Lacunar strokes account for 25% of ischaemic strokes, but their precise aetiology is unknown. Similarities between the retinal and cerebral small vessels mean that clarification of the exact relationship between retinal microvascular abnormalities and stroke, and particularly with stroke subtypes, may aid understanding of the aetiology of lacunar stroke and stroke risk. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: A systematic review of the literature was performed by searching Medline and Embase to October 2007 for studies in humans that investigated the association between retinal microvascular abnormalities and prevalent or incident stroke. Data and calculated summary risk ratios (sRR) were extracted for associations between retinal microvascular abnormalities and stroke, including stroke subtypes where possible, adjusted for key variables. 37 papers from 22 different studies were included with 62 975 subjects (mean age 62 years) among whom there were 2893 strokes. Stroke identification and diagnosis methods varied. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS&lt;/STRONG&gt;: Retinopathy was associated with incident stroke (sRR 2.1, 95% CI 1.7 to 2.6) and prevalent stroke (sRR 2.5, 95% CI 1.4 to 4.3). Incident stroke was also associated with retinal artery embolism (sRR 2.9, 95% CI 1.6 to 5.1) and venular widening (sRR 1.4, 95% CI 1.1 to 1.7). There was significant heterogeneity between studies for some associations. There were no data on retinal microvascular abnormalities and haemorrhagic versus ischaemic stroke or ischaemic stroke subtypes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS&lt;/STRONG&gt;: Retinal microvascular abnormalities are associated with stroke, but more data are required to clarify associations between specific types of retinal microvascular abnormality and stroke, as well as between different stroke subtypes. Future retinal-stroke studies should concentrate on carefully diagnosing and accurately sub-typing ischaemic stroke.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=250" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>94638</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.cps.ca/english/statements/FN/fn98-01.htm]]&gt;</url>
    <title>Retinopathy of Prematurity : Recommendations for Screening</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Canadian Paediatric Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ SCREENING,CHILD,EYES AND VISION,EYES,EYES,VISION,SCHOOL ENTRY,PHYSICAL (6-8 WKS),NEWBORN,PHYSICAL (&lt;72HRS),RETINOPATHY OF PREMATURITY,RETINOPATHY,RETINA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Fetus and Newborn Committee of the Canadian Paediatric Society (CPS) together with the Canadian Association of Paediatric Ophthalmologists jointly produced this guideline on screening recommendations for retinopathy of prematurity.&amp;nbsp; The guideline was first published in 1998 and&amp;nbsp;a revision was&amp;nbsp;in progress in&amp;nbsp;February 2009.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Table 1 summarises the recommendations for screening&amp;nbsp;the Canadian population&amp;nbsp;including&amp;nbsp;risk groups, who should examine the eyes, schedule of assessments and&amp;nbsp;long term follow-up.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=194" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=194" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=194" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102055</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11470690&amp;query_hl=27]]&gt;</url>
    <title>Risk factors associated with age-related nuclear and cortical cataract : a case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5.</title>
    <publicationDate>2001-08-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,LENS,AGE RELATED MACULAR DEGENERATION,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Aug 2001, vol. 108, no. 8, p. 1400-8, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To investigate possible risk factors for age-related nuclear and cortical cataracts in participants in the Age-Related Eye Disease Study (AREDS). &lt;/P&gt;
&lt;P&gt;DESIGN: Case-control study. &lt;/P&gt;
&lt;P&gt;PARTICIPANTS: Of the 4757 persons enrolled in AREDS, 4477 age 60 to 80 years are included in the study. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURES: Slit-lamp lens photographs were used to classify participants into one of three nuclear opacity groups (moderate nuclear, mild nuclear, and controls), ignoring cortical opacities. Retroillumination lens photographs were used to classify participants into one of three cortical opacity groups (moderate cortical, mild cortical, and controls), ignoring nuclear opacities. &lt;/P&gt;
&lt;P&gt;RESULTS: Persons with moderate nuclear opacities were more likely to be female, nonwhite, and smokers and to have large drusen. Moderate nuclear opacities were less common in persons with higher educational status, a history of diabetes, and among those taking nonsteroidal antiinflammatory drugs. Moderate cortical opacities were associated with dark iris color, large drusen, weight change, and, at a borderline level of significance, higher levels of sunlight exposure and use of thyroid hormones. Moderate cortical opacities were less common in persons with higher educational status. &lt;/P&gt;
&lt;P&gt;CONCLUSION: Consistent findings have now been reported across many studies for gender, educational status, sunlight exposure, and smoking. Our findings that use of nonsteroidal antiinflammatory drugs is inversely associated with nuclear cataract and that dark iris color and use of thyroid hormones may increase cortical cataract risk are less well substantiated and require further investigation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;cataract management in the NHS.&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102290</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/older/MDrisk.html]]&gt;</url>
    <title>Risk factors for AMD progression</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RETINA,AGE RELATED MACULAR DEGENERATION,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Summary produced by Bandolier of an AREDS study about the risk factors for the&amp;nbsp;age-related macular degeneration progression.]]&gt;</body>
  </document>
  <document>
    <id>314371</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17435508]]&gt;</url>
    <title>Risk of corneal inflammatory events with silicone hydrogel and low dk hydrogel extended contact lens wear: a meta-analysis</title>
    <publicationDate>2007-04-01T00:00:00</publicationDate>
    <publisher>Optometry and Vision Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,REFRACTIVE ERROR,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Optometry &amp;amp; Vision Science (Optom Vis Sci) 2007 Apr;84(4):247-56&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; High Dk silicone hydrogel (SH) lenses have been shown to significantly decrease the risk of hypoxic complications compared to traditional low Dk hydrogels. However, the risks of inflammatory complications with SH compared to low Dk lenses are not as clear. A meta-analysis was performed to combine the relevant literature to evaluate the risks of corneal inflammatory events in users of SH and low Dk hydrogel extended wear lenses. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic search was conducted using online databases, unpublished meeting abstracts, and retrieval of other cited references presented or published between 1990 and February 2006. Each study was evaluated for quality in terms of the research question, and these quality assessments were used to determine which studies should be used in subgroup analyses. A generalized linear mixed model framework with an underlying Poisson distribution for the occurrence of events was employed to combine information from the included studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Twenty-three studies published or presented on either or both arms by February 2006 were selected for analysis. A total of 9,336 subjects and 18,537 eyes comprised the entire sample. Seven studies were published in the 1990s. Eighteen studies (78%) were prospective, and 11 (48%) used randomization. The follow-up ranged from 4 to 36 months, with a median of 12 months. The rates of infiltrates for low Dk hydrogels and SH lenses were 7.7 (2.2, 26.7) and 14.4 (4.3, 48.2) per 100 eye-years, respectively. In the subset of five best quality studies, the unadjusted risk ratio for corneal inflammatory events for SH lenses compared to low Dk lenses was 2.18 (p &amp;lt; 0.005). Across studies, adjusted risk ratios ranged from 2.18 to 2.23 (p &amp;lt; 0.05), with strong confounding between material and length of wear. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Based on published or presented studies between 1991 and 2006, there is approximately a twofold higher risk for corneal inflammatory events in users of SH lenses when typically worn for up to 30 days extended wear when compared with low Dk extended wear lenses when typically worn for 7 days extended wear. The increased risk cannot be definitively linked to SH lens materials because the effect of material on outcome is confounded by length of wear.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=99" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>224102</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcgp-curriculum.org.uk/PDF/curr_15_5_Eye_problems.pdf]]&gt;</url>
    <title>Royal College of General Practitioners Curriculum Statement 15.5 - Eye Problems</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>The Royal College of General Practitioners</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CORNEA,GLAUCOMA,RETINA,LENS,UVEAL TRACT,LID,LACRIMAL,OCULAR MOTILITY,GLOBE,ORBIT,VITREOUS BODY,REFRACTIVE ERROR,LOW VISION,OPTIC NERVE AND VISUAL PATHWAYS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In August 2007 a national training curriculumn for GPs&amp;nbsp;was introduced providing trainees with a consistent standard of training regardless of where in the UK they are based.&amp;nbsp;&amp;nbsp; The RCGP curriculumn was&amp;nbsp;granted unconditional approval by the Postgraduate Medical Education and Training Board. &lt;/P&gt;
&lt;P&gt;Curriculum statement 15.5&amp;nbsp;describes the knowledge, skills and attributes that a general practitioner requires when managing patients with eye problems.&amp;nbsp; Curriculum statements should be read in conjunction with the other statements in the series.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;This document was last updated in March&amp;nbsp;2009. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=360" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=360" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=360" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>104775</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.orthoptics.org.uk/orthoptists/rules_of_professioanl_standards_and_code_of_ethics.pdf]]&gt;</url>
    <title>Rules of professional conduct and code of ethics</title>
    <publicationDate>2004-01-01T00:00:00</publicationDate>
    <publisher>British and Irish Orthoptic Society (BIOS)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ OCULAR MOTILITY,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document produced by BIOS in 2004 sets out for members and student members of the British Orthoptic Society the relevant ethical, moral, legal and professional considerations that underpin the reasoning of the Rules of Professional Conduct.&lt;/P&gt;
&lt;P&gt;The first section outlines the purpose and ethical background to the rules, the second section lists and then expands upon the statements of each of the seven rules of professional conduct and the appendices provide abstracts from pertinent regulatory Acts, a glossary of terms and abstracts of the Hippocratic Oath and Declaration of Helsinki. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalint=272" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=275" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=275" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>378679</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.abdo.org.uk/pdfs/whatsnew/Safety%20and%20protective%20eyewear%200610.pdf]]&gt;</url>
    <title>Safety and protective eyewear: a reference guide for ABDO members</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Association of British Dispensing Opticians (ABDO)</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LIVING WITH VISUAL IMPAIRMENT,REFRACTIVE ERROR,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Association of British Dispensing Opticians (ABDO) have produced this reference guide to safety and protective eyewear. The&amp;nbsp;guide covers Industrial prescription safety eyewear; Sunglass protection; and Sports and home protection.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=490" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=490" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=490" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102234</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/public/documents/digitalasset/dh_077625.pdf]]&gt;</url>
    <title>Sample Certificate of a Person as Sight Impaired (partially sighted) or as Severely Sight Impaired (blind)</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CERTIFICATION OF VISUAL IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is a sample of the revised Certificate of Vision Impairment 2003 certificate&amp;nbsp;from the Department of Health (August 2007).&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;In November 2003, the Department of Health, after&amp;nbsp;consultation with a wide range of professionals, other government departments and voluntary organisations working in the field of visual impairment&amp;nbsp;replaced form BD8 (1990) with CVI 2003.&amp;nbsp; The BD8 (1990)&amp;nbsp;had been used for certifying people as blind or partially sighted.&lt;/P&gt;
&lt;P&gt;From 1 September 2005 hospital eye clinics will need to use the revised Certificate to certify patients.&amp;nbsp;&amp;nbsp; The form BD8 will no longer be accepted. &lt;/P&gt;
&lt;P&gt;When signed by a consultant ophthalmologist, the CVI&amp;nbsp;is&amp;nbsp;the formal notification required by councils with social services responsibilities (or their agents) to register someone as sight impaired / partially sighted, or as severely sight impaired / blind.&amp;nbsp; Its second purpose is to record a standard range of diagnostic and other data that may be used for epidemiological analysis.&amp;nbsp; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380816</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.scotland.gov.uk/Publications/2010/07/02125835/0]]&gt;</url>
    <title>School-Age Sight Testing In Scotland Research</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>The Scottish Government</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ VISION,SCHOOL ENTRY,VISUAL IMPAIRMENT,EYES AND VISION,IN CHILDHOOD,SCREENING,CHILD,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In 2007, the Child and Maternal Health Division of the Scottish Government commissioned research to determine whether the routine sight testing of children in P7 identifies previously undetected significant sight problems. The research was undertaken by Ipsos MORI Scotland in collaboration with Dr John Ravenscroft of the University of Edinburgh and Dr Jennifer Skillen.&lt;/P&gt;
&lt;P&gt;This report from the Scottish Government published in July 2010 as a result of the commissioned research presents evidence on school-age sight testing research in Scotland, including a review of literature and primary research on testing at Primary 7 in two NHS Boards. This report is accompanied by a Research Findings.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311308</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17224952]]&gt;</url>
    <title>Screening for glaucoma in Canada: a systematic review of the literature</title>
    <publicationDate>2006-12-01T00:00:00</publicationDate>
    <publisher>Canadian Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Canadian Journal of Ophthalmology (Can J Ophthalmol) 2006 Dec;41(6):709-21&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; To provide a recommendation on screening for glaucoma in Canada based on a review of recent evidence available in the literature. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A systematic literature review was performed to identify publications from MEDLINE, EMBASE, HealthSTAR, and Cochrane databases from 1990 to 2005. Relevant articles were categorized as economic studies, epidemiologic and intervention studies, or policy papers. Web sites and publications from provincial, state, national, and international health authorities were reviewed for policy recommendations and guidelines. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;We identified 39 articles (34 epidemiology and intervention, and 5 economic studies) for the review. From the economic studies, 2 were simple cost analyses and 3 were full economic evaluations (cost-effectiveness). Gaps were observed from these economic studies, where incremental cost-effectiveness analyses of modelled screening programmes were not observed. A large number of alternatives (i.e., screening techniques) and diverse outcome measures were found in the 34 epidemiology and intervention studies. This shows that evidence on the effectiveness of glaucoma screening programmes is available to be used in future modelled analyses. Neutral recommendation made by the Canadian Task Force on Periodic Health Examination regarding glaucoma screening in Canada could be related to the lack of reliable data and models used in past cost-effectiveness analyses. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;INTERPRETATION:&lt;/STRONG&gt; A need exists to reevaluate the cost-effectiveness of a screening programme for glaucoma in Canada with updated efficacy and cost data. Health and monetary benefits could be improved compared with current practice and decision-makers would have the best available data when reevaluating the policy on screening for glaucoma.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=110" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>311305</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18414099]]&gt;</url>
    <title>Screening for open angle glaucoma: systematic review of cost-effectiveness studies.</title>
    <publicationDate>2008-04-30T00:00:00</publicationDate>
    <publisher>Journal of Glaucoma</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,COMMISSIONING,ASSESSMENT AND PLANNING,DISEASE/CONDITION GROUPS,EYE AND VISION PROBLEMS,COST EFFECTIVENESS,COMMISSIONING COMPETENCIES,PRIORITISE INVESTMENT,COMMISSIONING PROCESS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;&lt;SPAN title="Journal of glaucoma."&gt;Source: Journal of Glaucoma (J Glaucoma)&lt;/SPAN&gt; 2008 Apr-May;17(3):159-68&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To systematically review current evidence on the cost-effectiveness of screening strategies for open angle glaucoma (OAG). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MATERIALS AND METHODS:&lt;/STRONG&gt; Studies that reported both costs and outcomes of alternative screening strategies for OAG were identified by a highly sensitive search of electronic databases (eg, MEDLINE, EMBASE, NHS EED, HTA Database), last search December 2005. Data on costs regarding cases and years of visual impairment prevented, cases of blindness prevented, and cases of OAG detected were extracted. Incremental cost-effectiveness ratios were calculated using data provided in the included studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Four studies met the inclusion criteria. The latest of these was published in 1997. The screening tests and treatments reported in these studies are now not considered to be best practice. Furthermore, data were not reported in sufficient detail to reinterpret the results of the studies in terms of a common outcome measure. Finally, these studies suffered from methodologic weaknesses that further limit their usefulness for decision making. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Currently, there is insufficient economic evidence on which to base recommendations regarding screening for OAG. New technologies, potentially suitable as screening devices, and new treatments are available. Further research, both in terms of economic models and conduct of clinical trials with concurrent economic evaluation, may help inform policy makers regarding cost-effectiveness and acceptability of screening for OAG.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=74" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342497</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18614810]]&gt;</url>
    <title>Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Investigative Ophthalmology &amp; Visual Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Investigative Ophthalmology &amp;amp; Visual Science. 2008 Dec;49(12):5373-85. Epub 2008 Jul 9.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To assess the comparative accuracy of potential screening tests for open angle glaucoma (OAG). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Medline, Embase, Biosis (to November 2005), Science Citation Index (to December 2005), and The Cochrane Library (Issue 4, 2005) were searched. Studies assessing candidate screening tests for detecting OAG in persons older than 40 years that reported true and false positives and negatives were included. Meta-analysis was undertaken using the hierarchical summary receiver operating characteristic model. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Forty studies enrolling over 48,000 people reported nine tests. Most tests were reported by only a few studies. Frequency-doubling technology (FDT; C-20-1) was significantly more sensitive than ophthalmoscopy (30, 95% credible interval [CrI] 0-62) and Goldmann applanation tonometry (GAT; 45, 95% CrI 17-68), whereas threshold standard automated perimetry (SAP) and Heidelberg Retinal Tomograph (HRT II) were both more sensitive than GAT (41, 95% CrI 14-64 and 39, 95% CrI 3-64, respectively). GAT was more specific than both FDT C-20-5 (19, 95% CrI 0-53) and threshold SAP (14, 95% CrI 1-37). Judging performance by diagnostic odds ratio, FDT, oculokinetic perimetry, and HRT II are promising tests. Ophthalmoscopy, SAP, retinal photography, and GAT had relatively poor performance as single tests. These findings are based on heterogeneous data of limited quality and as such are associated with considerable uncertainty. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; No test or group of tests was clearly superior for glaucoma screening. Further research is needed to evaluate the comparative accuracy of the most promising tests.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=245" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314372</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11099713]]&gt;</url>
    <title>Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis</title>
    <publicationDate>2000-12-01T00:00:00</publicationDate>
    <publisher>Journal of the neurological sciences</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OPTIC NERVE AND VISUAL PATHWAYS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of the Neurological Sciences (J Neurol Sci) 2000 Dec 1;181(1-2):56-64&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;To quantify and characterize seasonal variation in monosymptomatic optic neuritis (MON) onsets, multiple sclerosis (MS) onsets and MS exacerbations (MSE), a meta-analysis was performed, using established methods and pooling weighted information obtained from nine reports on MON, six reports on MS onsets and nine reports on MSE, which fulfilled specific criteria for report quality and data homogeneity. The results suggested that MON, MS onsets and MSE in the Northern hemisphere present a similar pattern with highest frequencies in spring and lowest in winter. These differences were highest for MS onsets, 45% with 95% CI 36-55%, and lowest for MSE, 10% with 95% CI 7-13%, statistically significant and robust, insensitive to an alternative seasonal definition, not unduly influenced by any single primary study, and supported by fail-safe N calculations. Random variation, misclassification and publication bias were less likely to account for the reported generalized seasonal patterns.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=24" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79181</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band57/b57-4.html]]&gt;</url>
    <title>Second Cataract</title>
    <publicationDate>1998-11-02T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This article published in issue 57 of the Bandolier Journal in November 1998 discusses&amp;nbsp;the results of a randomised&amp;nbsp;trial into&amp;nbsp;the effectiveness of&amp;nbsp;second eye cataract surgery.]]&gt;</body>
  </document>
  <document>
    <id>342494</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19032617]]&gt;</url>
    <title>Self-management education programs for age-related macular degeneration: a systematic review</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Australasian Journal on Ageing</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Australasian Journal on Ageing 2008 Dec; 27(4):170-6&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To review the effectiveness of education programs to improve emotional status, daily living and self-efficacy in adults older than 60 years with age-related macular degeneration (AMD). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD: &lt;/STRONG&gt;Electronic searches of three databases and manual searches of references lists located randomised controlled trials (RCTs) and quasi-experimental studies. Health education programs aimed at increasing knowledge of AMD, skills training or behavioural change were included. Data extraction and quality assessment were undertaken by two reviewers. A narrative analysis was possible. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Three protocols were reported in four studies (n = 532) with three follow-up studies--all contained elements of self-management programs. Effect sizes for the three outcomes ranged from small to very large (0.14-1.21). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Self-management programs appear effective for older adults with AMD. Small sample size, use of non-traditional statistics and methodological quality meant only a narrative analysis was possible. Future studies with more robust methodology including intent-to-treat analysis are still required.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=244" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387683</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/new-genes-linked-to-short-sightedness.aspx]]&gt;</url>
    <title>Short-sighted claims over glasses</title>
    <publicationDate>2010-09-13T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,REFRACTIVE ERROR,SHORT SIGHT (MYOPIA),CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Short-sightedness could soon be remedied with eye drops rather than glasses, &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reported. Several other newspapers also predicted that glasses will become obsolete after research linked genetic variations to the common eye problem.&lt;/P&gt;
&lt;P&gt;The news is based on two well-conducted genetic studies that together tested the DNA of over 25,000 people from across Europe. It found that short-sighted people were more likely to possess up to three particular genetic variants, which the researchers say make a small contribution to the chances of having the condition.&lt;/P&gt;
&lt;P&gt;The researchers note that their findings highlight that the genetic component of short-sightedness is likely to be determined by several additional genetic variants acting together. Given this interpretation, the optimism shown in the newspapers is surprising. One lead researchers reportedly said that developing a treatment from these findings would be “a challenge” and will take at least 10 years. However, this cautious and realistic interpretation was not reflected in all news reports.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The studies have identified genetic variants in regions of the DNA that are linked to eyeball function. They do not yet explain how problems in these genes could lead to short-sightedness or indeed why only some people with these variants are short-sighted.&lt;/P&gt;
&lt;P&gt;The fact that a gene variant increases the susceptibility to a condition does not mean that it causes it. As the researchers note, the condition is likely to be caused by many different gene variants. It is not yet known if these are the most important variants or indeed how they may interact with the environmental factors associated with myopia or any undiscovered variants in nearby genes. [Continued]&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/09September/Pages/new-genes-linked-to-short-sightedness.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Hysi PG, Young TL, Mackey DA et al. &lt;A href="http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.664.html" target="_blank"&gt;A genome-wide association study for myopia and refractive error identifies a susceptibility locus at 15q25&lt;/A&gt;. Nature Genetics [Published online] 12 September 2010&lt;/P&gt;
&lt;P&gt;Solouki AM, Verhoeven VJM, van Duijn CM et al. &lt;A href="http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.663.html" target="_blank"&gt;A genome-wide association study identifies a susceptibility locus for refractive errors and myopia at 15q14&lt;/A&gt;. Nature Genetics [Published online] 12 September 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>314376</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/9789511]]&gt;</url>
    <title>Should we patch corneal abrasions? A meta-analysis</title>
    <publicationDate>1998-10-01T00:00:00</publicationDate>
    <publisher>The Journal of Family Practice</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CORNEAL ABRASION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Family Practice (J Fam Pract) 1998 Oct;47(4):264-70.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Eye patching is commonly recommended for treating corneal abrasions. This advice seems based more on anecdotes or disease-oriented evidence theorizing that there is faster healing or less pain when the eye is patched. This meta-analysis was performed to determine if eye patching is a useful treatment for corneal abrasions. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;We conducted a comprehensive search of both MEDLINE (1966 to 1997) and Science Citation Index to locate relevant articles. We reviewed the bibliographies of included studies, and ophthalmology and primary care texts. Local ophthalmologists and authors were contacted to identify any unpublished data. Controlled trials that evaluated eye patching compared with no patching in patients older than 6 years with uncomplicated corneal abrasions were considered. The outcomes of interest were healing rates and degree of pain. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Seven trials were identified for inclusion, of which five could be statistically combined. Healing rates were similar in the two groups. The summary ratios (95% confidence interval) of healing rates in the patch group as compared with the no-patch group were 0.87 (0.68 to 1.13) and 0.90 (0.75 to 1.10) at days 1 and 2, respectively. Six studies evaluated pain: four found no difference and two favored not patching. No differences in complication rates were noted between the patched and nonpatched groups. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Eye patching was not found to improve healing rates or reduce pain in patients with corneal abrasions. Given the theoretical harm of loss of binocular vision and possible increased pain, we recommend the route of harmless nonintervention in treating corneal abrasions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=6" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322543</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15121388]]&gt;</url>
    <title>Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology</title>
    <publicationDate>2004-05-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2004 May;111(5):1055-62&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To evaluate whether single-field fundus photography can be used as a screening tool to identify diabetic retinopathy for referral for further ophthalmic care. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A MEDLINE search of the peer-reviewed literature was conducted in June 2001 for the years 1968 to 2001 and updated in September 2003, yielding 145 articles. The search was limited to articles published in English. The Cochrane Library of clinical trials was also investigated. The authors reviewed the abstracts of these articles and selected 63 of possible clinical relevance for review by the panel. Of these 63 articles, the panel selected 32 for the panel methodologist to review and rate according to the strength of evidence. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Three of the 32 articles reviewed were classified as level I evidence, and 4 were classified as level II evidence. Evidence from level I studies demonstrates that as a tool to detect vision-threatening retinopathy, single-field fundus photography interpreted by trained readers has sensitivity ranging from 61% to 90% and specificity ranging from 85% to 97% when compared with the gold standard reference of stereophotographs of 7 standard fields. When compared with dilated ophthalmoscopy by an ophthalmologist, single-field fundus photography has sensitivity ranging from 38% to 100% and specificity ranging from 75% to 100%. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Single-field fundus photography is not a substitute for a comprehensive ophthalmic examination, but there is level I evidence that it can serve as a screening tool for diabetic retinopathy to identify patients with retinopathy for referral for ophthalmic evaluation and management. The advantages of single-field fundus photography interpreted by trained readers are ease of use (only one photograph is required), convenience, and ability to detect retinopathy. Further studies will be required to assess the implementation of single-field photography-based programs to confirm the clinical and cost-effectiveness of these techniques in improving population visual outcomes. Future research also should include establishing standardized protocols and satisfactory performance standards for diabetic retinopathy screening programs.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=187" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314381</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16151432]]&gt;</url>
    <title>Smoking and age-related macular degeneration: a review of association</title>
    <publicationDate>2005-09-01T00:00:00</publicationDate>
    <publisher>Eye</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Eye 2005 Sep;19(9):935-44&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; Age-related macular degeneration (AMD) is the leading cause of severe and irreversible vision loss in the Western world. As there is no effective treatment for all types of AMD, identifying modifiable risk factors is of great importance. This review evaluates the epidemiological evidence associating smoking with AMD. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Systematic review of published epidemiological studies evaluated against established criteria for evidence of a causal relationship. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;In total, 17 studies (cross-sectional studies, prospective cohort studies, and case-control studies) were included in the review. A total of 13 studies found a statistically significant association between smoking and AMD with increased risk of AMD of two- to three-fold in current-smokers compared with never-smokers. Five studies found no association between smoking and AMD. There was also evidence of dose-response, a temporal relationship and reversibility of effect. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; The literature review confirmed a strong association between current smoking and AMD, which fulfilled established causality criteria. Cigarette smoking is likely to have toxic effects on the retina. In spite of the strength of this evidence, there appears to be a lack of awareness about the risks of developing eye disease from smoking among both healthcare professionals and the general public.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=155" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314382</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18652983]]&gt;</url>
    <title>Smoking and the risk of age-related macular degeneration: a meta-analysis</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Annals of Epidemiology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Annals of Epidemiology (Ann Epidemiol) 2008 Aug:18(8):647-56&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; Some studies were undertaken to evaluate the association between cigarette smoking and age-related macular degeneration (AMD). This meta-analysis summarized the risk estimate of smoking and AMD and provided robust evidence for the association. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Relevant studies were identified by searching PubMed and MEDLINE (from 1966 to June 2007) and reviewing the reference lists of key articles. The summary relative risk ratio (RR) or odds ratio (OR) and 95% confidence interval (CI) were calculated. Study-specific risk estimates were pooled using a random-effects model. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Five prospective cohort and eight case-control studies met our inclusion criteria. Ever smoking was statistically significant associated with increased risk of AMD among cohort studies (RR, 1.61; 95% CI, 1.01-2.57) or case-control studies (RR, 1.76; 95% CI, 1.56-1.99). Current smokers were at higher risk of AMD than past smokers. Both geographic atrophy (GA) and neovascular AMD (NV) are subtypes of AMD. A significant relationship was found between smoking and GA risk. Smoking increased the risk of NV, with marginal nonsignificance (RR, 1.47; 95% CI, 0.92-2.37) in cohort studies and significance in case-control studies (RR, 1.96; 95% CI, 1.69-2.27). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This meta-analysis indicated smoking, especially current smoking, was significantly associated with increased risks of AMD and its subtypes.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=66" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319368</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=319368]]&gt;</url>
    <title>Standards for reporting trials, meta-analyses, observational studies and patient information</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Standards for reporting trials, meta-analyses, observational studies and patient information&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;The CONSORT (CONsolidated Standards of Reporting Trials) Statement&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The CONSORT Statement is an evidence-based, minimum set of recommendations for reporting RCTs.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;It offers a standard way for authors to prepare reports of trial findings, facilitating their complete and transparent reporting and aiding their critical appraisal and interpretation. &lt;/P&gt;
&lt;P&gt;The statement comprises a 25 item checklist and flow diagram together with brief descriptive text.&amp;nbsp;&amp;nbsp; Items in the checklist focus on reporting how the trial was designed, analysed and interpreted.&amp;nbsp; The flow diagram displays the progress of all participants throughout the trial.&amp;nbsp; The statement is available in several different languages. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.consort-statement.org/index.aspx?o=1438" target="_blank"&gt;Link here for the CONSORT Statement checklist &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement provides an evidence-based minimum set of items&amp;nbsp; for reporting systematic reviews and meta-analyses, and is an update and expansion of the QUOROM Statement. Although it focuses on randomized trials, the PRISMA Statement can also be used as a basis for reporting systematic reviews of other types of research, particularly evaluations of interventions.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The PRISMA Statement consists of a 27-item checklist and a four-phase flow diagram&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.prisma-statement.org/" target="_blank"&gt;Link here for the PRISMA statement&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.prisma-statement.org/statement.htm" target="_blank"&gt;Link here for the PRISMA checklist and flow diagram &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The MOOSE (Meta-analysis of Observational Studies in Epidemiology) checklist &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;In April 1997 a workshop was held to examine the reporting of meta-analyses of observational studies and to make recommendations to aid authors, reviewers, editors and readers.&amp;nbsp; The end result of the workshop was the MOOSE checklist.&amp;nbsp; The checklist contains specifications for reporting the background, search strategy, methods, results, discussions and conclusion.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.consort-statement.org/index.aspx?o=1347" target="_blank"&gt;Link here for consensus statement on MOOSE (JAMA, April 19, 2000—Vol 283, No. 15)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) Statement&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;An international, collaborative initiative of epidemiologists, methodologists, statisticians, researchers and journal editors involved in the conduct and dissemination of observational studies working towards strengthening the reporting of observational studies in epidemiology. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.strobe-statement.org/" target="_blank"&gt;Link here to the homepage of the STROBE statement website&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;STROBE checklists are available for: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.strobe-statement.org/index.php?eID=tx_nawsecuredl&amp;amp;u=0&amp;amp;file=fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_combined.pdf&amp;amp;t=1246982795&amp;amp;hash=dfd485cad85e7ef0a6addc5adf649fdc" target="_blank"&gt;cohort, case-control, cross-sectional studies (combined) &lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.strobe-statement.org/index.php?eID=tx_nawsecuredl&amp;amp;u=0&amp;amp;file=fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_cohort.pdf&amp;amp;t=1246982795&amp;amp;hash=0e0877c7dd800056136e88c7bac61e64" target="_blank"&gt;cohort studies&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.strobe-statement.org/index.php?eID=tx_nawsecuredl&amp;amp;u=0&amp;amp;file=fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_case-control.pdf&amp;amp;t=1246982795&amp;amp;hash=f3e8f2296999d8cc69725e19cbab6ec9" target="_blank"&gt;case-control studies&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.strobe-statement.org/index.php?eID=tx_nawsecuredl&amp;amp;u=0&amp;amp;file=fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_cross-sectional.pdf&amp;amp;t=1246982795&amp;amp;hash=cb0bb4a67abce1b3bd0434fb75cdc373" target="_blank"&gt;cross-sectional studies&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The STARD (STandards for Reporting of Diagnostic Accuracy) checklist&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;After identifying relevant publications the STARD steering group organised a consensus meeting with the aim of developing a checklist and flow diagram for studies of diagnostic accuracy. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://radiology.rsnajnls.org/cgi/reprint/226/1/24.pdf" target="_blank"&gt;Link here to&amp;nbsp;STARD statement (Radiology 2003; 26(1): 24-28)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EQUATOR Network (Enhancing the QUAlity and Transparency Of health Research)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The EQUATOR network is a global initiative which aims to improve the quality of health care by promoting the transparent and accurate reporting of health research.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nks.nhs.uk/equator.asp" target="_blank"&gt;Link here to the EQUATOR Network website&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;The DISCERN questionnaire &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;DISCERN is a&amp;nbsp;tool designed to&amp;nbsp;help health consumers and information providers assess&amp;nbsp;the quality of written information&amp;nbsp;about treatment choices for a health problem.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.discern.org.uk/discern.pdf" target="_blank"&gt;Link here for the DISCERN handbook&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>143491</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hpc-uk.org/assets/documents/10002367FINALcopyofSCPEJuly2008.pdf]]&gt;</url>
    <title>Standards of conduct, performance and ethics - your duties as a registrant</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Health Professions Council</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ OCULAR MOTILITY,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Health Professions Council (HPC) is an&amp;nbsp;independent UK-wide health regulator which sets the standards of professional training, performance and conduct for thirteen health professions including orthoptists.&amp;nbsp;&amp;nbsp;&amp;nbsp;A register of the health professionals who meet these standards is available online.&lt;/P&gt;
&lt;P&gt;This document&amp;nbsp;outlines the standards of conduct, performance and ethics for all health professionals on the HPC register.&amp;nbsp; These standards are effective from 1 July 2008. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143490</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hpc-uk.org/assets/documents/10000516Standards_of_Proficiency_Orthoptists.pdf]]&gt;</url>
    <title>Standards of Proficiency - Orthoptists</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>Health Professions Council</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Health Professions Council (HPC) is an&amp;nbsp;independent UK-wide health regulator which sets the standards of professional training, performance and conduct for thirteen health professions including orthoptists.&amp;nbsp;&amp;nbsp;&amp;nbsp;A register of the health professionals who meet these standards is available online.&lt;/P&gt;
&lt;P&gt;The Standards of Proficiency are the standards which every registrant must meet in order to become registered and to maintain their registration and include&amp;nbsp;generic and profession-specific elements.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79267</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/booth/cardiac/statmac.html]]&gt;</url>
    <title>Statins and macular degeneration</title>
    <publicationDate></publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Summary&amp;nbsp;produced by Bandolier on&amp;nbsp;a study&amp;nbsp;investigating the association between statin use&amp;nbsp;and age related maculopathy.]]&gt;</body>
  </document>
  <document>
    <id>333817</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/stem-cells-could-reverse-eye-damage.aspx]]&gt;</url>
    <title>Stem cells "restore sight"</title>
    <publicationDate>2009-12-23T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A new stem cell treatment has restored sight to a partially blind man, reported The Guardian. The newspaper said that stem cells grown on a special membrane were used to treat the patient and seven others with sight loss.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A new stem cell treatment has restored sight to a partially blind man,&amp;nbsp;reported &lt;EM&gt;The Guardian&lt;/EM&gt;. The newspaper said that stem cells grown on a special membrane were used to treat the patient and seven others with sight loss.&lt;/P&gt;
&lt;P&gt;This experimental trial was in patients with limbal stem cell deficiency, a painful eye disease that prevents the cornea renewing itself.&lt;/P&gt;
&lt;P&gt;This technique has shown a good preliminary outcome in this group of people. However, a larger trial with a longer follow-up is needed to determine whether the treatment is reliable, safe and effective in the long term.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study describes both a protocol for growing limbal stem cells and a method of transplantation that seems to be an effective treatment for people who have had their limbal stem cells depleted through injury.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/12December/Pages/stem-cells-could-reverse-eye-damage.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Kolli S, Ahmad S, Lako M, Figueiredo F. &lt;A href="http://www3.interscience.wiley.com/journal/123210049/abstract?CRETRY=1&amp;amp;SRETRY=0" target="_blank"&gt;Successful Clinical Implementation of Corneal Epithelial Stem Cell Therapy for Treatment of Unilateral Limbal Stem Cell Deficiency&lt;/A&gt;. &lt;EM&gt;Stem cells&lt;/EM&gt; 2009; Published Online: 10 Dec 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>273439</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.pcc.nhs.uk/uploads/Optometry/july_08/communityeyecare_updated_july_2008.pdf?ref=02145]]&gt;</url>
    <title>Step by step guide to commissioning community eye care services</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>NHS Primary Care Contracting</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Guide written by NHS Primary Care Contracting, originally published&amp;nbsp;in October 2007 and updated in July 2008.&lt;/P&gt;
&lt;P&gt;The guide has been updated&amp;nbsp;to incorporate alternative service cost models from the Royal College of Ophthalmologists.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The guide aims to offer a practical, analytical 'how to' approach to some of the key issues in commissioning high quality community eye care services locally. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314384</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/10929272]]&gt;</url>
    <title>Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials</title>
    <publicationDate>2000-06-01T00:00:00</publicationDate>
    <publisher>Journal of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OPTIC NERVE AND VISUAL PATHWAYS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Neurology (J Neurol) 2000 Jun:247(6):435-42&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;We conducted a meta-analysis of randomized controlled clinical trials on steroid treatment for multiple sclerosis and optic neuritis. Of the 25 trials comparing steroids and controls without steroid treatment that we identified 12 were selected for this review. A meta-analysis was conducted to calculate the overall odds ratio across the studies for the numbers of patients without functional improvement and with new relapses. The trials included a total of 1714 patients: 998 with multiple sclerosis and 716 with optic neuritis. Any type of corticosteroids or adrenocorticotropic hormone (ACTH) treatment was considered, as was any dosage, route of administration, and length of treatment. Main outcome measures were: (a) number of multiple sclerosis patients who did not improve by at least one point on the EDSS or equivalent scale, or number of optic neuritis patients without complete recovery of visual acuity at 8 or 30 days and at longer follow-up; (b) number of multiple sclerosis patients with at least one new relapse, or number of optic neuritis patients in whom definite multiple sclerosis was diagnosed at longer follow-up. We found that corticosteroids or ACTH produced a significant improvement in disability or visual acuity at 30 days (odds ratio 0.49; 95% CI 0.37-0.64). The improvement was not statistically significant at longer follow-up (0.85; 95% CI 0.67-1.09). The treatment did not significantly reduce the number of patients with relapses (0.74; 95% CI 0.54-1.01). Both low and high doses were effective for 30-day improvement, but only high-dose and short-term therapy were factors that identified subgroups with some reduction in the risk of new relapse. However, the power of the statistical analysis to detect a reliable difference in the subgroups was low. Steroid treatment is therefore effective in accelerating short-term recovery in patients with multiple sclerosis or optic neuritis. Whether steroids are also effective in reducing the risk of relapse, and the optimal dose and length of treatment must still be determined.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality&amp;nbsp;appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=25" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89374</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/asset.axd?id=d4a86d65-4ae4-4e62-8508-8618685e631c]]&gt;</url>
    <title>Summary Benchmark Collection for Preferred Practice Patterns</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Summary Benchmarks&amp;nbsp;contain a condensed version of the most relevant evidence-based recommendations of&amp;nbsp;Preferred Practice Patterns (PPP)produced by the American Academy of Ophthalmology.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;There&amp;nbsp;are 17 summaries,&amp;nbsp;one for each PPP and one&amp;nbsp;compilation of all&amp;nbsp;the summary benchmarks.&amp;nbsp;&amp;nbsp; This is the 2010 version of the compilation document. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=159" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=159" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=159" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89392</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=0be9a99e-ab26-458d-8be9-a7834d3b8a42]]&gt;</url>
    <title>Summary Benchmark: Age Related Macular Degeneration</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Age Related Macular Degeneration.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were&amp;nbsp;updated in October 2010.&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second and third pages summarise the key elements for initial and&amp;nbsp;follow up evaluations and management recommendations. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=42" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=42" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=42" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89388</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=b35859cf-9431-48fe-9115-30ee45780cbe]]&gt;</url>
    <title>Summary Benchmark: Amblyopia</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,AMBLYOPIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Amblyopia.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks&amp;nbsp;contain a condensed version of the most relevant evidence-based recommendations of&amp;nbsp;PPPs and were updated in October 2010.&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page summarises the key elements for initial examination history, initial physical exam, care management, follow up evaluation and patient education. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=45" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=45" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=45" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89395</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=f860fb6e-971b-40a1-a318-87e0575ef875]]&gt;</url>
    <title>Summary Benchmark: Bacterial Keratitis</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,KERATITIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=2 face=Arial&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;
&lt;P&gt;This is the Summary Benchmark of the Preferred Practice Pattern (PPP) for&amp;nbsp;bacterial keratitis.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were&amp;nbsp;updated in October 2010. &lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The second and third pages summarise the key elements for initial examination history, initial physical exam, diagnostic tests, care management, follow up evaluation and patient education. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=42" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=42" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=42" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>89403</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=12c43f6d-05f0-4b21-9c3b-1b7c92c016b9]]&gt;</url>
    <title>Summary Benchmark: Blepharitis</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LID,BLEPHARITIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Blepharitis.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were updated in October 2010. &lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page&amp;nbsp;summarises the key elements for initial and follow up examinations, care management, diagnostic tests,&amp;nbsp;and patient education. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=39" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=39" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=39" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89402</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=6ad462f2-d360-4504-889e-d63022d688e4]]&gt;</url>
    <title>Summary Benchmark: Cataract</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Cataract.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were updated in October 2010.&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page summarises the key elements for initial examination history, initial physical exam, care management, pre-operative care, follow up evaluation, Nd: YAG laser capsulotomy and patient education. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=38" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=38" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=38" target="_blank"&gt;NO&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89393</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=9a22f3af-2783-4ae4-bb33-9d8abc4cf954]]&gt;</url>
    <title>Summary Benchmark: Conjunctivitis</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CONJUNCTIVITIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Conjunctivitis.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were updated in October 2010.&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page summarises the key elements for initial examination history, initial physical exam, diagnostic tests, care management, follow up evaluation and patient education. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=32" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=32" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=32" target="_blank"&gt;NO&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89390</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=ea5c6d25-2ab9-4398-b00b-8efcb8cc5bc7]]&gt;</url>
    <title>Summary Benchmark: Diabetic Retinopathy</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for&amp;nbsp;Diabetic Retinopathy&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were updated in October 2010. &lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second and third pages page summarise the key elements for initial and follow up examinations and management recommendations. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=43" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=43" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=43" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89401</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=fdd1d69c-adf0-4910-916b-9623395c8305]]&gt;</url>
    <title>Summary Benchmark: Dry Eye</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LACRIMAL,DRY EYE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT size=2 face=Arial&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;
&lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Dry Eye.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were updated in October 2010.&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page summarises the key elements for initial examination history, initial physical exam, care management and patient education. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=37" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=37" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=37" target="_blank"&gt;NO&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/SPAN&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>89404</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=274e248e-7963-438f-a3e2-e66e67190f45]]&gt;</url>
    <title>Summary Benchmark: Esotropia</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,STRABISMUS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Esotropia.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were updated in October 2010.&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page summarises the key elements for initial examination history, initial physical exam, care management, follow up evaluation and patient education. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=117" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=117" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=117" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392355</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=5d8b1c00-4491-42b3-b72d-245ea0f9c214]]&gt;</url>
    <title>Summary Benchmark: Exotropia</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,STRABISMUS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Exotropia.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were&amp;nbsp;updated in October 2010.&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second and third pages summarise the key elements for initial and&amp;nbsp;follow up evaluations and management recommendations. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=503" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=503" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=503" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89394</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=09738d2e-4f86-4c1c-b76d-325ac2ca780c]]&gt;</url>
    <title>Summary Benchmark: Idiopathic Macular Hole</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Idiopathic Macular Hole.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were updated in October 2010. &lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page&amp;nbsp;summarises the key elements for initial evaluation, care management, surgical and postoperative care and patient education. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=41" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=41" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=41" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89389</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=1b1d99e1-46b9-4dab-a692-45e7aa450dfd]]&gt;</url>
    <title>Summary Benchmark: Posterior Vitreous Detachment, Retinal Breaks and Lattice Degeneration</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL TEARS AND DETACHMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for posterior vitreous detachment, retinal breaks and lattice degeneration.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were&amp;nbsp;updated in&amp;nbsp;October 2010. &amp;nbsp;&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how the recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page summarises the key elements for initial examination history, initial and follow up physical exam, care management,&amp;nbsp;surgical and postoperative care&amp;nbsp;and patient education. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=44" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=44" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=44" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89397</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=13780709-8d0a-4d7c-928e-40d2bb24f78a]]&gt;</url>
    <title>Summary Benchmark: Primary Angle Closure</title>
    <publicationDate>2010-10-01T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Primary Angle Closure.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were updated in October 2010. &lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page summarises the key elements for initial examination history, initial physical exam, diagnosis, management plan for patients in whom iridotomy is indiated, surgery and postoperative care, evaluation and follow up and patient education. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=117" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=117" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=117" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89398</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=13a96c9d-2605-42bd-8eed-bd6b770fdae0]]&gt;</url>
    <title>Summary Benchmark: Primary Open Angle Glaucoma</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Primary Open Angle Glaucoma.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence and were updated in October 2010. &lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second and third pages summarise the key elements for initial examination history, initial physical exam, management plan for patients in whom therapy is indicated, surgery and post operative care, patient education and follow up evaluation. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=35" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=35" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=35" target="_blank"&gt;NO&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>89399</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=af6ad430-0214-46d6-8582-184e85d825f4]]&gt;</url>
    <title>Summary Benchmark: Primary Open Angle Glaucoma Suspect</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Primary Open-Angle Glaucoma.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were&amp;nbsp;updated in October 2010.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page summarises the key elements for initial examination history, initial physical exam, management plan for patients in whom therapy is indicated, follow up evaluations and patient education. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSC Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=117" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=117" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=117" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>392357</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark.aspx?cid=5a0fc4c6-f6b9-4edb-b39a-1989a1277bd3]]&gt;</url>
    <title>Summary Benchmark: Refractive Errors &amp; Refractive Surgery</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>American Academy of Ophthalmology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,REFRACTIVE ERROR,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the summary benchmark of the Preferred Practice Pattern (PPP) for Refractive Errors &amp;amp; Refractive Surgery.&amp;nbsp; Both are produced by the American Academy of Ophthalmology.&amp;nbsp; Summary Benchmarks contain a condensed version of the most relevant evidence-based recommendations of PPPs and were&amp;nbsp;updated in October 2010.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The first page outlines the three principles on which PPPs have been written and how recommendations have been rated by a panel according to importance to the care process and strength of evidence.&amp;nbsp;&amp;nbsp; The second page summarises the key elements for initial examination history, initial physical exam, management plan for patients in whom therapy is indicated, follow up evaluations and patient education. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showappraisal.asp?appraisalInt=504" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=yes&amp;amp;appraisalInt=504" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/givefeedback.asp?answer=no&amp;amp;appraisalInt=504" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314386</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18061271]]&gt;</url>
    <title>Supplementary intracameral lidocaine for phacoemulsification under topical anesthesia.  A meta-analysis of randomized controlled trials</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;&lt;EM&gt;Source: Ophthalmology 2008 Mar; 115(3):455-87. Epub 2007 Dec 3&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;TOPIC:&lt;/STRONG&gt; We consider a meta-analysis of randomized controlled trials (RCTs) comparing topical anesthesia alone with topical and intracameral anesthesia for phacoemulsification. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CLINICAL RELEVANCE:&lt;/STRONG&gt; Topical anesthesia has become an increasingly popular option for day-case cataract surgery. Many surgeons now use supplementary intraoperative intracameral lidocaine, but the evidence base for the supplementary use of intracameral anaesthetic during cataract surgery has never been reviewed systematically. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS/LITERATURE REVIEWED:&lt;/STRONG&gt; The primary objective is to compare intraoperative pain for phacoemulsifications under topical anesthesia with and without intracameral anesthesia. The secondary objectives are to assess both adverse effects and complications attributable to choice of anesthesia and the need for additional anesthesia during surgery. Searches were made from the Cochrane Central Register of Controlled Trials, Medline, Excerpta Medica database, and Latin American and Caribbean Health Science Information Database up to and including June 8, 2006. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Eight RCTs, recruiting a total of 1281 patients, were identified. Our data comparison showed significantly lower intraoperative pain perception in patient groups using supplementary intracameral lidocaine. No significant difference in intraoperative adverse events, corneal toxicity, or the need for supplemental anesthesia was identified. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Intraoperative pain during cataract surgery under topical anaesthetic is reduced by intracameral lidocaine. Possible adverse effects of intracameral lidocaine cannot be excluded due to significant heterogeneity in outcome measures between different RCTs. Although a statistically significant reduction in intraoperative pain has been demonstrated, it is not yet possible to recommend this additional intervention without reservations.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=71" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314387</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17011954]]&gt;</url>
    <title>Surgical management of pseudophakic retinal detachments: a meta-analysis</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL TEARS AND DETACHMENT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2006 Oct; 113(10):1724-33&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To compare the success of pars plana vitrectomy (PPV) versus scleral buckle (SB) in the management of uncomplicated pseudophakic retinal detachments (RDs). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN: &lt;/STRONG&gt;Meta-analysis of published studies from 1966 to 2004 regarding surgical treatment of pseudophakic RDs. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Two thousand two hundred thirty eyes: 1579 operated by SB, 457 by PPV, and 194 by the combined method of PPV and SB. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; We compared reattachment and functional success rates after 3 commonly practiced surgical interventions for pseudophakic RDs: PPV, SB, and the combined method. Twelve hundred thirty-two articles were retrieved from Medline and by cross-reference searches. Articles with sufficient data on preoperative evaluation, applied surgical technique, and anatomical and functional success rates were included in this analysis. Articles regarding complex pseudophakic RDs, treatment by laser or pneumatic retinopexy, studies with indistinguishable treatment outcomes from phakic and pseudophakic RDs, or reviews without original data were excluded. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Anatomical success rates after initial surgical intervention and after reoperation(s) for primary failures, and best or final visual outcome at the end of follow-up. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Of 1232 papers, 29 matched inclusion criteria. After controlling for variation between study characteristics, PPV and the combined method resulted in higher initial reattachment rates (odds ratio [OR], 1.69; 95% confidence interval [CI], 1.07-2.68, and OR, 3.54; 95% CI, 1.57-7.97, respectively) as compared with SB. The differences between the procedures persisted for final reattachment outcome despite reoperation for primary failures. Final visual outcome also was found to depend on the choice of primary surgical intervention. After controlling for differences in the study characteristics, the probability of visual improvement was higher after PPV (OR, 2.34; 95% CI, 1.58-3.46) or the combined method (OR, 11.52; 95% CI, 4.42-30.04) as compared with SB. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS: &lt;/STRONG&gt;A meta-analysis of published literature implies that PPV with or without SB is more likely to achieve a favorable anatomical and visual outcome than conventional SB alone in uncomplicated pseudophakic RDs. However, the inherent limitations of differing study protocols, quality of included studies, and publication bias in a pooled analysis should be recognized.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=22" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317764</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18327526]]&gt;</url>
    <title>Surgical treatment of Graves' disease: evidence-based approach</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>World Journal of Surgery</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ THYROID &amp; PARATHYROID DISORDERS,EYES AND VISION,ENT AND AUDIOLOGY,SURGICAL PROCEDURES,THERAPEUTIC INTERVENTIONS,OTHER,CONDITIONS,CONDITIONS,HYPERTHYROIDISM,GRAVES' DISEASE,ORBIT,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: World Journal of Glaucoma (&lt;SPAN title="World journal of surgery."&gt;World J Surg)&lt;/SPAN&gt; 2008 Jul;32(7):1269-77&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; The optimal treatment of Graves disease (GD) is still controversial. Surgery is one treatment option along with radioactive iodine (RAI) and antithyroid medication. In this evidence-based review, we examine four issues: (1) Is surgery better than RAI or long-term antithyroid medication? (2) What is the recommended surgical approach? (3) How does the presence of Graves' ophthalmopathy (GO) influence the role of surgery? (4) What is the role of surgery in children with GD? &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; We conducted a systematic review of the literature using evidence-based criteria regarding these four issues. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; (1) There are no recommendations reaching any grade of evidence for which treatment to choose for adults with GD. (2) Total thyroidectomy has complication rates equal to those seen with lesser resections but it has higher cure rates and negligible recurrence rates (Level I-IV data leading to a grade A recommendation). (3) Data support surgery when severe GO is present, but RAI combined with glucocorticoids may be equally safe (Level II-IV data, grade B recommendation). The extent of thyroid resection does not influence the outcome of GO (Level II data, grade B recommendation). (4) Based on the available data, definitive treatment can be advocated for children (Level IV data, grade C recommendation) using either RAI or surgery. No recommendation can be given as to whether RAI or surgery is preferred owing to the lack of studies addressing this issue. Increased cancer risk with RAI in children below the age of 5 years supports surgery in this setting (Level I data, grade A recommendation). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; If surgery is considered for definitive management, evidence-based criteria support total thyroidectomy as the surgical technique of choice for GD. Available evidence also supports surgery in the presence of severe endocrine GO. Children with GD should be treated with an ablative strategy. Whether this is achieved by total thyroidectomy or RAI may still be debatable. Data on long-term cancer risk are missing or conflicting; and until RAI has proven harmless in children, we continue to recommend surgery in this group. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=91" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317767</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17588996]]&gt;</url>
    <title>Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivities</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CORNEA,KERATITIS,CONJUNCTIVITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2007 Dec;91(12):1656-61. Epub 2007 Jun 22&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIMS:&lt;/STRONG&gt; The aim of this study was to assess the efficacy of currently available topical drugs for vernal keratoconjunctivitis (VKC) through a meta-analysis of randomised clinical trials (RCTs). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Twenty-seven RCTs (n = 2184 eyes) that had evaluated the efficacy of topical drugs for the treatment of VKC were selected according to the set criteria; 10 of these trials were suitable for statistical analysis and were enrolled in the meta-analysis. Articles published up to December 2005 were identified from the following &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DATA SOURCES:&lt;/STRONG&gt; Medline, Embase, Lilacs, the Cochrane Controlled Trials Register, and references from relevant articles. Articles in any language published with an English abstract, were screened, and those selected for inclusion were written in English, French, German, Italian, Portuguese or Spanish. The quality of the trials was assessed by the Delphi list. Statistical analysis was performed using STATA software. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A significant improvement in all signs and symptoms, except photophobia, was observed after topical treatment for active VKC, independent of the type of treatment. Comparison of the efficacy of different drugs was not possible due to a lack of standardised criteria among studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; The currently available topical drugs are effective in treating acute phases of VKC. However, there is a lack of evidence to support the recommendation of one specific type of medication for treating this disorder. There is a need for standard criteria to assess diagnosis and therapy based on severity. There is also a need for RCTs assessing long-term effects of single drugs to control the disease and to prevent complications.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=42" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317768</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16905558]]&gt;</url>
    <title>Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration</title>
    <publicationDate>2006-09-15T00:00:00</publicationDate>
    <publisher>Human Molecular Genetics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Human Molecular Genetics (Hum Mol Genet) 2006 Sep 15:15(18):2784-90. Epub 2006 Aug 11&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and complement factor H (CFH) polymorphism has been found to associated with the AMD. We performed a meta-analysis to estimate the magnitude of the gene effect and the possible mode of action. A meta-analysis of eight studies assessing association between the CFH Y402H polymorphism and AMD was performed. Data extraction and study quality assessment were performed in duplicate, and heterogeneity and publication bias were explored. There was strong evidence for association between CFH and AMD, with those having CC and TC genotypes being roughly six and 2.5 times more likely to have AMD than patients with TT genotype, suggesting a co-dominant, multiplicative genetic model. The population attributable risk for the CC/TC genotype is 58.9%, i.e. the CFH polymorphism is involved in over half of all AMD. This meta-analysis summarizes the strong evidence for an association between CFH and AMD and indicates a multiplicative model with each C allele increasing the odds of AMD by approximately 2.5-fold. This result is at least as important at the population level as ApoE4 and Alzheimer's disease, playing a role in almost 60% of AMD at the population level.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=128" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317770</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18829807]]&gt;</url>
    <title>Systematic review of digital imaging screening strategies for retinopathy of prematurity</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Pediatrics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,RETINOPATHY OF PREMATURITY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Pediatrics 2008 Oct;122(4):825-30&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Retinal imaging with remote interpretation could decrease the number of diagnostic eye examinations that premature infants need for the detection of retinopathy of prematurity and thus decrease the time demand on the relatively small pool of ophthalmologists who perform retinopathy of prematurity examinations. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; Our goal was to review systematically the evidence regarding the reliability, validity, safety, costs, and benefits of retinal imaging to screen infants who are at risk for retinopathy of prematurity. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; We searched Medline, the Cochrane library, CINAHL, and the bibliographies of all relevant articles. All English-language studies regardless of design with primary data about our study questions were included. We excluded (1) studies that only included subjects with retinopathy of prematurity, (2) hypothetical models other than cost-effectiveness studies, and (3) validity studies without sufficient data to determine prevalence, sensitivity, and specificity or that only evaluated subjects for 1 component of retinopathy of prematurity (eg, plus disease only). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Studies of only 1 retinal imaging device (RetCam [Clarity Medical Systems, Inc, Pleasanton, CA]) met the inclusion criteria. There was a wide range in reported sensitivity, but specificity was high. There were several important limitations noted, including the eye as the unit of analysis instead of the individual or variations in the criteria for determining a true-positive or true-negative screening result. The risk of retinal hemorrhage resulting from imaging is low, and systemic effects (eg, bradycardia, hypertension, decreased oxygen saturation) are mild. No generalizable cost-effectiveness data were found. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; The evidence base is not sufficient to recommend that retinal imaging be routinely adopted by NICUs to identify infants who have serious retinopathy of prematurity.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=78" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322836</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322836]]&gt;</url>
    <title>Systematic reviews</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The eyes and vision specialist collection has searched for and quality appraised, using a tool based on QUORUM criteria, all the systematic reviews that have been published since 1997. &lt;/P&gt;
&lt;P&gt;Click on a&amp;nbsp;topic heading below and then&amp;nbsp;browse through the&amp;nbsp;titles of the reviews that have been published in your particular area of interest.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The reviews have been categorised according to the following health categories - epidemiology, screening, prevention, diagnosis, surgical intervention, therapeutic intervention, rehabilitation, quality of life, service delivery and organisation, economic evaluation, technology assessment and methodology.&amp;nbsp;&amp;nbsp; Click on&amp;nbsp;the review title&amp;nbsp;to view the PubMed abstract.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322827:0" name=internalLink&gt;Adnexal &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320320:0" name=internalLink&gt;Age-related macular degeneration&lt;/A&gt;&amp;nbsp;(Updated&amp;nbsp;May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320342:0" name=internalLink&gt;Cancer&lt;/A&gt;&amp;nbsp;(Updated April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322628:0" name=internalLink&gt;Conjunctiva and conjunctivitis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322643:0" name=internalLink&gt;Cornea, corneal abrasions and keratitis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322833:0" name=internalLink&gt;Drug induced ocular reactions&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320357:0" name=internalLink&gt;Glaucoma&lt;/A&gt;&amp;nbsp;(Updated&amp;nbsp;May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322830:0" name=internalLink&gt;Injuries&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372677:0" name=internalLink&gt;Lacrimal&lt;/A&gt;&amp;nbsp;(Updated&amp;nbsp;October 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320348:0" name=internalLink&gt;Lens and cataract&lt;/A&gt;&amp;nbsp;(Updated&amp;nbsp;May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:387535:0" name=internalLink&gt;Lid&lt;/A&gt; (Updated September 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322673:0" name=internalLink&gt;Low vision, blindness and visual impairment&lt;/A&gt;&amp;nbsp;(Updated&amp;nbsp;May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322700:0" name=internalLink&gt;Neuro-ophthalmology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322620:0" name=internalLink&gt;Ocular motility, amblyopia and strabismus&lt;/A&gt;&amp;nbsp;(Updated January 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320384:0" name=internalLink&gt;Orbit&lt;/A&gt;&amp;nbsp;(Updated&amp;nbsp;May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322583:0" name=internalLink&gt;Refractive error&lt;/A&gt;&amp;nbsp;(Updated&amp;nbsp;May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322701:0" name=internalLink&gt;Retina, retinal vascular occlusions, retinal detachments and retinitis&lt;/A&gt;&amp;nbsp;(Updated July 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320369:0" name=internalLink&gt;Retinopathy&lt;/A&gt;&amp;nbsp;(Updated&amp;nbsp;May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322695:0" name=internalLink&gt;Trachoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322812:0" name=internalLink&gt;Uveitis&lt;/A&gt;&amp;nbsp;(Updated Oct 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322831:0" name=internalLink&gt;Vitreous body&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;New systematic reviews will be identified on a half yearly basis.&amp;nbsp;&amp;nbsp;As soon as&amp;nbsp;the reviews have been appraised and added to the collection&amp;nbsp;our &lt;A href="http://www.library.nhs.uk/eyes/RSSFeed.aspx?feed=55" target="_blank"&gt;'new content' RSS feed&lt;/A&gt; and this homepage will be updated.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Quality appraisals&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/systematic.asp" target="_blank"&gt;To view all the&amp;nbsp;quality appraisals please click here&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:324630:0" name=internalLink&gt;To view the quality appraisals for Cochrane systematic reviews and NIHR Health Technology Assessments please click here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methodology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/Documents/SR%20search%20strategy.pdf" target="_blank"&gt;To view our search strategy please click here&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;The criteria used to identify systematic reviews is detailed in our &lt;A href="http://evslarchive.moorfields.nhs.uk/Documents/CDS_March_2009_V5.pdf" target="_blank"&gt;content development strategy&lt;/A&gt;. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322827</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322827]]&gt;</url>
    <title>Systematic reviews: Adnexal</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LID,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Adnexal&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322544:0" name=internalLink&gt;Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237571:0" name=internalLink&gt;Interventions for involutional lower lid entropion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317915:0" name=internalLink&gt;Treatment options and future prospects for the managment of eyelid malignancies: an evidence-based update&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:239070:0" name=internalLink&gt;Botulinum toxin type A therapy for blepharospasm&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238287:0" name=internalLink&gt;Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>320320</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=320320]]&gt;</url>
    <title>Systematic reviews: Age-related macular degeneration</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Age-related macular degeneration&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317978:0" name=internalLink&gt;Alcohol consumption and the risk of age-related macular degeneration: a systematic review and meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310724:0" name=internalLink&gt;Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310818:0" name=internalLink&gt;How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373452:0" name=internalLink&gt;HTRA1 Promotor Polymorphism and risk of age-related macular degeneration: a meta-analysis&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373450:0" name=internalLink&gt;Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314381:0" name=internalLink&gt;Smoking and age-related macular degeneration: a review of association&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314382:0" name=internalLink&gt;Smoking and the risk of age-related macular degeneration: a meta-analysis&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373457:0" name=internalLink&gt;Smoking history and the incidence of age-related macular degeneration - results from the Muenster Aging and Retina Study (MARS) cohort and systematic review&amp;nbsp;and meta-analysis of observational longitudinal studies&lt;/A&gt; (added May 2010)&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317768:0" name=internalLink&gt;Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317858:0" name=internalLink&gt;The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317860:0" name=internalLink&gt;The natural history of occult choroidal neovascularisation associated with age-related macular degeneration A systematic review&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342488:0" name=internalLink&gt;Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis &lt;/A&gt;(Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:236522:0" name=internalLink&gt;Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:236523:0" name=internalLink&gt;Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:318041:0" name=internalLink&gt;Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:318045:0" name=internalLink&gt;Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310788:0" name=internalLink&gt;Efficacy of (omega)-3 Fatty Acids in Preventing Age-Related Macular Degeneration. A Systematic Review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310802:0" name=internalLink&gt;Evidence for the effect of (Omega)-3 fatty acids on progression of age-related macular degeneration: A systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237086:0" name=internalLink&gt;Ginkgo biloba extract for age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical Interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:318010:0" name=internalLink&gt;Cataract surgery and the development or progression of age-related macular degeneration: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:266515:0" name=internalLink&gt;Laser photocoagulation for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320786:0" name=internalLink&gt;Laser treatment of drusen to prevent progression to advanced age-related macular degeneration&lt;/A&gt;&amp;nbsp;(Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:295758:0" name=internalLink&gt;Macular translocation for age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237594:0" name=internalLink&gt;Photodynamic therapy for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238380:0" name=internalLink&gt;Radiotherapy for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:312217:0" name=internalLink&gt;Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:270896:0" name=internalLink&gt;Surgical implantation of steriods with antiangiogenic characteristics for treating neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317854:0" name=internalLink&gt;The end of submacular surgery for age-related macular degeneration? A meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320786:0" name=internalLink&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372630:0" name=internalLink&gt;A systematic review on the effect of bevacizumab in exudative age-related macular degeneration&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:283679:0" name=internalLink&gt;Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:239000:0" name=internalLink&gt;Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317982:0" name=internalLink&gt;Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373467:0" name=internalLink&gt;Bevacizumab for ocular neovascular diseases: A systematic review &lt;/A&gt;(added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311298:0" name=internalLink&gt;Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372632:0" name=internalLink&gt;Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311299:0" name=internalLink&gt;Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314368:0" name=internalLink&gt;Ranibizumab for the treatment of neovascular age-related macular degeneration: a review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320803:0" name=internalLink&gt;Statins for age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317916:0" name=internalLink&gt;Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Rehabilitation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317964:0" name=internalLink&gt;Age-related macular degeneration and low-vision rehabilitation: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic Evaluation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:254790:0" name=internalLink&gt;Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:286855:0" name=internalLink&gt;Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Quality of Life and Functioning&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342494:0" name=internalLink&gt;Self-management education programs for age-related macular degeneration: a systematic review&lt;/A&gt;&amp;nbsp;(Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;List originally produced September 2009, when new content is added the date of addition to the list is shown e.g. "(Added Jan 2010)".&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;Back to systematic reviews homepage&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>320342</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=320342]]&gt;</url>
    <title>Systematic reviews: Cancer</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Cancer&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311023:0" name=internalLink&gt;Intermittant and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314350:0" name=internalLink&gt;Prognostic factors for progression of childhood optic pathway glioma: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317775:0" name=internalLink&gt;The association between host susceptibility factors and uveal melanoma: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372638:0" name=internalLink&gt;The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:260007:0" name=internalLink&gt;Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311142:0" name=internalLink&gt;Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1066 patients&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:312230:0" name=internalLink&gt;Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311234:0" name=internalLink&gt;Need for high-quality studies in health technology assessments: the case of a systematic review of treatment for retinoblastoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317915:0" name=internalLink&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Technology assessment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;A href="nelh:257014:0" name=internalLink&gt;Systematic review of effectiveness of different treatments for childhood retinoblastoma&lt;BR&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;Back to systematic reviews homepage&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322628</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322628]]&gt;</url>
    <title>Systematic reviews: Conjunctiva and Conjunctivitis</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CONJUNCTIVITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Conjunctiva and Conjunctivitis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;CONJUNCTIVA&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therpeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311036:0" name=internalLink&gt;Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullose acquisita: a systematic literature review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311218:0" name=internalLink&gt;Meta-analysis on the recurrrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placemnt in surgery for primary pterygium&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONJUNCTIVITIS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:236896:0" name=internalLink&gt;Antibiotics versus placebo for acute bacterial conjunctivitis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317767:0" name=internalLink&gt;Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317883:0" name=internalLink&gt;Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:317885:0" name=internalLink&gt;
&lt;P&gt;Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322643</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322643]]&gt;</url>
    <title>Systematic reviews: Cornea, Corneal abrasions and keratitis</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CORNEAL ABRASION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Cornea, Corneal abrasions and keratitis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;CORNEA&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317865:0" name=internalLink&gt;The prognostic role of donor corneoscleral rim cultures in corneal transplantation&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317944:0" name=internalLink&gt;A systematic literature review of surgical interventions for limbal stem cell deficiency in humans&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311019:0" name=internalLink&gt;Incidence of acute endophthalmitis following penetrating keratoplasty: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:270869:0" name=internalLink&gt;Interventions for recurrent corneal erosions&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CORNEAL ABRASIONS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238843:0" name=internalLink&gt;Patching for corneal abrasion &lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:314376:0" name=internalLink&gt;Should we patch corneal abrasions? A meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317880:0" name=internalLink&gt;Topical nonsteroidal anti-inflammatory drugs for corneal abrasions: meta-analysis of randomized trials&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;KERATITIS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310764:0" name=internalLink&gt;Confocal microscopy: a report by the American Academy of Ophthalmology&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237570:0" name=internalLink&gt;Ivermectin for onchocercal eye disease river blindness&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:279127:0" name=internalLink&gt;Medical interventions for fungal keratitis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314371:0" name=internalLink&gt;Risk of corneal inflammatory events with silicone hydrogel and low dk hydrogel extended contact lens wear: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317873:0" name=internalLink&gt;The treatment of herpes simplex virus epithelial keratitis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237910:0" name=internalLink&gt;Therapeutic interventions for herpes simplex virus epithelial keratitis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317876:0" name=internalLink&gt;Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment&lt;/A&gt;&lt;/P&gt;&lt;A href="nelh:270915:0" name=internalLink&gt;
&lt;P&gt;Topical corticosteroids as adjunctive therapy for bacterial keratitis&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;Back to systematic reviews homepage&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322833</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322833]]&gt;</url>
    <title>Systematic reviews: Drug induced ocular reactions</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Drug induced ocular reactions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;DRUG ADVERSE EVENTS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317962:0" name=internalLink&gt;A systematic review of drug induced ocular reactions in diabetes&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>320357</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=320357]]&gt;</url>
    <title>Systematic reviews: Glaucoma</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Glaucoma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317987:0" name=internalLink&gt;Association between MYOC.mt1 promoter polymorphism and risk of primary open-angle glaucoma: a systematic review and meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342478:0" name=internalLink&gt;Cigarette smoking and primary open angle glaucoma: a systematic review&lt;/A&gt;&amp;nbsp;(added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310768:0" name=internalLink&gt;Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310792:0" name=internalLink&gt;Epidemiological association between cigarette smoking and primary open-angle glaucoma: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372424:0" name=internalLink&gt;The association of primary open-angle glaucoma with mortality: a meta-analysis of observational studies&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317924:0" name=internalLink&gt;Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311308:0" name=internalLink&gt;Screening for glaucoma in Canada: a systematic review of the literature&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311305:0" name=internalLink&gt;Screening for open angle glaucoma: systematic review of cost-effectiveness studies&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:239258:0" name=internalLink&gt;Screening for prevention of optic nerve damage due to chronic open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342497:0" name=internalLink&gt;Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis&lt;/A&gt;&amp;nbsp;(added Jan 2010)&lt;A href="nelh:311305:0" name=internalLink&gt;&lt;/P&gt;&lt;/A&gt;
&lt;P&gt;&lt;STRONG&gt;
&lt;TABLE style="WIDTH: 556pt; BORDER-COLLAPSE: collapse" border=0 cellSpacing=0 cellPadding=0 width=741 x:str&gt;
&lt;COLGROUP&gt;
&lt;COL style="WIDTH: 556pt; mso-width-source: userset; mso-width-alt: 27099" width=741&gt;
&lt;TBODY&gt;
&lt;TR style="HEIGHT: 12.75pt" height=17&gt;
&lt;TD style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; BACKGROUND-COLOR: transparent; WIDTH: 556pt; HEIGHT: 12.75pt; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8" height=17 width=741 x:str="'Screening for glaucoma in Canada: a systematic review of the literature"&gt;&lt;FONT size=2 face="MS Sans Serif"&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR style="HEIGHT: 12.75pt" height=17&gt;
&lt;TD style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; BACKGROUND-COLOR: transparent; HEIGHT: 12.75pt; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8" height=17 x:str="'Screening for open angle glaucoma: systematic review of cost-effectiveness studies"&gt;&lt;FONT size=2 face="MS Sans Serif"&gt;&lt;/FONT&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311209:0" name=internalLink&gt;Mydriasis and glaucoma: exploding the myth A systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:239078:0" name=internalLink&gt;Aqueous shunts for glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:312162:0" name=internalLink&gt;Beta radiation for glaucoma surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372417:0" name=internalLink&gt;Efficacy and tolerability of nonpenetrating filtering surgery with and without implant in treatment of open angle glaucoma: a quantitative evaluation of the evidence&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372422:0" name=internalLink&gt;Efficacy and tolerability of nonpenetrating glaucoma surgery augmented with mitomycin C in treatment of open-angle glaucoma: a meta-analysis&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310814:0" name=internalLink&gt;Glaucoma drainage devices: a systematic literature review and current controversies&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311025:0" name=internalLink&gt;Interventions for angle-closure glaucoma: an evidence-based update&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237909:0" name=internalLink&gt;Intra-operative mitomycin C for glaucoma surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:293687:0" name=internalLink&gt;Laser peripheral iridoplasty for angle-closure&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:270877:0" name=internalLink&gt;Laser trabeculoplasty for open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:239158:0" name=internalLink&gt;Lens extraction for chronic angle-closure glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238004:0" name=internalLink&gt;Needling for encapsulated trabeculectomy filtering blebs&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:270948:0" name=internalLink&gt;Acupuncture for glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310687:0" name=internalLink&gt;A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317961:0" name=internalLink&gt;A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310706:0" name=internalLink&gt;Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372425:0" name=internalLink&gt;Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373443:0" name=internalLink&gt;Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372419:0" name=internalLink&gt;Efficacy and tolerability of latanoprost compared to dorzolamide combined with timolol in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trials&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342467:0" name=internalLink&gt;Efficacy and tolerability of prostaglandin analogs: A meta-analysis of randomized controlled clinical trials&lt;/A&gt;&amp;nbsp;(added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:318051:0" name=internalLink&gt;Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:312185:0" name=internalLink&gt;Interventions for improving adherence to ocular hypotensive therapy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237572:0" name=internalLink&gt;Interventions for normal tension glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311064:0" name=internalLink&gt;Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311063:0" name=internalLink&gt;Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:270874:0" name=internalLink&gt;Medical interventions for primary open angle glaucoma and ocular hypertension&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238640:0" name=internalLink&gt;Medical versus surgical interventions for open angle glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311153:0" name=internalLink&gt;Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311155:0" name=internalLink&gt;Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373440:0" name=internalLink&gt;Meta-analysis of articles evaluating routine intraocular pressure control in monotherapy in the United States and Germany&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372415:0" name=internalLink&gt;Meta-analysis of medical intervention for normal tension glaucoma&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311200:0" name=internalLink&gt;Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311232:0" name=internalLink&gt;Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311228:0" name=internalLink&gt;Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311225:0" name=internalLink&gt;Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:250837:0" name=internalLink&gt;Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:236850:0" name=internalLink&gt;Post-operative 5-Fluorouracil for glaucoma surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373446:0" name=internalLink&gt;Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317853:0" name=internalLink&gt;The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322541:0" name=internalLink&gt;The fading of reported effectiveness.&amp;nbsp; A meta-analysis of randomised controlled trials&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317911:0" name=internalLink&gt;Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta- analysis of randomized controlled trials&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317913:0" name=internalLink&gt;Treatment of ocular hypertension and open angle glaucoma: meta- analysis of randomised controlled trials&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic evaluation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:250838:0" name=internalLink&gt;Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Health Technology Assessment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:273810:0" name=internalLink&gt;The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;List originally produced September 2009, when new content is added the date of addition to the list is shown e.g. "(Added Jan 2010)".&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322830</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322830]]&gt;</url>
    <title>Systematic reviews: Injuries</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NHS CORE CONTENT WITHOUT A CATEGORY,INJURIES,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Injuries&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:304909:0" name=internalLink&gt;Vision screening of older drivers for preventing road traffic injuries and fatalities&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327180:0" name=internalLink&gt;Educational interventions for&amp;nbsp;the&amp;nbsp;prevention of eye injuries&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Co-morbidity and risk of accidental injury&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:318018:0" name=internalLink&gt;Chronic health problems and risk of accidental injury in the workplace: A systematic literature review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>372677</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=372677]]&gt;</url>
    <title>Systematic reviews: Lacrimal</title>
    <publicationDate>2010-04-27T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LACRIMAL,DRY EYE,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Lacrimal&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Therapeutic intervention &lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;SPAN lang=EN-GB&gt;&lt;A href="nelh:327200:0" name=internalLink&gt; &lt;P&gt;Assistive technology for rheumatoid arthritis&lt;/A&gt; (Added Oct 2010)&lt;SPAN lang=EN-GB&gt; &lt;P&gt;&lt;A href="nelh:392618:0" name=internalLink&gt;Efficacy of different dry eye treatments with artificial tears or ocular lubricants: A systematic review &lt;/A&gt;(Added Oct 2010)&lt;/P&gt; &lt;P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;A href="nelh:387493:0" name=internalLink&gt;Punctal occlusion for dry eye syndrome&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Therapeutic intervention (cost-effectiveness)&lt;/STRONG&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="nelh:372626:0" name=internalLink&gt;United States cost-effectiveness study of two dry eye ophthalmic lubricants&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;List originally produced September 2009, when new content is added the date of addition to the list is shown e.g. "(Added Jan 2010)".&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P align=right&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;Back to systematic reviews homepage&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>320348</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=320348]]&gt;</url>
    <title>Systematic reviews: Lens and cataract</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Lens and cataract&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310758:0" name=internalLink&gt;Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310689:0" name=internalLink&gt;A systematic overview of the incidence of posterior capsule opacification&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310702:0" name=internalLink&gt;Acute endophthalmitis following cataract surgery: a systematic review of the literature&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372637:0" name=internalLink&gt;Cataract surgical coverage remains lower in women&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238541:0" name=internalLink&gt;Day care versus in-patient surgery for age-related cataract&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:318047:0" name=internalLink&gt;Effect of AcrySof versus silicone or polymethyl methacrylate intraocular lens on posterior capsule opacification&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237798:0" name=internalLink&gt;Multifocal versus monofocal intraocular lenses after cataract extraction&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:293632:0" name=internalLink&gt;Peribulbar versus retrobulbar anaesthesia for cataract surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:312235:0" name=internalLink&gt;Routine preoperative medical testing for cataract surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373485:0" name=internalLink&gt;Safety of continuing warfarin therapy during cataract surgery: A systematic review and meta-analysis&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:266553:0" name=internalLink&gt;Sub-Tenon's anaesthesia versus topical anaesthesia for cataract surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:304923:0" name=internalLink&gt;Surgery for cataracts in people with age-related macular degeneration&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:293681:0" name=internalLink&gt;Surgery for post-vitrectomy cataract&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:236970:0" name=internalLink&gt;Surgical interventions for age-related cataract&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237800:0" name=internalLink&gt;Surgical interventions for bilateral congenital cataract&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317850:0" name=internalLink&gt;The consequences of waiting for cataract surgery: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317856:0" name=internalLink&gt;The incidence of after cataract following three different types of cataract surgery in children: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:266497:0" name=internalLink&gt;Interventions for preventing posterior capsule opacification&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311152:0" name=internalLink&gt;Medical prophylaxis and treatment of cystoid macular edema after cataract surgery The results of a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238539:0" name=internalLink&gt;Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314386:0" name=internalLink&gt;Supplementary intracameral lidocaine for phacoemulsification under topical anesthesia. A meta-analysis of randomized controlled trials&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:266523:0" name=internalLink&gt;Topical anaesthesia alone versus topical anaesthesia with intracameral lidocaine for phacoemulsification&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Service delivery and organisation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317952:0" name=internalLink&gt;A systematic literature review of the evidence on benchmarks for cataract surgery waiting time&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic evaluation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310815:0" name=internalLink&gt;Global cost-effectiveness of cataract surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;STRONG&gt;Cataract as a complication&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373487:0" name=internalLink&gt;Dose-response relationship of inhaled corticosteriods and cataracts: A systematic review and meta-analysis&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310773:0" name=internalLink&gt;Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;IOL design&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342470:0" name=internalLink&gt;Effect of intraocular lens design on posterior capsule opacification&lt;/A&gt; (Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310791:0" name=internalLink&gt;Efficacy of different intraocular lens materials and optic edge designs in preventing posterior capsular opacification: a meta- analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Quality of Life&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372614:0" name=internalLink&gt;Effectiveness of cataract surgery in reducing driving-related difficulties: a systematic review and meta-analysis&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;List originally produced September 2009, when new content is added the date of addition to the list is shown e.g. "(Added Jan 2010)".&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>387535</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=387535]]&gt;</url>
    <title>Systematic reviews: Lid</title>
    <publicationDate>2010-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LID,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Lid&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Therapeutic intervention &lt;/STRONG&gt;&lt;/P&gt;&lt;A href="nelh:387507:0" name=internalLink&gt;
&lt;P&gt;Interventions for acute internal hordeolum&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;Back to systematic reviews homepage&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322673</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322673]]&gt;</url>
    <title>Systematic reviews: Low vision, blindness and visual impairment</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Low vision, blindness and visual impairment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;LOW VISION&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310761:0" name=internalLink&gt;Blindness and visual impairment in the Americas and the Caribbean&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310812:0" name=internalLink&gt;Gender and blindness: a meta-analysis of population-based prevalence surveys&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317863:0" name=internalLink&gt;The prevalence and incidence of visual impairment in people of age 20-59 years in industrialised countries: a review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310721:0" name=internalLink&gt;Assessment of diagnostic tests to inform policy decisions - visual electrodiagnosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:236793:0" name=internalLink&gt;Community screening for visual impairment in the elderly&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310777:0" name=internalLink&gt;Effectiveness of screening older people for impaired vision in community setting: systematic review of evidence from randomised controlled trials&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373491:0" name=internalLink&gt;Screening older adults for impaired visual acuity: A review of the evidence for the U.S. Preventive Services Task Force&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Rehabilitation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342485:0" name=internalLink&gt;Effectiveness of assistive technologies for low vision rehabilitation: a systematic review&lt;/A&gt; (Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238322:0" name=internalLink&gt;Orientation and mobility training for adults with low vision&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237745:0" name=internalLink&gt;Reading aids for adults with low vision&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;LIVING WITH VISUAL IMPAIRMENT&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Health information needs&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310816:0" name=internalLink&gt;Health information needs of visually impaired people: a systematic review of the literature&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methodology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314362:0" name=internalLink&gt;Psychometric properties of vision-related quality of life questionnaires: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;VISUAL FUNCTIONING&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310766:0" name=internalLink&gt;Cumulative meta-analysis of the relationship between useful field of view and driving performance in older adults: current and future implications&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NIGHT VISION&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310712:0" name=internalLink&gt;Anthocyanosides of Vaccinum myrtillus bilberry for night vision - a systematic review of placebo-controlled trials&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;List originally produced September 2009, when new content is added the date of addition to the list is shown e.g. "(Added Jan 2010)".&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322700</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322700]]&gt;</url>
    <title>Systematic reviews: Neuro-ophthalmology</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OPTIC NERVE AND VISUAL PATHWAYS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Neuro-ophthalmology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314372:0" name=internalLink&gt;Seasonal patterns in optic neuritis and multiple sclerosis: A meta analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310694:0" name=internalLink&gt;A systematic review of diagnostic studies in myasthenia gravis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238126:0" name=internalLink&gt;Interventions for idiopathic intracranial hypertension&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237184:0" name=internalLink&gt;Surgery for nonarteritic anterior ischemic optic neuropathy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:239032:0" name=internalLink&gt;Surgery for traumatic optic neuropathy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237279:0" name=internalLink&gt;Corticosteroids for treating optic neuritis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310805:0" name=internalLink&gt;Evidence report. The medical treatment of ocular myasthenia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:239062:0" name=internalLink&gt;Medical and surgical treatment for ocular myasthenia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314384:0" name=internalLink&gt;Steroids for multiple sclerosis and optic neuritis: A meta-analysis of randomized controlled clinical trials&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:270949:0" name=internalLink&gt;Steroids for traumatic optic neuropathy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Rehabilitation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317852:0" name=internalLink&gt;The effect of visual training for patients with visual field defects due to brain damage: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317931:0" name=internalLink&gt;Visual deficit interventions in adult stroke and brain injury: a systematic review&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322620</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322620]]&gt;</url>
    <title>Systematic reviews: Ocular motility, amblyopia and strabismus</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,STRABISMUS,AMBLYOPIA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Ocular motility, amblyopia and strabismus&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310700:0" name=internalLink&gt;A systematic review of vision screening tests for the detection of amblyopia&lt;/A&gt;&lt;/P&gt;&lt;SPAN lang=EN-GB&gt;
&lt;P&gt;&lt;A href="nelh:341930:0" name=internalLink&gt;Diagnostic accuracy of vision screening tests for the detection of amblyopia and its risk factors: a systematic review&lt;/A&gt; (Added Jan 2010)&lt;/P&gt;&lt;SPAN lang=EN-GB&gt;
&lt;P&gt;&lt;A href="nelh:341935:0" name=internalLink&gt;Effectiveness of screening preschool children for amblyopia: A systematic review&lt;/A&gt; (Added Jan 2010)&lt;/P&gt;&lt;/SPAN&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;A href="nelh:239030:0" name=internalLink&gt;Vision screening for amblyopia in childhood&lt;/A&gt;&amp;nbsp;(Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238540:0" name=internalLink&gt;Adjustable versus non-adjustable sutures for strabismus&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:239077:0" name=internalLink&gt;Interventions for infantile esotropia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238468:0" name=internalLink&gt;Interventions for intermittent exotropia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322557:0" name=internalLink&gt;Interventions for intermittent distance exotropia: a review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:312206:0" name=internalLink&gt;Botullinum toxin for the treatment of strabismus&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327184:0" name=internalLink&gt;Conventional occlusion versus pharmacologic penalization for amblyopia&lt;/A&gt;&amp;nbsp;(Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238999:0" name=internalLink&gt;Interventions for stimulus deprivation amblyopia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:283733:0" name=internalLink&gt;Interventions for strabismic amblyopia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:295702:0" name=internalLink&gt;Interventions for unilateral refractive amblyopia&lt;/A&gt;&amp;nbsp;(Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Economic evaluation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:289065:0" name=internalLink&gt;The clinical effectiveness and cost effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years.&amp;nbsp; A systematic review and economic evaluation&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Technology assessment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:252276:0" name=internalLink&gt;Pre-school vision screening&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;List originally produced September 2009, when new content is added&amp;nbsp;the date of addition to the list is shown e.g. "(Added Jan 2010)".&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>320384</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=320384]]&gt;</url>
    <title>Systematic reviews: Orbit</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,ORBIT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Orbit&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:318035:0" name=internalLink&gt;Cigarette smoking and thyroid eye disease: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311296:0" name=internalLink&gt;Orbital tuberculosis: a review of the literature&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372635:0" name=internalLink&gt;A systematic review of outcomes following surgical decompression for dysthyroid orbitopathy&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310765:0" name=internalLink&gt;Corticosteroid treatment of periorbital haemangioma of infancy: a review of the evidence&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311295:0" name=internalLink&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Technology assessment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311293:0" name=internalLink&gt;Orbital implants in enucleation surgery: a report by the American Academy of Ophthalmology&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;GRAVES OPHTHALMOLOGY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:320386:0" name=internalLink&gt;Association of tumour necrosis factor alpha (TNF-alpha) polymorphisms with Graves' disease: A meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317764:0" name=internalLink&gt;Surgical treatment of Graves' disease: evidence-based approach&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311295:0" name=internalLink&gt;Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372620:0" name=internalLink&gt;Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: A systematic review&lt;/A&gt;&amp;nbsp;(added April 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373507:0" name=internalLink&gt;Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>324630</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=324630]]&gt;</url>
    <title>Systematic reviews: Quality appraisals - Cochrane and NIHR HTA's</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Quality appraisals - Cochrane and NIHR HTA's&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Please use the links below to view the quality appraisals carried out by the NHS Evidence - eyes and vision team on the Cochrane systematic reviews and NIHR Health Technology Assessments identified. &lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;Cochrane&lt;/STRONG&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=41" target="_blank"&gt;Acupuncture for glaucoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=108" target="_blank"&gt;Adjustable versus non-adjustable sutures for strabismus&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=93" target="_blank"&gt;Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=268" target="_blank"&gt;Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=145" target="_blank"&gt;Antiangiogenic therapy with interferon alfa for neovascular age- related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=172" target="_blank"&gt;Antibiotics for trachoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=214" target="_blank"&gt;Antibiotics versus control for toxoplasma retinochoroiditis&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=112" target="_blank"&gt;Antibiotics versus placebo for acute bacterial conjunctivitis&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=229" target="_blank"&gt;Antioxidant vitamin and mineral supplementation for preventing age- related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=70" target="_blank"&gt;Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=143" target="_blank"&gt;Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=142" target="_blank"&gt;Aqueous shunts for glaucoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=301" target="_blank"&gt;Assistive technology for rheumatoid arthritis&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=259" target="_blank"&gt;Beta radiation for glaucoma surgery&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=263" target="_blank"&gt;Botulinum toxin for the treatment of strabismus&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=175" target="_blank"&gt;Botulinum toxin type A therapy for blepharospasm&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=139" target="_blank"&gt;Community screening for visual impairment in the elderly&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=248" target="_blank"&gt;Conventional occlusion versus pharmacologic penalization for amblyopia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=102" target="_blank"&gt;Corticosteroids for treating optic neuritis&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=173" target="_blank"&gt;Day care versus in-patient surgery for age-related cataract&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=222" target="_blank"&gt;Early light reduction for preventing retinopathy of prematurity in very low birth weight infants&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=270" target="_blank"&gt;Educational interventions for the prevention of eye injuries&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=171" target="_blank"&gt;Environmental sanitary interventions for preventing active trachoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=298" target="_blank"&gt;Excimer laser refractive surgery versus phakic intraocular lenses for the correction of moderate to high myopia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=182" target="_blank"&gt;Face washing promotion for preventing active trachoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=228" target="_blank"&gt;Ginkgo biloba extract for age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=299" target="_blank"&gt;Interventions for acute internal hordeolum&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=260" target="_blank"&gt;Interventions for acute non-arteritic central retinal artery occlusion&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=177" target="_blank"&gt;Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=101" target="_blank"&gt;Interventions for herpes simplex virus epithelial keratitis&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=161" target="_blank"&gt;Interventions for idiopathic intracranial hypertension&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=262" target="_blank"&gt;Interventions for improving adherence to ocular hypotensive therapy&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=174" target="_blank"&gt;Interventions for infantile esotropia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=137" target="_blank"&gt;Interventions for intermittent exotropia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=213" target="_blank"&gt;Interventions for involutional lower lid entropion&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=208" target="_blank"&gt;Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=199" target="_blank"&gt;Interventions for normal tension glaucoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=35" target="_blank"&gt;Interventions for preventing posterior capsule opacification&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=264" target="_blank"&gt;Interventions for prevention of giant retinal tear in the fellow eye&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=53" target="_blank"&gt;Interventions for recurrent corneal erosions&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=37" target="_blank"&gt;Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=134" target="_blank"&gt;Interventions for stimulus deprivation amblyopia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=90" target="_blank"&gt;Interventions for strabismic amblyopia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=135" target="_blank"&gt;Interventions for trachoma trichiasis&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=247" target="_blank"&gt;Interventions for unilateral refractive amblyopia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=153" target="_blank"&gt;Intra-operative mitomycin C for glaucoma surgery&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=297" target="_blank"&gt;Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=73" target="_blank"&gt;Intravitreal steroids for macular edema in diabetes&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=249" target="_blank"&gt;Intravitreal steriods versus observation for macular edema secondary to central retinal vein occlusion&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=221" target="_blank"&gt;Ivermectin for onchocercal eye disease river blindness&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=87" target="_blank"&gt;Laser peripheral iridoplasty for angle-closure&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=152" target="_blank"&gt;Laser photocoagulation for choroidal neovascularisation in pathologic myopia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=52" target="_blank"&gt;Laser photocoagulation for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=45" target="_blank"&gt;Laser trabeculoplasty for open angle glaucoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=242" target="_blank"&gt;Laser treatment of drusen to prevent progression to advanced age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=133" target="_blank"&gt;Lens extraction for chronic angle-closure glaucoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=237" target="_blank"&gt;Macular translocation for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=141" target="_blank"&gt;Medical and surgical treatment for ocular myasthenia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=72" target="_blank"&gt;Medical interventions for fungal keratitis&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=50" target="_blank"&gt;Medical interventions for primary open angle glaucoma and ocular hypertension&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=170" target="_blank"&gt;Medical versus surgical interventions for open angle glaucoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=265" target="_blank"&gt;Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=116" target="_blank"&gt;Multifocal versus monofocal intraocular lenses after cataract extraction&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=188" target="_blank"&gt;Needling for encapsulated trabeculectomy filtering blebs&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=176" target="_blank"&gt;Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=136" target="_blank"&gt;Orientation and mobility training for adults with low vision&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=107" target="_blank"&gt;Patching for corneal abrasion&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=84" target="_blank"&gt;Pentoxifylline for diabetic retinopathy&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=56" target="_blank"&gt;Peribulbar versus retrobulbar anaesthesia for cataract surgery&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=1" target="_blank"&gt;Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=2" target="_blank"&gt;Pharmacotherapy for Behcet's syndrome&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=154" target="_blank"&gt;Photodynamic therapy for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=266" target="_blank"&gt;Photorefractive keratectomy (PRK) versus laser-assisted in-situ kertomileusis (LASIK) for hyperopia correction&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=106" target="_blank"&gt;Photorefractive keratectomy PRK versus laser-assisted in-situ keratomileusis LASIK for myopia&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=219" target="_blank"&gt;Post-operative 5-Fluorouracil for glaucoma surgery&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=300" target="_blank"&gt;Punctal occlusion for dry eye syndrome&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=180" target="_blank"&gt;Radiotherapy for neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=115" target="_blank"&gt;Reading aids for adults with low vision&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=304" target="_blank"&gt;Restricted versus liberal oxygen exposure for preventing morbidity and mortality in preterm or low birth weight infants&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=267" target="_blank"&gt;Routine preoperative medical testing for cataract surgery&lt;/A&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=178" target="_blank"&gt;Screening for correctable visual acuity deficits in school-age children and adolescents&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=114" target="_blank"&gt;Screening for prevention of optic nerve damage due to chronic open angle glaucoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=243" target="_blank"&gt;Statins for age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=55" target="_blank"&gt;Steroids for traumatic optic neuropathy&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=230" target="_blank"&gt;Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=33" target="_blank"&gt;Sub-Tenon's anaesthesia versus topical anaesthesia for cataract surgery&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=205" target="_blank"&gt;Supplemental oxygen for the treatment of prethreshold retinopathy of prematurity&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=258" target="_blank"&gt;Surgery for cataracts in people with age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=146" target="_blank"&gt;Surgery for nonarteritic anterior ischemic optic neuropathy&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=69" target="_blank"&gt;Surgery for post-vitrectomy cataract&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=151" target="_blank"&gt;Surgery for traumatic optic neuropathy&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=36" target="_blank"&gt;Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=117" target="_blank"&gt;Surgical interventions for age-related cataract&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=138" target="_blank"&gt;Surgical interventions for bilateral congenital cataract&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=269" target="_blank"&gt;Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=94" target="_blank"&gt;Therapeutic interventions for herpes simplex virus epithelial keratitis&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=34" target="_blank"&gt;Topical anaesthesia alone versus topical anaesthesia with intracameral lidocaine for phacoemulsification&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=46" target="_blank"&gt;Topical corticosteroids as adjunctive therapy for bacterial keratitis&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=241" target="_blank"&gt;Vision screening for amblyopia in childhood&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=261" target="_blank"&gt;Vision screening of older drivers for preventing road traffic injuries and fatalities&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=85" target="_blank"&gt;Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;NIHR Heatlh Technology Assessment systematic reviews&lt;/STRONG&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=206" target="_blank"&gt;Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=11" target="_blank"&gt;Preschool vision screening&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=65" target="_blank"&gt;Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=149" target="_blank"&gt;Systematic review of effectiveness of different treatments for childhood retinoblastoma&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=29" target="_blank"&gt;The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=60" target="_blank"&gt;The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: A systematic review and economic evaluation&lt;/A&gt;&lt;BR&gt;&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt; &lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt; &lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322583</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322583]]&gt;</url>
    <title>Systematic reviews: Refractive error</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,REFRACTIVE ERROR,SHORT SIGHT (MYOPIA),CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Refractive error&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Screening &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:239031:0" name=internalLink&gt;Screening for correctable visual acuity deficits in school-age children and adolescents&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311039:0" name=internalLink&gt;Interventions to retard myopia progression in children: an evidence-based update&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342475:0" name=internalLink&gt;Comparison of laser epithelial keratomileusis and photorefractive keratectomy for the correction of myopia: a meta-analysis&lt;/A&gt; (Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310797:0" name=internalLink&gt;Evaluation of the effectiveness of laser in situ keratomileusis and photorefractive keratectomy for myopia: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310809:0" name=internalLink&gt;Evidence for superior efficacy and safety of LASIK over photorefractive keratectomy for correction of myopia &lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:374535:0" name=internalLink&gt;Excimer laser refractive surgery versus phakic intraocular lenses for the correction of moderate to high myopia&lt;/A&gt;&amp;nbsp;(added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238844:0" name=internalLink&gt;Laser photocoagulation for choroidal neovascularisation in pathologic myopia&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238998:0" name=internalLink&gt;Photorefractive keratectomy PRK versus laser-assisted-in-situ keratomileusis LASIK for myopia&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:312226:0" name=internalLink&gt;Photorefractive keratectomy PRK versus laser assisted in situ keratomileusis (LASIK) for hyperopia correction&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;List originally produced September 2009, when new content is added the date of addition to the list is shown e.g. "(Added Jan 2010)".&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322701</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322701]]&gt;</url>
    <title>Systematic reviews: Retina, retinal vascular occlusions, retinal detachments and retinitis</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINAL TEARS AND DETACHMENT,RETINAL VASCULAR OCCLUSION,RETINITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Retina, retinal vascular occlusions, retinal detachments and retinitis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;RETINA - GENERAL &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314369:0" name=internalLink&gt;Retinal microvascular abnormalities and cognitive dysfunction: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN lang=EN-GB&gt;&lt;A href="nelh:341911:0" name=internalLink&gt;&lt;SPAN lang=EN-GB&gt;Retinal microvascular abnormalities and stroke: A systematic review&lt;/SPAN&gt;&lt;/A&gt;&amp;nbsp;(Added Jan 2010)&lt;BR&gt;&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311191:0" name=internalLink&gt;Meta-analysis of chromovitrectomy with indocyanine green in macular hole surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237569:0" name=internalLink&gt;Antibiotics versus control for toxoplasma retinochoroiditis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RETINAL VASCULAR OCCLUSIONS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;SPAN lang=EN-GB&gt;
&lt;P&gt;&lt;A href="nelh:341940:0" name=internalLink&gt;Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism, and Risk of Retinal Vein Occlusion: A Meta-analysis&lt;/A&gt;&amp;nbsp;(Added Jan 2010)&lt;/P&gt;&lt;/SPAN&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310770:0" name=internalLink&gt;Does this patient have temporal arteritis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311026:0" name=internalLink&gt;Interventions for branch retinal vein occlusions: an evidence-based systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311028:0" name=internalLink&gt;Interventions for central retinal vein occlusions: an evidence-based systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237060:0" name=internalLink&gt;Interventions for acute non-arteritic central retinal artery occlusion&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:304981:0" name=internalLink&gt;Intravitreal steriods&amp;nbsp;versus observation for macular&amp;nbsp;edema secondary to&amp;nbsp;central retinal vein occlusion&lt;/A&gt; (Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Quality of Life/Functioning&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311196:0" name=internalLink&gt;Meta-analysis of plasma homocysteine, serum folate, serum vitamin B12 and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RETINAL DETACHMENTS&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310690:0" name=internalLink&gt;A systematic review of anatomical and visual function outcomes in preterm infants after scleral buckle and vitrectomy for retinal detachment&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310703:0" name=internalLink&gt;An evidence-based analysis of surgical interventions for uncomplicated rhegmatogenous retinal detachment&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237799:0" name=internalLink&gt;Interventions for asymptomatic retinal breaks and lattice degeneration for preventing retinal detachment&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:312213:0" name=internalLink&gt;Interventions for prevention of giant retinal tear in the fellow eye&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314387:0" name=internalLink&gt;Surgical management of pseudophakic retinal detachments: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327173:0" name=internalLink&gt;Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:380422:0" name=internalLink&gt;Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.&lt;/A&gt;&amp;nbsp;(Added July 2010)&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RETINITIS PIGMENTOSA&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317855:0" name=internalLink&gt;The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;RETINOPATHY OF PREMATURITY&lt;/H3&gt;
&lt;P&gt;&lt;A href="nelh:236815:0" name=internalLink&gt;Restricted versus liberal oxygen exposure for preventing morbidity and mortality in preterm or low birth weight infants&amp;nbsp;&lt;/A&gt;(Added Dec 2010)&lt;/P&gt;
&lt;P&gt;List originally produced September 2009, when new content is added the date of addition to the list is shown e.g. "(Added Jan 2010)".&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;Back to systematic reviews homepage&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>320369</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=320369]]&gt;</url>
    <title>Systematic reviews: Retinopathy</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,RETINOPATHY OF PREMATURITY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Retinopathy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;DIABETIC RETINOPATHY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373481:0" name=internalLink&gt;A systematic meta-analysis of genetic association studies for diabetic retinopathy&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310795:0" name=internalLink&gt;Epidemiology of diabetic retinopathy and macular oedema: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373474:0" name=internalLink&gt;Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317871:0" name=internalLink&gt;The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:372622:0" name=internalLink&gt;The effects of complications and comorbidities on the quality of preventive diabetes care: a literature review&lt;/A&gt;&amp;nbsp;(added April 2010)&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Screening &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:322543:0" name=internalLink&gt;Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310776:0" name=internalLink&gt;Effectiveness of screening and monitoring tests for diabetic retinopathy--a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311291:0" name=internalLink&gt;Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317870:0" name=internalLink&gt;The quality of reporting of diagnostic accuracy studies in diabetic retinopathy screening: A systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310717:0" name=internalLink&gt;Aspirin in diabetic retinopathy A systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311150:0" name=internalLink&gt;Management of diabetic retinopathy: a systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:327217:0" name=internalLink&gt;Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342503:0" name=internalLink&gt;Interventions for diabetic macular oedema: a systematic review of the literature&lt;/A&gt; (Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342481:0" name=internalLink&gt;Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review&lt;/A&gt; (Added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:279149:0" name=internalLink&gt;Intravitreal steroids for macular edema in diabetes&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:283727:0" name=internalLink&gt;Pentoxifylline for diabetic&amp;nbsp;retinopathy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373476:0" name=internalLink&gt;Visual acuity of intravitreal triamcinolone for diabetic macular edema refractory to laser treatment: a meta-analysis&lt;/A&gt;&amp;nbsp;&amp;nbsp;(added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:279175:0" name=internalLink&gt;Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RETINOPATHY OF PREMATURITY (ROP)&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317773:0" name=internalLink&gt;Systemic fungal infection is associated with the development of retinopathy of prematurity in very low birth weight infants: a meta-review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Screening&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317770:0" name=internalLink&gt;Systematic review of digital imaging screening strategies for retinopathy of prematurity&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:236400:0" name=internalLink&gt;Early light reduction for preventing retinpathy of prematurity in very low&amp;nbsp;birth weight infants&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:373472:0" name=internalLink&gt;A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity&lt;/A&gt; (added May 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:342493:0" name=internalLink&gt;Foundations in newborn care: Pain management during retinopathy of prematurity eye examinations: a systematic review&lt;/A&gt;&amp;nbsp;(added Jan 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237204:0" name=internalLink&gt;Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238163:0" name=internalLink&gt;Supplemental oxygen for the treatment of prethreshold retinopathy of prematurity&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;HYPOTENSIVE RETINOPATHY&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317921:0" name=internalLink&gt;Value of routine funduscopy in patients with hypertension: systematic review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;List originally produced September 2009, when new content is added the date of addition to the list is shown e.g. "(Added Jan 2010)".&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P align=right&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322695</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322695]]&gt;</url>
    <title>Systematic reviews: Trachoma</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CORNEA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Trachoma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238379:0" name=internalLink&gt;Environmental sanitary interventions for preventing active trachoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238005:0" name=internalLink&gt;Face washing promotion for preventing active trachoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:314346:0" name=internalLink&gt;Preventing trachoma through environmental sanitation: a review of the evidence base&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:238381:0" name=internalLink&gt;Interventions for trachoma trichiasis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic interventions&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:237136:0" name=internalLink&gt;Antibiotics for trachoma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;Back to systematic reviews homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322812</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322812]]&gt;</url>
    <title>Systematic reviews: Uveitis</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,UVEAL TRACT,UVEITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Uveitis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Epidemiology&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310821:0" name=internalLink&gt;Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311301:0" name=internalLink&gt;Prevalence and characteristics of uveitis in the spondyloarthropathies: A systematic literature review&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317919:0" name=internalLink&gt;Uveitis: a global perspective&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Surgical intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:317934:0" name=internalLink&gt;Vitrectomy in the treatment of uveitis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Therapeutic intervention&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:392613:0" name=internalLink&gt;Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease &lt;/A&gt;(Added Oct 2010)&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:236821:0" name=internalLink&gt;Pharmacotherapy for Behcet's syndrome&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;List originally produced September 2009, when new content is added the date of addition to the list is shown e.g. "(Added Jan 2010)".&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;Back to systematic reviews homepage&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>322831</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=322831]]&gt;</url>
    <title>Systematic reviews: Vitreous body</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VITREOUS BODY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Systematic reviews: Vitreous body&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;VITREOUS HAEMORRHAGE&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Diagnosis&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:310697:0" name=internalLink&gt;A systematic review of Terson's syndrome: frequency and prognosis after subarachnoid haemorrhage&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;A href="nelh:322836:0" name=internalLink&gt;
&lt;P align=right&gt;Back to systematic reviews homepage&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>317773</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18046338]]&gt;</url>
    <title>Systemic fungal infection is associated with the development of retinopathy of prematurity in very low birth weight infants: a meta-review</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Journal of Perinatology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,RETINOPATHY OF PREMATURITY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;EM&gt;Source: Journal of Perinatology: official journal of the California Perinatal Association (J Perinatol) 2008 Jan;28(1):61-6. Epub 2007 Nov 29&lt;/EM&gt; 
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To study the association between systemic fungal infection (SFI) and the development of retinopathy of prematurity (ROP) and severe ROP in very low birth weight (VLBW) infants by systematic review and meta-analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;STUDY DESIGN:&lt;/STRONG&gt; A meta-review was performed using a fixed effects model. The exposure and outcomes studied were SFI and all ROP/severe ROP, respectively in VLBW infants. Results and effect sizes analyzed with Review Manager 4.2 software are expressed as relative risk (RR), odds ratio (OR), risk difference (RD) and number needed to harm (NNH) with 95% confidence intervals. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULT:&lt;/STRONG&gt; Data for severe ROP were available from eight studies and on all ROP from seven of those eight studies. Estimated gestational age ranged from 24.7+/-1.6 to 28.6+/-4 weeks and birth weight from 673 (median) (range 426 to 995) to 1108+/-266 g (mean+/-s.d.). A total of 261 of 303 babies with SFI had all ROP vs 1081 of 1648 babies without SFI (OR 3.4(*), 2.34-4.95) and 118 of 330 babies with SFI had severe ROP vs 235 of 1951 babies without SFI (OR 4.06(*), 3.05-5.42). The NNH was 5.56(*) (4.54-7.14) for all ROP and 4.54(*) (3.70 to 5.88) for severe ROP ((*) P&amp;lt;0.00001). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; SFIs are associated with the development of all degrees of ROP and severe ROP in VLBW infants.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=57" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102316</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10532441&amp;query_hl=13]]&gt;</url>
    <title>TAP study group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. One-year results of 2 randomised clinical trials - TAP report 1.</title>
    <publicationDate>1999-10-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Arch Ophthalmol 1999 Oct; 117:1329-1345&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To determine if photodynamic therapy with verteporfin (Visudyne; CIBA Vision Corp, Duluth, Ga) can safely reduce the risk of vision loss in patients with subfoveal choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD). &lt;/P&gt;
&lt;P&gt;DESIGN: Two multicenter, double-masked, placebo-controlled, randomized clinical trials. &lt;/P&gt;
&lt;P&gt;SETTING: Twenty-two ophthalmology practices in Europe and North America. &lt;/P&gt;
&lt;P&gt;PARTICIPANTS: Patients with subfoveal CNV lesions caused by AMD measuring 5400 microm or less in greatest linear dimension with evidence of classic CNV and best-corrected visual acuity of approximately 20/40 to 20/200. &lt;/P&gt;
&lt;P&gt;METHODS: Six hundred nine patients were randomly assigned (2: 1) to verteporfin (6 mg per square meter of body surface area) or placebo (5% dextrose in water) administered via intravenous infusion of 30 mL over 10 minutes. Fifteen minutes after the start of the infusion, a laser light at 689 nm delivered 50J/cm2 at an intensity of 600 mW/cm2 over 83 seconds using a spot size with a diameter 1000 microm larger than the greatest linear dimension of the CNV lesion. At follow-up examinations every 3 months, retreatment with the same regimen was applied if angiography showed fuorescein leakage. The primary outcome was the proportion of eyes with fewer than 15 letters lost (approximately &amp;lt;3 lines of loss), adhering to an intent-to-treat analysis. &lt;/P&gt;
&lt;P&gt;RESULTS: In each group, 94% of patients completed the month 12 examination. Visual acuity, contrast sensitivity, and fluorescein angiographic outcomes were better in the verteporfin-treated eyes than in the placebo-treated eyes at every follow-up examination through the month 12 examination. At the month-12 examination, 246 (61%) of 402 eyes assigned to verteporfin compared with 96 (46%) of 207 eyes assigned to placebo had lost fewer than 15 letters of visual acuity from baseline (P&amp;lt;.001). In subgroup analyses, the visual acuity benefit (&amp;lt; 15 letters lost) of verteporfin therapy was clearly demonstrated (67% vs 39%; P&amp;lt;.001) when the area of classic CNV occupied 50% or more of the area of the entire lesion (termed predominantly classic CNV lesions), especially when there was no occult CNV. No statistically significant differences in visual acuity were noted when the area of classic CNV was more than 0% but less than 50% of the area of the entire lesion. Few ocular or other systemic adverse events were associated with verteporfin treatment, compared with placebo, including transient visual disturbances (18% vs 12%), injection-site adverse events (13% vs 3%), transient photosensitivity reactions (3% vs 0%), and infusion-related low back pain (2% vs 0%). &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Since verteporfin therapy of subfoveal CNV from AMD can safely reduce the risk of vision loss, we recommend verteporfin therapy for treatment of patients with predominantly classic CNV from AMD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;age related macular degeneration management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102311:0" name=internalLink&gt;Verteporfin in Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>156796</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.eugs.org/eng/EGS_guidelines.asp]]&gt;</url>
    <title>Terminology and guidelines for glaucoma (III edition)</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>The European Glaucoma Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Third&amp;nbsp;edition of Teminology and Guidelines for glaucoma produced by the European Glaucoma Society (EGS) with the aim of improving the understanding of glaucoma, diagnosis and management of glaucoma.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Available in full text upon English, Spanish, Deutsch, French, Italian and Turkish. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;Registration with site required before downloading.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102029</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12383805&amp;query_hl=1]]&gt;</url>
    <title>The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty.</title>
    <publicationDate>2002-10-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American Journal of Ophthalmology, {Am-J-Ophthalmol}, Oct 2002, vol. 134, no. 4, p. 481-98, ISSN: 0002-9394.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To investigate the association of pre-intervention and post-intervention patient and eye characteristics with failure of argon laser trabeculoplasty (ALT) and trabeculectomy.DESIGN: Cohort study of participants in the Advanced Glaucoma Intervention Study.&lt;/P&gt;
&lt;P&gt;METHODS: This multicenter study took place between 1988 and 2001. Between 1988 and 1992, 789 eyes of 591 patients aged 35 to 80 years with advanced glaucoma were randomized into one of two surgical treatment sequences: argon laser trabeculoplasty (ALT)-trabeculectomy-trabeculectomy or trabeculectomy-ALT-trabeculectomy. Upon study-defined failure (based on maximum medications, sustained intraocular pressure (IOP) elevation, visual field defect, and disk rim deterioration) of each intervention, patients were offered the subsequent intervention. Potential follow-up was 8 to 13 years. This report is based on data from 779 eyes that had at least 3 months of follow-up. The main outcome measures are failure of ALT and trabeculectomy, whether as first or second interventions. Effect size is measured by the hazard ratio (HR) and its corresponding 95% confidence interval (CI) obtained from Cox multiple regression analysis, where HR corresponds to the coefficient of change in risk associated with a unit increase in a factor. For binary factors, this corresponds to the change in risk in eyes with the factor relative to the risk in eyes without the factor.&lt;/P&gt;
&lt;P&gt;RESULTS: Pre-intervention factors associated with failure of ALT are younger age (HR = 0.98, CI = 0.96-0.99, P =.009) and higher IOP (1.11, 1.08-1.15, P &amp;lt;.001). Pre-intervention factors associated with failure of trabeculectomy are younger age (HR = 0.97, CI = 0.95-0.99, P =.005) and higher IOP (1.04, 1.01-1.06, P =.002), as well as diabetes (2.86, 1.88-4.36, P &amp;lt;.001) and any postoperative complication (1.99, 1.35-2.93, P &amp;lt;.001). Individual postoperative complications significantly associated with increased risk of failure of trabeculectomy are elevated IOP (3.4, 1.9-6.1, P &amp;lt;.001) and marked inflammation (2.4, 1.3-4.6, P =.006).&lt;/P&gt;
&lt;P&gt;CONCLUSIONS: In this study, ALT failure was associated with younger age and higher pre-intervention IOP. Trabeculectomy failure was associated with younger age, higher pre-intervention IOP, diabetes, and one or more postoperative complications, particularly elevated IOP and marked inflammation. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7956270&amp;amp;query_hl=6" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7741836&amp;amp;query_hl=3" target="_blank"&gt;The Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9663214&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9663215&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9932993&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11115258&amp;amp;query_hl=18" target="_blank"&gt;The advanced glaucoma intervention study, 6: effect of cataract on visual field and visual acuity. The AGIS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102015:0" name=internalLink&gt;The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration .The AGIS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11735786&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11530042&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102031:0" name=internalLink&gt;The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15051195&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15522379&amp;amp;query_hl=27" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing progression of glaucoma from visual field fluctuations.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15350314&amp;amp;query_hl=18" target="_blank"&gt;Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102031</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12383806&amp;query_hl=1]]&gt;</url>
    <title>The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma.</title>
    <publicationDate>2002-10-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American journal of ophthalmology, {Am-J-Ophthalmol}, Oct 2002, vol. 134, no. 4, p. 499-512, ISSN: 0002-9394.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To examine the relationships between baseline risk factors and sustained decrease of visual field (SDVF) and sustained decrease of visual acuity (SDVA).&lt;/P&gt;
&lt;P&gt;DESIGN: Cohort study of participants in the Advanced Glaucoma Intervention Study (AGIS).&lt;/P&gt;
&lt;P&gt;METHODS: This multicenter study enrolled patients between 1988 and 1992 and followed them until 2001; 789 eyes of 591 patients with advanced glaucoma were randomly assigned to one of two surgical sequences, argon laser trabeculoplasty (ALT)-trabeculectomy-trabeculectomy (ATT) or trabeculectomy-ALT-trabeculectomy (TAT). This report is based on data from 747 eyes. Eyes were offered the next intervention in the sequence upon failure of the previous intervention. Failure was based on recurrent intraocular pressure elevation, visual field defect, and disk rim criteria. Study visits occurred every 6 months; potential follow-up ranged from 8 to 13 years. For each intervention sequence, Cox multiple regression analyses were used to examine the baseline characteristics for association with two vision outcomes: SDVF and SDVA. The magnitude of the association is measured by the hazard ratio (HR), where HR for binary variables is the relative change in the hazard (or risk) of the outcome in eyes with the factor divided by the hazard in eyes without the factor, and HR for continuous variables is the relative change in the hazard (or risk) of the outcome in eyes with a unit increase in the factor.&lt;/P&gt;
&lt;P&gt;RESULTS: Characteristics associated with increased SDVF risk in the ATT sequence are: less baseline visual field defect (hazard ratio (HR) = 0.86, P &amp;lt;.001, 95% CI = 0.82-0.90), male gender (HR = 2.23, P &amp;lt;.001, 1.54-3.23), and worse baseline visual acuity (HR = 0.96, P =.001, 0.94-0.98); in the TAT sequence: less baseline visual field defect (HR = 0.93, P =.001, 0.89-0.97) and diabetes (HR = 1.87, P =.007, 1.18-2.97). Characteristics associated with increased SDVA risk in both treatment sequences are better baseline acuity (ATT: HR = 1.05, P &amp;lt;.001, 1.02-1.09; TAT: HR = 1.06, P &amp;lt;.001, 1.03-1.08), older age (ATT: HR = 1.05, P =.001, 1.02-1.08; TAT: HR = 1.04, P =.002, 1.01-1.06), and less formal education (ATT: HR = 1.92, P =.001, 1.29-2.88; TAT: HR = 1.77, P =.002, 1.22-2.54).&lt;/P&gt;
&lt;P&gt;CONCLUSIONS: For SDVF, risk factors were better baseline visual field in both treatment sequences, male gender, and worse baseline visual acuity in the ATT sequence, and diabetes in the TAT sequence. For SDVA, risk factors in both treatment sequences were better baseline visual acuity, older age, and less formal education. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7956270&amp;amp;query_hl=6" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7741836&amp;amp;query_hl=3" target="_blank"&gt;The Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9663214&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9663215&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9932993&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11115258&amp;amp;query_hl=18" target="_blank"&gt;The advanced glaucoma intervention study, 6: effect of cataract on visual field and visual acuity. The AGIS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102015:0" name=internalLink&gt;The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration .The AGIS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11735786&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11530042&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102029:0" name=internalLink&gt;The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15051195&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15522379&amp;amp;query_hl=27" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing progression of glaucoma from visual field fluctuations.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15350314&amp;amp;query_hl=18" target="_blank"&gt;Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102015</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11024415&amp;query_hl=1]]&gt;</url>
    <title>The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration</title>
    <publicationDate>2000-10-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source : American Journal of Ophthalmology, {Am-J-Ophthalmol}, Oct 2000, vol. 130, no. 4, p. 429-40, ISSN: 0002-9394&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To investigate the association between control of intraocular pressure after surgical intervention for glaucoma and visual field deterioration. &lt;/P&gt;
&lt;P&gt;METHODS: In the Advanced Glaucoma Intervention Study, eyes were randomly assigned to one of two sequences of glaucoma surgery, one beginning with argon laser trabeculoplasty and the other trabeculectomy. In the present article we examine the relationship between intraocular pressure and progression of visual field damage over 6 or more years of follow-up. In the first analysis, designated Predictive Analysis, we categorize 738 eyes into three groups based on intraocular pressure determinations over the first three 6-month follow-up visits. In the second analysis, designated Associative Analysis, we categorize 586 eyes into four groups based on the percent of 6-month visits over the first 6 follow-up years in which eyes presented with intraocular pressure less than 18 mm Hg. The outcome measure in both analyses is change from baseline in follow-up visual field defect score (range, 0 to 20 units). &lt;/P&gt;
&lt;P&gt;RESULTS: In the Predictive Analysis, eyes with early average intraocular pressure greater than 17.5 mm Hg had an estimated worsening during subsequent follow-up that was 1 unit of visual field defect score greater than eyes with average intraocular pressure less than 14 mm Hg (P =.002). This amount of worsening was greater at 7 years (1.89 units; P &amp;lt;.001) than at 2 years (0.64 units; P =.071). In the Associative Analysis, eyes with 100% of visits with intraocular pressure less than 18 mm Hg over 6 years had mean changes from baseline in visual field defect score close to zero during follow-up, whereas eyes with less than 50% of visits with intraocular pressure less than 18 mm Hg had an estimated worsening over follow-up of 0.63 units of visual field defect score (P =.083). This amount of worsening was greater at 7 years (1.93 units; P &amp;lt;.001) than at 2 years (0.25 units; P =.572). &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: In both analyses low intraocular pressure is associated with reduced progression of visual field defect, supporting evidence from earlier studies of a protective role for low intraocular pressure in visual field deterioration.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles :&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7956270&amp;amp;query_hl=6" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7741836&amp;amp;query_hl=3" target="_blank"&gt;The Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9663214&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9663215&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9932993&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11115258&amp;amp;query_hl=18" target="_blank"&gt;The advanced glaucoma intervention study, 6: effect of cataract on visual field and visual acuity. The AGIS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11735786&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11530042&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=30&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=9856&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102029" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=30&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=9856&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102031" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15051195&amp;amp;query_hl=18" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15522379&amp;amp;query_hl=27" target="_blank"&gt;The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing progression of glaucoma from visual field fluctuations.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15350314&amp;amp;query_hl=18" target="_blank"&gt;Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317775</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16401785]]&gt;</url>
    <title>The association between host susceptibility factors and uveal melanoma: a meta-analysis</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology (Arch Ophthalmol) 2006 Jan;124(1):54-60&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To conduct a meta-analysis, using observational studies, to examine the association between host susceptibility factors and uveal melanoma. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A review of 132 published reports on risk factors for uveal melanoma revealed 10 case-control studies that provided enough information to calculate odds ratios (ORs) and standard errors for host susceptibility factors. Data from these studies were extracted and categorized. Summary statistics were calculated for all risk factors reported by at least 4 independent studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Summary statistics using meta-analysis are presented as ORs and their 95% confidence intervals (CIs). Statistically significant risk factors include light eye color (OR, 1.75 [95% CI, 1.31-2.34]), using 10 studies (1732 cases); fair skin color (OR, 1.80 [95% CI, 1.31-2.47]), using 5 studies (586 cases); and ability to tan (OR, 1.64 [95% CI, 1.29-2.09]), using 6 studies (1021 cases). Blond or red hair color, using 7 studies (1012 cases), was not a statistically significant independent risk factor (OR, 1.02 [95% CI, 0.82-1.26]). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION: &lt;/STRONG&gt;This meta-analysis yielded strong evidence associating the host susceptibility factors of iris color, skin color, and ability to tan with uveal melanoma.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=147" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372638</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19167086]]&gt;</url>
    <title>The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,UVEAL TRACT,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology. 2009 Mar;116(3):536-543.e2. Epub 2009 Jan 22&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To study the relationship between cutaneous and iris nevi with uveal melanoma. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Three researchers independently searched the literature using Medline from 1966 to August 2007 (with both Ovid and PubMed), EMBASE, MD Consult, and the Web of Science. All bibliographies were searched, and an attempt to contact all primary authors was made to find further unpublished studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Risk factor data were extracted into 4 a priori groups: (1) atypical cutaneous nevi, (2) common cutaneous nevi, (3) cutaneous freckles, and (4) iris nevi. RESULTS: Meta-analysis of 4 studies (850 cases) examining atypical cutaneous nevi yielded a summary odds ratio (OR) of 2.82 (95% confidence interval [CI], 1.10-7.26; P=0.032). Common cutaneous nevi were reported in 4 studies (825 cases), yielding a summary OR of 1.74 (CI, 1.27-2.39; P=0.001). Cutaneous freckles using 7 studies (2122 cases) found an OR of 1.22 (CI, 1.03-1.45; P=0.022). Iris nevi using 4 studies (825 cases) found an OR of 1.53 (CI, 1.03-2.27; P=0.036). There was no evidence of publication bias for the aforementioned risk factors, with the exception of atypical cutaneous nevi (P=0.03). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; This meta-analysis supports an association between uveal melanoma and atypical cutaneous nevi, common cutaneous nevi, cutaneous freckles, and iris nevi.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=280" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372424</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19204241]]&gt;</url>
    <title>The association of primary open-angle glaucoma with mortality: a meta-analysis of observational studies</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology. 2009 Feb;127(2):204-10&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE: &lt;/STRONG&gt;To conduct a meta-analysis to estimate the relationship between primary open-angle glaucoma (POAG) and mortality. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic search of the PubMed, Embase, and Web of Science databases yielded 9 cohort studies with relative risk (RR) estimates for all-cause mortality. The studies were critically reviewed by an expert in the field. The data were extracted and analyzed in a pooled analysis by the random-effects model. Meta-regression to assess for heterogeneity by several covariates and subgroup analysis on cardiovascular mortality were performed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A significant risk was not detected in the final pooled analysis (RR, 1.13; 95% confidence interval [CI], 0.97-1.31) for all-cause mortality. A meta-regression across mean follow-up time, age, and sex was not significant. A meta-regression across diabetes status in 3 of the 9 studies did not demonstrate significant results (P = .94). Subgroup analysis on cardiovascular mortality from 4 of the 9 studies was marginally significant (RR, 1.20; 95% CI, 1.00-1.43; P = .05), but insignificant after removal of a study in which POAG was ascertained by self and proxy report (RR, 1.12; 95% CI, 0.87-1.46). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; This meta-analysis does not demonstrate an association between POAG and all-cause or cardiovascular mortality.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhs_evidence/showsystematic.asp?study_id=272" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>273810</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1141.pdf]]&gt;</url>
    <title>The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation</title>
    <publicationDate>2007-11-01T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment programme (HTA)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,COMMISSIONING,ASSESSMENT AND PLANNING,DISEASE/CONDITION GROUPS,EYE AND VISION PROBLEMS,COST EFFECTIVENESS,COMMISSIONING COMPETENCIES,PRIORITISE INVESTMENT,COMMISSIONING PROCESS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Systematic review published&amp;nbsp;in Health Techonology Assessment 2007; Vol 11: number 41. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; To assess whether open angle glaucoma (OAG) screening meets the UK National Screening Committee criteria, to compare screening strategies with case finding, to estimate test parameters, to model estimates of cost and cost-effectiveness, and to identify areas for future research.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Major electronic databases were searched up to December 2005. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods:&lt;/STRONG&gt; Screening strategies were developed by wide consultation. Markov submodels were developed to represent screening strategies. Parameter estimates were determined by systematic reviews of epidemiology, economic evaluations of screening, and effectiveness (test accuracy, screening and treatment). Tailored highly sensitive electronic searches were undertaken.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Most potential screening tests reviewed had an estimated specificity of 85% or higher. No test was clearly most accurate, with only a few, heterogeneous studies for each test. No randomised controlled trials (RCTs) of screening were identified. Based on two treatment RCTs, early treatment reduces the risk of progression. Extrapolating from this, and assuming accelerated progression with advancing disease severity, without treatment the mean time to blindness in at least one eye was approximately 23 years, compared to 35 years with treatment.&amp;nbsp; Prevalence would have to be about 3–4% in 40 year olds with a screening interval of 10 years to approach cost-effectiveness. It is predicted that screening might be cost-effective in a 50-year-old cohort at a prevalence of 4% with a 10-year screening interval. General population screening at any age, thus, appears not to be cost-effective. Selective screening of groups with higher prevalence (family history, black ethnicity) might&lt;BR&gt;be worthwhile, although this would only cover 6% of the population. Extension to include other at-risk cohorts (e.g. myopia and diabetes) would include 37% of the general population, but the prevalence is then too low for screening to be considered cost-effective. Screening using a test with initial automated classification followed by assessment by a specialised optometrist, for test positives, was more cost-effective than initial specialised optometric assessment. The cost-effectiveness of the screening programme was highly sensitive to the perspective on costs (NHS or societal). In the base-case model, the NHS costs of visual impairment were estimated as £669. If annual societal costs were £8800, then screening might be considered cost-effective for a 40-year-old cohort with 1% OAG prevalence assuming a willingness to pay of £30,000 per quality-adjusted life-year. Of lesser importance were changes to estimates of attendance for sight tests, incidence of OAG, rate of progression and utility values for each stage of OAG severity. Cost-effectiveness was not particularly sensitive to the accuracy of screening tests within the ranges observed.&amp;nbsp; However, a highly specific test is required to reduce large numbers of false-positive referrals.&amp;nbsp; The findings that population screening is unlikely to be cost-effective are based on an economic model whose parameter estimates have considerable uncertainty. In particular, if rate of progression and/or costs of visual impairment are higher than estimated then screening could be cost-effective. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; While population screening is not cost effective, the targeted screening of high-risk groups may be. Procedures for identifying those at risk, for quality assuring the programme, as well as adequate service provision for those screened positive would all be needed. Glaucoma detection can be improved by increasing attendance for eye examination, and improving the performance of current testing by either refining practice or adding in a technology-based first assessment, the later being the more cost-effective option. This has implications for any future organisational changes in community eye-care services.&amp;nbsp; Further research should aim to develop and provide quality data to populate the economic model, by conducting a feasibility study of interventions to improve detection, by obtaining further data on costs of blindness, risk of progression and health outcomes, and by conducting an RCT of interventions to improve the uptake of glaucoma testing.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=29" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289065</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.hta.ac.uk/fullmono/mon1225.pdf]]&gt;</url>
    <title>The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the ages of 4-5 years: a systematic review and economic evaluation</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>NIHR Health Technology Assessment programme (HTA)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,STRABISMUS,AMBLYOPIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Systematic review published in Health Technology Assessment 2008 Vol 12 No 25. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims and objectives&lt;/STRONG&gt;&lt;BR&gt;The aim of this study was to estimate the cost-effectiveness of screening for amblyopia and strabismus in children up to the ages of 4–5 years by developing a decision-analytic model that incorporates and assesses all of the above criteria. At the outset it was recognised that there was likely to be significant uncertainty in key areas of the model, and an objective of the study was to identify the major areas of uncertainty and so inform future research priorities in this disease area.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods&lt;/STRONG&gt;&lt;BR&gt;Systematic literature reviews were undertaken of the prevalence and natural history of amblyopia and strabismus, the screening methods used in detecting amblyopia and strabismus, the effectiveness of treatment options for amblyopia and strabismus and health-related quality of life issues relating to amblyopia and strabismus. The review of treatment interventions for amblyopia and strabismus was restricted to high-quality reviews, meta-analyses and guidelines. The literature searches were undertaken in the period 18–24 January 2006. The data derived from the review informed the structure and implementation of the decision-analytic model. This was calibrated with screening data from Birmingham.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results&lt;/STRONG&gt;&lt;BR&gt;The amblyopia screening model was analysed in detail to estimate the cost and effects of six alternative screening options comprising screening at different ages (3, 4 and 5 years) and using alternative sets of tests (visual acuity testing and the cover tests, with and without autorefraction). The reference case results showed that screening programmes that included autorefraction dominated screening programmes without autorefraction. Analyses based on the cost per case of amblyopia prevented showed that screening at either 3 or 4 years prevented additional cases at a low absolute cost (£3000–6000). However, when these results were extrapolated to estimate the cost per quality-adjusted life-year (QALY) gained, the reference case analysis found that no form of screening is likely to be cost-effective at currently accepted values of a QALY.&lt;/P&gt;
&lt;P&gt;The wide-ranging sensitivity analyses found that the results were robust to most parameter changes. The only parameter that radically affected the results was the utility effect of loss of vision in one eye. No direct evidence of a utility effect was identified and the reference case assumed no effect. When a small effect is assumed (a reduction in utility of 2%), the incremental cost per QALY gained becomes extremely attractive for screening at both 3 and at 4 years. The expected value of perfect information was shown to be large when the unilateral vision loss utility parameter was allowed to vary, but not when it was kept constant at zero.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions&lt;/STRONG&gt;&lt;BR&gt;The cost-effectiveness results from the amblyopia screening and lifetime models show that the cost-effectiveness of screening for amblyopia is dependent on the long-term utility effects of unilateral vision loss. There is limited evidence on any such effect, although our subjective interpretation of the available literature is that the utility effects are likely to be minimal. Any utility study investigating such effects would need to be careful to avoid introducing bias.&lt;/P&gt;
&lt;P&gt;The reference case model did not represent potential treatment-related utility effects, primarily due to an increased probability of treated children being bullied at school. The evidence indicates that this may be a problem, and additional sensitivity analyses show that small utility decrements from bullying would improve the cost-effectiveness of early screening significantly.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recommendations for future research&lt;/STRONG&gt;&lt;BR&gt;A prospective study of the utility effects of bullying would usefully inform the analysis, although such a study would need to be carefully planned in order to distinguish whether the overall incidence of bullying decreases with reduced school-age treatment, or whether it is displaced to other children.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>143189</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.college-optometrists.org/download.cfm/docid/5F55BC0E-B07A-A8FC-00CA89AD29B94E40]]&gt;</url>
    <title>The College of Optometrists Higher Qualifications information pack - part 1</title>
    <publicationDate></publicationDate>
    <publisher>The College of Optometrists</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,RETINA,RETINOPATHY,OCULAR MOTILITY,REFRACTIVE ERROR,LOW VISION,DIABETIC RETINOPATHY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The College's Higher Qualifications consist of certificates and diplomas in specialist subject areas and a second tier award of Fellowship.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A diplomas consists of two specified certificates and the&amp;nbsp;award of any four certificate will lead to&amp;nbsp;Fellowship of the College.&amp;nbsp;&amp;nbsp;Diplomas are offered in Contact Lens Practice, Orthoptics, Ocular Conditions (Diabetes and Glaucoma), Glaucoma and Rehabilitation of Visual Impairment.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The&amp;nbsp;information pack contains a detailed syllabus for each certificate together with reading lists,&amp;nbsp;explanation of the format of the examination,&amp;nbsp;regulations, fees,&amp;nbsp;eligibility etc. &amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317850</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17452662]]&gt;</url>
    <title>The consequences of waiting for cataract surgery: a systematic review</title>
    <publicationDate>2007-04-01T00:00:00</publicationDate>
    <publisher>Canadian Medical Assocation Journal</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Canadian Medical Association Journal (CMAJ) 2007 Apr 24;176(9):1285-90.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Cataract surgery is the most common operative procedure performed in Canada, and how patients are affected by wait times for this surgery has important clinical, public health and health policy considerations. We conducted a systematic review to understand the relation between wait time for cataract surgery and patient outcomes and the variables that modify this relation. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; We performed an electronic search of 11 databases and the proceedings of 4 conferences. The search was restricted to studies published after the transition to phacoemulsification (1990). We assessed the quality of the included studies using the Jadad Scale for randomized controlled trials and the Newcastle-Ottawa Scale for cohort and case-control studies. The data were found to be inappropriate for meta-analysis, thus we performed a qualitative synthesis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; We found a total of 27 studies that met our inclusion criteria. When these studies were reviewed, a dichotomy was observed for the wait time-outcome relation: outcomes associated with wait times of &lt;OR= of times wait with associated outcomes than better were weeks 6&gt;or= 6 months. Patients who waited more than 6 months to receive cataract surgery experienced more vision loss, a reduced quality of life and had an increased rate of falls compared with patients who had wait times of less than 6 weeks. The outcomes associated with wait times between 6 weeks and 6 months remain unclear. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;INTERPRETATION:&lt;/STRONG&gt; Patients who wait more than 6 months for cataract surgery may experience negative outcomes during the wait period, including vision loss, a reduced quality of life and an increased rate of falls.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=123" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317852</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17135455]]&gt;</url>
    <title>The effect of visual training for patients with visual field defects due to brain damage: a systematic review</title>
    <publicationDate>2007-06-01T00:00:00</publicationDate>
    <publisher>Journal of Neurology, Neurosurgery and Psychiatry</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Neurology, Neurosurgery and Psychiatry (J Neurol Neurosurg Psychiatry) 2007 Jun:78(6):555-64. Epub 2006 Nov 29. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;The objective of this review was to evaluate whether systematic visual training leads to (1) a restitution of the visual field (restoration), (2) an increase in the visual search field size or an improvement in scanning strategies (compensation) and (3) a transfer of training-related improvements in activities of daily living such as reading. To retrieve relevant publications, computer-aided searches of databases (Medline, Embase, Cinahl, Cochrane Central Registers of Controlled Trials) and extensive reference tracing and hand searching were performed. Subsequently, all retrieved and blinded studies were scored on methodological quality. 14 studies were included, 2 randomised controlled trials (RCTs) and 12 within-subject repeated-measures designs (RMD). One of the two RCT studies had good quality. The internal validity of the RMD studies varied from poor to good. Five studies reported a significant effect of the vision restoration therapy (VRT), whereas two studies reported no effect using scanning laser ophthalmoscopy or Goldmann perimetry as outcome measure. All authors of the studies on scanning compensatory therapy (SCT) found a significant effect of up to 30 degrees visual search field, a significant increase in reading speed or decrease in reading errors. It is unclear to what extent patients benefit from restoration therapy in relation to a more efficient scanning strategy which enables them to read faster or to avoid obstacles in a better way. No study has given a satisfactory answer. SCT seems to provide a more successful rehabilitation with more simple and user-friendly training techniques. Validated questionnaires provide the most reliable subjective data to assess the transfer of the relevance of training procedures to activities of daily living of the patient. Hence, SCT is recommended until the effect of the VRT is defined.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=98" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250845</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/9780094]]&gt;</url>
    <title>The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma.  Collaborative Normal-Tension Glaucoma Study Group</title>
    <publicationDate>1998-10-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;American Journal of Ophthalmology [Am J Ophthalmol]. 1998 Oct; 126(4):498-505.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PubMed Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;PURPOSE: In a companion paper, we determined that intraocular pressure is part of the pathogenesis of normal-tension glaucoma by analyzing the effect of a 30% intraocular pressure reduction on the subsequent course of the disease. We report an intent-to-treat analysis of the study data to determine the effectiveness of pressure reduction. &lt;/P&gt;
&lt;P&gt;METHODS: One eligible eye of 145 subjects with normal-tension glaucoma was randomized either to no treatment (control) or to a 30% intraocular pressure reduction from baseline. To be eligible for randomization, the normal-tension glaucoma eyes had to show documented progression of field defects or a new disk hemorrhage or had to have field defects that threatened fixation when first presented for the study. Survival analysis compared time to progression of all randomly assigned patients during the course of follow-up from the initial baseline at randomization. In a separate analysis, data of patients developing cataracts were censored at the time that cataract produced 2 lines of Snellen visual acuity loss. &lt;/P&gt;
&lt;P&gt;RESULTS: Visual field progression occurred at indistinguishable rates in the pressure-lowered (22/66) and the untreated control (31/79) arms of the study (P = .21). In an analysis with data censored when cataract affected visual acuity, visual field progression was significantly more common in the untreated group (21/79) compared with the treated group (8/66). An overall survival analysis showed a survival of 80% in the treated arm and of 60% in the control arm at 3 years, and 80% in the treated arm and 40% in the controls at 5 years. The Kaplan-Meier curves were significantly different (P = .0018). The analyses gave different results because of a higher incidence of cataract in the group that underwent filtration surgery. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: The favorable effect of intraocular pressure reduction on progression of visual change in normal-tension glaucoma was only found when the impact of cataracts on visual field progression, produced largely by surgery, was removed. Lowering intraocular pressure without producing cataracts is beneficial. Because not all untreated patients progressed, the natural history of normal-tension glaucoma must be considered before embarking on intraocular pressure reduction with therapy apt to exacerbate cataract formation unless normal-tension glaucoma threatens serious visual loss.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=9780093%5BUID%5D" target="_blank"&gt;Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=14597032%5BUID%5D" target="_blank"&gt;Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma.&amp;nbsp;&amp;nbsp; &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11384564%5BUID%5D" target="_blank"&gt;Risk factors for progression of visual field abnormalities in normal-tension glaucoma.&amp;nbsp; &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=11158794%5BUID%5D" target="_blank"&gt;Natural history of normal-tension glaucoma.&amp;nbsp;&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=15646475%5BUID%5D" target="_blank"&gt;Some clinical implications of the collaborative normal tension glaucoma study.&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372622</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18942927]]&gt;</url>
    <title>The effects of complications and comorbidities on the quality of preventive diabetes care: a literature review</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Population Health Management</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Population Health Management. 2008 Aug;11(4):217-28&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;Although concurrent conditions such as complications and comorbidities are common in people with diabetes, both are often omitted from studies of the quality of diabetes preventive care. This systematic review of the literature on the quality of diabetes preventive care assesses not only trends in the reporting of and adjusting for complications and comorbidities, but also the limitations of current measures of complications and comorbidities. This review identified 34 studies in which the quality of diabetes preventive care was assessed with process measures and complications or comorbidities were reported. More often than not, the studies identified the presence of certain complications or comorbidities, counted complications or comorbidities, or used comorbidity indices to measure morbidity. While earlier studies reported the prevalence of complications or comorbidities, more recent studies use complications or comorbidities as covariates in regression models. Despite this progress, the effects of complications and comorbidities on care processes are unclear because of cross-study variation among measures of complications and comorbidities and because very few studies address the independent effects of complications and comorbidities. Effective measures of complications and comorbidity are necessary to evaluate the quality of diabetes preventive care, particularly for patients with concurrent conditions. Current reported measures of complications and comorbidities may not address constructs related to quality, underscoring the need for a methodology that is better than the approaches now documented in the literature.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=256" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317853</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18156371]]&gt;</url>
    <title>The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>British Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: British Journal of Ophthalmology (Br J Ophthalmol) 2008 Jan;92(1):7-12&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;AIM: &lt;/STRONG&gt;To systematically review the literature on the efficacy and harm of prostaglandin analogues (PGAs) compared to brimonidine and dorzolamide in treating elevated intraocular pressure (IOP). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Keywords were searched in major literature databases to identify relevant randomised clinical trials (RCTs) of PGAs for ophthalmic use. The study quality of RCTs was assessed using the Jadad scale. Outcomes assessed included reduction in IOP in individual patients, adverse events (AEs) and withdrawals due to AEs. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;&amp;nbsp;Eight unique RCTs evaluating a total of 1,722 individuals were included in this systematic review. Analysis did not show a significant reduction in the mean IOP from patients receiving latanoprost compared with those receiving brimonidine (WMD = -1.04; p = 0.30). On the other hand, the latanoprost group showed a significant reduction in mean IOP compared to the dorzolamide group (WMD = -2.64; p&amp;lt;0.00001). The number of ocular AEs (excluding hyperaemia) was significantly higher in the brimonidine group compared with the latanoprost group (RR = 0.66; p = 0.0005). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Latanoprost was found to be significantly superior to dorzolamide but not brimonidine. However, ocular adverse events were significantly fewer in latanoprost users than in brimonide users. Neither travoprost nor bimatoprost was compared to dorzolamide or brimonidine in the present literature.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=75" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317854</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16673139]]&gt;</url>
    <title>The end of submacular surgery for age-related macular degeneration? A meta-analysis</title>
    <publicationDate>2007-04-01T00:00:00</publicationDate>
    <publisher>Graefe's Archives for Clinical and Experimental Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Graefe's Archives for Clinical and Experimental Ophthalmology (Graefes Arch Clin Exp Ophthalmol) 2007 Apr; 245(4):490-501. Epub 2006 May 4. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; The aim of this meta-analysis was to summarize and to discuss the results of the four main submacular surgical procedures for age-related macular degeneration (AMD) as reported in the literature through 2004 and to compare them to the Submacular Surgery Trials (SST) data. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; The existing data in the literature on submacular surgery for AMD from 1992 to 2004 were evaluated. The main outcomes were proportion of patients with two or more lines of improvement in visual acuity (VA) and proportion with two or more lines of deterioration in VA after surgery. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Eighty-eight studies including 1,915 cases met the inclusion criteria. Estimates for the treatment outcome within the four groups of treatment based on a logistic regression model gave comparable results for removal of choroidal neovascularization (CNV) (improvement of VA 28%, deterioration of VA 25%), macular translocation (improvement of VA 31%, deterioration of VA 27%), and for transplantation of pigment epithelium (improvement of VA 22%, deterioration of VA 21%). Estimates for removal of subretinal hemorrhage were significantly different (improvement of VA 62%, deterioration of VA 13%). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Selected case series showed superior results of VA compared to the SST. The question of whether this is due to selection bias that seems inevitable when dealing with medium-sized nonrandomized case series or due to better results in single centers cannot be answered. In our opinion there still seem to be indications for submacular surgery such as in patients with AMD with low preoperative VA due to large hemorrhagic or fibrotic membranes or nonresponders to photodynamic therapy (PDT).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=15" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317855</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16883366]]&gt;</url>
    <title>The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review</title>
    <publicationDate>2006-08-01T00:00:00</publicationDate>
    <publisher>Canadian Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Canadian Journal of Ophthalmology (Can J Ophthalmol) 2006 Aug; 41(4):481-90.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Studies in preterm and term human infants have suggested that a dietary supply of omega-3 fatty acids is essential for optimal visual development. Several basic science studies support the hypothesis that omega-3 fatty acids may be useful therapeutic agents for pathologies of the retina and lens. As part of a systematic review of the effect of omega-3 fatty acids on eye health, the purpose of this study was to conduct a systematic review of the scientific-medical literature to appraise and synthesize the evidence for the effects of omega-3 fatty acids in preventing the development or progression of retinitis pigmentosa. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A comprehensive search was undertaken in MEDLINE, PREMEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Global Health, and Dissertation Abstracts. Unpublished literature was sought through manual searches of reference lists of included studies and key review articles and from the files of content experts. Searches were not restricted by language of publication, publication type, or study design. Eligibility criteria were applied to screen eligible studies on two levels. Data extraction and quality assessment were performed. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Six studies published between 1995 and 2004 met eligibility criteria in investigating the question of the possible value of omega-3 fatty acids in slowing the progression of retinitis pigmentosa. Meta-analysis was not performed because there was not enough available information for formal quantitative analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;INTERPRETATION:&lt;/STRONG&gt; There are trends in improvement of some retinitis pigmentosa outcomes with omega-3 fatty acids in the higher quality studies. Clinical research is preliminary in this field, however. Accordingly, definitive answers will require significantly more observational and interventional clinical research.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=131" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>304765</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_093389.pdf]]&gt;</url>
    <title>The General Ophthalmic Services Contracts (Payments) (No 3) Directions 2009</title>
    <publicationDate>2009-01-21T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Document published by the Department of Health on 21 January 2009.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The&amp;nbsp;Secretary of State for Health,&amp;nbsp;in exercise of powers conferred by section 120 of the National Health Service Act 2006 (a) and&amp;nbsp;after consultation with representative bodies&amp;nbsp;has&amp;nbsp;given direction regarding&amp;nbsp;GOS contracts payments. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371553</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_114690.pdf]]&gt;</url>
    <title>The General Ophthalmic Services Contracts (Payments) Directions 2010</title>
    <publicationDate>2010-03-25T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Document published by the Department of Health on 25 March 2010. &lt;/P&gt;
&lt;P&gt;The Secretary of State gives the following Directions as to payments to be made under general ophthalmic services contracts in exercise of the powers conferred by sections 120, 272(7) and (8) and 273(1) of the National Health Service Act 2006(1).&lt;/P&gt;
&lt;P&gt;The Directions come into force on 1 April 2010&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102036</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2255512&amp;query_hl=10]]&gt;</url>
    <title>The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group.</title>
    <publicationDate>1990-11-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ GLAUCOMA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Nov 1990, vol. 97, no. 11, p. 1403-13, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;The Glaucoma Laser Trial, a multicenter, randomized clinical trial involving 271 patients, was designed to assess the efficacy and safety of argon laser trabeculoplasty (ALT) as an alternative treatment with topical medication for controlling intraocular pressure (IOP) in patients with newly diagnosed, previously, untreated primary open-angle glaucoma (POAG). Each patient had one eye randomly assigned to ALT (the laser first (LF) eye) and the other eye assigned to timolol maleate 0.5% (the medication first (MF) eye). Medication was initiated or changed for either eye according to the same stepped regimen if the IOP was not controlled. Throughout the 2-year follow-up, LF eyes had lower mean IOPs than MF eyes (1-2 mmHg), and fewer LF eyes than MF eyes required simultaneous prescription of two or more medications to control IOP (P less than 0.001). After 2 years of follow-up, 44% of LF eyes were controlled by ALT, 70% were controlled by ALT or ALT and timolol, and 89% were controlled within the stepped medication regimen. After 2 years, 30% of MF eyes remained controlled by timolol, and 66% were controlled within the stepped regimen. There were no major differences between the two treatment approaches with respect to changes in visual acuity or visual field over the 2 years of follow-up. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2667508&amp;amp;query_hl=40" target="_blank"&gt;The Glaucoma Laser Trial. I. Acute effects of argon laser trabeculoplasty on intraocular pressure. Glaucoma Laser Trial Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1657527&amp;amp;query_hl=40" target="_blank"&gt;The Glaucoma Laser Trial (GLT): 3. Design and methods. Glaucoma Laser Trial Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1896168&amp;amp;query_hl=40" target="_blank"&gt;The Glaucoma Laser Trial: 4. Contralateral effects of timolol on the intraocular pressure of eyes treated with ALT. GLT Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8321504&amp;amp;query_hl=40" target="_blank"&gt;The Glaucoma Laser Trial (GLT): 5. Subgroup differences at enrollment. Glaucoma Laser Trial Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7611312&amp;amp;query_hl=40" target="_blank"&gt;The Glaucoma Laser Trial (GLT): 6. Treatment group differences in visual field changes. Glaucoma Laser Trial Research Group. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8540545&amp;amp;query_hl=40" target="_blank"&gt;The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102227</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_078295.pdf]]&gt;</url>
    <title>The identification, referral and registration of sight loss: action for social services departments and optometrists, and explanatory notes</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>PROTOCOL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CERTIFICATION OF VISUAL IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=teaserText&gt;This guidance from the Department of Health updated in&amp;nbsp;September 2007 describes the system for identifying, referring and registering people with serious sight problems.&amp;nbsp; &lt;/P&gt;
&lt;P class=teaserText&gt;Following extensive consultation with key stakeholders, significant changes have been made to the system for identifying people with serious sight problems, enabling them to gain access to specialist help, and registering those who meet the criteria. The main aims of the revision are: to improve the speed of referral for social care; increase the quality and type of information provided; improve the accessibility and understanding of the process for patients, and to update the terminology in line with consultation findings. The gathering of epidemiological data has also been overhauled.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102317</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7532394&amp;query_hl=16]]&gt;</url>
    <title>The impact of the Macular Photocoagulation Study results on the treatment of exudative age-related macular degeneration.</title>
    <publicationDate>1995-02-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ AGE RELATED MACULAR DEGENERATION,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Arch Ophthalmol 1995;113:185-189.&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To determine the percent of cases with all primary forms of exudative age-related macular degeneration that are eligible for treatment by the Macular Photocoagulation Study (MPS) guidelines in a retina clinic serving both as a primary care center and as a referral center. &lt;/P&gt;
&lt;P&gt;DESIGN: Fluorescein angiograms of patients with age-related macular degeneration examined at the Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, during a 5-year period (1985 to 1990) were randomly selected and reviewed. Angiograms showing all forms of exudative age-related macular degeneration were eligible. The first 100 eligible angiograms identified constituted the study series and were classified into four groups: active choroidal neovascularization (CNV), pigment epithelium detachment, hemorrhage, and disciform scars. The active CNVs were further divided into three subgroups: classic (well defined), occult (poorly defined), and combined. Eligibility for laser treatment was determined exclusively with use of the published MPS recommendations for treatment of extrafoveal, juxtafoveal, and subfoveal membranes. &lt;/P&gt;
&lt;P&gt;RESULTS: There were 10 cases in the pigment epithelium detachment group, 11 cases in the hemorrhagic group, and 16 cases with disciform scars. All of these 37 cases were ineligible for treatment by MPS guidelines. Sixty-three eyes had active membranes; 37 were classic CNVs (eight extrafoveal, seven juxtafoveal, and 22 subfoveal). All extrafoveal and juxtafoveal CNVs were found to be eligible for laser treatment. Eleven membranes of the subfoveal group were larger than 2 disc areas, a size for which the MPS did not demonstrate benefit from laser treatment. There were 19 membranes in the strictly occult CNV subgroup, all of them untreatable by MPS criteria. Seven cases had both occult and classic CNV, and all were larger than 3.5 disc areas and therefore ineligible for treatment. Overall, 26 cases were eligible for treatment by strict MPS criteria; these constitute 26% of the whole series and 41% of the active CNV cases in the series. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Our results indicate that the MPS guidelines for laser treatment are applicable only to a minority of the cases with exudative age-related macular degeneration presenting to our clinic. Further studies should be conducted to identify additional treatment modalities for this common eye disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;age related macular degeneration management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317856</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17984500]]&gt;</url>
    <title>The Incidence of after cataract following three different types of cataract surgery in children: a meta-analysis</title>
    <publicationDate>2007-06-01T00:00:00</publicationDate>
    <publisher>Annals of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Annals of Ophthalmology (Skoki, I11) 2007 Jun;39(2):123-7&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;Via meta-analysis, we assessed the effect of pediatric cataract surgery with posterior continuous curvilinear capsulorhexis (PCCC) with or without anterior vitrectomy (AV) on the incidence of after cataract. Group 1 consisted of pediatric cataract surgery with or without PCCC. Group 2 consisted of pediatric cataract surgery with PCCC with or without AV. The pooled odds ratio of after cataract in Group 1 was 0.21; in Group 2 it was 0.13. Pediatric cataract surgery with PCCC is superior to single cataract surgery in preventing the incidence of after cataract.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=54" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371566</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_114541.pdf]]&gt;</url>
    <title>The National Health Service (Miscellaneous Amendments Relating to Ophthalmic Services) Regulations 2010 (S.I.2010 No. 634)</title>
    <publicationDate>2010-03-25T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Letter issued on 25 March 2010 drawing the attention of chief executives to the National Health Service (Miscellaneous Amendments Relating to Ophthalmic Services) Regulations which come into force on 1 April 2010.]]&gt;</body>
  </document>
  <document>
    <id>289763</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.opsi.gov.uk/si/si2008/pdf/uksi_20081657_en.pdf]]&gt;</url>
    <title>The National Health Service (Optical Charges and Payments) Amendment (No. 2) Regulations 2008</title>
    <publicationDate>2008-07-04T00:00:00</publicationDate>
    <publisher>Office of Public Sector Information</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,EYES AND VISION,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Statutory Instrument 2008 No 1657, the National Health Service (Optical Charges and Payments) Amendment (No 2) Regulations 2008.&amp;nbsp;&amp;nbsp; Laid before Parliament on 1 July 2008 and to become effective from 1 August 2008. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289759</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_086017.pdf]]&gt;</url>
    <title>The National Health Service (Redemption of Optical Vouchers) Determination 2008</title>
    <publicationDate>2008-07-04T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Direction document published by Department of Health on 4 July 2008. &lt;/P&gt;
&lt;P&gt;This Determination concerns the redemption of optical vouchers, in relation to the National Health Service (Optical Charges and Payments) Amendment (No 2) Regulations 2008.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317858</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17675159]]&gt;</url>
    <title>The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2008 Jan;115(1):116-26. Epub 2007 Aug 6&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To describe the natural history and progression of visual loss in eyes with untreated neovascular age-related macular degeneration (AMD). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Systematic review and meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Four thousand three hundred sixty-two untreated neovascular AMD patients from published interventional studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A systematic review of the literature from 1980 to August 2005 was performed. Studies reporting disease progression outcomes for untreated patients with neovascular AMD were included. Outcome measures were summarized using simple counts and means. Random effects meta-analyses were conducted and tests of heterogeneity were performed where appropriate. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Changes in visual acuity (VA) loss, development of comorbidities, and fellow eye involvement. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Fifty-three primary studies were included. Nearly half of the studies (28) were randomized clinical trials. The quality of the studies was high, with over 80% providing level I or II evidence. Mean baseline VA among study patients was 0.64 logarithm of the minimum angle of resolution (logMAR) (approximately 20/87 Snellen). The mean VA change in logMAR progressed from 0.1 (1 line lost) at 3 months to 0.3 (2.7 lines lost) after 12 months and 0.4 (4 lines lost) after 24 months. The proportion of patients who developed severe vision loss (&amp;gt;6 lines) from baseline increased from 21.3% at 6 months to 41.9% by 3 years. The proportion of patients with VA worse than logMAR 1.0 (20/200 Snellen) increased from 19.7% at baseline to 75.7% by 3 years. Neovascular AMD developed in the fellow eye in 12.2% of patients by 12 months and in 26.8% by 4 years. Meta-analyses of vision outcome by subtype of neovascular AMD were not possible. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; A doubling of the visual angle of presenting VA may be expected to occur in the year after initial presentation in eyes with untreated neovascular AMD. No conclusions can be drawn as to the differences in rates of disease progression by neovascular AMD subtype. The diversity of reporting formats, paucity of long-term natural history data, and heterogeneity among the reported clinical studies impose limits to the clear understanding of long-term prognosis for visual function in neovascular AMD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=95" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317860</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16625262]]&gt;</url>
    <title>The natural history of occult choroidal neovascularisation associated with age-related macular degeneration.  A systematic review</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Annals of the Academy of Medicine, Singapore</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Annals of the Academy of Medicine, Singapore (Ann Acad Med Singapore) 2006 Mar;35(3):145-50.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;INTRODUCTION:&lt;/STRONG&gt; The purpose of this review is to combine the results of existing literature on the natural history of occult choroidal neovascularisation (CNV) associated with age-related macular degeneration (AMD). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MATERIALS AND METHODS:&lt;/STRONG&gt; Published reports evaluating eyes with occult CNV in AMD patients were selected for meta-analysis based on a computerised MEDLINE search. Pooled estimates of the proportions of eyes with a vision loss greater than 2 to 3 (moderate vision loss) or 6 lines (severe vision loss) at 1 year and 2 to 3 years, respectively, or developing a classic component on fluorescein angiography at 1 year were measured. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; There is no significant heterogeneity among published rates of visual loss and development of classic CNV. The overall pooled estimates (95% confidence limits) of the proportions of eyes with at least moderate or severe vision loss, respectively, were 59% (53% to 64.5%) and 34% (25% to 43%) at 1 year and 70% (64% to 76%) and 47% (40% to 54%) at 2 to 3 years; the overall pooled estimate of the percentage of eyes developing classic CNV at 1 year was 46% (39% to 54%). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; A substantial number of patients with occult CNV from AMD will develop at least moderate visual loss at 1 year and severe visual loss within 3 years. However, visual acuity may remain stable in up to 30% of patients. These results may help us to understand the exact role of new therapies and in planning future trials.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=120" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320562</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcn.org.uk/__data/assets/pdf_file/0005/259556/RCN_ophthalmic_nursing_6.pdf]]&gt;</url>
    <title>The nature, scope and value of ophthlamic nursing</title>
    <publicationDate>2009-07-02T00:00:00</publicationDate>
    <publisher>The Royal College of Nursing</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Revised document published by The Royal College of Nursing on 2 July 2009. &lt;/P&gt;
&lt;P&gt;The publication has been revised to reflect the current climate of clinical ophthalmic nursing care delivery and includes: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;a discussion on the fundamental nature of ophthalmic nursing 
&lt;LI&gt;questions on how ophthalmic nurses can contribute to health care 
&lt;LI&gt;information on the value of the role 
&lt;LI&gt;standards based on current empirical evidence 
&lt;LI&gt;an audit tool 
&lt;LI&gt;useful reading lists&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=442" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=442" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=442" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102037</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12049574&amp;query_hl=14]]&gt;</url>
    <title>The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.</title>
    <publicationDate>2002-06-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology, {Arch-Ophthalmol}, Jun 2002, vol. 120, no. 6, p. 701-13; discussion 829-30, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: Primary open-angle glaucoma (POAG) is one of the leading causes of blindness in the United States and worldwide. Three to 6 million people in the United States are at increased risk for developing POAG because of elevated intraocular pressure (IOP), or ocular hypertension. There is no consensus on the efficacy of medical treatment in delaying or preventing the onset of POAG in individuals with elevated IOP. Therefore, we designed a randomized clinical trial, the Ocular Hypertension Treatment Study. &lt;/P&gt;
&lt;P&gt;OBJECTIVE: To determine the safety and efficacy of topical ocular hypotensive medication in delaying or preventing the onset of POAG. &lt;/P&gt;
&lt;P&gt;METHODS: A total of 1636 participants with no evidence of glaucomatous damage, aged 40 to 80 years, and with an IOP between 24 mm Hg and 32 mm Hg in one eye and between 21 mm Hg and 32 mm Hg in the other eye were randomized to either observation or treatment with commercially available topical ocular hypotensive medication. The goal in the medication group was to reduce the IOP by 20% or more and to reach an IOP of 24 mm Hg or less. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURES: The primary outcome was the development of reproducible visual field abnormality or reproducible optic disc deterioration attributed to POAG. Abnormalities were determined by masked certified readers at the reading centers, and attribution to POAG was decided by the masked Endpoint Committee. &lt;/P&gt;
&lt;P&gt;RESULTS: During the course of the study, the mean +/- SD reduction in IOP in the medication group was 22.5% +/- 9.9%. The IOP declined by 4.0% +/-11.6% in the observation group. At 60 months, the cumulative probability of developing POAG was 4.4% in the medication group and 9.5% in the observation group (hazard ratio, 0.40; 95% confidence interval, 0.27-0.59; P&amp;lt;.0001). There was little evidence of increased systemic or ocular risk associated with ocular hypotensive medication. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Topical ocular hypotensive medication was effective in delaying or preventing the onset of POAG in individuals with elevated IOP. Although this does not imply that all patients with borderline or elevated IOP should receive medication, clinicians should consider initiating treatment for individuals with ocular hypertension who are at moderate or high risk for developing POAG. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10326953&amp;amp;query_hl=47" target="_blank"&gt;The Ocular Hypertension Treatment Study: design and baseline description of the participants. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10980763&amp;amp;query_hl=47" target="_blank"&gt;Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11024416&amp;amp;query_hl=47" target="_blank"&gt;Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11581049&amp;amp;query_hl=47" target="_blank"&gt;Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS).&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11874743&amp;amp;query_hl=47" target="_blank"&gt;Baseline visual field characteristics in the ocular hypertension treatment study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12049575&amp;amp;query_hl=47" target="_blank"&gt;The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11755836&amp;amp;query_hl=47" target="_blank"&gt;The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12742841&amp;amp;query_hl=47" target="_blank"&gt;Classification of visual field abnormalities in the ocular hypertension treatment study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12698045&amp;amp;query_hl=47" target="_blank"&gt;Ocular Hypertension Treatment Study (OHTS) commentary.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15531304&amp;amp;query_hl=47" target="_blank"&gt;Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=14962409&amp;amp;query_hl=47" target="_blank"&gt;The confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study: study design and baseline factors.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=14718290&amp;amp;query_hl=47" target="_blank"&gt;Racial differences in optic disc topography: baseline results from the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102038:0" name=internalLink&gt;The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15488816&amp;amp;query_hl=47" target="_blank"&gt;Baseline risk factors for the development of primary open-angle glaucoma in the Ocular Hypertension Treatment Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16157799&amp;amp;query_hl=59&amp;amp;itool=pubmed_docsum" target="_blank"&gt;Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16157798%5BUID%5D" target="_blank"&gt;Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102038</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197055&amp;query_hl=16]]&gt;</url>
    <title>The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals.</title>
    <publicationDate>2004-06-01T00:00:00</publicationDate>
    <publisher>Archives of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Archives of Ophthalmology, {Arch-Ophthalmol}, Jun 2004, vol. 122, no. 6, p. 813-20, ISSN: 0003-9950.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;BACKGROUND: The prevalence of glaucoma is higher in African American individuals than in white individuals. &lt;/P&gt;
&lt;P&gt;OBJECTIVE: To report the safety and efficacy of topical ocular hypotensive medication in delaying or preventing the onset of primary open-angle glaucoma (POAG) among African American participants in the Ocular Hypertension Treatment Study. &lt;/P&gt;
&lt;P&gt;METHODS: Eligibility criteria included age between 40 and 80 years, intraocular pressure between 24 and 32 mm Hg in one eye and between 21 and 32 mm Hg in the other eye, and no evidence of glaucomatous structural or functional damage by standard clinical measures. Participants were randomized to either the observation group or medication group. Of the 1636 participants randomized, 408 were self-identified as African American. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURE: The primary outcome was the development of reproducible visual field abnormality and/or reproducible optic disc deterioration attributed to POAG. &lt;/P&gt;
&lt;P&gt;RESULTS: Among African American participants, 17 (8.4%) of 203 in the medication group developed POAG during the study (median follow-up, 78 months) compared with 33 (16.1%) of 205 participants in the observation group (hazard ratio, 0.50; 95% confidence interval, 0.28-0.90; P =.02). &lt;/P&gt;
&lt;P&gt;CONCLUSION: Topical ocular hypotensive therapy is effective in delaying or preventing the onset of POAG in African American individuals who have ocular hypertension. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10326953&amp;amp;query_hl=47" target="_blank"&gt;The Ocular Hypertension Treatment Study: design and baseline description of the participants. &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10980763&amp;amp;query_hl=47" target="_blank"&gt;Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11024416&amp;amp;query_hl=47" target="_blank"&gt;Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11581049&amp;amp;query_hl=47" target="_blank"&gt;Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS).&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11874743&amp;amp;query_hl=47" target="_blank"&gt;Baseline visual field characteristics in the ocular hypertension treatment study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102037:0" name=internalLink&gt;The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12049575&amp;amp;query_hl=47" target="_blank"&gt;The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11755836&amp;amp;query_hl=47" target="_blank"&gt;The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12742841&amp;amp;query_hl=47" target="_blank"&gt;Classification of visual field abnormalities in the ocular hypertension treatment study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12698045&amp;amp;query_hl=47" target="_blank"&gt;Ocular Hypertension Treatment Study (OHTS) commentary.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15531304&amp;amp;query_hl=47" target="_blank"&gt;Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=14962409&amp;amp;query_hl=47" target="_blank"&gt;The confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study: study design and baseline factors.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=14718290&amp;amp;query_hl=47" target="_blank"&gt;Racial differences in optic disc topography: baseline results from the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15488816&amp;amp;query_hl=47" target="_blank"&gt;Baseline risk factors for the development of primary open-angle glaucoma in the Ocular Hypertension Treatment Study.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16157799&amp;amp;query_hl=59&amp;amp;itool=pubmed_docsum" target="_blank"&gt;Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&amp;amp;db=pubmed&amp;amp;details_term=16157798%5BUID%5D" target="_blank"&gt;Baseline&amp;nbsp;topographic optic disc measurements are associated with&amp;nbsp;the development of primary open-angle glaucoma: the&amp;nbsp;Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study&amp;nbsp;&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83645</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4104014.pdf]]&gt;</url>
    <title>The Opticians Act 1989 (Amendment) Order 2005</title>
    <publicationDate>2005-02-24T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The Opticians Act 1989 (Amendment) Order 2005,&amp;nbsp;together with a report on the consultation on a draft of this Order, Reform of the General Optical Council, and a Regulatory Impact Assessment.&amp;nbsp; This Order is being laid before Parliament. 
&lt;P&gt;&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>317863</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/14628970]]&gt;</url>
    <title>The prevalence and incidence of visual impairment in people of age 20-59 years in industrialized countries: a review</title>
    <publicationDate>2003-10-01T00:00:00</publicationDate>
    <publisher>Ophthalmic Epidemiology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,VISUAL IMPAIRMENT,LOW VISION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmic Epidemiology (Ophthalmic Epidemiol) 2003 Oct; 10(4):279-91.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Reviews on the prevalence of blindness and low vision in persons of age 20 to 59 years are lacking. We have therefore carried out a review based on a Medline search. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; The review was confined to epidemiological studies performed in Western Europe, North America and Australia covering the age group 20 to 59 years where there were comparable definitions of blindness and low vision according to the IAPB and WHO classification of blindness and low vision. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Three surveys, four register studies and two studies based on multiple sources matched our selection criteria. Blindness and low vision are described separately. Blindness: Only one study, based on multiple sources, covered the whole age group 20 to 59 years. In this study the overall prevalence of blindness was 0.08%. The prevalence of blindness was 0.04% among those 20-39 years old, whereas in the age group 40-59 years it was 0.1% in two surveys and one study on multiple sources. However, the prevalence was higher, 0.5% among whites and 0.7% among colored, in The Baltimore Eye Study. The definition of blindness was similar in all three studies. Low vision: Three studies provided data on the prevalence of low vision in the age group 20-59 years, although the number of cases was very small. In one study the prevalence of a visual acuity &amp;lt; or = 6/24 to 6/48 was 0.07% and in another the prevalence was 0.17% using &amp;lt; 6/18 to 0.5/60. No person with low vision was found in the third study. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; The existing epidemiological data on blindness and low vision among adults aged 20 to 59 years are insufficient. Epidemiological studies based on multiple sources are needed for the study of rare conditions such as blindness and low vision.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=198" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317865</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17324694]]&gt;</url>
    <title>The prognostic role of donor corneoscleral rim cultures in corneal transplantation</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2007 Mar;114(3):440-5&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To examine the discriminatory performance of donor corneoscleral rim cultures for predicting endophthalmitis after corneal transplantation.&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Systematic literature review. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Studies that reported the prevalence of donor rim cultures after refrigerated preservation of donor corneas distributed for keratoplasty. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS&lt;/STRONG&gt;: Random-effects meta-analysis estimated pooled sensitivity, specificity, likelihood ratios, and diagnostic odds ratios. Meta-regression and stratification explored study-level reasons for diagnostic performance. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;MAIN OUTCOME MEASURES:&lt;/STRONG&gt; Incidence of postkeratoplasty endophthalmitis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Of 17,614 corneal grafts, 2459 (14%) had a positive donor rim culture and 31 (0.2%) developed endophthalmitis. Twenty-one had concordant donor and recipient isolates, including 10 with Candida species. The sensitivity of donor rim cultures among 10 studies reporting postsurgical endophthalmitis was 67% (95% confidence interval [CI], 47%-83%), and specificity averaged 85%. Endophthalmitis occurred 12 (95% CI, 5-29) times more often among recipients of a culture-positive donor cornea. With Bayesian analysis, a culture-positive donor cornea would raise the infection risk to 1%, whereas fungal isolation from the donor rim predicts a 3% probability of fungal endophthalmitis. Pooling of studies was limited by a significant discrepancy among reports that could not be explained by differences in antibiotic supplementation of the preservation medium, method of culture inoculation, or type of culture medium. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Endophthalmitis after penetrating keratoplasty is more likely with a culture-positive donor rim, notably candidal endophthalmitis from fungal contaminants, but better evidence is needed to determine the prognostic value and manner of routine microbiological screening.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=18" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317870</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18954316]]&gt;</url>
    <title>The quality of reporting of diagnostic accuracy studies in diabetic retinopathy screening: a systematic review</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Clinical &amp; Experimental Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Clinical &amp;amp; Experimental Ophthalmology (Clin Experiment Ophthalmol) 2008 Aug;36(6):537-42.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; Diabetic retinopathy (DR) is a common cause of blindness among the working age group in the developed world. To identify potentially treatable DR, systematic screening is recommended. The aim of this study was to evaluate the quality of reporting of diagnostic accuracy studies in DR screening. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;We conducted a systematic literature survey in which a highly sensitive MEDLINE search was performed. The aim was to identify reports of diagnostic accuracy for DR screening published during 1995-2006. Two reviewers appraised all selected papers independently. The Standards for Reporting of Diagnostic Accuracy (STARD) checklist was used to evaluate the quality of reporting of each publication. For every manuscript, each item was scored as completely reported (score = 2), partly reported (score = 1) or not reported (score = 0). We calculated the total number of reported STARD items per article, summary scores for each STARD item and the average number of reported STARD items per year. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;A total of 5887 citations were identified from Medline search. Seventy-six fulfilled the criteria for inclusion. The mean score +/- SD of articles included in our study was 19.8 +/- 6.5 out of a maximum of 50. The mean number +/- SD of fully reported items among included studies was 8 +/- 3.3. Only 9 (11.8%) manuscripts completely reported at least 50% of the STARD items. Descriptions of key aspects of the methodology were frequently missing. Only 8% (6/76) of the manuscripts had a flow chart describing flow of participants within a study. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; The quality of reporting of diagnostic-accuracy studies for DR screening is suboptimal. Adherence to STARD guidelines may improve the quality of reporting of DR screening studies.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=96" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317871</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15902512]]&gt;</url>
    <title>The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Journal of Human Genetics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Journal of Human Genetics (J Hum Genet) 2005;50(6):267-75. Epub 2005 May 18. &lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;The association between retinopathy in type 2 diabetes [diabetic retinopathy (DR)] and the C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene has been investigated in several case-control studies. These studies rendered contradictory results, some indicating that the polymorphism is associated with the risk of developing DR whereas others concluded there is no association. To shed light on these inconclusive findings, a meta-analysis of all available studies relating the C677T polymorphism to the risk of developing DR was conducted. Four out of five identified studies included populations of East Asian descent, and only one involved samples from European descent (Caucasians). Overall, the meta-analysis suggested large heterogeneity between studies (p = 0.08, I(2) = 52%) and marginal association between C677T transition and the risk of developing DR: random effects odds ratio (OR) = 1.39 [95% CI (1.05, 1.83)]. The sensitivity analysis [exclusion of one East Asian study with the controls not in Hardy-Weinberg equilibrium (HWE)] showed no heterogeneity (p = 0.25, I(2) = 27%) and no significant association: fixed effects OR = 1.22 [95% CI (0.99, 1.51)] and random effects OR = 1.24 [95% CI (0.96, 1.60)]. The sub-group analysis for the East Asian population produced a significant association: fixed effects OR = 1.48 [95% CI (1.20, 1.83)] and random effects OR = 1.52 [95% CI (1.14, 2.03)]. However, sensitivity analysis in East Asians revealed that the association is marginal: fixed effects OR = 1.33 [95% CI (1.04, 1.70)] and random effects OR = 1.36 [95% CI (1.01, 1.83)]. There is a source of bias in the selected studies: the largest studies failed to show association while the smallest study claimed an association. The above findings reinforce the need for larger and more rigourous studies in this area.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=159" target="_blank"&gt;here&lt;/A&gt; to view the appraisal. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317873</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11190039]]&gt;</url>
    <title>The treatment of herpes simplex virus epithelial keratitis</title>
    <publicationDate>2000-01-01T00:00:00</publicationDate>
    <publisher>Transactions of the American Ophthalmological Society</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,KERATITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Transactions of the American Ophthalmological Society (Trans Am Ophthalmol Soc) 2000;98:505-32. &lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE&lt;/STRONG&gt;: Epithelial keratitis is the most common presentation of ocular infection by herpes simplex virus (HSV). Quantitative assessment of available therapy is needed to guide evidence-based ophthalmology. This study aimed to compare the efficacy of various treatments for dendritic or geographic HSV epithelial keratitis and to evaluate the role of various clinical characteristics on epithelial healing. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Following a systematic review of the literature, information from clinical trials of HSV dendritic or geographic epithelial keratitis was extracted, and the methodological quality of each study was scored. Methods of epithelial cauterization and curettage were grouped as relatively equivalent physicochemical therapy, and solution and ointment formulations of a given topical antiviral agent were combined. The proportion healed with 1 week of therapy, a scheduled follow-up day that approximated the average time of resolution with antiviral therapy, was selected as the primary outcome based on a masked evaluation of maximum treatment differences in published healing curves. The proportion healed at 14 days was recorded as supplemental information. Fixed-effects and random-effects meta-analysis models were used to obtain summary estimates by pooling results from comparative treatment trials. Hypotheses about which prognostic factors might affect epithelial healing during antiviral therapy were developed by multivariate analysis of the Herpetic Eye Disease Study dataset. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; After excluding 48 duplicate reports, 14 nonrandomized studies, 15 studies with outdated or similar treatments, and 29 trials lacking sufficient data on healing or accessibility, 76 primary reports were identified. These reports involved 4,251 patients allocated to 93 treatment comparisons of dendritic epithelial keratitis in 28 categories and 9 comparisons of geographic epithelial keratitis in 6 categories. For dendritic keratitis, idoxuridine was better than placebo at 7 days (combined odds ratio [OR], 3.59; 95% confidence interval [CI], 1.92-6.70), and at 14 days (OR, 4.17; 95% CI, 1.33-13.04), but pooling was limited by lack of homogeneity and low study quality. Direct comparisons at 1 week of treatment showed that trifluridine or acyclovir was significantly better than idoxuridine (OR, 3.12 and 4.56; 95% CI, 1.55-6.29 and 2.76-7.52, respectively), and indirect comparisons were also consistent with a clinically significant benefit. Vidarabine was not significantly better than idoxuridine in pooled treatment comparisons at 1 week (OR, 1.20; 95% CI, 0.72-2.00) but was better in 2 indirect comparisons (OR, 4.22 and 4.78; 95% CI, 1.69-10.54 and 2.15-10.65, respectively). At 14 days, trifluridine (OR, 6.05; 95% CI, 2.50-14.66), acyclovir (OR, 2.88; 95% CI, 1.39-4.78), and vidarabine (OR, 1.24; 95% CI, 0.65-2.37) were each better than idoxuridine. Trials of geographic epithelial keratitis also suggested that trifluridine, acyclovir, and vidarabine were more effective that idoxuridine. Other topical antiviral agents, such as bromovinyldeoxuridine, ganciclovir, and foscarnet, appeared equivalent to trifluridine or acyclovir. Oral acyclovir was equivalent to topical antiviral therapy and did not hasten healing when used in combination with topical treatment. Antiviral agents did not increase the speed of healing when compared to debridement but reduced the risk of recrudescent epithelial keratitis. The combination of physicochemical treatment with an antiviral agent seemed to be better than either physicochemical or antiviral treatment alone, but the heterogeneous cauterization and curettage techniques and the various treatment combinations limited valid quantitative summary effect measures. The combination of topical interferon with an antiviral agent was significantly better than antiviral therapy at 7 days (OR, 13.49; 95% CI, 7.39-24.61) but not at 14 days (OR, 2.36; 95% CI, 0.82-6.79). Finding apparent heterogeneity for some pooled estimates suggested that dissimilarities in patients, interventions, outcomes, or other logistical aspects of clinical trials occur across studies. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; The available evidence on the acute treatment of presumed HSV epithelial keratitis demonstrates the effectiveness of antiviral treatment and shows the log-logistic healing curve of treated dendritic epithelial keratitis. Topical trifluridine, acyclovir, and vidarabine were significantly more effective than idoxuridine but similar in relative effectiveness for dendritic epithelial keratitis. Physicochemical methods of removing infected corneal epithelium are effective, but adjunctive virucidal agents are needed to avert recrudescent epithelial keratitis. Whether debridement in combination with antiviral therapy is more beneficial than antiviral chemotherapy alone appears likely but remains inconclusive. The combination of topical interferon with an antiviral agent significantly speeds epithelial healing. Future trials of the acute treatment of HSV epithelial keratitis must aim to achieve adequate statistical power for assessing the primary outcome and should consider the effect of lesion size and other characteristics on treatment response.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=225" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284180</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_072779.pdf]]&gt;</url>
    <title>The way ahead: The local challenge</title>
    <publicationDate>2007-03-08T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NATIONAL SERVICE FRAMEWORKS (NSFS) AND EYE HEALTH,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This&amp;nbsp;report published on 8 March 2007&amp;nbsp;highlights the progress over&amp;nbsp;the first four years following the publication of the NSF Delivery Strategy. &lt;/P&gt;
&lt;P class=teaserText&gt;The Diabetes National Service Framework set out the first ever set of national standards for the treatment of diabetes to raise the quality of NHS services and reduce unacceptable variations between them. &lt;/P&gt;
&lt;P class=teaserText&gt;Page 47 within section 9&amp;nbsp;looks at&amp;nbsp;eye related complications of diabetes (detection and management). &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345496</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/laundry-detergent-accidents-blind-children.aspx]]&gt;</url>
    <title>Toddler eyes 'burnt by detergent'</title>
    <publicationDate>2010-03-05T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,IN CHILDHOOD,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Children’s eyes could be seriously damaged by capsules of laundry detergent, doctors have warned. &lt;/P&gt;
&lt;P&gt;Capsules of concentrated detergent first went on sale in 2001, designed to be less messy and inconvenient than washing powders and liquids. However, hospital records suggest that curious children can be injured if they burst the brightly coloured sacks and release the cleaning agents inside.&lt;/P&gt;
&lt;P&gt;In a letter to the &lt;EM&gt;British Medical Journal,&lt;/EM&gt; ophthalmologists from the Western Eye Hospital, London, say that the corrosive substances in the cleaning capsules can cause severe burns if they get into the eyes of toddlers. The doctors&amp;nbsp;reported that the capsules contribute to 40% of the chemical eye burns they treat infants for.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/03March/Pages/laundry-detergent-accidents-blind-children.aspx" target="_blank"&gt;NHS Choices commentary&amp;nbsp;&lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>266021</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=266021]]&gt;</url>
    <title>Top Eye Journals</title>
    <publicationDate></publicationDate>
    <publisher>NHS Evidence - eyes and vision</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NHS CORE CONTENT WITHOUT A CATEGORY]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Top Eye Journals&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Access the current contents pages of&amp;nbsp;key eye journals&lt;/H2&gt;
&lt;P&gt;&lt;A href="http://www.ajo.com/current" target="_blank"&gt;American Journal of Ophthalmology &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.aoj.org/" target="_blank"&gt;American Orthoptic Journal&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;A href="http://archopht.ama-assn.org/current.dtl" target="_blank"&gt;Archives of Ophthalmology*&lt;/A&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.orthoptics.org.au/OAA07/content/view/118/88/" target="_blank"&gt;Australian Orthoptic Journal&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.orthoptics.org.uk/journal/journal" target="_blank"&gt;British and Irish Orthoptic Journal&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://bjo.bmj.com/current.shtml" target="_blank"&gt;&lt;EM&gt;British Journal of Ophthalmology*&lt;/EM&gt; &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sciencedirect.com/science?_ob=PublicationURL&amp;amp;_cdi=7263&amp;amp;_pubType=J&amp;amp;_auth=y&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=2c2decaafa934d5a08fc0f02e3bd84c6" target="_blank"&gt;Contact Lens &amp;amp; Anterior Eye &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.corneajrnl.com/pt/re/cornea/currenttoc.htm" target="_blank"&gt;Cornea &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.co-ophthalmology.com/pt/re/coophth/currenttoc.htm" target="_blank"&gt;Current Opinion in Ophthalmology &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nature.com/eye/index.html" target="_blank"&gt;Eye&amp;nbsp;&amp;nbsp; &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.springerlink.com/content/0721-832X" target="_blank"&gt;Graefe's Archive for Clinical and Experimental Ophthalmology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sciencedirect.com/science/journal/1060135X" target="_blank"&gt;Insight - the Journal of the American Society of Ophthalmic Registered Nurses&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.iovs.org/current.shtml" target="_blank"&gt;&lt;EM&gt;Investigative Ophthalmology &amp;amp; Visual Science**&lt;/EM&gt; &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sciencedirect.com/science/journal/10918531" target="_blank"&gt;Journal of the American Association for Pediatric Ophthalmology &amp;amp; Strabismus &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sciencedirect.com/science/journal/08863350" target="_blank"&gt;Journal of Cataract and Refractive Surgery &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.glaucomajournal.com/pt/re/jglaucoma/currenttoc.htm;" target="_blank"&gt;Journal of Glaucoma &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.journalofpediatricophthalmology.com/" target="_blank"&gt;Journal of Pediatric Ophthalmology and Strabismus&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.afb.org/jvib/JVIB_Main.asp" target="_blank"&gt;&lt;EM&gt;Journal of Visual Impairment &amp;amp; Blindness*&lt;/EM&gt; &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://informahealthcare.com/oph" target="_blank"&gt;Neuro-Ophthalmology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www3.interscience.wiley.com/journal/118520573/home" target="_blank"&gt;Ophthalmic and Physiological Optics&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.op-rs.com/pt/re/oprs/currenttoc.htm" target="_blank"&gt;Ophthalmic Plastic and Reconstructive Surgery&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ophsource.org/periodicals/ophtha/current" target="_blank"&gt;Ophthalmology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.optvissci.com/pt/re/ovs/currenttoc.htm" target="_blank"&gt;Optometry &amp;amp; Vision Science &lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sciencedirect.com/science/journal/13509462" target="_blank"&gt;Progress in Retinal and Eye Research&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.retinajournal.com/pt/re/retina/currenttoc.htm" target="_blank"&gt;Retina&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.informaworld.com/smpp/title~db=all~content=g909705874~tab=toc" target="_blank"&gt;Strabismus&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sciencedirect.com/science?_ob=PublicationURL&amp;amp;_cdi=5167&amp;amp;_pubType=J&amp;amp;_auth=y&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=b40e5a2410be1e5d0ed9e3d83912d830" target="_blank"&gt;Survey of Ophthalmology&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;*Access to&amp;nbsp;Archives of Ophthalmology; British Journal of Ophthalmology; and Journal of Visual Impairment &amp;amp; Blindness is&amp;nbsp;available through Athens to all users from NHS England.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;**Access to&amp;nbsp;Investigative Ophthalmology &amp;amp; Visual Science (12 month delay) is&amp;nbsp;available through Athens to all users from NHS England.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Sign into your Athens account through&amp;nbsp;NHS Evidence - Health Information Resources (formerly the National Library for Health) and&amp;nbsp;the journals&amp;nbsp;can be accessed&amp;nbsp;via&amp;nbsp;the Books, Journals and Healthcare Databases link under Resources on&amp;nbsp;the Homepage. Alternatively, &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/" target="_blank"&gt;click here for Health Information Resources&amp;nbsp;- Search My Journals&lt;/A&gt;&amp;nbsp;webpage.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Further online journals may be available at at a local NHS level - log in to see what is available to you.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>317876</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15038942]]&gt;</url>
    <title>Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment</title>
    <publicationDate>2004-02-01T00:00:00</publicationDate>
    <publisher>Clinical Therapeutics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,KERATITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Clinical Therapeutics (Clin Ther) 2004 Feb;26(2):191-6&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Mycobacterium chelonae and Mycobacterium fortuitum are the 2 most commonly implicated species of nontuberculous mycobacteria in cases of bacterial keratitis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVES:&lt;/STRONG&gt; This article summarizes available data on the in vitro antibacterial activity against M chelonae or M fortuitum of 2 agents-amikacin and clarithromycin-that have been used in the treatment of bacterial keratitis. In addition, the article reviews the in vitro activity of 5 commercially available topical ocular fluoro-quinolones (in order of availability, ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin) that may have potential in the surgical prophylaxis and treatment of keratitis caused by M chelonae or M fortuitum. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A search of the English-language literature indexed on the MEDLINE, Life Sciences, EMBASE, BIOSIS, and Pharmaprojects databases from 1966 to October 7, 2003, was conducted using the terms Mycobacterium chelonae, Mycobacterium fortuitum, bacterial keratitis, topical antibiotic therapy, ocular infection-mycobacteria, and LASIK infections. Data on the minimum concentrations at which 90% of isolates were inhibited (MIC(90)s) were reviewed and compared. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; In the literature reviewed, the MIC(90) against M fortuitum was from 1 to 16 microg/mL for amikacin, from &lt;/=2 to&gt;/=8 microg/mL for clarithromycin, from 0.1 to 1 microg/mL for ciprofloxacin, from 0.5 to 3.13 microg/mL for ofloxacin, and &lt;/=2 to mL for levofloxacin. results were chelonae. The fourth-generation fluoroquinolones-gatifloxacin and moxifloxacin-had similar MIC(90)s fortuitum (both, 0.2 1 mL); however, moxifloxacin had greater activity than gatifloxacin against M chelonae (minimum inhibitory concentration range: moxifloxacin, 1.6="1" mL; gatifloxacin, 3.2 6.25 microg mL). &lt; P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Topical fluoroquinolones may be beneficial for ocular surgical prophylaxis and for the treatment of keratitis caused by M chelonae or M fortuitum. Based on their reported MIC(90)s, none of the antibacterials reviewed had greater in vitro activity than moxifloxacin. In addition, moxifloxacin had greater in vitro activity than gatifloxacin against M chelonae, one of the predominant nontuberculous mycobacterial species involved in bacterial keratitis. Pending the conduct of controlled clinical studies, these findings suggest that moxifloxacin may have utility in the prevention and treatment of atypical mycobacterial keratitis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=189" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317880</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15860701]]&gt;</url>
    <title>Topical nonsteriodal anti-inflammatory drugs for corneal abrasions: meta-analysis of randomized trials</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Academic emergency medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CORNEA,CORNEAL ABRASION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Academic Emergency Medicine: official journal of the Society for Academic Emergency Medicine (Acad Emerg Med) 2005 May;12(5):467-73.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVES:&lt;/STRONG&gt; To determine the effectiveness of topical nonsteroidal anti-inflammatory drugs (NSAIDs) in traumatic corneal abrasions. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; This was a systematic literature review and meta-analysis of randomized clinical trials (RCTs). The following databases were searched: MEDLINE (1966-2004), EMBASE (1980-2004), and Cochrane Central Register of Controlled Trials and Database of Systematic Reviews (first quarter 2004). The structured search strategy included a RCT filter and the terms "cornea," "wounds and injuries," "trauma," "corneal diseases," "eye injuries," "anti-inflammatory agents, nonsteroidal" and specific trade names of topical NSAIDs. In addition, four journals in ophthalmology and emergency medicine were hand searched. Two authors independently reviewed citations from the literature searches. To be included, studies had to be RCTs evaluating topical NSAIDs in traumatic corneal abrasions. Trials were included regardless of language or whether they were unpublished or published. Exclusion criteria were corneal ulcers, nonrandomized studies, animal studies, or perioperative setting. Outcomes were pain scale scores at 24 hours and adverse effects. Two independent reviewers assessed four trial quality components: randomization, double blinding, reporting of withdrawals, and concealment of allocation. Weighted mean difference, using a random effects model, was calculated. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Of the 200 citations identified, 11 RCTs met inclusion criteria. Eight trials were identified from the MEDLINE search, two from the EMBASE search, and one from conference proceedings. Seven trials enrolled fewer than 100 patients, and more than half of the studies were conducted in Europe. Five trials reported suitable data for analysis. The overall weighted mean difference for 459 patients was a reduction in pain by 1.30 points (95% confidence interval = -1.56 to -1.03) on the pain scale. Five of the trials met criteria for good quality. Transient stinging was a commonly noted adverse effect. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Topical NSAIDs are effective analgesics for traumatic corneal abrasions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=169" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317883</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17994441]]&gt;</url>
    <title>Topical non-steriodal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data</title>
    <publicationDate>2007-09-30T00:00:00</publicationDate>
    <publisher>Ophthalmic Epidemiology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CONJUNCTIVITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmic Epidemiology (Ophthalmic Epidemiol) 2007 Sep-Oct;14(5):311-9.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To assess the effect of topical Non-Steroidal Anti Inflammatory drugs in the treatment of allergic conjunctivitis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHOD:&lt;/STRONG&gt; Systematic Review. Data Sources and study selection: Reports of comparative randomized trials of topical NSAIDs and placebo identified by searches of Medline, Embase, the Cochrane Register of Controlled Trials. Data extraction and synthesis: Two reviewers assessed trials for eligibility and quality and extracted data independently. Data were synthesized (random effects model) and results expressed results for dichotomous outcomes as relative risk and continuous outcomes as weighted mean difference. Sensitivity analysis was used to examine potential heterogeneity by differences in study quality. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS: &lt;/STRONG&gt;Eight studies incorporating 712 patients were included. The difference between the decrease in allergic sign and symptom score for NSAID treatment compared to placebo was between 4 and 19 percentage points. Topical NSAIDs produced significantly greater relief for conjunctival itching (cardinal symptom) than did placebo (combined standardized mean difference -0.54 (p &amp;lt; 0.001; 95% confidence interval -0.84 to -0.24). The results for the other allergic symptoms: ocular burning/pain, eyelid swelling, photophobia and foreign sensation were not significant. Topical NSAIDs produced significantly greater reduction of conjunctival injection than did placebo (combined standardized mean difference -0.51 (p = 0.03; 95% confidence interval -0.97 to -0.05). Topical NSAIDs did not reduce the allergic signs of conjunctival chemosis, conjunctival mucus, eyelid swelling and corneal disturbance. Topical NSAIDs had a significantly higher rate of burning/stinging on application of medication compared to placebo (P &amp;lt; 0.0001; odds ratio 3.97 (95% CI 2.67 to 5.89). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; This meta-analysis confirms that topical NSAID are significantly more effective at relieving the cardinal symptom: conjunctival itching and improving the cardinal sign: conjunctival injection than placebo treatment. A systematic review comparing topical NSAIDs to topical antihistamines/mast cell stabilizers in treatment of allergic conjunctivitis is warranted as this will compare the topical NSAIDs to current therapeutic guidelines.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality&amp;nbsp;appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=47" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317885</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15186569]]&gt;</url>
    <title>Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness</title>
    <publicationDate>2004-06-01T00:00:00</publicationDate>
    <publisher>British Journal of General Practice</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CONJUNCTIVA,CONJUNCTIVITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: The British Journal of General Practice (Br J Gen Pract) 2004 Jun;54(503):451-6.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; Evidence for the effectiveness of topical treatments, in providing symptomatic relief from ocular allergy, remains uncertain. AIMS: To assess the effectiveness and relative efficacy of topical treatments for the management of seasonal allergic conjunctivitis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN OF STUDY&lt;/STRONG&gt;: A systematic review and meta-analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;SETTING:&lt;/STRONG&gt; A literature search of the Cochrane Library, Medline, and EMBASE bibliographic databases. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHOD:&lt;/STRONG&gt; Double-masked randomised controlled trials were identified, that compared the use of topical mast cell stabilisers (sodium cromoglycate, nedocromil, lodoxamide) with placebo, topical antihistamines with placebo, and topical mast cell stabilisers with topical antihistamines. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A meta-analysis of six trials showed that patients using sodium cromoglycate were 17 times (95% confidence interval [CI] = 4 to 78) more likely to perceive benefit compared with those using a placebo, although this estimate may be partially influenced by publication bias. Five trials indicated that those patients using nedocromil were 1.8 times (95% CI = 1.3 to 2.6) more likely to perceive their allergy to be moderately or totally controlled than those using a placebo. Four trials showed that those using antihistamines were 1.3 times (95% CI = 0.8 to 2.2) more likely to perceive a 'good' treatment effect than those using mast cell stabilisers, although this beneficial effect was not statistically significant. Limited evidence suggests that antihistamines might have a faster therapeutic effect compared to mast cell stabilisers. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Overall, these findings confirm the benefit of topical mast cell stabilisers and antihistamines over placebo for the treatment of allergic conjunctivitis. There is, however, insufficient evidence to recommend the use of one type of medication over another. Treatment preferences should therefore be based on convenience of use (with reduced frequency of instillation for some preparations), patient preference, and costs, especially as important side effects were not reported with any medication.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=184" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>321462</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rnib.org.uk/aboutus/Research/reports/eyehealth/Documents/Access_Health.pdf]]&gt;</url>
    <title>Towards an inclusive health service: a research report into the availability of health information for blind and partially sighted people</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LOW VISION,LIVING WITH VISUAL IMPAIRMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Report published by the RNIB presenting the results of research into the accessibility of health information for blind and partially sighted people. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=444" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=444" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=444" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>304470</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.rcophth.ac.uk/core/core_picker/download.asp?id=395]]&gt;</url>
    <title>Trainee selected component (TSC) guidance</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>The Royal College of Ophthalmologists</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Guidance published by The Royal College of Ophthalmologists in January 2009 on the Trainee Selected Component (TSC).&lt;/P&gt;
&lt;P&gt;The PMETB-approved Ophthalmic Specialty Training Curriculum includes the provision for trainees to undertake a period of focussed training in one topic under the title of "trainee selected component" (TSC).&amp;nbsp; This document describes the nature of TSCs and provides guidance on the aims, content and organisation of such posts.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The guidance does not constitute a strict curriculum but there should be good reason for&amp;nbsp;any significant degree of deviation. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=431" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=431" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=431" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>287689</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_084752.pdf]]&gt;</url>
    <title>Transitional arrangements in NHS (Performers Lists) Amendment Regulations 2008</title>
    <publicationDate>2008-05-13T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Four new regulations have been laid before Parliament, which make changes to arrangements for primary ophthalmic services. Implementation of the new regulations needs to be completed by 1 August 2008. Transitional Provisions allow PCTs to work as if the main regulations were already in force to enable implementation to be complete by August.&lt;/P&gt;
&lt;P&gt;These documents should be drawn to the attention of staff dealing with primary Ophthalmic Services.&lt;/P&gt;
&lt;P&gt;This document published on 13 May 2008 provides guidance on transitional provisions to introduce the General Ophthalmic Services Contract Regulations&amp;nbsp;2008 and the National Health Services (Performers Lists) Amendment Regulations 2008. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317911</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17073898]]&gt;</url>
    <title>Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Clinical &amp; Experimental Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Clinical &amp;amp; Experimental Ophthalmology (Clin Experiment Ophthalmol) 2006 Nov;34(8):755-64.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;BACKGROUND:&lt;/STRONG&gt; It is still uncertain whether travoprost has comparable or better efficacy compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension. The authors performed a meta-analysis of randomized controlled trials to evaluate the incidence of reported side-effects and intraocular pressure (IOP)-lowering effect of travoprost versus other prostaglandin analogues (latanaprost, bimatoprost, unoprostone) or timolol. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;Systematic literature retrieval was conducted in Pubmed, EMBASE, Chinese Bio-medicine Database and Cochrane Controlled Trials Register to identify the potentially relevant randomized controlled trials. The statistical analysis was performed by RevMan 4.1 software that was provided by the Cochrane Collaboration. The outcome measures were the incidence of reported side-effects (hyperaemia, iris pigmentation, eyelash changes) and mean IOP pooled over treatment visits. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; In total, 12 articles involving 3048 patients with open-angle glaucoma or ocular hypertension were included in this meta-analysis. The combined results showed that travoprost 0.004% was more effective than timolol or travoprost 0.0015% in lowering IOP, but not more effective than bimatoprost or latanoprost. Travoprost 0.004% caused a higher percentage of hyperaemia than timolol, latanoprost, or travoprost 0.0015%. There was an increased incidence of pigmentation with travoprost than timolol. Travoprost 0.004% caused a higher percentage of eyelash changes than timolol, latanoprost, or travoprost 0.0015%. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; According to data available, travoprost is more effective than timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. Compared with other prostaglandin analogues, travoprost appears to be equivalent to bimatoprost and latanoprost. Although a limited number of local side-effects were reported, no serious treatment-related side-effects were reported.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=118" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>84026</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4100524.pdf]]&gt;</url>
    <title>Treatment centres: delivering faster, quality care and choice for NHS patients</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,PATIENT AND PUBLIC INVOLVEMENT,PPI IN PRACTICE,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,INDIVIDUAL INVOLVEMENT,PATIENT CHOICE,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report published by the Department of Health in January 2005 outlines the progress made by the Treatment Centre programme to date. &lt;/P&gt;
&lt;P&gt;1. In April 2002, the Government announced unprecedented investment in the NHS in England in order to refocus health services on the needs of the patient and dramatically reduce the time that patients wait for treatment. &lt;/P&gt;
&lt;P&gt;2. One of the ways in which these objectives are being met is through new Treatment Centres, some run by the NHS and some by Independent Sector (IS) providers. This report:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;takes stock of achievements to date; and 
&lt;LI&gt;sets out the further impact that Treatment Centres are expected to have over the next year and beyond, as the NHS introduces patient choice for hospital treatment and moves closer to making waiting lists a thing of the past. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;3. Treatment Centres are streamlined units that provide safe, fast pre-booked surgery and diagnostic tests for patients. They often, though not exclusively, concentrate on procedures with the highest historic waiting times for treatment, for instance in orthopaedics and ophthalmology.&lt;/P&gt;
&lt;P&gt;4. The aims of the Treatment Centre programme are to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;help provide the extra capacity needed to deliver swift access to treatment for NHS patients; 
&lt;LI&gt;spearhead diversity and choice in clinical services for NHS patients;&lt;BR&gt;stimulate innovative models of service delivery and drive up productivity. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250840</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=DetailsSearch&amp;Term=15994659%5Buid%5D]]&gt;</url>
    <title>Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials</title>
    <publicationDate>2005-07-16T00:00:00</publicationDate>
    <publisher>British Medical Journal (BMJ)</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;BMJ. 2005 Jul 16;331(7509):134.&amp;nbsp; Epub 2005 Jul 1. Comment in: BMJ. 2005 July 16;331(7509):120-1.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This&amp;nbsp;resource&amp;nbsp;was identified during the Glaucoma National Knowledge Week held in November 2006.&amp;nbsp;&amp;nbsp; Please &lt;A href="http://www.library.nhs.uk/eyes/Page.aspx?prv=y&amp;amp;pagename=NKWGLAUCOM" target="_blank"&gt;click here&lt;/A&gt; to view the contents of the week. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PubMed Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;OBJECTIVE: Open angle glaucoma is one of the most common causes of blindness in industrialised nations. Treatments to lower ocular pressure are widely used in glaucoma prevention and treatment, despite conflicting evidence. &lt;/P&gt;
&lt;P&gt;DESIGN: We performed meta-analyses to reassess the effectiveness of pressure lowering treatment to delay the development of glaucoma in ocular hypertension, as well as progression of manifest open angle glaucoma. &lt;/P&gt;
&lt;P&gt;DATA SOURCES: Medline, Embase, and the Cochrane Library. &lt;/P&gt;
&lt;P&gt;SELECTION OF STUDIES: Eligible studies were randomised controlled trials with a concurrent untreated control group and information on time to glaucomatous changes to visual field and optic disc. Trial reports were reviewed independently by two investigators in an unblinded standardised manner. &lt;/P&gt;
&lt;P&gt;RESULTS: Meta-analysis of trials in ocular hypertension showed a significant preventive effect of reducing intraocular pressure on progression to glaucoma (hazard ratio 0.56, 95% confidence interval 0.39 to 0.81, P = 0.01; number needed to treat 12). Pooled data of studies in manifest glaucoma showed a significant delay of visual field deterioration (0.65, 0.49 to 0.87, P = 0.003; NNT = 7), with subgroup analysis showing a larger effect in patients with raised pressure and a reduced effect in normal tension glaucoma (subgroup comparison: not significant). &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Lowering intraocular pressure in patients with ocular hypertension or manifest glaucoma is beneficial in reducing the risk of visual field loss in the long term.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317913</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15994659]]&gt;</url>
    <title>Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials.</title>
    <publicationDate>2005-07-01T00:00:00</publicationDate>
    <publisher>British Medical Journal (BMJ)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: BMJ 2005 Jul 16;331(7509):134. Epub 2005 Jul 1. &lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; Open angle glaucoma is one of the most common causes of blindness in industrialised nations. Treatments to lower ocular pressure are widely used in glaucoma prevention and treatment, despite conflicting evidence. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; We performed meta-analyses to reassess the effectiveness of pressure lowering treatment to delay the development of glaucoma in ocular hypertension, as well as progression of manifest open angle glaucoma. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DATA SOURCES:&lt;/STRONG&gt; Medline, Embase, and the Cochrane Library. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;SELECTION OF STUDIES:&lt;/STRONG&gt; Eligible studies were randomised controlled trials with a concurrent untreated control group and information on time to glaucomatous changes to visual field and optic disc. Trial reports were reviewed independently by two investigators in an unblinded standardised manner. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Meta-analysis of trials in ocular hypertension showed a significant preventive effect of reducing intraocular pressure on progression to glaucoma (hazard ratio 0.56, 95% confidence interval 0.39 to 0.81, P = 0.01; number needed to treat 12). Pooled data of studies in manifest glaucoma showed a significant delay of visual field deterioration (0.65, 0.49 to 0.87, P = 0.003; NNT = 7), with subgroup analysis showing a larger effect in patients with raised pressure and a reduced effect in normal tension glaucoma (subgroup comparison: not significant). &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Lowering intraocular pressure in patients with ocular hypertension or manifest glaucoma is beneficial in reducing the risk of visual field loss in the long term.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=162" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317915</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11713084]]&gt;</url>
    <title>Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update</title>
    <publicationDate>2001-11-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,CANCER,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology 2001 Nov;108(11):2088-98a;quiz 209-100, 2121.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To provide evidence-based clinical recommendations for treatment options and future prospects for the management of common malignant eyelid tumors, including global ratings for the strength of published evidence supporting them. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CLINICAL RELEVANCE: &lt;/STRONG&gt;Approximately 5% to 10% of all skin cancers occur in the eyelid. Incidence studies indicate that basal cell carcinoma is the most frequent malignant eyelid tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanoma. Many therapeutic methods have been suggested to combat the morbidity and mortality associated with these lesions. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;LITERATURE REVIEWED:&lt;/STRONG&gt; A MEDLINE and PubMed literature search (1966-1999) was conducted for English language abstracts and appropriate (selected) full-text references retrieved regarding treatment of malignant eyelid tumors. These sources then were used to prepare recommendations for patient care. Each recommendation was rated according to: (1) its importance in the care process and (2) the strength of evidence supporting the given recommendation. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; All recommendations were rated as level A (very important to patient-care outcome). For basal cell carcinoma, squamous cell carcinoma, and sebaceous gland carcinoma, the published evidence supporting two recommendations (Mohs' micrographic surgery or excision with frozen-section control) were graded as I (providing strong evidence in support of a recommendation). For sebaceous gland carcinoma, the recommendations also included conjunctival map biopsies. The published evidence supporting all other recommendations for these three eyelid tumors were graded II (substantial evidence in support of a recommendation), primarily because of the small numbers of patients in each clinical study. For malignant melanoma, the recommendation for therapy (i.e., excision with variable margins depending on tumor thickness) was based on published papers individually variably rated as I, II, and III, reflecting ongoing debate as to the best method of therapy. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Published reports regarding the treatment of malignant eyelid tumors include a myriad of treatment options. The strongest evidence favors complete surgical removal using histologic controls for verifying tumor-free margins of excision.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=218" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102064</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3658348&amp;query_hl=43]]&gt;</url>
    <title>Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.</title>
    <publicationDate>1987-07-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETIC RETINOPATHY,RETINA,RETINOPATHY,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Jul 1987, vol. 94, no. 7, p. 761-74, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;The Early Treatment Diabetic Retinopathy Study (ETDRS) has recently shown that argon laser photocoagulation treatment is beneficial in reducing the risk of visual loss from clinically significant diabetic macular edema. The ETDRS treatment consisted of a combination of focal treatment to individual-leaking microaneurysms and grid treatment to areas of diffuse leakage and capillary nonperfusion. These techniques are described in detail, and the concepts of clinically significant macular edema and treatable lesions are defined. Guidelines for the application of ETDRS findings to clinical practice are discussed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102063" target="_blank"&gt;Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102065" target="_blank"&gt;Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102066" target="_blank"&gt;Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102067" target="_blank"&gt;Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=0&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=10543&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102068" target="_blank"&gt;Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2740076&amp;amp;query_hl=73" target="_blank"&gt;Detection of diabetic macular edema. Ophthalmoscopy versus photography--Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8287162&amp;amp;query_hl=73" target="_blank"&gt;C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062510&amp;amp;query_hl=102" target="_blank"&gt;Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062511&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062514&amp;amp;query_hl=73" target="_blank"&gt;Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062515&amp;amp;query_hl=73" target="_blank"&gt;Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=2062516&amp;amp;query_hl=73" target="_blank"&gt;Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1507375&amp;amp;query_hl=113" target="_blank"&gt;Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10577530&amp;amp;query_hl=108" target="_blank"&gt;Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 15.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=1543449&amp;amp;query_hl=94" target="_blank"&gt;Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9477980&amp;amp;query_hl=106" target="_blank"&gt;Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7661748&amp;amp;query_hl=73" target="_blank"&gt;Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=7826294&amp;amp;query_hl=73" target="_blank"&gt;Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8790092&amp;amp;query_hl=91" target="_blank"&gt;Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=9230827&amp;amp;query_hl=73" target="_blank"&gt;Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=10604663&amp;amp;query_hl=94" target="_blank"&gt;Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15735198&amp;amp;query_hl=97" target="_blank"&gt;Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=8545570&amp;amp;query_hl=100" target="_blank"&gt;Accommodative amplitudes in the Early Treatment Diabetic Retinopathy Study.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284181</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4136011.pdf]]&gt;</url>
    <title>Turning the corner: improving diabetes care</title>
    <publicationDate>2006-06-13T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,NATIONAL SERVICE FRAMEWORKS (NSFS) AND EYE HEALTH,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report published on 13 June 2006 highlights the progress over the first three years following the publication of the NSF Delivery Strategy. &lt;/P&gt;
&lt;P&gt;The Diabetes National Framework set out the first ever set of national standards for the treatment of diabetes to raise the quality of NHS services and reduce unacceptable variations between them.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102070</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4000644&amp;query_hl=53]]&gt;</url>
    <title>Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1.</title>
    <publicationDate>1985-04-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETIC RETINOPATHY,RETINOPATHY,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology, {Ophthalmology}, Apr 1985, vol. 92, no. 4, p. 492-502, ISSN: 0161-6420.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;Seven hundred forty-four eyes with very severe proliferative diabetic retinopathy (PDR) were followed with conventional management over a two-year period. Decreases in visual acuity were more frequent during the first year of follow-up than during the second, and were related to baseline visual acuity level and retinopathy severity. After two years, visual acuity was less than 5/200 in 45% of eyes with more than four disc areas of new vessels and visual acuity of 10/30 to 10/50 at baseline, but in only 14% of eyes with traction retinal detachment not involving the center of the macula and without active new vessels or fresh vitreous hemorrhage at baseline. Vitrectomy, which was undertaken only if retinal detachment involving the center of the macula occurred or if severe vitreous hemorrhage failed to clear after a one-year waiting period, had been carried out in 25% of eyes after two years of follow-up.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy&amp;nbsp;management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102069" target="_blank"&gt;Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102071" target="_blank"&gt;Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102072" target="_blank"&gt;Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=10543&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102073" target="_blank"&gt;Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5.&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>283438</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.vision2020uk.org.uk/ukvisionstrategy/core/core_picker/download.asp?id=13]]&gt;</url>
    <title>UK Vision Strategy: Setting the direction for eye health and sight loss services</title>
    <publicationDate>2008-04-18T00:00:00</publicationDate>
    <publisher>Royal National Institute of Blind People (RNIB)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,LID,LENS,UVEAL TRACT,CORNEA,GLAUCOMA,CONJUNCTIVA,LACRIMAL,OCULAR MOTILITY,ORBIT,VITREOUS BODY,REFRACTIVE ERROR,LOW VISION,CERTIFICATION OF VISUAL IMPAIRMENT,GUIDANCE AND POLICIES FOR THE NHS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Published on 18 April 2008 the UK Vision Strategy is a VISION2020 UK initiative led by RNIB working with partners from all areas of the eye health sector. &lt;/P&gt;
&lt;P&gt;The UK Vision Strategy aims to : &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Improve the eye health of the people of the UK 
&lt;LI&gt;Eliminate avoidable sight loss and deliver excellent support to those with a visual impairment 
&lt;LI&gt;Enhance the inclusion, participation and independence of blind and partially sighted people.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The Strategy is underpinned by the following values:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Fair and equitable access for all members of society to eye&lt;BR&gt;health, eye care and sight loss services. 
&lt;LI&gt;Person-centred delivery of excellent services and support in&lt;BR&gt;the most appropriate way for each individual. 
&lt;LI&gt;Evidence-based policies and services to guide resource&lt;BR&gt;allocation and effective services. 
&lt;LI&gt;Awareness of and respect for people with sight loss and full&lt;BR&gt;compliance with equality legislation.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=368" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=368" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=368" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102074</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11270671&amp;query_hl=62]]&gt;</url>
    <title>UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.</title>
    <publicationDate>2001-02-01T00:00:00</publicationDate>
    <publisher>Diabetologia</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ DIABETIC RETINOPATHY,RETINOPATHY,RETINA,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Diabetologia, {Diabetologia}, Feb 2001, vol. 44, no. 2, p. 156-63, ISSN: 0012-186X.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;AIMS/HYPOTHESIS: To determine risk factors related to the incidence and progression of diabetic retinopathy over 6 years from diagnosis of Type II (non-insulin-dependent) diabetes mellitus. &lt;/P&gt;
&lt;P&gt;METHODS: This report describes 1919 patients from within the United Kingdom Prospective Diabetes Study (UKPDS), with retinal photographs taken at diagnosis and 6 years later and with complete data available. Photographs were centrally graded for lesions of diabetic retinopathy using the modified Early Treatment of Diabetic Retinopathy Study Final scale. Risk factors were assessed after 3 months diet from the time of diagnosis of diabetes. Patients were seen every 3 months in a hospital setting. Biochemical measurements were done by a central laboratory. End points of vitreous haemorrhage and photocagulation were confirmed by independent adjudication of systematically collected clinical data. The main outcome measures were incidence and progression of retinopathy defined as a two-step Early Treatment of Diabetic Retinopathy Study (ETDRS) final scale change. &lt;/P&gt;
&lt;P&gt;RESULTS: Of the 1919 patients, 1216 (63 %) had no retinopathy at diagnosis. By 6 years, 22 % of these had developed retinopathy, that is microaneurysms in both eyes or worse. In the 703 (37 %) patients with retinopathy at diagnosis, 29 % progressed by two scale steps or more. Development of retinopathy (incidence) was strongly associated with baseline glycaemia, glycaemic exposure over 6 years, higher blood pressure and with not smoking. In those who already had retinopathy, progression was associated with older age, male sex, hyperglycaemia (as evidenced by a higher HbA1c) and with not smoking. &lt;/P&gt;
&lt;P&gt;CONCLUSION/INTERPRETATION: The findings re-emphasise the need for good glycaemic control and assiduous treatment of hypertension if diabetic retinopathy is to be minimised. &lt;BR&gt;Grant ID: 2 UO1 EY07049-09, Acronym: EY, Agency: NEI.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;diabetic retinopathy management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15534123&amp;amp;query_hl=67" target="_blank"&gt;Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.&lt;BR&gt;&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>372626</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19191178]]&gt;</url>
    <title>United States cost-effectiveness study of two dry eye ophthalmic lubricants</title>
    <publicationDate>2009-01-31T00:00:00</publicationDate>
    <publisher>Ophthalmic Epidemiology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LACRIMAL,DRY EYE,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Sources: Ophthalmic Epidemiology. 2009 Jan-Feb;16(1):22-30&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; Dry eye is thought to be the most common ocular problem in the United States. However, it is only recently that it has been recognized as a disease with significant economic burden and impact on quality of life. This article presents an economic model of cost-effectiveness of two ophthalmic lubricants commonly used in the treatment of dry eye-Systane and Refresh Tears. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHOD:&lt;/STRONG&gt; We conducted a meta-analysis, pooling the results of two clinical trials of patients with dry eye treated with Systane and Refresh Tears which presented response rates for improvements in ocular dryness, the key symptom of dry eye. An economic model was used to estimate the incremental cost-effectiveness ratio (ICER) for Systane versus Refresh Tears over a 12 month treatment period. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Systane is significantly more effective than Refresh Tears at improving symptoms of "dryness" (75% vs 41%). Systane costs on average $57.79 per year more than Refresh Tears. Assigning a quality-adjusted life year (QALY) gain of 0.03 to responders results in an incremental cost per QALY gain of $5,837. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Both Refresh Tears and Systane are effective and cost-effective interventions. Systane costs more than Refresh Tears, however clinical trial evidence shows it to be more effective. The ICER for Systane versus Refresh Tears is well below the generally accepted $50,000 per QALY threshold.&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=257" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317916</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18161610]]&gt;</url>
    <title>Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies</title>
    <publicationDate>2007-11-30T00:00:00</publicationDate>
    <publisher>Ophthalmic Epidemiology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmic Epidemiology 2007 Nov-Dec;14(6):367-74.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To examine the effect of lipid-lowering agents in the development of age-related macular degeneration (AMD) through the techniques of meta-analysis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Case-control and cohort studies presenting relative risks and 95% confidence intervals were identified through a literature review. Inclusion was limited to studies where both the exposure of interest (lipid-lowering agents) and outcome (AMD) were explicitly defined. Pooled estimates were computed using the random effects model. To quantify heterogeneity we calculated the proportion of total variance of between study variance using the Ri statistic. The Q statistic for heterogeneity was also calculated. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Eight studies were identified. The pooled relative risk (RR) for all studies was 0.74 (95% CI, 0.55-1.00). When only those studies examining the use of statins were pooled (n=7), the RR was 0.70 (95% CI, 0.48-1.03). Using the Ri statistic, the heterogeneity between studies was found to be 0.85 for all studies and 0.89 for studies examining statins. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Lipid-lowering agents, including statins, do not appear to lower the risk of developing AMD, although clinically significant effects cannot be excluded. The use of these agents in the prevention of AMD cannot be recommended until well designed prospective studies with long follow up have demonstrated a benefit.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=31" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317919</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/12854035]]&gt;</url>
    <title>Uveitis: a global perspective</title>
    <publicationDate>2002-12-01T00:00:00</publicationDate>
    <publisher>Ocular Immunology and Inflammation</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,UVEAL TRACT,UVEITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ocular Immunology and Inflammation (Ocul Immunol Inflamm) 2002 Dec;10(4):263-79. &lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To study the patterns of uveitis in various geographic regions. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; A systematic literature review was performed using the MEDLINE database, from 1966 to present. Studies that satisfied our described selection criteria were analyzed to provide a global perspective on uveitis. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Twenty-two studies, which were the best available representatives of Australia, North and South America, Europe, Asia, and Africa, were included in the final analysis. The distribution of uveitis cases according to the anatomical site of inflammation in the various regions, and the causes and clinical disease associations of anterior, intermediate, posterior, and pan-uveitis were studied for each of the regions and a comparative analysis was performed. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; There are similarities and distinct differences in the patterns of uveitis in the various geographic regions. Such patterns of uveitis are influenced by combinations of geographical, environmental, and genetic factors.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=204" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317921</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16002881]]&gt;</url>
    <title>Value of routine funduscopy in patients with hypertension: systematic review</title>
    <publicationDate>2005-07-05T00:00:00</publicationDate>
    <publisher>British Medical Journal (BMJ)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,RETINOPATHY,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: BMJ 2005 Jul 9;331(7508):73&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To evaluate the additional value of funduscopy in the routine management of patients with hypertension. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DESIGN:&lt;/STRONG&gt; Systematic review. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PARTICIPANTS:&lt;/STRONG&gt; Adults aged 19 or more with hypertensive retinopathy. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;DATA SOURCES:&lt;/STRONG&gt; Medline, Embase, and the Cochrane Library from 1990. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;REVIEW METHODS: &lt;/STRONG&gt;Studies were included that assessed hypertensive retinopathy with blinding for blood pressure and cardiovascular risk factors. Studies on observer agreement had to be assessed by two or more observers and expressed as a kappa statistic. Studies on the association between hypertensive retinopathy and hypertensive organ damage were carried out in patients with hypertension. The association between hypertensive retinopathy and cardiovascular risk was carried out in unselected normotensive and hypertensive people without diabetes mellitus. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; The assessment of microvascular changes in the retina is limited by large variation between observers. The positive and negative predictive values for the association between hypertensive retinopathy and blood pressure were low (47% to 72% and 32% to 67%, respectively). Associations between retinal microvascular changes and cardiovascular risk were inconsistent, except for retinopathy and stroke. The increased risk of stroke, however, was also present in normotensive people with retinopathy. These studies did not adjust for other indicators of hypertensive organ damage. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSION:&lt;/STRONG&gt; Evidence is lacking that routine funduscopy is of additional value in the management of hypertensive patients.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=163" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>267296</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band159/b159-4.html]]&gt;</url>
    <title>Value of Vision</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This article published in issue 159 of Bandolier discusses cost and value of modern medicine in relation to vision and age related macular degeneration.]]&gt;</body>
  </document>
  <document>
    <id>317924</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17003413]]&gt;</url>
    <title>Variations in primary open-angle glaucoma prevalence by age, gender and race: a Bayesian meta-analysis</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Investigative Ophthalmology &amp; Visual Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GLAUCOMA,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Investigative Ophthalmology &amp;amp; Vision Science (Invest Ophthalmol Vis Sci) 2006 Oct;47(10):425461.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To quantify the variation in primary open-angle glaucoma (OAG) prevalence with age, gender, race, year of publication, and survey methodology. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; Medline, EMBASE, and PubMed were searched for studies of OAG prevalence. Studies with defined population samplings were sought. Forty-six published observational studies of OAG prevalence (103,567 participants with 2509 cases of OAG) were identified for inclusion in the systematic review and meta-analysis. Data on the number of people and the number of cases of OAG by age, race, and gender were sought for each study. Additional information was obtained regarding whether the definition of glaucoma relied on raised intraocular pressure (IOP) and whether visual field examination was performed routinely on all individuals. Bayesian meta-analysis was used to model the associations between the log odds of OAG and age, race, gender, year of publication, method of visual field testing, and effect of reliance on IOP in the definition of OAG. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; Black populations had the highest OAG prevalence at all ages, but the proportional increase in prevalence of OAG with age was highest in white populations. The odds ratio per decade increase in age was 2.05 in white populations (95% credible interval, 1.91 to 2.18), 1.61 (95% credible interval, 1.53 to 1.70) in black populations, and 1.57 (95% credible interval, 1.46 to 1.68) in Asian populations. The average estimated prevalence in those older than 70 years of age was 6% in white populations, 16% in black populations, and 3% in Asian populations. After adjusting for age, race, year of publication, and survey methods, men were 1.37 (95% credible interval, 1.22 to 1.53) times more likely than women to have OAG. The prevalence of OAG was one third lower in studies in which routine visual fields were not assessed and that used an IOP criterion in the definition of glaucoma; this effect was reduced to the null after adjustment for age, racial group, and year of publication. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Although black populations had the highest prevalence of OAG at all ages, white populations showed the steepest increase in OAG prevalence with age. Men were more likely than women to have OAG.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/showsystematic.asp?study_id=14" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289002</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_098627]]&gt;</url>
    <title>Vascular programme briefing pack</title>
    <publicationDate>2009-04-29T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DEPARTMENT OF HEALTH (DH) GUIDANCE AND POLICIES,RETINA,RETINOPATHY,DIABETIC RETINOPATHY,CONDITIONS,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;The vascular programme briefing pack was prepared in 2009 to provide the ten strategic health authorities with an assessment of progress, opportunities and future challenges in key areas of vascular disease.&lt;/P&gt;
&lt;P&gt;The pack covers coronary heart disease, stroke, diabetes (including screening programmes for diabetic retinopathy) and renal disease. It provides comparator information at old SHA, new HA and old PCT levels (depending on the indicator). It is intended for use primarily by HA boards and their constituent trusts and networks.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102312</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11320011&amp;query_hl=6]]&gt;</url>
    <title>Verteporfin in Photodynamic Therapy Study Group Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.</title>
    <publicationDate>2002-06-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RETINA,AGE RELATED MACULAR DEGENERATION,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology. 2001 May;108(5):841-52.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To determine if photodynamic therapy with verteporfin (Visudyne; CIBA Vision Corp, Duluth, GA) can improve the chance of stabilizing or improving vision (&amp;lt;8 letter loss) safely in patients with subfoveal choroidal neovascularization (CNV) caused by pathologic myopia. &lt;/P&gt;
&lt;P&gt;DESIGN: Multicenter, double-masked, placebo-controlled, randomized clinical trial at 28 ophthalmology practices in Europe and North AMERICA: &lt;/P&gt;
&lt;P&gt;PARTICIPANTS: One hundred twenty patients with subfoveal CNV caused by pathologic myopia with a greatest linear dimension no more than 5400 microM and best-corrected visual acuity (Snellen equivalent) of approximately 20/100 or better. &lt;/P&gt;
&lt;P&gt;INTERVENTION: Patients were randomly assigned (2:1) to verteporfin (6 mg per square meter of body surface area; n = 81) or placebo (5% dextrose in water; n = 39) administered via intravenous infusion of 30 ml over 10 minutes. Fifteen minutes after the start of the infusion, a laser light at 689 nm was delivered at an intensity of 600 mW/cm(2) over 83 seconds to give a light dose of 50 J/cm(2) to a round spot size on the retina with a diameter of 1000, microM larger than the greatest linear dimension of the choroidal neovascular lesion. At follow-up examinations every 3 months, retreatment with either verteporfin or placebo (as assigned at baseline) was applied to areas of fluorescein leakage if present. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURES: The primary outcome was the proportion of eyes at the follow-up examination 12 months after study entry with fewer than eight letters (approximately 1.5 lines) of visual acuity lost, adhering to an intent-to-treat analysis. &lt;/P&gt;
&lt;P&gt;RESULTS: At baseline, more than 90% of each group had evidence of classic CNV (regardless of whether occult CNV was present) and only 12 (15%) and 5 (13%) cases in the verteporfin and placebo groups, respectively, had occult CNV (regardless of whether classic CNV was present). Seventy-nine of the 81 verteporfin-treated patients (98%) compared with 36 of the 39 placebo-treated patients (92%) completed the month 12 examination. Visual acuity, contrast sensitivity, and fluorescein angiographic outcomes were better in the verteporfin-treated eyes than in the placebo-treated eyes at every follow-up examination through the month 12 examination. At the month 12 examination, 58 (72%) of the verteporfin-treated patients compared with 17 (44%) of the placebo-treated patients lost fewer than eight letters (P &amp;lt; 0.01), including 26 (32%) versus 6 (15%) improving at least five letters (&amp;gt;/=1 line). Seventy (86%) of the verteporfin-treated patients compared with 26 (67%) of the placebo-treated patients lost fewer than 15 letters (P = 0.01). Few ocular or other systemic adverse events were associated with verteporfin therapy compared with placebo treatment. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Because photodynamic therapy with verteporfin can safely increase the chance of stabilizing or improving vision in patients with subfoveal CNV from pathologic myopia compared with a placebo, we recommend ophthalmologists consider verteporfin therapy for treatment of such patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current glaucoma management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=30&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=9866&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102311" target="_blank"&gt;Verteporfin in Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=9918&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102309" target="_blank"&gt;Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.&lt;/A&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102311</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11336929&amp;query_hl=6]]&gt;</url>
    <title>Verteporfin in Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.</title>
    <publicationDate>2001-05-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,RETINA,AGE RELATED MACULAR DEGENERATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Am J Ophthalmol. 2001 May;131(5):541-60.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To determine if photodynamic therapy with verteporfin (Visudyne; Novartis AG, Bulach, Switzerland), termed verteporfin therapy, can safely reduce the risk of vision loss compared with a placebo (with sham treatment) in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration who were identified with a lesion composed of occult with no classic choroidal neovascularization, or with presumed early onset classic choroidal neovascularization with good visual acuity letter score. &lt;/P&gt;
&lt;P&gt;METHODS: This was a double-masked, placebo-controlled (sham treatment), randomized, multicenter clinical trial involving 28 ophthalmology practices in Europe and North America. The study population was patients with age-related macular degeneration, with subfoveal choroidal neovascularization lesions measuring no greater than 5400 microm in greatest linear dimension with either 1) occult with no classic choroidal neovascularization, best-corrected visual acuity score of at least 50 (Snellen equivalent approximately 20/100), and evidence of hemorrhage or recent disease progression; or 2) evidence of classic choroidal neovascularization with a best-corrected visual acuity score of at least 70 (better than a Snellen equivalent of approximately 20/40); assigned randomly (2:1) to verteporfin therapy or placebo therapy. Verteporfin (6 mg per square meter of body surface area) or placebo (5% dextrose in water) was administered by means of intravenous infusion of 30 ml over 10 minutes. Fifteen minutes after the start of the infusion, a laser light at 689 nm delivered 50 J/cm(2) by application of an intensity of 600 mW/cm(2) over 83 seconds using a spot size with a diameter 1000 microm larger than the greatest linear dimension of the choroidal neovascularization lesion on the retina. At follow-up examinations every 3 months, retreatment with the same regimen was applied if angiography showed fluorescein leakage. The main outcome measure was at least moderate vision loss, that is, a loss of at least 15 letters (approximately 3 lines), adhering to an intent-to-treat analysis with the last observation carried forward to impute for missing data. &lt;/P&gt;
&lt;P&gt;RESULTS: Two hundred ten (93%) and 193 (86%) of the 225 patients in the verteporfin group compared with 104 (91%) and 99 (87%) of the 114 patients in the placebo group completed the month 12 and 24 examinations, respectively. On average, verteporfin-treated patients received five treatments over the 24 months of follow-up. The primary outcome was similar for the verteporfin-treated and the placebo-treated eyes through the month 12 examination, although a number of secondary visual and angiographic outcomes significantly favored the verteporfin-treated group. Between the month 12 and 24 examinations, the treatment benefit grew so that by the month 24 examination, the verteporfin-treated eyes were less likely to have moderate or severe vision loss. Of the 225 verteporfin-treated patients, 121 (54%) compared with 76 (67%) of 114 placebo-treated patients lost at least 15 letters (P =.023). Likewise, 67 of the verteporfin-treated patients (30%) compared with 54 of the placebo-treated patients (47%) lost at least 30 letters (P =.001). Statistically significant results favoring verteporfin therapy at the month 24 examination were consistent between the total population and the subgroup of patients with a baseline lesion composition identified as occult choroidal neovascularization with no classic choroidal neovascularization. This subgroup included 166 of the 225 verteporfin-treated patients (74%) and 92 of the 114 placebo-treated patients (81%). In these patients, 91 of the verteporfin-treated group (55%) compared with 63 of the placebo-treated group (68%) lost at least 15 letters (P =.032), whereas 48 of the verteporfin-treated group (29%) and 43 of the placebo-treated group (47%) lost at least 30 letters (P =.004). Other secondary outcomes, including visual acuity letter score worse than 34 (approximate Snellen equivalent of 20/200 or worse), mean change in visual acuity letter score, development of classic choroidal neovascularization, progression of classic choroidal neovascularization and size of lesion, favored the verteporfin-treated group at both the month 12 and month 24 examination for both the entire study group and the subgroup of cases with occult with no classic choroidal neovascularization at baseline. Subgroup analyses of lesions composed of occult with no classic choroidal neovascularization at baseline suggested that the treatment benefit was greater for patients with either smaller lesions (4 disc areas or less) or lower levels of visual acuity (letter score less than 65, an approximate Snellen equivalent of 20/50(-1) or worse) at baseline. Prospectively planned multivariable analyses confirmed that these two baseline variables affected the magnitude of treatment benefit. (ABSTRACT TRUNCATED)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;age related macular degeneration management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102312:0" name=internalLink&gt;Verteporfin in Photodynamic Therapy Study Group Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:102309:0" name=internalLink&gt;Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. &lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102313</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11884872&amp;query_hl=10]]&gt;</url>
    <title>Verteporfin Roundtable 2000 and 2001 Participants; Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators; Verteporfin in photodynamic therapy (VIP) study group principal investigators: Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.</title>
    <publicationDate>2002-02-01T00:00:00</publicationDate>
    <publisher>Retina</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,AGE RELATED MACULAR DEGENERATION,RETINA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Retina. 2002 Feb;22(1):6-18.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: Guidelines were developed based on best available scientific data as well as consensus of expert opinion in absence of controlled clinical trial data to: 1) assist ophthalmologists with selection of patients for whom photodynamic therapy with verteporfin, termed "verteporfin therapy," should be considered; and 2) offer suggestions regarding treatment, follow-up, and re-treatment. &lt;/P&gt;
&lt;P&gt;METHODS: Consensus from roundtable of retina specialists who either participated in randomized clinical trials evaluating verteporfin therapy or had clinical experience with verteporfin therapy was based on results of these trials and expert opinion. Additional input and advice were received from representatives on behalf of the Macula Society, the Retina Society, and the Vitreous Society, as well as principal investigators of randomized clinical trials evaluating verteporfin therapy. &lt;/P&gt;
&lt;P&gt;RESULTS: Patient selection criteria included the following: 1) in cases due to age-related macular degeneration (AMD), lesion composition either predominantly classic choroidal neovascularization (CNV) or occult with no classic CNV; 2) CNV location subfoveal or so close to the foveal center that conventional laser photocoagulation treatment almost certainly would extend under the center; 3) lesion etiology from AMD, pathologic myopia, or other causes in which the outcome without treatment is likely to be worse than with treatment; 4) vision at a level where further loss would be recognized as detrimental to the quality of life of the patient. Criteria did not include lesion size, except in cases composed of occult with no classic CNV in AMD in which therapy for lesions &amp;gt;4 Macular Photocoagulation Study (MPS) disc areas usually should be considered only when presenting with lower levels of best-corrected visual acuity. Criteria also did not include patient age, history of systemic arterial hypertension, or prior laser photocoagulation. Therapy should occur ideally within 1 week of the initial fluorescein angiogram on which the clinical decision to treat is based. Patients should return for follow-up at least as often as every 3 months after any initial or subsequent treatment to determine if there is fluorescein leakage from CNV. Re-treatment should be considered as often as every 3 months if fluorescein leakage from CNV is noted at that time. Re-treatment could be deferred if the biomicroscopic and fluorescein angiographic appearance of the lesion is unchanged and shows minimal leakage, especially when there is no subretinal fluid or fluorescein leakage from CNV underlying the center of the foveal avascular zone. Patients should avoid exposure of skin or eyes to direct sunlight or bright indoor light for 48 hours after treatment or until resolution of any swelling or discoloration from extravasation. &lt;/P&gt;
&lt;P&gt;CONCLUSION: These recommendations provide guidelines on the role of verteporfin therapy in the management of CNV due to AMD and other causes. Revisions of these guidelines may be required as new data become available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current&amp;nbsp;age related macular degeneration management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15689800&amp;amp;query_hl=18" target="_blank"&gt;Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102309</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12689884&amp;query_hl=2]]&gt;</url>
    <title>Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.</title>
    <publicationDate>2003-04-01T00:00:00</publicationDate>
    <publisher>Ophthalmology</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ SHORT SIGHT (MYOPIA),REFRACTIVE ERROR,EYES AND VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: Ophthalmology. 2003 Apr;110(4):667-73.&lt;/EM&gt;&lt;/P&gt;
&lt;H2&gt;PubMed Abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with verteporfin in patients with subfoveal choroidal neovascularization (CNV) caused by pathologic myopia. &lt;/P&gt;
&lt;P&gt;DESIGN AND SETTING: Multicenter, double-masked, placebo-controlled, randomized clinical trial at 28 ophthalmology practices in Europe and North America. &lt;/P&gt;
&lt;P&gt;PARTICIPANTS: Patients with subfoveal choroidal neovascular lesions caused by pathologic myopia measuring no more than 5400 micro m and best-corrected visual acuity (approximate Snellen equivalent) of 20/100 or better. &lt;/P&gt;
&lt;P&gt;METHODS: Similar to methods described for 1-year results with follow-up examinations beyond 1 year, continuing every 3 months (except Photograph Reading Center evaluations only at the month 24 examination). During the second year, the same regimen (with verteporfin or placebo as applied at baseline) was used if angiography showed fluorescein leakage from CNV. &lt;/P&gt;
&lt;P&gt;MAIN OUTCOME MEASURES: The primary outcome was the proportion of eyes with fewer than 8 letters (approximately 1.5 lines) of visual acuity loss at the month 24 examination, adhering to an intent-to-treat analysis and using the last observation carried forward method to impute for any missing data. &lt;/P&gt;
&lt;P&gt;RESULTS: Seventy-seven of 81 patients (95%) in the verteporfin group, compared with 36 of 39 patients (92%) in the placebo group, completed the month 24 examination. At this time point, 29 of 81 verteporfin-treated patients (36%) compared with 20 of 39 placebo-treated patients (51%) lost at least 8 letters (P = 0.11). The distribution of change in visual acuity at the month 24 examination was in favor of a benefit for the cases assigned to verteporfin (P = 0.05). This included improvement by at least 5 letters (equivalent to at least 1 line) in 32 verteporfin-treated cases [40%] vs. five placebo-treated cases (13%) and improvement by at least 15 letters (equivalent to at least 3 lines) in 10 verteporfin-treated cases (12%) vs. zero placebo-treated cases. No additional photosensitivity adverse reactions or injection site adverse events were associated with verteporfin therapy in the second year of follow-up. &lt;/P&gt;
&lt;P&gt;CONCLUSIONS: Verteporfin therapy for subfoveal CNV caused by pathologic myopia safely maintained a visual benefit compared with a placebo therapy through 2 years of follow-up. Although the primary outcome was not statistically significantly in favor of verteporfin therapy at 2 years as it had been at 1 year of follow-up, the distribution of change in visual acuity at the month 24 examination was in favor of the verteporfin-treated group and showed that this group was more likely to have improved visual acuity through the month 24 examination. The VIP Study Group recommends verteporfin therapy for subfoveal CNV resulting from pathologic myopia based on both the 1- and 2-year results of this randomized clinical trial.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;This resource has been included in the EVSL at the editorial discretion of the Management Group as this research contributes to the evidence base of current age related macular degeneration management in the NHS.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Related articles:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?categoryID=9918&amp;amp;dg=149&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102312" target="_blank"&gt;Verteporfin in Photodynamic Therapy Study Group Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.&amp;nbsp;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/eyes/viewResource.asp?mr=10&amp;amp;offset=30&amp;amp;dg=149&amp;amp;searchText=&amp;amp;attributeText=&amp;amp;categoryID=9866&amp;amp;attributeOptionID=&amp;amp;keywordID=&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D102311" target="_blank"&gt;Verteporfin in Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>94649</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.cps.ca/english/statements/CP/cp98-01.htm]]&gt;</url>
    <title>Vision screening in infants, children and youth</title>
    <publicationDate></publicationDate>
    <publisher>Canadian Paediatric Society</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ SCHOOL ENTRY,VISION,EYES AND VISION,VISUAL IMPAIRMENT,CHILD,SCREENING,CONDITIONS,LOW VISION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This guideline produced by the&amp;nbsp;Community Paediatrics Committee of the Canadian Paediatrics Society was reaffirmed in&amp;nbsp;April 2009.&amp;nbsp;&amp;nbsp; Following a brief introduction, the guideline summarises the vision screening recommendations for four age groups, newborn to three months, six and 12 months, three to five years, and six to eighteen years. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=197" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=197" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=197" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>317931</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17885320]]&gt;</url>
    <title>Visual deficit intervention in adult stroke and brain injury: a systematic review</title>
    <publicationDate></publicationDate>
    <publisher>American Journal of Physical Medicine &amp; Rehabilitation</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,SYSTEMATIC REVIEWS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American journal of physical medicine &amp;amp; rehabilitation / Association of Academic Physiatrists (Am Phys Med Rehabil) 2007 Oct;86(10):853-60.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;Visual deficits after cerebral injury are common. The variability in the types of injury sustained as well as their impact on function in the environment have produced multiple approaches at corrective intervention. To assess the effectiveness of these vision interventions, an extensive literature search was completed. The analysis of this review revealed some success with visual neglect disorders, but not enough evidence to comment definitively on interventions for hemianopsia, quadrantonopsia, diplopia, or convergence insufficiency. A lack of follow-up also limited efforts to assess the durability of documented gains. Additional research is necessary to clarify, quantify, and measure treatment outcomes for acquired visual dysfunction as well as to link laboratory testing to improvement in actual functioning for individuals in their environment.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by eyes and vision specialist collection management team.&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nhS_Evidence/showsystematic.asp?study_id=44" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>83887</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.dvla.gov.uk/~/media/pdf/medical/at_a_glance.ashx]]&gt;</url>
    <title>Visual Disorders</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>Driver and Vehicle Licensing Agency (DVLA)</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,DRIVING,LIVING WITH VISUAL IMPAIRMENT,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;These guidelines were produced by the DVLA and are intended for use by doctors.&amp;nbsp;&amp;nbsp; The standards are reviewed every six months, following updated advice from the Secretary of State's Honorary Medical Advisory Panels. &lt;EM&gt;Section 6 relates to visual disorders.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The law states that: A licence holder or applicant is suffering a prescribed disability if unable to meet the eyesight requirements, i.e. to read in good light (with the aid of glasses or contact lenses if worn) a registration mark fixed to a motor vehicle and containing letters and figures 79 millimetres high and 57 millimetres wide (i.e. pre 1.9.2001 font) at a distance of 20.5 metres, or at a distance of 20 metres where the characters are 50 millimetres wide (i.e. post 1.9.2001 font). If unable to meet this standard, the driver must not drive and the licence must be refused or revoked. &lt;/P&gt;
&lt;P&gt;Registration for sight impairment or severe sight impairment will normally be regarded as incompatible with holding a driving licence and should be notified. However, attention will be given to the standards indicated&amp;nbsp;in deciding on fitness to drive.&lt;/P&gt;
&lt;P&gt;The applicant or licence holder must notify DVLA unless stated otherwise. &amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>300071</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=300071]]&gt;</url>
    <title>Visual field loss after stroke</title>
    <publicationDate>2008-12-03T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LOW VISION,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;2&lt;/pageSequence&gt;&lt;pageTitle&gt;Visual field loss after stroke&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Dr Fiona Rowe,&amp;nbsp;Senior Lecturer in Orthoptics, &lt;A href="http://www.liv.ac.uk/orthoptics/index.htm" target="_blank"&gt;Directorate of Orthoptics and Vision Science, University of Liverpool&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This article is an additional feature of the &lt;A href="http://www.library.nhs.uk/stroke/Page.aspx?prv=y&amp;amp;pagename=SAEUINTRO0" target="_blank"&gt;Stroke Rehabilitation Annual Evidence Update&lt;/A&gt;&amp;nbsp;being hosted by the &lt;A href="http://www.library.nhs.uk/stroke/" target="_blank"&gt;Stroke Specialist Library&lt;/A&gt; between 1 and 5 December 2008.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=300071" target="_blank"&gt;Click here for&amp;nbsp;pdf version&lt;/A&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Background &lt;/H2&gt;
&lt;P&gt;Stroke is a vascular event in the brain that is commonly due to a blockage of blood supply (infarction due to thrombus or embolus) or bleed (haemorrhage). 110000 individuals are reported to have their first stroke per year in the UK population with 30000 having a recurrent stroke [1]. Many stroke survivors will have a functional disability following their stroke of which visual disability is just one aspect. One of the commonly recognised visual disabilities is the loss of visual field.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Visual field loss is a loss of part of the field of vision. This may occur centrally or peripherally. However, following stroke, loss of visual field is more usually peripheral in nature. Visual field loss is reported as occurring in 20-67%2-8 although some visual field impairment is due to a previous stroke or pre-existent ocular pathology[2]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Types of visual field loss&lt;/H2&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The most common type is complete homonymous hemianopia [A] which may occur to the right or left side. Other types include partial or incomplete homonymous hemianopia [B], superior or inferior quadrantanopia [C], macular sparing homonymous hemianopia [D], homonymous macular scotomas [E], temporal crescent defect [F], hemianopia with spared temporal crescent [G], altitudinal defect [H], bilateral hemianopiasI (cortical blindness) [2, 9-12].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;In view of partial and peripheral visual field defects, quantitative visual field assessment that tests peripheral and not just central visual field is often preferable. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;Rehabilitation for visual field loss &lt;/H2&gt;
&lt;P&gt;The most common rehabilitation incorporates targeted advice for individuals. This encompasses improving awareness of the visual field loss and employing visual search strategies to promote the individual’s ability to scan to the impaired side. These search strategies include increasing head movements and fast eye scanning movements to the impaired side [2,13,14]. In addition prisms and vision restorative therapy have been reported for their use in such rehabilitation. Treatment with prisms involves expanding the visual field in lateral gaze. Peli prisms [15] involve applying sector Fresnel prisms on the upper and lower sections of one spectacle lens. This has the effect of displacing images from the ‘blind’ visual field across into the seeing side. Patients may then make scanning head and eye movements to the blind side to view objects of interest on that side. Patients, particularly those who are younger or motivated, report improvement in functioning and obstacle avoidance [16]. However it appears that although patients may show adaptation to the field defect there is little objective alteration of the visual field boundaries. Despite doubt as to the long-term efficacy of this treatment advocates promote the increased speed of adaptation to visual field loss and the benefit of this to rehabilitation [15-18]. Visual restorative therapy includes flicker stimulation of the blind field which produces changes in cortical function with cortical reorganisation [19]. Improvement has been reported in locating moving flickering objects in the blind field, improved navigation skills, reading ability and visual sensitivity [20,21]. Although some expansion of the visual field loss has been noted, none of the treatment options have shown permanent amelioration of the visual field loss [20]. Because of the wide variances of results seen with visual search training, prism therapy or visual restorative therapy, the decision on which treatment option to opt for must be made according to the individual’s needs and requirements [22].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Recovery of the visual field &lt;/H2&gt;
&lt;P&gt;Visual fields can recover following damage to the geniculostriate pathway after cerebral infarction [23]. However patients with homonymous field defects from vascular disease seem to have a generally poor prognosis for spontaneous recovery [24]. Recovery of visual field loss is usually seen within the first 3-6 months if recovery is going to take place [2,25]. The rate of recovery may continue past this time period but is usually at a much slower rate. Improvement has been reported in approximately 50% of stroke survivors with visual field loss [3,4,19-22,24].&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Associated visual disabilities &lt;/H2&gt;
&lt;P&gt;It is not uncommon for stroke survivors to have co-existent visual inattention/neglect in association with their visual field loss [26]. In severe cases this can make the detection and diagnosis of the visual field defect very difficult and at times it is not possible to make the diagnosis in the acute phase. It is also common for visual field loss to be associated with poor central vision and abnormal eye movements, most typically impaired fast eye movements to the side of impaired vision which contribute to reading difficulties [2,14,25]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Impact of visual field loss &lt;/H2&gt;
&lt;P&gt;The impact of visual impairment can be wide ranging. Impact on functional performance can include general mobility, ability to judge distances due to diplopia or impaired stereo vision, reading impairment due to cortical or ocular dysfunction and visual hallucinations [2]. One of the immediate impacts is to general mobility and navigation with complaints of bumping into objects and clumsiness to the side of impaired vision [2,25]. Individuals with loss of visual field may lose their driving licence if the extent of field loss fails to satisfy the DVLA requirements in the UK [27,28]. For group 1 car drivers, the standards are a horizontal field of vision of 120 degrees and no significant defect within 20 degrees of central fixation. Individuals with hemianopia tend to have a worse impact on their driving performance than individuals with quadrantanopia [29]. However the large variances in driving performance versus extent of visual field loss mean than individual driving assessments are required regardless of the type and extent of visual field loss [29]. For individuals who have lost visual field and particularly those with impact to general function, the presence of visual field loss has been linked to depression, loss of confidence and impaired quality of life. Individuals with loss of visual field may also have great difficulty with reading [30-34]. Homonymous hemianopias are apparent on visual field testing but can also be reflected in changes of eye movements [14]. The extent of the visual field defect has a strong effect on the problems that individual patients experience during text reading [35,36]. Visual field loss is also associated with a higher risk of falls. Thus it is important to diagnose visual field impairment for this group of already compromised patients [37]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Assessment of visual field loss &lt;/H2&gt;
&lt;P&gt;Townend et al [38] reported the prevalence of post stroke visual field loss as relatively high but frequently underestimated by confrontation testing with patients often unaware of their field loss. Visual field loss should be measured by a quantifiable method which thus allows comparison of change over time [2,23]. This also establishes the extent of visual field loss. Kinetic perimetry using a moving target to assess the peripheral visual field may be undertaken with Goldmann or Octopus perimetry and static perimetry using on-off stationary targets to assess the central visual field may be undertaken with perimeters such as the Humphrey field analyser or Octopus. Where evaluation of field of vision for driving is required, an Estermann test should be undertaken [28]. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Guidelines and recommendations &lt;/H2&gt;
&lt;P&gt;Visual assessment for stroke survivors is acknowledged briefly in the National Stroke Strategy [39] where it is stated that vision and visual perceptual difficulties are components requiring multi-faceted stroke specific rehabilitation and support. National clinical guidelines produced for acute stroke and transient ischaemic attack by the National Institute for Clinical Excellence and the Royal College of Physicians [40] state that stroke can present with sudden loss of any neurological disturbance which can include visual loss. The Royal College of Physicians Intercollegiate Stroke Working Party have recently revised their guidance for stroke [41]. They state that visual field loss such as hemianopia is common and each specialist stroke rehabilitation centre should have easy access to orthoptic services. Every patient should receive a practical assessment of visual acuity, examination of visual field and provision of information on driving requirements. Any patient whose visual field defect causes practical problems should be taught compensatory techniques. However, treatment for hemianopia using prisms should only be provided if the treatment is supervised by someone with expertise in this treatment, if the effects are evaluated and the patient is aware that the treatment may not provide benefit for them. For patients with significant visual field defect or reduction in visual acuity, further specialist assessment should be sought for those wishing to return to driving. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The position statement [42] issued by the British and Irish Orthoptic Society (BIOS) for the Department of Health stroke strategy states that visual problems (including visual field defects) cause significant impairment and can be a barrier to rehabilitation. Orthoptists can advise on the strategies available to cope with visual field loss and can arrange ophthalmology referrals for partially sighted registration where applicable. It is recommended that the immediate post-acute phase is the optimum time for Orthoptic input and visual assessment. BIOS provide further specific standards and guidelines for vision assessment for stroke survivors in their document for the extended role of Orthoptists [43]. This states that visual field assessment may be qualitative or quantitative dependent on patient ability. Management of visual field loss incorporates the provision of advice on the presence and type of visual field defect, use of strategies to cope with visual field loss, use of prism applications and advice on their efficacy plus arrangement of formal visual field assessment follow-up and certification processes. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Help and advice &lt;/H2&gt;
&lt;P&gt;&lt;A href="http://www.stroke.org.uk/" target="_blank"&gt;Stroke Association&lt;/A&gt;&amp;nbsp;- The Stroke Association, serving England and Wales, offers information for individuals, their care givers, professionals in the field and the general public and has a network of information centres countrywide. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.chss.org.uk/" target="_blank"&gt;Chest, Heart and Stroke Scotland&lt;/A&gt;&amp;nbsp;- CHSS offer health advice, general information and a 'listening ear'. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.rnib.org.uk/" target="_blank"&gt;Royal National Institute for the Blind&lt;/A&gt;&amp;nbsp;-&amp;nbsp;RNIB has been offering support to people with severe sight loss for over 125 years. Information is provided on many aspects of visual disability but also on vision and stroke. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.orthoptics.org.uk/" target="_blank"&gt;British and Irish Orthoptic Society&lt;/A&gt; - The British and Irish Orthoptic Society provides information on the eye problems that occur following acquired brain injury. They have a stroke specialist interest group and actively support research on visual impairment following stroke. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.differentstrokes.co.uk/" target="_blank"&gt;Different Strokes&lt;/A&gt;&amp;nbsp;- Different Strokes is the only national organisation specifically dedicated to the needs of younger individuals affected by stroke. It provides information, advice and rehabilitation services to optimise recovery. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;6&lt;/pageID&gt;&lt;pageSequence&gt;3&lt;/pageSequence&gt;&lt;pageTitle&gt;Illustrations A-B&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;NORMAL VISION (for comparison)&lt;/H2&gt;
&lt;H2 align=left&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0000_NormalVision.JPG" name=nelh_tempImage0&gt;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;A. COMPLETE RIGHT HOMONYMOUS HEMIANOPIA&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0001_A.CompleteRightHomonymousHemianopia.JPG" name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;B. INCOMPLETE LEFT HOMONYNOUS HEMIANOPIA&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0002_B.IncompleteLeftHomonymousHemianopia.JPG" name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P align=left&gt;Images: Dr Fiona Rowe&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;7&lt;/pageID&gt;&lt;pageSequence&gt;4&lt;/pageSequence&gt;&lt;pageTitle&gt;Illustration C&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;NORMAL VISION (for comparison)&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0003_NormalVision.JPG" name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;C. SUPERIOR RIGHT QUADRANTANOPIA&lt;/H2&gt;
&lt;H2 align=left&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0004_C.SuperiorRightQuadrantanopia.JPG" name=nelh_tempImage0&gt;&lt;/H2&gt;
&lt;P align=left&gt;Images: Dr Fiona Rowe&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;8&lt;/pageID&gt;&lt;pageSequence&gt;5&lt;/pageSequence&gt;&lt;pageTitle&gt;Illustrations D-E&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;NORMAL VISION (for comparison)&lt;/H2&gt;
&lt;H2 align=left&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0005_NormalVision.JPG" name=nelh_tempImage1&gt;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;D. MACULAR SPARING LEFT HOMONYMOUS HEMIANOPIA&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0006_D.MacularSparingLeftHomonymousHemianopia.JPG" name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;E. HOMONYMOUS RIGHT MACULAR SCOTOMA&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage2 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0007_E.HomonymousRightMacularScotoma.JPG" name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P align=left&gt;Images: Dr Fiona Rowe&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;9&lt;/pageID&gt;&lt;pageSequence&gt;6&lt;/pageSequence&gt;&lt;pageTitle&gt;Illustrations F-G&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;NORMAL VISION (for comparison)&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0008_NormalVision.JPG" name=nelh_tempImage3&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;F. LEFT TEMPORAL CRESCENT DEFECT&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage3 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0009_F.LeftTemporalCrescentDefect.JPG" name=nelh_tempImage3&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;G. RIGHT HEMIANOPIA WITH SPARED TEMPORAL CRESCENT&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage4 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0010_G.RightHemianoiaWithSparedTemporalCrescent.JPG" name=nelh_tempImage4&gt;&lt;/P&gt;
&lt;P align=left&gt;Images: Dr Fiona Rowe&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;10&lt;/pageID&gt;&lt;pageSequence&gt;7&lt;/pageSequence&gt;&lt;pageTitle&gt;Illustrations H-I&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P align=left&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;NORMAL VISION (for comparison)&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage7 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0015_NormalVision.JPG" name=nelh_tempImage7&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;H. INFERIOR ALTITUDINAL DEFECT&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage5 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0016_H.InteriorAltitudinalDefect.JPG" name=nelh_tempImage5&gt;&lt;/P&gt;
&lt;H2 align=left&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2 align=left&gt;I. BILATERAL HEMIANOPIA (CORTICAL BLINDNESS)&lt;/H2&gt;
&lt;P align=left&gt;&lt;IMG id=nelh_tempImage6 src="https://rmsadmin.library.nhs.uk/libraryImages/Eyes%20and%20Vision/contentID300071/nelhImp_0017_I.BilateralHemianopia.JPG" name=nelh_tempImage6&gt;&lt;/P&gt;
&lt;P align=left&gt;Images: Dr Fiona Rowe&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;page&gt;&lt;pageID&gt;5&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;References&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Department of Health and National Audit Office. Reducing brain damage: faster access to better stroke care. London: TSO, 2005.[&lt;A href="http://www.nao.org.uk/pn/05-06/0506452.htm" target="_blank"&gt;free full-text (NAO)&lt;/A&gt;] &amp;nbsp;&lt;/P&gt;
&lt;P&gt;2.&amp;nbsp;Rowe F, Brand D, Jackson CA, Price A, Walker L, Harrison S, Eccleston C, Scott C, Akerman N, Dodridge C, Howard C, Shipman T, Sperring U, Macdiarmid S, Freeman C. Visual impairment following stroke: do stroke patients require vision assessment? Age and Ageing 2008; epub ahead of print: 21 Nov. [PubMed abstract (&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19029069" target="_blank"&gt;PM: 19029069)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;3.&amp;nbsp;MacIntosh C. Stroke re-visited: visual problems following stroke and their effect on rehabilitation. British Orthoptic Journal 2003; 60: 10-14. [&lt;A href="http://www.orthoptics.org.uk/journal/2003-abstracts" target="_blank"&gt;Publisher abstract (British and Irish Orthoptic Society)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;4.&amp;nbsp;MacDiarmid S, Rowe F, Parsons F. Interdisciplinary aspects of vision and communication deficits following stroke. British and Irish Orthoptic Journal 2007; 4: 21-26. [Publisher &lt;A href="http://www.orthoptics.org.uk/journal/2007-abstracts" target="_blank"&gt;abstract (British and Irish Orthoptic Society)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;5.&amp;nbsp;Gilhotra JS, Mitchell P, Healey PR, Cumming RG, Currie J. Homonymous visual field defects and stroke in an older population. Stroke 2002; 33 (Pt 10): 2417–20. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12364731" target="_blank"&gt;PubMed abstract (PM: 12364731)&lt;/A&gt;]&amp;nbsp; &lt;/P&gt;
&lt;P&gt;6.&amp;nbsp;Falke P, Abela BM, Krakau CE, Liljia B, Lindgarde F, Maly P, Stavenow L. High frequency of asymptomatic visual field defects in subjects with transient ischaemic attacks or minor strokes. J Intern Med 1991; 229 (Pt 6): 521–5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2045760" target="_blank"&gt;PubMed abstract (PM:2045760)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;7.&amp;nbsp;Maulaz AB, Bezerra DC, Bogousslavsky J. Posterior cerebral artery infarction from middle cerebral artery infarction. Arch Neurol 2005; 62 (Pt 6): 938-941. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15956164" target="_blank"&gt;PubMed abstract (PM: 15956164)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;8.&amp;nbsp;Suchoff IB, Kapoor N, Ciuffreda KJ, Rutner D, Han E, Craig S. The frequency of occurrence, types, and characteristics of visual field defects in acquired brain injury: a retrospective analysis. Optometry 2008; 79 (Pt 5) : 77-83. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18436166" target="_blank"&gt;PubMed abstract (PM:18436166)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;9.&amp;nbsp;Han SW, Sohn YH, Lee PH, Suh BC, Choi IS. Pure homonymous hemianopia due to anterior choroidal artery territory infarction. Eur Neurol. 2000; 43 (Pt 1): 35-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10601806" target="_blank"&gt;PubMed abstract (PM: 10601806)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;10.&amp;nbsp;Holt LJ, Anderson SF. Bilateral occipital lobe stroke with inferior altitudinal defects. Optometry 2000; 71 (Pt 11) : 690-702. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11101127" target="_blank"&gt;PubMed abstract (PM:11101127)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;11.&amp;nbsp;Isa K, Miyashita K, Yanagimoto S, Nagatsuka K, Naritomi H. Homonymous defect of macular vision in ischemic stroke. Eur Neurol. 2001; 46 (Pt 3): 126-30. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11598330" target="_blank"&gt;PubMed abstract (PM:11598330)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;12.&amp;nbsp;Wein F, Miller NR. An unusual right homonymous visual field defect. Surv Ophthalmol 2000; 44 (Pt 4): 324-328. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10667438" target="_blank"&gt;PubMed abstract (PM:10667438)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;13.&amp;nbsp;Hirayama K, Sakai S, Yamawaki R, Kondo Y, Sizuki T, Fujimoto C, Yamadori A, Mori E. [Visual search training for a case of homonymous field defect with multiple visual dysfunctions]. Abstract. No To Shinkei. 2004; 56 (Pt 5): 403-13. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15279198" target="_blank"&gt;PubMed abstract (PM:15279198)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;14.&amp;nbsp;Pambakian A, Currie J, Kennard C. Rehabilitation strategies for patients with homonymous visual field defects. J Neuroophthalmol 2005; 25 (Pt 2) : 136-142. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15937440" target="_blank"&gt;PubMed abstract (PM:15937440)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;15.&amp;nbsp;Peli E. Field expansion for homonymous hemianopia by optically induced peripheral exotropia. Optom Vis Sci 2000; 77 (Pt 9) :453-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11014672" target="_blank"&gt;PubMed abstract (PM:11014672)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;16.&amp;nbsp;Reinhard J, Schreiber A, Schiefer U, Kasten E, Sabel BA, Kenkel S, Vonthein R, Trauzettel-Klosinski S. Does visual restitution training change absolute homonymous visual field defects?: a fundus controlled study. Br J Ophthalmol 2005; 89 (Pt 1) : 30-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15615742" target="_blank"&gt;PubMed abstract (PM:15615742)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;17.&amp;nbsp;Pambakian AL, Mannan SK, Hodgson TL, Kennard C. Saccadic visual search training: a treatment for patients with homonymous hemianopia. J Neurol Neurosurg Psychiatry 2004; 75 (Pt 10): 1443–8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15377693" target="_blank"&gt;PubMed abstract (PM:15377693)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;18.&amp;nbsp;Poggel DA, Kasten E, Sabel BA. Attentional cueing improves vision restoration therapy in patients with visual field defects. Neurology 2004; 63 (Pt 11): 2069–76. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15596752" target="_blank"&gt;PubMed abstract (PM:15596752)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;19.&amp;nbsp;Henriksson L, Raninen A, Nasanen R, Hyvarinen L, Vanni S. Training-induced cortical representation of a hemianopic hemifield. J Neurol Neuros Psychiatry 2007; 78 (Pt 1): 74-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16980334" target="_blank"&gt;PubMed abstract (PM:16980334)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;20.&amp;nbsp;Sahrie A, Trevethan CT, Wesikrantz L, Olson J, MacLeod MJ, Murray AD, Dijkhuizen RS, Counsell C, Coleman R. Spatial channels of visual processing in cortical blindness. Eur J Neurosci 2003; 18 (Pt 5): 1189-96. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12956717" target="_blank"&gt;PubMed abstract (PM:12956717)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;21.&amp;nbsp;Mueller I, Mast H, Sabel BA. Recovery of visual field defects: A large clinical observational study using vision restoration therapy. Restor Neurol and Neurosci 2007; 25 (Pt 5-6): 563-572. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18334773" target="_blank"&gt;PubMed abstract (PM: 18334773)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;22.&amp;nbsp;Pelat VS, Dubin M, Whitney E. Homonymous hemianopia: a critical analysis of optical devices, compensatory training, and NovaVision. Current Treat Options in Neurol 2007; 9 (Pt 1): 41-47. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17288888" target="_blank"&gt;PubMed abstract (PM:17288888)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;23.&amp;nbsp;Zhang X, Kedar S, Lynn N, et al. Homonymous hemianopia in stroke. J Neuroophthalmol 2006; 26 (Pt 3): 180-183. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16966935" target="_blank"&gt;PubMed abstract (PM:16966935)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;24.&amp;nbsp;Zhang X, Kedar S, Lynn N, et al. Natural history of homonymous hemianopia. Neurology 2006; 66 (Pt 6): 901-905. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16567709" target="_blank"&gt;PubMed abstract (PM: 16567709)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;25.&amp;nbsp;Jones SA, Shinton RA. Improving outcome in stroke patients with visual problems. Age Ageing 2006; 35 (Pt 6): 560-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16820528" target="_blank"&gt;PubMed abstract (PM: 16820528)&lt;/A&gt;]&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;26.&amp;nbsp;Gottlieb DD, Miesner N. Innovative concepts in hemianopsia and complex visual loss - Low vision rehabilitation for our older population. Topics Gen Rehab 2004; 20 (Pt 3): 212-222. [&lt;A href="http://pt.wkhealth.com/pt/re/tgr/abstract.00013614-200407000-00009.htm" target="_blank"&gt;Publisher abstract (Wolters Kluwer Health)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;27.&amp;nbsp;Driver and Vehicle Licensing Agency. Drivers Medical Group. At a glance guide to the current medical standards of fitness to drive: for medical practitioners. Swansea: DVLA, September 2008. [&lt;A href="http://www.dvla.gov.uk/medical/ataglance.aspx" target="_blank"&gt;Free full-text (DVLA)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;28.&amp;nbsp;Elliott A, Keightley S. Visual standards for driving. Royal College of Ophthalmologists, April 2005. [&lt;A href="http://www.rcophth.ac.uk/docs/profstands/ophthalmic-services/VisualStandardsforDrivingApril2005.pdf" target="_blank"&gt;Free full-text (RCOphth)&lt;/A&gt;]&lt;/P&gt;
&lt;P&gt;29.&amp;nbsp;Racette L, Casson EJ. The impact of visual field loss on driving performance: evidence from on-road driving assessments. Optom Vis Sci 2005; 82 (Pt 8): 668-674. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16127331" target="_blank"&gt;PubMed abstract (PM:16127331)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;30.&amp;nbsp;Ramrattan RS, Wolfs RC, Panda-Jonas S, Jonas JB, Bakker D, Pols HA, Hofman A, de Jong PT. Prevalence and causes of visual field loss in the elderly and associations with impairment in daily functioning: the Rotterdam Study. Arch Ophthalmol 2001; 119 (Pt 12): 1788–94. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11735788" target="_blank"&gt;PubMed abstract (PM:11735788)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;31.&amp;nbsp;Granger CV, Cotter AC, Hamilton BB, Fiedler RC. Functional assessment scales: a study of persons after stroke. Arch Phys Med Rehabil 1993; 74 (Pt 2): 133–8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8431095" target="_blank"&gt;PubMed abstract (PM:8431095)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;32.&amp;nbsp;Nelles G, Esser J, Eckstein A, Tiede A, Gerhard H, Diener HC. Compensatory visual field training for&amp;nbsp; patients with hemianopia after stroke. Neurosci Lett 2001; 306 (Pt 3): 189–92. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11406327" target="_blank"&gt;PubMed abstract (PM:11406327)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;33.&amp;nbsp;Tsai SY, Cheng CY, Hsu WM, Su TP, Liu JH, Chou P. Association between visual impairment and depression in the elderly. J Formos Med Assoc 2003; 102 (Pt 2): 86–90. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12709736" target="_blank"&gt;PubMed abstract (PM:12709736)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;34.&amp;nbsp;West CG, Gildengorin G, Haegerstrom-Portney G, Schneck ME, Lott L, Brabyn JA. Is vision function related to physical functional ability in older adults? J Am Geriatr Soc 2002; 50 (Pt 1): 136-45. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12028258" target="_blank"&gt;PubMed abstract (PM:12028258)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;35.&amp;nbsp;Leff AP, Scott SK, Crewes H et al. Impaired reading in patients with right hemianopia. Ann Neurol 2000; 47 (Pt 2): 171-178. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10665487" target="_blank"&gt;PubMed abstract (PM:10665487)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;36.&amp;nbsp;Leff AP, Behrmann M. Treatment of reading impairment after stroke. Curr Opin Neurol 2008; 21 (Pt 6): 644-648. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18989106" target="_blank"&gt;PubMed abstract (PM:18989106)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;37.&amp;nbsp;Marx MS, Werner P, Cohen-Mansfield J, Feldman R. The relationship between low vision and performances of activities of daily living in nursing home residents. J Am Geriatr Soc 1992; 40 (Pt 10): 1018–20. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1401674" target="_blank"&gt;PubMed abstract (PM:1401674)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;38.&amp;nbsp;Townend BS, Sturm JW, Petsoglou C, O’Leary B, Whyte S, Crimmins D. Perimetric homonymous visual field loss post stroke. J Clin Neurosci 2007; 14 (Pt 8): 754-756. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17270447" target="_blank"&gt;PubMed abstract (PM:17270447)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;39.&amp;nbsp;Department of Health. National Stroke Strategy. London: DH, December 2007. [&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyandguidance/dh_081062" target="_blank"&gt;free full-text (DH)&lt;/A&gt;]&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;40.&amp;nbsp;National Collaborating Centre for Chronic Conditions. Stroke: national clinical guidance for diagnosis and initial management of acute stroke and transient ischaemic attack (TIA). London: Royal College of Physicians, 2008 [&lt;A href="http://www.rcplondon.ac.uk/pubs/contents/9c4488ac-d8f1-43d8-b9da-b801441bcdfb.pdf" target="_blank"&gt;free full-text (RCP)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;41.&amp;nbsp;Intercollegiate Stroke Working Party. National clinical guidance for stroke. 3rd ed. London: Royal College of Physicians, 2008. [&lt;A href="http://www.rcplondon.ac.uk/pubs/contents/6ad05aab-8400-494c-8cf4-9772d1d5301b.pdf" target="_blank"&gt;free full-text (RCP)&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;42.&amp;nbsp;British and Irish Othoptic Society. Position statement for department of Health Stroke Strategy. London: DH, 2008. [&lt;A href="http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/Stroke/DH_081389" target="_blank"&gt;free full-text linked to from DH NSF page&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;43. British and Irish Orthoptic Society. Competency Standards and Professional Practice Guidelines for the Extended Role of the Orthoptist. London: BIOS, 2006. [&lt;A href="http://www.orthoptics.org.uk/BIOS_Competencies_Standards_-_Extended_Roles_-_Master_Handbook.pdf" target="_blank"&gt;free full-text (BIOS)&lt;/A&gt;]&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>289966</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//eyes/ViewResource.aspx?resID=289966]]&gt;</url>
    <title>Visual Impairment and People with Learning Disabilities</title>
    <publicationDate>2008-07-14T00:00:00</publicationDate>
    <publisher>Eyes &amp; Vision Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ LEARNING DISABILITIES,HEALTH,EYES AND VISION,LOW VISION,SENSORY IMPAIRMENT,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Visual Impairment and People with Learning Disabilities&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;John Northfield, Clinical Lead, &lt;A href="http://www.library.nhs.uk/learningdisabilities/" target="_blank"&gt;Learning Disabilities Specialist Library&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://www.moorfieldsresearch.org.uk/NHS_Evidence/low_vision/low_vision_vipld.asp" target="_blank"&gt;Click here for Low Vision version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/learning_disabilities_0708/Learning_Disabilities.pdf" target="_blank"&gt;Click here for&amp;nbsp;pdf version&lt;/A&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;A href="http://evslarchive.moorfields.nhs.uk/learning_disabilities_0708/Learning_Disabilities_Pub_Types.pdf" target="_blank"&gt;Click here for pdf table of publication types of&amp;nbsp;cited references&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;
&lt;H2&gt;&amp;nbsp; &lt;/H2&gt;
&lt;H2&gt;Background and Issues&lt;/H2&gt;'Learning disability' as a term in the UK describes: 
&lt;UL&gt;
&lt;LI&gt;A state of arrested or incomplete development of mind&lt;/LI&gt;
&lt;LI&gt;Significant impairment of intellectual functioning&lt;/LI&gt;
&lt;LI&gt;Significant impairment of adaptive / social functioning&lt;/LI&gt;&lt;/UL&gt;This means that somebody with a learning disability will have difficulties in understanding, difficulties in learning new things and generalising these to new situations. They have difficulties with social tasks (e.g. communication, self-care, awareness of and responses to danger etc.) and these difficulties will vary dependent upon the extent and nature of the disability. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Healthcare for People with Learning Disabilities&lt;/H2&gt;Support for people with learning disabilities has moved away from the medical model to a social model based on inclusion and integration, which has created many challenges for healthcare support. There are a number of studies highlighting poorer health for many people with learning disabilities arising from - 
&lt;UL&gt;
&lt;LI&gt;undetected ill-health [refs 29-33]&lt;/LI&gt;
&lt;LI&gt;occurrence of other co-existing health problems [refs 1-28] &lt;/LI&gt;
&lt;LI&gt;barriers to access to healthcare services [refs 1-28]&lt;/LI&gt;
&lt;LI&gt;their need for support in seeking health care [refs 1-28]&lt;/LI&gt;&lt;/LI&gt;
&lt;LI&gt;poor contact with primary health care services [refs 29-33]&lt;/LI&gt;
&lt;LI&gt;few healthcare professionals having specific training in caring for people with learning disabilities [refs 29-33]&lt;/LI&gt;&lt;/UL&gt;Research findings indicate that training interventions can improve knowledge of and responses to people with learning disabilities and that health screening in primary care can improve the health of people with learning disabilities. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Visual Impairment in People with learning disabilities - the evidence &lt;/H2&gt;Amongst adults, the prevalence of visual impairment increases with the severity of the learning disability and with age 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;A literature review by the Valuing People Support Team&amp;nbsp;[35] found people with learning disabilities to be between 8.5 and 200 times more likely to have a visual impairment compared to the general population.&lt;/P&gt;
&lt;P&gt;In March 2006, the Down Syndrome Medical Interest Group reported [36] a high incidence of ocular disorder among people with Down's syndrome: 
&lt;UL&gt;
&lt;LI&gt;Refractive errors and/or squint often present from an early age&lt;/LI&gt;
&lt;LI&gt;Cataract and/or glaucoma occurring in infancy&lt;/LI&gt;
&lt;LI&gt;Nystagmus present in at least 10% of the DS population&lt;/LI&gt;
&lt;LI&gt;Keratoconus more common in adolescents and young adults&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Guidelines and recommendations&lt;/H2&gt;
&lt;H2&gt;The International Association for the Scientific Study of Intellectual Disability&lt;/H2&gt;For adults with an intellectual disability, routine screening for age-related visual loss at 45 years and every 5 years thereafter has been recommended If possible this should be done by an ophthalmologist. An extra vision check at age 30 years has been recommended for adults with Down syndrome. [37] 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;IASSID also provides specific guidelines on screening for visual impairment [38] which include guidance on which children and adults should be screened for visual impairment and when; current methods for screening and a screening protocol.&lt;/P&gt;
&lt;P&gt;
&lt;H2&gt;College of Optometrists guidelines on the examination of people with learning disabilities [39]&lt;/H2&gt;When examining a patient with learning disabilities, the optometrist has a duty to carry out whatever tests are necessary, using a range of tests and procedures that are appropriate to the needs of the patient and, where necessary, seeking a briefing from family members, carers and key workers. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Help and Advice&lt;/H2&gt;&lt;B&gt;Look Up&lt;/B&gt; is an information service focusing on eye care and vision for people with learning disabilities - a collaboration between SeeAbility and RNIB. [&lt;A href="http://www.lookupinfo.org/index.php?id=home" target="_blank"&gt;See Look Up website&lt;/A&gt;] 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Look Up&lt;/B&gt;provides over 30 factsheets [40] for additional advice and guidance. Of particular interest are 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.lookupinfo.org/index.php?id=251" target="_blank"&gt;Looking for eye problems in people with learning disabilities&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.lookupinfo.org/index.php?id=402" target="_blank"&gt;Consent for medical treatment and operations for people with learning disabilities&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.lookupinfo.org/fileadmin/user_upload/Logos___PDFs/Telling_the_Optometrist_About_Me_-_June_2007.pdf" target="_blank"&gt;Telling the optometrist about me form&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="http://www.lookupinfo.org/fileadmin/user_upload/Logos___PDFs/Feedback_from_the_optometrist_about_my_eye_test_-_June_2007.pdf" target="_blank"&gt;Feedback from the optometrist about my eye test form&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;The &lt;B&gt;RNIB&lt;/B&gt; offers information on visual impairment and learning disabilities services, for professionals and for service users and their families. Their National Practice and Development Team also offers training, consultancy, information and rehabilitation services: 
&lt;UL&gt;
&lt;LI&gt;&lt;A href="http://www.rnib.org.uk/livingwithsightloss/vild" target="_blank"&gt;Visual Impairment and Learning Disabilities (VILD) services&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;H2&gt;&amp;nbsp; &lt;/H2&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&amp;nbsp;&amp;nbsp; 1. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Alborz, A., McNally, R., Swallow, A., and Glendinning, C. From the cradle to the grave: a literature review of access to health care for people with learning disabilities across the lifespan: report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R &amp;amp; D (NCCSDO).&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2003. Manchester, NCCDSO. 3-7-2008. [&lt;A href="http://www.library.nhs.uk/learningdisabilities/ViewResource.aspx?resID=154801&amp;amp;tabID=289" target="_blank"&gt;abstract &amp;amp; link to full-text&lt;/A&gt;] [&lt;A href="http://www.sdo.lshtm.ac.uk/files/project/23-final-report.pdf" target="_blank"&gt;full-text pdf]&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;2. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Barr O, Gilgunn J, Kane T &lt;I&gt;et al&lt;/I&gt; . Health screening for people with learning disabilities by a community learning disability nursing service in Northern Ireland. &lt;I&gt;J Adv Nurs&lt;/I&gt; 1999;&lt;B&gt;29&lt;/B&gt;:1482-91. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10354244" target="_blank"&gt;PubMed abstract (PM:10354244)&lt;/A&gt;]&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;3. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Bell AJ, Bhate MS. Prevalence of overweight and obesity in Down's syndrome and other mentally handicapped adults living in the community. &lt;I&gt;J Intellect.Disabil Res&lt;/I&gt; 1992;&lt;B&gt;36 ( Pt 4)&lt;/B&gt;:359-64. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1388077" target="_blank"&gt;PubMed abstract (PM:1388077)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;4. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Branford D, Bhaumik S, Duncan F. Epilepsy in adults with learning disabilities. &lt;I&gt;Seizure&lt;/I&gt; 1998;&lt;B&gt;7&lt;/B&gt;:473-7. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9888491" target="_blank"&gt;PubMed abstract (PM:9888491)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;5. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Carter G, Jancar J. Mortality in the mentally handicapped: a 50 year survey at the Stoke Park group of hospitals (1930-1980). &lt;I&gt;J Ment.Defic Res&lt;/I&gt; 1983;&lt;B&gt;27 (Pt 2)&lt;/B&gt;:143-56. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/6225874" target="_blank"&gt;PubMed abstract (PM:6225874)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;6. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Carvill S. Sensory impairments, intellectual disability and psychiatry. &lt;I&gt;J Intellect.Disabil Res&lt;/I&gt; 2001;&lt;B&gt;45&lt;/B&gt;:467-83. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11737534" target="_blank"&gt;PubMed abstract (PM:11737534)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;7. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Cassidy G, Martin DM, Martin GHB &lt;I&gt;et al&lt;/I&gt;. Health checks for people with learning disabilities: community learning disability teams working with general practitioners and primary health care teams. &lt;I&gt;J Intellect Disabil.&lt;/I&gt; 2002;&lt;B&gt;6&lt;/B&gt;:123-36. [&lt;A href="http://jid.sagepub.com/cgi/content/abstract/6/2/123" target="_blank"&gt;publisher abstract]&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;8. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Cooke LB. Cancer and learning disability. &lt;I&gt;J Intellect Disabil Res&lt;/I&gt; 1997;&lt;B&gt;41 ( Pt 4)&lt;/B&gt;:312-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9297608" target="_blank"&gt;PubMed abstract (PM:9297608)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp;&amp;nbsp; &lt;/SPAN&gt;9. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Cooper SA. Deficient health and social services for elderly people with learning disabilities. &lt;I&gt;J Intellect Disabil Res&lt;/I&gt; 1997;&lt;B&gt;41 ( Pt 4)&lt;/B&gt;:331-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9297611" target="_blank"&gt;PubMed abstract (PM:9297611)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;10. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Dent JA, Vergnaud S, Piachaud J. HIV infection and people with learning disabilities. &lt;I&gt;Lancet&lt;/I&gt; 1994;&lt;B&gt;343&lt;/B&gt;:919. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7908380" target="_blank"&gt;PubMed abstract (PM:7908380)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;11. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Emerson E. Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. &lt;I&gt;J Intellect Disabil Res&lt;/I&gt; 2003;&lt;B&gt;47&lt;/B&gt;:51-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12558695" target="_blank"&gt;PubMed abstract (PM:12558695)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;12. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Henny MJ, van Schrojenstein Lantman-de Valk. Health in people with intellectual disabilities: current knowledge and gaps in knowledge. &lt;I&gt;Journal of Applied Research in Intellectual Disabilities&lt;/I&gt; 2005;&lt;B&gt;18&lt;/B&gt;:325-33. [&lt;A href="http://www3.interscience.wiley.com/journal/118711054/abstract" target="_blank"&gt;publisher abstract&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;13. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Holland AJ. Ageing and learning disability. &lt;I&gt;Br J Psychiatry&lt;/I&gt; 2000;&lt;B&gt;176&lt;/B&gt;:26-31. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10789322" target="_blank"&gt;PubMed abstract (PM:10789322)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;14. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Hollins S, Attard MT, von FN &lt;I&gt;et al&lt;/I&gt;. Mortality in people with learning disability: risks, causes, and death certification findings in London. &lt;I&gt;Dev Med Child Neurol&lt;/I&gt; 1998;&lt;B&gt;40&lt;/B&gt;:50-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9459217" target="_blank"&gt;PubMed abstract (PM:9459217)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;15. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Howells G. Are the medical needs of mentally handicapped adults being met? &lt;I&gt;J R Coll Gen Pract&lt;/I&gt; 1986;&lt;B&gt;36&lt;/B&gt;:449-53. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2964527" target="_blank"&gt;PubMed abstract (PM:2964527)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;16. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Jansen DE, Krol B, Groothoff JW &lt;I&gt;et al&lt;/I&gt;. People with intellectual disability and their health problems: a review of comparative studies. &lt;I&gt;J Intellect Disabil Res&lt;/I&gt; 2004;&lt;B&gt;48&lt;/B&gt;:93-102. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14723652" target="_blank"&gt;PubMed abstract (PM:14723652)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;17. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Kerr MP, Richards D, Glover G. Primary care for people with an intellectual disability: a group practice survey. &lt;I&gt;Journal of Applied Research in Intellectual Disabilities&lt;/I&gt; 1996;&lt;B&gt;9&lt;/B&gt;:347-52. [&lt;A href="http://apps.isiknowledge.com/InboundService.do?Func=Frame&amp;amp;product=WOS&amp;amp;action=retrieve&amp;amp;SrcApp=RefMan&amp;amp;UT=A1996WG22700005&amp;amp;SID=Z2l4Be1ej5oCBiOmm8l&amp;amp;Init=Yes&amp;amp;SrcAuth=ResearchSoft&amp;amp;mode=FullRecord&amp;amp;customersID=ResearchSoft&amp;amp;DestFail=http%3A%2F%2Fwww.isinet.com%2Fisi%2Fproducts%2Fesource%2Fservice.html" target="_blank"&gt;Web of Science abstract (ISI: A1996WG22700005)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;18. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Martin DM, Roy A, Wells MB. Health gain through health checks: improving access to primary health care for people with intellectual disability. &lt;I&gt;J Intellect Disabil Res&lt;/I&gt; 1997;&lt;B&gt;41 ( Pt 5)&lt;/B&gt;:401-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9373820" target="_blank"&gt;PubMed abstract (PM:9373820)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;19. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;McCulloch DL, Sludden PA, McKeown K &lt;I&gt;et al&lt;/I&gt;. Vision care requirements among intellectually disabled adults: a residence-based pilot study. &lt;I&gt;J Intellect Disabil Res&lt;/I&gt; 1996;&lt;B&gt;40 ( Pt 2)&lt;/B&gt;:140-50. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8731471" target="_blank"&gt;PubMed abstract (PM:8731471)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;20. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Morgan CL, Ahmed Z, Kerr MP. Health care provision for people with a learning disability. Record-linkage study of epidemiology and factors contributing to hospital care uptake. &lt;I&gt;Br J Psychiatry&lt;/I&gt; 2000;&lt;B&gt;176&lt;/B&gt;:37-41. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10789324" target="_blank"&gt;PubMed abstract (PM:10789324)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;21. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Bond L, Kerr M, Dunstan F &lt;I&gt;et al&lt;/I&gt;. Attitudes of general practitioners towards health care for people with intellectual disability and the factors underlying these attitudes. &lt;I&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;J Intellect Disabil Res&lt;/I&gt; 1997;&lt;B&gt;41 ( Pt 5)&lt;/B&gt;:391-400. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9373819" target="_blank"&gt;PubMed abstract (PM:9373819)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;22. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Broughton S, Thomson K. Women with learning disabilities: risk behaviours and experiences of the cervical smear test. &lt;I&gt;J Adv Nurs&lt;/I&gt; 2000;&lt;B&gt;32&lt;/B&gt;:905-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11095229" target="_blank"&gt;PubMed abstract (PM:11095229)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;23. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Howells G. Are the medical needs of mentally handicapped adults being met? &lt;I&gt;J R Coll Gen Pract&lt;/I&gt; 1986;&lt;B&gt;36&lt;/B&gt;:449-53. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2964527" target="_blank"&gt;PubMed abstract (PM:2964527)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;24. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Jones RG, Kerr MP. A randomized control trial of an opportunistic health screening tool in primary care for people with intellectual disability. &lt;I&gt;J Intellect Disabil Res&lt;/I&gt; 1997;&lt;B&gt;41 ( Pt 5)&lt;/B&gt;:409-15. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9373821" target="_blank"&gt;PubMed abstract (PM:9373821)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;25. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Pearson V, Davis C, Ruoff C &lt;I&gt;et al&lt;/I&gt;. Only one quarter of women with learning disability in Exeter have cervical screening. &lt;I&gt;BMJ&lt;/I&gt; 1998;&lt;B&gt;316&lt;/B&gt;:1979. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9641948" target="_blank"&gt;PubMed abstract (PM:9641948)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;26. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Stein K. Caring for people with learning disability: a survey of general practitioners' attitudes in Southampton and South-west Hampshire. &lt;I&gt;British Journal of Learning Disabilities&lt;/I&gt; 2008;&lt;B&gt;28&lt;/B&gt;:9-15. [&lt;A href="http://www3.interscience.wiley.com/journal/120191496/abstract" target="_blank"&gt;Publisher abstract&lt;/A&gt;]&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;27. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Tiller S, Wilson KI, Gallagher JE. Oral health status and dental service use of adults with learning disabilities living in residential institutions and in the community. &lt;I&gt;Community Dent Health&lt;/I&gt; 2001;&lt;B&gt;18&lt;/B&gt;:167-71. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11580093" target="_blank"&gt;PubMed abstract (PM:11580093)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;28. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Whitfield M, Langan J, Russell O. Assessing general practitioners' care of adult patients with learning disability: case-control study. &lt;I&gt;Qual Health Care&lt;/I&gt; 1996;&lt;B&gt;5&lt;/B&gt;:31-5. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10157270" target="_blank"&gt;PubMed abstract (PM:10157270)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;29. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Alborz, A., McNally, R., Swallow, A., and Glendinning, C. &lt;I&gt;Op. Cit.&lt;/I&gt; [&lt;A href="http://www.library.nhs.uk/learningdisabilities/ViewResource.aspx?resID=154801&amp;amp;tabID=289" target="_blank"&gt;abstract &amp;amp; link to full-text&lt;/A&gt;] &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.sdo.lshtm.ac.uk/files/project/23-final-report.pdf" target="_blank"&gt;full-text pdf&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;30. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Costello H, Bouras N, Davis H. The role of training in improving community care staff awareness of mental health problems in people with intellectual disabilities. &lt;I&gt;Journal of Applied Research in Intellectual Disabilities&lt;/I&gt; 2008;&lt;B&gt;20&lt;/B&gt;:228-35. [&lt;A href="http://www3.interscience.wiley.com/journal/118490149/abstract" target="_blank"&gt;Publisher abstract&lt;/A&gt;]&amp;nbsp;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;31. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Melville CA, Finlayson J, Cooper SA &lt;I&gt;et al&lt;/I&gt;. Enhancing primary health care services for adults with intellectual disabilities. &lt;I&gt;J Intellect Disabil Res&lt;/I&gt; 2005;&lt;B&gt;49&lt;/B&gt;:190-8. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15713194" target="_blank"&gt;PubMed abstract (PM:15713194)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;32. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Pointu A, Cole C. An education programme for social care staff: improving the health of people who have a learning disability and epilepsy. &lt;I&gt;British Journal of Learning Disabilities&lt;/I&gt; 2008;&lt;B&gt;33&lt;/B&gt;:39-43. [&lt;A href="http://www3.interscience.wiley.com/journal/118666784/abstract" target="_blank"&gt;Publisher abstract&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;33. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Wilson DN, Haire A. Health care screening for people with mental handicap living in the community. &lt;I&gt;BMJ&lt;/I&gt; 1990;&lt;B&gt;301&lt;/B&gt;:1379-81. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2148703" target="_blank"&gt;PubMed abstract (PM:2148703)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;34. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Carvill S. &lt;I&gt;Op. Cit. &lt;/I&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11737534" target="_blank"&gt;PubMed abstract (PM:11737534)&lt;/A&gt; ] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;35. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Warburg M. Visual impairment in adult people with intellectual disability: literature review. &lt;I&gt;J Intellect Disabil Res&lt;/I&gt; 2001;&lt;B&gt;45&lt;/B&gt;:424-38. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11679048" target="_blank"&gt;PubMed abstract (PM:11679048)&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;36. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Hatton, C. Key highlights of research evidence on the health of people with learning disabilities.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;2008. London, Valuing People Support Team. 3-7-2008. [&lt;A href="http://www.library.nhs.uk/learningdisabilities/viewResource.aspx?resid=29713&amp;amp;code=afec67537cf19e8835b209846e9b89c4" target="_blank"&gt;abstract &amp;amp; link to full-text&lt;/A&gt;] [&lt;A href="http://valuingpeople.gov.uk/echo/filedownload.jsp?action=dFile&amp;amp;key=657" target="_blank"&gt;link to full-text pdf&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;37. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Basic medical surveillance for people with Down's Syndrome. Ophthalmic problems.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;Down's Syndrome Medical Interest Group.&amp;nbsp;&amp;nbsp;&lt;FONT size=2 face=Arial&gt;2006.&lt;/FONT&gt;&amp;nbsp;[&lt;A href="http://www.library.nhs.uk/Eyes/ViewResource.aspx?resID=30290&amp;amp;tabID=288" target="_blank"&gt;abstract &amp;amp; link to full-text&lt;/A&gt;] &lt;A href="http://www.dsmig.org.uk/library/articles/guideline-vision-5.pdf" target="_blank"&gt;[link to full-text pdf&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;38. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Health guidelines for adults with an intellectual disability. Sensory impairment.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;IASSID.&amp;nbsp;&amp;nbsp;&lt;FONT size=2 face=Arial&gt;2002. &lt;/FONT&gt;[&lt;A href="http://www.iassid.org/pdf/healthguidelines-2002.pdf" target="_blank"&gt;full-text pdf - scroll to section 2.2&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;39. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;[IASSID guidelines on] visual impairment.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&amp;nbsp;&lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;IASSID. &lt;FONT size=2 face=Arial&gt;2002.&lt;/FONT&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;[&lt;A href="http://www.iassid.org/pdf/visual-imp.PDF" target="_blank"&gt;full-text pdf&lt;/A&gt;] &lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="TEXT-INDENT: -27pt; MARGIN: 0cm 0cm 18pt 27pt; tab-stops: right 18.0pt left 27.0pt; mso-layout-grid-align: none" class=MsoNormal&gt;&lt;SPAN style="FONT-FAMILY: Arial; FONT-SIZE: 10pt"&gt;&lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;40. &lt;SPAN style="mso-tab-count: 1"&gt;&amp;nbsp; &lt;/SPAN&gt;Code of ethics and guidelines for professional conduct. 24. Examining the adult patient with learning disabilities.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;London, College of Optometrists. &lt;FONT size=2 face=Arial&gt;2008. &lt;/FONT&gt;[&lt;A href="http://www.library.nhs.uk/Eyes/ViewResource.aspx?resID=95484&amp;amp;tabID=288" target="_blank"&gt;abstract and link to full-text&lt;/A&gt;]&lt;FONT face=Verdana&gt; &lt;/FONT&gt;[&lt;A href="http://www.college-optometrists.org/coo/download.cfm?uuid=6B61ED87-5633-B1D9-EABB112A3082F4A1&amp;amp;type=ethics_guidelines" target="_blank"&gt;link to full-text pdf]&lt;/A&gt; &lt;/SPAN&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>317934</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16376658]]&gt;</url>
    <title>Vitrectomy in the treatment of uveitis</title>
    <publicationDate>2005-12-01T00:00:00</publicationDate>
    <publisher>American Journal of Ophthalmology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,UVEAL TRACT,UVEITIS,CONDITIONS,SYSTEMATIC REVIEWS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;Source: American Journal of Ophthalmology 2005 Dec; 140(6):1096-105.&lt;/EM&gt;&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; To assess the evidence that pars plana vitrectomy (PPV) is useful in improving vision, reducing disease activity, or ameliorating cystoid macular edema (CME) in patients with uveitis. DESIGN: Review of the literature. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;METHODS: &lt;/STRONG&gt;A Medline search was conducted for relevant articles published in English, German, or French. Articles were analyzed for content and evidence level. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; A total of 44 interventional case series published between 1981 and 2005 were identified that included 1575 patients (1762 eyes). Evidence level was grade CII-3 indicating possibly improved clinical outcomes with fair or poor evidence. The average age of patients was 36 years with a median duration of uveitis before surgery of 48 months and a median follow-up of 1.9 years. Intermediate uveitis was present in 841 eyes. Cystoid macular edema and cataract were common co-morbidities, and there were large numbers of additional surgical procedures. Visual outcomes in 39 articles were stated as improved in 708 eyes (68%), unchanged in 202 eyes (20%), and worsened in 124 eyes (12%). Reduction in systemic medication following PPV was reported in 25 studies. The median reported percentage of patients per study with CME was 36% preoperatively and 18% postoperatively. &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; Based on the evidence in the literature, PPV is possibly relevant to the outcomes of improving vision and reducing inflammation and CME. Randomized, controlled, collaborative trials or hypothesis-based case series with precise outcome measures that incorporate control groups would improve the quality of evidence supporting PPV as an adjunct to the medical treatment of uveitis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This systematic review has been quality appraised by the eyes and vision specialist collection management team.&amp;nbsp;&amp;nbsp; Please click &lt;A href="http://www.moorfieldsresearch.org.uk/nHS_Evidence/showsystematic.asp?study_id=148" target="_blank"&gt;here&lt;/A&gt; to view the appraisal.&amp;nbsp;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79275</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band22/b22-1.html]]&gt;</url>
    <title>Vomiting after squint</title>
    <publicationDate>1995-12-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,STRABISMUS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This article&amp;nbsp;published in issue 22 of Bandolier Journal&amp;nbsp;in December 1995&amp;nbsp;summarises a systematic review on the measures taken to reduce postoperative vomitting following&amp;nbsp;corrective surgery on squints.&amp;nbsp;]]&gt;</body>
  </document>
  <document>
    <id>267299</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.medicine.ox.ac.uk/bandolier/band160/b160-6.html]]&gt;</url>
    <title>Waiting for cataracts</title>
    <publicationDate>2007-06-01T00:00:00</publicationDate>
    <publisher>Bandolier</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,LENS,CATARACT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Article published in issue 160 of Bandolier&amp;nbsp;regarding a recently published systematic review about the&amp;nbsp;consequences of delays in cataract surgery.]]&gt;</body>
  </document>
  <document>
    <id>101390</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.nhscareers.nhs.uk/nhs-knowledge_base/data/4905.html]]&gt;</url>
    <title>What does an Orthoptist do?</title>
    <publicationDate></publicationDate>
    <publisher>NHS Careers</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,OCULAR MOTILITY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;NHS Careers webpage&amp;nbsp;for allied healthcare professionals giving a broad definition of an orthoptist, then describing in more detail the nature of the job, where orthoptists might work, career prospects, entry and training requirements and funding.&amp;nbsp;&amp;nbsp; Further information on entry requirements, financial support, pay and benefits, state registration&amp;nbsp;and other types of allied healthcare professionals is provided through linked pages.&amp;nbsp;&amp;nbsp;The contact details for the British and Irish Orthoptic Society are also provided. &lt;/P&gt;
&lt;P&gt;This resource has been evaluated for quality by the EVSL Management Group. Please click &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/showappraisal.asp?appraisalInt=266" target="_blank"&gt;here&lt;/A&gt; for further information.&lt;BR&gt;Did this resource answer your query? &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=yes&amp;amp;appraisalInt=266" target="_blank"&gt;YES&lt;/A&gt; &lt;A href="http://www.moorfieldsresearch.org.uk/evsl/givefeedback.asp?answer=no&amp;amp;appraisalInt=266" target="_blank"&gt;NO&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>333504</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.cfwi.org.uk/intelligence/previous-projects/workforce-summaries/medical-ophthalmology/at_download/attachment1]]&gt;</url>
    <title>Workforce Summary – Medical Ophthalmology: 2008 – England only</title>
    <publicationDate>2008-06-19T00:00:00</publicationDate>
    <publisher>NHS Workforce Review Team</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The NHS Workforce Review Team (WRT) is "a group of dedicated healthcare workforce planners who provide objective modelling, analysis and evidence-based recommendations in order to enable patient-centred and clinically driven strategic decision making across the healthcare workforce."&lt;/P&gt;
&lt;P&gt;One of the outputs of the NHS Workforce Review Team is workforce summaries and proforma supply models for each specialty and profession.&lt;/P&gt;
&lt;P&gt;This specialty summary is on medical ophthalmology, with key information for the NHS in England (only). It includes information&amp;nbsp;on the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Brief speciality description and pattern of training; 
&lt;LI&gt;Current workforce; 
&lt;LI&gt;Demand drivers and estimates; 
&lt;LI&gt;Workforce supply; 
&lt;LI&gt;Summary of key issues.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>333506</id>
    <name>&lt;![CDATA[ Eyes and Vision]]&gt;</name>
    <rootDirectory>/eyes</rootDirectory>
    <url>&lt;![CDATA[http://www.cfwi.org.uk/intelligence/previous-projects/workforce-summaries/ophthalmology/at_download/attachment1]]&gt;</url>
    <title>Workforce Summary – Ophthalmology: 2008 – England only</title>
    <publicationDate>2008-06-19T00:00:00</publicationDate>
    <publisher>NHS Workforce Review Team</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EYES AND VISION,GUIDANCE AND POLICIES FOR THE NHS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The NHS Workforce Review Team (WRT) is "a group of dedicated healthcare workforce planners who provide objective modelling, analysis and evidence-based recommendations in order to enable patient-centred and clinically driven strategic decision making across the healthcare workforce."&lt;/P&gt;
&lt;P&gt;One of the outputs of the NHS Workforce Review Team is workforce summaries and proforma supply models for each specialty and profession.&lt;/P&gt;
&lt;P&gt;This specialty summary is on ophthalmology, with key information for the NHS in England (only). It includes information&amp;nbsp;on the following:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Brief speciality description and pattern of training; 
&lt;LI&gt;Current workforce; 
&lt;LI&gt;Demand drivers and estimates; 
&lt;LI&gt;Workforce supply; 
&lt;LI&gt;Summary of key issues.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
</documents>